<SEC-DOCUMENT>0001193125-25-058954.txt : 20250320
<SEC-HEADER>0001193125-25-058954.hdr.sgml : 20250320
<ACCEPTANCE-DATETIME>20250320160135
ACCESSION NUMBER:		0001193125-25-058954
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		92
FILED AS OF DATE:		20250320
DATE AS OF CHANGE:		20250320

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			OnKure Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001637715
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				472309515
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-282792
		FILM NUMBER:		25756367

	BUSINESS ADDRESS:	
		STREET 1:		6707 WINCHESTER CIRCLE, SUITE 400
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		(720) 307-2892

	MAIL ADDRESS:	
		STREET 1:		6707 WINCHESTER CIRCLE, SUITE 400
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Reneo Pharmaceuticals, Inc.
		DATE OF NAME CHANGE:	20150325
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>d184865dposam.htm
<DESCRIPTION>POS AM
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:okur="http://onkuretherapeutics.com/20241231" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2024" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>POS AM</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style="line-height:normal;background-color:white;"><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden133878648" contextRef="P01_01_2024To12_31_2024">POS AM</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden133878651" contextRef="P01_01_2024To12_31_2024">CO</ix:nonNumeric><ix:nonNumeric name="dei:EntityAddressStateOrProvince" id="hidden133878652" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">CO</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2024To12_31_2024" id="ixv-16444">0001637715</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalYearFocus" contextRef="P01_01_2024To12_31_2024" id="ixv-16445">2024</ix:nonNumeric><ix:nonNumeric name="dei:DocumentFiscalPeriodFocus" contextRef="P01_01_2024To12_31_2024" id="ixv-16446">FY</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2024To12_31_2024" id="ixv-16447">true</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="okur-20241231.xsd"/></ix:references><ix:resources><xbrli:context id="PAsOn12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:LabEquipmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">okur:DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:Performance-BasedStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-01-01</xbrli:startDate> <xbrli:endDate>2023-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">okur:ClinicalResearchSegmentMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePromissoryNoteMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_OneTimeTerminationBenefitsMemberusgaapRestructuringCostAndReserveAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">okur:Non-EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">okur:Non-EmployeesMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:Performance-BasedStockOptionsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-01-01</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-10-04</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-10-04</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-03-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P10_04_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-10-04</xbrli:startDate> <xbrli:endDate>2024-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To01_31_2025_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-01-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn06_30_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-06-30</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2025-01-01</xbrli:startDate> <xbrli:endDate>2025-01-01</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2025-01-01</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2022-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2023-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:context id="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001637715</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:instant>2024-12-31</xbrli:instant> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD"> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_shares"> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_sqft"> <xbrli:measure>utr:sqft</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_Year"> <xbrli:measure>utr:Year</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_pure"> <xbrli:measure>xbrli:pure</xbrli:measure> </xbrli:unit><xbrli:unit id="Unit_USD_per_Share"> <xbrli:divide> <xbrli:unitNumerator> <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unitNumerator> <xbrli:unitDenominator> <xbrli:measure>xbrli:shares</xbrli:measure> </xbrli:unitDenominator> </xbrli:divide> </xbrli:unit><xbrli:unit id="Unit_Segment"> <xbrli:measure>okur:Segment</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">As filed with the Securities and Exchange Commission on March 20, 2025 </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: right;"><div style="font-weight:bold;display:inline;">Registration <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">No.&#160;333-282792</div> </div></div><div style="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 4pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">POST-EFFECTIVE AMENDMENT NO. 1 TO </div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">FORM </div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="-sec-ix-hidden:hidden133878648;display:inline;">S-1</div></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">REGISTRATION STATEMENT </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Under </div></div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">The Securities Act of 1933 </div></div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 24pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2024To12_31_2024" id="ixv-47">O<div style="display:inline;">NKURE THERAPEUTICS, INC.</div></ix:nonNumeric><div style="display:inline;"></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Exact name of Registrant as specified in its charter) </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:7pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:top;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:stateprovnameen" id="ixv-17514">Delaware</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityPrimarySicNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-17515">2834</ix:nonNumeric></div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space:nowrap;display:inline;"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-17516">47-2309515</ix:nonNumeric></div></div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:top;text-align:center"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(State or other jurisdiction of</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">incorporation or organization)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(Primary Standard Industrial</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Classification Code Number)</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top;text-align:center"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">(I.R.S. Employer</div></div><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center; line-height: normal;"><div style="font-weight:bold;display:inline;">Identification Number)</div></div></td></tr></table><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="display:inline;"></div><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To12_31_2024" id="ixv-97"><div style="display:inline;">6707 Winchester Circle</div>, #400</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To12_31_2024" id="ixv-17517">Boulder</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden133878651;display:inline;">CO</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To12_31_2024" id="ixv-17518">80301</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To12_31_2024" id="ixv-17519">720</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To12_31_2024" id="ixv-17520">307-2892</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices) </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:ContactPersonnelName" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-17521">Nicholas A. Saccomano</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">President and Chief Executive Officer </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="display:inline;"></div><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-117"><div style="display:inline;">6</div><div style="display:inline;">707 Winchester Circle</div>, #400</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-17522">Boulder</ix:nonNumeric>, <div style="-sec-ix-hidden:hidden133878652;display:inline;">CO</div> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-17523">80301</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(<ix:nonNumeric name="dei:CityAreaCode" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-17524">720</ix:nonNumeric>) <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis" id="ixv-17525">307-2892</ix:nonNumeric></div> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 7pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name, address, including zip code, and telephone number, including area code, of agent for service) </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Copies to: </div></div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Tony Jeffries </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Jennifer Knapp </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">1155 Canyon Blvd., Suite&#160;400 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Boulder, CO&#160;80302 </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">(303)&#160;256-5900</div> </div></div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Approximate date of commencement of proposed sale to the public</div></div>: As soon as practicable after this registration statement becomes effective<div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">.</div></div> </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box:&#8194;&#9746; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744; </div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">non-accelerated</div> filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Rule&#160;12b-2</div> of the Exchange Act. </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:16%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:59%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:20%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:2%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">Large&#160;accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Accelerated&#160;filer</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9744;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityFilerCategory" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:entityfilercategoryen" id="ixv-17526">Non-accelerated filer</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#9746;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Smaller&#160;reporting&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntitySmallBusiness" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:boolballotbox" id="ixv-17527">&#9746;</ix:nonNumeric></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/>
<td colspan="2" style="height:6pt"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">Emerging&#160;growth&#160;company</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:boolballotbox" id="ixv-17528">&#9746;</ix:nonNumeric></td></tr></table><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:boolballotbox" id="ixv-17529">&#9744;</ix:nonNumeric> </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 6pt; margin-bottom: 0pt; text-indent: 4%; font-size: 8pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">The Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file a further amendment which specifically states that this Registration Statement shall thereafter become effective in accordance with Section&#160;8(a) of the Securities Act of 1933, or until <div style="display:inline;">the </div>Registration Statement shall become effective on such date as the Commission acting pursuant to said Section&#160;8(a) may determine. </div></div><div style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div></div></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="display: none"><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="okur-20241231.xsd"/></ix:references></ix:header></div><div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="dei:AmendmentDescription" contextRef="P01_01_2024To12_31_2024" id="ixv-224"> <div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><div style="display:inline;">EXPLANATORY </div>NOTE </div></div> <div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Post-Effective Amendment to Registration Statement on Form S-1 </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OnKure Therapeutics, Inc., a Delaware corporation, filed a Registration Statement on Form S-1 on October&#160;23, 2024, which was declared effective on October 30, 2024 (the &#8220;Registration Statement&#8221;). This Post-Effective Amendment No. 1 to Form S-1 (the &#8220;Post-Effective Amendment&#8221;) is being provided to include the fiscal year ended December 31, 2024 financial statements, contained in the Annual Report on Form 10-K for the year-ended December 31, 2024 filed on March 10, 2025 (the &#8220;Form 10-K&#8221;), as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information included in this filing amends the Registration Statement and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement. </div></ix:nonNumeric> <div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Background of the Business Combination </div></div> <div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As previously disclosed, on October&#160;4, 2024 (the &#8220;Closing Date&#8221;), OnKure Therapeutics, Inc., a Delaware corporation (previously named Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (&#8220;Reneo&#8221;)), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May&#160;10, 2024 (the &#8220;Merger Agreement&#8221;), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (&#8220;Merger Sub I&#8221;), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (&#8220;Merger Sub II&#8221;), and OnKure, Inc., a Delaware corporation (&#8220;Legacy OnKure&#8221;). </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on the Closing Date, (i)&#160;Reneo <div style="letter-spacing: 0px; top: 0px;display:inline;">effected </div>a reverse stock split of Reneo&#8217;s issued common stock at a ratio of 1:10 (the &#8220;Reverse Stock Split&#8221;), (ii) Reneo changed its name to &#8220;OnKure Therapeutics, Inc.&#8221;, (iii) Reneo reclassified all of its common stock as &#8220;Class&#160;A Common Stock&#8221;, (iv) Radiate Merger Sub I merged with and into Legacy OnKure (the &#8220;Merger&#8221;), with Legacy OnKure as the surviving company in the Merger and, after giving effect to such Merger, Legacy OnKure becoming a wholly-owned subsidiary of OnKure Therapeutics, Inc. (together, &#8220;OnKure&#8221; or the &#8220;Combined Company&#8221;). Pursuant to the terms of the Merger Agreement, prior to the Merger, Legacy OnKure determined that the Merger would qualify for the intended tax treatment even if only the merger with Merger Sub I was consummated, and therefore the parties determined not to consummate the second merger with Merger Sub II contemplated by the Merger Agreement. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms and subject to the conditions of the Merger Agreement, at the effective time of the Merger (the &#8220;Effective Time&#8221;), each share of Legacy OnKure outstanding as of immediately prior to the Effective Time was exchanged for shares of Class&#160;A Common Stock, all vested and unvested options to purchase shares of Legacy OnKure and OnKure restricted stock units (&#8220;RSUs&#8221;) were exchanged for comparable options and RSUs for Class&#160;A Common Stock, in each case, based on the exchange ratios calculated in accordance with the Merger Agreement. Each share of Reneo common stock and each option to purchase shares of Reneo common stock that was issued and outstanding as of immediately prior to the Effective Time remain issued and outstanding in accordance with its terms and such shares and options, subject to the reclassification to Class&#160;A Common Stock and Reverse Stock Split. </div> <div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Reneo entered into a Subscription Agreement (the &#8220;Subscription Agreement&#8221;) with certain investors (each, a &#8220;PIPE Investor&#8221;), pursuant to which the PIPE Investors subscribed for and purchased, and Reneo issued and sold to the PIPE Investors, on the Closing Date immediately prior to the Effective Time, an aggregate of 2,938,005 shares of Class&#160;A Common Stock at a price of approximately $22.895 per share (the &#8220;PIPE Shares&#8221;), for aggregate gross proceeds of approximately $65.0&#160;million (the &#8220;PIPE Financing&#8221;). Reneo granted the PIPE Investors certain registration rights in connection with the PIPE Financing. All references herein to the &#8220;Closing&#8221; refer to the closing of the transactions contemplated by the Merger Agreement, including the Merger and the transactions contemplated by the Subscription Agreement (the &#8220;Transactions&#8221;). </div> </div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the open of trading on October&#160;7, 2024, the Class&#160;A Common Stock of the Combined Company began trading on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;OKUR.&#8221; <br/></div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><span style="color:#ff4338"><span style="font-weight:bold">The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities, nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </span></span></p> <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="color:#ff4338"><span style="font-weight:bold">PRELIMINARY PROSPECTUS</span></span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:right"><span style="color:#ff4338"><span style="font-weight:bold">Subject to Completion, dated March 20, 2025</span></span></td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">2,938,005 Shares of Class&#160;A Common Stock </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g35j50.jpg" alt="LOGO" style="width:3.24in;height:0.926599in"/>
 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by certain of the selling securityholders named in this prospectus (each a &#8220;selling securityholder&#8221; and, collectively, the &#8220;selling securityholders&#8221;) of 2,938,005 shares of Class&#160;A Common Stock, par value $0.0001 per share (the &#8220;Common Stock&#8221;) issued in a private placement on October&#160;4, 2024 (the &#8220;PIPE Financing&#8221;). This prospectus also covers any additional securities that may become issuable by reason of stock splits, stock dividends or other similar transactions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering the offer and sale of these securities to satisfy certain registration rights we have granted. We will not receive any of the proceeds from the sale of the securities by the selling securityholders. We will pay the expenses associated with registering the sales by the selling securityholders, as described in more detail in the section titled &#8220;Use of Proceeds&#8221; appearing elsewhere in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling securityholders may sell the securities described in this prospectus in a number of different ways and at varying prices. We provide more information about how the selling securityholders may sell their securities in the section titled &#8220;Plan of Distribution&#8221; appearing elsewhere in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling securityholders may sell any, all or none of the securities and we do not know when or in what amount the selling securityholders may sell their securities hereunder following the effective date of this registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;OKUR.&#8221; On March 17, 2025, the last quoted sale price for our Common Stock as reported on Nasdaq was $4.82. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">We are an &#8220;emerging growth company,&#8221; as defined under the federal securities laws, and, as such, may elect to comply with certain reduced public company reporting requirements for future filings. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman;font-weight:bold">Investing in our securities involves a high degree of risk. Before buying any securities, you should carefully read the discussion of the risks of investing in our securities in the section titled &#8220;<a href="#tx835714_5">Risk Factors</a>&#8221; beginning on page 9 of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">You should rely only on the information contained in this prospectus or any prospectus supplement or amendment hereto. We have not authorized anyone to provide you with different information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold">Neither the Securities Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">The date of this prospectus is&#8195;&#8195;&#8195;&#8195;, 2025. </span></p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:95%"/>

<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Page</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_1">About This Prospectus</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">ii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_2">Market and Industry Data</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">ii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_3">Trademarks</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">ii</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_4">Prospectus Summary</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_5">Risk Factors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_6">Cautionary Note Regarding Forward-Looking Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_7">Use of Proceeds</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">67</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_8">Market Price of and Dividends on the Registrant&#8217;s Common Equity and Related Stockholder Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_10">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_11">Business</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_12">Management</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">106</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_13">Executive Compensation</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_14">Certain Relationships, Related Party and Other Transactions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">127</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_15">Principal Securityholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_16">Selling Securityholders</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">134</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_17">Description of Securities</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">138</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_18">Plan of Distribution</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_19">Legal Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_20">Experts</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">148</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_21">Where You Can Find Additional Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">149</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#tx835714_22">Index to Financial Statements</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on the information contained in this prospectus or in any free writing prospectus prepared by us or on our behalf. We have not authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. We are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">i </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_1">ABOUT THIS PROSPECTUS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of the registration statement on Form <span style="white-space:nowrap">S-1</span> that we filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) using the &#8220;shelf&#8221; registration process. Under this shelf registration process, the selling securityholders hereunder may, from time to time, sell the securities offered by them described in this prospectus. We will not receive any proceeds from the sale by such selling securityholders of the securities offered by them described in this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the selling securityholders have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus or any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. Neither we nor the selling securityholders take responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. Neither we nor the selling securityholders will make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also provide a prospectus supplement or post-effective amendment to the registration statement to add information to, or update or change information contained in, this prospectus. You should read both this prospectus and any applicable prospectus supplement or post-effective amendment to the registration statement together with the additional information to which we refer you in the section of this prospectus titled &#8220;<span style="font-style:italic">Where You Can Find Additional Information.</span>&#8221; </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_2">MARKET AND INDUSTRY DATA </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus includes industry and market data that we have obtained from industry publications, third-party studies and surveys, filings of public companies in their respective industries and related industry and internal company surveys. These sources include government and industry sources, which generally state that the information contained therein has been obtained from sources believed to be reliable. Although we believe the industry and market data to be reliable as of the date of this prospectus, this information could prove to be inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. We do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the forecasts from the sources relied upon or cited herein. Assumptions and estimates of future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#8220;<span style="font-style:italic">Risk Factors</span>.&#8221; These and other factors could cause future performance to differ materially from our assumptions and estimates. See &#8220;<span style="font-style:italic">Cautionary Statement Concerning Forward-Looking Statements</span>.&#8221; </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_3">TRADEMARKS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have proprietary rights to trademarks, trade names and service marks appearing in this prospectus that are important to our business. This prospectus may also contain trade names, trademarks and service marks belonging to other companies that are the property of their respective owners. Solely for convenience, trademarks, trade names and service marks may appear in this prospectus without the <sup style="font-size:75%; vertical-align:top">&#8482;</sup><sup style="font-size:75%; vertical-align:top"> </sup>and <sup style="font-size:75%; vertical-align:top">&#174;</sup> symbols, but such references, or their failure to appear, should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights or the rights of the applicable licensors with respect thereto. </p> <p style="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">ii </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_4">PROSPECTUS SUMMARY </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">This summary highlights information contained in greater detail elsewhere in this prospectus. This summary is not complete and does not contain all of the information you should consider in making your investment decision. You should read the entire prospectus carefully before making an investment in our Common Stock. You should carefully consider, among other things, our consolidated financial statements and the related notes and the sections titled &#8220;Risk Factors,&#8221; &#8220;Business,&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included elsewhere in this prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">ONKURE THERAPEUTICS, INC. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OnKure Therapeutics, Inc. (&#8220;OnKure&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. By improving selectivity for the oncogenic and mutated form of these cancer-driver proteins, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from <span style="white-space:nowrap">non-selective</span> inhibition of the <span style="white-space:nowrap">non-mutated</span> (or wild-type) version of the protein. We work under the belief that inhibiting target proteins with specific mutations instead of wild-type variants should enable precise patient selection that will, in turn, improve the probability of clinical success. We designed our current product candidates utilizing&#160;disciplined medicinal chemistry, <span style="white-space:nowrap">x-ray</span> crystallography and computational chemistry to inhibit specified mutated versions of phosphoinositide 3 kinase alpha (&#8220;PI3K&#945;&#8221;), a key mediator in cancer growth signaling. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">OKI-219,</span> is a highly selective inhibitor of PI3K&#945; harboring the H1047R mutation (&#8220;PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#8221;) that has a much smaller impact on wild-type PI3K&#945; (&#8220;PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>&#8221;). By minimizing the targeting of PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>&#160;(approximately&#160;80-fold&#160;selectivity for PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;over PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>), we believe&#160;OKI-219&#160;can achieve exposures required for activity in PI3K&#945;-mutated cancers with minimal effect on wild-type PI3K&#945; signaling, thus potentially limiting on-target toxicities, such as hyperglycemia, gastrointestinal (&#8220;GI&#8221;) effects, fatigue, and rash. We plan to initially focus on the development of <span style="white-space:nowrap">OKI-219</span> in patients with advanced breast cancer of genetic subtypes that are (a)&#160;both hormone receptor positive (&#8220;HR+&#8221;) and human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;); and (b)&#160;human epidermal growth factor receptor 2 positive (&#8220;HER2+&#8221;). We believe we can potentially expand the application <span style="white-space:nowrap">of&#160;OKI-219</span> by conducting appropriate clinical trials in earlier lines of treatment within breast cancer, other subtypes of breast cancer, and potentially in other solid tumors.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219&#160;is</span> currently being investigated in <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;first-in-human&#160;Phase</span></span> a/1b open-label trial evaluating OKI-219 as a monotherapy and in combination with fulvestrant or trastuzumab in subjects with advanced solid tumors, including breast cancer harboring a PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> mutation (&#8220;PIKture-01&#8221;). In Phase 1a, subjects receive escalating oral doses of OKI-219 starting at 300 mg twice daily (commonly referred to as &#8220;BID&#8221;) continuously. In Phase 1b we are currently assessing OKI-219 in combination with fulvestrant in patients with HR+/HER2- breast cancer, and in the future, plan to assess OKI-219 in combination with HER2+ targeted agents (e.g., trastuzumab) in patients with HER2+ breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, we announced the preliminary safety, tolerability, and pharmacokinetic (&#8220;PK&#8221;) data from PIKture-01 with a cut off date of October 28, 2024. These data showed that OKI-219 was well tolerated across all dose levels with no hyperglycemia, stomatitis, or rash observed at any dose, and only grade 1 treatment-related adverse events (&#8220;TRAEs&#8221;) were reported. No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events. OKI-219 dosed at 900 mg twice daily showed steady-state exposure levels with near-continuous coverage of the <span style="font-style:italic">in vivo </span>EC80 for pAKT inhibition. These data supported </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the initiation of Part 1b of PIKture-01 and we began enrolling patients in the fourth quarter of 2024 focusing initially on the evaluation of OKI-219 in combination with fulvestrant. To date, we have completed the enrollment of patients in the Part A monotherapy arm of PIKture-01 through the 1200 mg BID cohort level with no dose limiting toxicities observed in the completed cohorts. We are currently enrolling the last cohort with a top dose of 1500 mg BID and enrollment in Part A is almost complete. Additionally, we have enrolled patients in the Part B fulvestrant combination arm through the 900 mg BID cohort with no dose limiting toxicities observed for all completed cohorts through 600 mg BID and enrollment in the dose escalation portion of Part B is almost complete. We expect to report additional single-agent data and initial combination data with fulvestrant in the second half of 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Pharmacokinetic and Selectivity Profile</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OKI-219 has shown favorable PK data (Figure 1) in the PIKture-01 trial that support pharmacologically relevant exposures, potentially even at the lowest assessed dose levels, with a safety profile that is indicative of little or no inhibition of wild-type PI3K&#945;. At steady state, the exposures of OKI-219 exceed exposures associated with robust antitumor activity in preclinical models. The PK data are considered preliminary with a data cut-off of October 28, 2024. We plan to provide updated PK data in the second half of 2025. </p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g07g07.jpg" alt="LOGO" style="width:4.95333in;height:3.36667in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 1. Steady-state concentrations of OKI-219 at Day 15 across three dose levels in PIKture-01 Part A. Data cut off October 28, 2024. </span>Source:<span style="font-weight:bold"> </span>OnKure data.<span style="font-weight:bold"> </span></p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in Figure 2, 13 of the 14 patients that received a &gt;600 mg dose twice a day remained in the study as of the cutoff date. In addition, two patients with HR+/HER2- breast cancer who received the 300 mg dose showed prolonged stable disease, including one patient who sustained &gt;95% reduction in PIK3CA<sup style="font-size:75%; vertical-align:top">H1047R</sup> ctDNA and was on treatment for more than seven months. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g08g08.jpg" alt="LOGO" style="width:6.32in;height:3.07333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 2.&#160;Time on treatment data from PIKture-01 trial. Data cut off October 28, 2024. </span>Source:<span style="font-weight:bold"> </span>OnKure data.<span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Preclinical Data</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from preclinical <span style="font-style:italic">in vivo</span> models (Figure 3 and 4 below) of OKI-219 used in combination with standard-of-care (&#8220;SOC&#8221;) therapies for HR+ breast cancers&#160;show strong combination activity of OKI-219 in doublet combinations with SERDs and in triplet combinations with SERD + CDK4/6 inhibitors. Additionally, OKI-219 was well tolerated at doses well above those required for tumor regressions, supporting the ability to combine OKI-219 with SOC therapies in breast cancer. Additional preclinical combination studies are ongoing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center">


<img src="g184865g08g02.jpg" alt="LOGO" style="width:2.79333in;height:2.17333in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">


<img src="g184865g08g03.jpg" alt="LOGO" style="width:2.74667in;height:2.15667in"/>
</td></tr>
</table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 3. Preclinical comparison of tumor shrinkage for OKI-219 alone and in combination with fulvestrant or camizestrant vs. fulvestrant or camizestrant in an ER+HER2- breast cancer model.&#160;</span>Source:<span style="font-weight:bold"> </span>OnKure data.<span style="font-weight:bold"> </span></p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center">


<img src="g184865g09g01.jpg" alt="LOGO" style="width:2.6in;height:2.05625in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">


<img src="g184865g09g02.jpg" alt="LOGO" style="width:2.39306in;height:2.05278in"/>
</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Figure 4. Preclinical comparison of tumor shrinkage for OKI-219 alone and in combination with fulvestrant plus CDK 4/6 inhibitors vs. CDK 4/6 inhibitors alone and in combination with fulvestrant.&#160;</span>Source: OnKure data.<span style="font-weight:bold"> </span></p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetic analysis of tumors has become standard-of-care in oncology and has enabled oncologists to characterize tumors much more precisely than simple segmentation based on the tissue of origin. A more precise understanding of the genetic alterations driving the growth of specific tumors has also created an opportunity for the industry to develop drugs that are intended to target mutated or oncogenic forms of proteins that drive cancer growth and survival. In a number of notable cases, this approach has profoundly changed how these tumors are treated and has significantly improved outcomes for patients with cancers that depend on these oncogenes for survival. However, in many cases, it has been challenging to effectively target the mutated oncogenic form of a target protein. In <span style="white-space:nowrap">particular,&#160;non-selective&#160;inhibition</span> of the wild-type protein in normal tissues often leads to toxic effects that can limit effective target inhibition of the intended oncogenic protein in cancers and, therefore, offers suboptimal clinical benefit. One such challenging target is the oncogene PI3K&#945;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PI3K&#945; is an attractive target for cancer drugs because it is one of the most commonly mutated oncogenes in cancers and is a key mediator of abnormal cell growth. Furthermore, PI3K&#945; kinase mutations are clinically correlated with drug resistance and poor clinical outcomes. Single amino acid mutations such as E542K, E545K, H1047R, H1047L, and H1047Y account for over 70% of PI3K&#945; mutations. Notably, the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation is very common in breast cancer, being identified in approximately 14% of breast cancer cases. The PI3K&#945; inhibitor alpelisib has been approved to treat patients with advanced breast cancers harboring PI3K&#945; mutations. Alpelisib <span style="white-space:nowrap">is&#160;non-selective&#160;for</span> the key mutations, and its inhibition of not only mutant but also wild-type PI3K&#945; leads to significant toxicities in patients, such as hyperglycemia, rash and diarrhea. These toxicities can present significant challenges to optimal dosing and use in this patient population. We are focused on addressing the shortcomings of alpelisib and other first-generation PI3K&#945; inhibitors (e.g., inavolisib) by developing product candidates that target these genetic alterations selectively while sparing the wild-type PI3K&#945;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Development Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on the discovery and development of precision oncology therapies that targetbiologically validated drivers of cancers underserved by available therapies. Currently, we are focused on delivering highly selective drug candidates that preserve wild-type PI3K&#945; while effectively targeting the PI3K&#945;-mutated cancers, initially in advanced breast cancer. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, OKI-219, is advancing in a Phase 1 clinical trial.&#160;We are also actively pursuing multiple additional discovery programs that target oncogenic mutations of PI3K&#945;. We expect to announce a pan-mutant development candidate in the second quarter of 2025 targeting the most common PI3K&#225; mutations (i.e., H1047R, E545K, and E542K). Additionally, we are developing an allosteric inhibitor molecule designed to be highly selective by specifically targeting the PI3K&#945; E545K and E542K mutations (which are also known as helical domain mutations or e-mutants) and expect to announce a development candidate in 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">OnKure&#8217;s Clinical Pipeline </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g96g96.jpg" alt="LOGO" style="width:6.33309in;height:1.09321in"/>
 </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">CORPORATE INFORMATION </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;4, 2024 (the &#8220;Closing Date&#8221;), OnKure Therapeutics, Inc., a Delaware corporation (previously named Reneo Pharmaceuticals, Inc., a Delaware corporation and our predecessor company (&#8220;Reneo&#8221;)), consummated the previously announced merger pursuant to the terms of the Agreement and Plan of Merger, dated as of May&#160;10, 2024 (the &#8220;Merger Agreement&#8221;), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (&#8220;Merger Sub I&#8221;), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (&#8220;Merger Sub II&#8221;), and OnKure, Inc., a Delaware corporation (&#8220;Legacy OnKure&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on the Closing Date, (i)&#160;Reneo effected a reverse stock split of Reneo&#8217;s issued common stock at a ratio of 1:10, (ii) Reneo changed its name to &#8220;OnKure Therapeutics, Inc.&#8221;, (iii) Reneo reclassified all of its common stock as &#8220;Class&#160;A Common Stock&#8221;, and (iv)&#160;Radiate Merger Sub I merged with and into Legacy OnKure (the &#8220;Merger&#8221;), with Legacy OnKure as the surviving company in the Merger and, after giving effect to such Merger, Legacy OnKure becoming a wholly-owned subsidiary of OnKure Therapeutics, Inc. (together with its consolidated subsidiary, &#8220;OnKure&#8221; or the &#8220;Combined Company&#8221;). As of the open of trading on October&#160;7, 2024, the Class&#160;A Common Stock of the Combined Company (the &#8220;Common Stock&#8221;), formerly those of Reneo, began trading on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;OKUR.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our principal executive offices are located at 6707 Winchester Circle, Suite 400, Boulder, CO 80301, and our telephone number is (720) <span style="white-space:nowrap">307-2892.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our website address is www.onkuretherapeutics.com. The information on, or that can be accessed through, our website is not part of this prospectus, and you should not consider information contained on our website in deciding whether to purchase shares of our Common Stock. We have included our website address in this prospectus solely as an inactive textual reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We use the OnKure logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without a trademark symbol, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (the &#8220;JOBS Act&#8221;). We will remain an emerging growth company until the earliest to occur of: the last day of the fiscal year in which we have more than $1.235&#160;billion in annual revenues; the date we qualify as a &#8220;large accelerated filer,&#8221; with at least $700&#160;million of equity securities held by <span style="white-space:nowrap">non-affiliates;</span> the issuance, in any three-year period, by us of more than $1.0&#160;billion in <span style="white-space:nowrap">non-convertible</span> debt securities; and the last day of the fiscal year ending after the fifth anniversary of Reneo&#8217;s initial public offering (i.e., December&#160;31, 2026). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;107 of the JOBS Act provides that an emerging growth company can take advantage of the extended transition period provided in Section&#160;7(a)(2)(B) of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), for complying with new or revised accounting standards. In other words, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected not to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, we, as an emerging growth company, can adopt the new or revised standard at the time private companies adopt the new or revised standard. This may make comparison of our financial statements with certain other public companies difficult or impossible because of the potential differences in accounting standards used. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation <span style="white-space:nowrap">S-K.</span> Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We may continue to be a smaller reporting company in any given year if either (i)&#160;the market value of our stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $250&#160;million as of June 30th in the most recently completed fiscal year, or (ii)&#160;our annual revenue is less than $100&#160;million during the most recently completed fiscal year and the market value of our stock held by <span style="white-space:nowrap">non-affiliates</span> is less than $700&#160;million as of June 30th in the most recently completed fiscal year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless expressly indicated or the context requires otherwise, the terms &#8220;OnKure,&#8221; the &#8220;Combined Company,&#8221; the &#8220;Company,&#8221; the &#8220;Registrant,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; in this prospectus refer to OnKure Therapeutics, Inc., the parent entity formerly named Reneo Pharmaceuticals, Inc., after giving effect to the Merger, and as renamed OnKure Therapeutics, Inc., and where appropriate, our wholly-owned subsidiaries (including Legacy OnKure). </p>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">The Offering </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Shares of Common Stock Offered Hereunder </p></td>
<td>We are registering the resale by the selling securityholders named in this prospectus, or their permitted transferees, of an aggregate of 2,839,005 shares of Class&#160;A Common Stock (the &#8220;Common Stock&#8221;) issued in a private placement of securities by the Company on October&#160;4, 2024 (the &#8220;PIPE Financing&#8221;). </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Use of Proceeds </p></td>
<td>We will not receive any proceeds from the sale of our shares of Common Stock offered by the selling securityholders under this prospectus (the &#8220;Securities&#8221;). See the section titled &#8220;<span style="font-style:italic">Use of Proceeds</span>&#8221; appearing elsewhere in this prospectus for more information. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Class A Common Stock Outstanding </p></td>
<td>12,660,590 </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Combined Class A Common Stock and Non-Voting Class B Common Stock Outstanding </p></td>
<td>13,347,117 </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Risk Factors </p></td>
<td>See the section titled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our Common Stock. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="vertical-align:TOP">
<td style="width:38%"> <p style=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman">Nasdaq Symbol </p></td>
<td>&#8220;OKUR&#8221; </td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of shares of Common Stock outstanding is based on as of 12,660,590 shares of Common Stock as of December 31, 2024 and excludes the following, in each case as of December 31, 2024 and adjusted for the reverse stock split and applicable exchange ratios: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">221&#160;shares of our Common Stock issuable upon the exercise of outstanding options under the Legacy OnKure 2011 Stock Incentive Plan, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $4.24 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">190,557&#160;shares of our Common Stock issuable upon the exercise of outstanding options under the Legacy OnKure 2021 Stock Incentive Plan, which were assumed by the Company in connection with the Merger, with a weighted average exercise price of $16.59 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">213,254 shares of our Common Stock issuable upon the vesting of restricted stock units issued under the Legacy OnKure 2023 RSU Equity Incentive Plan, which were assumed by the Company in connection with the Merger; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">217,295&#160;shares of our Common Stock issuable upon the exercise of outstanding options under the Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan and UK <span style="white-space:nowrap">Sub-Plan,</span> with a weighted average exercise price of $45.24 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">218,489&#160;shares of our Common Stock issuable upon the exercise of outstanding options under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan, with a weighted average exercise price of $45.65 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">18,000&#160;shares of our Common Stock issuable upon the exercise of outstanding options that were not issued pursuant to a Reneo Equity Plan, with a weighted average exercise price of $88.50 per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">17,000 shares of our Common Stock issuable upon the vesting of restricted stock units issued under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan; </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<div style="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">
 <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">1,749,262&#160;shares of our Common Stock issuable upon the exercise of outstanding options under our 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;), with an exercise price of $18.17&#160;per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">747,867 shares of our Common Stock reserved for future issuance under the 2024 Plan, as well as any automatic increases in the number of shares of Common Stock reserved for future issuance under this plan; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">137,500 shares of our Common Stock reserved for future issuance under our 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;), as well as any automatic increases in the number of shares of Common Stock reserved for future issuance under this plan; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">686,527 shares of our <span style="white-space:nowrap">non-voting</span> Class&#160;B Common Stock, which are convertible into shares of our Common Stock on a 1:1 basis, subject to customary beneficial ownership limitations. </p></td></tr></table>
</div></div>

 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_5">RISK FACTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">An investment in shares of our Class&#160;A Common Stock involves a high degree of risk. In addition to the risk and uncertainties described under the section titled &#8220;Cautionary Note Regarding Forward-Looking Statements,&#8221; you should consider carefully the risks and uncertainties described below, together with all of the other information contained in this prospectus, including our consolidated financial statements and related notes, before deciding to invest in our Class&#160;A Common Stock. If any of the following events occur, our business, financial condition and operating results may be materially adversely affected. In that event, the trading price of our Class&#160;A Common Stock could decline, and you could lose all or part of your investment. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business or results of operations. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Summary Risk Factors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business operations are subject to numerous risks and uncertainties, including those outside of our control, that could cause our actual results to be harmed, including risks regarding the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are early in our development efforts and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have incurred significant net losses in each period since inception, and expect to continue to incur significant net losses for the foreseeable future. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have never generated revenue from product sales and may never achieve or maintain profitability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We are substantially dependent on OKI-219. If we are unable to advance OKI-219 through clinical development, obtain regulatory approval and ultimately commercialize such product candidate, or experience significant delays in doing so, our business will be materially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We have limited resources and are currently focusing our efforts on OKI-219 for development in particular indications and advancing our other discovery research programs. As a result, we may fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we would incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we experience delays or difficulties in the enrollment or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">If we are unable to obtain and maintain sufficient intellectual property protection for our technology and products and product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and, if approved, commercialize our product candidates may be adversely affected. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct, supervise and monitor certain aspects of our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements and meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The market price of our Class&#160;A Common Stock has been and is expected to continue to be volatile. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We expect to incur losses for the foreseeable future and might never achieve profitability. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We will need substantial additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital on favorable terms, on a timely basis or at all, we would be forced to delay, reduce or eliminate our product development and clinical programs and may not have the capital required to otherwise operate our business. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our Amended Certificate of Incorporation and the Amended Bylaws and provisions under Delaware law could make an acquisition of our company more difficult and may prevent attempts by our stockholders to replace or remove our management. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">As a result of the Merger, we are subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we are subject to more stringent reporting requirements, offering limitations and resale restrictions. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">An active trading market for our Class&#160;A Common Stock may not develop, and the holders of our Class&#160;A Common Stock may not be able to resell their shares of our Class&#160;A Common Stock for a profit, if at all. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">We could be subject to securities class action litigation, which is expensive and could divert management attention. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Operating History, Financial Position and Need for Additional Capital </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are early in our development efforts and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company, have no products approved for commercial sale and have never generated any revenue. Our operations to date have been limited to organizing the company, raising capital and developing our product candidates. We have not yet demonstrated our ability to obtain marketing approvals, manufacture a commercial-scale product or arrange for a third-party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. As a result, it may be difficult for investors to accurately predict our likelihood of success and viability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields. We also expect that, as we advance our product candidates, we will need to transition from a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
company with a research and development focus to a company capable of supporting commercial activities. We have not yet demonstrated an ability to successfully overcome such risks and difficulties, or to make such a transition. If we do not adequately address these risks and difficulties or successfully make such a transition, our business will suffer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have incurred significant net losses in each period since inception, and we expect to continue to incur significant net losses for the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have incurred significant net losses in each reporting period since inception, have not generated any revenue from the sale of products, and have funded our operations primarily from the sale and issuance of equity securities and convertible debt. Our net losses were $52.7&#160;million and $35.3&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $154.7&#160;million. We have no products approved for sale. As a result, we expect that it will be many years, if ever, before we have a commercialized product and generate revenue from product sales. Even if we succeed in receiving marketing approval for and commercializing one or more of our product candidates, we expect that we will continue to incur substantial research and development and other expenses to discover, develop and market additional product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from quarter to quarter such that a <span style="white-space:nowrap"><span style="white-space:nowrap">period-to-period</span></span> comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue, if any. Our prior losses and expected future losses have had and will continue to have an adverse effect on our working capital, our ability to fund the development of our product candidates, our ability to achieve and maintain profitability and the performance of our stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have never generated revenue from product sales and may never achieve or maintain profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never generated any revenue from commercial product sales. To become and remain profitable, we must develop and eventually commercialize product candidates with significant market potential, which will require us to be successful in a range of challenging activities. These activities can include completing preclinical studies and clinical trials of our product candidates, obtaining marketing approval for these product candidates, manufacturing, marketing and selling those products that are approved and satisfying any post-marketing requirements. We do not anticipate generating any revenue from product sales for many years. Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful and timely completion of clinical development <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> preclinical and clinical development of other pipeline programs and any other future programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and maintaining relationships with contract research organizations (or &#8220;CROs&#8221;) and clinical sites for the clinical development <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> any other future programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">timely receipt of marketing approvals from applicable regulatory authorities for any product candidates for which we successfully complete clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developing an efficient and scalable manufacturing process for our product candidates, including obtaining finished products that are appropriately packaged for sale; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establishing and maintaining commercially viable supply and manufacturing relationships with third parties that can provide adequate, in both amount and quality, products and services to support clinical development and meet the market demand for our product candidates, if approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">successful commercial launch following any marketing approval, including the development of a commercial infrastructure, <span style="white-space:nowrap">whether&#160;in-house&#160;or</span> with one or more collaborators; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a continued acceptable safety profile following any marketing approval of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commercial acceptance of our product candidates by patients, the medical community and third-party payors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfying any required post-marketing approval commitments to applicable regulatory authorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identifying, assessing and developing new product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining, maintaining and expanding patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">defending against third-party interference or infringement claims, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">entering into, on favorable terms, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining and maintaining coverage and adequate reimbursement by third-party payors for our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing any competing therapies and technological and market developments; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">attracting, hiring and retaining qualified personnel. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never be successful in achieving our objectives and, even if we do, may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease our value and could impair our ability to maintain or further our research and development efforts, raise additional necessary capital, grow our business and continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any changes in the manufacturing process, suppliers, or facilities will require further comparability analysis and approval by the U.S. Food and Drug Administration (the &#8220;FDA&#8221;) before implementation, which could delay our clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety and efficacy. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have not previously submitted an NDA to the FDA or similar approval filings to a comparable foreign regulatory authority for any product candidate. An NDA or other relevant regulatory filing must include extensive nonclinical and clinical data and supporting information to establish that the product candidate is safe and effective for each desired indication. The NDA or other relevant regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. We cannot be certain that our current or future product candidates will be successful in clinical trials or receive regulatory approval. If we do not receive regulatory approvals for current or future product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approval to market a product candidate, our revenue will depend, in part, upon the size of the markets in the territories for which we receive regulatory approval and have commercial rights, the availability of competitive therapies and whether there are sufficient levels of reimbursement and adoption by physicians. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will need substantial additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital on favorable terms, on a timely basis or at all, we would be forced to delay, reduce or eliminate our product development and clinical programs and may not have the capital required to otherwise operate our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Developing pharmaceutical products, including conducting preclinical studies and clinical trials, is expensive. We have not generated any revenues from the commercial sale of products and will not be able to generate any product revenues until, and only if, we receive approval to sell our product candidates from the FDA or other regulatory authorities. Our cash, cash equivalents and short term investments are expected to fund </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operations into the fourth quarter of 2026. However, as we have not generated any revenue from commercial sales to date and do not expect to generate any revenue for several years, if ever, we will need to raise substantial additional capital in order to fund our general corporate activities and to fund our research and development, including our currently planned clinical trials and plans for new clinical trials and product development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may seek to raise additional funds through various potential sources, such as equity and debt financings, or through strategic collaborations and license agreements. We can give no assurances that we will be able to secure such additional sources of funds to support our operations or, if such funds are available, that such additional financing will be sufficient to meet our needs. Moreover, to the extent that we raise additional funds by issuing equity securities, our stockholders may experience additional significant dilution and new investors could gain rights, preferences and privileges senior to the holders of common stock. Debt financing, if available, may involve restrictive covenants. To the extent that we raise additional funds through collaboration and licensing arrangements, it may be necessary to relinquish some rights to our technologies or product candidates, or grant licenses on terms that may not be favorable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Given our capital constraints, we will need to prioritize spending on our clinical and preclinical programs. If we are unable to raise sufficient funds to support our current and planned operations, we may elect to discontinue certain of our ongoing activities or programs. Our inability to raise additional funds could also prevent us from taking advantage of opportunities to pursue promising new or existing programs in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our forecasts regarding the sufficiency of our financial resources to support our current and planned operations are forward-looking statements and involve significant risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed elsewhere in this &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; section. These estimates are based on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than currently expected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Development and Commercialization of Our Product Candidates </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are substantially dependent on <span style="white-space:nowrap">OKI-219.</span> If we are unable to advance <span style="white-space:nowrap">OKI-219</span> through clinical development, obtain regulatory approval and ultimately commercialize such product candidate, or experience significant delays in doing so, our business will be materially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently <span style="white-space:nowrap">evaluating&#160;OKI-219&#160;in</span> a Phase 1 clinical trial. We will be required to demonstrate thorough, adequate and well controlled clinical trials <span style="white-space:nowrap">that&#160;OKI-219&#160;is</span> safe and effective, with a favorable benefit-risk profile, for use in its target indication before we can seek regulatory approvals for its commercial sale. Our initial clinical trials will begin with relatively small cohorts before expanding in size in subsequent cohorts. If safety issues arise in an early cohort, we may be delayed or prevented from subsequently expanding into larger trial cohorts. Our ability to generate product revenue, which we do not expect will occur for many years, if ever, will depend heavily on the successful clinical development and eventual commercialization <span style="white-space:nowrap">of&#160;OKI-219.&#160;We</span> are not permitted to market or promote any product candidate before we receive marketing approval from the FDA, European Medicines Agency (&#8220;EMA&#8221;) or any comparable foreign regulatory authorities, and we may never receive such marketing approvals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We have limited resources and are currently focusing our efforts on <span style="white-space:nowrap">OKI-219</span> for development in particular indications and advancing our other discovery research programs. As a result, we may fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are currently focusing our resources and efforts <span style="white-space:nowrap">on&#160;OKI-219&#160;and</span> advancing our other research programs. Because we have limited financial and managerial resources, we must focus on a limited number of research programs and product candidates and on specific indications. As a result, we may forgo or delay pursuit of opportunities for other indications or with other product candidates that may have greater commercial potential. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development activities <span style="white-space:nowrap">for&#160;OKI-219&#160;and</span> our other research programs may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target markets <span style="white-space:nowrap">for&#160;OKI-219&#160;and</span> our other research programs, or the product candidates we are currently developing in these programs, we may relinquish valuable rights to our product candidates or programs through collaboration, licensing or other strategic arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or program. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we would incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct preclinical studies in animals and extensive clinical trials in humans to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive and difficult to design and implement, can take many years to complete and has uncertain outcomes. The outcome of preclinical studies and early clinical trials may not predict the success of later clinical trials, and interim results of a clinical trial do not necessarily predict final results. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in advanced clinical trials due to lack of efficacy or unacceptable safety profiles, notwithstanding promising results in earlier trials. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety to result in regulatory approval to market any of our product candidates in any jurisdiction. Our product candidates may fail to demonstrate efficacy in humans, and particularly across tumor types. A product candidate may fail for safety or efficacy reasons at any stage of the testing process. A major risk we face is the possibility that none of our product candidates under development will successfully gain market approval from the FDA, EMA or other comparable foreign regulatory authorities, resulting in our being unable to derive any commercial revenue from them after investing significant amounts of capital in their development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the results of our ongoing or future preclinical studies and future clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, if our trials do not meet the clinical endpoints with statistical and clinically meaningful significance, or if there are safety concerns associated with our product candidates, we may be prevented or delayed in obtaining marketing approval for such product candidates. In some instances, there can be significant variability in safety or efficacy results between different preclinical studies and clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial protocols and the rate of dropout among clinical trial participants. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or adverse events. In such an event, our trials could be suspended or terminated and the FDA, EMA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may harm our business, financial condition and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, our product candidates could cause undesirable side effects in clinical trials related to on-target toxicity. <span style="white-space:nowrap">If&#160;on-target&#160;toxicity</span> is observed, or if our product candidates have characteristics that are unexpected, we may need to abandon their development or limit development to more narrow indications or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Many compounds that initially showed promise in early stage testing for treating cancer have later been found to cause side effects that prevented further development of the compound. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates are and will continue to be subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of drugs. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process must be successfully completed in the United States and in many foreign jurisdictions before a new drug can be approved for marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining approval by the FDA, EMA and other comparable foreign regulatory authorities is unpredictable, typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the type, complexity and novelty of the product candidates involved. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions, which may cause delays in the approval or the decision not to approve an application. For example, FDA&#8217;s Oncology Center of Excellence initiated Project Optimus to reform the dose optimization and dose selection paradigm in oncology drug development and Project FrontRunner to help develop and implement strategies to support approvals in early clinical setting, among other goals. How the FDA plans to implement these goals and their impact on specific clinical programs and the industry are unclear. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data are insufficient for approval and require additional preclinical, clinical or other data. Even if we eventually complete clinical testing and receive approval for our product candidates, the FDA, EMA and other comparable foreign regulatory authorities may approve our product candidates for a more limited indication or a narrower patient population than originally requested or may impose other prescribing limitations or warnings that limit the product candidate&#8217;s commercial potential. We have not submitted for, or obtained, regulatory approval for any product candidate, and it is possible that none of our product candidates will ever obtain regulatory approval. Further, development of our product candidates and/or regulatory approval may be delayed for reasons beyond our control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Applications for our product candidates could fail to receive regulatory approval for many reasons, including the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, EMA or other comparable foreign regulatory authorities may disagree with the design, implementation or results of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, EMA or other comparable foreign regulatory authorities may determine that our product candidates are not safe and effective, are only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety in the full population for which we seek approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, EMA or other comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may be unable to demonstrate to the FDA, EMA or other comparable foreign regulatory authorities that a product candidate&#8217;s risk-benefit ratio for its proposed indication is acceptable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, EMA or other comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the FDA, EMA or other comparable regulatory authorities may fail to approve companion diagnostic tests required for our product candidates; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the approval policies or regulations of the FDA, EMA or other comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even if clinical trials are successfully completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. For example, although we have sought and received feedback from the FDA on the designs of our clinical trials and intend to continue to do so, the FDA may ultimately disagree that our trials support approval <span style="white-space:nowrap">for&#160;OKI-219.&#160;Moreover,</span> results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available, to conduct additional trials in support of potential approval of our product candidates. Even if we secure regulatory approval for any of our product candidates, the terms of such approval may limit the scope and use of the product candidate, which may also limit its commercial potential. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">incur unplanned costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be delayed in obtaining marketing approval for our product candidates or not obtain marketing approval at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain marketing approval in some countries and not in others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain marketing approval for indications or patient populations that are not as broad as intended or desired; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtain marketing approval with labeling that includes significant use or distribution restrictions or safety warnings, including boxed warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to additional post-marketing testing requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">be subject to changes in the way the product is administered; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">have regulatory authorities withdraw or suspend their approval of the product. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that our planned clinical trials or any other future clinical trials will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the FDA and other regulatory authorities may change their policies, issue additional regulations or revise existing regulations, or take other actions, such as those implemented by the Department of Government Efficiency, which may prevent or delay approval of our products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. In view of the overturning of the <span style="font-style:italic">Chevron </span>doctrine in <span style="font-style:italic">Loper Bright Enterprises v. Raimondo</span>, this Supreme Court decision may invite various stakeholders to bring lawsuits against the FDA to challenge longstanding decisions and policies. Additionally, changes in the leadership of the FDA and other federal agencies under the Trump administration may also lead to new policies and changes in the regulations and operations of the FDA, which may impact our clinical development plans. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion and pricing of the product candidate in those countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, the pricing of a prescription drug candidate is subject to regulatory approval before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and establishing and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any future collaborator fails to comply with the regulatory requirements in international markets or fails to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our potential product candidates will be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we experience delays or difficulties in the enrollment or retention of subjects in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Trials may be subject to delays as a result of patient withdrawal or patient enrollment taking longer than anticipated. We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of subjects to participate to such trials&#8217; conclusion as required by the FDA, EMA or other comparable foreign regulatory authorities. Patient enrollment is a significant factor in the timing of clinical trials. While our Phase 1 dose-escalation and expansion cohort <span style="white-space:nowrap"><span style="white-space:nowrap">trial,&#160;OKI-219-101,&#160;known</span></span> <span style="white-space:nowrap">as&#160;PIKture-01,&#160;has</span> begun enrollment, future difficulties we experience relating to enrollment in our clinical trials, or complications in <span style="white-space:nowrap">the&#160;PIKture-01&#160;trial</span> or future clinical trials, could delay regulatory approval <span style="white-space:nowrap">for&#160;OKI-219&#160;or</span> our future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patient enrollment may be affected if our competitors have ongoing clinical trials for product candidates that are under development for the same indications as our product candidates, and subjects who would otherwise be eligible for our clinical trials instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment for any of our future clinical trials may be affected by other factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">size and nature of the patient population, and process for identifying patients; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">severity and difficulty of diagnosing the condition under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">availability and efficacy of approved drugs and other competing therapeutic candidates for the condition under investigation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the eligibility and exclusion criteria for the trial in question as defined in the protocol; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to recruit clinical trial investigators with the appropriate competencies and experience; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the design of the clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">perceived risks and benefits of the product candidate under study; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">participants&#8217; perceptions as to the potential advantages of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">efforts to facilitate timely enrollment in clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">participant referral practices of doctors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the ability to monitor participants adequately during and after treatment; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">proximity and availability of clinical trial sites for prospective trial subjects; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">continued enrollment of prospective subjects by clinical trial sites; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risk that subjects enrolled in clinical trials will drop out of the trials before completion. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our inability to enroll a sufficient number of subjects for our clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates and jeopardize our ability to obtain marketing approval for the sale of our product candidates. Furthermore, we expect to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials, and we will have limited influence over their performance. Even if we are able to enroll a sufficient number of subjects for our clinical trials, we may have difficulty maintaining enrollment of such subjects in our clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our product candidates are associated with undesirable side effects or have unexpected characteristics in preclinical studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may harm our business, financial condition and prospects significantly. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patients in our ongoing and planned clinical trials may suffer significant adverse events or other side effects not observed in our preclinical studies or previous clinical trials. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments, which can cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our clinical trials. The inclusion of critically ill patients in our clinical trials may result in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#8217; illnesses. For example, it is expected that some of the patients enrolled in our clinical trials will die or experience major clinical events either during the course of our clinical trials or after participating in such trials. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, and </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">other comparable regulatory authorities or an IRB may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or maintaining </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could materially harm our business, financial condition and prospects. Further, if any of our product candidates obtains marketing approval, toxicities associated with such product candidates previously not seen during clinical testing may also develop after such approval and lead to a requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on preclinical studies or early-stage clinical trials. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will be required to demonstrate with substantial evidence through well controlled clinical trials that our product candidates are safe and effective for use in a diverse population before we can seek marketing approvals for their commercial sale. Success in preclinical studies and early-stage clinical trials does not mean that future clinical trials will be successful. For example, we previously decided to cease developing another product candidate, known <span style="white-space:nowrap">as&#160;OKI-179,&#160;despite</span> promising early data. In addition, in December 2024, we announced preliminary safety, tolerability and PK data from <span style="white-space:nowrap">PIKture-01,</span> with a cutoff date of October&#160;28, 2024, which supported our initiation of Part 1b of <span style="white-space:nowrap">PIKture-01.</span> These data are considered preliminary, and we plan to provide updated data in the second half of 2025. We cannot predict whether these updated data will be consistent with the preliminary data announced in December 2024, or whether the data from Part 1b of <span style="white-space:nowrap">PIKture-01</span> will be positive or consistent with our preliminary data from Part 1a of <span style="white-space:nowrap">PIKture-01.</span> If the updated data from Part 1a or the future data from Part 1b of <span style="white-space:nowrap">PIKture-01</span> are not positive or fail to support further advancement of <span style="white-space:nowrap">OKI-219,</span> we could experience volatility or a substantial decline in our stock price. Further, even if such data are positive, future clinical trials of <span style="white-space:nowrap">OKI-219</span> may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Product candidates in later-stage clinical trials may fail to demonstrate sufficient safety and efficacy to the satisfaction of the FDA and other comparable foreign regulatory authorities despite having progressed through preclinical studies and early-stage clinical trials. Regulatory authorities may also limit the scope of later-stage trials until we have demonstrated satisfactory safety, which could delay regulatory approval, limit the size of the patient population to which we may market our product candidates, or prevent regulatory approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In some instances, there can be significant variability in safety and efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial protocols, differences in size and type of the patient populations, differences in and adherence to the dose and dosing regimen and other trial protocols and the rate of dropout among clinical trial participants. Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and adversely impact, our clinical trial outcomes. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may also experience issues in conducting our clinical trials that would delay or prevent us from satisfying the applicable requirements of the FDA and other regulatory authorities, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inability to generate sufficient preclinical, toxicology, or other in vivo or in vitro data to support the initiation of clinical trials for any future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching agreement with the FDA or other regulatory authorities as to the design or implementation of our clinical trials; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining regulatory authorization to commence a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">delays in reaching, or failing to reach, agreement on acceptable terms with clinical trial sites or prospective CROs, the terms of which can be subject to extensive negotiation and may vary significantly among different clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">obtaining approval at each trial site; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">recruiting suitable patients to participate in a clinical trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">having patients complete a clinical trial or return for <span style="white-space:nowrap">post-treatment&#160;follow-up;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">inspections of clinical trial sites or operations by applicable regulatory authorities, or the imposition of a clinical hold; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical sites, CROs or other third parties deviating from trial protocol or dropping out of a trial; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to perform in accordance with applicable regulatory requirements, including the FDA&#8217;s current GCP requirements, or applicable regulatory requirements in other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">addressing patient safety concerns that arise during the course of a trial, including occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adding a sufficient number of clinical trial sites; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing sufficient quantities of product candidate for use in clinical trials; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspensions or terminations by IRBs of the institutions at which such trials are being conducted, or by the FDA or other regulatory authorities due to a number of factors, including those described above. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates or significantly increase the cost of such trials, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in regulatory requirements or guidance, or receive feedback from regulatory authorities that requires us to modify the design of our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon development programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the number of patients required for clinical trials may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we or our investigators might have to suspend or terminate clinical trials for various reasons, <span style="white-space:nowrap">including&#160;non-compliance&#160;with</span> regulatory requirements, a finding that a product candidate has undesirable side effects or other unexpected characteristics, or a finding that the participants are being exposed to unacceptable health risks; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of clinical trials may be greater than we anticipate and we may not have funds to cover the costs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the supply or quality of product candidates or other materials necessary to conduct clinical trials may be insufficient or inadequate; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulators may revise the requirements for approving our product candidates, or such requirements may not be as we anticipate; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any future collaborators that conduct clinical trials may face any of the above issues and may conduct clinical trials in ways they view as advantageous to them but that are suboptimal for us. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not know whether any clinical trials we may conduct will demonstrate efficacy and safety sufficient to obtain approval to market any of our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Interim, <span style="white-space:nowrap">initial,&#160;&#8220;top-line&#8221;&#160;and</span> preliminary data from clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may publicly disclose interim, preliminary <span style="white-space:nowrap">or&#160;top-line&#160;data</span> from our preclinical studies and clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their condition. Preliminary <span style="white-space:nowrap">or&#160;top-line&#160;data</span> also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim, preliminary <span style="white-space:nowrap">and&#160;top-line&#160;data</span> should be viewed with caution until the final data are available. We also make assumptions, estimations, and calculations, and draw conclusions, as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, <span style="white-space:nowrap">the&#160;top-line&#160;or</span> preliminary results that we report may differ from future results of the same studies or trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. For example, in December 2024, we announced preliminary safety, tolerability and PK data from <span style="white-space:nowrap">PIKture-01,</span> with a cutoff date of October&#160;28, 2024, which supported our initiation of Part 1b of <span style="white-space:nowrap">PIKture-01.</span> These data are considered preliminary, and we plan to provide updated data in the second half of 2025. We cannot predict whether these updated data will be consistent with the preliminary data announced in December 2024, or whether the data from Part 1b of <span style="white-space:nowrap">PIKture-01</span> will be positive or consistent with our preliminary data from Part 1a of <span style="white-space:nowrap">PIKture-01.</span> If the updated data from Part 1a or the future data from Part 1b of <span style="white-space:nowrap">PIKture-01</span> are not positive or fail to support further advancement of <span style="white-space:nowrap">OKI-219,</span> we could experience volatility or a substantial decline in our stock price. Further, even if such data are positive, future clinical trials of <span style="white-space:nowrap">OKI-219</span> may not be successful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program or the approvability or commercialization of the particular product candidate, and could have a material adverse effect on the success of our business. In addition, the information we choose to disclose publicly regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure. If the <span style="white-space:nowrap">interim,&#160;top-line&#160;or</span> preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates may be harmed, which could harm our business, results of operations, prospects or financial condition. Further, disclosure of <span style="white-space:nowrap">interim,&#160;top-line&#160;or</span> preliminary data by us or by our competitors could result in volatility in the price of our Class&#160;A Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As product candidates progress through preclinical and clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of product candidates and jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may develop programs in combination with other therapies, which exposes us to additional risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to <span style="white-space:nowrap">develop&#160;OKI-219,&#160;and</span> may develop any other product candidate we develop, in combination with one or more currently approved cancer therapies or therapies in development. Patients may not be able to tolerate our product candidates in combination with other therapies, or dosing of our product candidates in combination with other therapies may have unexpected consequences. Even if any of our product candidates were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to risks that the FDA or other comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidates, or safety, efficacy, manufacturing or supply issues could arise with these existing therapies. In addition, it is possible that existing therapies with which our product candidates may be approved for use could themselves fall out of favor or be relegated to later lines of treatment. This could result in the need to identify other combination therapies for our product candidates or our products being removed from the market or being less successful commercially. If the FDA or other comparable foreign regulatory authorities do not approve or revoke their approval of these other therapies, or if safety, efficacy, commercial adoption, manufacturing or supply issues arise with the therapies we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or successfully market any or all of the product candidates we develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies is prohibitive, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We face substantial competition which may result in others discovering, developing or commercializing products before or more successfully than we do. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. Product candidates that we successfully develop and commercialize may compete with existing therapies, and new therapies that may become available in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. As a result of these factors, our competitors may succeed in obtaining approval from the FDA, EMA or other comparable foreign regulatory authorities or in discovering, developing and commercializing product candidates in our field before we do. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are multiple PI3K&#945;-pathway targeted agents either approved or under clinical development that will potentially compete <span style="white-space:nowrap">with&#160;OKI-219&#160;and</span> our PI3K&#945;-targeted portfolio. Alpelisib (Piqray, a PI3K&#945;-selective inhibitor marketed by Novartis) and capivasertib (Truquap, an AKT1 inhibitor marketed by AstraZeneca) are marketed medicines, both of which are approved for the treatment of PI3K&#945;-mutated breast cancer patients in combination with the selective estrogen receptor degrader (&#8220;SERD&#8221;) fulvestrant. Additionally, the PI3K&#945;-selective inhibitor inavolisib (Itovebi<sup style="font-size:75%; vertical-align:top">TM</sup>) was recently approved in combination with the SERD fulvestrant and the CDK4/6 inhibitor palbociclib (Ibrance<sup style="font-size:75%; vertical-align:top">TM</sup>) in endocrine resistant HR+/Her2- locally advanced or metastatic breast cancer. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are also aware of several novel PI3K-targeted therapies that are in clinical development. This includes both multiple <span style="white-space:nowrap">non-mutation-selective</span> PI3K inhibitors (gedatolisib (Celcuity Inc.); MEN1611 (menarini) and <span style="white-space:nowrap">TOS-358</span> (Totus Medicines)) and inhibitors designed to have greater selectivity for mutated PI3K&#945;, including <span style="white-space:nowrap">RLY-2608</span> (Relay <span style="white-space:nowrap">Therapeutics),&#160;STX-473&#160;(Loxo</span> Oncology). Multiple other companies have disclosed or published research efforts in PI3K inhibitors that are at an early stage, but could potentially advance to the clinical trial stage. Finally, there are numerous other investigational therapies, spanning many modalities that are being evaluated preclinically and in clinical trials for breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer or more effective, have fewer or less severe side effects or are more convenient or less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we can, which could make our development more complicated or result in our competitors establishing a strong market position before we are able to enter the market. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Technological advances or products developed by our competitors may render our technologies or product candidates obsolete, less competitive or not economical. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our product candidates, if approved, could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even <span style="white-space:nowrap">if&#160;OKI-219&#160;or</span> any other product candidate receives marketing approval, they may fail to achieve market acceptance among physicians, patients, third-party payors and others in the medical community. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">If&#160;OKI-219&#160;or</span> any other product candidate that we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. The degree of market acceptance <span style="white-space:nowrap">of&#160;OKI-219&#160;or</span> any other product candidate that we develop, if approved for commercial sale, will depend on a number of factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the efficacy and potential advantages of our product candidates compared to alternative treatments, including the existing <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care;</span></span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to offer products for sale at competitive prices; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical indications for which the product is approved; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the use of product candidates in the labeling approved by regulatory authorities, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required of alternative treatments and competitor products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost of treatment in relation to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the convenience and ease of administration compared to alternative treatments; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the willingness of the target patient population to try new therapies and of doctors to prescribe these therapies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the strength of our marketing and distribution support; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of market introduction of competitive products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of an approved product candidate for use as a combination therapy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the potential for our competitors to limit our access to the market through anti-competitive contracts or other arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unfavorable publicity relating to our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the prevalence and severity of any side effects; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any restrictions on the use of our products together with other medications. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of our product candidates are approved but do not achieve an adequate level of market acceptance, we may not generate or derive sufficient revenue from that product candidate and our financial results could be negatively impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market our product candidates on acceptable terms, we may be unable to successfully commercialize our product candidates that obtain regulatory approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">If&#160;OKI-219&#160;or</span> another product candidate is approved, we must build marketing, sales, distribution, managerial and <span style="white-space:nowrap">other&#160;non-technical&#160;capabilities</span> or make arrangements with third parties to perform these services for each of the territories in which we intend to sell and market our product candidates. We may not be successful in accomplishing these required tasks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Establishing and building out an internal sales and marketing team with technical expertise and supporting distribution capabilities to commercialize our product candidates will be expensive and time-consuming and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution capabilities could adversely impact the commercialization of any of our product candidates that we obtain approval to market, if we do not have arrangements in place with third parties to provide such services on our behalf. Alternatively, if we choose to collaborate, either globally or on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;territory-by-territory&#160;basis,</span></span> with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize any of our product candidates that receive regulatory approval, or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with one or more third parties, our future product revenue will suffer, and we may incur significant additional losses. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, if approved. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product liability claims could delay or prevent completion of our development programs. If our product candidates are approved for marketing, such claims could still result in an FDA, EMA or other regulatory authority investigation of the safety and effectiveness of such products, our manufacturing processes and facilities or our marketing programs. These investigations could potentially lead to a recall of our products or more serious enforcement actions, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in injury to our reputation, withdrawal of clinical trial participants, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, initiation of investigations by regulators, substantial monetary awards to patients or other claimants, the inability to commercialize our product candidates and decreased demand for our product candidates, if approved for commercial sale. We currently have product liability insurance that we believe is appropriate for our stage of development and may need to obtain higher levels prior to marketing any of our product candidates, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities and, if judgments exceed our insurance coverage, could adversely affect our results of operations and business and cause the price of our Class&#160;A Common Stock to decline. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain or obtain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses, including those caused by product liability claims. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. Sales of any of our product candidates that receive marketing approval will depend substantially, both in the United States and internationally, on the extent to which the costs of such product candidates will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There is significant uncertainty related to third-party payor coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&#160;&amp; Medicaid Services (&#8220;CMS&#8221;), an agency within the U.S. Department of Health and Human Services (&#8220;HHS&#8221;). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#8217;s decisions regarding coverage and reimbursement to a substantial degree. However, one third-party payor&#8217;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. As a result, the coverage determination process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our products to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly challenging the price, examining the medical necessity and reviewing the cost effectiveness of medical product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which might not include <span style="white-space:nowrap">all&#160;FDA-approved&#160;drugs</span> for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our products. Nonetheless, our product candidates may not be considered cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Outside the United States, the commercialization of therapeutics is generally subject to extensive governmental price controls and other market regulations, and we believe that the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics such as our product candidates. In many countries, particularly the countries of the European Union, medical product prices are subject to varying price control mechanisms as part of national health systems. In these countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost effectiveness of a product candidate to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow companies to fix their own prices for products but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our products may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates from third-party payors, the adoption of those products and sales revenue will be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are developing regulatory strategies for our product candidates outside the United States and, accordingly, we expect that we or our partners would seek regulatory approval of our product candidates outside of the United States. As such, we expect that we will be subject to additional risks related to operating in foreign countries if we or such partners obtain the necessary approvals, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">differing regulatory requirements and drug pricing regimes in foreign countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">economic weakness, including inflation, or political instability in particular foreign economies and markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign taxes, including withholding of payroll taxes; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">difficulties staffing and managing foreign operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">workforce uncertainty in countries where labor unrest is more common than in the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential liability under the FCPA or comparable foreign regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">business interruptions resulting from geopolitical actions, including war and terrorism. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These and other risks associated with our international operations or those of any applicable international partners may materially adversely affect our ability to attain or maintain profitable operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, there is currently significant uncertainty about the future relationship between the United States and various other countries, most significantly China, with respect to trade policies, including sanctions, treaties, tariffs, taxes, regulatory requirements, and other limitations on cross-border operations. For example, the Trump administration has announced plans to significantly increase tariffs on foreign imports into the United States, particularly from Canada and Mexico, and has already increased tariffs on imports from China. The U.S. government has made and continues to make significant additional changes in U.S. trade policy and may continue to take future actions that could negatively impact U.S. trade. For example, legislation has been introduced in Congress to limit certain interactions with certain Chinese biotechnology companies. We cannot predict what actions may ultimately be taken with respect to trade relations between the United States and China </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or other countries, what interactions, including products or services, may be subject to such actions, or what actions may be taken by the other countries in retaliation. If our interactions with parties affected by any such actions are limited or no longer possible, our business, liquidity, financial condition, or results of operations could be materially and adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Intellectual Property </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to obtain and maintain sufficient intellectual property protection for our technology and products and product candidates we may develop, or if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, and our ability to successfully develop and, if approved, commercialize our product candidates may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely upon a combination of patents, trademarks, trade secret protection and confidentiality agreements to protect the intellectual property related to our development programs and product candidates. Our success depends in part on our ability to obtain and maintain patent protection in the United States and other countries with respect <span style="white-space:nowrap">to&#160;OKI-219&#160;and</span> any future product candidates. We seek to protect our proprietary position by filing patent applications in the United States and abroad related to our development programs, product candidates and novel discoveries that are important to our business. The patent prosecution process is expensive and time-consuming, and we may not be able to file, prosecute, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patents and patent applications that we own may fail to result in issued patents with claims that <span style="white-space:nowrap">protect&#160;OKI-219&#160;or</span> any future product candidate in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can prevent a patent from issuing from a pending patent application, or be used to invalidate a patent. Even if patents do successfully issue and even if such patents <span style="white-space:nowrap">cover&#160;OKI-219&#160;or</span> any future product candidate, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated or held unenforceable. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, the scope and coverage of such patents may be so narrow that a third party could successfully design around our patents without materially impacting the therapeutic effectiveness of the resulting drug product. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators will be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the United States Patent and Trademark Office (the &#8220;USPTO&#8221;) and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the USPTO requires us to disclose all material references to the patent examiner during prosecution of our patent applications, and failure to do so could result in a third party successfully challenging our ability to enforce a patent against an infringer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patent applications may not result in any patents being issued; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not provide any competitive advantage; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors, many of whom have substantially greater resources than we do and many of which have made significant investments in competing technologies, may seek or may have already obtained patents that will limit, interfere with or block our ability to make, use and sell our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for treatments of diseases or conditions that prove successful, as a matter of public policy regarding worldwide health concerns; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">countries other than the United States may have patent laws that are less favorable to patentees, allowing foreign competitors a better opportunity to create, develop and market competing products. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent prosecution process is also expensive and time consuming, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications or maintain or enforce patents that may issue based on our patent applications, at a reasonable cost or in a timely manner or in all jurisdictions where protection may be commercially advantageous. We may not be able to obtain or maintain patent applications and patents due to the subject matter claimed in such patent applications and patents in the public domain. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, if we choose to license certain patent rights in the future from third parties, we may not have the right to control the preparation, filing and prosecution of such patent applications, or to maintain the patents, directed to technology that we license from those third parties. We may also require the cooperation of our future licensor, if any, to enforce the licensed patent rights, and such cooperation may not be provided. Therefore, any licensed patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. We cannot be certain that patent prosecution and maintenance activities by any of our future licensors have been or will be conducted in compliance with applicable laws and regulations, which may affect the validity and enforceability of such patents or any patents that may issue from such applications. If they fail to do so, this could cause us to lose rights in any applicable intellectual property that <span style="white-space:nowrap">we&#160;in-license,&#160;and</span> as a result our ability to develop and commercialize products or product candidates may be adversely affected, and we may be unable to prevent competitors from making, using and selling competing products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the patent applications we hold or <span style="white-space:nowrap">may&#160;in-license&#160;in</span> the future with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity <span style="white-space:nowrap">for&#160;OKI-219&#160;or</span> any future product candidate, it could dissuade other companies from collaborating with us to develop product candidates, and threaten our ability to <span style="white-space:nowrap">commercialize&#160;OKI-219&#160;or</span> future product candidates. Any such outcome could have a materially adverse effect on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions, and has been and will continue to be the subject of litigation and new legislation, resulting in court decisions, including U.S. Supreme Court decisions, which have increased uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. Publications in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our own patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result of these and other factors, the issuance, scope, validity, enforceability, and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or products, in whole or in part, or that effectively prevent others from commercializing competitive technologies and products. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. For example, the America </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Invents Act created new administrative post-grant proceedings, including post-grant review, inter partes review and derivation proceedings that allow third parties to challenge the validity of issued patents. This applies to all of our U.S. patents, even those issued before March&#160;16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, we may be subject to a <span style="white-space:nowrap">third-party&#160;pre-issuance&#160;submission</span> of prior art to the USPTO or become involved in opposition, derivation, reexamination, inter partes review, post-grant review or interference proceedings challenging our patent rights or the patent rights of others. The costs of defending patents or enforcing proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize their technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents and patent applications may be challenged in the courts or patent offices in the United States and abroad. Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by third parties before various patent offices or in courts. An adverse decision in any such challenge may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Generally, issued patents are granted a term of 20 years from the earliest <span style="white-space:nowrap">claimed&#160;non-provisional&#160;filing</span> date. In certain instances, patent term can be adjusted to recapture a portion of delay incurred by the USPTO in examining the patent application (patent term adjustment). The scope of patent protection may also be limited. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Without patent protection for our current or future product candidates, we may be open to competition from generic versions of such products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, the term of a patent can be increased by patent term adjustment, which is based on certain delays caused </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by the USPTO, but this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. The term of a U.S. patent may also be shortened if the patent is terminally disclaimed over an earlier-filed patent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration and specifics of FDA marketing approval <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> future product candidates, one or more of our U.S. patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments. The Hatch-Waxman Amendments permit a patent restoration term of up to five years beyond the normal expiration of the patent as compensation for patent term lost during drug development and the FDA regulatory review process, which is limited to the approved indication (or any additional indications approved during the period of extension). This extension is based on the first approved use of a product and is limited to only one patent that covers the approved product, the approved use of the product or a method of manufacturing the product. Such patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. However, the applicable authorities, including the FDA and the USPTO in the United States and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. We may not be granted an extension because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to extend the expiration date of our existing patents or obtain new patents with longer expiry dates, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to obtain approval of competing products following our patent expiration and launch their product earlier than might otherwise be the case. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laws governing analogous patent term extension (&#8220;PTE&#8221;) in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family. Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, apply prior to expiration of relevant patents or otherwise satisfy applicable requirements. If we are unable to obtain PTE or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our products will be shortened and our competitors may obtain approval of competing products following our patent expiration and may take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and patent applications will be due to the USPTO and other foreign patent agencies in several stages over the lifetime of our patents and patent applications. The USPTO and various foreign national or international patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of patent rights include, but are not limited to, failure to timely file national and regional stage patent applications based on our international patent application, failure to respond to official actions within prescribed time limits, <span style="white-space:nowrap">non-payment</span> of fees and failure to properly legalize and submit formal documents. If we or any of our licensors fails to maintain the patents and patent applications <span style="white-space:nowrap">covering&#160;OKI-219&#160;or</span> any future product candidate, our competitors may be able to enter the market, which would have an adverse effect on our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the biopharmaceutical industry expands and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties. There can be no assurance that our operations do not, or will not in the future, infringe, misappropriate or otherwise violate existing or future third-party patents or other intellectual property rights. Identification of third-party patent rights that may be relevant to our operations is difficult because patent searching is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our current and future product candidates in any jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Numerous U.S. and foreign patents and pending patent applications exist in our market that are owned by third parties. Our competitors in both the United States and abroad, many of which have substantially greater resources and have made substantial investments in patent portfolios and competing technologies, may have applied for or obtained, or may in the future apply for and obtain, patents that will prevent, limit or otherwise interfere with our ability to make, use and sell our product candidates. We do not always conduct independent reviews of pending patent applications and patents issued to third parties. Patent applications in the United States and elsewhere are typically published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Certain U.S. applications that will not be filed outside the United States can remain confidential until patents issue. In addition, patent applications in the United States and elsewhere can be pending for many years before issuance, or unintentionally abandoned patents or applications can be revived. Furthermore, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. As such, there may be applications of others now pending or recently revived patents of which we are unaware. These patent applications may later result in issued patents, or the revival of previously abandoned patents, that may be infringed by the manufacture, use or sale of our product candidates or will prevent, limit or otherwise interfere with our ability to make, use or sell our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. For example, we may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party&#8217;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect, and our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our products. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in third-party claims of intellectual property infringement, which may delay or prevent the development and commercialization <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> any future product candidate. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our commercial success depends in part on us avoiding infringement and other violations of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, derivation and administrative law proceedings, inter partes review and post-grant review before the USPTO, as well as oppositions and similar processes in foreign jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights and who allege that our product candidates, uses and/or other proprietary technologies </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
infringe their intellectual property rights. Numerous U.S.- and foreign-issued patents and pending patent applications owned by third parties exist in the fields in which we and our collaborators are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, and as we gain greater visibility and market exposure as a public company, the risk increases that our product candidates or other business activities may be subject to claims of infringement of the patent and other proprietary rights of third parties. Third parties may assert that we are infringing their patents or employing their proprietary technology without authorization. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Also, there may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our current and future product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our current or future product candidates may infringe. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, third parties may obtain patent rights in the future and claim that use of our technologies infringes upon their rights. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process, methods of treating certain diseases or conditions that we are pursuing with our product candidates, our formulations including combination therapies, or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtain a license under the applicable patents, or until such patents expire. Such a license may not be available on commercially reasonable terms or at all. In addition, we may be subject to claims that we are infringing other intellectual property rights, such as trademarks or copyrights, or misappropriating the trade secrets of others, and to the extent that our employees, consultants or contractors use intellectual property or proprietary information owned by others in their work for us, disputes may arise as to the rights in related or <span style="white-space:nowrap">resulting&#160;know-how&#160;and</span> inventions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our current and future product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement or other intellectual property claim against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our affected products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize one or more of our product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our product candidates, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be diminished. Accordingly, the price of our Class&#160;A Common Stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, or the patents or other intellectual property rights of any licensors, which could be expensive, time-consuming, and unsuccessful. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Competitors may infringe or otherwise violate our patents or other intellectual property rights, or those of our licensors. To counter infringement or unauthorized use or misappropriations, we or any future licensors may be required to file legal claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents or any of our current or future licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our or our licensors&#8217; patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing. The initiation of a claim against a third party may also cause the third party to bring counter claims against us, such as claims asserting that our patents are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, <span style="white-space:nowrap">obviousness,&#160;non-enablement,&#160;insufficient</span> written description or failure to claim patent-eligible subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review or post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. The outcome following legal assertions of invalidity and unenforceability is unpredictable. In any patent infringement proceeding, there is a risk that a court will decide that a patent of ours or a future licensor is invalid or unenforceable, in whole or in part, and that we do not have the right to stop the other party from using the invention at issue. There is also a risk that, even if the validity of such patents is upheld, the court will construe the patent&#8217;s claims narrowly or decide that we do not have the right to stop the other party from using the invention at issue on the grounds that our or any future licensors&#8217; patent claims do not cover the invention, or decide that the other party&#8217;s use of our or any future licensors&#8217; patented technology falls under the safe harbor to patent infringement under 35 U.S.C. &#167;271(e)(1). An adverse outcome in a litigation or proceeding involving our or any future licensors&#8217; patents could limit our ability to assert our own or any future licensors&#8217; patents against those parties or other competitors and may curtail or preclude our ability to exclude third parties from making and selling similar or competitive products. Any of these occurrences could adversely affect our competitive position and our business, financial condition, results of operations and prospects. Similarly, if we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in question. In this case, we could ultimately be forced to cease use of such trademarks. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. For any patents and patent applications that we license from third parties, we may have limited or no right to participate in the defense of such licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our current or future product candidates. Such a loss of patent protection could harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail, and even if successful, may result in substantial costs and distract our management and other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we establish infringement, the court may decide not to grant an injunction against further infringing activity and instead award only monetary damages, which may or may not be an adequate remedy. Furthermore, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our Class&#160;A Common Stock. Moreover, we cannot assure you that we will have sufficient financial or other resources to file and pursue such infringement claims, which typically last for years before they are concluded. Even if we ultimately prevail in such claims, the monetary cost of such litigation and the diversion of the attention of our management and scientific personnel could outweigh any benefit we receive as a result of the proceedings. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the expense and uncertainty of litigation, we may conclude that even if a third party is infringing our patents, any patents that may be issued as a result of our future patent applications, or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in our best interest or that of our stockholders. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some <span style="white-space:nowrap">other&#160;non-litigious&#160;action</span> or solution. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining, defending, maintaining and enforcing patents in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time-consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents, and may diminish our ability to protect our inventions, obtain, maintain, enforce and protect our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our future owned and licensed patents. The United States has enacted and implemented wide-ranging patent reform legislation. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on actions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce patents that we have licensed or that we might obtain in the future. Similarly, changes in patent law and regulations in other jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. For example, the complexity and uncertainty of European patent laws have also increased in recent years. In Europe, a new unitary patent system took effect June&#160;1, 2023, which will significantly impact European patents, including those granted before the introduction of such a system. Under the unitary patent system, European applications have the option, upon grant of a patent, of becoming a Unitary Patent which will be subject to the jurisdiction of the Unitary Patent Court (the &#8220;UPC&#8221;). As the UPC is a new court system, there is no precedent for the court, increasing the uncertainty of any litigation. Patents granted before the implementation of the UPC have the option of opting out of the jurisdiction of the UPC over the first seven years of the court&#8217;s existence and remaining as national patents in the UPC countries. Patents that remain under the jurisdiction of the UPC will be potentially vulnerable to a <span style="white-space:nowrap">single&#160;UPC-based&#160;revocation</span> challenge that, if successful, could invalidate the patent in all countries that are signatories to the UPC. We cannot predict with certainty the long-term effects of any potential changes. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to protect our intellectual property rights throughout the world, which could impair our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Patents are of national or regional effect, and filing, prosecuting and defending patents covering <span style="white-space:nowrap">OKI-219</span> and any future product candidate throughout the world would be prohibitively expensive. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States, even in jurisdictions in which we do pursue patent protection. Consequently, we may not be able to prevent third parties from practicing our or any future licensors&#8217; inventions in all countries outside the United States, even in jurisdictions where we or any future licensors do pursue patent protection, or from selling or importing products made using our or any future licensors&#8217; inventions in and into the United States or other jurisdictions. Competitors may use our or any future licensors&#8217; technologies in jurisdictions where we have not obtained patent protection to develop our own products and, further, may export otherwise infringing products to territories where we may have or obtain patent protection, but where patent enforcement is not as strong as in the United States. These unauthorized competitors&#8217; products may compete with our products in such jurisdictions and take away our market share where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products. This could make it difficult for us to stop the infringement of our patents or the marketing of competing products in violation of our intellectual property and proprietary rights generally. In addition, certain jurisdictions do not protect to the same extent or at all inventions that constitute new methods of treatment. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws within the United States. We may need to share our trade secrets and proprietary <span style="white-space:nowrap">know-how</span> with current or future partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors and those affiliated with or controlled by state actors. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. In addition, some courts inside and outside of the United States may be less willing or unwilling to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. Even if we are successful, such lawsuits would consume our time and other resources. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the protection afforded by patents, we may seek to rely on trade secret protection to protect <span style="white-space:nowrap">proprietary&#160;know-how&#160;that</span> is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve <span style="white-space:nowrap">proprietary&#160;know-how,&#160;information</span> or technology that is not covered by our patents. We may not be able to meaningfully protect our trade secrets. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any third parties who have access to our <span style="white-space:nowrap">proprietary&#160;know-how,&#160;information</span> or </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed to our competitors or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws within the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because we expect to rely on third parties to <span style="white-space:nowrap">manufacture&#160;OKI-219&#160;and</span> any future product candidates, and we expect to collaborate with third parties on the continuing development <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> any future product candidates, we must, at times, share trade secrets with them. We also expect to conduct R&amp;D programs that may require us to share trade secrets under the terms of our partnerships or agreements with CROs. We seek to protect our proprietary technology in part by entering into agreements containing confidentiality and use restrictions and obligations, including material transfer agreements, consulting agreements, manufacturing and supply agreements, confidentiality agreements or other similar agreements with our advisors, employees, contractors, contract manufacturing organizations (or &#8220;CMOs&#8221;), CROs, other service providers and consultants prior to disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are intentionally or inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on <span style="white-space:nowrap">our&#160;know-how&#160;and</span> trade secrets, a competitor&#8217;s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors CMOs, CROs, other service providers and consultants to publish data potentially relating to our trade secrets, although such agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover such trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#8217;s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Monitoring unauthorized disclosure and detection of unauthorized disclosure is difficult, and we do not know whether the steps we have taken to prevent such disclosure are, or will be, adequate. If we were to enforce a claim that a third party had illegally obtained and was using our trade secrets, it would be expensive and time-consuming, and the outcome would be unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are successful. For example, significant elements of our products, including confidential aspects of sample preparation, methods of manufacturing, and related processes and software, are based on unpatented trade secrets. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may become subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We employ individuals who were previously employed at other biotechnology or pharmaceutical companies, or at research institutions, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information <span style="white-space:nowrap">or&#160;know-how&#160;of</span> others in their work for us, we may become subject to claims that these individuals have or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of such individual&#8217;s current or former employer. Further, although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators, and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. An inability to incorporate such technologies or features would harm our business and may prevent us from successfully commercializing our technologies or product candidates. In addition, we may lose personnel as a result of such claims, and any such litigation, or the threat thereof, may adversely affect our ability to hire employees or contract with independent contractors. A loss of key personnel or their work product could hamper or prevent our ability to commercialize our technologies or product candidates, which could adversely affect our business, financial condition, results of operations and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may also be subject to claims that former employers, consultants or other third parties have an ownership interest in our patents or patent applications as an inventor <span style="white-space:nowrap">or&#160;co-inventor.&#160;The</span> failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions <span style="white-space:nowrap">regarding&#160;co-ownership&#160;of</span> potential joint inventions. Litigation may be necessary to resolve these and other claims challenging inventorship and/or ownership. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such challenges may also result in our inability to develop, manufacture or commercialize our technologies and product candidates without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future technologies and product candidates. Even if we are successful, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If our future trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest, and our business may be adversely affected. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or foreign agencies. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, which may not survive such proceedings. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">37 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to those of ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely affect our financial condition or results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, any proprietary name we propose to use with our current or future product candidates in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our intellectual property rights do not necessarily address all potential threats to our competitive advantage. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business or permit us to maintain our competitive advantage. The following examples are illustrative: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make formulations or compositions that are the same as or similar to our current or future product candidates, but that are not covered by the pending patent applications or patents that we own or any pending patent applications or patents that we <span style="white-space:nowrap">may&#160;in-license&#160;in</span> the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may be able to make products that are similar to our current or future product candidates, but that are not covered by the patents that we own or exclusively license and have the right to enforce; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our future licensors or collaborators, may not have been the first to make the inventions covered by the issued patents or pending patent applications that we own or <span style="white-space:nowrap">may&#160;in-license&#160;in</span> the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we, or our future licensors, may not have been the first to file patent applications covering certain of our or those licensors&#8217; inventions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing or otherwise violating our owned intellectual property rights or any patent applications that we may license in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">it is possible that our pending patent applications or those that we may own or license in the future will not lead to issued patents; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we either own or that we may license in the future may be revoked, modified or held valid or unenforceable, as a result of legal challenges by our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issued patents that we either own or may license in the future may not provide us with any competitive advantages; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">others may have access to the same intellectual property rights licensed to us in the future on a non-exclusive basis; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our competitors may conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not develop additional proprietary technologies that are patentable; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we cannot predict the scope of protection of any patent issuing based on our or any future licensors&#8217; patent applications, including whether the patent applications that we own or, in the future, <span style="white-space:nowrap">in-license,</span> will result in issued patents with claims directed to our product candidates or uses thereof in the United States or in other foreign countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a court may not hold that our patents are valid, enforceable or infringed; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may need to initiate litigation or administrative proceedings to enforce or defend our patent rights, which will be costly whether we win or lose; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may choose not to file a patent application in order to maintain certain trade secrets or <span style="white-space:nowrap">know-how,</span> and a third party may subsequently file a patent application covering such intellectual property; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may fail to adequately protect and police our trademarks and trade secrets; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the patents of others may have an adverse effect on our business, including if others obtain patents claiming subject matter similar to or improving the subject matter covered by our patent applications. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Any collaboration or partnership arrangements that we may enter into in the future may not be successful, which could adversely affect our ability to develop and commercialize our products. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future collaborations that we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborations are subject to numerous risks, which may include that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators have significant discretion in determining the efforts and resources that they will apply to collaborations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may not pursue development and commercialization of our products or may elect not to continue or renew development or commercialization programs based on trial or test results, changes in our strategic focus due to the acquisition of competitive products, availability of funding or other external factors, such as a business combination that diverts resources or creates competing priorities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator with marketing, manufacturing and distribution rights to one or more products may not commit sufficient resources to or otherwise not perform satisfactorily in carrying out these activities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we could grant exclusive rights to our collaborators that would prevent us from collaborating with others; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disputes may arise between us and a collaborator that cause the delay or termination of the research, development or commercialization of current or future product candidates or that results in costly litigation or arbitration that diverts management attention and resources; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborations may be terminated, and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable current or future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">collaborators may own <span style="white-space:nowrap">or&#160;co-own&#160;intellectual</span> property covering our products that results from our collaborating with them, and in such cases, we would not have the exclusive right to develop or commercialize such intellectual property; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a collaborator&#8217;s sales and marketing activities or other operations may not be in compliance with applicable laws resulting in civil or criminal proceedings. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with our obligations under any license, collaboration or other agreement, such agreements may be terminated, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our product candidates. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may license or otherwise acquire development or commercialization rights to current and future product candidates or data from third parties. If any future licensors fail to prosecute, maintain, enforce and defend such patents, or lose rights to those patents, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize future product candidates that may be subject of such licensed rights could be adversely affected. In spite of our efforts, any future licensors might conclude that we are in material breach of obligations under our license agreements. If we breach any material obligations, or use the intellectual property licensed to us in an unauthorized manner, we may be required to pay damages and the licensor may have the right to terminate the license, which could result in us being unable to develop, manufacture and sell products that are covered by the licensed technology or enable a competitor to gain access to the licensed technology. If <span style="white-space:nowrap">such&#160;in-licenses&#160;are</span> terminated, or if the underlying patents fail to provide the intended exclusivity, our competitors will have the freedom to seek regulatory approval of, and to market, products identical to our product candidates, and the licensors to <span style="white-space:nowrap">such&#160;in-licenses&#160;could</span> prevent us from developing or commercializing product candidates that rely upon the patents or other intellectual property rights which were the subject matter of such terminated agreements. Any of these events could adversely affect our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disputes may arise between us and our licensors regarding intellectual property subject to a license agreement, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope of rights granted under the license agreement and other interpretation-related issues; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">either party&#8217;s financial or other obligations under the license agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to sublicense patents and other rights under our collaborative development relationships to third parties; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our right to transfer or assign the license; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inventorship or ownership of inventions <span style="white-space:nowrap">and&#160;know-how&#160;resulting</span> from the joint creation or use of intellectual property by any of our licensors and us and our partners; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the priority of invention of patented technology. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If disputes over intellectual property that we license prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the affected product candidates, which would have a material adverse effect on our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, certain of our current or future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, we or our current or future licensors may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, ownership, claim scope or requests for patent term adjustments. If our current or future licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution or enforcement of our patents or patent applications, such patents may be invalid or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, even where we have the right to control patent prosecution of patents and patent applications under a license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our acquired technologies and current or future licensed technology may be subject to retained rights. Our predecessors or licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or future licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are limited in our ability to utilize acquired technologies or current or future licensed technologies, or if we lose our rights to critical acquired <span style="white-space:nowrap">or&#160;in-licensed&#160;technology,</span> we may be unable to successfully <span style="white-space:nowrap">develop,&#160;out-license,&#160;market</span> and sell our products. Our business strategy may depend on the successful development of acquired technologies, and current or future licensed technology, into commercial products. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, <span style="white-space:nowrap">out-license</span> or market and sell our product candidates. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may not be able to license or acquire new or necessary intellectual property rights or technology from third parties. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to <span style="white-space:nowrap">acquire,&#160;in-license&#160;or</span> use these third-party proprietary rights. Further, other parties, including our competitors, may have patents and have filed and are likely filing patent applications potentially relevant to our business. In order to avoid infringing these patents, we may find it necessary or prudent to obtain licenses to such patents from such parties. The licensing or acquisition of intellectual property rights is a competitive area, and several more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. No assurance can be given that we will be <span style="white-space:nowrap">successful&#160;in-licensing&#160;any</span> additional rights or technologies from third parties. Our inability to license the rights and technologies that we have identified, or that we may in the future identify, could have a material adverse impact on our ability to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
complete the development of our product candidates or to develop additional product candidates. Even if we were able to obtain a license, it could <span style="white-space:nowrap">be&#160;non-exclusive,&#160;thereby</span> giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. Failure to obtain any necessary rights or licenses may detrimentally affect our planned development of our current or future product candidates and could increase the cost and extend the timelines associated with the development of such other product candidates, and we may have to abandon development of the relevant program or product candidate. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may enter into license agreements in the future with others to advance our existing or future research or allow commercialization of our existing or future product candidates. These licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and product candidates in the future. In that event, we may be required to expend significant time and resources to redesign our product candidates, or the methods for manufacturing them, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business, financial condition, results of operations and prospects significantly. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or product candidates, resulting in either an injunction prohibiting their manufacture or future sale or, with respect to their future sale, an obligation on our part to pay royalties or other forms of compensation to third parties, which could be significant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Regulatory Approval and Other Legal Compliance Matters </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory oversight, which may result in significant additional expense, and we may experience unanticipated problems with our product candidates or be subject to penalties if we fail to comply with regulatory requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even if we obtain regulatory approval for one or more of our product candidates, such product candidates will be subject to ongoing regulatory requirements applicable to manufacturing, labeling, packaging, storage, advertising, promoting, sampling, record-keeping and submission of safety or other post-market information, among other things. Any regulatory approvals that we receive for our product candidates will require surveillance to monitor safety and efficacy. The FDA may also require a REMS, limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or requirements that we conduct potentially costly post-market testing and surveillance studies, including Phase 4 trials and surveillance to monitor the quality, safety and efficacy of the product candidate. An unsuccessful post-marketing study or failure to complete such a study could result in requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools as conditions of approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any new legislation addressing drug safety issues could result in delays in product development or commercialization or increased compliance costs. We must also comply with requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drug products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. As such, we will not be allowed to promote our products for indications or uses for which they do not have approval, commonly known <span style="white-space:nowrap">as&#160;off-label&#160;promotion.</span> The holder of an approved NDA must submit new or supplemental applications and obtain prior approval for certain changes to the approved product, product labeling or manufacturing process. A company that is found to have improperly promoted <span style="white-space:nowrap">off-label</span> uses of our products may be subject to significant civil, criminal and administrative penalties. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, drug manufacturers are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with FDA&#8217;s current Good Manufacturing </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Practices (&#8220;cGMPs&#8221;) and adherence to commitments made in the NDA or foreign marketing application. If we, the FDA or a comparable foreign regulatory authority discovers previously unknown problems with our product candidates, such as adverse events of unanticipated severity or frequency, or problems with the facility where the drug was manufactured, or if a regulatory authority disagrees with the promotion, marketing or labeling of that drug, a regulatory authority may impose restrictions relative to that drug, the manufacturing facility or us, including requesting a recall or requiring withdrawal of the drug from the market or suspension of manufacturing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure by us to comply with applicable regulatory requirements following approval of any product candidates may result in, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">manufacturing delays and supply disruptions where regulatory inspections identify observations of noncompliance requiring remediation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">revisions to the labeling, including limitation on approved uses or the addition of additional warnings, contraindications or other safety information, including boxed warnings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">imposition of a REMS, which may include distribution or use restrictions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">requirements to conduct additional post-marketing clinical trials to demonstrate the safety of the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or withdrawal of regulatory approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuance of fines, untitled letters, warning letters or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal by regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of a product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. It is difficult to predict how current and future legislation, executive actions and litigation, including the executive orders, will be implemented, and the extent to which they will impact our business and clinical development, and the FDA&#8217;s and other agencies&#8217; ability to exercise their regulatory authority, including the <span style="white-space:nowrap">FDA&#8217;s&#160;pre-approval&#160;inspections</span> and timely review of any regulatory filings or applications we submit to the FDA. To the extent any executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Disruptions at the FDA, the SEC or other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of user fees, statutory, regulatory and policy changes, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Changes in the leadership of the FDA and other federal agencies under the Trump administration, as well as policy changes including <span style="white-space:nowrap"><span style="white-space:nowrap">return-to-office</span></span> directives, hiring freezes, and layoffs, may also lead to changes in the operations of the FDA, which may have a material impact on the industry. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. If a prolonged government shutdown or other disruption occurs, or if global health or other concerns prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities in a timely manner, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns or delays could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Separately, in response to <span style="white-space:nowrap">the&#160;COVID-19&#160;pandemic,</span> the FDA announced its intention to postpone most inspections of foreign and domestic manufacturing facilities at various points. Even though the FDA has since resumed standard inspection operations of domestic facilities, if a prolonged government shutdown occurs, either for global health related reasons or other reasons, preventing the FDA or other regulatory authorities from conducting business as usual or conducting inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material effect on our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may face difficulties from changes to current regulations and future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The United States and many foreign jurisdictions have enacted or proposed legislative and regulatory changes affecting the healthcare system that could prevent or delay marketing approval of our product candidates or any future product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell a product for which we obtain marketing approval. Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes to our manufacturing arrangements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additions or modifications to product labeling; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recall or discontinuation of our products; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">additional record-keeping requirements. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad, including as a result of the new presidential administration. Any such changes imposed on us could adversely affect the operation of our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (as amended, the &#8220;ACA&#8221;), was passed, which substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacted the U.S. pharmaceutical industry. The ACA contained provisions that may reduce the profitability of drug products through, among other things, increased rebates for drugs reimbursed by Medicaid programs, extension of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. In August 2022, Congress passed the Inflation Reduction Act of 2022 (the &#8220;IRA&#8221;), which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including among other changes allowing the federal government to negotiate a maximum fair price for certain high-priced single-source Medicare drugs, imposing penalties and excise taxes for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to <span style="white-space:nowrap"><span style="white-space:nowrap">reduce&#160;out-of-pocket&#160;prescription</span></span> drug costs for beneficiaries. HHS has issued and will continue to issue and update guidance as these programs are implemented. Only high-expenditure, single-source drugs that have been approved for at least seven years (11 years for single-source biologics) qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, CMS selected 10 high-cost Medicare Part D drugs in 2023 and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected. However, various industry stakeholders, including pharmaceutical companies, the U.S. Chamber of Commerce and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges, as well as future legislative, executive and administrative actions and any future healthcare measures and agency rules implemented by the government on us and the pharmaceutical industry as a whole, is difficult or impossible to predict. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates if approved. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control prescription drug pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some cases, designed to encourage bulk purchasing and importation from other countries. A number of states are considering or have recently enacted drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our revenue prospects could be affected by changes in healthcare spending and policy in the United States and abroad. We operate in a highly regulated industry, and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict what initiatives may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare or impose price controls may adversely affect: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the demand for our product candidates, if we obtain regulatory approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to set a competitive price that we believe is fair for our products; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to generate revenue and achieve or maintain profitability; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the level of taxes that we are required to pay; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the availability of capital. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The implementation of cost containment measures or other healthcare reforms may lower the pricing of competitor products or procedures, which in turn may constrain the pricing of our product candidates, if approved, and prevent us from being able to generate revenue, attain profitability or commercialize our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure to what extent these legislative and regulatory proposals will be implemented by the federal and state governments, whether additional legislative changes will be enacted, whether FDA regulations, guidance or interpretations will be changed or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws and health information privacy and security laws, which could expose us to, among other things, criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare professionals, clinical investigators, CROs and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we plan to market, sell and distribute products for which we obtain marketing approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Laws that may affect our ability to operate include, but are not limited to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal AKS, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Violations are subject to civil and criminal fines and penalties, plus up to three times the remuneration involved, imprisonment and exclusion from government healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal civil and criminal false claims laws, including the FCA, which can be enforced through civil &#8220;qui tam&#8221; or &#8220;whistleblower&#8221; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting or causing to be presented claims for payment or approval from Medicare, Medicaid or other federal health care programs that are false or fraudulent; knowingly making or causing a false statement material to a false or fraudulent claim or an obligation to pay money to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing such an obligation. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. In addition, the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
fraudulent claim for purposes of the FCA. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery. When an entity is determined to have violated the federal civil FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, which created new federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the AKS, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans and healthcare clearinghouses as well as their respective business associates and their subcontractors that perform services for them that involve the use, or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the federal Physician Payments Sunshine Act, created under the ACA and its implementing regulations, which requires manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to payments or other transfers of value made to covered recipients, including physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), <span style="white-space:nowrap">certain&#160;non-physician&#160;healthcare</span> professionals (such as physician assistants and nurse practitioners, among others) and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">analogous and related state and foreign laws and regulations, such as state and foreign anti-kickback, false claims, consumer protection and unfair competition laws that may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government that otherwise restricts payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and marketing information, such as the tracking and reporting of gifts, compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Because of the breadth of these laws and the narrowness of available statutory exceptions and regulatory safe harbors, it is possible that some of our business activities, including our advisory board arrangements with physicians and any sales and marketing activities after a product candidate has been approved for marketing in the United States, could be subject to legal challenge and enforcement actions. If our operations are found to be in violation of any of the federal and state laws described above or any other governmental regulations that apply to us, we may be subject to significant civil, criminal and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations <span style="white-space:nowrap">of&#160;non-compliance&#160;with</span> these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are exposed to the risk that our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities. Misconduct by these parties could include failures to comply with FDA regulations, provide accurate information to the FDA, comply with federal and state health care fraud and abuse laws and regulations, accurately report financial information or data or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the health care industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Misconduct by these parties could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct by these parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological and radioactive materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological, or hazardous materials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, we may incur substantial costs to comply with current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations and can face serious consequences for violations. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, corrupt or improper payments or anything else of value to or from recipients in the public or private sector. Violations of such trade laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect <span style="white-space:nowrap">our&#160;non-U.S.&#160;activities</span> to increase in time. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations and other regulatory approvals, and we may be held liable for the corrupt or other illegal activities of our personnel, agents or partners even if we do not explicitly authorize or have prior knowledge of such activities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Restrictive laws and regulations govern the collection, use, transfer, and other processing of personal information.<sup style="font-size:75%; vertical-align:top"> </sup> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In conducting and enrolling patients in current or future clinical trials, we are subject to restrictions relating to privacy, data protection, and cybersecurity, and may be subject to additional restrictions associated with clinical operations in the future. For example, the collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the EU, including personal health data, is subject to the General Data Protection Regulation (&#8220;GDPR&#8221;), which is wide-ranging in scope and imposes numerous requirements on companies that process personal data. The GDPR permits data protection authorities to impose large penalties for violations, including potential fines of up to &#8364;20&#160;million or 4% of annual global revenues, whichever is greater, for the most serious violations. The GDPR also confers a private right of action on data subjects and consumer associations. Certain aspects of cross-border data transfers under the GDPR are uncertain as the result of legal proceedings in the EU, including a July 2020 decision by the Court of Justice for the European Union (&#8220;CJEU&#8221;) that invalidated the <span style="white-space:nowrap">EU-U.S.</span> Privacy Shield and called into question the efficacy and legality of using standard contractual clauses (&#8220;SCCs&#8221;). To address certain concerns of the CJEU, the European Commission issued revised SCCs in June 2021. The EU also has enacted numerous new laws and regulations addressing cybersecurity. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United Kingdom (&#8220;UK&#8221;), the Data Protection Act of 2018 implements and complements the GDPR and is effective along with a version of the GDPR referred to as the UK GDPR. These regimes authorize significant fines, up to the greater of &#163;17.5&#160;million or 4% of global turnover, and expose us to two parallel regimes and potentially divergent enforcement actions. Further, aspects of data protection in the UK remain uncertain. On June&#160;28, 2021, the European Commission issued an adequacy decision pursuant to which personal data generally may be transferred from the EU to the UK without restriction; however, this adequacy decision is subject to a four-year &#8220;sunset&#8221; period, after which it may be renewed. This decision may be revoked or modified at any time. Additionally, the UK&#8217;s Information Commissioner&#8217;s Office has issued standard contractual clauses to support personal data transfers out of the UK (&#8220;UK SCCs&#8221;). Regulatory guidance and other developments relating to cross-border personal data transfers, including the necessity of putting in place SCCs and UK SCCs, may increase the complexity of transferring personal data across borders and may require us to engage in additional contractual negotiations or to modify our policies and practices. Other jurisdictions also increasingly maintain laws and regulations addressing privacy, data protection, and cybersecurity. We may incur liabilities, expenses, and other operational losses under the GDPR and local laws of applicable EU member states, the UK, and other regions in connection with any measures we take to comply with them. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">49 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, in addition to HIPAA, HITECH, and state laws addressing health-related information, numerous federal and state laws and regulations govern the collection, use, disclosure, and other processing of information relating to individuals. In California, the California Consumer Privacy Act (&#8220;CCPA&#8221;) requires covered companies to provide disclosures to consumers about such companies&#8217; data collection, use and sharing practices, provide such consumers ways to <span style="white-space:nowrap">opt-out</span> of certain sales or transfers of personal information, and provide consumers with additional causes of action in data breach situations. The CCPA went into effect on January&#160;1, 2020, and was modified significantly by the California Privacy Rights Act (&#8220;CPRA&#8221;), which was approved by California voters in the 2020 election and became effective January&#160;1, 2023. The CCPA has prompted numerous proposals for federal and state privacy legislation. Numerous U.S. states have proposed, and in certain cases enacted, laws addressing privacy and cybersecurity matters. Many of these laws are comprehensive privacy statutes imposing obligations similar to the CCPA. Certain U.S. states have also enacted laws and regulations addressing specific subject matter, such as Washington State&#8217;s My Health, My Data Act which, among other things, provides for a private right of action. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Compliance with U.S. and international laws and regulations relating to privacy, data protection, and cybersecurity could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use, and disclose data, or, in some cases, impact our ability to operate in certain jurisdictions, and may increase our costs of doing business or require us to change our policies and practices. Any actual or alleged failure to comply with U.S. or international laws and regulations relating to privacy, data protection, or cybersecurity could result in governmental investigations, proceedings, and enforcement actions (which could include civil or criminal penalties), private litigation, adverse publicity, and harm to our reputation, and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose such information or impose other obligations or restrictions in connection with our use, retention, or other processing of information, and we may otherwise face contractual restrictions applicable to these activities. Claims that we have violated individuals&#8217; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Reliance on Third Parties </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct, supervise and monitor certain aspects of our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements and meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have relied upon, and plan to continue to rely upon, third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our preclinical studies and clinical trials and to monitor and manage data for our ongoing clinical programs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We rely on these parties for execution of our trials and generally do not control their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable clinical investigation plan and protocol as well as legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities, for all of our products candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties or CROs fails to comply with applicable GCPs, the clinical data may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">50 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, these investigators and CROs are not our employees, and we will not be able to control, other than by contract, the amount of resources, including time, which they devote to our product candidates and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of our product candidates, or if CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, our results of operations and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In many cases, our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are liquidated. If any of our relationships with these third parties terminates, we may not be able to timely enter into arrangements with alternative third parties or to do so on commercially reasonable terms, if at all. Switching or adding CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We contract with third parties for the manufacture of our product candidates for preclinical studies and clinical trials, and expect to continue to do so for additional clinical trials and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in development and commercialization and do not intend to develop such infrastructure and capabilities. We rely, and expect to continue to rely, on third party manufacturers for the production of our product candidates for preclinical studies and clinical trials under the guidance of members of our organization. Furthermore, we rely on single-source suppliers for our drug substance manufacturing (PharmaBlock Sciences (Nanjing), Inc.) and for our drug product manufacturing (STA Pharmaceutical Hong Kong Limited). We have entered into a master services agreement with each of these service providers; however, under the terms of the master services agreements, the service provider is not obligated to enter into any particular statement of work and there is <span style="white-space:nowrap">no&#160;pre-determined&#160;pricing</span> for the manufacturing services. If we were to experience an unexpected loss of supply of any of our product candidates or any of our future product candidates for any reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing preclinical studies and clinical trials. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">51 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to continue to rely on third-party manufacturers for the commercial supply of any of our product candidates for which we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of their agreements with us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or inconvenient for us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the breach by the third-party contractors of their agreements with us; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure of third-party contractors to comply with applicable regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the failure of third parties to manufacture product candidates according to our specifications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or placebo not being properly identified; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the misappropriation of our proprietary information, including our trade secrets <span style="white-space:nowrap">and&#160;know-how.</span> </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not have complete control over all aspects of the manufacturing process of, and are dependent upon, our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA, EMA or others, we will not be able to secure and/or maintain marketing approval for our manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA, EMA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates or drugs and harm our business and results of operations. Our current and anticipated future dependence upon others for the manufacture of our product candidates or drugs may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on a timely and competitive basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo thorough testing for identity, strength, quality, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">52 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
purity, potency and stability. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary. Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage, shipping, quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the manufacturing process, we may be required to provide preclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are discovered at the facilities of our manufacturers, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and adversely harm our business. If our manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would have an adverse effect on our business, financial condition, results of operations and growth prospects. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Our Business Operations </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To succeed, we must recruit, retain, manage and motivate qualified executives, and we face significant competition for experienced personnel. We are highly dependent on the principal members of our management and need to add executives with operational and commercialization experience as we plan for commercialization of our product candidates and operations as a public company. Failure to attract and retain qualified personnel, particularly at the management level, could adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The competition for qualified personnel in the biotechnology field is intense and, as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have difficulty attracting experienced personnel and may be required to expend significant financial resources in employee recruitment and retention efforts. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited, and the potential for successfully growing our business will be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we engage in <span style="white-space:nowrap">acquisitions,&#160;in-licensing&#160;or</span> strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities and subject us to other risks. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may engage in various acquisitions and strategic partnerships in the future, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any acquisition or strategic partnership may entail numerous risks, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">increased operating expenses and cash requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the assumption of indebtedness or contingent liabilities; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the issuance of equity securities resulting in dilution to our stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assimilation of operations, intellectual property, products and product candidates of an acquired company, including difficulties associated with integrating new personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the diversion of management&#8217;s attention from our existing product candidates and initiatives in pursuing such an acquisition or strategic partnership; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">53 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">loss of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">uncertainties in our ability to maintain key business relationships; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and our existing products or product candidates; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our inability to generate revenue from acquired intellectual property, technology or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, if we undertake such a transaction, we may incur <span style="white-space:nowrap">large&#160;one-time&#160;expenses</span> and acquire intangible assets that could result in significant future amortization expense. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our internal computer systems, or those of any of our CROs, manufacturers, other contractors or consultants, or potential future collaborators, may fail or suffer actual or suspected security or privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, significant liabilities, harm to our brand and material disruption of our operations, and potentially significant delays in our delivery to market. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Despite the implementation of security measures in an effort to protect systems that store our information, given their size and complexity and the increasing amounts of information maintained on our internal information technology systems and external processing and storage (e.g., cloud) systems, and those of our third-party CROs, other contractors (including sites performing our current or future clinical trials), consultants and other third-party service providers, these systems are potentially vulnerable to breakdown or other damage or interruption. Our systems and the systems of third parties who support our operations are vulnerable to service interruptions, system malfunction, natural disasters, terrorism, war (such as the ongoing conflicts in the Middle East and between Ukraine and Russia), and telecommunication and electrical failures, as well as security breaches and incidents arising from or caused by inadvertent or intentional actions by our employees, contractors, consultants, business partners, or other third parties, or from cyberattacks by malicious third parties (including the deployment of harmful malware, ransomware, <span style="white-space:nowrap"><span style="white-space:nowrap">denial-of-service</span></span> attacks, social engineering, and other means to affect service reliability and threaten the confidentiality, integrity, or availability of information), which may compromise our system infrastructure or lead to unauthorized access to or disruption of our or third-party systems and the unauthorized access to, misuse, disclosure, loss, destruction, alteration or dissemination of, or damage to, our data, including trade secrets or other confidential information, intellectual property, proprietary business information, and personal information. For example, companies have experienced an increase in phishing and social engineering attacks in recent years. Our employees generally work in a hybrid model in our office<span style="text-decoration:line-through">s</span> and from home, and we may need to adjust our working model from time to time. As a result, we may have increased cyber security and data security risks, due to increased use of home <span style="white-space:nowrap">wi-fi</span> networks and virtual private networks. While we implement controls to reduce the risk of a resulting cyber security or data security incident or breach, we may experience data security incidents, and there is no guarantee that the measures we have implemented will be adequate to safeguard all systems and data, especially with some employees working from home or in a hybrid model where it is more difficult for us to monitor. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any disruption, security incident, or security breach resulting in any loss, destruction, unavailability, alteration or dissemination of, or damage to, our data (including confidential information) or other data we or any of our CROs, other contractors, consultants, potential future collaborators, or other third-party service providers maintain or otherwise process, or our applications, or for it to be believed or reported that any of these occurred, could result in us incurring liability and reputational damage, and the development and commercialization of our product candidates could be delayed. For example, if a security incident were to cause interruptions in our operations, it could result in a material disruption of our programs and the development of our product candidates could be delayed. In addition, the loss or unavailability of clinical trial data for our product candidates could result in delays in our marketing approval efforts and result in us incurring significant costs to recover or reproduce the data. Furthermore, disruptions of our internal information technology systems or those of third </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">54 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
parties used in our business, or security breaches or incidents affecting us or any of our CROs, other contractors, consultants, potential future collaborators, or other third-party service providers, could result in the loss, misappropriation, or unauthorized access to, use or disclosure of, or the inability to access, data (including trade secrets or other confidential information, intellectual property, proprietary business information, and personal information), which could result in financial, legal, business, and reputational harm to us. Unauthorized access, use, or disclosure of personal information, including personal information regarding our clinical trial subjects or employees, could harm our reputation directly, compel us to notify individuals or regulators under data breach notification laws, cause us to incur costs related to investigation of the incident (including legal expenses, forensic examination costs, and remediation costs), subject us to mandatory corrective action, and otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could result in significant legal and financial exposure and reputational damage that could have an adverse effect on our business. Our preclinical studies in China could increase our risk to such disruptions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect to incur significant costs in our efforts to detect, prevent, and respond to security incidents. We also rely on third parties to manufacture our product candidates, and similar events relating to their systems could also have a material adverse effect on our business. There have been and may continue to be significant supply chain attacks and operational technology attacks globally, and we cannot guarantee that our systems or those of third-party service providers or other third parties that support us or our operations have not been breached or that they do not contain exploitable defects or bugs that could result in a security incident or breach of, or other disruption to, our systems or the systems of third parties that support us and our operations. To the extent that any disruption or security incident were to result in a loss, destruction or alteration of, or damage to, our data, or inappropriate disclosure of confidential or proprietary information, we could be exposed to litigation and governmental investigations, the further development and commercialization of our product candidates could be delayed, and we could be subject to significant fines or penalties for any noncompliance with certain state, federal or international laws relating to privacy, data protection, and information security. Litigation and governmental investigations could force us to spend money in defense or settlement, divert management&#8217;s time and attention, increase our costs of doing business, and adversely affect our reputation. We could be required to fundamentally change our business activities and practices in response to such litigation or investigations, which could have an adverse effect on our business. Any actual or perceived inability to adequately protect data in our possession, custody, or control could have a material adverse effect upon our reputation, business, operations, or financial condition. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our insurance policies may not be adequate to compensate us for the potential losses arising from any such disruption to, failure or security breach of, or incident impacting, our systems or third-party systems where information important to our business operations is stored. In addition, such insurance may not be available to us in the future on economically reasonable terms, or at all. Further, our insurance may not cover all claims made against us and could have high deductibles in any event, and defending a suit, regardless of its merit, could be costly and divert management attention. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="text-decoration:underline">Risks Related to Ownership of Our Class&#160;A Common Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The market price of our Class&#160;A Common Stock has been and is expected to continue to be volatile. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The market price of our Class&#160;A Common Stock has been and could continue to be subject to significant fluctuations. Some of the factors that may cause the market price of our Class&#160;A Common Stock to fluctuate include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">price and volume fluctuations in the overall stock market from time to time; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing and results of clinical trials for our current product candidates and any future product candidates that we may develop; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">commencement or termination of collaborations for our product development and research programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure to achieve development, regulatory or commercialization milestones under our collaborations; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">55 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure or discontinuation of any of our product development and research programs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">results of preclinical studies, clinical trials or regulatory approvals of product candidates of our competitors, or announcements about new research programs or product candidates of our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the level of expenses related to any of our research programs, clinical development programs or product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the results of our efforts to develop additional product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory actions with respect to our or our competitors&#8217; product candidates or products; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">developments or disputes concerning patent applications, issued patents or other proprietary rights; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announced or completed acquisitions of businesses, products or intellectual property by us or our competitors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated changes in the financial projections or development timelines we may provide to the public or our failure to meet those projections or timelines; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">market conditions in the biotechnology and pharmaceutical sectors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the structure of healthcare payment systems; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of our Class&#160;A Common Stock by us or our stockholders, or expectations that such sales may occur, and the expiration <span style="white-space:nowrap">of&#160;lock-up&#160;agreements;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the recruitment or departure of key personnel; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the public&#8217;s reaction to our press releases, other public announcements and our filings with the SEC; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">rumors and market speculation involving us or other companies in our industry; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fluctuations in the trading volume of our Class&#160;A Common Stock or the size of our public float; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated changes or fluctuations in our results of operations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">actual or anticipated developments in our business, our competitors&#8217; businesses or changes in the market valuations of similar companies and the competitive landscape generally; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in the market valuations of similar companies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">failure of securities analysts to maintain coverage of our Class&#160;A Common Stock, changes in actual or future expectations of investors or securities analysts or our failure to meet these estimates or the expectations of investors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">litigation involving us, our industry or both; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">governmental or regulatory actions or audits; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">regulatory or legal developments in the United States and other countries; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">general economic conditions and trends; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">announcement or expectation of additional financing efforts; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">sales of securities by us or our securityholders in the future; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">if we do not achieve the perceived benefits of the Merger as rapidly or to the extent anticipated by financial or industry analysts; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">changes in accounting standards, policies, guidelines, interpretations or principles. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">56 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the trading price of our Class&#160;A Common Stock. In addition, a recession, depression or other sustained adverse market event could materially and adversely affect our business and the value of our Class&#160;A Common Stock. Furthermore, market volatility may lead to increased shareholder activism if we experience a market valuation that activists believe is not reflective of our intrinsic value. Activist campaigns that contest or conflict with our strategic direction or seek changes in the composition of our Board could have an adverse effect on our operating results, financial condition and cash flows. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We expect to incur losses for the foreseeable future and might never achieve profitability. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may never become profitable, even if we are able to complete clinical development for one or more product candidates and eventually commercialize such product candidates. We will need to successfully complete significant research, development, testing and regulatory compliance activities that, together with projected general and administrative expenses, is expected to result in substantial increased operating losses for at least the next several years. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be unable to successfully integrate the businesses of Reneo and Legacy OnKure and realize the anticipated benefits of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger involved the combination of two companies that previously operated as independent companies. Following the Merger, we must devote significant management attention and resources to integrating the business practices and operations of the separate companies. We may fail to realize some or all of the anticipated benefits of the Merger if the integration process takes longer than expected or is more costly than expected. Potential difficulties in the integration process include the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the inability to successfully combine the businesses of Reneo and OnKure in a manner that permits us to achieve the anticipated benefits from the Merger in the time frame currently anticipated or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">creation of uniform standards, controls, procedures, policies and information systems; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential unknown liabilities and unforeseen increased expenses, delays or regulatory conditions associated with the Merger. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and other resources, different risk profiles and a longer history in the industry than we do. These competitors also may provide higher compensation, more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize our product candidates will be limited and the potential for successfully growing our business will be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to attract and retain management and other key personnel, we may be unable to continue to successfully develop or commercialize our product candidates or otherwise implement our business plan. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to compete in the highly competitive pharmaceuticals industry depends on our ability to attract and retain highly qualified managerial, scientific, medical, legal, sales and marketing and other personnel. We will be highly dependent on our management and scientific personnel. The loss of the services of any of these individuals could impede, delay or prevent the successful development of our product pipeline, completion of our planned clinical trials, commercialization of our product candidates <span style="white-space:nowrap">or&#160;in-licensing&#160;or</span> acquisition of new assets and could impact negatively our ability to implement successfully our business plan. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. We might not be able to attract or retain qualified management and other key personnel in the future due to the intense competition for qualified personnel among biotechnology, pharmaceutical and other businesses. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">57 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will incur additional costs and increased demands upon management as a result of complying with the laws and regulations affecting public companies. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incur significant legal, accounting and other expenses as a public company that Legacy OnKure did not incur as a private company, including costs associated with public company reporting obligations under the Exchange Act. Our management team consists of the executive officers of Legacy OnKure prior to the Merger, some of whom have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise related to public company reporting requirements and compliance with applicable laws and regulations to ensure that we comply with all of these requirements. Any changes we make to comply with these obligations may not be sufficient to allow us to satisfy our obligations as a public company on a timely basis, or at all. These reporting requirements, rules and regulations, coupled with the increase in potential litigation exposure associated with being a public company, could also make it more difficult for us to attract and retain qualified persons to serve on our Board or board committees or to serve as executive officers, or to obtain certain types of insurance, including directors&#8217; and officers&#8217; insurance, on acceptable terms. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We will continue to be an emerging growth company and a smaller reporting company, and it cannot be certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our Class&#160;A Common Stock less attractive to investors. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act of 2002, as amended (the &#8220;Sarbanes-Oxley Act&#8221;), reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1)&#160;the last day of the fiscal year (a)&#160;following the fifth anniversary of the closing of Reneo&#8217;s initial public offering, (b)&#160;in which we have total annual gross revenue of at least $1.235&#160;billion or (c)&#160;in which we are deemed to be a large accelerated filer, which requires, among other things, that the market value of our Class&#160;A Common Stock that is held <span style="white-space:nowrap">by&#160;non-affiliates&#160;to</span> exceed $700&#160;million as of the prior June 30th, and (2)&#160;the date on which we have issued more than $1&#160;billion <span style="white-space:nowrap">in&#160;non-convertible&#160;debt</span> during the prior three-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Even after we no longer qualify as an emerging growth company, we may still qualify as a &#8220;smaller reporting company,&#8221; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of Section&#160;404 of the Sarbanes-Oxley Act (if we are also <span style="white-space:nowrap">a&#160;non-accelerated&#160;filer</span> at that time) and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. It cannot be predicted if investors will find our Class&#160;A Common Stock less attractive because we may rely on these exemptions. If some investors find our Class&#160;A Common Stock less attractive as a result, there may be a less active trading market for our Class&#160;A Common Stock and the price of our Class&#160;A Common Stock may be more volatile. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. It is expected that we will continue to elect to use this extended transition period under the JOBS Act. As a result, our financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. As a result, changes in rules of GAAP or their interpretation, the adoption of new guidance, or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, once we are no longer an emerging growth company or a smaller reporting company or otherwise no longer qualify for these exemptions, we will be required to comply with these additional legal and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">58 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory requirements applicable to public companies and will incur significant legal, accounting and other expenses to do so. If we are not able to comply with the requirements in a timely manner or at all, our financial condition or the market price of our Class&#160;A Common Stock may be harmed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act and the rules and regulations of Nasdaq. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report on <span style="white-space:nowrap">Form&#160;10-K&#160;filing</span> for that year, as required by Section&#160;404 of the Sarbanes-Oxley Act. As a private company, Legacy OnKure was not required to test its internal controls within a specified period. This will require that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the matters described above in the context of Legacy OnKure being a private company, we may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we are not able to comply with the requirements of Section&#160;404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our Class&#160;A Common Stock could decline and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Amended and Restated Certificate of Incorporation and the Amended and Restated Bylaws and provisions under Delaware law could make acquiring us more difficult and may prevent attempts by our stockholders to replace or remove our management. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Provisions in our Amended and Restated Certificate of Incorporation (&#8220;Amended Certificate of Incorporation&#8221;) and our Amended and Restated Bylaws (&#8220;Amended Bylaws&#8221;) may discourage, delay or prevent a merger, acquisition or other change in control of the Company that stockholders may consider favorable, including transactions in which holders of our Common Stock might otherwise receive a premium price for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Common Stock, thereby depressing the market price of our Common Stock. In addition, because the Board will be responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove current management by making it more difficult for stockholders to replace members of the Board. Among other things, these provisions: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">authorize &#8220;blank check&#8221; preferred stock, which could be issued by the Board without stockholder approval and may contain voting, liquidation, dividend, and other rights superior to our Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide for a classified board of directors whose members serve staggered three-year terms; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">specify that special meetings of our stockholders can be called only by the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">prohibit stockholder action by written consent; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">59 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of the stockholders, including proposed nominations of persons for election to the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that vacancies on the Board may be filled only by a majority of directors then in office, even though less than a quorum; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">provide that our directors may be removed (i)&#160;only for cause and (ii)&#160;only by the affirmative vote of the holders of 66 2/3% or more of the outstanding shares of capital stock then entitled to vote at an election of directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expressly authorize the Board to make, alter, amend, or repeal the Amended Bylaws; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">require supermajority votes of the holders of our Common Stock to amend specified provisions of our Amended Certificate of Incorporation and Amended Bylaws. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the DGCL, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirors to negotiate with the Board, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then-current management by making it more difficult for stockholders to replace members of the Board, which is responsible for appointing the members of management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our Amended Bylaws provide that, unless we consent in writing to the selection of an alternative forum, certain designated courts will be the sole and exclusive forum for certain legal actions between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&#160;any derivative claim or cause of action brought on our behalf; (ii)&#160;any claim or cause of action for breach of a fiduciary duty owed by any of our current or former directors, officers or other employees, to us or our stockholders; (iii)&#160;any claim or cause of action against us or any of our current or former directors, officers or employees arising out of or pursuant to any provision of the DGCL, our Amended Certificate of Incorporation or our Amended Bylaws; (iv)&#160;any claim or cause of action seeking to interpret, apply, enforce, or determine the validity of our Amended Certificate of Incorporation or our Amended Bylaws; (v)&#160;any claim or cause of action as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware; and (vi)&#160;any claim or cause of action against us or any of our current or former directors, officers or employees governed by the internal affairs doctrine or otherwise related to our internal affairs, in all cases to the fullest extent permitted by law and subject to the court having personal jurisdiction over the indispensable parties named as defendants. This provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we consent in writing to the selection of an alternate forum, the United States federal district courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. In addition, our Amended Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to these exclusive forum provisions. The forum selection provisions in our Amended Bylaws may limit our stockholders&#8217; ability to litigate disputes with us in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. There is uncertainty as to whether a court would enforce such provisions, and investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Furthermore, the enforceability of similar choice of forum provisions in other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">60 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
companies&#8217; charter documents has been challenged in legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our Amended Bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over actions brought under the Securities Act or the rules and regulations promulgated thereunder. In addition, these forum selection provisions may impose additional litigation costs for stockholders who determine to pursue any such lawsuits against us. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate of Incorporation and Amended Bylaws provide that we will indemnify our directors and officers, in each case to the fullest extent permitted by Delaware law. In addition, as permitted by Section&#160;145 of the DGCL, our Amended Bylaws and the indemnification agreements that we have entered with our directors and officers provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may, in our discretion, indemnify employees and agents in those circumstances where indemnification is permitted by applicable law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are required to advance expenses, as incurred, to our directors and officers in connection with defending a proceeding, except that such directors or officers shall undertake to repay such advances if it is ultimately determined that such person is not entitled to indemnification; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are not obligated pursuant to our Amended Bylaws to indemnify a person with respect to proceedings initiated by that person against us or our other indemnitees, except with respect to proceedings authorized by our Board or brought to enforce a right to indemnification; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the rights conferred in our Amended Bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we may not retroactively amend the provisions of our Amended Bylaws to reduce our indemnification obligations to directors, officers, employees and agents. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will indemnify our directors and officers for serving us in those capacities or for serving other business enterprises at our request, to the fullest extent permitted by Delaware law. Delaware law provides that a corporation may indemnify such person if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the registrant and, with respect to any criminal proceeding, had no reasonable cause to believe such person&#8217;s conduct was unlawful. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent that a claim for indemnification is brought by any of our directors or officers, it would reduce the amount of funds available for use in our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We do not anticipate that we will pay any cash dividends in the foreseeable future. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current expectation is that we will retain our future earnings, if any, to fund the growth of our business as opposed to paying dividends. As a result, capital appreciation, if any, of our Class&#160;A Common Stock will be your sole source of gain, if any, for the foreseeable future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">An active trading market for our Class&#160;A Common Stock may not develop, and the holders of our Class&#160;A Common Stock may not be able to resell their shares of our Class&#160;A Common Stock for a profit, if at all. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the Merger, there had been no public market for shares of Legacy OnKure capital stock. An active trading market for our Class&#160;A Common Stock may never develop or be sustained. If an active market for our Class&#160;A Common Stock does not develop or is not sustained, it may be difficult for our stockholders to sell their shares of our Class&#160;A Common Stock at an attractive price or at all. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">61 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We could be subject to securities class action litigation, which is expensive and could divert management attention. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business, operating results, or financial condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Reneo&#8217;s winddown of its historical operations, the suspension of development activities and the Merger, resulting in the conversion of Legacy OnKure into a public company, made us subject to the SEC requirements applicable to reporting shell company business combinations. As a result, we are subject to more stringent reporting requirements, offering limitations and resale restrictions. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">According to SEC guidance, the requirements applicable to reporting shell company business combinations apply to any company that sells or otherwise disposes of its historical assets or operations in connection with or as part of a plan to combine with <span style="white-space:nowrap">a&#160;non-shell&#160;private</span> company in order to convert the private company into a public one. Prior to the Merger, Reneo suspended its development activities and, as such, we are subject to the SEC requirements applicable to reporting shell company business combinations, which are as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we were required file a Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;to</span> report the Form 10 type information (the <span style="white-space:nowrap">&#8220;Super&#160;8-K&#8221;)&#160;after</span> the closing of the Merger reflecting our status as an entity that is not a shell company; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are not eligible to use a <span style="white-space:nowrap">Form&#160;S-3&#160;until</span> one year after the filing of <span style="white-space:nowrap">the&#160;Super&#160;8-K;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we waited 60 calendar days after the filing of the <span style="white-space:nowrap">Super&#160;8-K&#160;to</span> file a <span style="white-space:nowrap">Form&#160;S-8&#160;for</span> our equity plans or awards; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">we are an &#8220;ineligible issuer&#8221; through October&#160;4, 2026, which will prevent us from (i)&#160;incorporating by reference in our <span style="white-space:nowrap">Form&#160;S-1&#160;filings,</span> (ii)&#160;using a free writing prospectus or (iii)&#160;taking advantage of the well-known seasoned issuer (also known as a &#8220;WKSI&#8221;) status despite our public float; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">investors who (i)&#160;were affiliates of OnKure at the time the Merger were submitted for the vote or consent of OnKure stockholders, (ii)&#160;received securities in the Merger and (iii)&#160;publicly offer or sell such securities will be deemed to be engaged in a distribution of such securities, and therefore would be underwriters with respect to resales of those securities, and accordingly such securities may not be included in the <span style="white-space:nowrap">Form&#160;S-1&#160;resale</span> shelf registration statement anticipated to be filed after the closing of the Merger unless such securities are sold only in a fixed price offering in which such investors are named as underwriters in the prospectus; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Rule 144(i)(2) limits the ability of holders of restricted securities and any affiliates of the public company to publicly resell Rule 145(c) securities per Rule 145(d), as well as any other of our &#8220;restricted&#8221; or &#8220;control&#8221; securities per Rule 144, until one year after the <span style="white-space:nowrap">Super&#160;8-K&#160;is</span> filed with the <span style="white-space:nowrap">SEC.&#160;Non-affiliate&#160;Reneo</span> stockholders prior the Merger are not subject to such restrictions on public resales of their shares. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing SEC requirements will increase our time and cost of raising capital, offering stock under equity plans, and complying with securities laws. Furthermore, such requirements will add burdensome restrictions on the resale of our Class&#160;A Common Stock by our affiliates and any holders of our &#8220;restricted&#8221; or &#8220;control&#8221; securities. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Future sales of shares by existing stockholders could cause our Class&#160;A Common Stock price to decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If existing securityholders sell, or indicate an intention to sell, substantial amounts of our Class&#160;A Common Stock in the public market after legal restrictions on resale discussed in this prospectus lapse, the trading price of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">62 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our Class&#160;A Common Stock could decline. Of the outstanding shares of our Class&#160;A Common Stock, approximately 6,733,253 shares will be available for sale in the public market beginning 180 days after the closing of the Merger as a result of the expiration <span style="white-space:nowrap">of&#160;lock-up&#160;agreements</span> between Reneo and OnKure on the one hand and certain securityholders of Reneo and OnKure on the other hand. All other outstanding shares of our Class&#160;A Common Stock, other than shares held by our affiliates and shares of our Class&#160;A Common Stock issued in the PIPE Financing, are currently freely tradable, without restriction, in the public market. In addition, shares of our Class&#160;A Common Stock that are subject to outstanding options or warrants will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of our Class&#160;A Common Stock could decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our executive officers, directors and principal stockholders have the ability to control or significantly influence all matters submitted to our stockholders for approval. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;1, 2025, our executive officers, directors and principal stockholders, in the aggregate, beneficially own approximately 55.5% of the outstanding shares of our Class&#160;A Common Stock. As a result, if these stockholders were to choose to act together, they would be able to control or significantly influence all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these stockholders, if they choose to act together, would control or significantly influence the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of voting power could delay or prevent an acquisition of us on terms that other stockholders may desire. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, the stock price and trading volume of our Class&#160;A Common Stock could decline. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trading market for our Class&#160;A Common Stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect to not provide research coverage of our Class&#160;A Common Stock, and such lack of research coverage may adversely affect the market price of our Class&#160;A Common Stock. In the event that we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our Class&#160;A Common Stock could decline if one or more equity research analysts downgrades our stock or issues other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on it regularly, demand for our Class&#160;A Common Stock could decrease, which in turn could cause our stock price or trading volume to decline. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">We may be subject to adverse legislative or regulatory tax changes that could negatively impact our financial condition. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service (the &#8220;IRS&#8221;) and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or our stockholders. Any change in tax law will be accounted for in the period of enactment. We will assess the impact of various tax reform proposals and modifications to existing tax treaties in all jurisdictions where we have operations to determine the potential effect on our business and any assumptions we will make about our future taxable income. We cannot predict whether any specific proposals will be enacted, the terms of any such proposals or what effect, if any, such proposals would have on our business if they were to be enacted. Such changes, among others, may adversely affect our effective tax rate, results of operation and general business condition. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Our ability to use net operating loss carryforwards and other tax attributes may be limited, including as a result of the Merger. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, we had U.S. federal net operating loss carryforwards of $219.4&#160;million. Under current law, U.S. federal net operating loss carryforwards generated in taxable periods beginning after </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">63 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
December&#160;31, 2017, may be carried forward indefinitely, but the deductibility of such net operating loss carryforwards is limited to 80% of taxable income for taxable periods beginning after December&#160;31, 2020. Net operating loss carryforwards may be subject to similar limitations under state law. In addition, under Sections 382 and 383 of the Code, U.S. federal net operating loss carryforwards and other tax attributes may become subject to an annual limitation in the event of certain cumulative changes in ownership. An &#8220;ownership change&#8221; pursuant to Section&#160;382 of the Code generally occurs if one or more stockholders or groups of stockholders who own at least 5% of a company&#8217;s stock increase their ownership by more than 50 percentage points (by value) over their lowest ownership percentage within a rolling three-year period. Legacy OnKure had not conducted a study to determine whether such an ownership change had occurred in the previous years to impair the use of its net operating loss carryforwards. Reneo may have experienced such ownership changes in the past, and we believe that Reneo experienced an ownership change in connection with the Merger and the PIPE Financing. Our ability to utilize these net operating loss carryforwards and other tax attributes to offset future taxable income or tax liabilities may be limited as a result of ownership changes, including, as discussed above, in connection with the Merger and the PIPE Financing or other transactions. Similar rules may apply under state tax laws. In addition, California has recently enacted a temporary suspension on the use of state net operating loss carryforwards for certain businesses, which may adversely affect us if we earn taxable income in the impacted tax years that is apportioned to California. Other state tax limitations may apply. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we earn taxable income, such limitations could result in increased future income tax liability to us, and our future cash flows could be adversely affected. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Unfavorable global economic conditions could adversely affect our business, financial condition, results of operations or cash flows. </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our results of operations could be adversely affected by general conditions in the global economy and in the global financial markets. A severe or prolonged economic downturn could result in a variety of risks to our business, including weakened demand for our product candidates and our ability to raise additional capital when needed on acceptable terms, if at all. A weak or declining economy could also strain our suppliers, possibly resulting in supply disruption, or cause our customers to delay making payments for our services. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the current economic climate and financial market conditions could adversely impact our business. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">64 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_6">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus contains or incorporates statements that constitute <span style="white-space:nowrap">forward-looking</span> statements within the meaning of the federal securities laws. Any express or implied statements that do not relate to historical or current facts or matters are forward-looking statements. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements include, but are not limited to, express or implied statements regarding our expectations, hopes, beliefs, intentions or strategies regarding the future. In some cases, you can identify forward-looking statements by terminology such as &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;seeks,&#8221; &#8220;target,&#8221; &#8220;endeavor,&#8221; &#8220;possible,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;contemplate&#8221; or the negative of these terms or other comparable terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting us will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond our control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. In addition to other factors and matters contained in or incorporated by reference in this document, we believe the following factors could cause actual results to differ materially from those discussed in the forward-looking statements: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">risks related to our early stage of development; the uncertainties associated with our product candidates, as well as risks associated with the clinical development and regulatory approval of product candidates, including potential delays in the completion of clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the significant net losses we have incurred since inception; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to initiate and complete ongoing and planned preclinical studies and clinical trials and advance our product candidates through clinical development; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the timing of the availability of data from our clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the outcome of preclinical testing and clinical trials of our product candidates, including the ability of those trials to satisfy relevant governmental or regulatory requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our plans to research, develop and commercialize our current and future product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the clinical utility, potential benefits and market acceptance of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to attract, hire, and retain skilled executive officers and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to protect our intellectual property and proprietary technologies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our reliance on third parties, contract manufacturers, and contract research organizations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the possibility that we may be adversely affected by other economic, business, or competitive factors; risks associated with changes in applicable laws or regulations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the risks and uncertainties identified from time to time in documents filed or to be filed with the SEC; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">other risks. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we consider immaterial or which are unknown. You are urged to carefully review the disclosures we make concerning these risks and other factors that may affect our business and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">65 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
operating results under the section entitled &#8220;<span style="font-style:italic">Risk Factors</span>&#8221; beginning on page&#160;9 of this prospectus. Additional factors that could cause actual results to differ materially from those expressed in the forward-looking statements are discussed in reports filed with the SEC and incorporated by reference herein. Please see the section entitled &#8220;<span style="font-style:italic">Where You Can Find Additional Information</span>&#8221; beginning on page&#160;149 of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any of these risks or uncertainties materialize or any of these assumptions prove incorrect, our results could differ materially from the forward-looking statements. Any public statements or disclosures by us following this prospectus that modify or impact any of the forward-looking statements contained in this prospectus will be deemed to modify or supersede such statements in this prospectus. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this prospectus and are qualified in their entirety by reference to the cautionary statements herein. We do not intend, and undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this document or to reflect the occurrence of unanticipated events, unless required by law to do so. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus also concerns product candidates that are under clinical investigation and which have not yet been approved for marketing by the FDA. Such product candidates are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">66 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_7">USE OF PROCEEDS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of the securities offered by the selling securityholders pursuant to this prospectus will be sold by the selling securityholders for their respective accounts. We will not receive any of the proceeds from the sale of the securities hereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to the registration of shares of our Class&#160;A Common Stock offered by the selling securityholders pursuant to this prospectus, the selling securityholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred by them in disposing of the securities. We will bear all other costs, fees and expenses incurred in effecting the registration of the securities covered by this prospectus, including, without limitation, all registration and filing fees, Nasdaq listing fees, and fees of our counsel and our independent registered public accountants. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">67 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_8">MARKET PRICE OF AND DIVIDENDS ON THE REGISTRANT&#8217;S COMMON EQUITY AND RELATED STOCKHOLDER MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Market Information and Holders </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A Common Stock (the &#8220;Common Stock&#8221;) is currently listed on The Nasdaq Global Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;OKUR.&#8221; Prior to the consummation of the Merger, Reneo&#8217;s common stock was historically quoted on The Nasdaq Global Market under the symbol &#8220;RPHM.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, there were approximately 12,660,590 shares of Common Stock issued and outstanding held of record by approximately 98 holders. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are also 686,527 shares of <span style="white-space:nowrap">non-voting</span> Class&#160;B Common Stock outstanding and held of record by one holder. The Class&#160;B Common Stock is convertible into Common Stock on a 1:1 basis at the election of such holder, subject to customary beneficial ownership limitations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dividend Policy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never declared or paid any cash dividends on our capital stock. We do not intend to pay cash dividends to our stockholders in the foreseeable future. Investors should not purchase our Common Stock with the expectation of receiving cash dividends. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, general business conditions, and other factors that our board of directors may deem relevant. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">68 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_10">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OF OPERATIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">The following discussion and analysis provides information that our management believes is relevant to an assessment and understanding of our consolidated results of operations and financial condition. The discussion should be read together with the audited financial statements and related notes that are included elsewhere or incorporated by reference in this prospectus. This discussion may contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in the section titled &#8220;Risk Factors&#8221; as set forth in this prospectus. </span></p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. By improving selectivity for the oncogenic and mutated form of these cancer-driver proteins, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from <span style="white-space:nowrap">non-selective</span> inhibition of the <span style="white-space:nowrap">non-mutated</span> (or wild-type) version of the protein. We work under the belief that inhibiting target proteins with specific mutations instead of wild-type variants should enable precise patient selection that will, in turn, improve the probability of clinical success. We designed our current product candidates utilizing disciplined medicinal chemistry, <span style="white-space:nowrap">x-ray</span> crystallography and computational chemistry to inhibit specified mutated versions of PI3K&#945;, a key mediator in cancer growth signaling. Our lead product candidate, <span style="white-space:nowrap">OKI-219,</span> is a highly selective inhibitor of PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> that has a much smaller impact on PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>. We plan to initially focus on the development of <span style="white-space:nowrap">OKI-219</span> in patients with advanced breast cancer of genetic subtypes that are (a)&#160;both HR+ and HER2-; and (b)&#160;HER2+. We believe we can potentially expand the application of <span style="white-space:nowrap">OKI-219</span> by conducting appropriate clinical trials in earlier lines of treatment within breast cancer, other subtypes of breast cancer, and potentially in other solid tumors. <span style="white-space:nowrap">OKI-219</span> is currently in a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> Phase 1a/1b clinical trial. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Merger </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On the Closing Date, Reneo consummated the previously announced Merger pursuant to the terms of the Merger Agreement, by and among Reneo, Merger Sub I, Merger Sub II, and Legacy OnKure. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Merger Agreement, on the Closing Date, (i)&#160;Reneo effected a reverse stock split of Reneo&#8217;s issued common stock at a ratio of 1:10, (ii) Reneo changed its name to &#8220;OnKure Therapeutics, Inc.&#8221;, (iii) Reneo reclassified all of its common stock as &#8220;Class&#160;A Common Stock&#8221; or &#8220;Class&#160;B Common Stock&#8221;, and (iv)&#160;Radiate Merger Sub I merged with and into Legacy OnKure, with Legacy OnKure as the surviving company in the Merger and, after giving effect to such Merger, Legacy OnKure becoming a wholly-owned subsidiary of OnKure Therapeutics, Inc.. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the closing of the Merger, Reneo completed a private placement with the PIPE Investors to purchase 2,839,005 shares of Common Stock at a price per share of approximately $22.895 per share for an aggregate purchase price of approximately $65.0&#160;million, including the conversion of outstanding convertible notes and accrued but unpaid interest thereon held by certain Legacy OnKure investors. In connection with the PIPE Financing, Reneo entered into a registration rights agreement with certain investors, pursuant to which Reneo agreed to use commercially reasonably efforts to prepare and file a registration statement with the SEC within 45 calendar days after the Closing Date, registering the resale of the shares of Common Stock issued pursuant to the PIPE Financing, which was filed in October 2024. Immediately after the effective time of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">69 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Merger, following the consummation of the PIPE Financing, shares received by Legacy OnKure stockholders represented approximately 53.6%, <span style="white-space:nowrap">pre-Merger</span> Reneo shares outstanding represented approximately 25.1%, and the shares purchased in the PIPE Financing&#160;represented approximately 21.3% of our outstanding Common Stock. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the open of trading on October&#160;7, 2024, our Common Stock began trading on Nasdaq under the symbol &#8220;OKUR.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Financial Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since our inception, our operations have primarily focused on raising capital, establishing and protecting our intellectual property portfolio, organizing and staffing our company, business planning, and conducting preclinical and clinical development of and manufacturing development for our product candidates. We do not have any product candidates approved for sale, have not generated any revenue from product sales, and do not expect to generate revenues from the commercial sale of any products for the foreseeable future, if ever. Since inception, we have incurred significant operating losses. Our net losses were $52.7&#160;million and $35.3&#160;million for the years ended December&#160;31, 2024 and 2023, respectively. As of December&#160;31, 2024, we had an accumulated deficit of $154.7&#160;million, and cash and cash equivalents of $110.8&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through private placements of our common stock, preferred stock and issuance of convertible debt. As of December&#160;31, 2024, we believe our cash resources are sufficient to fund our planned operations for at least the next 12 months from the date of issuance of these financial statements. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Components of Our Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Operating Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses primarily relate to expenses incurred in connection with the discovery and development of our product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">employee-related expenses, including salaries, severance, retention, benefits, insurance, and share-based compensation expense; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">expenses incurred under agreements with CROs, which are investigative sites that conduct our clinical trials, other clinical trial-related vendors and clinical consultants; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of acquiring, developing, and manufacturing and testing clinical and preclinical materials, including costs incurred under agreements with CMOs; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">costs associated with <span style="white-space:nowrap">non-clinical</span> activities and regulatory operations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">facilities, depreciation, market research, and other expenses, which include allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory supplies. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We make <span style="white-space:nowrap">non-refundable</span> advance payments for goods and services that will be used in future research and development activities. These payments are recorded as expenses in the period in which we receive or take ownership of the goods or when the services are performed. At any one time, we are working on multiple research or drug discovery programs and internal resources. Employees and infrastructure are not directly tied to any one program and are typically deployed across multiple programs; therefore, we do not track our research and development expenses on a program-specific basis. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">70 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Conducting preclinical studies and clinical trials necessary to obtain regulatory approval is costly and time-consuming. As we initiate new clinical trials, our research and development expenses may increase. Product candidates in later stages of development generally have higher development costs than those in earlier stages. As a result, we expect that our research and development expenses will increase substantially over the next several years as we advance product candidates through preclinical studies into and through clinical trials, continue to discover and develop additional product candidates, undertake activities to expand, maintain, protect and enforce our intellectual property portfolio, and hire additional research and development personnel. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Successful development of product candidates is highly uncertain and may not result in approved products. The probability of success for each product candidate may be affected by numerous factors, including clinical data, preclinical data, competition, manufacturability, and commercial viability. Completion dates and completion costs can vary significantly for each product candidate and are difficult to predict. We anticipate that we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to enter strategic alliances with respect to each program or product candidate, the scientific and clinical success of each product candidate, and ongoing assessments as to each product candidate&#8217;s commercial potential. We will need to raise additional capital and may seek strategic alliances in the future to advance our various programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses consist primarily of salaries, bonuses and related benefits, share-based compensation, and severance and retention benefits related to our executive, finance and administrative functions, professional fees for auditing, tax, consulting and legal services, as well as insurance, board of director compensation, consulting and other administrative expenses. We recognize general and administrative expenses in the periods in which they are incurred. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that our general and administrative expenses will increase over the next several years as we hire additional personnel to support the growth of our business. In addition, we will incur significant additional expenses associated with being a public company, including expenses related to accounting, audit, legal, regulatory, public company reporting and compliance, director and officer insurance, investor and public relations, and other administrative and professional services. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest Income </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest income primarily consists of interest income generated from our cash equivalents in interest-bearing money market accounts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Interest and Other Expense </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense consists primarily of interest expense generated from our convertible notes payable, which were converted at the time of the Merger. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">71 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Results of Operations </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Comparison of the Year Ended December&#160;31, 2024 and 2023 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our results of operations for the periods indicated (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:64%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year Ended</span><br/><span style="font-weight:bold">December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">$ Change</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="10"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Operating expenses:</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">43,795</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,115</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,680</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,591</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,819</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">36,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">17,452</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Loss from operations</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(54,386</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(36,934</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(17,452</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other income and (expense):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest income</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,013</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">390</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest and other expense</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(300</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total other income and (expense)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,713</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,623</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Net loss and comprehensive loss</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(52,673</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(35,311</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(17,362</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expenses were $43.8&#160;million for the year ended December&#160;31, 2024 compared to $32.1&#160;million for the year ended December&#160;31, 2023, an increase of $11.7&#160;million. This increase was primarily due to an increase in research and development costs, consisting of a $6.3&#160;million increase in clinical trial and manufacturing expenses and a $6.2&#160;million increase in personnel-related costs due to an increase in headcount, and higher severance, and share-based compensation charges. These increases were partially offset by a decrease in outsourced research of $0.9&#160;million. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect research and development expenses in 2025 to be higher than 2024 due to the continued efforts to advance of our clinical and preclinical programs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">General and Administrative Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">General and administrative expenses were $10.6&#160;million for the year ended December&#160;31, 2024 and $4.8&#160;million for the year ended December&#160;31, 2023, an increase of $5.8&#160;million. The increase was primarily related to increased personnel-related and consulting costs of $3.0&#160;million, increased professional service costs, which includes legal, audit and tax services, of $2.1&#160;million, and a $0.4&#160;million increase related to insurance and outside director compensation during 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect general and administrative expenses in 2025 to be higher than 2024&#160;as we operate as a public company for the full year in 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Income (Expense) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other income (expense) was $1.7&#160;million for the year ended December&#160;31, 2024 compared to $1.6&#160;million for the year ended December&#160;31, 2023. The change was primarily due to an increase in interest income due to an increase in cash and cash equivalents available to invest during the year ended December&#160;31, 2024 and increased interest expense related to convertible notes payable issued in 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect other income (expense) in 2025 to be higher than 2024 with higher average available cash available to invest during 2025. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">72 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Liquidity and Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since inception, we have not generated any revenue from product sales and have incurred significant operating losses and negative cash flows from our operations. We expect to continue to incur significant expenses and operating losses for the foreseeable future as we advance the clinical development of our product candidates. We expect that our research and development and general and administrative costs will continue to increase significantly, including in connection with conducting clinical trials and manufacturing our product candidates to support commercialization and providing general and administrative support for our operations, including the costs associated with operating as a public company following the Closing. As a result, we will need additional capital to fund our operations, which we may seek to obtain from equity or debt financings, collaborations, licensing arrangements or other sources. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have funded our operations primarily through private placements of equity and convertible debt. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least the next 12 months from the date of filing this prospectus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Funding Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our primary uses of cash to date have been to fund our research and development activities, including with respect to our PI3K&#945; and other programs, business planning, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital and providing general and administrative support for these activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have never generated any revenue from product sales and do not expect to generate any meaningful product revenue unless and until we obtain regulatory approval for our product candidates, and management does not know when, or if, that will occur. Until we can generate significant revenue from product sales, if ever, we will continue to require substantial additional capital to develop our product candidates and fund operations for the foreseeable future. We are subject to all the risks inherent in the development of new biopharmaceutical products, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may harm our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to complete the development of our product candidates and to build the sales, marketing and distribution infrastructure that we believe will be necessary to commercialize product candidates, if approved, we will require substantial additional capital. Accordingly, until such time that we can generate a sufficient amount of revenue from product sales or other sources, we expect to seek to raise any necessary additional capital through equity financings, debt financings or other capital sources, which could include income from collaborations, partnerships, licensing or other strategic arrangements with third parties. To the extent that we raise additional capital through equity financings or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, including restricting our operations and limiting our ability to incur liens, issue additional debt, pay dividends, repurchase our own Common Stock, make certain investments or engage in merger, consolidation, licensing or asset sale transactions. If we raise capital through collaborations, partnerships and other similar arrangements with third parties, we may be required to grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. We may be unable to raise additional capital from these sources on favorable terms, or at all. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ability to secure capital is dependent upon a number of factors, including our success in developing our product candidates. The failure to obtain sufficient capital on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including requiring us to delay, reduce or curtail our research, product development or future commercialization efforts. We may also be </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">73 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to license rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. We cannot provide assurance that we will ever generate positive cash flow from operating activities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our future funding requirements will depend on many factors, including: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, timing, progress, results and costs of researching and developing <span style="white-space:nowrap">OKI-219,</span> and conducting preclinical studies and clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the scope, timing, progress, results and costs of researching and developing other product candidates that we may pursue; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs, timing and outcome of regulatory review of our product candidates; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of future activities, including product sales, medical affairs, marketing, manufacturing and distribution for our product candidates for which we receive marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of manufacturing commercial-grade products and producing sufficient inventory to support commercial launch; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the revenue, if any, received from commercial sales of our products, should our product candidates receive marketing approval; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the cost and timing of attracting, hiring and retaining skilled personnel to support our operations and continued growth; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">our ability to establish, maintain and derive value from collaborations, partnerships or other marketing, distribution, licensing or other strategic arrangements with third parties on favorable terms, if at all; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the extent to which we acquire or <span style="white-space:nowrap">in-licenses</span> other product candidates and technologies, if any; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the costs associated with operating as a public company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A change in the outcome of any of these or other factors with respect to the development of <span style="white-space:nowrap">OKI-219</span> or any of our future product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we may need additional capital to meet the capital requirements associated with such operating plans. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Cash Flows </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table summarizes our cash flows for the years ended December&#160;31, 2024 and 2023 (in thousands): </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:72%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Years&#160;Ended&#160;December&#160;31,</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2024</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">2023</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center" colspan="6"><span style="font-weight:bold">(in thousands)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by (used in):</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(51,117</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(34,546</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,873</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(246</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">116,129</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net increase in cash and cash equivalents</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">80,885</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Operating Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities during the year ended December&#160;31, 2024 was $51.1&#160;million. This consisted primarily of a net loss of $52.7&#160;million, a net decrease in operating assets and liabilities of $4.0&#160;million, and an increase in <span style="white-space:nowrap">non-cash</span> share-based compensation of $4.3&#160;million. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">74 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in operating activities during the year ended December&#160;31, 2023 was $34.5&#160;million. This consisted primarily of a net loss of $35.3&#160;million, reduced by <span style="white-space:nowrap">non-cash</span> charges&#160;for share-based compensation, depreciation and amortization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Investing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by investing activities for the year ended December&#160;31, 2024 was $15.9&#160;million and consisted primarily of $15.9&#160;million of proceeds from the sale of <span style="white-space:nowrap"><span style="white-space:nowrap">available-for-sale</span></span> securities. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash used in investing activities for the year ended December&#160;31, 2023 was $0.2&#160;million for the purchase of property and equipment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Flows from Financing Activities </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities was $116.1&#160;million during the year ended December&#160;31, 2024 and primarily consisted of $54.6&#160;million of net proceeds from the PIPE Financing, $57.7&#160;million of cash acquired in connection with the Merger, and $5.9&#160;million of net proceeds from the issuance of convertible notes payable. These amounts were partially offset by payment of $2.0&#160;million of reverse recapitalization transaction costs in connection with the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities during the year ended December&#160;31, 2023 was $53.1&#160;million. This consisted primarily of proceeds of $53.8&#160;million from the sale of shares of Legacy OnKure&#8217;s preferred stock, partially offset by the payment of $0.7&#160;million of issuance costs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Cash Requirements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion below summarizes our significant contractual obligations and commitments as of December&#160;31, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Leases</span>. See Note 5 of Notes to Consolidated Financial Statements included in this prospectus for information regarding our leases, including the future operating lease minimum payments. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Critical Accounting Policies and Estimates </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements. We base our estimates on historical experience, known trends and events, and various other factors that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Actual results may differ materially from these estimates under different assumptions or conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting policies are the most critical for fully understanding and evaluating our financial condition and results of operations. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Accrued Research and Development Expenses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We record research and development expenses in the period in which we receive or take ownership of the applicable goods or when the applicable services are performed. We are required to estimate our expenses </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">75 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
resulting from our obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. We reflect research and development expenses in our financial statements by matching those expenses with the period in which services and efforts are expended. We account for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. We determine accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, we adjust our rate of expense recognition if actual results differ from our estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Share-Based Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase Common Stock, and restricted stock units for Common Stock, are granted to employees, board of directors, <span style="white-space:nowrap">and&#160;non-employee&#160;consultants.</span> Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying Common Stock, expected term of the option before exercise, expected volatility of our Common Stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of 10 years. We have limited historical stock option activity and therefore estimate the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. We will continue to apply this process until enough historical information regarding the volatility of our stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time <span style="white-space:nowrap">of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes</span> with maturities approximately equal to the expected term of the stock options. We have historically not declared or paid any dividends and do not currently expect to do so in the foreseeable future, and therefore have estimated the dividend yield to be zero. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stock-based compensation expenses year-over-year have increased due to more equity grants awarded in 2024 to attract and retain key scientific or management personnel. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Recent Accounting Pronouncements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of recent accounting pronouncements that may potentially impact our financial position, results of operations or cash flows is disclosed in Note 2 to our consolidated financial statements included elsewhere in this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">76 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_11">BUSINESS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Overview </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, we are committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. By improving selectivity for the oncogenic and mutated form of these cancer-driver proteins, we aim to discover and develop drugs with improved safety and efficacy by sparing toxicity that arises from <span style="white-space:nowrap">non-selective</span> inhibition of the <span style="white-space:nowrap">non-mutated</span> (or wild-type) version of the protein. We work under the belief that inhibiting target proteins with specific mutations instead of wild-type variants should enable precise patient selection that will, in turn, improve the probability of clinical success. We designed our current product candidates utilizing disciplined medicinal chemistry, <span style="white-space:nowrap">x-ray</span> crystallography and computational chemistry to inhibit specified mutated versions of phosphoinositide <span style="white-space:nowrap">3-kinase</span> alpha (&#8220;PI3K&#945;&#8221;), a key mediator in cancer growth signaling. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">OKI-219,</span> is a highly selective inhibitor of PI3K&#945; harboring the H1047R mutation (&#8220;PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#8221;) that has a much smaller impact on wild-type PI3K&#945; (&#8220;PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>&#8221;). By minimizing the targeting of PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup><span style="white-space:nowrap">&#160;(approximately&#160;80-fold&#160;selectivity</span> for PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;over PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>), we believe <span style="white-space:nowrap">OKI-219</span> can achieve exposures required for activity in PI3K&#945;-mutated cancers with minimal effect on wild-type PI3K&#945; signaling, thus potentially limiting <span style="white-space:nowrap">on-target</span> toxicities, such as hyperglycemia, gastrointestinal (&#8220;GI&#8221;) effects, fatigue, and rash. We plan to initially focus on the development of <span style="white-space:nowrap">OKI-219</span> in patients with advanced breast cancer of genetic subtypes that are (a)&#160;both hormone receptor positive (&#8220;HR+&#8221;) and human epidermal growth factor receptor 2 negative (&#8220;HER2-&#8221;); and (b)&#160;human epidermal growth factor receptor 2 positive (&#8220;HER2+&#8221;). We believe we can potentially expand the application of <span style="white-space:nowrap">OKI-219</span> by conducting appropriate clinical trials in earlier lines of treatment within breast cancer, other subtypes of breast cancer, and potentially in other solid tumors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219</span> is currently being investigated in a <span style="white-space:nowrap"><span style="white-space:nowrap">first-in-human</span></span> Phase 1a/1b open-label trial evaluating <span style="white-space:nowrap">OKI-219</span> as a monotherapy and in combination with fulvestrant or trastuzumab in subjects with advanced solid tumors, including breast cancer harboring a PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> mutation <span style="white-space:nowrap">(&#8220;PIKture-01&#8221;).</span> In Phase 1a, subjects receive escalating oral doses of <span style="white-space:nowrap">OKI-219</span> starting at 300 mg twice daily (commonly referred to as &#8220;BID&#8221;) continuously. In Phase 1b we are currently assessing <span style="white-space:nowrap">OKI-219</span> in combination with fulvestrant in patients with HR+/HER2- breast cancer, and in the future, plan to assess <span style="white-space:nowrap">OKI-219</span> in combination with HER2+ targeted agents (e.g., trastuzumab) in patients with HER2+ breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, we announced the preliminary safety, tolerability, and pharmacokinetic (&#8220;PK&#8221;) data from <span style="white-space:nowrap">PIKture-01</span> with a cut off date of October&#160;28, 2024. These data showed that <span style="white-space:nowrap">OKI-219</span> was well tolerated across all dose levels with no hyperglycemia, stomatitis, or rash observed at any dose, and only grade 1 treatment-related adverse events (&#8220;TRAEs&#8221;) were reported. No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events. <span style="white-space:nowrap">OKI-219</span> dosed at 900 mg twice daily showed steady-state exposure levels with near-continuous coverage of the <span style="font-style:italic">in vivo </span>EC<sub style="font-size:75%; vertical-align:bottom">80</sub> for pAKT inhibition. These data supported the initiation of Part 1b of <span style="white-space:nowrap">PIKture-01</span> and we began enrolling patients in the fourth quarter of 2024 focusing initially on the evaluation of <span style="white-space:nowrap">OKI-219</span> in combination with fulvestrant. To date, we have completed the enrollment of patients in the Part A monotherapy arm of <span style="white-space:nowrap">PIKture-01</span> through the 1200 mg BID cohort level with no dose limiting toxicities observed in the completed cohorts. We are currently enrolling the last cohort with a top dose of 1500 mg BID and enrollment in Part A is almost complete. Additionally, we have enrolled patients in the Part B fulvestrant combination arm through the 900 mg BID cohort with no dose limiting toxicities observed for all completed cohorts through 600 mg BID and enrollment in the dose escalation portion of Part B is almost complete. We expect to report additional single-agent data and initial combination data with fulvestrant in the second half of 2025.<span style="font-style:italic"> </span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">77 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Pharmacokinetic and Selectivity Profile </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219</span> has shown favorable PK data (Figure 1) in the <span style="white-space:nowrap">PIKture-01</span> trial that support pharmacologically relevant exposures, potentially even at the lowest assessed dose levels, with a safety profile that is indicative of little or no inhibition of wild-type PI3K&#945;. At steady state, the exposures of <span style="white-space:nowrap">OKI-219</span> exceed exposures associated with robust antitumor activity in preclinical models. The PK data are considered preliminary with a data <span style="white-space:nowrap">cut-off</span> of October&#160;28, 2024. We plan to provide updated PK data in the second half of 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g07g07.jpg" alt="LOGO" style="width:4.95333in;height:3.36667in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 1. Steady-state concentrations of <span style="white-space:nowrap">OKI-219</span> at Day 15 across three dose levels in <span style="white-space:nowrap">PIKture-01</span> Part A. Data cut off October</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;28, 2024. </span>Source:<span style="font-weight:bold"> </span>OnKure data. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">78 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As shown in Figure 2, 13 of the 14 patients that received a &#8805;600 mg dose twice a day remained in the study as of the cutoff date. In addition, two patients with HR+/HER2- breast cancer who received the 300 mg dose showed prolonged stable disease, including one patient who sustained &gt;95% reduction in PIK3CA<sup style="font-size:75%; vertical-align:top">H1047R</sup> ctDNA and was on treatment for more than seven months. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g08g08.jpg" alt="LOGO" style="width:6.32in;height:3.07333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 2.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;Time on treatment data from <span style="white-space:nowrap">PIKture-01</span> trial. Data cut off October</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;28, 2024. </span><span style="font-weight:bold"></span>Source:<span style="font-weight:bold"> </span>OnKure data. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Preclinical Data </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Results from preclinical <span style="font-style:italic">in vivo</span> models (Figure 3 and 4 below) of <span style="white-space:nowrap">OKI-219</span> used in combination with <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> (&#8220;SOC&#8221;) therapies for HR+ breast cancers&#160;show strong combination activity of <span style="white-space:nowrap">OKI-219</span> in doublet combinations with SERDs and in triplet combinations with SERD + CDK4/6 inhibitors. Additionally, <span style="white-space:nowrap">OKI-219</span> was well tolerated at doses well above those required for tumor regressions, supporting the ability to combine <span style="white-space:nowrap">OKI-219</span> with SOC therapies in breast cancer. Additional preclinical combination studies are ongoing. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center">


<img src="g184865g08g02.jpg" alt="LOGO" style="width:2.79333in;height:2.17333in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">


<img src="g184865g08g03.jpg" alt="LOGO" style="width:2.74667in;height:2.15667in"/>
</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 3. Preclinical comparison of tumor shrinkage for <span style="white-space:nowrap">OKI-219</span> alone and in combination with fulvestrant or camizestrant vs. fulvestrant or camizestrant in an ER+HER2- breast cancer model.</span><span style="font-weight:bold"></span>&#160;Source:<span style="font-weight:bold"> </span>OnKure data. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">79 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:51%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:47%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;text-align:center">


<img src="g184865g09g01.jpg" alt="LOGO" style="width:2.6in;height:2.05667in"/>
</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center">


<img src="g184865g09g02.jpg" alt="LOGO" style="width:2.39333in;height:2.05333in"/>
</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 4. Preclinical comparison of tumor shrinkage for <span style="white-space:nowrap">OKI-219</span> alone and in combination with fulvestrant plus CDK 4/6 inhibitors vs. CDK 4/6 inhibitors alone and in combination with fulvestrant.</span><span style="font-weight:bold"></span>&#160;Source: OnKure data. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Genetic analysis of tumors has become <span style="white-space:nowrap"><span style="white-space:nowrap">standard-of-care</span></span> in oncology and has enabled oncologists to characterize tumors much more precisely than simple segmentation based on the tissue of origin. A more precise understanding of the genetic alterations driving the growth of specific tumors has also created an opportunity for the industry to develop drugs that are intended to target mutated or oncogenic forms of proteins that drive cancer growth and survival. In a number of notable cases, this approach has profoundly changed how these tumors are treated and has significantly improved outcomes for patients with cancers that depend on these oncogenes for survival. However, in many cases, it has been challenging to effectively target the mutated oncogenic form of a target protein. In <span style="white-space:nowrap">particular,&#160;non-selective&#160;inhibition</span> of the wild-type protein in normal tissues often leads to toxic effects that can limit effective target inhibition of the intended oncogenic protein in cancers and, therefore, offers suboptimal clinical benefit. One such challenging target is the oncogene PI3K&#945;. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PI3K&#945; is an attractive target for cancer drugs because it is one of the most commonly mutated oncogenes in cancers and is a key mediator of abnormal cell growth. Furthermore, PI3K&#945; kinase mutations are clinically correlated with drug resistance and poor clinical outcomes. Single amino acid mutations such as E542K, E545K, H1047R, H1047L, and H1047Y account for over 70% of PI3K&#945; mutations. Notably, the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation is very common in breast cancer, being identified in approximately 14% of breast cancer cases. The PI3K&#945; inhibitor alpelisib has been approved to treat patients with advanced breast cancers harboring PI3K&#945; mutations. Alpelisib <span style="white-space:nowrap">is&#160;non-selective&#160;for</span> the key mutations, and its inhibition of not only mutant but also wild-type PI3K&#945; leads to significant toxicities in patients, such as hyperglycemia, rash and diarrhea. These toxicities can present significant challenges to optimal dosing and use in this patient population. We are focused on addressing the shortcomings of alpelisib and other first-generation PI3K&#945; inhibitors (e.g., inavolisib) by developing product candidates that target these genetic alterations selectively while sparing the wild-type PI3K&#945;. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Development Pipeline </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are focused on the discovery and development of precision oncology therapies that target </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">biologically validated drivers of cancers underserved by available therapies. Currently, we are focused on delivering highly selective drug candidates that preserve wild-type PI3K&#945; while effectively targeting the PI3K&#945;-mutated cancers, initially in advanced breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate, <span style="white-space:nowrap">OKI-219,</span> is advancing in a Phase 1 clinical trial.&#160;We are also actively pursuing multiple additional discovery programs that target oncogenic mutations of PI3K&#945;. We expect to announce a <span style="white-space:nowrap">pan-mutant</span> development candidate in the second quarter of 2025 targeting the most common PI3K&#945; mutations (i.e., H1047R, E545K, and E542K). Additionally, we are developing an allosteric inhibitor molecule designed to </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">80 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be highly selective by specifically targeting the PI3K&#945; E545K and E542K mutations (which are also known as helical domain mutations or <span style="white-space:nowrap">e-mutants)</span> and expect to announce a development candidate in 2026. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Clinical Pipeline </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g96g96.jpg" alt="LOGO" style="width:6.33309in;height:1.09321in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Strategy </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our strategic objective is to conceive, develop and commercialize one or more mutation-specific PI3K&#945; inhibitors to address the needs of patients in breast cancer and beyond. With three PI3K&#945; inhibitor programs, we are committed to developing product candidates that address the needs of patients who suffer from diseases implicated by PI3K&#945;, a key mediator in cancer growth signaling. We rely on the experience of our team in precision kinase inhibitor drug design and development to carry out our strategy. In doing so, we intend to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Rapidly advance and expand the clinical development of our highly selective PI3K</span>&#945;<span style="font-style:italic">H</span><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">1047R</sup></span><span style="font-style:italic"></span><span style="font-style:italic"> inhibitor,</span><span style="font-style:italic"></span><span style="font-style:italic"><span style="white-space:nowrap">&#160;OKI-219</span></span>. The Phase 1 dose-escalation and expansion cohort <span style="white-space:nowrap"><span style="white-space:nowrap">trial,&#160;OKI-219-101,&#160;known</span></span> as <span style="white-space:nowrap">PIKture-01,&#160;is</span> currently enrolling two arms: a) a monotherapy arm in patients with advanced solid tumors with a PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation and b) a combination arm evaluating <span style="white-space:nowrap">OKI-219</span> in combination with fulvestrant, a selective estrogen receptor degrader (&#8220;SERD&#8221;), in patients with PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>-mutated, HR+/HER2- advanced breast cancer.&#160;We also plan to initiate additional trials or arms of <span style="white-space:nowrap">PIKture-01</span> to evaluate <span style="white-space:nowrap">OKI-219&#160;in</span> combination with trastuzumab in patients with PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>-mutated, HER2+ advanced breast cancer, and certain combinations of <span style="white-space:nowrap">OKI-219</span> with fulvestrant and CDK inhibitors in ER+ metastatic breast cancer. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Discover and develop a PI3K</span>&#945;<span style="font-style:italic"></span><span style="font-style:italic"> inhibitor development candidate that selectively targets all the most common PI3K</span>&#945;<span style="font-style:italic"></span><span style="font-style:italic"> mutations</span>. We are actively pursuing a <span style="white-space:nowrap">pan-mutant</span> molecule to target all the most common PI3K&#945; mutations (i.e., H1047R, E545K, and E542K) that may have the potential to treat a </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top;text-align:left">broader patient population. Our research and development team has extensive expertise in discovering early development candidates with favorable drug properties, and we plan to announce a <span style="white-space:nowrap">pan-mutant</span> development candidate in the second quarter of 2025. </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Discover and develop a PI3K</span>&#945;<span style="font-style:italic"></span><span style="font-style:italic">&#160;inhibitor development candidate specifically targeting helical domain mutations</span>. We are also applying our precision drug design approach and our team&#8217;s expertise to develop kinase inhibitors for PI3K&#945; E542K and E545K mutations (also known as helical domain mutations or <span style="white-space:nowrap">e-mutants).</span> These mutants are well known oncogenic drivers, and highly selective inhibitors targeting these mutations have the potential to further expand our addressable patient population. We anticipate announcing a development candidate in 2026. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">d)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-style:italic">Conduct clinical and regulatory programs to support our global regulatory and commercialization strategy</span>. We retain worldwide rights to&#160;all our programs. We plan to expand our clinical development and seek regulatory approval for our current and future product candidates in the United States and abroad. Our long-term goal is to commercialize our products by establishing a commercial organization on our own and/or by leveraging the capabilities of potential commercial partners in the United States and outside the United States. We plan to evaluate strategic opportunities that we believe can maximize the commercial potential of our product candidates with collaborators whose development and commercial capabilities could be complementary. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">81 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Genetic Tumor Profiling is Unlocking Novel Targets for Cancer Therapy </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Over the past 20 years, drug developers have translated findings from tumor genetic analysis into greater insight into tumor biology, a development that has led to a major improvement in anti-cancer therapies. Tumors are no longer simply classified based on their tissue of origin; rather, they are segmented based on genetic alterations, which frequently predict the likely pathogenesis of a specific malignancy and/or its sensitivity to treatment with specific targeted therapies. As a key part of this genetic analysis, mutations in critical signaling pathways have been identified, many of which are potential targets for precision medicines. The signaling axis encompassing PI3K/AKT and mammalian target of rapamycin (&#8220;mTOR&#8221;) is believed to be a key growth driver of tumor cells and is often considered a master regulator of cancer. PI3K activity is upregulated by upstream oncogenes and growth factor receptors, or by activating mutations of PI3K itself, and aberrant PI3K activation is a common hallmark in tumor cell growth in both hematologic malignancies and solid tumors. PI3K activation is believed to contribute to cancer cell survival, angiogenesis, and tumor metastasis. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are three subtypes of PI3K, known as Type I, Type II and Type III. Type I PI3K is believed to drive the proliferation of tumor cells and has been a key target for drug development. There are four biochemical variants, also known as isoforms or subtypes, of Type I PI3K: PI3K&#945;, PI3K&#223;, PI3K<span style="FONT-FAMILY:SYMBOL">g</span>&#160;and PI3K<span style="FONT-FAMILY:SYMBOL">d</span>. While they are differentiated from each other in sequence and structure, all these variants are based on the same fundamental kinase sequence, structure, and function. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PI3K&#945; is one of the most commonly mutated oncogenes in cancer. PI3K&#945; can be activated by oncogenic point mutations in the PI3K&#945; gene. The three most common mutations of PI3K&#945; are H1047R, E542K and E545K. Mutation of PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;in a mouse model has induced breast cancer tumorigenesis and is also associated with drug resistance to HER2-targeting agents in breast cancer. PI3K&#945; is mutated in up to 36% of breast cancer cases. Notably, the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation is also found in approximately 14% of breast cancer cases, making this an attractive target for novel therapeutics in metastatic breast cancer. In addition, targeting mutated PI3K&#945; is a clinically-validated approach following approvals of three drugs for patients with PI3K&#945;-mutated breast cancers: 1) the PI3K&#945; inhibitor alpelisib, marketed by Novartis as PIQRAY<sup style="font-size:75%; vertical-align:top">&#174;</sup>, approved in combination with fulvestrant for the treatment of HR+, HER2-, locally advanced or metastatic breast cancer with PI3K&#945; mutations, 2) the AKT inhibitor capivasertib, marketed by AstraZeneca as TRUQAP<sup style="font-size:75%; vertical-align:top">&#174;</sup>, also approved in combination with fulvestrant for the treatment of HR+, HER2-, locally advanced or metastatic breast cancer with PI3K&#945; mutations and 3) the PI3K&#945;-selective inhibitor inavolisib (Itovebi<sup style="font-size:75%; vertical-align:top">TM</sup>) which was recently approved in combination with the SERD fulvestrant and the CDK4/6 inhibitor palbociclib (Ibrance<sup style="font-size:75%; vertical-align:top">TM</sup>) in endocrine-resistant HR+/Her2- locally advanced or metastatic breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Both alpelisib and inavolisib <span style="white-space:nowrap">are&#160;ATP-competitive&#160;PI3K&#945;</span> kinase inhibitors that do not distinguish between mutant and wild-type PI3K&#945;. Likewise, capivasertib inhibits the pathway downstream of PI3K&#945;, and also does not differentiate between inhibition of wild-type and mutated PI3K&#945; signaling. Unlike these <span style="white-space:nowrap">drugs,&#160;OKI-219&#160;is</span> a specific and selective allosteric inhibitor of H1047R-mutated <span style="white-space:nowrap">PI3K&#945;.&#160;OKI-219&#160;is</span> designed to bind at an allosteric site located adjacent to the H1047R mutation which is distal from the active site. This has been shown in <span style="white-space:nowrap">numerous&#160;x-ray&#160;images</span> <span style="white-space:nowrap">of&#160;OKI-219&#160;bound</span> to PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Drug-related toxicities associated <span style="white-space:nowrap">with&#160;non-selective&#160;PI3K&#945;</span> pathway inhibitors such as alpelisib and capivasertib are caused by inhibiting the wild-type PI3K&#945; enzyme in normal tissues and limit the therapeutic dosing of these agents, resulting <span style="white-space:nowrap">in&#160;sub-optimal&#160;dosing</span> and limited efficacy. Adverse events commonly associated with PI3K&#945; inhibitors include hyperglycemia, rash, diarrhea, and stomatitis. Tumor sequencing analysis has led to the identification of specific mutations in the PI3K&#945; genes that offer novel drug targets for precision medicine with the potential to minimize the toxicities <span style="white-space:nowrap">of&#160;non-selective&#160;PI3K&#945;</span> inhibitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are utilizing our precision medicine small molecule drug discovery platform to identify and develop therapeutic candidates that specifically bind to and inhibit the major PI3K&#945; mutations. We believe that by avoiding the targeting of wild-type PI3K&#945;, our product candidates have the potential to improve upon the safety, efficacy, or both, of <span style="white-space:nowrap">other&#160;non-selective&#160;PI3K&#945;</span> inhibitors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">82 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Our Product Candidate </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">OKI-219,</span></span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;a Targeted Inhibitor of PI3K</span></span>&#945;<span style="font-weight:bold"><span style="font-style:italic"><sup style="font-size:75%; vertical-align:top">H1047R</sup></span></span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our lead product candidate <span style="white-space:nowrap">is&#160;OKI-219,&#160;an</span> orally administered small molecule designed to selectively bind to and inhibit PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>, while avoiding inhibition of wild-type PI3K&#945;. As <span style="white-space:nowrap">such,&#160;OKI-219&#160;is</span> designed to avoid the adverse effects of inhibiting wild-type PI3K&#945; in patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219&#160;is</span> currently being investigated in <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;first-in-human&#160;Phase</span></span> 1a/1b trial. This is an open-label, international trial designed to <span style="white-space:nowrap">evaluate&#160;OKI-219&#160;for</span> safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy with planned sites in the United States, European Union, and Asia.&#160;In December 2024, we reported preliminary safety, tolerability, and pharmacokinetic data from the <span style="white-space:nowrap">PIKture-01</span> trial. <span style="white-space:nowrap">OKI-219</span> was well tolerated across all dose levels tested with no hyperglycemia, and only grade 1 treatment-related adverse events were reported. No dose interruptions, delays, reductions, or discontinuations were reported for any adverse events. <span style="white-space:nowrap">OKI-219</span> dosed at 900 mg twice daily showed steady-state exposure levels with near-continuous coverage of the in vivo EC<sub style="font-size:75%; vertical-align:bottom">80</sub> for pAKT inhibition. These data supported the initiation of Part 1b of <span style="white-space:nowrap">PIKture-01</span> evaluating <span style="white-space:nowrap">OKI-219</span> in combination with fulvestrant in the fourth quarter of 2024. We expect to provide additional single agent data and initial combination data with fulvestrant in the second half of 2025. We will require additional Phase 2 and Phase 3 clinical trials to demonstrate <span style="white-space:nowrap">that&#160;OKI-219&#160;is</span> safe and effective before we can seek regulatory approvals for the commercial sale <span style="white-space:nowrap">of&#160;OKI-219.</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Commercial Opportunity in Breast Cancer </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Breast cancer is the most diagnosed cancer worldwide and is the leading cause of cancer death in women. In the United States, there were an estimated 300,590 new cases of breast cancer in 2023, resulting in 43,700 deaths. According to the National Cancer Institute, approximately 70% of breast cancer patients are HR+/HER2-, approximately 14% are HER2+ and approximately 11% are classified as triple negative, with the remaining 6% of patients being unclassified. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">PI3K&#945; is the most commonly mutated oncogene in breast cancer. Mutations in the PI3K pathway are associated with increased failure of clinical treatments in advanced breast cancer, such HER2 therapy, endocrine therapy, and CDK inhibitor therapy.&#160;Notably, the activity of fulvestrant with or without CDK inhibitors in advanced or metastatic breast cancer is worse in PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R </sup>mutated tumors, suggesting that adding PI3K&#945; inhibitors to standard of care therapies in HR+ and HER2+ breast cancer may have strong clinical benefit in patients with PI3K&#945;-mutated cancers. The currently approved drugs, such as inavolisib and alpelisib show strong clinical benefit in combination with fulvestrant +/- CDK inhibitors in PI3K&#945;-mutated breast cancers, however these agents are still associated with significant toxicity from targeting the WT form of the enzyme, which is thought to limit the clinical benefit and quality of life for patients.&#160;While a number of molecules with modest selectivity for mutations versus WT PIK3CA are being developed, we believe that highly-selective inhibition of mutated PI3K&#945; is necessary to enable optimal target coverage and clinical benefit without eroding safety and quality of life due to inducing PI3K&#945;-related toxicity.</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe the potential market opportunity for PI3K&#945; inhibitors is large.&#160;Total new HR+/HER2- advanced breast cancer patients each year with the most common PI3K&#945; mutations (i.e., H1047, E542 and E545) is approximately 29,000 in the U.S. and &gt;60,000 in the U.S.+ EU5+Japan (see Figure 5). The single most common PI3K&#945; mutation, PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> , is found in approximately 14% of all breast cancers.&#160;As a comparison, the HER2+ population in breast cancer also accounts for approximately 14% of all patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The other common PI3K&#945; mutations (i.e. PI3K&#945;<sup style="font-size:75%; vertical-align:top">E542K </sup>and PI3K&#945;<sup style="font-size:75%; vertical-align:top">E545K</sup>) are less prevalent, and combined are found in approximately 10% of breast cancers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that there is a significant market opportunity for a highly-selective PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;inhibitor, with the ability to target an annual population of ~17,000 patients in the United States and &gt;35,000 patients in the United States+EU5 countries (UK, Spain, Italy, Germany and France)+Japan with PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>-mutated tumors across all lines of metastatic breast cancer (see Figure 5). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">83 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the data from the <span style="white-space:nowrap">PIKture-01</span> trial, as of the October&#160;28, 2024 cutoff date, and the selectivity of <span style="white-space:nowrap">OKI-219</span> <span style="white-space:nowrap">(approximately&#160;80-fold&#160;selectivity</span> for PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;over PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>), we believe we have the opportunity with <span style="white-space:nowrap">OKI-219</span> to optimize efficacy and safety in patients with PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>-mutated tumors, thus being well positioned to be an important therapeutic in this sizeable patient population.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g00n05.jpg" alt="LOGO" style="width:6.30556in;height:2.44259in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Figure 5. Estimated breast cancer incidence metrics across certain regions of the world. </span>Source: OnKure third party research </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations of Currently Approved PI3K Inhibitors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mutations in the PI3K/AKT/mTOR signaling axis occur frequently in many cancer types. PI3K&#945; is frequently mutated and activated in cancer, and aberrant PI3K&#945; activation is believed to be involved in tumor growth and metastasis. PI3K&#945; is composed of two components, a regulatory subunit, p85&#945;, and catalytic subunit, p110&#945;. An <span style="white-space:nowrap"><span style="white-space:nowrap">activating&#160;gain-of-function&#160;mutation</span></span> in the catalytic p110&#945; region of PI3K&#945; is one of the most common drivers of mutations in solid tumors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to its role in mediating signaling in multiple cell types in humans, inhibition of the normal wild-type PI3K&#945; enzyme is associated with a diverse range of toxicities, including hyperglycemia, rash, diarrhea, nausea, and stomatitis, which present a challenge to maintenance of patients on therapy. Hyperglycemia is one of the readily monitorable key toxicities in both patients and animal models that limits the efficacy of currently approved PI3K&#945; inhibitors and is often used as a sentinel indicator of <span style="white-space:nowrap">on-target</span> activity vs wild-type PI3K&#945;, however other effects, such as rash and GI toxicities can also be severe and debilitating for patients. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alpelisib (Piqray<sup style="font-size:75%; vertical-align:top">TM</sup>) was the first PI3K&#945; inhibitor approved, in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer.&#160;At the approved dose in the <span style="white-space:nowrap">SOLAR-1</span> trial for alpelisib, toxicities expected for inhibition of wild-type PI3K&#945; for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer were common.&#160;Other adverse events may be associated with the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PI3K&#945;-mutated, advanced or metastatic breast cancer.&#160;Increases in glucose were observed in 79% of patients treated with alpelisib (39% Grade 3 or 4) in this study. Other adverse events commonly associated with PI3K inhibition were also frequently observed: diarrhea (58%, 7% Gr3/4); nausea (45%, 2.5% Gr3/4); rash (52%, 20% Gr3/4); fatigue (42%, 5% Gr3/4) and stomatitis (30%, 2.5% Gr3/4). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">84 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Capivasertib (Truqap<sup style="font-size:75%; vertical-align:top">TM</sup>) is an AKT inhibitor developed by AstraZeneca, indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations. Capivasertib adverse events associated with PI3K pathway inhibition have also been commonly observed, highlighting the safety challenges of broadly inhibiting this pathway.&#160;Specifically, in the <span style="white-space:nowrap">CAPItello-291</span> study that supported approval of capivasertib, while the rate of hyperglycemia (37% overall, 3.1% Gr3/4) was lower than observed with alpelisib, other PI3K-related AEs were more notable, including: diarrhea (77% overall, 12% Gr3/4); cutaneous (56%, 15% Gr3/4); fatigue (38%, 1.9% Gr3/4); stomatitis (25%, 1.9% Gr3/4) and nausea (35%, 1.3% Gr3/4). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Inavolisib (Itovebi<sup style="font-size:75%; vertical-align:top">TM</sup>, Genentech) is a PI3K&#945;-selective inhibitor that was approved in 2024, in combination with fulvestrant and palbociclib in endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer.&#160;While the tolerability profile of inavolisib is considered to be manageable, this molecule still shows frequent adverse events associated with inhibition of the wild-type form of PI3K&#945;.&#160;These include increases in fasting glucose (85% overall, 22% Gr2 and 12.6% with Gr3/4); stomatitis (51% overall, 6% Gr3/4); diarrhea (48% overall, 3.7% Gr3/4); rash (26% overall, 0% Gr3/4), fatigue (38% overall, 1.9% Gr3/4) and nausea (28% overall, 0.6% Gr3/4).</p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While initial PI3K&#945; pathway inhibitors are active clinically, the frequent rate of adverse events due to inhibition of the wild-type PI3K&#945; pathway impact their use and are a challenge for patients, highlighting the need for more-selective inhibitors of mutated PI3K&#945; that can limit <span style="white-space:nowrap">on-target</span> toxicity. By minimizing the targeting of PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup><span style="white-space:nowrap">&#160;(approximately&#160;80-fold&#160;selectivity</span> for PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;over PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>), we <span style="white-space:nowrap">believe&#160;OKI-219&#160;can</span> achieve exposures required for activity in PI3K&#945;-mutated cancers with minimal effect on wild-type PI3K&#945; signaling, thus limiting the <span style="white-space:nowrap">on-target</span> toxicities, such as hyperglycemia, GI effects, fatigue, and rash. We believe that this is a key differentiator <span style="white-space:nowrap">for&#160;OKI-219&#160;compared</span> to <span style="white-space:nowrap">first-generation&#160;non-selective&#160;PI3K&#945;</span> inhibitors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2024, we announced preliminary safety, tolerability, and PK data from <span style="white-space:nowrap">PIKture-01</span> as of a data cut off on October&#160;28, 2024. <span style="white-space:nowrap">OKI-219</span> was well tolerated across all dose levels with no hyperglycemia, stomatitis, or rash observed with other PI3K&#945; inhibitors. Additionally, only grade 1 TRAEs were reported, with no dose interruptions, delays, reductions, or discontinuations reported for any adverse events. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g00n06.jpg" alt="LOGO" style="width:5.27in;height:2.95333in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 6. Initial TRAEs observed across dose levels in <span style="white-space:nowrap">PIKture-01</span> Part A.</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-weight:bold">Data cutoff October</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;28, 2024.</span><span style="font-weight:bold"></span><span style="font-weight:bold">&#160;</span>Source: OnKure data. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">85 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Blood-Brain Barrier Penetration </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brain metastases are estimated to occur in 98,000 to 170,000 cancer patients in the United States each year and in 10% to 26% of patients who die from their cancers. The observed growth in the incidence of brain metastasis over the last decade is believed to be partially attributed to the challenges of chemotherapeutic agents gaining access to the brain. While clinical outcomes for systemic malignancies have improved, the survival prognosis for brain metastasis has remained poor and for many patients remains at less than one year. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The blood-brain barrier (the &#8220;BBB&#8221;) is a semi-permeable membrane that regulates the transfer of substances from the circulatory system into the brain and provides protection for the brain from potentially harmful substances present in the rest of the body. The BBB is composed of cells that line blood vessels, known as endothelial cells, which are joined to each other with tight junctions and are surrounded by a layer of cells known as pericytes found in the capillary basement membrane. The tight junctions limit the entry of most molecules greater than approximately four hundred Daltons in molecular weight. While it is protective of the brain and contributes to overall health, the BBB nonetheless presents a challenge to physicians seeking to deliver anti-cancer agents to the brain and to treat brain metastasis. Preclinical data <span style="white-space:nowrap">for&#160;OKI-219&#160;in</span> a rat model suggest <span style="white-space:nowrap">that&#160;OKI-219&#160;is</span> highly brain-penetrant, reaching free drug concentrations in the brain similar to those observed in plasma, indicating potential utility in central nervous system disease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Distribution <span style="white-space:nowrap">of&#160;OKI-219&#160;through</span> the BBB and into the brain has also been confirmed in both dogs and monkeys. We believe that the ability <span style="white-space:nowrap">of&#160;OKI-219&#160;to</span> penetrate the BBB may enable it to effectively treat patients with brain metastasis in addition to those with systemic malignancies. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Current <span style="white-space:nowrap"><span style="white-space:nowrap">Standard-of-Care</span></span> in Breast Cancer </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many cancers are treated with combinations of two or more anti-cancer drugs. Specifically, in breast cancer, the choice of therapy is dependent on the type and stage of disease. Breast cancers are segmented diagnostically based on growth drivers, including hormonal receptors such as estrogen and progesterone receptors and the HER2/neu receptor. Approximately 70% of breast cancers over-express an estrogen receptor (&#8220;ER&#8221;) or progesterone receptor and are classified as HR+/HER2-. If diagnosed with early-stage disease, patients are usually treated with endocrine therapy, such as aromatase inhibitors or tamoxifen in the adjuvant setting, or they may receive chemotherapy before hormonal inhibitors if they are diagnosed with later-stage, intermediate or high-risk disease. For patients initially diagnosed with metastatic HR+/HER2- disease, and for those who have disease that has progressed to become metastatic HR+/HER2- disease, first-line treatment includes an aromatase inhibitor plus a CDK4/6 inhibitor, or the SERD, fulvestrant, plus a CDK4/6 inhibitor. In the second-line setting, treatment can vary depending on identified mutations in various genes. Patients with PI3K&#945; mutations are eligible to receive fulvestrant plus a PI3K&#945;- <span style="white-space:nowrap">or&#160;AKT-targeting&#160;agent</span> such as alpelisib or capivasertib. For patients with ESR1 mutations, physicians may prescribe a SERD such as elacestrant, a next-generation SERD marketed by Stemline Therapeutics, a subsidiary of Menarini Group, as Orserdu<sup style="font-size:75%; vertical-align:top">&#174;</sup>. For other patients, fulvestrant with or without the mTOR inhibitor everolimus would be indicated. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 14% of breast cancer patients over-express the HER2/neu receptor and are classified as HER2+. These patients are treated with HER2-targeting agents such as trastuzumab, marketed by Roche as Herceptin<sup style="font-size:75%; vertical-align:top">&#174;</sup>; generic biosimilars to trastuzumab; pertuzumab, marketed by Roche as Perjeta<sup style="font-size:75%; vertical-align:top">&#174;</sup>; ado-trastuzumab emtansine or T-DM1, marketed by Roche as Kadcyla<sup style="font-size:75%; vertical-align:top">&#174;</sup>; fam-trastuzumab deruxtecan-nxki or T-DXd, marketed by Daiichi Sankyo and AstraZeneca as Enhertu<sup style="font-size:75%; vertical-align:top">&#174;</sup>; and tucatinib, marketed by Pfizer as Tukysa<sup style="font-size:75%; vertical-align:top">&#174;</sup>. Typically, in early-stage or metastatic disease, the standard-of-care is trastuzumab plus chemotherapy, with or without pertuzumab. Ado-trastuzumab emtansine was the standard-of-care in second-line metastatic disease until the approval of trastuzumab deruxtecan in 2019. Trastuzumab deruxtecan is frequently prescribed in second-line HER2+ disease, whereas ado-trastuzumab emtansine is now typically used in the third-line setting. In patients with disease that progresses on all these therapy regimens, a triple combination of tucatinib, trastuzumab and capecitabine is often used in the fourth-line or salvage setting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">86 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Approximately 10% of breast cancer patients do not over-express HR or HER2 receptors. These tumors are classified as triple negative breast cancer (&#8220;TNBC&#8221;). Patients with TNBC are treated with chemotherapy, sacituzumab govitecan, marketed by Gilead as Trodelvy<sup style="font-size:75%; vertical-align:top">&#174;</sup>, immunotherapy such as pembrolizumab, marketed by Merck as Keytruda<sup style="font-size:75%; vertical-align:top">&#174;</sup>, or atezolizumab, marketed by Genentech as Tecentriq<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beyond HR and HER2 receptors, breast cancer patients are also screened <span style="white-space:nowrap">for&#160;PD-L1&#160;positivity,</span> which encompasses approximately 40% of patients, as well as for mutations in the germline BRCA1 or BRCA2 genes. The prevalence of a BRCA1 or BRCA2 mutation is only 3%&#8211;4% in HR+/HER2- patients but is approximately 15% in patients with TNBC. <span style="white-space:nowrap">In&#160;PD-L1&#160;positive,</span> triple negative breast cancer, patients are treated with atezolizumab or pembrolizumab, while two Poly ADP Polymerase inhibitors (&#8220;PARP inhibitors&#8221;) are approved for BRCA1/2 mutants: Olaparib, marketed by AstraZeneca as Lynparza<sup style="font-size:75%; vertical-align:top">&#174;</sup>, and talazoparib, marketed by Pfizer as Talzenna<sup style="font-size:75%; vertical-align:top">&#174;</sup>. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The PI3K&#945;-targeting agent alpelisib and <span style="white-space:nowrap">the&#160;AKT-targeting&#160;agent</span> capivasertib are currently approved in combination with fulvestrant in advanced HR+/HER2- breast cancer, providing a proof of concept for targeting mutated PI3K&#945; in this disease. These therapies have significant toxicity, however, which presents a challenge for their use. We believe that the ability to safely combine with fulvestrant or other SERDs is a critical advantage for any new therapy targeting PI3K&#945;-mutated HR+ breast <span style="white-space:nowrap">cancer.&#160;OKI-219&#160;was</span> tested in combination with a next-generation SERD known as camizestrant in a preclinical breast cancer model utilizing the T47D cell line. T47D is an estrogen receptor-positive luminal A subtype breast cancer cell line that harbors the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation and is frequently utilized in research of hormonal signaling in breast cancer. In mouse xenograft models implanted with T47D cells, monotherapy treatment with camizestrant at 10mg/kg QD resulted in slower tumor growth than the control but did not result in significant tumor volume reduction from baseline. Similarly, monotherapy dosing <span style="white-space:nowrap">with&#160;OKI-219&#160;at</span> 25mg/kg QID resulted in delay of tumor growth as well. The combination <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> camizestrant resulted in significant and dose-dependent tumor shrinkage, supporting the potential for combination therapy <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> SERDs in metastatic breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We tested the combination <span style="white-space:nowrap">of&#160;OKI-219&#160;with</span> tucatinib, an anti-HER2 small molecule tyrosine kinase inhibitor, in the HER2+ PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;HCC1954 breast cancer cell line. This cell line is resistant to tucatinib treatment, and in mouse xenograft models implanted with HCC1954 cells this was demonstrated by the continued tumor growth with 50mg/kg BID tucatinib <span style="white-space:nowrap">dosing.&#160;OKI-219&#160;monotherapy</span> at 200mg/kg QD appears to limit the tumor&#8217;s ability to grow but is not effective enough by itself to drive tumor shrinkage. The combination of tucatinib <span style="white-space:nowrap">and&#160;OKI-291&#160;resulted</span> in tumor shrinkage, suggesting that inhibiting mutant PI3K&#945; in combination with targeting HER2 can overcome poor responses to HER2-targeting agents used alone. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that breast cancer is an ideal tumor type for the initial development of mutant-selective PI3K&#945; inhibitors due to several factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that PI3K&#945; inhibitors have been approved in PI3K&#945;-mutated HR+ metastatic breast cancer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the high prevalence of the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation in breast cancer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the poor prognosis of patients with metastatic breast cancer who have PI3K&#945; mutations; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the fact that PI3K&#945; mutations appear to be truncal, meaning that they originate early in cancer development and, when mutated, are found in most cancer cells in a patient. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that initially focusing on PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;in advanced breast cancer patients may enable the eventual development <span style="white-space:nowrap">of&#160;OKI-219&#160;in</span> earlier lines of therapy as well as in patients with tumors with different tissues of origin besides breast and expanding the patient population that may benefit from treatment <span style="white-space:nowrap">with&#160;OKI-219.</span> </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">87 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Phase <span style="white-space:nowrap">1&#160;PIKture-01&#160;Trial</span> </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219&#160;is</span> currently being investigated in <span style="white-space:nowrap">the&#160;PIKture-01&#160;trial,</span> a Phase 1a/1b trial. This is an open-label international trial with sites in the United States, European Union, and Asia designed to evaluate the safety, tolerability, PK, PD, and preliminary antitumor activity <span style="white-space:nowrap">of&#160;OKI-219&#160;as</span> monotherapy as well as in combination with fulvestrant or trastuzumab. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">The&#160;PIKture-01&#160;trial</span> has three parts: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Part A</span>&#160;is a dose-ranging basket trial of solid tumors with a target enrollment of 24 subjects testing <span style="white-space:nowrap">OKI-219</span> as a monotherapy. This part of the trial is enrolling patients with solid tumors with the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation for whom there is no effective available therapy. The starting dose is 300mg BID, and this trial uses a Bayesian Optimal Interval design. We have dosed up to 1500mg BID. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Part B</span><span style="font-weight:bold"></span>&#160;is <span style="white-space:nowrap">investigating&#160;OKI-219&#160;in</span> combination with fulvestrant in HR+/HER2- advanced breast cancer. These patients must have locally advanced, unresectable or metastatic cancer with the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation and have received at least one prior line of hormonal therapy and at least one prior line of CDK 4/6 inhibitor therapy in the advanced or metastatic setting unless contraindicated. Part B was initiated in the fourth quarter of 2024. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold">Part C</span>&#160;will <span style="white-space:nowrap">investigate&#160;OKI-219&#160;in</span> combination with trastuzumab in HER2+ advanced breast cancer with the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation. These patients must have HER2+, locally advanced unresectable or metastatic breast cancer and also have received prior taxane, trastuzumab, pertuzumab, tucatinib or trastuzumab deruxtecan unless unavailable or contraindicated. Part C has not been initiated. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We expect that both Part B and Part C will initially enroll patients in <span style="white-space:nowrap">a&#160;single-arm&#160;dose</span> escalation trial and then would investigate high and low doses to comply with FDA&#8217;s project OPTIMUS dose exploration requirement. The objective of a dose-finding trial is to find the optimum dose instead of utilizing the maximum tolerated dose, which historically has been the dose chosen for pivotal trials of cancer drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary endpoint of Part A is to assess the safety <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> to identify the maximum tolerated dose and pharmacologically active dose(s) (&#8220;PAD&#8221;). Secondary endpoints include additional measures of safety and tolerability designed to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess plasma PK <span style="white-space:nowrap">of&#160;OKI-219;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the effect of food on the PK <span style="white-space:nowrap">of&#160;OKI-219;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">estimate preliminary antitumor activity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the dose-response impact of circulating tumor DNA (&#8220;ctDNA&#8221;); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the PD activity <span style="white-space:nowrap">of&#160;OKI-219&#160;and</span> its association with PK, safety, and efficacy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For Parts B and C, the primary endpoints during dose-ranging are to assess the safety <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> taken in combination with fulvestrant or trastuzumab and to identify two PAD doses that will be utilized during the dose optimization portion, for which the primary endpoint is to compare two PAD dose levels <span style="white-space:nowrap">of&#160;OKI-219&#160;plus</span> a fixed dose of fulvestrant or trastuzumab in order to identify the recommended Phase 2 dose. Secondary endpoints include additional measures of safety and tolerability <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> taken in combination with fulvestrant or trastuzumab, and are designed to: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the plasma PK <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> in combination with fulvestrant or trastuzumab; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the effect of food on the PK <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> in combination with fulvestrant or trastuzumab; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">estimate preliminary antitumor activity <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> taken in combination with fulvestrant or trastuzumab; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the dose-response impact of ctDNA <span style="white-space:nowrap">of&#160;OKI-219&#160;when</span> taken in combination with fulvestrant or trastuzumab; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">88 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">assess the PD activity <span style="white-space:nowrap">of&#160;OKI-219&#160;and,</span> finally, determine the impact <span style="white-space:nowrap">of&#160;OKI-219&#160;dosing</span> in combination with fulvestrant or trastuzumab on blood glucose and insulin. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, exploratory endpoints for all parts include an exploration of predictive biomarkers of response <span style="white-space:nowrap">to&#160;OKI-219&#160;in</span> blood and tumor tissue as monotherapy and while in combination with fulvestrant and trastuzumab. For dose optimization only, we also seek to determine the impact <span style="white-space:nowrap">of&#160;OKI-219&#160;on</span> quality of life. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During dose optimization, we anticipate that 20 participants will be randomized between two PAD levels in parts B and C. A sample size of 20 participants in each arm will provide 79% power to detect an increase in objective response rate from 5% to 20% within each PAD arm using <span style="white-space:nowrap">a&#160;one-sided&#160;exact</span> binomial test at the 10% level of significance. Monotherapy is not powered to assess efficacy. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g184865g10g40.jpg" alt="LOGO" style="width:5.85667in;height:2.75667in"/>
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Figure 7. <span style="white-space:nowrap">PIKture-01</span> trial design, key eligibility criteria and key endpoints as of October&#160;28, 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">OKI-219&#160;Potential</span> Future Trials </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">OKI-219&#160;was</span> designed to target the PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup>&#160;mutation to maintain or improve upon the efficacy and simultaneously to minimize the toxicities associated with first-generation PI3K&#945;<sup style="font-size:75%; vertical-align:top">WT</sup>&#160;inhibitors. We anticipate that this precision targeting of the H1047R mutation and minimal inhibition of wildtype PI3K&#945; should <span style="white-space:nowrap">enable&#160;OKI-219&#160;to</span> safely combine with one or two other cancer drugs and potentially result in synergistic clinical efficacy. We plan to <span style="white-space:nowrap">explore&#160;OKI-219&#160;in</span> combination with other drugs in multiple lines of treatment in breast cancer. Based on initial data from these combination studies, a number of possible development strategies will be considered, including <span style="white-space:nowrap">developing&#160;OKI-219&#160;in</span> combination with a SERD in second-line breast cancer patients; developing <span style="white-space:nowrap">OKI-219</span> in patients who have disease that has progressed on prior inavolisib or alpelisib treatment; and development of <span style="white-space:nowrap">OKI-219</span> in front-line metastatic breast cancer, in combination with CDK inhibitors, plus either an aromatase inhibitor or a SERD. With positive data in the metastatic setting, we would consider <span style="white-space:nowrap">developing&#160;OKI-219&#160;in</span> combination with an AI+ a CDK inhibitor in the adjuvant setting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold"><span style="white-space:nowrap">Pan-mutant</span> PI3K</span>&#945;<span style="font-weight:bold"></span><span style="font-weight:bold"> Precision Kinase Inhibitor Program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A key goal of cancer therapy is to improve efficacy, while maintaining a very well tolerated side effect profile, thus improving patient benefit and quality of life for patients.&#160;Our focus is on discovering and developing highly mutant-selective PI3K&#945; inhibitors that can improve target coverage and efficacy in PI3K&#945;-mutated cancers compared to existing agents, while also improving safety by sparing inhibition of wild type </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">89 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">PI3K&#945;.&#160;OKI-219</span> has approximately <span style="white-space:nowrap">80-fold</span> selectivity for PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> over the wild type form of the enzyme, a profile that may optimize the potential for efficacy and safety for treatment of tumors with a PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047R</sup> mutation, the most common PI3K&#945; mutation in breast cancer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that to fully target all the most common PI3K&#945; mutations in SOC combinations in HR+ mBC a PI3K&#945; <span style="white-space:nowrap">&#8220;Pan-mutant&#8221;</span> inhibitor will need to demonstrate approximately <span style="white-space:nowrap">10-fold</span> selectivity against each of the most common mutations (PI3K&#945;<sup style="font-size:75%; vertical-align:top">H1047X</sup>, PI3K&#945;<sup style="font-size:75%; vertical-align:top">E542K </sup>and PI3K&#945;<sup style="font-size:75%; vertical-align:top">E545K</sup>).&#160;Currently, we are aware of no compounds in clinical development that can achieve this level of selectivity across all the most common mutations, leaving an opportunity for development and approval of a <span style="white-space:nowrap">pan-mutant</span> PI3K&#945; inhibitor for patients regardless of their PI3K&#945; mutation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are actively developing <span style="white-space:nowrap">pan-mutant</span> candidates with activity and selectivity (&gt;10X) across the&#160;most common PI3K&#945; mutations (i.e., H1047R, E545K, and E542K).&#160;We believe a highly selective and potent <span style="white-space:nowrap">pan-mutant</span> inhibitor has the potential to achieve a maximal efficacy and safety profile in combinations in metastatic breast cancer, and may further enable sufficient activity as a single agent to target PI3K&#945;-mutated advanced cancer populations beyond breast cancer.&#160;This represents a significant patient population for which there are no current targeted therapies: Approximately 11% of all cancers harbor mutations in PI3K&#945;, and no PI3K&#945;-targeted therapies have shown sufficient efficacy to gain approval as a single-agent, potentially due to poor selectivity limiting the ability to get sufficient target inhibition without dose-limiting toxicities.&#160;We propose that a highly selective pan-mutant inhibitor may have the efficacy to enable use in this underserved patient population beyond breast cancer. We expect to announce a <span style="white-space:nowrap">pan-mutant</span> development candidate in the second quarter of 2025. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Helical Domain PI3K</span>&#945;<span style="font-weight:bold"></span><span style="font-weight:bold"> Precision Kinase Inhibitor Program </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, we are leveraging our discovery engine to develop a highly selective allosteric inhibitor molecule specifically targeting the PI3K&#945; E545K and E542K mutations (which are also known as helical domain mutations or <span style="white-space:nowrap">e-mutants)</span> and expect to announce a development candidate in 2026. Overall, the aim of our discovery engine is to deliver highly selective drug candidates that preserve wild-type PI3K&#945; while effectively targeting the vast majority of PI3K&#945;-mutated cancers, in breast and other cancers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Competition </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. While we believe that our technology, the expertise of our team, and our development experience and scientific knowledge provide us with competitive advantages, we face increasing competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Product candidates that we successfully develop and commercialize (whether alone or in partnership with others) may compete with existing therapies and new therapies that may become available in the future. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Many of our competitors, either alone or with their collaborators, have significantly greater financial resources, established presence in the market, and expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement, and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel, in establishing clinical trial sites and patient registration for clinical trials, and in-licensing or acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with larger companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors. Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer or more effective, have fewer or less-severe side effects, or are more convenient or less expensive than products that we may develop. Our competitors also may obtain FDA or other </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">90 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
regulatory approval for their products more rapidly than we can, which could result in those competitors establishing a strong market position before we are able to enter the market or could otherwise make the development or commercialization of our products more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and patient convenience. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are multiple PI3K&#945;-pathway targeted agents either approved or under clinical development that may compete <span style="white-space:nowrap">with&#160;OKI-219&#160;and</span> our PI3K&#945;-targeted portfolio. These include the marketed medicines alpelisib (Piqray<sup style="font-size:75%; vertical-align:top">&#174;</sup>, a PI3K&#945;-selective inhibitor marketed by Novartis) and capivasertib (Truqap<sup style="font-size:75%; vertical-align:top">&#174;</sup>, an AKT1 inhibitor marketed by Astra Zeneca), both of which are approved for the treatment of PI3K&#945;-mutated breast cancer patients in combination with the SERD fulvestrant. The PI3K&#945;-selective inhibitor inavolisib (Itovebi<sup style="font-size:75%; vertical-align:top">TM</sup>) was recently approved in combination with the SERD fulvestrant and the CDK4/6 inhibitor palbociclib (Ibrance<sup style="font-size:75%; vertical-align:top">&#174;</sup>) in endocrine resistant HR+/Her2- locally advanced or metastatic breast cancer. We are also aware of several novel PI3K-targeted therapies that are in clinical development. These include both <span style="white-space:nowrap">multiple&#160;non-mutation-selective</span> PI3K inhibitors such as gedatolisib (Celcuity Inc.), MEN1611 (Menarini), <span style="white-space:nowrap">and&#160;TOS-358&#160;(Totus</span> Medicines), and inhibitors designed to have greater selectivity for mutated PI3K&#945;, <span style="white-space:nowrap">including&#160;RLY-2608</span> (Relay Therapeutics), <span style="white-space:nowrap">STX-473&#160;(Scorpion</span> Therapeutics) and SNV4818 (Synnovation Therapeutics). Multiple other companies have disclosed or published research efforts in PI3K inhibitors that are at an early stage but could potentially advance to the clinic. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Finally, there are numerous other investigational therapies, spanning many modalities that are being evaluated preclinically and in clinical trials for breast cancer. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Manufacturing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not own or operate, and currently have no plans to establish any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical testing, and expect to rely on third parties for commercial manufacturing should any of our product candidates obtain marketing approval. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need to invest in our own manufacturing facilities, equipment and personnel while also enabling us to focus our expertise and resources on the discovery and development of our product candidates. In addition, we generally expect to rely on third parties for the manufacture of any companion diagnostics we may develop. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To date, we have obtained the regulatory starting materials and cGMP-compliant active pharmaceutical ingredients from three different suppliers, but could contract with other CMOs for these materials as the raw materials we use are commonly used and are available from multiple sources. We also currently rely on two CMOs, for the drug product <span style="white-space:nowrap">for&#160;OKI-219,&#160;but</span> may contract with other CMOs for the manufacture of drug product in the future. We are in the process of developing our supply chain for our product candidates and intend to put in place framework agreements under which third-party CMOs will generally provide us with necessary quantities of API and drug product on <span style="white-space:nowrap"><span style="white-space:nowrap">a&#160;project-by-project&#160;basis</span></span> based on our development requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As we advance our product candidates through development, we plan to explore adding backup suppliers for the API and drug product <span style="white-space:nowrap">for&#160;OKI-219&#160;and</span> future product candidates in order to protect against any potential supply disruptions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Intellectual Property </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We strive to protect and enhance the proprietary technologies, inventions and improvements that are commercially important to our business by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States directed to these technologies, inventions, improvements and to our drug candidates. We also rely on trade <span style="white-space:nowrap">secrets,&#160;know-how,&#160;trademarks,</span> continuing technological innovation and licensing opportunities to develop and maintain our proprietary and intellectual property position. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">91 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of&#160;February 1, 2025, our owned and licensed patent portfolio included 150 patents and patent applications, including two licensed U.S. issued patents and six owned U.S. issued patents, covering various aspects of our proprietary technology, product candidates, and related inventions and improvements. The patent portfolio also includes 36 licensed patents issued in jurisdictions outside of the United States, and 30 owned patent applications pending in jurisdictions outside of the United States that, in many cases, are counterparts to the foregoing U.S. patents and patent applications. Our licensed patents relate to a patent family that is no longer material to our business. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PI3K Platform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We currently own 16 patent families directed to our PI3K platform technology as summarized below. The patent families are differentiated based on the chemical structures of the PI3K inhibitor compounds. All of the family members are currently at the application stage and exist as one or more U.S. provisional (&#8220;USP&#8221;) applications, a Patent Cooperation Treaty (&#8220;PCT&#8221;) application, or as U.S. and <span style="white-space:nowrap">non-U.S.</span> national phase applications. Several of our current patent applications relate to and include composition of matter claims <span style="white-space:nowrap">for&#160;OKI-219.&#160;Four</span> of the families which are at the PCT application stage also have a Taiwanese (&#8220;TW&#8221;) application. The U.S. provisional applications secure an early filing date and provide an additional twelve months of patent protection beyond the normal <span style="white-space:nowrap">20-year</span> lifetime of any patent granted thereon. The PCT applications are single-application placeholders for filings in a majority of the countries and geographic regions of the world. The types of claims for each application are listed, and an expiration year for each family based on the actual or projected PCT filing dates is also provided. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 1: 15 applications/product and method of treatment claims/2043 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 2: PCT and TW applications/product and method of treatment claims/2043 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 3: PCT application/product and method of treatment claims/2043 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 4: PCT and TW applications/product and method of treatment claims/2043 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 5: PCT and TW applications/product and method of treatment claims/2044 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 6: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 7: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 8: 2 USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 9: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 10: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 11: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 12: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 13: USP application/product and method of treatment claims/2045 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 14: USP application/product and method of treatment claims/2046 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 15: USP application/product and method of treatment claims/2046 expiration </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Family 16: USP application/product and method of treatment claims/2046 expiration </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">92 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot guarantee that our owned pending patent applications, or any patent applications that we may in the future file or license from third parties, will result in the issuance of patents. We also cannot predict the scope of claims that may be allowed or enforced in our patents. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we may not obtain or maintain adequate patent protection for any of our programs and product candidates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms of individual patents depend upon the legal terms of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing <span style="white-space:nowrap">a&#160;non-provisional&#160;patent</span> application. In the United States, the patent term of a patent that covers <span style="white-space:nowrap">an&#160;FDA-approved&#160;drug</span> may also be eligible for patent term extension, which permits patent term restoration as compensation for the patent term lost during the FDA regulatory review process. The Hatch-Waxman Act permits a patent term extension of up to five years beyond the expiration of the patent. Similar provisions are available in Europe and <span style="white-space:nowrap">other&#160;non-U.S.&#160;jurisdictions</span> to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval, we expect to apply for patent term extensions on patents covering those products. We also plan to seek patent term extensions on any of our issued patents in any jurisdiction where available, but there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to patent protection, we also rely on trademark registration, trade secrets, know how, other proprietary information, and continuing technological innovation to develop and maintain our competitive position. We protect and maintain the confidentiality of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through contractual means, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Therefore, we may not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#8217;s relationship with us is to be kept confidential and not disclosed to third parties except in specific circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment or from the employee&#8217;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent positions of biotechnology companies like us are generally uncertain and involve complex legal, scientific and factual questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development or commercial strategies, alter our products or processes, obtain licenses, or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in derivation proceedings in the USPTO to determine priority of invention. For more information, see the section entitled &#8220;<span style="font-style:italic">Risk Factors&#8212;Risks Related to our Intellectual Property</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Government Regulation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our product candidates and our operations are subject to extensive regulation by the FDA and other federal and state authorities in the United States, as well as comparable authorities in other countries. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">93 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA and other federal, state, local and foreign authorities regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, and export and import of drug and combination products. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety, and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Drug Development </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, the FDA regulates drugs under the Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Drug products and substances are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process, or post-market may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current product candidates and any future small molecule product candidates must be approved by the FDA through the new drug application (&#8220;NDA&#8221;) process before they may be legally marketed in the United&#160;States. The process generally involves the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">completion of extensive preclinical studies in accordance with applicable regulations, including the FDA&#8217;s good laboratory practice requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">submission to the FDA of an IND, which must become effective before clinical trials may begin; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approval by an institutional review board (&#8220;IRB&#8221;) or ethics committee at each clinical trial site before each trial may be initiated; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">performance of adequate and well controlled clinical trials in accordance with applicable Investigational New Drug Application (&#8220;IND&#8221;) regulations, good clinical practice (&#8220;GCP&#8221;) requirements and other clinical trial-related regulations to establish the safety and efficacy of an investigational product for each proposed indication; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">preparation and submission to the FDA of an NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a determination by the FDA within 60 days of its receipt of an NDA to file the application for review; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">satisfactory completion <span style="white-space:nowrap">of&#160;an&#160;FDA&#160;pre-approval&#160;inspection&#160;of&#160;the</span> manufacturing facility or facilities where the drug product will be produced to assess compliance with cGMP requirements to assure that the facilities, methods, and controls are adequate to preserve the drug identity, strength, quality, and purity; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the NDA; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the drug in the United States; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">compliance with any post-approval requirements, including the potential requirement to implement a risk evaluation and mitigation strategy (&#8220;REMS&#8221;), and the potential requirement to conduct post-approval studies. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">94 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Preclinical and Clinical Studies </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preclinical and clinical testing and approval process requires substantial time, effort, and financial resources, and we cannot be certain that any approvals for any future product candidates will be granted on a timely basis or at all. Preclinical tests generally involve laboratory evaluations of drug chemistry, formulation, and stability, as well as studies to evaluate toxicity in animals, including pharmacology, pharmacokinetics, toxicokinetic, and metabolism studies that support subsequent clinical testing in humans. The results of the preclinical studies, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical protocol, are submitted to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational product to humans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The central focus of an IND submission is the general investigation plan and the protocol(s) for human studies. An IND must become effective before clinical trials may begin. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For each successive clinical trial conducted with the investigational drug, a separate, new protocol submission to an existing IND must be made, along with any subsequent changes to the investigational plan. Sponsors are also subject to ongoing reporting requirements, including submission of IND safety reports for any serious adverse experiences associated with use of the investigational drug or findings from preclinical studies suggesting a significant risk for human subjects, as well as IND annual reports on the progress of the investigations conducted under the IND. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical studies involve the administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#8217;s control, in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative, and must monitor the clinical trial until completed. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries, including the website maintained by the U.S. National Institutes of Health, ClinicalTrials.gov. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A sponsor that wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of an NDA. The FDA will generally accept a well designed and well conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an onsite inspection if deemed necessary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Clinical trials in the United States generally are conducted in three phases, known as Phase&#160;1, Phase&#160;2, and Phase&#160;3. Although the phases are usually conducted sequentially, they may overlap or be combined. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">95 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase&#160;1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase&#160;2 clinical trials typically involve studies in a limited population of disease-affected patients to determine possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage, and dosing schedule. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Phase&#160;3 clinical trials generally involve a large number of patients at multiple sites and are designed to evaluate the effectiveness of the product for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include comparisons with placebo and/or other comparator treatments. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Post-approval clinical trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&#160;4 clinical trials as a condition of approval of an NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical study investigators. Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA, and written IND safety reports must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the drug, findings from animal or<span style="font-style:italic">&#160;in vitro</span>&#160;testing that suggest a significant risk for human subjects, and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional animal safety studies and also must develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of our product candidates. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that our product candidates do not undergo unacceptable deterioration over their labeled shelf life. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">NDA Review </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following completion of clinical trials, data are analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling, chemistry, and manufacturing information in a request for approval to market the drug for one or more specified indications. The application must include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">96 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
product&#8217;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of an NDA must be obtained before a drug may be marketed in the United States. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Prescription Drug User Fee Act, as amended (the &#8220;PDUFA&#8221;), each NDA must be accompanied by an application user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for each marketed human drug. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a qualifying small business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA reviews all submitted NDAs before it accepts them for filing to determine if they are sufficiently complete to permit a substantive review, and the FDA may request additional information rather than accepting the NDA for filing. In this event, the application must be resubmitted with the additional information and is subject to payment of additional user fees. The FDA must make a decision on accepting an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA <span style="white-space:nowrap">begins&#160;an&#160;in-depth&#160;substantive&#160;review</span> of the NDA. Under the PDUFA, the FDA has agreed to certain performance goals in the review of NDAs <span style="white-space:nowrap">through&#160;a&#160;two-tiered</span> classification&#160;system: standard review and priority review. According to the PDUFA performance goals, the FDA endeavors to review applications subject to standard review within ten months, whereas the FDA&#8217;s goal is to review priority review applications within six months. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review process is often extended by FDA requests for additional information or clarification. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may refer applications for novel drug products or products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation, and recommendation as to whether the application should be approved and under what conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Before approving an NDA, the FDA will typically <span style="white-space:nowrap">conduct&#160;a&#160;pre-approval&#160;inspection&#160;of</span> the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. The FDA also closely analyzes the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the FDA evaluates an NDA and conducts inspections of manufacturing facilities, it will issue an Approval Letter or a Complete Response Letter. An Approval Letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data, including the potential requirement to conduct additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, or to conduct additional preclinical studies or manufacturing changes. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data and information are submitted, the FDA may decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive, and the FDA may interpret data differently than we interpret the same data. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Expedited Development and Review Programs </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA has a fast-track program that is intended to expedite or facilitate the process of reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast-track designation if they are intended </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">97 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast-track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request that the FDA designate the product for fast-track status at any time before receiving NDA approval, but ideally no later than <span style="white-space:nowrap">the&#160;pre-NDA&#160;meeting</span> with the FDA. Any product submitted to the FDA for marketing, including under a fast-track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A product may also be eligible for accelerated approval if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, such product must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (&#8220;IMM&#8221;), which endpoint is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. The FDA may withdraw drug approval or require changes to the labeled indication of the drug if confirmatory post-market trials fail to verify clinical benefit or do not demonstrate sufficient clinical benefit to justify the risks associated with the drug. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure safe use of the drug. The Food and Drug Omnibus Reform Act made several changes to the FDA&#8217;s authority and its regulatory framework, including, among other changes, reforms to the accelerated approval pathway, such as requiring the FDA to specify conditions for post-approval study requirements and setting forth procedures for the FDA to withdraw a drug on an expedited basis <span style="white-space:nowrap">for&#160;non-compliance&#160;with</span> post-approval requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, a drug may be eligible for designation as a breakthrough therapy if (a)&#160;it is intended, alone or in combination with one or more other drugs or biologics, to treat a serious or life-threatening condition and (b)&#160;preliminary clinical evidence indicates that it may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast-track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast-track designation, priority review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Post-Approval Requirements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Following approval of a new product, the product is subject to continuing regulation by the FDA, including, among other things, requirements relating to facility registration and drug listing monitoring and record-keeping adverse event and other periodic reporting, product sampling and distribution, and product promotion and advertising. The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although physicians may prescribe legally available <span style="white-space:nowrap">drugs&#160;for&#160;off-label&#160;uses,&#160;manufacturers</span> may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in conjunction with their first use or first publication. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After approval, if there are any changes to the approved product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require the development of additional data or preclinical studies and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">98 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
clinical trials. There also are continuing user fee requirements, under which FDA assesses an annual program fee for each product identified in an approved NDA. In addition, quality control, drug manufacture, packaging, and labeling products must continue to conform to cGMP requirements after approval. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products in accordance with cGMP regulations. Manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. The discovery of violative conditions, including failure to conform to cGMP regulations, could result in enforcement actions, and the discovery of problems with a product after approval may result in restrictions on a product, its manufacturer, or the NDA holder, including recalls. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also place other conditions on approvals including the requirement for a REMS, to assure the safe use of the product. If the FDA concludes that a REMS is needed, the NDA sponsor must submit a proposed REMS. The FDA will not approve the product without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription, or dispensing of products. Product approvals may be <span style="white-space:nowrap">withdrawn&#160;for&#160;non-compliance&#160;with&#160;regulatory</span> standards or if problems occur following initial marketing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may withdraw approval of a product if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Corrective action could delay drug distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, problems with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical studies to assess new safety risks or imposition of distribution restrictions, or other restrictions under a REMS program. Other potential consequences include, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the product from the market, or product recalls; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">fines, warning letters, or holds on clinical trials; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">refusal of the FDA to approve pending applications or supplements to approved applications; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">suspension or revocation of product approvals; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">product seizure or detention, or refusal to permit the import or export of the product; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">mandated modifications of promotional materials and labeling and the issuance of corrective information; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">issuance of safety alerts, Dear Healthcare Provider letters, press releases, or other communications containing warnings or other safety information about the product; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">injunctions or the imposition of civil or criminal penalties. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also must comply with the FDA&#8217;s advertising and promotion requirements, such as those <span style="white-space:nowrap"><span style="white-space:nowrap">related&#160;to&#160;direct-to-consumer&#160;advertising,&#160;the</span></span> prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling, <span style="white-space:nowrap">known&#160;as&#160;&#8220;off-label&#160;use,&#8221;&#160;industry-sponsored</span> scientific and educational activities, and promotional activities involving the internet and social media. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The FDA may also require post-approval studies and clinical trials if it finds that scientific data, including information regarding related drugs, make this appropriate. The purpose of such studies would be to assess a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">99 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
known serious risk or signals of serious risk related to the drug or to identify an unexpected serious risk when available data indicate the potential for a serious risk. The FDA may also require a labeling change if it becomes aware of new safety information that it believes should be included in the labeling of a drug. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to comply with the applicable regulatory requirements at any time during the product development process, the approval process, or after approval may subject an applicant or manufacturer to, among other things, adverse publicity, warning letters, corrective advertising, and potential civil and criminal penalties. FDA sanctions could include refusal to approve pending applications, withdrawal of an approval, clinical hold, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, mandated corrective advertising or communications with doctors, debarment, restitution, disgorgement of profits, or civil or criminal penalties. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">U.S. Patent-Term Restoration and Marketing Exclusivity </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depending upon the timing, duration, and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#8217;s approval date. An application for patent extension must be filed with the USPTO within 60 days of FDA approval of the drug product even if the product cannot be commercially marketed at that time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The patent term restoration period <span style="white-space:nowrap">is&#160;generally&#160;one-half&#160;the&#160;time</span> between the effective date of an IND or the issue date of the patent, whichever is later, and the submission date of an NDA plus the time between the submission date of an NDA or the issue date of the patent, whichever is later, and the approval of the NDA application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond our current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant NDA. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Market exclusivity provisions under the FDCA also can delay the submission or the approval of certain applications. The FDCA provides a five-year <span style="white-space:nowrap">period&#160;of&#160;non-patent&#160;marketing&#160;exclusivity</span> within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not approve an abbreviated new drug application (&#8220;ANDA&#8221;), or a 505(b)(2) NDA, submitted by another company for another version of such drug, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent <span style="white-space:nowrap">invalidity&#160;or&#160;non-infringement.&#160;The</span> FDCA also provides three years of marketing exclusivity for an NDA, 505(b)(2) NDA or supplement to an existing NDA if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the original active agent. Such three-year and five-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well controlled clinical trials necessary to demonstrate safety and effectiveness. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">100 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Other U.S. Regulatory Matters </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as, sell, market, and distribute any products for which we obtain marketing approval. The applicable federal, state, and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to the following: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Anti-Kickback Statute (&#8220;AKS&#8221;), which makes it illegal for any person, including a prescription drug or medical device manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Moreover, the Patient Protection and Affordable Care Act of 2010 (&#8220;ACA&#8221;) provides that the government may assert that a claim including items or services resulting from a violation of the federal AKS constitutes a false or fraudulent claim for purposes of the federal False Claims Act (&#8220;FCA&#8221;). </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The FCA, including the civil FCA that can be enforced by private citizens through civil whistleblower or qui tam actions, and civil monetary penalties prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government, and/or impose exclusions from federal health care programs and/or penalties for parties who engage in such prohibited conduct. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;) prohibits, among other things, executing or attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">HIPAA also imposes obligations on covered entities such as health insurance plans, healthcare clearinghouses, and certain health care providers and their respective business associates and their covered subcontractors, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program, with specific exceptions, to annually report to the CMS information regarding certain payments and other transfers of value to physicians (defined to include doctors, dentists, optometrists, podiatrists, and chiropractors), <span style="white-space:nowrap">certain&#160;non-physician&#160;healthcare</span> professionals (such as physician assistants and nurse practitioners, among others), and teaching hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The federal Foreign Corrupt Practice Act (&#8220;FCPA&#8221;) prohibits any U.S. individual or business from paying, offering, or authorizing payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with: accounting provisions requiring them to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations; analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed <span style="white-space:nowrap">by&#160;non-governmental&#160;third-party</span> payors, including private insurers; state laws that require biotechnology companies to comply with the biotechnology industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government; state and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">101 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
local laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures and require the registration of their sales representatives; state laws that require biotechnology companies to report information on the pricing of certain drug products; and state and foreign laws that govern the privacy and security of health information in some circumstances (such as Washington&#8217;s My Health, My Data Act, which, among other things, provides for a private right of action), many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Manufacturing, sales, promotion, and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. In addition, the distribution of pharmaceutical and/or medical device products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical and/or medical device products. Products must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act of 1970 as well as other applicable consumer safety requirements. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The failure to comply with any of these laws or regulatory requirements could subject companies to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in significant civil, criminal, and administrative penalties, including damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs such as Medicare and Medicaid, integrity oversight and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings, injunctions, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Coverage and Reimbursement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant uncertainty exists as to the coverage and reimbursement status of any product candidate for which we may seek regulatory approval. Sales in the United States will depend, in part, on the availability of sufficient coverage and adequate reimbursement from third-party payors, which include government health programs such as Medicare, Medicaid, TRICARE, and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which our customers may seek reimbursement for our product candidates can be subject to challenge, reduction, or denial by third-party payors. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The process for determining whether a third-party payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. A third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Additionally, in the United States there is no uniform policy among payors for coverage or reimbursement. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, but also have their own methods and approval processes. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. If coverage and adequate reimbursement are not available, or are available only at limited levels, successful commercialization of, and/or a satisfactory financial return on, any product we develop may not be possible. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct expensive studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">102 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United&#160;States and generally prices tend to be significantly lower. For more information, see the section entitled &#8220;<span style="font-style:italic">Risk Factors&#8212;We may face difficulties from changes to current regulations and</span><span style="font-style:italic">&#160;future legislation. Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations</span>.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Healthcare Reform </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the United States, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect the profitable sale of product candidates. Among policy makers and payors in the United States, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In March 2010, the ACA was passed, which substantially changed the way healthcare is financed by both the government and private insurers, and significantly impacts the U.S. pharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The ACA, among other things: (1)&#160;increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations; (2)&#160;created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics that are inhaled, infused, instilled, implanted, or injected; (3)&#160;established an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in certain government healthcare programs; (4)&#160;expanded the availability of lower pricing under the 340B drug pricing program by adding new entities to the program; (5)&#160;expanded the eligibility criteria for Medicaid programs; (6)&#160;created a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research; (7)&#160;created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (and 70% commencing January&#160;1, <span style="white-space:nowrap"><span style="white-space:nowrap">2019)&#160;point-of-sale&#160;discounts</span></span> off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D; and (8)&#160;established a Center for Medicare Innovation at the CMS, to test innovative payment and service delivery models to lower Medicare and Medicaid spending, potentially including prescription drugs. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Since its enactment, there have been executive, judicial, and congressional challenges to certain aspects of the ACA. For example, in June 2021 the U.S. Supreme Court held that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case on procedural grounds without specifically ruling on the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">103 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
constitutionality of the ACA. Further, prior to the U.S. Supreme Court ruling, on January&#160;28, 2021, President Biden issued an executive order that initiated a special enrollment period in 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This executive order also instructs certain governmental agencies to review existing policies and rules that limit access to health insurance coverage through Medicaid or the ACA, among others. It is possible that the ACA will be subject to judicial or congressional challenges in the future. It is unclear how any such challenges and healthcare measures promulgated by the Biden administration will impact the ACA, our business, financial condition, and results of operations. Complying with any new legislation or reversing changes implemented under the ACA could be time-intensive and expensive, resulting in a material adverse effect on our business. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Other legislative changes have been proposed and adopted since the ACA was enacted. These changes include aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, effective April&#160;1, 2013, which, due to subsequent legislative amendments, will stay in effect through 2032, unless additional congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several providers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in Medicare and other healthcare funding, which could have a material adverse effect on customers for our drugs, if approved, and accordingly, our financial operations. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, there has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in several congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drug products. For example, the American Rescue Plan Act of 2021 eliminated the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than they receive on the sale of products, which could have a material impact on our business. In August 2022, Congress passed the IRA, which includes prescription drug provisions that have significant implications for the pharmaceutical industry and Medicare beneficiaries, including allowing the federal government to negotiate a maximum fair price for certain high-priced single-source Medicare drugs, imposing penalties and excise tax for manufacturers that fail to comply with the drug price negotiation requirements, requiring inflation rebates for all Medicare Part B and Part D drugs, with limited exceptions, if their drug prices increase faster than inflation, and redesigning Medicare Part D to <span style="white-space:nowrap"><span style="white-space:nowrap">reduce&#160;out-of-pocket&#160;prescription</span></span> drug costs for beneficiaries, among other changes. Only high-expenditure, single-source drugs that have been approved for at least seven years (11 years for single-source biologics) qualify for negotiation, with the negotiated price taking effect two years after the selection year. For 2026, the first year in which negotiated prices become effective, CMS selected 10 high-cost Medicare Part D drugs in 2023, negotiations began in 2024, and the negotiated maximum fair price for each drug has been announced. CMS has selected 15 additional Medicare Part D drugs for negotiated maximum fair pricing in 2027. For 2028, up to an additional 15 drugs, which may be covered under either Medicare Part B or Part D, will be selected, and for 2029 and subsequent years, up to 20 additional Part B or Part D drugs will be selected. Various industry stakeholders, including certain pharmaceutical companies and the Pharmaceutical Research and Manufacturers of America, have initiated lawsuits against the federal government asserting that the price negotiation provisions of the IRA are unconstitutional. The impact of these judicial challenges and other legislative, executive, and administrative actions of the government on us and the pharmaceutical industry as a whole is unclear. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access, and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. A number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">104 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
increase our compliance burden and expose us to greater liability under such state laws once we begin commercialization after obtaining regulatory approval for any of our products. Further, the FDA has authorized the state of Florida to develop an importation program to import certain prescription drugs from Canada for a limited period to help reduce drug costs, provided that Florida&#8217;s Agency for Health Care Administration meets the requirements set forth by the FDA. Other states may follow Florida. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our drug candidates or additional pricing pressures. We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose regulatory approval that may have been obtained and we may not achieve or sustain profitability. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Foreign Regulation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our product candidates to the extent we choose to develop or sell any product candidates outside of the United States. The approval process varies from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employees and Human Capital Resources </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&#160;7, 2025, we had 46 employees, 35 of whom were engaged in research and development activities. We also engage contractors and consultants. None of our employees are represented by a labor union or covered under a collective bargaining agreement. We have not experienced any work stoppages due to employee disputes, and we consider our relationship with our employees to be good. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our human capital resources objectives include, as applicable, identifying, recruiting, retaining, incentivizing, and integrating our existing and new employees, advisors, and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of OnKure by motivating such individuals to perform to the best of their abilities and achieve our objectives. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Facilities </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our corporate headquarters is located in Boulder, Colorado, and consists of approximately 15,000 square feet of office and laboratory space pursuant to a lease that expires in December 2026, with the option to extend for a five-year period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the Merger, we assumed the lease of approximately 5,100 square feet of office space for the former Reneo headquarters in Irvine, California under a <span style="white-space:nowrap">non-cancelable</span> operating lease through November 2026. In January 2025, we subleased this space for the remaining duration of the lease. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We lease all of our facilities and do not own any real property. We believe that our existing facilities are adequate and suitable for our current needs and that, should it be needed, suitable additional or alternative space will be available as and when needed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Legal Proceedings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we may become involved in legal proceedings relating to claims arising from the ordinary course of business. Information pertaining to legal proceedings is described in Note&#160;14 to our annual audited consolidated financial statements appearing elsewhere in this prospectus and incorporated by reference herein. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">105 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_12">MANAGEMENT </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth the names, ages, and positions of our executive officers and members of the our Board of Directors (the &#8220;Board&#8221;) as of March&#160;1, 2025: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:33%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:60%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">66</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">President and Chief Executive Officer and Class&#160;I Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Leverone, C.P.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">51</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Financial Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Agresta, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">52</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Medical Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dylan Hartley, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">56</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Chief Scientific Officer</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee</span> Directors</span></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isaac Manke, Ph.D. (1) (2) (3)*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">48</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;I Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Michael Carruthers (1)*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">67</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Phillips, Ph.D. (1) (2)*</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">54</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie M. Jansen, M.D., Ph.D.&#160;(3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Grey</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">72</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;III Director (4)</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward T. Mathers (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center">64</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap">Class&#160;II Director (4)</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Committee Chair </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Audit Committee of the Board </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Compensation Committee of the Board </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Member of the Nominating and Corporate Governance Committee of the Board </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See &#8220;Board of Directors&#8221; below for discussion of Class&#160;I &#8211; III Director service terms. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Nicholas Saccomano, Ph.D</span>. has served as our Chief Executive Officer and President and a member of the Board since the closing of the Merger. He previously served as Legacy OnKure&#8217;s Chief Executive Officer since September&#160;2023, as President since May 2024, and as a member of the Legacy OnKure board of directors since March 2021. Dr.&#160;Saccomano has over 30 years of experience in pharmaceutical and biotechnology research and development, with expertise in discovery research, clinical development, portfolio strategy, technology and clinical candidate licensing, and scientific partnering. Prior to joining Legacy OnKure, he was the Chief Science Officer at Pfizer Inc.&#8217;s Boulder facility (previously Array BioPharma, Inc. prior to its acquisition by Pfizer, Inc. in 2019) from August 2019 to January 2022, the Chief Scientific Officer at Array BioPharma Inc. from May 2014 to August 2019, and the Chief Technology Officer at SomaLogic from July 2009 to May 2014. Dr.&#160;Saccomano currently serves on the board of directors of BioLoomics, Inc., Gyges Therapeutics, Kestrel Therapeutics Inc., and Modulo Bio, Inc. Dr.&#160;Saccomano holds a B.S. from the State University of New York at Buffalo and a Ph.D. in organic chemistry from Columbia University. We believe Dr.&#160;Saccomano is qualified to serve on the Board because of his role as our President and Chief Executive Officer and his extensive leadership and operational experience within the pharmaceutical and biotech industries. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jason Leverone, C.P.A</span>. has served as our Chief Financial Officer since the closing of the Merger. He previously served as Legacy OnKure&#8217;s Chief Financial Officer since January 2022. Prior to joining Legacy OnKure, Mr.&#160;Leverone was the Chief Financial Officer and Secretary of Viridian Therapeutics (NASDAQ: VRDN) (formerly miRagen Therapeutics prior to a reverse merger that closed in October 2020) from November 2008 to May 2021, and Senior Director of Finance and Controller of Replidyne, Inc., a publicly traded biotechnology company, from November 2005 to February 2009. He began his professional career in public accounting at Ernst&#160;&amp; Young LLP and continued with Arthur Andersen LLP. Mr.&#160;Leverone is a Certified Public Accountant and holds a B.S. in business administration from Bryant University. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Samuel Agresta, M.D</span>. has served as our Chief Medical Officer since the closing of the Merger. He previously served as Legacy OnKure&#8217;s Chief Medical Officer since February 2024. Prior to joining Legacy </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">106 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
OnKure, he was Chief Medical Officer at Foghorn Therapeutics Inc. from September 2019 to September 2023, Director and Chief Medical Officer at Infinity Pharmaceuticals, Inc. from August 2018 to August 2019, and Vice President and Head of Clinical Development at Agios Pharmaceuticals Inc. from December 2011 to August 2018. Prior to these roles, Dr.&#160;Agresta served as Senior Medical Director at Merrimack Pharmaceuticals, Inc. and Genentech, Inc. Dr.&#160;Agresta holds a B.S. from Georgetown University, an M.P.H. and T.M. from Tulane School of Public Health and Tropical Medicine, an M.D. from Tulane University Medical School and an M.S. in clinical investigation from the University of South Florida. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Dylan Hartley, Ph.D</span>. has served as our Chief Scientific Officer since the closing of the Merger. He previously served as Legacy OnKure&#8217;s Chief Scientific Officer since July 2024. Dr.&#160;Hartley has over 20 years of experience in drug research and development, including expertise in pharmacology, toxicology, drug metabolism and pharmacokinetics. Most recently, Dr.&#160;Hartley served as Vice President, Head of Research at Pfizer, Inc.&#8217;s Boulder facility (previously Array BioPharma, Inc. prior to its acquisition by Pfizer, Inc. in 2019) from September 2021 to July 2024. Dr.&#160;Hartley held a succession of roles of increasing responsibility at Array BioPharma, Inc. since 2011. He holds a B.A. in biological sciences from the University of Northern Colorado and a Ph.D. in pharmaceutical sciences from the University of Colorado Health Sciences Center. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Non-Employee&#160;Directors</span> </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Isaac Manke, Ph.D</span>. has been a member of the Board since the closing of the Merger and previously served on the Legacy OnKure board of directors since March 2021. Dr.&#160;Manke has more than 15 years of experience in the life science industry as an investor, research analyst, consultant and scientist. Dr.&#160;Manke has served as a General Partner at Acorn Bioventures since April 2020, where he focuses on investing in small cap public and private biotechnology companies. Prior to Acorn, Dr.&#160;Manke spent 11 years at New Leaf Venture Partners (NLV) through 2019. In addition to private venture investments, during his time at NLV, he also led the firm&#8217;s public investment activities. Dr.&#160;Manke has been a board member for several biotechnology companies, including Q32 Bio Inc. (NASDAQ: QTTB) since October 2020, True North Therapeutics (acquired by Bioverativ), Karos Pharmaceuticals (acquired by an undisclosed company), and Addex Therapeutics Ltd (NASDAQ: ADXN) since 2016. Dr.&#160;Manke holds a B.A. in biology and a B.A. in chemistry from Minnesota State University (Moorhead), and a Ph.D. in biophysical chemistry and molecular structure from the Massachusetts Institute of Technology. We believe Dr.&#160;Manke is qualified to serve on the Board because of his education and his experience in the life sciences industry and in venture capital. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Andrew Phillips, Ph.D</span>. has been a member of the Board since the closing of the Merger and previously served on the Legacy OnKure board of directors since March 2021. He was appointed as Chairman in connection with the closing of the Merger. Dr.&#160;Phillips has served as President and Chief Executive Officer of Aleksia Therapeutics, Inc., a biotechnology company, and Nexo Therapeutics, Inc., a biotechnology company, since August 2022. Previously, Dr.&#160;Phillips served as a Managing Director at Cormorant Asset Management, an investment manager, from August 2020 to August 2022. Dr.&#160;Phillips has served as on the board of directors of Enliven Therapeutics, Inc. (NASDAQ: ELVN) since December 2020, and MoonLake Immunotherapeutics, Inc. (NASDAQ: MLTX), since April 2021. He has also served as the Chief Financial Officer of Helix Acquisition Corp. from April 2021 to April 2022, and since June 2021, he has served as Chief Executive Officer of Blossom Bioscience Ltd. From January 2016 to March 2020, Dr.&#160;Phillips was with C4 Therapeutics, Inc. (NASDAQ: CCCC), a clinical-stage biopharmaceutical company focused on therapeutics for the treatment of cancer and other diseases, where he served as Chief Executive Officer from May 2018 to March 2020, President from September 2016 to May 2018 and Chief Scientific Officer from January 2016 to May 2018. From July 2014 to January 2016, he served as Senior Director, Center for Development of Therapeutics at the Broad Institute, a biomedical and genomic research organization. From June 2010 to January 2015, Dr.&#160;Phillips was a Professor of Chemistry at Yale University, and from July 2001 to June 2010, he was Assistant Professor, Associate Professor, and Professor of Chemistry and Biochemistry at the University of Colorado. He holds a B.Sc. in biochemistry and a Ph.D. in chemistry from the University of Canterbury in New Zealand. We believe Dr.&#160;Phillips is qualified to serve on the Board because of his extensive experience in the biotechnology industry, his education and his leadership experience as a senior executive. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">107 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">R. Michael Carruthers</span>&#160;has been a member of the Board since the closing of the Merger and previously served on the Legacy OnKure board of directors since March 2021. Mr.&#160;Carruthers has served as the Chief Financial Officer of Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a publicly traded biopharmaceutical company, since September 2020. Mr.&#160;Carruthers consulted as Chief Financial Officer of OnKure between March 2019 and May 2021, and has served on the board of directors of Elevation Oncology (NASDAQ: ELEV), a publicly traded biopharmaceutical company, since May 2021. Mr.&#160;Carruthers previously served as Chief Financial Officer of Brickell Biotech, Inc., a publicly traded biopharmaceutical company, from December 2017 to October 2020, and ClinOne, Inc., clinical trial management company, from August 2018 to May 2020. He also served as Interim President of Nivalis Therapeutics, Inc., a publicly traded biopharmaceutical company, from January 2017 to August 2017 and Chief Financial Officer and Secretary from February 2015 to August 2017. From December 1998 to February 2015, he served as Chief Financial Officer of Array BioPharma Inc. a publicly traded biopharmaceutical company. Prior to Array, he served as Chief Financial Officer of Sievers Instruments, Inc., a water purification technology company, Treasurer and Controller for the Waukesha division of Dover Corporation, a global manufacturing company, and a Senior Auditor with Coopers&#160;&amp; Lybrand, LLP. Mr.&#160;Carruthers studied accounting at Western Colorado University, and received a B.S. in accounting from the University of Colorado Boulder and a M.B.A. from the University of Chicago. We believe Mr.&#160;Carruthers is qualified to serve on the Board because of his experience serving as chief financial officer for publicly traded biopharmaceutical companies and his extensive knowledge of corporate finance and strategic planning. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Valerie M. Jansen, M.D., Ph.D.,</span>&#160;joined the Board in connection with the closing of the Merger. She has served as the Chief Medical Officer of Elevation Oncology, Inc. (NASDAQ: ELEV) since October 2021 and as the Vice President of Clinical Development from April 2021 to October 2021. Prior to that, she served as Executive Medical Director of Mersana Therapeutics (NASDAQ: MRSN) from January 2020 to April 2021. Prior to Mersana Therapeutics, Dr.&#160;Jansen was employed at Eli Lilly and Company (NYSE: LLY), where she served as Senior Medical Advisor from September 2017 to January 2020. Prior to Eli Lilly, Dr.&#160;Jansen was employed at the Vanderbilt University Medical Center from July 2010 to July 2018 serving, most recently, as Adjunct Instructor in Medicine. Dr.&#160;Jansen received a B.A. in Chemistry from Maryville College, a Ph.D. in Molecular Sciences from the University of Tennessee Health Science Center and an M.D. from the University of Chicago Pritzker School of Medicine. We believes Dr.&#160;Jansen is qualified to serve on the Board because of her experience serving as chief medical officer and other clinical development roles for biopharmaceutical companies. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Michael Grey</span>&#160;has been a member of the Board since the closing of the Merger. He previously served as Executive Chairman of Reneo&#8217;s board of directors from December 2017 until the closing of the Merger, and as Chairman of Reneo&#8217;s board of directors and Reneo&#8217;s Chief Executive Officer from September 2014 to December 2017. Mr.&#160;Grey has served as the Executive Chairman of the board of the following life science companies: Spruce Biosciences, Inc. (NASDAQ: SPRB) since March 2018, Plexium, Inc., a private company, since August 2020, and Theolytics Ltd., a private company, since November 2023. Mr.&#160;Grey has served as Chairman of Sorriso Pharmaceuticals, Inc., a private company, since April 2022 and as Chief Executive Officer from April 2021 to April 2022. Additionally, Mr.&#160;Grey previously served in the below listed capacities for the following life science companies: Executive Chairman and Chief Executive Officer of Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) from May 2018 to March 2019, Chief Executive Officer of Amplyx Pharmaceuticals, Inc., a private company, from September 2014 to December 2017 and then as Executive Chairman from January 2018 until April 2020, and as Executive Chairman of Curzion Pharmaceuticals, Inc., a private company, from May 2019 to April 2020. Mr.&#160;Grey has served on the board of directors of Mirum Pharmaceuticals since May 2018 and as Chair since March 2019. Mr.&#160;Grey also previously served on the board of directors of the following publicly traded life science companies: BioMarin Pharmaceuticals (NASDAQ: BMRN) from December 2005 until May 2021, Horizon Therapeutics plc (NASDAQ: HZNP) from January 2011 until October 2023, and Mirati Therapeutics Inc. from November 2014 to June 2021. Mr.&#160;Grey has also served as a venture partner at Pappas Ventures, a venture capital firm, since January 2010. Mr.&#160;Grey has more than 45 years of experience in the pharmaceutical and biotechnology industries and has held senior positions at a number of companies, including President and Chief Executive Officer of SGX Pharmaceuticals, Inc. (sold to Eli Lilly in 2008), President and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">108 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Chief Executive Officer of Trega Biosciences, Inc. (sold to LION Bioscience, Inc. in 2001) and President of BioChem Therapeutic Inc. Prior to these, Mr.&#160;Grey served in various roles with Glaxo, Inc., and Glaxo Holdings PLC, culminating in his position as Vice President, Corporate Development and director of international licensing. Mr.&#160;Grey received a B.S. in chemistry from the University of Nottingham in the United Kingdom. We believe that Mr.&#160;Grey&#8217;s extensive experience managing and leading both early stage and established companies within the pharmaceutical and biotechnology industries qualify him to serve on the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Edward T. Mathers</span>&#160;has been a member of the Board since the closing of the Merger and previously served as a member of Reneo&#8217;s board of directors from December 2017 until the closing of the Merger. Mr.&#160;Mathers is Partner at New Enterprise Associates, Inc. (NEA), a private venture capital firm focusing on technology and healthcare investments. Mr.&#160;Mathers serves on the board of directors of the following publicly traded life science companies: Trevi Therapeutics, Inc. (NASDAQ: TRVI) since July 2017, Inozyme Pharma, Inc. (NASDAQ: INZY) since January 2017, Rhythm Pharmaceuticals, Inc. (FSE: 1RV.F) since March 2010, Synlogic, Inc. (NASDAQ: SYBX) since October 2012, Senti Biosciences, Inc. (NASDAQ: SNTI) since July 2016 and MBX Biosciences, Inc. (NASDAQ: MBX) since July 2020. Mr.&#160;Mathers previously served on the board of directors of the following publicly traded companies: ObsEva SA (OTC: OBSEF) from November 2015 to June 2023, Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) from November 2018 to September 2022, Akouos, Inc. from October 2017 to December 2022, Lumos Pharma, Inc. from January 2014 to March 2020, Ra Pharmaceuticals, Inc. from February 2010 to April 2020, and Liquidia Technologies, Inc. from July 2009 to May 2019. From 2002 to 2008, Mr.&#160;Mathers served as Executive Vice President, Corporate Development and Venture at MedImmune, Inc., a biopharmaceutical company, and led its venture capital subsidiary, MedImmune Ventures, Inc. Before Joining MedImmune in 2002, Mr.&#160;Mathers was Vice President, Marketing and Corporate Licensing and Acquisitions at Inhale Therapeutic Systems, a biotechnology company. Previously, Mr.&#160;Mathers spent 15 years a Glaxo Wellcome, Inc. (GlaxoSmithKline), where he held various sales and marketing positions. Mr.&#160;Mathers received a B.S. in Chemistry from North Carolina State University. We believe that Mr.&#160;Mathers&#8217; experience as a venture capitalist, as an executive and in business development and his experience in serving on the board of directors for several public and private pharmaceutical and life sciences companies qualifies him to serve on the Board. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There are no family relationships among any of our directors or executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independence of the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required under the Nasdaq listing rules, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by its board of directors. Our Board consults with counsel to ensure that its determinations are consistent with relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent listing standards of the Nasdaq, as in effect from time to time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Consistent with these considerations, after review of all relevant identified transactions or relationships between each director, or any of his or her family members, and us, our senior management and our independent registered public accounting firm, the Board has affirmatively determined that the following five directors are independent directors within the meaning of the applicable Nasdaq listing standards: Mr. R. Michael Carruthers, Dr. Isaac Manke, Dr. Andrew Phillips, Mr. Edward T. Mathers and Dr. Valerie M. Jansen. In making this determination, the Board found that none of the directors had a material or other disqualifying relationship with us. Dr. Saccomano, our President and Chief Executive Officer is not an independent director by virtue of his employment relationship with us. Mr. Grey is not considered an independent director because of his recent former service as Reneo&#8217;s Executive Chairman. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our business and affairs are organized under the direction of the Board. Our executive officers are appointed by and serve at the discretion of our Board. The Board currently consists of seven directors divided into three </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">109 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
staggered classes, with one class to be elected at each annual meeting to serve for a three-year term. Andrew Phillips serves as Chairman of our Board. The primary responsibilities of the Board are to provide oversight, strategic guidance, counseling and direction to our management. The Board meets on a regular basis and additionally as required. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of our Amended Certificate of Incorporation and the Amended Bylaws, the Board is divided into three classes, Class&#160;I, Class&#160;II and Class&#160;III, with members of each class serving staggered three-year terms. The members of the classes are divided as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;I directors are Nicholas Saccomano and Isaac Manke, and their terms will expire at the annual meeting of stockholders to be held in 2025; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;II directors are R. Michael Carruthers, Valerie M. Jansen and Edward T. Mathers, and their terms will expire at the annual meeting of stockholders to be held in 2026; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the Class&#160;III directors are Andrew Phillips and Michael Grey, and their terms will expire at the annual meeting of stockholders to be held in 2027. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Committees of the Board </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Board has three standing committees: an audit committee, a compensation committee and a nominating and corporate governance committee. Each committee operates pursuant to a charter, which is available at investors.onkuretherapeutics.com. The Board may establish other committees from time to time. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audit committee of the Board (the &#8220;Audit Committee&#8221;), was established by the Board in accordance with Section&#160;3(a)(58)(A) of the Securities and Exchange Act of 1934 (the &#8220;Exchange Act&#8221;), to oversee our corporate accounting and financial reporting processes and audits of our financial statements. For this purpose, the audit committee performs several functions. The Audit Committee is responsible for the following activities, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">select, retain, compensate, evaluate, oversee and, where appropriate, terminate our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and <span style="white-space:nowrap">pre-approve</span> the scope and plans for the audits and the audit fees and <span style="white-space:nowrap">pre-approve</span> <span style="white-space:nowrap">all&#160;non-audit&#160;and</span> tax services to be performed by the independent auditor; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">evaluate the independence and qualifications of our independent registered public accounting firm; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review our financial statements, and discuss with management and our independent registered public accounting firm the results of the annual audit and the quarterly reviews, including a review of our disclosures under the &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; discussion in our Annual Reports on Form <span style="white-space:nowrap">10-K</span> and Quarterly Reports on Form <span style="white-space:nowrap">10-Q;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and discuss with management and our independent registered public accounting firm the quality and adequacy of our internal controls and our disclosure controls and procedures; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">discuss with management our procedures regarding the presentation of our financial information, and review earnings press releases and guidance; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">oversee the design, implementation and performance of our internal audit function, if any; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">set hiring policies with regard to the hiring of employees and former employees of our independent auditor and oversee compliance with such policies; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review, approve and monitor related party transactions; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">110 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">adopt and oversee procedures to address complaints regarding accounting, internal accounting controls and auditing matters, including confidential, anonymous submissions by our employees of concerns regarding questionable accounting or auditing matters; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and discuss with management and our independent auditor the adequacy and effectiveness of our legal, regulatory and ethical compliance programs; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and discuss with management and our independent auditor our guidelines and policies to identify, monitor and address enterprise risks, including the oversight of risks from cybersecurity threats. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Audit Committee are R. Michael Carruthers, Andrew Phillips and Isaac Manke.&#160;R.&#160;Michael Carruthers is the Chair of the Audit Committee and is a financial expert under the rules of the SEC. To qualify as independent to serve on the Audit Committee, listing standards of Nasdaq and the applicable SEC rules require that a director not accept any consulting, advisory or other compensatory fee from us, other than for service as a director, or be an affiliated person of us. The composition of the Audit Committee complies with the applicable requirements of the rules and regulations of Nasdaq and the SEC. The Audit Committee met four times during the fiscal year. References to the &#8220;Audit Committee&#8221; in this prospectus refer to our Audit Committee and, with respect to <span style="white-space:nowrap">pre-Merger</span> actions, its predecessor committee of the Reneo board of directors. The Board has adopted a written charter of the Audit Committee that is available to stockholders<span style="font-weight:bold"> </span>on our website at investors.onkuretherapeutics.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The compensation committee of our Board (the &#8220;Compensation Committee&#8221;) is responsible for the following activities, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review, approve or make recommendations to the Board regarding the compensation for our executive officers, including our chief executive officer; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review, approve and administer our employee benefit and equity incentive plans; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">establish and review the compensation plans and programs of our employees, and ensure that they are consistent with our general compensation strategy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determine or make recommendations to the Board <span style="white-space:nowrap">regarding&#160;non-employee&#160;director</span> compensation; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">approve or make recommendations to the Board regarding the creation or revision of any clawback policy. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Compensation Committee are Andrew Phillips, Isaac Manke, and Edward Mathers. Dr.&#160;Phillips is the Chair of the Compensation Committee. Each member of the Compensation Committee is <span style="white-space:nowrap">a&#160;&#8220;non-employee&#8221;&#160;director</span> within the meaning of <span style="white-space:nowrap">Rule&#160;16b-3&#160;of</span> the rules promulgated under the Exchange Act and independent within the meaning of the independent director guidelines of Nasdaq. The composition of the Compensation Committee complies with the applicable requirements of the rules and regulations of Nasdaq. The Compensation Committee met two times during the fiscal year. References to the &#8220;Compensation Committee&#8221; in this prospectus refer to our Compensation Committee and, with respect to <span style="white-space:nowrap">pre-Merger</span> actions, its predecessor committee of the Reneo board of directors. The Compensation Committee has adopted a written charter that is available to stockholders on our website at investors.onkuretherapeutics.com. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee Processes and Procedures </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Typically, the Compensation Committee meets as it deems appropriate. The agenda for each meeting is usually developed by the Chair of the Compensation Committee.<span style="font-weight:bold"> </span>However, from time to time, various members of management and other employees as well as outside advisors or consultants<span style="font-weight:bold"> </span>may be invited by the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">111 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Compensation Committee to make<span style="font-weight:bold"> </span>presentations, to provide financial or other<span style="font-weight:bold"> </span>background information or advice or to otherwise participate in Compensation Committee meetings. The Chief Executive Officer may not participate in, or be present during, any deliberations or determinations of the Compensation Committee regarding his compensation or individual performance objectives. The Compensation Committee has the sole authority to retain compensation consultants to assist in its evaluation of<span style="font-weight:bold"> </span>executive<span style="font-weight:bold"> </span>and director compensation, including the authority to approve the consultant&#8217;s reasonable fees and other retention terms. In general, the Compensation Committee has set executive compensation to be competitive with compensation provided by peer companies identified by the Compensation Committee, to promote retention of our executive officers and to incentivize our executive officers in achieving our short- and long-term corporate goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2024, in connection with the Merger, the Legacy OnKure board of directors and its compensation committee and Reneo&#8217;s board of directors reviewed our current employee and director compensation. As part of this review, the Legacy OnKure compensation committee recommended approval of the OnKure Therapeutics, Inc. 2024 Equity Incentive Plan (the &#8220;Plan&#8221;), and the Plan was subsequently approved by the boards of directors of Legacy OnKure and Reneo and by Reneo&#8217;s stockholders on September&#160;26, 2024, and ratified by the Board following the completion of the Merger. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The current compensation for the Named Executive Officers was recommended by the Legacy OnKure compensation committee, approved by the boards of directors of Legacy OnKure and Reneo in 2024, and ratified by the Board following the completion of the Merger. See &#8220;<span style="font-style:italic">New OnKure Employment Agreements&#8221; </span>below for discussion of current compensation for the Named Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, the Compensation Committee has made most of the significant adjustments to annual compensation, determined bonus and equity awards and established new performance objectives at one or more meetings held during the first quarter of the year. However, the Compensation Committee also considers matters related to individual compensation, such as compensation for new executive hires, as well as high-level strategic issues, such as the efficacy of our compensation strategy, potential modifications to that strategy and new trends, plans or approaches to compensation, at various meetings throughout the year. Generally, the Compensation Committee&#8217;s process comprises two related elements:<span style="font-weight:bold"> </span>the determination of compensation levels and the establishment of performance objectives for the current year. The Legacy OnKure compensation committee in conjunction with the Legacy OnKure&#8217;s board of directors served similar functions with respect to the assessment and determination of compensation for the Legacy OnKure executives. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Compensation Committee reviews and approves the compensation of our Chief Executive Officer and our other executive officers, including annual base salaries, annual and long-term incentive or bonus awards, employment agreements, and severance and change in control agreements/provisions, in each case as, when and if appropriate, and any special or supplemental benefits. For executives other than the Chief Executive Officer, the Compensation Committee solicits and considers evaluations and recommendations submitted to the Compensation Committee<span style="font-weight:bold"> </span>by the Chief Executive Officer. The Compensation Committee evaluates the performance of the Chief Executive Officer in light of Company and individual goals and objectives, and makes appropriate recommendations for improving performance. In performing the evaluation, the Chair of the Compensation Committee may solicit comments from the other <span style="white-space:nowrap">non-employee</span> members of the Board and lead the Board in an overall review of the Chief Executive Officer&#8217;s performance in an executive session of <span style="white-space:nowrap">non-employee</span> members of the Board. If the compensation for the Chief Executive Officer or any other executive officer is governed by an employment agreement, the Compensation Committee approves such employment agreement and any amendments thereto. In connection with the Merger, the Legacy OnKure board of directors and the Reneo board of directors approved and we entered into new employment agreements with the Chief Executive Officer and other executive officers, and these agreements were ratified by the Board following the completion of the Merger.&#160;See &#8220;<span style="font-style:italic">New OnKure Employment Agreements&#8221; </span>below for discussion of current compensation for the Named Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For all executives as part of its deliberations, the Compensation Committee may review and consider, as appropriate,<span style="font-weight:bold"> </span>materials such as financial reports and projections, operational data, tax and accounting information, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">112 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
tally sheets that set forth the total compensation that may become payable to executives in various hypothetical scenarios, executive and director stock ownership information, company stock performance data, analyses of historical executive compensation levels and current Company-wide compensation levels. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nominating and Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The nominating and corporate governance committee of the Board (the &#8220;Nominating and Corporate Governance Committee&#8221;) has responsibility for the following activities, among other things: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and assess and make recommendations to the Board regarding desired qualifications, expertise and characteristics sought of Board members; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">identify, evaluate, select or make recommendations to the Board regarding nominees for election to the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">develop policies and procedures for considering stockholder nominees for election to the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review our succession planning process for our chief executive officer and any other members of our executive management team; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and make recommendations to the Board regarding the composition, organization and governance of the Board and its committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and make recommendations to the Board regarding our corporate governance guidelines and corporate governance framework; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">oversee director orientation for new directors and continuing education for the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">oversee the evaluation of the performance of the Board and its committees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">review and monitor compliance with our code of business conduct and ethics, and review conflicts of interest of the director and officers other than related party transactions reviewed by the Audit Committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">administer policies and procedures for communications with <span style="white-space:nowrap">the&#160;non-management&#160;members</span> of the Board. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The members of the Nominating and Corporate Governance Committee are Isaac Manke and Valerie&#160;M.&#160;Jansen. Dr.&#160;Manke is the Chair of the Nominating and Corporate Governance committee. The composition of the Nominating and Corporate Governance Committee meets the requirements for independence under, and complies with, any applicable requirements of the rules and regulations of Nasdaq. The Nominating and Corporate Governance Committee did not meet during the 2024 fiscal year. References to the &#8220;Nominating and Corporate Governance Committee&#8221; in this prospectus refer to our Nominating and Corporate Governance Committee and, with respect to <span style="white-space:nowrap">pre-Merger</span> actions, its predecessor committee of the Reneo board of directors. The Nominating and Corporate Governance Committee has adopted a written charter that is available to stockholders on our website at investors.onkuretherapeutics.com. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Nominating and Corporate Governance Committee periodically reviews the compensation of <span style="white-space:nowrap">non-employee</span> Directors for service on the Board and committees thereof. In 2024, the Nominating and Corporate Governance Committee began a review of its Director compensation levels considering general market conditions in the life science industry, and in comparison to other clinical stage biopharmaceutical companies, and the Nominating and Corporate Governance Committee recommended, and the Board approved, revised compensation for <span style="white-space:nowrap">non-employee</span> Directors, discussed in &#8220;Director Compensation&#8221; below. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">It is the responsibility of the Nominating and Corporate Governance Committee to adopt a process for identifying and evaluating director nominees, including stockholder nominees. Before recommending an individual to the Board for membership on the Board, the Nominating and Corporate Governance Committee will canvass its members and our management team for potential candidates for the Board. The Nominating and </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">113 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporate Governance Committee also uses its network of contacts to identify potential candidates and, if it deems appropriate, may also engage a professional search firm. The Nominating and Corporate Governance Committee will consider stockholders&#8217; recommendations for nominees to serve as director if notice is timely received by our Secretary. Candidates nominated by stockholders will be evaluated in the same manner as other candidates. The Nominating and Corporate Governance Committee keeps the Board apprised of its discussions with potential nominees, and the names of potential nominees received from our current directors, management and stockholders, if the stockholder notice of nomination is timely made. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Board has not adopted a fixed set of minimum qualifications for candidates for membership on the Board, the Nominating and Corporate Governance Committee generally considers several factors in its evaluation of a potential member, such as the candidate&#8217;s character, professional ethics and integrity, judgment, business acumen, education, professional background and field of expertise including industry or academic experience in the pharmaceutical and biotechnology fields, experience in corporate governance and management, understanding of our business, the reasonable availability of the potential member to devote time to our affairs, as well as any other criteria deemed relevant by the Board or the Nominating and Corporate Governance Committee. However, the Nominating and Corporate Governance Committee retains the right to modify these qualifications from time to time. Candidates for director nominees are reviewed in the context of the current composition of the Board, our operating requirements and the long-term interests of stockholders. In conducting this assessment, the Nominating and Corporate Governance Committee typically considers diversity, age, skills and such other factors as it deems appropriate given our current needs and the current needs of the Board, to maintain a balance of knowledge, experience and capability. The Nominating and Corporate Governance Committee believes it is essential that Board members come from a variety of backgrounds and experiences. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the case of incumbent directors whose terms of office are set to expire, the Nominating and Corporate Governance Committee reviews these directors&#8217; overall contributions to us and the Board during their terms, including level of attendance, level of participation, quality of performance and contribution to the Board&#8217;s responsibilities and actions, and any relationships and transactions that might impair the directors&#8217; independence. In the case of new director candidates, the Nominating and Corporate Governance Committee also determines whether the nominee is independent for Nasdaq and SEC purposes, which determination is based upon applicable Nasdaq<span style="font-weight:bold"> </span>listing standards, applicable SEC rules and regulations and the advice of counsel, if necessary. The Nominating and Corporate Governance Committee conducts any appropriate and necessary inquiries into the backgrounds and qualifications of possible candidates after considering the function and needs of the Board. The Nominating and Corporate Governance Committee meets to discuss and consider the candidates&#8217; qualifications and then determines whether to recommend a nominee to the Board by majority vote. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to recommend individuals for consideration by the Nominating and Corporate Governance Committee to become nominees for election to the Board may do so by delivering a written recommendation to our Corporate Secretary. The recommendation must include the candidate&#8217;s name, home and business contact information, detailed biographical data, relevant qualifications, a signed letter from the candidate confirming willingness to serve, information regarding any relationships between the candidate and us and evidence of the recommending stockholder&#8217;s ownership of Company stock. Such recommendations must also include a statement from the recommending stockholder in support of the candidate. Stockholders may also nominate candidates directly for election to the Board at our annual meeting of stockholders by following the notice, deadline and other requirements set forth in our Bylaws. To date, the Nominating and Corporate Governance Committee has not rejected a timely director nominee from a stockholder. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2024, the Nominating and Corporate Governance Committee did not pay any fees to assist in the process of identifying or evaluating director candidates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">114 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholder Communications with the Board </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Stockholders who wish to communicate with the Board may do so by written message to our General Counsel or Chief Financial Officer at our offices. Communications sent in accordance with this process will be transmitted by us to the appropriate Board members. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Compensation Committee Interlocks and Insider Participation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each member of the Compensation Committee is <span style="white-space:nowrap">a&#160;&#8220;non-employee&#8221;&#160;director</span> within the meaning <span style="white-space:nowrap">of&#160;Rule&#160;16b-3&#160;of</span> the rules promulgated under the Exchange Act and is independent within the meaning of the independent director guidelines of Nasdaq. None of our executive officers serves as a member of the Board or Compensation Committee of any entity that has one or more executive officers who serves on our Board or Compensation Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Non-Employee&#160;Director</span> Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain an outside director compensation policy that is designed to provide a total compensation package that enables us to attract and retain, on a long-term basis, high-caliber directors. See &#8220;<span style="font-style:italic">Director Compensation&#8221; </span>below for discussion of current compensation for our <span style="white-space:nowrap">non-employee</span> directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">115 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_13">EXECUTIVE COMPENSATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section provides information regarding the compensation of our principal executive officer (Nicholas Saccomano), and our two other highest paid executive officers who were serving as executive officers on December 31, 2024 (Jason Leverone and Samuel Agresta). This section also includes compensation information for certain former executives of the Company (then known as Reneo Pharmaceuticals). The individuals listed below are collectively referred to herein as the &#8220;NEOs&#8221; or &#8220;Named Executive Officers.&#8221; </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:Times New Roman;font-weight:bold">Summary Compensation Table </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal years ended December&#160;31, 2024 and December&#160;31, 2023, compensation awarded to, paid to, or earned by our current and former principal executive officer and our two most highly compensated executive officers as of December&#160;31, 2024, collectively, the Named Executive Officers: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9.5pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name and</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Principal Position</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Year</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Salary<br/>($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Bonus<br/>($)<sup style="font-size:75%; vertical-align:top">(2)(6)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock<br/>Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Awards<br/>($)<sup style="font-size:75%; vertical-align:top">(3)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)<sup style="font-size:75%; vertical-align:top">(4)(6)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D. (1)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">462,145</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">279,598</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,773,422</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,515,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><span style="font-style:italic">President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">67,709</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">22,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">86,958</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">132,185</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">308,852</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Samuel Agresta, M.D. (5)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">416,727</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">183,360</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,228,619</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,362</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,841,068</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><span style="font-style:italic">Chief Medical Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Jason Leverone, C.P.A.</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">382,958</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">168,501</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2,113,312</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">13,799</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td>
<td style="white-space:nowrap;vertical-align:top;text-align:right">2,678,570</td>
<td style="white-space:nowrap;vertical-align:top">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman"><span style="font-style:italic">Chief Financial Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">346,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">91,476</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">311,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">28,972</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13,315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">791,947</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9.5pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:Times New Roman">Gregory J. Flesher (6)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">453,365</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,326,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,779,607</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Former President and Chief Executive Officer</span></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">563,942</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,762</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">569,704</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported under &#8220;Salary&#8221; in the above table represent the actual amounts paid during the calendar year. For Dr.&#160;Saccomano&#8217;s 2023 Salary, the amount reported represents a prorated salary following Dr.&#160;Saccomano&#8217;s appointment as Chief Executive Officer in September 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent discretionary bonuses paid based upon the achievement of Legacy OnKure company goals for the years ended December&#160;31, 2024 and 2023, as determined by the Legacy OnKure board of directors and our Board, as applicable. Cash bonuses earned and reported above in 2023 were paid in 2024, and cash bonuses earned and reported above in 2024 for Drs. Saccomano and Agresta and Mr.&#160;Leverone were paid in 2025. See &#8220;Executive Compensation&#8221; for descriptions of the bonuses. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the stock option awards granted during 2024 and 2023, computed in accordance with FASB ASC 718, Compensation&#8212;Stock Compensation. The assumptions used in calculating the grant date fair value of the awards disclosed in this column are set forth in Note 12 to the audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by the Named Executive Officer upon the vesting of the stock options, the exercise of the stock options, or the sale of the common stock underlying such stock options. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported for Drs. Saccomano and Agresta and Mr.&#160;Leverone represent matching contributions under Legacy OnKure&#8217;s 401(k) plan. For Mr.&#160;Flesher, all Other Compensation includes (i)&#160;matching contributions under Reneo&#8217;s 401(k) plan, (ii)&#160;premiums paid for group term life insurance and (iii)&#160;fringe benefits paid on behalf Reneo&#8217;s named executive officers in 2023. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Dr.&#160;Agresta was hired in February 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Flesher ceased providing services as President and Chief Executive Officer concurrent with the close of Merger on October&#160;4, 2024. Mr.&#160;Flesher received a <span style="white-space:nowrap">one-time</span> separation payment equal to 150% of his 2024 base salary ($894,992) plus 150% of his 2024 target annual bonus ($431,250) pursuant to the terms of his participation in the Reneo Severance Plan (as defined below). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">116 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Narrative Disclosure to Summary Compensation Table </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Compensation Elements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following describes the material terms of the elements of our compensation program for our Named Executive Officers during 2024: </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Base Salary </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board and Compensation Committee recognize the importance of base salary as an element of compensation that helps to attract and retain the named executive officers. We provide a base salary as a fixed source of income for our Named Executive Officers for the services they provide to us during the year, which allows us to maintain a stable executive team. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See &#8220;New OnKure Employment Agreements&#8221; below for a discussion of 2024 base salary for Dr.&#160;Saccomano, Dr.&#160;Agresta and Mr.&#160;Leverone. See <span style="white-space:nowrap">&#8220;Pre-Merger</span> Employment Agreement with Mr. Flesher; Consulting Agreement with Mr. Flesher&#8221; for a discussion of 2024 base salary for Mr. Flesher. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">New OnKure Employment Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reneo and Legacy OnKure entered into new employment agreements with certain eligible employees of OnKure, including Dr.&#160;Saccomano, Dr.&#160;Agresta and Mr.&#160;Leverone related to their continued employment with OnKure and as executive officers of the Combined Company on <span style="white-space:nowrap">an&#160;at-will&#160;basis,</span> each of which includes terms for base salary, benefits, target annual bonus opportunities and eligibility to participate the benefit plans, and which agreements became effective as of the Closing (the &#8220;New Employment Agreements&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the New Employment Agreements, Dr.&#160;Saccomano&#8217;s annual base salary became $600,000 and he has a target annual bonus opportunity equal to 55% of his base salary ($330,000); Dr.&#160;Agresta&#8217;s annual base salary became $482,000 and he has a target annual bonus opportunity equal to 40% of his base salary ($192,800); and Mr.&#160;Leverone&#8217;s annual base salary became $444,000 and he has a target annual bonus opportunity equal to 40% of his base salary ($177,600). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Merger</span> Employment Agreement with Mr.&#160;Flesher; Consulting Agreement with Mr.&#160;Flesher </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the period in 2024 prior to the closing the Merger, Mr.&#160;Flesher&#8217;s annual base salary was $575,000 and had a target annual bonus of 50% of his base salary, which was subject to his continued employment through the payment date. Mr.&#160;Flesher ceased providing services as President and Chief Executive Officer concurrent with the close of Merger on October&#160;4, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Reneo board of directors approved a consulting agreement with Mr.&#160;Flesher that became effective on that same date, pursuant to which Mr.&#160;Flesher agreed to provide consulting services to OnKure to assist with transition and post-transaction integration efforts for approximately five hours per month for a period of six months following the Effective Time (as defined in the Merger Agreement) of the Merger in exchange for <span style="white-space:nowrap">a&#160;one-time&#160;cash</span> payment in the gross amount of $20,000, payable within ten days following <span style="white-space:nowrap">the&#160;six-month&#160;anniversary</span> of the closing the Merger, unless the consulting agreement was terminated for &#8220;cause&#8221; (as defined therein) prior to such time in accordance with its terms). </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Termination and Change of Control Arrangements </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dr.&#160;Saccomano, Dr.&#160;Agresta and Mr.&#160;Leverone </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the New Employment Agreements entered into with Dr.&#160;Saccomano, Dr.&#160;Agresta and Mr.&#160;Leverone provides that if, other than during the period beginning three months before a &#8220;change in control&#8221; (as defined in each such New Employment Agreement) through <span style="white-space:nowrap">the&#160;one-year&#160;anniversary</span> of a change in control (the &#8220;CIC Period&#8221;), the applicable executive officer&#8217;s employment with the Combined Company is terminated either (x)&#160;by the Combined Company without &#8220;cause&#8221; (as defined in each such New Employment Agreement, and excluding </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">117 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
by reason of death or &#8220;disability&#8221; (as defined in each such New Employment Agreement)) or (y)&#160;by the executive officer for &#8220;good reason&#8221; (as defined in each such New Employment Agreement), then the executive officer will receive the following severance payments and benefits if he timely executes and does not revoke a separation agreement and release of claims in the Combined Company&#8217;s favor: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A lump sum cash payment equal to 100% of the executive officer&#8217;s base salary as in effect immediately before such termination (or, if the termination is due to a resignation for good reason based on a material reduction in the executive&#8217;s base salary, then executive&#8217;s annual base salary in effect immediately prior to the reduction); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combined Company payment or reimbursement of the premiums required for continued coverage pursuant to the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;COBRA&#8221;) under the Combined Company&#8217;s group health, dental and vision care plans for the executive officer and his eligible dependents for up to 12 months. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If, during the CIC Period, the applicable executive officer&#8217;s employment with the Combined Company is terminated either (x)&#160;by the Combined Company without cause (and excluding by reason of his death or disability) or (y)&#160;by the executive officer for good reason, the executive officer will receive the following severance payments and benefits if he timely executes and does not revoke a separation agreement and release of claims in the Combined Company&#8217;s favor: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A lump sum cash payment equal to 100% (or 150% for Dr.&#160;Saccomano) of the executive officer&#8217;s base salary as in effect immediately before such termination (or, if the termination is due to a resignation for good reason based on a material reduction in the executive&#8217;s base salary, then executive&#8217;s annual base salary in effect immediately prior to the reduction), or if greater, the base salary in effect immediately before the change in control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">A lump sum cash payment equal to 100% (or 150% for Dr.&#160;Saccomano) of the executive officer&#8217;s target bonus opportunity as in effect immediately before such termination or if greater, the target bonus opportunity in effect immediately before the change in control; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Combined Company payment or reimbursement of the premiums required for continued coverage pursuant to COBRA under the Combined Company&#8217;s group health, dental and vision care plans for the executive officer and his eligible dependents for up to 12 months (or 18 months for Dr.&#160;Saccomano); and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">100% accelerated vesting and exercisability of the outstanding and unvested equity awards (other than equity awards subject to performance-based vesting criteria) granted to the executive officer. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such New Employment Agreements also provide that, if any of the amounts provided for under the New Employment Agreement or otherwise payable to the executive officer would constitute &#8220;parachute payments&#8221; within the meaning of Section&#160;280G of the Internal Revenue Code or 1986, as amended, and could be subject to the related excise tax, the executive officer would receive (to the extent he is entitled to such receipt) either the full payment of benefits under the executive officer&#8217;s New Employment Agreement or such lesser amount that would result in no portion of the payments and benefits being subject to the excise tax, whichever results in the greater amount <span style="white-space:nowrap">of&#160;after-tax&#160;benefits</span> to the executive officer. The New Employment Agreements do not provide for any <span style="white-space:nowrap">tax&#160;gross-ups&#160;in</span> connection with a change in control. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Mr.&#160;Flesher </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, the Reneo board of directors approved the acceleration of vesting, to the extent not previously vested, of all Reneo stock options and Reneo restricted stock units held by Reneo&#8217;s directors and executive officers, including Mr.&#160;Flesher, effective as of the Effective Time (as defined in the Merger Agreement and which Effective Time was the closing of the Merger). In addition, in connection with the Merger, the Reneo board of directors approved an amendment to all Reneo stock options held by certain Reneo </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">118 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
optionholders, including Mr.&#160;Flesher, to provide that the applicable exercise window following termination of service with Reneo (or its affiliates) other than for Cause (as defined in the applicable Reneo Equity Plan) is the longer of (a)&#160;a period of three months following termination of service; or (b)&#160;a period commencing on the date of termination of service and ending on <span style="white-space:nowrap">the&#160;six-month&#160;anniversary</span> of the Effective Time (but in no event may an option be exercised beyond its maximum term).&#160;In the event that the Merger Agreement had been terminated pursuant to its terms, the applicable exercise window would have been the longer of: (i)&#160;a period of three months following termination of service; or (ii)&#160;a period of three months following termination of the Merger Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Flesher ceased providing services as President and Chief Executive Officer concurrent with the close of Merger on October&#160;4, 2024. Mr.&#160;Flesher received a <span style="white-space:nowrap">one-time</span> separation payment of $894,992 pursuant to the terms of his employment agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Equity Incentive Plans</p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Plan and the Legacy OnKure 2023 RSU Equity Incentive Plan, if, in the event of a merger or change in control (as defined in the applicable plan) a successor (or an affiliate thereof) does not assume, substitute for or continue an award (or portion thereof), then such award (or its applicable portion) will fully vest, all restrictions on such award (or its applicable portion) will lapse, all performance goals or other vesting criteria applicable to such award (or its applicable portion) will be deemed achieved at 100% of target levels and such award (or its applicable portion) will become fully exercisable, if applicable, for a specified period before the transaction, unless specifically provided otherwise under the applicable award agreement or other written agreement with the participant authorized by the administrator. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, unless specifically provided otherwise under the applicable award agreement or other written agreement with the participant authorized by the administrator, if an option or stock appreciation right (or a portion of such award) granted under the Plan is not assumed, substituted or continued, the administrator will notify the participant that such option or stock appreciation right (or its applicable portion) will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right (or its applicable portion) will terminate upon the expiration of such period. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With respect to awards granted to <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> under the Plan while such individual was <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> that are assumed or substituted for in the merger or change in control and the service of <span style="white-space:nowrap">such&#160;non-employee&#160;director</span> is terminated (other than upon his or her voluntary resignation that does not include a resignation at the request of the acquirer) on or following the merger or change in control, all such awards will fully vest, all restrictions on such awards will lapse, all performance goals or other vesting criteria applicable to such awards will be deemed achieved at 100% of target levels and such awards will become fully exercisable, if applicable, unless specifically provided otherwise under the applicable award agreement or other written agreement with <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> authorized by the administrator. Under our Outside Director Compensation Policy, as described more fully below, in the event of a change in control, each <span style="white-space:nowrap">non-employee</span> will fully vest in his or her outstanding awards granted under such policy, as of immediately prior to the change in control, provided that the <span style="white-space:nowrap">non-employee</span> director continues to be a <span style="white-space:nowrap">non-employee</span> through immediately prior to such change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Legacy OnKure 2021 Stock Incentive Plan, in the event of Corporate Transaction (as defined in the Legacy OnKure 2021 Stock Incentive Plan), the administrator is not obligated to accelerate the vesting of equity awards in the event the awards are not assumed or substituted for.&#160;The administrator also has discretion to suspend the right of grantees to exercise outstanding awards during a limited period of time preceding the closing of a Corporate Transaction if such suspension is administratively necessary to facilitate the closing of the transaction, and may terminate optionholders&#8217; right to early exercise options, such that following closing of a Corporate Transaction an option may only be exercised to the extent vested. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the Named Executive Officers&#8217; options and restricted stock units granted in 2023 provides that, if during the period beginning three months prior to through (and inclusive of) the date 12 months following a </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">119 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#8220;change in control&#8221; (as defined in the 2023 RSU Plan for the restricted stock unit), and in the award agreement for the options; provided that the Merger did not constitute a change in control for purposes of these awards), the Named Executive Officer&#8217;s service provider status is terminated by Legacy OnKure or its successor without &#8220;cause&#8221; (as defined in the applicable award agreement) (and excluding by reason of the Named Executive Officer&#8217;s death or disability (as defined in the applicable equity plan), or by the Named Executive Officer for &#8220;good reason&#8221; (as defined in the applicable award agreement), 100% of the then-unvested options or restricted stock units under the award will immediately vest. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">2024 Annual Cash Bonuses </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Named Executive Officer was eligible to participate in an annual cash incentive compensation program that provides participants with an opportunity to earn variable cash incentive compensation based on individual and company performance. For 2024, Dr.&#160;Saccomano&#8217;s target bonus was 55% of his earned salary, Dr.&#160;Agresta&#8217;s target bonus was 40% of his earned salary and Mr.&#160;Leverone&#8217;s target bonus was 40% of his earned salary. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The determination of the 2024 bonus amounts was discretionary based on the Board&#8217;s assessment of Company performance against corporate goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The actual annual cash bonuses awarded to each of Dr.&#160;Saccomano, Dr.&#160;Agresta and Mr.&#160;Leverone for 2024 performance are set forth in the &#8220;Bonus&#8221; column of the Summary Compensation Table for Fiscal 2024 above. Mr.&#160;Flesher did not remain employed through the payment date of 2024 bonuses and therefore did not receive an annual bonus in 2024. However, he did become entitled to a severance payment that was calculated, in part, by reference to his 2024 target annual bonus as described above. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mr.&#160;Flesher received a bonus related to the closing of the Merger equal to 150% of his target annual bonus for 2024 pursuant to the terms of his employment agreement with Reneo. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Special Performance Bonus </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to his employment agreement with Reneo, Mr.&#160;Flesher had&#160;the opportunity to earn a special performance bonus in the amount of $7.5&#160;million in the event that during Mr.&#160;Flesher&#8217;s continued service to Reneo, either (i)&#160;Reneo&#8217;s market value exceeds $750&#160;million utilizing the volume-weighted average of the Nasdaq closing sale price of Reneo Common Stock for each of the 30 trading days immediately prior to the measurement date, or (ii)&#160;the fair market value of the net proceeds available for distribution to Reneo Stockholders in connection with a Change in Control (as defined in the Reneo Severance Plan) exceeds $750&#160;million, as determined in good faith by the Reneo Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Although the Merger constituted a Change in Control for purposes of Mr.&#160;Flesher&#8217;s bonus opportunity, the required net proceeds threshold was not met in connection with the Merger and thus Mr.&#160;Flesher did not receive this bonus. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive Incentive Compensation Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the completion of the Merger, the Reneo board of directors and the Legacy OnKure board of directors approved an Executive Incentive Compensation Plan (the &#8220;Incentive Compensation Plan&#8221;), and the Board ratified the Incentive Compensation Plan following the closing of the Merger, to provide periodic incentive bonus opportunities to our employees (or employees of our subsidiaries). The Incentive Compensation Plan became effective at the Effective Time (as defined in the Merger Agreement). The Compensation Committee administers the Incentive Compensation Plan. Bonuses to our Named Executive Officers for 2024 were not governed by the Incentive Compensation Plan; however, it is expected that from time to time certain employees, including our Named Executive Officers, may be eligible and selected, subject to their continued employment, to participate in the Incentive Compensation Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">120 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">No Nonpublic Material Information Taken into Account for Executive Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Board and Compensation Committee do not take material nonpublic information into account when determining the timing and terms of any stock option grant.&#160;The timing of any stock option grants to recipients in connection with new hires, promotions or other <span style="white-space:nowrap">non-routine</span> grants is tied to the event giving rise to the award (such as an employee&#8217;s commencement of employment or promotion effective date). We have not timed the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During fiscal year 2024, and in connection with the closing of the Merger, we awarded options to certain of our Named Executive Officers in the period beginning four business days before the filing of a report on Form <span style="white-space:nowrap">8-K</span> that disclosed material nonpublic information, and ending one business day after such filing.&#160;The following table provides information concerning each such award: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:46%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant</span><br/><span style="font-weight:bold">Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>securities<br/>underlying<br/>the award</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Exercise<br/>price of<br/>the<br/>award<br/>($/sh)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant<br/>date&#160;fair<br/>value of<br/>the<br/>award</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage&#160;change&#160;in&#160;the</span><br/><span style="font-weight:bold">closing market price of</span><br/><span style="font-weight:bold">the securities underlying</span><br/><span style="font-weight:bold">the award between the</span><br/><span style="font-weight:bold">trading day ending</span><br/><span style="font-weight:bold">immediately prior to the</span><br/><span style="font-weight:bold">disclosure of material</span><br/><span style="font-weight:bold">nonpublic information</span><br/><span style="font-weight:bold">and the trading day</span><br/><span style="font-weight:bold">beginning immediately</span><br/><span style="font-weight:bold">following the disclosure<br/>of material nonpublic<br/>information</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">542,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">-1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Leverone, C.P.A.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">130,611</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">-1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Agresta, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,396</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16.18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">-1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Employee Benefit Plans </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">401(k) Plan </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reneo had maintained a 401(k) retirement savings plan that was terminated prior to the Merger. Through 2024, eligible employees of Legacy OnKure and, following the Merger, us and our subsidiaries, were eligible to participate in a <span style="white-space:nowrap">tax-qualified</span> defined contribution plan under Section&#160;401(k) of the Code sponsored by Insperity, a professional employer organization, on the terms applicable to such plan. Effective as of December&#160;31, 2024, we and our subsidiaries ceased participating in the Insperity 401(k) plan and, effective in March 2025, we adopted a new 401(k) plan in which eligible employees of us and our subsidiaries may participate. Under the Insperity 401(k) plan and the new Company 401(k) plan, eligible employees were able to elect or may elect, as applicable, to defer a portion of their compensation, within the limits prescribed by the Code, on <span style="white-space:nowrap">a&#160;pre-tax&#160;(traditional)</span> <span style="white-space:nowrap">or&#160;post-tax&#160;(Roth)</span> basis, through contributions to the applicable 401(k) plan. As <span style="white-space:nowrap">a&#160;tax-qualified&#160;retirement</span> <span style="white-space:nowrap">plan,&#160;pre-tax&#160;contributions</span> to the applicable 401(k) plan and earnings on <span style="white-space:nowrap">those&#160;pre-tax&#160;contributions</span> are not taxable to the employees until distributed from the applicable 401(k) plan, and earnings on Roth contributions are not taxable when distributed from the applicable 401(k) plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Health and Welfare Benefits </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All of our full-time employees, including our Named Executive Officers, are eligible to participate in our health and welfare benefits, including medical, dental and vision insurance, medical and dependent care flexible spending accounts, group life and disability insurance and 401(k) plan. Named Executive Officers are eligible to participate in all our employee benefit plans on the same basis as other employees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We do not offer any defined benefit pension plans or nonqualified defined compensation arrangements for our employees, including our Named Executive Officers. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">121 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Outstanding Equity Awards at Fiscal <span style="white-space:nowrap">Year-End</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows for the fiscal year ended December&#160;31, 2024, certain information regarding outstanding equity awards at fiscal <span style="white-space:nowrap">year-end</span> for the Named Executive Officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A description of the equity incentive plans we maintain is set forth in Note 12 to our financial statements included in this prospectus. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:42%"/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option Awards <sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Grant</span><br/><span style="font-weight:bold">Date</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options</span><br/><span style="font-weight:bold">(#)&#160;Exercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Options</span><br/><span style="font-weight:bold">(#)&#160;Unexercisable</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option&#160;Exercise<br/>Price</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top"> (2)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option<br/>Expiration<br/>Date</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/11/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,359</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/10/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/30/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">618</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">867</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/29/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/14/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,898</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/14/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">30,124</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">512,108</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/3/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Leverone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/11/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,215</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,566</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(5)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/10/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/30/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,217</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,105</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8/29/2033</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,256</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">123,355</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/3/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Agresta, M.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/6/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,588</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(6)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.99</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2/5/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/4/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,299</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">124,097</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">&#8201;(4)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.20</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10/3/2034</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory J. Flesher</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/21/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">105,264</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">48.80</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1/20/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/10/2021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">19,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">66.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/9/2031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/9/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">29,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18.00</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12/8/2032</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All of the outstanding stock option awards granted on October&#160;4, 2024 were granted under and subject to the terms of the 2024 Equity Incentive Plan and cover shares of Class&#160;A Common Stock and all of the outstanding stock option awards listed that were granted to Dr.&#160;Saccomano, Mr.&#160;Leverone and Dr.&#160;Agresta prior to October&#160;4, 2024 were granted under and subject to the terms of the Legacy OnKure 2021 Stock Incentive Plan and cover shares of Company Class&#160;A Common Stock. Mr.&#160;Flesher&#8217;s January&#160;21, 2021 stock option award was granted under and subject to the terms of the 2014 Reneo Stock Incentive Plan and the December&#160;10, 2021 and December&#160;9, 2022 stock option awards were granted under and subject to the terms of the 2021 Reneo Stock Incentive Plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The stock option awards listed that were granted Dr.&#160;Saccomano, Mr.&#160;Leverone and Dr.&#160;Agresta prior to October&#160;4, 2024 were granted with a per share exercise price equal to the fair market value of one share of Legacy OnKure Class&#160;A Common Stock on the date of grant, as determined in good faith by the Legacy OnKure board of directors based on third party valuations of Legacy OnKure Class&#160;A Common Stock. Exercise prices and share numbers are disclosed on a post-Merger basis. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the award vested on May&#160;1, 2023 and 1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option vest monthly thereafter, subject to the optionee continuing to be a service provider to us through each such date. The award also is subject to certain acceleration of vesting provisions as described under &#8220;Termination and Change in Control Arrangements&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/36<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option shall vest on November&#160;4, 2024 and each month thereafter, subject to the optionee continuing to be a service provider to us through each such date. The award also is subject to certain acceleration of vesting provisions as described under &#8220;Termination and Change in Control Arrangements&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/4<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option vested on January&#160;3, 2023 and 1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option vest on the first day of each month thereafter, subject to the optionee continuing to be a service provider to us through each such date. The award also is subject to certain acceleration of vesting provisions as described under &#8220;Termination and Change in Control Arrangements&#8221; above. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">122 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">1/4<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option vested on February&#160;5, 2025 and 1/48<sup style="font-size:75%; vertical-align:top">th</sup> of the shares subject to the option vest on the first day of each month thereafter, subject to the optionee continuing to be a service provider to us through each such date. The award also is subject to certain acceleration of vesting provisions as described under &#8220;Termination and Change in Control Arrangements&#8221; above. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Stock Awards <sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of&#160;Shares&#160;or<br/>Units of Stock That<br/>Have Not Vested</span><br/><span style="font-weight:bold">(#) Unvested</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Market&#160;Value&#160;of</span><br/><span style="font-weight:bold">Shares&#160;or&#160;Units&#160;of</span><br/><span style="font-weight:bold">Stock&#160;That&#160;Have<br/>Not Vested</span><br/><span style="font-weight:bold">Price</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,556&#8201;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">39,182</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Leverone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">16,331&#8201;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(2)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">140,447</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory J. Flesher</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000&#8201;</td>
<td style="white-space:nowrap;vertical-align:bottom"><sup style="font-size:75%; vertical-align:top">(3)</sup>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">86,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All of the outstanding restricted stock unit awards for Dr.&#160;Saccomano and Mr.&#160;Leverone were granted under and subject to the terms of the Legacy OnKure 2023 RSU Equity Incentive Plan and cover shares of Class&#160;A Common Stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Both a &#8220;Service-Based Requirement&#8221; and a &#8220;Liquidity Event Plus Service Requirement&#8221; must be met in order for the RSU to vest. 1/16<sup style="font-size:75%; vertical-align:top">th</sup> of the RSUs met the &#8220;Service-Based&#8221; requirement on June&#160;20, 2023 and 1/16<sup style="font-size:75%; vertical-align:top">th </sup>of the RSUs are scheduled to meet the Service-Based Requirement on each three-month anniversary thereafter, subject to the optionee continuing to be a service provider to us through each such date. The Liquidity Event Plus Service Requirement will be satisfied on the 181<sup style="font-size:75%; vertical-align:top">st</sup> day following the closing of the Merger. The award also is subject to certain acceleration of vesting provisions as described under &#8220;Termination and Change in Control Arrangements&#8221; above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The vesting of Mr.&#160;Flesher&#8217;s stock award was accelerated such that the award became fully vested at the time of the Merger. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Compensation </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OnKure&#8217;s policy was to provide each director who is neither an employee nor affiliated with funds invested in Legacy OnKure preferred stock with an annual retainer of $40,000, which generally was paid in quarterly installments, subject to the director&#8217;s continued service to Legacy OnKure. Dr.&#160;Saccomano was not eligible to receive this retainer for fiscal 2024 given his status as chief executive officer of Legacy OnKure. Legacy OnKure also reimbursed its directors for expenses associated with attending meetings of the Legacy OnKure board of directors and its committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Dr.&#160;Saccomano is Legacy OnKure&#8217;s only director who was an employee director during 2024. See the section entitled &#8220;<span style="font-style:italic">Executive Compensation</span>&#8221; above for information about Dr.&#160;Saccomano&#8217;s compensation that he received for serving as Legacy OnKure&#8217;s Chief Executive Officer during 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During the portion of 2024 prior to the Merger, Michael Grey and Edward Mathers served on the Reneo board of directors, and each was compensated for such services pursuant to Reneo&#8217;s <span style="white-space:nowrap">Non-Employee</span> Director Compensation Policy (the &#8220;Reneo Director Policy&#8221;). Pursuant to the Reneo Director Policy, Mssrs. Grey and Mathers were entitled to an annual retainer of $40,000 plus, for Mr.&#160;Grey, an additional annual retainer of $30,000 for his service as <span style="white-space:nowrap">non-executive</span> Chair of the Reneo board of directors and, for Mr.&#160;Mathers, an additional annual retainer of $5,000 for his services on the Reneo compensation committee. Mr.&#160;Grey received an annual fee of $100,000 for his services as Reneo Executive Chairman in lieu of the cash fees he would otherwise receive as a <span style="white-space:nowrap">non-employee</span> member of Reneo&#8217;s board of directors pursuant to the Reneo Director Policy. The annual retainers were paid in equal annual installments in arrears on the last day of each fiscal quarter in which the service occurred. Neither of Mssrs. Grey and Mathers received any Reneo equity awards in 2024 pursuant to the Reneo Director Policy. Upon the closing of the Merger, no further payments were made under the Reneo Director Policy. In connection with the Merger, the Reneo board of directors approved the acceleration of </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">123 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vesting, to the extent not previously vested, of all Reneo stock options and Reneo restricted stock units held by Reneo&#8217;s directors and executive officers, including Mssrs. Grey and Mathers, effective as of the Effective Time. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table presents the total compensation that each of our <span style="white-space:nowrap">then&#160;non-employee&#160;directors</span> received during the fiscal year ended December&#160;31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:49%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Fees&#160;Earned</span><br/><span style="font-weight:bold">or Paid in</span><br/><span style="font-weight:bold">Cash</span><br/><span style="font-weight:bold">($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Option</span><br/><span style="font-weight:bold">Awards</span><br/><span style="font-weight:bold">($)<sup style="font-size:75%; vertical-align:top">(1)</sup></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Nonqualified<br/>Deferred<br/>Compensation<br/>Earnings ($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">All Other<br/>Compensation<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total ($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isaac Manke, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">14,752</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">262,309</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Michael Carruthers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">43,740</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">291,297</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Phillips, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">21,336</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">268,893</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie M. Jansen, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">258,286</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Grey</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">85,849</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">333,406</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Mathers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">49,021</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">247,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">296,578</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In accordance with SEC rules, this column reflects the aggregate grant date fair value of the equity awards granted during 2024, computed in accordance with FASB ASC Topic 718, Compensation-Stock Compensation. The assumptions used in calculating the grant date fair value of the awards disclosed in this column are set forth in Note 12 to our audited financial statements included elsewhere in this prospectus. These amounts do not reflect the actual economic value that will be realized by <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> upon vesting, settlement or exercise of equity awards or the sale of the common stock underlying such equity awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes $76,096 of cash fees paid by Reneo prior to the Merger. Mr.&#160;Grey received an annual fee of $100,000 for his services as Reneo Executive Chairman in lieu of the cash fees he would otherwise receive as a <span style="white-space:nowrap">non-employee</span> member of Reneo&#8217;s board of directors pursuant to the Reneo Director Policy. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes $38,048 of cash fees earned by Mr.&#160;Mathers for his service as a <span style="white-space:nowrap">non-employee</span> director of Reneo for January&#160;1, 2024 through the Merger that were paid directly to NEA by Reneo. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table lists all outstanding stock and option awards held <span style="white-space:nowrap">by&#160;non-employee&#160;directors</span> as of December&#160;31, 2024. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:69%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">Shares</span><br/><span style="font-weight:bold">Underlying<br/>Outstanding<br/>RSU<br/>Awards</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of</span><br/><span style="font-weight:bold">Shares</span><br/><span style="font-weight:bold">Underlying<br/>Outstanding<br/>Options</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isaac Manke, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Michael Carruthers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,065</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">18,384</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Phillips, Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie M. Jansen, M.D., Ph.D.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Grey</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">40,236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Mathers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">20,200</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director Compensation Policy </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In 2024, the compensation committee of the Legacy OnKure board of directors retained Pearl Meyer&#160;&amp; Partners, LLC, a third-party compensation consultant, to provide the Legacy OnKure board of directors and its compensation committee with an analysis of publicly available market data regarding practices and compensation levels at comparable companies and assistance in determining compensation to be provided to <span style="white-space:nowrap">our&#160;non-employee&#160;directors.</span> Based on the discussions with and assistance from the compensation consultant with Legacy OnKure&#8217;s compensation committee, in connection with the Merger, the Legacy OnKure board of directors and the Reneo board of directors approved an Outside Director Compensation Policy that provides for </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">124 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
certain compensation <span style="white-space:nowrap">to&#160;non-employee&#160;directors</span> of the Combined Company, with the Outside Director Compensation Policy becoming effective as of immediately prior to the Effective Time. The Outside Director Compensation Policy was ratified by our Board following the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Cash Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Outside Director Compensation Policy provides for the following cash compensation program <span style="white-space:nowrap">for&#160;non-employee&#160;directors</span> following the closing of the Merger: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$40,000 per year for service as <span style="white-space:nowrap">a&#160;non-employee&#160;director;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$30,000 per year for service <span style="white-space:nowrap">as&#160;non-employee&#160;chair;</span> </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$15,000 per year for service as Chair of the Audit Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$7,500 per year for service as a member of the Audit Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$10,000 per year for service as Chair of the Compensation Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$5,000 per year for service as a member of the Compensation Committee; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$8,000 per year for service as Chair of the Nominating and Corporate Governance Committee; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">$4,000 per year for service as a member of the Nominating and Corporate Governance Committee. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">RSU Award in Lieu of Cash Retainers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Outside Director Compensation Policy, <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> may elect to convert 100% of his or her retainer fees with respect to services to be performed in a future fiscal year (or portion of a fiscal year with respect to certain initial elections) into an award of RSUs (a &#8220;Retainer Award&#8221;), in accordance with the election procedures under the Outside Director Compensation Policy, and in addition, (i)&#160;individuals who <span style="white-space:nowrap">were&#160;non-employee&#160;directors</span> as of immediately following the closing of the Merger has the option to make such election with respect to retainer fees payable for services provided as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> in fiscal year 2024, and (ii)&#160;individuals who <span style="white-space:nowrap">become&#160;non-employee&#160;directors</span> following the closing of the Merger may make such election with respect to retainer fees payable for services provided as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> for their initial year of service as <span style="white-space:nowrap">a&#160;non-employee&#160;director.</span> Retainer Awards will be granted automatically on the last day of the fiscal quarter to which such election relates, subject to continued service through such date. The number of shares subject to a Retainer Award will be determined by dividing (x)&#160;the aggregate annual amount of cash fees described above applicable to <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> as of the last day of the applicable fiscal quarter for which <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> receives the Retainer Award, by (y)&#160;the fair market value of a share of our Class&#160;A Common Stock on the date of grant of the Retainer Award (which, under the Plan generally is the closing sales price of a share of our Class&#160;A Common Stock on the date of the grant of the Retainer Award (or, if no closing sales price was reported on that date, on the last trading day such closing sales price was reported)). Each Retainer Award will be fully vested as of the date of grant. No outside directors elected to receive Retainer Awards for services provided as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> in fiscal year 2024. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Equity Compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each individual serving as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> as of immediately following the Effective Time was granted an award of stock options to purchase 15,300 shares of Class&#160;A Common Stock (the &#8220;Closing Award&#8221;). The Closing Award was granted automatically on the date of the closing of the Merger. Each Closing Award is scheduled to vest in equal monthly installments over the next&#160;36&#160;months on the same day of each relevant month as the applicable vesting date, in each case subject to <span style="white-space:nowrap">the&#160;non-employee&#160;director</span> continuing to be a service provider through the applicable vesting date. The Closing Awards were not permitted to be exercised prior to the time that a Registration Statement on <span style="white-space:nowrap">Form&#160;S-8</span> relating to the issuance of our Class&#160;A Common Stock under the Plan became effective, which occurred on December&#160;9, 2024. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">125 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Initial Award</span>. Each individual who first becomes <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> following the closing of the Merger will receive, on the first trading day on or after the date on which such individual first becomes <span style="white-space:nowrap">a&#160;non-employee&#160;director,</span> an award of stock options to purchase 15,300 shares of our Class&#160;A Common Stock (an &#8220;Initial Award&#8221;), provided that if an individual was an employee director, becoming <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> due to termination of the individual&#8217;s status as an employee will not entitle such individual to an Initial Award.&#160;Further, such stock options were not permitted to be exercised prior to the time that a Registration Statement on <span style="white-space:nowrap">Form&#160;S-8</span> relating to the issuance of our Class&#160;A Common Stock under the Plan became effective, which occurred on December&#160;9, 2024. Each Initial Award will be scheduled to vest as to 1/36th of the shares subject to the Initial Award each month following the Initial Award&#8217;s grant date on the same day of the month as such grant date (or on the last day of the month, if there is no corresponding day in such month), in each case subject to continued services through the applicable vesting dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Annual Award</span>. On the first trading day immediately following each Annual Meeting of our stockholders (an &#8220;Annual Meeting&#8221;) that occurs after the closing of the Merger, <span style="white-space:nowrap">each&#160;non-employee&#160;director</span> will receive an award of stock options to purchase 7,650 shares of our Class&#160;A Common Stock (the &#8220;Annual Award&#8221;). If an individual commenced service as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> after the date of the Annual Meeting that occurred immediately prior to such Annual Meeting (or if there is no such prior Annual Meeting, then after the closing of the Merger), then such Annual Award will be prorated based on the number of whole months that the individual served as <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> prior to the Annual Award&#8217;s grant date during <span style="white-space:nowrap">the&#160;12-month&#160;period</span> immediately preceding such Annual Meeting (with any resulting fractional share rounded down to the nearest whole share). The Annual Award will be scheduled to vest in full on the earlier of <span style="white-space:nowrap">the&#160;one-year&#160;anniversary</span> of the Annual Award&#8217;s grant date or the day immediately prior to the date of the next Annual Meeting that occurs after the Annual Award&#8217;s grant date, subject to continued services through the applicable vesting dates. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change in Control</span>. In the event of a change in control (as defined in the Plan), each&#160;non-employee director&#8217;s then-outstanding equity awards that were granted to him or her while <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> will accelerate vesting in full, provided that he or she remains <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> through immediately prior to such change in control. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Award Terms</span>. Each Retainer Award, Closing Award, Initial Award and Annual Award will be granted under the Plan (or its successor plan, as applicable) and applicable forms of award agreement under such plan. Other than Retainer Awards, awards will have a maximum term to expiration of ten years from their grant and <span style="white-space:nowrap">a&#160;per-share&#160;exercise</span> price equal to 100% of the fair market value of a share of our Class&#160;A Common Stock on the award&#8217;s grant date. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Director Compensation Limits</span>. The Outside Director Compensation Policy will provide that in any fiscal year, <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> may be granted equity awards (with the value of equity awards based on its grant date fair value determined in accordance with U.S. GAAP for purposes of this limit) and be provided any cash retainers or fees with an aggregate value of no more than $750,000, provided that such amount is increased to $1,000,000 in the fiscal year of initial service as <span style="white-space:nowrap">a&#160;non-employee&#160;director.</span> Equity awards granted or other compensation provided to <span style="white-space:nowrap">a&#160;non-employee&#160;director</span> for services provided as an employee or consultant (other than <span style="white-space:nowrap">a&#160;non-employee&#160;director),</span> or provided before the closing of the Merger, will not count toward this annual limit. For purposes of determining when cash retainers or fees are provided, any deferral elections to delay payout timing will be disregarded. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">126 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_14">CERTAIN RELATIONSHIPS, RELATED PARTY AND OTHER TRANSACTIONS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Described below are any transactions occurring since January&#160;1, 2023 and any currently proposed transactions to which we, Legacy OnKure or Reneo was a party and in which: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the amounts involved exceeded or will exceed the lesser of $120,000 and 1% of the average of our, OnKure&#8217;s or Reneo&#8217;s total assets at <span style="white-space:nowrap">year-end</span> for the last two completed fiscal years, as applicable; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any of our, OnKure&#8217;s or Reneo&#8217;s directors, executive officers or holders of more than 5% of our, OnKure&#8217;s or Reneo&#8217;s capital stock, or an affiliate or immediate family member of the foregoing persons, had or will have a direct or indirect material interest. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PIPE Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On May&#160;10, 2024, in connection with the execution of the Merger Agreement, Reneo entered into the Subscription Agreement with certain existing OnKure stockholders and new investors relating to the PIPE Financing. Pursuant to the Subscription Agreement, the PIPE Investors purchased shares of our Class&#160;A Common Stock at a purchase price of approximately $22.895 per share, for an aggregate purchase price of $65.0&#160;million. The closing of the PIPE Financing occurred on October&#160;4, 2024 in connection with the closing of the Merger. The table below sets forth the number of shares of our Class&#160;A Common Stock purchased by related party holders in the PIPE Financing: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:62%"/>

<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Participant</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;of&#160;Class&#160;A<br/>Common Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total&#160;Purchase&#160;Price<br/>($)</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures, L.P. <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">199,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,560,475.97</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Citadel <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">360,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,260,412.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Cormorant <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">379,018</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,677,700.47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund,&#160;Ltd. <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">136,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,117,115.51</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund,&#160;Ltd. <sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">207,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,742,905.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P. <sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">169,975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,891,615.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Isaac Manke, a member of the Legacy OnKure board of directors and a member of our Board, is a partner at Acorn Capital Advisors, GP, LLC, the general partner of Acorn Bioventures, L.P. Entities affiliated with Acorn held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and hold more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel Multi-Strategy Equities Master Fund Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. Citadel CEMF Investments Ltd., an affiliate of Citadel Multi-Strategy Equities Master Fund Ltd., purchased 360,792 shares of Class A Common Stock in the PIPE for a total purchase price of $8,260,412.19. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Cormorant collectively held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and hold more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Deep Track Biotechnology Master Fund, Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Perceptive Life Sciences Master Fund, Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Samsara BioCapital, L.P. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the closing of the PIPE Financing, in connection with the Subscription Agreement, we entered into a registration rights agreement with the PIPE Investors, pursuant to which we agreed to prepare and file a resale registration statement with the SEC within 45 calendar days following the closing of the PIPE Financing for purposes of registering the resale of the shares issued in the PIPE Financing. We also agreed, among other things, that we will indemnify the PIPE Investors, their officers, directors, members, employees and agents, successors </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">127 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and assigns under the Subscription Agreement from certain liabilities and pay all fees and expenses (excluding any legal fees of the selling holder(s), and any underwriting discounts and selling commissions) incident to our obligations under the registration rights agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Support Agreements Under the Merger Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Merger Agreement, (i)&#160;certain stockholders of Legacy OnKure, owning approximately 98.3% of the outstanding shares of Legacy OnKure&#8217;s preferred stock and approximately 77.3% of the outstanding shares of Legacy OnKure&#8217;s capital stock, entered into support agreements with Reneo and Legacy OnKure to vote all of their shares of Legacy OnKure&#8217;s capital stock in favor of the adoption of the Merger Agreement and the related transactions contemplated thereby and (ii)&#160;certain stockholders of Reneo holding approximately 34.7% of the outstanding shares of Reneo&#8217;s common stock, including Reneo&#8217;s common stock issuable within 60 days upon (A)&#160;exercise of options held by such holders or (B)&#160;settlement of RSUs held by such holders, entered into support agreements with Reneo and Legacy OnKure to vote all of their shares of Reneo&#8217;s capital stock in favor of the Merger Agreement and the related contemplated transactions and against any alternative acquisition proposals. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Lock-Up</span> Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently and in connection with the execution of the Merger Agreement, certain executive officers and the directors of Legacy OnKure, certain stockholders of Legacy OnKure and the directors of Reneo that remained on our Board following the closing of the Merger, entered into <span style="white-space:nowrap">lock-up</span> agreements pursuant to which, and subject to specified exceptions, they have agreed not to transfer their shares of our Common Stock for the <span style="white-space:nowrap">180-day</span> period following the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy OnKure and Reneo Indemnification Agreements </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OnKure and Reneo each entered into separate indemnification agreements with each of its directors and officers, respectively, in addition to the indemnification provided for in their respective certificate of incorporation and bylaws. The indemnification agreements, certificates of incorporation and bylaws generally require both Legacy OnKure and Reneo to indemnify its directors, executive officers and certain controlling persons to the fullest extent permitted by Delaware law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Director and Officer Indemnification </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered, and intend to continue to enter, into indemnification agreements with each of our directors and executive officers.&#160;These agreements, among other things, require us or will require us to indemnify each director (and in certain cases their related venture capital funds) and executive officer to the fullest extent permitted by Delaware law, including indemnification of expenses such as attorneys&#8217; fees, judgments, fines, and settlement amounts incurred by the director or executive officer in any action or proceeding, including any action or proceeding by or in right of us, arising out of the person&#8217;s services as a director or executive officer. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation and our Bylaws provide that we will indemnify each of our directors and officers to the fullest extent permitted by the DGCL. Further, we have purchased a policy of directors&#8217; and officers&#8217; liability insurance that insures our directors and officers against the cost of defense, settlement, or payment of a judgment under certain circumstances. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Sublease Agreement </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On January 10, 2025, we entered into a sublease agreement with Ambros Therapeutics, Inc. (&#8220;Ambros Therapeutics&#8221;), pursuant to which we subleased certain office space to Ambros Therapeutics for their corporate headquarters. Mr. Flesher, the President and Chief Executive Officer of Reneo prior to the Merger, is acting </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">128 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
President and the Chief Executive Officer and a stockholder of Ambros Therapeutics. The premises are located in Irvine, California. The approximate value of the transaction is $450,000 over the term of the Sublease. The Sublease was considered by us in accordance with our Related Person Transactions Policy, and approved by Audit Committee. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Legacy OnKure Transactions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Private Placements of Securities </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Series C Preferred Stock Financing </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023, Legacy OnKure issued and sold an aggregate of 19,463,456 shares of its Series C Preferred Stock at a purchase price of $2.7633 per share for an aggregate purchase price of approximately $53.8&#160;million. As part of this transaction, also in March 2023, Legacy OnKure issued an aggregate of 27,780,350 shares of its Series C Preferred Stock in exchange for the conversion of any shares of preferred stock of Legacy OnKure then held by such purchaser. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Purchasers of Legacy OnKure&#8217;s Series C Preferred Stock included funds related to certain of its directors and holders of more than 5% of its capital stock at the time of the financing (or subsequent closings of such financings). The following table presents the number of shares (including shares that the purchaser received upon conversion of other series of preferred stock of Legacy OnKure then held by such purchaser) and the total purchase price paid by these entities: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:68%"/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Investor</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares&#160;of&#160;Series<br/>C Preferred<br/>Stock</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Total<br/>Purchase<br/>Price</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures, L.P. <sup style="font-size:75%; vertical-align:top">(1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">8,567,245</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,007,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel Multi-Strategy Equities Master Fund Ltd. <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,589,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Cormorant <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,074,472</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund, Ltd. <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">3,618,861</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,999,999</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. <sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,506,321</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,465,617</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P. <sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,518,007</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,484,609</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Isaac Manke, a member of the Legacy OnKure board of directors and a member of our Board, is a partner at Acorn Capital Advisors, GP, LLC, the general partner of Acorn Bioventures, L.P. Entities affiliated with Acorn held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and hold more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel Multi-Strategy Equities Master Fund Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Entities affiliated with Cormorant collectively held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and hold more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Deep Track Biotechnology Master Fund, Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Perceptive Life Sciences Master Fund, Ltd. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Samsara BioCapital, L.P. held more than five percent of outstanding Legacy OnKure&#8217;s capital stock and holds more than five percent of our outstanding capital stock. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Investors&#8217; Rights Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OnKure was a party to an amended and restated investors&#8217; rights agreement with certain holders of its capital stock, including Acorn Bioventures, L.P., entities affiliated with Cormorant, Citadel Multi-Strategy Equities Master Fund Ltd., Deep Track Biotechnology Master Fund, Ltd., Perceptive Life Sciences Master Fund, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">129 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Ltd. and Samsara BioCapital, L.P. (the &#8220;OnKure IRA&#8221;). Under the OnKure IRA, certain holders of its capital stock had the right to demand that Legacy OnKure file a registration statement or request that their shares of OnKure capital stock be covered by a registration statement that Legacy OnKure was otherwise filing. The OnKure IRA was terminated in connection with the closing of the Merger. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Voting Agreement </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Legacy OnKure was a party to an amended and restated voting agreement, as amended, with certain holders of its capital stock, including, among others, Anthony Piscopio, its former President and Chief Executive Officer, Keith Olivia, its former General Counsel, Senior Vice President of Corporate Affairs and Secretary, and Jim Winkler, its former Chief Scientific Officer, Acorn Bioventures, L.P., entities affiliated with Cormorant, Citadel Multi-Strategy Equities Master Fund Ltd., Deep Track Biotechnology Master Fund, Ltd., Perceptive Life Sciences Master Fund, Ltd. and Samsara BioCapital, L.P. Upon the closing of the Merger, the obligations of the parties to the voting agreement to vote their shares terminated and none of the OnKure stockholders have any special rights regarding the nomination, election or designation of members of our Board pursuant to such agreement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Policies and Procedures for Approval of Related Person Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have adopted a formal, written policy regarding related person transactions.&#160;This policy provides that a related person transaction is a transaction, arrangement or relationship or any series of similar transactions, arrangements or relationships, in which we are a participant and in which a related person has, had or will have a direct or indirect material interest and in which the aggregate amount involved exceeds $120,000.&#160;For purposes of this policy, a related person means any of our executive officers and directors (including director nominees), in each case at any time since the beginning of our last fiscal year, or holders of more than 5% of any class of our voting securities and any member of the immediate family of, or person sharing the household with, any of the foregoing persons. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Audit Committee has the primary responsibility for reviewing and approving, ratifying, or disapproving related person transactions.&#160;In determining whether to approve, ratify, or disapprove any such transaction, our Audit Committee will consider, among other factors, (1) whether the transaction is fair to us and on terms no less favorable than terms generally available to unaffiliated third parties under the same or similar circumstances, (2) the extent of the related person&#8217;s interest in the transaction, (3) whether there are business reasons for us to enter into such transaction, (4) whether the transaction would impair the independence of any of our outside directors, and (5) whether the transaction would present an improper conflict of interest for any of our directors or executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The policy grants standing pre-approval of certain transactions, including (1) certain compensation arrangements for our directors or executive officers, (2) transactions with another company at which a related person&#8217;s only relationship is as a non-executive employee, director, or beneficial owner of less than 10% of that company&#8217;s shares, provided that the aggregate amount involved does not exceed the greater of $200,000 or 5% of such company&#8217;s total annual revenues and the transaction is on terms no less favorable than terms generally available to unaffiliated third parties under the same or similar circumstances, (3) charitable contributions by us to a charitable organization, foundation or university at which a related person&#8217;s only relationship is as a non-executive employee or director, provided that the aggregate amount involved does not exceed the greater of $200,000 or 5% of such organization&#8217;s total annual receipts, (4) transactions where a related person&#8217;s interest arises solely from the ownership of our common stock and all holders of our common stock received the same benefit on a pro rata basis and (5) any indemnification or advancement of expenses made pursuant to our organizational documents or any agreement. In addition to our policy, our Audit Committee charter provides that our Audit Committee shall review and approve or disapprove any related person transactions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">130 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_15">PRINCIPAL SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Security Ownership of Certain Beneficial Owners </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth information regarding the beneficial ownership of Class&#160;A Common Stock as of March&#160;1, 2025: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each person known by us to be the beneficial owner of more than 5% of our outstanding Class&#160;A Common Stock; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">each of our executive officers and directors; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">all of our directors and executive officers as a group. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership is determined according to the rules of the SEC, which generally provide that a person has beneficial ownership of a security if such person possesses sole or shared voting or investment power over that security. Under those rules, beneficial ownership includes securities that such person has the right to acquire, such as through the exercise of stock options, within 60 days of March&#160;1, 2025. Shares subject to warrants and options that are currently exercisable or exercisable within 60 days of March&#160;1, 2025 are considered outstanding and beneficially owned by the person holding such warrant and/or options for the purpose of computing the percentage ownership of that person but are not treated as outstanding for the purpose of computing the percentage ownership of any other person. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as noted by footnote, and subject to community property laws where applicable, based on the information provided to us, we believe that the individuals and entities named in the table below have sole voting and investment power with respect to all shares shown as beneficially owned by them. Unless otherwise noted, the business address of each of our directors and executive officers is 6707 Winchester Circle, Suite 400, Boulder, CO 80301. The percentage of beneficial ownership of the Combined Company is calculated based on 12,749,299 shares of Class&#160;A Common Stock and 686,527 shares <span style="white-space:nowrap">of&#160;non-voting&#160;Class&#160;B</span> Common Stock outstanding. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:74%"/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"><span style="font-weight:bold">Beneficial Owner</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percentage<br/>Shares<br/>Beneficially<br/>Owned</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Directors and Named Executive Officers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano, Ph.D. (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">129,223</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samuel Agresta, M.D. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">30,132</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jason Leverone, C.P.A. (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">41,353</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dylan Hartley, Ph.D. (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,812</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory J. Flesher (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">167,582</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Isaac Manke, Ph.D. (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">R. Michael Carruthers (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,004</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Phillips, Ph.D. (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Valerie M. Jansen, M.D., Ph.D. (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,550</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Grey (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">95,370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Edward Mathers (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,450</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">All current directors and executive officers as a group (10 persons) (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">320,994</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">5% Stockholders</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Cormorant Asset Management LP (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,837,739</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">13.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures, L.P. (14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,439,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10.7</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Citadel Advisors (15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,330,146</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.9</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,004,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P. (17)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">824,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (18)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">706,733</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.3</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Represents beneficial ownership of less than 1%. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">131 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 126,945 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Saccomano exercisable within 60 days of March&#160;1, 2025 and 2,278 restricted stock units that vest within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 30,132 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Agresta exercisable within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 33,188 shares of Class&#160;A Common Stock subject to options held by Mr.&#160;Leverone exercisable within 60&#160;days of March&#160;1, 2025 and 8,165 restricted stock units that vest within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,812 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Hartley exercisable within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;Flesher ceased providing services as President and Chief Executive Officer on October&#160;4, 2024. Consists of (i) 12,320 shares of Class&#160;A Common Stock and (ii) 155,262&#160;shares of Class&#160;A Common Stock subject to options held by Mr.&#160;Flesher that are exercisable within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,550 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Manke exercisable within 60&#160;days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 4,972 shares of Class&#160;A Common Stock subject to options held by Mr.&#160;Carruthers exercisable within 60 days of March&#160;1, 2025 and 2,032 restricted stock units that vest within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,550 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Phillips exercisable within 60&#160;days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 2,550 shares of Class&#160;A Common Stock subject to options held by Dr.&#160;Jansen exercisable within 60 days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of (i) 49,476 shares of Class&#160;A Common Stock held by The Grey Family Trust dated November&#160;12, 1999 (the Grey 1999 Trust), (ii) 13,408 shares of Class&#160;A Common Stock held by Michael Grey and Rondi Rauch <span style="white-space:nowrap">Grey,&#160;Co-Trustees&#160;of</span> The Grey 2014 Irrevocable Children&#8217;s Trust u/a/d 12/17/14 (the Grey 2014 Trust), and (iii) 32,486 shares of Class&#160;A Common Stock subject to options held by Mr.&#160;Grey exercisable within 60 days of March&#160;1, 2025. Mr.&#160;Grey, Reneo&#8217;s former Executive Chairman and a member of the Board of the Combined Company, is trustee of each of the Grey 1999 Trust and Grey 2014 Trust, and in such capacity has the power to vote and dispose of such shares held by the Grey 1999 Trust and Grey 2014 Trust. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(11)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 7,450 shares of Class&#160;A Common Stock subject to options held by Mr.&#160;Mathers exercisable within 60&#160;days of March&#160;1, 2025. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(12)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">See Notes (1)&#160;through (11) above. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(13)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G/A filed on October&#160;16, 2024. Consists of (i) 434,934 shares of Class&#160;A Common Stock held by Cormorant Global Healthcare Master Fund, LP (&#8220;Master Fund&#8221;); (ii) 1,109,451 shares of Class&#160;A Common Stock held by Cormorant Private Healthcare Fund III, LP (&#8220;Fund III&#8221;); (iii) 235,480 shares of Class&#160;A Common Stock held by Cormorant Private Healthcare Fund IV, LP (&#8220;Fund IV&#8221;); (iv) 7,945 shares of Class&#160;A Common Stock held by CRMA SPV, LP (&#8220;CRMA&#8221;); (v) 49,929 shares of Class&#160;A Common Stock held by Cormorant Private Healthcare Fund&#160;V, LP (&#8220;Fund V&#8221;). Cormorant Global Healthcare GP, LLC serves as the general partner of Master Fund, Cormorant Private Healthcare GP III, LLC serves as the general partner of Fund III, Cormorant Private Healthcare GP IV, LLC serves as the general partner of Fund IV, Cormorant Private Healthcare GP V, LLC serves as the general partner of Fund V, and Cormorant Asset Management, LP (&#8220;Cormorant&#8221;) serves as the investment manager to Master Fund, Fund III, Fund IV, Fund V and CRMA. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant and therefore may be deemed to share voting and investment power over such shares. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. The address for each of reporting person is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(14)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G filed on October&#160;9, 2024. Consists of (i) 1,439,674 shares of Class&#160;A Common Stock held by Acorn Bioventures, L.P.. Acorn Capital Advisors, GP, LLC (&#8220;Acorn GP&#8221;) is the general partner of Acorn Bioventures L.P. Acorn GP has discretionary authority to vote and dispose of the shares held by Acorn Bioventures L.P. and, accordingly, Acorn GP may be deemed to have beneficial ownership of such shares. Anders Hove is the manager of Acorn GP and, in his capacity as such, may be deemed to beneficially own the shares held by Acorn Bioventures L.P. Dr.&#160;Isaac Manke, a member of the </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">132 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="vertical-align:top;text-align:left">
Board, is a partner at Acorn GP. Each of Acorn GP, Dr.&#160;Hove and Dr.&#160;Manke disclaim beneficial ownership of the shares held by Acorn Bioventures L.P., except to the extent of their respective pecuniary interests therein. The business address for these persons is 420 Lexington Avenue, Suite 2626, New York, NY 10170. </td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(15)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G filed on October&#160;11, 2024. Consists of (i) 702,044 shares of Class&#160;A Common Stock held by Citadel Multi-Strategy Equities Master Fund Ltd. (&#8220;CM&#8221;), (ii) 267,310 shares of Class&#160;A Common Stock issuable upon conversion of Class&#160;B Common Stock held by CM, and (iii) 360,792 shares of Class&#160;A Common Stock held by Citadel CEMF Investments Ltd. (&#8220;CEMF Investments&#8221;). Does not include 419,217 shares of Class&#160;A Common Stock otherwise issuable to CM upon conversion of Class&#160;B Common Stock due to a 9.9% beneficial ownership limit. The Class&#160;B Common Stock <span style="white-space:nowrap">is&#160;non-voting.&#160;Citadel</span> Advisors LLC (&#8220;Citadel Advisors&#8221;) is the portfolio manager of CM and CEMF Investments. Citadel Advisors Holdings LP (&#8220;CAH&#8221;) is the sole member of Citadel Advisors. Citadel GP LLC (&#8220;CGP&#8221;) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&#160;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the shares held by CEMF. This response is not and shall not be construed as an admission that Mr.&#160;Griffin or any of the Citadel related entities listed above is the beneficial owner of any securities of the Combined Company other than the securities actually owned by such person (if any). The address for each of these persons is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(16)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G filed on October&#160;10, 2024. Consists of 1,004,439 shares of Class&#160;A Common Stock held by Perceptive Life Sciences Master Fund, Ltd. Perceptive Advisors LLC (the &#8220;Advisor&#8221;) serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd. (the &#8220;Master Fund&#8221;). Joseph Edelman is the managing member of the Advisor. Each of Mr.&#160;Edelman and the Advisor disclaims, for purposes of Section&#160;16 of the Exchange Act, beneficial ownership of the shares held by the Master Fund, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr.&#160;Edelman or the Advisor is the beneficial owner of such securities. The address for Perceptive Life Sciences Master Fund, Ltd. and Perceptive Advisors LLC is 51 Astor Place, 10th Floor, New York, NY 10003. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(17)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G filed on October&#160;11, 2024. Consists of 824,155 shares of Class&#160;A Common Stock held by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC (&#8220;Samsara LLC&#8221;) is the general partner of by Samsara BioCapital, L.P. (&#8220;Samsara LP&#8221;) and therefore may be deemed to beneficially own the shares held by Samsara LP. Dr.&#160;Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. The address for Samsara LP is 628 Middlefield Road, Palo Alto, CA 94301. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(18)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Based on information taken from Schedule 13G filed on January&#160;31, 2025. The Vanguard Group reported that it has sole dispositive power with respect to 705,988 shares and shared dispositive power with respect to 745 shares. The address for the Vanguard Group is 100 Vanguard Blvd., Malvern, PA 19355. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">133 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_16">SELLING SECURITYHOLDERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale by the selling securityholders from time to time of up to an aggregate of 2,839,005 shares of Class&#160;A Common Stock that were issued to certain investors in the PIPE Financing. The selling securityholders may from time to time offer and sell any or all of the shares of Class&#160;A Common Stock set forth below pursuant to this prospectus and any accompanying prospectus supplement. When we refer to the &#8220;selling securityholders&#8221; in this prospectus, we mean the persons listed in the table below and their permitted transferees who later come to hold any of the selling securityholders&#8217; interest in the Class&#160;A Common Stock in accordance with the terms of the applicable agreements governing their respective registration rights, other than through a public sale. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth, as of October&#160;4, 2024 (after giving effect to the Merger), the names of the selling securityholders, the aggregate number of shares of Class&#160;A Common Stock beneficially owned by the selling securityholders, the aggregate number of shares of Class&#160;A Common Stock that the selling securityholders may offer pursuant to this prospectus and the number of shares of Class&#160;A Common Stock that would be beneficially owned by the selling securityholders after the sale of the shares of Class&#160;A Common Stock offered hereby assuming that the selling securityholders sell all of the shares of Class&#160;A Common Stock covered by this prospectus. The percentage of beneficial ownership after the offered shares of Class&#160;A Common Stock are sold is calculated based on 12,652,811 shares of Class&#160;A Common Stock and 686,527 shares of <span style="white-space:nowrap">non-voting</span> Class&#160;B Common Stock outstanding immediately after giving effect to the Merger and the PIPE Financing. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have determined beneficial ownership in accordance with the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Unless otherwise indicated below, to our knowledge, the persons and entities named in the tables have sole voting and sole investment power with respect to the shares of Class&#160;A Common Stock set forth below, subject to community property laws where applicable. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot advise you as to whether the selling securityholders will in fact sell any or all of such Class&#160;A Common Stock. In addition, the selling securityholders may sell, transfer or otherwise dispose of, at any time and from time to time, the Class&#160;A Common Stock in transactions exempt from the registration requirements of the Securities Act after the date of this prospectus. For purposes of this table, we have assumed that the selling securityholders will have sold all of the shares of Class&#160;A Common Stock covered by this prospectus upon the completion of the offering. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">134 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling securityholder information for each additional selling securityholder, if any, will be set forth by a prospectus supplement to the extent required prior to the time of any offer or sale of such selling securityholder&#8217;s shares pursuant to this prospectus. Any prospectus supplement may add, update, substitute, or change the information contained in this prospectus, including the identity of each selling securityholder and the number of shares registered on its behalf. A selling securityholder may sell or otherwise transfer all, some or none of such shares in this offering. See &#8220;<span style="font-style:italic">Plan of Distribution</span>.&#8221; </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:54%"/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>

<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td rowspan="2" style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name of Selling Securityholder</p></td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Common&#160;Stock<br/>Beneficially<br/>Owned<br/>Prior to<br/>Offering</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom" rowspan="2">&#160;&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number&#160;of<br/>Shares of<br/>Common<br/>Stock&#160;Being<br/>Offered</span></td>
<td style="vertical-align:bottom" rowspan="2">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Common Stock<br/>Beneficially<br/>Owned&#160;After&#160;the<br/>Offered Shares of<br/>Common&#160;Stock<br/>are&#160;Sold</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Number</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><span style="font-weight:bold">Percent</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Acorn Bioventures, L.P.<sup style="font-size:75%; vertical-align:top"> (1)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,439,674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">199,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,240,485</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Global Healthcare Master Fund,<br/>LP <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">434,934</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">329,089</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">105,845</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cormorant Private Healthcare Fund V, LP <sup style="font-size:75%; vertical-align:top">(2)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">49,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">49,929</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Citadel CEMF Investments Ltd. <sup style="font-size:75%; vertical-align:top">(3)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">360,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">360,792</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Perceptive Life Sciences Master Fund, Ltd. <sup style="font-size:75%; vertical-align:top">(4)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,004,439</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">207,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">797,282</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deep Track Biotechnology Master Fund,<br/>Ltd. <sup style="font-size:75%; vertical-align:top">(5)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">660,136</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">136,147</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">523,989</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samsara BioCapital, L.P. <sup style="font-size:75%; vertical-align:top">(6)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">824,155</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">169,975</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">654,180</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5.2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc. <sup style="font-size:75%; vertical-align:top">(7)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">463,586</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">95,610</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">367,976</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">StepStone Master G, L.P. <sup style="font-size:75%; vertical-align:top">(8)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">491,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">199,189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">292,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Affinity Healthcare Fund, LP <sup style="font-size:75%; vertical-align:top">(9)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">174,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">174,708</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Altium Growth Fund, LP <sup style="font-size:75%; vertical-align:top">(10)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">218,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">218,386</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Boulder Ventures VIII, L.P. <sup style="font-size:75%; vertical-align:top">(11)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">43,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">43,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities affiliated with Monashee Investment Management, LLC <sup style="font-size:75%; vertical-align:top">(12)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">131,031</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sphera Biotech Master Fund LP <sup style="font-size:75%; vertical-align:top">(13)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">87,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">87,354</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Entities Affiliated with Vestal Point Capital, LP&#160;<sup style="font-size:75%; vertical-align:top">(14)</sup></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">516,710</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">436,772</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">79,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total Shares</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,901,449</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,839,005</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,062,444</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than 1% </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Acorn Capital Advisors, GP, LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Acorn GP</span></span>&#8221;) is the general partner of Acorn Bioventures L.P. Acorn GP has discretionary authority to vote and dispose of the shares held by Acorn Bioventures L.P. and, accordingly, Acorn GP may be deemed to have beneficial ownership of such shares. Anders Hove is the manager of Acorn GP and, in his capacity as such, may be deemed to beneficially own the shares held by Acorn Bioventures L.P. Dr.&#160;Isaac Manke, a member of the Board, is a partner at Acorn GP. Each of Acorn GP, Dr.&#160;Hove and Dr.&#160;Manke disclaim beneficial ownership of the shares held by Acorn Bioventures L.P., except to the extent of their respective pecuniary interests therein. The business address for these persons is 420 Lexington Avenue, Suite 2626, New York, NY 10170. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Cormorant Global Healthcare GP, LLC serves as the general partner of Master Fund, Cormorant Private Healthcare GP III, LLC serves as the general partner of Fund III, Cormorant Private Healthcare GP IV, LLC serves as the general partner of Fund IV, Cormorant Private Healthcare GP V, LLC serves as the general partner of Fund V, and Cormorant Asset Management, LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Cormoran</span></span>t&#8221;) serves as the investment manager to Master Fund, Fund III, Fund IV, Fund V and CRMA. Bihua Chen serves as the managing member of Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare GP III, LLC, Cormorant Private Healthcare GP IV, LLC and Cormorant Private Healthcare GP V, LLC, and the general partner of Cormorant and therefore may be deemed to share voting and investment power over such shares. Each of the reporting persons disclaims beneficial ownership of the shares except to the extent of its pecuniary interest therein. The address for each of reporting person is 200 Clarendon Street 52nd Floor, Boston, Massachusetts 02116. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">135 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Citadel Advisors LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Citadel Advisors</span></span>&#8221;) is the portfolio manager of Citadel CEMF Investments Ltd. Citadel Advisors Holdings LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">CAH</span></span>&#8221;) is the sole member of Citadel Advisors. Citadel GP LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">CGP</span></span>&#8221;) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&#160;Griffin, as the owner of a controlling interest in CGP, may be deemed to have shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition of, the shares held by CEMF. This disclosure is not and shall not be construed as an admission that Mr.&#160;Griffin or any of the Citadel related entities listed above is the beneficial owner of any securities of the Combined Company other than the securities actually owned by such person (if any). The address for each of these persons is c/o Citadel Enterprise Americas, Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, FL 33131. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Perceptive Advisors LLC (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Advisor</span></span>&#8221;) serves as the investment manager to Perceptive Life Sciences Master Fund, Ltd. (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Master Fund</span></span>&#8221;). Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of the shares held by the Master Fund, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities. The address for Perceptive Life Sciences Master Fund, Ltd. And Perceptive Advisors LLC is 51 Astor Place, 10th Floor, New York, NY 10003. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Mr.&#160;David Kroin is the managing member of Deep Track Capital GP, LLC, the general partner of Deep Track Capital, L.P., and by virtue of such status may be deemed to be the beneficial owner of the shares owned by Deep Track Master Fund. Deep Track Capital, L.P. and Mr.&#160;Kroin disclaim beneficial ownership over the shares held by Deep Track Biotechnology Master Fund, Ltd., except to the extent of their respective pecuniary interests. The address for Deep Track Biotechnology Master Fund, Ltd. and Deep Track Capital, LP. is 200 Greenwich Avenue, 3rd Floor, Greenwich, CT 06830. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(6)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Samsara BioCapital GP, LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Samsara LLC</span></span>&#8221;) is the general partner of Samsara BioCapital, L.P. (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Samsara LP</span></span>&#8221;) and therefore may be deemed to beneficially own the shares held by Samsara LP. Dr.&#160;Srinivas Akkaraju, MD, Ph.D. has voting and investment power over the shares held by Samsara LLC and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Samsara LLC disclaims beneficial ownership in these shares except to the extent of its respective pecuniary interest therein. The address for Samsara LP is 628 Middlefield Road, Palo Alto, CA 94301. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(7)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The registered holders of the referenced shares to be registered are the following funds and accounts under management by subsidiaries of BlackRock, Inc.: BlackRock Health Sciences Term Trust. BlackRock, Inc. is the ultimate parent holding company of such subsidiaries. On behalf of such subsidiaries, the applicable portfolio managers, as managing directors (or in other capacities) of such entities, and/or the applicable investment committee members of such funds and accounts, have voting and investment power over the shares held by the funds and accounts which are the registered holders of the referenced shares. Such portfolio managers and/or investment committee members expressly disclaim beneficial ownership of all shares held by such funds and accounts. The address of such funds and accounts, such subsidiaries and such portfolio managers and/or investment committee members is 60 State Street, 19th/20th Floor, Boston, MA&#160;02109. Shares shown include only the securities being registered for resale and may not incorporate all shares deemed to be beneficially held by the registered holders or BlackRock, Inc. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(8)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">StepStone Group LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">StepStone</span></span>&#8221;) is the investment manager of StepStone Master G, L.P. StepStone Group Holdings LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">StepStone Group Holdings</span></span>&#8221;) is the general partner of StepStone, and StepStone Group Inc. is the sole managing member of StepStone Group Holdings. The business address of StepStone and StepStone Master G, L.P. is 4225 Executive Square, Suite 1600, La Jolla, CA 92037. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(9)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Affinity Asset Advisors, LLC (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Advisor</span></span>&#8221;) is the investment manager of Affinity Healthcare Fund, LP (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Fund</span></span>&#8221;) and exercises investment discretion with regard to the shares of Common Stock owned by the Fund. Michael Cho is the managing member of the Advisor. The Fund and the Advisor have the shared power to vote or to direct the vote and to dispose or direct the disposition of such shares of Common Stock of the Issuer owned by the Fund. The Advisor may be deemed to be the beneficial owner of such shares of Common Stock of the Issuer owned by the Fund by virtue of its position as investment manager of the Fund. The principal business address of each of the Fund and the Advisor is 767 Third Avenue, 15th Floor, New&#160;York, NY 10017. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">136 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(10)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Altium Capital Management, LP, the investment manager of Altium Growth Fund, LP, has voting and investment power over these securities. Jacob Gottlieb is the managing member of Altium Capital Growth GP, LLC, which is the general partner of Altium Growth Fund, LP. Each of Altium Growth Fund, LP and Jacob Gottlieb disclaims beneficial ownership over these securities. The principal address of Altium Capital Management, LP is 152 West 57th Street, 20th Floor, New York, NY 10019. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(11)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 38,620 shares held by Boulder Ventures VIII, L.P. and 5,057 shares held by Boulder Ventures VIII (Annex), L.P. BV Partners VIII LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">BV GP</span></span>&#8221;) is the general partner of Boulder Ventures VIII L.P. and Boulder Ventures VIII (Annex) L.P. BV GP has the discretionary authority to vote and dispose of the shares held by Boulder Ventures VIII L.P. and Boulder Ventures VIII (Annex) L.P. and, accordingly, BV GP may be deemed to have beneficial ownership of such shares. Kyle Lefkoff is a Managing Member of BV GP and, in his capacity as such, may be deemed to beneficially own the shares held by Boulder Ventures VIII L.P. and Boulder Ventures VIII (Annex) L.P. Mr. Lefkoff disclaims beneficial ownership of the shares held by Boulder Ventures VIII L.P. and Boulder Ventures VIII (Annex) L.P., except to the extent of his pecuniary interest therein. The business address for Mr. Lefkoff and Boulder Ventures is 1941 Pearl Street, Suite 300, Boulder, Colorado, 80302. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(12)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Consists of 35,379 shares held by BEMAP Master Fund LTD (&#8220;<span style="font-weight:bold"><span style="font-style:italic">BEMAP</span></span>&#8221;), 11,792 shares held by Mission Pure Alpha LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Mission</span></span>&#8221;), 40,620 shares held by Monashee Pure Alpha SPV I LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Pure Alpha</span></span>&#8221;) and 43,240 shares held by Blackstone CSP-MST FMAP Fund (&#8220;<span style="font-weight:bold"><span style="font-style:italic">FMAP</span></span>&#8221;). BEMAP, Mission, Pure Alpha, and FMAP are managed by Monashee Investment Management, LLC (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Monashee Management</span></span>&#8221;). Jeff Muller is CCO of Monashee Management and has voting and investment control over Monashee Management and, accordingly, may be deemed to have beneficial ownership of the shares held by BEMAP, Pure Alpha, Mission, and FMAP. Jeff Muller, however, disclaims any beneficial ownership of the shares held by these entities. The business address of BEMAP, Pure Alpha, Mission, FMAP and Mr. Muller is c/o Monashee Investment Management, LLC, 75 Park Plaza, 4th Floor, Boston, Massachusetts 02116. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(13)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Sphera Biotech Master Fund LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Sphera Biotech</span></span>&#8221;) has delegated its investment management authority to Sphera Global Healthcare Management LP (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Sphera Management</span></span>&#8221;). Accordingly, Sphera Management may be deemed to have beneficial ownership of the shares held by Sphera Biotech. Sphera Management disclaims beneficial ownership of such shares, except to the extent of its pecuniary interest therein. Sphera Biotech and Sphera Management business address is 4 Yitzhak Sadeh, Building A, 29th Floor, Tel Aviv 6777520, Israel. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">(14)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Shares listed under &#8220;Common Stock Beneficially Owned Prior to Offering&#8221; consist of (i) 258,882 shares held by Vestal Point Master Fund, LP and (ii) 257,828 shares held by an account separately managed by Vestal Point Capital, LP. The sole general partner of Vestal Point Master Fund, LP is Vestal Point Partners GP, LLC. The managing member of Vestal Point Partners GP, LLC is Ryan Wilder. The sole general partner of Vestal Point Capital, LP is Vestal Point Capital, LLC. The managing member of Vestal Point Capital, LLC is Mr. Wilder. As a result, Mr. Wilder may be deemed to have voting and investment power over the securities held by Vestal Point Master Fund, LP and the account separately managed by Vestal Point Capital, LP. Mr. Wilder disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein. The address of these entities and Mr. Wilder is c/o Vestal Point Capital, LP, 632 Broadway, Suite 602, New York, NY 10012. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please see the sections titled &#8220;<span style="font-style:italic">Certain Relationships, Related Party and Other Transactions</span>&#8221; appearing elsewhere in this prospectus for information regarding material relationships with our selling securityholders within the past two years. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">137 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_17">DESCRIPTION OF SECURITIES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our capital stock and provisions of our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws are summaries and are qualified by reference to our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws and applicable provisions of Delaware corporate law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Authorized Capital Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The total number of authorized shares of capital stock consists of (i)&#160;210,000,000&#160;shares of common stock, par value $0.0001 per share, of which 200,000,000&#160;shares are designated Class&#160;A Common Stock and 10,000,000&#160;shares are designated Class&#160;B Common Stock and (ii)&#160;10,000,000&#160;shares of preferred stock, par value $0.0001 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class&#160;A Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of Class&#160;A Common Stock are entitled to one vote for each share held of record on all matters on which stockholders are entitled to vote generally, except that holders of shares of Class&#160;A Common Stock will have no voting power with respect to, and will not be entitled to vote on, any amendment to the Amended<span style="font-style:italic"> </span>Certificate of Incorporation (including any certificate of designations relating to any series of Preferred Stock) that relates solely to the terms of any outstanding preferred stock if the holders of such preferred stock are entitled to vote as a separate class thereon under the Amended<span style="font-style:italic"></span>&#160;Certificate of Incorporation or under the DGCL. The holders of Class&#160;A Common Stock do not have cumulative voting rights in the election of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Dividends </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of Class&#160;A Common Stock are entitled to receive dividends when, as and if declared by the board of directors out of funds legally available therefor, subject to any statutory or contractual restrictions on the payment of dividends and to any restrictions on the payment of dividends imposed by the terms of any outstanding preferred stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Distributions on Liquidation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon its liquidation, dissolution or winding up and after payment in full of all amounts required to be paid to creditors and to the holders of preferred stock having liquidation preferences, if any, the holders of shares of Class&#160;A Common Stock will be entitled to receive pro rata the remaining assets available for distribution. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Other Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock have no preemptive, subscription, redemption or conversion rights and no sinking fund provisions are applicable to our common stock. The rights, preferences and privileges of holders of common stock are subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Class&#160;B Common Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as expressly set forth below with respect to voting rights and conversion rights only, the Class&#160;B Common Stock has the same rights and powers of, ranks equally to, shares ratably with and is identical in all respects and as to all matters to Class&#160;A Common Stock. If we in any manner subdivide or combine the shares of Class&#160;A Common Stock, then the shares of Class&#160;B Common Stock will be subdivided or combined in the same proportion and manner, and if we in any manner subdivide or combine the shares of Class&#160;B Common Stock, then the outstanding shares of Class&#160;A Common Stock will be subdivided or combined in the same proportion and manner. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">138 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Voting Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of shares of Class&#160;B Common Stock shall have no voting rights and are not entitled to vote on any matter, including the election of directors, at any time. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Conversion Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of Class&#160;B Common Stock are convertible into a corresponding number of fully paid and nonassessable shares of Class&#160;A Common Stock upon written notice by the holder thereof. Notwithstanding anything to the contrary in the Amended Certificate of Incorporation, no holder of Class&#160;B Common Stock shall be entitled to receive, and we shall not deliver to any such holder, any Class&#160;A Common Stock upon conversion of the Class&#160;B Common Stock to the extent (but only to the extent) that, after such receipt, such converting holder and its affiliates (together, the &#8220;Related Holders&#8221;) would beneficially own in the aggregate, directly or indirectly, shares of Class&#160;A Common Stock in excess of the Beneficial Ownership Limitation Percentage (as defined below) (this provision, the &#8220;Beneficial Ownership Limitation&#8221;). For the avoidance of doubt, in the event that the Related Holders beneficially own in the aggregate, directly or indirectly, shares of Class&#160;A Common Stock equal to or in excess of the Beneficial Ownership Limitation Percentage without taking into account the conversion of Class&#160;B Common Stock, then none of the Class&#160;B Common Stock shall be convertible into shares of Class&#160;A Common Stock until such time as the Related Holders no longer beneficially own in the aggregate, directly or indirectly, shares of Class&#160;A Common Stock equal to or in excess of the Beneficial Ownership Limitation Percentage. The &#8220;Beneficial Ownership Limitation Percentage&#8221; means initially 9.9% of the then-outstanding shares of Class&#160;A Common Stock. Any holder of Class&#160;B Common Stock may increase the Beneficial Ownership Limitation Percentage with respect to such holder upon 61 days&#8217; prior written notice (but, prior to the Restriction Lapse Date (as defined below), not above 9.9% of the then-outstanding shares of Class&#160;A Common Stock) and may decrease the Beneficial Ownership Limitation Percentage at any time upon providing written notice of such election; provided, however, that no holder may make such an election to change the Beneficial Ownership Limitation Percentage with respect to such holder unless all holders managed by the same investment advisor as such electing holder make the same election. &#8220;Restriction Lapse Date&#8221; means the date that the original recipient of Class&#160;B Common Stock (the &#8220;Original Recipient&#8221;) issued Class&#160;B Common Stock as merger consideration pursuant to the Merger Agreement, and the Original Recipient&#8217;s affiliates cease to hold any shares of Class&#160;B Common Stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Preferred Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our board of directors is authorized, without action by the stockholders, to designate and issue up to an aggregate of 10,000,000 shares of preferred stock in one or more series. Our board of directors can designate the rights, preferences and privileges of the shares of each series and any of its qualifications, limitations or restrictions. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of common stock. The issuance of preferred stock, while providing flexibility in connection with possible future financings and acquisitions and other corporate purposes could, under certain circumstances, have the effect of restricting dividends on our common stock, diluting the voting power of our common stock, impairing the liquidation rights of our common stock, or delaying, deferring or preventing a change in control of the Company, which might harm the market price of our common stock. Our board of directors will make any determination to issue such shares based on its judgment as to our best interests and the best interests of our stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Annual Stockholder Meetings </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Bylaws provide that annual stockholder meetings will be held at a date, time and place, if any, as may be designated by the board of directors. To the extent permitted under applicable law, we may conduct meetings by remote communication as provided by the DGCL. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">139 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Anti-Takeover Effects of the Certificate of Incorporation, Amended Bylaws and Certain Provisions of Delaware Law </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Amended Certificate of Incorporation, our Amended Bylaws and certain provisions of the DGCL contain provisions, which are summarized in the following paragraphs, that are intended to enhance the likelihood of continuity and stability in the composition of the board of directors. These provisions are intended to avoid costly takeover battles, reduce our vulnerability to a hostile or abusive change of control and enhance the ability of the board of directors to maximize stockholder value in connection with any unsolicited offer to acquire us. However, these provisions may have an&#160;anti-takeover&#160;effect&#160;and may delay, deter or prevent a merger or acquisition of us by means of a tender offer, a proxy contest or other takeover attempt that a stockholder might consider in its best interest, including those attempts that might result in a premium over the prevailing market price for the shares held by stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Authorized but Unissued Capital Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Delaware Law does not require stockholder approval for any issuance of shares that are authorized and available for issuance. However, the listing requirements of Nasdaq, which would apply so long as Class&#160;A Common Stock remains listed on Nasdaq, require stockholder approval of certain issuances equal to or exceeding 20% of the then outstanding voting power of our capital stock or then outstanding number of shares of Class&#160;A Common Stock. These additional shares may be used for a variety of corporate purposes, including future public offerings, to raise additional capital or to facilitate acquisitions. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors will be authorized to generally issue shares of one or more series of preferred stock on terms calculated to discourage, delay or prevent a change of control of the Company or the removal of its management. Moreover, our authorized but unissued shares of preferred stock will be available for future issuances in one or more series without stockholder approval and could be utilized for a variety of corporate purposes, including future offerings to raise additional capital, to facilitate acquisitions and employee benefit plans. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">One of the effects of the existence of authorized and unissued and unreserved Class&#160;A Common Stock or preferred stock may be to enable our Board to issue shares to persons friendly to current management, which issuance could render more difficult or discourage an attempt to obtain control of the Company by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity of its management and possibly deprive its stockholders of opportunities to sell their shares of Class&#160;A Common Stock at prices higher than prevailing market prices. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Vacancies and Newly Created Directorships </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation and Amended Bylaws provide that, subject to any rights of any series of preferred stock that may be designated, any vacancies on the board of directors, and any newly created directorships, will be filled only by the affirmative vote of a majority of the remaining directors then in office, even if less than a quorum, and any director so chosen will hold office until the earlier expiration of the term of office of the director whom he or she has replaced or his or her successor shall be duly elected and qualified or until such director&#8217;s earlier death, disqualification, resignation or removal. No decrease in the number of directors shall shorten the term of any director then in office. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Removal of Directors </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the Amended Bylaws, subject to the right of any series of preferred stock, any or all members of the board of directors may be only removed for cause by at least a 66 2/3% vote of the shares then entitled to vote generally in the election of directors, voting together as a single class. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">140 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">No Cumulative Voting </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under Delaware Law, the right to vote cumulatively does not exist unless the certificate of incorporation specifically authorizes cumulative voting. The Amended Certificate of Incorporation does not authorize cumulative voting. Therefore, stockholders holding a majority in voting power of the shares of Class&#160;A Common Stock entitled to vote generally in the election of directors will be able to elect all directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Special Stockholder Meetings </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation and the Amended Bylaws provide that special meetings of stockholders may be called only by the chair of the board of directors, the chief executive officer or at the direction of the board of directors pursuant to a written resolution adopted by a majority of the total number of directors that the Company would have if there were no vacancies. Any business transacted at a special meeting of stockholders will be limited to matters set forth in the notice of the special meeting. These provisions may have the effect of deterring, delaying or discouraging hostile takeovers, or changes in control or management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Director Nominations and Stockholder Proposals </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Bylaws contain advance notice procedures with respect to stockholder nominations for the election as directors. In order for any matter to be &#8220;properly brought&#8221; before a meeting, a stockholder will have to comply with advance notice requirements and provide us with certain information. Generally, to be timely, a stockholder&#8217;s notice must be received at our principal executive offices not less than 90&#160;days nor more than 120&#160;days prior to the first anniversary date of the immediately preceding annual meeting of stockholders. The Amended Bylaws also specify requirements as to the form and content of a stockholder&#8217;s notice. The Amended Bylaws allow the chair of the meeting at a meeting of the stockholders to adopt rules and regulations for the conduct of meetings which may have the effect of precluding the conduct of certain business at a meeting if the rules and regulations are not followed. These provisions may also defer, delay or discourage a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#8217;s own slate of directors or otherwise attempting to influence or obtain control of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Stockholder Action by Written Consent </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Section&#160;228 of the DGCL, any action required to be taken at any annual or special meeting of the stockholders may be taken without a meeting, without prior notice and without a vote if a consent or consents in writing, setting forth the action so taken, is or are signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares of stock entitled to vote thereon were present and voted, unless the certificate of incorporation provides otherwise. The Amended Certificate of Incorporation precludes stockholder action by written consent. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These provisions may have the effect of deterring hostile takeovers or delaying or preventing changes in control of the Company or its management, such as a merger, reorganization or tender offer. These provisions are intended to enhance the likelihood of continued stability in the composition of the board of directors and its policies and to discourage certain types of transactions that may involve an actual or threatened acquisition of the board of directors. These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal. The provisions are also intended to discourage certain tactics that may be used in proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and, as a consequence, they also may inhibit fluctuations in the market price of our shares that could result from actual or rumored takeover attempts. Such provisions may also have the effect of preventing changes in management. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendments to Governing Documents </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended Certificate of Incorporation and Amended Bylaws, the board of directors is expressly empowered to adopt, amend or repeal the Amended Bylaws. Any adoption, amendment or repeal of the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">141 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Amended Bylaws by the board of directors shall require the approval of a majority of the authorized number of directors. Our stockholders also have power to adopt, amend or repeal the Amended Bylaws; provided, however, that, in addition to any vote of the holders of any class or series of stock required by law, such action by stockholders shall require the affirmative vote of the holders of at least 66 2/3% of the voting power of all of the then-outstanding shares of the capital stock entitled to vote generally in the election of directors, voting together as a single class. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">DGCL Section&#160;203 </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the provisions of Section&#160;203 of the DGCL regulating corporate takeovers. In general, those provisions prohibit a Delaware corporation, including those whose securities are listed for trading on Nasdaq, from engaging in any business combination with any interested stockholder for a period of three&#160;years following the date that the stockholder became an interested stockholder, unless: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the transaction is approved by the board of directors before the date the interested stockholder attained that status; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on or after such time the business combination is approved by the board of directors and authorized at a meeting of stockholders by at <span style="white-space:nowrap">least&#160;two-thirds&#160;of&#160;the</span> outstanding voting stock that is not owned by the interested stockholder. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;203 defines a business combination to include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any merger or consolidation involving the corporation and the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any sale, transfer, lease, pledge, exchange, mortgage or other disposition involving the interested stockholder of 10% or more of the assets of the corporation; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the corporation to the interested stockholder; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">subject to exceptions, any transaction involving the corporation that has the effect of directly or indirectly increasing the proportionate share of the stock of any class or series, or securities convertible into the stock of any class or series, of the corporation beneficially owned by the interested stockholder; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the direct or indirect receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial benefits provided by or through the corporation. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Generally, Section&#160;203 defines an interested stockholder as any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Dissenters&#8217; Rights of Appraisal and Payment </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, with certain exceptions, including the circumstances where the Common Stock is, at the effective date of a merger or consolidation, either listed on a national securities exchange or held of record by more than 2,000 holders, our stockholders will have appraisal rights in connection with a merger or consolidation of the Company. Pursuant to the DGCL, stockholders who properly request and perfect appraisal rights in connection with such merger or consolidation will have the right to receive payment of the fair value of their shares as determined by the Delaware Court of Chancery. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">142 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stockholders&#8217; Derivative Actions </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the DGCL, any stockholders may bring an action in our name to procure a judgment in our favor, also known as a derivative action, provided that the stockholder bringing the action is a holder of our shares at the time of the transaction to which the action relates or such stockholder&#8217;s stock thereafter devolved by operation of law. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Exclusive Forum </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation provides that unless we consent in writing to the selection of an alternative forum, the Court of Chancery in the State of Delaware (or, if the Court of Chancery does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for any (i)&#160;derivative action or proceeding brought on behalf of the Company, (ii)&#160;action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or our stockholders, (iii)&#160;action asserting a claim arising pursuant to any provision of the DGCL or the Amended Certificate of Incorporation or Amended Bylaws, or (iv)&#160;action asserting a claim governed by the internal affairs doctrine. This provision does not apply to any actions arising under the Securities Act. Any person or entity purchasing or otherwise acquiring or holding any interest in any security of the Company shall be deemed to have notice of and consented to the forum provisions in the Amended Certificate of Incorporation. However, the enforceability of similar forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be unenforceable. Additionally, Section&#160;22 of the Securities Act creates concurrent jurisdiction for federal and state courts over actions brought under the Securities Act or the rules and regulations promulgated thereunder and stockholders cannot waive compliance with the federal securities laws and the rules and regulations thereunder. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Limitations on Liability and Indemnification of Officers and Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The DGCL authorizes corporations to limit or eliminate the personal liability of directors and officers to corporations and their stockholders for monetary damages for breaches of directors&#8217; and officers&#8217; fiduciary duties, subject to certain exceptions. The Amended Certificate of Incorporation will include a provision that eliminates the personal liability of directors and officers for monetary damages to the corporation or its stockholders for any breach of fiduciary duty as a director or an officer. The effect of these provisions is to eliminate the rights of the Company and our stockholders, through stockholders&#8217; derivative suits on our behalf, to recover monetary damages from a director or an officer for breach of fiduciary duty as a director or an officer, including breaches resulting from grossly negligent behavior. However, exculpation will not apply to any breaches of a director&#8217;s or officer&#8217;s duty of loyalty, acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, or for any transaction from which such director or officer derived an improper personal benefit. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Amended Certificate of Incorporation and the Amended Bylaws generally provide that we must defend, indemnify and advance expenses to our directors and officers to the fullest extent permitted or required by the DGCL. We are expressly authorized to carry directors&#8217; and officers&#8217; liability insurance providing indemnification for our directors, officers and certain employees for some liabilities. We believe that these indemnification and advancement provisions and insurance are useful to attract and retain qualified directors and executive officers. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The limitation of liability, indemnification and advancement provisions in the Amended Certificate of Incorporation and Amended Bylaws may discourage stockholders from bringing a lawsuit against directors or officers for breach of their fiduciary duties. These provisions also may have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit the Company and our stockholders. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">143 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transfer Agent and Registrar </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Class&#160;A Common Stock is Equiniti Trust Company, LLC. The transfer agent&#8217;s address is 6201 15th Avenue, Brooklyn, New York 11219. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Listing </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Class&#160;A Common Stock is listed on the Nasdaq Global Market under the symbol &#8220;OKUR.&#8221; </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">144 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_18">PLAN OF DISTRIBUTION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders, which as used herein includes donees, pledgees, transferees or other <span style="white-space:nowrap"><span style="white-space:nowrap">successors-in-interest</span></span> selling shares of common stock or interests in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may use any one or more of the following methods when disposing of shares or interests therein: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on any national securities exchange or quotation service on which the securities may be listed or quoted at the time of sale; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in transactions otherwise than on these exchanges or systems or in the <span style="white-space:nowrap"><span style="white-space:nowrap">over-the-counter</span></span> market; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">block trades in which the broker-dealer will attempt to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">an exchange distribution in accordance with the rules of the applicable exchange; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">privately negotiated transactions; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in settlement of short sales; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">broker-dealers may agree with the selling stockholders to sell a specified number of such shares at a stipulated price per share; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through the distribution of the common stock by any selling stockholder to its partners, members or stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">directly to one or more purchasers; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">through delayed delivery requirements; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by pledge to secured debts and other obligations; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a combination of any such methods of sale; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any other method permitted by applicable law. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, a selling stockholder that is an entity may elect to make a pro rata <span style="white-space:nowrap">in-kind</span> distribution of shares to its members, partners or stockholders pursuant to the registration statement of which this prospectus is a part by delivering a prospectus with a plan of distribution. Such members, partners or stockholders would thereby receive freely tradeable securities pursuant to the distribution through a registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">145 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
pledgees or secured parties may offer and sell the shares of common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus. The selling stockholders also may transfer the shares of common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling stockholders for purposes of this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of our common stock or interests therein, the selling stockholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions they assume. The selling stockholders may also sell shares of our common stock short and deliver these securities to close out their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The selling stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as supplemented or amended to reflect such transaction). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate proceeds to the selling stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less discounts or commissions, if any. Each of the selling stockholders reserves the right to accept and, together with their agents from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents. We will not receive any of the proceeds from this offering. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act, provided that they meet the criteria and conform to the requirements of that rule, or another available exemption from the registration requirements of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The selling stockholders and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale of the shares may be underwriting discounts and commissions under the Securities Act. (it being understood that the Selling Stockholders shall not be deemed to be underwriters solely as a result of their participation in this offering). Selling stockholders who are &#8220;underwriters&#8221; within the meaning of Section&#160;2(a)(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To the extent required, the shares of our common stock to be sold, the names of the selling stockholders, the respective purchase prices and public offering prices, the names of any agents, dealer or underwriter, and any applicable commissions or discounts with respect to a particular offer will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement that includes this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In order to comply with the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have advised the selling stockholders that the anti-manipulation rules of Regulation M under the Securities Exchange Act of 1934, as amended, may apply to sales of shares in the market and to the activities of the selling stockholders and their affiliates. In addition, to the extent applicable, we will make copies of this prospectus (as it may be supplemented or amended from time to time) available to the selling stockholders for the purpose of satisfying the prospectus delivery requirements of the Securities Act. The selling stockholders may indemnify any broker-dealer that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under the Securities Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">146 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all expenses of the registration of the shares pursuant to the registration rights agreement with the selling stockholders dated October&#160;4, 2024 (the &#8220;Registration Rights Agreement&#8221;), including, without limitation, SEC filing fees and expenses of compliance with state securities or &#8220;Blue Sky&#8221; laws; provided, however, that we will not be responsible for any underwriting fees, discounts or commissions attributable to the sale of the shares and any legal fees and expenses of counsel to the selling stockholders. We have agreed pursuant to the Registration Rights Agreement to indemnify the selling stockholders against liabilities, including liabilities under the Securities Act and state securities laws, relating to the registration of the shares offered by this prospectus. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have agreed with the selling stockholders pursuant to the Registration Rights Agreement to use commercially reasonable efforts to cause the registration statement of which this prospectus constitutes a part to be declared or otherwise become effective and to remain continuously effective until the earlier of (1)&#160;such time as all of the shares covered by this prospectus have been disposed of pursuant to and in accordance with such registration statement or (2)&#160;the date that all the shares covered by this prospectus cease to be Registrable Securities as defined in the Registration Rights Agreement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There can be no assurance that any selling stockholder will sell any or all of the shares registered pursuant to the registration statement, of which this prospectus forms a part. Once sold hereunder, the shares will be freely tradable in the hands of persons, other than our affiliates. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">147 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_19">LEGAL MATTERS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby has been passed upon for us by Wilson Sonsini Goodrich&#160;&amp; Rosati, Professional Corporation. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_20">EXPERTS </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of OnKure Therapeutics, Inc. as of December&#160;31, 2024 and 2023, and for each of the years in the two-year period ended December 31, 2024, have been included herein and in the registration statement in reliance upon the report of KPMG LLP (&#8220;KPMG&#8221;), independent registered public accounting firm, appearing elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Change in Certifying Accountant </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On November 7, 2024, Ernst &amp; Young LLP (&#8220;EY&#8221;) was dismissed as our independent registered public accounting firm. The decision to dismiss EY was approved by the Audit Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The reports of EY on our consolidated financial statements for the fiscal years ended December&#160;31, 2022 and December&#160;31, 2023 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that the 2022 audit report contained an explanatory paragraph regarding our ability to continue as a going concern. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During our fiscal years ended December&#160;31, 2022 and December&#160;31, 2023 and the subsequent interim period through November 7, 2024, there were (i) no disagreements (as defined in Item 304(a)(1)(iv) of Regulation&#160;S-K and the related instructions thereto) with EY on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of EY, would have caused it to make reference to the subject matter of the disagreement in connection with its report and (ii)&#160;no reportable events (as described in Item 304(a)(1)(v) of Regulation&#160;S-K). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We provided EY with a copy of the foregoing disclosures and requested EY to furnish us with a letter addressed to the SEC stating whether it agrees with the statements made by us and, if not, stating the respects in which it does not agree. A copy of EY&#8217;s letter to the SEC dated November 7, 2024 regarding these statements is filed as Exhibit 16.1 hereto. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">KPMG served as the independent registered public accounting firm of Legacy OnKure prior to the consummation of the Merger. On November 7, 2024, the Audit Committee engaged KPMG as our independent registered public accounting firm. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">During Legacy OnKure&#8217;s fiscal years ended December&#160;31, 2022 and December&#160;31, 2023 and the subsequent period from January&#160;1, 2024 to September&#160;30, 2024, neither Legacy OnKure nor anyone on its behalf consulted KPMG regarding: (i)&#160;the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on Legacy OnKure&#8217;s financial statements, and neither a written report nor oral advice was provided to Legacy OnKure that KPMG concluded was an important factor considered by Legacy OnKure in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii)&#160;any matter that was the subject of a disagreement (as defined in Item&#160;304(a)(1)(iv) of Regulation S-K and the related instructions thereto) or a reportable event (as described in Item&#160;304(a)(1)(v) of Regulation&#160;S-K). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">148 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="tx835714_21">WHERE YOU CAN FIND ADDITIONAL INFORMATION </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have filed with the SEC a registration statement on Form <span style="white-space:nowrap">S-1</span> under the Securities Act that registers the shares of our Class&#160;A Common Stock to be sold in this offering. The registration statement, including the attached exhibits and schedules, contains additional relevant information about us and our capital stock. The rules and regulations of the SEC allow us to omit from this prospectus certain information included in the registration statement. For further information about us and the Securities, you should refer to the registration statement and the exhibits and schedules filed with the registration statement. With respect to the statements contained in this prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are subject to the informational reporting requirements of the Exchange Act. We file reports, proxy statements and other information with the SEC under the Exchange Act. Our SEC filings are available over the Internet at the SEC&#8217;s website at http://www.sec.gov. Our website address is https://onkuretherapeutics.com/. The information on, or that can be accessed through, our website is not part of this prospectus. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">149 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="display: none"><ix:header><ix:hidden><ix:nonNumeric name="us-gaap:LeaseExpirationDate1" id="hidden133878813" contextRef="P01_01_2024To12_31_2024">2026-12-31</ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentExtensibleList" id="hidden133878841" contextRef="P01_01_2024To12_31_2024">http://onkuretherapeutics.com/20241231#ClinicalResearchSegmentMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis" id="ixv-17537">P1Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="hidden133878817" contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis">P3Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" id="hidden133878837" contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden133878830" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">P2Y</ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="hidden133878831" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">P3Y</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="okur-20241231.xsd"/></ix:references></ix:header></div><div style="null;text-indent: 0px;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="tx835714_22" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman'; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </div></div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"><div style="font-size: 12pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width: 96%; font-family: &quot;Times New Roman&quot;;"/>
<td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/>
<td style="font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_1">Report of Independent Registered Public Accounting Firm (KPMG LLP; Denver, Colorado; PCAOB ID: 185)</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_2">Consolidated Balance Sheets</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-3</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_3">Consolidated Statements of Operations and Comprehensive Loss</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_4">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_5">Consolidated Statements of Cash Flows</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/>
<td colspan="4" style="height: 6pt; font-family: &quot;Times New Roman&quot;;"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: 'Times New Roman'; line-height: normal;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><a href="#fin155184865_6">Notes to Consolidated Financial Statements</a></div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">F-7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="clear:both;max-height:0pt;"></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-1 </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_1" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: 'Times New Roman'; text-align: center;"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div></div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">To the Stockholders and Board of Directors of </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">OnKure Therapeutics, Inc.: </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Opinion on the Consolidated Financial Statements </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We have audited the accompanying consolidated balance sheets of OnKure Therapeutics, Inc.&#160;and subsidiaries (the Company) as of December&#160;31,&#160;2024 and 2023, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows for the years then ended and the related notes (collectively, the consolidated financial statements).&#160;In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles. </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis for Opinion </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion. </div></div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">/s/ KPMG LLP </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have served as the Company&#8217;s <div style="letter-spacing: 0px; top: 0px;display:inline;">auditor </div>since 2021. </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">Denver, Colorado </div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">March 10, 2025 </div></div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"><div style="font-size: 8pt; letter-spacing: 0px; top: 0px;display:inline;">&#160;</div></div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><div style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; letter-spacing: 0px; top: 0px;display:inline;">F-2 </div></div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Content</a></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_2" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ONKURE THERAPEUTICS, INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Balance Sheets </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except par value and share data) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:77%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">ASSETS</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17544">110,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17545">29,876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid expenses and other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17546">2,242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17547">3,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17548">113,003</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17549">33,766</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17550">1,025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17551">1,432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> asset</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17552">770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17553">478</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17554">109</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17555">58</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total assets</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17556">114,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Assets" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17557">35,734</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS&#8217; EQUITY (DEFICIT)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17558">2,968</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17559">3,417</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17560">7,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17561">3,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liabilities, current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17562">536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17563">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total current liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17564">10,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17565">7,285</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17566">549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17567">466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17568">11,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17569">7,751</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Commitments and contingencies (Note 14)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" xsi:nil="true" id="ixv-17570"></ix:nonFraction></td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"><ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" xsi:nil="true" id="ixv-17571"></ix:nonFraction></td>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible preferred stock, Series C, $<ix:nonFraction name="okur:ConvertiblePreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17572"><ix:nonFraction name="okur:ConvertiblePreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17573">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="okur:ConvertiblePreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17574">no</ix:nonFraction> shares and <ix:nonFraction name="okur:ConvertiblePreferredStockSharesAuthorized" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17575">7,404,919</ix:nonFraction> shares authorized; <ix:nonFraction name="okur:ConvertiblePreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17576"><ix:nonFraction name="okur:ConvertiblePreferredStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17577">no</ix:nonFraction></ix:nonFraction> shares and <ix:nonFraction name="okur:ConvertiblePreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17578"><ix:nonFraction name="okur:ConvertiblePreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17579">6,840,620</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively; liquidation preference of $<ix:nonFraction name="okur:ConvertiblePreferredStockLiquidationPreferenceValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17580">195,823</ix:nonFraction> as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="PAsOn12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17581">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17582">129,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stockholders&#8217; equity (deficit):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Preferred stock, $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17583">0.0001</ix:nonFraction> par value; <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17584">10,000,000</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17585"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17586"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17587"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17588">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding at December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17589">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17590">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, Class&#160;A, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17591"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17592">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17593">200,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17594">943,840</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17595"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17596">12,660,590</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17597"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17598">313,747</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17599">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17600">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock, Class&#160;B, $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17601"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17602">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17603">10,000,000</ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17604">226,285</ix:nonFraction> shares authorized; <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17605"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17606">686,527</ix:nonFraction></ix:nonFraction> and <ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17607"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17608">no</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31, 2024 and December&#160;31, 2023, respectively</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17609">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-17610">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Additional <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">paid-in</div> capital</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17611">258,551</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17612">209</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accumulated deficit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17613">154,724</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17614">102,051</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17615">103,828</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17616">101,842</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Total liabilities, convertible preferred stock, and stockholders&#8217; equity (deficit)</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17617">114,907</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17618">35,734</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-3 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_3" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ONKURE THERAPEUTICS, INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Operations and Comprehensive Loss </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share and per share data) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands, except share<br/> and per share amounts)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17619">43,795</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17620">32,115</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17621">10,591</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17622">4,819</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total operating expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17623">54,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17624">36,934</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Loss from operations</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17625">54,386</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17626">36,934</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other income and (expense):</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17627">2,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17628">1,623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:InterestAndOtherExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17629">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total other income and (expense)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17630">1,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:InterestIncomeExpenseNet" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17631">1,623</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss and comprehensive loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17632">52,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17633">35,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss per share attributable to common stockholders:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17634"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17635">15.28</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17636"><ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17637">124.41</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted average shares outstanding:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Basic and diluted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17638"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17639">3,447,071</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17640"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17641">283,817</ix:nonFraction></ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-4 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_4" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ONKURE THERAPEUTICS, INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Changes in Stockholders&#8217; Equity </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands, except share data) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:45%"/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:1%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Additional</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="white-space:nowrap;display:inline;">Paid-In</div></div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Capital</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="3" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Total</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Stockholders&#8217;</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="3" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Convertible Preferred<br/> Stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;A Common stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Class&#160;B Common<br/> stock</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" rowspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Accumulated</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Deficit</div></div></td>
<td rowspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="border-right: 0.75pt solid rgb(0, 0, 0); vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17642">3,738,936</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17643">64,389</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17644">182,769</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17645">2,656</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17646">57,074</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17647">54,418</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series C Preferred Stock under a stock purchase agreement, net of issuance costs of $<ix:nonFraction name="okur:StockIssuanceCostNet" contextRef="P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17648">0.7</ix:nonFraction>&#160;million</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17649">2,818,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17650">53,059</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A Common Stock and Series C Preferred Stock in exchange for Series A, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">A-1,</div> and Series B Preferred Stock under a stock purchase agreement</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17651">283,492</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17652">12,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17653">127,476</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17654">2,711</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17655">9,666</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17656">12,377</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A Common Stock for cash upon the exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17657">3,502</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17658">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17659">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17660">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17661">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17662">35,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17663">35,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2023</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17664">6,840,620</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17665">129,825</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17666">313,747</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17667">209</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17668">102,051</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17669">101,842</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Convertible Preferred Stock for Class&#160;A and B Common Stock in connection with the Merger</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17670">6,840,620</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17671">129,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17672">6,154,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17673">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17674">686,527</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17675">129,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17676">129,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A Common Stock in the Concurrent Financing, less issuance costs</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodSharesConcurrentFinancing" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17677">2,571,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodValueConcurrentFinancing" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17678">54,428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodValueConcurrentFinancing" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17679">54,428</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of common stock to former stockholders of Reneo Pharmaceuticals, Inc. in the reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17680">3,343,604</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17681">65,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17682">65,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reverse recapitalization transaction costs of OnKure</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17683">2,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17684">2,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A Common Stock for the conversion of Convertible Promissory Notes</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17685">267,269</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17686">6,120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17687">6,120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A common stock for the settlement of restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17688">7,700</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Class&#160;A Common Stock from the exercise of stock options</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17689">2,476</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17690">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17691">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustment for fractional shares in the reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:AdjustmentForFractionalSharesInTheReverseRecapitalization" contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17692">35</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17693">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17694">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17695">52,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17696">52,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Balance, December&#160;31, 2024</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17697">12,660,590</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17698">1</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17699">686,527</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#8212;&#8194;</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17700">258,551</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17701">154,724</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">)&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">$</div></div></td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17702">103,828</ix:nonFraction></div></div></td>
<td style="white-space:nowrap;vertical-align:bottom"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="BORDER-RIGHT:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-5 </div></div></div></div><div></div></div><div><div style="line-height:normal;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_5" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ONKURE THERAPEUTICS, INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Consolidated Statements of Cash Flows </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(In thousands) </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:83%"/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:2%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:7pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" style="vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">(in thousands)</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from operating activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17703">52,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17704">35,311</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments to reconcile net loss to net cash used in operating activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17705">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17706">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17707">459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DepreciationDepletionAndAmortization" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17708">417</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> asset - operating</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17709">203</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17710">143</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Amortization of debt issuance costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17711">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Non-cash</div> interest expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:Non-CashInterestExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17712">120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Loss on sales of <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">available-for-sale</div></div> securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17713">54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in operating assets and liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid and other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17714">2,256</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17715">1,497</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accounts payable, accrued and other liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17716">5,927</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17717">1,713</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 7em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17718">281</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17719">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash used in operating activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17720">51,117</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17721">34,546</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from investing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from sales of marketable securities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17722">15,925</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Purchases of property and equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17723">52</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17724">246</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by (used in) investing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17725">15,873</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17726">246</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash flows from financing activities:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the issuance of common stock in Concurrent Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfPrivatePlacement" contextRef="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17727">58,881</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of issuance costs associated with the Concurrent Financing</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17728">4,327</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash acquired in connection with the reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17729">57,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of reverse recapitalization transaction costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:PaymentOfReverseRecapitalizationTransactionCosts" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17730">2,045</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the issuance of Convertible Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17731">53,783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of issuance costs associated with the issuance of Convertible Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17732">723</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from issuance of convertible notes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromConvertibleDebt" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17733">6,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Payment of issuance costs associated with the issuance of convertible notes payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17734">142</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Proceeds from the issuance of common stock in connection with equity plans</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17735">26</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17736">65</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net cash provided by financing activities</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17737">116,129</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17738">53,125</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net increase in cash and cash equivalents</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17739">80,885</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17740">18,333</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents, beginning of period</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17741">29,876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17742">11,543</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Cash and cash equivalents, end of period</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17743">110,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17744">29,876</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Supplemental cash flow information:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest paid</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Supplemental disclosure of noncash financing activities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use</div></div> asset obtained in exchange for new operating lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17745">219</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Issuance of Series C Preferred Stock conversion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17746">23,313</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ConversionOfSeriesCPreferredStock" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17747">129,825</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Conversion of convertible note payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ConversionOfConvertibleNotePayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17748">6,120</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assets acquired in connection with the reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:AssetsAcquiredInConnectionWithTheReverseRecapitalization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17749">17,222</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other liabilities assumed in connection with the reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17750">9,459</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Reverse recapitalization transaction costs included in accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17751">40</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Concurrent Financing issuance costs included in accounts payable</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17752">37</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 9pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Concurrent Financing issuance costs paid by Reneo prior to Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17753">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">The accompanying notes are an integral part of these consolidated financial statements. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-6 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="fin155184865_6" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">ONKURE THERAPEUTICS, INC. </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Notes to Consolidated Financial Statements </div></div><ix:nonNumeric name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878774" id="ixv-12668"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization and Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OnKure Therapeutics, Inc., (&#8220;OnKure&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. The Company was formed in 2014 as Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) under the laws of the State of Delaware. On October&#160;4, 2024, the Company changed its name to OnKure Therapeutics, Inc. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger with Reneo </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;4, 2024, Radiate Merger Sub I, Inc. (&#8220;Merger Sub I&#8221;) a&#160;wholly-owned subsidiary of Reneo completed its merger with and into OnKure, Inc. (referred to herein as &#8220;Legacy OnKure&#8221;), with Legacy OnKure continuing as the surviving entity as a wholly-owned subsidiary of Reneo. This transaction is referred to as the &#8220;Merger.&#8221; Following the Merger, Reneo changed its name to OnKure Therapeutics, Inc. Legacy OnKure remains as a wholly-owned subsidiary of the Company. The Merger was effected pursuant to an Agreement and Plan of Merger, dated as of <ix:nonNumeric name="us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1" contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis" format="ixt:date-monthname-day-year-en" id="ixv-17754">May 10, 2024</ix:nonNumeric> (the &#8220;Merger Agreement&#8221;), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation Radiate Merger Sub II, LLC, a Delaware limited liability company (&#8220;Merger Sub II&#8221;), and Legacy OnKure. In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo&#8217;s common stock for an aggregate purchase price of $<ix:nonFraction name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17755">65.0</ix:nonFraction>&#160;million contingent upon the concurrent consummation of the Merger (the &#8220;Concurrent Financing&#8221;).&#160;On October&#160;4, 2024 (the &#8220;Closing Date&#8221;), the Merger and the Concurrent Financing closed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). For accounting purposes, Legacy OnKure is considered the accounting acquirer and Reneo is the acquired company based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#8217;s board of directors and senior management. Accordingly, the Merger was treated as the equivalent of Legacy OnKure issuing stock to acquire the net assets of Reneo. As a result of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company and the reported operating results prior to the Merger are those of Legacy OnKure. Legacy OnKure&#8217;s historical financial statements became the historical consolidated financial statements of the combined company. All issued and outstanding Legacy OnKure common stock, convertible preferred stock, restricted stock units, and options to purchase common stock prior to the effective date of the Merger have been retroactively adjusted to reflect the exchange ratio for all periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 3 for further discussion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of the Company discusses with management macroeconomic and geopolitical developments, including inflation, instability in the banking and financial services sector, tightening of the credit markets, international conflicts,&#160;cybersecurity, and sanctions so that the Company can be prepared to react to new developments as they arise.&#160;The board of directors and the management of the Company are carefully monitoring these developments and the resulting economic impact on its financial condition and results of operations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-7</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878774" continuedAt="TextSelectionAppend_133878774_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878774_1" continuedAt="TextSelectionAppend_133878774_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878774_2" continuedAt="TextSelectionAppend_133878774_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878774_3"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had recurring losses from operations, an accumulated deficit of $<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" sign="-" format="ixt:num-dot-decimal" id="ixv-17757">154.7</ix:nonFraction>&#160;million and cash and cash equivalents of $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17758">110.8</ix:nonFraction>&#160;million as of December&#160;31, 2024. The Company&#8217;s ability to fund its ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities, issuing debt or other financing vehicles. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had determined that substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following the completion of the Merger and Concurrent Financing, as described in more detail in Note 3, management believes the Company&#8217;s cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements and as such substantial doubt has been alleviated. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to secure capital is dependent upon success in discovering and developing its drug candidates. The Company cannot provide assurance that additional capital will be available on acceptable terms, if at all. The issuance of additional equity or debt securities will likely result in substantial dilution to the Company&#8217;s stockholders. Should additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from the Company&#8217;s assets or discharge liabilities in the normal course of business, which may, among other alternatives, cause the Company to delay, substantially reduce, or discontinue operational activities to conserve cash, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to discover and develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated. </div></ix:continuation><ix:nonNumeric name="us-gaap:SignificantAccountingPoliciesTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878776" id="ixv-12709"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><ix:nonNumeric name="okur:BasisOfPresentationAndConsolidationPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12712"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP and reflect the operation of the Company and its wholly owned subsidiaries, OnKure, Inc. and Merger Sub II. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SegmentReportingPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12718"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in&#160;<ix:nonFraction name="us-gaap:NumberOfOperatingSegments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_Segment" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-17759">one</ix:nonFraction>&#160;operating segment: clinical research. All equipment and other property and equipment are physically located within the United States<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:UseOfEstimates" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878783" id="ixv-12726"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-8</ix:exclude> </div></ix:nonNumeric></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878783" continuedAt="TextSelectionAppend_133878783_1"><ix:continuation id="TextSelection_133878776" continuedAt="TextSelectionAppend_133878776_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_1" continuedAt="TextSelectionAppend_133878776_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_2" continuedAt="TextSelectionAppend_133878776_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878776_3" continuedAt="TextSelectionAppend_133878776_4"><ix:continuation id="TextSelectionAppend_133878783_1"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and disclosure of contingent assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates. The most significant estimates relate to external research and development expenses, and the fair value of stock options and restricted stock awards and units. </div></ix:continuation><ix:nonNumeric name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12754"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">from&#160;non-owner&#160;sources.</div> The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods <div style="display:inline;">presented</div>. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ResearchAndDevelopmentExpensePolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12761"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred in performing research and development activities. The costs include employee-related expense, including salaries, severance, benefits, share- based compensation, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, depreciation, and facilities and overhead costs. </div></ix:nonNumeric><ix:nonNumeric name="okur:AccruedResearchAndDevelopmentExpensesPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12766"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records research and development expenses in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. </div></ix:nonNumeric><ix:nonNumeric name="okur:PatentCostsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12771"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878789" id="ixv-12776"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase common stock, and restricted stock units for common stock, are granted to employees, board of directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">and&#160;non-employee&#160;consultants.</div> Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-9</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_133878789" continuedAt="TextSelectionAppend_133878789_1"><ix:continuation id="TextSelectionAppend_133878776_4" continuedAt="TextSelectionAppend_133878776_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_5" continuedAt="TextSelectionAppend_133878776_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_6" continuedAt="TextSelectionAppend_133878776_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878776_7" continuedAt="TextSelectionAppend_133878776_8"><ix:continuation id="TextSelectionAppend_133878789_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of <ix:nonNumeric name="okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-17762">10</ix:nonNumeric> years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. The Company will continue to apply this process until enough historical information regarding the volatility of its stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes</div> with maturities approximately equal to the expected term of the stock options. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. (See Note 12). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for grants under its various Equity Incentive Plans and employee stock purchase plan (&#8220;ESPP&#8221;). The Company accounts for all stock-based awards granted to employees and directors at their fair value and recognizes compensation expense over the award&#8217;s vesting period. Determining the amount of stock-based compensation to be recorded requires the Company to develop estimates of fair values of stock options as of the grant date. The Company calculates the grant date fair values of stock options using the Black-Scholes valuation model, which requires the input of subjective assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. The fair value of restricted stock awards granted to employees is based on the quoted closing market price per share on grant date. </div></ix:continuation><ix:nonNumeric name="okur:CommonStockValuationPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12803"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Stock Valuation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lack of marketability for the Company&#8217;s common stock prior to the Merger, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#8217; Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted prior to the Merger, the Company had considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#8217;s research and development programs, including their stages of development, and the Company&#8217;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock; and the market performance of peer companies in the biopharmaceutical industry. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueOfFinancialInstrumentsPolicy" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12809"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash, receivables, prepaid and other current assets, accounts payable, and accrued expenses approximate their fair values because of the short maturity of these instruments. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-10</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878776_8" continuedAt="TextSelectionAppend_133878776_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_9" continuedAt="TextSelectionAppend_133878776_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_10" continuedAt="TextSelectionAppend_133878776_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878776_11" continuedAt="TextSelectionAppend_133878776_12"><ix:nonNumeric name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12834"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All highly liquid investments with maturities of 90 days or less, at the time of purchase, are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value. The Company&#8217;s cash and cash equivalents consist of money held in demand depository accounts and money market funds. The carrying amount of cash and cash equivalents was $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17764">110.8</ix:nonFraction>&#160;million and $<ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17765">29.9</ix:nonFraction>&#160;million as of December&#160;31, 2024, and 2023, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&#160;1. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ConcentrationRiskCreditRisk" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12839"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions above federally insured limits of $<ix:nonFraction name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17766"><ix:nonFraction name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17767">250,000</ix:nonFraction></ix:nonFraction> as of December&#160;31, 2024 and 2023. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held and of the money market funds in which these investments are made. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12844"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company carries its property and equipment at cost, less accumulated depreciation, amortization and impairment, if any. Expenditures for renewals or betterments that materially extend the useful life of an asset or increase its productivity, such as leasehold improvements, are capitalized. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <div style="display:inline;"><div style="-sec-ix-hidden:hidden133878817;display:inline;">three</div></div> to <div style="display:inline;"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentUsefulLife" contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis" format="ixt-sec:durwordsen" id="ixv-17768">seven years</ix:nonNumeric></div>. Leasehold improvements are amortized over the <div style="-sec-ix-hidden:hidden133878837;display:inline;">shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets</div>. Repair and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12853"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. <ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17769"><ix:nonFraction name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17770">No</ix:nonFraction></ix:nonFraction> impairment charges were recorded during the years ended December&#160;31, 2024 and 2023. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeLeasesPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878700" id="ixv-12858"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Leasing &#8211; Lessee Accounting </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. The Company&#8217;s operating lease agreements are primarily for office space and research labs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For operating leases with a term greater than one year, the Company recognizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">the&#160;right-of-use&#160;(&#8220;ROU&#8221;)</div></div> assets and lease liabilities related to the lease payments on its balance sheet. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The ROU assets represent the Company&#8217;s right to use the underlying assets for the term of the lease and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising for the agreements. ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is periodically reviewed for impairment unless a triggering event occurs. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, except for the ones that depend on index or rate, are excluded from the calculation of the ROU assets and lease liabilities and are recognized as variable lease expense in the statements of operations and comprehensive loss in the period in which they are incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-11</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_133878700" continuedAt="TextSelectionAppend_133878700_1"><ix:continuation id="TextSelectionAppend_133878776_12" continuedAt="TextSelectionAppend_133878776_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_13" continuedAt="TextSelectionAppend_133878776_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_14" continuedAt="TextSelectionAppend_133878776_15"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878776_15" continuedAt="TextSelectionAppend_133878776_16"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:continuation id="TextSelectionAppend_133878700_1">As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company uses its estimated incremental borrowing rate in its present value calculations. One of the Company&#8217;s lessee agreements include an option to extend the lease, which the Company does not include in its minimum lease term unless it is reasonably certain to exercise such option. Operating leases with a term of less than one year are recognized as a lease expense over the term of the lease, with no asset or liability recognized on the balance sheet.</ix:continuation> </div><ix:nonNumeric name="us-gaap:IncomeTaxPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12884"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently payable and deferred taxes. The Company accounts for income taxes using the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, and operating losses and tax credit carryforwards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is recorded to the extent it is more likely than not that some portion of a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company&#8217;s significant deferred tax assets are net operating loss carryforwards, tax credits, and accruals. The Company has provided a valuation allowance equal to its net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that most of its deferred tax assets will not be realized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting for uncertain tax positions requires a more likely than not threshold for recognition in the financial statements. The Company recognizes a tax benefit based on whether it is more likely than not that a tax position will be sustained. The Company records a liability to the extent that a tax position taken or expected to be taken on a tax return exceeds the amount recognized in the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has <ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17773"><ix:nonFraction name="us-gaap:UnrecognizedTaxBenefits" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17774">no</ix:nonFraction></ix:nonFraction> unrecognized tax benefits as of December&#160;31, 2024 and 2023. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as general and administrative expenses. No such expenses have been recognized during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and the United Kingdom (&#8220;UK&#8221;). As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities in the United States, and the UK tax returns from 2018 forward are subject to examination. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878702" id="ixv-12893"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncemen</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">issued&#160;ASU&#160;2023-07,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>&#160;to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period, with early adoption permitted. The disclosure related to this ASU are in Note 4 below. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2023-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes (Topic 740):</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Improvements to Income Tax Disclosures</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which</div> requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-12</ix:exclude> </div></ix:nonNumeric></ix:continuation></div></div><ix:continuation id="TextSelection_133878702" continuedAt="TextSelectionAppend_133878702_1"><ix:continuation id="TextSelectionAppend_133878776_16" continuedAt="TextSelectionAppend_133878776_17"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_17" continuedAt="TextSelectionAppend_133878776_18"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878776_18" continuedAt="TextSelectionAppend_133878776_19"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878776_19"><ix:continuation id="TextSelectionAppend_133878702_1"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <div style="white-space:nowrap;display:inline;">220-40):</div> Disaggregation of Income Statement Expenses</div></div>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on its financial statements. </div></ix:continuation></ix:continuation><ix:nonNumeric name="okur:MergerAgreementAndConcurrentFinancingTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878782" id="ixv-12938"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Merger Agreement and Concurrent Financing </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in Note 1, Merger Sub I merged with and into Legacy OnKure, with Legacy OnKure surviving as a wholly-owned subsidiary of the Company on October&#160;4, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, each then-outstanding share of Legacy OnKure common stock was converted into the right to receive <ix:nonFraction name="okur:CommonStockSharesConvertibleConversionRatio" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="6" scale="0" format="ixt:num-dot-decimal" id="ixv-17776">0.023596</ix:nonFraction> shares of common stock of Reneo based on the Common Exchange Ratio, which was reclassified as Class&#160;A Common Stock in connection with the Merger, and each then-outstanding share of Legacy OnKure preferred stock was converted into the right to receive <ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionRatio" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_pure" decimals="6" scale="0" format="ixt:num-dot-decimal" id="ixv-17777">0.144794</ix:nonFraction> shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio; provided that one holder of Legacy OnKure preferred stock elected to receive <ix:nonFraction name="us-gaap:PreferredStockConvertibleSharesIssuable" contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17778">686,527</ix:nonFraction> shares that it would otherwise have received in the form of Class&#160;A Common Stock in an equal number of shares of Class&#160;B Common Stock. Upon the closing of the Merger, (i)&#160;an aggregate of <ix:nonFraction name="okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17779">6,470,281</ix:nonFraction> shares of Class&#160;A Common Stock and <ix:nonFraction name="okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" contextRef="P10_04_2024To10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17780">686,527</ix:nonFraction> shares of Class&#160;B Common Stock of the combined company were issued in exchange for the shares of Legacy OnKure capital stock outstanding as of immediately prior to the Closing and (ii)&#160;outstanding shares of Reneo common stock were reclassified into an aggregate of approximately <ix:nonFraction name="okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17781">3,343,604</ix:nonFraction> shares of Class&#160;A Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each then-outstanding option to purchase shares of Legacy OnKure common stock was assumed and converted into an option to purchase Class&#160;A Common Stock based on the Common Exchange Ratio, and each then-outstanding RSU of Legacy OnKure corresponding to shares of Legacy OnKure preferred stock was assumed and converted into RSUs covering <ix:nonFraction name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17782">213,254</ix:nonFraction> shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Reneo common stock, each option to purchase shares of Reneo common stock and each RSU award covering shares of Reneo common stock that was issued and outstanding as of immediately prior to the Closing remained issued and outstanding in accordance with its terms and such shares, options and RSUs, subject to the Reverse Stock Split, were reclassified as Class&#160;A Common Stock but were otherwise unaffected by the Merger; provided that, to the extent not previously vested, all such options and RSUs held by Reneo&#8217;s directors and executive officers vested at Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger Agreement, Reneo entered into a subscription agreement with certain investors, pursuant to which the investors subscribed for and purchased, concurrent with the closing of the Merger, an aggregate of <ix:nonFraction name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17783">2,839,005</ix:nonFraction>&#160;shares of Class&#160;A Common Stock at a price of approximately $<ix:nonFraction name="us-gaap:SaleOfStockPricePerShare" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17784">22.895</ix:nonFraction>&#160;per share for aggregate gross proceeds of approximately $<ix:nonFraction name="okur:GrossProceedsFromIssuanceOfCommonStock" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17785">65.0</ix:nonFraction>&#160;million, including the conversion of previously funded Convertible Promissory Notes principal of $<ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17786">6.0</ix:nonFraction>&#160;million and accrued interest there on of $<ix:nonFraction name="okur:DebtInstrumentAccruedInterest" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17787">120</ix:nonFraction>&#160;thousand, on October&#160;4, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, the authorized shares of Class&#160;A Common Stock of the Company are <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17788">200,000,000</ix:nonFraction>&#160;with par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17789">0.0001</ix:nonFraction>&#160;and Class&#160;B Common Stock of the Company are <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17790">10,000,000</ix:nonFraction> with par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17791">0.0001</ix:nonFraction>. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-13</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878782" continuedAt="TextSelectionAppend_133878782_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878782_1" continuedAt="TextSelectionAppend_133878782_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878782_2" continuedAt="TextSelectionAppend_133878782_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878782_3"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in October 2024 the Company adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) and 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;). Under the 2024 Plan a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17793">2,480,000</ix:nonFraction> shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. Under the 2024 ESPP, an aggregate of <ix:nonFraction name="okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17794">137,500</ix:nonFraction>&#160;shares of Class&#160;A Common Stock are currently reserved and available for issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger was accounted for as a reverse recapitalization in accordance with GAAP, with Legacy OnKure as the accounting acquirer of Reneo. Legacy OnKure was determined to be the accounting acquirer based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#8217;s board of directors and senior management. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, Legacy OnKure&#8217;s historical financial statements became the historical consolidated financial statements of the combined company for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders Reneo, the legal acquirer, and a recapitalization of the equity of Legacy OnKure, the accounting acquirer. The final transaction amounts have been recorded as a reduction of proceeds in stockholders&#8217; equity. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company, which approximated book value due to the short-term nature.&#160;Reneo&#8217;s development programs had ceased prior to the Merger and were deemed to be de minimis in value at the transaction date. No goodwill or intangible assets were recognized. </div><ix:nonNumeric name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-12967"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the recapitalization, excluding the Concurrent Financing, the Company acquired the assets and liabilities listed below (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17795">57,736</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17796">15,979</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17797">690</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17798">553</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17799">9,072</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17800">387</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17801">65,499</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:SegmentReportingDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878704" id="ixv-13049"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Segment </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a publicly listed company with a single reportable segment: clinical research. Because the Company has <ix:nonFraction name="us-gaap:NumberOfReportableSegments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17802">one</ix:nonFraction> reportable segment, before adopting the ASU, it provided only the entity-wide disclosures required by ASC 280. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="-sec-ix-hidden:hidden133878841;display:inline;">clinical research segment</div> has <ix:nonFraction name="us-gaap:Revenues" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17803">no</ix:nonFraction> revenues. The accounting policies of the clinical research segment are the same as those described in the summary of significant accounting policies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription" contextRef="P01_01_2024To12_31_2024" id="ixv-17804">The Chief Operating Decision Maker (&#8220;CODM&#8221;) assesses the performance for the clinical research segment and decides how to allocate resources based on operating expenses as reported on the income statement. The measure of segment assets is reported on the balance sheets as total consolidated assets.</ix:nonNumeric> The CODM considers a variety of factors, including actual and projected expenses in deciding whether to invest funds in the clinical research segment or into other parts of the entity, such as for acquisitions or to pay dividends. The Company does not have intra-entity sales or transfers. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-14</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878704" continuedAt="TextSelectionAppend_133878704_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878704_1" continuedAt="TextSelectionAppend_133878704_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878704_2" continuedAt="TextSelectionAppend_133878704_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878704_3"><ix:nonNumeric name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13075"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s CODM is the senior executive committee that is comprised of the <ix:nonNumeric name="okur:SegmentReportingCODMIndividualTitleAndPositionOrGroupName" contextRef="P01_01_2024To12_31_2024" id="ixv-17806">Chief Financial Officer and the Chief Executive Officer</ix:nonNumeric>. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:76%"/>
<td style="vertical-align:bottom;width:16%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Clinical&#160;Research<br/> Segment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Direct program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:DirectProgramExpense" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17807">27,398</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Indirect program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:IndirectProgramExpense" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17808">2,157</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Workforce salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:WorkforceSalariesAndBenefits" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17809">15,102</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17810">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General corporate expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:GeneralCorporateExpenses" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17811">5,199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:InterestAndOtherExpense" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17812">300</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17813">54,686</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reconciliation of loss:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:InterestIncomeOperating" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17814">2,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments and reconciling items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="okur:AdjustmentsAndReconcilingItems" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17815">2,013</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" sign="-" format="ixt:num-dot-decimal" id="ixv-17816">52,673</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:LesseeOperatingLeasesTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878734" id="ixv-13220"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s headquarters are located in Boulder, Colorado, where it leases <ix:nonFraction name="us-gaap:AreaOfRealEstateProperty" contextRef="PAsOn12_31_2024" unitRef="Unit_sqft" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17817">14,790</ix:nonFraction> square feet of office and lab facilities under&#160;operating leases that expire in <div style="display:inline;"><div style="-sec-ix-hidden:hidden133878813;display:inline;">December 2026</div></div>, <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseOptionToExtend" contextRef="P01_01_2024To12_31_2024" id="ixv-17818">with <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="P01_01_2024To12_31_2024" format="ixt:fixed-true" id="ixv-17819">rights to extend</ix:nonNumeric> for a <ix:nonNumeric name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="PAsOn12_31_2024" format="ixt-sec:durwordsen" id="ixv-17820">5 year</ix:nonNumeric> period</ix:nonNumeric>. In the Merger with Reneo, the Company assumed the lease in Irvine, California, where it leases office space under a lease agreement that expires in November 2026 (&#8220;Irvine lease&#8221;). In January 2025, the Company entered into a sublease agreement on the Irvine lease. See Note 16 for further discussion. </div><ix:nonNumeric name="okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13226"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use&#160;assets</div></div> and lease liabilities for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:12%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17821">770</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17822">478</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17823">536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17824">208</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17825">549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17826">466</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17827">1,085</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiability" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17828">674</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LeaseCostTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13344"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease expense for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:80%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17829">236</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17830">173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17831">187</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:VariableLeaseCost" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17832">201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-15</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_133878734" continuedAt="TextSelectionAppend_133878734_1"><div></div></ix:continuation></div><div><div style="line-height:normal;display: inline;"><ix:continuation id="TextSelectionAppend_133878734_1" continuedAt="TextSelectionAppend_133878734_2"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878734_2" continuedAt="TextSelectionAppend_133878734_3"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878734_3" continuedAt="TextSelectionAppend_133878734_4"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878734_4"><ix:nonNumeric name="okur:ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13419"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease term, discount rates, and additional information for operating leases are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term &#8211; operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2024" format="ixt-sec:duryear" id="ixv-17834">1.87</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="PAsOn12_31_2023" format="ixt-sec:duryear" id="ixv-17835">2.92</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate &#8211; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-17836">4.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="PAsOn12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-17837">4.5</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows for operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17838">315</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeasePayments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17839">210</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13496"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maturities of the Company&#8217;s operating lease liabilities were as follows as of December&#160;31, 2024 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17840">571</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17841">560</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17842">1,131</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17843">46</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17844">536</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17845">549</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:continuation><ix:nonNumeric name="us-gaap:EarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13572"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock shares to be issued upon <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">if-converted</div> method for the convertible Series C Preferred Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">if-converted</div> method for the convertible promissory note, exercise of all outstanding stock options and restricted stock units were excluded from the diluted net loss per share calculation for the twelve months ended December&#160;31, 2024 and 2023 because such shares are anti-dilutive. </div><ix:nonNumeric name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13578"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:3%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17846">5,191,375</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17847">6,135,306</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Promissory Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17848">149,650</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-17849">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17850">2,393,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17851">178,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17852">213,254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17853">214,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17854">17,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-17855">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17856">7,965,103</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17857">6,527,974</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><ix:nonNumeric name="us-gaap:FairValueDisclosuresTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878757" id="ixv-13704"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div>, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-16</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878757" continuedAt="TextSelectionAppend_133878757_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878757_1" continuedAt="TextSelectionAppend_133878757_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878757_2" continuedAt="TextSelectionAppend_133878757_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878757_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC Topic 820 identifies fair value as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes between the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 &#8211; Inputs, other than quoted prices in active markets, which are observable for the asset or liability, either directly or indirectly. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 &#8211; Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#8217;s financial assets are subject to fair value measurements on a recurring basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company categorizes its money market funds as Level&#160;1, using the quoted prices in active markets. The fair value of the Company&#8217;s investments in certain money market funds is their face value and such instruments are classified as Level&#160;1 and are included in cash and cash equivalents on the consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17859"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17860"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17861"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17862"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17863"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17864"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17865"><ix:nonFraction name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17866">No</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> assets or liabilities were transferred into or out of their classifications during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Merger, the Company acquired certain short-term investments in debt securities that were carried at fair value and classified as current assets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">available-for-sale</div></div> and represented the investment of funds available for current operations. During the year ended December&#160;31, 2024, the Company sold these short-term investments for proceeds of $<ix:nonFraction name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17867">15.9</ix:nonFraction>&#160;million which resulted in a realized loss of approximately $<ix:nonFraction name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-17868">54,000</ix:nonFraction>. The Company had <ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17869"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt-sec:numwordsen" id="ixv-17870">no</ix:nonFraction></ix:nonFraction> <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">available-for-sale</div></div> securities as of December&#160;31, 2024 or 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:OtherCurrentAssetsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13763"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Prepaid expenses and other current assets </div></div><ix:nonNumeric name="us-gaap:ScheduleOfOtherAssetsTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13766"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid clinical trial expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:PrepaidClinicalTrials" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17871">152</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:PrepaidClinicalTrials" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17872">3,192</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid insurance expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17873">537</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidInsurance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17874">68</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17875">1,553</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherPrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17876">630</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17877">2,242</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PrepaidExpenseCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17878">3,890</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-17 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%;clear:both"/><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13875"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Property and Equipment, Net </div></div><ix:nonNumeric name="us-gaap:PropertyPlantAndEquipmentTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-13878"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17879">705</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17880">706</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17881">1,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17882">1,090</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware and software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17883">189</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17884">141</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17885">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17886">160</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17887">2,144</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17888">2,097</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17889">1,119</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17890">665</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17891">1,025</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17892">1,432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17893">459,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:DepreciationExpenseOnReclassifiedAssets" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17894">417,000</ix:nonFraction>, respectively. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14026"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Accrued Expenses </div></div><ix:nonNumeric name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14029"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17895">3,173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17896">1,663</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contract manufacturing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:AccruedManufacturingExpense" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17897">1,565</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:AccruedManufacturingExpense" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17898">1,627</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trial costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:AccruedClinicalTrialCosts" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17899">1,302</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17900">986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17901">370</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17902">7,026</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17903">3,660</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued compensation includes severance costs. For further information see Note 14. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878761" id="ixv-14141"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17904">210,000,000</ix:nonFraction> shares of common stock, of which <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17905">200,000,000</ix:nonFraction> shares have been designated as Class&#160;A Common Stock and <ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17906">10,000,000</ix:nonFraction> shares have been designated as Class&#160;B Common Stock, both with a par value of $<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17907">0.0001</ix:nonFraction> per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of Class&#160;A Common Stock is entitled to one vote. Class&#160;B Common Stock is not entitled to vote on any matter on which the holders of Class&#160;A Common Stock or Preferred Stock are entitled to vote. All holders of common stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors, subject to the preferential rights of the holders of preferred stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&#160;B Common Stock is convertible into a corresponding number of shares of Class&#160;A Common Stock upon written notice of the holder, subject to defined beneficial ownership limitations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-18</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878761" continuedAt="TextSelectionAppend_133878761_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878761_1" continuedAt="TextSelectionAppend_133878761_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878761_2" continuedAt="TextSelectionAppend_133878761_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878761_3" continuedAt="TextSelectionAppend_133878761_4"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue <ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17909">10,000,000</ix:nonFraction> shares of preferred stock, with a par value of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17910">0.0001</ix:nonFraction> per share. As of December&#160;31, 2024, <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-17911"><ix:nonFraction name="okur:PreferredStockSharesDesignated" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-17912">no</ix:nonFraction></ix:nonFraction>ne of these shares of preferred stock have been designated or issued. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company&#8217;s Preferred Stock was classified as temporary equity in the accompanying consolidated balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that were outside of the Company&#8217;s control whereby the Company could be obligated to redeem the convertible preferred stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered probable to occur. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Series C Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023, the Company entered into a Series C Purchase Agreement pursuant to which the Company issued <ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17913">2,818,192</ix:nonFraction> shares of Series C Preferred Stock at a purchase price of $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17914">19.06</ix:nonFraction> per share, which resulted in gross proceeds of approximately $<ix:nonFraction name="us-gaap:PreferredStockValueOutstanding" contextRef="PAsOn03_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17915">53.8</ix:nonFraction>&#160;million, as well as the conversion of all Series A Preferred Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;A-1&#160;Preferred</div> Stock, and Series B Preferred Stock. In conjunction with the Merger, immediately following the Closing, each then-outstanding share of Legacy OnKure preferred stock converted into Class&#160;A or Class&#160;B Common Stock. <ix:nonFraction name="okur:ConvertiblePreferredStockSharesAuthorized" contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17916"><ix:nonFraction name="okur:ConvertiblePreferredStockSharesIssued" contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17917"><ix:nonFraction name="okur:ConvertiblePreferredStockSharesOutstanding" contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-17918">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> Convertible Preferred Shares are authorized, issued or outstanding at December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s convertible preferred stock had the following characteristics as of December&#160;31, 2023:&#8195; </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion of Preferred Stock into Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of preferred stock, at the option of the holder, was convertible into a number of shares of common stock as determined by multiplying the number of shares of preferred stock being converted by the conversion rate. The conversion rate in effect at any time for conversion of preferred stock is determined by dividing the Original Issue Price by the Conversion Price. The Original Issue Price for the Series C Preferred Stock was $<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="PAsOn03_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17919">19.06</ix:nonFraction> per share. The Conversion Price was subject to certain adjustments as provided in the Company&#8217;s restated certificate of incorporation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock would have automatically converted to common stock upon the closing of an initial public offering of the Company&#8217;s common stock in which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the&#160;per-share&#160;price</div> is at least $<ix:nonFraction name="us-gaap:PreferredStockConvertibleConversionPrice" contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementClassOfStockAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17920">38.19</ix:nonFraction> and gross proceeds of not less than $<ix:nonFraction name="us-gaap:ConversionOfStockAmountIssued1" contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis" unitRef="Unit_USD" decimals="-6" scale="6" format="ixt:num-dot-decimal" id="ixv-17921">75</ix:nonFraction>&#160;million, or the date and time specified by vote or the written consent of the holders of at least a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each preferred stockholder was entitled to the number of votes equal to the number of shares of Class&#160;A Common Stock into which such holder&#8217;s shares are convertible. At any time when a defined number of shares of Series C Preferred Stock are outstanding, the Company was restricted from certain actions described in the Company&#8217;s restated certificate of incorporation without the vote or written consent of the holders of a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company could not have declared, paid or set aside any dividends on any shares of any other class or series of capital stock unless each holder of the preferred stock first received a dividend based upon a formula in the Company&#8217;s restated certificate of incorporation. <ix:nonFraction name="us-gaap:Dividends" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-17922"><ix:nonFraction name="us-gaap:Dividends" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="INF" scale="3" format="ixt-sec:numwordsen" id="ixv-17923">No</ix:nonFraction></ix:nonFraction> dividends were declared during the years ended December&#160;31, 2024 or 2023. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-19</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878761_4" continuedAt="TextSelectionAppend_133878761_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878761_5" continuedAt="TextSelectionAppend_133878761_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878761_6" continuedAt="TextSelectionAppend_133878761_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878761_7"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution or winding up of the Company, certain qualifying mergers, sales or transactions with a special purpose acquisition companies, and other deemed liquidation events as defined in the Company&#8217;s restated certificate of incorporation, unless the holders of a majority of the then outstanding shares of Series C Preferred Stock, voting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis,</div> elected otherwise, prior to and in preference to any distribution to the holders of common stock, holders of Series C Preferred Stock were entitled to be paid out of the assets of the Company legally available for distribution, or the consideration received in such transaction, an amount per share of Series C Preferred Stock equal to the greater of: <ix:nonNumeric name="us-gaap:PreferredStockDividendPaymentTerms" contextRef="P01_01_2024To12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis" id="ixv-17925">i) 1.50 times the Series C Original Issuance Price plus all declared and unpaid dividends on Series C Preferred Stock or ii) such amount per share that would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately prior to such event.</ix:nonNumeric> If upon liquidation, dissolution, or winding up of the Company, the assets and funds of the Company are insufficient to permit the payment of the full preferential amounts to the holders of preferred stock, then the holders shall share ratably in any distribution of the assets available for distribution, in proportion to the respective amounts which would otherwise be payable in respect of the shares held by the preferred stockholders. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of all preferential amounts required to be paid to the holder of shares of preferred stock, the remaining assets available for distribution to its stockholders would have been distributed to the holders of shares of common stock, pro rata based on the number of shares held by each holder. The liquidation preference as of December&#160;31, 2023 was $<ix:nonFraction name="us-gaap:PreferredStockLiquidationPreferenceValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17926">195.8</ix:nonFraction>&#160;million. </div></ix:continuation><ix:nonNumeric name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878752" id="ixv-14222"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Share-Based Compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s share-based compensation plans are described below: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company established an equity incentive plan (the &#8220;2024 Plan&#8221;). The 2024 Equity Incentive Plan became effective upon the closing of the Merger, and will continue in effect for a period of <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2024To12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-17927">ten years</ix:nonNumeric> from its effectiveness, unless terminated earlier by the administrator. The 2024 Plan provides for the grant of stock options, RSUs and RSAs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">employees,&#160;non-employee&#160;directors,</div> advisors, and consultants. Under the 2024 Plan a total of <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17928">2,480,000</ix:nonFraction> shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. As of the effective date of the 2024 Plan, awards granted under the 2011, 2021 and 2023 Plans that are forfeited or otherwise become available will be included and available for issuance under the 2024 Plan. Under the 2024 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other awards to individuals who are employees, officers, directors or consultants of the Company and its affiliates. The Company issues new shares in settlement of equity awards under the 2024 Plan. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 RSU Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, the Company established an equity incentive plan (the &#8220;2023 Plan&#8221;). The 2023 Plan provided for the grant of restricted stock units (&#8220;RSU&#8221;) to employees, directors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2023 Plan were cancelled. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, the Company established an equity incentive plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provided for the grant of stock options and RSA to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">employees,&#160;non-employee&#160;directors,</div> advisors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2021 Plan were cancelled.&#8195; </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-20</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878752" continuedAt="TextSelectionAppend_133878752_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_1" continuedAt="TextSelectionAppend_133878752_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_2" continuedAt="TextSelectionAppend_133878752_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878752_3" continuedAt="TextSelectionAppend_133878752_4"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2011 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2011, the Company established an equity incentive plan (the &#8220;2011 Plan&#8221;). The 2011 Plan provided for the grant of stock options and restricted stock awards (&#8220;RSA&#8221;) to employees, <div style="white-space:nowrap;display:inline;">non-employee</div> directors, advisors, and consultants. Shares are no longer available for issuance under the 2011 Plan, which was subsequently terminated in March 2023. Upon the close of the Merger, all shares available for issuance under the 2011 Plan were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as part of the Merger with Reneo discussed in Note 1, the Company assumed outstanding awards under the following Reneo Equity Incentive Plans and certain awards not issued pursuant to a Reneo Equity Plan: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reneo 2021 and 2014 Equity Incentive Plans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Reneo Board of Directors adopted the Reneo 2021 Equity Incentive Plan (&#8220;Reneo 2021 Plan&#8221;), which is the successor to Reneo&#8217;s 2014 Equity Incentive Plan and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">UK&#160;Sub-Plan</div> (&#8220;2014 Plan&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 ESPP </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company established the 2024 ESPP. Under the 2024 ESPP, an aggregate of <ix:nonFraction name="okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17930">137,500</ix:nonFraction> shares of Class&#160;A Common Stock are currently reserved and available for issuance. As of December&#160;31, 2024, no <div style="display:inline;">offering </div>periods have been established under the 2024 ESPP. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Shares Reserved for Future Issuance </div></div></div><ix:nonNumeric name="okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14278"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had reserved shares of its common stock for future issuance as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"/>
<td style="vertical-align:bottom;width:4%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/> Reserved</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17931">2,393,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units under the 2023 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17932">213,254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17933">17,000</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Equity Incentive Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17934">747,867</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17935">137,500</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17936">3,509,445</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the Company&#8217;s equity incentive plans have an exercise price equal to or in excess of the market value of the Class&#160;A Common Stock at the date of grant and expire no more than <ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:duryear" id="ixv-17937">10</ix:nonNumeric> years from the date of grant. Generally, options become exercisable ratably over a period of <div style="-sec-ix-hidden:hidden133878831;display:inline;">three</div> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-17938">four years</ix:nonNumeric> from the date of grant. Stock options granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">to&#160;non-employees&#160;generally</div> vest quarterly over <div style="-sec-ix-hidden:hidden133878830;display:inline;">two</div> to <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" format="ixt-sec:durwordsen" id="ixv-17939">three years</ix:nonNumeric>. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-21</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878752_4" continuedAt="TextSelectionAppend_133878752_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_5" continuedAt="TextSelectionAppend_133878752_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_6" continuedAt="TextSelectionAppend_133878752_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878752_7" continuedAt="TextSelectionAppend_133878752_8"><ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14377"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s stock option activity and related information for the year ended December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:49%"/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="PAsOn12_31_2023" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17941">178,232</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2023" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17942">16.74</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-17943">8.88</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17944">16</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed in reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17945">467,100</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17946">47.39</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17947">1,775,318</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17948">18.13</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17949">2,476</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17950">10.19</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17951">740</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17952">21.62</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17953">23,610</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17954">38.34</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17955">2,393,824</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17956">23.54</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-17957">7.90</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17958">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="PAsOn12_31_2024" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17959">654,636</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="PAsOn12_31_2024" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17960">38.08</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-17961">3.07</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-17962">1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All outstanding options as of December&#160;31, 2024 are expected to vest. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested stock options of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17963">26.5</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-17964">2.8</ix:nonNumeric> years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company&#8217;s common stock as of December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted for the years ended December&#160;31, 2024, and 2023 was $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17965">16.05</ix:nonFraction> and $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17966">5.51</ix:nonFraction>, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted performance-based stock options. During the year ended December&#160;31, 2023, the Company granted <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17967">8,449</ix:nonFraction> performance-based shares, which are included in the table above. The company recognized $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17968">30,000</ix:nonFraction> and $<ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-17969">13,000</ix:nonFraction> in performance-based compensation expense for the years ended December&#160;31, 2024 and 2023, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates stock awards fair value on the date of grant using the Black-Scholes valuation, with the vesting being subject to service requirements. The Company accounts for forfeitures when they occur. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878791" id="ixv-17970">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: </ix:nonNumeric></div><ix:continuation id="TextSelection_133878791"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2024To12_31_2024" format="ixt-sec:duryear" id="ixv-17971">5.77</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonNumeric name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="P01_01_2023To12_31_2023" format="ixt-sec:duryear" id="ixv-17972">5.73</ix:nonNumeric></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-17973">126.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-17974">32.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-17975">3.80</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="4" scale="-2" format="ixt:num-dot-decimal" id="ixv-17976">4.31</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-17977">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-17978">0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate. </div></div>The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">zero-coupon</div> bonds with maturities similar to those of the expected term of the award being valued. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-22</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878752_8" continuedAt="TextSelectionAppend_133878752_9"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_9" continuedAt="TextSelectionAppend_133878752_10"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_10" continuedAt="TextSelectionAppend_133878752_11"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878752_11" continuedAt="TextSelectionAppend_133878752_12"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility.</div></div> The expected volatility assumption was based on the volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected term. </div></div>The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield. </div></div>The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" id="ixv-17980">RSA typically vests <ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-17981">25</ix:nonFraction>% on the first anniversary of the issuance date and incrementally vest monthly for the <ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis" format="ixt-sec:durwordsen" id="ixv-17982">three-year</ix:nonNumeric> period thereafter.</ix:nonNumeric> In the event of a termination of services, all unvested shares are forfeited, and the Company has the option to purchase all outstanding vested shares at their fair market value. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><ix:nonNumeric name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" id="ixv-17983">RSU vests based on a service-based requirement and a liquidity event plus service requirement.</ix:nonNumeric> <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-17984">No</ix:nonFraction> RSU had vested as of December&#160;31, 2023. <ix:nonNumeric name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878759" id="ixv-17985">The following table summarizes RSU and RSA activities during the year ended December&#160;31, 2024: </ix:nonNumeric></div><ix:continuation id="TextSelection_133878759"><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:6%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17986">214,436</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17987">22.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:fixed-zero" id="ixv-17988">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="0" scale="0" format="ixt:fixed-zero" id="ixv-17989">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested (RSA)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17990">638</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17991">0.83</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17992">544</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17993">22.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17994">213,254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17995">22.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-17996">213,254</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis" unitRef="Unit_USD_per_Share" decimals="2" scale="0" format="ixt:num-dot-decimal" id="ixv-17997">22.88</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:continuation><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested RSU awards of $<ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-17998">2.8</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of approximately <ix:nonNumeric name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" format="ixt-sec:duryear" id="ixv-17999">2.0</ix:nonNumeric> years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the RSUs in the table above, in connection with the Merger, the Company assumed <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18000">24,700</ix:nonFraction> RSUs which were fully vested at the time of the Merger. The RSUs were releasable upon set time frames after completion of the Merger. From the Merger through December&#160;31, 2024, <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P10_04_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18001">7,700</ix:nonFraction> RSUs were released. The remaining <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="P01_01_2025To01_31_2025_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18002">17,000</ix:nonFraction> RSUs were released in January 2025. There was <ix:nonFraction name="okur:UnamortizedCompensationCost" contextRef="PAsOn12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-18003">no</ix:nonFraction> unamortized compensation cost related to these RSUs as of the Merger or December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2024 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company&#8217;s Board of Directors adopted the ESPP, which became effective immediately upon completion of the Merger with Reneo. As of December&#160;31, 2024, no shares have been issued under the ESPP. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-23</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878752_12" continuedAt="TextSelectionAppend_133878752_13"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_13" continuedAt="TextSelectionAppend_133878752_14"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878752_14" continuedAt="TextSelectionAppend_133878752_15"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878752_15"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation Expense </div></div></div><ix:nonNumeric name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-14941"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the allocation of share-based compensation expense related to the company&#8217;s share-based awards (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:5%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18005">2,896</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18006">98</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18007">1,634</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18008">101</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18009">4,530</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18010">199</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded accelerated share-based compensation expenses related to modifications of RSUs under certain separation agreements of $<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt:num-dot-decimal" id="ixv-18011">1.7</ix:nonFraction>&#160;million during the year ended December&#160;31, 2024, which is reflected in the above table. See Note 14 for further discussion on severance. There were <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis" unitRef="Unit_USD" decimals="INF" scale="6" format="ixt-sec:numwordsen" id="ixv-18012">no</ix:nonFraction> such modifications during the year ended December&#160;31, 2023. </div></ix:continuation><ix:nonNumeric name="us-gaap:IncomeTaxDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878746" id="ixv-15036"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. </div><ix:nonNumeric name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-15040"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the income tax benefit are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"/>
<td style="vertical-align:bottom;width:10%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:9%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax at statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18013">21.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18014">21.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal deduction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18015">3.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18016">3.6</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18017">0.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18018">0.2</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-18019">2.3</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" sign="-" format="ixt:num-dot-decimal" id="ixv-18020">0.1</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18021">22.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18022">24.7</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18023">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_pure" decimals="3" scale="-2" format="ixt:num-dot-decimal" id="ixv-18024">0.0</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><ix:nonNumeric name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-15167"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of deferred income taxes are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"/>
<td style="vertical-align:bottom;width:8%"/>
<td/>
<td/>
<td/>
<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18025">53,984</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18026">9,027</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D tax credit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18027">837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18028">837</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18029">32,729</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18030">11,123</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18031">1,903</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18032">783</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18033">978</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18034">104</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18035">424</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsOther" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18036">337</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18037">90,855</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsGross" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18038">22,211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18039">90,855</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(<ix:nonFraction name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal" id="ixv-18040">22,211</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18041">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right"><ix:nonFraction name="us-gaap:DeferredTaxAssetsNet" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:fixed-zero" id="ixv-18042">&#8212;</ix:nonFraction>&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table></ix:nonNumeric><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18043">3.1</ix:nonFraction>&#160;million of net operating loss carryforwards (&#8220;NOLs&#8221;) and $<ix:nonFraction name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18044">0.8</ix:nonFraction>&#160;million of research and experimental credits which expire through <ix:nonNumeric name="okur:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" contextRef="P01_01_2024To12_31_2024" id="ixv-18045">2037</ix:nonNumeric>, and approximately $<ix:nonFraction name="us-gaap:OperatingLossCarryforwards" contextRef="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18046">216.5</ix:nonFraction>&#160;million of federal and state net operating loss carryforwards which have an indefinite life. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-24</ix:exclude> </div></ix:nonNumeric></div></div></div><ix:continuation id="TextSelection_133878746" continuedAt="TextSelectionAppend_133878746_1"><div></div></ix:continuation></div><ix:continuation id="TextSelectionAppend_133878746_1" continuedAt="TextSelectionAppend_133878746_2"><div><div style="line-height:normal;display: inline;"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></div></div></ix:continuation></div> <div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878746_2"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2024, the Company had federal and state tax credit carry forwards of approximately $<ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18048"><ix:nonFraction name="us-gaap:TaxCreditCarryforwardAmount" contextRef="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18049">6.9</ix:nonFraction></ix:nonFraction>&#160;million. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in <ix:nonNumeric name="okur:TaxCreditCarryforwardExpirationPeriod" contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis" id="ixv-18050">2034</ix:nonNumeric>, if unused. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, the Company&#8217;s ability to use NOLs and research tax credit carry forwards to offset future taxable income may be limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section&#160;382. If ownership changes within the meaning of IRC Section&#160;382 are identified as having occurred, the amount of NOLs and research tax carryforwards available to offset future taxable income and income tax liabilities in future years may be significantly restricted or eliminated. Further, deferred tax assets associated with such NOLs and research tax credits could be significantly reduced upon realization of an ownership change within the meaning of IRC Section&#160;382. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers projected future taxable income and tax planning strategies in making this assessment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2024 and 2023, the Company has <ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2024" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-18051"><ix:nonFraction name="us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued" contextRef="PAsOn12_31_2023" unitRef="Unit_USD" decimals="INF" scale="0" format="ixt-sec:numwordsen" id="ixv-18052">no</ix:nonFraction></ix:nonFraction>t accrued any interest or penalties related to uncertain tax positions. The Company does not anticipate that there will be a significant change in the amount of unrecognized tax benefits over the next 12 months. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and the UK. The UK subsidiary operations ceased in 2024. The Company&#8217;s federal and state income tax returns for all years will remain open to examination by federal and state tax authorities for three years from the date of utilization of any net operating loss carryforwards. The Company&#8217;s federal and state returns since inception are subject to examination due to the carryover of net operating losses. The Company has not been, nor is it currently, under examination by any tax authorities. The UK tax returns from 2018 through 2024, are subject to examination by the UK tax authorities. </div></ix:continuation><ix:nonNumeric name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" continuedAt="TextSelection_133878743" id="ixv-15379"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Legal Proceedings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger Proceedings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, two complaints were filed in the Supreme Court of the State of New York, County of New York, captioned<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Thomas</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;v.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Reneo Pharmaceuticals, Inc., et al.</div></div>, Index No.&#160;654628/2024 (filed September&#160;5, 2024) and<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Kent v. Reneo Pharmaceuticals, Inc., et al.</div></div>, Index No.&#160;654642/2024 (filed September&#160;6, 2024) (together, the &#8220;Complaints&#8221;). The Complaints generally allege that the Proxy Statement/Prospectus filed by Reneo with the SEC misrepresented and/or omitted certain purportedly material information relating to Reneo management&#8217;s financial projections for Reneo and OnKure, the data and inputs underlying the financial valuation analyses that support the fairness opinion provided by Leerink Partners, Reneo&#8217;s financial advisor, and potential conflicts of interest with Leerink Partners LLC, Evercore Group L.L.C., and LifeSci Capital LLC, which were the placements agents for the Concurrent Financing that closed concurrently with the Merger. The Complaints assert violations of negligent misrepresentation and concealment in violation of New York common law and negligence in violation of New York common law. The Complaints sought orders enjoining the proposed Merger, or in the event that the Merger was consummated, orders rescinding the Merger or awarding actual and punitive damages, as well as all of the plaintiffs&#8217; fees and expenses in connection with the litigation, including reasonable attorneys&#8217; and experts&#8217; fees and expenses. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-25</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_133878743" continuedAt="TextSelectionAppend_133878743_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878743_1" continuedAt="TextSelectionAppend_133878743_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878743_2" continuedAt="TextSelectionAppend_133878743_3"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878743_3" continuedAt="TextSelectionAppend_133878743_4"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the outcome of the Complaints or any other litigation that might be filed arising out of the Merger or the Concurrent Financing. The Company and the individual defendants intend to vigorously defend against the Complaints and any subsequently filed, similar actions. It is possible additional lawsuits may be filed arising out of the Merger or the Concurrent Financing. Absent new or significantly different allegations, the Company will not necessarily disclose such additional filings. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">time-to-time</div></div> in the future, the Company could be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business, which may have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Clinical Trial Collaboration and Supply Agreement with Pfizer </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, as amended in December 2024, the Company entered into a clinical trial collaboration and supply agreement under which Pfizer Inc. (&#8220;Pfizer&#8221;) agreed to supply drug product in connection with a clinical trial. The agreement continues until the earlier of the completion of all obligations of the parties or the termination of the contract by either party as defined in the agreement. The Company may terminate the agreement if the clinical trial is deemed to be unsafe, regulatory authorities raise concerns, or if Pfizer does not uphold its obligations outlined in the agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Indemnification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs because of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Severance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A former officer of the Company terminated his employment with the Company on May&#160;24, 2024 and entered into a separation agreement and release on that date. The separation agreement and release provides for payments and benefits including continuing payments of base salary for a period of 14&#160;months following termination of employment, payment for or reimbursement for COBRA premiums for up to 14 months following termination of employment, a full accelerated vesting of his equity awards and extension of the post-termination exercise period applicable to his Options through the earlier of 12 months following termination of service or the applicable option expiration date. During the year ended December&#160;31, 2024, the Company recorded an expense of $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2024To12_31_2024_OneTimeTerminationBenefitsMemberusgaapRestructuringCostAndReserveAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18054">622,000</ix:nonFraction> for these severance benefits in research and development expense, of which $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18055">326,000</ix:nonFraction> remains unpaid and is included in accrued compensation. See Note 12 for discussion of stock-based compensation recorded for the modifications of equity awards discussed above. The related RSU shares were released in January 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Reneo employees became employees of the Company to assist with the Merger transition through the end of the year December&#160;31, 2024 at which time they were terminated and received severance benefits in accordance with the Reneo severance agreements. The Company recorded expense of $<ix:nonFraction name="us-gaap:SeveranceCosts1" contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18056">225,000</ix:nonFraction> for severance benefits for these employees for the year ended December&#160;31, 2024, which is included in General and Administrative expenses and of which, approximately $<ix:nonFraction name="us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense" contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18057">154,000</ix:nonFraction> remains unpaid as of December&#160;31, 2024 and is included in accrued compensation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>F-26</ix:exclude> </div></ix:continuation></div></div><ix:continuation id="TextSelectionAppend_133878743_4" continuedAt="TextSelectionAppend_133878743_5"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878743_5" continuedAt="TextSelectionAppend_133878743_6"><ix:exclude><hr style="color:#999999;height:3px;width:100%;clear:both"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_133878743_6" continuedAt="TextSelectionAppend_133878743_7"><ix:exclude><div style="font-size: 10pt; margin-top: 1.67em; margin-bottom: 1.67em;font-weight: bold;"><div style="font-weight:bold;display:inline;"><a href="#toc">Table of Contents</a></div></div></ix:exclude></ix:continuation></div></div><div><div style="line-height:normal;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_133878743_7"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Employee Benefit Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company established a qualified 401(k) plan in June 2021 which covers all employees who meet eligibility requirements. The Company matches its employee contributions up to a maximum amount of <ix:nonFraction name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-18059">4</ix:nonFraction>% of the participant&#8217;s compensation. During the years ended December&#160;31, 2024, and 2023, the Company made matching contributions of approximately $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2024To12_31_2024" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18060">360,000</ix:nonFraction>&#160;and $<ix:nonFraction name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="P01_01_2023To12_31_2023" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18061">294,000</ix:nonFraction>, respectively. See Note 16. </div></ix:continuation><ix:nonNumeric name="okur:ConvertiblePromissoryNoteDisclosureTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-15452"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Convertible Promissory Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2024, the Company entered into convertible promissory note agreements with certain of its existing investors for up to $<ix:nonFraction name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="PAsOn06_30_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18062">12.0</ix:nonFraction>&#160;million. At closing, the Company received total proceeds of $<ix:nonFraction name="us-gaap:ShortTermBorrowings" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18063">6.0</ix:nonFraction>&#160;million and had the ability to draw up to an additional $<ix:nonFraction name="okur:AdditionalProceedsFromAcquisition" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="-5" scale="6" format="ixt:num-dot-decimal" id="ixv-18064">6.0</ix:nonFraction>&#160;million in the event the Merger with Reneo had not closed by September&#160;30, 2024, but no additional draw was made. The notes bore interest at rates from <ix:nonFraction name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-18065">6</ix:nonFraction>% per annum. All unpaid principal and accrued interest were due in December 2025, unless earlier converted. In October 2024, the unpaid notes and accrued unpaid interest automatically converted into shares issued in the Concurrent Financing at the price per share paid by investors in the Concurrent Financing. See Note 3 for further discussion. The Company incurred $<ix:nonFraction name="us-gaap:DeferredFinanceCostsNet" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18066">142,000</ix:nonFraction> of debt issuance costs related to the convertible promissory notes during the year ended December&#160;31, 2024. Debt issuance costs are amortized as a component of interest expense over the term of the related debt using the straight-line method, which approximates the interest method. The Company recognized $<ix:nonFraction name="us-gaap:AmortizationOfFinancingCosts" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18067">148,000</ix:nonFraction> in interest expense related to the amortization of the debt issuance costs for the year ended December&#160;31, 2024 and a $<ix:nonFraction name="okur:GainLossOnConversionOfDebt" contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal" id="ixv-18068">114,000</ix:nonFraction> loss on the conversion for the year ended December&#160;31, 2024, both of which are recorded in interest and other expense in the Statement of Operations. As of December&#160;31, 2024, the Company had <ix:nonFraction name="okur:AccruedInterest" contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt-sec:numwordsen" id="ixv-18069">no</ix:nonFraction> accrued interest related to the convertible promissory notes. </div></ix:nonNumeric><ix:nonNumeric name="us-gaap:SubsequentEventsTextBlock" contextRef="P01_01_2024To12_31_2024" escape="true" id="ixv-15456"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">16. Subsequent Events </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Sublease</div> </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, the Company entered into a sublease on the Irvine lease for all of the leased square footage. The sublease rent payments will be approximately $<ix:nonFraction name="us-gaap:PaymentsForRent" contextRef="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal" id="ixv-18070">450,000</ix:nonFraction> over the term of the lease, which expires in <ix:nonNumeric name="okur:SubleaseExpirationPeriod" contextRef="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis" format="ixt:date-monthname-year-en" id="ixv-18071">November 2026</ix:nonNumeric>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Available for Issuance Increase </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2024 Plan provides that on the first day of each fiscal year, the number of shares of our Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18072">2,407,100</ix:nonFraction> shares, (ii) <ix:nonFraction name="okur:PercentageOfNumberOfOutstandingSharesOfCommonStock" contextRef="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-18073">5</ix:nonFraction>% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the Company&#8217;s board of directors may determine. The Company&#8217;s ESPP provides that on the first day of each fiscal year, the number of shares of Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) <ix:nonFraction name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18074">481,500</ix:nonFraction>&#160;shares, (ii) <ix:nonFraction name="okur:PercentageOfNumberOfOutstandingSharesOfCommonStock" contextRef="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_pure" decimals="2" scale="-2" format="ixt:num-dot-decimal" id="ixv-18075">1</ix:nonFraction>% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the board of directors may determine. On January&#160;1, 2025, the number of shares of Class&#160;A common stock available for issuance under the 2024 Plan and the ESPP increased by <ix:nonFraction name="okur:IncreaseInNumberOfSharesAvailableForIssuance" contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18076">667,355</ix:nonFraction>&#160;and <ix:nonFraction name="okur:IncreaseInNumberOfSharesAvailableForIssuance" contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis" unitRef="Unit_shares" decimals="INF" scale="0" format="ixt:num-dot-decimal" id="ixv-18077">133,471</ix:nonFraction>&#160;shares, respectively, pursuant to these provisions. </div></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">F-27 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PART II </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION NOT REQUIRED IN PROSPECTUS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left"><span style="font-weight:bold">ITEM&#8201;13.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">OTHER EXPENSES OF ISSUANCE AND DISTRIBUTION. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth all expenses to be paid by the Registrant, other than underwriting discounts and commissions, in connection with this offering. All amounts shown are estimates. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:83%"/>

<td style="vertical-align:bottom;width:7%"/>
<td/>
<td/>
<td/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,676</td>
<td style="white-space:nowrap;vertical-align:bottom">*&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Printing and engraving</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">65,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent and registrar fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">12,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">190,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&#160;</p></td>
<td>&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">*</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Previously paid. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left"><span style="font-weight:bold">ITEM&#8201;14.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">INDEMNIFICATION OF DIRECTORS AND OFFICERS. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&#160;145 of the DGCL authorizes a corporation to indemnify its directors and officers against liabilities arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses (including attorneys&#8217; fees) judgments, fines and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&#160;145 permits corporations to pay expenses (including attorneys&#8217; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&#160;145 provides that a corporation has the power to purchase and maintain insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the power to indemnify the director or officer against such liability under Section&#160;145. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reneo has adopted provisions in its charter that eliminate or limit the personal liability of Reneo&#8217;s directors to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended. Consequently, a director will not be personally liable to Reneo or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability for: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any breach of the director&#8217;s duty of loyalty to Reneo or its stockholders; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">any transaction from which the director derived an improper personal benefit. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable remedies such as an injunction or rescission. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Reneo&#8217;s bylaws provide that: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reneo will indemnify its directors, officers and, in the discretion of its board of directors, certain employees to the fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Reneo will advance expenses, including attorneys&#8217; fees, to its directors and, in the discretion of its board of directors, to its officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of Reneo, subject to limited exceptions. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have entered into separate indemnification agreements with our directors and officers that may be broader than the specific indemnification provisions contained in the Delaware General Corporation Law. We have entered into agreements with our officers and directors to provide contractual indemnification in addition to the indemnification provided for in our certificate of incorporation. Our bylaws also permit us to maintain insurance on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware law would permit such indemnification. We have obtained a policy of director&#8217;s and officer&#8217;s liability insurance that insures our officers and directors against the cost of defense, settlement or payment of a judgment in some circumstances and insures us against our obligations to indemnify our officers and directors. These indemnification provisions and the indemnification agreements may be sufficiently broad to permit indemnification of directors and officers for liabilities, including reimbursement of expenses incurred, arising under the Securities Act of 1933, as amended, or the Securities Act. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left"><span style="font-weight:bold">ITEM&#8201;15.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">RECENT SALES OF UNREGISTERED SECURITIES. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have sold the securities described below within the past three years which were not registered under the Securities Act. All of the sales listed below were made pursuant to an exemption from registration afforded by Section&#160;4(a)(2) of the Securities Act (and Regulation D thereunder) or Rule 701 promulgated under Section&#160;3(b) of the Securities Act. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">PIPE Shares </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Concurrently with the execution of the Merger Agreement, Reneo entered into the subscription agreement with the PIPE Investors, pursuant to which, immediately following the Effective Time, the PIPE Investors subscribed for and purchased an aggregate of 2,839,005 shares of Common Stock at a price of approximately $22.895 per share for aggregate gross proceeds of approximately $65&#160;million. </p> <p style="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Plan-Related Issuances </span></p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;4, 2024, we granted to certain of our officers, directors, employees, consultants, and advisors, options to purchase an aggregate of 1,733,150 options to purchase shares of Common Stock with an exercise price of $18.20 per share under our 2024 Plan. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left"><span style="font-weight:bold">ITEM&#8201;16.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Exhibits</span></span>. We have filed the exhibits listed on the accompanying Exhibit Index of this Registration Statement. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:90%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;2.1&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124dex21.htm">Agreement and Plan of Merger, dated May&#160;10, 2024, by and among Reneo Pharmaceuticals, Inc., Radiate Merger Sub I, Inc., Radiate Merger Sub II, LLC and OnKure, Inc. (incorporated by reference to Exhibit&#160;2.1 to the Registrant&#8217;s Current Report on <span style="white-space:nowrap">Form&#160;8-K</span> filed on May&#160;13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex31.htm">Certificate of Amendment to Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex32.htm">Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;3.3</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex33.htm">Amended and Restated Bylaws (incorporated by reference to Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312521087741/d63585dex42.htm">Amended and Restated Investors&#8217; Rights Agreement, by and among Reneo and certain of its stockholders, dated December&#160;9, 2020 (incorporated by reference to Exhibit&#160;4.2 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended, filed on March&#160;19, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714dex51.htm">Opinion of Wilson Sonsini Goodrich &amp; Rosati, P.C. (incorporated by reference to Exhibit 5.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-282792) filed with the SEC on October 23, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.1+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312521087741/d63585dex108.htm">Form of Indemnity Agreement by and between the Registrant and its directors and executive officers (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1, as amended, filed April 5, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000095017023062910/rphm-ex10_1.htm">Sales Agreement, dated November 13, 2023, by and between the Registrant and Leerink Partners LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, filed on November 13, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.3+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312521105697/d63585dex101.htm">Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and UK <span style="white-space:nowrap">Sub-Plan</span> (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended, filed on April&#160;5, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.4+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/0001637715/000119312521087741/d63585dex102.htm">Forms of Grant Notice, Stock Option Agreement and Notice of Exercise under the Reneo Pharmaceuticals, Inc. 2014 Equity Incentive Plan, as amended, and UK <span style="white-space:nowrap">Sub-Plan</span> (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended, filed on April&#160;5, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.5+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312521105697/d63585dex103.htm">Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended, filed on April&#160;5, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.6+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000095017023009978/rphm-ex10_18.htm">Forms of (i)&#160;Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise, (ii)&#160;Stock Option Grant Notice&#8212;International, Stock Option Agreement&#8212;International and Notice of Exercise&#8212;International and <span style="white-space:nowrap">(iii)&#160;Non-Employee</span> Director Stock Option Grant Notice, Stock Option Agreement and Notice of <span style="white-space:nowrap">Exercise&#8212;Non-Employee</span> Director under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.18 to the Registrant&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K,</span> filed on March&#160;27, 2023). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.7+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312521105697/d63585dex105.htm">Forms of (i)&#160;Restricted Stock Unit Award Grant Notice and Award Agreement and (ii)&#160;Restricted Stock Unit Award Grant Notice&#8212;International and Award Agreement&#8212;International under the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.5 to the Registrant&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-1,</span> as amended, filed on April&#160;5, 2021). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:89%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.8+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000155837021015674/rphm-20210930xex10d4.htm">Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise for Inducement Grant Outside of the Reneo Pharmaceuticals, Inc. 2021 Equity Incentive Plan (incorporated by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> filed on November&#160;12, 2021). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.9+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000095017022023250/rphm-ex10_2.htm">Reneo Pharmaceuticals, Inc. Severance Benefit Plan, as amended as of September&#160;27, 2022, and form of Participation Agreement thereunder (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q,</span> filed on November&#160;8, 2022). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.10&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124dex101.htm">Form of Reneo Support Agreement (incorporated by reference to Exhibit&#160;10.1 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.11&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124dex102.htm">Form of OnKure Support Agreement (incorporated by reference to Exhibit&#160;10.2 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.12</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124dex103.htm">Form of <span style="white-space:nowrap">Lock-Up</span> Agreement (incorporated by reference to Exhibit&#160;10.3 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.13&#8224;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524136785/d838124dex104.htm">Subscription Agreement dated May&#160;10, 2024 (incorporated by reference to Exhibit&#160;10.4 to the Registrant&#8217;s Current Report on Form <span style="white-space:nowrap">8-K</span> filed on May&#160;13, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.14+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1014.htm">OnKure Therapeutics, Inc. 2024 Equity Incentive Plan, and forms of agreement thereunder (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.15+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1015.htm">OnKure Therapeutics, Inc. 2024 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.15 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.16+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1016.htm">OnKure, Inc. 2011 Stock Incentive Plan, as amended, and forms of agreement thereunder (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.17+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1017.htm">OnKure, Inc. 2021 Stock Incentive Plan, as amended, and forms of agreement thereunder (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.18+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1018.htm">OnKure, Inc. 2023 RSU Equity Incentive Plan, and forms of agreement thereunder (incorporated by reference to Exhibit 10.18 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024).</a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.19+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1019.htm">OnKure Therapeutics, Inc. Executive Incentive Compensation Plan (incorporated by reference to Exhibit 10.19 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.20+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1020.htm">OnKure Therapeutics, Inc. Form of Executive Employment Agreement (incorporated by reference to Exhibit 10.20 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.21+</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1021.htm">OnKure Therapeutics, Inc. Outside Director Compensation Policy (incorporated by reference to Exhibit 10.21 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.22</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1022.htm">Form of Indemnification Agreement (incorporated by reference to Exhibit 10.22 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;10.23</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524234487/d836681dex1023.htm">Registration Rights Agreement dated October&#160;4, 2024 by and among OnKure Therapeutics, Inc. and certain parties thereto (incorporated by reference to Exhibit 10.23 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;16.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000095017024123265/okur-ex16_1.htm">Letter from Ernst &amp; Young, LLP dated November 7, 2024 (incorporated by reference to Exhibit 16.1 to the Registrant&#8217;s Current Report on Form 8-K filed on October 8, 2024). </a></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:88%"/></tr>

<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;21.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000095017025036252/okur-ex21_1.htm">List of Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#8217;s Annual Report on Form 10-K filed with the SEC on March 10, 2025). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d184865dex231.htm">Consent of KPMG LLP, independent registered public accounting firm. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;23.2</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714dex51.htm">Consent of Wilson Sonsini Goodrich&#160;&amp; Rosati, P.C. (included in Exhibit 5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;24.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1637715/000119312524241926/d835714ds1.htm#sig">Power of Attorney (incorporated by reference to the signature page to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-282792) filed with the SEC on October 23, 2024). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.INS</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Instance Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.SCH</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Schema Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.CAL</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.DEF</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Definition Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.LAB</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Labels Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">101.PRE</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">107</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="http://www.sec.gov/Archives/edgar/data/1637715/000119312524241926/d835714dexfilingfees.htm">Filing Fee Table (incorporated by reference to Exhibit 107 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-282792) filed with the SEC on October 23, 2024). </a></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">+</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Indicates management contract or compensatory plan. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left">&#8224;</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Schedules and exhibits to this Exhibit omitted pursuant to Regulation <span style="white-space:nowrap">S-K</span> Item 601(a)(5). The Registrant agrees to furnish supplementally a copy of any omitted schedule or exhibit to the SEC upon request. </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Financial Statement Schedules</span></span><span style="font-style:italic">. </span>All financial statement schedules are omitted because the information called for is not required or is shown either in the consolidated financial statements or in the notes thereto. </p></td></tr></table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%;vertical-align:top;text-align:left"><span style="font-weight:bold">ITEM&#8201;17.</span></td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">UNDERTAKINGS. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(a)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned Registrant hereby undertakes: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any prospectus required by section 10(a)(3) of the Securities Act; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &#8220;Calculation of Registration Fee&#8221; table in the effective registration statement. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">provided, however,</span> that paragraphs (a)(1)(i), (a)(1)(ii) and (a)(1)(iii) of this section do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the SEC by the registrant pursuant to section 13 or section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement, or is contained in a form of prospectus filed pursuant to Rule 424(b) that is part of the Registration Statement. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(3)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(4)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability under the Securities Act to any purchaser: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If the registrant is relying on Rule 430B: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(A)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:18%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(B)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&#160;for the purpose of providing the information required by section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">If the registrant is subject to Rule 430C (&#167; 230.430C of this chapter), each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A (&#167; 230.430A of this chapter), shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any statement that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such date of first use. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(5)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="vertical-align:top;text-align:left">
statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: </td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(i)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(ii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(iii)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:13%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(iv)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(b)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top;text-align:left">(c)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The undersigned registrant hereby undertakes that: </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(1)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4)&#160;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:9%">&#160;</td>
<td style="width:4%;vertical-align:top;text-align:left">(2)</td>
<td style="vertical-align:top;text-align:left"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="sig">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Post Effective Amendment No. 1 to Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on March 20, 2025. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:7%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:92%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">ONKURE THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style=" BORDER-BOTTOM:0.75pt solid #000000;vertical-align:bottom">&#160;</td>
<td style="BORDER-BOTTOM:0.75pt solid #000000;vertical-align:top">/s/ Nicholas A. Saccomano</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas A. Saccomano</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Executive Officer</p></td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%;clear:both"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, this Post Effective Amendment No.&#160;1 to Registration Statement on Form <span style="white-space:nowrap">S-1</span> has been signed by the following persons in the capacities and on the dates indicated: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:43%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:40%"/>

<td style="vertical-align:bottom;width:2%"/>
<td style="width:15%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Signature</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date</p></td></tr>


<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Nicholas A. Saccomano</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Nicholas A. Saccomano</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Executive Officer, President and Director (Principal Executive Officer)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">/s/ Jason Leverone</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Jason Leverone</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chief Financial Officer<br/>(Principal Financial and Accounting Officer)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Isaac Manke</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">R. Michael Carruthers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Andrew Phillips</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Chairman of the Board</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Michael Grey</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Valerie M. Jansen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman;text-align:center">*</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;text-align:center">Edward T. Mathers</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;text-align:center"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;text-align:center">Director</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap;text-align:center">March&#160;20,&#160;2025</td></tr>
</table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:10%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:89%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">*By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jason Leverone</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Jason Leverone</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">As Attorney-in-Fact</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">II-9 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>d184865dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KPMG LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Suite 800 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1225 17th Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, CO 80202-5598 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the use of our audit report dated March&nbsp;10, 2025, with respect to the consolidated financial statements of OnKure Therapeutics, Inc.,
included herein, and to the reference to our firm under the heading &#147;Experts&#148; in the registration statement, and to the reference to our firm under the heading &#147;Experts&#148; in the prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ KPMG LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Denver, Colorado </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2025 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>okur-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-March-2025 [07:09:08] {PM}-->
<schema targetNamespace="http://onkuretherapeutics.com/20241231" elementFormDefault="qualified" xmlns:okur="http://onkuretherapeutics.com/20241231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xmlns:currency="http://xbrl.sec.gov/currency/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:exch="http://xbrl.sec.gov/exch/2024" xmlns:naics="http://xbrl.sec.gov/naics/2024" xmlns:sic="http://xbrl.sec.gov/sic/2024" xmlns:us-types="http://fasb.org/us-types/2024" xmlns:stpr="http://xbrl.sec.gov/stpr/2024" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2024" xmlns:srt-types="http://fasb.org/srt-types/2024" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:roleType roleURI="http://onkuretherapeutics.com/role/CoverPage" id="CoverPage">
<link:definition>1001 - Document - Cover Page</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>1002 - Statement - Consolidated Balance Sheets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" id="ConsolidatedBalanceSheetsParenthetical">
<link:definition>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<link:definition>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" id="ConsolidatedStatementsOfChangesInStockholdersEquity">
<link:definition>1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" id="ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<link:definition>1006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows" id="ConsolidatedStatementsOfCashFlows">
<link:definition>1007 - Statement - Consolidated Statements of Cash Flows</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/OrganizationAndBusiness" id="OrganizationAndBusiness">
<link:definition>1008 - Disclosure - Organization and Business</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>1009 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing" id="MergerAgreementAndConcurrentFinancing">
<link:definition>1010 - Disclosure - Merger Agreement and Concurrent Financing</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/Segment" id="Segment">
<link:definition>1011 - Disclosure - Segment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/Leases" id="Leases">
<link:definition>1012 - Disclosure - Leases</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/NetLossPerShare" id="NetLossPerShare">
<link:definition>1013 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/FairValueMeasurements" id="FairValueMeasurements">
<link:definition>1014 - Disclosure - Fair Value Measurements</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
<link:definition>1015 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNet" id="PropertyAndEquipmentNet">
<link:definition>1016 - Disclosure - Property and Equipment, Net</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/AccruedExpenses" id="AccruedExpenses">
<link:definition>1017 - Disclosure - Accrued Expenses</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/Equity" id="Equity">
<link:definition>1018 - Disclosure - Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensation" id="ShareBasedCompensation">
<link:definition>1019 - Disclosure - Share-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/IncomeTaxes" id="IncomeTaxes">
<link:definition>1020 - Disclosure - Income Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
<link:definition>1021 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes" id="ConvertiblePromissoryNotes">
<link:definition>1022 - Disclosure - Convertible Promissory Notes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SubsequentEvents" id="SubsequentEvents">
<link:definition>1023 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" id="SummaryOfSignificantAccountingPoliciesPolicies">
<link:definition>1024 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables" id="MergerAgreementAndConcurrentFinancingTables">
<link:definition>1025 - Disclosure - Merger Agreement and Concurrent Financing (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SegmentTables" id="SegmentTables">
<link:definition>1026 - Disclosure - Segment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesTables" id="LeasesTables">
<link:definition>1027 - Disclosure - Leases (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>1028 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" id="PrepaidExpensesAndOtherCurrentAssetsTables">
<link:definition>1029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables" id="PropertyAndEquipmentNetTables">
<link:definition>1030 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
<link:definition>1031 - Disclosure - Accrued Expenses (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationTables" id="ShareBasedCompensationTables">
<link:definition>1032 - Disclosure - Share-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
<link:definition>1033 - Disclosure - Income Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails" id="OrganizationAndBusinessNarrativeDetails">
<link:definition>1034 - Disclosure - Organization and Business (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" id="SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<link:definition>1035 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails" id="MergerAgreementAndConcurrentFinancingAdditionalInformationDetails">
<link:definition>1036 - Disclosure - Merger Agreement and Concurrent Financing - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails" id="MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails">
<link:definition>1037 - Disclosure - Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails" id="SegmentAdditionalInformationDetails">
<link:definition>1038 - Disclosure - Segment - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails" id="SegmentScheduleOfSegmentReportingInformationBySegmentDetails">
<link:definition>1039 - Disclosure - Segment - Schedule of Segment Reporting Information by Segment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesDetails" id="LeasesDetails">
<link:definition>1040 - Disclosure - Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails" id="LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails">
<link:definition>1041 - Disclosure - Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails" id="LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails">
<link:definition>1042 - Disclosure - Leases - Schedule of Lease Expense for Operating Leases (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails" id="LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails">
<link:definition>1043 - Disclosure - Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
<link:definition>1044 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails" id="NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails">
<link:definition>1045 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails" id="FairValueMeasurementsAdditionalInformationDetails">
<link:definition>1046 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails">
<link:definition>1047 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" id="PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<link:definition>1048 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" id="PropertyAndEquipmentNetAdditionalInformationDetails">
<link:definition>1049 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/AccruedExpensesDetails" id="AccruedExpensesDetails">
<link:definition>1050 - Disclosure - Accrued Expenses (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails" id="EquityAdditionalInformationDetails">
<link:definition>1051 - Disclosure - Equity - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails" id="ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails">
<link:definition>1052 - Disclosure - Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails" id="ShareBasedCompensationStockOptionsAdditionalInformationDetails">
<link:definition>1053 - Disclosure - Share-Based Compensation - Stock Options - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails" id="ShareBasedCompensationSharesReservedForFutureIssuanceDetails">
<link:definition>1054 - Disclosure - Share-Based Compensation - Shares Reserved for Future Issuance (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" id="ShareBasedCompensationStockOptionActivityDetails">
<link:definition>1055 - Disclosure - Share-Based Compensation - Stock option activity (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails" id="ShareBasedCompensationAssumptionsDetails">
<link:definition>1056 - Disclosure - Share-Based Compensation - Assumptions (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails" id="ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails">
<link:definition>1057 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails" id="ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails">
<link:definition>1058 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails" id="ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails">
<link:definition>1059 - Disclosure - Share-Based Compensation - Non-cash stock-based compensation expense (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails" id="ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails">
<link:definition>1060 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails" id="IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails">
<link:definition>1061 - Disclosure - Income Taxes - Summary of components of income tax benefit (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails" id="IncomeTaxesComponentsOfNetDeferredTaxesDetails">
<link:definition>1062 - Disclosure - Income Taxes - Components of net deferred taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails" id="IncomeTaxesNarrativeDetails">
<link:definition>1063 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" id="CommitmentsAndContingenciesAdditionalInformationDetails">
<link:definition>1064 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails" id="ConvertiblePromissoryNotesNarrativeDetails">
<link:definition>1065 - Disclosure - Convertible Promissory Notes (Narrative) (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" id="SubsequentEventsAdditionalInformationDetails">
<link:definition>1066 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="okur-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="okur-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="okur-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="okur-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" />
<import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd" />
<import namespace="http://xbrl.sec.gov/currency/2024" schemaLocation="https://xbrl.sec.gov/currency/2024/currency-2024.xsd" />
<import namespace="http://xbrl.sec.gov/exch/2024" schemaLocation="https://xbrl.sec.gov/exch/2024/exch-2024.xsd" />
<import namespace="http://xbrl.sec.gov/naics/2024" schemaLocation="https://xbrl.sec.gov/naics/2024/naics-2024.xsd" />
<import namespace="http://xbrl.sec.gov/sic/2024" schemaLocation="https://xbrl.sec.gov/sic/2024/sic-2024.xsd" />
<import namespace="http://xbrl.sec.gov/stpr/2024" schemaLocation="https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" />
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" />
<import namespace="http://fasb.org/us-types/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd" />
<import namespace="http://fasb.org/srt-types/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd" />
<import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<element name="ConvertiblePreferredStockSeriesCMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ConvertiblePreferredStockSeriesCMember" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockParOrStatedValuePerShare" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_ConvertiblePreferredStockParOrStatedValuePerShare" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSharesAuthorized" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_ConvertiblePreferredStockSharesAuthorized" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSharesIssued" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_ConvertiblePreferredStockSharesIssued" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockSharesOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_ConvertiblePreferredStockSharesOutstanding" substitutionGroup="xbrli:item" />
<element name="ConvertiblePreferredStockLiquidationPreferenceValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_ConvertiblePreferredStockLiquidationPreferenceValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="InterestAndOtherExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_InterestAndOtherExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ClassACommonStockAndSeriesCPreferredStockMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ClassACommonStockAndSeriesCPreferredStockMember" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesConcurrentFinancing" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuedDuringPeriodSharesConcurrentFinancing" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodValueConcurrentFinancing" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuedDuringPeriodValueConcurrentFinancing" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AdjustmentForFractionalSharesInTheReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="StockIssuanceCostNet" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuanceCostNet" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="Non-CashInterestExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_Non-CashInterestExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PaymentOfReverseRecapitalizationTransactionCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_PaymentOfReverseRecapitalizationTransactionCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConversionOfSeriesCPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ConversionOfSeriesCPreferredStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="ConversionOfConvertibleNotePayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ConversionOfConvertibleNotePayable" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AssetsAcquiredInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="MergerAgreementAndConcurrentFinancingAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_MergerAgreementAndConcurrentFinancingAbstract" substitutionGroup="xbrli:item" />
<element name="MergerAgreementAndConcurrentFinancingTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_MergerAgreementAndConcurrentFinancingTextBlock" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNoteAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ConvertiblePromissoryNoteAbstract" substitutionGroup="xbrli:item" />
<element name="ConvertiblePromissoryNoteDisclosureTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ConvertiblePromissoryNoteDisclosureTextBlock" substitutionGroup="xbrli:item" />
<element name="BasisOfPresentationAndConsolidationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_BasisOfPresentationAndConsolidationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="AccruedResearchAndDevelopmentExpensesPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="PatentCostsPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_PatentCostsPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="CommonStockValuationPolicyTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_CommonStockValuationPolicyTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" substitutionGroup="xbrli:item" />
<element name="ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" type="dtr-types:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" substitutionGroup="xbrli:item" />
<element name="MergerAgreementMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_MergerAgreementMember" substitutionGroup="xbrli:item" />
<element name="AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_AccountingPoliciesTable" substitutionGroup="xbrldt:hypercubeItem" />
<element name="AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_AccountingPoliciesLineItems" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" substitutionGroup="xbrli:item" />
<element name="ReneoMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ReneoMember" substitutionGroup="xbrli:item" />
<element name="TwentyTwentyFourEquityIncentivePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_TwentyTwentyFourEquityIncentivePlanMember" substitutionGroup="xbrli:item" />
<element name="TwentyTwentyFourEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" substitutionGroup="xbrli:item" />
<element name="CommonStockSharesConvertibleConversionRatio" type="xbrli:pureItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_CommonStockSharesConvertibleConversionRatio" substitutionGroup="xbrli:item" />
<element name="StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" substitutionGroup="xbrli:item" />
<element name="GrossProceedsFromIssuanceOfCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_GrossProceedsFromIssuanceOfCommonStock" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" substitutionGroup="xbrli:item" />
<element name="DebtInstrumentAccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_DebtInstrumentAccruedInterest" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="SegmentReportingCODMIndividualTitleAndPositionOrGroupName" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" substitutionGroup="xbrli:item" />
<element name="ClinicalResearchSegmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ClinicalResearchSegmentMember" substitutionGroup="xbrli:item" />
<element name="DirectProgramExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_DirectProgramExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="IndirectProgramExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_IndirectProgramExpense" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="WorkforceSalariesAndBenefits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_WorkforceSalariesAndBenefits" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GeneralCorporateExpenses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_GeneralCorporateExpenses" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="AdjustmentsAndReconcilingItems" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AdjustmentsAndReconcilingItems" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="ConvertiblePromissoryNoteMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ConvertiblePromissoryNoteMember" substitutionGroup="xbrli:item" />
<element name="UnvestedRestrictedStockUnitsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_UnvestedRestrictedStockUnitsMember" substitutionGroup="xbrli:item" />
<element name="UnreleasedRestrictedStockUnitsAssumedInMergerMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" substitutionGroup="xbrli:item" />
<element name="PrepaidClinicalTrials" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_PrepaidClinicalTrials" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="LabEquipmentMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_LabEquipmentMember" substitutionGroup="xbrli:item" />
<element name="ComputerHardwareAndSoftwareMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_ComputerHardwareAndSoftwareMember" substitutionGroup="xbrli:item" />
<element name="AccruedManufacturingExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_AccruedManufacturingExpense" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedClinicalTrialCosts" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_AccruedClinicalTrialCosts" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="PreferredStockSharesDesignated" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_PreferredStockSharesDesignated" substitutionGroup="xbrli:item" />
<element name="Non-EmployeesMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_Non-EmployeesMember" substitutionGroup="xbrli:item" />
<element name="Performance-BasedStockOptionsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_Performance-BasedStockOptionsMember" substitutionGroup="xbrli:item" />
<element name="UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" substitutionGroup="xbrli:item" />
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" type="dtr-types:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" substitutionGroup="xbrli:item" />
<element name="UnamortizedCompensationCost" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_UnamortizedCompensationCost" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="RestrictedStockAndRestrictedStockUnitsRSUsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" substitutionGroup="xbrli:item" />
<element name="DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" substitutionGroup="xbrli:item" />
<element name="DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="TaxCreditCarryforwardExpirationPeriod" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_TaxCreditCarryforwardExpirationPeriod" substitutionGroup="xbrli:item" />
<element name="AdditionalProceedsFromAcquisition" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_AdditionalProceedsFromAcquisition" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="GainLossOnConversionOfDebt" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_GainLossOnConversionOfDebt" substitutionGroup="xbrli:item" xbrli:balance="credit" />
<element name="AccruedInterest" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_AccruedInterest" substitutionGroup="xbrli:item" xbrli:balance="debit" />
<element name="PercentageOfNumberOfOutstandingSharesOfCommonStock" type="dtr-types:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" substitutionGroup="xbrli:item" />
<element name="IncreaseInNumberOfSharesAvailableForIssuance" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" id="okur_IncreaseInNumberOfSharesAvailableForIssuance" substitutionGroup="xbrli:item" />
<element name="SubleaseExpirationPeriod" type="xbrli:gYearMonthItemType" abstract="false" xbrli:periodType="duration" nillable="true" id="okur_SubleaseExpirationPeriod" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>okur-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-March-2025 [07:09:08] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SegmentScheduleOfSegmentReportingInformationBySegmentDetails" roleURI="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#AccruedExpensesDetails" roleURI="http://onkuretherapeutics.com/role/AccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesComponentsOfNetDeferredTaxesDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails" />
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedManufacturingExpense" xlink:label="loc_okur_AccruedManufacturingExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_okur_AccruedManufacturingExpense" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedClinicalTrialCosts" xlink:label="loc_okur_AccruedClinicalTrialCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_okur_AccruedClinicalTrialCosts" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" use="optional" order="4" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" use="optional" order="12" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" use="optional" order="14" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset" use="optional" order="17" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" use="optional" order="18" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_NetIncomeLoss" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_ShareBasedCompensation" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" use="optional" order="8" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization" use="optional" order="9" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" use="optional" order="10" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" use="optional" order="11" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts" use="optional" order="12" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-CashInterestExpense" xlink:label="loc_okur_Non-CashInterestExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_okur_Non-CashInterestExpense" use="optional" order="13" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1" use="optional" order="14" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" use="optional" order="15" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" use="optional" order="16" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts" use="optional" order="17" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" use="optional" order="18" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts" use="optional" order="19" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" use="optional" order="20" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" use="optional" order="21" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt" use="optional" order="22" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xlink:label="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" use="optional" order="23" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" use="optional" order="24" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_InterestIncomeExpenseNet" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="loc_us-gaap_InterestIncomeOperating" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_InterestAndOtherExpense" xlink:label="loc_okur_InterestAndOtherExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="loc_okur_InterestAndOtherExpense" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_OperatingIncomeLoss" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_OperatingExpenses" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense" use="optional" order="7" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" use="optional" order="5" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" use="optional" order="6" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" use="optional" order="7" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" use="optional" order="8" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" use="optional" order="3" weight="-1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" use="optional" order="5" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" use="optional" order="2" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" use="optional" order="3" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" use="optional" order="4" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" use="optional" order="5" weight="-1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xlink:label="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" use="optional" order="6" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PrepaidClinicalTrials" xlink:label="loc_okur_PrepaidClinicalTrials" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="loc_okur_PrepaidClinicalTrials" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="loc_us-gaap_PrepaidInsurance" use="optional" order="2" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent" use="optional" order="3" weight="1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" use="optional" order="1" weight="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" use="optional" order="2" weight="-1" />
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsAndReconcilingItems" xlink:label="loc_okur_AdjustmentsAndReconcilingItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating" />
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_okur_AdjustmentsAndReconcilingItems" xlink:to="loc_us-gaap_InterestIncomeOperating" use="optional" order="1" weight="1" />
</calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>okur-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-March-2025 [07:09:08] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#CoverPage" roleURI="http://onkuretherapeutics.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#OrganizationAndBusinessNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancingAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SegmentScheduleOfSegmentReportingInformationBySegmentDetails" roleURI="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails" roleURI="http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#EquityAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationStockOptionsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationSharesReservedForFutureIssuanceDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationStockOptionActivityDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConvertiblePromissoryNotesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_105" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_147" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentInformationTable_147" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1108" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1108" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1109" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1108" xlink:to="loc_dei_AddressTypeDomain_1109" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1109_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1108" xlink:to="loc_dei_AddressTypeDomain_1109_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1110" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_1109" xlink:to="loc_dei_BusinessContactMember_1110" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentType_104" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_113" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityRegistrantName_113" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_114" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityIncorporationStateCountryCode_114" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_115" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityTaxIdentificationNumber_115" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_116" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressAddressLine1_116" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_117" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressCityOrTown_117" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_118" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressStateOrProvince_118" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_119" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressPostalZipCode_119" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_120" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_CityAreaCode_120" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_LocalPhoneNumber_121" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_129" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityFilerCategory_129" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_130" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntitySmallBusiness_130" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_131" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityEmergingGrowthCompany_131" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_132" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityExTransitionPeriod_132" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_138" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityCentralIndexKey_138" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_139" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentFiscalYearFocus_139" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_140" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentFiscalPeriodFocus_140" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_141" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentFlag_141" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1106" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityPrimarySicNumber_1106" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1107" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_ContactPersonnelName_1107" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1111" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentDescription_1111" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_165" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_150" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_165" xlink:to="loc_us-gaap_AssetsAbstract_150" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_158" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_150" xlink:to="loc_us-gaap_AssetsCurrentAbstract_158" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_151" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_151" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_166" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_166" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_172" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AssetsCurrent_172" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_176" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_176" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_179" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_179" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_182" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_182" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_185" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_Assets_185" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_157" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_165" xlink:to="loc_us-gaap_StatementTable_157" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_156" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_157" xlink:to="loc_us-gaap_StatementClassOfStockAxis_156" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_170" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_156" xlink:to="loc_us-gaap_ClassOfStockDomain_170" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_170_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_156" xlink:to="loc_us-gaap_ClassOfStockDomain_170_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_okur_ConvertiblePreferredStockSeriesCMember_152" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_okur_ConvertiblePreferredStockSeriesCMember_152" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_161" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_us-gaap_CommonClassAMember_161" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_167" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_us-gaap_CommonClassBMember_167" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_165" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_154" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_154" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_153" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_AccountsPayableCurrent_153" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_162" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_162" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_168" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_168" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_173" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_LiabilitiesCurrent_173" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_183" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_Liabilities_183" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_163" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_CommitmentsAndContingencies_163" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_169" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_169" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_174" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_StockholdersEquityAbstract_174" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_155" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_PreferredStockValue_155" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_164" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_CommonStockValue_164" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_171" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_AdditionalPaidInCapital_171" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_181" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_StockholdersEquity_181" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_184" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_184" use="optional" order="33" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_194" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_StatementTable_191" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_190" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementClassOfStockAxis_190" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_196" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_196" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_196_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_196_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_189" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_196" xlink:to="loc_us-gaap_CommonClassAMember_189" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_193" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_196" xlink:to="loc_us-gaap_CommonClassBMember_193" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockParOrStatedValuePerShare" xlink:label="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare_188" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare_188" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesAuthorized" xlink:label="loc_okur_ConvertiblePreferredStockSharesAuthorized_192" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesAuthorized_192" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesIssued" xlink:label="loc_okur_ConvertiblePreferredStockSharesIssued_195" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesIssued_195" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesOutstanding" xlink:label="loc_okur_ConvertiblePreferredStockSharesOutstanding_197" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesOutstanding_197" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockLiquidationPreferenceValue" xlink:label="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue_198" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue_198" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_199" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_199" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_200" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_200" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_201" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesIssued_201" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_202" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_202" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_203" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_203" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_204" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_204" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_205" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesIssued_205" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_206" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_206" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_250" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_234" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_234" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_239" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockholdersEquity_239" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_244" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_SharesOutstanding_244" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_249" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_249" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_252" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_252" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing_253" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing_253" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodValueConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing_254" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing_254" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_255" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_255" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_256" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_256" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts_257" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts_257" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares_258" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares_258" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue_259" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue_259" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_260" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_260" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_261" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_261" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_262" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_262" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xlink:label="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization_263" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization_263" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_264" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_264" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_265" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_NetIncomeLoss_265" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_232" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_StatementTable_232" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_235" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_235" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_229" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_235" xlink:to="loc_us-gaap_EquityComponentDomain_229" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_229_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_235" xlink:to="loc_us-gaap_EquityComponentDomain_229_default" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_230" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_PreferredStockMember_230" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_237" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_CommonStockMember_237" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_242" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_242" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_248" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_RetainedEarningsMember_248" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_240" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_240" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_240" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_240" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233_default" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClassACommonStockAndSeriesCPreferredStockMember" xlink:label="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember_228" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" xlink:to="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember_228" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_246" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_StatementClassOfStockAxis_246" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_246" xlink:to="loc_us-gaap_ClassOfStockDomain_245" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_246" xlink:to="loc_us-gaap_ClassOfStockDomain_245_default" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_231" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_231" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_238" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_CommonClassAMember_238" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_243" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_CommonClassBMember_243" use="optional" order="37" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_275" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_273" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_275" xlink:to="loc_us-gaap_StatementTable_273" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_274" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_273" xlink:to="loc_us-gaap_StatementClassOfStockAxis_274" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_274" xlink:to="loc_us-gaap_ClassOfStockDomain_276" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_274" xlink:to="loc_us-gaap_ClassOfStockDomain_276_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_272" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_276" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_272" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuanceCostNet" xlink:label="loc_okur_StockIssuanceCostNet_271" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_275" xlink:to="loc_okur_StockIssuanceCostNet_271" use="optional" order="6" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_297" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_283" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_NetIncomeLoss_283" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_289" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_ShareBasedCompensation_289" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_298" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_298" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_310" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_310" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_314" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_314" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-CashInterestExpense" xlink:label="loc_okur_Non-CashInterestExpense_318" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_okur_Non-CashInterestExpense_318" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_322" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_322" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_282" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_282" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_294" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_294" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_303" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_303" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_StatementTable_284" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_288" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_288" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_288" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_288" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285_default" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_302" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" xlink:to="loc_us-gaap_PrivatePlacementMember_302" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_286" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_286" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_290" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_290" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_299" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_299" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_306" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_306" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts_311" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts_311" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_315" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_315" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_319" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_319" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_323" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_323" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xlink:label="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable_327" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable_327" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_330" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_330" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_332" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_332" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_312" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_312" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_280" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_280" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_292" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_292" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfSeriesCPreferredStock" xlink:label="loc_okur_ConversionOfSeriesCPreferredStock_301" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConversionOfSeriesCPreferredStock_301" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfConvertibleNotePayable" xlink:label="loc_okur_ConversionOfConvertibleNotePayable_308" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConversionOfConvertibleNotePayable_308" use="optional" order="41" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization_313" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization_313" use="optional" order="42" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization_317" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization_317" use="optional" order="43" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xlink:label="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable_321" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable_321" use="optional" order="44" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable_325" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable_325" use="optional" order="45" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger_328" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger_328" use="optional" order="46" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_484" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_482" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_StatementTable_482" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_480" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_482" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_480" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_480" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_480" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_479" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" xlink:to="loc_okur_MergerAgreementMember_479" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_478" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_478" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_483" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_483" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_485" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_485" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_486" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_486" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesLineItems" xlink:label="loc_okur_AccountingPoliciesLineItems_503" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesTable" xlink:label="loc_okur_AccountingPoliciesTable_497" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_okur_AccountingPoliciesTable_497" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_494" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" xlink:to="loc_us-gaap_TypeOfAdoptionMember_494" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_494_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" xlink:to="loc_us-gaap_TypeOfAdoptionMember_494_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_496" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_496" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_501" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_srt_RangeAxis_501" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_493" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_501" xlink:to="loc_srt_RangeMember_493" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_493_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_501" xlink:to="loc_srt_RangeMember_493_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_490" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_493" xlink:to="loc_srt_MinimumMember_490" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_499" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_493" xlink:to="loc_srt_MaximumMember_499" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_491" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_NumberOfOperatingSegments_491" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_500" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_500" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_502" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_502" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_504" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_504" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_505" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_505" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_506" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_506" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_507" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_507" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm_508" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm_508" use="optional" order="21" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_561" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_542" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_542" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_552" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542" xlink:to="loc_us-gaap_ClassOfStockDomain_552" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_552_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542" xlink:to="loc_us-gaap_ClassOfStockDomain_552_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_539" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_552" xlink:to="loc_us-gaap_CommonClassAMember_539" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_547" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_552" xlink:to="loc_us-gaap_CommonClassBMember_547" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_549" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_549" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_544" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_549" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_544" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_544_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_549" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_544_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_534" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_544" xlink:to="loc_us-gaap_ConvertibleDebtMember_534" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_551" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_551" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_537" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551" xlink:to="loc_us-gaap_EquityComponentDomain_537" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_537_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551" xlink:to="loc_us-gaap_EquityComponentDomain_537_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_538" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_537" xlink:to="loc_us-gaap_CommonStockMember_538" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_555" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_555" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_543" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" xlink:to="loc_okur_MergerAgreementMember_543" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_557" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_dei_LegalEntityAxis_557" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_553" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_553_default" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReneoMember" xlink:label="loc_okur_ReneoMember_536" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_okur_ReneoMember_536" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_559" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_PlanNameAxis_559" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_535" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_559" xlink:to="loc_us-gaap_PlanNameDomain_535" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_535_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_559" xlink:to="loc_us-gaap_PlanNameDomain_535_default" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_533" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_535" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_533" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_546" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_535" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_546" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_540" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_540" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockSharesConvertibleConversionRatio" xlink:label="loc_okur_CommonStockSharesConvertibleConversionRatio_548" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_CommonStockSharesConvertibleConversionRatio_548" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_550" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_550" use="optional" order="30" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xlink:label="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding_554" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding_554" use="optional" order="31" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_556" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_556" use="optional" order="32" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_558" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_558" use="optional" order="33" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_560" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_560" use="optional" order="34" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_562" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_562" use="optional" order="35" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_okur_GrossProceedsFromIssuanceOfCommonStock_563" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_GrossProceedsFromIssuanceOfCommonStock_563" use="optional" order="36" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_564" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_564" use="optional" order="37" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_565" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_565" use="optional" order="38" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:label="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_566" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_566" use="optional" order="39" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_568" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_568" use="optional" order="40" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DebtInstrumentAccruedInterest" xlink:label="loc_okur_DebtInstrumentAccruedInterest_569" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_DebtInstrumentAccruedInterest_569" use="optional" order="41" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_596" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1121" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xlink:to="loc_srt_TitleOfIndividualAxis_1121" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_1121" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_1121" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_591" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_591" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_590" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_591" xlink:to="loc_us-gaap_SegmentDomain_590" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_590_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_591" xlink:to="loc_us-gaap_SegmentDomain_590_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClinicalResearchSegmentMember" xlink:label="loc_okur_ClinicalResearchSegmentMember_593" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_590" xlink:to="loc_okur_ClinicalResearchSegmentMember_593" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_594" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_OperatingExpensesAbstract_594" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DirectProgramExpense" xlink:label="loc_okur_DirectProgramExpense_588" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_DirectProgramExpense_588" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IndirectProgramExpense" xlink:label="loc_okur_IndirectProgramExpense_595" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_IndirectProgramExpense_595" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_WorkforceSalariesAndBenefits" xlink:label="loc_okur_WorkforceSalariesAndBenefits_599" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_WorkforceSalariesAndBenefits_599" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_601" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_601" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GeneralCorporateExpenses" xlink:label="loc_okur_GeneralCorporateExpenses_602" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_GeneralCorporateExpenses_602" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_InterestAndOtherExpense" xlink:label="loc_okur_InterestAndOtherExpense_603" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_InterestAndOtherExpense_603" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_592" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" xlink:to="loc_us-gaap_InterestIncomeOperating_592" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsAndReconcilingItems" xlink:label="loc_okur_AdjustmentsAndReconcilingItems_597" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" xlink:to="loc_okur_AdjustmentsAndReconcilingItems_597" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_600" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_NetIncomeLoss_600" use="optional" order="19" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_609" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_609" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_606" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_609" xlink:to="loc_us-gaap_LeaseContractualTermAxis_606" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_608" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_606" xlink:to="loc_us-gaap_LeaseContractualTermDomain_608" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_608_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_606" xlink:to="loc_us-gaap_LeaseContractualTermDomain_608_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_607" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_607" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_612" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LeaseExpirationDate1_612" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_613" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_613" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_614" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_614" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_615" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_615" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_okur_ConvertiblePreferredStockSeriesCMember_648" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_ConvertiblePreferredStockSeriesCMember_648" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteMember" xlink:label="loc_okur_ConvertiblePromissoryNoteMember_653" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_ConvertiblePromissoryNoteMember_653" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_655" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_us-gaap_EmployeeStockOptionMember_655" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsMember_656" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_UnvestedRestrictedStockUnitsMember_656" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:label="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_657" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_657" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_651" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_651" use="optional" order="10" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_669" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_662" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_StatementTable_662" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_663" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_662" xlink:to="loc_us-gaap_AwardTypeAxis_663" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_666" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_662" xlink:to="loc_srt_TitleOfIndividualAxis_666" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_666" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_666" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_660" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_660" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_665" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_665" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_667" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_667" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_670" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_670" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_672" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_672" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_673" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_673" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674" use="optional" order="14" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_LabEquipmentMember" xlink:label="loc_okur_LabEquipmentMember_733" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_okur_LabEquipmentMember_733" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_737" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_737" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ComputerHardwareAndSoftwareMember" xlink:label="loc_okur_ComputerHardwareAndSoftwareMember_739" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_okur_ComputerHardwareAndSoftwareMember_739" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_740" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_740" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_730" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_730" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_735" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_735" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_738" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_738" use="optional" order="11" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_769" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_758" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_758" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_753" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_us-gaap_StatementClassOfStockAxis_753" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_768" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_753" xlink:to="loc_us-gaap_ClassOfStockDomain_768" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_768_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_753" xlink:to="loc_us-gaap_ClassOfStockDomain_768_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_756" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonClassAMember_756" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_763" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonClassBMember_763" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_772" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_772" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_774" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonStockMember_774" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_761" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_761" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_761" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_761" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_srt_RangeAxis_765" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_757" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_765" xlink:to="loc_srt_RangeMember_757" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_757_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_765" xlink:to="loc_srt_RangeMember_757_default" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_755" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_757" xlink:to="loc_srt_MinimumMember_755" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_760" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_760" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_764" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_764" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_775" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_775" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_776" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_776" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesAuthorized" xlink:label="loc_okur_ConvertiblePreferredStockSharesAuthorized_777" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesAuthorized_777" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesIssued" xlink:label="loc_okur_ConvertiblePreferredStockSharesIssued_778" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesIssued_778" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesOutstanding" xlink:label="loc_okur_ConvertiblePreferredStockSharesOutstanding_779" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesOutstanding_779" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_781" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_Dividends_781" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_783" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_783" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaap_PreferredStockDividendPaymentTerms_784" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockDividendPaymentTerms_784" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_785" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_785" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_786" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockSharesIssued_786" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PreferredStockSharesDesignated" xlink:label="loc_okur_PreferredStockSharesDesignated_787" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_PreferredStockSharesDesignated_787" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_789" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_789" use="optional" order="29" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_790" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_790" use="optional" order="30" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_798" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_PlanNameAxis_798" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_795" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_798" xlink:to="loc_us-gaap_PlanNameDomain_795" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_795_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_798" xlink:to="loc_us-gaap_PlanNameDomain_795_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_793" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_795" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_793" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_801" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_795" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_801" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_803" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_StatementClassOfStockAxis_803" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_805" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_803" xlink:to="loc_us-gaap_ClassOfStockDomain_805" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_805_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_803" xlink:to="loc_us-gaap_ClassOfStockDomain_805_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_796" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_805" xlink:to="loc_us-gaap_CommonClassAMember_796" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_806" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_806" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_806" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_806" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800_default" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_797" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" xlink:to="loc_okur_MergerAgreementMember_797" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_802" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_802" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:label="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_804" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_804" use="optional" order="17" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_816" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_us-gaap_PlanNameAxis_816" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_816" xlink:to="loc_us-gaap_PlanNameDomain_813" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_816" xlink:to="loc_us-gaap_PlanNameDomain_813_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_810" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_813" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_810" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_821" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_srt_TitleOfIndividualAxis_821" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_821" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_821" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-EmployeesMember" xlink:label="loc_okur_Non-EmployeesMember_818" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" xlink:to="loc_okur_Non-EmployeesMember_818" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_824" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_srt_RangeAxis_824" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_815" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_815_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_814" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MinimumMember_814" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_820" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MaximumMember_820" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_827" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_us-gaap_AwardTypeAxis_827" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823_default" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_826" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" xlink:to="loc_us-gaap_EmployeeStockOptionMember_826" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Performance-BasedStockOptionsMember" xlink:label="loc_okur_Performance-BasedStockOptionsMember_829" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" xlink:to="loc_okur_Performance-BasedStockOptionsMember_829" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_811" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_811" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_819" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_819" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_822" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_822" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_828" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_828" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_831" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_831" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_832" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_832" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_843" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_839" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_843" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_839" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_836" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_839" xlink:to="loc_us-gaap_PlanNameAxis_836" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_837" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_836" xlink:to="loc_us-gaap_PlanNameDomain_837" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_837_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_836" xlink:to="loc_us-gaap_PlanNameDomain_837_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember_835" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember_835" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:label="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_840" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_840" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_842" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_842" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_845" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_845" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_841" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_839" xlink:to="loc_us-gaap_AwardTypeAxis_841" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_841" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_841" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844_default" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_846" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" xlink:to="loc_us-gaap_EmployeeStockOptionMember_846" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_838" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_843" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_838" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_851" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_851" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization_857" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization_857" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_869" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_869" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_872" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_872" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_875" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_875" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_881" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_881" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_854" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_854" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice_858" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice_858" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_866" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_866" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_870" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_870" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_873" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_873" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_876" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_876" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_882" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_882" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_849" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_849" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_855" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_855" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_863" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_863" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_867" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_867" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_871" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_871" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_877" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_877" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_899" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_PlanNameAxis_899" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_894" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_899" xlink:to="loc_us-gaap_PlanNameDomain_894" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_894_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_899" xlink:to="loc_us-gaap_PlanNameDomain_894_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_904" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_AwardTypeAxis_904" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_904" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_904" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_910" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" xlink:to="loc_us-gaap_RestrictedStockMember_910" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_913" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_913" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_908" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_908" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_898" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" xlink:to="loc_okur_MergerAgreementMember_898" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_911" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_911" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_896" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_911" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_896" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_896_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_911" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_896_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_897" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_896" xlink:to="loc_us-gaap_SubsequentEventMember_897" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_914" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_VestingAxis_914" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_895" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_914" xlink:to="loc_us-gaap_VestingDomain_895" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_895_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_914" xlink:to="loc_us-gaap_VestingDomain_895_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_900" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_895" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_900" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_905" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_895" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_905" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_893" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_893" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_903" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_903" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_906" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_906" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_909" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_909" use="optional" order="26" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_912" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_912" use="optional" order="27" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_915" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_915" use="optional" order="28" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnamortizedCompensationCost" xlink:label="loc_okur_UnamortizedCompensationCost_917" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_okur_UnamortizedCompensationCost_917" use="optional" order="29" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_928" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_928" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_931" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_931" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_936" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_936" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_924" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xlink:to="loc_us-gaap_PlanNameAxis_924" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_922" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_924" xlink:to="loc_us-gaap_PlanNameDomain_922" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_922_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_924" xlink:to="loc_us-gaap_PlanNameDomain_922_default" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_929" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xlink:to="loc_us-gaap_AwardTypeAxis_929" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_929" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_929" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xlink:label="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember_935" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" xlink:to="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember_935" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_926" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_926" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_934" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_934" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_937" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_937" use="optional" order="18" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_950" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_950" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_951" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_950" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_951" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_951_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_950" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_951_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_954" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_954" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_956" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_951" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_956" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_953" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_953" use="optional" order="7" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_962" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xlink:to="loc_us-gaap_PlanNameAxis_962" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_961" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_962" xlink:to="loc_us-gaap_PlanNameDomain_961" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_961_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_962" xlink:to="loc_us-gaap_PlanNameDomain_961_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_964" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xlink:to="loc_us-gaap_AwardTypeAxis_964" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965_default" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_967" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_967" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_960" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_960" use="optional" order="9" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1017" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1017" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1015" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1017" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1015" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1018" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1015" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1018" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1018_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1015" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1018_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1019" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1018" xlink:to="loc_us-gaap_DomesticCountryMember_1019" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xlink:label="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember_1026" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1018" xlink:to="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember_1026" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1021" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1021" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1025" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1025" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xlink:label="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod_1027" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod_1027" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1029" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1029" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_okur_TaxCreditCarryforwardExpirationPeriod_1030" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_okur_TaxCreditCarryforwardExpirationPeriod_1030" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1035" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1035" use="optional" order="12" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1042" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1042" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1043" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1042" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1043" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1040" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1043" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1040" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1040_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1043" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1040_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_1038" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1040" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_1038" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1046" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1042" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1046" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1039" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1046" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1039" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1039_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1046" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1039_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1044" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1039" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1044" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1045" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_SeveranceCosts1_1045" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_1047" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_1047" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1049" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1049" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1050" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1050" use="optional" order="13" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1069" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1063" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1063" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1062" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1063" xlink:to="loc_us-gaap_CreditFacilityAxis_1062" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1064" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_1062" xlink:to="loc_us-gaap_CreditFacilityDomain_1064" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1064_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_1062" xlink:to="loc_us-gaap_CreditFacilityDomain_1064_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1061" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_1064" xlink:to="loc_us-gaap_ConvertibleDebtMember_1061" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1067" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1063" xlink:to="loc_srt_RangeAxis_1067" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1059" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1067" xlink:to="loc_srt_RangeMember_1059" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1059_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1067" xlink:to="loc_srt_RangeMember_1059_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1060" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1060" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_1068" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_ShortTermBorrowings_1068" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdditionalProceedsFromAcquisition" xlink:label="loc_okur_AdditionalProceedsFromAcquisition_1070" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_AdditionalProceedsFromAcquisition_1070" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1071" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1071" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1072" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1072" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1073" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1073" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GainLossOnConversionOfDebt" xlink:label="loc_okur_GainLossOnConversionOfDebt_1074" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_GainLossOnConversionOfDebt_1074" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedInterest" xlink:label="loc_okur_AccruedInterest_1075" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_AccruedInterest_1075" use="optional" order="16" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1101" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1089" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_us-gaap_SubsequentEventTable_1089" xbrldt:contextElement="segment" xbrldt:closed="true" use="optional" order="1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1088" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_srt_RangeAxis_1088" use="optional" order="2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1085" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1088" xlink:to="loc_srt_RangeMember_1085" use="optional" order="3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1085_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1088" xlink:to="loc_srt_RangeMember_1085_default" use="optional" order="4" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1083" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1085" xlink:to="loc_srt_MaximumMember_1083" use="optional" order="5" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1092" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1092" use="optional" order="6" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1082" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1092" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1082" use="optional" order="7" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1082_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1092" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1082_default" use="optional" order="8" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1086" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1082" xlink:to="loc_us-gaap_SubsequentEventMember_1086" use="optional" order="9" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" use="optional" order="10" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" use="optional" order="11" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087_default" use="optional" order="12" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1079" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" xlink:to="loc_us-gaap_EmployeeStockMember_1079" use="optional" order="13" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1097" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_PlanNameAxis_1097" use="optional" order="14" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1097" xlink:to="loc_us-gaap_PlanNameDomain_1081" use="optional" order="15" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1097" xlink:to="loc_us-gaap_PlanNameDomain_1081_default" use="optional" order="16" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_1078" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1081" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_1078" use="optional" order="17" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1099" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1099" use="optional" order="18" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1094" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1094" use="optional" order="19" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1094_default" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1094_default" use="optional" order="20" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1084" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1094" xlink:to="loc_us-gaap_CommonClassAMember_1084" use="optional" order="21" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1080" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1080" use="optional" order="22" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xlink:label="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock_1091" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock_1091" use="optional" order="23" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IncreaseInNumberOfSharesAvailableForIssuance" xlink:label="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance_1093" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance_1093" use="optional" order="24" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaap_PaymentsForRent_1098" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_us-gaap_PaymentsForRent_1098" use="optional" order="25" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_SubleaseExpirationPeriod" xlink:label="loc_okur_SubleaseExpirationPeriod_1100" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_SubleaseExpirationPeriod_1100" use="optional" order="26" />
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClinicalResearchSegmentMember" xlink:label="loc_okur_ClinicalResearchSegmentMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="loc_okur_ClinicalResearchSegmentMember" order="1.0" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>okur-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-March-2025 [07:09:08] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CoverAbstract" xml:lang="en-US">Cover [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationTable" xml:lang="en-US">Document Information [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentInformationLineItems" xml:lang="en-US">Document Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityTaxIdentificationNumber" xml:lang="en-US">Entity Tax Identification Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressAddressLine1" xml:lang="en-US">Entity Address, Address Line One</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressCityOrTown" xml:lang="en-US">Entity Address, City or Town</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressStateOrProvince" xml:lang="en-US">Entity Address, State or Province</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressPostalZipCode" xml:lang="en-US">Entity Address, Postal Zip Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_CityAreaCode" xml:lang="en-US">City Area Code</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LocalPhoneNumber" xml:lang="en-US">Local Phone Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntitySmallBusiness" xml:lang="en-US">Entity Small Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityEmergingGrowthCompany" xml:lang="en-US">Entity Emerging Growth Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityExTransitionPeriod" xml:lang="en-US">Entity Ex Transition Period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityPrimarySicNumber" xml:lang="en-US">Entity Primary SIC Number</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPrimarySicNumber" xlink:to="lab_dei_EntityPrimarySicNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_ContactPersonnelName" xml:lang="en-US">Contact Personnel Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_ContactPersonnelName" xlink:to="lab_dei_ContactPersonnelName" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AmendmentDescription" xml:lang="en-US">Amendment Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xml:lang="en-US">Entity Addresses, Address Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_AddressTypeDomain" xml:lang="en-US">Address Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_BusinessContactMember" xml:lang="en-US">Business Contact [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_BusinessContactMember" xlink:to="lab_dei_BusinessContactMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_okur_ConvertiblePreferredStockSeriesCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockSeriesCMember" xml:lang="en-US">Convertible Preferred Stock Series C [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockSeriesCMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_okur_ConvertiblePreferredStockSeriesCMember" xml:lang="en-US">Convertible Series C Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockSeriesCMember" xlink:to="lab_okur_ConvertiblePreferredStockSeriesCMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockSeriesCMember" xml:lang="en-US">Convertible preferred stock series C.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Common Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassAMember" xml:lang="en-US">Class A Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Common Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonClassBMember" xml:lang="en-US">Class B Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassBMember" xlink:to="lab_us-gaap_CommonClassBMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsAbstract" xml:lang="en-US">Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents carrying amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating Lease, Right-of-Use Asset</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xml:lang="en-US">Operating lease right-of-use asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other Assets, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating Lease, Liability, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Operating lease liabilities, current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Current operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xml:lang="en-US">Less: Current portion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Operating lease liability, net of current portion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Long-term operating lease liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xml:lang="en-US">Noncurrent operating lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 14)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xml:lang="en-US">Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xml:lang="en-US">Convertible preferred stock, Series C, $0.0001 par value; no shares and 7,404,919 shares authorized; no shares and 6,840,620 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively; liquidation preference of $195,823 as of December 31, 2023</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:to="lab_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity (deficit):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2024</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockValue" xml:lang="en-US">Common stocks</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Equity, Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity (deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_StockholdersEquity" xml:lang="en-US">Ending Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockParOrStatedValuePerShare" xlink:label="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockParOrStatedValuePerShare" xml:lang="en-US">Convertible Preferred Stock Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockParOrStatedValuePerShare" xml:lang="en-US">Convertible preferred stock par or stated value per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare" xlink:to="lab_okur_ConvertiblePreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockParOrStatedValuePerShare" xml:lang="en-US">Convertible preferred stock par or stated value per share.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesAuthorized" xlink:label="loc_okur_ConvertiblePreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockSharesAuthorized" xml:lang="en-US">Convertible Preferred Stock Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockSharesAuthorized" xml:lang="en-US">Convertible preferred stock shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockSharesAuthorized" xlink:to="lab_okur_ConvertiblePreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockSharesAuthorized" xml:lang="en-US">Convertible preferred stock shares authorized.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesIssued" xlink:label="loc_okur_ConvertiblePreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockSharesIssued" xml:lang="en-US">Convertible Preferred Stock Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockSharesIssued" xml:lang="en-US">Convertible preferred stock shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockSharesIssued" xlink:to="lab_okur_ConvertiblePreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockSharesIssued" xml:lang="en-US">Convertible preferred stock shares issued.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesOutstanding" xlink:label="loc_okur_ConvertiblePreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockSharesOutstanding" xml:lang="en-US">Convertible Preferred Stock Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockSharesOutstanding" xml:lang="en-US">Convertible preferred stock shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockSharesOutstanding" xlink:to="lab_okur_ConvertiblePreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockSharesOutstanding" xml:lang="en-US">Convertible preferred stock shares outstanding.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockLiquidationPreferenceValue" xlink:label="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePreferredStockLiquidationPreferenceValue" xml:lang="en-US">Convertible Preferred Stock Liquidation Preference Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePreferredStockLiquidationPreferenceValue" xml:lang="en-US">Convertible preferred stock liquidation preference value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue" xlink:to="lab_okur_ConvertiblePreferredStockLiquidationPreferenceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePreferredStockLiquidationPreferenceValue" xml:lang="en-US">Convertible preferred stock liquidation preference value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Convertible Preferred Stock Beginning Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Convertible Preferred Stock Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, Par value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementAbstract" xml:lang="en-US">Income Statement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Operating Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Loss from operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income and (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeOperating" xml:lang="en-US">Interest Income, Operating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_InterestIncomeOperating" xml:lang="en-US">Interest income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_InterestIncomeOperating" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOperating" xlink:to="lab_us-gaap_InterestIncomeOperating" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_InterestAndOtherExpense" xlink:label="loc_okur_InterestAndOtherExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_InterestAndOtherExpense" xml:lang="en-US">Interest And Other Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_okur_InterestAndOtherExpense" xml:lang="en-US">Interest and other expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_InterestAndOtherExpense" xml:lang="en-US">Interest and other expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_InterestAndOtherExpense" xlink:to="lab_okur_InterestAndOtherExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_InterestAndOtherExpense" xml:lang="en-US">Interest and other expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Interest Income (Expense), Operating</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_InterestIncomeExpenseNet" xml:lang="en-US">Total other income and (expense)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss and comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">NetIncomeLoss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Earnings Per Share, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareBasic" xml:lang="en-US">Net loss per share attributable to common stockholders, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Earnings Per Share, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xml:lang="en-US">Weighted-average shares used in computing net loss per share, basic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xml:lang="en-US">Weighted-average shares used in computing net loss per share, diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xml:lang="en-US">Sale of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xml:lang="en-US">Sale of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClassACommonStockAndSeriesCPreferredStockMember" xlink:label="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ClassACommonStockAndSeriesCPreferredStockMember" xml:lang="en-US">Class A Common Stock And Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ClassACommonStockAndSeriesCPreferredStockMember" xml:lang="en-US">Class A Common Stock and Series C Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember" xlink:to="lab_okur_ClassACommonStockAndSeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ClassACommonStockAndSeriesCPreferredStockMember" xml:lang="en-US">Class A common stock and series C preferred stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Beginning Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_SharesOutstanding" xml:lang="en-US">Ending Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xml:lang="en-US">Stock Issued During Period, Shares, Concurrent Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xml:lang="en-US">Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xlink:to="lab_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xml:lang="en-US">Stock issued during period, shares, concurrent financing.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodValueConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuedDuringPeriodValueConcurrentFinancing" xml:lang="en-US">Stock Issued During Period Value Concurrent Financing</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuedDuringPeriodValueConcurrentFinancing" xml:lang="en-US">Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing" xlink:to="lab_okur_StockIssuedDuringPeriodValueConcurrentFinancing" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuedDuringPeriodValueConcurrentFinancing" xml:lang="en-US">Stock issued during period value concurrent financing.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issuance of stock (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issuance of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xml:lang="en-US">Adjustments to Additional Paid in Capital Reverse Recapitalization Transaction Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xml:lang="en-US">Reverse recapitalization transaction costs of OnKure</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xlink:to="lab_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xml:lang="en-US">Adjustments to additional paid in capital reverse recapitalization transaction costs.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xml:lang="en-US">Stock Issued During Period, Conversion Of Convertible Promissory Notes, Shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xml:lang="en-US">Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xlink:to="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xml:lang="en-US">Stock issued during period, conversion of convertible promissory notes, shares.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xml:lang="en-US">Stock Issued During Period, Conversion of Convertible Promissory Notes, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xml:lang="en-US">Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xlink:to="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xml:lang="en-US">Stock issued during period, conversion of convertible promissory notes, value.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xml:lang="en-US">Issuance of Class A common stock for the settlement of restricted stock units (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issuance of Class A Common Stock from the exercise of stock options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xml:lang="en-US">Issuance of Class A Common Stock from the exercise of stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xlink:label="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xml:lang="en-US">Adjustment for fractional shares in the reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xlink:to="lab_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xml:lang="en-US">Adjustment for fractional shares in the reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeriesCPreferredStockMember" xml:lang="en-US">Series C Preferred Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeriesCPreferredStockMember" xlink:to="lab_us-gaap_SeriesCPreferredStockMember" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuanceCostNet" xlink:label="loc_okur_StockIssuanceCostNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuanceCostNet" xml:lang="en-US">Stock Issuance Cost Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuanceCostNet" xml:lang="en-US">Stock issuance cost net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuanceCostNet" xlink:to="lab_okur_StockIssuanceCostNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuanceCostNet" xml:lang="en-US">Stock issuance cost net.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrivatePlacementMember" xml:lang="en-US">Private Placement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xml:lang="en-US">Amortization of right-of-use asset - operating</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of Debt Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xml:lang="en-US">Amortization of debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-CashInterestExpense" xlink:label="loc_okur_Non-CashInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_Non-CashInterestExpense" xml:lang="en-US">Non-cash Interest Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_Non-CashInterestExpense" xml:lang="en-US">Non-cash interest expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_Non-CashInterestExpense" xlink:to="lab_okur_Non-CashInterestExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_Non-CashInterestExpense" xml:lang="en-US">Non-cash interest expense.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Gain (Loss) on Disposition of Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xml:lang="en-US">Loss on sales of available-for-sale securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Change in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid and other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xml:lang="en-US">Accounts payable, accrued and other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xml:lang="en-US">Lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xml:lang="en-US">Proceeds from sales of marketable securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xml:lang="en-US">Proceeds from the issuance of common stock in Concurrent Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfPrivatePlacement" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payments of Stock Issuance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xml:lang="en-US">Payment of issuance costs associated with the Concurrent Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xml:lang="en-US">Proceeds from Sale of Interest in Corporate Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xml:lang="en-US">Cash acquired in connection with the reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PaymentOfReverseRecapitalizationTransactionCosts" xml:lang="en-US">Payment of reverse recapitalization transaction costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_okur_PaymentOfReverseRecapitalizationTransactionCosts" xml:lang="en-US">Payment of reverse recapitalization transaction costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts" xlink:to="lab_okur_PaymentOfReverseRecapitalizationTransactionCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PaymentOfReverseRecapitalizationTransactionCosts" xml:lang="en-US">Payment of reverse recapitalization transaction costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from Issuance of Convertible Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xml:lang="en-US">Proceeds from the issuance of Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xml:lang="en-US">Payments for Repurchase of Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xml:lang="en-US">Payment of issuance costs associated with the issuance of Convertible Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from Convertible Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xml:lang="en-US">Proceeds from issuance of convertible notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xlink:label="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xml:lang="en-US">Payment of Issuance Costs Associated with the Issuance of Convertible Notes Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xml:lang="en-US">Payment of issuance costs associated with the issuance of convertible notes payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xlink:to="lab_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xml:lang="en-US">Payment of issuance costs associated with the issuance of convertible
 notes payable.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xml:lang="en-US">Proceeds from the issuance of common stock in connection with equity plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xml:lang="en-US">Net increase in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xml:lang="en-US">Cash and cash equivalents, end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xml:lang="en-US">Supplemental disclosure of noncash financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xml:lang="en-US">Right-of-use asset obtained in exchange for new operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of Stock, Amount Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Issuance of Series C Preferred Stock conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConversionOfStockAmountIssued1" xml:lang="en-US">Conversion of stock amount issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockAmountIssued1" xlink:to="lab_us-gaap_ConversionOfStockAmountIssued1" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfSeriesCPreferredStock" xlink:label="loc_okur_ConversionOfSeriesCPreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConversionOfSeriesCPreferredStock" xml:lang="en-US">Conversion of Series C Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConversionOfSeriesCPreferredStock" xml:lang="en-US">Conversion of Series C Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConversionOfSeriesCPreferredStock" xlink:to="lab_okur_ConversionOfSeriesCPreferredStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConversionOfSeriesCPreferredStock" xml:lang="en-US">Conversion of series C preferred stock.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfConvertibleNotePayable" xlink:label="loc_okur_ConversionOfConvertibleNotePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConversionOfConvertibleNotePayable" xml:lang="en-US">Conversion of Convertible Note Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConversionOfConvertibleNotePayable" xml:lang="en-US">Conversion of convertible note payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConversionOfConvertibleNotePayable" xlink:to="lab_okur_ConversionOfConvertibleNotePayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConversionOfConvertibleNotePayable" xml:lang="en-US">Conversion of convertible note payable.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Assets Acquired in Connection with the Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Assets acquired in connection with the reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xlink:to="lab_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Assets acquired in connection with the reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Other Liabilities Assumed in Connection with the Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Other liabilities assumed in connection with the reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xlink:to="lab_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xml:lang="en-US">Other liabilities assumed in connection with the reverse recapitalization.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xlink:label="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xml:lang="en-US">Reverse Recapitalization Transaction Costs Included in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xml:lang="en-US">Reverse recapitalization transaction costs included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xlink:to="lab_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xml:lang="en-US">Reverse recapitalization transaction costs included in accounts payable.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xml:lang="en-US">Concurrent Financing Issuance Costs Included in Accounts Payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xml:lang="en-US">Concurrent Financing issuance costs included in accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xlink:to="lab_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xml:lang="en-US">Concurrent financing issuance costs included in accounts payable.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xml:lang="en-US">Concurrent Financing Issuance Costs Paid by Reneo Prior to Merger</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xml:lang="en-US">Concurrent Financing issuance costs paid by Reneo prior to Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xlink:to="lab_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xml:lang="en-US">Concurrent financing issuance costs paid by reneo prior to merger</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization and Business</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Accounting Policies [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingAbstract" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_MergerAgreementAndConcurrentFinancingAbstract" xml:lang="en-US">Merger Agreement and Concurrent Financing [Abstract)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract" xlink:to="lab_okur_MergerAgreementAndConcurrentFinancingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_MergerAgreementAndConcurrentFinancingAbstract" xml:lang="en-US">Merger agreement and concurrent financing.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingTextBlock" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_MergerAgreementAndConcurrentFinancingTextBlock" xml:lang="en-US">Merger Agreement and Concurrent Financing [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_MergerAgreementAndConcurrentFinancingTextBlock" xml:lang="en-US">Merger Agreement and Concurrent Financing</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingTextBlock" xlink:to="lab_okur_MergerAgreementAndConcurrentFinancingTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_MergerAgreementAndConcurrentFinancingTextBlock" xml:lang="en-US">Merger Agreement and Concurrent Financing [Text Block]</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segment Reporting [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeasesAbstract" xml:lang="en-US">Leases [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Lessee, Operating Leases [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xml:lang="en-US">Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value Disclosures [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xml:lang="en-US">Other Current Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsTextBlock" xlink:to="lab_us-gaap_OtherCurrentAssetsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xml:lang="en-US">Accrued Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EquityAbstract" xml:lang="en-US">Equity [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">IncomeTaxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteAbstract" xlink:label="loc_okur_ConvertiblePromissoryNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePromissoryNoteAbstract" xml:lang="en-US">Convertible Promissory Note [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePromissoryNoteAbstract" xlink:to="lab_okur_ConvertiblePromissoryNoteAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePromissoryNoteAbstract" xml:lang="en-US">Convertible promissory note.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteDisclosureTextBlock" xlink:label="loc_okur_ConvertiblePromissoryNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePromissoryNoteDisclosureTextBlock" xml:lang="en-US">Convertible Promissory Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ConvertiblePromissoryNoteDisclosureTextBlock" xml:lang="en-US">Convertible Promissory Notes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePromissoryNoteDisclosureTextBlock" xlink:to="lab_okur_ConvertiblePromissoryNoteDisclosureTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePromissoryNoteDisclosureTextBlock" xml:lang="en-US">Convertible promissory note disclosure.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xml:lang="en-US">Basis Of Presentation And Consolidation Policy [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xml:lang="en-US">Basis of Presentation and Consolidation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:to="lab_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for basis of presentation used to prepare the financial statements and principles followed in consolidating or combining the separate financial statements.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued Research And Development Expenses [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued Research and Development Expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:to="lab_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xml:lang="en-US">Accrued research and development expenses.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PatentCostsPolicyTextBlock" xlink:label="loc_okur_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PatentCostsPolicyTextBlock" xlink:to="lab_okur_PatentCostsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PatentCostsPolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for patent costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockValuationPolicyTextBlock" xlink:label="loc_okur_CommonStockValuationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Common Stock Valuation [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Common Stock Valuation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_CommonStockValuationPolicyTextBlock" xlink:to="lab_okur_CommonStockValuationPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_CommonStockValuationPolicyTextBlock" xml:lang="en-US">Common Stock Valuation.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xml:lang="en-US">Concentration of Credit Risk</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-Lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leasing - Lessee Accounting</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xml:lang="en-US">Summary of Acquired Assets and Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xml:lang="en-US">Schedule of Segment Reporting Information by Segment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule Of Lease Related Assets And Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of lease related assets and liabilities.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Lease, Cost [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xml:lang="en-US">Schedule of Lease Expense for Operating Leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xlink:label="loc_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Lease Term, Discount Rates, and Additional Information for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of lease term, discount rates, and additional information for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xlink:to="lab_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of lease term, discount rates, and additional information for operating leases.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xml:lang="en-US">Schedule of Maturities of lease liabilities by fiscal year for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Anti-Dilutive Securities Outstanding Not Included in Diluted Net Loss Per Share Calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Schedule of Other Assets [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of Property and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Payables and Accruals [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Summary of common stock reserved for future issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xml:lang="en-US">Tabular disclosure of common shares reserved for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Summary of the Company's stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Summary of weighted-average assumptions to determine the fair value of the employee stock option</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xml:lang="en-US">Summary of RSU and RSA activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Summary of Non-cash stock-based compensation expense recorded</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Summary of components of income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Components of net deferred taxes asset and liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xml:lang="en-US">Business Acquisition [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_MergerAgreementMember" xml:lang="en-US">Merger Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_MergerAgreementMember" xml:lang="en-US">Merger Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_MergerAgreementMember" xlink:to="lab_okur_MergerAgreementMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_MergerAgreementMember" xml:lang="en-US">Merger Agreement.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xml:lang="en-US">Business Acquisition, Date of Acquisition Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xml:lang="en-US">Date of agreement and plan of merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:to="lab_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xml:lang="en-US">Aggregate purchase price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesTable" xlink:label="loc_okur_AccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccountingPoliciesTable" xml:lang="en-US">Accounting Policies [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccountingPoliciesTable" xlink:to="lab_okur_AccountingPoliciesTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccountingPoliciesTable" xml:lang="en-US">Accounting policies table.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xml:lang="en-US">Accounting Standards Update [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfAdoptionMember" xml:lang="en-US">Accounting Standards Update [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember" xlink:to="lab_us-gaap_TypeOfAdoptionMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeAxis" xml:lang="en-US">Statistical Measurement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_RangeMember" xml:lang="en-US">Statistical Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_srt_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesLineItems" xlink:label="loc_okur_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccountingPoliciesLineItems" xlink:to="lab_okur_AccountingPoliciesLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccountingPoliciesLineItems" xml:lang="en-US">Accounting policies line items.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xml:lang="en-US">Federally insured limits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful lives of property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xml:lang="en-US">Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xml:lang="en-US">Estimated useful life of property and equipment, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xml:lang="en-US">Impairment charges</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized Tax Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xml:lang="en-US">Unrecognized tax benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants, Maximum Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xml:lang="en-US">Options granted maximum contractual term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xlink:to="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xml:lang="en-US">Share based compensation arrangement by share based payment award options grants, maximum contractual term</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xml:lang="en-US">Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xml:lang="en-US">Long-Term Debt, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xml:lang="en-US">Long-Term Debt, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Debt [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Promissory Note [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertibleDebtMember" xml:lang="en-US">Convertible Promissory Note</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReneoMember" xlink:label="loc_okur_ReneoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ReneoMember" xml:lang="en-US">Reneo [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ReneoMember" xlink:to="lab_okur_ReneoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ReneoMember" xml:lang="en-US">Reneo.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_TwentyTwentyFourEquityIncentivePlanMember" xml:lang="en-US">Twenty Twenty Four Equity Incentive Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_TwentyTwentyFourEquityIncentivePlanMember" xml:lang="en-US">2024 Equity Incentive Plan [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:to="lab_okur_TwentyTwentyFourEquityIncentivePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_TwentyTwentyFourEquityIncentivePlanMember" xml:lang="en-US">Twenty twenty four equity incentive plan.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">Twenty Twenty Four Employee Stock Purchase Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">2024 ESPP [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">2024 Employee Stock Purchase Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:to="lab_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xml:lang="en-US">Twenty twenty four employee stock purchase plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xml:lang="en-US">Business Acquisition [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Conversion of convertible preferred stock into common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockSharesConvertibleConversionRatio" xlink:label="loc_okur_CommonStockSharesConvertibleConversionRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_CommonStockSharesConvertibleConversionRatio" xml:lang="en-US">Common Stock Shares Convertible, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_CommonStockSharesConvertibleConversionRatio" xml:lang="en-US">Common stock exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_CommonStockSharesConvertibleConversionRatio" xlink:to="lab_okur_CommonStockSharesConvertibleConversionRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_CommonStockSharesConvertibleConversionRatio" xml:lang="en-US">Common stock shares convertible, conversion ratio.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Preferred Stock, Convertible, Conversion Ratio</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionRatio" xml:lang="en-US">Preferred exchange ratio</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionRatio" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionRatio" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xlink:label="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xml:lang="en-US">Stock Issued During Period, Shares, Exchange of Capital Stock Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xml:lang="en-US">Common stock shares issued in exchange for the shares of capital stock outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xlink:to="lab_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xml:lang="en-US">Stock Issued During Period, Shares, Exchange of Capital Stock Outstanding</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xml:lang="en-US">Stock issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xml:lang="en-US">Preferred Stock, Convertible, Shares Issuable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleSharesIssuable" xml:lang="en-US">Exchange of stock, preferred stock holders choose to receive shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleSharesIssuable" xlink:to="lab_us-gaap_PreferredStockConvertibleSharesIssuable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of Stock, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xml:lang="en-US">Sale of stock price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_okur_GrossProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Gross Proceeds From Issuance Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Gross proceeds from sale of stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_GrossProceedsFromIssuanceOfCommonStock" xlink:to="lab_okur_GrossProceedsFromIssuanceOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_GrossProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Gross proceeds from issuance of common stock.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Total shares of common stock reserved for future issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Stock were initially reserved for issuance.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Number of shares of available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:label="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved and Available for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xml:lang="en-US">Stock were initially reserved and available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:to="lab_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xml:lang="en-US">Common stock, capital shares reserved and available for future issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt Instrument, Face Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xml:lang="en-US">Debt instrument principal amount</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DebtInstrumentAccruedInterest" xlink:label="loc_okur_DebtInstrumentAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_DebtInstrumentAccruedInterest" xml:lang="en-US">Debt Instrument Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_DebtInstrumentAccruedInterest" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_DebtInstrumentAccruedInterest" xlink:to="lab_okur_DebtInstrumentAccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_DebtInstrumentAccruedInterest" xml:lang="en-US">Debt instrument accrued interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xml:lang="en-US">Cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xml:lang="en-US">Short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xml:lang="en-US">Other assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xlink:label="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Operating Lease Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xml:lang="en-US">Long-term operating lease liability</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xlink:to="lab_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xml:lang="en-US">Business combination, recognized identifiable assets acquired and liabilities assumed, long-term operating lease liability.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xml:lang="en-US">Net assets acquired</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_NumberOfReportableSegments" xml:lang="en-US">Number of Reportable Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_Revenues" xml:lang="en-US">Revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExtensibleList" xlink:label="loc_us-gaap_SegmentExtensibleList" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentExtensibleList" xml:lang="en-US">Segment [Extensible Enumeration]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentExtensibleList" xlink:to="lab_us-gaap_SegmentExtensibleList" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="loc_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xml:lang="en-US">Segment Reporting, Expense Information Used by CODM, Description</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xml:lang="en-US">CODM Description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:to="lab_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xlink:label="loc_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xml:lang="en-US">Segment Reporting C O D M Individual Title and Position or Group Name</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xml:lang="en-US">CODM title and Position</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xlink:to="lab_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xml:lang="en-US">Segment reporting, CODM, individual title and position or group name.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xml:lang="en-US">Segments [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentDomain" xml:lang="en-US">Segments [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClinicalResearchSegmentMember" xlink:label="loc_okur_ClinicalResearchSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ClinicalResearchSegmentMember" xml:lang="en-US">Clinical Research Segment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ClinicalResearchSegmentMember" xlink:to="lab_okur_ClinicalResearchSegmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ClinicalResearchSegmentMember" xml:lang="en-US">Clinical research segment.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xml:lang="en-US">Segment Reporting Information [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DirectProgramExpense" xlink:label="loc_okur_DirectProgramExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_DirectProgramExpense" xml:lang="en-US">Direct Program Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_DirectProgramExpense" xml:lang="en-US">Direct program expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_DirectProgramExpense" xlink:to="lab_okur_DirectProgramExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_DirectProgramExpense" xml:lang="en-US">Direct program expense</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IndirectProgramExpense" xlink:label="loc_okur_IndirectProgramExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_IndirectProgramExpense" xml:lang="en-US">Indirect Program Expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_IndirectProgramExpense" xlink:to="lab_okur_IndirectProgramExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_IndirectProgramExpense" xml:lang="en-US">Indirect program expense</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_WorkforceSalariesAndBenefits" xlink:label="loc_okur_WorkforceSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_WorkforceSalariesAndBenefits" xml:lang="en-US">Workforce Salaries and Benefits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_WorkforceSalariesAndBenefits" xml:lang="en-US">Workforce salaries and benefits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_WorkforceSalariesAndBenefits" xlink:to="lab_okur_WorkforceSalariesAndBenefits" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_WorkforceSalariesAndBenefits" xml:lang="en-US">Workforce salaries and benefits</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Share-Based Payment Arrangement, Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GeneralCorporateExpenses" xlink:label="loc_okur_GeneralCorporateExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_GeneralCorporateExpenses" xml:lang="en-US">General Corporate Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_GeneralCorporateExpenses" xml:lang="en-US">General corporate expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_GeneralCorporateExpenses" xlink:to="lab_okur_GeneralCorporateExpenses" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_GeneralCorporateExpenses" xml:lang="en-US">General corporate expenses</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xml:lang="en-US">Segment Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xml:lang="en-US">Reconciliation of loss:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsAndReconcilingItems" xlink:label="loc_okur_AdjustmentsAndReconcilingItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AdjustmentsAndReconcilingItems" xml:lang="en-US">Adjustments and Reconciling Items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_okur_AdjustmentsAndReconcilingItems" xml:lang="en-US">Adjustments and reconciling items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AdjustmentsAndReconcilingItems" xlink:to="lab_okur_AdjustmentsAndReconcilingItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AdjustmentsAndReconcilingItems" xml:lang="en-US">Adjustments and reconciling items</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualAxis" xml:lang="en-US">Title and Position [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Title and Position [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xml:lang="en-US">Lessee, Lease, Description [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xml:lang="en-US">Lease Contractual Term [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xml:lang="en-US">Lease Contractual Term [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xml:lang="en-US">Lessee, Lease, Description [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of Real Estate Property</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AreaOfRealEstateProperty" xml:lang="en-US">Area of real estate property</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty" xlink:to="lab_us-gaap_AreaOfRealEstateProperty" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LeaseExpirationDate1" xml:lang="en-US">Lease Expiration Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseExpirationDate1" xlink:to="lab_us-gaap_LeaseExpirationDate1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Option to Extend</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" xml:lang="en-US">Operating lease option to extend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xml:lang="en-US">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="lab_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xml:lang="en-US">Operating lease rights to extend renewal term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Operating Lease, Liability</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_OperatingLeaseLiability" xml:lang="en-US">Total lease liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLeaseCost" xml:lang="en-US">Operating lease cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable Lease, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_VariableLeaseCost" xml:lang="en-US">Variable lease expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xml:lang="en-US">Weighted-average remaining lease term - operating leases (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xml:lang="en-US">Weighted-average discount rate - operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="loc_us-gaap_PaymentsForOperatingActivitiesAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForOperatingActivitiesAbstract" xml:lang="en-US">Payments for Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForOperatingActivitiesAbstract" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:to="lab_us-gaap_PaymentsForOperatingActivitiesAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating Lease, Payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_OperatingLeasePayments" xml:lang="en-US">Operating cash flows for operating leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xml:lang="en-US">2025</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xml:lang="en-US">2026</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xml:lang="en-US">Total future minimum lease payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xml:lang="en-US">Less: Imputed interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteMember" xlink:label="loc_okur_ConvertiblePromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible Promissory Notes [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ConvertiblePromissoryNoteMember" xlink:to="lab_okur_ConvertiblePromissoryNoteMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ConvertiblePromissoryNoteMember" xml:lang="en-US">Convertible promissory note.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Common Stock Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_UnvestedRestrictedStockUnitsMember" xml:lang="en-US">Unvested Restricted Stock Units [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_UnvestedRestrictedStockUnitsMember" xlink:to="lab_okur_UnvestedRestrictedStockUnitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_UnvestedRestrictedStockUnitsMember" xml:lang="en-US">Represents information relating to Unvested restricted stock units.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:label="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xml:lang="en-US">Unreleased Restricted Stock Units Assumed in the Merger [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xml:lang="en-US">Unreleased Restricted Stock Units Assumed in Merger</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:to="lab_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xml:lang="en-US">Unreleased restricted stock units assumed in merger.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xml:lang="en-US">Assets transferred into L3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xml:lang="en-US">Assets transferred out of L3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xml:lang="en-US">Liabilities transferred into L3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xml:lang="en-US">Liabilities transferred out of L3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xml:lang="en-US">Proceeds of short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xml:lang="en-US">Realized loss from short-term investments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Fair Market Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xml:lang="en-US">Debt securities available-for-sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PrepaidClinicalTrials" xlink:label="loc_okur_PrepaidClinicalTrials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PrepaidClinicalTrials" xml:lang="en-US">Prepaid Clinical Trials</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_PrepaidClinicalTrials" xml:lang="en-US">Prepaid clinical trial expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PrepaidClinicalTrials" xlink:to="lab_okur_PrepaidClinicalTrials" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PrepaidClinicalTrials" xml:lang="en-US">Prepaid clinical trials.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid Insurance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PrepaidInsurance" xml:lang="en-US">Prepaid insurance expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidInsurance" xlink:to="lab_us-gaap_PrepaidInsurance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherPrepaidExpenseCurrent" xml:lang="en-US">Other prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPrepaidExpenseCurrent" xlink:to="lab_us-gaap_OtherPrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Total prepaid expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_LabEquipmentMember" xlink:label="loc_okur_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_LabEquipmentMember" xml:lang="en-US">Lab Equipment [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_LabEquipmentMember" xlink:to="lab_okur_LabEquipmentMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_LabEquipmentMember" xml:lang="en-US">Lab equipment.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ComputerHardwareAndSoftwareMember" xlink:label="loc_okur_ComputerHardwareAndSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ComputerHardwareAndSoftwareMember" xml:lang="en-US">Computer Hardware and Software [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ComputerHardwareAndSoftwareMember" xlink:to="lab_okur_ComputerHardwareAndSoftwareMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ComputerHardwareAndSoftwareMember" xml:lang="en-US">Computer hardware and software</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xml:lang="en-US">Furniture and Fixtures [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: Accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" xml:lang="en-US">Depreciation Expense on Reclassified Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:to="lab_us-gaap_DepreciationExpenseOnReclassifiedAssets" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Employee-related Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xml:lang="en-US">Accrued compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedManufacturingExpense" xlink:label="loc_okur_AccruedManufacturingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccruedManufacturingExpense" xml:lang="en-US">Accrued Manufacturing Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AccruedManufacturingExpense" xml:lang="en-US">Accrued contract manufacturing costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccruedManufacturingExpense" xlink:to="lab_okur_AccruedManufacturingExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccruedManufacturingExpense" xml:lang="en-US">Accrued manufacturing expense</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedClinicalTrialCosts" xlink:label="loc_okur_AccruedClinicalTrialCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccruedClinicalTrialCosts" xml:lang="en-US">Accrued Clinical Trial Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AccruedClinicalTrialCosts" xml:lang="en-US">Accrued clinical trial costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccruedClinicalTrialCosts" xlink:to="lab_okur_AccruedClinicalTrialCosts" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccruedClinicalTrialCosts" xml:lang="en-US">Accrued clinical trial costs.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Accrued other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Stock, Class of Stock [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xml:lang="en-US">Preferred Stock, Convertible, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockConvertibleConversionPrice" xml:lang="en-US">Conversion price of preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockConvertibleConversionPrice" xlink:to="lab_us-gaap_PreferredStockConvertibleConversionPrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_Dividends" xml:lang="en-US">Dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Dividends" xlink:to="lab_us-gaap_Dividends" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Liquidation Preference, Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_us-gaap_PreferredStockLiquidationPreferenceValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaap_PreferredStockDividendPaymentTerms" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockDividendPaymentTerms" xml:lang="en-US">Preferred Stock, Dividend Payment Terms</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockDividendPaymentTerms" xml:lang="en-US">Preferred Stock Dividend Payment Terms</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendPaymentTerms" xlink:to="lab_us-gaap_PreferredStockDividendPaymentTerms" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PreferredStockSharesDesignated" xlink:label="loc_okur_PreferredStockSharesDesignated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PreferredStockSharesDesignated" xml:lang="en-US">Preferred Stock Shares Designated</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_PreferredStockSharesDesignated" xml:lang="en-US">Preferred stock, shares designated</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PreferredStockSharesDesignated" xlink:to="lab_okur_PreferredStockSharesDesignated" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PreferredStockSharesDesignated" xml:lang="en-US">Preferred stock shares designated.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Preferred Stock, Value, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PreferredStockValueOutstanding" xml:lang="en-US">Preferred stock, value, outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValueOutstanding" xlink:to="lab_us-gaap_PreferredStockValueOutstanding" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Grant and expire period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-EmployeesMember" xlink:label="loc_okur_Non-EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_Non-EmployeesMember" xml:lang="en-US">Non-employees [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_Non-EmployeesMember" xml:lang="en-US">Non-employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_Non-EmployeesMember" xlink:to="lab_okur_Non-EmployeesMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_Non-EmployeesMember" xml:lang="en-US">Non-employees.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Performance-BasedStockOptionsMember" xlink:label="loc_okur_Performance-BasedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_Performance-BasedStockOptionsMember" xml:lang="en-US">Performance-Based Stock Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_Performance-BasedStockOptionsMember" xml:lang="en-US">Performance-Based Stock Options [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_Performance-BasedStockOptionsMember" xlink:to="lab_okur_Performance-BasedStockOptionsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_Performance-BasedStockOptionsMember" xml:lang="en-US">Performance-based stock options.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xml:lang="en-US">Unrecognized compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted-average vesting term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted-average grant-date fair value of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Shares granted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xml:lang="en-US">Unvested Restricted Stock Units under Two Thousand Twenty Three Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xml:lang="en-US">Unvested Restricted Stock Units under 2023 Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xlink:to="lab_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xml:lang="en-US">Unvested Restricted Stock Units under Two Thousand Twenty Three Plan.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Outstanding at beginning of period (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xml:lang="en-US">Assumed in reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xlink:to="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xml:lang="en-US">Expired (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xml:lang="en-US">Forfeited (In shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xml:lang="en-US">Outstanding at end of period (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xml:lang="en-US">Exercisable (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted-Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at beginning of period (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xml:lang="en-US">Assumed in reverse recapitalization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xlink:to="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xml:lang="en-US">Share based compensation arrangement by share based payment award options assumed in reverse recapitalization weighted average exercise price.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Exercised (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Expired (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Forfeited (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Outstanding at end of period (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xml:lang="en-US">Exercisable (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xml:lang="en-US">Weighted-Average Remaining Contractual Term (in years) / Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Weighted Average Remaining Contractual Term (in years), Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Weighted-average assumptions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk-free interest rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term (in years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockMember" xml:lang="en-US">Restricted Stock Awards (RSAs) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingAxis" xml:lang="en-US">Vesting [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_VestingDomain" xml:lang="en-US">Vesting [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xml:lang="en-US">25% on First Anniversary</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xml:lang="en-US">Incrementally Vest Monthly for Three-Year Period Thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xml:lang="en-US">Vesting rights, description</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xml:lang="en-US">Vesting percentage</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Shares vested</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xml:lang="en-US">Vested (RSA)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnamortizedCompensationCost" xlink:label="loc_okur_UnamortizedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_UnamortizedCompensationCost" xml:lang="en-US">Unamortized Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_UnamortizedCompensationCost" xml:lang="en-US">Unamortized compensation cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_UnamortizedCompensationCost" xlink:to="lab_okur_UnamortizedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_UnamortizedCompensationCost" xml:lang="en-US">Unamortized compensation cost.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xlink:label="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xml:lang="en-US">Restricted Stock and Restricted Stock Units (RSUs) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xml:lang="en-US">Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xlink:to="lab_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xml:lang="en-US">Restricted stock and restricted stock units.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">Unvested at Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xml:lang="en-US">RSUs outstanding and Unvested at End</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xml:lang="en-US">Weighted Average Grant Date Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested at Beginning</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">RSUs outstanding and Unvested at End</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Vested (RSA)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xml:lang="en-US">Forfeited</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Statement of Income Location, Balance [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Statement of Income Location, Balance [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Stock-Based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Share-Based Payment Arrangement, Accelerated Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xml:lang="en-US">Accelerated share-based compensation expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Federal tax at statutory rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xml:lang="en-US">State taxes, net of federal deduction</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xml:lang="en-US">R&amp;D credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xml:lang="en-US">Income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Deferred tax assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xml:lang="en-US">R&amp;D tax credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xml:lang="en-US">Deferred R&amp;D expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xml:lang="en-US">Accrued expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Share-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Total deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred tax assets, net of valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xml:lang="en-US">Operating Loss Carryforwards [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Jurisdiction [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Jurisdiction [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DomesticCountryMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xlink:label="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xml:lang="en-US">Domestic Tax Jurisdiction and State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xml:lang="en-US">Federal and State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xlink:to="lab_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xml:lang="en-US">Domestic tax jurisdiction and state and local jurisdiction.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Net operating loss carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xml:lang="en-US">Net operating loss carryforwards, subject to expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xlink:label="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xml:lang="en-US">Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xml:lang="en-US">Net operating loss carryforwards, subject to expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xlink:to="lab_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xml:lang="en-US">Deferred tax assets operating loss carryforwards subject to expiration period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax credit carry forwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_okur_TaxCreditCarryforwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax Credit Carryforward Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax credit carry forwards expiration</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_TaxCreditCarryforwardExpirationPeriod" xlink:to="lab_okur_TaxCreditCarryforwardExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_TaxCreditCarryforwardExpirationPeriod" xml:lang="en-US">Tax credit carryforward expiration period.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xml:lang="en-US">Income Tax Examination, Penalties and Interest Accrued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanTable" xlink:to="lab_us-gaap_DefinedContributionPlanTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xml:lang="en-US">Restructuring Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xml:lang="en-US">Type of Restructuring [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_OneTimeTerminationBenefitsMember" xml:lang="en-US">One-time Termination Benefits [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OneTimeTerminationBenefitsMember" xlink:to="lab_us-gaap_OneTimeTerminationBenefitsMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedContributionPlanDisclosureLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Severance Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SeveranceCosts1" xml:lang="en-US">Termination benefits costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xml:lang="en-US">Deferred Compensation Arrangement with Individual, Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xml:lang="en-US">Accrued compensation unpaid</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:to="lab_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Percentage of employee contribution match</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Matching contributions made by employees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xml:lang="en-US">Line of Credit Facility [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityAxis" xml:lang="en-US">Credit Facility [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_CreditFacilityDomain" xml:lang="en-US">Credit Facility [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xml:lang="en-US">Line of Credit Facility [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short-Term Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_ShortTermBorrowings" xml:lang="en-US">Short term borrowings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdditionalProceedsFromAcquisition" xlink:label="loc_okur_AdditionalProceedsFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AdditionalProceedsFromAcquisition" xml:lang="en-US">Additional Proceeds From Acquisition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AdditionalProceedsFromAcquisition" xml:lang="en-US">Additional proceeds from acquisition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AdditionalProceedsFromAcquisition" xlink:to="lab_okur_AdditionalProceedsFromAcquisition" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AdditionalProceedsFromAcquisition" xml:lang="en-US">Additional proceeds from acquisition.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt Issuance Costs, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xml:lang="en-US">Debt issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GainLossOnConversionOfDebt" xlink:label="loc_okur_GainLossOnConversionOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_GainLossOnConversionOfDebt" xml:lang="en-US">Gain (loss) on Conversion of Debt</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_GainLossOnConversionOfDebt" xml:lang="en-US">Gain (loss) on conversion of debt</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_GainLossOnConversionOfDebt" xlink:to="lab_okur_GainLossOnConversionOfDebt" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_GainLossOnConversionOfDebt" xml:lang="en-US">Gain (loss) on conversion of debt.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedInterest" xlink:label="loc_okur_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_AccruedInterest" xml:lang="en-US">Accrued Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_AccruedInterest" xml:lang="en-US">Accrued interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_AccruedInterest" xlink:to="lab_okur_AccruedInterest" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_AccruedInterest" xml:lang="en-US">Accrued interest.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">Employee Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_EmployeeStockMember" xml:lang="en-US">ESPP [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xlink:label="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage Of Number Of Outstanding Shares Of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of number of outstanding shares of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xlink:to="lab_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xml:lang="en-US">Percentage of number of outstanding shares of common stock.</label>
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IncreaseInNumberOfSharesAvailableForIssuance" xlink:label="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_IncreaseInNumberOfSharesAvailableForIssuance" xml:lang="en-US">Increase In Number Of Shares Available For Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_IncreaseInNumberOfSharesAvailableForIssuance" xml:lang="en-US">Increase in number of shares available for issuance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance" xlink:to="lab_okur_IncreaseInNumberOfSharesAvailableForIssuance" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_IncreaseInNumberOfSharesAvailableForIssuance" xml:lang="en-US">Increase in number of shares available for issuance.</label>
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaap_PaymentsForRent" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_us-gaap_PaymentsForRent" xml:lang="en-US">Payments for Rent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_us-gaap_PaymentsForRent" xml:lang="en-US">Sublease rent payments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRent" xlink:to="lab_us-gaap_PaymentsForRent" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_SubleaseExpirationPeriod" xlink:label="loc_okur_SubleaseExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_okur_SubleaseExpirationPeriod" xml:lang="en-US">Sublease Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_okur_SubleaseExpirationPeriod" xml:lang="en-US">Sublease expiration period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_okur_SubleaseExpirationPeriod" xlink:to="lab_okur_SubleaseExpirationPeriod" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_okur_SubleaseExpirationPeriod" xml:lang="en-US">Sublease expiration period.</label>
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>okur-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 18-March-2025 [07:09:08] {PM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#CoverPage" roleURI="http://onkuretherapeutics.com/role/CoverPage" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedBalanceSheets" roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedBalanceSheetsParenthetical" roleURI="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfOperationsAndComprehensiveLoss" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquity" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConsolidatedStatementsOfCashFlows" roleURI="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#OrganizationAndBusiness" roleURI="http://onkuretherapeutics.com/role/OrganizationAndBusiness" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancing" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#Segment" roleURI="http://onkuretherapeutics.com/role/Segment" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#Leases" roleURI="http://onkuretherapeutics.com/role/Leases" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#NetLossPerShare" roleURI="http://onkuretherapeutics.com/role/NetLossPerShare" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#FairValueMeasurements" roleURI="http://onkuretherapeutics.com/role/FairValueMeasurements" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNet" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNet" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#AccruedExpenses" roleURI="http://onkuretherapeutics.com/role/AccruedExpenses" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#Equity" roleURI="http://onkuretherapeutics.com/role/Equity" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensation" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensation" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxes" roleURI="http://onkuretherapeutics.com/role/IncomeTaxes" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#CommitmentsAndContingencies" roleURI="http://onkuretherapeutics.com/role/CommitmentsAndContingencies" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConvertiblePromissoryNotes" roleURI="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SubsequentEvents" roleURI="http://onkuretherapeutics.com/role/SubsequentEvents" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancingTables" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SegmentTables" roleURI="http://onkuretherapeutics.com/role/SegmentTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesTables" roleURI="http://onkuretherapeutics.com/role/LeasesTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#NetLossPerShareTables" roleURI="http://onkuretherapeutics.com/role/NetLossPerShareTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNetTables" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#AccruedExpensesTables" roleURI="http://onkuretherapeutics.com/role/AccruedExpensesTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationTables" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesTables" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesTables" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#OrganizationAndBusinessNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancingAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails" roleURI="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SegmentAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SegmentScheduleOfSegmentReportingInformationBySegmentDetails" roleURI="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails" roleURI="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails" roleURI="http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#FairValueMeasurementsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" roleURI="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#PropertyAndEquipmentNetAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#AccruedExpensesDetails" roleURI="http://onkuretherapeutics.com/role/AccruedExpensesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#EquityAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationStockOptionsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationSharesReservedForFutureIssuanceDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationStockOptionActivityDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationAssumptionsDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesComponentsOfNetDeferredTaxesDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#IncomeTaxesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#CommitmentsAndContingenciesAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#ConvertiblePromissoryNotesNarrativeDetails" roleURI="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails" />
<roleRef xlink:type="simple" xlink:href="okur-20241231.xsd#SubsequentEventsAdditionalInformationDetails" roleURI="http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails" />
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/CoverPage">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_101" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationTable" xlink:label="loc_dei_DocumentInformationTable_147" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_101" xlink:to="loc_dei_DocumentInformationTable_147" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_102" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_us-gaap_StatementClassOfStockAxis_102" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_102" xlink:to="loc_us-gaap_ClassOfStockDomain_108" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_1108" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_1108" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AddressTypeDomain" xlink:label="loc_dei_AddressTypeDomain_1109" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_1108" xlink:to="loc_dei_AddressTypeDomain_1109" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_BusinessContactMember" xlink:label="loc_dei_BusinessContactMember_1110" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_1109" xlink:to="loc_dei_BusinessContactMember_1110" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentInformationLineItems" xlink:label="loc_dei_DocumentInformationLineItems_105" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_147" xlink:to="loc_dei_DocumentInformationLineItems_105" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_104" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentType_104" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_113" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityRegistrantName_113" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_114" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityIncorporationStateCountryCode_114" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_115" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityTaxIdentificationNumber_115" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_116" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressAddressLine1_116" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_117" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressCityOrTown_117" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_118" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressStateOrProvince_118" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_119" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityAddressPostalZipCode_119" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_120" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_CityAreaCode_120" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_LocalPhoneNumber_121" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_129" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityFilerCategory_129" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_130" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntitySmallBusiness_130" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_131" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityEmergingGrowthCompany_131" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_dei_EntityExTransitionPeriod_132" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityExTransitionPeriod_132" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_138" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityCentralIndexKey_138" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_139" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentFiscalYearFocus_139" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_140" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_DocumentFiscalPeriodFocus_140" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_141" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentFlag_141" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_dei_EntityPrimarySicNumber_1106" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_EntityPrimarySicNumber_1106" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_ContactPersonnelName" xlink:label="loc_dei_ContactPersonnelName_1107" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_ContactPersonnelName_1107" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription" xlink:label="loc_dei_AmendmentDescription_1111" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_105" xlink:to="loc_dei_AmendmentDescription_1111" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_149" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_157" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_149" xlink:to="loc_us-gaap_StatementTable_157" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_156" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_157" xlink:to="loc_us-gaap_StatementClassOfStockAxis_156" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_170" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_156" xlink:to="loc_us-gaap_ClassOfStockDomain_170" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_okur_ConvertiblePreferredStockSeriesCMember_152" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_okur_ConvertiblePreferredStockSeriesCMember_152" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_161" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_us-gaap_CommonClassAMember_161" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_167" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_170" xlink:to="loc_us-gaap_CommonClassBMember_167" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_165" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_157" xlink:to="loc_us-gaap_StatementLineItems_165" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_150" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_165" xlink:to="loc_us-gaap_AssetsAbstract_150" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_158" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_150" xlink:to="loc_us-gaap_AssetsCurrentAbstract_158" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_151" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_151" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_166" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_166" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_172" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_AssetsCurrent_172" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_176" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_176" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_179" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_179" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_182" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_182" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_185" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_158" xlink:to="loc_us-gaap_Assets_185" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_165" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_154" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_154" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_153" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_AccountsPayableCurrent_153" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_162" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_162" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_168" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_168" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_173" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_LiabilitiesCurrent_173" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_177" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_183" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_154" xlink:to="loc_us-gaap_Liabilities_183" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_163" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_CommitmentsAndContingencies_163" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue" xlink:label="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_169" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue_169" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_174" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_159" xlink:to="loc_us-gaap_StockholdersEquityAbstract_174" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_155" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_PreferredStockValue_155" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_164" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_CommonStockValue_164" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_171" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_AdditionalPaidInCapital_171" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_175" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_181" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_StockholdersEquity_181" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_184" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_174" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_184" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_187" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_191" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_187" xlink:to="loc_us-gaap_StatementTable_191" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_190" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementClassOfStockAxis_190" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_196" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_190" xlink:to="loc_us-gaap_ClassOfStockDomain_196" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_189" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_196" xlink:to="loc_us-gaap_CommonClassAMember_189" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_193" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_196" xlink:to="loc_us-gaap_CommonClassBMember_193" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_194" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_191" xlink:to="loc_us-gaap_StatementLineItems_194" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockParOrStatedValuePerShare" xlink:label="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare_188" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockParOrStatedValuePerShare_188" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesAuthorized" xlink:label="loc_okur_ConvertiblePreferredStockSharesAuthorized_192" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesAuthorized_192" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesIssued" xlink:label="loc_okur_ConvertiblePreferredStockSharesIssued_195" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesIssued_195" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesOutstanding" xlink:label="loc_okur_ConvertiblePreferredStockSharesOutstanding_197" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockSharesOutstanding_197" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockLiquidationPreferenceValue" xlink:label="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue_198" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_okur_ConvertiblePreferredStockLiquidationPreferenceValue_198" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_199" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_199" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_200" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_200" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_201" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesIssued_201" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_202" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_202" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_203" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_203" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_204" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_204" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_205" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesIssued_205" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_206" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_194" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_206" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_208" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_209" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_208" xlink:to="loc_us-gaap_OperatingExpensesAbstract_209" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_210" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_209" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_210" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_213" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_209" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_213" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_215" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_209" xlink:to="loc_us-gaap_OperatingExpenses_215" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_217" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_209" xlink:to="loc_us-gaap_OperatingIncomeLoss_217" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_208" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_211" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_InterestIncomeOperating_211" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_InterestAndOtherExpense" xlink:label="loc_okur_InterestAndOtherExpense_214" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_okur_InterestAndOtherExpense_214" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeExpenseNet" xlink:label="loc_us-gaap_InterestIncomeExpenseNet_216" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_InterestIncomeExpenseNet_216" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_218" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_NetIncomeLoss_218" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_219" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_EarningsPerShareBasic_219" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_220" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_EarningsPerShareDiluted_220" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_221" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_212" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_222" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_226" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_232" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_226" xlink:to="loc_us-gaap_StatementTable_232" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_235" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_235" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_229" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_235" xlink:to="loc_us-gaap_EquityComponentDomain_229" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_230" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_PreferredStockMember_230" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_237" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_CommonStockMember_237" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_242" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_242" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_248" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_229" xlink:to="loc_us-gaap_RetainedEarningsMember_248" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_240" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_240" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_240" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClassACommonStockAndSeriesCPreferredStockMember" xlink:label="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember_228" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_233" xlink:to="loc_okur_ClassACommonStockAndSeriesCPreferredStockMember_228" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_246" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_StatementClassOfStockAxis_246" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_245" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_246" xlink:to="loc_us-gaap_ClassOfStockDomain_245" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_231" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_231" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_238" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_CommonClassAMember_238" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_243" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_245" xlink:to="loc_us-gaap_CommonClassBMember_243" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_250" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_232" xlink:to="loc_us-gaap_StatementLineItems_250" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_250" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_234" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_234" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_239" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockholdersEquity_239" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_244" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_SharesOutstanding_244" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_249" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_249" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_252" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_252" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing_253" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodSharesConcurrentFinancing_253" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodValueConcurrentFinancing" xlink:label="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing_254" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodValueConcurrentFinancing_254" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_255" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_255" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_256" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_256" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts_257" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts_257" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares_258" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares_258" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue" xlink:label="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue_259" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue_259" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_260" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_260" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_261" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_261" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_262" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_262" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentForFractionalSharesInTheReverseRecapitalization" xlink:label="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization_263" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization_263" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_264" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_264" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_265" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_NetIncomeLoss_265" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_266" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_266" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_267" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_StockholdersEquity_267" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaap_SharesOutstanding_268" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_227" xlink:to="loc_us-gaap_SharesOutstanding_268" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_270" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_273" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_270" xlink:to="loc_us-gaap_StatementTable_273" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_274" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_273" xlink:to="loc_us-gaap_StatementClassOfStockAxis_274" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_276" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_274" xlink:to="loc_us-gaap_ClassOfStockDomain_276" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_272" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_276" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_272" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_275" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_273" xlink:to="loc_us-gaap_StatementLineItems_275" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuanceCostNet" xlink:label="loc_okur_StockIssuanceCostNet_271" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_275" xlink:to="loc_okur_StockIssuanceCostNet_271" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_278" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_284" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_278" xlink:to="loc_us-gaap_StatementTable_284" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_288" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_288" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_288" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrivatePlacementMember" xlink:label="loc_us-gaap_PrivatePlacementMember_302" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_285" xlink:to="loc_us-gaap_PrivatePlacementMember_302" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_297" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_284" xlink:to="loc_us-gaap_StatementLineItems_297" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_283" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_NetIncomeLoss_283" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_279" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_289" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_ShareBasedCompensation_289" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_298" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_298" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_310" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_310" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_314" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_314" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-CashInterestExpense" xlink:label="loc_okur_Non-CashInterestExpense_318" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_okur_Non-CashInterestExpense_318" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_322" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_322" use="optional" order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_295" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_282" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_282" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_294" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_294" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_303" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_303" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_333" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_309" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_286" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_286" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_296" use="optional" order="22" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_291" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_304" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_290" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPrivatePlacement_290" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_299" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_299" use="optional" order="26" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_306" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_306" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfReverseRecapitalizationTransactionCosts" xlink:label="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts_311" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_okur_PaymentOfReverseRecapitalizationTransactionCosts_311" use="optional" order="28" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_315" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock_315" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_319" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock_319" use="optional" order="30" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_323" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_323" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable" xlink:label="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable_327" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable_327" use="optional" order="32" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_330" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_330" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_332" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_300" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_332" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_307" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_312" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_312" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_316" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_316" use="optional" order="37" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_297" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" use="optional" order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_280" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_280" use="optional" order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_292" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_292" use="optional" order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfSeriesCPreferredStock" xlink:label="loc_okur_ConversionOfSeriesCPreferredStock_301" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConversionOfSeriesCPreferredStock_301" use="optional" order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConversionOfConvertibleNotePayable" xlink:label="loc_okur_ConversionOfConvertibleNotePayable_308" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConversionOfConvertibleNotePayable_308" use="optional" order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization_313" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization_313" use="optional" order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization" xlink:label="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization_317" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization_317" use="optional" order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable" xlink:label="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable_321" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable_321" use="optional" order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable_325" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable_325" use="optional" order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger" xlink:label="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger_328" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_324" xlink:to="loc_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger_328" use="optional" order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/OrganizationAndBusiness">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_359" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_360" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_359" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_360" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_362" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_363" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_362" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_363" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingAbstract" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_365" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingTextBlock" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingTextBlock_366" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_365" xlink:to="loc_okur_MergerAgreementAndConcurrentFinancingTextBlock_366" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/Segment">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_368" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_369" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_368" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_369" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/Leases">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_371" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_372" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_371" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_372" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/NetLossPerShare">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_374" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_375" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_374" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_375" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/FairValueMeasurements">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_377" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_378" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_377" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_378" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_383" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherCurrentAssetsTextBlock" xlink:label="loc_us-gaap_OtherCurrentAssetsTextBlock_384" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_383" xlink:to="loc_us-gaap_OtherCurrentAssetsTextBlock_384" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNet">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_386" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_387" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_386" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_387" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/AccruedExpenses">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_389" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_390" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_389" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_390" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/Equity">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_392" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_393" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_392" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_393" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensation">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_395" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_396" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_395" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_396" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxes">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_398" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_399" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_398" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_399" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/CommitmentsAndContingencies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_402" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_401" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_402" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteAbstract" xlink:label="loc_okur_ConvertiblePromissoryNoteAbstract_407" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteDisclosureTextBlock" xlink:label="loc_okur_ConvertiblePromissoryNoteDisclosureTextBlock_408" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_ConvertiblePromissoryNoteAbstract_407" xlink:to="loc_okur_ConvertiblePromissoryNoteDisclosureTextBlock_408" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SubsequentEvents">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_410" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_411" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_410" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_411" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_413" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_BasisOfPresentationAndConsolidationPolicyTextBlock" xlink:label="loc_okur_BasisOfPresentationAndConsolidationPolicyTextBlock_414" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_okur_BasisOfPresentationAndConsolidationPolicyTextBlock_414" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_415" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_415" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_416" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_UseOfEstimates_416" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_417" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_417" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_418" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_418" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock" xlink:label="loc_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_419" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock_419" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PatentCostsPolicyTextBlock" xlink:label="loc_okur_PatentCostsPolicyTextBlock_420" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_okur_PatentCostsPolicyTextBlock_420" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_421" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_421" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockValuationPolicyTextBlock" xlink:label="loc_okur_CommonStockValuationPolicyTextBlock_422" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_okur_CommonStockValuationPolicyTextBlock_422" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_423" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_423" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_424" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_424" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_425" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_425" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_426" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_426" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_427" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_427" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_428" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_428" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_429" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_429" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_430" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_413" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_430" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingAbstract" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_435" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_436" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_435" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_436" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SegmentTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_438" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_439" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_438" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_439" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_441" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock_442" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_441" xlink:to="loc_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock_442" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_443" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_441" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_443" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock" xlink:label="loc_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock_444" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_441" xlink:to="loc_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock_444" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_445" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_441" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_445" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_447" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_448" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_447" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_448" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_454" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_455" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_454" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsTableTextBlock_455" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_458" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_457" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_458" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/AccruedExpensesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_460" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_461" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_460" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_461" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock" xlink:label="loc_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_464" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" xlink:to="loc_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock_464" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_465" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_465" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_466" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_466" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_467" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_467" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_468" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_463" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_468" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesTables">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_470" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_473" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_470" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_473" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_474" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_470" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_474" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_482" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_477" xlink:to="loc_us-gaap_StatementTable_482" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_480" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_482" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_480" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_480" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_479" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_481" xlink:to="loc_okur_MergerAgreementMember_479" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_484" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_482" xlink:to="loc_us-gaap_StatementLineItems_484" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1" xlink:label="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_478" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1_478" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_483" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_483" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_485" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_485" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_486" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_484" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_486" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_488" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesTable" xlink:label="loc_okur_AccountingPoliciesTable_497" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_488" xlink:to="loc_okur_AccountingPoliciesTable_497" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_494" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_489" xlink:to="loc_us-gaap_TypeOfAdoptionMember_494" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_498" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_496" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_495" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_496" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_501" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_srt_RangeAxis_501" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_493" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_501" xlink:to="loc_srt_RangeMember_493" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_490" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_493" xlink:to="loc_srt_MinimumMember_490" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_499" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_493" xlink:to="loc_srt_MaximumMember_499" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccountingPoliciesLineItems" xlink:label="loc_okur_AccountingPoliciesLineItems_503" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesTable_497" xlink:to="loc_okur_AccountingPoliciesLineItems_503" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_491" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_NumberOfOperatingSegments_491" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_500" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_500" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_502" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_502" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_504" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_504" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_505" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration_505" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_506" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_506" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_507" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_507" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm_508" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_AccountingPoliciesLineItems_503" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm_508" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_532" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_532" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_542" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_StatementClassOfStockAxis_542" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_552" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_542" xlink:to="loc_us-gaap_ClassOfStockDomain_552" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_539" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_552" xlink:to="loc_us-gaap_CommonClassAMember_539" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_547" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_552" xlink:to="loc_us-gaap_CommonClassBMember_547" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_549" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_549" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_544" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_549" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_544" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_534" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_544" xlink:to="loc_us-gaap_ConvertibleDebtMember_534" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_551" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_551" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_537" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_551" xlink:to="loc_us-gaap_EquityComponentDomain_537" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_538" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_537" xlink:to="loc_us-gaap_CommonStockMember_538" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_555" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_555" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_555" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_543" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_545" xlink:to="loc_okur_MergerAgreementMember_543" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_557" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_dei_LegalEntityAxis_557" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_553" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_557" xlink:to="loc_dei_EntityDomain_553" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ReneoMember" xlink:label="loc_okur_ReneoMember_536" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_553" xlink:to="loc_okur_ReneoMember_536" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_559" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_PlanNameAxis_559" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_535" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_559" xlink:to="loc_us-gaap_PlanNameDomain_535" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_533" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_535" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_533" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_546" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_535" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_546" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_561" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_541" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_561" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_540" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_540" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockSharesConvertibleConversionRatio" xlink:label="loc_okur_CommonStockSharesConvertibleConversionRatio_548" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_CommonStockSharesConvertibleConversionRatio_548" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionRatio" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionRatio_550" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionRatio_550" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding" xlink:label="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding_554" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding_554" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_556" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_556" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleSharesIssuable" xlink:label="loc_us-gaap_PreferredStockConvertibleSharesIssuable_558" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_PreferredStockConvertibleSharesIssuable_558" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_560" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_560" use="optional" order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_562" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_562" use="optional" order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GrossProceedsFromIssuanceOfCommonStock" xlink:label="loc_okur_GrossProceedsFromIssuanceOfCommonStock_563" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_GrossProceedsFromIssuanceOfCommonStock_563" use="optional" order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_564" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_564" use="optional" order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_565" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_565" use="optional" order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:label="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_566" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_566" use="optional" order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_568" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_568" use="optional" order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DebtInstrumentAccruedInterest" xlink:label="loc_okur_DebtInstrumentAccruedInterest_569" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_561" xlink:to="loc_okur_DebtInstrumentAccruedInterest_569" use="optional" order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementAndConcurrentFinancingAbstract" xlink:label="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_572" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_572" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_573" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_573" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_574" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_574" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_575" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets_575" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_576" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_576" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability" xlink:label="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability_577" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability_577" use="optional" order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_578" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_MergerAgreementAndConcurrentFinancingAbstract_571" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_578" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_580" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments" xlink:label="loc_us-gaap_NumberOfReportableSegments_581" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_580" xlink:to="loc_us-gaap_NumberOfReportableSegments_581" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Revenues" xlink:label="loc_us-gaap_Revenues_582" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_580" xlink:to="loc_us-gaap_Revenues_582" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentExtensibleList" xlink:label="loc_us-gaap_SegmentExtensibleList_583" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_580" xlink:to="loc_us-gaap_SegmentExtensibleList_583" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription" xlink:label="loc_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_584" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_580" xlink:to="loc_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription_584" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName" xlink:label="loc_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName_1124" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_580" xlink:to="loc_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName_1124" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_587" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_587" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_1121" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xlink:to="loc_srt_TitleOfIndividualAxis_1121" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_1121" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_1122" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_591" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_591" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_590" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_591" xlink:to="loc_us-gaap_SegmentDomain_590" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ClinicalResearchSegmentMember" xlink:label="loc_okur_ClinicalResearchSegmentMember_593" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_590" xlink:to="loc_okur_ClinicalResearchSegmentMember_593" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_596" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_589" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_596" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_594" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_OperatingExpensesAbstract_594" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DirectProgramExpense" xlink:label="loc_okur_DirectProgramExpense_588" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_DirectProgramExpense_588" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IndirectProgramExpense" xlink:label="loc_okur_IndirectProgramExpense_595" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_IndirectProgramExpense_595" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_WorkforceSalariesAndBenefits" xlink:label="loc_okur_WorkforceSalariesAndBenefits_599" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_WorkforceSalariesAndBenefits_599" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_601" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_601" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GeneralCorporateExpenses" xlink:label="loc_okur_GeneralCorporateExpenses_602" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_GeneralCorporateExpenses_602" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_InterestAndOtherExpense" xlink:label="loc_okur_InterestAndOtherExpense_603" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_594" xlink:to="loc_okur_InterestAndOtherExpense_603" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestIncomeOperating" xlink:label="loc_us-gaap_InterestIncomeOperating_592" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" xlink:to="loc_us-gaap_InterestIncomeOperating_592" use="optional" order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdjustmentsAndReconcilingItems" xlink:label="loc_okur_AdjustmentsAndReconcilingItems_597" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_598" xlink:to="loc_okur_AdjustmentsAndReconcilingItems_597" use="optional" order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_600" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_596" xlink:to="loc_us-gaap_NetIncomeLoss_600" use="optional" order="18" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_605" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_609" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_605" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_609" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="loc_us-gaap_LeaseContractualTermAxis_606" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_609" xlink:to="loc_us-gaap_LeaseContractualTermAxis_606" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="loc_us-gaap_LeaseContractualTermDomain_608" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_606" xlink:to="loc_us-gaap_LeaseContractualTermDomain_608" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_609" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_607" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_607" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaap_LeaseExpirationDate1_612" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LeaseExpirationDate1_612" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_613" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseOptionToExtend_613" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_614" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_614" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_615" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_611" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_615" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_623" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_624" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_624" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_625" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_625" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_626" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_626" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_627" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_623" xlink:to="loc_us-gaap_OperatingLeaseLiability_627" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_629" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_630" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_629" xlink:to="loc_us-gaap_OperatingLeaseCost_630" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_631" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_629" xlink:to="loc_us-gaap_VariableLeaseCost_631" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_633" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_635" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_633" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_635" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_636" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_633" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_636" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForOperatingActivitiesAbstract" xlink:label="loc_us-gaap_PaymentsForOperatingActivitiesAbstract_637" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_633" xlink:to="loc_us-gaap_PaymentsForOperatingActivitiesAbstract_637" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_634" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PaymentsForOperatingActivitiesAbstract_637" xlink:to="loc_us-gaap_OperatingLeasePayments_634" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_639" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_640" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_640" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_641" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_641" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_642" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_642" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_643" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_643" use="optional" order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_644" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_639" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_645" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_647" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_647" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_650" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_652" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSeriesCMember" xlink:label="loc_okur_ConvertiblePreferredStockSeriesCMember_648" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_ConvertiblePreferredStockSeriesCMember_648" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteMember" xlink:label="loc_okur_ConvertiblePromissoryNoteMember_653" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_ConvertiblePromissoryNoteMember_653" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_655" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_us-gaap_EmployeeStockOptionMember_655" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsMember_656" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_UnvestedRestrictedStockUnitsMember_656" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:label="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_657" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_649" xlink:to="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_657" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_647" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_651" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_654" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_651" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_659" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_662" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_659" xlink:to="loc_us-gaap_StatementTable_662" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_663" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_662" xlink:to="loc_us-gaap_AwardTypeAxis_663" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_663" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_668" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_666" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_662" xlink:to="loc_srt_TitleOfIndividualAxis_666" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_666" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_661" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_669" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_662" xlink:to="loc_us-gaap_StatementLineItems_669" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_660" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_660" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_665" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_665" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_667" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3_667" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_670" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3_670" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_672" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_672" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_673" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_673" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_669" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_674" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_723" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PrepaidClinicalTrials" xlink:label="loc_okur_PrepaidClinicalTrials_724" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_723" xlink:to="loc_okur_PrepaidClinicalTrials_724" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidInsurance" xlink:label="loc_us-gaap_PrepaidInsurance_725" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_723" xlink:to="loc_us-gaap_PrepaidInsurance_725" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherPrepaidExpenseCurrent" xlink:label="loc_us-gaap_OtherPrepaidExpenseCurrent_726" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_723" xlink:to="loc_us-gaap_OtherPrepaidExpenseCurrent_726" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_727" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_723" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_727" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_729" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_729" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_732" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_LabEquipmentMember" xlink:label="loc_okur_LabEquipmentMember_733" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_okur_LabEquipmentMember_733" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_737" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_737" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ComputerHardwareAndSoftwareMember" xlink:label="loc_okur_ComputerHardwareAndSoftwareMember_739" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_okur_ComputerHardwareAndSoftwareMember_739" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_740" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_731" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_740" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_734" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_730" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_730" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_735" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_735" use="optional" order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_738" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_736" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_738" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_742" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationExpenseOnReclassifiedAssets" xlink:label="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets_743" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_742" xlink:to="loc_us-gaap_DepreciationExpenseOnReclassifiedAssets_743" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/AccruedExpensesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_745" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_745" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_746" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedManufacturingExpense" xlink:label="loc_okur_AccruedManufacturingExpense_747" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_745" xlink:to="loc_okur_AccruedManufacturingExpense_747" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedClinicalTrialCosts" xlink:label="loc_okur_AccruedClinicalTrialCosts_748" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_745" xlink:to="loc_okur_AccruedClinicalTrialCosts_748" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_749" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_745" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_749" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_750" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_745" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_750" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_752" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_758" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_752" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_758" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_753" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_us-gaap_StatementClassOfStockAxis_753" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_768" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_753" xlink:to="loc_us-gaap_ClassOfStockDomain_768" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_756" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonClassAMember_756" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassBMember" xlink:label="loc_us-gaap_CommonClassBMember_763" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonClassBMember_763" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeriesCPreferredStockMember" xlink:label="loc_us-gaap_SeriesCPreferredStockMember_772" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_SeriesCPreferredStockMember_772" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_774" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_768" xlink:to="loc_us-gaap_CommonStockMember_774" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_761" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_761" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_761" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_759" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_765" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_srt_RangeAxis_765" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_757" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_765" xlink:to="loc_srt_RangeMember_757" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_755" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_757" xlink:to="loc_srt_MinimumMember_755" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_769" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_758" xlink:to="loc_us-gaap_ClassOfStockLineItems_769" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_760" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_760" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_764" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_764" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockConvertibleConversionPrice" xlink:label="loc_us-gaap_PreferredStockConvertibleConversionPrice_775" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockConvertibleConversionPrice_775" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConversionOfStockAmountIssued1" xlink:label="loc_us-gaap_ConversionOfStockAmountIssued1_776" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_ConversionOfStockAmountIssued1_776" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesAuthorized" xlink:label="loc_okur_ConvertiblePreferredStockSharesAuthorized_777" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesAuthorized_777" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesIssued" xlink:label="loc_okur_ConvertiblePreferredStockSharesIssued_778" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesIssued_778" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePreferredStockSharesOutstanding" xlink:label="loc_okur_ConvertiblePreferredStockSharesOutstanding_779" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_ConvertiblePreferredStockSharesOutstanding_779" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Dividends" xlink:label="loc_us-gaap_Dividends_781" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_Dividends_781" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue_783" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue_783" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockDividendPaymentTerms" xlink:label="loc_us-gaap_PreferredStockDividendPaymentTerms_784" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockDividendPaymentTerms_784" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_785" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_785" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_786" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockSharesIssued_786" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PreferredStockSharesDesignated" xlink:label="loc_okur_PreferredStockSharesDesignated_787" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_okur_PreferredStockSharesDesignated_787" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_789" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_789" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValueOutstanding" xlink:label="loc_us-gaap_PreferredStockValueOutstanding_790" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_769" xlink:to="loc_us-gaap_PreferredStockValueOutstanding_790" use="optional" order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_792" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_792" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_798" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_PlanNameAxis_798" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_795" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_798" xlink:to="loc_us-gaap_PlanNameDomain_795" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_793" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_795" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_793" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_801" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_795" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_801" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_803" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_StatementClassOfStockAxis_803" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_805" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_803" xlink:to="loc_us-gaap_ClassOfStockDomain_805" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_796" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_805" xlink:to="loc_us-gaap_CommonClassAMember_796" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_806" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_806" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_806" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_797" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_800" xlink:to="loc_okur_MergerAgreementMember_797" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_799" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_794" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_802" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_802" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance" xlink:label="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_804" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_807" xlink:to="loc_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance_804" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_809" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_809" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_816" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_us-gaap_PlanNameAxis_816" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_813" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_816" xlink:to="loc_us-gaap_PlanNameDomain_813" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_810" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_813" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_810" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_821" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_srt_TitleOfIndividualAxis_821" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_821" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Non-EmployeesMember" xlink:label="loc_okur_Non-EmployeesMember_818" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_812" xlink:to="loc_okur_Non-EmployeesMember_818" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_824" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_srt_RangeAxis_824" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_815" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_824" xlink:to="loc_srt_RangeMember_815" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_814" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MinimumMember_814" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_820" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_815" xlink:to="loc_srt_MaximumMember_820" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_827" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_us-gaap_AwardTypeAxis_827" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_827" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_826" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" xlink:to="loc_us-gaap_EmployeeStockOptionMember_826" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_Performance-BasedStockOptionsMember" xlink:label="loc_okur_Performance-BasedStockOptionsMember_829" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_823" xlink:to="loc_okur_Performance-BasedStockOptionsMember_829" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_817" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_811" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_811" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_819" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_819" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_822" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_822" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_825" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_828" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_828" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_831" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_831" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_832" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_830" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_832" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_839" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_834" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_839" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_836" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_839" xlink:to="loc_us-gaap_PlanNameAxis_836" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_837" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_836" xlink:to="loc_us-gaap_PlanNameDomain_837" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember" xlink:label="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember_835" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember_835" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember" xlink:label="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_840" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember_840" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_842" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_842" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEmployeeStockPurchasePlanMember" xlink:label="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_845" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_837" xlink:to="loc_okur_TwentyTwentyFourEmployeeStockPurchasePlanMember_845" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_841" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_839" xlink:to="loc_us-gaap_AwardTypeAxis_841" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_841" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_846" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_844" xlink:to="loc_us-gaap_EmployeeStockOptionMember_846" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_843" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_839" xlink:to="loc_us-gaap_ClassOfStockLineItems_843" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_838" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_843" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_838" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_848" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_848" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_853" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_851" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_851" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization_857" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization_857" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_861" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_865" use="optional" order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_869" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_869" use="optional" order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_872" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_872" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_875" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_875" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_881" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_850" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_881" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_854" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_854" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice" xlink:label="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice_858" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice_858" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_862" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_866" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_866" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_870" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_870" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_873" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_873" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_876" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_876" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_882" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_856" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_882" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_852" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_849" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_849" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_855" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_855" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_863" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_863" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_867" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_867" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_871" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_871" use="optional" order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_877" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_860" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_877" use="optional" order="27" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_884" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_884" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_885" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_885" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_887" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_887" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_888" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_888" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_889" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_886" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_889" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_891" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_891" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_899" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_PlanNameAxis_899" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_894" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_899" xlink:to="loc_us-gaap_PlanNameDomain_894" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_904" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_AwardTypeAxis_904" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_904" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember" xlink:label="loc_us-gaap_RestrictedStockMember_910" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" xlink:to="loc_us-gaap_RestrictedStockMember_910" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_913" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_907" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_913" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_908" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_908" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_908" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_MergerAgreementMember" xlink:label="loc_okur_MergerAgreementMember_898" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_902" xlink:to="loc_okur_MergerAgreementMember_898" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_911" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_911" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_896" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_911" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_896" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_897" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_896" xlink:to="loc_us-gaap_SubsequentEventMember_897" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_914" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_VestingAxis_914" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_895" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_914" xlink:to="loc_us-gaap_VestingDomain_895" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_900" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_895" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_900" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_905" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_895" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_905" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_901" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_893" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_893" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_903" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_903" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_906" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_906" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_909" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_909" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_912" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_912" use="optional" order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_915" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_915" use="optional" order="24" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_UnamortizedCompensationCost" xlink:label="loc_okur_UnamortizedCompensationCost_917" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_916" xlink:to="loc_okur_UnamortizedCompensationCost_917" use="optional" order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_919" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_919" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_924" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xlink:to="loc_us-gaap_PlanNameAxis_924" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_922" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_924" xlink:to="loc_us-gaap_PlanNameDomain_922" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_929" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xlink:to="loc_us-gaap_AwardTypeAxis_929" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_929" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_RestrictedStockAndRestrictedStockUnitsRSUsMember" xlink:label="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember_935" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_932" xlink:to="loc_okur_RestrictedStockAndRestrictedStockUnitsRSUsMember_935" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_925" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_923" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_928" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_928" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_931" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_931" use="optional" order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_936" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_936" use="optional" order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_938" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_921" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_938" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_933" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_926" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_926" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_930" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_934" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_934" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_937" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_937" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_939" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_927" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_939" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_949" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_949" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_950" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_950" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_951" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_950" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_951" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_954" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_951" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_954" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_956" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_951" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_956" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_952" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_953" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_955" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_953" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_958" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_962" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xlink:to="loc_us-gaap_PlanNameAxis_962" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_961" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_962" xlink:to="loc_us-gaap_PlanNameDomain_961" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_964" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xlink:to="loc_us-gaap_AwardTypeAxis_964" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_964" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_967" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_965" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_967" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_963" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_960" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_966" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost_960" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_994" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_995" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_995" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_996" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_996" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_997" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_997" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_998" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_998" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_999" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_999" use="optional" order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1000" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_994" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1000" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1002" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1002" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1003" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_1003" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1005" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_1005" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1006" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_1006" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1007" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_1007" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1008" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1008" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1009" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1009" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1010" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1010" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1011" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1011" use="optional" order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_1012" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1004" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_1012" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1014" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_1017" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1014" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_1017" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_1015" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1017" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_1015" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_1018" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_1015" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_1018" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DomesticCountryMember" xlink:label="loc_us-gaap_DomesticCountryMember_1019" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1018" xlink:to="loc_us-gaap_DomesticCountryMember_1019" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember" xlink:label="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember_1026" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_1018" xlink:to="loc_okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember_1026" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_1017" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_1021" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_OperatingLossCarryforwards_1021" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1025" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration_1025" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod" xlink:label="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod_1027" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod_1027" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_1029" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_1029" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TaxCreditCarryforwardExpirationPeriod" xlink:label="loc_okur_TaxCreditCarryforwardExpirationPeriod_1030" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_okur_TaxCreditCarryforwardExpirationPeriod_1030" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1035" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_1020" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued_1035" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1037" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1042" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1037" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1042" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1043" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1042" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1043" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1040" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1043" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1040" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OneTimeTerminationBenefitsMember" xlink:label="loc_us-gaap_OneTimeTerminationBenefitsMember_1038" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_1040" xlink:to="loc_us-gaap_OneTimeTerminationBenefitsMember_1038" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_1046" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1042" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_1046" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1039" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_1046" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1039" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1044" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1039" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1044" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1042" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1045" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_SeveranceCosts1_1045" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense" xlink:label="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_1047" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense_1047" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1049" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_1049" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_1050" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_1048" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_1050" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails">
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_ConvertiblePromissoryNoteAbstract" xlink:label="loc_okur_ConvertiblePromissoryNoteAbstract_1057" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityTable" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_1063" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_okur_ConvertiblePromissoryNoteAbstract_1057" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_1063" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_1062" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1063" xlink:to="loc_us-gaap_CreditFacilityAxis_1062" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_1064" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_1062" xlink:to="loc_us-gaap_CreditFacilityDomain_1064" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConvertibleDebtMember" xlink:label="loc_us-gaap_ConvertibleDebtMember_1061" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_1064" xlink:to="loc_us-gaap_ConvertibleDebtMember_1061" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1067" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1063" xlink:to="loc_srt_RangeAxis_1067" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1059" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1067" xlink:to="loc_srt_RangeMember_1059" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityLineItems" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_1069" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_1063" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_1069" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1060" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_1060" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShortTermBorrowings" xlink:label="loc_us-gaap_ShortTermBorrowings_1068" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_ShortTermBorrowings_1068" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AdditionalProceedsFromAcquisition" xlink:label="loc_okur_AdditionalProceedsFromAcquisition_1070" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_AdditionalProceedsFromAcquisition_1070" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1071" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_1071" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_1072" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_1072" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCosts" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_1073" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_1073" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_GainLossOnConversionOfDebt" xlink:label="loc_okur_GainLossOnConversionOfDebt_1074" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_GainLossOnConversionOfDebt_1074" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_AccruedInterest" xlink:label="loc_okur_AccruedInterest_1075" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_1069" xlink:to="loc_okur_AccruedInterest_1075" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails">
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_1077" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1089" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_1077" xlink:to="loc_us-gaap_SubsequentEventTable_1089" use="optional" order="1" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1088" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_srt_RangeAxis_1088" use="optional" order="2" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1085" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1088" xlink:to="loc_srt_RangeMember_1085" use="optional" order="3" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1083" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1085" xlink:to="loc_srt_MaximumMember_1083" use="optional" order="4" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_1092" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_1092" use="optional" order="5" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1082" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_1092" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1082" use="optional" order="6" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_1086" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1082" xlink:to="loc_us-gaap_SubsequentEventMember_1086" use="optional" order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" use="optional" order="8" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_1095" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" use="optional" order="9" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_1079" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1087" xlink:to="loc_us-gaap_EmployeeStockMember_1079" use="optional" order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1097" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_PlanNameAxis_1097" use="optional" order="11" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1081" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1097" xlink:to="loc_us-gaap_PlanNameDomain_1081" use="optional" order="12" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_TwentyTwentyFourEquityIncentivePlanMember" xlink:label="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_1078" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1081" xlink:to="loc_okur_TwentyTwentyFourEquityIncentivePlanMember_1078" use="optional" order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1099" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1099" use="optional" order="14" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1094" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1099" xlink:to="loc_us-gaap_ClassOfStockDomain_1094" use="optional" order="15" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonClassAMember" xlink:label="loc_us-gaap_CommonClassAMember_1084" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1094" xlink:to="loc_us-gaap_CommonClassAMember_1084" use="optional" order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_1101" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1089" xlink:to="loc_us-gaap_SubsequentEventLineItems_1101" use="optional" order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1080" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_1080" use="optional" order="18" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_PercentageOfNumberOfOutstandingSharesOfCommonStock" xlink:label="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock_1091" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock_1091" use="optional" order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_IncreaseInNumberOfSharesAvailableForIssuance" xlink:label="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance_1093" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_IncreaseInNumberOfSharesAvailableForIssuance_1093" use="optional" order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsForRent" xlink:label="loc_us-gaap_PaymentsForRent_1098" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_us-gaap_PaymentsForRent_1098" use="optional" order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
<loc xlink:type="locator" xlink:href="okur-20241231.xsd#okur_SubleaseExpirationPeriod" xlink:label="loc_okur_SubleaseExpirationPeriod_1100" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_1101" xlink:to="loc_okur_SubleaseExpirationPeriod_1100" use="optional" order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g184865g00n05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g00n05.jpg
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MTI^&9GB1WK/]*QY$,0V'\,S/$CO6?Z4_#,SQ([UG^E8\B&(;#^&9GB1WK/\
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M*X;Q S[9_I6.+]:7^\Q?/'ZT1B'K=$12J(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B N$_P$GS3^I<UPG^ D^:?U(/(YZ5_%_3TK^*%Q$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0%^U)_>H?GM_6OQ7[4G]ZA^>W]:#5]O_OK)YIO
MX%D2UW;_ .^LGFF_@61(B.0B(B1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1!WFAORQLGYY%]X*KVZ_E92_F;?OO4IH;\L;)^>1?>
M"J]NOY64OYFW[[T1ZLX1$1(B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
M(B B(@(B("(B B(@(B("(B#7M3_$G:?]+]ZR%:]J?XD[3_I?O60H0(B("(B
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M\(PYN]U@X X#HZ4&0(N]U==+9=JR"HM-L;;?[/$T3"-TOR>(QY,=071("(B
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ME.V5K)6AW1O$XST9POEU#JK3UPL]12T&F*>CJ9  R=N[EF"#U#O#'TH(9$1
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ME_O,7SQ^M?DOUI?[S%\\?K0>MT1%*@B(@(B("(B B(@(B("(B B(@(B("(B
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M9/SR+[P57MU_*RE_,V_?>I30WY8V3\\B^\%5[=?RLI?S-OWWHCU9PB(B1$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$&O:G
M^).T_P"E^]9"M>U/\2=I_P!+]ZR%"!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0%L.V;\DM/_ #A^S6/+8=LWY):?^</V:(8\
MB(B1$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 7ZT
MO]YB^>/UK\E^M+_>8OGC]:#UNB(I42W/FU_\JK]!O\R<^;7_ ,JK]!O\R\Q[
M7;K<+>^U^T*ZIIM\2[W)2EN]C=QG!\I6><Y[[XYN/K#^U=LVK<>CEB]5+V_S
MYM?_ "JOT&_S)SYM?_*J_0;_ #+Q!SGOOCFX^L/[4YSWWQS<?6']J<.UM*>+
M4]O\^;7_ ,JK]!O\R<^;7_RJOT&_S+Q!SGOOCFX^L/[4YSWWQS<?6']J<.UM
M)Q:GM_GS:_\ E5?H-_F3GS:_^55^@W^9>(.<]]\<W'UA_:G.>^^.;CZP_M3A
MVMI.+4]O\^;7_P JK]!O\R<^;7_RJOT&_P R\0<Y[[XYN/K#^U.<]]\<W'UA
M_:G#M;2<6I[?Y\VO_E5?H-_F3GS:_P#E5?H-_F7B#G/??'-Q]8?VISGOOCFX
M^L/[4X=K:3BU/;_/FU_\JK]!O\R<^;7_ ,JK]!O\R\0<Y[[XYN/K#^U.<]]\
M<W'UA_:G#M;2<6I[?Y\VO_E5?H-_F3GS:_\ E5?H-_F7B#G/??'-Q]8?VISG
MOOCFX^L/[4X=K:3BU/;_ #YM?_*J_0;_ #)SYM?_ "JOT&_S+Q!SGOOCFX^L
M/[4YSWWQS<?6']J<.UM)Q:GM_GS:_P#E5?H-_F3GS:_^55^@W^9>(.<]]\<W
M'UA_:G.>^^.;CZP_M3AVMI.+4]O\^;7_ ,JK]!O\R<^;7_RJOT&_S+Q!SGOO
MCFX^L/[4YSWWQS<?6']J<.UM)Q:GM_GS:_\ E5?H-_F3GS:_^55^@W^9>(.<
M]]\<W'UA_:G.>^^.;CZP_M3AVMI.+4]O\^;7_P JK]!O\R<^;7_RJOT&_P R
M\0<Y[[XYN/K#^U.<]]\<W'UA_:G#M;2<6I[?Y\VO_E5?H-_F3GS:_P#E5?H-
M_F7B#G/??'-Q]8?VISGOOCFX^L/[4X=K:3BU/;_/FU_\JK]!O\RX2:WMCXWM
M$57D@CWC?YEXCYSWWQS<?6']JU#8M=:VX>WO=&JGJ]V:(-Y:0OP#G.,J8M6I
M.-+M^;E9X<'I'L7\YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL7/FSM+?Z
M]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFS
MFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>
M'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1
M[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YM
MUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP
M>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q
M>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<
M6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+
MJ3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%
MO8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN
M+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%
MU)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]B
MWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-
MG:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z
M]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFS
MFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>
M'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1
M[$YMUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YM
MUGAP>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP
M>D>Q>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q
M>D_<6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<
M6U^+J3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+
MJ3[%O8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%
MO8GN+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[$YMUGAP>D>Q>D_<6U^+J3[%O8GN
M+:_%U)]BWL3-G:3Z]WFSFW6>'!Z1[%^E/IZK9/&\OAPUP)PX]_S+T?[BVOQ=
M2?8M[%PELUL$3R+?29 /_HM[%.;.TF:]V5[4:IFJ3;3;@YGM?E-_EANYWMW&
M,9[Q4'S;K/#@](]BV#9O2TM?#7FKI89BQS-WE&!V,YZ,JS]Q;7XNI/L6]BM7
M%JFK&)5HJJJC,2\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L
M6]BIFSM*WU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8
MF;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.T
MGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O
M-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-N
ML\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#
MTCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)
MS;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/
M#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](
M]B])^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])
M^XMK\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK
M\74GV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74G
MV+>Q/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q
M/<6U^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U
M^+J3[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3
M[%O8F;.TGU[O-G-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<6U^+J3[%O8
MF;.TGU[O/VFK346W4%NK:AT9AIYV2O#"22 <G'!=YM+'.:^05EO[B)E.(B)N
M!R'./5GOA:O?+3;H;-7RQT%*U[('N:YL3000T^1=+L\H:.NLLTE5202O$Y:#
M(P..-UO?5XBU-,U8E755JQEBG-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/
M<6U^+J3[%O8J9L[2M]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M
M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD
M^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V
M)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM
M)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[
MS9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;
MK/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@
M](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B
M<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZS
MPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2
M/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2
M?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:
M_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)
M]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL
M3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M
M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD
M^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V
M)FSM)]>[*;S51UNSJAL,0<*R#D]YSAAG#.<'IZ^\H+FW6>'!Z1[%KUII:677
MM;2/IH74[0_$9:"T8QU*U]Q;7XNI/L6]BO7%JGTE6FJJKE+S9S;K/#@](]B<
MVZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V*F;.TK?7N\V<VZSPX/2/8G-NL
M\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#T
MCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+T
MG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BV
MOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2
M?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[
M$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;
M7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI
M/L6]B9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]
MB9L[2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[
M2?7N\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N
M\V<VZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<V
MZSPX/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX
M/2/8G-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8
MG-NL\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8G-NL
M\.#TCV+TG[BVOQ=2?8M[$]Q;7XNI/L6]B9L[2?7N\V<VZSPX/2/8K[:#61ZA
ML5KHZ$.;+2D%YE& >YQPQE:K[BVOQ=2?8M[%$Z(I:6KOMUBJ*:&2./.ZU[0X
M#NL< KTQ:F)G$^"LU51,1ED7-NL\.#TCV)S;K/#@](]B])^XMK\74GV+>Q/<
M6U^+J3[%O8J9L[2M]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?
MBZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^
MQ;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)
MFSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)
M]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S
M9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K
M/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@]
M(]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<
MVZSPX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSP
MX/2/8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/
M8O2?N+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?
MN+:_%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_
M%U)]BWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]
MBWL3W%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3
MW%M?BZD^Q;V)FSM)]>[S9S;K/#@](]B<VZSPX/2/8O2?N+:_%U)]BWL3W%M?
MBZD^Q;V)FSM)]>[S9S;K/#@](]BYP:>JV31N+X<-<">Z/?\ ,O2'N+:_%U)]
MBWL7%UEM@8[%NI.C_DM[%.;.TGU[NI;K:V.&1%5>@W^9%G,70?.BZNZT,.+4
MQK;9\)9_-+_ LQ6G;;/A+/YI?X%F*K5S8T\A$10D1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 6M;".FO_ .]#^]9*M:V$=-?_ -Z']ZFGFB>3V,B(
MN!WB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@+A-\#)\TKFN$WP,GS2D"%V3_ 7+YT?
M\2O5!;)_@+E\Z/\ B5ZM;WGEE9\D"(BR:B(B B(@(B("(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B#K]1?B"Y?FTGW2I_9=^()_SAWW6J@U%^(+
ME^;2?=*G]EWX@G_.'?=:M8^W+*?N0L$1%DU$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$00%D^,JX>9_P"Y7Z@+)\95P\S_
M -ROUK=YQ[,K/*?<1$6341$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M 1$0$1$!$1 1$0%G^SW\H[S]/WUH"S_9[^4=Y^G[ZUH\M3*OS4M 1$6341$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%_'^\=YE_5
M_'^\=YD&)Q=!\Z)%T'SHO9<3&MMGPEG\TO\  LQ6G;;/A+/YI?X%F*Y:N:M/
M(1$4)$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%K6PCIK_P#O0_O6
M2K6MA'37_P#>A_>IIYHGD]C(B+@=XB(@(B("(B B(@(B("(B B^&&\6V>Z36
MV"X4<EQA;O24K)FF5@X<2S.0.(ZNL+[D!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$7XQU5/)4201SQ/GC&7QM>"YOG'2$'[(B^*ANUNKZFIIZ&X
M4E344QW9XH9FO=$<XPX Y:<@]/>0?:B(@(B("(B B(@(B("X3? R?-*YKA-\
M#)\TI A=D_P%R^='_$KU06R?X"Y?.C_B5ZM;WGEE9\D"(BR:B(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B#K]1?B"Y?FTGW2I_9=^
M()_SAWW6J@U%^(+E^;2?=*G]EWX@G_.'?=:M8^W+*?N0L$1%DU$1$!$1 1$0
M$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$00%D^,JX>9_
M[E?J LGQE7#S/_<K]:W><>S*SRGW$1%DU$1$!$1 1$0$1$!$1 1$0$1$!$1
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MU9V44!FWAEN!R._G]$!!M>@-KMFUE>Q:8*"YV^M?$9H15Q -E8.D@@E?'?\
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M;$28GSSEXB)&#@<!T$].5SUCL@TCJRZ/N5QH98:^3X2:EE,9D\KAQ!/EQE:
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MO9)X*)N-^4/8\,SP&\&DD?2M_P!G5MI![(77U0(F&>!@=$,=!DW2]P\N>O\
MZCWUY_O&N]65TEYIJZ\5TD-:7,J::1Y<P#>S@-/!F" .&.\IBJ9GP5FF(CQ4
MNU24.T-I(#14=BS$TMKF\GFJ')M\$9XY#NZX\?.IRV[,]8W*R"[T5@JY:!S.
M4:\;H<]O?:PG><.]@<>I:]MB@BJM#[)Z>I.()1!')\TQ1 _[)[(_5^HM-:SL
M='8*ZIH*2&D;-'' =UDC]]S<.'0X -:-TY''RJ*:IY0F:8\9EU'LHZ&EHH=&
MBEI8:<NI90_DXPS..3Z<><K/K7LIUM=+8RX46GZEU*]N^PO<QCG-[X:XAQ^K
MBMRVU4T5UVA;+8+FQIBJ)SRS'#@[+XB6D>4\,+]-IEVL%NVFT]7=M<W:U55
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M?3\R:*^KX?'SLF^3=]]7':G.R;Y-WWU<=J[FPWB@OUII[G9ZEE50U )CE:"
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MOJ^(3/.F?Y.7O[%O\R<Z9_DY>_L6_P RID371T_,FBOJ^(3/.F?Y.7O[%O\
M,G.F?Y.7O[%O\RID371T_,FBOJ^(3/.F?Y.7O[%O\R<Z9_DY>_L6_P RID37
M1T_,FBOJ^(3/.F?Y.7O[%O\ ,G.F?Y.7O[%O\RID371T_,FBOJ^(3/.F?Y.7
MO[%O\R<Z9_DY>_L6_P RID371T_,FBOJ^(3/.F?Y.7O[%O\ ,G.F?Y.7O[%O
M\RID371T_,FBOJ^(3/.F?Y.7O[%O\R<Z9_DY>_L6_P RID371T_,FBOJ^(3/
M.F?Y.7O[%O\ ,G.F?Y.7O[%O\RID371T_,FBOJ^(3/.F?Y.7O[%O\R<Z9_DY
M>_L6_P RID371T_,FBOJ^(3/.F?Y.7O[%O\ ,G.F?Y.7O[%O\RID371T_,FB
MOJ^(3/.F?Y.7O[%O\R<Z9_DY>_L6_P RID371T_,FBOJ^(3/.F?Y.7O[%O\
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M? R?-*0(79/\!<OG1_Q*]4%LG^ N7SH_XE>K6]YY96?) B(LFHB(@(B("(B
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M2VV'7FI]'UVLV:KJ:0Q\K-!0P@M8]D><]!P.@@ @YQQ*Z.JA?<M2;5JJC&_
MRFF!<WB#BH8?U,<?H6E;,:ZGCV /D>]H;34M8V3CT'>D./I#A]:O/AXPSI\?
M"76_A7K6[&FWP\F;V:@V\/W1N\KC>Y3=Z/><<=&?(NBOT&O=)Z7M^KI=5U-6
M^4QOGHI 3'&'C(&"=T]0. ,9X*(FHIV;#J>I+3R3K\]P/DY -S];2%LVV6NI
MY-B4<C7M+:ME+R.#[[BUW#Z 5.(B<1NB)F8S.S2--71E[T_;KG&W<;5T[)MW
MP2X D?0>"[%2VRR!]-L[T]'*"'^TXW8/5D9'^Q52L)YMXY"(BA(B(@(B("(B
M B(@+^2?!N\R_J_DGP;O,@P:+H/G1(N@^=%ZCS(9/ML^$L_FE_@68K3MMGPE
MG\TO\"S%95<VE/(1$4)$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0%
MK6PCIK_^]#^]9*M:V$=-?_WH?WJ:>:)Y/8R(BX'>(B(/)=KTW9M7[;=<T>J;
MG/1TL$]1)%(RI;$=X3!H&7 C&">'D5=['2JN%-K_ %58J&Z5-UTK1-<(*B1Y
M>P/$@#-T]'%N_P!' [N5*:>L.E[_ +<M=4^M'T[**.>HDB,U4:<<IRX'3O#/
M G@NSV8RPV#V0$U@T-<9:W2TS'.G8V7E8FXBWB0[H.'X =Y<9*)75X]D!8+=
M5W6B%LN,UPH:MU(V!H;F;=+@YX.3AHW>OCQ'EQW^JMK-IL%)90VBKZ^[7:GC
MJ*:VTK-Z;=>,C>[W6.&2<'@L[V 4L$NV/:)421,=/#4S"-Y&2P.G?G'>S@+I
M]?LN,/LF,T][AL,\]/&*.NJ86R,:##NX =PXN#VY[Y0;!H+:E;M4WRHL=5;K
MA9;Y"W?-'7,W7.;P)QY<$'! X<1GBNFONVNEH[C<::TZ8OUVBM\KX:FJ@@Q$
MQS"0[CQX#!Z<+K-.Z%K/PKVK4-_UW;;M=J>)[6TT,$<4LL>XYO0UW0-_.<%=
M+8M=:NU[/J*IM=_LVEK-;7D%D\#9)"T[W=.WO-Q/#CU(-3TSM*L%^T15ZHAE
MEIZ"C#O;3)F]W$YH!+<#.<@C&.G(4YIW;+'>Z^@$>D]0PVJNG;3P7)\&8BYS
MMT$D< ,]."5G7L>J&UW393K2AU!5LI;945#8Y:ASPP1Y: '9/ =UN]*0774^
MQJ\V&U,OM%J'3-=-N0T[<&1C"X9P.);[[(P2TH/[J?;#<Z/;/ 88KTVR4>]!
M-:VL&].YN^TO:W/$$X.>\%Z*TY=6WRQ4-SCIYZ9E5$V40SMW9&9ZG#OK!]<5
M4%O]E3IRIKIHZ>G%*W,LK@UHRR5HR3PZ>"]"4M1#5T\<]+-'/!(-YDD;@YKA
MWP1P*#SSM;O%YUSM8I=G5FKY*"W1@>W)(R1OG<Y1Q=CI ;@!O07=/5BIT_L,
MHM+7^UW;35_NM/+33,=4QS.:YE3&#W3.Y#<9&>G(4)J&NCT#[)\WB];T5JKV
MAPG() 8^+<+OH>./D6[/U_I05-#31Z@MU145TK(*>*FG;,Y[G' X-S@9/2<!
M!)ZCVQT]NO5PMMHTU?;U);Y#%52TL!Y.-PZ1GB>'E 7>Z*VDV?5VE+A?+<RH
M8V@:\U--(T"1A:W>QTX.0.!S]2S>VZYU;K;5.IJ2Q7NT:7M=GD+7.J(&R22#
M><W?.]P_PDD\,9 X]*G_ &.[B[2>U F5LV8<\HT8#_[.?B!Y4%A-[(JP&UQ5
M-#9[K53D.?/ QK1[78#C+W9(X]/Z\+0-,;0;%?\ 14NJ(IW4UM@#O;/+C#H7
M-XEI SD\1C&<Y"S#V,5+ [9!J![H8R^6IGCD<6C+VB%F >^.)X>4K-])QU,O
ML9]8MIMXM9=(GR!O@#DL_N/T(->H-O\ ::RMC+=/WMMHDF$ N)B!C#B<#/'
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M.E?)L^VC67753=8+*RL8^W.:V4U$8:';Q< 6X)X=R>G!062(B B(@(B("(B
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MWB1@%N[D\<'ATK[IXW_^)^G?N.W/:Q[K'#^[N"5\;_\ Q.4#]QVY[6]]CA\
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M>(X+9;7H2Q6[2M3IV*F?):JAQ?+'+(27$XXYX$>]'1WE-4NQ#1T%6)G05DS
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MQRHO9&Z4^R/NPJ+Y'?IA22-?<8XVQMF(;&.#6DCAC=X'J79;#_C/VJ?]Z?\
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MG);=6Y<<'P7=?6>!#N)R%JFC-FM=8=87"^UM]=7S5E(Z&20Q[LG*.+27#C@
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MX8QT>7BNGU-4Z.FUS=H*72=?J>^.(-7R8+HXBT!N!D\,8&>'3PROLL&S+5=
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M]5-RHJ!$=UO=,.,9S_@_W4:H^33/ILS;6MQJ(-B&B;?#(Z."M<[EB#C>#''
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M4Y9AK .C=QT$=\+MD01UFV9:1LUPBK;?9HF543@^-[Y9)-QPX@@.<0"%8HB
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M6LUN_P ;=%P\#[I6E+I[1RH]G/8YU^XB(N9T"(B B(@(B("(B B(@(B("(B
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M6-& PG('#JXB-33$9E%4SAJZB]I6N8](44;*:G%==IVN?%2AV,1M!+Y''J:
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MIVV9K#,UD]3B=\0&=\ ='#CC!\F5_-M#C=]0:-TMDF"OK>7J6CKC9CA]1?\
M4M U54QV[2MVJ'!K8H*.5^.@8##P2(B(C_IXS,_\=(-H%L.SQNK3')[6<SA
M/?F3>W.3\^]PSWN*^"VZPU!3:FLMLU/9Z.CCO+9#3&GJ"]\3F-WBV0$8S@@<
M%&:9TO<KML+L<5MC9)615ON@VGD?NB9K97]QD\!D8*[#4%QO+-56R^WNTLI[
MA!&^ELMFCJ&SRSSR##Y'N;P:P#I\RMICQA75/-<ZSU1+:YZ6TV2!E;J&N/\
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M;'(^FJ=^2#/1O#)!_5Y0OY38U#[("J,W=TVGZ$-B!X@2OQQ\_=N]$+ZO9$U
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M?I*+4UNTOK[757J!TC+I*Z)M%$8W%T\08=UL>!UG=_\ P+8F-:QC6L:&M:,
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MPW(I#O#RD#!QY0M*:*9GFSFNJ(Y+:P[;+;67BGH+Q::RT&H($<LQWF\>@NX
M@'O\0M97FSV0&K]-ZGH;0VQU@JZNGD>7/;$YNZQPZ,N ZP."] Z8G?4Z;M,\
MI)DEI(GN)ZR6 E173B(E-%69F'SZPU-;M)V62YW>1S86D,8Q@R^1QZ&M'?X'
MZEFE'MZMKJJ$7"QW"DHI3AM27!_#OXP,CS$KIO9-3/J;UIFVEQ$+M]Y'?+G-
M;GZ #]:K]O\ ;:8;*Z@1PL8VAD@,  QN#>#,#Z'$*::8Q&?5$U3F<>BVONIK
M79=.NO=;4M]S]QKV/9W1EWO>AHZR>I9C%M\MW+QOJ+#<8;>]VZVIWFG/T='T
M K.-<72>?8]H*E>\ECW5)(ST\D_<;]0<MEVJVBEBV,5E)'$P1T5-"Z$ >]+2
MWB/HS]94Z8CFC5,YQZ*ZXZIM%!ICG!/5M-K,3962M&=\.]Z .^>C"S)FWVW<
MLQ\M@N,=O<_=%1O-)/T=&?)O++]072=^Q72U"Y[N2]O5/#/3N<1^T*W#7UGI
M8]A]31,B8(J6WQ/CP.AS-TY\_ \?*4T13S-4U<E]:;A2W:VTU?;YFS4M0P21
MO'6#_P#G0OJ67^QQJ7S[-HHWDD054L;/(,AWZW%:@LJHQ.&M,YC(LTMOQO57
MZ7[,+2UFEM^-ZJ_2_9A='9^5?M+"_P Z/>&EHB+F= OXYP:TN<0&@9)/4OZN
MEUK:JJ^:5N=LH*AM-45<)B;*[. #TYQQXC(^E(']M.J;%=ZV2DM=WH:NI9DF
M**9KG8'20,\1YE]U/<Z"HKZBAIZVFEK:< S0,E:9(P>C>:#D?2LCJMB@H[-:
M9]-5XH-340#I*K??R<S^L]9;Y,#HX$%=AIK2EST18M6ZDO=QCKK_ %%+)*Z2
M/):W=:YPXD#))QU # PKZ:?25(JJ]8?3JO;#:K/>9+5:Z"KO-=$XMD;3<&M<
M.D9XDD=>!CRJAV>:UCUE2UKQ;JJWSTCVLEBJ/*,C!^CO!8-L@UK!I2VW%]/I
M^MN]WGEWI98NAD( P"[#C[[>)X=[BMQV;;0[;KF"I%)#+25M/@RT\A!.#T.:
M1TCJZL*U=&(Y*T5ZI\96JQNX;>[11U]32FSU[S!*Z,N#V#."1GI\BV1>8=$:
MM.A;SJB6OL%961555D/:S=$8:]^<DC_J"BBF)RFNJ8PVS9MKZDUU!7R45%44
MOM1S&NY8@[V\#C&/,NCUCMAM=BO<MIM]!57:MA);,(" UCATMSQ)(Z^'!=QH
MK:!9M56>OJ;.Q\%121F2:FE:&N;P.#PX$<.GZ\+.?8NP-J:G4MRG DJW.B9R
MCN)[HO<[ZR!]2F*8\9F.2-4^$1+1MG6T>U:WY>&ECEI*^!N\^FFP26YQO-(Z
M1G ZEU6M-KUKT]>GVBBH:F[5\1Q*R @-8>MN>))'7@<%!4N[9?9-5+*5H9%*
MZ1SV-X [],7G_P"7%?3[&.,5]ZU3=:D!]9_9#E#Q/]HZ1SOK+0IFB(^I$5S/
M@T;9UM*M6MI9Z6GBFH[C"W?=338)+<X):1TX)&>@\5<KSW(QMJ]D^T4H#(ZB
M0%S6\ =^GR[ZW9*]"*E<1')>B9G.1$147=?J+\07+\VD^Z5/[+OQ!/\ G#ON
MM5!J+\07+\VD^Z5/[+OQ!/\ G#ONM6L?;EE/W(6"(BR:B_.IGAI:>2>IECA@
MC:7/DD<&M:!TDD] 7Z*3VH::K=6Z4EM-OJXZ5\LK'/=)G=<UISCAY<'Z%,<_
M%$\G;V/4=FOIE%FN=)6NB]^V&0.+?*1WO*NNU+K6U6;3USNT,T=Q9;WMBGBI
M)6O<QY<&[KN/ Y/7WE!WC9!/;*JAN.SRXBTW*&/DI>5D<62\,%V<.P3UC&.C
MHPJS9;HE^D+)50W"I96W"MF,]3* 2TGJ SQ/6<GK)5IBF/'*L35/A,(G_P 0
MEH\2U_VC.U7FS?7=)KJDK9Z*CJ*44KVL<)2#O9&>!'F4Q[(2_P -CT;[GTS8
MVUMT<81AH!;$.+S]/!OZ17?;%]-<VM"444S-VLJ_^*J,CB'. PT^9H://E3,
M4Z<X13-6K&5C<:R"WV^IK:M^Y34T3II78SNM:"2<>8%9!6;>Z"-_*4VG[C+0
M;VZ*A[@P'S#!'^ZV2HABJ()(*B-DL,K2Q\;QEKFD8((/2"%@NTK:S8JS3-TT
MY:[75"5P-*.6C9'%'AV,@!Q/#'#@$HC/H5SCU;%H[4]NU;8X[I:GOY$N+'LD
M&'1O'2UP[_$'Z5GU]VX6JCN=126BUUEU93DB2>)P:SATEO Y'EX!==H.@=IG
M83?ZN"MIZBHJ8IY]ZFD#VPN,88&Y'^(8R?.OL]C'10QZ(KZH,;RT]:YCW8XE
MK6-P/-W3OK4Z:8S*-4SB%QL_UO:];6V6IMG*1RPD-FIY0-^,GH/#@0<'!\BC
M]0[;K5;[K44-IME7=O:Y(EFA<&LX=..!) [_  "SC1M2_3NLMH]/0DQQ04%=
MR8;PW2R3N#]&2KKV+M'"W2-UK QO+RUIA<['$M;&P@?6\J9HBG,HBN:L0N]G
MNN[7K>@FFMHDAG@($U/+C>9GH/#@0<'CY%5KSWLE8+7MVU-;Z8;E,?;3 P=
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M01,8XY<UK  3WROU+01@@$>4(G+RSM8UY8=I%@H['H^P5]9>#.QS)?:C6F,
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MI(VYXM?+O =\@/:<>54>TO5FSW4=AL3]8T-Q;;KC"^HHJX0$.A(.Z1EI)!.
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M]5ODH]YS0).2<X!S"X=#03AP=D'&/K7I&FIX:6!D%+#'#"P8;'&T-:T=X <
MNLO6F;)>Y&R7>TT59*T8#YH6N<!WL].%;B1.<JQ;QC#$MG33K?;9=-3TT,@M
M=.'EKWC&<Q\DP><C+L=6%UNR>_T>S36&H[1JA\E)'(6L$O)N<-Z-SMTX:"<.
M:\D''>7HVVV^CME*VFMU+!24[>B*&,,:/H"^*]:;LM[>Q]WM5%62,&&OFA:Y
MP'>!Z<)KB?">1HF/&.;$=#/.N=NU9J6BBD%JI.[$CVXSB/DV#SGWV.\"O0B^
M6V6ZBM=*VFME)3TE.WB(X(PQN>_@+ZE2JK*]-.F!$156=?J+\07+\VD^Z5/[
M+OQ!/^<.^ZU4&HOQ!<OS:3[I4_LN_$$_YP[[K5K'VY93]R%@B(LFHB(@(B$
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M=61PZ5Z!K*2GKJ:2FK8(JBGD&'Q2L#VN'E!X%=7:-*6"SU)J+79J"EJ/^;%
MT.'F.,A(KCPSZ$T3XX]6#[8-.5>E[?H>XLC,@MM/'33N;T-E80\9/>)+_J7V
M[9-HMGU=I:AL^FWSU=955#'OCY%S2S .&<1Q<7$=&>@KT!5TT%9324]7#%/!
M(,/CE8'-<.\0>!74VK26G[15>V;99;?2U'5+' T.'F..'T*8KCPSZ(FB?''J
MXZ$M#[#HZSVR; FIZ9C9 .@/QEW^Y*[U$64SEK$8$1$$!9/C*N'F?^Y7Z@+)
M\95P\S_W*_6MWG'LRL\I]Q$19-11>UG61T5I=U;!$):V>3D*<.]ZUY!.\[R
M \.O@K1?)<[9076!L%TH:6MA:[>$=1$V1H/?PX'CQ*F,1/BB<X\'F;9?J+2M
MMNT^H]8U]367^20OC!@<]L1/^,GK=WNH#_;=IM?6DZ$J=540FJK?#D;H;N/+
MM\-Q@]'$A=AS,TO\F[+ZC%_*IS:9I.ONNE:;3NDZ:BH:&>H!JMP")D<8.]P:
M!QR[!X=[RK29IJE2(JIA^M+M,MLF@6ZKGHJR.BY;D7Q- >]IW]W/2 0H':QM
M"T3J#1=324&*RY2;O(?\*YCH79!+MYP&.&1P)SE;'8=/6^RZ<IK)3P,?0PQ\
MF6R-#A)GBXN'02223YU\D.A]+P50J(M/6ILP.0X4S.![X&,!1$TQ.4S%4QAC
MFE-,7:N]CW>::2&4R33FLHXB#O&-I83@>7=?@=><]:_79IM4LFG]FGN=<)9&
MW2B$K88!$X\MO.+FX<!@<78.2.A>@  !@< N@JM&::JZTUE38;9+4N.\Z1U,
MTEQ[YX<3YTUQ/-&B8Y,)V>:,K[AL@U=4B!_+7$1NI68XR"%V_D#RDD#RA=IL
MHVI6336SUUMNLDK+A1.E,, B<>6#G%P (&!Q)'$A>@(V-C8UD;0UC1@-:, #
MO!=%6Z-TW6UKJNKL5MFJ7'>=(^G:2X]\\./TJ=<3G4C1,<F8>QCLM3!;;Q>Z
MJ-S&5SV1PDC&\&[Q<X>3+@/H*VU<8HV11MCB8UD;1NM:T8 '> 7)4JJU3E>F
MG3&!9MKKXPM/_P"C^U*TE9MKKXPM/_Z/[4K?LOGGVECVGR?[#241%S.@1$0$
M1$&1[;=<V&/3U^TRZJ?[KF-C>2$3L9):_P!]C'0NL]C]K2R4NGJ#3D]2]MVF
MJ)"R/DG$'))'=8QT!:S7Z9L-QJGU-PLELJJE^-Z6>DC>]V!@9)&3P"XT6E[!
M0U4=30V.U4U1&<LEAI(V/;U<"!D+353IPSTU:LI^[;1J*W;0:/2CZ*HDJ*@L
M;R[2-UI>,CATE9AK6=NB]O\ 37^Y1O%LJ@V3E TG ,7).QWR#QQTX(5YI;0]
M?+M&NNKM3B+EM\LM\#'[XC9C=#CY=W \Y)[ROKM:K?=Z;VO=:*FK(,Y#)XP\
M ]\9Z"D3%,F)JAYYVFWBBVCZ^T[0Z3+ZIT7</J&QN;P+@2>(!PT G/E7V;19
M':,VZV[4E9')[G5&X\R-;GAR?)/ [Y XX\H6Z673UHL8>+/;*.B+^#C!$&EW
MG(XE?1=+90W:E--=*.GK*<G/)SQA[<]_!ZU/$B/#T1HGGZO/.UG4-'M,U)IV
MR:3=)5M8YV]+R3FC+RW)PX X:&DDX7T[38SHO;)9=12PR&V/;%E[1G@QO)O:
M/*&X./*MSLNG+-8R\V>UT=$YXPYT,36N<.\2..%]=SMM%=*5U-<Z2GJZ=QR8
MYXP]N>_@I%<1X1R-$SXSS>>=K^IZ+:/=]/6/2+I*UW*.+I.2<P;SL <' '
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MUW35YU=16RSVQT4-NDJ!)73/?@M:WH ;_BZ2?. J^V6:AMUC@M%/3L-OBAY
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MJ7B[1PU0 )B8Q\CFY[X:#CZ54GH..E8)['VW4-^N6J;E?*:"MN9G;GVPP/+
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MN4S&*I4MV:*HG,0E^8ED\"J]9?VIS$LG@57K+^U5"*G>+O5*_ M=,)?F)9/
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M]J<Q+)X%5ZR_M50B=XN]4G M=,)?F)9/ JO67]J<Q+)X%5ZR_M50B=XN]4G
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M+IN?9H_USV_O5_XYHB+F= B(@(B("(B B(@(B("(B B(@(B(("R?&5</,_\
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MA&.:]H<QP<T]!!R"O)^S71GX0-9:VMMTNU?3V>FKGS24U,\-Y:1TD@:22",
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MEC<Z0\E2[@E=!DX!R,GN<9 .3Y5VGL<;M9:C3=5;;72RTU=3O$M5RKP\REW
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M,FJ"[X3_ (;_ />J9B(C4B)F?I=OLOUOJ"+7%7HW6<K*BL9O"&<  [S1O8R
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M4M&UEPKVAM1+ON/* =6"<#H'0 K4S$<T3$SR1%QVR6*'3MNN5N8:ZJJYA":
M2ALT1P<EPX\ 0 ._D+Z-<0;0;K?WT6EJBDM=ICB:35RXWI'GI X.(QY /.NS
MH=F&DJ&^MN]-:6,JFOY1C=]QC8_IW@S.!Y.H=2Y;0V:S?[1YD2T48P_VS[8
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M+1Y9'=*K=Y2=P!+-[H:,Y X=T3CHQA36Q[3]?J_7-5KJ\1<E2B9\D#>J23H
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M C)+#EK@"1O C@1T\ MD1.).3AQAY_K=/:UVGZBM;M4VIEHM%$>['O<@D%V
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MCHG\HRFI:<1AYX9R<#IP.H^3"UA*:9)JAD'LBM-UUVMEHN5OI'UHMTK^7IV
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M^G[Z[?G17?)F[>BWM4GI*Z3T5XN,T-LJZM\N=Z.$#>C[K/']2THLU13,;_\
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M7Z7[,+2UFEM^-ZJ_2_9A=/9^5?M+GO\ .CWAI:(BYG0(B("(B B(@(B("(B
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M>=$AZ'>=%]#+P(7&AO>UOG9_$JE2VAO>UOG9_$JE>;5S>E1Y1$157$1$!$1
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MEME!!16^".GI(&AD448PUC1U (,/UQK35E_VM/T+HZY4UF93LS)52L#G2.W
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M62B:\QSO<7-!;)NM+<DX#FY./(NET_07#;/JJ\U-QNM526BC(Y&&(Y#0XD,
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M1-<1O/KHPT?HO/[E%/AB$SXYET.UO7]PJM,:8H[%*^EJ[[ R>9T3MUS0[ #
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M>U0>Z!+3CB<\!O C QC'T*3TG3RR[-=?SQ@\F/:7T_VQ)_V6][ IHSLJM.'
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ME>SRDT#05K8ZV:X7"OD$M55RMW3(1G  R<#BX]).25<(B N$WP,GS2N:X3?
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M/LT?ZY[?WJ_\<T1%S.@1$0%GNTG3.L+]7MYN7^"WVUU-R,U/)D;[B7;QX-/
MM('T+0D4Q./%$QGP89H[9;K?3%2P6[4E#3T;YF25$41>>4 /'I9WN"_FUOV[
MJ/:QI^PV.HG$U,QLE08WD-AR[>+CCK#0#]('6MT7P4EFMM)<ZJXTU%!%7U6!
M-4-8-^0#J)^@?4KQ<\<RIH\,0Y55IMU7,9:NWTD\I&"^6%KG8\Y"SC5&R^2Y
M[1K1?*$6R"U4HBY:F,>Z7[KW./<ANZ<@@<5JB*D53')>:8EG^U79S#K.V4;:
M*:.AKZ'(IW;O<%IQW! Z!P&".CO<5&_@LUAJ2LH8]=:BAJ+;2'N8X7%SW#K_
M ,+1DCAO')6Y(K17,1A6:(F<H':CLYI]8V.BIJ.5E%64 Q2O+<L#< %AQQQP
M''JPHEVRO6>HIJ*FUKJ2":U4ARUD+B]Y'1UM:,XX;QR0MT1(KF(P31$SE^5'
M314=)#34S!'!"QL<;!T-:!@#Z@OU1%1<1$00%D^,JX>9_P"Y7Z@+)\95P\S_
M -ROUK=YQ[,K/*?<1$63471ZTH;O<=/5%-IRO9;[DYS2R=_0 ' D=!Z1GJ7>
M(D>!+ '[(]<OU +X[4EO-V!!%3E^]P;N^!CHX*DVB5%TTUL6GI-0W7VU>ZAX
M@;40D@O)DWL X!X,!!X+6U\%TLUMNTE*^YT4%4ZF?RD)E8';CN^,^8*^O,QE
M31B)PBMG]AOU#LDCM_MMU+>YX9)(I)B7& O)+0>G&!CS$E0ESV1ZYNEVIKG<
M-26^>OIMWD9G%^\S==O-QW'43E;^B17,3DFB)C")T_I:[U&C;E9=<7-ETDK'
M.:)8O\$9:W !('$.!/0LZI]E>O+515=ELVI:-ECJ7.WVN<YCB#P/#=.,CI =
MQ6]HD5S!-$2B=);.[;8M$56G97&I;6M=[;FQNE[G#&1WL<,>;*SNGV5Z[LU-
M66G3^I:1EEJG'?#G.8X@C!X;AP2.!W3Q6](D5S!-$2DMF>BJ;1%@-##+[8J9
MG\K43[N-]V,  =0 Z/I[ZK415F<^,K1&(Q LVUU\86G_ /1_:E:2LVUU\86G
M_P#1_:E='9?//M+#M/D_V&DHB+F= B(@(B("F]H6E(-9::FM51,Z!Q<)8I@,
M[CQG!QUC!(^E4B*8G'C")C/@PRGV?[3*:S&P4^I;<VS%ABQD[PC/2T'D]X#!
MZ,JQT]LNMMLT!7::J9WU!KN[J*@-W3RG#=+1U!N!CZ>^M"16FN95BB(8'#LK
MU]1VR:P46I:-M@E<=YF\X$M)X\-PD9ZP'8/%:7IW0%LM&A)M,.+IX*ECA4S8
MW72/<,%P[V,#'>P%8HDUS*8HB&"4^RO7EGI*RSV+4M(RR5+COASG,<01@\-P
MX)'3@\5J&S71=-HC3_M""4U%1*_E:B<MQONQC@.H ='T]]5:*)KF? BB($1%
M581$0%G^SW\H[S]/WUH"S_9[^4=Y^G[ZUH\M3*OS4M 1$6341$026T73MWO]
MOI.;UYDM5?2RF1KP7!L@((W78ZOH/F6:W+9AKW5,L$&K=34DE!$_> C)<<]\
M,#&@G&>)*W=%:*YCDK-$3S9!MBBI-([)Z73]IDFC?+)'3T[6.[N3#MYY.._U
M^5P7TU&A+Y=-C5JTX:]M/<@6RU!G>X@M+G.Y-Q&3PWFCO=RM'N%FMMQK*.KK
MZ*"HJ:-Q=3R2,#C$3CBWO'@/J7WJ=>(1H\6"V397K^QTAI;/JFBHX"XO+(7R
M-!=WSW'$J_MFC;E7Z!KM/ZUN@N-14O<14QDDQC@68) R0X9_V5VB37,D41#
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FCY$GLTQ5%.>9%S,3++(>AWG1=Y#%'NG^S9T^"$7JZWFQV>=W_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g184865g00n06.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g00n06.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1W&4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $4< 5H  QLE1QP"   "   < E  "')R,SDR,SDX' (% "1-:6-R;W-O
M9G0@5V]R9" M($9I9W5R92 V(%)I9&5R+F1O8W@ .$))300E       0'CHM
M_!.JFV,WT4&5\NYBF3A"24T$.@      Y0   !     !       +<')I;G1/
M=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E
M $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;654
M15A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\
M9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M
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M9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M"G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M    3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M        4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN
M9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,
M969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!2
M96-T5&]P;&]N9P      .$))30/M       0 2P    !  $!+     $  3A"
M24T$)@      #@             _@   .$))300-       $    6CA"24T$
M&0      !    !XX0DE- _,       D           $ .$))32<0       *
M  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8
M 0"AF9H !@       0 R     0!:    !@       0 U     0 M    !@
M     3A"24T#^       <   _____________________________P/H
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H   X0DE-! @
M     !     !   "0    D      .$))301$       0     @   D    )
M     #A"24T$'@      !      X0DE-!!H      S\    &
M  -V   &+0    4 9P P &X ,  V     0                         !
M              8M   #=@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #=@    !29VAT;&]N9P  !BT    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M W8     4F=H=&QO;F<   8M     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !: * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MOWW?]'_R*6QW[[O^C_Y%)2S*Z]C?:.!V"IYEV70YWHXC;AN8&0-8+7NM<?\
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M_25NJQEM;+:SN98 YI\01+4_YO;CY*22E))))*?_V3A"24T$(0      5P
M  $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0 00!D
M &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ T     0 X0DE-
M!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L
M!0    $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @   !0   "=
M 3L  @    D   "QAVD !     $   "\    Z    2P    !   !+     %!
M9&]B92!0:&]T;W-H;W @,C4N-R H5VEN9&]W<RD ,C R-3HP,SHQ-2 P,SHT
M,#HS-@!R<C,Y,C,Y.      #H $  P    '__P  H ( !     $   8MH ,
M!     $   -V          8! P #     0 &   !&@ %     0   38!&P %
M     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M        2     $   !(     3A"24T#_0      "           _^$!3D5X
M:68  $U- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %
M 0   '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M    "0   +&':0 $     0   +P   #H   !+     $   $L     4%D;V)E
M(%!H;W1O<VAO<" R-2XW("A7:6YD;W=S*0 R,#(U.C S.C$U(# S.C0P.C,V
M ')R,SDR,SDX      .@ 0 #     ?__  "@ @ $     0  !BV@ P $
M 0   W8         !@$#  ,    !  8   $:  4    !   !-@$;  4    !
M   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M*"@H*"@H*"@H_\  $0@#=@8M P$B  (1 0,1 ?_$ !P  0 " P$! 0
M       %!@$$!P(( __$ &,0  $# @($!@T)! <$!@D!"0$  @,$!081!Q(A
M,1,505.1T0@4%B)14E1587&2D[$R-7)S=(&AH^$S-#9"%R,W1;*SP21B=8(E
M.$.BPM(8)U9D=I25\/$F1&6#M"A&8V;#_\0 %@$! 0$
M  $"_\0 &A$! 0$! 0$!             !$!03$A O_:  P# 0 "$0,1 #\
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MB*H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B!R%:=I_=3](K<Y"M.T_NI^D41N(B(HB(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/QKOW.;Z*]4G[K%]$+S7?N<WT
M5ZI/W6+Z(1'Z(B(HB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(
MB("(B B(@+(6%D(-.Y_L8_K MSD6G<_V,?U@6YR*)C"(BJB(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B LA860@TY_G*#Z)6X5IS_
M #E!]$K<*)C"(B*(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("R%A9"#>PI\Y5OJ'^BM*JV%/G*M]0_T5I65P5"C_ 'RN^N*OJH4?
M[Y7?7%7#7ZHB*H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B!R%:=I_=3](K<Y"M.T_NI^D41N(B(HB(@(B("(B
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MD<UKA.YI+M;/=EZOQ5T"H@\1XML&&98([_=(*"2=I=$V0.)> <B1D"HC^E7
MV[NFHL_H2?\ E7(>RV.5WPSX.U91E_SA;VC[0EA[$&"[/=JRJKV5-9!PCQ&Y
MH:#F1LV>A0=?M&.\*WFH;3VN_P!!43N.38^$U'./H#LLU897MABDDE<&QQM+
MW./( ,R>A?'NFG E%@*]4$=HN#YF5,1D#'D"2$@Y;2.0\AV;BOH_ ==6W'1!
M0U=T+W5<ELDUGO\ E/ :X-<?6 $$E8L=X7O]P;06:]4U96.:7")C7@D#:=X
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M7S$?#2,FD='3PQ/U.];L+G'TG/9Z$J.[X8Q?8,4,>;#=(*MS "^,9M>WUM<
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M7OU7 'PD;,^E<@PE<KKHRTI.M8JBZ&.M;25C&')D\>L!GD?0<QX$(^PGO9&
M9'M:#LS<<EECVO;K,<US?"TYA?-O9+XXIJZI=A:GIJB*KM=9KR3EXU) 8SL
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M@GZG=$TZVJ<LN'&U?4N-03A&_  DFAGR'_(5DU\K=CWAJWXFQRYEWB;44M+
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M(9'@<&00TD'O K5%V06(F1L8,.4)U6AN>4N>P>M3!]+Q_+'K7QKH\_MWMO\
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M%LEHZ>GF,KGSR!SW.(R&P;AM7=]!=A-@T=4,4D\$\M4YU4YT#P]@UMS<QL)
M S]*8NK\B(J@B(@(B("(B B(@+(6%D(-.Y_L8_K MSD6G<_V,?U@6YR*)C"(
MBJB(B B(@(B("(B B(@(XAHS<0!Z3DOE/LAKW=*#2E6Q4=RK8(6P0.$<<SFM
MSX,9[ 5ONP%I.QE:X[Y6W9VM/&)8::6J=&[5.T:K ,FY\FY2D?3JROF301I
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MJ(R&.,;!GWQ<=Y)&S[UTW1!@>HP%8*VW55;#6/J*GAP^)I: -4#(Y^I7I82
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M-T91LE>7]JSL.49/(QPY/7TK2H^QVJ7T54^YWZ&2O>T"'58XL:<QF7D[3LS
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M Y"M.T_NI^D5N<A6G:?W4_2*(W$1$41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MJ[^(J#Z+O@5,\JAJ[^(J#Z+O@5,\J)@B(BB(B B(@(B("(B B)F@(B(")FB
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MU-_@W;4%@:]KV!S""UP!!'*%#08EML^*JC#L$KY;G3T[:F=C6$MB8X][K.W
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M66CI(J=TC6['%C TD>O)!SIW9#Z/P"375V0_]RDZET&+%-I=A1N))*H06AT
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M_5-^"Q>_FFJ^@4LOS31_5-^"(W41$41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MD=;*ZFJVQD!Y@D#]4G=GDM]!QVF K.RDJG2C)U!8&LCRY=9^9_QE=B7'7?\
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M/J(G8CQ)B+$-+"\/CI+A5ET.SD<WEY/ NIT\$=/ R&")D4,;0UD; &M:!N
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MJ.DCBK*YP?4S#:^4@9#,GD W#<MZ:)DT3XYF-DC>-5S7#,.!Y".4+VB"L6G
M6%K/<G7&V6&WT]:3F)61#-A_W>1OW9* T[W^6SX#GHJ!CI;K>7BVTD+?E.=)
MF''U!N>WU+HQW+\)Z2">6*2>"*22(ET;GM!+#X0>1!&8+L4>&L+6NS0D.;1T
M[(BX#+6<!M=]YS/WJ:6 LH"(B B(@(B("(B B(@AL2_L*3[0WX%3#=RA\2_L
M*3[0WX%3#=R)UE$1%$1$!$1 1$0$1$!1=RL%LN=QMUPKZ**>MMSG/I)7_*A<
M[+,CUY!2B(,!9.Y$.Y!Q[!#3@S3+BBQUAX.BQ&X72W.(R:Z3;PK!R9[<_4U=
M7NEOI+K;YZ&X0,J*2=I9)$_<]IW@KU/1T\\\,TU/%)+"28WO8"69[\CR+]P$
M'X4%%!;Z*"CHHFPTT#!'%&W<QH&0 ^Y:-WP[:;Q76^LNE!#55-ODX6E?)F>"
M?L[X#/+/O0I9$#E0[D1!'6>RV^S"JXLI(Z<U4SJB=S<\Y)';W.)VDK:K:.GK
MJ66FK8(JBFE;JOBE8'M</ 0=A"_=$%<P]@C#6':M]59;)14=2_/.6.,:P!W@
M$[0/0,@J/I[J9;O%8L#V_-U7?ZM@GU=O!4T;@Y[SZ-GWY%=;.Y?@:2!U4VI=
M!$:EK=02E@U@WP9[\D&:.GCI::*G@;JQ1,#&@<@&P!?LL 'E64!$1 1$0$1$
M!$1 0[D0[D$-7?Q%0?1=\"IGE4-7?Q%0?1=\"IGE1,$1$41$0$1$!$1 0[D1
M!3KUHSP?>[I47&[8?HZFNG(,LS];6?D !N/@ 6D-#V <_P"%Z#_O=:OR((+"
MV$K%A2.HCP[;(*".=P=*(L^_(V#/,^DJ=.Y$0<DTV4[K)>\*X\A#BVR57 5@
M8W,]K3=ZYQ]6?_>75J::.IIXIX'M?%*T/8YIS#@1F"E13Q5,#X:F)DL3QDYC
MQK-</2"O4,;8HV1Q,:R-@#6M:,@ -P 01UNL-LMUTN%QH:.*"NN#FNJIFYYR
MENP$]*@;QHQP=>+E/7W/#]'4UDQUI)7ZV;CZ=JN2(*#_ $/8!_\ 9>A_[W6K
M'AC"EDPO!-!A^W0T,4SM>1L6??'P[2IM$$=Q+;^/..321FZ<#VN*EVUXCSSU
M1GN&>W8I#+>LH@JS]'V$WW@W5^';:ZN+M<R&$'-V>>MJ[L\]N>6:QI,Q(W"6
M"+K=MAGBBU:=G*^5VQC0-YVD;N3-6H[E^%52P53&MJ8(IFM<'M;(T. (W$9\
MOI05#0UAU^&='EHHZEI%;+'VU5:S<G<+)WY!](SU?N5V6 ,EE 1$0$1$!$1
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M B(@TKW\TU7T"LV3YHH_JF_!8O?S35?0*S9/FBC^J;\$1N(B(HB(@(B("(B
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M0WX%3#=RA\2_L*3[0WX%3#=R)UE$1%$1$!$1 1$0$1$ [EQ@XDQ5I(Q'<Z#
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MJK\16^^U=)PETM[7LIIM=PU&O!#AD#D<P3O""9"T[S2]NV>NI,R.'@?%F/\
M>:1_JMP(=R#E'8Q57;&A^V1EI:^FEG@<#OS$A.WI5DLVDK"]SN]?:C<XJ.XT
M=0^G=3UAX!SRTY9LULM8'T;54]$S6X2Q[B_!=0X-;/4<<6\99!T4NQX'AU2
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MO/TX/\UJZFHK$V'[;B>SS6J^4W;5#-JE\>NYF9:<QM:0=X"#8L?S+;_L\?\
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MJ*&I;J21.)&8]8W>L*11!K6RBAMU!3T5*'"GIXVQ1ASBXAK1D 2=IV<JV41
M1$0$1$ [E"W+#-JN=^MMYKZ7AKA;0[M5[GNRB+MY#<\L_20II$ (B("(B B(
M@(B("(B AW(AW((:N_B*@^B[X%3/*H:N_B*@^B[X%3/*B8(B(HB(@(B("(B
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M%3/*B8(B(HB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MQZE,HA$-P-YYZF_'J3@+SS]-^/4IE$(JE\CN8A@,\L!'##5U<]^1]"DN!O)
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M)WVFQ+AZAO%%%/%3U<8D8R=FJ]H\!"8MO5/A[#=QNU;$^:FI(72R1L )<!O
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MV::.-SSJM#G %Q\ \*_7-<:T;8.L^.<*QXFQC2,NMVNSGRODD>[*!FL0R.,
M]Z /!MSSVJQ:(ZRHIJ7$ECK:A\U/8+B^CIII7%SS3ZH>P/<=Y =EGZ @O\T\
M4(:9I61AS@UNNX#,G<!Z5JWRZ4UEM%7<J]SVTE+&997,87D-&\Y#:5SW##7:
M0,8G$]1JR88M;G0V5A&RHE^3)4D'> 06M^\[UTV2-LC',D:U['#)S7#,$'DR
M0:MEN=)>;527*VS-GHZJ)LL4@_F:1F/5ZN1;JY!H"GEM==C'!L[\V6&XGM4$
M[1!*2YH_#/\ YEU] 1$0$1$!$1 1$0$1$&E>_FFJ^@5FR?-%']4WX+%[^::K
MZ!6;)\T4?U3?@B-Q$1%$1$!$1 1$0$1$'F5[8XGO>0UK07$GD 5#_I?P("0<
M2T.>>66LKZ]H<PM< 01D0>5<7[([#EEH-$MXJ:"SVZFJ&OAU98:5C'#.1O*!
MF@[+#(V6-DD9#F/ <TC<0=R_0[EI6/YFH/L\?^$+=.Y!5\?XSH\%VREJJRGJ
M*N:KJF4E/34P!DED=N !(V;%^6(-(F%</7)U!>KS34=:UK7.AD=WP!&8S5,N
M3SB7LC*"VRAKZ+#=M=6ZI'_;RY-!^X%I^Y=+K\.V:XU!J+A:+?53D9&2>F8]
MQ'@S(S0?EAG$MHQ/0RUEAKX:VFCD,;I(CF X '+H(4!5:6,$4=5-3U.(J*.:
M%Y8]I=M:0<B%4^QGC9':<8QQ,:R-F(:EK6M  : &@ #P+I4N%,/32/DFL-I?
M(\ESG.HXR7$[R21O05PZ8,!Y?Q+0C_F5TH:^FKK=!7TLS)*.:,31R@]ZYA&8
M.?@R7![C9+3I1QIQ-AZU6^FP=:9 ;E7TM-'$^IG&9$,;@,]4;,R/#ZL[SIB8
M:;!UILM&TP6ZNN-);*C@N]X.F<\-<!X!D WU%!9+7CG#%TO#[9;[[;JBM;_V
M<<[3K'P-V]]]V:LO(N>:5<,V7^C&[,CHJ>D%MI'U-&^%C8S#+&TN86D#9M ]
M>:_>_P",JBV8!M-=3T[:G$5U@A914?.U$C0<O0T9DD^ (+527FWU=WK;7354
M<M=1M:Z>)IS,8=\G6\&:B<<XQH\&PVVINL%0ZBK*IM(Z>( M@<[/5<_,_)V'
M:-RSH_PPW#%B,<TAGNE8\U=PJ3OFJ';7N] &X#P +\M*>'XL38 OEKE&9DIG
M/C]$C!K,/M (+6-ZRJ5H9O[\2Z-;#<I3G,Z 0R$C:7QG4)Z6E75 1$0$1$!$
M1 1$0$1$$-B7]A2?:&_ J8;N4/B7]A2?:&_ J8;N1.LHB(HB(@(B("(B B(@
M+#GM8TN>X-:-I).0"\S2,AB?)*X,C8-9SCN "X1ANSU&FJXW"]XGJ*J/"5/4
M/@MENIY#$V=K3D9)2-IS^.>[+:'=:>HAJ&:]/-'*W=FQP</P7ZKC&(-"]%8Z
M)]TT9S5EEOU(#)%&RH?)%49;>#>UY.>>0Y5=]$^,68ZP517H1B*=V<51&,\F
M2MV. SY.4>@A!<%&XCOEOP[9JJZWBI;34-.W6DD=MRVY 9#>2>122Y!II:,2
MXLP7@K-QBJZPU]6T'5SBA:3EGZ=O0$'5K=5Q5U#35=/K\#/&V1FNTM.JX9C,
M':-Z_2>HAIV:]1-'$WPO<&C\55]*&+68'P/<;V8VRRP-#((G9@/E<<FM.7)F
M<SZ 50\-:'Z/$EOCO6DR6KO-[KFB=\+JA\<-+K#/@V-:1EER\GQ0=H:]KVAS
M'!S3N(.8*SF/"N XLLTVA&6FQ+A2HJI,,23LI[E:ZF5TK(6/.0DCSV@@Y#?R
MCD.R^:5:^2KME@M%#4R00X@N$5)+4PNR<("'/=JGD+@W+/TH+[%4P2OD9%-&
M]\9R>UK@2T^GP+]5Q_'V!K%@W"TF),+4IMUULNI4QRQ/=_7M:YH<R7,]^'#/
M//;GM5SQQC"+#F&(Z^*%U17UI;!04C1FZ>=X.HSU<I/( 4%I;-$^22-DC'2,
MRUVAP);GNS'(HBY8GM5KQ#:[+75!AK[F']J-<PZLA;O;K999^C//:H_1UA8X
M9L\O;DW;5YKY357"I.TR3.WM'^XW<T>#UJN=D':G56 GWBE)9<;#/'<J9XW@
ML<-8>K+,_<$'3D49AB[17W#UMNL RBK*=D[1X-89Y?BI- 1$0$1$!$1 1$0$
M.Y$.Y!#5W\14'T7? J9Y5#5W\14'T7? J9Y43!$1%$1$!$1 1$0$1$ [E4\1
M:1,*X=N;[?>KU2TE8QH>8I';0#N*MAW**K\/6:XU)J+A:+=53D9&2>F8]Q W
M#,C-!^>%\36C%%')5V&OAK:>.3@G21',!V0.700IE<:[&B-D5NQI'$QK(V8B
MJ6M8T9!H&J  !N"[+R(/QK*F&CI)JFJD;%!"PR2/<<@UHVDE0F!<308NL,5X
MHZ2JIJ29[A#VP '2,!(UP 3D#ELS50[(RX3TVC.JH*+]ZN]1%;F?\[N^W>$
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M1U_@XE;_ (@@[-JC5R+1EX,EQO1#31V'2KI$L-O'!VULL%6R(;!&][27:HW
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M8[E4-;MW#-IV=*[$N4=C#0R4>B6@EF:YKZR>:JR/@<\@=(:#]ZZN@(B("(B
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M\)J*=E@PW$XZT=/4:\\V7@>1WN?J 5VOETI<%8*GKZU]144MJI1K.<=:675
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MY1S(.SP*'Q-7W.6SX?P#;*F2/$5PH8Q6U;'9NHH&M DE)\9Q!:WPDK9O>&<
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MJUF'L'W&N8P!ENH9)FM V91L) _[JYUIXSX]T<G+O>/X/BK[I#HI+E@'$E%
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M%P8&PG!:HY75%2Y[IZJI=OFE<>^=ZMP'H"MH64%/TC5=X=;H+-AJ*=MTNC^
M%8(R8Z./^>5SMP(;GJC/,G)2=DPS06?"46'Z1CA1,IS3DGY3\P0YQ(_F)))/
MA*G -JR@Y-A&\77 6'X,,77#=ZN,MOUH*.KM].)8:J($F,D@]X<B =;+<2K)
MHIP_7V.PULU[9'%=KM737*JBC=K-B=)D P'ER:UH]>:NF2C\13U]+8ZZ>ST8
MK;BR)QIZ<O#!(_D!)( &:#EVC%QNVF[21=P 8:4P6V-V[:T=^/:8NQ*D:(<)
M2X3PE'%<,G7BND=6W"3//6G?M<,^7+8/N5W0$1$!$1 1$0$1$!$1!I7OYIJO
MH%9LGS11_5-^"Q>_FFJ^@5FR?-%']4WX(C<1$11$1 1$0$1$!$1 5!TYX=N>
M*=&URM-CIVU%?,Z(LC<]K =60$[7$#<"K\B#4M44D%MHXIAE)'"QKAOR(: 5
MMG<B'<@X_3 V7LFJITQRAO\ 9F\$2=\L1&;1_P K25V!4?29@^LQ)Q+762KA
MHKS::QM3!-*TEKF;GQNR&>3AEN\"NS,\AK#(\J#F^A;"UWPU;L40WFG%+)77
MBHJX"V1KRZ-^6J[83ENW%13+=I5PG,^GL]1:\5VK-QCXP>8*EF9)R+AL._E_
M!=?1!Q:ZT&E3'5N?9;S0VC#%HJP8ZR:"H[8J'1\K69'5&>Y=5PS9*3#M@H+1
M;F%M)1Q-BCSVD@<I]).T^DJ41!0I</W._P"D47&_4[([#9@#:H-=KC/.1WT[
MP,\M49AH.WE4OI PY+B2PB"BJ!37*EJ(ZVCF<,VLGC.;=8<K3M!]:LR(.47>
MGQ[C"A&'KO8J"SVV=S&7"O97"8RQ YN;"P#,%V66;MP*O.+KC3X;P9=*XEL4
M5'1R.9MRVAIU0/OR"GCN5(TJX1KL;6>BL\%;%26UU4R6OSS+Y8FG/@VY;-I\
M/@""/['JS263118X9QE-.QU6_9EGPCBX?]TA='7B&)D,3(HF-9&QH:UK1D !
ML "]H"(B B(@(B("(B B(@AL2_L*3[0WX%3#=RA\2_L*3[0WX%3#=R)UE$1%
M$1$!$1 1$0$1$ [EQ2&RXHT6XANE1A:SNO\ A.Z3FJDHX7AL]%(3WW!M/RFD
M<GH&[>>UH@XO?L3XXQQ;7V?"V$[A8XZL&*IN-V BX&,[':C<\R[([_\ \CI6
M!\,4.#\,T-EM;7=K4S<M9WRGN.USCZ2<RIT#)90#N7(,4Q\2]D/A2[RG5I[K
M;YK;K'++7;WX &_,DM"Z^=RY_IHPE6XHPU326(M;?;551UU"XY#-[3M9F2,@
M1^(""S8RPY1XLPQ<+'<];M6LCU'.;EK-.>8<,^4$ _<N7V#$&-M'] RQXAPK
M77ZAHV\#17&U 2NDB&QG",SS!R V_P#Y/8+9-/46^FFK*8TM2^-KI8"X.X-V
M6UN8V'(\JV2$'%+A9\3:6+Q01XCLTM@P912BI[7G>.V:R5OR6N:"=5NT_KR=
MJ#0&Y   ;!X O2<B#G'%U9C/2 *N[4=138?P[,#0QRL+.W*KEF(.]C-S?"23
MFI'2=9[K6TMHN>'HVSW.SUK:QM.YP;P\>JYLC 3N<6N.7I5U'J64')\4W*Y:
M0K?'ANWX>O5OI:J>+C*KN$ @;!"QX>X,S)UW'5 &68V[U9=+]=':M%>)YI#W
MO%\L#<SEF7M,8_%P5R 7.=+&'+QBZX8;LU- !A\5C:NZ3N>,G,C.;8M7/,ZQ
MY<MFQ!+Z'[5+9=&>&J"H!$T5&PO!Y'.[XC[B5<%Y8T,:&L:&M R &S(+T@(B
M("(B B(@(B("'<B'<@AJ[^(J#Z+O@5,\JAJ[^(J#Z+O@5,\J)@B(BB(B B(@
M(B("(B AW(B#F^A/"]VPQ38I9>J9M.ZNO4]9!E(U^O$[+)W>DY;MQVKI!1$'
M)^R1@?#@>DOT#29K'<:>N! )R:'ZIV<OR@NG6^IBKK=354+A)!41-D8[D<UP
MS!Z"ORQ!::6^V2NM=P9KTM7$Z&1OH(Y/3RJ%T:6.Z8:PG26:\U<%:ZBSA@GB
MU@70@]X' [B!LV> (*9/@_%N"KY7UVCAU!66BX2F>>S5SC&V*0[W1/&[,\BT
M;K0Z5,<T3[->;?:<,6BI_JZN>&HX>=T?*&9$@9[MJ[4B",PW9J3#UAH+1;FN
M;244+88PXYD@#>3X3O\ O57LN'KE<L>UN)<1Q<#'1AU+9Z37#N"C/RYG99C7
M?E]PV*]H@J&D+#E;=H+?<K$Z%E^M$_;-'PY(CDS!:^-Y&T-<TD9CT*N5=#C+
M&U104&([)26*R4U3'45>K6-J7U?!NUFL8&C8PN )+MJZDAW(*+IMO3+#HNQ#
M52%N<E,ZF8#RND&H!_WE*:-+,;!@.Q6U^?"04D8?GXY:"[\25&:1,&56,[C8
M()ZJ&&Q4%6*VJAR)?4/;\AN6[5WYY^%7@#([D&41$!$1 1$0$1$!$1 1$00M
MN_B*X_1;\ II0MN_B*X_1;\ II$P4+AG^\?M+O@II0N&?[Q^TN^"'4TB(BB(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@.^2?4H;"GS:[ZP_ *9=\D^I0V%/FUWUA^ 1.IE$1%$1$!$1 1$0$1$!
M$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!I7OYIJOH%9LGS11_5
M-^"Q>_FFJ^@5FR?-%']4WX(C<1$11$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$00V)?V%)]H;\"IANY0^)?V%)]H;\"IANY$ZR
MB(BB(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B AW(
MAW((:N_B*@^B[X%3/*H:N_B*@^B[X%3/*B8(B(HB(@(B("(B B(@(B("(B B
M(@(B("(B B(@(B("(B B(@(B("(B B(@(B((6W?Q%<?HM^ 4TH6W?Q%<?HM^
M 4TB8*%PSON/VEWP4UR*K6FZTM#+7LJ7/:YU0YPR:3FAJTHH?NCMW.O]V[J3
MNCMW.O\ =NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O\ =NZD[H[=
MSK_=NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O]V[J3NCMW.O]V[J
M0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_W;NI.Z.W<Z_W;NI"IA%#]
MT=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_=NZD[H[=SK_ ';NI"IA%#]T=NYU
M_NW=2=T=NYU_NW=2%3"*'[H[=SK_ ';NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2
M=T=NYU_NW=2%3"*'[H[=SK_=NZD[H[=SK_=NZD*F$4/W1V[G7^[=U)W1V[G7
M^[=U(5,(H?NCMW.O]V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4
MPBA^Z.W<Z_W;NI.Z.W<Z_P!V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z
M.W<Z_P!V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_
MW;NI.Z.W<Z_W;NI"I@_)*AL*?-KOK#\ G=';B,N%?[MW4HZP7FCI*$QSO>UY
M>3L83LR'H0JU(H?NCMW.O]V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[
MMW4A4PBA^Z.W<Z_W;NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"
M*'[H[=SK_=NZD[H[=SK_ ';NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"*'[H[
M=SK_ ';NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_=
MNZD[H[=SK_=NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O]V[J3NCM
MW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_W;NI.Z.W<Z_P!V
M[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_P!V[J3NCMW.O]V[J0J8
M10_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_W;NI.Z.W<Z_W;NI"IA%#]T=N
MYU_NW=2=T=NYU_NW=2%;=[^::KZ!2R?-%']4WX**N=^H9[?/%'(\O<W(#4/4
MLVR_4$%OIHGR/#V1M:1J'>!ZD*L**'[H[=SK_=NZD[H[=SK_ ';NI"IA%#]T
M=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_ ';NI.Z.W<Z_W;NI"IA%#]T=NYU_
MNW=2=T=NYU_NW=2%3"*'[H[=SK_=NZD[H[=SK_=NZD*F$4/W1V[G7^[=U)W1
MV[G7^[=U(5,(H?NCMW.O]V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[M
MW4A4PBA^Z.W<Z_W;NI.Z.W<Z_P!V[J0J810_=';N=?[MW4G=';N=?[MW4A4P
MBA^Z.W<Z_P!V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.
MW<Z_W;NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_=N
MZD[H[=SK_=NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O]V[J3NCMW
M.O\ =NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5C$O["E^O;\"IANY5:]WFCJ8H
M&PO>2R8//>$;,BI$8CMP'[5_NW=2%3**'[H[=SK_ ';NI.Z.W<Z_W;NI"IA%
M#]T=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_=NZD[H[=SK_=NZD*F$4/W1V[G
M7^[=U)W1V[G7^[=U(5,(H?NCMW.O]V[J3NCMW.O]V[J0J810_=';N=?[MW4G
M=';N=?[MW4A4PBA^Z.W<Z_W;NI.Z.W<Z_P!V[J0J810_=';N=?[MW4G=';N=
M?[MW4A4PBA^Z.W<Z_P!V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4
MA4PBA^Z.W<Z_W;NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"*'[
MH[=SK_=NZD[H[=SK_=NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O]
MV[J3NCMW.O\ =NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O\ =NZD
M[H[=SK_=NZD*F$.Y0_=';N=?[MW4G=';N=?[MW4A6*[^(J#Z+O@5,\JJE5>:
M-]YI)V/>8HP0XZAY0?0I/NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4
MPBA^Z.W<Z_W;NI.Z.W<Z_P!V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z
M.W<Z_P!V[J3NCMW.O]V[J0J810_=';N=?[MW4G=';N=?[MW4A4PBA^Z.W<Z_
MW;NI.Z.W<Z_W;NI"IA%#]T=NYU_NW=2=T=NYU_NW=2%3"*'[H[=SK_=NZD[H
M[=SK_=NZD*F$4/W1V[G7^[=U)W1V[G7^[=U(5,(H?NCMW.O]V[J3NCMW.O\
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MVSV0O:(/'!1\VSV0G!1\VSV0O:(/'!1\VSV0G!1\VWH"]H@_,PQ9Y\$SV0G
MQ\TSH"_1$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@H^;9[(7M$'C@H^;9[(3@
MH^;9[(7M$'AD;&$EC&M)\ R7M$0$14#3/BZZ8.PQ2UUCCHY*R>MBI0*MKG,
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MYQ?+B:KCH(+Y34TM%--FV-XC:6O&L=@.:#IERPZQN$>)+/<JFR0Q1MCCJ8'
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M6KM@3"6WSMR>YFL,B<B" 3N\(""!P);:S&V(8\=8DII::FB!99+;-_V,9_\
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M=!IY6SPQRLSU'M#AF,CD?0=R#]$1$!%J7>X06NVU-=5<)P$#"]_!L+W9#P-
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M'O3;C14U6QED@+1/$V0#OSNS""\4F/,)5E5%34>);/-43.$<<<=9&YSW$Y
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M.W)36 <75]UNETL&)J"&@Q#;=1\C()->*>)_R9(R=N6S(@[OAC0> W1)A4-
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M_M%7<Y#'3"&B8?\ :*EPV-C!V@$@[]P5??5Z5*8FX2V[#512@:QM<,T@J,O
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MXR<PC8YKAR$$$$>A1NE+^S;%/_#*C_+<OST9X>@P[ATPTEV?=XJF>2K[;(:
M\O.9(U=F6>9V>%?II2_LWQ3_ ,,J/\MR"MZ/,>X3I<"X?IZK$UGCGBH(&/C?
M61AS7!@!!!.PYJZVR^6Z_4-3+AZYT5=J9LX2"5LK6/RV9ZI]1R59T;X9L<N
M<.2362V/D?;X'.<ZE82XF,;22%<;=;J&W1O9;J.FI&/.;FP1-8"?2  @K>C'
M$M7B.P3<<Q107NWU4M%7Q1 AC96'>W/;JEI:1ZUXO6):QND:QX8M4<3N%@?7
MW"60$\' .]:&Y'Y3G\IY 5 W4LP7I<9=ZB7@K-B6F[6J"?DQU4+=9CCX-9@<
M/6%M:&XY[K37C&%PC+:F^U/"4X=O92,&K"WT9C-W_,@\UF+<18DN]SMVCZEM
M[8K7,::JN-T+N",PWLB8S:[+E.8'^NWAW%5ZHK_2X>QS14E/<*MCG4=?0O)I
MJHM&;F .[YC\LSD=^W(^'GVB[#]XG-]LL&-[A:[A;:^83T+*6%V37/+FR@N&
M9#@0<_2K:_ =5-B&R<>X\K*^>BJ!6T]'+! PR%@()&J <LG$'+PH-G&V.KI8
MM(EIP];K>VO-RH))((0-5SIP_(:SR<FL#0XDY'<M*[7[2-A2EGO=_H\/W"RP
M#A*F"WNE9/!'GM<"_O7Y#?NW+];V/_ZB,,^BR57^,*V:3O[-\5_\)JO\EZ"M
MZ6:F]W71M5UV$:JV"W36Z>:J[<8]SI('1$C@]4Y!V1._9N7XZ(:?&\=HL+[S
M66"3#_%T7!14L,K:@#@VZF9)U=V]?G9&N?V-C T%SCAQXR\/]0Y6_1O+'-H^
MPTZ)X<WBVF&8/*(F@H*I/BG%F)[[>[=@2"TTE-9ZDT=36W0O=PLP ):QC-N0
MS&TG:K/ABHQ;VO6Q8FH;7VS$T&">AG<8Z@Y'9JN&;,MF\G>H*IP'15=^N5[P
MGB.NL]PJ)2*T4;V2PR2MWE\3@1K#<=H7C!>)+Y!I N^$,1U=)<G4=$ROBKX(
M>!<6%P!9*P$M:[;F,N3:@LFCVMO]PPQ35&+Z"&@O#G.$D,1S: ''5.\Y9CTK
MQI1_LVQ7_P +J?\ *<IRU7*BNM%'66RJAJZ23/4FA>'M=D<CD1L4'I1_LVQ7
M_P *JO\ *<@_+10/_5EA7_A=/_EM4?I6P?!?;'47&W,;38FM\9GMU?'WLD<C
M<R&ZW*T[B#LVJ1T4?V984_X73_Y;5H:5L808=L,U%2.;4XAKXS#;J!G?232.
M[T'5\4;R3LV(-.JOCL2: Z^\2C*:KL,[Y0!D.$X%P=EZ-8%3&B/^R["?_"Z?
M_+:H6:QR8;T UUHG.M/2V&=DI&[7X%Q=EZ-8E3>B+9HOPE_PNG_RVH+7DN9X
MR_MOT?C_ -UK_P#"Q=.Y"N8XR_MPT?\ V6O_ ,+$'1+FZICMM7)01,FK&1.=
M#&\Y![P#J@GD!.2C,$U5YK<,T%1B:CBH[N^/.>&)V;6G/9X<LQMRSV9J;ED9
M#$^25[61L!<YSCD !O)7X6ZMIKC1Q5=!415%+,W6CEB<'-</""$%4TU;-%&*
MOL$GP4W@[9A.S?8XO\(4'IJ_LHQ5]@D^"G<'[,)V<<O:D7^$(*?IBPO'48?J
ML2V:-E)BFT1FJHZV/O7]YM<QW(YKFZPR/A6]6:0:2WZ/K-B*>"6:HND, I*.
M+Y<\\K06QCP;>7DR6GIDQ1%0X>J</6LMJ\3WB,TM%0,.;W:^QSR.1K6ZQS.S
M8JUCBT=R5!HKJ*P:]JP[4QPUT^6;8LXA&)3Z [EY,P@L!J-*K2:\T6%S!JZQ
MM@EEX?Z/"Y:NM]V2WH-)MJET<W'%W:]2R&WZT531O $L<[2&F(\F>;F[?3FK
MJ:NG%(:LSQ]JAG"&76&H&Y9YY[LLN5<CT:QVG$%CQ[<[DR*/"]ZN<@C,YX-D
ML8:UADVY9:SMQWYH)6FJ=*E=##<H(,+4]++&)6VZ9TQF (S#72 :H=NY,E9<
M18M9A?!\5XQ#1R153PR/M&G<)7.G?L$33LUCGR^LJMC!5\PS:)784QI6,I*:
M$NBIKK%'4Q!H&8;KY!S6Y#+/,Y!4K'%[N&,=$N!L7RO=;!#<XZBMDIF!XIV!
MSXC,UK@<P#D>78[[T%W=5Z5&@7'B[#3J?+6-J;-(*@CQ>%RU-;[LE<,&8DI,
M4V2*XT;)(B2Z*:GEV/@E:<GQN'A!'P*J,&#<15%.RH@TEW.2![==LC*.G+7
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MKXIP'8,2U+*NXT99<(VZC*RFD=!,!X-=A!(]!5I1!6L*X*L6&))9K30AM9,
M):N9[I9I,O"]Y)^X;%M4V&;=!B>KQ!P;Y+I41-@X65Y=P<8_E8#L:"=IRWJ;
M1!"WW#-MO=9;JRMA(K;?*)J:IC<621GE;K#;JD':-Q7Z.L-$[$L=^+'FXLI#
M1A^L<N#+]<C+=GF-ZED006*,)63%$,4=[M\=087:T,N99)$?"U[2'#I4;AS1
MYAZQ5S*ZGI):FX1@B.KK9WU$C ?%+R=7[LE;T01-38:*IQ#27J6-QKZ6%\$3
MM8Y!KB"=GW!:V+,)6?%=-##>J0RF!W"02L>Z.2%V[-KFD$?H%/H@KE'@VT4F
M&*VPPPS<7UK7MJ->=[WR:XR<2]Q)SR]*EK9;J>VVFEMM,P]J4T#:>-CCK=XU
MH: <]^P+=1!0J[13A:IJ7RPTE30LD.M+!0U4M/%(3OS8QP;T *R4&&++06)]
MEI+51Q6IX+7THC!8_/?K _*)Y25,H@Y^=$>%1*>#IZZ&D.PT<5=,V CE&H'9
M9>C<M;2G@FFNV [?AJSV>+M45],UD<0U64L8?F^3+9N;KCTZWA7240>6C5:&
MM;D ,@%#VW#=OM^(;I>H8WNN-Q#&S2R/+LFL&36M!^2/0-Y4TB H2HPU;Y\5
M4N(C&]MTIZ=U*)&/(#XB2=5PY0"<QZ5-H@Y[6:)<.U-TN%>V2ZTT]?.ZHG[6
MKY8FO>3M.32 O5)HHLE+50U$==?B^)X>T/NDS@2#GM!=M"Z B"K8HP'A_$E6
M*RXT.K< P,;64\CX9@!GD-=A!(V\JQAC 5AP[5]NT5+)-<-34[;JYGSRAN>X
M.>3JCU9*U(@A+'A>U62Z7>XVVE$-7=91-5/UB==P]>[>3]Z_3%.'Z+$]DGM-
MU;(^BG+>%8QY9K@$'(D<F8"ET0?G!$R")D430V-C0UK1N &S)?E=*&FN=MJJ
M&NB$M+4Q.AE8=SFN!!'05LH@@3A2T386BP]7T@KK5'$V(15),AU6_)VG;F,A
MD=XR4';=%F%Z&LCJ.TZBJX!P?3Q5=3+-% 1NU&.<0,N39L5Z1!$X;L-%AVW&
MAMC',IS*^;)SBXZSW%SMI])*T<28+LF([Q:;G=J-LU7;'E].XDC(Y@Y.'*,P
M#D59$08 ]"IE]T:X;N]?)7NI9Z*NF.<T]!424SIOIZA /KWJZ(@@\+85LV%J
M22GL5!'2ME=KRN!+GR.\+G.)+OO*]VG#E!:[U>+I21O;5W9\;ZIQ<2'%C2UN
M0Y-A4RB"N8HP98L3NBEO-O9-4Q#**H8YT<L8\ >TAV7HSR6AA[1SAVR7"*OC
MIJBLKX<^!J*ZHDJ'Q9C(ZNN2&^L#/:KDB"$Q-A:SXGIXX;Y0157!'6BD.;9(
MCX6/&3FG8-Q4-8M&F&[1<8J\4L];70[8IZ^H?4F(^%NN2 ?2-JNB(,<JK.-,
M$VG& H.-Q4A]#(98'P3.B<QQ&1(+3GR*SH@YS_1#8O+\0?\ U6?_ ,RMV&+!
M38<M?:%#+5RPAY?K5,[IGYG_ 'G$G[E,(@K=PP79*_%U!B6JHVONU$S4BDS.
M0WY$C<2-8Y'DS5BRS!!V@A>D042X:*L+5=6^>&DJ*#A7:TT5#524\<IY2YC'
M!OX*SX>L%KP[;FT-DH8:.E!SU(VY:Q\+CO<3X2<U*(@B;!8:*Q-KVV]CF"MJ
MY*V;6<3G*_+6(\&X;%XO>'*"\U]JK*Z-[Y[9/VS3%KRW5?EEF1RJ91!$8EP[
M:\36TT%[HV55-K![0[,%CAN<UPVM(\(4=9,"V*TVNKH&4KZN"L %3V]*^H,H
M&X'7)V#D5H1!S[^B'"G"$-@KVT9!#J)M?,(' \A9KY9>A7BVT-+;:*"CM]/'
M34D# R.*-NJUC1N  6RB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
M B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
> B(@(B("(B B(@(B("(B B(@(B("(B B(@(B(/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g184865g07g07.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g07g07.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2%44&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP"   "   < E  "')R.#,Q,# R' (% #--:6-R;W-O
M9G0@5V]R9" M($]+55(@+2!"=7-I;F5S<R!396-T:6]N(%)I9&5R+F1O8W@X
M0DE-!"4      ! %I?*S\&<?]]JX5I3:P\AB.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             #\@  !<X    & &<
M,  W &< ,  W     0                         !              7.
M   #\@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #\@    !29VAT;&]N9P  !<X    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   _(     4F=H=&QO
M;F<   7.     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    %.$))300,     !;#     0   *    !M   !X   S&   !:G !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !M * # 2(
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M_P"D]6O]&MY))3RO_-[ZX;&M=U_>16]MA](-+W.L]1ONK_H_Z+V;ZOTF/O\
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MOI66NJ=7ORO3_2>GZ'I^@MSIO3<?IF+]EQRXU^I9;[C)FU[[G-G]QGJ;*_\
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MK,9V.U[K'NBL?I-OZ1[O<Y_N?9]-)3=Z?_0,;_BF?]2%85?I_P#0,;_BF?\
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MY'^C6KZC"8#A,D1/<?2"YXT>M-C6#K%%!#=Y'HYM<!KOT>1^@^T>W^5C6_\
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M44+:VVU/J?.VQI:Z#!@B#[@@81H^D?8OCGR@B\DZ!_>+29T[)QV-;A9CVL:
M!5>!<R .)_17_P#@Z?[5U.G^D8@N:.7XSP3_ -LW^B[_ #++E> @ :F-).I3
MI</8D(.4GYHQGXD<,O\ &AP_\YR&]7PA=E-=:<>QP:1ZK',VDM@;M[5!F<PU
MC_+&/N$:.V1RUSF;M];^WI[UI4?TK)^+/^I64]V3BWUUY_4Z]K 'V5O8!N9[
MW;=Y&UWMKV?^"^S]&RR.5BKVLC3T]?[[,,>+(30D"(QTXN+B]'Z/!B=+#OQ1
M2QHOJ?80#:YCFG<^ 'O]OTMR69T[$S=MEC2VY@_19%9++63_ *.YGN_L?S?[
MZR\/#^TY;&NLQLRJDN^U!V.UCY(<RL,FOWM]1N[_ -*>I6M)W1NDN_[1T@^+
M6!I_Z&U&),H_**VU/_HZS-AQ1/#*1.E_+Q?]/VD)NZK@'].P]1QA_AJ6AM[1
M_P +C#]'D?U\;99_W54?J[9BVXE[\7;Z;LFX^T1R[<R6_2;^B]/Z2..C=/:9
M8Q]9_D6VL_ZBQJCT7'9CXCV-:6S?<3+MQTL>P>[^JQ.CQ@U^B1WXOQ8#"((X
M9RD.TXZ_27')T$DDD]3_ /_4ZOZE''9D]5IIN?>1>7N?;BG'=)=8'_K!?9]H
M9ZN_]'MI]"SU?T-=5E=5?39/]'M_J._(N8^K[,JQW6:,;,Q7W$.:+L>RRUU>
M0]V18W>+[LEOHX[;*F-V5T?IJ\FCTOU=:F/C=7QL:QV9D-R"W#KJV20#;7ZW
MK9'J>GO_ $];ZM_L_P $DIMXU(NZ;BL)(VLI?(\6;+8_Z"N+*;TZW*P\=]67
M;C T5 AD1H![O=^<ZO?6B5],RV7LM=U"Y[6%OZ(ANTM;[=K]-SG/;_./_?25
M3HI++;TG.920.HW66FHL!LC;N):YML5['_19Z?M?_P"")-Z1E0!9U+(>-9@M
M:2?[ ]K4E.HDLO\ 8^3[IZCD%SM021I!);#0-GYW[J);TN][MS<Z^IQV2&D%
ML-#0YK66;_YS;NW?324Z"2S:NEY=9:3U&][@'!V[;!EKF,.V/;Z;CZB>KI-[
M+FVNS\BPM+202 #MTAS&;:_?7[7^S_A$E.BDLJGHEE181G7DL<UP)=,@'=Z3
MY/NJV^QO_7/TGO1!TJP->T9+CN^C()]P?ZK+'^_WN_P=_P#I:_\ 1I*;E=+F
M776%P(MVD-B(VC;]*?<G-%+K/5<QIL(#=Q$F&DN;_FN<J Z1>QI]/.N:XU>F
M),M#Q5]G9=L)_-_GOI^^Q,[H^2X.#NHY'N:YK=I @N$;I^E[/S/_ $O^FL%!
M/$=[Z5]CH5X]%3G/JK:QS_IEH F"YVL?RGO1%FV]*RW6O?7U"ZIKG%^QH! )
MC0;]WMW?F?\ J3U&;TG+:Q[?VC>7N# +#&X;-^Z/\'^D]3]S_!L]3U4:K91)
M.I-NF@XM#Z*W,<\/W6/>"!M@/<ZW;])WT=ZI6]'O>069UU;FL#!8-7P'6/\
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M '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #(
M,0    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R
M  (    4    G0$[  (    )    L8=I  0    !    O    .@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C4Z
M,#,Z,30@,#4Z-34Z,S4 <G(X,S$P,#(      Z !  ,    !__\  * "  0
M   !   %SJ #  0    !   #\@         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4Y%>&EF  !-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @
M !0   "= 3L  @    D   "QAVD !     $   "\    Z    2P    !   !
M+     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-3HP,SHQ
M-" P-3HU-3HS-0!R<C@S,3 P,@     #H $  P    '__P  H ( !     $
M  7.H , !     $   /R          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
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MS@,!(@ "$0$#$0'_Q  =  $  @,! 0$!            !@<$!0@# @$)_\0
M:!   0,# 00""@T'"08#!0$1  $" P0%$08'$B$Q$T$(%"(V46%Q@;&R%A<R
M5G)S=)&3E*'1TA4C-4)2=<$S-#=#5&*"DL(8)%-5L^$X1/!C=H.BPV6$T^(E
M)B=%1D=79)5(AJ.T\?_$ !L! 0 # 0$! 0             #! 4" 08'_\0
M0A$!  (! @,#"08#" (!!0$   $" P01!2$Q$D%Q$R(R,S11@:&Q%&&1P='P
M0H+A!A4C-4-2<K(D<V(V1$7"\=+_V@ , P$  A$#$0 _ .J0
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M*9KE^9% S   !@2WFUQ2+'+<J)DB+A6NG:B_-DSF.:]J.8J.:J9147**@'Z
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M=:KC '3X!C5=PHJ-<5=93P+X)96M]*@9(/.">*HC22GECEC7DYCD<B^=#T
MP%O5K2985N5$DR.W-SIV[V]RQC/,]ZNNI*-J.K*J"!J\EED1N?G4#(!YT\\-
M3$DM-+'-$[D^-R.1?.AZ  ?CW-8U7/5&M1,JJKA$,2"ZVZ>;H8*^DDF_89,U
M7?,B@9@   P9+O;8IUAEN-&R9%PL;IVHY/-DSD5%1%1<HO6@ 'Q/-%3PNEJ)
M611-XN>]R-1/*JF/1W.@K9%915M+4/:F5;%*UZHGAPB@98,.6ZV^*HZ"6OI&
M3_\ #=,U'?-G)F)QY  5QMRUM/H_1%96V2MHVW>&6)J12*USD:YW'N%7/(@&
MP#:_>=6WVXTVK*ZWQ4\,#7QKNMA[K..>>('0P/&DJJ>LBZ6DGBGBSC?B>CD^
M=#&9>K6^9(F7*B=*J[J,2=JN5?!C/,#/!XSU=-3RQQSU$,4DJ[K&O>C5>O@1
M%YGL !@2WJUPRK'+<J)DB<-UT[47YLF<UR.:CFJBM5,HJ<E _0:36%ZALM@N
M-1VW305<=+++ V9[4WG-:JIA%7CQP<X[(MN6J-1;0+5:[_6V^.VS])TSEB;'
MC=C<Y.ZSPXH@'5)2FM^R&L.E]4U5E2V5E:ZDD6*HF8YK&M<G-&HONL>;D7%1
MW"CKM[M*KIZC=]UT4C7X\N%.=]HVPFS7K6U9<H=64MM;5S=+4TTR,<]CG>ZW
M<O3GSPJ=8'0.G;Q1Z@LE'=;:]SZ.KC26-7)A<+X4ZE-@:?1UDH].:8MUIMCU
MDHZ6)&1O5V5>G/>SX^9MWN:QJN>Y&M3FJKA /T&'!=;?42K%!7TDLJ+C<9,U
MRY\B*9@ 'A65E+1,1]94PT[%7".E>C$5?.?E)74E:Q[Z.J@J&,7#G12(]$\N
M% R 8<-UM\\_0PU])),BXW&3-5WS9,P  8#KS:VR]&ZY422?LK.W/S9 SP&J
MCFHK5147BBIU@
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M\."H=#@
M                                                 C>TBGN]7H:]
M4NG&-?=)Z9T4*.?N^ZX+A>I<*N/&20 <*6_4FT[9=)VH]+I0PIG=@JXEDA\>
M[G+>KJ-A<MOFT"[T3Z&*6*!TJ;BOI*;=D7/@7BJ+Y#M>:"&=JMFBCD14QA[4
M4QH+1;J=V]!04L:^%D34_@!R-L,V-W^Z:JH+YJ.AGH+72S-J<53-V2H<BY1$
M:O'"KQ553D7IV1.A*S7.B616AB/N=#-T\,:JB=(F%1S47J7&%\Q:2)A,)P0
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M236VEHE5\$,[-V29ZHJ(NZO%$3.<KS.KP
M
M                                       #&N-!27*E?37"FBJ:=_NH
MY6HYJ^93QM-FMMGC?':J&FHV/7+FP1HQ'+X\&>
M            "KA,KR*=I^R!TQ6:D99;9172NJ9*CM:)T,;5;*[>PBIEW+KR
M!<0-%J;5]ATLRE=J*Z4]N2IWNBZ=<;^[C>QCP;R?.:'VWM ^^JW?YE^X"=@A
M5)M5T+5RI%!JFUJ]5PB.FW/M7!,:6HAJJ=D]+-'-!(F621N1S7)X45.8'H
M         /B>6.""2:9R,BC:KWN7DB(F54@_MO:!]]5N_P R_<!.P1K3>N],
M:EK74=AO5)75+6=(L<3E54;X?M-CJ/4%JTW;TKK[70T-(KTC265<)O+E43[%
M V@()[;V@??5;O\ ,OW#VW] ^^JW?YE^X"=@A&T/:/;-#V>@NE=2UE7;ZQ=U
MDU*U'-:JIEN<JG-,X\AZ[--HMDV@T%3465TL<E,_<E@G1$D:B\G815X+QX^)
M0)D
M
M
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MIW:S614JK"E%=52/"8PC9.'V ?T*!\QNWHVN3K1%/H
M
M                                        TFH-46RP5]HH[C)(R>Z5
M"4M,C6*Y'/7DB^#F;LJ+;=WY[,?WY'ZS2W0
M
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MYD.#MFEOGU=M6M4;D<]]16)4RJB;W!J[[E^P#^@-*SHZ:)G[+$3[#T"<$P
M
M                                                        "HMM
MW?GLR_?D?K-+=*BVW=^>S+]^1^LTMT
M
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M^$OX
M
M     5%MN[\]F7[\C]9I;I0^U>V7.DVGZ&JZR[R5=#4WN'M>D5B-2GPYN<+U
MY+X
M
M
M                                              /F:6.&)\LSVQQL
M17.>Y<(U$ZU7J*:V@]D)IG3;WTMG:Z^5S<HO0/1L+%\;^OS(OE N<'&UX[);
M5]7(JVZGH*"-4X-;'TBIX\NR:VG[(3:!2JBSU<$J*N<2TK$S\R(!VV#F+2_9
M1[TT<6I;$B1*J(L]')Q;X55CN?F5"_='ZRL.KZ+MG3]QAJD1,OC1<21_";S0
M"0                J+;=WY[,OWY'ZS2W2HMMW?GLR_?D?K-+=
M
M
M
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MN[\]F7[\C]9I;I46V[OSV9?OR/UFEN@
M
M
M
M             93PE5=DK;KO<]G"4^GZ>JJ*WMV)VY3(JNW41V5X=7(Y4]AN
MT7JM%\_R. _H!E/"><ZIT,G']53@+V&[1?\ E%]_R./U-&[1?^47W_(X"1]C
M)_312_ G]53MTX^['+16I;+M1H:R[66NI:5L4J+++$K6IEJXXG8(
M        %1;;N_/9E^_(_6:6Z5%MN[\]F7[\C]9I;H
M                                                U.JZ>IJM/5L%
M USJE[,,1KMU<Y3K.JQVIB'EIVB9;8%$W>BOEH;$ZXK40MD549F?>RJ<^2J>
M]OL^I+C1,J:)M1+#(B[K^G1,X7')5\1>^PUV[7;C;]_>J_:IWV[/-=X,6U1R
M16VECG14E;$UK\KE<HG'B910F-IV6HG>  'CT
M
M
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MTMT
M         :#5^IZ?3--!-4T\TR2N5J)'CACRJ>6M%8WEQDR5QUF]YVB$:VQ_
MS2U?&O\ 5-_LW[S;?_C]=Q76L=7TVJ(:6.EIIX%IWJYW2*F%RF.&"5;+M10U
M%.RQMAD2:FC=(Z5<;KLOSPZ_UBY;)6='28GK/ZJ.+4XKYNU6>4\H\5@  J-$
M
M
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MR9\:)DV0                %1;;N_/9E^_(_6:6Z5%MN[\]F7[\C]9I;H
M
M   U&H]/4&H((HKDV1S(G;S=QZMXFW!Y,1,;2YO2MZ]FT;PYPKZ2*@U!=:2!
M%2&"=\;$5<KNHY43B6MLQL='!;(+PQ']NU#'1R*KU5N$=C@G^%"L+_WW7WY7
M+ZZEQ[..\VW_ ./UW%C'6)T-/&?K+&X9CK,SO'29V_%)0 0-L
M
M
M                  "';8?RQ[6U\]C252W=8V)!VKGI<](W.[CCRSYC$VU5
MVJ+=HQ*K0[)9+K'51JK(XVR*Z/CO)NKS3ERXE'VSLC-5V29M/J_3T<BM<K7*
MD;J>151?'E/L JB/0^T.*KEJ8K#?XZB155\C()&N<JKE<JAG>Q[:K_8=5_\
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M]U]^5R^NI<>SCO-M_P#C]=Q8Q>PT\9^LL?AG6WC/U24 %=L
M         ?CG(UJN<J(U$RJKR1#],>Y0.J;=50,PCY8G,3/+*HJ!Y/*.3Q_+
M%M_YC1_3M^\?EBV_\QH_IV_><_ZGTI7::[7_ "@ZG7I\[O1.5W+&<Y1/";&S
M;/;M=[9#6TKZ-(94RU'R*BX_RE&-5DF>S%.;#KQ346O..,/G1W;_ -%^-<CV
MHYJHYJIE%1<HI^F-;('4MNI8)%17Q1-8N.643!DEZ&Y'..8  ]
M
M                                                QZRAI*Z)8ZVE
M@J(UYMEC1Z?,ID$,VR_E;VM+[['.W/RKT;.@[3STN>D;G=QQY9\P&IU'L2T+
M?7/?+9HZ.5V>[HEZ'"KUX3A]A7%\[%ZC1'RZ=U%5T\J85C*F-'HG^)JHOV%#
MQ:UU_-7.HX+]J"2K:JM6%E1(YZ*B\4PBY/>X:IVD6Z+I+A==34T:\$?-),Q/
MG4#H#8_H+:+H[6M.R\7)]9IQ&2,<UM8KV)P[E=QR\...2'0)P):]7[3JNGZ>
MV7?4]3 CO=Q/ED;E.KAE"VMA&VV]UNJH-.:RE6J;4JL4-2]B,DCDZFNPB91>
M7AS@#H>32MDEU&M^FMM/+=E8V-*F1B.<UK<XW<\N?4<BTG_BP=_[P/\ 64[4
M.*Z3_P 6#O\ W@?ZZ@7WV4CE;L<NB(N,S0(OC3I$--V'C439?6KA$5;I+GZ.
M(L';!IR356SF]VJG;OU$D/20MZU>Q4<U/.K<><Y\[&G:=9-%V>[6/5,TE"JU
M*U$;W1JJ;VZC7-5$XHO<IU :7:"Y\?940+"F9$N]$K41.:YC.SCC;9]#+M+[
M(J6_T<,B6VGK>WWN>GN(V+^;1<<$551O#R^ Z%VA[7M.Z#O<5KO45P?4R0-J
M$6GB:YNZKG(G%7)Q[E0*\[,QRII2QMRNZM6Y53P]RI9&P9J-V.Z81$Q_NB^L
MXC79.6&34NRKMZWQ22RT4D=8UC6Y<L:HJ.X)X$=GS$,V-;:].6#9>RV7R66&
MX6R-[(H48JK4)E7-1J\D7CCC@"'[%5<SLEZKHTYU%:BIX$P\['.3.Q1LM7>=
MH5VU540N;2PQR(V147#II%3*(OB;G/E0ZS   "G=M51#)KC9K''+&^2.^1[[
M&N15;W3>:=1<11NUVP6VV[2= W.BINCK:^]P]L2;[EW\.;C@JX3S8+R
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MRV;=Y=L^+7TJ5,?M%O!CX/\ ,<OA'Y)* "VV
M %7;5+1>ZR[,JK9'.ZDBI^[?')NHBHJJO#/@*ZM,-XNU4M-;GU,TR-5ZM;*J
M</#Q7QH5,FJFENSV61J.*6PY?)>3F?=]_AR=+ A>R^V72V6VK9>8Y8Y'2Y8D
MC][AA/&I-"Q2W:KO,;-+#DG+2+S&V_<  [2@
M
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MI;I0^U?3L5LVHZ&NK*VNFDN%[AWH9I=Z*+#F^X;U%\
M  /B6&.9J-E8UZ(N<.3)]@$3MT5+M0BCAOT;8F(Q.UFKAJ8X[SBR;124[:"C
MD2"-']$Q=Y&IG.$*YVJ]\$?R5OK.+.M?Z,I/B6>A"IAC_%NW-?:?L>#G[V2
M"VPP         KC4VTB:S7RKM[;9'*D"HB/654SP1>6#C)DKCC>R#/J<>GKV
MLD[0T%T_I(_^[H_2A<R<CGV>^.J+RMZ6G1).E2?H4=P56XX9\Q=6DKPZ^V."
MO?"V!TF>X1V\B854\!?UEXGR<?<K:3/2]IBL]>?P;@ %-H
M          .=[_WW7WY7+ZZEQ[..\VW_ ./UW%.7_ONOORN7UU+CV<=YMO\
M\?KN+&+V&GC/UEC\,ZV\9^J2@ KM@                       !5&W/G:?
M))_I)ELV[R[9\6OI4K3:"ZM?>IFW3IDIVRO[6Z9,-W>&=W/-.1C6FZWMK(Z&
MU5%4J-1=R&'*JB>)$)\?#;3DG)%XYPQ<<]C67R^^-MN_N7R"(;.Y+Q)!6_EQ
M*M'HYO1]L-5.&%SC)+R/)3R=IKONV*6[==P '#H
M85\_0M?\0_U5*<V-=]LWR=_K-+COGZ%K_B'^JI3FQKOME^3O]9I4S^MHQ]=[
M7@^*\  6VP
M                                         1G:5J632&A[K?H*=E3)
M1,:]L3W;J.R]K>*^<DQK[_9J"_VBIM=WIVU-#4(C98G*J(Y$5%3EQYH@',#N
MRFN:IAVF:%?+.[[C\;V4=P8N6:7M[5\*3.^XNGVD-GGO;@^FD_$>%=L(V?55
M,^)MB2G5R8Z2&>1'-\:954^P");)-N]=KK6=-9*BRTU)'*Q[EE9*YRINMSR4
MOLXZV1/]@FWZ;3,,4%P@=6/HTG='^<CX+AR+U+C@[JYG8H
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M_C]=Q3E_[[K[\KE]=2X]G'>;;_\ 'Z[BQB]AIXS]98_#.MO&?JDH *[8
M                    51MTYVGR2?Z36[,N^^F^+D]!LMNG.T^23_2:W9EW
MWTWQ<GH)M!US^$?26'3V[)_+]%T@ A;@                       #"OGZ
M%K_B'^JI3FQKOME^3O\ 6:7'?/T+7_$/]52G-C7?;+\G?ZS2IG];1CZ[VO!\
M5X  MM@
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MD]!LMNG.T^23_2:W9EWWTWQ<GH)M!US^$?26)3V[)_+]%T@ A;8
M              #"OGZ&K_B'^JI3FQKOME^3O]9I86TIMP=9F?DWMC@Y>EZ%
M<=QA<Y\13]#4OHY%FH)G0285JOA7==CP90DKH)U$UO%HC;N9&MC?48[?[?FZ
M.!5&EH]3K?*)]9^5%I%=ERR/56XQU\2USK-A\E.V^[3QY/*1OML  A2
M
M                       -;J*Q6W4=IFME[I(ZRAEQOQ2<EQR7AQ1?&AS?
MKOL9)VU+ZG1%P9T?%R4M:]4<B^!KT3T_.=1 #AV6U;7M&N?3P_EZGC:[=7M6
M598U\FZJH?"WC;#7(M/VQJE^_P#JHV1,^<[E& .-;/L)V@ZKF;5:BJ644;\*
MLE;/TLBI\%N>/E5"_MF>QG36AGQUD43Z^[MS_OE1Q5OP&\F\//XRS
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M_7.ATY'/&DOTO:_E,?KG0Z<BYJ?5X_!F\+]3'A'T  4VD
M      !SM-/*E1+^=D]V[]9?"=$G.4W\O-\-?2:?#?XOA^:EK/X6#2JJU50J
MJJKE5557GQ,SI9&Q*UDCVHB=3E3!A4G\XJ/*OI4RW^Y=Y%)N'>HCQM_VECZ3
MU?QGZNBK?QH*95_X;?0>YCV[^84WQ3?09!CSUE])'0 !X]
M       %4;=.=I\DG^DUNS+OOIOBY/0;+;ISM/DD_P!)K=F7??3?%R>@FT'7
M/X1])8E/;LG\OT72 "%M@                       ,*^?H6O^3O\ 54YP
MH?Y&7X2G1]\_0M?\G?ZJG.%#_(R_"4GT7M4>$_DQN(>T8O"72MO_ )C!\!/0
M>YX6_P#F,'P$]![D,]9;%>@ #QZ
M                                                        $6VG
M:MCT3HNXWI[$EEA9NP1+R?(O!J+XL\5\2*!*0<'5NV':+>ZQ\D%ZKFJO'HJ*
M/<:U/(U/2>/MA;3L<+SJ#YG_ ' =[@Y/['W5VN+OM)HJ34-RN\]O='(KV5*.
MW%5&KCFGA.L                :;5SK\RS/72D=#)<]]NZVM5R1[O7RXY K
MO;=WY[,OWY'ZS2W3G76LFLY-;[/?9I!:(HTO4/0=H*Y55=YN=[>5>HZ*
M                  *IVI]\47R9OK.-)H7ORMWQCO5<;O:GWQ1?)F^LXTFA
M>_*W?&.]5Q+P[TL_A^J_Q?V72_'\EX@ B4         ^9?Y)_P %3Z/F7^2?
M\%0.>M)?I>U_*8_7.ATY'/&DOTO:_E,?KG0Z<BYJ?5X_!F\+]3'A'T  4VD
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MJ/H9.731IEJ^5.:$\IJB&JA;+3RLEC=R<U<H9F3#?%.UH7Z9*W]&7J ")V
M                "J-NG.T^23_2:W9EWWTWQ<GH-EMTYVGR2?Z36[,N^^F^
M+D]!-H.N?PCZ2Q*>W9/Y?HND $+;                        85\_0M?\
MG?ZJG.%#_(R_"4Z/OGZ%K_D[_54YPH?Y&7X2D^B]JKX3^3&XA[1B\)=*V_\
MF,'P$]![GA;_ .8P? 3T'N0SUEL5Z  /'H
M
M  5QV06EJO5>S2X4MM8^6MIU;510LYRJWFWRX5<)UK@L<ANV*DNU=LVOE-IU
MM2ZZR1L2!*=^Y)GI&YPN4QPR!778H7.Q-T*ZV-DIH;]#/(ZKBDPV5R*[N7<>
M*IC">)4+RZ2#]N/YT."W;*=HSZA\[M/7-9W+O.D5S=YR^-<Y/1=F6TW_ ))=
M_I4_$!WDQ\3G88YBKXE0^SE#L?M$:WLNTFBK=06RXT] R*1'232(K456KCK7
MK.KP                *BVW=^>S+]^1^LTMTJ+;=WY[,OWY'ZS2W0
M             'S,BK$]&YWE1<8/H <U7RWW:@JG)=63QR8WDZ23>7=55QUK
MUGM0T]75O@AH$D?5O5-Q(W8<OAXY\&28;9/TLGR9GKN-3L][ZK3\)?44<,QQ
M'EZ?=^K'U/#JZ7-3#6TS%Z1//NWF8Y?@N^B:]E)"V3.^C$1V5SQP>P ;$<@
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MEX;RKEB^?J)I&]DK&OC<U[')E'-7**9F3%?'.UH7:9*WC>LOH $;L
M      51MTYVGR2?Z36[,N^^F^+D]!LMNG.T^23_ $FMV9=]]-\7)Z";0=<_
MA'TEB4]NR?R_1=( (6V                        PKY^A:_Y._P!53G"A
M_D9?A*='WS]"U_R=_JJ<X4/\C+\)2?1>U5\)_)C<0]HQ>$NE;?\ S&#X">@]
MSPM_\Q@^ GH/<AGK+8KT  >/0
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M\4X$J.,]D*U>S_L@Y-.QSK)!)4OM\J_\1G%6.5$Z^#5^<[,
M    J';=WY[,OWY'ZS2WBA]J^FJ"U;4-#7:E6=:NXWN'IM^17,[ES<;J=1?
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M5M_\Q@^ GH/<\+?_ #&#X">@]R&>LMBO0 !X]
M
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M^+D]!LMNG.T^23_2:W9EWWTWQ<GH)M!US^$?26)3V[)_+]%T@ A;8
M                #"OGZ%K_ )._U5.<*'^1E^$IT??/T+7_ "=_JJ<X4/\
M(R_"4GT7M5?"?R8W$/:,7A+I6W_S&#X">@]SPM_\Q@^ GH/<AGK+8KT  >/0
M
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MY$F@CGG\(^DL2D_^=D_E^BZ@?,<C)$58WM>B<]U<GT0MP
M        !A7S]"U_R=_JJ<X4/\C+\)3H^^?H6O\ D[_54YPH?Y&7X2D^B]JK
MX3^3&XA[1B\)=*V_^8P? 3T'N>%O_F,'P$]![D,]9;%>@ #QZ
M
M                 P[S;:6\6JKMUPC26DJHW12L7K:J84XJU]L,U-I.W7:\
M2OH9+/1N5S7MF7I',5Z-:N[CGQ3/$[A-+K.[V^PZ6N=TO+&R4%+"LDD;FHY'
M^!N%ZU7"><#A[0&R+4VN[-)=+"E#VK',M.[IYMQ=Y$15X87AAR$F3L;=>>"T
M_6E_";6;LF;W32/98].62BI%<KFQJQ[E\J[KFIGAX#S_ -J#6'_*K']%+_\
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M7D7%LJJ)9=.=%)C<A>K6<,<,Y]*J7,4_^#3QGZR^>X9CF+9(]TS_ -MDS !
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MZ6KIJVJ9!-+,CF(_@BIA$Y\BS6/:]J.8Y'-7DJ+E%*>KK,99F7T&GF)QQ#]
M!53@                    #"OGZ%K_ )._U5.<*'^1E^$IT??/T+7_ "=_
MJJ<X4/\ (R_"4GT7M5?"?R8W$/:,7A+I6W_S&#X">@]SPM_\Q@^ GH/<AGK+
M8KT  >/0                                                   "
MN=;:HO-KOTE-;WM2!&-5$Z'>XKXR7#BMEMV:H\F2,<;RL8%,IKW4"KA)XE7P
M) F2Q]#7*KNMA957!<SJ]S5[C=X(O@),NEOBKVK;.,>>N2=H;\ %9.
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M(NOHDQ_72^AQ=#41$PB(B>(IC1O?_%\?+Z'%SE[7^G'@JZ7T9\0 %%:
M                         J_LDJ>[5&RJY-LC97.:YCZA(E7>Z)%RN,<5
MXX5?%DM AFV5;JW9G?ET_P!M+=.B:D/:J*LG\HW.[CCRSY@*<[$75-9<ZF[V
MZ\7VIJ98HF+2TE1,K\MRN^YN>/#N>OADZ6/YX-T;K9E4ZICL%[94*JJLC*5[
M5ROD0V\=%M3C9NQ1:N8G@19T0#O@'*'8_P &OF;2:)=2MU$ENZ*3>[=67H\[
MJXSO<.>#J\                "HMMW?GLR_?D?K-+=*BVW=^>S+]^1^LTMT
M      &HU?WKW;Y-)Z#;FHU?WKW;Y-)Z#O'Z<>+F_HR@FQ[])W/XIGI4M(JW
M8]^D[G\4STJ6D6-=ZZ?@ATOJX  5%A5>T[5ESM=YEMM))$E+)3IO(Z-%7NLH
MO$KZFF=+&CW+Q3P(=!:A@B?9[@]T;'/2G?ARM3/N5.?J5$WG8_XG#YR7AU9C
M53,SOO$_6&7J,6?'YTY)FEIGS>Z-H\5G;,=6W34%RJX;D^)T<<*/;N1[O'*(
M6,>5/!%$B+'%&Q53FUJ(>I7QUFM=K3NNZ;%?%CBM[=J?>  [3J@VR?I9/DS/
M7<:G9[WU6GX2^HIMMLGZ63Y,SUW&IV>]]5I^$OJ*2<-]//X?JK\4]KP_^NO_
M &LO4 $:P$ VA:M[41]LMLB=LKPFD;^HG@3QF9KW5B6J%U%0.1U=(W#G(O\
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M3BOC5>M3,:B-:B-1$1.2(?IIX<%<4<NKZ;2:'%I8\WK[P $RZ
M     &-<_P!&U7Q3O0IDF-<_T;5?%.]"GD]'>/TH<VT_\[J?A+Z5+VV<=YMO
M_P ?KN*)I_YW4_"7TJ7MLX[S;?\ X_7<3X/\OIXS]99&B];D\;?5)0 0M0
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MPE)]%[57PG\F-Q#VC%X2Z5M_\Q@^ GH/<\+?_,8/@)Z#W(9ZRV*]  'CT
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M7KD@U?3571JY'3N3=1>6]E/XEZ&GK_3CP_5EZ6LQ29GW_H  HK
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M/ N\Y=V&[#M0V?65'?=5Q1T<5"O2Q0I*V1\DF%1,[JJB(F<\SJ(
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MHJ"+#U]W*[B]Z^-?X&X"*BIP!U6L5C:'V%*5I7LUC:  'KH
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MZ%K_ (A_JJ<XT/\ (R_"4GT7M5?"?R8W$/:,7A+I2W_S&#X">@]SPM_\Q@^
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M[/\ OQH?A/\ 54NXV-=Z<>'ZOG]/,[6C[P %%8
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M96S+OPIOBY/08NU_OLD^ SU4,K9EWX4WQ<GH.^&?_<?OWLS/_F-_#'_UA=(
M.&F      5$5,*B*@ &IN6F[/<D5*RVTTBK^LC-UWSIQ(;==E-!.KG6ZLEIE
M7BC'IOM^\L@$5\-+^E"MET>#-Z=8E0UWV<WV@WG0Q,K(TZX%X_,N"*U=%544
MBQUE-- ].J1BM7[3J,\:JE@JXECJ88Y8UYM>W*%:^AK/HSLS,O \=N>.TQ\W
M+1ZQ3R1\$=E/ I>]SV=Z?K=Y64SZ61?UH'[OV+E"&W39171JYULK89F]3)4W
M%^?BA%7#J,$]K'/X,S)PG589[5.?@@D5:U>$C=WQIR,J-[7IEKD7R'[=M+WF
MTJO;M!,C4_K&)OM^=#2HJM=E.#DZS0P<;S8_-SUW^4HXUF;#/9RQ^/*6[:JH
MJ*U51?"AO[/J^\6Q6HRJ=/"G]7-W2?/S0AT59(U,.7>3QF5%512<%7=7QFQA
MXAI=5'9WY^Z5[#K\=ND[2M^S;1:&I<D=Q@?2/_;1=YGWH2:IO='':*BX4TL=
M5%$Q7JD3T7."@4XIZ#[C>^-'I&YS=Y,.W5YIX"2^@QS.]>33IJ[1'/FL2X[2
M*6HM]3"EMJ&K)$YF5>WAE%0JZW\8I$\+OX&1+_)/\.%,>V_R3_A$7D:8M53L
M1W3^3.SY;7U%.U[I7+IC6\%SKZ2VLHIHWO:J;[G(J<&JO\";%);.^_"@_P ?
MJ.+M*VLQ5QWVK[FWIKS>N]@ %18        .2'/*OEUQM8W)%<^B948W%5<)
M#&O+SX_^8OJ\SK2V>NJ&^ZB@>]/*C54I38#$DVJ+I._BYE/P7QJ]/N+^D\S'
MDR=\0BR<YBJVKUJJQV&ICI+I71TLSV(]C%8Y<MRJ(O!/"BGA7ZYTU0U"P5-X
MIFRIP5&Y?CRX12INR![[:+Y$WUWDBM>R&V3::C?43U"W.6%)$D:_#&N5,HF,
M<CV-/AKCK?),\WG;M,S$1T6C;+C1W2D;4VZIBJ('<GQNRAI[MK73UHKY**XW
M*."ICPKF*QZXRF4Y(5)L*KIZ35E7;D>JT\T3E<WJWFJF%^;),-:6?0U5J*IF
MOUPDAN+D;TC&RJF$QPX87J.;::F/+-+;S&W=U>Q>9KO"0>V1I/\ YS%]')^$
MD5IN-)=J"*MMTR34LN=R1$5$7"JB\_&BE0^Q[9E_S:7Z9?PD\H[G8M*Z#CJK
M?.LMJ@8[H%5V72.5SNY3.,KO9.<N&D1'DXMO,]\/:VG^+9@;6-8^QNT=KT,B
M)=*G@S"IF)O6]4^Q/^QC[(:*^2V]UVU!<JZ99TQ!!-(JHC/VU1>M>K_N5KI6
MF]G.L9KGJ2KIXZ9BH^5)'HQ'X]S&U%7E_ F?MD5T>O66:/\ )J6E*E(.E1%R
MC.6=[>Q]F"S?!-,?D:1O/69_*'$7WGM3T;?;=9$N.E>WX^$]O=TF4YJQ>"IZ
M%\QZ;$[TZYZ0;33R*^HHGK"JJN55G-J_,N/,2;4G07+2=V;#+'-&^EE1',<C
MDRC5ZT\94W8\3N;=[K BKN.@:_'C1<?Q(J1V]+:)_AE[/+)&W>O, &>F
M                    "L]K7Z1M_P 4[TEF%9[6OTC;_BG>DKZKU<M7@WM=
M?C]$=V?]^-#\)_JJ7<4CL_[\:'X3_54NXUM=Z<>#"TW2WB  HK
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M8YSJ:A1>Y@8[@J?WEZU(PU%<J(U%557@B)S,/-K)GS<;"UO&+7\S3\H]_?\
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MTGQ<GJJ7V<:3-DMCGM6F?B^:X+$6P3,^_P#0 !.V0
M  ,:Y_HZJ^*=Z%,DQ;HY&VZIWE1,QN1,KXE/)Z.J>E#GO3'?K;/ES/7.CCG#
M3*HFM+:JJF.W6>N=&M>URX:YJKXE*6A]&63P[T\W_*7T "\U
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MO6>5KFX<W.$1J^1$^=5';F-/:UIYVDV\^(CN30 &>F
M      "L]K7Z1M_Q3O2685GM:_2-O^*=Z2OJO5RU>#>UU^/T1W9_WXT/PG^J
MI=Q2.S_OQH?A/]52[C6UWIQX,+3=+>( "BL
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M;Y-)Z#O'Z<>+F_HR@FQ[])W/XIGI4M(JW8]^D[G\4STJ6D6-=ZZ?@ATOJX
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M,?9GWX4WQ<GH,C:-WV5/P(_50Q]F??A3?%R>@DX;TS_OWM#C/JM)X?\ ^5T
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M$=0U<,WB:[BGFYE')@R8_2A9IEI?I+. !$D
M             K/:U^D;?\4[TEF%9[6OTC;_ (IWI*^J]7+5X-[77X_1'=G_
M 'XT/PG^JI=Q2.S_ +\:'X3_ %5+N-;7>G'@PM-TMX@ **P
M                 !7FWO4\^E=F=TJZ)[HZV=$IH9&KQ8Y_!7>5$SYP-%J_
M9OLXUUJ>KHV2P0:BC8LU4E!+A^,HF7M3+<Y5.K/'B0^\;"MG^BZ-MUU3>;@Z
MWI*R/$F$:JKR1=U,FN[$C1EV972ZRFJ(FVZICEI4C=E9)5WFY=X,(Y%3S%Q[
M:=!3[0M*,M5-<&T4L<S9VN>S>:]414PO6G,#>Z$HM-4=@@31L="VUN1%:ZD5
M%1_#FY>:KY>)(3CGL?[S=M";7)M(7%^(JJ=U)40HN\U)6YW7M^_P*=C
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MHTIHU1CU:B[Z\<*>7LMGQ_-8O\ZDD=;:)SE<ZD@5RKE55B<3\_)=!_8Z?Z-
M,N-V_&UWA1%/U>01$1$1$PB ")/U7,U[D[5CX+CW:AFJYG.1.U8^*X]VI(EM
ME"JY6C@S\6@2V4*+E*.GS\6@&6U<HBGS([<C<[GA%4^@J(J*B\44"(^RR?\
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MS=6W1G=1K(KF-<[P*K793R\2S=A]KI[3LLTY%3,1J34<=2_'6^1J.55\ZDY
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MVG??;;N1S3%@U'2WVCEK(IVTS'9?F=%3&/!DM, ZS9IS3O,*6/'&.-H  0I
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M309*^CS6::JENO)98-/:M36BYX;2UL?2+_5O7==\RFX*=JS6=K1LLQ:+<X
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M$G!5;E<HJ8Y+_ L<IK:8BQ;>=F<L+E25[:F-^%_4QU^+BI<H
M  (GM6T_5ZIV?WFRVU\<=75QM;&Z151J*CVNXJGB0EAYU$T=-3RSSO;'#$U7
MO>Y<(UJ)E57S <<N[&?6*N5>W+5]*_\ "?G^S/K'^V6KZ5_X22[1>R7J^W9*
M30U-$RG8N.W*J/>=)XVLSP3RY7R$1MG9(:YIZMCZM]OK(47NHWTR-SYVJB@6
M)L5V):CT7KRDO-TJ:"2EBCD:Y(GN5V5:J)S:AT@0/9+M,M6T6TOFH6NI[A3-
M;VU2OYL5>MJ_K-X<R>   !\RR,AC=)*]K(VIESG+A$3QJ<R;:.R J:.]16[0
M%;"Z&!O^\5G1M>V1Z_JMWNI/#X2W-M&A*[:!8:&U4-R;;XF522U#W(J[[$:J
M81$Y\5ZSE[LA]!VC9_<+#;K*DKNEI7RSS2OWG2/W\9\")A.2(!V=I2LFN&F+
M/6U3D=45%'#-(Y$QESF(JKCRJ;0T>A.\G3W[NI_^FTW@%5[==JT>SNWP4U%"
MRIO58U70L>O<QL1<;[DZ^/).O"E/OVP[4],=IW?4]IWK15X6-D],D;7(O'@Y
MJ91<<LF!MU;^6.R/H+=5+O4_24=,C5Y;CE153YW*7SV0U#!4[';]TS$5::)D
ML2_LN1Z(B_:H$NT1J6DU?I:WWRWHYL%7'O;CE17,5%5%:OC145#>%"=AU<))
M]"7*B>[+*:M5S$QR1S47GY44OL   *@VVN:NM=F:(Y%5+W'E,\NZ:6^41M8T
MU;K5M.T+=J1DJ5EQO</3JZ17-7=<W&$ZB]P      0+;+WNT7RUGJN)Z0+;+
MWNT7RUGJN/)[O&/JJZWU%FJV/?I2Y_$L]92TBK=CWZ4N?Q+/64M(N:[UT_!U
MI?5P'X_W#O(?IH=5ZDI;#2?G%Z2ID3$<35X^5? A6I2;SV:]4UK16-Y4='_+
M-^$>,'.7X:^D]HOY5GE/&'G+\-?2;%O:Z_\ &?K#+OZBO_*?HQKA+RB;Y5-Y
ML]TT[4-Y;TS%[0@7>G=C@O@;Y_01^@I*BZ5\=-3,62>=VZB)_P"N1T9I:QT^
MG[1%14Z95.ZD?^V]>:GS.2\Z[43EGT8Z,G0Z>==GG+?T8_<1^K:11LBC;'&U
M&L:B-:U$PB(G4:36]1-2Z9K9::1T<J(U$<G-,N1%^PWIH];+2IINK2M>]L2H
MB)N+ARNSE$3SH6<GH3L^STD1Y:F\;\X^JC+C_,I/-Z4,:S?UOF_B9-Q_F4GF
M])CV1JO=(UO%7*U$\N5,3^)>UO\ ]3:?_A/_ .[;P4\U3+T=/%)+(OZK&JY2
M5V?05?5HCZY[:2-?U53>?]Q+]"V"2RT,CJKA5S+W;4<CFHB*N,>8DQHXM+&V
M]UW6\:O%II@VVCOZM#9]*6JV(US*=LTR?UDJ;R_]C?(B-3")A "W6L5C:(8.
M3+?+/:R3O( #I&   0C:O^B*+Y1_I4FY"-J_Z(HOE'^E2'/ZN5_AGM5/%G;-
M.]:+XU_K$I(MLT[UHOC7^L2DZP^KCP1Z_P!IR>,@ )%0  'E44\-3$L=1$R6
M->;7M14(=>] 4M2KI+9)VK(O'HU3+%^XFP.+XZW]*%C!JLNGG?';91EVLEPM
M3U2LIWM8G!)&IEB^<UJ+CBBJBIUHN#H.1C9&*R1J.:O!45,HI$KWH6@K$=)0
M?[I.O'AQ8OF*=]),<Z/H-+QVEO-SQM]\=$*L>K[G:U:UTJU,"<.CE7.$\2\T
M)_8]96RYX9(_M6=?U)51$7R*5Q>M-7*T*JU,._%U2Q]TWS^#SFE7D15S9,4[
M2MY>'Z76U[=.OOAT,BHJ9145/"@*4LNIKG:%:VGGWX$YQ2IEOFZT)]9-<VZN
MW8ZO>I)UPG=<6*OE^\N8]32_7DP=5PC/@YUCM1]WZ):#\8YKVHYCD<U>2HN4
M4_2PR@     ,:Y_HVJ^*=Z#),:Y_HVJ^*=Z#R>CO'Z4*SV6]\,WR=WK-+5*J
MV6]\,WR=WK-+5*^D]6U.-^U?"  %ED                        *@VA]]
M\_P8_0A;S?<IY"H=H???/\&/T(6\WW*>0JX/3OXMKB?L^G\/RA^@ M,4
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M=]?;4J36%PM-99;-9H'T]%3UK%;-.]^]O2*U?<IA?L3QER@
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M  SVJGBSMFG>M%\:_P!8E)%MFG>M%\:_UB4G6'U<>"/7^TY/&0 $BH
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M,WR=WK-+5*JV6]\,WR=WK-+5*^D]6U.-^U?"  %ED
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M?\7J*7@4=LZ[[+;_ (O44O$U]=Z<>"MH/5  **Z
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MV[OSV9?OR/UFENE$[6:.\0;3M"SW"Y,J;;-?(>U:9L*-6'NFYR[]8O8
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MWK1?&O\ 6)21'9Q40Q:8B;)+&UW2/7#G(B\R7(N4RG(]P^KCP1Z^)^TY/&0
M$JF             !J+SIRVW=%6JIT27JE9W+D\YMP>36+1M+O'DOBMVJ3M*
MJKWH2OI%?+0.2J@3CN\GHGDZ_,1&6-\3U9*QS)&\%:Y,*AT&:Z[V6@NT2LK:
M=KUZGHF')YRIDTD3SHW-+QV]?-SQO'OCJI2WU]5;YTEH9WPO\+5Y^8F]CV@J
MU&QWB%7=72Q)]JI]QC7O0%5!O26J3MAG_#>J(Y/(O)2&U5--23.AJ87Q2)S:
M],*5M\F&6O-=)Q&N_*9^:];=<J2XPI+13LE;XEXIY4YH?5S_ $;5?%.]!0]-
M434LJ2T\KXI$Y.8[=4WM?JZYU]J=05*QJUV-Z1J*CE1%1?X%B-7$QYT<V7?@
M5ZY(G';>-^_K'ZO?9Q604FHD2=^[TT?1,X*N7*Y,)XN1;J'/2*J+EJJB^%.&
M"U-G=^;76]*&H=BIIT1$X81S.2<<\5X+D\TF6(\R7?&]%,_^17X_JF( +SYH
M                       !4&T/OOG^#'Z$+>;[E/(5#M#[[Y_@Q^A"W(7L
MDC1T;FN;X47)5P>G?Q;7$_9M/X?E#[ !:8H                       "(
M[4.]IORAGH<?.R[O=?\ './K:AWM-^4,]#CYV7=[K_CG%7_7^#9C_+/YDP*Z
MVR3O;16Z!,[CY'.=YD3[RQ2)[2+))=[%O4K%DJ:9W2,8G-R=:)X_N&MK:^"T
M5ZL++$S28A -.7+42VQM+IR!600Y61[(VJKW+QXJIN]*ZXN,=W;;]0)O;[^C
MWE8C7L=X^28,'1NMH[#;G6^LI'NZ-ZJU6<%3*\45/":^D94ZPUIVU3TZLC61
MKY%3DQC?"OAX&/CR32*>2O,V]RM6VT1V9Y^YZ:G;VSM&6.7&XZIB8ODRA<LD
M3'TKH7HG1N8K53Q8P5;M1LM12W5EXI&/6%R-5[TX]&]J\%7Q<CUJMI:261T4
M=(K:Q\>XKU=W"+C&\A:Q9::?)DC+UGYI*VC':T6:G98]T>L$9'[A\4C7>1./
MI1#RT0U*G:#"L^-[II9,?WD1RDCV2V&>%\MVJF.8U[.CA1R854SQ=]GI-'J2
M@JM):N;<:>)74RR]+&Y4[E<KQ8J^=2K7';'BIDMTB=_I^B.*S%:VGWK,UG&R
M72MT;(B*B0.<F?"B93[4(/L8D=VQ<HD_D]UKO/E3'U1K]+M:5H:*E?&Z?N9'
M.7/#P-3QDHV8V*6TVB2>K8Z.JJG;RL7]5J<D\O67?*5U&JK;'TB.<I8F+Y(F
MO<F11&H*62NU]74D+D;)/5]&CO!GADO<IC_]J[_EYUQ*-XK$^\SQOM'WLG66
MAZ>Q6-*VFJ))'L>UKVO1,*B\,IX#QT7I==4PRU-QJY>AI\01HBY=P3.,KR1,
MH3?:EWGU/QD?K&!L<[WZOY2OJM(9TV.-5&/;ELX\G7RO9VY;(1)#+I36S8::
M9RI'*Q-[K<QV,HOF)-M=O$T<D%KA>K(7,Z67'#>XKA/L-%K_ +_9/AQ>A"6[
M3]-5-TCAKK=$LT\3=Q\;>:MXKE/"05K?L9:4Z1/RWEY$3V;UJU]HV:0S6R.2
MNJI&U,C$=NQHFZS*<O&1.W4<MOUW1T<\B2/@K&1[WA1%1$^PW5LUS?*2DCMZ
M4+9YV(D;'/8[?3'!,IUFDM:U3]<43K@CDJW5C'2H[FBJJ*1Y)PS%?)1S[W-N
MQR[,+Z !](O   BNIM"VF][\O1]K5COZZ+AE?&G)2I-3:)NUAWGRQ]L4F>$T
M/%,?WDYH="A4145%1%1>:*5LNFIDY])9VJX9AU'/;:??#E0DNFM:7:PN8R&;
MIJ1%XP2\4\R\T+1U/L\M=W<^>E_W*K7CO1M3<5?&W[BIM0Z4NUA<JUM,JP9X
M3Q]TQ?N\Y0MAR8)[4/GLNCU.AMVZ]/?'YKBTQKNU7S=BWUI:M><4O!%7Q+R4
MEARHG/Q]1+],:^NMD1L,CDK*1/ZN5R[S4\3BQBUO=D:&EXW_  ZB/C'Z+\!'
M=-ZPM%^:UE+4)'4KS@E[EV?%X?,2(O5M%HWB6_CR4RU[5)W@ !T[     &NN
MECMMT:J5U)%*O[2IAWSIQ(;=MFT+LNM-6Z)?^'-W3?GYEA@FQY\F/T91WQ4O
MUA15VTK=[7EU12*^-/ZR'NTQZ4-'CQ<3I$U-VT[:[JU>VZ2-7K_6,3==\Z%W
M'Q'NO'X*MM'_ +94715=10R]+1SO@D1?=,<J$LM.T*ZTJHVN2.LB3AE4W7_.
MAM;MLUPCGVJK55ZHY_Q)]Q#KIIR[6O>6KHI4C3^L9W;?G0M1?!J/=/U0=G+B
M235>M_RE1TOY)FJZ.9CG+*U%W<ICAQ3F0:_5]77T['UM3-4.8[#5D<KL)CJ/
MGGR/&X?S3_'_  */%,-,>CM%8]WU)R6O3),S_#;Z,JAJ)J5\<U-*^*5J<'L7
M"IYRQ-EMTKZ^Z5K*VLGJ&MA:J)(]787>YE;1^X;Y"?;(/TO</B&^L7M36)PS
M/W.=),]JL+4 !A-<                             <]=F53U#])66=C5
M6FCJU;(O4CE:N[Z%)%V*5;15&RJGIZ5&)4TL\C*E$YJY7;R*O^%43/B\1/=I
M&DJ?6VCKA8ZIR1K.W,4JIGHY$XM=\_-/!DXJ;-K38SJJIB@?-05&]N.=N;T%
M4Q%X*F4PY/M3/4!WV:S5%70T.G;E4W98^T(X'K,DBHC5;A<HN?#R\YR33=DW
MK*.%6S4=GF?C@]8'HOE7#R'ZPVH:TVB]':ZRH=+3RO3=H:&'=;([.4X)ESNK
MFJ@2/L6(IIMKL<E-O=!'!,^3"\-U>"9\ZH=K%/=CGLOET)9I[A=]U;U<6,WV
M-7/01\^C\N>*^1$ZN-P@                5%MN[\]F7[\C]9I;I46V[OSV
M9?OR/UFEN@     %/;4^^M?D[/2XA%7SA^,0LW:!IRZW34*U-#2++#T+&[V^
MU.**OA4@^H-/W.TP4\]PI5AB=,UB.WVKQX^!36MDI]FBN\;\OK#$UM+;6G;D
MPNLNK9MWGT7E?ZZE1VBTUUVEDCMT*S/C3><B.1N$7RJ7)H>AJ+=INFI:R+HI
MV*[+,HN,N5>:'O$+1V.SOSW6])$]K=E:GNK+-8JRM>J;T;%W$5?=.7@B?.<U
MS2R3S22RO5\KU5SG+UJI96VB]=+5TUIA<N[#^=FQUN5.Y3S)E?.5S04LM=60
M4M.W>FE>C&IXU/DM7D[=^S'<P^+ZB<V?R5>E>7Q6'LTLB)IV\WB9G=.ADAAR
MG5NKO+Z$\Q#*;W3OC/XE\SV^*UZ0J**G1$CAI'-\J[JY7SE#4WNG?&+Z3:X7
MC\GFBO\ \9^L-F^GC3Z7%CCWSOX[.BJ^MAM]!)55#D;'&W*^/Q%'72OFN5?-
M5U"JKY'91/V4ZD\Q+MI-[6>9EJ@7N(<.E5.MW4GF(;1TTM9514].W>EE<C6I
MXS*U.3MV[,=S] X-I(P8O+7ZS\H2?9W9/RA<EK)VYIZ545,IP<_J3S<_F+8,
M"PVV.TVN"DB1.X;W3OVG=:_.9Y<PX_)UV[V!Q#5SJLTV[HY0  E40
M   :C5=NFNEDGI*96)*_&%>N$YE?^P"\8]W2_2+]Q:X(<F"N2=Y7]+Q'-I:=
MC'MLJCV 7A/UZ7_.OW%I4<;H:2&-^-YC&M7'A1#U![CPUQ^BYU6NRZN(C)MR
M  2J0                  !AW&V45QB6.MIHY6KUN3BGD7F9@/)B)Y2ZK::
M3O6=I5S>]GKV[TMIJ-Y.J&7^"D!5%1RHO-%PIT(5EM!TVRBQ<*"%K*;&)6L1
M$1JYY^/*K]A1U&GBL=JCZ3A7%+9+^1SSOOTE!S]8]S';S'.:Y.MJX4_/+Y":
MZ:T0MSMC*NKGD@63BQJ(BY;U+YRK2EKSM5MZC4X]/7M99VA$V5]8SW%74)Y)
M7'LR]71GN+E5IY)5)J_9NS]2XN\\:&._9Q4?J7"+SL4E\AECN4?[QT-NLQ^'
M]$99J2\MY7.I7RNR>[-77QG*X/\ .UJ_P-R[9U<$]S6TJ^9R'@_9]=V^YDI7
M?XU3^ [&:/>?:.'V[Z_A_1BQZWOC?=5+7^6-OW&0S7UW;[I*=WE9_P!SR=H.
M]MSB*G=Y)3P?HR^,S_N:.^#(W[SW_'CWFW#K?[?DVC-HEP;[NDIG?.G\3W;M
M'J4]U;H5\DJI_ CC]+WEF<V^5?)A?0ICOL5T9[JW57FC51Y7-'O_  /L?#[=
M(C\?ZIBS:1_Q+8O^&7_L>[=I%-^M;IT\DB*5^^WUK/=TE0GEC7[CQ=#*WW44
MB>5BGGVC+'>?W5HK=*_.?U6;'M$MR^[I:IOF1?XF0S7]G=S;4M\K$^\JA45.
M;53S'SE/"A[&JR.9X)I9Z1/XKBCUM9'\ZES?A,4R&:LLCN5PC3RHJ?P*5X>%
M#].HU=_=".> Z>>DS\OT7>S4EF?RN5-YWX/>.\VR3W%PI%\DS?O*)/S"+U'O
MVRWN1SP#%W7E?S*ZD?[BJ@=Y)$4]6S1.]S(Q?(Y#GS=3P'TU[F>X<K?(N#J-
M9/N<3_9^.[)\OZNA,IX4,2ZU\-NH)JJ=S4;&U51%<B;RHF41/&I1C*NI9[BH
MF3R/4_9JZJGBZ*:IFDCSG=<Y503K.7*'%> 3%HWOO'@]+S<);I<IZN?.](O!
M%QE&]2+CP(2O9WJ)E%(^W5KVLIWY?'(]R-;&O%5157GGA\Q"$!5IDM2W:;F?
M28\V'R,QR[ON="HN4RG($#TYKFBCH*>FN;YTJ&-1KI5;O([Q\"84%SHJ]B.I
M*J*7/4UW'YN9J4RUO'*7Q6HT>;3S,7K.WO[F8 "15
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MXRRMFUAN=IN=9+<*58(Y(D:U=]KLKGQ*IJ:F]8PS69Y[(-)69FLK! !AM<
M                           #$N=LH;K3+3W.CIZN!?U)XT>GS*AE@"!2
M[']"22*]VFZ)%7J:U43YD)#I[2-@TZKELEGH:)[N;XH6M=\^,F\
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M?DL<8*=9Z^']7H #0?*@
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M.JQ?P[Q]W[W3 &)17*BK4S25<,WB8]%7YC+)HF)Z,^U9K.UHV  >N0
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MS^SY?^-OHT^SKOLMO^+U%+Q*/V==]EM_Q>HI>!KZ[TX\%;0>J  45T
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MJ53,32)B)JIQ:WCQ1<\45%^PG)QIJS6G-QQ?-7+J/,[HV  3LL
M                                 QKG^C:KXIWH,DQKG^C:KXIWH/)Z
M.\?I0K/9;WPS?)W>LTM4JG9;WPS?)W>LTM8KZ3U;4XW[5\(  660
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M^SY?^-OHU&SKOLMO^+U%+P*.V==]EM_Q>HI>)KZ[TX\%;0>J  45T
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MYS7.65.>/!DML]RTK2?,MVH^Y4K-^<9*S$Q[P $3H
M                        B]SU=9^UZNG[97I=UT>.C=SXIX"4$)J-GU+/
M42RNK9T61ZNPB)UKY"++-]O,A=T4:>;3.HF8]VR)Z"N=+:KQ)/72;D2PJQ';
MJKQRG@\BEJ6BZTEV@=-0R](QKMU5W53CYR)>US2?VZH^9OW$DTU8X[%22013
M/E1[]_+D3^!%IZY*>;,<EWB>;2ZC?+CM/:Y>'T;< %IB@
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M(IZ)QY'O)Q,;=0 'KP       !\1PQQJJQQL:OA1,'V (C8
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M.XQN$R:%]=BU==ZUVF'7#,T9JS->D=SV ! U0
M      *F[*"WUM?LGKUH=]6T\K)YVM7G&BX7AUHBJB^8MDA^UK5=/H[0ESNM
M3!%5.1G114\JX;*]W!&KX4YJJ>!% I'L=-EFC=4Z(;>+U ZXW%T[XY(W3.:V
M%&KA$W45.:87*^'Q%L>TEL_][T/TC_O.++'?-1TMSJJK2TU?02S.571VS?8U
M$5>2(WJ).NN-JW_--2_1O^X#L#36S+26FKK'<K)9XZ6MC:K6R->Y51%3"\U)
MD<I[ -4:]N>TBCIM25U[FMSHI%>RJ8Y&91JXSE/#@ZL
MJ+;=WY[,OWY'ZS2W2A]J^G8+9M0T-=(JJLEEN%[AWXI95=''AS?<)U%\
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MU4<Z>+XOBTS-\/\ R_1?D;&QMPQK6IX&I@^@BHO)4!<;
M
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MT\[F-1'2/B3+U\*GZ_3%E?SME-YF8]!8^QV][,_O[#OMV94B,>(N:31UB?\
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MN-'/*O%&13M<Y?,BF<<O["=C^K]([0J.[7NCIXJ*..1KG,J&O5%5JHG!#J
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MZ5DEXBE9$^%&L5\J.X[R>-2R "?'CC'7LPO:?!73X_)UG>/O  =IP
M
M      C&N=0U-@AI'TL<#UF<Y'=*B\,(G+"IX3F]HI':E+@PVSWC'3K*#[0^
M^^?X,?H0MYON4\A1%ZNLEWN3ZVH2)DCD:BHS.[PX>$G&E]:UUTO5/13Q4K8Y
M,Y5B.WN"9\)2P9:Q>WWR^AXAH<MM/CVCT(Y_A'Z+  !??,@
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MJ2\L]S<JG'C=DR8]87UG*N<OPF-7^!N)-G5<GN*R!4\;50Q9- 7=N=QU,_\
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MHJ+E_/X:EC13SV9&+3X_[GT^7;SNGU2( &DI@
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M8[T9/E3_ $-)V>Z7'%:1,=[G2ZFV728:3TK6  %E(
M
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M8LB)A)'(B(JH=2'>DO:UKQ,[[?U0?VAT^+%AT]\>/L3:)F8[^[KX;@ +KY8
M                     J(O-$  QZVC@K*:2GG8BQR-W78X<"AM:VF:S5#Z
M6;BB/16/1%1')QY9YXY'0)4VW#^<6[X#O24]92)Q]KOAUESWKH\^+NFL_)H-
MG=AEO53NN8Y*1KLR/5J[JHF,M14Z^)>T,;8HVQL3#6IA$(#L5[V:CY2[T(6
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M^#UV,=Z,GRI_H:3L@FQCO1D^5/\ 0TG8T_JZO=![-3P@ !,M@
M
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M5F,)43X5S?@IR0F!UIL,XHF;=90<=XGCUUL=,6\UI&V\]9F>L_( !:8(
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M@
M                                                    (CM0[VF_
M*&>AQ\[+N]U_QSCZVH=[3?E#/0X^=EW>Z_XYQ5_U_@V8_P L_F3  %IC
M    -=J*[P6*RU=RJ\K%3LWE:G-R]2)Y5P1_9]K5=8I5216N6DIH%1O2OE1R
M.<O4G!.2>DB79%W%T5HM= QZHDTKI7HG6C4PGK*2?9;0I9]F]&Z)$Z62)U4Y
M53FYV53[$1/,5O*6G-V(Z1#=^PX<7"XU-XWO>VU>O*(__B;@H"@VS7Y5FCEH
M:2HG>B-@;&QR8=GK3*JODX'I#M?U';[A&V]VNG;"JHKH^B?$_=\*97^!S]MQ
M)9_LOKXF8VC?QZ^"^P1B^:AD?H>:]Z;:E5(Z-KX&JQ7;V7(B]RG'AQ^8JQ-H
M^O?^3L^I2?>29-13'.TJ>CX-J-76UJ3$;3M.\[3NOHAUTVDZ8M=PGHJRND94
MP.5DC4@>N%\J(0_1^N-97/4E#1W.ULBHY7XE>E*]NZF%ZU7AU$AU-LZTK45%
M=>;NZ>+?599I.GW6I]ASY6V2O:Q?--7AV#1Y_)<0F9WCEV)B>>[U]MG2/_,9
M?JTGW&QOFL8*'24>HK=227"A?A5W7=&J-553>XIX>'G.?K58J75>LFV^P1NH
M[>KO=S2;[D8G-RYYJO4B?>ITA'I^EIM).L4#56E2F=3IO<57*+Q7QY7)'@RY
M<L6Z?U7.*\/X?PZ^*([4S,Q,UF?X?AMM/Q8^A-64NKK0ZMI8W0/9(L<D+G(J
MM7J7/6BHJ$C.?-@-=)1:PK+;(N&U$#LI_?8N?1O'09-ILLY<>\]6=QO0UT.K
MMBQ^C.TQX2  G9                           !!-L_>@SY4ST.)V03;-
MWHL^5,]#B'/ZNRGK_9LG@\MBG>Q4?*7>A"P"O]BG>Q4?*7>A"P!I_50<.]FI
MX  )EP                             1+:?K>ET!IG\LUU)-5Q=.R#HX
M7(CLNSQX^0J;_:EL*<]/W/Z1GWEP[0M%VW7=@_(]ZDJ64O3-FS3O1KMYJ+CB
MJ*F.*]16+^QGT,Q,OK;VU/"M3&G_ -,#5_[4M@SGV/W+/QC#YE[)_3DS=V73
ME>]O@<^-3;M[&70[DRVLO:IX4J8__O9^_P"S)HC^UWSZS'_][ V&S;;G9]:Z
MFI[%;[/64DDK'.1[W,W4W4SR0N$J[0FQ#3&BM0PWFT5%T?5Q-<UJ5$S',PY,
M+P1B>DM$                "HMMW?GLR_?D?K-+=*BVW=^>S+]^1^LTMT
M    %?[:^]>F^5M]5Y8!7^VOO7IOE;?5>0ZCU5E/B'LU_!Z[&.]&3Y4_T-)V
M038QWHR?*G^AI.QI_5U>Z#V:GA  "9;
M
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MLN$J;W0P.57?WGJB>C>.A#O1>KF??*I_:F8^V5IWUK$?6?S  7'S0
M                   !!-LW>BSY4ST.)V03;-WHL^5,]#B'/ZNRIK_9K^#R
MV*=[%1\I=Z$+ *_V*=[%1\I=Z$+ &G]55YP[V:G@  F7
M             !$]JFK4T3H6YWQL;99X&M9#&[DZ1SD:W/BXY7R'$;ZG6NTN
M]5+X5N=WJ^,KXHE<K8D5>I.34XG4'9;N5NR9415PZOA14\*8>O\ !#5=AO2P
MLT'=ZIK&]/+<%C<_'%6MC8J)G_$OS@4%I'6FK-EFJ%BF[;A6-S6U5OJ][=<W
MG[E>2XY*AW;9;E3WBT4=QHG*ZFJHFS1JJ87=<F4SX^)S!V9U#3Q7G3M:R-&U
M$\,L<CT3BY&*U4]92\MALCI=E.FW/7*]JHGF153^ $Z
M %1;;N_/9E^_(_6:6Z4/M7IKY%M/T-+<ZZFGM<E[A[3@CCW7Q=TW.\N.)?
M     *_VU]Z]-\K;ZKRP"O\ ;7WKTWRMOJO(=1ZJRGQ#V:_@]=C'>C)\J?Z&
MD[()L8[T9/E3_0TG8T_JZO=![-3P@ !,M@
M
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MJ1$3P^$DH!Y6L4CLUZ/<^?)J,DY<L[VGK( #I$
M     03;-WHL^5,]#B=D$VS=Z#/E3/0XAS^KLJ:_V:_@\MBG>Q4?*7>A"P"O
M]BG>Q4?*7>A"P!I_55><.]FIX  )EP                             4
MMV7/]$Z?O"'T/.7M';3-5:-MLM!IZY)2TDLJS.9T+'Y>J(BKER*O)$/Z"U5+
M3U<715<$4\><[DC$<F?#A3#_ "%:/^54'U=GW ?S[UKKS4&M74CM25W;:TJ.
M2+\VUF[O8S[E$\"&YL6V/6UAM%+;+7=TAHZ9NY''T$;MU/*J9.Z_R%:/^54'
MU=GW#\A6C_E5!]79]P'-&P3:OK#56T:BME\NB5%%)'(YT:0,;E4:JIQ1$4ZH
M,.FM5OI94EIJ"DAE3@CXX6M5/.B&8                !46V[OSV9?OR/UF
MENE1;;N_/9E^_(_6:6Z      "';4K16WFP04]MAZ69M0UZMRB<-UR9X^5"8
M@YO2+UFLHLV*,V.<=NDHELPM-99]-OIKC%T4RU#WHW*+P5$\'D4EH I6*5BL
M/<.*,-(QUZ0  Z2
M
M     8URG=2T%1.Q$5T;%<B+RX(9)^/8U[5:]J.:O!45,HIY/1[68B8F5.7_
M %=57N@2EJ88&,WT?EF<\,^%?&-/:MJK)1+34\,#V*Y7Y?G.5\BEK_DJW?V"
MD^A;]P_)-N_L%)]"W[BI]GR;]KM<V[_>>E\GY+R7F]=MWGIVO?<[-2UDK6M?
M*W*HWDG$V)\Q11PQHR%C6,3DUJ81/,?1;CE'-B9)BUIFL;0  ]<
M                                          P[S5/H;55U4:-5\,3G
MHCN640HK4^N;AJ*VI15D%+'&DB29C1R+E$5.M5\)?\L;)8W,E:U[')A6N3**
MGD,#\@VC_E5!]79]Q7SXKY.59VAGZ[2Y=1'9I?LQW_>HW2VMJ_3E ^DHX*:2
M-[UD59455RO#J5/ 7M8ZM]?:*2JE1J/FB:]R-Y(JH>7Y!M'_ "J@^KL^XV$4
M;(HVQQ,:QC4PC6IA$3Q(,&*^/E:=X-#I<NFCLWOO'=]SZ !8:
M                    \:VK@H:.:JK)60T\+%?)(]<(UJ<U4YDU]V34S:R2
MFT701] Q5;VW6-5V_P"-K$5,)SY_8!U"#B"3LB=H+G*YMPHVI^RVC9A/G3)L
M[+V2NLJ6>-;G%;ZZ%/=-6'HW.\Z+A/F [,!!ME6TJS[1;9+/;$DIZRG1O;-+
M+C>8J\E1?UF\%X^@G(                %1;;N_/9E^_(_6:6Z5%MN[\]F7
M[\C]9I;H
M
M
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M*=R'./8\;%KEI^\LU+JMC8*J)O\ NM'E'.:Y4PKWJG!%PN$3CS.C@
M         *BVW=^>S+]^1^LTMTJ+;=WY[,OWY'ZS2W0
M
M
M
M                        #SJ:B&FCZ2IFCACSC>D<C4SY5,7\L6S_ )C1
M_3M^\@^WS1]RUMH"2UV7HEK65#*AK)'[J/W4<FZB\D7CU\#AN>RU]+?76:MB
M[5N#)DIWLG<C$8_..*KP1/'R _HY^6+9_P QH_IV_>/RQ;/^8T?T[?O.)4V!
M;0G(BMM$2M7BBI5Q+_J"; -HG_)X_K<7X@.WX+A15$B1P5E/+(O)K)6N5?,B
MF2<M;!MDFL-*;1*.ZWRW1P44<<C7/2H8_"JU43@BYYG4H
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M\4W;-IKJ:MI\XZ2GE;(W/E13[N%PH[='')<*N"E9(](F.FD1B.>O)J9YJO@
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MN?MY9+039!H?\DK0OT_2/56;JU#FJLRKC&]O\\]?,TNU#^EW9C\IJ?\ IEL
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M]FE<W:7M DUKN2-MEII6T-"R5N/SSVYF>GDRC?(H%JZ8M$%AT];K52-1L-'
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M3:+M5S.1L5+;J!DTKU7Q(F$\ZEIR6.T5MHAH*BU4C[>S"LI98&JQF.6&JF$
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M"V#C';A_XCH/E5%_H.SBI=8;$K=J;7K=4U%WK(*ALD4G0,C:K?S>,)E>/'=
MMH   :[45)6UUEJZ6U5ZV^NE9NQ52,1_1+GGNKS*\]A&T'_]Y#__ .7,^\#&
MVW=^>S+]^1^LTMTYVUK8M1V?7&SUVI-3.OC)+U"D35IFQ=$J.;E>"\<G1(
M #%CMM#'<9+A'1TS:^1G1OJ6Q-25S>'<J[&53@G#/490 &!=++:[LC4NMMHJ
MU&\&]LP-DQY-Y%,\ :]+':4I(*1+70I2P/22*'M=FY&].3FMQA%3PH9%PH*2
MXTSJ:X4L%73N5%6*>-)&JJ<4X+P,@ ?C&M8U&L1&M1,(B)A$0UEPT[9+E4)4
M7&SVVKG3E)/2LD<GG5%4V@ PW6N@=/2SNH:59J5%2GD6%N]#GGN+C+<^(S
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M*&EK847*,J(6R-1?#AR*>U)304=/'3TD,4$$:;K(XF(UK4\"(G!#U  +Q3B
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MZ5M%2U\*PUU-!4Q+S9-&CV_,I[@#5VS3MEM<W2VRSVZCE_;IZ5D;OG:B&T
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M@@DHE8V2HA<QJNWVKA,]? #IAU%2NJVU3J>):EJ*C958F\B>)>9D
M          5%MN[\]F7[\C]9I;I0VU;3-':MJ.A[M3S5;ZBXWR'I62R[T;<.
M;C<3J+Y
M
M
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M]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ
M20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7
MHOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^
M>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/
M-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7
MXA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9
M/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFD
MO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;
M]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ
M20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7
MHOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^
M>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/
M-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7
MXA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9
M/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFD
MO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;
M]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ
M20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7
MHOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^
M>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/
M-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7
MXA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9
M/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFD
MO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;
M]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ
M20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7
MHOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^
M>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/
M-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7
MXA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9
M/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFD
MO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;
M]GFDO?/9/KT7XA[/-)>^>R?7HOQ 20$;]GFDO?/9/KT7XA[/-)>^>R?7HOQ
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M,5$RY>:J=D'A045-;Z2*EH:>*GIHFHQD434:UJ)R1$0]P
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M6_Z,G  @_M2Z&][5O^C'M2Z&][5O^C)P (/[4NAO>U;_ *,>U+H;WM6_Z,G
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M%[7-F^GK;0V!UAT[3QR37:"*=8(E55A7>WD7'5R)Y[4VAO>U;_HR<*B+S3(
M@_M2Z&][5O\ HQ[4NAO>U;_HR< "#^U+H;WM6_Z,>U+H;WM6_P"C)P (/[4N
MAO>U;_HQ[4NAO>U;_HR< "#^U+H;WM6_Z,>U+H;WM6_Z,G  @_M2Z&][5O\
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M)5A;C>QG&?G4WH         $,VM:Y;L^TI^6GT#J].G9!T22]'[I%7.<+X/
M4M-V4]-+&^.72#WQO16N:ZN14<B\%3^3+ZUYH^UZWL:6F^).M(DK9OS,FX[>
M:BHG'SJ5W_LWZ#_X=T^M_P#8#DC6MSLUUOLE;IVT/L]+)W3J59^F:QV>.ZNZ
MF$\1<&@NR3N5AL$=OO\ ;77F:%=V.I[82)^YC@UW<KO*GA^<LV;L?]FT$CHY
MIZV-[>;75R(J?89$?8Y: E8CXVW)[5Y*E7E%^P#RV7;>HM=ZMI[&S3[Z)96/
M=TRU228W4SRW$])=I6VBMB^E-'7^&\69E<E9$US6K+4;[<*F%X8+)
M                   U6JK]1:8T_77FZ/5E'21[[]U,JO'"(B>%55$3RG,Z
M;;-IFHUN-QTI8H%L]&[+U93++N-Y]T[/%<)G@!U:"J-A6UIFT:EJJ6NIHZ2\
MTC=^2.+/1OC5<(YN554X\%3R%K@                         #G7:1MWO
M$>KYM,[/K;#6U4<G0].]CI5D>G-&-1>2+UKGD!T4#EJ+;EKW2-]I*7:'8HHZ
M:?NG(L"Q2;F<;S%1<+A?$=-VFX4]UM=)<*&3I*6JB;-$_P +7)E%^T#*
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MUT3W)63OCZ1D>.",;Q1%7/->K!;VS&]5>H=!62[7)6+65=.V256-W6Y7P)U
M2<%#;7]M5QLVJH]*Z%H8J^[JJ1R2/8LF[(O)C&HJ95.O)&K#MVU=IS5-/:MI
M=GBIX)G-1TG0K#)$U?U\95'-_P#60.G@&JCD16KE%ZP
M      07:MM(M.@+)+-5SQR721B]JT:+ETCN2*J=34ZU\7A(5V.&TK4&OZB^
MMU ^E<VDZ+HDAAW,;V_G/'CR0"[P5OMKVH4^SBT4[V4[:RZ5:N2G@<[#41$X
MN<J<<<O*4PNU_:ZEH]D2V&#\AJB/25:)W1[N<9SO;V/&!U>"N]BNTRGVCV&:
M=86TMRI'-94P-55:BJG!S57J7"^3!8@
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M1.'MB$LNF-O%);62.<U*R:W2;O)Z)O-X^+*(IW"
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MG<KXSL78+JV_:PTE4U^IX60UC*MT36M@6+N$:U4X+SXJO$"R0
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MKZ)*E\<"JC8WHY4143J143ER [*!@V*IEK;-0U-2U&S30L>]$ZE5,J9P
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M;E;W.5^8F9#-C-ODM>R_3=+,U62MI&O<U4PJ*[NN/CXDS
M     .H #F2Z["?R7IV_ZCU?>9;Q<XJ662.-%=N-=C@JO<N\Y4\'!#'["SC4
MZI\E/_\ 4+YVK?T<:C^12>@H7L*_YQJGR4__ -0"[]>[,].ZYJH*B_P32S0,
MZ.-S)5;NIG/48&UO4EFT)LVK()TB7I*9:.DI,IO2*J;J83P(BY5?%X<&[VD:
MWMF@]-RW6ZN5RJO1P0,]U-)A51J>+AQ7J.9M(:2U)MWU4[4>IYW4]BC?T>\W
MN>Y3^JB3S\7+X^:@27L-;%5(M^OLG21TK]RFB3&&R.3+G+YLHGG.G37:>LM!
MIZSTMKM%.VGHJ=B,C8G'AX57K5?";$
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M;(J'9U#/52U';UXJ$W7S[NZV-O[+$]*]? M$
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M8GZK*YZ(GFW3LH 47L V9:KT3?[C5ZFJJ>:">!(XTBJ72JCLYY*B%Z
M
M
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MG3EV@OMBH+I2_P A60MF9Y')D#8@
M
M
M
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MBO57_P"H"<
M
M
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M/4,:CF-SE43'A7"KY$+%
M
M
M
M
M
&     __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g184865g08g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g08g02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2"N4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %P< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(X,S$P,#(< @4
M,TUI8W)O<V]F="!7;W)D("T@3TM54B M($)U<VEN97-S(%-E8W1I;VX@4FED
M97(N9&]C>#A"24T$)0      $/*=/.JJ11_YFKV==_&<FP\X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T#\@      "@  ________   X0DE-! T       0   !:.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             "C    T8    & &< ,  X &< ,  R     0
M                       !              -&   "C
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "C     !29VAT;&]N
M9P   T8    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   HP     4F=H=&QO;F<   -&     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    &.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M_IT9_P"V^8MQ<GU'KF#U7)Z&<3U/;U7;+F. /IX^1N=ZFM;-S;JWLJL>R_\
MX+]'8NL24I))))2DDDDE*24+;64UNM?.Q@ET N,?U6RY"M>\V8Q8]S&O<=S8
M D;'60[>W>WZ*!-()3R#PJ+AUG]K M-/[,V>X&?4W?Z_V$;!KKKI>&-# ;;9
M#0!^>\=E0??T8?6-E+LMXZD:2!B[W^GMG?JW^;]3V_S6_P"A^D])"I2 H'3U
M'A_=6FR(^8.],KA]8#=9Z+JO3%G#H_F_=L%'M]EG\UZWVG?^D]3TOT:'DM^L
MSFN&,^MEC15SM+7';9]H+/9OK;ZGH_SG_6U5RJ.B'+>;LJUEEEY],!NC[1ZH
ML9_-N^V-J=ZU>V[U/L^STD#/Q?J^:2<K*N%3ACFFT,D@-9>VO].VIV[>WU]W
MJ_S6S_K:<O=6T?6,9N0:'4.QSM..+. -K-^[T]MOJ>JV_P#/]/T]BEZOU@?<
MX-IIKKKLJY=I960W[2UKO>[=7N?Z?Z.KW_H_^%5"ZCHHZEEVNR[L:VYP-[FN
M-0:6,KJ$W[6O;7=Z+?2WOV775W>DI7-Z8QSLC)ZL]];7T9%!:\$U@!M8L<[]
M(WT[]KO7?LJJ]*S])_I$E.QTY^6_$8[-J;1?+@:VQ :'.%?#K/I5[/SU8!!
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MR'N<\.M,M&1AM+W5,VUMVUTIHU'A_P!):-?[M_XW]84Z.91C8K.K;&LK P6
MO, G3+ ]2UWO?_UQRMY9>[)Z8^JLVUBUSG6,+-H!IM8'>Y[=_P!/_![TU^+8
M[(SGDNL;;CL8VIP9LEOJQ'M]3\[\]6+H99B-]M<./LX_,>V&?>G%<6'2J;*:
M+&V6"TNON>"&[(W6/<6_2?\ G*ZJ;+33B6V/+:MMEA!>1MU>Z.[/ZJM,<'-#
M@0X$ APX,]PD-@H;!DDDDBE22222E))))*4DDDDI_]3TVW P;\AF3=CUVWU1
MZ5KVASF0=[?3<X?H_=^XJ/7>B7=5%/HYC\,U;PXM#B'M?LECFMMI_P!']/\
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M &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  (  R #  ,@ Q     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !\   !^ 3(  @   !0   "= 3L  @    D   "QAVD !     $
M  "\    Z    2P    !   !+     %!9&]B92!0:&]T;W-H;W @,C(N," H
M5VEN9&]W<RD ,C R-3HP,SHQ-" P-CHS-#HT.0!R<C@S,3 P,@     #H $
M P    '__P  H ( !     $   -&H , !     $   *,          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!3D5X:68  $U- "H    (  @!$@ #
M 0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    'P   'X!,@ "    %    )T!.P "    "0   +&':0 $     0   +P
M  #H   !+     $   $L     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD
M;W=S*0 R,#(U.C S.C$T(# V.C,T.C0Y ')R.#,Q,# R      .@ 0 #
M ?__  "@ @ $     0   T:@ P $     0   HP         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M*"@H*"@H*"@H*"C_P  1" *, T8# 2(  A$! Q$!_\0 '0 !  (# 0$! 0
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MHV,_3C;CK;DY7,396HOM,"_RR<;H96]6NA:J+_ "Y
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M]$_^#;3Z3O?WE0Y6)J>@QQ-9NJ]>B%C@
M          @>N.&>+U?E8+V2<Y9(41&IY'I1X>4X8)J]F=\]61G)X:JNR(3@
M 57A^"^%I9%LUE[K%6)_B0P.WV:I(]=Z QFK(JZSM2*S7V2*5J?-0F( AFA.
M'^-TFLTT/Y^Y-\^9W=2/YK@UB<AGI\A%,Z&.P[FFB3?9Q:8 P,%B*>#QL5'&
MPMBKQIT:A]YKZ'O?8/\ PJ9AAYKZ'O?8/_"H')OR>/WJW?B=^(Z^.0?D\?O5
MN_$_\1U\      %5$3JNQ\>-%_S&?S(5M\H#+7</H62SCI5BEYT;S)["#</M
M.2:ATQ!D+^H',G>G5/$VV Z#;(QR;M>U4]RGXLT2+LLC$^MR%)ZRQ]K1^A;]
MS&95UB79?65V^QJ^&6D<IJW2D64N9B1LLN^R(]0.@FJCDW:J*GN/TYRX<ZLS
M>!XKS:2R=M+-/F<G/WVV3VDKXS<3[.D\CAX,.^&5ME^TVZ;[)OL!<2JB)NJ[
M!%14W1=T*LXO:DFBX;>FXJTUMI[6N56KVW3J9'!+4?IV@ZTV5NL?:YE1RJO7
M;9 +*YDWVW3?V;GXZ1C?G/:GUJ<V8W5N5L<;)J,5WGH^(J(U.VQBTK63U-Q9
MRV*O99:U.-55GK;=O(#IQ)HE[2L_F0_5D8WYSVI]:E2U- L2PQT>H'O>Q=^7
MQ.Y6^(ES6J.*N1P<F2?'5KN5J;.VZ(!U$V1COFO:OU*?2JB)NJHB'-G%"CG>
M&JT,O0RSI8%E1CHW.554WFJ<UK/5TV&J8"JZ#'6V-6>PG39?/J!>S7M>GJ.1
MWU+N?IS9<S.=X;<0<7BGWTN5[JM:]JKS*FZI_MW.DF+S-1?:FX'Z%5$[JB?6
M"AM<:JRFHN*5+2^"F\"&!R^,_?;?V@7PCD5=D5%7ZS]541-U5$3WG/&A]3Y&
M+C)D<9D;W_"0IR(BKTW0D7RB=42XW2D3\->:R=7]>5>NVX%RHN_8_-TWVW3<
MKW1-S,Y/AC1L4IF+DGQ(J.>FZ;[%":DUOJ_3^K[T65O(LR1KRHWM[@.O/$9S
M<O.WF]F_4^CEQE;4L'#MVLW9)WIC7\Z,YNG+]1>'"O5G]J-%U<E95&SM9M/[
M$5/,"9JJ)W5$"JB)NJIM[3F+C=Q+REG*MJZ=D='0KO1'2HFW.I>F!BFS>A*K
M)IE;-/ W>1.^^P$F\:)5V21F_P 2'TCFJGSD_P!RBM?Z0ETMIF_E'9J9)8VJ
ML35>O5WL(KA\UJ*KP5M9RS;?X\DRMB<J]>4#IWQHO^8S^9#[14<FZ*BI[B@.
M'.C<GJG24&4LYB5LTZ=/77H8_##5F;P_%&UH_)V$MP(]6-?WVV]X'0X543NJ
M("C.)NHLI<XI87 X6PK&-<GC(GU@7F"&<0M4_P!EM(6;4,T;KT$2;-7KNJ(:
MKA;K*36NCUFNSQQ7I>9B(B;;>P"R$5%[*B@HCA7J_*8S7V0TIJ&;Q%?(KH7K
M[.I>X   #6Y_*)B:*V'1K)LNVR&Q?ORKR_.VZ$'UJ^_^37).C?"YO(#Q;Q$8
MJ;^AO_W-A@=9,REYM9*SF*OFJE8-VV-SI-TS<JU:VWB>\MH7*##QJVG1KZ6B
M(OEL9A45OJG7N3I:F?AL+B'W9F)NKFK_ /!N='9O4&1N2QYO#/HPM;NU[M^J
M^SL5YJ5<[_>I:334D;)U:B.YT3;R)DLVIZ>E,E-G9H5G8S=BQHB;?[ 6!NFV
M^Z;$9U]JENE,5#<= L_B2I&C47VD)_+>1_NK?=6RGI*OV1^YX<1;$EKA=@9[
M+N:625BN=[^H%M8VTERC#81.7Q&H[;V&3NGM*E;FKFELI4?>F1,7/7W:O?9V
MW0Q'ZIS.(T+D]0V/SCYI.6!B^Q>P%QH]JN5$<U53R13]<]K?G.1/K4YUT_?U
M55R=')QT+"QVE1[^9V[=E-IKIVH<AJ)RS/?%19&CFK&[;E7W@7)F\W2PT44E
M^5L;9'<K=U3JIGPS1RPLE8Y%C<FZ+OTV.?\ 6D$NH-)8QS\BDSXIDBYFKMMV
M)%Q+FR&%T%IZECK*LED<V)S]^JIL!</.WEWYF[>W<_&2,?\ ,>UWU+N5SDJT
M>GM%K!D;[W3S;<JH[JJ^XKS2^;S&FM9X^K;BG96N]465W-NGDH'13GM;\YR)
M]:GE;LQU:LEB9R)%&G,J^XI"O5S&J]8ZBK?E%T-:LSGC1%V-QI'(VL[PUS-6
MY+O)65T:2>U$V LG3V>HY^H^QCI4DC8_D79?,VA4/R<\4M'3]Z195>CIU1$W
M+>                                                    8>:^A[
MWV#_ ,*F88>:^A[WV#_PJ!R;\GC]ZMWXG_B.OCD'Y/'[U;OQ/_$=?      %
M3?*77;AY)]HA'>$O#W#Y;1-*W-?LLD>GK-:]$1"W=::7I:MP[L=DN9(7+ONW
MN0VAP@J8^LVO2S60A@3LQJKM]X&FXJ8"EIOAE?AIV))FN1>LCD<1+A3I?4UW
M03+.&RGA-<U>2/FVZEINX74Y\;-2OY.Y;@E394D7?;_N2?1^FJ>E</'C<>KE
M@9VW YYX&UZ5O665H:H5R:AYG-8]5ZK[3\XZ<.9*.4POY$AO76S2_GEVYN3U
MBZ4X9X=FMDU/"Z2*]ONJ-Z(I.',:[;F:CMNVZ;@4)Q-TA4TYPQDGAGL/E>UB
M.;(NZ(NW4^>#'#W&9O0]:[-;MMD>Y45K';(G1/ZER:PTW3U3AI,;D%<D#UW7
ME/W2&G:FE\+'C<?S+ Q=TW YATOCX,1QUDIUI'OCCD5J.?W[F=I?!4M1<;<W
M5OV'P-3F<BL5$55+OBX8X:+5S]0M=)Z8YW,J>6YKK_!_$V,]8R]:Y:J6YEW<
MZ-?_ ) S,9PYPV-N-LQ9"RY[$WV=(FQ0N!QM[)\;,Q!B[7H\K95];?;=-R]8
M>&#8IF2?E_).1J[[*Y>O_<S-/\-,1A-3S9RL^5UR7OS 4-Q,QV7P>L,4W65E
M]O#/D3E5%W0N'7W$K$:)TY6AQ/AV+<L2>C0M7LGDJDJUYHK&:TQ\=7*M7:-W
M,Q[>Z*1#)<$<%D)*\EBU:=) B-8Y5[(G\0(IPUT%?U)EUU=K"?\ XB9?$K0N
M5%Y?83*QH[5#\HZ>/,;0<^Z,W\C,I<,F5+%>1F=R*LA5%;'S+M]7<L&-O)&U
MNZKLFVZ@8[62P8Q6N=SRLC7K[5V.<.#BOFXSY^2TF\R/=MOW3J=,^1SGJC'7
M="<9JV<@K22XW(2>ND35Z;KY@:#!X*KJ'CIFJMR:6)O,JHL:]?(VGR@M#8_3
MVE8K-:U9DD61$Y9';IW+AP.@,12U1-J:JLB6[2<RM=V3<V.N]'8_66,;1R:O
M2)KN9%:!J^"J[\.\4J?\I#F?CHUTW$C(<G56MYE^HZ]TUA:VG\/!CJ>ZPPMY
M45>Y%,OPKP65U!8RUMKW33-Y'-\M@*WM92I+\G*3DG8KD1&<N_7?IY'SP\P>
M?=P6FAP7,RU=WV5>GJKOV)C#P4Q,;_!]-G7&\W.M7KRJO^Y9^,H5\91AITHV
MQ5X6HUC6IT1 ./.(&,SNF]'TL;EJK6_G>99N7JY?K.E.#UK)6M'5%RD*1*UC
M4CV3NW8S]>:)QVLZ<-?*.>C(G(].7VF_Q5&/&XZ"G J^'"Q&-W]B <]?*'S3
M]0:IQ&D:+^=%F3Q49[5V[DGXSXN+ \&8<=&B(V!&LZ)W4E]7AGAH=82:C?XD
MUUSN9$?U1JF\UEIBGJO#/QN15R0N7?=O<"B>&VE]4V^'C+6&RGAM<Q59'S>[
MMW,+@G%!;U#FJ>4D6/537*V.63NJ[]=CH?26G:FF,-%C:"N6"/MS=R/0\,\/
M!K9VIH'21W7.YG-;\U5 UN(TOJ/&Y!;M_+^)6C:Y[F[_ ,2!<(6IJSBQF-0J
MO,RNY6-^LZ!R%5MVE-6D<YK)6JU5;WV4CVA=#XO1M>>/%M7>=_.][NZ@0KC5
MH*'(8#)9*JZW-?5JJR%B[HJ_4:;@-P^9'@*N1R7IE6['(J^$[HA>ZHBILJ(J
M>\\+4S*=2696>I&U7*UJ <VZR7P_E"XYU=?7W1'<ITPSYJ?4<[<-L1=U?Q7O
M:GNUY(JE5ZM8DC53?OL=%    -3J7&.RN/6NQW*N^YM@!6S= 6$3;QC9Z=TA
M-C,BVP^7=$\B; G8  @1:'2;(]82YQ)EYI$V5GD2'(TX[]*:K.F\<K>53( %
M.R<);DC9:;LJ],:Y_.UGL)?J#0\65TGC\*LZL94<U4?[=MR9@"%ZUT'6U1IZ
MIC)YWQ^CJU4>G==C:3Z5I6-+LPD^[H&,1J.VZHJ>9( !6N&T'E:V1B],RTC\
M? [\U&B^7L/35>@;M[(.M8K(OC21O*^.1?5V+& %;S\,H$TDN+KV'-L+(DJR
M?]1GYO0RYG3N(Q]NTOB47H]7_P";8G( C&L]*Q:BPS*JOY)HMEC?[T(;5X87
M[.<Q^1S.369U+I&U.VQ;( B.G=&QX?-Y?(,F5RWX^16_Y3YT?HJ' 8G(45F6
M2.V]SE]VY, !#.'FCY=)>G1)966O/)SM:OD3,
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MM<S^*E2X7(6,CC\_/9QS[7I2N\.3EW[;F76S4F2X,Y&I=54N5GHG(O=&\R;
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MVDKHU7;(KM@+]AECGC22)Z/8O94/LK'@S/.LF8K>,^>G#-M"]W94]Q9P
M                             P\U]#WOL'_A4S##S7T/>^P?^%0.3?D\
M?O5N_$_\1U\<@_)X_>K=^)_XCKX
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MBVUD2O*O,_VJ[VF3)I:A+A*N+F9SUJRIR(OEL;WF;LJ[ILG=0Q[7INQR.3W
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MCF6)OGJU53<F8 UV"PM+!TDK8^)(V=U7S5?>;$
M            8>:^A[WV#_PJ9AAYKZ'O?8/_  J!R;\GC]ZMWXG_ (CKXY!^
M3Q^]6[\3_P 1U\
M          !^.5&M5579$\R.:GU33Q6,FEAFCEG3HUJ+YDBD8DD;F.[.392
MZMT-%/CII*+G+.B\W*OF89YR16?#AS\1;)%)G%'555[4&2NV'326I=U7HB.7
MH3KAIK*1+'H.5FWC5/4D>O92M)Z\M>5T<L;FO:NRHJ$PX=Z6ES%U9;+7LJ,3
M=5V5-U/(PVO%XFG=\OP.7B)XB-3,S\UX5K<%IJNKRLD1/-JGL:W"X>#$QN;7
M5R[^TV1[E=S'O=WUU=Z][NJ?-V[NM=:V,!4L/JTJ'K2R1KLKNR&-J'!7-!35
M\OC,E/-41Z-FBE=TV/6RZ31'$2YDIJ\LM#)(C5>Q-^3JB[J>FNL_'JV.#"8:
M&2;Q9$625$W:U"RS]XE:A6NF!R<=AT-.3ED?LO14WW//$9&[Q$SK9Z5AU?#4
MG)ORKLKU_P#J*8W$[ -?'IG%2,=)6B5K'[)T5-T$]&?AQJ6I-C&2/P=U4;)&
MW_"O_P!W S\W?MP\8<32CF>VKX6RLWZ+T4M-SD5%:UR<VW3J5)G8Y+'&+$SP
ML>L3X.CT3MT4EE'3%VEFWY&;)S20(JN\)7+ML!'-4:)E\'(Y7(9N>%[45\:(
M_9J>Q#,T38SF<X?\J3>%<:]S&2OW]9J>9$LYJ9NL-1R8^],^EAZ<GKMWV679
M2X-/.HNPL28I$2HUO*Q$]P'.>)S&:DNR8&[D)49+<\.27F7?OMT4L'"I/HW7
MM7%,R,EJC;CW5)';JBD2P=>HDN93+5)D<ZXOAV&M^9U7KN;C2>+?EN(<%F%\
M\]2HS99I-UW7ZP+PM-D=7D; Y&R*GJJOD<X9K,:@P.M;M2U?<^29VS$YEV1%
M7ZSI0YTXD8NW=XB6;%>O(_P51W1.Z;@;K/XR;2#<+FZUZ>26=Z.G:YW1=^I9
M&8UKC,/#46_(C9;#$<UB>\KC5N8KZJH8+$XM'26HWM;,Q$W5FW3J;#5.)9+K
MO!06J_C111M:NZ=.R@2>/B=@9*\DC)E5T:[.9UW0E6$R]3-466J$K9(W)Y+V
M*OQ&GL>W-ZB5<;'RHQW(G+TWZ]C/X%1318K+,D:]C4L;,:ODG7L!),_KS$8:
MZM6:7Q)FIN]K.O+]9GZ8U3CM1T9;6.DYXXNCO<5;C'4,5J/4K=34O&EE5SH9
M)&[^KMV3<]>%%N*II;4%ZI75D2.=R,1/K S[-ZYD)M1Y"O8>D,2<K$1>B;?_
M /#=: U)%%INI'=L>-<ED5.7?=378NJK>&F4LLA<R>TURJU4Z^9!^'-"]I*_
M6R64C?:IVWJQJ.3?PU7S NK4NK,;I](VWI?STG5L:=S'TMK;%:CMR5:,GY^-
M-W,7NA#M3+6I\0X;N;K>DXZ6+:-SDW1JFMX<6*5WB?DI\53]'K(U4W1.B@76
M                                          !AYKZ'O?8/_"IF&'FO
MH>]]@_\ "H')OR>/WJW?B?\ B.OCD'Y/'[U;OQ/_ !'7P
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M+L[D:J[ 3(&LP&;IYVHMF@]71(NVZIL;, # DR]*+(MHOG:EER;HSS4SP
M 'RLC$?R*YJ.]F_4#Z      ?CWM8U7/<C6IW55V#7(YJ.:J*B]E0#]
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M4YO">W;Q4[[+[P.9/D\?O5N_$_\ $=?'('R=U1W%2XK5145SME3XCK\
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M=U\]E.PSD'Y/'[U;OQ._$=?
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M+\6<[^58TD6LQ%@:[LWJG8VW&:G6BT\R]'&UEN&1OAO3HOU&7K'1]JUE&9?
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MT FP/-\T;'L8YZ(YWS4]IYS7:T$K8Y9F->[LBJ!D ^))8XXU>][6L3KNJ]#
MNYFI7Q-J^V5LD5=BO=LOL V0([HK55356+==I+ZC7*U?<;J.[6DD\-DS'/\
M8B@9 ,1V2J-L> ZPQ)?\JJ>\T\4+4=+(UB+YJNP'H#PK7*]KF]'F9)MWV4CC
MM:X]NK%P3G;6-N_O E0    #$RW/^3+/AJJ/\-=E0Y0P&H]/XRYD8-0:9DN3
MNF5WBN8O7_L=<N1'(J*B*B]T(QD*VDH+#FWH<8V9>JH]&[@1'@UG,!E9;28/
M".QSD3UE5NV__8M8TNGTP2*_\AMJ(O\ B\#;_P &Z         &'FOH>]]@_
M\*F88>:^A[WV#_PJ!R;\GC]ZMWXG_B.OCD'Y/'[U;OQ/_$=?
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M:216OV1R)[5Z%I6=.TK&;@RDC?\ B8DV:IC9/25"_G(,LY%9;BV]9//8"1
M   /&ZZ1E.9T";R(Q5:GO.5,9B,!FLIDY=3:AGK7DF5/#YEV1#J?*.>S'671
MKL](U5/]CD[3]G13[^274\4ZW%F7UD3R_P!@+FX-X3 8J6RN"R\E]SDV<CE5
M=BU2J>#+])NEM?V6;(CMO7YBU@        !AYKZ'O?8/_"IF&'FOH>]]@_\
M"H')OR>/WJW?B?\ B.OCD'Y/'[U;OQ/_ !'7P
M              !#=-_MOG/J3[R9$-TW^V^<^I/O)D8</\,^L_RPX?X9]9_E
MYV?U:7X%^XBG#C]4O_;J2NS^K2_ OW$4X<?JE_[=2+^;7]E_-K^TO !T-V@U
MS^SL_P 33,TU]"UOA,/7/73T_P 33,TVFV&K(O\ E.>/.GT8QYL^C.M5H;4+
MHK$;9(W=VN[*4_QOP.+IX_#K6I11JZVB*K4[I["Y2K./?T=A?]8AM?X97R?#
M*;X/ 8JM7K3UJ,,<J,14<B=>QO#&Q?T=6^S;]QDEH6CL  )
M                                                     !6/$3B%
M:T?F&QW<;)8Q,B(CI&)OMN1FMJ3A3ED=9DIL9(Y=W(]FR[_[EV7J5:_ Z&Y!
M'-&Y-E:]NY"+W"/2=N7Q'47,55WV8[9 (*G$W1VG'/KZ+Q<DUV5>7U&=-RX-
M(7[>3P5:YD(? GE3F6-?(P<!H/3V"D22ACXTD3LY_K*2=$1$V1-D3R0
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M4Y/AE96+^CJWV;?N,DQL7]'5OLV_<9)>%J]@ !(
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M
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MC),/#R1RXRLZ%[7L\--E:NZ=C,+PM'8  2
M                                        #%RCW18ZR^-=G-8JHO\
M Y-P?]@KM_)2:K?8CN^,OS.B*AUM<?''4E?,F\;6JKD]QSCEM7<+_P I6$L8
M>=TR.5'.1B]5 GG!>'1L4MK^R,LSWJGK^(I;!57!O-:/R4UIFE*CZ\C?G\R*
M6J  "JB=U  ^6R,<Y6M>U53R13]>YK$W<Y$3VJ!^@_&N1R;M5%3VH?+I6-=R
MN>U'>Q5 ^S#S7T/>^P?^%3,,/-?0][[!_P"%0.3?D\?O5N_$_P#$=?'(/R>/
MWJW?B=^(Z^                                 A>I_VJQOQ(30A>I_V
MJQOQ(30PQ?'?U88OBOZA\OC8]=W,:J^]-SZ!NW5AHF*->*>K$\-FVR=.7WH6
M<QC6)LQJ-3W)L5IH?]ZFK/J3[T+, \;OZG/]F[[BO."/T9EO]8XL.[^IS_9N
M^XKS@C]&9;_6. LD *NR*J]D @_&?]@;OQ,^\V7#?]D*'P)]R$ XWZTJ)@+6
M,K*CWJ]J*[V=38<)-;T[&&IT+*I'(C4:CO)>AS>/3F[_ (<?]5B\7EW^/VF'
M$/4::6TM=R7+S/C8O(GOV.&=6:ORVI<E);R-J1ZJ[F8U5Z-^HZHX[ZDQMW3%
MG#4Y/2+\FZ(UB;\O0X_NT)Z<RQSQJUR>TWB\3.G1&2DVY(GJO#Y//$K)P:@@
MPN2L/GISKLWF7?E4ZS1=TW0X@X&Z?M7=:4)_#<D4;T<JG;S$V8U/8@K:)F8C
MY)IDK>9BOR?H ++@
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M=(K2-0  NT
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MG'OZ.PO^L07^&4Y/AE96+^CJWV;?N,DQL7]'5OLV_<9)>%J]@ !(
M                                                          *A
MXG\2\OHS4#(F8M]G&JB<TC6[['UA.(.@]:3,].KPQV^W_$M1/^^Y/=5Y? 8Z
MF]-035VQ;=6R)NISOKS)\/,PUS=-T9Y[W9KHT5J(H'3F,;2958W')"D&R;)%
MMMM_ RRC_DZX74^-2W+G&21T)$3P&O=OT+P         &'FOH>]]@_\ "IF&
M'FOH>]]@_P#"H')OR>/WJW?B?^(Z^.0?D\?O5N_$_P#$=?
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MM^XR3&Q?T=6^S;]QDEX6KV  $@
M                                K/7?"BKK#4+,A>O2LA3;>%O9=B2:
M8T%I[3D?+CL= CO-[V(J_<;_ ",[JU&>9B;N8Q7(A%>'VLH=0X^S+9FBCFBE
M5BL5R(NP$S:B-1$:B(B=D0'E!9AGW\&5C]O\KMSU         &'FOH>]]@_\
M*F88>:^A[WV#_P *@<F_)X_>K=^)_P"(Z^.0?D\?O5N_$_\ $=?
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M\,K5Q?T=6^S;]QDFJPV2I35*T<-F-[_#;LB+U[&U)CLM'8 !*0
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M8L/>U$V:YW0FAYU_T$?PH>AM'9K   D
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MSK?H(_A0]#:.S6.P "4@
M                          Q\CX:4+'C_ *+D7F^HY=P4W$"*SDET9&W\
MFK87V+U.H[T*V*<T**B*]BM15.>&\).(%&W:7$:BBKUY9%>C$>J 3_A%-K>6
M6S_;-C4C1/S:IMW+/*VX5:7U9@)K#M49=MZ-Z>HU';[%D@        ##S7T/
M>^P?^%3,,/-?0][[!_X5 Y-^3Q^]6[\3_P 1U\<@_)X_>K=^)_XCKX
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M[ ,3(S6(F(M:/G532NS%YMI(%@]=>W0E*2@P<;/9EYO28^3;L9P
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M6_6IHYIH?R]&[Q6;;=]Q"6^!\LD9)\Q[7?4I]
M                                          4+Q(U;D-)\09)L716V
MY[4141N_D8B\;=1[K_\ CDG\BEH1X>RNO9[TL#'UG,V1SDW)AZ/!_P F/^5
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MR_[%H$XX:VK$UVPV:5STV\RQ2M>&*+Z=8W:J=/,LHJ
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M,W'&D#>54[;$I-)-^T$?U$K-C3Q]:FJK7B:Q5[[(90
M
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M:-N3-B\*W+_L  ED
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MO9\QQ'%SQF6V>?F  U8@
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MZ5_PFIY.M0>^XY?1GHBQM<6 >C@OSTBTP]#'GGB*QDM74S\@ &JX
M
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M66^'2FC>C$VV;Y&:1C2*U7.E]'IN@5$[N3N2<UBMJ]+]W17>O>  2L
M
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M5%K(Q2XVZ]9'0M16.7OL6P<&;%.*\TEI6=QN  &20
M                                                       ",ZST
MOB\SC+C\C6;*YL3W(JIV5$4DQAYKZ'O?8/\ PJ!Q]P5PN.S7$6U3O5VO@C<[
ME:J=$V78[!QF-K8R#P:<38X_)$38Y-^3S^]2[\3OQ'7P
M      5-T5/:1'(Z,COK*VQ:>Z*3NQ>Q+@7I>U.M1#*&A8:#&1U+3XXVKOLW
MS)?7C\&%D>ZKRIMNOF>@%\EK_%(\[,$=B%T4J<S'=%0TZZ6Q*ILZJUR=^IO
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MC4  .=8
M                    -7;U!B:EQ*EG(5X["]/#<]-P-H8>:^A[WV#_ ,*F
M6UR/:CFJBM7LJ&)FOH>]]@_\*@<F_)X_>K=^)_XCKXY!^3S^]6[\3OQ'7P
M                                         #\>U'-5KDW14V4_0!JU
MP.-555:S%W[[H?K<%CFO1S:S$5.VR&S!;GM]QCW:<=NJZO)NC%3;H1Z71&+F
M1J2^(]&KNFZ]B4@FN2U?AD:3'Z:IT;*3Q.D5R=D5>ANP"+6FW61&=:X.]F((
MVX^PD+VKU5?,@#^%>4?=2TZ[#XJ=2Y0;8^)OCC5436)1+1&G\EAG3?E&TV9'
M)LW;R): 8WO-YYI2  J
M                               ,7*V%J8RU8;WBB<]/X(<O:?Q;]5UM
M6Y^[:D])JN<L77ML=19.MZ7CK-??;Q8W,W^M#E_&V,AHY=3Z=EH/DDO.5L3N
M7??<"TN!>J)[?#B6[F)7/]#<Y'/7JO*ABY3COH^2G<K^+8YU8^/YB=5V5/:;
M7@CI&;":!6CF(O7M.5SXU_RJ9&6X4Z.9C[LZ8>)'I&]_-NO?95 YEX0ZOQ>F
MM=VLIDUD]%D5W+RIUZKN=")Q]T:J[>-9_D3^I0W!/3^*S?$2U0R==)JK5=RL
M5?>=&Y;@_I*?&68JN)CCG>Q48Y'+T4#6/X^:-;WFL_R)_4_$X^Z-5=O%L_R)
M_4UG#;@AB\94NMU+29:E?+O$JNWV;_ DV7X/Z3GQEJ*IB8H[#XU2-R.7H[;H
M!K7\>]',[S6?Y$_J&<?-&N79)K'\B?U-7PSX'XK%XRPW4])EJT^3=BJ[=$;_
M  /?B'P2PV2Q#(].T65;:/W5R.VW3^(&8O'W1J*J>+9_D3^I^LX^:.>NR2V?
MY$_J9VG^#FE:N'K0W\7'-::Q$D>KNZD=XF<$,9E,779I>G'4M,DW<Y';;M_B
M!LUX^Z-1519;/\B?U/UG'S1KM]IK/3_H3^IL<)P>TI7Q%.&[B8Y++(FME>J_
M.=MU4JOY0^BM.Z=H8M^*HMK22V$8]6KW0"PO[_M&_P#-L_R)_4^DX]Z.5BN\
M:Q_(G]3,T[PKT=8PM*:3#QN>^-KE5RKU78B5S@52?Q!@O05FMP6^\D'-W WW
M]_VC?^;9_D3^I]_W]Z.Y.;QK&WP)_4WO]TNC-_H:'_=2!S<"J#N(;+S*S4P*
M-3>#F\P-ZG'W1O\ S;/\B?U/MW'K1S6[^-8V^!/ZFVM\(='259F18B)KW-5&
MN15Z*5KHK@(E+5\UC.0MGQ*([DCYT[^0$Q3C[HW?;Q;/\B?U/I_'O1K>\UC^
M1/ZFUR'"'2$U&Q'!B(V2OC5K'(Y>B[=%(APSX&X_%LR']IZC+;I'_F=W;\K?
MX ;A./VC57]+9_D3^I^NX^:-:O6:Q_(G]3WU7PMT?4T[?GBQ$;)(XE<UR+V7
M8KOY.VB-.ZBP-^?+4&69H["M:KE[- GK./FC7KLDUC^1/ZGX[C[HU%5/%L]/
M^A/ZF%Q'X)8C)X5L>FJ,=6ZU^_,CMMT_B;G3/!S2]3 TH,GBXY;C(T25ZN[N
M Q&<?-'.79)K"?6Q/ZGXO'W1J*J>-9_D3^IA<1N"6'R>'9'INC'5MH]%5R.V
MW;Y]S>8'@YI2KAZL-[%QRVF,1)'J[NX#"CX]Z->O2:Q_(G]3Y_O^T;_S;/\
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MW<T&;X5:.@Q%R5F'B:YD3G(J*NZ*B$"^2HR.*YJJ*'I&R9$:GL3=0.A0
M
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MLQKF?3VGYO!6BQ5DDVZ.5$ O\%9\&-<VM45[=+*]<C354D<B;;]2S
M
M      !0?RG$=!?TS;<Q701S>NO^7UD+\--JO3>/U/C'T<G$CXU[.VZM7VH!
M0.L)X\_Q6TTN)D2PD<<:OV_PG2Z=$0ANC.'F'TK,Z>HUT]A4V225-U1/<3(
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M H:>QS*>-A;'&WNJ)U=[U-J
M
M      >-RS#3K26++TCAC3=SE[(A'4U[IUS5<W(QN8B[*Y.R 2@&'C,I2RD/
MBT+,<[/:QVYF
M
M                             0_BYNG#S-JU51?1W=4*H^35IK&9S0UE
M^3@\=ZSJF[E+9XM,<_A]FFL:KG+ [9$*E^3AJ3'Z>T1:ARCWQ3-F<Y&*WJJ
M:W)SV>&G&2A2QMF1V+NJBK7<Y=D12T^(7$M-*WJE."DEF>=J+ZSN5$W*SCQ.
M1XF\5ZN8=5=7Q5%R(CWIMS(FZF/Q$\:QQFJ0ZDCE_(4+D:US&]T3W@3_ $UQ
MD@R&I&X7(44K67MW8J/W1R^PV^D>)<6:U7?P5JJE6Q6YE15=\Y$*,D6A8XX8
MQ^!J2LHL>U$<Y%ZH23CO6ET;JYNI,>WE6Y'X:JWV]E LS0_$QNJ]7Y/#5Z2L
MBI.5%FWW1VR[%D%2_)XTW^3=-S9:RQJV\B[Q>;SV7J6T
M
M                                                       'Q-$R
M:-T<K4>QR;*U4W135?V8P_-S)0@3W(TW  \J]>&M&D<$;(V)Y-38\,ABZ601
M$N5HIMNRN:BJ9@ UL&"Q=>5DL-&!LC/FN1B;H5+Q'TEJ+7>J*=6>)(<-7?NK
MEZ;]2[ !B8BC'C,95I0)M'!&D;?X&6
M                                                         ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g184865g08g03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g08g03.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2"B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %P< 5H  QLE1QP!6@ #&R5'' (   (  !P"4  (<G(X,S$P,#(< @4
M,TUI8W)O<V]F="!7;W)D("T@3TM54B M($)U<VEN97-S(%-E8W1I;VX@4FED
M97(N9&]C>#A"24T$)0      $/*=/.JJ11_YFKV==_&<FP\X0DE-!#H
M .4    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
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M;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L
M  !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG
M3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F14
M56YT1B-2;'0               !";&0@56YT1B-2;'0               !2
M<VQT56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0
M<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M     %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M        $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O
M;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T
M4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M    $ $L     0 ! 2P    !  $X0DE-!"8       X             /X
M #A"24T#\@      "@  ________   X0DE-! T       0   !:.$))3009
M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  -!    !@             "AP   S@    & &< ,  X &< ,  S     0
M                       !              ,X   "AP
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   "AP    !29VAT;&]N
M9P   S@    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   H<     4F=H=&QO;F<   ,X     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    &.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M1"8!($QV')5#-ZACMP*LFW=379=2&[P9UL9MTKW_ $D"=#WI!/VTEIIK-^8
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M &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #
M,@ Q     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H
M!0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !\   !^
M 3(  @   !0   "= 3L  @    D   "QAVD !     $   "\    Z    2P
M   !   !+     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R
M-3HP,SHQ-" P-CHS,SHU-0!R<C@S,3 P,@     #H $  P    '__P  H (
M!     $   ,XH , !     $   *'          8! P #     0 &   !&@ %
M     0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48"
M @ $     0              2     $   !(     3A"24T#_0      "
M        _^$!3D5X:68  $U- "H    (  @!$@ #     0 !   !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    'P   'X!,@ "
M    %    )T!.P "    "0   +&':0 $     0   +P   #H   !+     $
M  $L     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(U.C S
M.C$T(# V.C,S.C4U ')R.#,Q,# R      .@ 0 #     ?__  "@ @ $
M 0   SB@ P $     0   H<         !@$#  ,    !  8   $:  4    !
M   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0
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M
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MQ_V/<8&$T3/B-<Y#-U[F]>XGK0=>G4"=
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M47^*I]I">'+)-?<9<CGIF^)1INWBZ;M39>AK-39"7&_*16U6KK8D8B;1IY]
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M'*U?(#)!!M<<1L/IN&6-UIJW6*B>'LOO-UI/5>,U+5:_'66RR(Q'/:B*BMW
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MJ6I-+Y#'^*^FL'J0HY?6ZJ!?((9HS7E74-N6G- ZG<9VB>O5Q,P
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M.<K=N?N7">5:M#69R5XVQM]S4V/4
M   ,7*^S+?PG?@I0/R8/I5K'XO\ <I?V5]F6_A._!2@?DP?2K6/Q?[E Z(
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M1-^79 (=5U=J'5^R81B0I#$DCE1?G+[B>: U,NH,/++91L<]5_A3=>G,A7G
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M[\W?J!T #X@55AC5>ZM0^P
M     Q<K[,M_"=^"E _)@^E6L?B_W*7]E?9EOX3OP4H'Y,'TJUC\7^Y0.B
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M'/%(YS8Y&N<WNB+V/0    !\.FC;(C'/:CU[(J]5 ^P
M!BY7V9;^$[\%*!^3!]*M8_%_N4O[*^S+?PG?@I0/R8/I5K'XO]R@=$
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MR&.SF/EB9)6[MD\^I"-,9"_JKBA7O3HQS8$15Y$Z)ML!8&J8OROKK&T62?\
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MOSJQ&4QK&R1Q*U)$7R[ 63'OR-YOG;=0?D2JZ-JN39RHBJ@ ^@
M     8N5]F6_A._!2@?DP?2K6/Q?[E+^ROLRW\)WX*4#\F#Z5:Q^+_<H'1
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M\)WX*4#\F#Z5:Q^+_<I?V5]F6_A._!2@?DP?2K6/Q?[E Z(
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MLY8F*YK=_G*59H?A?8QNI[=JU9F;#UY5:[YQ/.(>+DNZ1LQ5]W20LYFIYNV
MA>,H:QU/27+QY1*C)=W0PKOV_D2[1V:OQ8V:/4[?!FKNY5F=V?\ 6:_0.L<8
MW2L4=R5*\]1G+(QZ=>GN-+JKB R_IRS)5HO\%TB1LD>WI]H%AXW4N(R5A8*=
MV*25/V-^JGQ;U5A:D\D-C(P,EC79S5=U3[3G^Y%/A-88*:*U!)+*WF>D';KO
MW-[I;#5,SG-6RY!CGN2/F3?R7KV N--5819HXDR,'/)\U.;N;#)N:N.F=X[8
M6\N_BJO1/K*'SF"ITN&3;T*/6VR?9LGFB;ECYI[Y.$O.]SED=2:JKY[[(!OX
MLO1Q6+ADNWV2,=VEWW1QZXK4V(RMAT%&[%+,U-U:B]40JS\O8K"<-Z#<K'X]
MF9.6%JIOLODJF)@].U\-IB_E<?9;)FK#5=R,7YK5\@+;356$]+]%_*,'C[\O
M+S>9[Y?/XS$-8N0N10\_S4<O53G?'X!;V'AMOOP,M+*BJU5]?N2?6&#6VN._
MYQB6XH^OCKZKD1 )[K3B!C\)@&Y*I,RQ&YZ-16J;VCJ2A+I^KE;-B.&O,Q'<
MSEV1%4H%TE*_HZW3?6D58)-W.V]7??R);Q(C@7AI@(*:JE9R-1>7^ %LU<]C
M;5-UJ"W&^NWN]%Z'CC]3X?(6DK5;T3YU[,WZJ0G)RUM,\-**4ZW,L\:-W5-]
ME5.ZE6VTLX;/86ZVS7?//(GJP^2=>X'0^1U1AL=8=!<OPQS-[L5W5#TDSU%V
M#L9.K89-7BC<_F:N_9%*AH8:IFN*&:_*+72-8S=$7MV4R^&<:/BUCC'(JTHF
M/1C%[)\X":\+];1:SQ,]EK>26*5S%;]2+W!&OD[P4H=-W$KM1MGTAZ/3SVW
M&WU5IO*RZRI9/&(Q]3EY9V.\]SVUSIRZ_2RX[2]>&%\KOTNR(G3S)X%5$157
ML@&GTAB5PNGJ=)[N:2-B<Z__ #>9N"F-:\5,M7U%/BM+XQUU8/GO1-S*X>:X
MU7FM0-J9C#OK5E[O5FVP%N@ #\<UKTV>U')[E3<^'01.Y=XV+R]MVIT/0 ?,
MD;)&*R1J.:O=%3=#XKUX:S.2"-D;?<U-CU 'A/4KSR-?-#&][?FJYJ*J'NG3
ML !BY7V9;^$[\%*!^3!]*M8_%_N4O[*^S+?PG?@I0/R8/I5K'XO]R@=$
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MRX  :M0
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MKOH6#?\ ]X[^A/B*1M6(A&.-JQL  LN
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MX6MTE-^V6CX(?0:'XCOZ$^(#P1^@T/Q'?T)\17I!3M@ !98
M                                                    /QZ\K'*G
M543<#%OY&E08CKMF&!J]$\1R(?5*]5NLYJ=B*9J>;'(IRWQ%1VL-09UV3RKJ
MC:")X-;FY>;R-QPNYM.ZTQM7&9!UN"U"BRQ\W,C55.H'2H"         #%RO
MLRW\)WX*4#\F#Z5:Q^+_ '*7]E?9EOX3OP4H'Y,'TJUC\7^Y0.B
M                       :NUGL?5F=%--L]O?H>2:FQ:]K&_V(>.9T_CYH
M;%B6)5DY57=%-!HG 8^WCI'S1.<Y'JFZJ<MKY8OPQLYK7RQ?AC9.X)631-DC
M7=KDW13[/.O RO"D<2;-3LAZ'3'3FZ8_=%N(/LZ#XB&_Q7LZO]Q#0<0?9T'Q
M$-_BO9U?[B&-?.M[0PKYMO:&40W4+576F)]W_P"3::O@R\]!&X.7PI]^JE,Z
MB_/*MK/$59K/-8F_5N+9JS:NT>L+9JS:O+UAT("(:,JZD@M3+GK/BQ*GJH2\
MU:A6/"/Z1:O_ -7_ %4LXK'A'](M7_ZO^J@6<1WB%]$,C]PD1'>(7T0R/W"+
M=)5OVRT?!'Z#0_$=_0GQ >"/T&A^([^A/B*](*=L  ++
M                                                  5=D55[(!4O
M$O@U3U=D/3J5OT"R]?TJM3H_^1LN%W"REHKFGEG]-O*O25R?-3ZMR,ZRXF:B
MEU'8QFC*'I/HWZQRM13.X=ZHUWDM0-@U!C4AI+W=R(FP%P          #%RO
MLRW\)WX*4#\F#Z5:Q^+_ '*7]E?9EOX3OP4H'Y,'TJUC\7^Y0.B
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MV  %E@
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M$;1R2$ $I
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M6\K_ $?9W9_[/\_<>WR3DF;F-4I;W]*1S?$^W?K_ +@='@
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MWF6F##P[WM.\S_W8 !LZ
M                         @'%?1>3U=!29BLHZ@L*KS;*J<V_V$_/QZ\K
M'*G543<#G:UPDS5"-'7M;) B^3Y%3<D_#3A[D\1FV9)^J$R=5.\;7JXAUO$K
MQ(XBY2ME\NZI#63]'"CN7MT,S0U>30_$]F#Q^4=>I3MW<Q5YN7<#H@  5MQ>
MX;+K[T/_ )I(/ 3;JF^_7<A-#@AEH4;C)<TUV#1R.6)$7KL7^ *[U[PUK:@T
MS0Q]&1M:>AMX$BI[C6:"X96J.=;F]4W&Y#(1,\.)=NR=BUP!2FI.$F4?J2[=
MT_E&U:F0W2S%LJ;HO<L?06DZFD,%'CZFRJG61_[RDD &-E.F-M;?^Z=^!0'R
M8/I5K'XO]RE_97V9;^$[\%*!^3!]*M8_%_N4#H@
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MN$6Z2K?MEH^"/T&A^([^A/B \$?H-#\1W]"?$5Z04[8  66
M                                                   "-ZLUGA]+
M3TXLS82#TI=F*O8DA%-?:%Q6M:4<&58O/%OX<B=V[@075G#;":XO/S&G,OX-
MN3K(ZN[HJ?P-[PVX64=(V5OS6);F1=T\23KL5ME^%64T<Y]G3VK%@B9ZRQRR
M<O3W=S;<(N*V7R^IDP.5B;88F[4L,7?K]H%]@         #%ROLRW\)WX*4#
M\F#Z5:Q^+_<I?V5]F6_A._!2@?DP?2K6/Q?[E Z(
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MW[9:/@C]!H?B._H3X@/!'Z#0_$=_0GQ%>D%.V  %E@
M                                              K+C1/J]L6.K:+3
M:297)*[W>XLT_'*B-5R^2;@4!A.#>=S,C;FL<S(YS^KX&NW+9TGH;!Z88GY,
MIM9+YR+U53+P6IJ.9R%NI4?O+6^>AO            Q<K[,M_"=^"E _)@^E
M6L?B_P!RE_97V9;^$[\%*!^3!]*M8_%_N4#H@
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M^D<C]PBW25;]LM'P1^@T/Q'?T)\0'@C]!H?BN_H3XBO2"G;  "RP
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M  T:
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M"W[ZDB([H+V"W[ZDB*8/+K[*8?+@ !JU
M                                    #\>F[')OMT[GZ?DB<T;D]Z*@
M'*^?R]'3?$S+>F8A<TC^SN57<I..%^L,7E=3MK4]++0E7M-R;;$6O?G?I;B!
ME;>+P*7J\RJC5D9S)LI-N'.J=5Y/4;8,QIJ&C67O*V/EV N0          8N
M5]F6_A._!2@?DP?2K6/Q?[E+^ROLRW\)WX*4#\F#Z5:Q^+_<H'1
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M/W3:_;+6_;+7:"]@M^^I(B.Z"]@M^^I(BF#RZ^RF'RX  :M0
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MJ2(I@\NOLIA\N  &K4
M                      *9XY9QFF]5Z4RDD3I6PO<O(GGU0N8K7B/AW977
M.E?%J>D4V/7Q=V[M1-_,".KQ[H>6*G_DO^#?:'XLU-49MN.AH2PN7]IR*3/\
MT\#_ /"*?_VT,BCI_$T)_&I8^M#+^\QB(H&S   !5V157R.;(M67<OQ1R^-O
M9N2ECX9>1BH_9$Z@=)@H'BGJ'(8BKA\#@<L^PZY)LMEC^NWVF5H;4>7TMKM-
M+9^V^Y%)%XC97NW5%VW O0'-.0S&I-7:HU!;QF2FJTL0CG-C8]41VW_X+1X-
MZTEU/I"2WDMFS5%5LKU7OMOU_P!@)WE?9EOX3OP4H'Y,'TJUC\7^Y2Q\GQ2T
MHM.W$F3B5_(YNW,G5>J%:_)9D9/J/5T\2[QO>BM7W^LH'18
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MRF'RX  :M0
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M1&&+UKPVCH^P ;M@
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MM6W%&['/A^%;AWW  68@
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MB.7N7 0O1V8QM6M7QM=NTFW54\U)H;8J<%=GFZ_5?J<]KQ.\?3V  :.(
M
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M<D$")SKV*VM:4OU$;XB?/79! Q](-3\X8.A<Z%<:=TE?J9:*S*B)&U/>6.)
M $
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MD<J=MRGM6:RU1J/T;TG'N_0/YDZ?66Z[4U=^D*N+V<^PD;4<OD1MNR)\UO\
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M13 YZ2[<;&N)DKM<G1ZH2LK:DTG:4@ *@
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MR/?7FZ<JKV.B3'48?A6Y3O$]&N+)7)6+5Z2  P:
M                                                      TFIL'C
MLEC;2WJL<WZ-WSD^HY[^3MIO$Y;56I_3ZC)O1)=H4=V;ZRG2N5]F6_A._!2@
M?DP?2K6/Q?[E Z!I4X*4*158TCC3LU#W    #PO58KM62O8;S1/394.?=?\
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M.KG>9>II-/VL7#5AIX^6/U6IZJ=U-V;X<5L5(I>7=H]-&FQ1CB=P &KJ
M
M         1+.<0L!ALHW'V[7_,*NSD:F_+]I)J-R"]5CL5)&RPO3=KFKN!\9
M7V9;^$[\%*!^3!]*M8_%_N4O[*^S+7PG?@4#\F#Z5:Q^+_<H'1
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M5;D(V]55.C_K+!,,M+TMPWZIB8F-X  9)
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MMV1#-+I
M                      >5J6&&![[+V,B1/65Z[(:K3U3!Q.L3X*.JUTJ[
MRO@_:7ZRK/E'Y2TD.,PU69T3;<C>=6KW3<C..;9T!Q%P=&G;DEJ7FL65CEZ=
M0.DP?C5YFHJ>:;GZ      #\>YK&JYZHUJ=U4_2L./5#)2:1LW<=?DKM@:BN
M8U=N;J!+\M#IR6Y!=R:4G6(U_12R.3=%^HWT4C)HT?$]KV+V5%W13CGA57L<
M0<U+CLC;D:VK#XB*BKU5-_\ !;/R?=079LGF<#:D66&D]4C<O=$10+O
M  !XVK=>HSFLS,B;[W+L8&0Q^(S<,<UV"O;CB]9CW]4;]9%=;:$_./+MN7<G
M-7I1,ZQM7I]ISX_4V3QDFI,1C[LLF-67P8Y=^FV^P'6F.R6/M*L-"U!*L:;*
MV-R+R[&<<HST+6@J>F,MC[LKIKCMYD<O1VZG4^/F](HUYE[R1M=_- /<
M /B:6.&-7RO:QB=U<NR'V1+B#IJ34E*.'T^2I78O-)R+W0#=V:^+SU58IV07
M8$7JU?60_*UW%4GLQT$]>%T:<K84<B;?5L<UXS-6<#KG*PZ<O26,;3A7Q.=>
MZHB]3 Q]"?+Z*S6MEN2MO06%Y$1>G<#K8$,X0YVQJ#0]&[<7>=4Y7+[R9@
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M9J]]]@.DZMF"W"DM:5DL:]G,7=#U* X:9"SIKBM;THEA\]%6JYO-Y="_P
M
M         *1^4?B[;FXK+U('S-JO1'M8BJNVY'*OI.N^)&"MTZDL=6DUB2O<
MWHFVQT;8@BLQ.BGC;)&[NUR;HIXT,=4Q[5;3KQPHO?E3;<#):G*U$]R;'Z
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M2A2*K"R*-/)B;'N
M                                                        K?BE
MQ0BT-=IU'4'VIK/S>5VP%D J5O%3(4XV6LOI^U7HN1'+*J*B-1?/L6-IO/4-
M18R.]BYV30O3]E=]E]R@;0#=/>@W^L
M
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M7OU.8N&VG?RSQ7EQJ+X^)Q\BO3;JB=3KQC48QK6ILU$V0#]
M
M                                                         #9
M  --JS#29W#S48[<E3Q$V61G?8 #3\/= XW1<$OHBK-:F_63N3JXF(
M
2                    !__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g184865g08g08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g08g08.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1ED4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP"   "   < E  "')R.#,Q,# R' (% #--:6-R;W-O
M9G0@5V]R9" M($]+55(@+2!"=7-I;F5S<R!396-T:6]N(%)I9&5R+F1O8W@X
M0DE-!"4      ! %I?*S\&<?]]JX5I3:P\AB.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             #F@  !V@    & &<
M,  X &< ,  X     0                         !              =H
M   #F@                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #F@    !29VAT;&]N9P  !V@    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   YH     4F=H=&QO
M;F<   =H     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    '.$))300,      [4     0   *    !.   !X   DD    ZX !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !. * # 2(
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M+M_[!H+K\<N]N3AQISBR9CW?]IOWDX'E^N0?XR3AYC_,S_Q)/4_M[HXU.74
M-2=R?]O=(_[EU?YRY*VVMU9:W)P"70"'XA+2TGWAP&-^XKF%@9&;N;AV8+Q4
M&$C[.&PUXW5?2QA^8G <N=L@/^%_Z"LG'-  SQRC9H<4>'5Z']N](_[EU?YR
MI961]7\DV%^<YAM<USS5?97JQKJV[?3<W8W:[W[/IJK_ ,WNK^.#_P!LL_\
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M_P!PZ?\ ,";^J_K_ /-3ZO!C^W>D?]RZO\Y+]N](_P"Y=7WJ7[%Z3_W#I_S
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M?]+\U4K\Y]=CFD5RTD.FRUL?G#Z-#VI*6+V8USW6!K<:TAWJP[:RP^Q[;/\
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MLI;:;&L$!]I=8\_U['.]ZF6WD$%S(.A]I_\ )HJ22G__V3A"24T$(0
M5P    $!    #P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !0
M00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  R #  ,@ Q     0 X
M0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0    $   !N
M 1L !0    $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @   !0
M  "= 3L  @    D   "QAVD !     $   "\    Z    2P    !   !+
M  %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-3HP,SHQ-" P
M-CHQ,CHS.0!R<C@S,3 P,@     #H $  P    '__P  H ( !     $   =H
MH , !     $   .:          8! P #     0 &   !&@ %     0   38!
M&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $     0
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M     0   YH         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M!@0%!@4$!@8%!@<'!@@*$ H*"0D*% X/#! 7%!@8%Q06%AH=)1\:&R,<%A8@
M+" C)B<I*BD9'RTP+2@P)2@I*/_; $,!!P<'"@@*$PH*$R@:%AHH*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*/_
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M0O$D_]H # ,!  (1 Q$ /P#:D
M
M                                                 ^99&11ODE<C
M(V(KG.5<D1$Y3Z,;B;R=NGV:3W5)IC&<!Y$QAAU4V7J@[9!PPP]TU0=LA1%
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M1>)5]"&7PQB&VXFMGPA9JA)Z776/71,O&3+-/S0#+
M
M
M
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MYGSHQ[<G(U41$S3[LP+'
M
M
M
M                                               \M3;:&JF;+4T=
M--*WB?)$USD^]4/4 ")DF2<0                    #XFACGB='/&R2-W&
MU[45%^Y3KHZ*EHF.91TT%.URYJD4:,1>H[P                      >26
MV4$M3OB6BI7S\>Z.B:KNO+,]8
M
M                                                      >#$,TE
M/8+G- ]62QTTKV.3C:J-544Z<.[I4V"V3SSROEEIHGO<J[556HJJ!E0=6X_6
MR]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K
M [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R
M]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K
M[0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]
M8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [
M0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8
MW'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0
M=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W
M'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=
M6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'
MZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6
MX_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'Z
MV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X
M_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV
M7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_
M6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7
MK [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6
MR]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K
M [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R
M]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K
M[0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]
M8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [
M0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8
MW'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0
M=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W
M'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=
M6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'
MZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [0=6
MX_6R]8W'ZV7K [0=6X_6R]8W'ZV7K [08JTRRNNEWADE?)'%*Q&([_2BQM54
MZU4 94                                          8S%'DS=_L<WN
M..,*^3%G^QP^XASBCR9N_P!CF]QQQA7R8L_V.'W$ R@   $<EQSAJ*:2*2\4
MJ/8Y6N3-5R5.-.(ZIHJJ_#&*)F(\TC!&>'F&.F:;\^X</,,=,TWY]QUP;G3/
M8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIF
MF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--
M^?<.'F&.F:7\^X<&YTSV-Z-4F!&>'N&.F:7\^X</,,=,TWY]PX-SIGL;T:I,
M",\/,,=,TWY]PX>X8Z9IOS[AP;G3/8WHU28$9X>X8Z:I?S[AP]POTU2]:]PX
M-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP]
MPQTS3?GW#@W.F>QO1JDP(SP]PQTS3?GW#A[ACIFF_/N'!N=,]C>C5)@1GA[A
MCIFF_/N'#W#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-
MZ-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IO
MS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?G
MW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C
M/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-S
MIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQ
MTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACI
MFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-
M4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[
MAP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#
MAYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#
MS#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIG
ML;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS
M3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF
M_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F
M!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP
M;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AY
MACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#
M'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;
MT:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP]PQTS3?
MGW#@W.F>QO1JDP(SP]PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/
MN'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&
M>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G
M3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYAC
MIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3
M--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:
MI,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW
M#@W.F>QO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'
M#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'
MF&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/
M8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIF
MF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--
M^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,
M",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@
MW.F>QO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S
M#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&
M.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8W
MHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIFF_
M/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?
M<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",
M\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.
MF>QO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#S#'
M3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.'F&.F:;\^X<&YTSV-Z-4F!&>'F&.F
M:;\^X</,,=,TWY]PX-SIGL;T:I,",\/,,=,TWY]PX>88Z9IOS[AP;G3/8WHU
M28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>QO1JDP(SP\PQTS3?GW#AYACIFF_/N
M'!N=,]C>C5)@1GAYACIFF_/N'#S#'3--^?<.#<Z9[&]&J3 C/#S#'3--^?<.
M'F&.F:;\^X<&YTSV-Z-4F!&>'N&.F:;\^X</,,=,TWY]PX-SIGL;T:I,",\/
M,,=,TWY]PX>88Z9IOS[AP;G3/8WHU28$9X>88Z9IOS[AP\PQTS3?GW#@W.F>
MQO1JDP(SP\PQTS3?GW#AYACIFF_/N'!N=,]C>C5)@1GAYACIFF_/N'#W#'3-
M-^?<.#<Z9[&]&J3 Q%FQ+9[U/)#:[A#4RL;KN8Q5S1.+,RYQ53-,X3"8G$ !
M   ##VC]MWS^-'_28!:/VW?/XT?])@!#,          #RW6XTMJH)JVX3,@I
M84UGR/7)&H17PHX.Z<INM3KTW?\ *^__ ,%/>0H;1U;=&]3AILF,*YT%TW1Z
M*UKW)XFS)=C5](&S]HOMLO%"ZLME=!4T[4S<Z-Z+J^M.3[R/.TH8/:]S5O=,
MCFKDNU2G-"E"Z/&>*9<,NE?AAD,D:2R9^.W)=3_W?]B*Z.*'!5757A<<53J=
M6S94^JYR9IFN?$B@;28?Q;8L0/<RT7.FJ)&_^FUZ:WK1./(S;W(QJN<N343-
M5-2'4UBI-+&'F:-JJ:IC5[5<YRJN3\US1%5$V:IMA7?L^HS^2=GU*!CL/8GL
M^(75#;/7153J=<I$8OQ5%UQ/9[5=J2V5]=%#752(L,3EVN155$_-%-?M >*K
M)ABKQ M\KXZ3=I$W-'-<NMDJY\2';I"Q%:L3:8<)5=CJV5<$;8XG/:U4R=NC
MURVIS*@%TW+2)A:VUT]'6WBGBJ8'*R1BKM:J<:'=9L=X:O%4VFM]XI9)W?%8
MKT:KEYDSXU-=*NEPW5:9<21XQG6"V[XF5'(JIX^MLXD7TF.TET6!J)M _ 5?
M43U[I/';K.5&I_I5,T3)<P-P@5AC#'UOLV$:JVU=V938F90-_5HU=9LJL14V
MY99F/T1:2[948<M]%B&]LDO<TJQHQ[7:RJKLFHJHF7,!9EZOUMLBTJ72KCIU
MJI$BA1Z[7NYD.FT8GL]WN-506ZNBGJZ9526-J[6Y+DOYE<X]5+_IFPK8U5'0
MT#%KGIS.X_\ \6]9!-%N([3AK25B>JO=9'20R/F8USD5<UW7/D3T ;!7[$UH
ML,U+%=ZZ*FDJ55(D>OQLLN]#P7G'N&K-<9:&Y76""JBRUXW+M3-,T*0TX8JL
MF*+WA=UBKXZQ()'))JM<FKFYF7&G+DO4>''5/8JG3W<8L5RK#:%1%E>U5147
M<4U>)%Y<@+Q9I0P>][6MO=-FJY)M.^X:1,+6ZNGHZR\4\=3"[5D8J_%7F*IM
M^'M#E57004MREDGDD1L;=T>F;L]B?%(?5TN&ZG3)B2/&$RP6U*B3)R*J>,G$
MFQ% V,L^/,,WBJ2GH+Q223.^*U7HU7>A,^-3*WR]VVQTBU-VK8*6+D61Z(J^
MI.4U/TET.!*..WNP'73U%P=-D]JJY6HW+8J9HFW/(M6_Z,KSC3%]FKL23HMF
MCH8F3,9)E(V1(\W;,N-7\O,!:V'\1VC$$3I+/7T]4C/C)&]%<WUIQH98UHL-
MEI<-:?J2UX1J)7TK%1*EBNUM5,O':J\N2=1LN  ,567EU-4OA2UW.;5_]2*%
M'-7U+F!]8H\F;O\ 8YO<<<85\F+/]CA]Q##XAOKI</W2-;1=F:U+*FLZ!$1/
M$7:OC&8PKY,6?['#[B 90  #6Z!K427Q6_XTG(GG*;(FM\/%+_&D]Y3TO9__
M *_+]V;:?*'WDWS6]2#)OFMZD /29#)OFMZD&3?-;U(  R;YK>I!DWS6]2
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M3?-;U(,F^:WJ0 !DWS6]2#)OFMZD  9-\UO4@R;YK>I  &3?-;U(,F^:WJ0
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M\2!98T7)9&(J<BJ!]@^6O8_XKFN]2YGTJHU,U5$3G4 #AKD<F;514YT4Y
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M:9Q-HV:[LU?#O4S3/Q  =*
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MKM.G2#:*Z.^5ER?3JE$Y[$2763+FXB0X[F930X9FG3]5'4-<_P!":IW35/\
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M^M=B<R<B'723OI:F.>+8^-VLAJBW_1NHQ6DO&<'723MJJ6*>/XLC4<AV&5(
M"4                                                      >.\U
MB4%NFFS\?+59_N7B[SVY;"$XRKM\5K:5B^)3YH[TNY>KB.J*=Z<$L?8[@ZAN
M3)G*JL=XLGI1?_TS+&R].SG*H)]A2NWY;$8]V<L*ZB^KD_[EMZG_ -(AF  4
M           !RSXZ>LX.6?'3UD"F,0+E?KE_'=_,\![\0_M^Y?QW?S,>?/W/
MQS_EZ=/E"4Z.%_\ VB7^"XLTK+1QEPA5?J7%FGJ[#_U,>T?C  ;%
M         $ 3C($>Q?5/9'%3-54;)XSO3EQ$6R)5BZE=)%%4,VI'XKO4O*14
M^*]L;^:JWOAA_A^Q_P#$.%RRCA>>,[W^<??^6'Y.ZDJ9J.IBJ:61T<\3D>Q[
M5R5%0V^PS<?A>P4%>J9+40M>J>E4VFH5#23U]7#24D:R3S.1C&IRJIM_ARW)
M:;%0T"+GO>%L:KZ43:<>S\<:M'G_ /,^'N6NK&>W_P!9$ 'J/@0
M
M                     8>T?MN^?QH_Z3 +1^V[Y_&C_I, (9@
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M]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV'
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M]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV'
MYA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ
M,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HR
MY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV' YA/29
M:-6O&]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK
M^XV' YA/29:-6O&]*[HRY>RO[AO2NZ,N7LK^XV' YA/29:-6O&]*[HRY>RO[
MAO2NZ,N7LK^XV' YA/29:-6O&]:_DMERS^RO[B-28(J))'/?!>%<Y<U7>;NX
MVL!,>TJJ?*$Y:G5JCP&F^;W?V-W<>ZT87J[94K-%2W9^::JL6C>B+^1M "9]
MIUS&$P9:G5KQO2NZ,N7LK^X;TKNC+E[*_N-AP<\PGI1EHU:\;TKNC+E[*_N&
M]*[HRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;T
MKNC+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F
M$])EHU:\;TKNC+E[*_N"4E<G_P#3+E[*_N-AP.83TF6C5K5+AV.61\DN':IS
MWKK.<M$_-5ZCXX,0?1NH]B?W&S .<['1#K@?&6MM+8MZ2;I2V&LADRRUF4;T
M7+J/7O2NZ,N7LK^XV'!,;?,>5*)V>)\Y:\;TKNC+E[*_N&]*[HRY>RO[C8<$
M\PGI1EHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*[
MHRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;TKNC
M+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F$])
MEHU:\;TKNC+E[*_N&]*[HRY>RO[C8<#F$])EHU:\;TKNC+E[*_N&]*WHRY>R
MO[C8<#F$])EHU:Y5M#<)J2:..UW%7N1&HF]7[=OJ)[5Z';'<&03LDJZ&1T;5
MDCB5NKK9;=BHN1: ,>U7*=JB(KI\F_8=IO[!,SL]<TXHK@_ =EPLNZT,3I:M
M4U5J)E17Y>C9DGW$J **:(HC"F"_M%W:*YN7:IJF??( #I2
M
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MKGAA[VR (_A?&%EQ+ C[96QNER170.75D9ZT7_L2 MB8GQAZ-%=-<;U,XP
MET
M
M
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M\GK;/LMO9J=V@ !VT
M
M
M                             ,/:/VW?/XT?])@%H_;=\_C1_P!)@!#,
M                                          #&8H\F;O\ 8YO<<<85
M\F+/]CA]Q#G%'DS=_L<WN..,*^3%G^QP^X@&4   QS[%:7O<]]LHG.<N:JL+
M<U7J,B0*7213LFE8VUU3D8]S-;78F>2Y9\97<KHI_&U;-9OW<>#[O/QP2OX
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MN:BI(J+GFF>S(SY;1--4;U+%?XU%4V[LSC'Q  =J
M
M
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M2M1J;JZ%%1BN]&9[#5'B^BB<8Q  $@
M
M
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MC=^1;%'2T]%3L@I(8X(6)DUD;4:B?<AW MIHBGR8K&SV[$86XP  =+P
M
M
M
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MACFO:CF.1S5VHJ+FBG)TO
M
M
M                                      &'M'[;OG\:/^DP"T?MN^?Q
MH_Z3 "&8          $'TW?\K[]_!3WD*)T<0:-9,--=C*L2&Z[J[-NL_P")
MLRXD5.<O;3;_ ,K[]_!3WD*,T:1:-GX9:N,JF&.Z[L[-KM;/4V9<2+Z0,KH5
MH7<-,55.&W2KAED,D:22)_B-R743U\OJ(OHWBP1+4WCAW4I J3?\.NLY,TS7
M/B13+Z/JJFI]*]72X,J*J3#TL4B2->JZJM1BYKES(O$=FA7!%GQD[$D5XC>L
MD4N44K'9*S-5XM@0QDD5A9I:P^W1K++-'KL5SE5<M?-<\LTSU=7CSY3:ZNS2
MWU&?'N3OY*:Y:,:YVC;2+-AG$-)2HRH?E%7N8B2-SSU51WFNXE-CJY<Z"H5%
MS18G9=2A+6K0-B^Q85K+^M_N$='N\GZO6:Y=;)5SXD4[<?XEM&*=,.$JNPUC
M*RGB2.)[VHJ9.W1RY;4YE0\V@K!UEQ957Y+W2[ON$OZM<\LLU7,[L=X8M>%-
M+^$Z.RP;A!*D<KVYYYNW1R9]2($,35QX:DTRXC;C.;<;9OB;)V:IX^MLXD5>
M<Q^DZGP*QEOX 5,L]<Z3)Z-5RM3S<LT3;F22S8>MV)M.V([?=X5FIEEG=JHN
M62H[C/BMMS=#NDJ&HFH65]AJ53<IIV(YT:9[5:O%KM_D!9N,](%LLV$JRT5E
MX;2XH90-3<VM=KI*YB*FW++/:8W0_I,M#L-VZWXAOVZWR:98T9*CE>JN?DU,
MT3+E0RND? =AO]ENV(*2A6LNDU+ND#XG9ZZHWQ53GV9&$T/:,[6[#ENN=^M$
ML%YAF63]=XJYM?FU<ON0)>S'3OA[33A>RZV<-OC6MD1.1W'_ /BWK(%HPQ-9
M\,:2L3U5^KF4<,CY6,<Y%76=NF>6Q/03W1W_ /.M,^,[UL=#3-;11.3:FS)-
MGX/S*^T9X6M.*M(^)J6]4^[Q1OED:F>62[IE_P!P._3;BZQXJO>&'6"X1UB4
M\CDEU&N35S<S+C1./)3R8Y987Z>[@W%LNY6=43=7YJF2[BFKQ;>/(]&FG!]E
MPE>L,,L=+N&^)7+(NMGK9.9E_-3IQLEB=I]N"8L>UEGR3=7.SR1=Q35XDY\@
M)%06S0Q55L$%+7Z]1(]&QMUY$S<J[/\ 20RIBPT_3)B-F,IMQMB5$B([-4\;
MDXD52<VYVABCKH*FGKJ=)HGH]BY/XT79_I(U8;%:\5Z<<14ESCWQ1R222LU5
MRSS1%1>H(1W2=!@...W\ :J:>O67QT17*Q$Y.-$76SR+7O.B^ZXNQA9KCB2=
MKK1%0Q1S0MDRD;(D?C)Q9;7\?H(1<;:FA[2/#42T$=PL%4J;C+/&CG,3-%7)
M>+7;_+F)OIGTHI;F0V/#E7$RJK(VR25Z/\6GC=Q*F7*J=2!*)6.RT=B_2!I;
M?@^61U-"O_%-5VLC$R\=JKRY)U*;+%,:':[ >'W1T-MOT-QO]P<C9:A6.UI7
MK_I;FFQ,^?C.K&6B?%%[Q/<[C0XJ2FIJF77CA5TGZM,N+9L NPQ%;>)J:IDB
M;:Z^9K>*2.-%:[U;3VVJGDI+71TT\FZRPPLC?)YZHU$5?O/4!$L0WN:7#]TC
M6SW)B.I94UG1IDGB+M7:9G"ODQ9_L</N(<XH\F;O]CF]QQQA7R8L_P!CA]Q
M,H  !KY+_F*G^/)[RFP9KY+_ )BI_CR>\IAVWW/=]B^5S\OW?( ,#W
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M^#=&]CPRQLC(4K*U$VU$[45?N3B0FA9;HJI\WH[!LUZQ3_<JQ^&@ "UZ(
M
M
M
M           ,/:/VW?/XT?\ 28!:/VW?/XT?])@!#,          #PWNU4=[
MM=1;KE"DU).W5D8JY9IQD+\#>".AF_C<6$ (]AS!>'\.0U$=FM<%-OANK*YN
M:N>G,JJ?6%L'V7"[ZI]DHTIW5*YRKK*NMUF? $:Q5@?#^*:B"HO=O943PMU6
M29JUR)GGEFGI,_%3114;*5K56%D:1(BKGXJ)EQ^H[@!'\+8/LF%GU+[)1I3N
MJ519%UE7/K%ZP=9+U?*.[W&C2:OI$1L,NLJ:J(JJGYJI( !';?@NQ6_$=1?:
M2A:RZ5"N62;65557+FNP].*<,6G%-"RDOE&RJAC?NC$=L5KLLLT5/69D >"Q
M6BCL=LAM]MC6.EA3)C%<KLDYLU/>J9HJ+Q* !A\.8;M6'(JB.STK8&U$BRR;
M557.Y\U/-8<&6.PW6KN5JHFP5E5GNKT<JZV:YK^9(0!@,3X/LF)JBCFO5&E3
M)2*JPJKE35S5%7B]2&,OVC/"M^NL]QNEL;-639:\BO5,\DR3\D)D *^30Y@E
M%14L[<T_ZW&>M6"+!:K[+>*&@;%<)$U72(Y>+)$XO4A(P!A\4X9M.**!E'?*
M1E5 QZ2-155%:[G14(N_0]@MZYOM*/5$R172.79S<98  A-HT6X2M%RIZ^@M
M38ZJG>DD;]=5U7)Q*38    ,9BCR9N_V.;W''&%?)BS_ &.'W$.<4>3-W^QS
M>XXXPKY,6?['#[B 90  "IY]'][WQ.L<U"YCI'/:JN<BY*JKS%L KN6J;GXF
MK9=LN;+CN8>.JI/!_??E*#\3NX>#^^_*4'XG=Q;8*LI;:^<7]([*D\']]^4H
M/Q.[AX/[[\I0?B=W%M@92V<XOZ1V5)X/[[\I0?B=W#P?WWY2@_$[N+; RELY
MQ?TCLJ3P?WWY2@_$[N'@_OORE!^)W<6V!E+9SB_I'94G@_OORE!^)W</!_??
ME*#\3NXML#*6SG%_2.RI/!_??E*#\3NX>#^^_*4'XG=Q;8&4MG.+^D=E2>#^
M^_*4'XG=P\']]^4H/Q.[BVP,I;.<7]([*D\']]^4H/Q.[AX/[[\I0?B=W%M@
M92V<XOZ1V5)X/[[\I0?B=W#P?WWY2@_$[N+; RELYQ?TCLJ3P?WWY2@_$[N'
M@_OORE!^)W<6V!E+9SB_I'94G@_OORE!^)W</!_??E*#\3NXML#*6SG%_2.R
MI/!_??E*#\3NX>#^^_*4'XG=Q;8&4MG.+^D=E2>#^^_*4'XG=P\']]^4H/Q.
M[BVP,I;.<7]([*D\']]^4H/Q.[AX/[[\I0?B=W%M@92V<XOZ1V5)X/[[\I0?
MB=W#P?WWY2@_$[N+; RELYQ?TCLJ3P?WWY2@_$[N'@_OORE!^)W<6V!E+9SB
M_I'94G@_OORE!^)W</!_??E*#\3NXML#*6SG%_2.RI/!_??E*#\3NX>#^^_*
M4'XG=Q;8&4MG.+^D=E2>#^^_*4'XG=P\']]^4H/Q.[BVP,I;.<7]([*D\']]
M^4H/Q.[AX/[[\I0?B=W%M@92V<XOZ1V5)X/[[\I0?B=W#P?WWY2@_$[N+; R
MELYQ?TCLIVKT972M:QM9';)VL55:CW.7)>H\O@BJ/F5HZW%V LIMS1&%-4Q'
MPF557M&NN<:J*9G_  I/P15'S*T=;R5X P978=NZSS;SCI6T[HF1P*O&KD7E
MY-A8()W)F8WJIG#69ES5M]<TS3%-,8^'A&#JJJ:"KA6*JB9-$JHJL>W-%5%S
M38OI.UJ(UJ(U$1$V(B %C"
M
M
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M>Y\4"-FA1?\ 2BJJ*G7D7*>G9N<6B*GP/M+8IV#::MGF<</TGQ@ !:P@
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M2H$J!$L#I-!<;]1RUE351TU0UD;JB17N1-7G):
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MX(F10L:R-B(UK6IDB(G(A]GIV;<6J(IA\)[1VVK;MHJVBJ,,?=\/<  L8@
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M-<CDS:J*G.BG(      !Y&7*A?7.HF5E.ZL:F;H$D373_P!N>9ZP
M             "+82\H<4?:F^Z2DBV$O*'%'VIONDI!
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MZBNGHX:F)U5!END2.\9N:9IFAZRV)Q8(F)\@ $I
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MBV$O*'%'VIONDI!
M              ,/:/VW?/XT?])@%H_;=\_C1_TF $,P1K&F-['@^G:^\U:,
MF>BK' Q-:23+F3D]:Y(24URQA\"NTXUK<=I(MMW%J4J/SW//),M;_ISUN+E
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M?8X?<0#*   :^2?X]3_&D]Y38,U\E_S%3_'D]Y3#MON>[[%\KGY?N^0 8'N
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MI-FKN5T8W:<)  =M
M                             17#WEMB7U0>Z2HBN'O+;$OJ@]T"5
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MONDI(MA+RAQ1]J;[I*00
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M252XEP)1LEA>NZ3PK(UJ(Y<T<W)538J%UNW2>VNUX]2:2+;&J_%<J<6?K/2
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M72QT\+4RR8FU?6O*I[P:(HB/&'AV[%NW5-5,>,@ .EP
M                                                         !%<
M/>6V)?5![I*B*X>\ML2^J#W0)4        "/4-^KJZMF936ESJ6*H=3NG6=J
M?%7)5U1=,134]54Q6^VRU[:1J.J'L>C=3-,\DSXURVY 2$'GMU9#<*&"KIG:
MT,S$>U?0IZ
M                            "+82\H<4?:F^Z2DBV$O*'%'VIONDI!
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M<S/DUEY +>!P][61J]SD1B)FJKQ(AYK=<*2Y0+-05,51$BZNO&Y')GS >H
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MXX3I*8@ L;@
M                               BN'O+;$OJ@]TE1%</>6V)?5![H$J
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M ''P9BOIZD]E_N2H 17X,Q7T]2>R_P!Q\&8KZ>I/9?[DJ $5^#,5]/4GLO\
M<?!F*^GJ3V7^Y*@!%?@S%?3U)[+_ ''P9BOIZD]E_N2H 17X,Q7T]2>R_P!Q
M\&8KZ>I/9?[DJ $5^#,5]/4GLO\ <?!F*^GJ3V7^Y*@!%?@S%?3U)[+_ '.^
M@M^(XZR)]9>:::G:OCQMIM57)Z\R1@                      BV$O*'%'
MVIONDI(MA+RAQ1]J;[I*00
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MC&CI$X2U*;RU4W."H\:=O-MSV)Z%VEC@&FFG=C!]'9M1:HBB)F?\@ .EH
M
M              $5P]Y;8E]4'NDJ(KA[RVQ+ZH/= E0        /E\L<:M21
M[6JY<FHJY9KZ#JFK*:!^I/40QORSU7O1%R [P$5%1%1<T7E
M
M     !%L)>4.*/M3?=)21;"7E#BC[4WW24@@
M                                  &'M'[;OG\:/^DP"T?MN^?QH_Z3
M "$!_21IIZK L#*>)\KDK&*J,3/),G&8PSH]PS-ARU2U=DIUJ'TD3I5=FBZR
ML3//;SD^ $3\'.$N@Z7\^\D5KMU):J&*CM\#8*6+-&1MXDS7/^:GJ
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M+&D/#X-+/\YN/:M_\1X-+/\ .;CVK?\ Q/=X0,,=+0_A=W#P@88Z6A_"[N'
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M31$R(S#CS#4LL<;+M!KO<C6HJ.3-5XDXB3)M.:K=5'XHG\UENW11^"  '*P
M
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M;"7E#BC[4WW24D6PEY0XH^U-]TE((
M                           !A[1^V[Y_&C_I, M'[;OG\:/^DP AF"E[
M[BFXX6TS-2^WC<L.U;/$B1Z*QGBY)K)QM76+H*OQ]H>H,88@DNT]SJ*:1[&L
M5C(T<FSTY@3)F,<.O:CFWJ@R7Z]O>9>AJZ>NIF5%'-'/ _/5DC<CFKDN7&GJ
M*13]'2TKGE>ZE<OJ&]Y;6"\/0X6PW1V>FF?-%3(Y$D>B(JYN5W$GK S8
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MY^_\VZP,/@VKEKL*6FJJ/\::FC>_UJAF#W*9QC%^3W;<VZYHGW3@  EP
M
M        $5P]Y;8E]4'NDJ(KA[RVQ+ZH/= E0                   P6.;
MK-9<*W&NI6YSQ1KJ9IFB*NS-376CQ5>Z.Y)<&7*=]0CLW:[LVN]"H;-FV*K:
M*9JB<&>]M$6IPF&TX.BWU&^Z"FJ%;JK+&U^KS9IF=YDF,/!HCQ  0
M                                                         (MA
M+RAQ1]J;[I*2+82\H<4?:F^Z2D$
M                          P]H_;=\_C1_P!)@%H_;=\_C1_TF $,P43I
M)K\28TQ_+@_#=6M!2T<>O4RM>K=;-$S5V6W),T3).<O8IO2EH_O[\3,Q3@:J
MW&XJW5J(M?55RIQ*G(J*FQ4 @]KM]\;HDO'P5<I$J[3=WS23),Y'.;&W)=55
M7[\E+WT;WV;$F"K7=*EJ-GFCRDRY7-56JOWY9_>:^VG FDBZTU39Y5=06ZJG
M6>I69VHU[E7:J[,W)Z$-D\+62GP[8**U4BJL5-&C=9?]2\:KZ,US4#*
M                !4/Z26':JZX6I;E0QOFDM\BJ^-B9KJ.XW?<J(6\<.:CF
MJUR(K5V*B\H%-X>TXX=9A2!UQ66*YT\#8WT^JJK(]$RS:O,I#JFY8OTA:-\2
MU=7'KT$<[)J:-D?C+DY7.1%Y4:W_ +%RU>C#!E76.JI\/TBSN=K*J*YJ9^I%
MR_(E5%1TU#21TM'!'!31IDR.-J-:U/0@%#X/TLX:MFC-MNJXU;74\+H=Z:G^
M*JY[>;)<]OWD)H;75TFA"_5]3"Z&"NKH'0-<BIFUKES5/1XV7W&PM1HSP=45
M^_)</T:U&MK9IK(F?^U%R_(S=XP[:;S9TM5RH8IK<FKE!M:U-7BRRRRR UCQ
M92STF#='U]? ZHM].QT<C<LVY[JYVWFS1"5:8])M@Q5@I+396R5==521N:Q6
M+G$J+G^+D+S@P]:8+$RS,H(5M;&ZC:9Z:S43//ESY5S,19M'6$K-<&UMML=+
M#5-7-LGC.R7G3654S H3&=LFMMXT74%P:N[,I6;HQZ;4SESU53T9Y$I_2DRW
M3#'%_F5_[%PWO"=COESHKA=;?'4UE'_@2N<Y%9MSY%RXQB7"=DQ,M,M]M\=8
MM.[6BUG.357[E0#,P?X,?^U#["(B(B)L1-@ QF*/)F[_ &.;W''&%?)BS_8X
M?<0YQ1Y,W?['-[CCC"ODQ9_L</N(!E   -;X>*7^-)[RFR!4"Z-;\Q\J15=K
M=&LCG-5RR(N2JJ[=ANV*Y1;WMZ</)1?HFJ(P1$$O\&^(/G5IZY.X>#?$'SJT
M]<G<>AF;74S<&O1$ 2_P;X@^=6GKD[AX-\0?.K3UR=PS-KJ.#7HB )?X-\0?
M.K3UR=P\&^(/G5IZY.X9FUU'!KT1 $O\&^(/G5IZY.X>#?$'SJT]<G<,S:ZC
M@UZ(@"7^#?$'SJT]<G</!OB#YU:>N3N&9M=1P:]$0!+_  ;X@^=6GKD[AX-\
M0?.K3UR=PS-KJ.#7HB )?X-\0?.K3UR=P\&^(/G5IZY.X9FUU'!KT1 $O\&^
M(/G5IZY.X>#?$'SJT]<G<,S:ZC@UZ(>[X]/]IB]]#8UGQ&^HJ./1M?5FAW6K
MM:1LE9(Y6+(JY-7/9FA;K4R:B<QY^VW**\-V<6FQ1-,3$@ ,*\*\TRX0FQ)9
MH:BVQH^X4BJK6(FV1B\;4]/*A88.+E$7*9IEIV/:KFQWJ;]KSAI9-#+!(Z.:
M)\<C5R5KVJBI]RDBP+A&NQ3=X888I&4;7(L]1J^*QO+]YL_7V*U7"7=*VW4L
M\GG/C15ZSVTM+!20I%2PQPQ)Q,C:C4ZD,%/L_"K&J?!]??\ ^8S5:FFU;PKG
MWX^$%)3QTM-%! U&Q1M1C43D1#M /2?$3,S.,@ "
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MHB.>KW)GEQ<2GFX$8=Z,C[1_>!F]_4GSF#\:#?U)\Y@[1#"<",.]&1]H_O'
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M((
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M]5VFC#>G#%,P =+
M                                      "*X>\ML2^J#W25$5P]Y;8E
M]4'N@2H                    !1&/H'X-TD4MXI&Y03+N_H5>)Z?\ <O&B
MJ8ZRC@J87:T4K$>U>=%3,A^EZR)=\(U$L;$6II/UT:\JHGQDZC':$+ZMRP[)
M;Y5SEH%1K57E8O%_W/0N_P!_9Z;GOI\)9+?]N[-'NGQ6. #SVL
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MMA+RAQ1]J;[I*00
M             ##VC]MWS^-'_28!:/VW?/XT?])@!#,%%Z5-).)8,8KAS!4#
MM\P(B2*V%)7/<J9Y(B\2(F1>AKWI$QE28$TOR7&@I'2U$U,D=='(Y$1[5R5%
M8O(NQ ,9PFTU?,JS_P#QS.XO/1U4WFKP?;Y\3,>R[.1V[M?&D:IXRY>*G%LR
M*H_^(VAZ$E[9.XM_!&(8\589HKS#"Z&.I1RHQRYJF3E;Q_<!G     $0TMU]
M7;-'EZK+=424U5%$BQRQKDYJZR)L*4P3;=)F+[(ETMN+JB.!9'1ZLM0[/-,N
M\N+3=_ROOW\%/>0HW1IA+&]YPPVJPU?G4-!NKF)"DJM\9,LUR3UH!,=%.-<2
M1XCON%<453ZNJI8I-SF^,Z-[47/-W*A$L%.TB8VJ+G\#XKJX6TDNJY)IU3C5
M<LNHR&BR:HPACN]8<Q!1,?>*^)R;\237=\57(G-DO'SD4T>V+%EW6^28.N+Z
M62GD598F2[FLJYKEM"$RH,28WP!I M=IQ7=77*EK<E<US]TS8JJW-JKM145.
M(V)K'JVBG>Q51R1N5%YER4UET*VR@Q1C;?6*KM5S7^A>KHZ.=/\ $U<]JNY<
MN8V9K]E!4Y?)N_DH2IS]';$-XOE5?VWBY55:V&1$C2=^MJ;5XCC2MB&\6W2[
MA:WT%SJ:>AJ(XUE@C?DR15D>FU.78B%7:,L/8HOM5=^"EW6W;E+^NRD5FOFJ
MY<1[+I9;_8]*>%Z?%-Q6X5DCXY(Y%>K]5FNY,LU]**!F;A7XWQ%I3OMCL&(Z
MND;#/*L;%F5K&,:[+)$0^,2UNDK1O/17"[WY:^FE?JZCY-T:[+:K51>+9RF*
MJ;3?+QIFQ)389KEH:_=YG)(C]3-J.XLSHLMHJ+YI 9A_27>:Z&>!Z-8R1^ND
MKMGB([B3-.)0-FKAB&.CP=+?T@?)''2[ZW)%R54U<\LSIP!BB/&&&X+O#2R4
MK)7.;N3W(Y4R7+C0JS2_A+%KG7BX6^\[AAR*F;_P:2*B:C6(BIJ\7(1W1!A?
M&5;0VBY6N^+3V1E2CGTNZJB*UK_&3+T[>L"R-)]YN7#7"-ALM;44LD\^[5.X
MNRUXD5-B^C)'&!T.8CO-UTCXEH[C<ZJJHX5E6**1^;6929)ES;-A[K,OPY^D
M1=ZC65\%GHDA8O(CE1$5.MSRJ,,V3$-\Q]B*'"UR6WU+)I72/1ZLUF[IQ;/3
MD!9^G_$%XLMYPO':+E4T<<[WI*V%^JDF3F<?/QKUD;QK<<87;3+78<PYB"JH
MD<B+%'NJMC:B1(Y>+[R):0</8GL5XL"8LNRW%9I5W#.17ZF3FZW'Q9YIU&7Q
MK;+M=]/UPH\/5BT=R>B+',CM751(45=OJ10)/%@72PDC5?C!ZM1454WP[:A@
M*ZOQOB+2C?;'8<25=*D$[]1BS*UC6IEL3(DUEP%I)IKQ13UN*'24L<K72L6=
MRZS47:F7*0*IM5[O&F;$M-AFN6BK]\2N21'ZF:)R9A#+8GK-)>C>2BN-VO[J
MZEEDW/5?)NC57C5%:OH1=I(\?XQQ5B'%=JPY@N26@2JI8ZA\V62YO9NF6OEL
M1&]97UJM%5>L?LP]I*O5?3U$#D2-KW;HCW+EDU'<2(Y.)38K'6*[/@2R1U-4
MQJS(W<J2F8GCR*B9(U.9$Y5"578'Q1B_"^DBGPKB^M=<8ZM4:U[W:ZHJ_%<C
MN;G0O\IG1=A2\7O%,V.\8Q[C52HBT-,FS4:J;%5.1$3BY>4Z\8Z6L063$URM
MM)AM:B"FEU(Y5:Y==,N/8!=1UOJ(6.5KYHVN3C17(BG3:JA]9:Z.IFCW*6:%
MDCH_-56HJI]QY:S#]KK*E\]311R3/^,Y<\U Z\35,#L-W9$GB55I)4^.GF*=
MF%?)BT?8X?<0Q&(L-6>'#UTECH(FO92RN:NW8J,4R^%?)BT?8X?<0#*   :[
M5/\ G*O^/)[RFQ)KM4_YRJ_CR>\IW;_%^3S/:/E3^?[.L %[RP
M      ZJG_+R_P"U3M.NI_R\O^U1/D3Y-A[3^RJ/^"SW4-4M)+W1Z1+\]CG-
M>VK<J.:N2HOH-K;3^RJ/^"SW4-4-)B__ ,0,0?:G'FW?PPV^V?\ II_S^R0X
M,TM7JQK'!='.N="U,LI%_6M3T.Y?O+RPCCBR8IB1;=5(V?B=3RY-D1?5R_<:
MW81P+?<4.:^WTNI2*NVIF759]W*OW%ZX(T5V?#<T59.Z2NN3%S;,]<FL7_I:
MG_<6YK_)7[-N;7.$3&-/Q_980 -#W@
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M3/D4                      BV$O*'%'VIONDI(MA+RAQ1]J;[I*00
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M,<'S%&R*-&1,:QC=B-:F2)]Q] '2P
M                                                    BN'O+;$O
MJ@]TE1%</>6V)?5![H$J       !@V86M3:Q*A8'/5'[HV-[U=&UW.C5V'W<
M,-6VOJW5%3$]RORUV(]48_+SF\2F9 '#&-C8UC&HUC4R1$3)$0Y
M &/Q#;8[Q9*V@F1%;/$YGJ7+8O69 $Q,TSC")C&,)4GH8N,UGQ+7X?KU5FOG
MJHY<LI&KM3[T+L*.TO6Z:P8OH\0T/B).YKE5ORC>/K0N6SU\5TME-6TZYQS,
M1Z>C/D-VVQ%>[?I_]?JS;-.[C:GW/8 # U
M           !D                       "+82\H<4?:F^Z2DBV$O*'%'V
MIONDI!
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M.8Y'-7B5%S13JFJ*O)HM7J+U.]1.,.0 =+0
M
M(KA[RVQ+ZH/=)417#WEMB7U0>Z!*@#JJJB&D@=-531PPM^,^1R-:GK50.T$-
MKM).'*9R-CJWU/(JPQN5$^_(]UHQQA^Z2-B@N,<<[N*.;.-5Z]B@20   5WB
M6*&DO%+)!35E!,E8Q9+I*Y=S<U>-N:*N:+Q;41#W-M\.)*V_35ZR:U++O:FU
M7*FXY-1=9OI55S^Y )L##8,K)J["]NJ*EROF=%DYR\;E153/[\C,@ 8BOQ):
M;?5.IJRM9%,U$56JURY9^I#S\,;#TE'^!W<!GP8#AC8>DH_P.[APQL/24?X'
M=P&?!@.&-AZ2C_ [N'#&P])1_@=W 9\& X8V'I*/\#NX<,;#TE'^!W<!Y](]
MBX085JJ9B9SQ_KHO]S<]GWIF0_0/>]UMU79IW?K8'K+$B^:O&GW*3CAA8>D8
M_P #NXIB>NI,+Z2V7"US[K;I'Z[E:BM35?\ &;MYCT-E_O6JK$^?G#)>_MUQ
M=C_$MA@8!N,K K45+E'DJ9_%=W#AC8>DH_P.[CSVMGP8#AC8>DH_P.[APQL/
M24?X'=P&?!@.&-AZ2C_ [N'#&P])1_@=W 9\& X8V'I*/\#NX<,;#TE'^!W<
M!GP8#AC8>DH_P.[APQL/24?X'=P&?!@.&-AZ2C_ [N'#&P])1_@=W 9\& X8
MV'I*/\#NX<,;#TE'^!W<!GP8#AC8>DH_P.[APQL/24?X'=P&?!@.&-AZ2C_
M[N'#&P])1_@=W 9\& X8V'I*/\#NX<,;#TE'^!W<!GP8#AC8>DH_P.[APQL/
M24?X'=P&?!@.&-AZ2C_ [N'#&P])1_@=W 9\& X8V'I*/\#NX<,;#TE'^!W<
M!GP8#AC8>DH_P.[APQL/24?X'=P&?!@.&-AZ2C_ [N'#&P])1_@=W 9\& X8
MV'I*/\#NX[J3%%FK*F.GIJYDDSUR:U&NVKU 9D                    !%
ML)>4.*/M3?=)21;"7E#BC[4WW24@@
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M(Y=O\D)A;+?26RD936^GCIX&)DC&-R0]1-%K=\97;'[-IV:=^9QJ  6O2
M
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M@0[@!T[TI_D(OP(-Z4_R$7X$.X =.]*?Y"+\"'+::!CD<V&-')Q*C4.T
M                  $6PEY0XH^U-]TE)%L)>4.*/M3?=)2"
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MK7O' ;#W1L?6O>8[PE67Y*N['^X\)5E^2KNQ_N,(T-_9?@R/ ;#W1L?6O>.
MV'NC8^M>\QWA*LOR5=V/]QX2K+\E7=C_ '&$:&_LOP9'@-A[HV/K7O.RDP=8
MJ2JAJ8+?&V:%Z/8[-?%<G$IBO"59?DJ[L?[G=0:0;/6U]-21,K&RU$B1,5\6
M2:R\6:YC"-$Q7LV/A@EX .FL
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M !F,P &8S  9C, !F,P &8S  9C, !F,P &8S  9C, !F,P &8S  9C,
M                  BV$O*'%'VIONDI(MA+RAQ1]J;[I*00
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M2MV'VCF9W:J?'T^R=@ N>H
M                                               !%</>6V)?5![I
M*B*X>\ML2^J#W0)48/'-+-6X1NM-2QNEGEA5K&-XU4SAX;Y<6VFT5=?)&Z1M
M/&KU8WC=ER 57/58BFDPR],,5:? _&F?^)XJ-^[B+#PM>+C==\?"5GFMNYY:
MFZ.SU\R!U&*L38CM-;6VIU%;**GB?*OZU'S.:C57+T+LYD)1HRM4T%H9=:NX
MU5;4W&)DC]V=FC/0@0F8 "4#J+Q373%"-N2RQ6^@D_X>)87YS3<6NN2?%3/9
MUG;C".S33UB24U7\,K&C870L>CGNR\755-G'SDVU4YD.<DSSR3,#Q6)M4VS4
M3;BN=8D+4F_W9;3V@ 8"ZX4H+G7/JJB6L;(]$14CG<UNST(>3@+:_EKA[4XE
M0 BO 6U_+7#VIPX"VOY:X>U.)4 (KP%M?RUP]J<. MK^6N'M3B5 "*\!;7\M
M</:G#@+:_EKA[4XE0 BO 6U_+7#VIPX"VOY:X>U.)4 (KP$M?R]P]J<51I2P
MVF%[W25M L^]9\EUED57:Z?&3/CVH; D7TDV)+_A6I@8W.>+]=%LVZR9[$]:
M&K8[O#NQCY3X2HVBC?HG#SAX[5A.RW.W4]935%>L4S$>F54[E/5P%M?RUP]J
M<1703?-WM=39ZA_ZZG?ND:*NW47C3[E+4*]HM<*Y-#NU7Q*(J17@+:_EKA[4
MX<!;7\M</:G$J!2L17@+:_EKA[4X<!;7\M</:G$J $5X"VOY:X>U.' 6U_+7
M#VIQ*@!%> MK^6N'M3AP%M?RUP]J<2H 17@+:_EKA[4X<!;7\M</:G$J $5X
M"VOY:X>U.' 6U_+7#VIQ*@!%> MK^6N'M3AP%M?RUP]J<2H 17@+:_EKA[4X
M<!;7\M</:G$J $5X"VOY:X>U.' 6U_+7#VIQ*@!%> MK^6N'M3AP%M?RUP]J
M<2H 17@+:_EKA[4X<!;7\M</:G$J $5X"VOY:X>U.' 6U_+7#VIQ*@!%> MK
M^6N'M3AP%M?RUP]J<2H 17@):_EKA[4X[[?@^W4-9%4PRUKI(US1'U#G)]Z$
MC                      !%L)>4.*/M3?=)21;"7E#BC[4WW24@@
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MTVXW:(P@ !+L
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M9>*O4>A?_O6*;WOCPEEM?V[DV_=/C";@ \]J
M                                1;"7E#BC[4WW24D6PEY0XH^U-]TE
M((
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MOP3B[@ =+@
M                                      BN'O+;$OJ@]TE1%</>6V)?
M5![H$J.FMI8*VEDIJN-LL$B:KV.XG(=P \]%0TM!"D5%30T\:?Z8F(U/R/0
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M%'VIONDI(MA+RAQ1]J;[I*00
M                      ##VC]MWS^-'_28!:/VW?/XT?\ 28 0S
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M5*:UT<-+"B991MRS]:\:_>>XUTQ,1XOJK%-RBB(NU8R  Z7
M
M             17#WEMB7U0>Z2HBN'O+;$OJ@]T"5         X5[4>C5<FL
MNU$SVG5+54\+M66>)CN9ST10.X!%S3--J                  8S$UK9>;#
M74$B(N[1*UJ\SN1>O(R8)IJFF8F$3&,82I?0E=);=>J_#]:NHJYN8U>1[5R<
MG4704;I4H9\-XVI;_1-5L<[FR9IL37;\9/O3^9=-LK(KA04]73N1T4S$>U4]
M*&W;:8KW;]/E5^K-LTS3C;GW/2 #"U
M                       "+82\H<4?:F^Z2DBV$O*'%'VIONDI!
M                                                    ,/:/VW?/
MXT?])@%H_;=\_C1_TF $,P                             BV,\"VC%]
M5;ZB[[YW2A55BW&353:J+MV+GQ(9?$5FI<06:JMEPW3>U0W5?N;M5V7H4R0
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M^]X;99[?;'3NM]'# ^=ZOE<QNU[E7-55>-3W $1&'DNB(B,(  2D
M
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M+RAQ1]J;[I*2+82\H<4?:F^Z2D$
M                          P]H_;=\_C1_P!)@%H_;=\_C1_TF $,P
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MW$C+HF)\GL45TUQO4SC  "70
M                                                 $5P]Y;8E]4'
MNDJ(KA[RVQ+ZH/= E0                               !KEI8M=;1XO
MK)JEDKX*A4?%+JJJ*G-GZ#8TZYX(:AFK/$R1N>>3VHJ&G9=HR]>]ABIO6N+3
MABH71!B>DP]<JNDNCGPQ5:L1KW;&L<F?QN;//C+\BD9+&U\3VO8Y,T<U<T5"
M%X[T?T&(J=TM*R.EN34\65J9-?Z'(G\RNL.XJO. +FZTWV*6:A9L2/C5O_4Q
M>5/0:KE%.V8W+7XO?"BBJK9_Z*_+5?8/%9[I1WBACJ[=.R:!_$K5XEYEYE/:
M>;,3$X2V1./C  "$@
M    (MA+RAQ1]J;[I*2+82\H<4?:F^Z2D$
M                                 P]H_;=\_C1_TF 6C]MWS^-'_28
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MCX+M(_TN;VK^XRF,=$%XO-#AF*BNM'!-:J%M,][FNVO;_J;D8[P3:0OIQ_\
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M-K)A9[*B)CZJX)MWQ,N:HO\ TIR$V +XIBGPA[-NU1:IW:(P@ !*P
M
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MT?MN^?QH_P"DP"T?MN^?QH_Z3 "&8
M           &,Q1Y,W?['-[CCC"ODQ9_L</N(<XH\F;O]CF]QQQA7R8L_P!C
MA]Q ,H   !5<VD.\)/.V.DMZ,9(YC=;7SR153;M*[EVFW^)JV;8[FTX\/W+4
M!5'A$O?S6W=3^\>$2]_-;=U/[RG-VVKE&T?#NM<%4>$2]_-;=U/[QX1+W\UM
MW4_O&;MG*-H^'=:X*H\(E[^:V[J?WG9!I"O#JB%LE)0:CI&M75U\\E5$7+:3
M&UVSE&T?#NM, ZZ>>*HCW2GD9+'GEK,7-#2\MV
M
M                 17#WEMB7U0>Z2HBN'O+;$OJ@]T"5
M                       5,TR7B  K'2!HSAN:R5]@;'3UV>L^+B9)Z4YE
M,'@?2-5V>I^"<5I+J,=J),]/'B]#DY4])=1%<;X*M^*:?6E3<:YC<HZAJ;4]
M"\Z&ZUM--5/"O^,:^^&:NS,3OVO"?U2:GGBJ8(YJ>1LD3T1S7-7-%0["@+5=
M[_HUNV\;E"LEOD=GJ*N;7-S^-&O(OH+KP[?:#$%O;5VR=)(UXVKL<Q>94Y"N
M_LM5K^J/&F?>[M7HN>$^$Z,H #*N
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M5'7-D7BS3)O&NW;Z#88@.C?1=:,#U,U93SSUMQE;J.J)\DR;GQ(B<7K)\
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MOC<U<J&)=:)BKRYKR^HFW75/A+OV=MM^]X5TXQJL< %[V
M
M                   (KA[RVQ+ZH/=)417#WEMB7U0>Z!*@       # W'$
ML-'<I:*.AKJN:)K72;WBUD;K<6:Y^@SQ$L04=71S72\6J\1TSDB:LT,D;7L5
M6(N2*J[4S1?S ED;M>-KLE;FB+DO&AR>*QUCKA9Z*LDC6-\\+9',7D54S/:
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M,@)                      BV$O*'%'VIONDI(MA+RAQ1]J;[I*00
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MB,(  $@
M                                        17#WEMB7U0>Z2HBN'O+;
M$OJ@]T"5        &+K</VJMK4JZJBAEJ$R\=R<>7%GSF4 !$1$1$3)$
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MRM:B*[++/9QGV!A[1^V[Y_&C_I, M'[;OG\:/^DP AF
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MRPXCW.'=MY5[MF]Y]F:_]+N)?Y^@YBY$SA+!1MMJNY-K'"8G#Q3@ %C6
M
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MMI\Q1,AB;'$QK(VIDUK4R1$/HT44[L>;Z#9K$V*-R:IG_( #MH
M
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MC5;YJ=0U6^:G4<@#C5;YJ=0U6^:G4<@#C5;YJ=1\OB8]CF.8U6N3)4RXT/L
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M>Y]  ER
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MWD]:%SH7TUQ5Y/8V?:+>T4[UN0 '2\
M
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MRN; LGQ(T17/=ZFIM D((/AG2IA/$=?'14%Q5E7(NK''/&Z-7KZ,]BDX
M   !';#C*TWR^W.T4#YUK+>Y6SH^)6MS1<MBKL7:@$B
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MQJ9@ MB(CPAZ5-,4QA3&$  )=
M
M
M                                                  #3?%_E5>?M
M<OO*>2UVRMNU4VFMM+-53N7+4B8KLO7S%TT6AV:XXDN%PQ!4LCHY:E\C(('9
MO>U554S=R%KV"P6RP4J4]HHXJ:/+;JIXSO2J\:F2FU5/F^:L^R;EVJ:KG],>
MJO=%6 +YAY\=7<;Q-!&J;;=$NLS_ -RKLS]1:H!IIIBF,(>_8L4V*-RCR%V(
MIKEAZTT^D+3AB%V($=/1T+56.!7+DJ(K6HWU;<]AL::[8RH;_HTTD5N*;+1[
M[M5P7]8UJ*J(BY*K79<6U,T4Z7,AI[P%9;/A1+Y8:5ENK*25J?J<T1R+_P!T
MR//?])V([2S!#;9&VJ=<+<U\E.YNLZ:365B;>/;EF8;%&+<1Z7'TV'K+:):.
MB>]'S.?MR5.5SLMB)^9E<:6E;1I3T96Z)BO91PPQ*]K5R54>N:^C-<PA[\&Z
M2,6TV/Z>PXTHF1I6Y)&U(]1T:KQ*B\J'NTCZ1L1)C),+X'HV35D;4=))J:ZJ
MO&J(G$B)RJIC](D;W:?\+N;&]S42/-4:JHFTQV-*RYZ/-+]1B"*A=76^MBR7
M4]*;6Y\BHO)S!+-8,TC8ENNDNBL-YI6T"-A<VIIW1[5>B?&1>/)3[QOI(Q+6
MXOK,-X"MZ3S46R:?5UUS3CV<2(B[,U(O@ZYU]YT^4MQNE)O*:I@5[8%^,R-6
M)JZWIRR.Z[5=WT4Z3[W=DM<M;:;HJJU[$7+)5ULD7+C1=F0$UT6:1[G=;]-A
MG%U#O2],:KV.U59KHB9JBM7B7E/-A'&EVK<8X\HYEIMQMD<SZ?5A1KD5KG9:
MRIQ\1A]%U+>,::39L;W*C6BHH8UBB:J*FNNKJHB<^2<:GFP'&],?Z4%W.3)8
M:A$757;XS^(#&6[2?I#N]CJ)+30,G;1.<^HK&0*Y-7CU<N+8FTLO!^DEUPT7
MUN)[I3-;-0JYDD<:Y)(Y,D3+FS5R$7T'QO311B9JL<CEWQDBM5%7]6IC]&MF
MJ+UH%Q%;8$U*B:I>K$D\7-6JQR)MY]7+[P.BETGZ0'6VLOTEE1]CD8](Y&1*
MB0\:(]%Y41<L\]A;&B&_5V),"T5RNCV254CY$<YK=5%1'*B;/44;;L<W]FCV
MNP@VQOUZ6FDCFJ7(J-BA3/65WIY.HM[]'S_E=;?]\OOJ!8P
M             P]H_;=\_C1_TF 6C]MWS^-'_28 0S
M                         QF*/)F[_8YO<<<85\F+/]CA]Q#G%'DS=_L<
MWN..,*^3%G^QP^X@&4
M
M
M
M    !$1$R1$1 J(JHJHF:  ,DSSRVE3:1]%URO>)4OV&;R^W5SFHDC'/<UN:
M)DCD5/1R9%L@"J=%^BRIPY?I[]B&Y?"%U>U6L5JJJ-SXW*J[54M94S3)>(
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M!W$7TMG]E8.#N(OI;/[*PEP B/!W$7TMG]E8.#N(OI;/[*PEP @'P9B/X?\
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MMG]E82X 1'@[B+Z6S^RL'!W$7TMG]E82X 1'@[B+Z6S^RL'!W$7TMG]E82X
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MO$B(B9)Z$!E@
M!TTU+!3+*L$38UE>LC\O]3EY3N
M                     .K>T.^]];FW?&IN>ORZN>>76=H
M                                         !UST\4ZQK,Q'K&])&9_
MZ7)Q+^:G8
M    ==1!'4P/AG8CXGIJN:O$J'U&QL<;61HC6-1&HB<B(?0
M                                         !U4U-#2L<RGC;&USE<J
M-Y57C4[0
M                                     ,5B7$-LPU;'5]ZJV4U,BZJ.
M<BJKG+Q(B)QJ94H#](=S[IC7"UBE>J4DCFR*B<JN<K5_) +)P;I0PQBVO6AM
M=7(RMVJV&>-6.>B<:MXT4FQKAIFL5OP7C'"ERPY31T+W2(US(LT15:Y-OKR7
M+[C8R%^Z0QO\YJ*!]@
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M#1I3I.]SG4T\D#55<_%3)4_F!9X
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M=,ROF6343=<URUE7-?7L,G^C34NH[UB:RM>Y88Y-U:BKL3)=78!?H
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M""@L[-[4-3$C5A8OBYN9GQ>L#8<
M                                                    *'_2/H:J
MW7?#V*:=BR14LC8Y,DSU<E5R9^O:GW%\'Q/#%40NBJ(V2Q.3)S'M1R+ZT4#6
M;%V)H-+6.\,T.'X*AL$#D=(Z9F2M7/-R[%79DB;39N-J,C:U.)$1#'VFR6RT
M:_P90T],K_C+'&B*OWF1
M           "(Z59;O3X)N%1A]D,E5"W='1RQ))K,3C1&KL5>XHN]Z6Z*]Z+
M.#U50R/OLB)$[<XFLB3)V>LU$XEY-5$-HC%1X<LT=>M:RUT;:KCW1(FYY\_%
MQ@43C'!-QI] -MCE@<M=1/2>2-J9JR-W'LYTV?F8#&ND.FQG@G#V%K11U/PF
MUT4<J.;LUFMU$1N6:KGGGQ)D;5*B.145$5%XT4Q=%AZT4-8ZKH[;20U+MJR,
MB1%^[F XPI;G6G#=MH'Y:]/ V-V7.B;3*@
M                       5!^E!EX/(L_GD?\G$GL%O6[:(J6B8B*^>W*QG
M^[57+\\B676UT5VIDI[E2Q5,*.UD9(W-,^<]%-!%2T\<%/&V.&-J-8QJ9(U.
M9 -5L$:0Z7!NCZ^X6NE'5)='/E;$B-1&YO35765=J99<RYDST>X/KIM!%\@D
MA5E3=8W5$3,E1SD3QF[.=<OS+FK</VBNK&U=9;:2:H;Q2/B15^_G,HB(U$1J
M(B)L1$ U2LVDVEM.B:HPI/2U"7A->%OBIJ(U7<NW//C3+(NO0/8I[!HZHX*R
M-8YYWNJ',=QIK999_<A+IL.V>:X;^EME(^KSSW5T3555Y^+C])E
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M\]T,4<$38H(V1QM3)K&)DB)Z$0#[
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M+S[1;;=1VRGW"WTT--#GGJQ,1J*O.N0'J
M
M
M
M
M
M
M
M
M                 J[39I%J<'P4E!9XF/NE7M1STSW-O$BHG*JK_("T0:Q5
M6+]*^'X6W:[P524.:.?N\#-3)5V(N6UN?W%Y8.QG2XAP4V_HQ(]2)SIXD=\1
M[4VMS7\O6!*P5SHHTA2XXJKL^:GAHZ>!S&P1(_6>J+GFJKR\7(A8<4T<N>Y2
M,?EQZKD7(#[!\)-$Z18TE8LB<;4<F?4=%?<:*WL:^X5E-2L<N2.GE:Q%7[U
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MZAC7=2KF!D0<-<CFHK5147B5#D
M
M
M
M
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M&HUJ9-1,D1.0H+]'&@JKQ?[WBRYZTDTB) R1?]3ERUE]:(B)]Y?P2UPTT_\
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MD[*>_1OPS=;%8[E47:"2D963-?#!)L=JHF6LJ<A<(
M
M
M
M
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MJ=S<L2*F2*_)=7/[\BBH\!8SQMC.@N6.604M#1Y9QL<BHY$7/5:B+RKRJ7\
M.&-1C4:U,FHF2(?+H8G.UG1L<[G5J*?8
M
?                                      /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g184865g09g01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g09g01.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2%B4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP"   "   < E  "')R.#,Q,# R' (% #--:6-R;W-O
M9G0@5V]R9" M($]+55(@+2!"=7-I;F5S<R!396-T:6]N(%)I9&5R+F1O8W@X
M0DE-!"4      ! %I?*S\&<?]]JX5I3:P\AB.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -S    !@             ":0   PP    ? $\
M2P!5 %( (  M "  0@!U ', :0!N &4 <P!S "  4P!E &, = !I &\ ;@ @
M %( :0!D &4 <@ M #,    !                          $
M     PP   )I                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   )I     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ":0    !2
M9VAT;&]N9P   PP    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     4X0DE-! P     %I\    !    H    '\   '@  #N(
M%H, &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( '\
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M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ .T^M>?G8=F
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MFWZ&Y$24\!_SR^LK.GA[:*WM:\L9U XF5L>]M#+&X/V'?]K^T69SOLOVW?\
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M:&-QJQ6ZH/N'Z.IEWZ*^_P#TN3[_ -!_-6*'5>IT=6;T#J5=(N;;EUV]/QG
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M &@ ;P!T &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ',
M: !O '  (  R #  ,@ Q     0 X0DE-!"(      49-30 J    "  ( 1(
M P    $  0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @
M 3$  @   !\   !^ 3(  @   !0   "= 3L  @    D   "QAVD !     $
M  "\    Z    2P    !   !+     %!9&]B92!0:&]T;W-H;W @,C(N," H
M5VEN9&]W<RD ,C R-3HP,SHQ-" P-CHS-#HS, !R<C@S,3 P,@     #H $
M P    '__P  H ( !     $   ,,H , !     $   )I          8! P #
M     0 &   !&@ %     0   38!&P %     0   3X!*  #     0 "   "
M 0 $     0   48" @ $     0              2     $   !(     3A"
M24T#_0      "           _^$!3D5X:68  $U- "H    (  @!$@ #
M 0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M    'P   'X!,@ "    %    )T!.P "    "0   +&':0 $     0   +P
M  #H   !+     $   $L     4%D;V)E(%!H;W1O<VAO<" R,BXP("A7:6YD
M;W=S*0 R,#(U.C S.C$T(# V.C,T.C,P ')R.#,Q,# R      .@ 0 #
M ?__  "@ @ $     0   PR@ P $     0   FD         !@$#  ,    !
M  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0
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M8 V8=VCRW*"K<9P7PF4Q=>6GJNK[[*P.$9=V)'96?C^$I_)K)@<C?,LVY>)
M20-NRJ#7FA=,:<PYR.F=2F6<?$R/GZG_ &5B>S)JK*YW$Y.CDY7S1UX]XY'?
MA_N@Y[QNE!:UVW &;8&4Q^(NON&7#V'0>'O116#,Z=F[CU\@5R_0N0XWC+[Q
M==X<4=D\Q/DNR,;G\9FJ4_T9<CL%D>[@T]NB#A[5U>S9XBWJ]%SA/)8Y6D$[
M[E=)\)>#\NELE'E\C>\>Z6]1UZ;C[U1E$ \;G[C_ /4_]EV=F++Z6(MV8V\S
MXHG/ ^\!!S_K;@Z[):JO7LSJ2*M0ED+XVS/Z@'[E5_$?15?1(@NX+4$5L.<!
M^9?\35]8J6WQ(XB/I9_*25Z[Y'#<G8-&_8+8\9N'^G='8Z%V+RTMJV]P!B<_
MFV'J@OG@5J2UJ/AX9+\CI+$&\9>X]3T7*F=I6K_$F]3Q[W-L2W"QI!Z@DKHO
MV7QMP_O=.O.?P5+Z=.W')W\?_P#[()=J/@!>I:8ER9R7C7HV&65AW\ANO7V6
M=4779NQ@;4TDM65KG .._*0/)=':Q.VE<MM__&?_ .TKE+V8/^I'_P#5_P"!
M0>'M#:%BTMG1=@F+VWGNDY3Y=5+^"G!^#(4<5J66X1\7B"/KW!7K[7K7>-B'
M<IY>5W7^:FO 75V#@T'C,?-?BCN-^$QN[[DHA<:B/%+,Y+!Z5L7,-"Z:TWL&
MC<J7=^R_'L:]I:\ @^11+A;B/K34^IJ4,.HJ\L43';M+V[=?Z*2\.^(>LL;6
MH8_'TYI* <&[AG3;^BM3VFM-W<MI^DS"X\SO;+N[PF]5-^#V'?C]"8Z'(4VP
MVFM^)KAU1"8XR62?'UI9FELKXVN<#Y'9>.?^Q;O[IWX+/6!G_L6[^Z=^")<%
M8O$WLWK5V.QDCV3S3N:' GIU*MO4GL^7<9@)LC6R7C6X(S*]NQZD=]E7F@=1
M0:8XG,R%L?F&SN#R!V&ZZBU?Q3TS7TE:L5\A'-+- X1Q '?<CS05)[-.N+]?
M4$NGLI-++ ]I\,/.Y8[=3/B_PML:EU$,C+G64\>YH#V2O( ^2JKV><?8SG$Z
M3(11[11!TKCY#KV7QQ2U!DM4<378FU=?6H^)X0&^P W/5$/W7?"_&Z<PS\EA
MM35;4L(YG1L?\1^2LKV5]5W\I1N8J_.^9M=O.QSSN1U[*'\0.%FE]-:.FR,>
M<EEO>%S1QF3</=LL[V1/M;)_NC^(01#C9_U?;_G;^)5V<<?^CE?^'9_[ J4X
MV?\ 5]O^=OXJZ^.7_1R#^'9_[ @Y\X2:"R>NK4U6O:?6HQCFD=N=NZWW$WA1
MD^'M6/*X^\^6!IV<]FX+2MK[-&N\9IVS:Q^7E$$<S=VR$=-]U,/:*XCX6WI2
M3#8NRRW-8V+G,ZAHW1+9<+.)L\_"W(W<@3+<QD6P<X_6Z=-_Z*EM.8W/<8-8
M61/<D$>_._F)+6-4QX4:9O6N$.I961.WFB_-CS=L"M)[.FKJ6CM4WZV:/@1V
M6>&7N'U2#_\ "#WXB\&\CHC%?3&,OOE9%MSEFX+59GL]\0[&8TIDX,J]TL^*
MA\3G<>KF@'I_LOOCIQ)P1T7:QV.N1VK%H  ,&X W4+]FC3]NQ@-4VRSEBM5C
M%$?\3MBB$*R^4U!Q7U[)2@L2-A<_E;'O\+6@[>2F6H_9ZR6,Q7O>&R!GNQ['
MD:"#]^RA/##/,T+Q+E?F6.C8)'1OW';KW736I^+>F,+A_?8[S+3R 6Q1[[E$
MM-H?#Y["\*LM6U-.Z67W=WAAQZM'*>BI7V<F[\3Y-R>G-Y_>NAJNL<?K7AYE
M;^+YVM%=P<UXV(.Q7/?LX[#BA+O_ .O\40D/M(Z\R,VHQIG$S20QQ@"3D.W.
MXE>6 ]GR[D]/LOW<CX=V:/Q&L(/?;INH][0%*SA.*SLI/$?=Y2V1A]0%T%I7
MBIIJWI6"W/D(H9(H1XD3M]]P/)$H+P)T1J_3.I)_I.=[<6UI;X;B=G'?R59<
M:]OROC;MXK?Q*Z'T#Q:PNL<U-C*3)8YV EI<.C@%SOQJ&W%X ^4K?Q071QY'
M_P!DXON9%_[5'O9&^RLJ>N_3\5(>//7@E'_DB_\ :H][(WV1E/7I^*(4MQ.C
MFFXDW(JA(G?+RM([[DE6=![/.0MX+WVWE-\@^/Q QVYZ[;[*NM>7QB^*\UTC
M<0SAQ'?S74U#BMI>733<@<C&U[803$0>;FV[(ESKPDU5E=#Z_&(OS2NK%W@O
MB<[H#OWV*[*8X.:'#L1N%P_0DFUOQ>%BA'N)9P\;=.@(7;\+2R)C3W:T!!](
MB("(B B(@(B("(B B(@_'-#FEK@"TC8@^:J/7W [!ZDGEMTR:5I_4AC1RD_)
M6ZB#F>K[-<GO#?><J3"#V Z[*Y.'_#G":*B/T=%XEAPV=,\#F4T1!'=?Z=_M
M3IBUBA+X1FV^+Y*#<'>%$FA,A:M36Q,91L %;:(-%K33-+5>#FQN08"QXW:[
M;<M/J%5/#K@UD=&ZGBR-7*DUVD\T?8.'WJ\T04GQ.X+R:OU/]*171$'=7-(5
ML:7Q?T+I^CCB_G]VC#.;U6T1 58\9.&DFO6U/"M^ 8-^A[%6<B#F%OLV6V'X
M,J&G[EEXKV=[E3)5[#\L2V-X<5TFB"+ZNTO]/:-DP@G+"Z(1\_R&R@_!SA))
MH/-V;\MP3>+$8PT?-7 B"HN*W!V'6N3&1CO20V WEY3U"AF)]FU@ML=E,FY\
M(/4-'4A=((@T>D=+XW2N+91Q4#8V-[NV',[YK>(B FR(@(B(/F1O/&]G^($*
MC<=P/DJ:[CSIO[QLE\3DV5Z(@^)8F2P.BD:',<WE<#YA4/K?V?*64R<ES#6C
M5\1W,Z,@; J^T0<[-]FZI]#R-=D9'9 _5<1T5B<'^'K]"XNU6EL^,Z?;?;R5
MBH@HJ/@?*S7GT[[^#%XOB<NW57IRCDY#U&VR_40<_:Q]G\9C4MC(U+HBBFDY
MW,V[=>JNK26"@TY@*F+J_P!W W;?;;<^96W1!']::1QFKL6ZEE8@X'ZL@ YF
M_)49D?9L_P#%/-#)N; 3V</)=)H@K'A;PCQNA['OK)Y9[SF\I<>P6'Q-X+X[
M662DR3;,L%UXV/F"K:1!S12]FR3WAGOF5<8 >H'?97GH;1V,T;B6T<6SI^L]
MP&[E)$04OQ.X'4=4Y1^2QTYJ6I/KMV'*3ZK9\(>%C]#.NR37G3OL-Y>7R"M5
M$%%P<#Y(]>OSIO#PC+X@;MU5Y2,;)&Z-XW:X;$'S"^D043K7@%6R67?D<%>?
M3ED<7.:.@!)\ME@/]G9EG&.]]S$\U_R>[J NA4003A3H4Z*TY/CGV/&=*[?F
M'ETV4&QO!"6KKYV>=?!C\?Q@S;[]U>B(,+-4OI+$W*7-R^/$Z/?TW&RJ+A3P
M:ET7J?Z5EO>* UP#0/574B"+<0=%8_6N'=2R Y7 'PY !NTJFL/[.LM'+Q6#
ME3X,;PX #KT71R(/.M%X->.,N+N1H;N?/9>B(@(B("P,_P#8MW]T[\%GKQNU
MVVZDL#R0V1I:2/O0<-:!T[4U3Q%DQ=YSFQ32/&[>XZJV)/9L:<B2W)N]SYMP
M-NH"GFD>"V+TYJEN:@MROE:XN#2/56N@BV@=$8K1>-]VQ<>[W#XY7 <SE"N)
MO!;'ZLOG)4IW5+Q[D#H?O5O(@YZH^SRZ:K,W,YF>=X;M$-]PTJ7\'.%C]!7K
M=B2WX_C,Y -OO5K(@I#77!6346M/IJ.]R,)!+"/0J=:]T6=2Z*CP;)_#='$U
M@>?/8;*:H@YVH>S;4&+>VWD'^^GZKFCH$TY[.->#(MES%]TT#3OR-'==$H@P
ML3C*N*QL-"G$UE>)@8&[=Q]ZJCB)P+Q&I+LE_'R.IVY#NX- Y2KD1!SI@/9O
MKQ76R9C(OEA:=^5@[J^\!AJ6"QD-#'0MBKQ-Y0 ._P UL$05EQ*X08;64K[>
MYJWSW>QHV=\U7.,]FP"XPY#)N=7!ZAHZD+I-$$7QFB\=A])6,'BF>#%+$8R_
M;J21MN57O#3@S)I'53LM)=$K>NS1]Y5U(@C6N-&8K6..-7*Q;D#X)&@<S?DJ
M/N>S83<?[KE"*Q/0$==ETJB"O>&7"W$:'9XT&\]YS=G2N Z?)1/77!634>L_
MIIE[D:7AQ;MZ'=7<B"$\0-%'5&A&X%D_AN8U@#]O-HV6MX.<.7:"IVXI+/CN
MG]!V5D(@H+4? (9O5<^1FO[5IG<SF@=5K,K[-L;KF^.R3FUCW:\=5T@B"ON&
M7"[$:&9XM?>>\YNSI7@=/DK!1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M/B^K "0"K$Q.-J8FA%3Q\+(:\30UK&A!EHB("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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M:C_2]/?Q#5T&N?/:C_2]/?Q#4%[83[(I_NF_@LU86$^R*?[IOX+-0$1$!$1
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MO6R<UKOK 'YK$P]-]#'0UI)G3.C:&\[NY68@_&M:WZH ^2_41 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!<^>U'^EZ>_B&KH-<^>U'^EZ>_B&H+VPGV
M13_=-_!9JPL)]D4_W3?P6:@(B("(B B(@(B("(B B(@(B("(B B(@(B("(AZ
M E 15AJ?BG] Y04YL;(XN.S';=U.M-95V8Q45Q\#H"\;\K@@VJHKVB>(=#$5
M'X.&!D]^3E>YQ ^$;JS-5:UQ^#_,-YK-UW1L,0YNOWKGSC%PZS^:;-JRQ''&
M^38&#FZ@$]$$HX=\0KNL<16P&#KLI7&,#)YV[#X?56A5P-?2.'FNQ5SD<EM\
M<CNKGE07V=.&\NFJ+LQD2/>K3!R,!WY6J[D%%:,R^<J:RO79L!R17']PS;E'
M]%>D;N9C7$;$@';T7[L/1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$
M1$!$1 1$0%SY[4?Z7I[^(:N@USY[4?Z7I[^(:@O;"?9%/]TW\%FK"PGV13_=
M-_!9J B(@(B("(B B(@(B("(B B(@(B("(B B+2ZNJ9*YAI8\+:-:WW:\(-T
MA(:"3T ZE4EP[FUIF,Y.V]EW^[4I V1I/U^JL/5FKJF'8:D(-O(2#E;#'U(W
M\SZ(*,XT<4,<_5]"&G"V5N/?^<<1W._93_#ZPRG$&C%#I>'W6B&AEBQV+?DJ
M&XC\-\[7U!#/)".;).YF-&_PDE=/<'-'NT=I""G.\/L2 /D('8[=D&RTMHVA
M@F^*[>U>=]>>7J2M!Q0PFI\^QU+$.B;2=L22[8[C^:L9$$+X<8_4.+I"IG2Q
MT<;0UA#MRIHB("(B B(@*):SUI#IA[!/5EE:>[FCH%+5$^)T]*OI6VZ\Z(;C
M9O/MN3]RUP1$WB+1M$^'QHO6\&J)G-KU98V#]=PZ*7J$\(YZ-C2-<TC$7M)#
MPW;<'[U-E.>*UR36L:T5\"+X,L8DY#(P/_P\PW_HOM8I$18F5R-;%TI+=V01
MPL&Y)09:*O!Q0ID>\>X6O<-]O&Y?]U*K.HZ,6FY,W&_Q*C(_$W'?9!N44?&K
M,<S2\.<G?X=65G,P$]7?</Z+#.M:L6 ARUF!\4$S^1@/0G[T$L1>52=MFM%.
MSZLC0X?S4>U7J^II^6.N^*6>U)]6-@WZ(),BB^E-9T<_++7:U]>Y$-W12=#M
MZK!M\2L%5S$N.DD>)8ANXGH$$V10"KQ/QDF19!/!/#7E=RQ3N'PDJ?-<'M#F
MD%I&X(\T'ZB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("T6L]3T]*8=^0OMD>P=&LC&Y<5C<1<W9P&EK5VBUAM#9L?/VW)5 9#
M47$7/UQ%:Q$<T-?\Z9'#X-OF@WEKBMKK,V7G3N",=/?=CGLZD?U67@^-6:Q=
MN.'6V%D@A>X-$L;-O^59?"K4#L_I>%]B&**U#^;D;$/AW'HI+E<31RU?P,A5
MBGC[[/:#L@]\?;BOTH+59W-#,P/:?N*]UX4:L-*K'6K,#(8QRM:/(*HO:!U#
MJ/3V/BLXD^'3,@!>#L=]D%R(N3\)J_6N0Q%K4,5UWN]"0-<SF.SA_53+6^OL
MWEZ.FJ>#?[O/D6CQ7-.W4[!!?R*B-)<0<QBJ^H\7F'">[C6$QO<=R3LHKAM<
MZLQ,6-U'?L&:A?G\,Q.=N!N=O5!U"N?/:D_2]/?Q#?Q*MC46N<;I^.D;[)RZ
MU&)&^&SF&VRH7CSK#':FNX)F/9.UT<[23(WE\T'3&$^R*?[IOX+-6%A/LBG^
MZ;^"S4!$1 1$0$1$!$1 1$0$1$!$1 1$0><L\4) EE8PGMS. 7Y'9@D?RQS1
MO=Z-<"H7Q/TK'FL9-<=>GJR5X]QR=CLM#P7TPVMCFY>;(V+$KG$;//38(+74
M%XR:ODT=H^Q>K-#K#O@9O]ZR-2Z[IXYYJXQOO^0/1L<74 _>0HOD-"Y/75.:
M35T[X(W#>*"/J&_RW0<_<.^).?IY^:""?[3E#7]/J[GN%UCI#2=/%1"[+O9R
M,S>9\\G4]?14CP7X44QJR_;O2ND9CIMHF;#8G<[;KIAH#0 !L @H_B7+J7)Z
MBHOIX[\U2=S [?6ZJVM*W+=[#039"#P9RT M6V1 1$0$18V0NP8^J^Q:?R1,
M[E3$;[0,E%%JFO=/V[+8(;P=*3L!LI0TAS00=P1N%-J6I_E&B)V_)7B.)[R"
M0T;[!5O;XMXRK>=4EHW/%!VVY58\TC(8GR2.#6,!<XGR"YWU1Q"Q\VO*U^M2
MBDJ53R$D#=_J>RZN'AC+,Q-=J7MT^J_L5D&9#&Q7 Q\3)&\VT@V("YVX[YA^
M0U3X$$YEIP, :&_5#O-6)!D<OQ 8UF-!HX3LZ5O1SAZ+8:HT=A\?HRS$VJV5
M\;=_%>/B)]=UKQYKQLL3;S[>RMXZZZA5_ %V19J=[J_/[@&.\8>1.W3^:L+4
M?$;(TF7HZN(FYH@0R4L.P^];[A-0KTM(5S7A:PR$N<X=W%3"2-DC',>T.:X;
M$$=PHY'(I;--K5VG'2:UUMQU8U5FILJ;[[\WO/-S;[]OY*Z]-<3,I9QU0VL3
M+,]VS72M8=G?>MI<X/X"SEW7>>9C'.YS W;EW5AU:T-6O'!7C:R*,!K6M&P
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M1VA\_/;KU5@8.]<JX-EC4\E>";EYG.#N@"Y?USJ'(9C4=B>U8>[PGEL0!Z,
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M_)_W5,5[1,]SA3,WMOVE+;.E\1/%R>Y0LZ;;M;LJNXH:!=1H.R.,GE?"P_'
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M! "T-Y>7GW"L'B'Q)P>D)(ZV18;5A_>%FQ(^:Q>'_%+$:MR7T?CJ4U=X!/Q
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M])UN69@K-;SF3?IMZH,A%B1Y*I)CFWFSL]T+>82D]-EBQZ@QKZ0MBRWW<NY
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M&F'?1$3._P "(BV:B(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MOM46_4+LQQS%.=TS:E>/X&#H-P#U5MXW4="_#=DKR$LIDB0^FR#<.<&M)<0
M/,HQS7MW8X.'J#NH;J+/0970F2NXN4@-:6AWF#NM=P^U-!7Q.+H9&1QMVG$1
MN/F@L1%I9=24(\[]$N>?>@WF/H M/9XC8*O== Z9Q8UW*Z4#X04$R11[.ZOQ
M6'JPS3S\_C#>-K.I<%'\]Q"J?V5OW<87^]0-W,9'4(+!107A_K)N3T&W-9/F
M8(]_$.WHMIIG6F,U&V1^.,CHF;[O(Z(),BAUCB#BJU_W:R)(AS<O.>RR=0:Y
MP^#=6;;F<?>!O'RC?=!*$4;TQK'&:AGG@IN>V>'JZ-XV*AVE-?V<EQ(R6%E8
M[P(WEK.G;8E!:J+YED;%&Y\C@UH[DJ%2\1<2S4T>*\9I:X=9/0H)NB\H;,4]
M?QHGA\6V_,%"YN)V"9;LUF.EDFKG:0-'9!.46NQF9I9/&>_TI1)7V[C\%'SQ
M"Q,=]M6P)(2YW('N[;[H)>9&!_*7M#N^V_5&/8_?D<UVW?8[JK,_?L.XDP-K
MSDUGURX 'H>BU>@M>5<7-F8<G++*YL^X(&_*$%THM=2S5&YB?I*"=KJ@;SE_
MH/O48BXFX%]ML1?*V)SN5LQ;\)*"<+\<0UI+B !W)6FU%J7'8&JR:Y+OXG]V
MUO4O^2P,9K#$9NA<Y'OC\)A,C'#8@()/&]LC>:-P<WU!7THM3U'A<9IEN0\?
MEI[D-W.Y)]%^:>USB\Y<%.N9(K3F\S&2-VYAZH),9X@USO$9LWHX[]E^B:,\
MNTC/B[=>ZIS0>5:QNL9,[8>:<5P@'?ZHW*Q==:C9C-8:>LU[$@Q;X6EC1^L@
MO!%&]/:RQ6<O/IU9'-M-'-X;QL2/521 5=<9<\=/T,?;?,Z*$3#G(/ENK%5>
M<8<$_/T<?5\!TT)F'B #?8;H-18XJ<.[W))=DK3REHW,D <?ZD*0Z'UMI+,W
M'4M-N@;,=R6Q1!F_]%AQ<'='^&SFQ;-]ANMUIC0&G]-73:Q%)L,VQ',$$K1$
M0$1$!$1 7/GM2?I>GOXAOXKH-<^>U'^EZ>_B&H+VPGV13_=-_!9JPL)]D4_W
M3?P6:@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("
MJCB?IB]<R;LA79S0AHWV\E:ZU&JSM@['7;HL.1CC)28GT<W*P5SXIK?PKGAE
MI>]#E8\C.TLK\I /KT4LU#HRM9I6WUS,ZRX$M'-T)6UT4=\!!N=^I6\66'C4
MG%J>^V?'XF.F&*1'9ST[16<#W#W.3OZ*S--Z(KLQ5<W_ !FV1U< [;93G9$Q
M\*E)W/=3C_#<."9F.^_=\0QMAB9&S?E:-ANJ^XP8"?(TJ&2I1F6>A,)2P>;0
MK$1P#@0X @]P5V>'H*^/%#&NPCK3(I/? -A7(._,HW6PUJGPSU7?L0N;8RS'
M3>'Y@'?_ +JT_H'%>/XWN%;Q/7D'X+/DACDA,4D;71$;%A'39!0^+T2:?#G#
MYO LDBRU=OBR#S>-SN%NM99MVI] T+L<+A.)VMEC /0^:MV*&**$0QQM;$!L
M& =-EX,QE)D9C95A$9/,6AO3?UV01*32T^5K8RPV]+ &0MW8"M+Q+U=8P$5;
M 4 \VYV!KK!W^%I\U:+0&M :  .@ 6%>Q%"_()+E2&:0#8.<W<A!$.%U7"XV
MJ^MC[!LWW_'/*X=2?/KZ*%\5HM^(562Q6?-3;$/$#1W"N.AB:-![GU*T<3SW
M+1LO:>E6GD$DT$3W@;!SF@E!SOJNEB\MCZV-PCKDDLTHY823M'\U?^!HFC@J
M=*3J8H6QN_D.J^Z^'QU>P9X*4#)C^N&#=9R"N-9<,J6;R^*MP;L$$_B3 GZS
M>BG6*QE;%P>#386L]"LU$%1XZGOQTR+_ ';X#4Z/V\]EH\'GH=.P:LHY""06
M7N>6-V/Q=U>0JP-LFP(6"<C8R;=2/FL:QAL=9G,T]*O)*>[G,!)05-HYLDO!
M_)O\%S7/+BUI'4]5^R8V7\F-7*P0$Y"B[G8-NNRN"*E6BKF"."-L)[L#=A_1
M?3:T#8# V)@A(V+-NB"F-"8[)9_3V<SEJ-S;]B$QP[]]P#OLHIC,?B'X">#*
MB2.Z)2'1;=2=UTG7KQ5XA'!&R.,?JM&P6')A,9)8\=]&N9>_-R!!4.I,1CZF
M Q$%ELS'CK%._J&_-:?"R7'5M14'5F6V"+<6&,V#AU5_6Z-6Y"(K5>*6,=FN
M:" OBIC:=2%T5>M%&QPV<&M'7YH*FQ[FV."-F&M%RR,+FN8!U[K<</F28KA0
MZ:E3:VTUKW!O+U)Z*PH<?4A@?#%6B;$\[N8&]#_)>T4$4,/A11L;'VY0.B#F
M/4,S+FDIKER0ORKIOAA8".7JI/BZ+[V0T<;]7Q=A\0>-]OFKG.!Q1>YYQ]8N
M<=SO&%E-I5F.C+:\8,?U"&CX?D@K.*K[KQD9[K7$4+HOB+&[ ]%BZ9,=/B]E
MXYZ_(Z9Y\-^W?JK9]V@]X\?PF>-MMS[=5YNH576FV37C-@=I.7XOZH/6Q"R>
M%T4HW8X;$*NY>%N.?JN/(CF]W )+-_-60B#"%2*EBI(*[>6-L;@!_(JA= 9?
M#XR_JUF1KL?.YQ <6<Q)Z]/P70DS/$ADCWVYFEO]5#-*</J&%M9&>PR*TZV_
MG^-F^R"+\/XLCAN&V7MQ5GB61SGPQ.'8>NRKK4LC+&EJ]V60RY:2?K&P$<O5
M=0-BC;%X88T1[;<NW3;Y+ &!Q0>7?1];<G<_FQW05#C([4F9P,DL3^?W,\QV
M[=%@Z2S&'Q=/4\63HAUF20\O,S<NWW&P5[MI5FO:YL$8<T;-(:.@6))@<5)(
M9),?7<\G<DL'5!4^F,'DV<,<J6,D:V=QECB)Z\GF%@97.86UH"MBZN-'TD7!
M@C$?Q-=N>NZO=L;&1B-K&B,#8- Z;?)8+,)C&63890KB8_K<@05+D:TV#L::
MLZ@K/LUX8@V0D;AI\MUO;&8Q.9Q^9;AL?RRBNX.E:WEYNBL>W4KVXC%:ACEC
M/ZKV[A>53&TJD3HJU6&)CALX-:!O\T% 9&A;;I+!W7UWR4()QXT>W3OW(5E8
MC4. RNI*T.,QX-DPDMG:SEY!Z*<BE6%8U_ C\ __ (^4;?T7C1Q5"@XNIU(8
M7'S:W8H*$95L?V8UNUT#]S>) V[C<KSSTD>/NZ+L9*H9:S*[0X.;N&E=!_1]
M3DE9[M%RRGF>.4?$?O7G:Q-"TQC+-."1K!LT.8#RC[D%7XZ2MG>*-6[@ZWAU
MX8=I)FMY0>_16ZL6CCZE!I;3KQ0@]^1NVZRD!$1 1$0$1$!$1 1$0%SY[4?Z
M7I[^(:N@USY[4?Z7I[^(:@O;"?9%/]TW\%FK"PGV13_=-_!9J B(@(B("(B
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MU9HU\TFEL8^US>,81S<W=!N41$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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MNO'\X'=MO12Q$%<NX0:<=FY+YC?R/?SF#?X-U8<$4<$3(H6AD;1LUH[ +[1
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DB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g184865g09g02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g09g02.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[2)^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP"   "   < E  "')R.#,Q,# R' (% #--:6-R;W-O
M9G0@5V]R9" M($]+55(@+2!"=7-I;F5S<R!396-T:6]N(%)I9&5R+F1O8W@X
M0DE-!"4      ! %I?*S\&<?]]JX5I3:P\AB.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -S    !@             ":    LX    ? $\
M2P!5 %( (  M "  0@!U ', :0!N &4 <P!S "  4P!E &, = !I &\ ;@ @
M %( :0!D &4 <@ M #,    !                          $
M     LX   )H                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   )H     %)G:'1L;VYG   "S@    9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   ":     !2
M9VAT;&]N9P   LX    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     <X0DE-! P     %[L    !    H    (D   '@  $ X
M%Y\ &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( (D
MH ,!(@ "$0$#$0'_W0 $  K_Q $_   !!0$! 0$! 0         #  $"! 4&
M!P@)"@L!  $% 0$! 0$!          $  @,$!08'" D*"Q   00! P($ @4'
M!@@% PPS 0 "$0,$(1(Q!4%181,B<8$R!A21H;%"(R054L%B,S1R@M%#!R62
M4_#A\6-S-1:BLH,F1)-49$7"HW0V%])5XF7RLX3#TW7C\T8GE*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8W1U=G=X>7I[?'U^?W$0 " @$"! 0#! 4&!P<&
M!34!  (1 R$Q$@1!46%Q(A,%,H&1%*&Q0B/!4M'P,R1BX7*"DD-3%6-S-/$E
M!A:BLH,')C7"TD235*,79$55-G1EXO*SA,/3=>/S1I2DA;25Q-3D]*6UQ=7E
M]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$  A$#$0 _ /55SWUKZIEX
M%G3JF9/[-P<J]S,WJFUCO0 ;OIK_ %AME%7VNS]#]HOK]*E="F(!$'4%)3YW
M;];?K*W&QCCO=E,L;G@9C:ZQZF/COQ&T]<^R.#'6>C3=D[,2A];,NQG^B6UT
MCKV?;U3J./6^SJN'0, 8UK10PLKOQ_7NZA<\_9&VUVO_ $K_ $_^L4KJD@ !
M $ =@DIX#!^LG4LC%OR,;K7VZC&SL&EE@KQQ=:RVYN'G^IBUU[L?!N]3]0>_
M];_1_P [Z2O_ %3ZWU_+Z]E8'4,BG-HJH?9=;C&NRJJ\7NJIHHMQF,].N[&W
M?JV<^_._5_4>NP#6C@#7^"0 '"2G&Z1G?6/+LZE7U#"IPO0M+,&S>^QKOT=;
MVD@UT>M3ZC_Y^MU?_<?T_P!!ZBXS ^N_5ND= JNS+:\G(S,%_4*+LHV'U<AV
M2,=V'3[FMV4X[O5^SX^STO\ B%Z:F@<0DIX9GUKZWB6W8[ S+=FY^9A=/=:'
MD,R:\MM%%%YJ_P"T;,&QV3_I?U2_])_-I'Z]]6=9U0,HQ*FX@>*FY%K:GTEF
M17A5_;VV9#?Z2RWUZOZ'7_@/6_2_:5W,)0#.G/*2GS^SZ]=6JKOSVW8MM'[+
MJR\7'=5947VF^S$R'LWV.L]*O9NM_26_HOLSZ/\ "76W<SZY=5PNL.Z9:,6U
M]5%@O#&O8YM]>(_J>]K;+C;;B/\ 2]/^CL_\->I^B79P/!*!,QKXI*?/[OKE
M]8SB4/LLPL1WJ]-NMR0QYI;C=0;=^CRO6=^B]&VC])D>LSV6_P"!74]6SNOX
M_5.G4=.PJ\G"R'EN7>Y[FE@#+'Z[:K&U,]K',M=_/6?JOZ+U/66O \/).DIX
MWZX==ZI0.L8M#F4XF#T^K(=;6Y]>3ZEUEM-8IN8=E5;/0W6/V>I^9_A-]5#'
M^NW5L/.ZG0?3ZH*<GJ09B,+OM53,8.NQ[+=K?2^P.V_9?]+O?^BLOL]3'7H$
M!))3P;_KYU5N(/?T_P#GWU?M@^K^SCLQVYS:6[7.O^T/<[[-_.?SE7L]2[]6
M37?6WJ&!9FAEM%+;,_(_6>HV7/HK%.-A7LP:/18U['Y3K['XS/\ @K_U>^]_
MHKO8$1&B4#P\TE/G'4^O=7JHZK<S-N;9BNZL*'!P 8VG(Z770WT]OIV>C7D7
M,JL>SU*V6V+K/JMUS)ZQ5EF_T+?LM_I5YF)N./<TL9;-/JES]U/J>A=_PC%M
MP$DE/__0]522224UZL['MS<C!;N%^*VM]H<US1MMW^D^NQPV6M_0VL_1_GUJ
MPLK&(/UGZC!F,+"GR_2=26JDI2'=?1CL]2^QE3)#=[W!HDG:UNYW[R(@9N#B
MYU'V?+K]6DN:\L)(&YA%E;O:6_0L:U_]=)33R?K'T;%<1=D@-#/5]1H<]FT6
MMPS^EJ#V;_M5E='I?SJDSZP=*=FG!]4MR&V>BYKF/#18=VROU=OH[K=C_2_2
M?I%!_P!6>A65>E9AUV5P]NU\NTLL^TV_3<?IY ];_C$9O1.E-RF98QFB^MSG
MM=K&YS[;W6;)]/U/6R<BS?M]GK6)*;R2222E))))*4DDDDI22222E))))*4D
MDDDI_]'U5)5+.IXE>6,-WJ>J2&R*;75@N&YK7Y+*W8[/[=J.<G';NFU@VDAT
MN&A WN#OZK/>DISL5K1]9^HD  NP\(N(')]3J(]RU5EXW_BFZ@?'"PH_[=ZD
MM1)2DDDDE*20W7T,M90^QC;K03767 .<&_3V,^D_9^<@8.=]KMRZ]K6_9+C1
M+; \F&LMEX9_,N_2_P T_P!Z2FVDDDDI22H5=;P;>K6](9ZOVNFMMKYJL#-K
MBYH_3.9Z7YG[W_%H-GUCP:G%CVO]42/3:W>XN86MR&>S<UOH[V?3=^D_P22G
M5267;]8^EU,=8ZPNK81O>UKB '-=97IMW/W^WVU_Z12LZ]A4W6,N/IU5N:P6
M'DN>UM_\T/TC:_2?_.N24Z22RQ]8^FGO8!L;8'%CA(=ZGMCZ37-]'\__ $E2
MO8F57ET"^J?3<7!I/<-<ZO=_:VI*3))))*4DDDDI_]+M7,MP?K5C8^$S'HP\
MVNV_- -8NNN][FO]-[_M%FS]^FK_ (Q-?]1/J_?=D7V5V>IE6V76$/(]]H_2
M;1_7_2_^H?T2CFMQ_P#GEA.?=0W--+OLU9%WJ&D!WVAOM=]D<[=ZGIV.]/\
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M^<24A=A=>-3W-SF5Y%C2"0S<QI!=Z7I-L]K?:=MGZ-)N!UL76V'/#@Z14TL
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M $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4
M( !0 &@ ;P!T &\ <P!H &\ <  @ #( ,  R #$    ! #A"24T$(@     !
M1DU- "H    (  @!$@ #     0 !   !&@ %     0   &X!&P %     0
M '8!*  #     0 "   !,0 "    'P   'X!,@ "    %    )T!.P "
M"0   +&':0 $     0   +P   #H   !+     $   $L     4%D;V)E(%!H
M;W1O<VAO<" R,BXP("A7:6YD;W=S*0 R,#(U.C S.C$T(# V.C0Q.C0R ')R
M.#,Q,# R      .@ 0 #     ?__  "@ @ $     0   LZ@ P $     0
M F@         !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !
M/@$H  ,    !  (   (!  0    !   !1@("  0    !              !(
M     0   $@    !.$))30/]       (          #_X0%.17AI9@  34T
M*@    @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H
M  ,    !  (   $Q  (    ?    ?@$R  (    4    G0$[  (    )
ML8=I  0    !    O    .@   $L     0   2P    !061O8F4@4&AO=&]S
M:&]P(#(R+C @*%=I;F1O=W,I #(P,C4Z,#,Z,30@,#8Z-#$Z-#( <G(X,S$P
M,#(      Z !  ,    !__\  * "  0    !   "SJ #  0    !   ":
M       & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@
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M59&2P>$C,U*!L1=B8W*A)#1#T24G-4535'2R\28V9(+PHO_$ !D! 0 # 0$
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MX(W"Y4X1:-T-?@Q5FWEQ]N.=S&#FZ;@]!W70>5UUIW!Y%F,O9"**R-FAA(_
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MJ#(U*51PHCF8-F;].O54_HW4&?Q&H;-W"Q%]^1Q,@#=]CO\ ^:[QRE6.:A:
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MI^KXEM_-*[Y(FGXG%!'.-.KY='Z0EMU6<T\I\-I]-QW7+.@-99JQJ-E$VYO
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M>;X&CR5S\&]O]G&%V[>%_-1;VFR1P]=L?_$4HX,_=OA/ROYH)HB(@(B("(B
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M+P(';<O3:3;S.RM2/"9[-,$F7O.@IO&[J[/3T_<JQSN-P%;4]9M2K==08=K
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M_=R@R$E9A<6.)Z- W.RS<?!2N2/4O#JUK1$S5K^#.J<5C))8+M2-MG8N9/S
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M5642Y1^XDYN[1OV"_.(5"OE3#)DO%>UO;<= OGAM@:U>]++B7OC<!U]"O/\
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M.PPC/N[AL7?K$^JU>F^'=#!Y 6V6[-AS1LQLAZ-""O\ %9B]'IG4SXK+V/\
M>"T2 ]6#=2S3&F<;3BQN1ARQ%N2,/?\ 'OXA(W/G]5):&C<93IY"LUKGQ77%
MT@=ZGT6GP7#/'8G*17&W+4PB)+(GGX0@C%*9T=75DD3RQXWV</Q6)J2!N5JZ
M7@LV_!$CAS2$]U9S=)X]L>08.?EN_P!Y]%@:AT#C<UC:=.66:(5?[M[#U013
M"L9@.),.,Q5MTE.9@,D8.X!]2K:44TCH;':;L268I);-I_3Q9>X"E:)$1$!$
M1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 6LU-6EMZ>R->OUED@>
MUH]3L5LU3&NM4:[TYJB66I1%S#;DM:QNYV05E7R[L-B[N#NZ)\?(.<6B4Q$E
MV_GV5]\&\7<Q>C867XC!)([Q!"1MR#T44P/&'"WY&?;F'GI6@=C))&-M_P#-
M6UC,A6R51EFE*V6%W9S2@RD1$!$1 1$05%[3GW>N_,4IX-?=MA/R?YJ&^TUD
M*9T2^I[S'[R'[^'S=5,N#7W;X3\G^:":(B("T6N,R=/Z5R&3$(F=!'S!A[$K
M>J(\5,Q1Q&CKSL@SQ62LY&Q^;B@XX9K&YDM9NNV&-#+4P$D3>W*3V7;6/NT\
M;IFG.X-@@$+2UG;R[+DO0%71\.KYK.;=+X#=I8(A_CW[+I;$59=42PW;+'18
MF+;P(3TWV[$JR*3[V\0LICWYM[*VU%I'-:DRUC)4Z!9#*[X1VZ>JMCAQA9,'
MI]E:Q"V*;N[;N2O'(ZO@Q]DUHXOACZ +[_3*N^HZ1H >!VWZK)?XSAR?RNWL
MUYHR3CW:(BOYI7)(R-I<]P:!ZJA.)NL8*FII(A!)*P-Z.'8J9V<E?RI<]K_!
MKCN]_0*B->VA8U!.R.7Q(8OA:X=CZE1P\%/BV7TLM-TCS/F8_+V>=;/.*.V/
M]=?X6/I/4$N3QLTCY12J-ZDR.V)'T6EU9CK6I:CI,17FDK5=W.GEZ>)^"R>"
M6G6:DDL'*&1].IREC/U7'?L5<FJM.07\$S'UGNIP-/00].GHMF/A\7X9F[5C
MS'M[SJ/\RYBOKQNT[F?O_P <^\)M*R9_4L#Y0SW.L\.E#OUMO)=1U*D%2(1U
MH61L VV:W95KH?A]%@LQ':CNSDM._(#T=^*M!6\GF5Y=NU)G7XQIU7#.'Y9:
MG4N(K9K&NK7(&SQGKRE0_ \/,9C\DRR,;&'L.[7>BGN0L.K5G2L9SD>2TF)U
M,W(V_!CBZ@[%9XIFGS2\Q$?2/9;6U8B8FL3M(CLR,[#HT=@JSU!=N3ZDJV(L
M7*8H#L[9AV>K.19\^'UHB-L^2DWC43I'9,-3SE-EB6L:M@CH6C8A:[W#.8-Q
M=3G-VL.I:\]0%,T\E,X*SYCQ/W@G#$^?K]U+ZNUE%=R-8"KX9@(\3F[D[JU<
M#EZ64H135)6$$ <N_4'T5?\ $/3-5V:K6(N6,3N D:%(8]$0UH6G&6I8'@#;
M8]-UCP^M7);QO[L''_B*Y;]M3#+UMC[<]-UJG?EK&%I):T[ K%T#1N&HR];R
M,TXD!'(X[CNHMK>SJ3$8\P6)?%JR@M+V]5X\-=6OHQFE>;(ZKONUX'RE1ZU/
M7W:)C_J)Y...3%;1,3I<"\YFQ.;M,&$?[R\*>1J7!_V:=CSZ ]5K]68XWL9*
M]EA\+XHW.!;YG9;[6^69CR].;ZCM7RVL4==KO[(1AW^[LO20.,;N3YMNB@O#
MC'320"_9MRR.W+0PGHIO:G;6KR3/!+6#<[+G#?OC[3&MN<66<E>]H:9N,NB]
M[QXW<]EO6;AHYNI\U%&Z[Q9G$/+-SD\NVP4I@E;-"R1F_*X;C=<<>N*N_3G:
MZ>5&?VF/#[(!!![%83L74<\O,0+M]]UFHKK4K?\ JC96]J_TR_&,:QH:T; +
M]18=YMMSV^ZN:&[==TM;I7<05CM.MLB>Q% -YI&L'U*^V/;(T.8X.:>Q"JOB
M39S=1\7APNG83^J-UOM$.S,^&9),/#)[-=TV66.3EWVFGRS[??\ O#T;_#XK
M@C-WCRFZ$[#JO&H)A%M8(+_HH]Q*EL0Z.R#J<IBGY-FO'<+96=QMYLQJ=-W?
MFF=5?]G.B?.#T#G=%'LEJB;'ZCQV+GBCVG8#))OT:5#:V-N8+AQ'?&3L2W9F
M@N>X]MSY+PU3CYL]F=-57671/FKMYY0?B/U4H7)%(R5O-&]KV^K3NOR6:*+;
MQ9&,W[<QV58Z*JVM,Z\M8(9&6Y3? )0)#N6E:R/%W=;:NRK+F6EKP5.D<<1V
MVV*"Y 01N#T7FR:*1SFQR,<YO<!P)"I['ZNR;] 9=C92+-28UF6'>8WVW6YT
MQH^QCFT<O%G9GS6(Q)*R5WPN);OT03K#NR3C/]IMA: [^S\,[]/JLYDT3WEK
M)&.<.X#@2%2F&U#E(-,ZBF;;>Z=LY8Q[S\@W\E(M,Z-L8X4<O'G9GS31B25D
MC_A=S-WV"#?8+4US,6\M4A@C9+5.T9)Z'KYK]S6IK.)R.*J6(8BZR[:1^_1J
MA>.GE@JZKFKR&.8#H\>NZQM35I\U6TQ7?9<R65P#I2>J(71%+'*-XWM>/5IW
M7VJFT[5MZ3XA1XB+)2VZ=E@<62G<M)5GY2>6M0FFKQF65C=VM'FB65N-]M^J
M\K4[*U:6>4@,C:7$GZ*@G\0-5#7+FC'R[;!O@<O397)G(#E](V8[)?7=+ 2[
ME[M.R#5:#U'D=16;T\T5=F.C<61%IW<>OFID7 ;;D=526E,;]A<-\G;IW9C*
MZ4C<GY=B>RV&K\E>AP.EGQW'L?*\<[@>KD$VS&I):.K,;BFPM=':^9Y/4*4
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M/QK0QH:T  =@%^HB@$1$!$1!BSXVE/.)IZD$DH[/<P$_O65L-MMAMVV1$
M; ;!?(B8T$!C0#UV 7TB O*2M!*29(8WD^;F@KU1!\0PQPMVBC8P>C1LOHL:
M226C<]-]E^H@^(XHX@1&QK >IY1LOM$0$\D1!^-:UHV: !Z!?AC8YO*6M+?0
MCHOI$'S'%'$"(V-8#_A&R21,E;M(QKQZ.&Z^D0    !L OAL,;9"]L; \]W
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M$!:^IA<;4R$UZM2ABN3?WDK6[.=^*V"(-1-IK#39$7I<;6=;!W\0L&^_JMN
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MY+4KOBA@?R!SOUE,5$>%>GAIS1E"H]@%@MYY3ML23UZJ7("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B M/<TSB+N49D+=*.6VP[M>[KL41!N!T'1$1 1$0$1$!$1 1$0$1
M$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1
0$!$1 1$0$1$!$1 1$0?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g184865g10g40.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g10g40.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[1\X4&AO=&]S:&]P(#,N,  X0DE-! 0
M     %0< 5H  QLE1QP"   "   < E  "')R.#,Q,# R' (% #--:6-R;W-O
M9G0@5V]R9" M($]+55(@+2!"=7-I;F5S<R!396-T:6]N(%)I9&5R+F1O8W@X
M0DE-!"4      ! %I?*S\&<?]]JX5I3:P\AB.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !+
M  $  0$L     0 !.$))300F       .             #^    X0DE-! T
M      0   !:.$))3009       $    'CA"24T#\P      "0
M 0 X0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF
M9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       !
M #4    ! "T    &       !.$))30/X      !P  #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@  #A"24T$"       $     $   )    "0      X0DE-!!X
M  0     .$))300:      -!    !@             #.P  !MT    & &<
M,0 P &< -  P     0                         !              ;=
M   #.P                     !                         !     !
M        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M!     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M   #.P    !29VAT;&]N9P  !MT    &<VQI8V5S5FQ,<P    %/8FIC
M 0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)
M1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U
M=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   SL     4F=H=&QO
M;F<   ;=     W5R;%1%6%0    !        ;G5L;%1%6%0    !
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M300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M  0    $.$))300,     !2H     0   )\   !+   !X   C*   !2, !@
M ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,
M"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,
M# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,
M# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !+ )\# 2(
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M_OPW,W?G>H]N_P#J(O[2MH>ZO+HR66;/5%5N7C-<&!VQ[FM9D5.V[7;][_\
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M]'_"_P"C0O\ G1>"?U>HB1KNR9 AD[A^SOI>HYS-BL#.ZL6[O6I$D@-./[C
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M[[+^C_I6SM/VCU/\)_U[Z7[WYG_!I-^S>M5M]?AFSU/7W1N_POJ?G?2_GO\
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M '     4 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P "  ,@ P #(
M,0    $ .$))300B      %&34T *@    @ " $2  ,    !  $   $:  4
M   !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    ?    ?@$R
M  (    4    G0$[  (    )    L8=I  0    !    O    .@   $L
M 0   2P    !061O8F4@4&AO=&]S:&]P(#(R+C @*%=I;F1O=W,I #(P,C4Z
M,#,Z,30@,#8Z-30Z-#( <G(X,S$P,#(      Z !  ,    !__\  * "  0
M   !   &W: #  0    !   #.P         & 0,  P    $ !@   1H !0
M  $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @(
M!     $              $@    !    2     $X0DE- _T       @
M     /_A 4Y%>&EF  !-30 J    "  ( 1(  P    $  0   1H !0    $
M  !N 1L !0    $   !V 2@  P    $  @   3$  @   !\   !^ 3(  @
M !0   "= 3L  @    D   "QAVD !     $   "\    Z    2P    !   !
M+     %!9&]B92!0:&]T;W-H;W @,C(N," H5VEN9&]W<RD ,C R-3HP,SHQ
M-" P-CHU-#HT,@!R<C@S,3 P,@     #H $  P    '__P  H ( !     $
M  ;=H , !     $   ,[          8! P #     0 &   !&@ %     0
M 38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
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M*"@H*"@H*"@H*"@H*"@H*"@H*/_  !$( SL&W0,!(@ "$0$#$0'_Q  <  $
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M98X8G23/;'&T9<YQP .TE?I<P;<]H,][O$UFM=0YMII7;C]QQ'3R \2>T \
M/)E;^'T,M?+;##/.,(M:M]VTZ4M=0^"*6IKI&'=<:>+O0?ZSB,_)E:CV_M/>
M#KE\S/O+F=%Z\>':,1SMS3KY.F/;^T]X.N7S,^\GM_:>\'7+YF?>7,Z*_P ?
MH_">?FZ8]O[3W@ZY?,S[R>W]I[P=<OF9]Y<SHG\?H_!Y^;IEFWW3I< ^@N;1
MV[K#C_[E.-(Z\T_JO++16YJ ,F"5I8\?(>?R$KBY?6EJ)J2=D]-*^*9A#FO8
MXM(/:"%AGX=I3'^/*5C7RCJ[T15[L8UP[6&GGMKG,%THR(Y@/_F-QWK_ )>.
M?*/*K"7C:FG.GE..76'7C,91<"(BP41$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M-YN>HXZT'T1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!:G5L[J72MYJ(R
M0^*CF>TCJ(8XK;+2:Y_ J_\ Q"?^&Y98=T)/1Q$>96$/-%]6\X1$0$1$!$1
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MJY\>1&00?(NC%Y*VV4-<6FMHZ>H+>72QAV/G""A=&BLVD[;VZSIJ&II=.6Z
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M*:GBCBE%?N!S&@'=$D.!\ _S7ANU;3: ]4%>;_K"EF=:+C3AM'6]"7MC=AG
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M:YBFN]4ZKO<H=73PD,D@D:<[@X'RG/7O*.Z+V/U$NT34U/5UU]I*&C?$ZFK
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M5F/??+)(9*9V]N$OWFN:2.8^!!#-!;#]*WC9E27*N=4RW.MI>G[H;,0(G$'
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M1/=S<R, GYEZ' .:0X @\""HO8=>Z=OMP%#;Z]QJG NC9/3R0]*!UL+V@/\
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M4P&V4UXBEKZBGI>F9AAPZ0LQB4-)83S'>^163<[3;KK&UESH:6L8TY#9XFO
M/RA?>"EIZ>F;3P011P-&!&QH#0.S""I)^Y[W6V."KVC6JO>ZKBGI(::WQ&4O
M:X.&Z6N)9D#!/#@2"MMI6ZVFPZQU?3:AJZ:BNU57=TQRU;Q'T]*6-$>XYV X
M-PX8!X'*G5#8K3;ZF2HH;914T\G%\D4#6N=\) 7[N=HMUU:UMSH*6K:TY:)X
MFOP?)D((!LWK[5<]I&MZNP]&ZCDCH_Y6)N&2O#9 Y[>T9&,]9!4CV@2Z8=04
MU%K"6&"GJ7_R$LN6".1O'(D_^6[L.0I%34-+2R/DIJ:&%[VM8YS&!I(;G ..
MH9./A7ZJZ6GK('0U<$4\3AAS)&AP(^ H*KHZUEBU/9*'2>J)]00UDYCJ;=-4
MBKZ"#=),PD&7,#3NC!)!WL+[;*[Q9].V*X6S45=1VZ^0UU1+7-K)6Q/E+I'%
MLH+B-YI9NX([,=2L2UV6UVG>]:[=1T>][[H(6LS\P2Y6.U7.5DERMM'5R,]Z
MZ>%KR/@)""F1$\:(O=9#&Z*TUVJ(*FW C =":F'OVCJ:YP<0/+GK4W9D[;:U
MK' /.GFX\G\NIQ-1TT\#8)J>*2%I:YK',!:"TY! \A (612TXK#5B"+NHLZ,
MS;HWRW.=W//&>.$%8;*M0:>L.AF6Z]5]%;;G1.D%P@K)!'*9=XESR'<7;W,'
MCD$+U;!9*673]]DM\?14;KU5.ACW=W<87 M&.KAC@IW5V2UUE7'55=MHYZF/
MWDLD+7/;\!(RO52TE/2"04L$4(D>9'B-@;O./-QQS)[4$7VN_BSU+\1E^R5]
M+S1SW#9A5T=&SI*BHM)BC8/RG&+ "DU33PU5/)!4Q,FAD!:^.1H<UP/40>:_
M;&M8QK&-#6M&  , !!5)UGI]NQKH/76E-8+/W(:02 S],(=PQ]'[[>WN')>*
MY4\-1H+9+#4M;)&:^@):>()%/(1^T*T?8_9^[)*OUJH>ZI,A\O0-WW9X')QE
M>HV^C,5-$:6 Q4Q#H&=&,1$# +1U8!(X((1M3H:2IN6B34T\4A]?(F=^T'@8
MY#CX,@</(OSM/8R+4.@9V!K9FWIL37C@0UT;PYOP$!3V>F@J'1.GACE,+Q)&
M7M!W' $;P[#Q/'RK%124]2Z%U1!%*Z%_21E[02QWYPSR/'F@KO2%UM%@U%JR
MDU#64M#=Y[E)5!]6\1F>F<!T1:YV YK1WN >!!43U*^GK=$[5+G:6@6*L$0I
MY&#=9-(UH;-(SM!.!O#F0>:NBZ6>VW5K6W.WTE8&G+1/$U^/@R%]9*"DEH31
M24L#J,MW3 6 L([-WEA!$=845E;H:@I[I<([/2Q&G--4X&[#*PAT9(/#&6C@
M>"U^G=55WLQM]EENMDU!3U44K^Z;>T-EI]P AT@:]S=TYQU<<*PIZ:"> P3P
MQR0D;IC>T%I'9A>6UV6UVHO-KMU)1E_OC!"UF]\. @]Z(B B(@(B("(B B(@
M(B("(B B(@(B("(B B(@(B("(B B(@(B("@VW+\4NJ/BA^T%.5#-L]-)5[*]
M3Q0-+I.XGN '6&]\?V H(1ZDG\6%1_>,OV(U=2HCU(=SII=#W&VMD;W7!6.F
M>S/'<>UH!Q\+2KW0%X[Q;*2\6VHM]QB$U).W<D83C>"]B(-)J'2EEU!!%'=K
M?#.8ANQRXW9(QV->.^'R%?C3&D;)IGIG6>B9%++PDF>2^1P["]V7$>3*WR((
MQJ+0>G=05HK+G;F.JL .FB<8G2#L>6X+AY#E;ZVT%);*&*CM]-%34L3=UD43
M UK1\ 7I1!$:G9QI6INAKY;1 9G/Z1[!D1/=G.\Z,=Z3GK(4M8UK&AK&AK0,
M  8 "RB#7OLU"^_17ET -QCIW4K9<GA&7!Q;CES 7ZJK31U5UHKC/"'5E$U[
M8),GO \ .^? 7N1!X:^TT5?6T%75PB2>AD=)3NR>\<6EI/S%1/7$554W1D-=
MHJEU#9@P%LH?&Z>-_'(W) !CER*G2(*YT98*J;5,5WJ+!!IZVT%*ZFH:)CF%
M[W2.!?(\,X-X-: ./6<JQD1 1$08?[QWP+E?U(_X;:A^+'^(%T_=:V"W6VJK
M*R1L5/!$Z21[C@  $E<S>I!II9=1ZBKFL/<XA$9=CAO.?D#Y@4'4:(B H]0_
MTA'_ %S_ )J0J/4/](1_US_FN?7[L4E(41%T*+2:Y_ J_P#Q"?\ AN6[6DUS
M^!5_^(3_ ,-RRP[H2>CB$\T0\T7U;SA2O2&O[]I*AGI+)/#'#-)TKP^(/.]@
M#K\@"BBRUI>X-8"YQ. !S)6&>&.<5E%PL3,<X61[=6L_URE\V:L.VTZR<TM-
M92X(Q_NS5 [E:Z^UR,CN=%4T;WC>8V>,L+AVC*]5BTW>+\VH=:+?/5,IV[TK
MV#@SAGB>WAR6GR-"(O;%,M^?2VI[?*B!%TL!='>I<_!^]?&6?97.*Z.]2Y^#
M]Z^,L^RN+C_8G\-NCWKK1$7S[M$1$!$1 1$0$1$&NO%BM=Y=3.NUOI:PTS^D
MA,\37]&[AQ;D<#P"V*(@UM58;557BGNM3;J66Y4[=R&I?$TR1MX\ [&0.^/S
ME>"JT1I>KK>ZZG3UIEJ<[W2/I(RXGMSA2%$&MNMAM5VMS*"YVZDJJ%A#FP2P
MM<QI (!#2,# )7VK;70UUL=;JVCIZBA<P,=3RQAS"T<ANGAPP%[$0:-FDM/L
MIJ.G%EMW04;R^F8:=F(23DEHQPX\>"]]#:;=05-344-#2T\]2[?FDBB:UTA[
M7$#BO:B B(@(B("(B M=1V*UT5UJKG26^EAN%4,3U#(FMDD'#WS@,GD.:V*(
M-;;;%:K96557;[?2TU55'>GEBB:UTISG+B!Q^5+78;5:9JR6V6ZDI9:QV_4.
MAB:PRNXG+L#B>)Y]JV2(([[!]+=-4S>QVT]+4M+97=R1Y>#S!X=:V(L=J%F%
MI];J0VP-W12F%IBQG.-W&.:V*(-+!I2P4]IEM<-EMS+=*=Z2F;3,$;SVEN,$
M\!Q7QI=$Z8I)*22ET_:H9*5_20/CI6-=&[.<@@<#D!2!$&IO6F[)?'Q/O-IH
M*Y\7O'5$#9"WX"05^J?3UHIKJ;G3VRCBN!8(NZ&0M#]P# ;O 9Q@ 86T1!I+
MQI/3]ZJ6U%VLEMK*AO*2>F8]WSD97JN-BM5RM8MM?;J2HMXP1320M=&,<N]Q
MC@MBB#75]BM=PM3+976^EJ+>P-:VGEB:Z,!OO0&D8X8"]M+!%2TT5/31LB@B
M8&,8P8:UH&  .H87T1 1$0$1$!$1 1$0$1$!$1 1$0$1$!<L:YU_M#K]K%WT
MYI&J>3!,Z*"FA:P9:QN2<NZ^9YKJ=<N:0_XM[G\8J?X10?/?V^_H*WZ4'I3?
MV^_H*WZ4'I74Z(.6-_;[^@K?I0>E-_;[^@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]
MOOZ"M^E!Z5U.B#EC?V^_H*WZ4'I3?V^_H*WZ4'I74Z(.6-_;[^@K?I0>E-_;
M[^@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]OOZ"M^E!Z5U.B#EC?V^_H*WZ4'I3?V^
M_H*WZ4'I74Z(.6-_;[^@K?I0>E-_;[^@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]OO
MZ"M^E!Z5U.B#EC?V^_H*WZ4'I3?V^_H*WZ4'I74Z(.6-_;[^@K?I0>E-_;[^
M@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]OOZ"M^E!Z5U.B#EC?V^_H*WZ4'I3?V^_H
M*WZ4'I74Z(.6-_;[^@K?I0>E-_;[^@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]OOZ"
MM^E!Z5U.B#EC?V^_H*WZ4'I3?V^_H*WZ4'I74Z(.6-_;[^@K?I0>E-_;[^@K
M?I0>E=3H@Y8W]OOZ"M^E!Z4W]OOZ"M^E!Z5U.B#EC?V^_H*WZ4'I3?V^_H*W
MZ4'I74Z(.6-_;[^@K?I0>E-_;[^@K?I0>E=3H@Y8W]OOZ"M^E!Z4W]OOZ"M^
ME!Z5U.B#EC?V^_H*WZ4'I3?V^_H*WZ4'I74Z(./=4ZPVQ:1IZ>JU%45-%#-)
MN1ND$3@YP&<=[GJ75VE:Z6YZ8L]?4[O3U5'#/)NC WG,#CCY2J2]6-^"E@^.
MN^P5<>S_ / 33?\ =M-_":@WR(B#5:M_!6]?$IOL.7#AYE=QZM_!6]?$IOL.
M7#AYE>QX7VY.7B.L,(B+U7.(B("(B B(@LKU//XRZ/\ L9OL%=7KE#U//XRZ
M/^QF^P5U>O"\2]W\?MU\/VB(B\]O$1$!$7XFX0R?U2@_:*G-F&@-/7S0]NNE
MTIII:Z<RNDF-3("2)7@'@>' !>.:XU4FQW7U*VY3U]-;)YJ6CKW2ESWQ@,.-
M_P#*+22W>SQP@N]% M8Z>L59IQE[O5MJ;A/1T+=V.!TA>_AD-#6GB22M3L)I
M+1#;+E4454/7:H<UU;0!T@[AY[D89)WPX9RX^^.2@M-%2VBM9&WZ#T[8K;40
MS:IN9E;2QU#\B-O2OS+(3U  X'-Q&!Y)/?)8]E^SJZW&*62X7(_RCYZEQ)J*
MEY#0X]C<GWHY 8\J"PEYYZRG@J::GFE:R:I<6Q,/-Y#2XX^0$JJ-5W/4FAM'
M4FIIKG4W2LF+(ZZDE#1$UTC< Q #O=UY;PXY!.5M&6R]TL6AJ:NNCY;UTLKY
MZJ>+I=UY@D+F[H(X#.Z.*"=7.]V^V&1M;4=&Z.(3.:&.<0S>W=[ !.,\%YZK
M5%FI;727&:N8*2K = ]K7.,@(SEK0,GAY%'Z6GN$.O*OURK(JQQLQW'QT_1!
MO\J>![YV5'=$U,5E&G+E>Y&T]M?88Z>&>889'*';SFD_DES0WLSN^1!:E'5T
M]921U5+-'-3R-WFR,=EI'PK5UNJK-14-)5U%:!3U;BR!S8WOZ0C.<  D\ 3E
M0.FIKQ66">GM=KGELMSN51428F$$G<Q((:T.Y"1V\<_FD]JW&E[O)-9KI7WV
MT,I([)43MI.##T;&;S=QH;R(:-W/7E!O8];:??15-6+@!!3R,BE+HI YKW^]
M;NEN<G(ZE[K)?[9>^E%MJFROBQOL+7,>W/(EK@#CRX4#O%#7T>B+;4ST[7WJ
MMO%+6SQ/<6@2/F:1&3@X#6[K>OWJVMF[MK-HKJB^006ZKI:!T=-3P/,@J8WN
M:7/+\#.ZYH&[CAO9ZT$[10W56JKE;=56^Q6BUQUM174LDT;Y)3&V-S7-&7G!
M[W!ZN). M._6FJZ:[#3U5IVCEU!-'T]-)!5.[E=%G#G/);O-W>'#CG(Y(+*1
M0[3&IKH_4DNG=4T-+2W7N?NRGDHY'/AGBWMUV-X AS21D>4%;'1-^EU#8WUT
M\+(7MJ9X-UA)&(Y7,!X]H;E!($56ZJU5?J[9A>[K9HZ6EJ:6HJZ=[S(]I9'$
M][-]A'Y?>@]BDMFK]6,TS-57&VVVKN(:PTT%+4N8V5IQDO>\<#Q)Y'D@EJ*O
M:76-]MU]M=%JB@M+::YS]S02V^J=(Z*7!(:]KAQ!QC(Y%:F.[:W=M7O-OHQ:
M9*6*EAD;#--*&-B+W@/  _G"!QZN 06D*NG-8ZD%1$:IK!(8=\;X:3C>W>>,
M]:^RB+KQ2T^T6OI)Z*CAZ&U,JI+@6@2EO2.&X3CWHQGFM12ZKUC=J/UXL>G+
M?)979DIXZFK='4U,74]HW=UN\.(!R@L5%7]TVBAM@TU=;-;I*T7BK-&VG>>C
MD9)NR=Z>H$/9@D\ADKZTNIM2VV_VVBU9:;=#17*4T\%715+GB.7=<YL;VN )
MR&GB.""=HB("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B
M("_$T3)H9(I6AT;VEKFGD0>87[1!S%JS8YJS1^II[[LPJ#W.\DM@9*&2Q-/$
MM[[ <W/R_#S7D]D>WD<.YZGA_P#L=/Z%U0B#E?V2;>?U:I\SI_0GLDV\_JU3
MYG3^A=4(@Y7]DFWG]6J?,Z?T)[)-O/ZM4^9T_H75"(.5_9)MY_5JGS.G]">R
M3;S^K5/F=/Z%U0B#E?V2;>?U:I\SI_0GLDV\_JU3YG3^A=4(@Y7]DFWG]6J?
M,Z?T)[)-O/ZM4^9T_H75"(.5_9)MY_5JGS.G]">R3;S^K5/F=/Z%U0B#E?V2
M;>?U:I\SI_0GLDV\_JU3YG3^A=4(@Y7]DFWG]6J?,Z?T)[)-O/ZM4^9T_H75
M"(.3:W3NV3:(QMNOQ?!;]X.?TYCACY\RUG%V/@70FR_0U#H'3++71.,LKW=+
M43NYRR'K\@'(!2Y$!$1 4>H?Z0C_ *Y_S4A4>H?Z0C_KG_-<^OW8I*0HB+H4
M6DUS^!5_^(3_ ,-RW:TFN?P*O_Q"?^&Y98=T)/1Q">:(>:+ZMYPK.V)Z)MFK
M:BOEN=3/"^B?&Z,1/:W>SD\<@]BK%>BWS&"M@>)G0@/:2\'D,\UJU<9RPF,9
MJ66,Q$W+K?:#LZM&LZZDJ;K5U4#Z>(Q,$,C6@@G.3D%:VV632VRBQ7>MCKI'
M.GC ?T\H>YY .ZQK0!S)5=>J"M5SIH+)=I[O/<H)&NBZ9L+8F1@X<WWG/.3Q
M/8J7=+OG+Y-X]KG97G:'#9:NG$3G_C\-^>I&.73F<\GMXHB+UG,+H[U+GX/W
MKXRS[*YQ71WJ7/P?O7QEGV5Q<?[$_AMT>]=:(B^?=HB(@(B("(B B(@(B("(
MB B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(
MB B(@(B("Y<TA_Q;W/XQ4_PBNHURYI#_ (M[G\8J?X10=1HB("(B > XJ#3:
MGOU\K:ZFT5;Z)U/13&GEN-QD<(9)&\'-C8SOG8/ NX#/+*FT[#)#(P<"YI"K
MS93=:&SVEVD[G414EZMDLK7PS$,,S'2N<R5F??-<'#B.OF@VMJU1<J2^4=DU
M=004M96!W<M71O+Z:=P&2SCWS'X!.#P..!7JT]J26X:BU7053(8J>SS11LD!
M(+FNB#R79..&5HM97*FU%J73MBLLK:NLI+C%<*N2 [S:6*,.SO.' .<2&AO,
MY*B<NF[IJK7.T.V4MR];[6Z:G=,8VY?-+T#=QA_^GPRX=?)!8VF-15VHKC65
M5'2Q,TW$#'3U+\])52 X+V#.!'P.">?,<%]=G6H9]4:5@NE7#%#-)-/&61YW
M0&2O8.?D:%YM"Z@-=2S66Z0P4.H+9&&55'%P86XPV6(=<;NK'+D5H=D<=PEV
M44S+/4T]-6&KJMV2>$RL [JDSEH<W/#RH)KJ2KO%-3PLL%MBK:J5^Z7S3".*
M 8]\_P#*(\C1E1JGU%J:V7>CM>IZ6T]-<VR,H:BA=)T;96-WMV1KN.".L'J6
MVEN\^EM/U-?K&YT4Q8[O'4U.8=[. &!A>XN<3V'K6ITM2U%[O<&IM2/93U3&
M/CM]LZ0.[D8[@7.X\97 #/8.':@^5CU?>*.\WZAUBRV,;:Z)E<Z6WMDQN.WL
M@AQ)SWJ^=/J36M1:V:@CLUI]97PBI;1F=_=;HB-X'>]X'8XX^3*_=!!%5;7]
M405#&R0R6FF:]CAD.!<_(*U-SME#9-*SQ2Z[J3IJ.$QQTK71.D<WD(F2COSU
M- ''J061IV[TM_L=#=K>YSJ2LA;-'O#! (Y$=HY*)7>^:KJ=9W"S:9CLC8:*
MFAF>^O$I<XR;W+<.,#=7NV0VVHM.SBQ4E; :>=L)>Z$\X@]SGAA\H#@/D4;K
M)-1Q[6-0>QBGM4SC04G2]W2/;CC)C=W1^]!(K%J2[0:BAL&K*2CAKZJ%\])4
M43W&&<,QOMP[OFN&<]F"O+M"UQ4Z<N%)36RA;7&)AK;EG.8*1K@'/''B[B<#
M_E*_5#9;D+PS56M*VC$UMII6P4U(PMAIVN'\H\N<27$@8Y #"B6F*K4]=+>[
M_3:0IKC3:@.89*BY"$FD +8F[AC=@%I+CQX[R"T-1W8VW2]PNU(&3=!2NJ(\
M^]?AN1RZBHC:;AM&K[;1W!D.E705$+)Q$.G:\M<T. SD@'BM!8JROIMEFJ=-
M7^,07:T4DK6Q&7I":9["Z([W#>P"69Q^2I]I.YT%+HBRR5-;30QQV^ O=)*U
MH:!&WF2>"#]Z0U.R_P#=U+44LE#=[>\15M&]P=T;B,M+7#@YK@,@K2;4]1:F
MTK;I[S:HK1-:::-AE94B3IBXOW>]W2!CB.?E7PT,\7S:'J34MO&;-)304,%0
M!WM4^-SR][>UHR&AW(\<+Z;?/Q47SX(OXK4$_8<M![0O'672DH[E;Z">0MJ:
MXO; W=)WBQN\[CR'#M7KC_FF_ %6&I]#W&JUG8:B#4&HC3NFJ7RR,E9BC!C.
MZ&=YP!)W>.>""T5 ;I?=5U>LKC9M,QV1L-%3PS/?7B4N<9"\<-PX_(_:II:J
M-U!;X:5]545;HQ@SU#@Z1_'F2 !^Q5M)8I;UM5U&(;U=;7T5%29[AD:SI,NE
M]]O-/+_-!++/6Z@M]+<*S6LMEBHJ>+I!)0ME[T#)<7;Q/# ZEO*VXTE%:Y;C
M53MCHHHC,^4YP& 9S\RB&J-/U-!LTU11LN5RN\TU#/N&L>U[\]&X;K<-"U6N
M]2V:38G7S17*ED956LPPAD@<Y[W1X#0 <YSS'5@YY(-YJK4-32:DT5#;JAHH
M+I4R-G[P'I(Q ][<$C(X@'@I1:KE27:B;5VZ=L].XN:'M[6DM(X]A!"K:\#_
M .+;)!_]0_\ X-Z^%XO4NS^_:DHQ&707EO=EGC#??UKB&/B ':]T;OE<@L.7
M4UEAM]97RW*G91TDI@FE<[#62#&6^4\>033FI[-J2&66R7"&K;$<2!N6N;\+
M3@CX<*J+]8JK2UTT11MKJ*DM\,4X?67" S0&N>=[><-YH#G9DW7$\.2WC;7-
M4:PI:J\:JL9J*>DGZ:"AI>@EE@<P@[YZ5W>M)#AD<P@EGL^TMZ[FV>O=)W:'
M]'N9.[O9QN[V-W.>&,K52;5=,PZKJK'/6=') P9F+'D&3>+3'C=YC&<\N*B;
M+G/H;2-$Z@J=.:BTQ3.:R(@B.H>S>[W=(+FR2?("2.U26.KI*7;/<.[)8H!)
M8X7LZ8AN0V9^\>/9D9^%!*KIJBRVJ2>.XW&"GD@:QSV/)WL.)#<#F<[IX#/)
M?"_:ST]871MNUUIZ>1X!$?%S\$9!+6@D#RE1^UT=-4;9KU52Q,DEAM5,(G$
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M[Z:LEXJ(ZBZVFBK)X_>230M<X?*0MLB#6-L%I;05=$VVTC:.K)=40B(!DI(
M.\.1X #Y%[)J.FGH7T<T$;Z1\?1.A<W+2S&-W'9C@ONB#7UMDME=;([=66^E
MGH(VM:RGDC#F- &!@'E@+T6ZAI;;1QTEOIXJ:EC&&11-#6MXYX >5>A$!$1
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M1$%E>IY_&71_V,WV"NKURAZGG\9='_8S?8*ZO7A>)>[^/VZ^'[1$1>>WB(B
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MLFAHK'+KC2,<W^U,W+O;[H)1*X.SDQAW$<N& IO2OD/JJ;W)2 .F]:=Z(.X
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MF4%I+#FAPPX CL(4$TKJVM9IZXF]P5%RN-LN,EMD?00<:AS2-UX;G#>#AGB
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M^OHI*ZE%T=TE-'!T[I!T$G ,_*X\4$WH]46"MJ64]'?+743O.&1Q5<;G./D
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MJHF4EMIHJ:F9[V.-N %ZUYO%<5.O-=(AT:>G& B(N1L$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M._%-ICXH/M%!.$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 4>H?Z0C_KG_-2%1ZA_I"/^N?\ -<^OW8I*0HB+H41$0%H]2ZLL
MFFHPZ]7&&F+@2V,G>>[X&CBM3M4UDS1NFI*J/=?7S'HJ:,G\KK<1V#T+D2[7
M.MNU;+5W*IEJ:B0[SGR.R5W<)P<Z\;LIJ&G4U=G*.KIR7;EI%CRUIN$@_.;
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MM!Y@^4*LYO4\:%DD<YL%?&"<[K:DX'SA!M/;SV>^'SYI/]Q/;SV>^'SYI/\
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M^:0>.>(X8X]2"4(JWLVVO0UVNT5OIKLYDTKQ'&Z:%S&/<> &\1P^7"L@G'-
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MJ93GEU;,=7+&*ATJ=OFGB<FV7 _"UGI7.UYJF5UYN%7$TMCJ*B29K3S <XD
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M3R<3UC'/FMWL?O>I+9M1U#HC4EXEO,5) )X*F;B[\D\SQXA_$$G!'!!>*(B
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MM5_BO_N@ZC1<N>PG;GX=JO\ %?\ W3V$[<_#M5_BO_N@ZC1<N>PG;GX=JO\
M%?\ W3V$[<_#M5_BO_N@ZC1<N>PG;GX=JO\ %?\ W3V$[<_#M5_BO_N@ZC1<
MN>PG;GX=JO\ %?\ W3V$[<_#M5_BO_N@ZC1<N>PG;GX=JO\ %?\ W3V$[<_#
MM5_BO_N@ZC1<N>PG;GX=JO\ %?\ W3V$[<_#M5_BO_N@ZC1<N>PG;GX=JO\
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MEKUW1-H*ASMSNJ)A:QI['L))'PCYET,JA]43L_HM2:0K;O34S6WJWQ]*R5@
M,C&^^8[MX9(\H06ZQS7L:]C@YKAD$'((653?J6]4U%_T'+05KM^:TRBG8X\S
M$6Y;GX,.'P *Y$!$1 15[KO:_I/1\DM-5UW==QCR#24HWW-/8X\F_*<^14_6
M>J*U/=ZE\.E=,P<^]WFR5#\? W 0=1(N6QM VVR-Z5FG:KH^>!:G8_=E?ANW
MK7M@>&ZFTU!N X)EIY*=Q^7./V(.IT51Z(V]Z3U"Z."XRNLU:\X#*DYC)\DG
M+Y\*VXWMDC:^-P<QP!:YIR"#UA!E$1 7+FD/^+>Y_&*G^$5U&N7-(?\ %O<_
MC%3_  B@ZC1$0$1$!$1 1$0$1$!$1 1$0$1$!$1!![-$VY[5+_7S$N]:*:&@
MIP>33(T2R$>4]X,^1139[JZZ6NZ2PZGJWU5HNMSJ8*"J=DFEE;*YO0O/YI &
MZ>W(4NTGNTNT+6M(X[KYGTM8P'FYIA#"1Y 8\+RZ.TR*_0UVLU_HY(XJNNJR
M62-W7;KIG.:\=G40?@*#Z4-?5NVT7:A=43.HV6:*5L&\=P/,I!<!RSCAE>U^
MI[^'$#1%T< < BLI>/\ W%%-G=BU%;-IMW%^9-44E/:XZ*DN9!_VIC9"6EQ_
M2 '!^#/6I _9O2O>YWLDU8,G.!>)@!^U!L[G8:G4$U+45MRNENI! -Z@I9Q$
M>D/$E\C.)QP& <<.M12S7NIT[J'6E$VMJ[G8[+;FU@=4R=))#-NO<Z+I#Q=E
MK0<'./E7MVA7:\6:CMMBL5!>:B.>,1U-T@IWU4E/$.!(Q[Z4XZ^6<K]Z<9;+
MCIJMTK16B_T,%122QRU-PHGQF4O!:Y[I'>^>=[/'F@^5FTI=KOIV"YW/4]VB
MOU7$)VR4T^Y!3EW?-8V+&Z0 0#O9)X\5J+A>)KKHO3>KZEC8[M9KA'%5%@P#
MF403 ?\ *0XGYNQ;:S:GOUGT_!::[2EUJK[21"",T[ ZEJ-T8:_ILX:" "0>
M(.5K;_9Y;!LFH[%5RMENMQKJ=CRWD^>2I8]X'D'?8/D06RB(@(B("(B B(@(
MB("(B B(@(B("(B#G[U8WX*6#XZ[[!5Q[/\ \!--_P!VTW\)JISU8WX*6#XZ
M[[!5Q[/_ ,!--_W;3?PFH-\B(@U6K?P5O7Q*;[#EPX>97<>K?P5O7Q*;[#EP
MX>97L>%]N3EXCK#"(B]5SB(B B(@(B(+*]3S^,NC_L9OL%=7KE#U//XRZ/\
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MV QCG15!8Y_8 =W*W-)<*3:E?:FD=*1IFW%KGT4C2Q]P?S;(X'B8!U?G$9/
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M;*&02DXRUNX,1Q@];N1/P'M0=7!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
M1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M[_0GNFKMXK4_U[_0@N+VG=">+U-\[O2GM.Z$\7J;YW>E4[[IJ[>*U/\ 7O\
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M_P#<N1>-LOF _P!1/<N1>-LOF _U$'0'K[:/"M!YPSTIZ^VCPK0><,]*Y_\
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MZJUC9KKK:V2T-CJ&;MKBE?EE)/G#75 Q@2/&=T\0W..?%;[7OXQ-G?QRI_\
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MK9QLTU*<$XHI#@<SP7JT_I"@M%SENCYZRX7:6/H75M;+TD@CSG<;@!K6Y&<
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MN+>FGMLC(AY2\\ /*O#8])7275$.H=6W.GKJVEB?%1TU+"8X*7?]\X9)+G$
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M7VGJJ%:_JE?QA1?$8OM/54+Z7A?9Q_IP:G=(B(NA@(B("(B LM]\%A9;[X)
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MMXI;3,YSI+93U993.WN+N&-X GB0' +.MK1-61Z;T[:J/<M9JXI*DM:!'%!
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MN9L$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1 1$0$1$!$1
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M1=95T,M%-/+(Z2FE]\P]YP/_ +JR-J;0W9M>&L  %,  !RXA2(B(QY<YG_\
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MB*H(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
MB(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B B(@(B("(B
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MU@)R=T8ROIA,(/E)#'(X.DC8]PY%S02%^I(V2MW96->WL<,A?M95'Y#&AFZ
M W&, <,+$44<(Q$QK!V-&%^TP@^0IX QS1#&&N]\-T8/PK]"*,!@W&X9Q:,>
M]^#L7[PLJC"8640,(B("(LX5H819PB#&%G"(@(BSA4819PLHM,)A91"F%E,+
M**PF%E$#"(B B+.%:&$6<(@QA9PLX3"HPBRLH,83"(@RL(LJE,(LX6<)2TPF
M%E,(M,865G"R J/RLX6<+*#\X6<+*)0QA91$H$1%01$P@(F%E$83"RBH81$0
M$19P@PBSA9PBOSA9 7Z1!C"+*80$6<(@QA0+;N/_ ,E-]^"'^*Q3Y0+;P/\
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MR,@G%)T4A&&OW8W!V#UX)4G3"DYV6BMXHZB7:+IZJ9!(ZFBHZEDDH'>L+MW
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M+Q16FEM$VF+HZ]T\+8-YH;W*YS1@/Z7.-W@#VJ.TMCND>P6LM<E%.;D97_R
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M:EQC/:X1 ;V?)G"^^OK%7WNTVXVU\!N=NK(:Z)LI+8Y7,SEI[ <J4K]=&_\
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M+54[V4]7+'!+&'?S#RXM=D]8:0?+A;'4^L+39*![C5Q559(-RGI*9XDEF>>
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M8:.J8]LKP_>D<7C#GEQSEWE*D&$PKNGY6Y>>WTK*&@I:2$N='3Q,A:7<R&M
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MP:UH[23R0?1$:0YH+2"TC((Y$(@(LX6<(/RLX7XIJB"JC,E+-',P.+"Z-P<
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MVN&WB@AMU)'1!P?T#8FAF\""#C&,Y X^1>E]+ ^KCJGPQNJ8VEC)2WOFM/,
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M*VFJ+':6QZ1LMO>\/&:;?%,TMXY((&,\N:\6@+/<+9376JO38(KA<ZUU7)#
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MUEM,721R3MEST@)&"T8Y#]J"3(BB^K-55%DO%JM=!9I;K67!DKXV,J&P[HC
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MNI+*QT53.ZG(CP"3O2!KF<<\^(RO1-;=<]QNKF:AI!7!O2"W=QM[GSSZ/?\
M?^3>RHU?K?74&PFV4,\;J2X1RTK-V4<8W],,9'S*42ZDU+W"ZD;I&M=>MTQ]
M)OL[CWN6_P!)O9W>O&,]2RKER6D.U]<*K5.B--WJGK9:&&>X4\4E%T3'='.)
M7-+MXC.6D'AR*G5XK[AI+3,TU96R7RY35#8*7I8V1;TCSNM:0P 8!!)/-:&\
M:,N%+LRMEJH0*ZY4%7%7R,:0WIGB0O>UI/\ 6./@"W%_@KM9::G%-;ZRT7"E
MJ8ZJC%P:&[\K#D9 )PWF/ERG+\#S5-NUQ0T#Z\:CI:NKA899* T3&PR8&3&U
MP[X=@)*\NI=8W"ITGI.[:7#&37>NBAZ*8 M[YK\L<<< '-XD<>"]U7J/4M7;
M9*.DTC707B1AC=).]@I8G$8+Q)GO@,YP!DKRUNE:BUZ?T-:K?')5MMERBDGD
M:WDT-DWGGL&\[]J1]Q\M2U.K-&VHWZKO<5YI:=S>ZZ(TC(0YKG;N8W-X@@D<
M\K[7"#6U-8Y;T;_3"HAA-4^V"C;T.Z!O&/?]]G'#.>:V^U2WU=ST%=J.W4\E
M352B/<BC&7.Q(TG'R E;N]023:>N$$+"^:2DD8U@YEQ80!\ZD3R1J);A<;]I
M"W7+3M726Q]9''.^:L9T@BC<W)P,XWN7/@M!'=KM8[]9V56IZ._V^X5+:.2$
M1Q,EB>X'=>W<YMR..>U>*XZ<NDVSK1=,^UR5HMO0ON%K+PQTK6LP1Q."6GCN
MGFOQ66R2OO>GI[)H;UII*:XQ2U%3)31PS8&<@-;QW.LD^16(A:?2Y6B\R[7F
M,AU)402OM3Y8Y&TT1,4?3?S0!;Q'7D\5*[Y<*^VWK2-#'5N>RLFDAJG.8W,P
M;$2">'#B,\,+Q:FBN%MUU07^DM=7<Z3N!]#*RD#3)&[?WVNW21D'EY%][U3U
MUSO6BZYMOJ(FP3RRU+'X)IPZ(@;V#CGP4ZT/+/7WW4M_N-'IVXQ6JUVQXIZB
MI,#999I\9+6!W>AH!&2>.5N],TU_I'5<-_KZ:XP@M--4LCZ*0CK:]H[WAPP0
MM$R"Z:1U'=9Z*TU-UL=TE%4_N4AT]//@-<-PD;S3@'(Y+?Z:N=VN<U7)<K,^
MUT;=T4PGD!FDY[Q<T9#1RP.?-)Z"-;:Y98--VJ6GBZ:>.\4CHXLXWW!Q(;GR
ME?>LMNNZ6CDKHM0T=571MZ1UO-$UM._'$L:[WX[ <KZ;6[7=+KIZ@AL<)EK8
M[E3S-X9# UQ.^[_E'#*_-9J74\]!)246D*V*]/;N;\[V=R,/6[I [OAU@8RK
M'0CH\&IM87*?2NE+KIK<CJ+K6PPF&5H()=D&-QZ@'#F./!2)E!J>FL%1'Z]T
M53>'N#A43TP9#"W\H!K>)QQQD_"M!<-+5=NL>@[91125?K9<Z>6ID8.#0"XO
M>?)DE;?:E9[A>M+"FM49G>RIBEFI1)T?=,33ET>]U93ET@1ZY7>\Z9%+<I]7
M4-]I.GCAJ:+HH6/+7NW=Z,LXY!(.#G@I/J"[5M'K?2MNIIMRCKNZ>Z(]T'?W
M& MX\Q@GJ4$U7:G7:U10Z=V=OMTC9X7RU$M+%#*P!X)$8;Q=Y3RP"IOJ2WU=
M3KW2%93T\DE+2]U]/*T=['O1@-S\)5FAI8Z[55ZUSJ:T6ZZ16^VT$D)$YIVR
M2-WHP=Q@/#B<DDYQ@86QT[=+Q;=8/TUJ"M9<W34IK:2M;"V)VZ';KF/:WAD<
M""%ZM+6^KI=9ZRJJBGDCIJN>G=!(X=[*&Q8)'P'@OQ66VL?M6MER93R&@CM,
MT+YP.]:\R-(:?+@*<N@D=WE?3VBOFA=NRQ4\CV.QG!#20?G5>Z.;K?4VE;?=
MI=2P6]]1 UT,4=$Q^_U;\A(_*(SAN, JP;S$^:S7"*)I?))32L:T<R2P@!:O
M9S15-NT+8*.NA?!504C&2QO&',<.8*D34$=$3TK<M7:UHIJAMRI[##1RNHY.
M@IVS/GG8>_>-_@UG' '/FMGIO55934&J8=3.CGJ].',U1 S<%1&6%[7!O4X@
M$$<EZ]EUMK+99+E#<::2GDDNM5,QKQ@N8Y^6N^ A>*BTY45]ZVAT]?!+!0W=
ML$4,Q'!XZ)S7%O;@D++ES5K[;6ZBN]NCNCM9VBUSU#1+%;A%%)'$T\6M>YQW
MB<8R01A:S7-XJ=6;'+M<8:HT1I0^GKJ:)K)&32,>T$!YSWN<.!':O3:[<RTT
M$5NO&S>*X5U.T1"KHJ.%\-2!P#RX\6DCGGK4AO6G:FZ;+KE::2TT5IKZRG)[
MCIBT1MDR"!O  9.Z 2KRB1L=,6Z\45B<9KT;C/+3,[E%1 QC(7;G '< )'$9
M^!1>\3:GM-MJK@_7-HFKJ5CII* P1,A>&@DL''?!X8!RMPRHN]^T=<;5%:+C
M9[@VW] R:IW6-=+N[I#""21P]]Y5$'6@^P]UJHMFH9>FTAA?/4PQ&,.W2"]L
MO$O=GB,<<J1'R0D6JM6U;H]*Q4%;#98;W&9I+A4QA[8!N!PC&>]WB3@$]BW%
MJMFHA#6LFU7%74TT6*>I92QB6&3(XY;WCAC/ A>,2W&VZ7L5#4:6DO%$*&-E
M7&"QTD3PT#'1.]]UY[%K](666/6?KE9['5Z=LW<SF5,$^&=TR$]Z1$"=W=_.
MZ^2?1'EV.6NZ-MTU2Z_3OHX[C5-DI.YXPV5P>07;V-X9/' *W-UIM1NKZ@SZ
MUMMG87'N>FCIXSAGY)>9#DGMQ@=B^6B3<].5-79*FQ5\T4ERFGCKHMPP&*1V
M\'..<@CK&,K06:S2V>2Z0ZAT3-J&Y3UDDT5P$44[)F./>!SGG^3P.&.2O6;5
MN*/6UP=LWOEU>R">ZVF62D?+$-Z&5[7!O2@#\G#MXCR%>G3]/J*L%'6TFN*"
MZPN<UU1$VDBZ-S.&0PL[YIYXRO'L^H[Y8-*WQQT\P5TESEFCMS9&QL,;MWA&
MX\-T#..0.%JK[9YK[4TDFG=&UU@O;*F.5]Q>UE.R)H=W^2T_RF1PQCCE*@3*
MGO=:W5FJZ5Y?44ENIJ>:GIVM&=YS'.< >9)("C>EJG4FIK3!=*#6UO;63 2&
MW-I(W1PG]&\>_P CD2I%24EQI=:ZNN%/0ND;/34W<N^[<9,]C'9:'=7' )45
MU-1G4-#41NV>U]-J)["(JM@CC9'+U/Z=I&0#Q\ORI%"UH@X1M$A!?@;Q P">
MM0N]4^H7W*H,NL[=9:<G_9J>.GC+MSJ+S(<D_!P4JL4%52V:@@N,_=%9% QD
M\OZ1X: X_*565#9Y+5<[T-1:-GU'5U=8^>GKVPQSM=$?>L)>?Y/=Y8Y+'&$A
ML[?J"JOFSG6$=Q?3S5MMCJZ*6HI\='/NQ$A[1U9!Y+5ZC_%3H+XY:_\ )??2
M%BNU+HO7E-5686^IKIJE]-1P ;F'0@-;'C@1GAPZUZKY8[G/LXT;0PT4SZRD
MJK>^>$#OHVL]^3\'6L^42K;WZY7J[:KGT_INJBM[**)DU=7OB$KFE^2R.-IX
M9(&22O+'<;[IK45LMFH+FRZT%X>ZGIJP0-AEIY@,AK@WO7 ]1QS7WO%+=K!K
M2JOUJM\ETMMQA9'74T#ATT;X\ADC 2-X8X$<UYW4UVU?JBS5E;::BT6:T3&K
M8*LMZ:IFQAHW 3NM'/CS4@;+1U\G.GKH;_4"2NLL\\-9+NAN\UF7-?@<!EF%
MK]EFH+S='5U#JC<%QW8ZZG :&_[-*,L'#K:1@_"M9KK3%VK=6/@M<+S9]0-A
MCNDK/_D]"[.]_P"IAW?+A>[:?:+T*FAN^D:<R7'H9+9*UG MAD'!_P#Z' 'Y
M4J)_)R>*36ET@MU96"6$NNUV-!9!.&MBBC;WIE>1@EN6O=Q)Y!+E=KYIJA-V
MEUA;+[# -^KH2R&(N9^48BTY#@.0.<K9ZJT0*C25CH[=#3U=38G1R4]/4M!B
MJMUNZYC\\.^&3GM6M9!35!B@I-E44587M$CJNF@C@C&>^(D&=[ARP.*L5]!M
MK_?KK<]14.G]*SPTDDU&+A4U\T6_T,).&AK3P+W>7DHMM%I=1VV"QPW2YQWB
MWS7:E_EG4[898'B3(SN\'-(X<L@A2K4-LN5GU=3:EL-";A3]QB@JZ"(ADG1A
MQ<Q\>< D<MWL6CUI)J/5;;6RAT[74-OI+A3U$QJPT32X>/>L!.&M&224Q(6J
M_P!^[X5^<+]OXO<1RRL86M&,(LX64&$PLHJ,*O\ ;[^*:_?!#_&8K!5?;??Q
M37[X(?XS%ECUA8ZJ^]1M_36I?B\7VG+J1<M^HV_IK4OQ>+[3EU(NIL%#=LOX
MJ]5?$)?W*9*&[9?Q5ZJ^(2_N0<R>I=_#NX?W<_[;%TZN8O4N_AW</[N?]MBZ
M=6S'HPRZB(BR8JFVXZMU7IJHMC=-1%M+,TF29L E)>#[SB#CA\ZLRQSU-59:
M"HN$/05DL#'S1?F/+1D?.O<"1R)"PHHB(J@J]VMW2D+;3IVJN$%#%<YPZKEE
M?N!M,SB\9[7' 'RJPE&K5IHLU1>[W=NYZJ:LW(*:,LWFPP,Y#B/?$\2HL(K4
MZCLE%M'M-PL]WH)J.YQBVUD,,P<6N:/Y&3 ZAC=SV%>S7=NDNNTC2E#W5/34
M\E+5]T="\L=)& W+ 1Q&>61QQE2;5.F:"^Z?KK8:>GIS41[K)HX6AT;AQ:X$
M#J("\<%AN,E^TS=+A44[Y[=0RT]3N9_E)'@#>;PY<,G**CNH;'0Z&J['<]+Q
MR43JBY0457$)7O9/%(2#D.)[X<P>:\5_TA8:S;+0P55MBEAK+=/4SM+G=_('
MC#N?/X%-]:V*>_4ELBII8XS2W&"L<9,\6QNR0,=:\VJ;!<:B_P!!?]/U%)'=
M*2&2F,58QSHI(WG)R6\00>24-;K.GBH;WL\I*1G14\5SZ)C&DX#1$0 MK<M:
MT%ONDM!+;[W)+&\,+X+?))&3VAPX$>5?F[6&XW2ITI55=12]TVNK[IJ>C:YK
M9.](PP<<<^LJ59/:414^I=(V&MVP6>&KML<L=;05,]0TN=_*2-(PX\>KR+=Z
MHIH:#5^SFCHV"&FAJ*B..-I.&M$/ +9ZJT_<*J^6R_6&HI8[I0QR0".K8XPR
MQOY@[O$$<QA8OVG:^]6RTSS5T--J&VR]TP5$,9Z'I,8+2TG):1P/%%:[;8XM
MT*\M)![MI>1_^JU>;:'0/NFT/1]"*J>FBF95],Z!Y8\L#&DM!ZL\L]A*_.I]
M*ZKU7:V4UYN5J@$$\<T<-'$\-E<UV<O<XD\!G#0.>.*D]XL<U;K.PWB.6-L%
MO94-D8[.\[I&@#'5PP@A&MM,0Z6%JJ=&S3VBHK:V.AJ#'*Y[962=[O$.)[X<
MP>>5Z=<:.MNF]/5M^T\:FDO5 !.*PU#WOFW3WPDR<.!'-2[6%DGO<5J;3RQQ
MFDN$-6_?SWS6.R0,=:^^L[5+?=,7.V4\C(Y:J%T;7/S@$]N$I+1O4TTU_P!8
M6?3,D\M/;*BWNN58('%CY@" V,.'$-R<G"\6IK!2:&HX+[I42T(@J86U=*V5
MSXZJ)[PPM+7$C>[[(*DFH--25TEKN-MJQ17RV1[D$[F;\;VEN',>WAEI^'(6
MO]CM^OU51OU?74 HJ.9L[**W1N#9WMXM,CGG. >.Z."*TU988M0;7[[2U\T_
MK9';:9\M-'*Z,3.WCNAQ;QP.)QUG"LJF@CIJ>*"!@9#$T,8T=30, +24-DGI
M]<W>^/EC,%91PT[6#.\',)))ZL<5OTA%9ZQ.C9]15,5\AO%[K6!I?34S9IXZ
M4'D-UF TG&>.2O!I74[K5I_6[K<VM-OLX;);X*]CA+%O,)W7!W?;H<,C/4I-
M[']066\W:KTK66TT]UG[IJ(;A&\F*3&"6%IX@]A7[TWI*JI:K4[]05D5R9>@
MP2%K-S(#"UPW>0'' XG@%%>6W;.;/6VZGJ[ZZJN%XGC;-+7NJ7MD#G#/>;I
M:!G@,+4;5M-4$E!IA]Q8ZOK&5]+1.JIR=^2(OXAV,#CD\<96[I+-K&TTL=KM
M-XM<UNB;N0U-;3N=41,ZFX!W7X' $X6RU'IF:[:9I:'UP<^XT<D51#63,!WY
MHSD%[1U'EP5&BVD6:WZ>V87>DLM,VCI]]C]QCB>)>W)R23U+W7SI+%M M%W#
MBVW76,6RK&> EP3"_P G(MSY5^K[9-0ZBT;<;;>*BULKZAS>C-,QXC8 X$YS
MDDG"W>K[&S46FJVU2/Z,S,'1R#G'(TY:[Y" B-)5 :AVCTU.UQ-%IU@J)@#P
M=52 AC3_ %6@N^51]MKHKOH;6S;G *@4UTN$\(>3WCV@[I&#U94RT+89K!:9
M6U\[:FYU<[ZJMG;RDE=V>0  +\V/3CJ6U7^AKI&217.LJ9LQYRV.7JX]8"*C
MVD=!V"HT#!'!1-IY[I;6,GG:]V\2X!V>)_. /R+[VK5LE-LXK*NL[^\6G>M\
M\9YOJFX8S';O$M/RE>O34-[TS204VHKI9A8Z2,4\,P8Z.5YSB/?).Z#U<.:T
M++11WW:T^IM=3TULI&Q5MP;&X.B?6-WFQ#(YN .3\""::(L\ECTS1T=2[I*T
M@S54A_+F>=YY^<X^11G7[]*27V.#43+K<ZOH0YMOI!+*R-N3W[F,Q@GM*L-0
M^Z6*]T6I*V]:6JZ 2U\<;*JFKV.+"6##7-<TY'#JY(D([L\K&^O6I;3IP7&G
MMT=$RHHZ:XQO88)G%S>]#^.YP"T=NI]*TL$,>NJ&\T&I <5-RG=,&OE)]\R9
MA+0#U<E/+#IN\TM_N]VN5WBFJJ^B9 U\4.!3O#B1NM/-HR.9R3G*^59;-;5U
M'46NKN=B?05$;H9*H4C^F+'#!.YO;F<%16IUY2Q/U)35&HK?<KKI1M$UL3:(
MND:R;>XOD8PASLMQ@\0O+5WNQV+0%UJM#552.DJ(J8QDR/?2.>X-[V-_?-."
M<#M [%*YK3J*TPTD&EKA;W4-/ R!M+<(7'&Z,;PD8<Y//&%Y*;14M?'>ZC4U
M7%+<+M%'$\T4?1LIQ&=YA9G)+@[!WCV85$+G9I2"EEEM=MUA3WQK"Z.Y=QU!
MF=*!P+\\' G&1C&%N=0S7.]V72]QO=KN,]E,3GW6@HP6S&7&&N+ 0XM!!. >
ML+?LHM=L HO7JT.IF@,%>ZF>:DM_.+<[F]Y>U;:^TNH":>:P7.D8^-FY)!6T
M^\R8_G%S2"T_!P2A%](MTXZCO+- OGI+F:5S11U#I&"-Y!W']')R.<<0HQ:*
M?2%+%21:MHKU:]1C=;45]2^9N_,>;FS-);@GY,*=4FG;W6W?UZOMPHH;K#2O
MI:/N" F.'?YO=OG+SY#@+SW&SZSN]!46>YW*Q^MU1&89:F*E?TSF'@<,+MT'
M&>/4@C^JKM;[EKFYVW45/>*VSVZ*%L5'0P22122/;OF20LY\"  2OMI*Z4]O
MU92T6FK??8;#4PR&H@KJ:5L=/(QI<UT;G\@0"",XY*2UVF*^WUL=RTE7QTU8
MVECHY:>L:7P5#&##'.W<$/ _*"V6GX-1=/+/J.OH7M+-QE+10EL;3G.\7.)<
M3U=001#2.GZ#7-J&H]4-FKIJN:0T\#IGMCI8VO+6M:UI''AQ*SI*V/M.UR]T
MAJYZJ!MKB-.9W[[XXR_WA<>)P<X)ZL+:1Z>U!I^:J9I&MMQMM3,Z?N2X1/(I
MWN.7&-S#Q!/'=*^FF-*5]KUA7WRXW,5\M;2-BE<6;A$@=^2WD&!H  SGKZT&
MSVA?@%J/^[Y_L%1G2V@+3<]+VFJU")[A<I:6-YJ.Z'MZ(%HW6QAI : ,#EU9
M4RU/;I+OINZVV%[62U=-) US^0+FD GYU%K18=8V&UTEJM-UM4U#%$UC9:V%
M[IH.'$-P0'@<<9QPPB0C[W78Z:NDSJB2OO&D+GOT]0XY=/ &@ECL<SN.(/P!
M236=U%[MEBM%I>[&I"TF1IXQTH ?([R=[WOPDK9:=I+3HVC%OJ[M$^LJGR5<
MTU9*UCZAYQO.P3R' 8Z@HYLBLX9476[-D?+;A*^CM!?R;2B0O);Y"YV >QJ*
ML5L;:>DZ*D8&MBCW8F#J &&C]@4*V*-B.SZCG9QJ*B>>6J>??/FZ1P<7>7@%
M.5#JC3%SM%QK*_1M?3TPK']+46^LB+Z=TF.+VEN',)Z\<"B/;M*@@GT#?VU0
M:6,I7RM)_)>WOF$>7> 4-U/=G4UIV8W.["=\@ECEGZ*(O>2803AHXDJ0R:8O
M.H9*<ZQN-*:*"02BW6Z-S(IG Y'2.<27 ''#@%MM36.:ZW73E5!)'&RV5AJ)
M&NSES=W&&X01B^[0Z"XTK[19;;=*N[7!CX*:">D= QQ(.27/P, <>M>#7%+[
M&=#:(I:MSI3;KA1ME,32\N+<EVZ!Q/7@*=:RL0U%9G4K)W4U9$\3TE2WWT,K
M?>N'DY@^0KP:DL-QOMNT^*B:ECK:*M@K*DLWMQQ9[X,Z^/5E%:VY;4+0QK8J
M.WWFHK:E_04\+Z)\(DD=P:W>?@<_E\BW.SNQ3Z;T;;K76.:ZIB#W2;ARUKG/
M+BT>09Q\B]^J[)3:DLU1;ZTO:V3OXY&G#HI!Q:]I[05]K&VX,M5,R]/@DN#6
M[LLD&=QY')PSQR1C/ERB(1K"URWC:C9:,5<M-2/M<W=0A=NOEBZ3W@=S&3C)
M''&5Y]76*CT%:V:@TF)+>^FGB%33B9SXJF)S@US7-<3Q[".*WFJ=*5UUU;;;
MY;KD*&:WTKXXCN[X<\NSA[>MA:2",@\5\9=-W[44]*W5];;O6ZEG;4-I;=&]
MO3O:<MZ1SS[T=@17ZL&[I[7]QL+0X45V:;G19/!L@P)F?*>^PLZ,>^^ZDO>H
MYAFF8_UMMW9T3"2]X[=YYY]@6JVH5U'>K5;&Z;N=/+J%U:UMO=32->\$Y;)G
M')H:79/: IY9+;#9[/16VE&(*2%L+?+@<_E.3\J(B&W ANSNL<<X;/ 3@9/\
MX%^JW:I8:.'I327MSMX-:PV^2/><>0WGX ^4K;[0;!/J73$ULI)8X97RQO#Y
M,[N&O#CR^!;>]VREO=JJK;<F&6DJ6;DC<\<=H\HYH*[J[-66;8WJOURC;#6U
MQGKGTX=D0F1P(9GR8ZEN;/5:U%GMXBM%C=&*:+=)KW@D;@P2-Q>F>P7>LV=U
M^GZZKIYJU\)IH*KOL/8"-QTG7O8''"\U'%K^EHZ>G8-+.;#&V($]/DAH R?F
M17YVC@SMTG2W)C.XJFZPMK(\YC)W'$-)ZV[P'S!3H\SE1^JLLNHM+26S5C*8
MS3?SAH2X-:0[+7,+N((X+5QT.N:%K:2DNMFK:9@#655;3O$X;U;P:=UQ\O#*
M(].U4D[.M09_5'+Y7K3U7<J;3UVLE5#2WJVP-Z!U0TNB>Q\8#V/ X\>T+Z7/
M3=QKM$W6T5=V-;<*YC\U$L8C8PN_):UN<-'9Q7LNEKO)IJ!UDN[*2II86Q.A
MFA$L$^ !WPX.'+@04&J?JZZV26FCU=8^YJ>>5L(KZ&<30M<XX&^#AS03UE?3
M;",;.+\#S$(^T%YZFP:EU$V*EU376N&ULE9+)!;HG[U1NG>#7.>>]&0#P"WF
MN;--J'2MQM=-)'%-4Q[C7/SNCB#QP@V]%_N5-_8L^R%%]I5%*;-#>:'>[OLD
MHKH@">_:/YQGERS>4J@88Z>&,G)8QK2?@&%^GL:]CF/ +7 @@]8*HA&MKD;[
M8[);;),0=1O: \<"REP'2N\AW3CY5]=811P:CT)#"W=BCN.XQO8T0O "^>A]
M$RZ=OM=53U8J*2-CJ:V1==/ YY>YIX<\X'P!;O4%FFN5XT]5Q21L9;:LU$C7
M9RX;CFX'EXJ#>A0?27XR]=__ ,E_#<I+2PW5M]K):FK@?:71,%/ V/#V/SWQ
M<[K'_P"?5QUUJLE1;M3:HN[YXNCN3(#$ "3&8V.!+NWB<\$$C4'U+^-G17Q>
MM^P%MMGE;=+CI"@K+\YCJZ??>7-CZ/+-\[AW>KO<%>'6-BO59J6Q7K3\MO$]
MNCG88ZW?W7]( /R>/#!0A,1S5&W BDV9ZVI*1SA:HKWT#=P^\B<YAE:/)DD?
M*5/9*'7-R:ZGK;G9K92O&Z^6WPR/FQUAI><-/EZEO+?IJUT.F_6&*F#K:6.8
M^.0[QDWN+BX]9).<H=&UIXHH*>*&F:UD$;&MC:WD&@< /)A0G:+FGU#HFLI0
M&UYN@I@X#OG0O'\HWRC@%^J6RZML,#*&P76VUMMC&["VZ1/Z6%O4W?8>^ \J
M]]CTQ/%>_7W4%P-QNXC,409'T<%,T\Q&SB<GK<3E!&JG4=#I_:QJ)U?'7/;+
M14P;W+2OGQ@=>Z."_-RO<>T&[VZUV&DJVPVVNAK*ZJJHNAZ%K22UK6N[XN=C
M')3&WV6>EUK>+TZ5A@K:>&%C!G>:6<R>I?*]6&IDU-;;[:)XH:N+_9ZMDF=R
MIISG@<?E-)):45)''+B>U03;@<;,KL>QT)_[C5M;%7W6IUKJ6EJ9&/M%((&T
MN(MTM>YI+AO?E=7SA?O:%89]3:2K+322QPS3N86ODSNC=>'=7P(C5NVDVG<#
M:6W7^IJ, ,B;;)6EQ[,N  ^$K3UEKK+9L@U4^YQ""LK^ZJY].UV\(>D)(9D<
M,@<U9X)P!D\L+3ZOM<M[TO=+9 ]D<M73NB:]^=T$C&3A!H[3?-2MM-"UFC97
MM%/& [US@&\-P8.,KU:JL%;>FV>YVZ:.WWRVN,T F'21@N;A\;\<QC(R%(J"
M$TU!2P.(+HH61DCD2UH'^2UVH:&[57036.["AJ(-[,4L(EAGSU/' C':#UH-
M#/JZ[:?;$[6%D;!2/D;$:^WSB:)A<< N:<.:/+Q4W4$K]/:FU+3BWZHKK5!:
MM]KY8[=$_I)PTYW2YY[T'KP%.AP&!P X! 1$501$0$1$!41ZJW_<=,_VE1^Z
M-7NJ(]5;_N.F?[2H_=&L<NBX]5D^I5_%-!\<F_>%;RJ'U*OXIH/CDW[PK>6M
ML$1$'.OJQ_Z'T[_;2_N"^?J<?Q?R?')/LM7T]6/_ $/IW^VE_<%^/4X?B_?\
M<D^RQ:.([&&?1:*SA91<#13&%E,+\=-%T_0]-'T^-[H]\;V.W'/"*_:+*(,8
M6<(@YH"**:"NM;<ZG4[:Z<S-H[M+30 M W(P!AO <>?6OIKNYUEL]CW<,QA[
MJN\%--AH._&[>RWCVX"RVS=+23HH#J*]TUDVG4LURJW04+;-(2W)(<\S- PT
M<W? ,K<V36]ENUP;0Q/JJ6LD&8HJVG= 91_R;WOOWJ[)JRDE65I-9WQNGM.5
M5?NE\^!%3Q@9+YGG=8/G/S K6;/[A=3ZXV34]2VHOEO>USYFM#1-$\9:X 8Y
M'+3\"1C-65RM+L(H%JMUZLM^L=1!?ZN2DK[M'3OHWQ1[C8W9.Z#N[W5CFMIJ
MB^7#UW@T_IEL!O$T9J)9J@9BI80<;Y YDG@ KL*2I,*&2V'5T$/34>KC4UC>
M/155'&('^0AHWF_""I?2F8TT)JA&*C<'2",DM#L<<9ZLJ3%%/HLKXUE53T5.
MZHK:B*G@;SDE>&-'RE:W3^HK??S4FU&>6& @&=T+F1O)S[QQ]]C'5VA*^I3<
M(HUKZ]55DLT+K>(VUE9514<4THS' YYQON'8/0M+J*DU3INRU-X&JN['4;3+
M-3U=+&R&5HYM;NC+2>KB>*RC&UB$_11&HKKA>[_16^@K9K53&W1W"9T<;73/
M+W$-8"X$ #!SP[%\:75%5!IM[:D-J;X*V6UTVZW=;53-<6M?CJ;COG=F"FTI
M-,+*\MIIZJFMM-#<*HUE6Q@$L^Z&]([K( Y#L\B^5]O%#8K<^NNL_0TS7!N=
MTN+G'DT <23V!2OH4]Z847LNN[)=;E%01FLI:J8$PLK*5\'38Y[A=S7GCFE]
MN&2#I']#ZQA_1[QW=[I\9QVJ[9^I28X3"B.SZ>22MUATTKG-CO$C6[[LAC=Q
MG 9Y!?B3:5IR.>1O2UKZ>-Y8^LCI)'4[2#C^< QCR\E=LWR*E,L+*UC[Y0-K
MK;2B;?=<6/?2R,&]')NC) <.&<<1VK\WK4%NLM3;H+C/T4E?-T$ QG+O+V#E
MQ\JE%-JB\%ZNU)9J1M17.>&/E9"P,;O.<][@UH Z^)6JO^M+/9+B:"H=55-<
MUN^^GHJ=T[XV]K@WE\J1$ST*21%KK!>:"_T K+34"> N+"<%KFN'-KFGB#Y"
MM!4;1M.PUDL#9JN=D+]R6IIZ1\D$9'/+P,?-E6,9D3!%"]G5;W?<]7RQU/=%
M/ZZNZ%X?O-W"QI&[Y%-<),43R8191$8PO+=J%MRMT]&Z>HIQ*W'2T\A9(WCG
M+7#DO6B#0:;TO362IGK'U=;<;E.T1OK*V3?DW <A@X !N>. %OT3"7:B+.%G
M"#5:CLL%_MG<-6^5D72QS;T9 .6.#ASZLA;3B<K.%E!^<+.%E$!$PLH,)A93
M"H819PB#"SA$0,(B("RL+* L+.%G"#" %?I$5C"SA%G"#"+*QE!G"+"809RL
M+.$51A96<)A!A96408PBRB B86<*C"+*(,8641 1%G"*PBSA$*8PLX6<)A%8
M65E%1C"RB("(F$!$PLJC"8640,*OMOWXI;]\$/\ &8K!5?;?OQ2W[X(?XS%<
M>L+"O?4;?TUJ7XO%]IRZD7+?J-OZ:U+\7B^TY=2+J;!0W;+^*O57Q"7]RF2A
MNV7\5>JOB$O[D',GJ7?P[N']W/\ ML73JYB]2[^'=P_NY_VV+IU;,>C#+J(B
M+)B(HWJ_6]ATB:=M]K'0R3_S;&1E[B.6\0.04@IIXJJFBJ*>1LD,K!(Q[3D.
M:1D$?(BOHB(B"_+Y(V>_D8W^LX!?I5UJFS6Z^[5;11WBCBK*7UKG?T<F<;P>
MW!X*+"PV/9)GHWM?CGNN!7Z58:\TQ:=&Z8K-1:6A]:+G0ECXW0R.#)<N ,;F
M$D.!![%,KO<[S'W)'9;&*R:>(2ODFJ&PQ0_\I/$D^0!!O446LFI:^HO%78[Q
M:V4-ZCIC50[DW205#,XX.QD8) ((ZU'-#W/5M1J#4<4]);I(8K@QDP?6//<X
MW!D1C=XC''JXH4L-E?1ON$E RJA=71QB5].'C?:PG <1V+TJ.4U71MU[<J84
M,$=3';HYY*W\M["]PW#Y!C*U]'JB^WN,UVF;!#4V@.<V.>JJQ"^I#203&W!P
M,@X+L90I,T44EUG _0]TU!1TTG24#)!-23]Z^.5GOF.Q^_K"\=/JG4==:HKO
M;=,1OMCHA,&S5@9/*W&2YC,8 [ 3D\$*3=%7.OM2UEQV6R7O2X:VEJ(#(^62
M4QRP#> PT#.79R#Q"ENF)[W/1AU^I*&G/1L,1IIW2E_>\2[+1@\D*;E%H-<Z
MA]B^G9KJ8.Z&Q21L+,X)#GAI(\O%?"/4M3266NO6H;<+7;8F"2!AE$D[P>0<
MT<&N/##<\R@DR*&3:EU+1T3[I<-+-9:F,Z1\<56'U4;/SBS&"<<=T'*^NKM;
M4]AM-EN=/ ZNHKC/'&TQ9WMQ[<@M'6>0QY4LI+D4*K]4ZAM-(^YW;3#66E@#
MY!3U8DJ86=;G,P <=8!6POFK(:3UMI[33.NERN;.EI*>-P8'1XR9'N/!K0$L
MI)440CU3<[9<J"CU7:(J)E?*(*>JI*CIHND/)K\@%N>HKYW?6%=3:TFTW;+,
M:^L[E94QNZ81M )(<7D\FC \I)PEE)HL*M]:W+5-/J?2D5'34+6S3XW.ZWM;
M+)T1+F/PWWH.<'K4EN>HI['9:6:\T;'W:IE%/!0T4F_TLI/>M:YP'#'$D\D*
M2-%#9]47FR"*HU79(*2VRR-C-32573=SEQP.D;@<,\"1D!>[4.II:&\T]DL]
MO=<;S/$9Q'T@CBBC!QOR/ZAV<.*%-W6U])0]!W;4Q0=/((8ND=C?>>31VDKT
MJIM>7>Y/N.DK??K4VBJGWB"6*6GGZ:&0-=WPS@%KAD<".*MH^^/PH//6T=-7
MTSZ:NIX:FG?[Z*9@>T_""OQ;+;0VNF[GME'3T<&=[HX(PQN>W ZU%J?5=VO<
ME1)I*S05EN@D,/==74] V9[3AW1C!) /#>/!>VT:LCN5JO,QHY:6XVD/;5T<
MS@2QX:7##AP+3C@4$F1:S2US-\TY:[HZ(0NK:=DYC!R&[PSC*A]QU3=;QH+4
M-=::2GBGHZBHI';TY:6LC!S(T@>^Y</VH4L-%#]GUPO4FEZ"JU!%1143:".5
MM4RH<^20;H)<\$#'#B>)7RH]47^]4_KAIO3T$]I)/0RU=7T,E0T'WS&X. <<
M-X\4LI-447N&L(Z2RV^J%LK77*X/Z&FMCVADSI!G(.> :,$[W+&.U>2?5-XL
MKX)=56.&EM\TK8NZJ.JZ80.<<-Z1I .,D#(RA29HHGJ?5E3:-34%EH[3)<:F
MM@?)$(Y WOVD#OB> ;@DD^1:^XZZN&GJJ"FU187,EJP11NMTW3MEDX8B.0-U
MW'GR2RD\10NIU5>K-44LFI;%#2VRIF;!W13573.IW..&](,#AD@9"VFH]0S4
M%RI[1:* W*]5#'2M@Z41LBC:0#)(X\ADX&.:%) BC%MU'717JEM&I;6R@K*L
M.-+/3S=+!,6C)9D@%KL<<$<<+R,U/>KM67%FF+)35-);ZEU)+/5U?1=+*WWP
M8 #RR.)0I,D7EM5145=OAFKJ)U#4N!WZ=T@D+""1[X<#G&?E6NM-\=5:AN]F
MJX6P55%N2Q;KLB:%XX/'P'(*HW3W-8QSGN#6M&23R [5\+=7TESHXZNW5,-5
M2R9W)H7;S78.#@_"M34WHR:FELM/31SQ0T3JFLD<[A&#D,9CK+L'/D6KTI>?
M_P GEMN%CT\#TQ<(K=2/:QK"7N&=YW(9&2?*H)'=+-;+NU@NMNHZT,]YW1"U
M^[\&1P7MBC9#$R*%C8XF -:Q@P&@<@!U!1!VIKU:JRB;JFR4])0UDS:=E525
M73"*1WO0\$#@<8R%,L8.$'S=-$TD.EC:1U%X!1DL;SADD;CV-<"JF@M.EKGM
M*UM[*HK=(^.2EZ'NN4,(!BXXR1V!3;2>G=)4-:^ITO2VUM3N]&^2ED#R&GJ.
M"<9Q^Q!)B0 22 !S)Y!88]KQECFN':TY5=V6W>V#+7734$DLED94/IZ"WQR&
M-CFL.#)+NG+B3R&<#"^M]T13V*VU%TT,#:+G2,,Q9&]QAJ&-&71O821Q YCB
M@G[WM8,O<UH[7'"PR6-YPR2-Q[&N!5<:\J:/5.E]%U$D(DH;C=J4OA?R(<R3
M>:?ER%LKGLXTO3T%5/;K<RV54,;I(ZNED?&^)P!(=G..&.M"DT?+&PX?)&T]
MCG +'=$/Z>+Z84"TA8K1KC2EDO>JK535]TFIQ&^>4'+PUS@'<".>,_*M%LFT
M1IJZ:3-7<;+2U%2*ZI8)'@YW6R$-'/J"64MY?ECV/)#'L<1S#7 J!S,EUKJJ
MZVV:IJ*?3UG+*>>G@>8W5<Q&]WSAQ#&C' 8R5[ALXT]321SV6":SUL;@YM31
M3.:_GQ!R2' ^4(-_16&T4-<^MHK50T]8\$.FB@:UYSSX@+8D@ DD #F3R"R!
MDXY*N;';!M ;4WC4CY)K09WQ6ZW,D<R,1M<07RAI[YQ/43@ (+$8YKQECFN'
M:TY620,9(&> R>:K[4&CH=-VNIN^ALVJOI&&>2%CW.AJHVC>=&YA)'$ X(PO
MUJNX17:/0%PI\B*JND$K0>8S&\X^1"D_3J)Z@L]:K]E))KG4%XCN<\K=.6RH
M-''1PR&,U$S??ND+3DM'(#/6@GS'L?GHWM?CGND%94'KMG5NI*62?1S38[TP
M9@J()';KC^;(TDAS3Y0M[HF]'46EZ"YOCZ.:5F[,P<FR-.ZX#R9!0;M?E[V,
MQOO8W/+>< H[M!OM18-/&:@8UUPJIHZ.EW_>MED.&N/D'/Y%KX-FMBEC#]01
M27NY.'\M5UDKR7.Z]T @-'8 @F;WM8,O<UH[7' 7X$\)Y31?3"CE/H>SBVRV
MRM;/<;891+#2UDAD;3X&,,//'PDJNZ.PZ+OFT/ULMU';K?2VB7,@;)N35M0#
M[QH)SN-(.>LE"EU_N"PQS7C+'-<.UIRH-J42:DUY#IBHED99X*+N^MCC<6&H
M)?NL87#B&]9 YKPZCL=)H-E'?=+QFA@BJ8HJ^D8]QBJ8GN#.+23AP+@00EE+
M(18F>R&.21YQ&QI>3V #)/S*$V[5&I+O;XKM:=,T\MIE!="V6N#*B5@)&\&X
MW1G'(E!-T4;O^II:"JM]MM]MEK;W71]*REWPUL+1S=*_DT Y'E(X+]6:[7LW
M-M#J"R,I.D8Y\5523]-#WO-K^ +3QX9YH)%RY(H72ZKO%],U1I.RP5=KBD,0
MJZRJZ 3N:<.Z,8.0#PR>"]MLU=%<+%>:QM'+3U]I$C*JCF(RR1K=[&\.!:>I
MP2RDG11+1&I[EJ>CI+D;.RBM$T&^9Y9^_<_''=9CWF<C>.,XROC1:IO=\C=6
MZ8L$53: ]S&3U=6(7U&Z<$QMP<#(."[FA29HM5IF^T]_M[ZFGCD@EBD=!44\
MOOX)6^^8[Y^?6O-JK40L?<5/3T<UPN=>\QTM+$0"X@9+G$^]:,C)\JHVUPKJ
M2VT<E7<:F*EI8\%\LKMUK<G'$_"O0"" 0<@\054>UR\WN+9_<J74-EBIF56Y
M'%4TE3TS&OW@0UX(!&0#QY<AUJ>7"^NM^H--6D0->VZ-E!D+L&/HXP[@.O.5
M+*2!%H-;:@=INTP5C*=M09:N&FW7.W<;[L9^1>#5.KJFSZLH+%16IUPJ:ZG?
M+"&R!G?M=C#B>#6XR2?(A225UQHJ!U.VNJX*<U$@BA$KPWI'GDUO:5ZU#M2U
M_01Z7-]M%%/6U-QCA#=_?;32'.'L=CB1A9O^KZJWZOAL%#:'W"JJ*4SPELH8
M-X.P=\G@UH&22A27HHG0:FN5/?Z.T:FM45%-7;W<E12U'31/<T9+#D M=C/P
MX6:[5%;47NKM&E[6RX55$&]USU$_0P0EW$,S@ESL<< <$*2M%"Z365:W5=LT
M]=K,:.OJND<][9>DB+&M)#HW <>(P0<$<%-$!$15!$1 1$0%1'JK?]QTS_:5
M'[HU>ZHCU5O^XZ9_M*C]T:QRZ+CU63ZE7\4T'QR;]X5O*H?4J_BF@^.3?O"M
MY:VP1$0<Z^K'_H?3O]M+^X+\^IP_%\_XY)]EB_7JQ_Z'T[_;2_N"_/J;_P 7
MS_CDGV6+1Q'8PSZ+3PB(N!I%44>S*[MVM/U(+FT6XSFHWMX]*?\ Z>.SJSGD
MK=PLX6>.4XW2Q-,(LHL4,(!Q6<(J*FT=IF.\W?6%0^ZWFB+;U,S<HJOHF'D<
MD8/'CS7UU?IB.S5FEJEEVO5877JGCZ.MJ^E8,[QR!@<>'/X58MIM%%:GUSZ&
M(QNK:AU5/EQ.]([F>/+ER6;K:J.Z]Q]W1F3N2H;50X<1NR-S@\.?,\%LW\V6
M[FA%]=0LVW:=]<#&'FV2BF+\8Z;?.,>7&]CRKV[7NA-CH(R1Z[.KX#;F_EF4
M2#.[\F<K?7C2]GO5:*NZ43*F80&F!>3@,+M[AV'(SD<5\;/HZR6FM;64U(^6
ML8,,GJ9GSOC'8TO)W?D2,HY3\%HQJZON%UU_34=ILYN]+8<5$[!.R%O=#P=S
M)=P.ZW)P.LKP7VY7NWZIM.J;KIYUKH:5IHJZ?NR.8&&1V&DM;Q[UY!RK)M=J
MI+9W6:.,M?53.J)GN<7.>\\R2?@Y=2^ESM]-=+=4T-?$):6H88Y&'\II2,HC
MZ+:)[22#4Z/(.0;Y3X/R.7GJIH[!M8EKKG(V&@O-#'2P3O.&B>-V>C)ZB1Q&
M5*I[!;YZ6UT\\3WQVR2.6FWI'9:Y@PTDYX\.U>JYVVBNM&^EN=)#5TSN)CE8
M'#/;Y#Y4B8Z)#[54T5)325%5(R&"-N\^20[K6CM)*S!+'/!'- ]LD4C0]CVG
M(<T\00>Q1B/9[IQKVF6CFJ8V>]AJ*J66(?\ H<XA2J.-L4;(XVM9&P!K6M&
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M<'_U*'VZY5UMV*Z:DH9YJ6EEJ.BKJR!F_)34YE?O/:.WEQXX5Q!H#0T !H&
M .&%AD<;(^C9&QL>,;C6@-^9*+4;J233I]:6V/5%[O<_KC3N<R2L,\#&[W-_
M>@ \L#.>*O9_OW?"O/'1TL;"R.EIV,)WMUL30,]N,<_*OLD02J6EK]*TFTK6
MXU5):&O=+2]#W>QCCCHN.[O ^3./(IMI>]Z1EK32Z8JK,:IXWW14(8US@WK(
M:!G"WDU!1S2%\U'2RO/-SX6N)^4A(*&DIW[]/24T3\8WHXFM/S@((!I^YQ:
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M2=HW2'@<0UPQQ[5M)-HFFG/BBMU?ZZU4K@UE/01NFD.3S.!@#X2%+7 .:6N
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MM0P21O'6#^X^1>QAPX$'&..52-'55$>CY:.DF?!:;SJ:2DBGC)&Y2/?QW#U
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M[CL_O78Q&"N;_53Z-DLVL&ZAIF8H;J>_(_)G:..?A''YU9VQ/6;=6:3CCJ9
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M=TI+)::NYW*4Q4=+&997AI=NM',X'$KVJ&;:/Q5:I^(R?N0>(;7](]&)#4W
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M%NG^:WMS>SRY\,<UBAU!;*V^7"ST]4UURH PU$!!#FAXRTC/,8(XCEE0N/\
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M'_9MUY#6/8\;SR0 <Y'-2V^7.Z4&M="6U]8',K!4-K=Q@:V9S("X''' WN.
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MPQ/Q44[,-D8Z+?BEW3D GCD<LA?'3-LUGJ+25MO%;JN2W5LU+'+#3TU+&Z,
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M<]=7&NT1IRYTSA0W":[P4%?$P9#7"7<D8,YX''S%!;**L=9ZNDFUI)IBFO\
M1Z=IJ6G;45=?,6=(XO/>11AYP#@$DX.."^.G]7.MFLK78G:GHM2VZYA[8IVN
MC[HIY6@NP[H^#FD \<#!P@M1?.JJ(:6FEJ*F1D4$32^21YPUK0,DD]0PJWM5
M1J'7U7<ZNCO,EBL5+4OI*04L3'RU)8<.D<YX(#<\  .I?/7%FU%[6FHX+Q?G
M/%)2SR15-+$UCZJ(1.[R9I! X\,MQD=B"S&3QR4S9XG"2)S0]KF<=X$9!':M
M9I2]C4-D@N3:&LH!*7#H*R/<D;@D<1\BT>S"RU5NT];:BHOEPN$<U#"605 C
M#(<L!PW=:#Y.)*B=+J2_1[-M.:K?6OF9253G71FXW^6IC,Z-QP!S:,$8[$%O
MHH9M)O\ 5T-@HJ?3TK#=KQ41TE$\8<&[_%TOP-;EV?@4:N^J)+CJFOL?LNI-
M/VRU-BBFJ'NB%55S%H<=W?X-: 1D[O/*"V%\*^KAH*&HJZI^Y3T\;I9'8SAK
M023@>0*O=%ZM>S5_L:JM046H(9Z<U%'6P;G2-W3AT<H8<9Q@AV!GBI=KG\"=
M0_W?4?PW((S'M@TA)&V1M77]"X B0VZHW,=N=S&/*II9;M07NWQ5UIJX:NDD
M'>R1.WA\'D/D4-V?ZLT_1Z L+*N^6V)\5!")&OJ6 M(8,@C*BND[_2V:/:5J
MVUPDZ<=+'+2'=W(ZB8,+7N9_REQ8,\CQ*"Z45-TMXK:FW,N<^TVTTUZDCZ3N
M%O<[J2-Q&1'@G?(ZM[>SUK]7':54772>F+A35D5AH[I/)!77-T8E92.8' M:
M3WO?.;@./#""XD4.T;25L<DM3#K W^UNC. ^.(N:_A@B2/'#&>!"BFB/9AK"
MDN4E7?WVNW4U?404\E+ QT\^[*X9<7 @-:,-  R<')06XBK&CUE<=*7&^VC6
M-0RO-OMYNE+6Q1"-\\ .ZYKFC@'AV!PYY7VL]IUC?[5!>JO5,EKJZJ,3P4--
M2QO@A:X9:Q^\"YYP>)R$%D(JGNNM+P[93J2KE?%2:DL\DE)4& =YTC7<'M!S
MP<T@_*MDZQZVJK0+J=4&FO)CZ5E!'2QFE:<9Z-V>^/E=O(+&15/J#:!<)-G^
ME;O3R1VF.\31Q5U>Z+I&4+3D.< >'OA@%W#CQ4AT=!5,G[NIM:F_VCHR9(Y(
MXG$.QP<U\>,#R$%!-T5*V;5DFKZ9]WK->T6G(7R/%'00.@WFQM<0U\O29)+L
M9W1@ $*9[+]6R:CBN]%65%)5UMIJ! ^KI"#%4L<W>9(,$@$C.6@\"$&_U5J2
MV:6M@N%ZG?#3&1L0+(W2$N=R #02HW%M:T@Z5C)J^II0XX#ZJBFA9\KG- 'R
ME>#;Y(R+3%FDD>UD;+W1.<YQP&@2<23U*07S6NCX+54/NEZM4M&6D21]*V7?
M!ZMT9+O@P@E,4C)HF21/:^-X#FN:<AP/(@]B_2K#05'>J+9%;HH:^*S/!=(V
M:LBWS3TQ>2W@2!O;I'ON 6GJM4S:9NMEDH=<4VIH:ZOAHJFBD,)>T2''21F/
M!&#U'(06\^OI&7".A?41-K)&&1D)<-]S1P) YX&5Z52NI]/UM3MTM,4>H[G3
MNJ+;42QR1MBS  YO>-RPC=/ER?*I#KG4M58ZZP:8I;W34515PNDJKM7[F]'$
MSAO-!PTO<>'+ X\$%DHJ?.L!I6Z6K<UG2ZFMM;5,I)H'NA-1 YYPV1ICQO-!
MY@CD59-OH;G#J"YU=7=.GML[8Q34?0AO0$##CO<SD\?E0?;45[H=/6>HNEVF
M,-%3@&1X87D9(:. !)XD*)#:YI$.:)JRLIVDXWYZ">-@^%SF !9VZD-V87=S
MB  Z DGJ_EXUN*W6NE:>AD?67^U= &8?FI8[(QQ&,\?@02"DJ8*RFCJ*2:.:
M"1H<R2-P<UP[00M56:HL]'J>BT]45C67:LC,L,&Z>^:,YX\A[T\#V*(;$V&U
MZ$KJFJ8^CM3Z^IJJ)LPW>CI2[+20>0YGX"HQ!IRNU!I6\ZX:QWK]4U;+K:FD
M<600_P U'_ZV[V1GCOA!=5;5145'4552[<@@C=+([&<-:"2?F"@K-K^D7QMD
M94W Q.&0\6VHW2.W.YR6SJ;W3ZCV65EXH_YFLM4LH!YM)C=EI\H.1\B^VR[C
ML[TWG]0A^P$&RTYJ&TZCHC5V2NAK(0<.,;N+#V.'-I\A6U58ZX@9IW:-I"\V
MI@AENM8;971QC J&.:XM>X#FYI&<J;V"AN='+<G76Y]WLGJ724S>A#.@C/)G
M#GCM0-4ZCMNE[8+A>9GPTQD;$"R)TA+G<@&M!)Y*-0[6=(OFCCEKZFFWSNA]
M5130LSY7.: /E*\^W"5D.G+/+*]L<;+S2.<]QP&C?/$GJ6VU%K32$5DK/7&]
M6N6F?$YKXNF;(9,@]Z&@DN)[,(/?JO5%'IRS4]RF9)4T\\\,## 0<F1P:UV2
M<8XY6_7/EXI;C;?4\6..6F>VJ9<()*:FGX.##4[T3'=G M^#*G&HK;K*RV.K
MU!'JDU5QI8C4/H'4D;:1X R8Q^6.O#M[*"RT4/NEQKKQH^UW6VWFFL--50QU
M%14U$39#'&]H.&[Q#0<D#)RHG;=32V35MCHJ76-/JB@NDSJ:6%QB,U.[=RV1
MICQWO#!!'6$%N(JPN=7JF[;4;KI^U706ZT144$\E0(FR21.)=WK >&7=9.<!
MJ_>O+AJ.CUAHRQ:>N(C=715#*B>HC:_@QC?Y4CAEPXD#@,D=2"S$51ZPJ]7Z
M#-KFH;P=0,N=4VWF"OA9'T<T@(9(TL [W(XM/S]:^^L1JG0]CEU.=2RW84A8
M^LH9Z:-D4D9(#NCW1O-(SD<2@M5%%-9R5LM#1STNHZ;3]N<"ZHJ)8F.D((&Z
M&EYW6]><@J+:6U'/1:[M]CBU72ZGMUQ@F>'YC,]*^, ]\8^!:X$\QU(+415M
M2UM]UU>;N+5=WV6P6VH-&V2GB8^>IF:!OG+P0UH)P,#CA>NON=_T3I6]5E\K
M(+R*<QMMT@CZ*65SR&-9*!WOOBWB.K*"?+3:IU!!IVCI:FJBEE;4545(T1XR
M'2.P"<GDHJW3NMS;_7"35Q9>BSI#1MI(S1AW/HQPW\=6]O9ZUHM1:E&K-FVG
M+JZ(03OO5+%/".4<K)BUP^#(^9!<"* 7FZ7G4.LJG3>G:X6RDM\+);C7"(22
M[S\[D<8=P'!I))!7Q;7WO1FIK-0WJ[F\62[2FEBGGA:R>GGQEC268#FNXCEP
MP@L5%65FJK]K^KN=91WN6R6&DJWT=.RDA8Z:H=&<.D<]X.!O9  '4L6>XZHM
M^U*AT]>[A%6V\T$L\50R(1NGPX =(T< YN#Q& 00@FMCOS;M=+Q1-M]=3>ML
MS83-41[K)\C.8SGB.'[0MRJ[H-736^IVAU=UF=-16:8&"(  AHA#MT?">WM7
MXM=DUG>;9#=J[5;[9<)VB:.BI:6-]/"#Q:UV\-YYQS.1Q06.BAVH/7UNGK>Z
MMU!;;#(UN+C5MB#VYQC^3,A ;D]H/-1G3^I)[9K>T6B#5M/J>W71LK3DQ&:F
M>QH<'9CP"T\1@A!/J+4$%7JBY6-D4K:BAABF?(<;KA)G ''/4LZ3O\&I;.VX
MTL4L43I9(MV7&]ECRT\B>L*-:?\ QPZM^(T?[GJ*6"JN=KV207FT3O:;9<9Z
MFI@:T$5$ J'=(TYY8;EW#L070BA>N]5FBT935FGWMGKKP8J:V$#@^28=X[CU
M '>X]BEM!#)3T-/#-.^HECC:U\KP 7D#BXXX<4'DU'?+?IRSU%TO%0*>B@QT
MDA!.,D <!Q/$A>NWUD%QH*>MHY!+35$;98GCDYKAD'YBJ^U1 W6&T:V6,$26
MJR,]<+@W&6OE=EL,9^8OQY OMLMF]9:V]:*J"X&T2=-1%W-]'(XN9QZ]TY:?
MD06$OG55$5+3RU%3(R*")I>][S@-:.9)[%6]JJK]M K+E66^]36.P4E2^CIQ
M30L=-4/8</D<YX(#=[(  ZE\=;6;4AV;ZD@O5_+Q2P2R05%+$UCZF$1'+)FD
M$#CUMQGR(+-BJ8IJ1M33O$T+V"1CHSO![2,@CMR%J](7X:DL<5R;05UO$CWL
MZ"MCW)!NN+<D9Y'&5&]DEGJK?H^T5<U[KZV&>V0&.FG$>Y!_)M.&[K0>'+B3
MP45M.K+U3[/-.ZMKJ^2:GIZ^:*YL+&X?3F:2,/X#FSO,8\N4%SHH;M&OU31T
M5LMEDFW;O>JEE-2R- =T;,ATDF.QK X_#A1F]:KDN.L+EI_V54NG;;:61,EJ
M7NB[IJI7#)#=_O0T#&2&\R@MA?"OJX:"AJ*NJ?N4\$;I9'8SAH&2<#R!5UHS
M5[X]9LTQ47^CU#!4TSJFDKH"SI&EA&]'(&''(Y#N&>(4PUU^!=^^(S_8<@C4
M>V#2$D39655P=$X!PD%MJ"TCMSN8PI;IS4-JU)0]UV2NAK( =UQC=Q:>QPY@
M^0K3;(N.R_2O]VP?8"T>LJ&.P[1-*WZV#H9KE5^M=;%&,-J&/8]S7N YN:6<
M^Q!9**L[54ZAU[6W2JHKQ)8K'1U3Z2E%+"Q\M2YAPZ1SG@@-SP  ZCE?2TZE
MOEHO-_TY>7,NE=16XW"W5+(NC?5L&06/:. <';HX8SE!9"*GM'UMRU3;Z:OH
M-I$9O4C Z2A;2PF*)V.,9B.'\.6<]65LM7:MDJ-8/TW!J2CT_2TE.V6MK)=P
M32/<3NQQ;YP. R3@\P@L]%5VF]6/MVL+?8I-3T6I+?<F/%/.PQ]T4\C!O;LG
M1\'-<"<' P0IQIF@NM RO%YNOKBZ:I?+ >A$?0Q'&&<.>.U!^-6:JM.E*6GJ
M+W/)%'/*(8A'"^5SWD$X#6@GJ6AI=J^D9ZF.!]PFI72.#6NJZ26!A)_YGM _
M:M;MGGBI;EH2>IE9%!'?87/D>X-:T8=Q)/);;6&LM'#3M=%<[M;:JGFB='W.
MR5LKY20<-:T9))ZD&_U/J.V:9M!N=XG=%1[[6;[(W2$EQP  T$G*C VN:1#@
M):RM@:3@R3V^>-@^%SF #Y5#[]1W&W[#=*TMZ#FU\591A[7<VCI>]!\H;NCY
M%=KFM>PM>T.:1@@C((0?"WUM-<:*&KH)XJBEF;O1RQ.#FN':"%Z%5MBI9;)M
M0U+IVRS=RT-QMGKC"QK=YE)4;Q87-9R )<'8Y9"L+3U+6T5EI*:ZUW=]=&S$
MM3T89TASSW1R[$&P1$0$1$!$1 1$0$1$!$1 1$0%%MJ=OJKKL[U#06Z!U165
M%&^.*)O-[B. "E*(*RLNL[Y066@HG[/]1OEIZ>.$D&'=):T \=_EP7VT?IJN
MN=]U1?\ 4MN;;XKY3QT?K89!(YL3&EI=(YO#>=GD.05CH@K"SU.K="4<5FJ+
M+5:HML W:6NHI&-F;&.#8Y(WD<0.&0<87U?;=0:]N-ODU#;C8;!05#:GN%\K
M99JU[3EG2;O>M8",[N22592((*RTUXVVR7<TK_6PV$4HJ.&[TO3[VYVYQQ7H
MTE;*VDU[K>MJ:=\=)6R4AIY3C$H;#NNQ\!X*9(@I_:KH2YNK3<M(1YCN-13B
M[4+0 )=R5KVSMZM\8P>T%6/7W&YP:DME#36AU1;:ADCJBNZ8-%.6CO1NXR<G
M@MRB#SW)CI+?4LC!<]T;@ .LX53[/]0W_3.CK79JO0>H9IZ.+HW21=#NN[XG
M(R\'K5P(@K;3]OO>H->.U/<K4^PT\%O?14\,LC7SRN>X$O=N\&@8X#)XJ+:8
MLMPL-L%DK]F\%XN[9'YNTQA?#4$N)$DCWY>/*,$J\D00;958ZFAV<06B_43(
M)7&H9-3D#=W7ROX ?FD'YBHGLFLU=)JBI@KIA56?29FMMMD)WND>YV2XG\YC
M-V/R<58^J-,4VH33.FKKG12P;P9)0U3H20[&0<<#RZQ\"]FG;)0:>M,-MM4/
M14L62 7%SG.)R7.<>)))))*"O]4Z:FM&KJ^_4VE:+4UON38^Z:9T<9J()&#=
MWH]\8<TC&6Y!R,K:Z(@DJ*VJK!H.AT['%'BG?(V)M1(\YSPC!W6XX<\J>H@J
M&_RUUY9-37W92:RY.:6,J8YH'1DXX.$QP]HX]F0O9;]+WVANVS9M>^6XOM;*
MEM;5YR&%T)#02>)XD-!\BM)$%.U]EKK)K/4%==-&G5T%SF;+25#1%(ZF:!CH
M2V0]ZT'CD<^M;/9A9+K0W[6-5<;%!9H:[N=U-34Q:8@!&06C=P"X<-XX R3A
M6>B"(;(K966?9U9*"YT[Z:L@AW9(GXRT[Q[%YMF]IKK;=]:RU],^".LO#ZBG
M<['\I&6- </)D%3A$$9V@:7.JK)'3059H;A2SLJZ.J:W>,,S,X..L')!\A6A
M9K'5U&SN:XZ#K:JN;PZ:AJHS3R?\P<X@MSV$'"L1$$&TGI^[5.HI]4ZM,#+@
M^#N>CH83OLH8B<N&]^4]QQD@=6%#]#7?4-BFU-/1V26^6B>^5@$=&]K:BGD#
M^)(<0'-=PY'(XJZ5J]/V.DL459'0])NU=5)62=([>_E)#EV.P>1!$]+6F\WK
M6?LNU'0BTF"D-%16[I!*]K7.#GR2.'#>.  !R"U^A1?]*W6NL,VFZJJHJFYS
M5$=SBF8(FPR/+LN!.]O#/(!6@B"!6&SW"GU3M J9J61D%>Z(TKSC$N( TX^7
MAQ6TV6V^JM6S^Q4-Q@=!5P4S621.YM(ZN"E*((7LNM=;:Z74#;C3/IW5%YJJ
MB(.QW\;GY:X8ZB%XK;8KF=<;0IPV6CAN=-314=9PQO" M+FX.>]<0K!1!1UC
MM-?0V*"Q/V7T<MWCCZ)URJ.ADIY'8XS.><O)/$[N,]2VTFG+N=@]JLHH)?76
M)M,'TPQO-W9VN=UXX $JVT0%"K1:JZ':OJ"YRTSVT%10TT44QQNO<TNW@/@R
M%-400O9E:ZVV#5'KA3/@[JOE74P[V._B<X%KACJ*^=GM-=#M>U#=):9[;?46
MVFABG.-U[VN=O =?#(4X1!5^A8K[I"ZW"PR:>JJVCK;K-61W.&5@A9%*=[O@
M3O;S>/ #BM;+IJ72-UN8.B*75-KKJI]7!-##":BF+R2Z-XD]\W/(@\!S5Q(@
MA&E:*:2S76H=I*AT]+/&Z.&"$1],]NZ?YPL  R>0R5L-F%!56O0%BH;A"Z"K
M@I6,DC=S:X#DI.B"I-=Z5O1U540:?IW&SZI;'#=Y6.W>Y>C<-Z3'7OQDL^1;
MS:IIJKN-AL\5FH(JZEMM7'/+:B\1LJHF@CH^/#AP(!X<%/T04G<+97WJX6":
MT[/(K%34EUIYIYY(X65!:UW'=#/R!S))[."GM1;:QVU>BN;:=YH&6>6G=-PW
M1(9F.#?AP"5+T0?BH!=!*UHR2T@#Y%3>S6^:ATGHNWV6LT'?YZBE#P9(3#N.
MR]SAC+P>M7.B"MZ6UW_6M\MERU/0"R6BUSBII[:91-+42CWKY2.#0WF&C/'F
MM=>=-SZ=U-=KC'H^CU3:KI-W26-BB-52RD ._G!WS#C(P>!)5LH@@NC8*@PW
M"OAT1;M/SM9NTD;C&V:7AD[YC;WC2=WK)Y^11/4T=?J2DJ:.KV7/BO<S"R.X
M"6'<A?CA()AA_ \<8RKF1!7\5@NU-J;0+JM\E>;;15,-;6]1D,;&AQSQ[X@K
MQ6^VZCT/67.'3-!2W^R554^I93&J$$])(_B]N2"TMSQ'(C*LU1"Y[/[95W6H
MN5'67:TUE20Z=]NK'1"4@8RYO%N<<,X01+3\=\J-MT=5?7TPF]97N[DIB7-H
MV&4!K7//OG$AQ)P/(I1HNUUM%K/6U75TSXJ:MJX7T\CL8D:(6M)'RC"VNE-(
MVG3!JY+;',^KJRUU355,SI9IR!@%SG']@P%OT$(J;57.VRT-V;3/-M999*=U
M1PW1(9FN#>W.!E;+0.I*C4]KK*NKMQH'05DU*&=)T@>&.W=X.P,\<CAV%25>
M:VT%+;*-E)00,@IF%Q;&P8 ))<?G))^5!!=JL%S;>=(W2UVBKNK+=622SQ4N
M[OAIC+0>^(',K$VM]4U6(;3L_NC*A_ 27">**)GE<6N<2/(%8B((3IW0D5/I
MR^4=]G%=<+\Y\ERG:, N<W=#6=8:T<&K46JXZNT510V:MT_5ZDHZ5G1TURH9
M6"21@]Z)(WD8<!@9!(*LU$%<P6O4&M+Y;:_4U"VRV2W3"HBM;I1-+4S =X^1
MS>]:UN<AHSQYK[W'2T=VVL.KKM9Z>MM+;,(625,+)&";IB< .S@[IYX4_1!6
M][TK[%=2T.I=&6:)V\!1W"WTD;(Q+"X\)&C@-YAP?*."ET-RNC]6U%N?9W,M
M#*9LK+ETP(?(3@Q[F,CAUYZO*MTB",;3Z"JN>SZ_T5O@=45<](]D43<9>X\@
M,J,VG6E_HK/1T@V>ZA?/#"R+B^%K"X #GO\  >7"LU$$"TQ8+O=-4QZLU;'%
M25<,#J>AML3^D;2L<>^>Y_Y3W<N'#"UD<=^T-JF_ST-@J;]:;U4BM:ZCD8V2
MGEW0US7->1D'=!R"K01!5^BZ#4=1M6N>H;[:3;Z6KM+(88^D$G1%LGO'.'-W
M N.. R MULDM5=:+'=8;G3/IY9;O5SL:_'?1OD):[AU$*;(@INILU=8]7:AJ
M;IHHZMCN=3T])6-$4CH&8 $+A(>]:#UCGE;O9/9;I;;WJRIN=E@L\5;-!)!3
MTQ:8FM$>"&XP"1UG R<JR405=LQCOVD]W2U7IVJFIFUD\K;K'*SH.B>]SP2"
M=[>XXQA+/HRKN>G]H-IN<4E$+K=YYZ65P!RTAA9( #RWF\O(K11!6T&J=:T5
M(RV5&BJBMNT;1'W;'51MI)2!CI-X]\.W=QE:Z[Z%N%LV4"S4N;E=9KC%75+H
MANA\CJAKY" >H#]@5M(@U.J:>:JTK=Z:FC,D\M'+&Q@YN<6$ ?.O%LWH:FVZ
M!T]15\+H*NGH(8I8W<V.# ""I&B"O;O1WO2NL+C?[%:W7FVW5D0K**&1K)XY
M8QNB1F]P<"W (R#P7RH*"]ZQU;:+W?;3)8[;9C))2TLTK9)JB5[=W?>&\&!H
MS@9)R58Z((/HRTUU%M!UU755,^*DKIJ5U-*[&)0V$-=CX#P4UF!="\ 9)!PO
MVB"M-FNS^U,T#;:?4FFK=ZZ='(V<U%+&Z7)>[&78)S@CK7WT=I^LME#>M$U]
M),_3[87B@KP1WT,N083U[[,G!ZQCL5B(@I:W6RLTU116BY;-*._34S1'#<:*
M"G#*AHX-+P_BUV,9Y\>*F1-VL^E*62VZ-MKZB9Q=66RDF9$&M(_)):&O=C&<
MX\BFZ(*>M=FJ[OK"SW"SZ/FT>RCE,E95.,<9J8\?S/1QDAP)P=X\L+S:.NFH
M++?M9U=NLS[U:9;U)')!32!M1#(&,[\!Q#7-((&,@C"NI:JPV&CL;[D^AZ7-
MPJG5DV^[/\HYK6G'8,-'!!"[;9;OK'4K+YJBV>M%#24LU+14+Y!),[I1A\DA
M' =[P#1Y5Y;!5:GT%:H=.#3%9?Z2C!CHJ^CFC;TD><M;(UQ!80#@D9'!6FB"
ML8=,7I^DM;7"ZPQNU!?X'XI*=V\(FMB+(X@XXWCVGEDJ::-I9Z+1EDI*J-T5
M3#00Q21NYM<(P"#\H6Z1!6VF*?4&GM'5XIK"VOK'W:JE-'+.V(OA?*XAS201
MDC' XYK2T]HJKYJ>S5=IT/+I2:DJVSU5Q>Z*(OC .]$&1GO]_@,E7&B"G9--
MRZ0NER:=$4FJ;96U4E7!/!#":BG+R28WB3WS0>1!Y'BI)9:B>SZ8O=]]AEOL
MLT,+Y8:2)T;)96,:3B1S6[K<D=I4^7PKZ.GN%%/25L39J:=ACDC=R<TC!!0>
M335RDO&G[=<9Z9U+)5T[)G0N.2S> .,\.U174]BO%KU.=4Z1C@J9Y81!<+;(
M_H^[&M)+'-?R:]N2./#"G4;&QQM9&T-8T!K6CD .I?I!74NK-8W2,TEHT556
MZJ>-TU=SJ(Q#">6]AA)?CG@87PO.AYK3L;OUAM9EN5TJX99992 'U50\Y<[Y
M?W *S$001FSC3M?HZ*WU=AMM-5RT3(GS1TL;98Y-P=\' 9W@[CE>:GIK_4;+
M-06*ZT4C[M34510PS, #:X=&X1R,'5O9&0>M6(B"!VW9SIRLT71T%ST];H:J
M6ACBGD;2QME8_< <=X#.\#GCVK\Z9J]2631URH:FS25]RLPZ"C<'MC;<8P.\
M<#^2<<".T>53Y$'FMDT]1;J6:LI^Y:F2)KY("[>Z-Q&2W/7@\,J$ZBLM[L>J
MJG5&E(8Z]M7$R*X6ES^B-06<&RL>> >!PP>!"GZ(*YGU/K&]Q.H;/H^JM$TK
M3&ZON4\8CI\_E-:TDO(ZAP6OUKH6JH]C,NF[#TU=<#+%(^8@=)-*9FO?*>/P
MGGR"M9$%<NU5K6GA-N.BY:F[-&XVL94L%&_A_.$D[P'7NXSU94>U9IY^F="Z
M5M\\S:BL=?J6>IE:,!\KYMYV!V9.!Y KG41ET!:JC4,5VKJFZ5CX:CNN"FJ*
MMSX(9?SFLZL=0Y!!H-:Z5FI-72ZIHM/T>I(JJG93U=OF9'TC=S.[+$YX(S@D
M%O#/!>O1<+JR]MJ!L]HM/TD+"6U,[(6U!DZMQK <#&<DE6$B"K[?'J#9[57*
MCHK#4Z@LE9525E,ZCD8V6E+SET3FN(R,\00>OBM^(K[JK15\I;U;H+//7T\M
M/3T_3=*^-KF%H,A'#.3G ZE,400G9U=;V^DI+/=],5EL%#2,A?5R31NCD>P!
MO> ')! )SU<E^=G5@ECV7TUDOM(8GR1SQ3028/>OD?S^$$*<(@J;9CIC4%-J
M)HU.QSJ+3M,ZWVJ5YSW0'./\MSX$1M8SY2OKJ/34MCU7<KS3Z2H]3VZYECYH
M.CC-332M:&Y9OC#F$ $C((*M1$$'T%3NGKJBLDT/1:;A8T-@>6Q"HD)YY#!A
MK<8Z\J1:NIYJO2EZIJ6,R5$U%-'&QO-SC&X #Y2MLB"OM,;.[!-H6VT5YTW;
M65KJ&.*H<:6,2A^Z X[P&=[/7E>:S:=N=ST->]$:@@?'%2L[DH[C@%M3%C,;
M]T?E-P X=>.O*LI$%-4T-;;H&VZOV3T-QN,0Z/NRDBIFTTY'#?RX;S >>"#A
M2Z[/NEFL5!!0Z-H+A2O8>[:&CE8P1N/YC7-#7C.<YP5-T05+I6QU=5K:DO5L
MTQ)I"VT\$K:N%SF,->YP[T&.,EH#3QWCQ*UNSF]:CL-IN#X+!-?+3472L=%W
M#(ULU.X3.!:YKR 6DC((/#)RKL(R"#R*UFG+'2:?H'T=OZ3H7SR5!Z1V\=Z1
MQ<[Y,DH('1:1N.KZZ]WC6%*VV.N%N-JIZ&.02OA@)WG/>X<"\NXX'(!9ME]U
MCIVUT]CGT?4W:KI(VT\%?35,;8)VM&ZU[]XYC. ,C!ZU9R(*FO.CKNS93J6G
MDC;6:AO,LE9/%3^]#WD8C:3C(:T 9\A5IM:[N0-QWVX!CY%]D05CIJ/4&G-F
M.GZ-NF!=)8XWLK:)\[8Y&-WG$;H(+7<^1(7@L%BJ;IK*W7*VZ1DTC24PD[M>
MYT;#6!S<"/HXR01GCO'LX*W404I;-.S:)A-GJ-G]-J>CC>YU+<::"#I"QQ)#
M)6OP<MSC>S@C"LC0M))!:GS5&GK?8)YWY-+2;I(8/>[Y:T NY\LCRJ1H@@6V
M6R5E^T];*6AHC6[MUI99HL CHFO[\D'@1CFOWJ[9O9KE9GLL-NMMHN\+VSTE
M9!2,88Y6G(S@<6GD1V%3I$%8:PM]_P!5Z)L=5+:'-K*.JCJ*^R2R!K:QK"0Z
M/>SC=)[X9X<!E1G4%IN-_ELCK-LY98XJ6Z4L\\[XX&3%C9 2&AGY(YDD]7)7
MJB"NM=4%VM^N['JNU6N:[PTM+-1STM.]K90'D$/;O$ X(P1GK7PUA8*^]R6/
M5<>GZ6IN%)"^.ILM?N/,L3R#NM><M:]I&0>7$A68B"L=-Q>N5XIFMV84=GIX
MSOS55;' US<<A&& DG../#DI59]1U-?K2_6.2W&&"VLA>RJ$N\)>D;G!;CO3
MSZ^I21>:FH*6EJJNIIX&1SU;FOG>!QD+6AH)^  !!%MK]KK+SL_N=!;J9U54
MRNAW86XRX"9A//AR!6S@T9IB)S)(].69DC<$.;0Q @_16_1!"]J-NN-\LM-I
M^UPS-@N=0R&LJ8R *>G'%Y^$@;H'E7XCV6:3CC;&RAJFL: T-%PJ0 .S'2*;
MH@J^QZ>N5@H]9Z8HJ"9UBDII)[3)O[P!D8X/@XG/!W$9[2O/I#55_LFE+5:Y
MM :ADJ*.F9 YS3#N.+1C()?G'#L5L(@KVSV:]ZFU)0:BU;21VR&V[QH+4R42
MD/<"#+*X<-[!P .2E.G;C<Z^6YMNMH=;F4]4Z*F<9@_NB,<I. X9[%N400C:
MY9:F^V&VTM)1]V!MTII9HL CHFN.\2#P(PMW2Z0TW2SLFIM/VB&9A!;)'1QM
M<T]H(;P6\1!!]K]IKKQI>EIK73/J9F7&EE+&8R&-E:7'CV *0:RIIJW2EXIJ
M6,RSS4LC(V-YN<6D +<(@J"_:8O#]*: F-I]=8[+!'W?9)'M;TYZ$-Z^]<YC
MAD \"O*^U7&ZZHTO76[045@H*.X"2>0LA9.X;KADAG)@^$Y)'#@KI1!#[1;*
MR':?J"XRT[VT-114T<4QQA[F[^\!\&0OCJ2U5U3M/T?<8*9[Z&DAK&SS#&(R
M]@#<_"0ILB"%;4+7772/3 MU,^H--?*6IFW,=Y&UQWG'/4%^]L-KK;SLVOMO
MM=.^IK)X0V.)F,N.\.65,D05?M L5PDN^FKOZQ#45NH*=T51:RYN6O<!B5K7
M=ZYPY8/R+Q6*U7&KVAZ=NT&BX-.VJGCJF/W&QMF)<P &4,X 9X 9)Y\E;J(*
MSAI[YH&\78VFQU%]L5SJ36AE+(UL]-,X /&ZX@.:2,Y!&,KV5E!?==Z/O%'?
M+;%83.6.H&&7I96.80\/DQP]\UO =658"(*W;JO6PIO6YVB)GW<#HS6"KC%&
MXXQT@=[['7NXSU97CK]#UEGV>6&R4 ?<*N"[05=3(T ;Q,I?(_CU#/S*U$05
M]?K=>--:PJM2Z>MKKO37"!D-PH8Y R4.83NRQEW!QPX@M.%\(*6^:WU':*Z]
M666QV:T3&JAAJ)6OGJ9L8:2&Y#&MXGF<Y"LA$%9T-MU'HFNND>F:"EOUEJZI
MU2VE-4()J65_%XR06EI/'J(RM;9([[5;;:2KOKJ5LPM$C^Y*9Q>VDC,F&ASC
M[YQ.<G '#@IA=- 6RLNE3<:2LNUJK:G!GDMU8Z$2D# +F\6YQCCC/!>[2ND;
M5IEU5+;F3R5=60:FKJ9G333$<MYSC^P8""-6_2<]RJMHM'=()(*.\3!L$W [
MS3"&[[?@/;V+X6_46LK';H+15:,J;K74S&PQUM+51MIYV@8#W%QWF' &1@\5
M9B(*MU[9;Y7U&E;U7V6GOC;>V0U]GAD&XY[VX#V!_!Y:>IWR+7V^TW&OUWIB
MZ4>AX=/6NEDFZ5P9$V=V]&0"\,X!N>7$GCU*XD00ZRVRM@VG:DN,M.]M%4TE
M+'#,<8>YH=O ?!D+\;,K/44.B#;KQ2F&22>IWX9,'+'RO(^<%31:/4^FJ?4(
MIC/6W*CEIRXQRT-4Z%W?#!!QP/#M""MMF-FK)-95=OJG":PZ1EFIK:_.\'OE
M.\ 3RS$SO/)E7!63.IZ6:9D,DSF-+A''[Y^.H9ZUX=.6.AT]:V4%KB<R!KG/
M<7N+WR/<<N>YQXEQ/$DK9H*MT?LSH:ZW2W?5])4F_P!TE=5536U<L?1;Q[V+
MO' $-&!\Z_5WT2S2E]LM_P!&6ZIFG9/W+7P=TOE=+2R<"?Y1Q]X0' #RJT$0
M5A;X;[L[J;C1VZP55_L=7525D#Z25C9J9TG%T;F.(RW>!((/7Q6\$=_U5HR_
M4M[ML%GFKH)(*6 3=*]C7,P#(1PSD\AU*9H@@6S2NO<=IHK!=]-5EO\ 6VB9
M3NK'RQNBE>P!HW,')! )Y<%\]FFF9!LKCL.HZ)T1F-2R:"3!.Z^9Y':.((*L
M%$%6;,-/W[U[%3JVG<TV&F]:[;(YV\)V[QWJ@<>!<P,;\ 7SU)IB>R:ONE^@
MTM2:IH+KT;IJ8QQ]T4TC!N[S"\8<UPYC(.0K71!!M!T[I[A-6/T/0Z;@8S=A
M>YL0J7N//@P8:W'ERI'JZFFK-*WBFI8S)/-22QQL'-SBP@#YUMD05'HG4^H-
M/Z.L]HGT#J&6IH:2.G<YAA#'.:W&02_..'8MW9;/?=2:EH=1:KIF6NGMX=W%
M:&RB4B0@CII'C@78)  Y95@H@J^WQ:@V>UERI*&Q5.H+)6U<E93NHY&-EI2_
MBZ)S7$9;GB"#UG*]>G;5J"IOUVUC=;?#2W*6A[CM]J=/O=&T'>_E) ,9<X-Y
M X':K%1!2>JZ2X:JHJJC]K*2AO\ ,W=CN9FA:V!W5()F]^<<\8X\EM+]I"LL
M]X@OK+%1ZL,U%#2W&"=C#.Z2,'$T9>",G/%O#D%;"(*_T3":N\&H.SZCT]2Q
M,)943,A;4.?V-:P' QG))[%N=":FJ-2LO+JJW=P]P5\E$W$O2"4- [[.!CGR
MZE)UY+9;:.UP/@M]/'3Q/D?,YK!S>XESG'RDE!"]JMAJ;]6:09%0"NI(+O'+
M5L<UKF"'!#BX'F.*DM'I/3M#4-GHK#::>=ARV2*CC:YI\A R%ND003;/;[A<
M=(1,M%#-7U,-=3S]!#C><UK\G&3A?"77>H9&[E#L\OKISP;W1+#$S/E=O' ^
M16$B""Z7L%UMLU[U3>6QUNI:^G 91PNQ' Q@)93L<>T\W<L\5*-.5E=<+)25
M5UMYMU=*S>EI3('F,YY;PY\,'Y5LD0$1$!$1 1$0$1$!$1 1$0$1$!1;:G<*
MJU;.M0UUOF=!5T]&^2*1O-K@.84I4,VT?BJU3\1D_<@U-DT;=*NRV^OCUOJ)
ME5-3QS=^Z%\8<YH/%ICXC)Y96HNVH;G7[,M=VV]R1NO-F;+32U%.TQMF;N;S
M) ,\"0>(');?3]%KV;3%L937?3U/ ^CB$<@HI72,;N#!XR8)Q\B\VJ=,,TQL
M?U7$^KEKZ^J@FJ:NMF #YY7#B<#D,  #J 0>ZBVG6*FM$$K8KK5T%/$QD]QI
MJ*22GC(&'9>!QP>9 *EU;J.U4>G?7V:L:;48VRMGC:7AS78W<!H).21@#M7Z
MT[14T&FK=20P1LIFTL;!&&C=QNCAA5CIC4DFE]B5IJ:>FCJ)GU+Z. 3.(BC+
MJE[6N>>IC>'S()92[2K,^MI:>NI;O:V5;Q%3SW"A?#%*\\FAQY$^7"]^J]<V
M32MPHJ.]32Q2U<;Y(2R(O#MTM&Z .)<2X  #BJPVS,U+!HD^O]]L$L$E53[E
M/3TCF2/=TK3B-SI#RXGER!4MU;3PU&VW0O3QMDZ.CKI&!PSAP#,'X>*#?W37
M5IM-AH+O=XZV@HZR=M.WNF L?&3G#GM/%K< G/8O#%M/L!FINZH[G1454\1T
M]?5T3XJ>9QY /(X9\H"\&VN&.HI=)03L;)#)J"C:]CAD.&\>!\B]6W2"*793
MJ!LD;7!D&\T$<B"""$'ZJ-JFGH8W5(9=);2QVZ^Z14,CJ5AS@Y?CB,]8!"D=
MZU-:K-9HKI6U/^QS;HA=$QTAE+O>AH:"23U+\24%*S1IH6P1BD%%T0BQWN[N
M8QCX%7%EU14V#9)H2&BA@EKKH8:"":K)$,#CG#WXXD #@!C*"96O:%::VZTU
MNJJ6ZVNIJLBF]<:-T#9R.ICCPSCJ."O=JC6-JTY4TU)5NJ*BXU0+H**DA=-/
M(T<W!HZAVG"J_:@W4%.=+1Z@OEEJFNOE(8H*:E=%,2'^^!+W< #QX=84LL$E
M/2[8]4QW4QLN%53TS[>Z7 +Z=K"'MC)['Y) 02/3&L;9J&JJ:.G;5TEQIFA\
MM'6P.@F:TG =@\QY02M;5;2K-'654-%37:YQTKS'/44%$^:&)PY@N',CKQE;
M+5,U/56R]T=KGIG7\VV;HF1O;TP!:0T\.(&]CY5J=C=5;?:RL;:-T,38*9L=
M0PD-='*/YP/'4[>R3GM0;^DU59*O3;K_ $]RIW6=K"]U5G#6@<\YX@CL/%1M
M^TVQU%&^1T-VI:"=A;#<*BADCII,\ 0_' 'M. JUN!@EL&J*^C9TFD?91332
MM8W,4D+=T3N':POP3CAP*N?4E?9&Z,KIZZ:D=:'T;LG>:6/86' ;VY'  <\\
M$$+V.ZBI;5LPT/#=))A)<C)3Q3$%S>DWWD-<[J)P<? K"U-?*+3=CJKK<W/%
M+3@%W1MWG.)(: T=9)('RJK-#:;.I_4Z66@C>8JUD+IZ24<XIV2O<QP[.(Q\
M!*]%KU"=I5\TQ1LB+:&@B%RNT9&0VI:7,C@=V$/#G8/4T()?=]HEBM-T];*U
MU6+D88YHZ6.G=))+OYPUC6Y)<-TYZAVKT:;UM:K[=)K7&RMH;K%'TKJ.OIW0
MREF<;P!X$9["M):Z:"3;=>YY(F.FAM%,V-Y&2T&23..SD%]M8QL9M,T',QH;
M*YU;&YXX%S>AS@]HR 4'NN^O[707.HM]/1W:YU=-@3LM]$^81$C(#G<!G!SC
M*VFGM3VK4%GDN5JJ#+3Q%S96EA:^)S??,<T\0X=A4/HK_J/5%YOL>GJBT6FD
MM=8ZB<*R!TTTSV@$O(#FAK3D8YYP5J=DCY7U>THSUE)62]W=_/2,W(GNZ'CN
MC)QQX'B>(02"AVLV"XTC*FTTMYN$>YTDO<E"^3H!_P Y' 'KP"2O4[:=IR:.
MG-HDK+S--'TS8+;2OF>UF2,N&!N\0>!P?(O+L#@BAV2Z>Z*-C>DB>]Y ]\XR
M.R3VKR;$*"EI(=8OIX61N?J&J:2T8[T;N!\ R>'E02_3&I[5JFW5%1:II'"!
MYAJ(I&&.6"0<V/:>((6DT!5:?LVA9:R@KZL6>&>H?)47*3+VN$C@_)[,@X])
M7@TA&V+:OM!;$T-:^&BD<!P!<62 GX>"@$K?_P C]CFJ(W26NGU.Z6X- RWN
M<54N\7#K:"6DH++AVHV)Q@DJ:>[T5OG(;'<*NA?%3.SP;WYY ]I "V%]UU:[
M5=/6R."X7*XA@E?3VZE=.Z-IY%V. SU<5M[E7V:*TF>Y55 +:X#OYGLZ(@\N
M)X'JPH?6Z=K8=6W2\Z,U#005E4(VU]#5QB:-SF-PPY:X.8=T\NM!+M-7^CU%
M0.JZ!M0QK)#%)'40.ADC>,9:6N [1Y%M5"]':R=7NO5)J".BH*RTU#:>HGBF
MS32%PRTL<[''B 6GB"IH@J.S45TU9KC6L$VI[U04]LK(H:>*CDC:T-=&''.\
MP]:V8J;WHG5%CH;C>9;S8[M*ZE:^JB:*BGFW2YO?- WFG!!R."T6DXM1R;0]
MHATW56J!@N$/2BN@DD)/1#&Z6N&/E4NM6D+M4ZEIKYJ^\0U\M&'=QT5+3F*"
M!SA@R<7$N=C(X\D'ZL=VJY=J.JZ"HJ7&@I*6DDBC=C=C+FN+C\N%XZ*[UVNK
M^Q]BJYZ+2UNE_E*N-H#KC*#[R,G_ .4,<7#F> [5%[MIVMU3M=U7:FU[J*SR
MTE&ZO,)(FE:&NW8VGJ:3G>/8,=:D>@+G4:8KHM#ZCW&20,W;16[H8VOA;^3C
MD)&# (Z^?E(2ZV:CH;CJ&[6:G;4"LM@C,Y?$6L.^,C==UK0;:KE6VG9S<JRU
MU4E+5MDIVMFCQO-#IF-.,^0E3&*III*J>"&>%]1%CI8VO!>S/+>',9\J@/J@
MM[VJKMN$!W2TV">6>Z(T'W]@UW@BZ>WZXOXJFMWF=T]#-'G_ )F[@R/E44U;
MJ.OONPF^3W01P7:BJ3159IR6LZ2.=H+FG.<$8/RE2V:V[0*RD,!OM@HVO;NF
M:GH9'2,':T.DQGX5']I6G*;3&PNZVNFEEGQNOFGE.9)Y'RM+WN/:24$@EVI:
M?@A[IZ.Z26EIW772.AD=2M/6=_'$>4#"D=[U/:;-9X;G6U.:2<L$#H6.E,Q<
M,M# T$DGJ7WK**F;IZ:C%/%W(*8QB'=&[N[N,8[,*K;%JBJL.RG0=/10T\M=
M='1T,$U8X]#3DYPY^.)P!@ $=2":VG:#::Z[4]MJ::Z6NJJ<]S"XT;H!.1S#
M">&?(<%?74^O+)IJ\0VRZRSMJYZ<U$+(X72&7O@T,:&\2XD\!CM5<[2F7^GJ
M](1Z@O=EJ@Z^TAB@I:5T4Q(<<N!+W< #QX=8XJ376GAG]4!9'31M>Z"Q3R1E
MPSNNZ5K<CRX<1\J"07K7EGL=JM5PO0JZ"GN,G1QB>$M=&=TN[]O-O!O[EXZ;
M:98G5--'71W.V0U1W::IN%&^"&8]C7'D<#/'"U6V"&*HONSV*>-LD3K['EKA
MD'#'D9'P@+]^J$I8:G9?<&31M<&STY;P]Z>F:.'9P)'RH/9)M5T['&VJDCNC
M+0YP:+JZAD%+DG [\CEGAG&%(-2:JM6GJ2FGN$TKNZG;E-'3PNF?.[&<-:T'
M/!>?7='3C9]?*40QBG;;Y6MCW1N@!AP,>3"A%-J>X6[2.SBSVIE)ZXWFBC8R
MLKB3% &0M<3@8+G'. ,A!,+!KNUW>\"TN@N-MN;V&2.FN-*Z!TK1S+,\#CLS
ME?;4NM;38+A!;I^ZJNZSL,D=#10.FF<P<W;HY#AS)"K[4?KW#K_0T-^O-GK)
MN[GN9#1TSHI6CHG N.7N[WD.KC\"WVAI(:7:1K6GNKHV7B>:*:G,I =)2]&
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M2Q553&TRO#6,'=#PT9/ =@5C? @J2V4=TU7K_6M-+J:\V^EME3!%3PT3XVM
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MCR84IV<U]GDT#:)+9+2QT45*QKPTAHC>&X>'=C@[.<]:K[9?>:"TVC:?>;9
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M1:Q++&V"H@?-(UK'$$RD/:&N.,XQR03.76%F&CWZGAJ346=L)GZ6%I)+1G/
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M'N")EH='T1IH\L;NYSCO<'FMJV-K8A&!A@&[CR+](@U-#INT46GA8J>AB]:
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M008[)=$;Y/K#'T9.\8>GEZ+/]GO;O[%,Z.E@HJ6*FHX8X*>)H;''&T-:T#J
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,(B B(@(B("(B#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g184865g35j50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g35j50.jpg
M_]C_X  02D9)1@ ! 0$!0P%#  #_[1;Z4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !X< 5H  QLE1QP"   "   < @4 "C@S-S0W-U\P,30X0DE-!"4
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M;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T
M;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M     $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M
M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="
M0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M     $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M    0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0\/7
M       *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M              !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R
M:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P
M4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +
M8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! !0\/7  $  @%#P]<
M 0 ".$))300F       .             #^    X0DE-! T       0   !:
M.$))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M      H  0         ".$))30/U      !( "]F9@ ! &QF9@ &       !
M "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M   &       !.$))30/X      !P  #_____________________________
M ^@     _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@  #A"
M24T$"       $     $   )    "0      X0DE-!$0      !     "   "
M0    D      .$))300>       $     #A"24T$&@     #00    8
M         2P   09    !@!D ', <  P #  ,P    $
M         0             $&0   2P                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   2P     4F=H=&QO;F<   09    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $L     %)G:'1L;VYG   $&0    -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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MUY_-_P %]J]3_KWJ)*=A))))3__9.$))300A      !7     0$    / $$
M9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    % !! &0 ;P!B &4 ( !0
M &@ ;P!T &\ <P!H &\ <  @ #( ,  R #0    ! #A"24T$(@     !,DU-
M "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!
M*  #     0 "   !,0 "    'P   '(!,@ "    %    )&':0 $     0
M *@   #4   !1     $   %$     4%D;V)E(%!H;W1O<VAO<" R-2XY("A7
M:6YD;W=S*0 R,#(T.C V.C$X(#$S.C$V.C(Q       #H $  P    '__P
MH ( !     $   09H , !     $   $L          8! P #     0 &   !
M&@ %     0   2(!&P %     0   2H!*  #     0 "   " 0 $     0
M 3(" @ $     0              2     $   !(     3A"24T#_0
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M*  #     0 "   " 0 $     0   3(" @ $     0              2
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M  $  @,! 0$             !08$!P@# @'_Q !2$  ! P,!!0,&!PL)!0D
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M*#3RC)1KQ>YA=O25]X=P/FQ4!>[],NY"7RE#*3D-(Y9[SWFOHZ9O 5CS%?\
MF3^^LZ%HRY/*'G/91D==Y6\?F'[ZBG+B%PNG)/'VQ_!CUO0KT2.[+D(8CH*W
M5G  K;ECMZ+7;68J,$I&5J_&4>9KQL=CB6AL]@DK>4,*=5ZQ_<*E*['#>'_2
MISGW/_1+"'*5?:+_ #&U^D)^JJJCH[XR0OSC]4U>]76R1=;8AB+N=H'0L[QP
M,8(^VH#3VE[A O$:2^&>R;)*MU>3R(JI>6]6=[&<8MK37]S62?-DO5:7G_\
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M6=,C-3(CT:2@.,/(+:T'DI)&"*]:4!&6^SMP]/HM'G$AYA#)8#CI!<W<$#B
M!P'#ETKVLEM:L]HB6Z.MQ;,9L-(4X05$#OP!6;2@%05TTZ)M[;NK%RFP9B(Y
MBYC]F04%6]Q"T*Z@?-4[2@('X"G_ -9KO_DC?PJE94%B9;W(4Y(DL.-]FX'
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/D]:SJ4H!2E* 4I2@/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g184865g96g96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g184865g96g96.jpg
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M*"@H*"@H*"@H*/_  !$( 4@'; ,!(@ "$0$#$0'_Q  <  $  @,! 0$
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MRO9E4>J<JFS(EL^8?]]0/O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24
M(O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24
M(O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24
M(O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24 (O:^F\G[RCM?3>3]Y24
M(O:^F\G[RCM?3>3]Y24 -974D,3(U8S"J]&KO7DWDGM?3>3]Y3Y<OFXOQ6_W
M)8$7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I
M* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I
M* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I
M* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y3XZ@ID:JI
M'XOK*2SX_P"0[[ -?0T<$M*Q[V9<N<KE><S]KZ;R?O*?;9]!C_/]5)($7M?3
M>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3
M>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3
M>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3
M>3]Y1VOIO)^\I* $7M?3>3]Y2-7TD,5.KHV8=E$Y5-F1+I]$7[R?J!][7TWD
M_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD
M_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD
M_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD
M_>4=KZ;R?O*2@!%[7TWD_>4=KZ;R?O*2@!%[7TWD_>4C6^DAFI]J1F795.53
M9D2U?1$^\H'WM?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1
MVOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1
MVOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1
MVOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1
MVOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y1VOIO)^\I* $7M?3>3]Y3
M';D1L<S6\B2*B$XA4'R9_P 5P'NW_P#,?C.)1%M__,?C.)0
M                        !$E_S*'[BDLB2_YE#]Q26
M                       1/^U?_*_N2R)_VK_Y7]R6
M              0ZOZ;2?:XF$.K^FTGVN)@
M     (EL^8?]]261+9\P_P"^H$L                               $2
MY?-Q?BM_N2R)<OFXOQ6_W)8                              /C_ )#O
ML/I\?\AWV 1[9]!C_/\ 5221K9]!C_/]5)(
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M745#+H[8AFBD:B(Y'-145%W[MIO^X'?     !$MGS#_OJ2R);/F'_?4"6
M     #S*KVQ/=&Q'O1JJUJKC:7Q)GQ%66OA>=<]:U.E:7359VWIW2-D:ZIC1
MB;'*NU_]\H%J@K_37"A;;Y?[AI[L&KH-24B/3L"K5J<:YJ95&/:JHO/]F],H
M9N"[A&I.$!EU6DM]11.M\C(Y$F<UVTKMKDQS;('=      !CJ9XZ:"2:=Z,B
MC3:<Y?$@&0%?VCA4LUYU^W2EMIJY]4ULCI9IHEA:Q6MSC9=ARK]J)^98
M     $2Y?-Q?BM_N2R)<OFXOQ6_W)8         '!<*/"*S@]@I:JOM%15T5
M0_BFS0RM14?A5PK5W\B+O-?=.%J&QV:T7C4&G[C1V>Z(Q8:J*2.9&[3=IJ/:
MCD5/!W^/D4"S05QJ3A6M]EONG:%*&:LI;[Q:T=9!*W8<U[FMRJ+O3&TA8X
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MB<JJ!+!4M7PT16K5E'9]1Z8NMGBK'(V"IJ',7**N$<K4W8SRX550MH
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MXSX_&7RU<M151454Y%\0'T       $2Y?-Q?BM_N2R)<OFXOQ6_W)8
M  %$?M?_ / MG_\ F2?^U(0M36+4NO\ @KT=IZS6*6FIHX:6:6X5D\+8\-AV
M4V6M>YZHNUGY*+NY#I/VBM+:AUI9[=:M/6EU1Q%1V2^H?411L^0YNRB.=E5\
M+FQ]IWO!W#7T>C;107:@DH:NBI8J9['R,>CE8Q&[358Y=RX\>%]050/"W87:
M9U#P366CF;+-1*R)DLK5V7/2:/PE1-^-KQ9Y#L:;56J-/\/-#I6Z7KMO;+C#
MQF'TS(N*56/5-G9W[E9XU7<O/O,_#+I'4>HM?:4N5EM#JFBL\K999%J(F<9_
MB->J-1SD7D;X\;SSJ+2>I*WAZL^K*>S2.M%'&R%[EJ(4>O@O17(W;Y$V_MW*
M!,NU]U*ESUBZ_P!?-INW4;52RRL?"UE0Y$=A</:JR*N&KA-R9QC)S5#PN:CJ
M> BKU$D4;KQ3UR4#ZED2*C6JC5XU6<F?"1.;*IN\1FM&DM=4_"%J^LN5H@N2
M7*&6FH[E45C4931N5=G9;O<B;*HFRB)R<N%R>^"73.M-)Z(?:ZK3L4G&7;C:
MBGEJ(7)44SHME[<95$WM:J97>JHG)D#J]$:I@O-3'=+-JV6ZV.GHI9*ZCJV1
M-J()$V5:[#6-7&$>G-GD53@+=PIWF^Z.U#J."\.I+M3U:,MUHB@:^-T2;"JC
MTV5<Y51SM^TGR=V#IM.<&447"?->;99:BP6%U!)3U%-+*S_'ED16JC&L<Y&L
M1%1>5-Z)A#7\%^G=<\&5?=;+2V"&]VBJGXVGK&UK(&L7&-IR+EV]$;E$3=C=
MD"X])79U]TS:[H^!U/)5T[)7PN146-RIX3=_,N4,.HZVV::T[=+A5Q,2FV7R
M2QHW*SO=NV<?ZG.7#43UHAM:!M2VBA2O?$^KV4XUT35:Q7>/9155<?:4SPC0
M\*=SU?'4:=LE$VU6]R]AI43POVW\G'*U7;G8SLYWHBKXU4(W7[.^B:S1VC9G
M79BPW"Y3=D/@\BW&&M7U\JK]N/$6F5SP4TFNGUUSK^$58F3[$<-'#"Z/8:W*
MJ]<,5=ZKL<N_<6,      #X_Y#OL/I\?\AWV 1[9]!C_ #_5221K9]!C_/\
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M3.\VX            1)?\RA^XI+(DO\ F4/W%)8
M   $:GH::FJJBHIXDCEJ%1TJM541ZI_J5.3.-V>5<)GD0D/:CF.:N<*F-RX7
M_=#Z (UNH::W4K:>BA;#"U579;XU5<JJKRJJKO55WJO*20         (G_:O
M_E?W)9$_[5_\K^Y+                    >)X8ZB%\4\;)8GILN8]J.:Y.
M947E/8 QTU/#2P,@I88X86)AL<;4:UJ>I$Y#(       0ZOZ;2?:XF$.K^FT
MGVN)@                              (EL^8?]]261+9\P_[Z@2P
M                           1+E\W%^*W^Y+(ER^;B_%;_<E@
M                      ^/^0[[#Z?'_(=]@$>V?08_S_5221K9]!C_ #_5
M22                            B73Z(OWD_4ED2Z?1%^\GZ@2P
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M3VVGDVVPM;O<Y5PB95V]$3<F< 64  @     $2U?1$^\I+(EJ^B)]Y0)8
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M^*X#W;_^8_&<2B+;_P#F/QG$H
M   B2_YE#]Q261)?\RA^XI+
M (G_ &K_ .5_<ED3_M7_ ,K^Y+                              (=7]
M-I/M<3"'5_3:3[7$P                              $2V?,/^^I+(EL
M^8?]]0)8                               (ER^;B_%;_<ED2Y?-Q?BM
M_N2P                              ?'_(=]A]/C_D.^P"/;/H,?Y_JI
M)(UL^@Q_G^JDD                           !$NGT1?O)^I+(ET^B+]Y
M/U E@                            !$M7T1/O*2R):OHB?>4"6
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MB3&[Q;]_K)-NSCI7X,U:+CF^<4\'N;YQ3P91V<2  J
M                 QL_S"+[JFP->S_,(ONJ; SGNUI[  (H
M                      -=5_3T_#_N!5_3T_#_ +@(
M             ,$_ST7VJ9#'/\]%]JF0
M  'BD^;7[RGL\4GS:_>4#,                               ##4_)9]
M]#,8:GY+/OH9@                              ?%Y%/I\7D4#'2?1V_
MG^IE,5)]';^?ZF4                           !AJOF5^U#,8:KYE?M0
M#;@ *                           1;7]$3[R_J2B+:_HB?>7]0)0
M                                 0Z#DG_%<3"'0<D_XK@/<WSBG@]S
M?.*>#2.S*0 %0                                  &-G^81?=4V!KV
M?YA%]U38&<]VM/8 !%                                  !KJOZ>GX
M?]P*OZ>GX?\ <!                             !@G^>B^U3(8Y_GHOM
M4R                               \4GS:_>4]GBD^;7[R@9@
M                        8:GY+/OH9C#4_)9]]#,
M             #XO(I]/B\B@8Z3Z.W\_U,IBI/H[?S_4R@
M             ,-5\ROVH9C#5?,K]J ;< !0
M  "+:_HB?>7]241;7]$3[R_J!*
M   "'0<D_P"*XF$.@Y)_Q7 >YOG%/![F^<4\&D=F4@ *@
M                   ,;/\ ,(ONJ; U[/\ ,(ONJ; SGNUI[  (H
M                           -=5_3T_#_ +@5?T]/P_[@(
M                  ,$_P ]%]JF0QS_ #T7VJ9
M          >*3YM?O*>SQ2?-K]Y0,P
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M                              'BD^;7[RGL\4GS:_>4#,
M                     ##4_)9]]#,8:GY+/OH9@
M           ?%Y%/I\7D4#'2?1V_G^IE,5)]';^?ZF4
M          !AJOF5^U#,8:KYE?M0#;@ *
M1;7]$3[R_J2B+:_HB?>7]0)0
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ML_S"+[JFP->S_,(ONJ; SGNUI[  (H   !YXQGUV_P"X'H
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M._D0^2WJXQZ ;=FSL=5JU'.5\:>-^SN1,(GYY-C36&>"6]/[+C<MRY?\%?\
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M$1$8A\:9F9S( "H
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M1.RN53GV4=_NNY#<VNFTC?M'05==4R2T#H6+/%/<YU:QR(F6JU9.5%3<F.;
MY5-/6J/\'%,]EAHJ*B*BHJ+O14.)X9*2"?@^N\LS-M\4;7,RJX:NVF_')GUG
M76[8[7TW$Q20Q<4W8CD^4U,;D7UG,<+O_5Q?/PF_^MIE9Z7*?WA:NTM[I?\
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MS7)R*B^,]    !%I[C1U%;4T=/5025=-L\?"QZ*^+:3+=I.5,H2@
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MY5T\=.QKUSR^$B9WGM+%:$N"UR6J@2N5=I:CL=G&9Y]K&<FQ XIU,  (
M #75?T]/P_[@5?T]/P_[@(  "L.%*O66Z0435\"!FTY/^\[_ /A$_P!SB3>:
MX>LFJK@J^)Z-_P!FHAHS]-Z:F*+5,1H_.>HJXKM4SJ  W8@
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MJN"N*H7V #\L_3           PU/R6??0S&&I^2S[Z&8
M              'Q>13Z?%Y% QTGT=OY_J93%2?1V_G^IE
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M9Z&5DU]_F[+K:6S6];C/1(WLA..2)K7*FTC$547+\87')O3*[SB^$"_6_5O
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M/9JMU14::M<%-;WM:BU<5+V.E0[?N:FRBN1-_A<F5PF=^.:J(BG.!TP ,5
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M_DOZE:'Z/T=R*[-,Z='Y[U5N:+LQKU  >IYP
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M 'YA^D          !AJ?DL^^AF,-3\EGWT,P
M      /B\BGT^+R*!CI/H[?S_4RF*D^CM_/]3*
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MR  ,)G.-XP  &-^0 "HBIA>0       &-G^81?=4V!KV?YA%]U38&<]VM/8
M!%                                  !KJOZ>GX?]P*OZ>GX?\ <!
M 8ZB&.H@DAF8CXI&JUS5Y%12FM5Z?FL=:J8<^DD7_"E_LOK+I,%;205M,^GJ
MXFRPO3"M<AZO2^IFQ5^)>;U/IXOT_E0(.ZOV@*B)SI;0])HN7BGKAZ?8O(OL
M..K*"KHGJVKIIH53Z[%0^[:OV[L9IE\2Y8KM3^J$8 &S(
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M8\':Y,^L] "!:+9';8YE1RRU-1(LM1.Y/"D>N[/J1$1$1/$B(3P"S.>L@ "
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M&#L.E_AH?Y$"4=,G)3P_R(9P.*=3AA\:U&IAJ(B<R(?0"*
M  PU/R6??0S&&I^2S[Z&8                              'Q>13Z?%Y
M% QTGT=OY_J93%2?1V_G^IE                            8:KYE?M0S
M&&J^97[4 VX "@                          $6U_1$^\OZDHBVOZ(GWE
M_4"4                                     $.@Y)_Q7$PAT')/^*X#
MW-\XIX/<WSBG@TCLRD !4                                  !C9_F
M$7W5-@:]G^81?=4V!G/=K3V  10
M :ZK^GI^'_<"K^GI^'_<!                             !@G^>B^U3(
M8Y_GHOM4R                               \4GS:_>4]GBD^;7[R@9@
M                               8:GY+/OH9C#4_)9]]#,
M                    #XO(I]/B\B@8Z3Z.W\_U,IBI/H[?S_4R@
M                    ,-5\ROVH9C#5?,K]J ;< !0
M         "+:_HB?>7]241;7]$3[R_J!*
M          "'0<D_XKB80Z#DG_%<![F^<4\'N;YQ3P:1V92  J
M                         QL_S"+[JFP->S_,(ONJ; SGNUI[  (H
M                              -=5_3T_#_N!5_3T_#_ +@(
M                     ,$_ST7VJ9#'/\]%]JF0
M          'BD^;7[RGL\4GS:_>4#,
M ##4_)9]]#,8:GY+/OH9@                              ?%Y%/I\7D
M4#'2?1V_G^IE,5)]';^?ZF4                           !AJOF5^U#,
M8:KYE?M0#;@ *                           1;7]$3[R_J2B+:_HB?>7
M]0)0                                     0Z#DG_%<3"'0<D_XK@/
M<WSBG@]S?.*>#2.S*0 %0                                  &-G^8
M1?=4V!KV?YA%]U38&<]VM/8 !%
M!KJOZ>GX?]P*OZ>GX?\ <!                             !@G^>B^U3
M(8Y_GHOM4R                               \4GS:_>4]GBD^;7[R@9
M@                               8:GY+/OH9C#4_)9]]#,
M                     #XO(I]/B\B@8Z3Z.W\_U,IBI/H[?S_4R@
M                     ,-5\ROVH9C#5?,K]J ;< !0
M          "+:_HB?>7]241;7]$3[R_J!*
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M #LV#Z_L4=FP?7]B@ .S8/K^Q1V;!]?V* !"J)F/JT>U<MV,9QX\CCF<_L
M<<SG]@XYG/[  '',Y_8..9S^P !QS.?V#CF<_L  <<SG]@XYG/[  '',Y_8.
M.9S^P !QS.?V#CF<_L  <<SG]@XYG/[  '',Y_8..9S^P !QS.?V#CF<_L
M<<SG]@XYG/[  '',Y_8..9S^P #%*]KI(U1=R9R>^-9S^P !QK.?V#C6<_L
M <:SG]@XUG/[  '&LY_8.-9S^P !QK.?V#C6<_L  <:SG]@XUG/[  '&LY_8
M.-9S^P !QK.?V#C6<_L  <:SG]@XUG/[  '&LY_8.-9S^P !QK.?V#C6<_L
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M@ .S8/K^Q1V;!]?V*  [-@^O[%'9L'U_8H #LV#Z_L4QV_*LE=A<.D54]:
#?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">POS AM<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ONKURE THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2309515<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6707 Winchester Circle, #400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">307-2892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001637715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPrimarySicNumber', window );">Entity Primary SIC Number</a></td>
<td class="text">2834<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text"> EXPLANATORY NOTE  Post-Effective Amendment to Registration Statement on Form S-1  OnKure Therapeutics, Inc., a Delaware corporation, filed a Registration Statement on Form S-1 on October&#160;23, 2024, which was declared effective on October 30, 2024 (the &#8220;Registration Statement&#8221;). This Post-Effective Amendment No. 1 to Form S-1 (the &#8220;Post-Effective Amendment&#8221;) is being provided to include the fiscal year ended December 31, 2024 financial statements, contained in the Annual Report on Form 10-K for the year-ended December 31, 2024 filed on March 10, 2025 (the &#8220;Form 10-K&#8221;), as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K.  The information included in this filing amends the Registration Statement and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement. <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember', window );">Business Contact [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">6707 Winchester Circle, #400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boulder<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">80301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">307-2892<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_ContactPersonnelName', window );">Contact Personnel Name</a></td>
<td class="text">Nicholas A. Saccomano<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_ContactPersonnelName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of contact personnel</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_ContactPersonnelName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPrimarySicNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Primary Standard Industrial Classification (SIC) Number for the Entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPrimarySicNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:sicNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_BusinessContactMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 110,761<span></span>
</td>
<td class="nump">$ 29,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">3,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">113,003<span></span>
</td>
<td class="nump">33,766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">770<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">109<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">114,907<span></span>
</td>
<td class="nump">35,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,968<span></span>
</td>
<td class="nump">3,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">7,026<span></span>
</td>
<td class="nump">3,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">10,530<span></span>
</td>
<td class="nump">7,285<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,079<span></span>
</td>
<td class="nump">7,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 14)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">258,551<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(154,724)<span></span>
</td>
<td class="num">(102,051)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td>
<td class="nump">103,828<span></span>
</td>
<td class="num">(101,842)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, convertible preferred stock, and stockholders' equity (deficit)</a></td>
<td class="nump">114,907<span></span>
</td>
<td class="nump">35,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=okur_ConvertiblePreferredStockSeriesCMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue', window );">Convertible preferred stock, Series C, $0.0001 par value; no shares and 7,404,919 shares authorized; no shares and 6,840,620 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively; liquidation preference of $195,823 as of December 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">129,825<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stocks</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stocks</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=okur_ConvertiblePreferredStockSeriesCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=okur_ConvertiblePreferredStockSeriesCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockParOrStatedValuePerShare', window );">Convertible preferred stock par or stated value per share</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,404,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840,620<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840,620<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockLiquidationPreferenceValue', window );">Convertible preferred stock liquidation preference value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,823<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">943,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">12,660,590<span></span>
</td>
<td class="nump">313,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">12,660,590<span></span>
</td>
<td class="nump">313,747<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">226,285<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, issued</a></td>
<td class="nump">686,527<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, outstanding</a></td>
<td class="nump">686,527<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock liquidation preference value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock par or stated value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 43,795<span></span>
</td>
<td class="nump">$ 32,115<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">10,591<span></span>
</td>
<td class="nump">4,819<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">54,386<span></span>
</td>
<td class="nump">36,934<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(54,386)<span></span>
</td>
<td class="num">(36,934)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income and (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="nump">2,013<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_InterestAndOtherExpense', window );">Interest and other expense</a></td>
<td class="num">(300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Total other income and (expense)</a></td>
<td class="nump">1,713<span></span>
</td>
<td class="nump">1,623<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss and comprehensive loss</a></td>
<td class="num">$ (52,673)<span></span>
</td>
<td class="num">$ (35,311)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic</a></td>
<td class="num">$ (15.28)<span></span>
</td>
<td class="num">$ (124.41)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted</a></td>
<td class="num">$ (15.28)<span></span>
</td>
<td class="num">$ (124.41)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic</a></td>
<td class="nump">3,447,071<span></span>
</td>
<td class="nump">283,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted</a></td>
<td class="nump">3,447,071<span></span>
</td>
<td class="nump">283,817<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_InterestAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_InterestAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income (expense) classified as operating.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Class A Common Stock [Member]</div></th>
<th class="th"><div>Class A Common Stock and Series C Preferred Stock [Member]</div></th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Preferred Stock [Member] </div>
<div>Class A Common Stock and Series C Preferred Stock [Member] </div>
<div>Convertible Preferred Stock [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Class A Common Stock [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Class B Common Stock [Member]</div>
</th>
<th class="th">
<div>Common Stock [Member] </div>
<div>Class A Common Stock and Series C Preferred Stock [Member] </div>
<div>Class A Common Stock [Member]</div>
</th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Class A Common Stock [Member]</div>
</th>
<th class="th">
<div>Additional Paid-in Capital [Member] </div>
<div>Class A Common Stock and Series C Preferred Stock [Member]</div>
</th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th">
<div>Accumulated Deficit [Member] </div>
<div>Class A Common Stock and Series C Preferred Stock [Member]</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred Stock Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,738,936<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2022</a></td>
<td class="num">$ (54,418,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,389,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,656,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (57,074,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">182,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,818,192<span></span>
</td>
<td class="nump">283,492<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,377,000)<span></span>
</td>
<td class="nump">$ 53,059,000<span></span>
</td>
<td class="nump">$ 12,377,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (2,711,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (9,666,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Class A Common Stock from the exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Class A Common Stock from the exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NetIncomeLoss</a></td>
<td class="num">$ (35,311,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35,311,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred Stock Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,840,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2023</a></td>
<td class="num">$ (101,842,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 129,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(102,051,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,840,620)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,154,093<span></span>
</td>
<td class="nump">686,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger</a></td>
<td class="nump">129,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (129,825,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodSharesConcurrentFinancing', window );">Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,571,736<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodValueConcurrentFinancing', window );">Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs</a></td>
<td class="nump">54,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,428,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,343,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of stock</a></td>
<td class="nump">65,499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65,499,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts', window );">Reverse recapitalization transaction costs of OnKure</a></td>
<td class="num">(2,085,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,085,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares', window );">Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">267,269<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue', window );">Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes</a></td>
<td class="nump">$ 6,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Issuance of Class A common stock for the settlement of restricted stock units (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of Class A Common Stock from the exercise of stock options (in shares)</a></td>
<td class="nump">2,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of Class A Common Stock from the exercise of stock options</a></td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization', window );">Adjustment for fractional shares in the reverse recapitalization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation expense</a></td>
<td class="nump">4,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,530,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NetIncomeLoss</a></td>
<td class="num">$ (52,673,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52,673,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Convertible Preferred Stock Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2024</a></td>
<td class="nump">$ 103,828,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258,551,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (154,724,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,660,590<span></span>
</td>
<td class="nump">686,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AdjustmentForFractionalSharesInTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for fractional shares in the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AdjustmentForFractionalSharesInTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to additional paid in capital reverse recapitalization transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, conversion of convertible promissory notes, shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, conversion of convertible promissory notes, value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuedDuringPeriodSharesConcurrentFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period, shares, concurrent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuedDuringPeriodSharesConcurrentFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuedDuringPeriodValueConcurrentFinancing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value concurrent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuedDuringPeriodValueConcurrentFinancing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuanceCostNet', window );">Stock issuance cost net</a></td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuanceCostNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock issuance cost net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuanceCostNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">NetIncomeLoss</a></td>
<td class="num">$ (52,673,000)<span></span>
</td>
<td class="num">$ (35,311,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">4,530,000<span></span>
</td>
<td class="nump">199,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">459,000<span></span>
</td>
<td class="nump">417,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use asset - operating</a></td>
<td class="nump">203,000<span></span>
</td>
<td class="nump">143,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_Non-CashInterestExpense', window );">Non-cash interest expense</a></td>
<td class="nump">120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on sales of available-for-sale securities</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Change in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">2,256,000<span></span>
</td>
<td class="num">(1,497,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued and other liabilities</a></td>
<td class="num">(5,927,000)<span></span>
</td>
<td class="nump">1,713,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Lease liabilities</a></td>
<td class="num">(281,000)<span></span>
</td>
<td class="num">(210,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,117,000)<span></span>
</td>
<td class="num">(34,546,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">15,925,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(52,000)<span></span>
</td>
<td class="num">(246,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">15,873,000<span></span>
</td>
<td class="num">(246,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit', window );">Cash acquired in connection with the reverse recapitalization</a></td>
<td class="nump">57,736,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PaymentOfReverseRecapitalizationTransactionCosts', window );">Payment of reverse recapitalization transaction costs</a></td>
<td class="num">(2,045,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock', window );">Proceeds from the issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,783,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock', window );">Payment of issuance costs associated with the issuance of Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(723,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from issuance of convertible notes payable</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable', window );">Payment of issuance costs associated with the issuance of convertible notes payable</a></td>
<td class="num">(142,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from the issuance of common stock in connection with equity plans</a></td>
<td class="nump">26,000<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">116,129,000<span></span>
</td>
<td class="nump">53,125,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">80,885,000<span></span>
</td>
<td class="nump">18,333,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">29,876<span></span>
</td>
<td class="nump">11,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">110,761<span></span>
</td>
<td class="nump">29,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use asset obtained in exchange for new operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Issuance of Series C Preferred Stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,313,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConversionOfSeriesCPreferredStock', window );">Conversion of Series C Preferred Stock</a></td>
<td class="nump">129,825,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConversionOfConvertibleNotePayable', window );">Conversion of convertible note payable</a></td>
<td class="nump">6,120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization', window );">Assets acquired in connection with the reverse recapitalization</a></td>
<td class="nump">17,222,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization', window );">Other liabilities assumed in connection with the reverse recapitalization</a></td>
<td class="nump">9,459,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable', window );">Reverse recapitalization transaction costs included in accounts payable</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable', window );">Concurrent Financing issuance costs included in accounts payable</a></td>
<td class="nump">37,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger', window );">Concurrent Financing issuance costs paid by Reneo prior to Merger</a></td>
<td class="nump">89,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Proceeds from the issuance of common stock in Concurrent Financing</a></td>
<td class="nump">58,881,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with the Concurrent Financing</a></td>
<td class="num">$ (4,327,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets acquired in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concurrent financing issuance costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concurrent financing issuance costs paid by reneo prior to merger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConversionOfConvertibleNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of convertible note payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConversionOfConvertibleNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConversionOfSeriesCPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Conversion of series C preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConversionOfSeriesCPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_Non-CashInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-cash interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_Non-CashInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other liabilities assumed in connection with the reverse recapitalization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of issuance costs associated with the issuance of convertible
 notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PaymentOfReverseRecapitalizationTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment of reverse recapitalization transaction costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PaymentOfReverseRecapitalizationTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse recapitalization transaction costs included in accounts payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire preferred stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow resulting from the sale of an interest in a corporate unit during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInterestInCorporateUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Business</a></td>
<td class="text"><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">1. Organization and Business </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">OnKure Therapeutics, Inc., (&#8220;OnKure&#8221; or the &#8220;Company&#8221;) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. The Company was formed in 2014 as Reneo Pharmaceuticals, Inc. (&#8220;Reneo&#8221;) under the laws of the State of Delaware. On October&#160;4, 2024, the Company changed its name to OnKure Therapeutics, Inc. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger with Reneo </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&#160;4, 2024, Radiate Merger Sub I, Inc. (&#8220;Merger Sub I&#8221;) a&#160;wholly-owned subsidiary of Reneo completed its merger with and into OnKure, Inc. (referred to herein as &#8220;Legacy OnKure&#8221;), with Legacy OnKure continuing as the surviving entity as a wholly-owned subsidiary of Reneo. This transaction is referred to as the &#8220;Merger.&#8221; Following the Merger, Reneo changed its name to OnKure Therapeutics, Inc. Legacy OnKure remains as a wholly-owned subsidiary of the Company. The Merger was effected pursuant to an Agreement and Plan of Merger, dated as of May 10, 2024 (the &#8220;Merger Agreement&#8221;), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation Radiate Merger Sub II, LLC, a Delaware limited liability company (&#8220;Merger Sub II&#8221;), and Legacy OnKure. In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo&#8217;s common stock for an aggregate purchase price of $65.0&#160;million contingent upon the concurrent consummation of the Merger (the &#8220;Concurrent Financing&#8221;).&#160;On October&#160;4, 2024 (the &#8220;Closing Date&#8221;), the Merger and the Concurrent Financing closed. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;). For accounting purposes, Legacy OnKure is considered the accounting acquirer and Reneo is the acquired company based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#8217;s board of directors and senior management. Accordingly, the Merger was treated as the equivalent of Legacy OnKure issuing stock to acquire the net assets of Reneo. As a result of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company and the reported operating results prior to the Merger are those of Legacy OnKure. Legacy OnKure&#8217;s historical financial statements became the historical consolidated financial statements of the combined company. All issued and outstanding Legacy OnKure common stock, convertible preferred stock, restricted stock units, and options to purchase common stock prior to the effective date of the Merger have been retroactively adjusted to reflect the exchange ratio for all periods presented. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note 3 for further discussion. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risks and Uncertainties </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The board of directors of the Company discusses with management macroeconomic and geopolitical developments, including inflation, instability in the banking and financial services sector, tightening of the credit markets, international conflicts,&#160;cybersecurity, and sanctions so that the Company can be prepared to react to new developments as they arise.&#160;The board of directors and the management of the Company are carefully monitoring these developments and the resulting economic impact on its financial condition and results of operations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidity and Capital Resources </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company had recurring losses from operations, an accumulated deficit of $154.7&#160;million and cash and cash equivalents of $110.8&#160;million as of December&#160;31, 2024. The Company&#8217;s ability to fund its ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities, issuing debt or other financing vehicles. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company had determined that substantial doubt about the Company&#8217;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following the completion of the Merger and Concurrent Financing, as described in more detail in Note 3, management believes the Company&#8217;s cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements and as such substantial doubt has been alleviated. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s ability to secure capital is dependent upon success in discovering and developing its drug candidates. The Company cannot provide assurance that additional capital will be available on acceptable terms, if at all. The issuance of additional equity or debt securities will likely result in substantial dilution to the Company&#8217;s stockholders. Should additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from the Company&#8217;s assets or discharge liabilities in the normal course of business, which may, among other alternatives, cause the Company to delay, substantially reduce, or discontinue operational activities to conserve cash, which could have a material adverse effect on the Company&#8217;s ability to achieve its intended business objectives. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#8217;s financial condition and its ability to discover and develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2. Summary of Significant Accounting Policies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP and reflect the operation of the Company and its wholly owned subsidiaries, OnKure, Inc. and Merger Sub II. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in&#160;one&#160;operating segment: clinical research. All equipment and other property and equipment are physically located within the United States<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and disclosure of contingent assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates. The most significant estimates relate to external research and development expenses, and the fair value of stock options and restricted stock awards and units. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">from&#160;non-owner&#160;sources.</div> The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods <div style="display:inline;">presented</div>. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred in performing research and development activities. The costs include employee-related expense, including salaries, severance, benefits, share- based compensation, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, depreciation, and facilities and overhead costs. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records research and development expenses in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase common stock, and restricted stock units for common stock, are granted to employees, board of directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">and&#160;non-employee&#160;consultants.</div> Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of 10 years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. The Company will continue to apply this process until enough historical information regarding the volatility of its stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes</div> with maturities approximately equal to the expected term of the stock options. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. (See Note 12). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for grants under its various Equity Incentive Plans and employee stock purchase plan (&#8220;ESPP&#8221;). The Company accounts for all stock-based awards granted to employees and directors at their fair value and recognizes compensation expense over the award&#8217;s vesting period. Determining the amount of stock-based compensation to be recorded requires the Company to develop estimates of fair values of stock options as of the grant date. The Company calculates the grant date fair values of stock options using the Black-Scholes valuation model, which requires the input of subjective assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. The fair value of restricted stock awards granted to employees is based on the quoted closing market price per share on grant date. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Stock Valuation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lack of marketability for the Company&#8217;s common stock prior to the Merger, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#8217; Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted prior to the Merger, the Company had considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#8217;s research and development programs, including their stages of development, and the Company&#8217;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock; and the market performance of peer companies in the biopharmaceutical industry. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash, receivables, prepaid and other current assets, accounts payable, and accrued expenses approximate their fair values because of the short maturity of these instruments. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All highly liquid investments with maturities of 90 days or less, at the time of purchase, are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value. The Company&#8217;s cash and cash equivalents consist of money held in demand depository accounts and money market funds. The carrying amount of cash and cash equivalents was $110.8&#160;million and $29.9&#160;million as of December&#160;31, 2024, and 2023, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&#160;1. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions above federally insured limits of $250,000 as of December&#160;31, 2024 and 2023. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held and of the money market funds in which these investments are made. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company carries its property and equipment at cost, less accumulated depreciation, amortization and impairment, if any. Expenditures for renewals or betterments that materially extend the useful life of an asset or increase its productivity, such as leasehold improvements, are capitalized. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <div style="display:inline;"><div style="-sec-ix-hidden:hidden133878817;display:inline;">three</div></div> to <div style="display:inline;">seven years</div>. Leasehold improvements are amortized over the <div style="-sec-ix-hidden:hidden133878837;display:inline;">shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets</div>. Repair and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Leasing &#8211; Lessee Accounting </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. The Company&#8217;s operating lease agreements are primarily for office space and research labs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For operating leases with a term greater than one year, the Company recognizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">the&#160;right-of-use&#160;(&#8220;ROU&#8221;)</div></div> assets and lease liabilities related to the lease payments on its balance sheet. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The ROU assets represent the Company&#8217;s right to use the underlying assets for the term of the lease and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising for the agreements. ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is periodically reviewed for impairment unless a triggering event occurs. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, except for the ones that depend on index or rate, are excluded from the calculation of the ROU assets and lease liabilities and are recognized as variable lease expense in the statements of operations and comprehensive loss in the period in which they are incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company uses its estimated incremental borrowing rate in its present value calculations. One of the Company&#8217;s lessee agreements include an option to extend the lease, which the Company does not include in its minimum lease term unless it is reasonably certain to exercise such option. Operating leases with a term of less than one year are recognized as a lease expense over the term of the lease, with no asset or liability recognized on the balance sheet. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently payable and deferred taxes. The Company accounts for income taxes using the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, and operating losses and tax credit carryforwards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is recorded to the extent it is more likely than not that some portion of a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company&#8217;s significant deferred tax assets are net operating loss carryforwards, tax credits, and accruals. The Company has provided a valuation allowance equal to its net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that most of its deferred tax assets will not be realized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting for uncertain tax positions requires a more likely than not threshold for recognition in the financial statements. The Company recognizes a tax benefit based on whether it is more likely than not that a tax position will be sustained. The Company records a liability to the extent that a tax position taken or expected to be taken on a tax return exceeds the amount recognized in the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no unrecognized tax benefits as of December&#160;31, 2024 and 2023. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as general and administrative expenses. No such expenses have been recognized during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and the United Kingdom (&#8220;UK&#8221;). As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities in the United States, and the UK tax returns from 2018 forward are subject to examination. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncemen</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">issued&#160;ASU&#160;2023-07,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>&#160;to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period, with early adoption permitted. The disclosure related to this ASU are in Note 4 below. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2023-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes (Topic 740):</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Improvements to Income Tax Disclosures</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which</div> requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <div style="white-space:nowrap;display:inline;">220-40):</div> Disaggregation of Income Statement Expenses</div></div>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on its financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger Agreement and Concurrent Financing<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_MergerAgreementAndConcurrentFinancingAbstract', window );"><strong>Merger Agreement and Concurrent Financing [Abstract)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_MergerAgreementAndConcurrentFinancingTextBlock', window );">Merger Agreement and Concurrent Financing</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">3. Merger Agreement and Concurrent Financing </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As described in Note 1, Merger Sub I merged with and into Legacy OnKure, with Legacy OnKure surviving as a wholly-owned subsidiary of the Company on October&#160;4, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Closing, each then-outstanding share of Legacy OnKure common stock was converted into the right to receive 0.023596 shares of common stock of Reneo based on the Common Exchange Ratio, which was reclassified as Class&#160;A Common Stock in connection with the Merger, and each then-outstanding share of Legacy OnKure preferred stock was converted into the right to receive 0.144794 shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio; provided that one holder of Legacy OnKure preferred stock elected to receive 686,527 shares that it would otherwise have received in the form of Class&#160;A Common Stock in an equal number of shares of Class&#160;B Common Stock. Upon the closing of the Merger, (i)&#160;an aggregate of 6,470,281 shares of Class&#160;A Common Stock and 686,527 shares of Class&#160;B Common Stock of the combined company were issued in exchange for the shares of Legacy OnKure capital stock outstanding as of immediately prior to the Closing and (ii)&#160;outstanding shares of Reneo common stock were reclassified into an aggregate of approximately 3,343,604 shares of Class&#160;A Common Stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, each then-outstanding option to purchase shares of Legacy OnKure common stock was assumed and converted into an option to purchase Class&#160;A Common Stock based on the Common Exchange Ratio, and each then-outstanding RSU of Legacy OnKure corresponding to shares of Legacy OnKure preferred stock was assumed and converted into RSUs covering 213,254 shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Reneo common stock, each option to purchase shares of Reneo common stock and each RSU award covering shares of Reneo common stock that was issued and outstanding as of immediately prior to the Closing remained issued and outstanding in accordance with its terms and such shares, options and RSUs, subject to the Reverse Stock Split, were reclassified as Class&#160;A Common Stock but were otherwise unaffected by the Merger; provided that, to the extent not previously vested, all such options and RSUs held by Reneo&#8217;s directors and executive officers vested at Closing. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger Agreement, Reneo entered into a subscription agreement with certain investors, pursuant to which the investors subscribed for and purchased, concurrent with the closing of the Merger, an aggregate of 2,839,005&#160;shares of Class&#160;A Common Stock at a price of approximately $22.895&#160;per share for aggregate gross proceeds of approximately $65.0&#160;million, including the conversion of previously funded Convertible Promissory Notes principal of $6.0&#160;million and accrued interest there on of $120&#160;thousand, on October&#160;4, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, the authorized shares of Class&#160;A Common Stock of the Company are 200,000,000&#160;with par value of $0.0001&#160;and Class&#160;B Common Stock of the Company are 10,000,000 with par value of $0.0001. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, in October 2024 the Company adopted the 2024 Equity Incentive Plan (the &#8220;2024 Plan&#8221;) and 2024 Employee Stock Purchase Plan (the &#8220;2024 ESPP&#8221;). Under the 2024 Plan a total of 2,480,000 shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. Under the 2024 ESPP, an aggregate of 137,500&#160;shares of Class&#160;A Common Stock are currently reserved and available for issuance. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Merger was accounted for as a reverse recapitalization in accordance with GAAP, with Legacy OnKure as the accounting acquirer of Reneo. Legacy OnKure was determined to be the accounting acquirer based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#8217;s board of directors and senior management. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, Legacy OnKure&#8217;s historical financial statements became the historical consolidated financial statements of the combined company for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders Reneo, the legal acquirer, and a recapitalization of the equity of Legacy OnKure, the accounting acquirer. The final transaction amounts have been recorded as a reduction of proceeds in stockholders&#8217; equity. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the effective time of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company, which approximated book value due to the short-term nature.&#160;Reneo&#8217;s development programs had ceased prior to the Merger and were deemed to be de minimis in value at the transaction date. No goodwill or intangible assets were recognized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the recapitalization, excluding the Concurrent Financing, the Company acquired the assets and liabilities listed below (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">57,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">15,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">553</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(9,072</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(387</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">65,499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_MergerAgreementAndConcurrentFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger agreement and concurrent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_MergerAgreementAndConcurrentFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_MergerAgreementAndConcurrentFinancingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger Agreement and Concurrent Financing [Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_MergerAgreementAndConcurrentFinancingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">4. Segment </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is a publicly listed company with a single reportable segment: clinical research. Because the Company has one reportable segment, before adopting the ASU, it provided only the entity-wide disclosures required by ASC 280. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The <div style="-sec-ix-hidden:hidden133878841;display:inline;">clinical research segment</div> has no revenues. The accounting policies of the clinical research segment are the same as those described in the summary of significant accounting policies. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Chief Operating Decision Maker (&#8220;CODM&#8221;) assesses the performance for the clinical research segment and decides how to allocate resources based on operating expenses as reported on the income statement. The measure of segment assets is reported on the balance sheets as total consolidated assets. The CODM considers a variety of factors, including actual and projected expenses in deciding whether to invest funds in the clinical research segment or into other parts of the entity, such as for acquisitions or to pay dividends. The Company does not have intra-entity sales or transfers. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s CODM is the senior executive committee that is comprised of the Chief Financial Officer and the Chief Executive Officer. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Clinical&#160;Research<br/> Segment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Direct program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Indirect program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Workforce salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General corporate expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reconciliation of loss:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments and reconciling items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">52,673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">5. Leases </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s headquarters are located in Boulder, Colorado, where it leases 14,790 square feet of office and lab facilities under&#160;operating leases that expire in <div style="display:inline;"><div style="-sec-ix-hidden:hidden133878813;display:inline;">December 2026</div></div>, with rights to extend for a 5 year period. In the Merger with Reneo, the Company assumed the lease in Irvine, California, where it leases office space under a lease agreement that expires in November 2026 (&#8220;Irvine lease&#8221;). In January 2025, the Company entered into a sublease agreement on the Irvine lease. See Note 16 for further discussion. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use&#160;assets</div></div> and lease liabilities for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease expense for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease term, discount rates, and additional information for operating leases are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term &#8211; operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1.87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate &#8211; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows for operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maturities of the Company&#8217;s operating lease liabilities were as follows as of December&#160;31, 2024 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(46</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">6. Net Loss Per Share </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company computes basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock shares to be issued upon <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">if-converted</div> method for the convertible Series C Preferred Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">if-converted</div> method for the convertible promissory note, exercise of all outstanding stock options and restricted stock units were excluded from the diluted net loss per share calculation for the twelve months ended December&#160;31, 2024 and 2023 because such shares are anti-dilutive. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5,191,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,135,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Promissory Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">214,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,965,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,527,974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">7. Fair Value Measurements </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC Topic 820, <div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Fair Value Measurement</div></div>, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">ASC Topic 820 identifies fair value as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes between the following: </div><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;1 &#8211; Observable inputs such as quoted prices in active markets for identical assets or liabilities. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;2 &#8211; Inputs, other than quoted prices in active markets, which are observable for the asset or liability, either directly or indirectly. </div></td></tr></table><div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top;text-align:left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td style="vertical-align:top;text-align:left"><div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: left; line-height: normal;">Level&#160;3 &#8211; Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. </div></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#8217;s financial assets are subject to fair value measurements on a recurring basis. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company categorizes its money market funds as Level&#160;1, using the quoted prices in active markets. The fair value of the Company&#8217;s investments in certain money market funds is their face value and such instruments are classified as Level&#160;1 and are included in cash and cash equivalents on the consolidated balance sheets. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No assets or liabilities were transferred into or out of their classifications during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the Merger, the Company acquired certain short-term investments in debt securities that were carried at fair value and classified as current assets <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">available-for-sale</div></div> and represented the investment of funds available for current operations. During the year ended December&#160;31, 2024, the Company sold these short-term investments for proceeds of $15.9&#160;million which resulted in a realized loss of approximately $54,000. The Company had no <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">available-for-sale</div></div> securities as of December&#160;31, 2024 or 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">8. Prepaid expenses and other current assets </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid clinical trial expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid insurance expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,553</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">9. Property and Equipment, Net </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware and software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023 was $459,000 and $417,000, respectively. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">10. Accrued Expenses </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contract manufacturing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trial costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">7,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued compensation includes severance costs. For further information see Note 14. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">11. Equity </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 210,000,000 shares of common stock, of which 200,000,000 shares have been designated as Class&#160;A Common Stock and 10,000,000 shares have been designated as Class&#160;B Common Stock, both with a par value of $0.0001 per share. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of Class&#160;A Common Stock is entitled to one vote. Class&#160;B Common Stock is not entitled to vote on any matter on which the holders of Class&#160;A Common Stock or Preferred Stock are entitled to vote. All holders of common stock are entitled to receive dividends when and as declared or paid by the Company&#8217;s board of directors, subject to the preferential rights of the holders of preferred stock. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Class&#160;B Common Stock is convertible into a corresponding number of shares of Class&#160;A Common Stock upon written notice of the holder, subject to defined beneficial ownership limitations. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.0001 per share. As of December&#160;31, 2024, none of these shares of preferred stock have been designated or issued. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Convertible Preferred Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2023, the Company&#8217;s Preferred Stock was classified as temporary equity in the accompanying consolidated balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that were outside of the Company&#8217;s control whereby the Company could be obligated to redeem the convertible preferred stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered probable to occur. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;"><div style="text-decoration:underline;display:inline;">Series C Preferred Stock </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2023, the Company entered into a Series C Purchase Agreement pursuant to which the Company issued 2,818,192 shares of Series C Preferred Stock at a purchase price of $19.06 per share, which resulted in gross proceeds of approximately $53.8&#160;million, as well as the conversion of all Series A Preferred Stock, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">Series&#160;A-1&#160;Preferred</div> Stock, and Series B Preferred Stock. In conjunction with the Merger, immediately following the Closing, each then-outstanding share of Legacy OnKure preferred stock converted into Class&#160;A or Class&#160;B Common Stock. No Convertible Preferred Shares are authorized, issued or outstanding at December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s convertible preferred stock had the following characteristics as of December&#160;31, 2023:&#8195; </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Conversion of Preferred Stock into Common Stock </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of preferred stock, at the option of the holder, was convertible into a number of shares of common stock as determined by multiplying the number of shares of preferred stock being converted by the conversion rate. The conversion rate in effect at any time for conversion of preferred stock is determined by dividing the Original Issue Price by the Conversion Price. The Original Issue Price for the Series C Preferred Stock was $19.06 per share. The Conversion Price was subject to certain adjustments as provided in the Company&#8217;s restated certificate of incorporation. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock would have automatically converted to common stock upon the closing of an initial public offering of the Company&#8217;s common stock in which <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">the&#160;per-share&#160;price</div> is at least $38.19 and gross proceeds of not less than $75&#160;million, or the date and time specified by vote or the written consent of the holders of at least a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Voting Rights </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each preferred stockholder was entitled to the number of votes equal to the number of shares of Class&#160;A Common Stock into which such holder&#8217;s shares are convertible. At any time when a defined number of shares of Series C Preferred Stock are outstanding, the Company was restricted from certain actions described in the Company&#8217;s restated certificate of incorporation without the vote or written consent of the holders of a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis.</div> </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Dividends </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company could not have declared, paid or set aside any dividends on any shares of any other class or series of capital stock unless each holder of the preferred stock first received a dividend based upon a formula in the Company&#8217;s restated certificate of incorporation. No dividends were declared during the years ended December&#160;31, 2024 or 2023. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Liquidation Preference </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon any liquidation, dissolution or winding up of the Company, certain qualifying mergers, sales or transactions with a special purpose acquisition companies, and other deemed liquidation events as defined in the Company&#8217;s restated certificate of incorporation, unless the holders of a majority of the then outstanding shares of Series C Preferred Stock, voting as a separate class on <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">an&#160;as-converted&#160;basis,</div> elected otherwise, prior to and in preference to any distribution to the holders of common stock, holders of Series C Preferred Stock were entitled to be paid out of the assets of the Company legally available for distribution, or the consideration received in such transaction, an amount per share of Series C Preferred Stock equal to the greater of: i) 1.50 times the Series C Original Issuance Price plus all declared and unpaid dividends on Series C Preferred Stock or ii) such amount per share that would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately prior to such event. If upon liquidation, dissolution, or winding up of the Company, the assets and funds of the Company are insufficient to permit the payment of the full preferential amounts to the holders of preferred stock, then the holders shall share ratably in any distribution of the assets available for distribution, in proportion to the respective amounts which would otherwise be payable in respect of the shares held by the preferred stockholders. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the payment of all preferential amounts required to be paid to the holder of shares of preferred stock, the remaining assets available for distribution to its stockholders would have been distributed to the holders of shares of common stock, pro rata based on the number of shares held by each holder. The liquidation preference as of December&#160;31, 2023 was $195.8&#160;million. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">12. Share-Based Compensation </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s share-based compensation plans are described below: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company established an equity incentive plan (the &#8220;2024 Plan&#8221;). The 2024 Equity Incentive Plan became effective upon the closing of the Merger, and will continue in effect for a period of ten years from its effectiveness, unless terminated earlier by the administrator. The 2024 Plan provides for the grant of stock options, RSUs and RSAs to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">employees,&#160;non-employee&#160;directors,</div> advisors, and consultants. Under the 2024 Plan a total of 2,480,000 shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. As of the effective date of the 2024 Plan, awards granted under the 2011, 2021 and 2023 Plans that are forfeited or otherwise become available will be included and available for issuance under the 2024 Plan. Under the 2024 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other awards to individuals who are employees, officers, directors or consultants of the Company and its affiliates. The Company issues new shares in settlement of equity awards under the 2024 Plan. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2023 RSU Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In September 2023, the Company established an equity incentive plan (the &#8220;2023 Plan&#8221;). The 2023 Plan provided for the grant of restricted stock units (&#8220;RSU&#8221;) to employees, directors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2023 Plan were cancelled. </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2021 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In February 2021, the Company established an equity incentive plan (the &#8220;2021 Plan&#8221;). The 2021 Plan provided for the grant of stock options and RSA to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">employees,&#160;non-employee&#160;directors,</div> advisors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2021 Plan were cancelled.&#8195; </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2011 Equity Incentive Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2011, the Company established an equity incentive plan (the &#8220;2011 Plan&#8221;). The 2011 Plan provided for the grant of stock options and restricted stock awards (&#8220;RSA&#8221;) to employees, <div style="white-space:nowrap;display:inline;">non-employee</div> directors, advisors, and consultants. Shares are no longer available for issuance under the 2011 Plan, which was subsequently terminated in March 2023. Upon the close of the Merger, all shares available for issuance under the 2011 Plan were cancelled. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as part of the Merger with Reneo discussed in Note 1, the Company assumed outstanding awards under the following Reneo Equity Incentive Plans and certain awards not issued pursuant to a Reneo Equity Plan: </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Reneo 2021 and 2014 Equity Incentive Plans </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In March 2021, the Reneo Board of Directors adopted the Reneo 2021 Equity Incentive Plan (&#8220;Reneo 2021 Plan&#8221;), which is the successor to Reneo&#8217;s 2014 Equity Incentive Plan and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">UK&#160;Sub-Plan</div> (&#8220;2014 Plan&#8221;). </div><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">2024 ESPP </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company established the 2024 ESPP. Under the 2024 ESPP, an aggregate of 137,500 shares of Class&#160;A Common Stock are currently reserved and available for issuance. As of December&#160;31, 2024, no <div style="display:inline;">offering </div>periods have been established under the 2024 ESPP. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Shares Reserved for Future Issuance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had reserved shares of its common stock for future issuance as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/> Reserved</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units under the 2023 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Equity Incentive Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">747,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">137,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,509,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Stock Options </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Options granted under the Company&#8217;s equity incentive plans have an exercise price equal to or in excess of the market value of the Class&#160;A Common Stock at the date of grant and expire no more than 10 years from the date of grant. Generally, options become exercisable ratably over a period of <div style="-sec-ix-hidden:hidden133878831;display:inline;">three</div> to four years from the date of grant. Stock options granted <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">to&#160;non-employees&#160;generally</div> vest quarterly over <div style="-sec-ix-hidden:hidden133878830;display:inline;">two</div> to three years. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s stock option activity and related information for the year ended December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">16.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed in reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">467,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">47.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,775,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">18.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,476</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(740</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(23,610</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">38.34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">23.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">654,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">38.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All outstanding options as of December&#160;31, 2024 are expected to vest. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested stock options of $26.5&#160;million, expected to be recognized over a weighted-average period of approximately 2.8 years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company&#8217;s common stock as of December&#160;31, 2024. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The weighted-average grant-date fair value of options granted for the years ended December&#160;31, 2024, and 2023 was $16.05 and $5.51, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has granted performance-based stock options. During the year ended December&#160;31, 2023, the Company granted 8,449 performance-based shares, which are included in the table above. The company recognized $30,000 and $13,000 in performance-based compensation expense for the years ended December&#160;31, 2024 and 2023, respectively. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company estimates stock awards fair value on the date of grant using the Black-Scholes valuation, with the vesting being subject to service requirements. The Company accounts for forfeitures when they occur. The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">126.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">32.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.31</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Risk-free interest rate. </div></div>The Company bases the risk-free interest rate assumption on the U.S. Treasury&#8217;s rates for U.S. Treasury <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">zero-coupon</div> bonds with maturities similar to those of the expected term of the award being valued. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected volatility.</div></div> The expected volatility assumption was based on the volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected term. </div></div>The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Expected dividend yield. </div></div>The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSA typically vests 25% on the first anniversary of the issuance date and incrementally vest monthly for the three-year period thereafter. In the event of a termination of services, all unvested shares are forfeited, and the Company has the option to purchase all outstanding vested shares at their fair market value. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">RSU vests based on a service-based requirement and a liquidity event plus service requirement. No RSU had vested as of December&#160;31, 2023. The following table summarizes RSU and RSA activities during the year ended December&#160;31, 2024: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">214,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested (RSA)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(638</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(544</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested RSU awards of $2.8&#160;million, expected to be recognized over a weighted-average period of approximately 2.0 years. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the RSUs in the table above, in connection with the Merger, the Company assumed 24,700 RSUs which were fully vested at the time of the Merger. The RSUs were releasable upon set time frames after completion of the Merger. From the Merger through December&#160;31, 2024, 7,700 RSUs were released. The remaining 17,000 RSUs were released in January 2025. There was no unamortized compensation cost related to these RSUs as of the Merger or December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">2024 Employee Stock Purchase Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In October 2024, the Company&#8217;s Board of Directors adopted the ESPP, which became effective immediately upon completion of the Merger with Reneo. As of December&#160;31, 2024, no shares have been issued under the ESPP. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation Expense </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the allocation of share-based compensation expense related to the company&#8217;s share-based awards (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">4,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recorded accelerated share-based compensation expenses related to modifications of RSUs under certain separation agreements of $1.7&#160;million during the year ended December&#160;31, 2024, which is reflected in the above table. See Note 14 for further discussion on severance. There were no such modifications during the year ended December&#160;31, 2023. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">IncomeTaxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">13. Income Taxes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the income tax benefit are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax at statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal deduction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(0.1</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(24.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of deferred income taxes are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D tax credit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">90,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(90,855</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(22,211</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had approximately $3.1&#160;million of net operating loss carryforwards (&#8220;NOLs&#8221;) and $0.8&#160;million of research and experimental credits which expire through 2037, and approximately $216.5&#160;million of federal and state net operating loss carryforwards which have an indefinite life. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div></div><div><div style="line-height:normal;display: inline;"></div></div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2024, the Company had federal and state tax credit carry forwards of approximately $6.9&#160;million. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2034, if unused. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to Internal Revenue Code (&#8220;IRC&#8221;) Sections 382 and 383, the Company&#8217;s ability to use NOLs and research tax credit carry forwards to offset future taxable income may be limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section&#160;382. If ownership changes within the meaning of IRC Section&#160;382 are identified as having occurred, the amount of NOLs and research tax carryforwards available to offset future taxable income and income tax liabilities in future years may be significantly restricted or eliminated. Further, deferred tax assets associated with such NOLs and research tax credits could be significantly reduced upon realization of an ownership change within the meaning of IRC Section&#160;382. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers projected future taxable income and tax planning strategies in making this assessment. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At December&#160;31, 2024 and 2023, the Company has not accrued any interest or penalties related to uncertain tax positions. The Company does not anticipate that there will be a significant change in the amount of unrecognized tax benefits over the next 12 months. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and the UK. The UK subsidiary operations ceased in 2024. The Company&#8217;s federal and state income tax returns for all years will remain open to examination by federal and state tax authorities for three years from the date of utilization of any net operating loss carryforwards. The Company&#8217;s federal and state returns since inception are subject to examination due to the carryover of net operating losses. The Company has not been, nor is it currently, under examination by any tax authorities. The UK tax returns from 2018 through 2024, are subject to examination by the UK tax authorities. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">14. Commitments and Contingencies </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Legal Proceedings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Merger Proceedings </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Merger, two complaints were filed in the Supreme Court of the State of New York, County of New York, captioned<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Thomas</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;v.</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Reneo Pharmaceuticals, Inc., et al.</div></div>, Index No.&#160;654628/2024 (filed September&#160;5, 2024) and<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Kent v. Reneo Pharmaceuticals, Inc., et al.</div></div>, Index No.&#160;654642/2024 (filed September&#160;6, 2024) (together, the &#8220;Complaints&#8221;). The Complaints generally allege that the Proxy Statement/Prospectus filed by Reneo with the SEC misrepresented and/or omitted certain purportedly material information relating to Reneo management&#8217;s financial projections for Reneo and OnKure, the data and inputs underlying the financial valuation analyses that support the fairness opinion provided by Leerink Partners, Reneo&#8217;s financial advisor, and potential conflicts of interest with Leerink Partners LLC, Evercore Group L.L.C., and LifeSci Capital LLC, which were the placements agents for the Concurrent Financing that closed concurrently with the Merger. The Complaints assert violations of negligent misrepresentation and concealment in violation of New York common law and negligence in violation of New York common law. The Complaints sought orders enjoining the proposed Merger, or in the event that the Merger was consummated, orders rescinding the Merger or awarding actual and punitive damages, as well as all of the plaintiffs&#8217; fees and expenses in connection with the litigation, including reasonable attorneys&#8217; and experts&#8217; fees and expenses. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We cannot predict the outcome of the Complaints or any other litigation that might be filed arising out of the Merger or the Concurrent Financing. The Company and the individual defendants intend to vigorously defend against the Complaints and any subsequently filed, similar actions. It is possible additional lawsuits may be filed arising out of the Merger or the Concurrent Financing. Absent new or significantly different allegations, the Company will not necessarily disclose such additional filings. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">time-to-time</div></div> in the future, the Company could be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business, which may have a material adverse effect on the Company&#8217;s consolidated results of operations or financial position. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Clinical Trial Collaboration and Supply Agreement with Pfizer </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In August 2020, as amended in December 2024, the Company entered into a clinical trial collaboration and supply agreement under which Pfizer Inc. (&#8220;Pfizer&#8221;) agreed to supply drug product in connection with a clinical trial. The agreement continues until the earlier of the completion of all obligations of the parties or the termination of the contract by either party as defined in the agreement. The Company may terminate the agreement if the clinical trial is deemed to be unsafe, regulatory authorities raise concerns, or if Pfizer does not uphold its obligations outlined in the agreement. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Indemnification </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs because of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December&#160;31, 2024. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Severance </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A former officer of the Company terminated his employment with the Company on May&#160;24, 2024 and entered into a separation agreement and release on that date. The separation agreement and release provides for payments and benefits including continuing payments of base salary for a period of 14&#160;months following termination of employment, payment for or reimbursement for COBRA premiums for up to 14 months following termination of employment, a full accelerated vesting of his equity awards and extension of the post-termination exercise period applicable to his Options through the earlier of 12 months following termination of service or the applicable option expiration date. During the year ended December&#160;31, 2024, the Company recorded an expense of $622,000 for these severance benefits in research and development expense, of which $326,000 remains unpaid and is included in accrued compensation. See Note 12 for discussion of stock-based compensation recorded for the modifications of equity awards discussed above. The related RSU shares were released in January 2025. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain Reneo employees became employees of the Company to assist with the Merger transition through the end of the year December&#160;31, 2024 at which time they were terminated and received severance benefits in accordance with the Reneo severance agreements. The Company recorded expense of $225,000 for severance benefits for these employees for the year ended December&#160;31, 2024, which is included in General and Administrative expenses and of which, approximately $154,000 remains unpaid as of December&#160;31, 2024 and is included in accrued compensation. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Employee Benefit Plan </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company established a qualified 401(k) plan in June 2021 which covers all employees who meet eligibility requirements. The Company matches its employee contributions up to a maximum amount of 4% of the participant&#8217;s compensation. During the years ended December&#160;31, 2024, and 2023, the Company made matching contributions of approximately $360,000&#160;and $294,000, respectively. See Note 16. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePromissoryNoteAbstract', window );"><strong>Convertible Promissory Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePromissoryNoteDisclosureTextBlock', window );">Convertible Promissory Notes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">15. Convertible Promissory Notes </div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2024, the Company entered into convertible promissory note agreements with certain of its existing investors for up to $12.0&#160;million. At closing, the Company received total proceeds of $6.0&#160;million and had the ability to draw up to an additional $6.0&#160;million in the event the Merger with Reneo had not closed by September&#160;30, 2024, but no additional draw was made. The notes bore interest at rates from 6% per annum. All unpaid principal and accrued interest were due in December 2025, unless earlier converted. In October 2024, the unpaid notes and accrued unpaid interest automatically converted into shares issued in the Concurrent Financing at the price per share paid by investors in the Concurrent Financing. See Note 3 for further discussion. The Company incurred $142,000 of debt issuance costs related to the convertible promissory notes during the year ended December&#160;31, 2024. Debt issuance costs are amortized as a component of interest expense over the term of the related debt using the straight-line method, which approximates the interest method. The Company recognized $148,000 in interest expense related to the amortization of the debt issuance costs for the year ended December&#160;31, 2024 and a $114,000 loss on the conversion for the year ended December&#160;31, 2024, both of which are recorded in interest and other expense in the Statement of Operations. As of December&#160;31, 2024, the Company had no accrued interest related to the convertible promissory notes. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePromissoryNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePromissoryNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePromissoryNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible promissory note disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePromissoryNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">16. Subsequent Events </div></div><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"><div style="display:inline;">Sublease</div> </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In January 2025, the Company entered into a sublease on the Irvine lease for all of the leased square footage. The sublease rent payments will be approximately $450,000 over the term of the lease, which expires in November 2026. </div><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Available for Issuance Increase </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s 2024 Plan provides that on the first day of each fiscal year, the number of shares of our Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) 2,407,100 shares, (ii) 5% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the Company&#8217;s board of directors may determine. The Company&#8217;s ESPP provides that on the first day of each fiscal year, the number of shares of Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) 481,500&#160;shares, (ii) 1% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the board of directors may determine. On January&#160;1, 2025, the number of shares of Class&#160;A common stock available for issuance under the 2024 Plan and the ESPP increased by 667,355&#160;and 133,471&#160;shares, respectively, pursuant to these provisions. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_BasisOfPresentationAndConsolidationPolicyTextBlock', window );">Basis of Presentation and Consolidation</a></td>
<td class="text"><div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Basis of Presentation and Consolidation </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s consolidated financial statements are prepared in accordance with GAAP and reflect the operation of the Company and its wholly owned subsidiaries, OnKure, Inc. and Merger Sub II. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Segment Information </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company operates in&#160;one&#160;operating segment: clinical research. All equipment and other property and equipment are physically located within the United States<div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">.</div></div> </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">Use of Estimates </div></div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preparation of the Company&#8217;s consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">and disclosure of contingent assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates. The most significant estimates relate to external research and development expenses, and the fair value of stock options and restricted stock awards and units. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Comprehensive Loss </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">from&#160;non-owner&#160;sources.</div> The Company&#8217;s comprehensive loss was the same as its reported net loss for all periods <div style="display:inline;">presented</div>. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred in performing research and development activities. The costs include employee-related expense, including salaries, severance, benefits, share- based compensation, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, costs to manufacture or have manufactured clinical trial materials, depreciation, and facilities and overhead costs. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock', window );">Accrued Research and Development Expenses</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Accrued Research and Development Expenses </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company records research and development expenses in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Patent Costs </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Compensation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Share-Based Compensation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase common stock, and restricted stock units for common stock, are granted to employees, board of directors, <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">and&#160;non-employee&#160;consultants.</div> Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#8217;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of 10 years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. The Company will continue to apply this process until enough historical information regarding the volatility of its stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes</div> with maturities approximately equal to the expected term of the stock options. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. (See Note 12). </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company recognizes stock-based compensation expense for grants under its various Equity Incentive Plans and employee stock purchase plan (&#8220;ESPP&#8221;). The Company accounts for all stock-based awards granted to employees and directors at their fair value and recognizes compensation expense over the award&#8217;s vesting period. Determining the amount of stock-based compensation to be recorded requires the Company to develop estimates of fair values of stock options as of the grant date. The Company calculates the grant date fair values of stock options using the Black-Scholes valuation model, which requires the input of subjective assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. The fair value of restricted stock awards granted to employees is based on the quoted closing market price per share on grant date. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_CommonStockValuationPolicyTextBlock', window );">Common Stock Valuation</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Common Stock Valuation </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Due to the lack of marketability for the Company&#8217;s common stock prior to the Merger, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#8217; Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted prior to the Merger, the Company had considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#8217;s research and development programs, including their stages of development, and the Company&#8217;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#8217;s financial position, including cash on hand, and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#8217;s common stock; and the market performance of peer companies in the biopharmaceutical industry. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Fair Value of Financial Instruments </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The carrying amounts of the Company&#8217;s financial assets and liabilities, such as cash, receivables, prepaid and other current assets, accounts payable, and accrued expenses approximate their fair values because of the short maturity of these instruments. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Cash and Cash Equivalents </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All highly liquid investments with maturities of 90 days or less, at the time of purchase, are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value. The Company&#8217;s cash and cash equivalents consist of money held in demand depository accounts and money market funds. The carrying amount of cash and cash equivalents was $110.8&#160;million and $29.9&#160;million as of December&#160;31, 2024, and 2023, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&#160;1. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Concentration of Credit Risk </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions above federally insured limits of $250,000 as of December&#160;31, 2024 and 2023. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held and of the money market funds in which these investments are made. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Property and Equipment, Net </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company carries its property and equipment at cost, less accumulated depreciation, amortization and impairment, if any. Expenditures for renewals or betterments that materially extend the useful life of an asset or increase its productivity, such as leasehold improvements, are capitalized. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between <div style="display:inline;"><div style="-sec-ix-hidden:hidden133878817;display:inline;">three</div></div> to <div style="display:inline;">seven years</div>. Leasehold improvements are amortized over the <div style="-sec-ix-hidden:hidden133878837;display:inline;">shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets</div>. Repair and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized. </div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Impairment of Long-Lived Assets </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December&#160;31, 2024 and 2023. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leasing - Lessee Accounting</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Leasing &#8211; Lessee Accounting </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company determines if an arrangement is a lease at inception. The Company&#8217;s operating lease agreements are primarily for office space and research labs. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For operating leases with a term greater than one year, the Company recognizes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">the&#160;right-of-use&#160;(&#8220;ROU&#8221;)</div></div> assets and lease liabilities related to the lease payments on its balance sheet. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The ROU assets represent the Company&#8217;s right to use the underlying assets for the term of the lease and the lease liabilities represent the Company&#8217;s obligation to make lease payments arising for the agreements. ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is periodically reviewed for impairment unless a triggering event occurs. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, except for the ones that depend on index or rate, are excluded from the calculation of the ROU assets and lease liabilities and are recognized as variable lease expense in the statements of operations and comprehensive loss in the period in which they are incurred. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div>As the interest rate implicit in the Company&#8217;s leases is not readily determinable, the Company uses its estimated incremental borrowing rate in its present value calculations. One of the Company&#8217;s lessee agreements include an option to extend the lease, which the Company does not include in its minimum lease term unless it is reasonably certain to exercise such option. Operating leases with a term of less than one year are recognized as a lease expense over the term of the lease, with no asset or liability recognized on the balance sheet.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;"><div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;">Income Taxes </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently payable and deferred taxes. The Company accounts for income taxes using the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, and operating losses and tax credit carryforwards. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A valuation allowance is recorded to the extent it is more likely than not that some portion of a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company&#8217;s significant deferred tax assets are net operating loss carryforwards, tax credits, and accruals. The Company has provided a valuation allowance equal to its net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that most of its deferred tax assets will not be realized. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accounting for uncertain tax positions requires a more likely than not threshold for recognition in the financial statements. The Company recognizes a tax benefit based on whether it is more likely than not that a tax position will be sustained. The Company records a liability to the extent that a tax position taken or expected to be taken on a tax return exceeds the amount recognized in the financial statements. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has no unrecognized tax benefits as of December&#160;31, 2024 and 2023. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as general and administrative expenses. No such expenses have been recognized during the years ended December&#160;31, 2024 and 2023. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is subject to taxation in the United States and the United Kingdom (&#8220;UK&#8221;). As of December&#160;31, 2024, the Company&#8217;s tax years since inception are subject to examination by taxing authorities in the United States, and the UK tax returns from 2018 forward are subject to examination. </div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;"><div style="font-style:italic;display:inline;">Recently Issued Accounting Pronouncemen</div></div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">ts </div></div></div><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2023, the FASB <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">issued&#160;ASU&#160;2023-07,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</div></div>&#160;to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company&#8217;s 2024 fiscal year annual reporting period, with early adoption permitted. The disclosure related to this ASU are in Note 4 below. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2023, the FASB issued <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">ASU&#160;2023-09,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Taxes (Topic 740):</div></div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Improvements to Income Tax Disclosures</div></div><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">&#160;(&#8220;ASU&#160;2023-09&#8221;),&#160;which</div> requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2024, the FASB issued ASU <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;">2024-03,</div><div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"><div style="font-style:italic;display:inline;">&#160;Income Statement&#8212;Reporting Comprehensive Income&#8212;Expense Disaggregation Disclosures (Subtopic <div style="white-space:nowrap;display:inline;">220-40):</div> Disaggregation of Income Statement Expenses</div></div>. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this pronouncement. </div><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on its financial statements. </div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_BasisOfPresentationAndConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of presentation used to prepare the financial statements and principles followed in consolidating or combining the separate financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_BasisOfPresentationAndConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_CommonStockValuationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Valuation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_CommonStockValuationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for patent costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 36<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-36<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-29<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Merger Agreement and Concurrent Financing (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_MergerAgreementAndConcurrentFinancingAbstract', window );"><strong>Merger Agreement and Concurrent Financing [Abstract)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Summary of Acquired Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As part of the recapitalization, excluding the Concurrent Financing, the Company acquired the assets and liabilities listed below (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:84%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Amount</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash and cash equivalents</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">57,736</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Short-term investments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">15,979</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other current assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">690</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">553</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(9,072</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Long-term operating lease liability</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(387</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net assets acquired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">65,499</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_MergerAgreementAndConcurrentFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger agreement and concurrent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_MergerAgreementAndConcurrentFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Paragraph 1<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information by Segment</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company&#8217;s CODM is the senior executive committee that is comprised of the Chief Financial Officer and the Chief Executive Officer. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:76%"></td>
<td style="vertical-align:bottom;width:16%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Clinical&#160;Research<br/> Segment</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Operating expenses:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Direct program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">27,398</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Indirect program expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">2,157</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Workforce salaries and benefits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">15,102</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Stock-based compensation expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">4,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General corporate expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">5,199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest and other expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">300</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Segment net loss</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">54,686</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Reconciliation of loss:</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Interest income</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">(2,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Adjustments and reconciling items</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,013</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Net loss</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">52,673</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">Right-of-use&#160;assets</div></div> and lease liabilities for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:65%"></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:12%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"><div style="white-space:nowrap;display:inline;">right-of-use</div></div> assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">770</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">478</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Current operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">536</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">208</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Noncurrent operating lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">466</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total lease liabilities</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,085</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">674</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Expense for Operating Leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease expense for operating leases as included in the Company&#8217;s financial statements are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:80%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease cost</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">236</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Variable lease expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">187</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock', window );">Schedule of lease term, discount rates, and additional information for operating leases</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Lease term, discount rates, and additional information for operating leases are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As&#160;of&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average remaining lease term &#8211; operating leases (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1.87</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2.92</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Weighted-average discount rate &#8211; operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Cash paid for amounts included in the measurement of lease liabilities:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating cash flows for operating leases</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">315</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">210</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of lease liabilities by fiscal year for operating leases</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate maturities of the Company&#8217;s operating lease liabilities were as follows as of December&#160;31, 2024 (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:86%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2025</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">571</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2026</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total future minimum lease payments</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,131</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: imputed interest</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(46</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(536</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Operating lease liability, net of current portion</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">549</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease related assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of lease term, discount rates, and additional information for operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Anti-Dilutive Securities Outstanding Not Included in Diluted Net Loss Per Share Calculation</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Series C Preferred Stock</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5,191,375</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">6,135,306</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Convertible Promissory Notes</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">149,650</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Outstanding stock options</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">214,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">7,965,103</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">6,527,974</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid clinical trial expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">152</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,192</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Prepaid insurance expense</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">537</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">68</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,553</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">630</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total prepaid expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,242</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,890</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Property and equipment, net, consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:68%"></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Lab equipment</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">705</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">706</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Leasehold improvements</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,090</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Computer hardware and software</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">189</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">141</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Furniture and fixtures</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">160</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, gross</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,144</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,097</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Less: Accumulated depreciation and amortization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(1,119</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(665</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Property and equipment, net</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued expenses</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Accrued expenses consisted of the following (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:66%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,<br/> 2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1,663</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued contract manufacturing costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,565</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,627</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued clinical trial costs</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">986</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">370</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">7,026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">3,660</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock', window );">Summary of common stock reserved for future issuance</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of December&#160;31, 2024, the Company had reserved shares of its common stock for future issuance as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">
<tr>
<td style="width:81%"></td>
<td style="vertical-align:bottom;width:4%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares<br/> Reserved</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Common stock options outstanding</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested restricted stock units under the 2023 Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unreleased restricted stock units assumed in the Merger</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">17,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Equity Incentive Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">747,867</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Available for future grants under the 2024 Employee Stock Purchase Plan</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">137,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total shares of common stock reserved for future issuance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3,509,445</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of the Company's stock option activity</a></td>
<td class="text"><div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A summary of the Company&#8217;s stock option activity and related information for the year ended December&#160;31, 2024 is as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:92%;border:0;margin:0 auto">
<tr>
<td style="width:49%"></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Options Outstanding</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number<br/> of Options</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Exercise<br/> Price</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Remaining<br/> Contractual<br/> Term<br/> (in years)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Aggregate<br/> Intrinsic<br/> Value<br/> (in&#160;thousands)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">178,232</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">16.74</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">8.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Assumed in reverse recapitalization</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">467,100</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">47.39</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,775,318</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">18.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Exercised</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2,476</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">10.19</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expired</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(740</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.62</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(23,610</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">38.34</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">2,393,824</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">23.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">7.90</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Options exercisable &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">654,636</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">38.08</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of weighted-average assumptions to determine the fair value of the employee stock option</a></td>
<td class="text">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Year&#160;Ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term (years)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5.77</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">5.73</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">126.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">32.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.80</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">4.31</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of RSU and RSA activities</a></td>
<td class="text">The following table summarizes RSU and RSA activities during the year ended December&#160;31, 2024: <div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Number&#160;of</div></div><br/> <div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Shares</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Weighted<br/> Average<br/> Grant&#160;Date<br/> Fair Value</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2023</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">214,436</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Granted</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Vested (RSA)</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(638</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.83</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Forfeited</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(544</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">RSUs outstanding &#8211; December 31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Unvested balance as of December&#160;31, 2024</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">213,254</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">22.88</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of Non-cash stock-based compensation expense recorded</a></td>
<td class="text"><div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table shows the allocation of share-based compensation expense related to the company&#8217;s share-based awards (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:79%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Research and development</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">2,896</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">98</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">General and administrative</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">1,634</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">101</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">4,530</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">$</td>
<td style="vertical-align:bottom;text-align:right">199</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of components of income tax benefit</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The components of the income tax benefit are as follows: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:9%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">Years&#160;ended&#160;December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Federal tax at statutory rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">21.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">State taxes, net of federal deduction</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">3.6</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D credits</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.1</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.2</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(2.3</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(0.1</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Change in valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(22.0</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(24.7</td>
<td style="white-space:nowrap;vertical-align:bottom">)%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Income tax benefit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">0.0</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of net deferred taxes asset and liabilities</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Significant components of deferred income taxes are as follows (in thousands): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">
<tr>
<td style="width:71%"></td>
<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">As of December&#160;31,</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2024</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"><div style="letter-spacing: 0px; top: 0px;display:inline;"><div style="font-weight:bold;display:inline;">2023</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets:</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Net operating loss carryforwards</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">53,984</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">9,027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">R&amp;D tax credit</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">837</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred R&amp;D expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">32,729</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">11,123</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Accrued expenses</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">1,903</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">783</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Share-based compensation</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">978</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">104</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Other</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">424</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">337</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Total deferred tax assets</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">90,855</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">22,211</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(90,855</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom;text-align:right">(22,211</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt">
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Deferred tax assets, net of valuation allowance</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right">&#8212;&#8194;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td style="vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;">&#160;</div></td>
<td>&#160;</td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization and Business (Narrative) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Oct. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (154,724)<span></span>
</td>
<td class="num">$ (102,051)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,761<span></span>
</td>
<td class="nump">$ 29,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember', window );">Merger Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1', window );">Date of agreement and plan of merger</a></td>
<td class="text">May 10,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate purchase price</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date when the business acquisition agreement was executed, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Narrative) (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents carrying amount</a></td>
<td class="nump">$ 110,761,000<span></span>
</td>
<td class="nump">$ 29,876,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Federally insured limits</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm', window );">Options granted maximum contractual term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment, net</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of property and equipment, net</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration', window );">Estimated useful life of property and equipment, net</a></td>
<td class="text">us-gaap:UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounting policies line items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options grants, maximum contractual term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger Agreement and Concurrent Financing - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Oct. 04, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember', window );">2024 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">943,840<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | 2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="nump">2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Reneo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding', window );">Common stock shares issued in exchange for the shares of capital stock outstanding</a></td>
<td class="nump">3,343,604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Conversion of convertible preferred stock into common stock</a></td>
<td class="nump">213,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_CommonStockSharesConvertibleConversionRatio', window );">Common stock exchange ratio</a></td>
<td class="nump">0.023596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionRatio', window );">Preferred exchange ratio</a></td>
<td class="nump">0.144794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding', window );">Common stock shares issued in exchange for the shares of capital stock outstanding</a></td>
<td class="nump">6,470,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Merger Agreement [Member] | 2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="nump">2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Merger Agreement [Member] | 2024 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance', window );">Stock were initially reserved and available for issuance</a></td>
<td class="nump">137,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Merger Agreement [Member] | Reneo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_GrossProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock | $</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Common Stock [Member] | Merger Agreement [Member] | Reneo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Stock issued</a></td>
<td class="nump">2,839,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock price per share | $ / shares</a></td>
<td class="nump">$ 22.895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member] | Convertible Promissory Note [Member] | Merger Agreement [Member] | Reneo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument principal amount | $</a></td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_DebtInstrumentAccruedInterest', window );">Accrued interest | $</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">226,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding', window );">Common stock shares issued in exchange for the shares of capital stock outstanding</a></td>
<td class="nump">686,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleSharesIssuable', window );">Exchange of stock, preferred stock holders choose to receive shares of common stock</a></td>
<td class="nump">686,527<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member] | Common Stock [Member] | Merger Agreement [Member] | Reneo [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved and available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_CommonStockSharesConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock shares convertible, conversion ratio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_CommonStockSharesConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_DebtInstrumentAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_DebtInstrumentAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_GrossProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross proceeds from issuance of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_GrossProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exchange of Capital Stock Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion for each share of preferred stock to be converted.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleSharesIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common shares issuable upon conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleSharesIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=okur_ReneoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=okur_ReneoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_MergerAgreementAndConcurrentFinancingAbstract', window );"><strong>Merger Agreement and Concurrent Financing [Abstract)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 57,736<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Short-term investments</a></td>
<td class="nump">15,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets', window );">Other assets</a></td>
<td class="nump">553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued expenses</a></td>
<td class="num">(9,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability', window );">Long-term operating lease liability</a></td>
<td class="num">(387)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Net assets acquired</a></td>
<td class="nump">$ 65,499<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business combination, recognized identifiable assets acquired and liabilities assumed, long-term operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_MergerAgreementAndConcurrentFinancingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger agreement and concurrent financing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_MergerAgreementAndConcurrentFinancingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>Segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentExtensibleList', window );">Segment [Extensible Enumeration]</a></td>
<td class="text">Clinical Research Segment [Member]<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription', window );">CODM Description</a></td>
<td class="text">The Chief Operating Decision Maker (&#8220;CODM&#8221;) assesses the performance for the clinical research segment and decides how to allocate resources based on operating expenses as reported on the income statement. The measure of segment assets is reported on the balance sheets as total consolidated assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName', window );">CODM title and Position</a></td>
<td class="text">Chief Financial Officer and the Chief Executive Officer<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Segment reporting, CODM, individual title and position or group name.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates component of entity engaging in business activity from which revenue is recognized and expense is incurred. Includes, but is not limited to, transaction with another component of same entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment - Schedule of Segment Reporting Information by Segment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_InterestAndOtherExpense', window );">Interest and other expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Reconciliation of loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeOperating', window );">Interest income</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="num">(1,623)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AdjustmentsAndReconcilingItems', window );">Adjustments and reconciling items</a></td>
<td class="num">(2,013)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">52,673<span></span>
</td>
<td class="nump">$ 35,311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=okur_ClinicalResearchSegmentMember', window );">Clinical Research Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_DirectProgramExpense', window );">Direct program expense</a></td>
<td class="nump">27,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_IndirectProgramExpense', window );">Indirect Program Expense</a></td>
<td class="nump">2,157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_WorkforceSalariesAndBenefits', window );">Workforce salaries and benefits</a></td>
<td class="nump">15,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">4,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_GeneralCorporateExpenses', window );">General corporate expenses</a></td>
<td class="nump">5,199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_InterestAndOtherExpense', window );">Interest and other expense</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Reconciliation of loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 54,686<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AdjustmentsAndReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments and reconciling items</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AdjustmentsAndReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_DirectProgramExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct program expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_DirectProgramExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_GeneralCorporateExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>General corporate expenses</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_GeneralCorporateExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_IndirectProgramExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indirect program expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_IndirectProgramExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_InterestAndOtherExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest and other expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_InterestAndOtherExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_WorkforceSalariesAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Workforce salaries and benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_WorkforceSalariesAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1)(e))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477346/946-830-45-39<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column E)(Footnote 6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=okur_ClinicalResearchSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=okur_ClinicalResearchSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>ft&#178;</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of real estate property</a></td>
<td class="nump">14,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease Expiration Date</a></td>
<td class="text">Dec. 31,  2026<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Operating lease option to extend</a></td>
<td class="text">with rights to extend for a 5 year period<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease rights to extend renewal term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">$ 770<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liabilities</a></td>
<td class="nump">536<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liabilities</a></td>
<td class="nump">549<span></span>
</td>
<td class="nump">466<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">$ 674<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Expense for Operating Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">$ 173<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease expense</a></td>
<td class="nump">$ 187<span></span>
</td>
<td class="nump">$ 201<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term - operating leases (years)</a></td>
<td class="text">1 year 10 months 13 days<span></span>
</td>
<td class="text">2 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate - operating leases</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForOperatingActivitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows for operating leases</a></td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 210<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">1,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="num">(536)<span></span>
</td>
<td class="num">$ (208)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">$ 549<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">7,965,103<span></span>
</td>
<td class="nump">6,527,974<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePreferredStockSeriesCMember', window );">Convertible Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">5,191,375<span></span>
</td>
<td class="nump">6,135,306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePromissoryNoteMember', window );">Convertible Promissory Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">149,650<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-Based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,393,824<span></span>
</td>
<td class="nump">178,232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">213,254<span></span>
</td>
<td class="nump">214,436<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember', window );">Unreleased Restricted Stock Units Assumed in the Merger [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">17,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePreferredStockSeriesCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePreferredStockSeriesCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePromissoryNoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_ConvertiblePromissoryNoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Assets transferred into L3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Assets transferred out of L3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3', window );">Liabilities transferred into L3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3', window );">Liabilities transferred out of L3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds of short-term investments</a></td>
<td class="nump">15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Realized loss from short-term investments</a></td>
<td class="num">(54,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PrepaidClinicalTrials', window );">Prepaid clinical trial expenses</a></td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 3,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance expense</a></td>
<td class="nump">537<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPrepaidExpenseCurrent', window );">Other prepaid expenses</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">630<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Total prepaid expenses</a></td>
<td class="nump">$ 2,242<span></span>
</td>
<td class="nump">$ 3,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PrepaidClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Prepaid clinical trials.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PrepaidClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 2,144<span></span>
</td>
<td class="nump">$ 2,097<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(1,119)<span></span>
</td>
<td class="num">(665)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">1,432<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_LabEquipmentMember', window );">Lab Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">705<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,090<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">189<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 160<span></span>
</td>
<td class="nump">$ 160<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_LabEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_LabEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=okur_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationExpenseOnReclassifiedAssets', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 459,000<span></span>
</td>
<td class="nump">$ 417,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationExpenseOnReclassifiedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-7<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 44<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482190/360-10-35-44<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationExpenseOnReclassifiedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 3,173<span></span>
</td>
<td class="nump">$ 1,663<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccruedManufacturingExpense', window );">Accrued contract manufacturing costs</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,627<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccruedClinicalTrialCosts', window );">Accrued clinical trial costs</a></td>
<td class="nump">1,302<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">986<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued expenses</a></td>
<td class="nump">$ 7,026<span></span>
</td>
<td class="nump">$ 3,660<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AccruedClinicalTrialCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical trial costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AccruedClinicalTrialCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AccruedManufacturingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued manufacturing expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AccruedManufacturingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">210,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of stock amount issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,313,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,404,919<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">6,840,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Dividends', window );">Dividends</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Liquidation Preference, Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred Stock, Shares Authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PreferredStockSharesDesignated', window );">Preferred stock, shares designated</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.06<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValueOutstanding', window );">Preferred stock, value, outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountIssued1', window );">Conversion of stock amount issued</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">943,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember', window );">Class B Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">226,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, Par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember', window );">Series C Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesAuthorized', window );">Convertible preferred stock shares authorized</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesIssued', window );">Convertible preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ConvertiblePreferredStockSharesOutstanding', window );">Convertible preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockDividendPaymentTerms', window );">Preferred Stock Dividend Payment Terms</a></td>
<td class="text">i) 1.50 times the Series C Original Issuance Price plus all declared and unpaid dividends on Series C Preferred Stock or ii) such amount per share that would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately prior to such event.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,818,192<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockConvertibleConversionPrice', window );">Conversion price of preferred stock</a></td>
<td class="nump">$ 38.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ConvertiblePreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible preferred stock shares outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ConvertiblePreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PreferredStockSharesDesignated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Preferred stock shares designated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PreferredStockSharesDesignated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Dividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -SubTopic 405<br> -Topic 942<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477787/942-405-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Dividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockConvertibleConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share conversion price of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockConvertibleConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendPaymentTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendPaymentTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesCPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details) - shares<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant and expire period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="nump">2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Class A Common Stock [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="nump">2,480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember', window );">2024 ESPP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Stock were initially reserved for issuance.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember', window );">2024 ESPP [Member] | Class A Common Stock [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance', window );">Stock were initially reserved and available for issuance</a></td>
<td class="nump">137,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares reserved and available for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="nump">1,775,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,530,000<span></span>
</td>
<td class="nump">$ 199,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 26,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average vesting term</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value of options granted</a></td>
<td class="nump">$ 16.05<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=okur_Performance-BasedStockOptionsMember', window );">Performance-Based Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant and expire period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Grant and expire period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Non-employees | Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Non-employees | Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=okur_Performance-BasedStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=okur_Performance-BasedStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=okur_Non-EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=okur_Non-EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Compensation - Shares Reserved for Future Issuance (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">3,509,445<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Common Stock Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">2,393,824<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember', window );">Unvested Restricted Stock Units under 2023 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">213,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember', window );">Unreleased Restricted Stock Units Assumed in Merger</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">17,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">747,867<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember', window );">2024 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total shares of common stock reserved for future issuance</a></td>
<td class="nump">137,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock option activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at beginning of period (in shares)</a></td>
<td class="nump">178,232<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization', window );">Assumed in reverse recapitalization</a></td>
<td class="nump">467,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,775,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(2,476)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (In shares)</a></td>
<td class="num">(740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (In shares)</a></td>
<td class="num">(23,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Outstanding at end of period (in shares)</a></td>
<td class="nump">2,393,824<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">654,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at beginning of period (in dollars per share)</a></td>
<td class="nump">$ 16.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice', window );">Assumed in reverse recapitalization</a></td>
<td class="nump">47.39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">18.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">10.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share)</a></td>
<td class="nump">21.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">38.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Outstanding at end of period (in dollars per share)</a></td>
<td class="nump">23.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable (in dollars per share)</a></td>
<td class="nump">$ 38.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (in years) / Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term (in years), Options Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Options Outstanding</a></td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term (in years), Exercisable</a></td>
<td class="text">3 years 25 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options assumed in reverse recapitalization weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted-average assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.31%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">126.20%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">5 years 9 months 7 days<span></span>
</td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 04, 2024</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards (RSAs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">RSA typically vests 25% on the first anniversary of the issuance date and incrementally vest monthly for the three-year period thereafter.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards (RSAs) [Member] | 25% on First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards (RSAs) [Member] | Incrementally Vest Monthly for Three-Year Period Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards (RSAs) [Member] | Merger Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="nump">24,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_UnamortizedCompensationCost', window );">Unamortized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock Awards (RSAs) [Member] | Merger Agreement [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Shares vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Vesting rights, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">RSU vests based on a service-based requirement and a liquidity event plus service requirement.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_UnamortizedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unamortized compensation cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_UnamortizedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=okur_MergerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details) - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested at Beginning | shares</a></td>
<td class="nump">214,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (RSA) | shares</a></td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited | shares</a></td>
<td class="num">(544)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding and Unvested at End | shares</a></td>
<td class="nump">213,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at Beginning | $ / shares</a></td>
<td class="nump">$ 22.88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (RSA) | $ / shares</a></td>
<td class="nump">0.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited | $ / shares</a></td>
<td class="nump">22.88<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding and Unvested at End | $ / shares</a></td>
<td class="nump">$ 22.88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=okur_RestrictedStockAndRestrictedStockUnitsRSUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=okur_RestrictedStockAndRestrictedStockUnitsRSUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Non-cash stock-based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,530<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">2,896<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 1,634<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost', window );">Accelerated share-based compensation expenses</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of components of income tax benefit (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal deduction</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">R&amp;D credits</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(22.00%)<span></span>
</td>
<td class="num">(24.70%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Income tax benefit</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of net deferred taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 53,984<span></span>
</td>
<td class="nump">$ 9,027<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">R&amp;D tax credit</a></td>
<td class="nump">837<span></span>
</td>
<td class="nump">837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Deferred R&amp;D expenses</a></td>
<td class="nump">32,729<span></span>
</td>
<td class="nump">11,123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accrued expenses</a></td>
<td class="nump">1,903<span></span>
</td>
<td class="nump">783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">978<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">424<span></span>
</td>
<td class="nump">337<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">90,855<span></span>
</td>
<td class="nump">22,211<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(90,855)<span></span>
</td>
<td class="num">(22,211)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration', window );">Net operating loss carryforwards, subject to expiration</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod', window );">Net operating loss carryforwards, subject to expiration period</a></td>
<td class="text">2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued', window );">Income Tax Examination, Penalties and Interest Accrued</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">3,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_TaxCreditCarryforwardExpirationPeriod', window );">Tax credit carry forwards expiration</a></td>
<td class="text">2034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember', window );">Federal and State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 216,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carry forwards</a></td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards subject to expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_TaxCreditCarryforwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax credit carryforward expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_TaxCreditCarryforwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Additional Information) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Accrued compensation unpaid</a></td>
<td class="nump">$ 326,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Percentage of employee contribution match</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions made by employees</a></td>
<td class="nump">$ 360,000<span></span>
</td>
<td class="nump">$ 294,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Termination benefits costs</a></td>
<td class="nump">225,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense', window );">Accrued compensation unpaid</a></td>
<td class="nump">154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember', window );">One-time Termination Benefits [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Defined Contribution Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Termination benefits costs</a></td>
<td class="nump">$ 622,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The compensation expense recognized during the period pertaining to the deferred compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483043/710-10-30-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OneTimeTerminationBenefitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Convertible Promissory Notes (Narrative) (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Promissory Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Short term borrowings</a></td>
<td class="nump">6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AdditionalProceedsFromAcquisition', window );">Additional proceeds from acquisition</a></td>
<td class="nump">$ 6,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rates</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs</a></td>
<td class="nump">$ 142,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of debt issuance costs</a></td>
<td class="nump">148,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_GainLossOnConversionOfDebt', window );">Gain (loss) on conversion of debt</a></td>
<td class="num">(114,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_AccruedInterest', window );">Accrued interest</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_AdditionalProceedsFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional proceeds from acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_AdditionalProceedsFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_GainLossOnConversionOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) on conversion of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_GainLossOnConversionOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2025</div></th>
<th class="th"><div>Jan. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Oct. 04, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,509,445<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember', window );">2024 Equity Incentive Plan [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,480,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRent', window );">Sublease rent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_SubleaseExpirationPeriod', window );">Sublease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2026-11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | 2024 Equity Incentive Plan [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock', window );">Percentage of number of outstanding shares of common stock</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_IncreaseInNumberOfSharesAvailableForIssuance', window );">Increase in number of shares available for issuance</a></td>
<td class="nump">667,355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | ESPP [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of available for issuance</a></td>
<td class="nump">481,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock', window );">Percentage of number of outstanding shares of common stock</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_okur_IncreaseInNumberOfSharesAvailableForIssuance', window );">Increase in number of shares available for issuance</a></td>
<td class="nump">133,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Subsequent Event [Member] | 2024 Equity Incentive Plan [Member] | Class A Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of available for issuance</a></td>
<td class="nump">2,407,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_IncreaseInNumberOfSharesAvailableForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in number of shares available for issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_IncreaseInNumberOfSharesAvailableForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_PercentageOfNumberOfOutstandingSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of number of outstanding shares of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_PercentageOfNumberOfOutstandingSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_okur_SubleaseExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sublease expiration period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">okur_SubleaseExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>okur_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash payments to lessor's for use of assets under operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=okur_TwentyTwentyFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>86
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( "Z =%I&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( "Z =%H,2GL#\0   "L"   1
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MA> [P26OI%B]3:X__*["+AB[M__,^.Z;\46P;>#77;2?4$L#!!0    ( "Z
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M+'_\ 07PTI;=2,%:N9)]KL05?;FB<@/TK('8'+"O5?I(,YV\=1:WH?PZE&D
MCTN$8!B@Q>SQ,)^^&9Y'8;"W:@'U]D ])]!;P4J:)H!]TRU*,EF#YFK#A*Z#
MP_FR =^&#@X180]W8/>-2#2'=M3^'K7O1/V)*YH= =#O/1LA B'I0.R;$1(&
M R,;[#$&KXRL[OI"/=<C:E9 J?NPFH*"*1O4H \58K\#U&+D$6S'&>YQADZ<
M?VB45*7% \B8[LQ F!9\QM=GE3ZIA]8&-^PA"4/80=NW\<+(#C;:@XW<8.N5
M.3SAD644YQU8?1M_ -5\CVI^Q'(<1C6W+$-O#L,.L+X9\4/BV;$AV' -/*KO
M9BF]3[-4I<S>?'=A1NJ^8T5K)WU L,@Y)==QS"O=;T%)G^E]QJP)HW[_F@=1
M9U8L5L1#X<"L-&2(G/QC (J*-8W7"A#WJPSBH NP;T6"8*##HH;!D)O"NGWA
M8/E,]ZVWY,+H0BMXTJ\STL/>-\)PH!I1PVG(36IM>C@ ;L79)R@$?=)M9A:S
M$$?^ -2&R)";R7[CQ<.98B('?'B\K;#[I.5[W59G,?*&> TUQ(;<S+8=WM?P
M6;A*JYH>PKY9&/IH &+#:<A-:BN>YZDRA+M5-#$OS-"R(M9PP;O?N6( >:=6
MX,[(]L8%K!WP_P=J9]^0)(J<'?].\?C+AF<)$_*G6GMH&?).;[/2.%6G]N;O
MY-TW-_^1HK7S;^@8N?E8B]HUT\6? &E&8@I.X#F$$&DR$$ +\8I= @2G^I+Y
M W)#A5&^E=IPD?[+DDM0\)>KJ92F37,!]'9<*KV83(E2!?3VB.7W6HTX=E@W
MJ,_IO<;B,FEOM!K*QTYV75XG26KZLBY3H^[/]#XRIF6JR]:ZZX+])NQ'OM_=
M@-CL#M15&VO#U/A5IJ[R*JNWPKLE:@79I^$SY'LA]KHH;880PZ&F@@_VKV[*
MWO8]Z2PN*_0^02-((MQ5&A8[C1Q%WH#"QPV78S>7]SKVU'3$1[T]2;4V F6W
M7DS+_(X\^V1NU;D6.X?0Q0WM8S?MWS%ANOL*-/5?=T+P]X>Z4O^Q@G;&?/,[
MAY&BM4>@41/8'T7J8Z<H>7/2(T5K)]W($>R6(RO72GY9$U8.:+J\6?#AU(/>
M=([F;D(PIL$T\N TP+##$O7+DU=HHC;J7B53H,.4K'Z]FCU?ZAG4!9?0^J7K
M-BEFWA'R-3A!<W\:8:+WF^:T%\DZWWV5U:4ABPG"\P@/*%S<2#'\BA3+],88
M7 ,CR70R1U3D=^@FQ^(<*5H[^T:*X=&E&!Y5BHT5K9U_(\6P6XKM9KVN1NL^
M 5M>CG27YM$*B30*B;@5TG95WAR_*MWQWCHK8T5K9]]H+H+&7I7$J>+>G/](
MT=KY-TJ.N)7<JZMRY^\[&J;39(MK=O"%R'R>^T#%0UI(O<%?:Q]X'FIGL?WB
MM3U1O*P_&MUSI7A>'VX8U;-D#/3]-=<;U]V)^0ZU_^ZX_ ]02P,$%     @
M+H!T6J0G>(WE P  8A(  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RU
M6-N.VS80_15"+8H$2%<BK8N]M0UDO2C:AP!&C*0/11]H:6P+*XD.2=MIOSXD
MI=5E=;,WJ1]L49K+.=3,')CS"^-/X@ @T=<TR<3".DAYO+=M$1X@I>*.'2%3
M3W:,IU2J)=_;XLB!1L8I36SB.+Z=TCBSEG-S;\V7<W:229S!FB-Q2E/*_WV
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M7_KU8Y8D@IGE3U&^9EU)W:E(_4#"EDB8@8292)B%A-E(F(.$N4B8AX3Y2%B
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MTF_U9\HTHHG#:\'Y<":]X(<>.T6 T@PHS832+"C-AM(<*,V]L"5YT*@^E!9
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MT!RFSBB#NXB:5#O1!Q,7I%-O":494)H)I5E0F@VE.5":V]*T<TW)@X;UH;0
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MS#!!,0X8]!(1T1L%J]$2I4[JIB<]UX&8)92#T4>\T:!/D-ZKX">4?QDAXS%
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MF$PB>J:3:>^AT1JE_9D,",Y6.[JCX9@X3'M_*IG]'_/T!M+QN/=9629.K%]
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M^A> E@UHOS:4^OV$'8S_*U;_ E!+ P04    "  N@'1:9J]9?98%   Z#@
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M!3[NR+$!GJ\LM-[><(#^<W'Y+U!+ P04    "  N@'1:/O_JZ8P"   '!@
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ME(:XT&T+^OF@L@9TGDMI7@4;8/L[F_X%4$L#!!0    ( "Z =%HN,1O"P@(
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MVY(F.BH;0.>%)*5;PU[0_4?,_@!02P,$%     @ +H!T6M @%'XL"   RA<
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M@:\:B_)8"U!!JI98QBJXCQ^&X"&O0B*URCH405!D3U#XB$+W*%H<XM2F,-D
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MA8D&]48[V2)@(H6B&T\<<$XGK@$P5X4)/2Z=9:Y-L(:9<@0=Z129*3Y0!(2
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MB?##20J/ML10, ?GDZX9_P<*;6O1YR#4Y<)Q4NAD+MI]K2.D316U%=A5XT.
MS+H[HX\HWR31HW73H#H2\7#$Y='RLIM?474].O91ZA]<(^HXT>)ER0.H-2'?
M*':[N_O8=;Z&[,WS9>Y6N)4RGC0OX3KH?7=>D,L7I/P0;),N)4@E!D):5KA3
MLHL&>+^TX-D]Q "[6^K\'U!+ P04    "  N@'1:A(17R-0#   -"@  &0
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MAMIMH'5W"A\FSD#_ IS_!5!+ P04    "  N@'1:\OX(H,45  "H1@  &0
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M)3=&W6V;:SD^U(C\R*;PA9#6<<( 7-X8U)0Z;6CU-N>2DL#2:Z8OX'X.H.$
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M&X&ZI@7X?F5M$WZA#>(?IWGS_U!+ P04    "  N@'1:G3X&:.0"  !$!@
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M/BNHK /9<RE-N[$)N@_5_#=02P,$%     @ +H!T6J_<-5 @!   C L  !D
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M&+6ES:AF970V*V7TO[Q@*\3WN9%OQ6_.J5(1'"AZ$Q+,!D48C],"BPT_B-X
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ML(:;![GYAMM\!I8ODUR[+VS:V#CV(&NTD?463 KJ2K0K>]V^PQY@%'P"B+:
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M#CQ0[;1H#2/7KD.7TE"_NVU) Q:5#:#S0DJS,^P%W<A._P%02P,$%     @
M+H!T6B3,MXS8!0  AP\  !D   !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL
MG5?;<N(X$'WG*U3,99,JQ_B&;7*ABF2RN_.0F5282VUM[8.P&U#%MAA)AC!?
MORT)')(0+[,/";*M/MVM/GTDG:^XN)=S $4>RJ*2%]VY4HO37D]F<RBI=/D"
M*OPRY:*D"A_%K"<7 FANC,JB%WA>W"LIJ[K#<_/N5@S/>:T*5L&M(+(N2RK6
MEU#PU477[VY?W+'97.D7O>'Y@LY@#.KKXE;@4Z]!R5D)E62\(@*F%]V1?WJ9
MZOEFPC<&*[DS)CJ3">?W^N%C?M'U=$!00*8T L6?)5Q!46@@#./'!K/;N-2&
MN^,M^N\F=\QE0B5<\>([R]7\HIMV20Y36A?JCJ_^A$T^?8V7\4*:_V2UF>MU
M259+Q<N-,490LLK^TH?-.AQB$&P, A.W=62B_$ 5'9X+OB)"ST8T/3"I&FL,
MCE6Z*&,E\"M#.S4<SZF DTO,*R=7O,1:2VJ6Z^@+G10@C\]["MWHR;UL WEI
M(8-7(/V W/!*S26YKG+(GP+T,+XFR& ;Y&70BO@!,I>$OD,"+XA:\,(FZ=#@
MA0<D?4O7R#%%1D+0:@9F_/=H(I5 PORS+WN+'>W'UDUT*A<T@XLN=HD$L83N
M\/T;/_;.6B*/FLBC-O3AV/8.X5.2\;+$.B%#LGNR\903;%,RK54M@# I:UIE
ML"^'=B\CJ1W@JD,Y =&LO$/4' Q+:+4F<YH_NI5Z18T54_)I:'LB(E3BZP(%
M09YV3#%DYVK7AB\T!Q&O5E+1*F?5C 1.. B=-(@Z7ZLE2 7&O1(LTT-K5U?:
M?8VT$R96C#HDMP6M2."'3M#7M@(5P53^%6N*09;XCE4&X@;$#-'\Q/$\KS-:
M4E;HQMA-:X;,>>XV(M<_:J;6Y"/F6VGEL7$D4>*D<?)+0.6BX&L ,C91WM8B
MFV,"%L\/$Z>/@7WABA8[93B8'21$^X$31?T6>O8;>O8/I><.57Z33\IJE1C7
M9A\QV_%'V\WCF8?W;]+ 3\Y>\4.00;@&!56FK'8GTQ/T<FB4-5!!0(O52]+C
M0CVAZ^<--3\_4K/SJ38FW\T6@"#-8#2;"9BAW\9LE]$F:O_LA<\0V98Z01B0
MM\2/W20BJ9NFYJ$S>F2G@"4(Y(& C"X8EI_]M&E%<>+XGD>BQ T'G3\TJ=#"
M=Y*D[X1^2OS4]</.]0.(C.E&. J<*(G),?$]UQ_@AP43^G42>?@R\-TXZ. 6
M. 6FS.S0B7W])4S=,/JES*+'+L9T@M#M1R1Q!Y[.K0$"&YAICM>!XG[DQ&&,
MEAB&EY+0]1(-T\+BN&%Q?"B+5YM*GE!<:SRD6'78!*HX[O\*!&[+8'@TI4R0
M)2UJV/(3MKV[2\Q]O&^-:/^F\@7Q6^.KY:.,718TNS\99W->:(&P#;) ^=/E
M*GD.Q?].9RM;*Q!/E?TOW5;7+]JJ8XF /-=4 R/ VBTYTGTHCTG?31+];^?[
MDF/WLD(WLQ_$;D#>D3!P/?*N<\?D_<E48$P,::XUG0AL..1#BI])Y(8^SFJ
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M--ZF]+8B66V2W!.3*F6:8J%>0<!U@.I?,B8W%9TW^W=5_ ]02P,$%     @
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M>A%+\O)_]% ?ZXQ0M,\%2^O"L@5IG%5_R:?:B$8!?*J 5Q?PC@KXWHD"?EW
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M9^T07)J;86W:$$CA*J9PS5#1%_;O:$:9.<)!B0-4+812T\U5T.$.0!TN*':
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M5T15&X+MRI<FW3(A6%I^W%(B;S[% ?+[.\;$XT;Q'J;#B[H6_P-02P,$%
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M3CM\E/PPPW\!8,@ ]U.M73LA@NY_Q>H?4$L#!!0    ( "Z =%K"23,O+P0
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M#W)U"ZT?)S"37+M?LFIC X]DM3:R;,&HH&2B&>E+FX<-0#@X (A:0+0+Z!T
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MTUFF43Q(_.6FC[<QX47<Q6S)ZW?R^D?E/5'%Z P+OE$'3;7O$]A_>_GEQ8[
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MC46U;F;X[($T 3B_%$)O.Z:R=@]I_!=02P,$%     @ +H!T6F[*I:N? P
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M@/I]R9B\'^C3=_UO2_ 74$L#!!0    ( "Z =%H$HH'K< (  -4%   9
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MRQKG+BB;@-^74IK=QA[03_+B-U!+ P04    "  N@'1:*)D./J4"  "[!P
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M6/0EB L^^DD\1=_EG4TE8:YXKXI\6=G@W<_OYP.I*H[,!^NTDH>D$G2A$HC
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M#GHG7=5D6=M.;/>=+_O ^8^)4V_J"JTI5^UA\=6E>\BIH76%UCQ\JAUM:+6
M_]-#YN\<V1/*R))!HZ/:A"F7LK1 >:+EU)7Z)T>-J2E[<P(K4<QWF2I.':N[
MU2GO-#_;].OIQ1'Q Q%KFDG$8*5#@\Y _QR(XM2U&"B^S0\NEUPIGN:7&R )
M"#-!/U]QKIX'9H'J['OR+U!+ P04    "  N@'1:H%E9*S8%  !>(@  &0
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M (-?,T?6I6;OO:F/@<_3#0P"^6R5R.S=]NYLMDGB"E]>IWL)7IP?X\MQNF7
M+F"RG1=WE,_#1* (9@K2N>@J;\"SS0Q90[)ENA]@RJ1D<7JX !H UQW4]S/&
MY'-##[#;4C+Z'U!+ P04    "  N@'1:FSS2(6P#  "3#@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6R]5UUOVS@0_"N$#BBNP#42]6'9.5M X[2X
M !?42)K>0W$/C+RVB8BD2E)V\^]+4HKLPK(*&$I?;%'4SLXN1QQQNA/R26T
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M81KHZ],\5T\'IH-J[^7P7U!+ P04    "  N@'1:1 (7[GX#   B"P  &0
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MPY2:6)3F .TOA-#/$T-0M\6C?P%02P,$%     @ +H!T6I>P$57S @  # L
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M#!-L5T'H 'R^XESM)_H%=0,<_@-02P,$%     @ +H!T6OJ!_YFI @  (@<
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ME\ZLNJM4$T%+W>[?J)"7!SU,Y?T.F#*0[Q>4BL^)ND$T-\;H'U!+ P04
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M4%&-C]5"\=),8#=<X3QG'J<X<H/0!_#]F'.U6F@']1 ?_P502P,$%     @
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M'2B[ ;^OI33[B570](CQ+U!+ P04    "  N@'1:_I]K>Y\#  !W#@  &0
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M=[+>+;!\B0;9H>HMV%HFZ020//)?!^ITM^?"7;0P%^YO48[KA=\A6I"E%!E
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M6@!*PU T59EN/\#1[P>\;4>F@?<+G#NQO6.7LM!WXFP!0*T_%$T5H+/^CM;
M D_]36/'4[]]K >HX0>E82B:JD=G^!V]X0>:^IM6^B/#'HW<\8D2H+_.@](P
M%$U5HML-</26^XX\QFF9]F?X_\&=ZCMY]DP$^EL_* U#T52YNYT'QP->(X#N
M&X#2 E :AJ*IRG3[!H[6_;YUC> /_)9AC>W310+H_@ H#4/1:@7,WH.!*2TV
MU1.93$SN9<;K9P3;=]NG/J^K9QW-[O+ZD=$[4FSBC*&$WHM0ZV(LOBI%_11F
M?<+S7?68X3KG/$^KPRTE$2WD!>+S^SSGSR>R@?99V/F_4$L#!!0    ( "Z
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MTP8>6!R(]+)<XZN-5\C^.L#6=%^%8#/%*Q&;*9YK0-QY X\D<:\V%@<\L%7
M:@?BN^- 3;E]H@A6%=.&[6 <21(,@5ITUV@<(]F)X>->'VR71%&2N!' W JB
M"$-@-^((I@ T8$@4F??@SOLHV+RG@N:WW-%?4$L#!!0    ( "Z =%J7BKL<
MP    !,"   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$
M^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8E
MCVG.D4*NU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^
MKSI,<4)I2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE
M?QW']I#3Z:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @
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M^M])]7@^MUPO?UE^[9S<XQ><TVU%??X+4$L#!!0    ( "Z =%JE?PYQ[@$
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M2P$"% ,4    "  N@'1:#$I[ _$    K @  $0              @ '#
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  N@'1:F5R<(Q &  "<)P
M$P              @ 'C 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   ( "Z =%I-@>[^L08  +L9   8              " @20(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  N@'1:_"E6GR<&  "#'
M&               @($+#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L!
M A0#%     @ +H!T6J0G>(WE P  8A(  !@              ("!:!4  'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( "Z =%H9HN>+& 0
M -L.   8              " @8,9  !X;"]W;W)K<VAE971S+W-H965T-"YX
M;6Q02P$"% ,4    "  N@'1:;QX(:ZP+  "3CP  &               @('1
M'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ +H!T6O#,
M:MU+ @  V00  !@              ("!LRD  'AL+W=O<FMS:&5E=',O<VAE
M970V+GAM;%!+ 0(4 Q0    ( "Z =%HA]@:A+@@  '4K   8
M  " @30L  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  N
M@'1:7A-ME \,  #4'P  &               @(&8-   >&PO=V]R:W-H965T
M<R]S:&5E=#@N>&UL4$L! A0#%     @ +H!T6I)EZ"<<%0  X#X  !@
M         ("!W4   'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0
M   ( "Z =%KCO&L$)PD  -X9   9              " @2]6  !X;"]W;W)K
M<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ +H!T6EI$^16:!   Z@D
M !D              ("!C5\  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q0
M2P$"% ,4    "  N@'1:YK!0*1 $  "D"0  &0              @(%>9
M>&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( "Z =%K"WI9%
MV0,  &,(   9              " @:5H  !X;"]W;W)K<VAE971S+W-H965T
M,3,N>&UL4$L! A0#%     @ +H!T6F:O67V6!0  .@X  !D
M ("!M6P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  N
M@'1:/O_JZ8P"   '!@  &0              @(&"<@  >&PO=V]R:W-H965T
M<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "Z =%KKX_K'!0,  -H&   9
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M970R,"YX;6Q02P$"% ,4    "  N@'1:&#+48A\)  #:%@  &0
M    @($,F   >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    (
M "Z =%H8:;L[9P0  +$*   9              " @6*A  !X;"]W;W)K<VAE
M971S+W-H965T,C(N>&UL4$L! A0#%     @ +H!T6H2$5\C4 P  #0H  !D
M             ("! *8  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"
M% ,4    "  N@'1:\OX(H,45  "H1@  &0              @($+J@  >&PO
M=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( "Z =%J=/@9HY (
M $0&   9              " @0?   !X;"]W;W)K<VAE971S+W-H965T,C4N
M>&UL4$L! A0#%     @ +H!T6@HM,EXM P  M 8  !D              ("!
M(L,  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  N@'1:
MK]PU4" $  ","P  &0              @(&&Q@  >&PO=V]R:W-H965T<R]S
M:&5E=#(W+GAM;%!+ 0(4 Q0    ( "Z =%KUM CP)0,  +@&   9
M      " @=W*  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%
M  @ +H!T6EW=.)F9 @  [P4  !D              ("!.<X  'AL+W=O<FMS
M:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  N@'1:,_,D.-<"   \!@
M&0              @($)T0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+
M 0(4 Q0    ( "Z =%IK$)&6HP(  +X%   9              " @1?4  !X
M;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ +H!T6B3,MXS8
M!0  AP\  !D              ("!\=8  'AL+W=O<FMS:&5E=',O<VAE970S
M,BYX;6Q02P$"% ,4    "  N@'1:8ZA#K[H#  "&"   &0
M@($ W0  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( "Z
M=%KY73/ORP(  &,)   9              " @?'@  !X;"]W;W)K<VAE971S
M+W-H965T,S0N>&UL4$L! A0#%     @ +H!T6ED.C>!4!   E1(  !D
M         ("!\^,  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4
M    "  N@'1:F]Z]LW (  "T2P  &0              @(%^Z   >&PO=V]R
M:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( "Z =%H%]7MLT (  &<'
M   9              " @27Q  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL
M4$L! A0#%     @ +H!T6HSC^ 5B P  8P@  !D              ("!+/0
M 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  N@'1:PDDS
M+R\$  !'$@  &0              @('%]P  >&PO=V]R:W-H965T<R]S:&5E
M=#,Y+GAM;%!+ 0(4 Q0    ( "Z =%H=(4[WP@(  %H'   9
M  " @2O\  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @
M+H!T6BN_3HN: @  0 <  !D              ("!)/\  'AL+W=O<FMS:&5E
M=',O<VAE970T,2YX;6Q02P$"% ,4    "  N@'1:_<<N"(,"  !:!@  &0
M            @('U 0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4
M Q0    ( "Z =%I'1$VT* ,  .P(   9              " @:\$ 0!X;"]W
M;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ +H!T6D!?0YW3 @
MX @  !D              ("!#@@! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX
M;6Q02P$"% ,4    "  N@'1:IA!A<S,$  !=%   &0              @($8
M"P$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "Z =%I,
M4YEY[@(   P)   9              " @8(/ 0!X;"]W;W)K<VAE971S+W-H
M965T-#8N>&UL4$L! A0#%     @ +H!T6@>O:["; @  5 <  !D
M     ("!IQ(! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "Z =%J>-.W #00   <7   9              "
M@;\E 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ +H!T
M6J!962LV!0  7B(  !D              ("! RH! 'AL+W=O<FMS:&5E=',O
M<VAE970U,RYX;6Q02P$"% ,4    "  N@'1:FSS2(6P#  "3#@  &0
M        @(%P+P$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0
M   ( "Z =%H>JVY@#P4   $;   9              " @1,S 0!X;"]W;W)K
M<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ +H!T6OVI9,O& @  U0<
M !D              ("!63@! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q0
M2P$"% ,4    "  N@'1:E!7HFM<%  "'*0  &0              @(%6.P$
M>&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( "Z =%I$ A?N
M?@,  "(+   9              " @61! 0!X;"]W;W)K<VAE971S+W-H965T
M-3@N>&UL4$L! A0#%     @ +H!T6I>P$57S @  # L  !D
M ("!&44! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  N
M@'1:^H'_F:D"   B!P  &0              @(%#2 $ >&PO=V]R:W-H965T
M<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( "Z =%ISY_R&#@,  #X)   9
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M970V-2YX;6Q02P$"% ,4    "  N@'1:$"$6H54%   7*P  &0
M    @($B70$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    (
M "Z =%JO$)3\4P,  -@5   -              "  :YB 0!X;"]S='EL97,N
M>&UL4$L! A0#%     @ +H!T6I>*NQS     $P(   L              ( !
M+&8! %]R96QS+RYR96QS4$L! A0#%     @ +H!T6D3>AEHP!0  CBL   \
M             ( !%6<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( "Z
M=%H>WYE>' (  #TG   :              "  7)L 0!X;"]?<F5L<R]W;W)K
M8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "Z =%JE?PYQ[@$  ) F   3
M          "  <9N 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !* $H
*/10  .5P 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>130</ContextCount>
  <ElementCount>324</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>48</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>1001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1008 - Disclosure - Organization and Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/OrganizationAndBusiness</Role>
      <ShortName>Organization and Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1009 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1010 - Disclosure - Merger Agreement and Concurrent Financing</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing</Role>
      <ShortName>Merger Agreement and Concurrent Financing</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>1011 - Disclosure - Segment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/Segment</Role>
      <ShortName>Segment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>1012 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>1013 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>1014 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>1015 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>1016 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>1017 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>1018 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>1019 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>1020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>1021 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>1022 - Disclosure - Convertible Promissory Notes</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes</Role>
      <ShortName>Convertible Promissory Notes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>1023 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>1024 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>1025 - Disclosure - Merger Agreement and Concurrent Financing (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables</Role>
      <ShortName>Merger Agreement and Concurrent Financing (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>1026 - Disclosure - Segment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SegmentTables</Role>
      <ShortName>Segment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/Segment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>1027 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>1028 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>1029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>1030 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/PropertyAndEquipmentNet</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>1031 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/AccruedExpenses</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>1032 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>1033 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/IncomeTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>1034 - Disclosure - Organization and Business (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails</Role>
      <ShortName>Organization and Business (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/OrganizationAndBusiness</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>1035 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>1036 - Disclosure - Merger Agreement and Concurrent Financing - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails</Role>
      <ShortName>Merger Agreement and Concurrent Financing - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>1037 - Disclosure - Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails</Role>
      <ShortName>Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>1038 - Disclosure - Segment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails</Role>
      <ShortName>Segment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>1039 - Disclosure - Segment - Schedule of Segment Reporting Information by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails</Role>
      <ShortName>Segment - Schedule of Segment Reporting Information by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>1040 - Disclosure - Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesDetails</Role>
      <ShortName>Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/LeasesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>1041 - Disclosure - Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>1042 - Disclosure - Leases - Schedule of Lease Expense for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails</Role>
      <ShortName>Leases - Schedule of Lease Expense for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>1043 - Disclosure - Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails</Role>
      <ShortName>Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>1044 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>1045 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>1046 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>1047 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>1048 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>1049 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>1050 - Disclosure - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/AccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/AccruedExpensesTables</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>1051 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>1052 - Disclosure - Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>1053 - Disclosure - Share-Based Compensation - Stock Options - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>1054 - Disclosure - Share-Based Compensation - Shares Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails</Role>
      <ShortName>Share-Based Compensation - Shares Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>1055 - Disclosure - Share-Based Compensation - Stock option activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock option activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>1056 - Disclosure - Share-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>1057 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>1058 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>1059 - Disclosure - Share-Based Compensation - Non-cash stock-based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Non-cash stock-based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>1060 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails</Role>
      <ShortName>Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>1061 - Disclosure - Income Taxes - Summary of components of income tax benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Summary of components of income tax benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>1062 - Disclosure - Income Taxes - Components of net deferred taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Components of net deferred taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>1063 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>1064 - Disclosure - Commitments and Contingencies (Additional Information) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies (Additional Information) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>1065 - Disclosure - Convertible Promissory Notes (Narrative) (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails</Role>
      <ShortName>Convertible Promissory Notes (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="d184865dposam.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>1066 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="POS AM" isDefinitelyFs="true" isUsgaap="true" original="d184865dposam.htm">d184865dposam.htm</File>
    <File>okur-20241231.xsd</File>
    <File>okur-20241231_cal.xml</File>
    <File>okur-20241231_def.xml</File>
    <File>okur-20241231_lab.xml</File>
    <File>okur-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g184865g00n05.jpg</File>
    <File>g184865g00n06.jpg</File>
    <File>g184865g07g07.jpg</File>
    <File>g184865g08g02.jpg</File>
    <File>g184865g08g03.jpg</File>
    <File>g184865g08g08.jpg</File>
    <File>g184865g09g01.jpg</File>
    <File>g184865g09g02.jpg</File>
    <File>g184865g10g40.jpg</File>
    <File>g184865g35j50.jpg</File>
    <File>g184865g96g96.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="491">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="27">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>93
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d184865dposam.htm": {
   "nsprefix": "okur",
   "nsuri": "http://onkuretherapeutics.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "d184865dposam.htm"
     ]
    },
    "schema": {
     "local": [
      "okur-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/currency/2024/currency-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/exch/2024/exch-2024.xsd",
      "https://xbrl.sec.gov/naics/2024/naics-2024.xsd",
      "https://xbrl.sec.gov/sic/2024/sic-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "okur-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "okur-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "okur-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "okur-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 264,
   "keyCustom": 60,
   "axisStandard": 20,
   "axisCustom": 0,
   "memberStandard": 26,
   "memberCustom": 17,
   "hidden": {
    "total": 14,
    "http://fasb.org/us-gaap/2024": 7,
    "http://xbrl.sec.gov/dei/2024": 7
   },
   "contextCount": 130,
   "entityCount": 1,
   "segmentCount": 48,
   "elementCount": 487,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 491,
    "http://xbrl.sec.gov/dei/2024": 27
   },
   "report": {
    "R1": {
     "role": "http://onkuretherapeutics.com/role/CoverPage",
     "longName": "1001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "dei:EntityRegistrantName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
     "longName": "1002 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "1003 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "okur:ConvertiblePreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "okur:ConvertiblePreferredStockParOrStatedValuePerShare",
      "unitRef": "Unit_USD_per_Share",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R4": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "longName": "1004 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
     "longName": "1005 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis",
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
     "longName": "1006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "okur:StockIssuanceCostNet",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis",
      "name": "okur:StockIssuanceCostNet",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
     "longName": "1007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://onkuretherapeutics.com/role/OrganizationAndBusiness",
     "longName": "1008 - Disclosure - Organization and Business",
     "shortName": "Organization and Business",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies",
     "longName": "1009 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing",
     "longName": "1010 - Disclosure - Merger Agreement and Concurrent Financing",
     "shortName": "Merger Agreement and Concurrent Financing",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:MergerAgreementAndConcurrentFinancingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:MergerAgreementAndConcurrentFinancingTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://onkuretherapeutics.com/role/Segment",
     "longName": "1011 - Disclosure - Segment",
     "shortName": "Segment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://onkuretherapeutics.com/role/Leases",
     "longName": "1012 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://onkuretherapeutics.com/role/NetLossPerShare",
     "longName": "1013 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://onkuretherapeutics.com/role/FairValueMeasurements",
     "longName": "1014 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets",
     "longName": "1015 - Disclosure - Prepaid Expenses and Other Current Assets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OtherCurrentAssetsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://onkuretherapeutics.com/role/PropertyAndEquipmentNet",
     "longName": "1016 - Disclosure - Property and Equipment, Net",
     "shortName": "Property and Equipment, Net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://onkuretherapeutics.com/role/AccruedExpenses",
     "longName": "1017 - Disclosure - Accrued Expenses",
     "shortName": "Accrued Expenses",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://onkuretherapeutics.com/role/Equity",
     "longName": "1018 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensation",
     "longName": "1019 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://onkuretherapeutics.com/role/IncomeTaxes",
     "longName": "1020 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://onkuretherapeutics.com/role/CommitmentsAndContingencies",
     "longName": "1021 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes",
     "longName": "1022 - Disclosure - Convertible Promissory Notes",
     "shortName": "Convertible Promissory Notes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ConvertiblePromissoryNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ConvertiblePromissoryNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://onkuretherapeutics.com/role/SubsequentEvents",
     "longName": "1023 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies",
     "longName": "1024 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "24",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:BasisOfPresentationAndConsolidationPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables",
     "longName": "1025 - Disclosure - Merger Agreement and Concurrent Financing (Tables)",
     "shortName": "Merger Agreement and Concurrent Financing (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "25",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://onkuretherapeutics.com/role/SegmentTables",
     "longName": "1026 - Disclosure - Segment (Tables)",
     "shortName": "Segment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://onkuretherapeutics.com/role/LeasesTables",
     "longName": "1027 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://onkuretherapeutics.com/role/NetLossPerShareTables",
     "longName": "1028 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables",
     "longName": "1029 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables",
     "longName": "1030 - Disclosure - Property and Equipment, Net (Tables)",
     "shortName": "Property and Equipment, Net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://onkuretherapeutics.com/role/AccruedExpensesTables",
     "longName": "1031 - Disclosure - Accrued Expenses (Tables)",
     "shortName": "Accrued Expenses (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationTables",
     "longName": "1032 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://onkuretherapeutics.com/role/IncomeTaxesTables",
     "longName": "1033 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails",
     "longName": "1034 - Disclosure - Organization and Business (Narrative) (Details)",
     "shortName": "Organization and Business (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "34",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:RetainedEarningsAccumulatedDeficit",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis",
      "name": "us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R35": {
     "role": "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails",
     "longName": "1035 - Disclosure - Summary of Significant Accounting Policies (Narrative) (Details)",
     "shortName": "Summary of Significant Accounting Policies (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "35",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
     "longName": "1036 - Disclosure - Merger Agreement and Concurrent Financing - Additional Information (Details)",
     "shortName": "Merger Agreement and Concurrent Financing - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "36",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ReneoMemberdeiLegalEntityAxis",
      "name": "okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "okur:MergerAgreementAndConcurrentFinancingTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R37": {
     "role": "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails",
     "longName": "1037 - Disclosure - Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)",
     "shortName": "Merger Agreement and Concurrent Financing - Summary of Acquired Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails",
     "longName": "1038 - Disclosure - Segment - Additional Information (Details)",
     "shortName": "Segment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "Unit_Segment",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails",
     "longName": "1039 - Disclosure - Segment - Schedule of Segment Reporting Information by Segment (Details)",
     "shortName": "Segment - Schedule of Segment Reporting Information by Segment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "okur:AdjustmentsAndReconcilingItems",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R40": {
     "role": "http://onkuretherapeutics.com/role/LeasesDetails",
     "longName": "1040 - Disclosure - Leases (Details)",
     "shortName": "Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:AreaOfRealEstateProperty",
      "unitRef": "Unit_sqft",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails",
     "longName": "1041 - Disclosure - Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details)",
     "shortName": "Leases - Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseLiability",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails",
     "longName": "1042 - Disclosure - Leases - Schedule of Lease Expense for Operating Leases (Details)",
     "shortName": "Leases - Schedule of Lease Expense for Operating Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails",
     "longName": "1043 - Disclosure - Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details)",
     "shortName": "Leases - Schedule of Lease Term, Discount Rates, and Additional Information for Operating (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "longName": "1044 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails",
     "longName": "1045 - Disclosure - Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details)",
     "shortName": "Net Loss Per Share - Schedule of Anti-Dilutive Securities Not Included in Diluted Net Loss Per Share Calculation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "longName": "1046 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails",
     "longName": "1047 - Disclosure - Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "shortName": "Prepaid Expenses and Other Current Assets - Schedule of Prepaid Expense and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "okur:PrepaidClinicalTrials",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "okur:PrepaidClinicalTrials",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherAssetsTableTextBlock",
       "us-gaap:OtherCurrentAssetsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
     "longName": "1048 - Disclosure - Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "shortName": "Property and Equipment, Net - Schedule of Property and Equipment, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails",
     "longName": "1049 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DepreciationExpenseOnReclassifiedAssets",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://onkuretherapeutics.com/role/AccruedExpensesDetails",
     "longName": "1050 - Disclosure - Accrued Expenses (Details)",
     "shortName": "Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
     "longName": "1051 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:Dividends",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
     "longName": "1052 - Disclosure - Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Equity Incentive Plans and ESPP Plan - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R53": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
     "longName": "1053 - Disclosure - Share-Based Compensation - Stock Options - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Stock Options - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
     "longName": "1054 - Disclosure - Share-Based Compensation - Shares Reserved for Future Issuance (Details)",
     "shortName": "Share-Based Compensation - Shares Reserved for Future Issuance (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
     "longName": "1055 - Disclosure - Share-Based Compensation - Stock option activity (Details)",
     "shortName": "Share-Based Compensation - Stock option activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails",
     "longName": "1056 - Disclosure - Share-Based Compensation - Assumptions (Details)",
     "shortName": "Share-Based Compensation - Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "4",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
     "longName": "1057 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
     "longName": "1058 - Disclosure - Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details)",
     "shortName": "Share-Based Compensation - Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R59": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails",
     "longName": "1059 - Disclosure - Share-Based Compensation - Non-cash stock-based compensation expense (Details)",
     "shortName": "Share-Based Compensation - Non-cash stock-based compensation expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
     "longName": "1060 - Disclosure - Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details)",
     "shortName": "Share-Based Compensation - Share-Based Compensation Expense - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails",
     "longName": "1061 - Disclosure - Income Taxes - Summary of components of income tax benefit (Details)",
     "shortName": "Income Taxes - Summary of components of income tax benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "Unit_pure",
      "xsiNil": "false",
      "lang": null,
      "decimals": "3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails",
     "longName": "1062 - Disclosure - Income Taxes - Components of net deferred taxes (Details)",
     "shortName": "Income Taxes - Components of net deferred taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails",
     "longName": "1063 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
     "longName": "1064 - Disclosure - Commitments and Contingencies (Additional Information) (Details)",
     "shortName": "Commitments and Contingencies (Additional Information) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails",
     "longName": "1065 - Disclosure - Convertible Promissory Notes (Narrative) (Details)",
     "shortName": "Convertible Promissory Notes (Narrative) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "P01_01_2024To12_31_2024",
      "name": "us-gaap:AmortizationOfFinancingCosts",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "PAsOn06_30_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-5",
      "ancestors": [
       "div",
       "okur:ConvertiblePromissoryNoteDisclosureTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    },
    "R66": {
     "role": "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
     "longName": "1066 - Disclosure - Subsequent Events - Additional Information (Details)",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "PAsOn12_31_2024",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "unitRef": "Unit_shares",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "td",
       "tr",
       "table",
       "okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis",
      "name": "us-gaap:PaymentsForRent",
      "unitRef": "Unit_USD",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d184865dposam.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_AccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccountingPoliciesLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Line Items]",
        "documentation": "Accounting policies line items."
       }
      }
     },
     "auth_ref": []
    },
    "okur_AccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccountingPoliciesTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Table]",
        "documentation": "Accounting policies table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpenses"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Expenses",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r55",
      "r60",
      "r788"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r698"
     ]
    },
    "okur_AccruedClinicalTrialCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccruedClinicalTrialCosts",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Clinical Trial Costs",
        "terseLabel": "Accrued clinical trial costs",
        "documentation": "Accrued clinical trial costs."
       }
      }
     },
     "auth_ref": []
    },
    "okur_AccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccruedInterest",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 9.0
      },
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses",
        "totalLabel": "Total accrued expenses",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_AccruedManufacturingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccruedManufacturingExpense",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Manufacturing Expense",
        "terseLabel": "Accrued contract manufacturing costs",
        "documentation": "Accrued manufacturing expense"
       }
      }
     },
     "auth_ref": []
    },
    "okur_AccruedResearchAndDevelopmentExpensesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AccruedResearchAndDevelopmentExpensesPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Research And Development Expenses [Policy Text Block]",
        "terseLabel": "Accrued Research and Development Expenses",
        "documentation": "Accrued research and development expenses."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r128",
      "r524"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r698",
      "r851"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r567",
      "r731",
      "r732",
      "r733",
      "r734",
      "r797",
      "r852"
     ]
    },
    "okur_AdditionalProceedsFromAcquisition": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AdditionalProceedsFromAcquisition",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Proceeds From Acquisition",
        "terseLabel": "Additional proceeds from acquisition",
        "documentation": "Additional proceeds from acquisition."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AddressTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AddressTypeDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Address Type [Domain]",
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types."
       }
      }
     },
     "auth_ref": []
    },
    "okur_AdjustmentForFractionalSharesInTheReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AdjustmentForFractionalSharesInTheReverseRecapitalization",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment for fractional shares in the reverse recapitalization",
        "documentation": "Adjustment for fractional shares in the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "okur_AdjustmentsAndReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AdjustmentsAndReconcilingItems",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments and Reconciling Items",
        "negatedTotalLabel": "Adjustments and reconciling items",
        "documentation": "Adjustments and reconciling items"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Axis]",
        "documentation": "Information by amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r157",
      "r158",
      "r159",
      "r160",
      "r170",
      "r229",
      "r230",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r262",
      "r263",
      "r267",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r463",
      "r464",
      "r475",
      "r476",
      "r477",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r508",
      "r509",
      "r510",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "okur_AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Additional Paid in Capital Reverse Recapitalization Transaction Costs",
        "terseLabel": "Reverse recapitalization transaction costs of OnKure",
        "documentation": "Adjustments to additional paid in capital reverse recapitalization transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock based compensation expense",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r327"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Stock-based compensation expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r359",
      "r368"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCosts",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of debt issuance costs",
        "documentation": "Amount of amortization expense attributable to debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r301",
      "r726",
      "r804"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r180"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AreaOfRealEstateProperty",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of real estate property",
        "documentation": "Area of a real estate property."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "Total assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r106",
      "r130",
      "r152",
      "r184",
      "r192",
      "r217",
      "r221",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r422",
      "r424",
      "r465",
      "r517",
      "r601",
      "r662",
      "r663",
      "r698",
      "r712",
      "r757",
      "r758",
      "r810"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "auth_ref": []
    },
    "okur_AssetsAcquiredInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "AssetsAcquiredInConnectionWithTheReverseRecapitalization",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Acquired in Connection with the Reverse Recapitalization",
        "terseLabel": "Assets acquired in connection with the reverse recapitalization",
        "documentation": "Assets acquired in connection with the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current",
        "totalLabel": "Total current assets",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r135",
      "r152",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r422",
      "r424",
      "r465",
      "r698",
      "r757",
      "r758",
      "r810"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Market Value",
        "verboseLabel": "Debt securities available-for-sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r244",
      "r449",
      "r512",
      "r688",
      "r692",
      "r743",
      "r798",
      "r799",
      "r800"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "okur_BasisOfPresentationAndConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "BasisOfPresentationAndConsolidationPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Basis Of Presentation And Consolidation Policy [Text Block]",
        "terseLabel": "Basis of Presentation and Consolidation",
        "documentation": "Disclosure of accounting policy for basis of presentation used to prepare the financial statements and principles followed in consolidating or combining the separate financial statements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r413",
      "r681",
      "r682"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r413",
      "r681",
      "r682"
     ]
    },
    "us-gaap_BusinessAcquisitionDateOfAcquisitionAgreement1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionDateOfAcquisitionAgreement1",
     "presentation": [
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition, Date of Acquisition Agreement",
        "terseLabel": "Date of agreement and plan of merger",
        "documentation": "Date when the business acquisition agreement was executed, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Acquisition [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r413"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "totalLabel": "Net assets acquired",
        "documentation": "Amount of assets acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Short-term investments",
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets",
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedLabel": "Accrued expenses",
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "okur_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Long-term Operating Lease Liability",
        "negatedLabel": "Long-term operating lease liability",
        "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, long-term operating lease liability."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingSummaryOfAcquiredAssetsAndLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets",
        "terseLabel": "Other assets",
        "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date."
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_BusinessContactMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "BusinessContactMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Contact [Member]",
        "documentation": "Business contact for the entity"
       }
      }
     },
     "auth_ref": [
      "r714",
      "r715"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents carrying amount",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r126",
      "r651"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of period",
        "periodEndLabel": "Cash and cash equivalents, end of period",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r75",
      "r148"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash and cash equivalents",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r75"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "okur_ClassACommonStockAndSeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ClassACommonStockAndSeriesCPreferredStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class A Common Stock And Series C Preferred Stock [Member]",
        "terseLabel": "Class A Common Stock and Series C Preferred Stock [Member]",
        "documentation": "Class A common stock and series C preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://onkuretherapeutics.com/role/CoverPage",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r131",
      "r132",
      "r133",
      "r152",
      "r174",
      "r175",
      "r177",
      "r179",
      "r186",
      "r187",
      "r233",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r303",
      "r304",
      "r308",
      "r311",
      "r319",
      "r465",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r589",
      "r610",
      "r629",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r717",
      "r727",
      "r735"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r186",
      "r303",
      "r304",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r561",
      "r562",
      "r563",
      "r564",
      "r680",
      "r717",
      "r727"
     ]
    },
    "okur_ClinicalResearchSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ClinicalResearchSegmentMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Clinical Research Segment [Member]",
        "documentation": "Clinical research segment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 14)",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r100",
      "r518",
      "r588"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r275",
      "r276",
      "r647",
      "r749",
      "r754"
     ]
    },
    "us-gaap_CommonClassAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassAMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class A [Member]",
        "terseLabel": "Class A Common Stock [Member]",
        "documentation": "Classification of common stock representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_CommonClassBMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonClassBMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Class B [Member]",
        "terseLabel": "Class B Common Stock [Member]",
        "documentation": "Classification of common stock that has different rights than Common Class A, representing ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "okur_CommonStockCapitalSharesReservedAndAvailableForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "CommonStockCapitalSharesReservedAndAvailableForFutureIssuance",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Capital Shares Reserved and Available for Future Issuance",
        "terseLabel": "Stock were initially reserved and available for issuance",
        "documentation": "Common stock, capital shares reserved and available for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total shares of common stock reserved for future issuance",
        "terseLabel": "Stock were initially reserved for issuance.",
        "verboseLabel": "Number of shares of available for issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r702",
      "r703",
      "r705",
      "r706",
      "r707",
      "r708",
      "r731",
      "r732",
      "r734",
      "r797",
      "r850",
      "r852"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, Par value",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r589"
     ]
    },
    "okur_CommonStockSharesConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "CommonStockSharesConvertibleConversionRatio",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Shares Convertible, Conversion Ratio",
        "terseLabel": "Common stock exchange ratio",
        "documentation": "Common stock shares convertible, conversion ratio."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common stock, outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r589",
      "r607",
      "r852",
      "r853"
     ]
    },
    "okur_CommonStockValuationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "CommonStockValuationPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Valuation [Policy Text Block]",
        "terseLabel": "Common Stock Valuation",
        "documentation": "Common Stock Valuation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stocks",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r520",
      "r698"
     ]
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Loss",
        "documentation": "Disclosure of accounting policy for comprehensive income."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ComputerHardwareAndSoftwareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ComputerHardwareAndSoftwareMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Computer Hardware and Software [Member]",
        "documentation": "Computer hardware and software"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r109"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Federally insured limits",
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity."
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "okur_ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concurrent Financing Issuance Costs Included in Accounts Payable",
        "terseLabel": "Concurrent Financing issuance costs included in accounts payable",
        "documentation": "Concurrent financing issuance costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Concurrent Financing Issuance Costs Paid by Reneo Prior to Merger",
        "terseLabel": "Concurrent Financing issuance costs paid by Reneo prior to Merger",
        "documentation": "Concurrent financing issuance costs paid by reneo prior to merger"
       }
      }
     },
     "auth_ref": []
    },
    "dei_ContactPersonnelName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "ContactPersonnelName",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contact Personnel Name",
        "documentation": "Name of contact personnel"
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConversionOfConvertibleNotePayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConversionOfConvertibleNotePayable",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Convertible Note Payable",
        "terseLabel": "Conversion of convertible note payable",
        "documentation": "Conversion of convertible note payable."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConversionOfSeriesCPreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConversionOfSeriesCPreferredStock",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Series C Preferred Stock",
        "terseLabel": "Conversion of Series C Preferred Stock",
        "documentation": "Conversion of series C preferred stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConversionOfStockAmountIssued1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConversionOfStockAmountIssued1",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Conversion of Stock, Amount Issued",
        "terseLabel": "Issuance of Series C Preferred Stock conversion",
        "verboseLabel": "Conversion of stock amount issued",
        "documentation": "The value of the financial instrument issued [noncash or part noncash] in the conversion of stock. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r21"
     ]
    },
    "us-gaap_ConvertibleDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertibleDebtMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Debt [Member]",
        "verboseLabel": "Convertible Promissory Note [Member]",
        "terseLabel": "Convertible Promissory Note",
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r85",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679"
     ]
    },
    "okur_ConvertiblePreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Liquidation Preference Value",
        "terseLabel": "Convertible preferred stock liquidation preference value",
        "documentation": "Convertible preferred stock liquidation preference value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock [Member]",
        "documentation": "Preferred stock that may be exchanged into common shares or other types of securities at the owner's option."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r308",
      "r705",
      "r706",
      "r707",
      "r708"
     ]
    },
    "us-gaap_ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Nonredeemable or Redeemable, Issuer Option, Value",
        "terseLabel": "Convertible preferred stock, Series C, $0.0001 par value; no shares and 7,404,919 shares authorized; no shares and 6,840,620 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively; liquidation preference of $195,823 as of December 31, 2023",
        "documentation": "Value of outstanding nonredeemable convertible preferred stock or outstanding convertible preferred stock that is redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r63"
     ]
    },
    "okur_ConvertiblePreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Par or Stated Value Per Share",
        "terseLabel": "Convertible preferred stock par or stated value per share",
        "documentation": "Convertible preferred stock par or stated value per share."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePreferredStockSeriesCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockSeriesCMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Series C [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "verboseLabel": "Convertible Series C Preferred Stock [Member]",
        "documentation": "Convertible preferred stock series C."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockSharesAuthorized",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Shares Authorized",
        "terseLabel": "Convertible preferred stock shares authorized",
        "documentation": "Convertible preferred stock shares authorized."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockSharesIssued",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Shares Issued",
        "terseLabel": "Convertible preferred stock shares issued",
        "documentation": "Convertible preferred stock shares issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Conversion of convertible preferred stock into common stock",
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r63",
      "r89",
      "r314"
     ]
    },
    "okur_ConvertiblePreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePreferredStockSharesOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Preferred Stock Shares Outstanding",
        "terseLabel": "Convertible preferred stock shares outstanding",
        "documentation": "Convertible preferred stock shares outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePromissoryNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePromissoryNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note [Abstract]",
        "documentation": "Convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePromissoryNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePromissoryNoteDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Note Disclosure [Text Block]",
        "terseLabel": "Convertible Promissory Notes",
        "documentation": "Convertible promissory note disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ConvertiblePromissoryNoteMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ConvertiblePromissoryNoteMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Convertible Promissory Notes [Member]",
        "documentation": "Convertible promissory note."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r755"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r755",
      "r756"
     ]
    },
    "okur_DebtInstrumentAccruedInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "DebtInstrumentAccruedInterest",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument Accrued Interest",
        "terseLabel": "Accrued interest",
        "documentation": "Debt instrument accrued interest."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument principal amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r291",
      "r473",
      "r474",
      "r676",
      "r677",
      "r696"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rates",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r292"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "terseLabel": "Realized loss from short-term investments",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r745"
     ]
    },
    "us-gaap_DeferredCompensationArrangementWithIndividualCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredCompensationArrangementWithIndividualCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Compensation Arrangement with Individual, Compensation Expense",
        "terseLabel": "Accrued compensation unpaid",
        "documentation": "The compensation expense recognized during the period pertaining to the deferred compensation arrangement."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r92"
     ]
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFinanceCostsNet",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs",
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs."
       }
      }
     },
     "auth_ref": [
      "r760",
      "r802",
      "r803",
      "r805"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Total deferred tax assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r387"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "terseLabel": "Deferred R&amp;D expenses",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance",
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Subject to Expiration",
        "terseLabel": "Net operating loss carryforwards, subject to expiration",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are subject to expiration dates."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "okur_DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets Operating Loss Carryforwards Subject To Expiration Period",
        "terseLabel": "Net operating loss carryforwards, subject to expiration period",
        "documentation": "Deferred tax assets operating loss carryforwards subject to expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "R&amp;D tax credit",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Share-based compensation",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accrued expenses",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r795"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesComponentsOfNetDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r388"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions made by employees",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DefinedContributionPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanDisclosureLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent",
        "terseLabel": "Percentage of employee contribution match",
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DefinedContributionPlanTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Contribution Plan [Table]",
        "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans."
       }
      }
     },
     "auth_ref": [
      "r323"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r184",
      "r197",
      "r221",
      "r662",
      "r663"
     ]
    },
    "us-gaap_DepreciationExpenseOnReclassifiedAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationExpenseOnReclassifiedAssets",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation Expense on Reclassified Assets",
        "terseLabel": "Depreciation and amortization expense",
        "documentation": "For the asset that is reclassified back to held and use from held-for-sale, the depreciation expense recognized when the asset is reclassified. This represents the difference between the carrying value at the time the decision to reclassify is made and the carrying amount that the asset would have had if it had never been classified as held for sale (including consideration of depreciation expense)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r31"
     ]
    },
    "okur_DirectProgramExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "DirectProgramExpense",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Direct Program Expense",
        "terseLabel": "Direct program expense",
        "documentation": "Direct program expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r329",
      "r360",
      "r361",
      "r363",
      "r684"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Dividends": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Dividends",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividends",
        "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r91"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentInformationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentInformationTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Information [Table]",
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction [Member]",
        "terseLabel": "Federal",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "okur_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Domestic Tax Jurisdiction and State and Local Jurisdiction [Member]",
        "terseLabel": "Federal and State",
        "documentation": "Domestic tax jurisdiction and state and local jurisdiction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share attributable to common stockholders, basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r172",
      "r174",
      "r177",
      "r178",
      "r179",
      "r183",
      "r411",
      "r421",
      "r447",
      "r448",
      "r514",
      "r528",
      "r654"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r143",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r174",
      "r177",
      "r178",
      "r179",
      "r183",
      "r411",
      "r421",
      "r447",
      "r448",
      "r514",
      "r528",
      "r654"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r180",
      "r181",
      "r182"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Income tax benefit",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r376",
      "r687"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal tax at statutory rate",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r376",
      "r399",
      "r687"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "negatedLabel": "Change in valuation allowance",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r379",
      "r687",
      "r730",
      "r789"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r730",
      "r789",
      "r790"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal deduction",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r378",
      "r687",
      "r730",
      "r789"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesSummaryOfComponentsOfIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "R&amp;D credits",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r687",
      "r730",
      "r789",
      "r791"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "verboseLabel": "Weighted-average vesting term",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r362"
     ]
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option",
        "verboseLabel": "Common Stock Options Outstanding",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressesAddressTypeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Addresses, Address Type [Axis]",
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r716"
     ]
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r715"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r713"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r118",
      "r139",
      "r140",
      "r141",
      "r154",
      "r155",
      "r156",
      "r158",
      "r165",
      "r167",
      "r169",
      "r185",
      "r237",
      "r243",
      "r263",
      "r321",
      "r394",
      "r395",
      "r407",
      "r408",
      "r409",
      "r412",
      "r420",
      "r421",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r446",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r479",
      "r500",
      "r527",
      "r546",
      "r547",
      "r548",
      "r567",
      "r629"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r454",
      "r455",
      "r456",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r511",
      "r688",
      "r693"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers Into Level 3",
        "terseLabel": "Liabilities transferred into L3",
        "documentation": "Amount of transfers of financial instrument classified as a liability into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3",
        "terseLabel": "Liabilities transferred out of L3",
        "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Assets transferred into L3",
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457",
      "r690"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Assets transferred out of L3",
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r457",
      "r690"
     ]
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments",
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "okur_GainLossOnConversionOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "GainLossOnConversionOfDebt",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (loss) on Conversion of Debt",
        "terseLabel": "Gain (loss) on conversion of debt",
        "documentation": "Gain (loss) on conversion of debt."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on sales of available-for-sale securities",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r613"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "okur_GeneralCorporateExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "GeneralCorporateExpenses",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "General Corporate Expenses",
        "terseLabel": "General corporate expenses",
        "documentation": "General corporate expenses"
       }
      }
     },
     "auth_ref": []
    },
    "okur_GrossProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "GrossProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross Proceeds From Issuance Of Common Stock",
        "terseLabel": "Gross proceeds from sale of stock",
        "documentation": "Gross proceeds from issuance of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "terseLabel": "Impairment charges",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r30",
      "r82",
      "r689"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r83"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r266",
      "r270",
      "r451",
      "r453",
      "r457",
      "r541",
      "r543",
      "r614",
      "r650",
      "r691",
      "r821"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r266",
      "r270",
      "r451",
      "r453",
      "r457",
      "r541",
      "r543",
      "r614",
      "r650",
      "r691",
      "r821"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r376",
      "r377",
      "r383",
      "r391",
      "r687",
      "r794"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r376",
      "r377",
      "r383",
      "r391",
      "r687",
      "r794"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "IncomeTaxes",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r372",
      "r376",
      "r380",
      "r381",
      "r382",
      "r385",
      "r390",
      "r400",
      "r401",
      "r402",
      "r403",
      "r566",
      "r687"
     ]
    },
    "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Examination, Penalties and Interest Accrued",
        "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations."
       }
      }
     },
     "auth_ref": [
      "r792"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r374",
      "r375",
      "r385",
      "r386",
      "r389",
      "r393",
      "r560"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "terseLabel": "Accounts payable, accrued and other liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Change in operating assets and liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Lease liabilities",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r719",
      "r725"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "okur_IncreaseInNumberOfSharesAvailableForIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "IncreaseInNumberOfSharesAvailableForIssuance",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase In Number Of Shares Available For Issuance",
        "terseLabel": "Increase in number of shares available for issuance",
        "documentation": "Increase in number of shares available for issuance."
       }
      }
     },
     "auth_ref": []
    },
    "okur_IndirectProgramExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "IndirectProgramExpense",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indirect Program Expense",
        "documentation": "Indirect program expense"
       }
      }
     },
     "auth_ref": []
    },
    "okur_InterestAndOtherExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "InterestAndOtherExpense",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest And Other Expense",
        "negatedLabel": "Interest and other expense",
        "terseLabel": "Interest and other expense",
        "documentation": "Interest and other expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Operating",
        "totalLabel": "Total other income and (expense)",
        "documentation": "Amount of interest income (expense) classified as operating."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r738"
     ]
    },
    "us-gaap_InterestIncomeOperating": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestIncomeOperating",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails": {
       "parentTag": "okur_AdjustmentsAndReconcilingItems",
       "weight": 1.0,
       "order": 1.0
      },
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_InterestIncomeExpenseNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income, Operating",
        "terseLabel": "Interest income",
        "negatedLabel": "Interest income",
        "documentation": "Amount of operating interest income, including, but not limited to, amortization and accretion of premiums and discounts on securities."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r611",
      "r639",
      "r640",
      "r662",
      "r709",
      "r710",
      "r724",
      "r854"
     ]
    },
    "okur_LabEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "LabEquipmentMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lab Equipment [Member]",
        "documentation": "Lab equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r718"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r494",
      "r718"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Schedule of Lease Expense for Operating Leases",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r807"
     ]
    },
    "us-gaap_LeaseExpirationDate1": {
     "xbrltype": "dateItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseExpirationDate1",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease Expiration Date",
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r493"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r494"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r484",
      "r494"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leasing - Lessee Accounting",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r483"
     ]
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]",
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "verboseLabel": "Schedule of Maturities of lease liabilities by fiscal year for operating leases",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r808"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum lease payments",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2025",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2026",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: Imputed interest",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r492"
     ]
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Option to Extend",
        "terseLabel": "Operating lease option to extend",
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease rights to extend renewal term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r806"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r478"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "totalLabel": "Total liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r55",
      "r56",
      "r59",
      "r60",
      "r61",
      "r62",
      "r152",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r423",
      "r424",
      "r425",
      "r465",
      "r587",
      "r655",
      "r712",
      "r757",
      "r810",
      "r811"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, convertible preferred stock, and stockholders' equity (deficit)",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r101",
      "r522",
      "r698",
      "r729",
      "r746",
      "r801"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES, CONVERTIBLE PREFERRED STOCK, AND STOCKHOLDERS' EQUITY (DEFICIT)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r125",
      "r152",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r423",
      "r424",
      "r425",
      "r465",
      "r698",
      "r757",
      "r810",
      "r811"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r281",
      "r728",
      "r755"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58"
     ]
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LineOfCreditFacilityTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Line of Credit Facility [Table]",
        "documentation": "Disclosure of information about short-term and long-term contractual arrangements with lender under which borrowing can occur up to maximum amount. Includes, but is not limited to, letter of credit, standby letter of credit, and revolving credit arrangement."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r58",
      "r281",
      "r728",
      "r755"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r750",
      "r751",
      "r752"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r33",
      "r750",
      "r751",
      "r752"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r324",
      "r369",
      "r450",
      "r506",
      "r540",
      "r542",
      "r556",
      "r579",
      "r580",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r648",
      "r649",
      "r668",
      "r680",
      "r683",
      "r692",
      "r693",
      "r694",
      "r695",
      "r699",
      "r759",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "okur_MergerAgreementAndConcurrentFinancingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "MergerAgreementAndConcurrentFinancingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement and Concurrent Financing [Abstract)",
        "documentation": "Merger agreement and concurrent financing."
       }
      }
     },
     "auth_ref": []
    },
    "okur_MergerAgreementAndConcurrentFinancingTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "MergerAgreementAndConcurrentFinancingTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancing"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement and Concurrent Financing [Text Block]",
        "terseLabel": "Merger Agreement and Concurrent Financing",
        "documentation": "Merger Agreement and Concurrent Financing [Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_MergerAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "MergerAgreementMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Merger Agreement [Member]",
        "terseLabel": "Merger Agreement",
        "documentation": "Merger Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r324",
      "r369",
      "r450",
      "r506",
      "r540",
      "r542",
      "r556",
      "r579",
      "r580",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r648",
      "r649",
      "r668",
      "r680",
      "r683",
      "r692",
      "r693",
      "r694",
      "r699",
      "r759",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r146"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r76",
      "r77"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      },
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net loss and comprehensive loss",
        "terseLabel": "NetIncomeLoss",
        "negatedTotalLabel": "Net loss",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r77",
      "r102",
      "r123",
      "r136",
      "r137",
      "r141",
      "r152",
      "r157",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165",
      "r168",
      "r169",
      "r176",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r411",
      "r421",
      "r448",
      "r465",
      "r526",
      "r609",
      "r627",
      "r628",
      "r710",
      "r757"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "okur_Non-CashInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "Non-CashInterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-cash Interest Expense",
        "terseLabel": "Non-cash interest expense",
        "documentation": "Non-cash interest expense."
       }
      }
     },
     "auth_ref": []
    },
    "okur_Non-EmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "Non-EmployeesMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-employees [Member]",
        "terseLabel": "Non-employees",
        "documentation": "Non-employees."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosure of noncash financing activities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income and (expense):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r663",
      "r737"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r657",
      "r667",
      "r737"
     ]
    },
    "us-gaap_OneTimeTerminationBenefitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OneTimeTerminationBenefitsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "One-time Termination Benefits [Member]",
        "documentation": "A lump sum payment to an involuntarily terminated employee in conjunction with exit or disposal activities."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r672",
      "r673",
      "r674"
     ]
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r656",
      "r736",
      "r738",
      "r739",
      "r740",
      "r741"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r486",
      "r697"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability",
        "totalLabel": "Total lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 1.0
      },
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion",
        "verboseLabel": "Current operating lease liabilities",
        "negatedLabel": "Less: Current portion",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails": {
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0,
       "order": 2.0
      },
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating lease liability, net of current portion",
        "terseLabel": "Long-term operating lease liabilities",
        "verboseLabel": "Noncurrent operating lease liabilities",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows for operating leases",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r482",
      "r488"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/LeasesScheduleOfRightOfUseAssetsAndLeaseLiabilitiesForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Operating lease right-of-use asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "terseLabel": "Amortization of right-of-use asset - operating",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r726"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "verboseLabel": "Weighted-average discount rate - operating leases",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r697"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "verboseLabel": "Weighted-average remaining lease term - operating leases (years)",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r490",
      "r697"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/OrganizationAndBusiness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization and Business",
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure."
       }
      }
     },
     "auth_ref": [
      "r51",
      "r97",
      "r557",
      "r558"
     ]
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_OtherCurrentAssetsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherCurrentAssetsTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets",
        "documentation": "The entire disclosure for other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "okur_OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Liabilities Assumed in Connection with the Reverse Recapitalization",
        "terseLabel": "Other liabilities assumed in connection with the reverse recapitalization",
        "documentation": "Other liabilities assumed in connection with the reverse recapitalization."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherPrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherPrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Prepaid Expense, Current",
        "terseLabel": "Other prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r722",
      "r747"
     ]
    },
    "okur_PatentCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PatentCostsPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patent Costs [Policy Text Block]",
        "terseLabel": "Patent Costs",
        "documentation": "Disclosure of accounting policy for patent costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 23.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of Issuance Costs Associated with the Issuance of Convertible Notes Payable",
        "negatedLabel": "Payment of issuance costs associated with the issuance of convertible notes payable",
        "documentation": "Payment of issuance costs associated with the issuance of convertible \n notes payable."
       }
      }
     },
     "auth_ref": []
    },
    "okur_PaymentOfReverseRecapitalizationTransactionCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PaymentOfReverseRecapitalizationTransactionCosts",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 19.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payment of reverse recapitalization transaction costs",
        "negatedLabel": "Payment of reverse recapitalization transaction costs",
        "documentation": "Payment of reverse recapitalization transaction costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForOperatingActivitiesAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Operating Activities [Abstract]",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRent",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Rent",
        "terseLabel": "Sublease rent payments",
        "documentation": "Cash payments to lessor's for use of assets under operating leases."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_PaymentsForRepurchaseOfPreferredStockAndPreferenceStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsForRepurchaseOfPreferredStockAndPreferenceStock",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 21.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for Repurchase of Preferred Stock and Preference Stock",
        "negatedLabel": "Payment of issuance costs associated with the issuance of Convertible Preferred Stock",
        "documentation": "The cash outflow to reacquire preferred stock during the period."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 17.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of Stock Issuance Costs",
        "negatedLabel": "Payment of issuance costs associated with the Concurrent Financing",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "okur_PercentageOfNumberOfOutstandingSharesOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PercentageOfNumberOfOutstandingSharesOfCommonStock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage Of Number Of Outstanding Shares Of Common Stock",
        "terseLabel": "Percentage of number of outstanding shares of common stock",
        "documentation": "Percentage of number of outstanding shares of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "okur_Performance-BasedStockOptionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "Performance-BasedStockOptionsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Performance-Based Stock Options [Member]",
        "terseLabel": "Performance-Based Stock Options [Member]",
        "documentation": "Performance-based stock options."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionPrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Price",
        "terseLabel": "Conversion price of preferred stock",
        "documentation": "Per share conversion price of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_PreferredStockConvertibleConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleConversionRatio",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Conversion Ratio",
        "terseLabel": "Preferred exchange ratio",
        "documentation": "Number of common shares issuable upon conversion for each share of preferred stock to be converted."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_PreferredStockConvertibleSharesIssuable": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockConvertibleSharesIssuable",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Convertible, Shares Issuable",
        "terseLabel": "Exchange of stock, preferred stock holders choose to receive shares of common stock",
        "documentation": "Number of common shares issuable upon conversion of preferred stock."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_PreferredStockDividendPaymentTerms": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockDividendPaymentTerms",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Dividend Payment Terms",
        "terseLabel": "Preferred Stock Dividend Payment Terms",
        "documentation": "Specific information regarding dividend payment dates or timing and whether or not dividends are paid on a cumulative basis."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r36",
      "r63"
     ]
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockLiquidationPreferenceValue",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Liquidation Preference, Value",
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r308",
      "r320"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r701",
      "r702",
      "r705",
      "r706",
      "r707",
      "r708",
      "r850",
      "r852"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r303"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, authorized",
        "terseLabel": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r589"
     ]
    },
    "okur_PreferredStockSharesDesignated": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PreferredStockSharesDesignated",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock Shares Designated",
        "terseLabel": "Preferred stock, shares designated",
        "documentation": "Preferred stock shares designated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, issued",
        "terseLabel": "Preferred stock, shares issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r303"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, outstanding",
        "periodStartLabel": "Convertible Preferred Stock Beginning Balance (in shares)",
        "periodEndLabel": "Convertible Preferred Stock Ending Balance (in shares)",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r589",
      "r607",
      "r852",
      "r853"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued or outstanding at December 31, 2024",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r519",
      "r698"
     ]
    },
    "us-gaap_PreferredStockValueOutstanding": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValueOutstanding",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Value, Outstanding",
        "terseLabel": "Preferred stock, value, outstanding",
        "documentation": "Value of nonredeemable preferred shares and preferred shares redeemable solely at option of issuer, held by shareholders. Excludes preferred shares repurchased and held as treasury shares."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r589"
     ]
    },
    "okur_PrepaidClinicalTrials": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "PrepaidClinicalTrials",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Clinical Trials",
        "terseLabel": "Prepaid clinical trial expenses",
        "documentation": "Prepaid clinical trials."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r723"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense, Current",
        "totalLabel": "Total prepaid expenses",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r245",
      "r246",
      "r652"
     ]
    },
    "us-gaap_PrepaidInsurance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidInsurance",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance expense",
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r653",
      "r669",
      "r747"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Private Placement [Member]",
        "terseLabel": "Private Placement",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromConvertibleDebt",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 22.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Proceeds from issuance of convertible notes payable",
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfConvertiblePreferredStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfConvertiblePreferredStock",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 20.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Convertible Preferred Stock",
        "terseLabel": "Proceeds from the issuance of Convertible Preferred Stock",
        "documentation": "The cash inflow from issuance of preferred stocks identified as being convertible into another form of financial instrument, typically the entity's common stock."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfPrivatePlacement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfPrivatePlacement",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Issuance of Private Placement",
        "verboseLabel": "Proceeds from the issuance of common stock in Concurrent Financing",
        "documentation": "The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 24.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from the issuance of common stock in connection with equity plans",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12"
     ]
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale",
        "verboseLabel": "Proceeds of short-term investments",
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r144",
      "r145",
      "r744"
     ]
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales of marketable securities",
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfInterestInCorporateUnit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfInterestInCorporateUnit",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 18.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from Sale of Interest in Corporate Unit",
        "terseLabel": "Cash acquired in connection with the reverse recapitalization",
        "documentation": "The cash inflow resulting from the sale of an interest in a corporate unit during the period."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r493"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r110",
      "r113",
      "r114"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r127",
      "r525"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r493"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 16.0
      },
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r493",
      "r516",
      "r525",
      "r698"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r110",
      "r113",
      "r523"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r493"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of property and equipment, net",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]",
        "terseLabel": "Estimated useful life of property and equipment, net",
        "documentation": "Indicates description of term of useful life for property, plant, and equipment when not stated as numeric value."
       }
      }
     },
     "auth_ref": [
      "r748"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r322",
      "r324",
      "r355",
      "r356",
      "r357",
      "r369",
      "r450",
      "r504",
      "r505",
      "r506",
      "r540",
      "r542",
      "r556",
      "r579",
      "r580",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r648",
      "r649",
      "r668",
      "r680",
      "r683",
      "r692",
      "r693",
      "r694",
      "r695",
      "r699",
      "r703",
      "r753",
      "r759",
      "r799",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r277",
      "r278",
      "r279",
      "r280",
      "r322",
      "r324",
      "r355",
      "r356",
      "r357",
      "r369",
      "r450",
      "r504",
      "r505",
      "r506",
      "r540",
      "r542",
      "r556",
      "r579",
      "r580",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r648",
      "r649",
      "r668",
      "r680",
      "r683",
      "r692",
      "r693",
      "r694",
      "r695",
      "r699",
      "r703",
      "r753",
      "r759",
      "r799",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reconciliation [Abstract]",
        "terseLabel": "Reconciliation of loss:"
       }
      }
     },
     "auth_ref": []
    },
    "okur_ReneoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ReneoMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reneo [Member]",
        "documentation": "Reneo."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r650",
      "r662",
      "r818"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r370"
     ]
    },
    "okur_RestrictedStockAndRestrictedStockUnitsRSUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "RestrictedStockAndRestrictedStockUnitsRSUsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock and Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) [Member]",
        "documentation": "Restricted stock and restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Stock Awards (RSAs) [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r272",
      "r273"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r91",
      "r521",
      "r550",
      "r555",
      "r565",
      "r590",
      "r698"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r154",
      "r155",
      "r156",
      "r158",
      "r165",
      "r167",
      "r169",
      "r237",
      "r243",
      "r263",
      "r394",
      "r395",
      "r407",
      "r408",
      "r409",
      "r412",
      "r420",
      "r421",
      "r429",
      "r432",
      "r433",
      "r436",
      "r446",
      "r476",
      "r479",
      "r546",
      "r548",
      "r567",
      "r852"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Revenues",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues",
        "terseLabel": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r142",
      "r152",
      "r184",
      "r193",
      "r194",
      "r215",
      "r221",
      "r225",
      "r227",
      "r228",
      "r233",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r465",
      "r515",
      "r662",
      "r757"
     ]
    },
    "okur_ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reverse Recapitalization Transaction Costs Included in Accounts Payable",
        "terseLabel": "Reverse recapitalization transaction costs included in accounts payable",
        "documentation": "Reverse recapitalization transaction costs included in accounts payable."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-of-use asset obtained in exchange for new operating lease liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r697"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate purchase price",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Stock issued",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock price per share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/AccruedExpensesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued expenses",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Anti-Dilutive Securities Outstanding Not Included in Diluted Net Loss Per Share Calculation",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47",
      "r413"
     ]
    },
    "okur_ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Common Stock, Capital Shares Reserved for Future Issuance [Table Text Block]",
        "terseLabel": "Summary of common stock reserved for future issuance",
        "documentation": "Tabular disclosure of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Summary of components of income tax benefit",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r796"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Components of net deferred taxes asset and liabilities",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r793"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationNonCashStockBasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Summary of Non-cash stock-based compensation expense recorded",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "okur_ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule Of Lease Related Assets And Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Right-of-use Assets and Lease Liabilities for Operating Leases",
        "documentation": "Schedule of lease related assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "okur_ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Lease Term, Discount Rates, and Additional Information for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of lease term, discount rates, and additional information for operating leases",
        "documentation": "Schedule of lease term, discount rates, and additional information for operating leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfOtherAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/PrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Other Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "documentation": "Tabular disclosure of the carrying amounts of other assets. This disclosure includes other current assets and other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/PropertyAndEquipmentNetScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r493"
     ]
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]",
        "terseLabel": "Summary of Acquired Assets and Liabilities",
        "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information by Segment",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r27",
      "r28"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of RSU and RSA activities",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of the Company's stock option activity",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r11",
      "r93"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of weighted-average assumptions to determine the fair value of the employee stock option",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35",
      "r36",
      "r37",
      "r38",
      "r39",
      "r86",
      "r88",
      "r90",
      "r91",
      "r131",
      "r132",
      "r133",
      "r186",
      "r303",
      "r304",
      "r306",
      "r308",
      "r311",
      "r317",
      "r319",
      "r561",
      "r562",
      "r563",
      "r564",
      "r680",
      "r717",
      "r727"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r184",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r271",
      "r274",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r659",
      "r662",
      "r663",
      "r670",
      "r700",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_SegmentExtensibleList": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentExtensibleList",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment [Extensible Enumeration]",
        "documentation": "Indicates component of entity engaging in business activity from which revenue is recognized and expense is incurred. Includes, but is not limited to, transaction with another component of same entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_SegmentReportingCODMIndividualTitleAndPositionOrGroupName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "SegmentReportingCODMIndividualTitleAndPositionOrGroupName",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting C O D M Individual Title and Position or Group Name",
        "terseLabel": "CODM title and Position",
        "documentation": "Segment reporting, CODM, individual title and position or group name."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/Segment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r204",
      "r206",
      "r207",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r225",
      "r226",
      "r228",
      "r657",
      "r660",
      "r661",
      "r662",
      "r664",
      "r666",
      "r667"
     ]
    },
    "us-gaap_SegmentReportingExpenseInformationUsedByCodmDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingExpenseInformationUsedByCodmDescription",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Expense Information Used by CODM, Description",
        "terseLabel": "CODM Description",
        "documentation": "Description of nature of expense information used by chief operating decision maker (CODM) to manage operation when segment expense information by category is not disclosed."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r207",
      "r221"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information",
        "documentation": "Disclosure of accounting policy for segment reporting."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213",
      "r214",
      "r224",
      "r227",
      "r658",
      "r659",
      "r665"
     ]
    },
    "us-gaap_SeriesCPreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeriesCPreferredStockMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Series C Preferred Stock [Member]",
        "terseLabel": "Series C Preferred Stock [Member]",
        "documentation": "Series C preferred stock."
       }
      }
     },
     "auth_ref": [
      "r720",
      "r721",
      "r761"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Severance Costs",
        "terseLabel": "Termination benefits costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Accelerated Cost",
        "terseLabel": "Accelerated share-based compensation expenses",
        "documentation": "Amount of additional cost recognized for award under share-based payment arrangement from occurrence of event accelerating recognition of cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r684"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting rights, description",
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r347"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r345"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodStartLabel": "Unvested at Beginning",
        "periodEndLabel": "RSUs outstanding and Unvested at End",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodStartLabel": "Unvested at Beginning",
        "periodEndLabel": "RSUs outstanding and Unvested at End",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Shares vested",
        "negatedLabel": "Vested (RSA)",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (RSA)",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r346"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "verboseLabel": "Weighted-average assumptions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r356"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r355"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r357"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "verboseLabel": "Stock-Based Compensation",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r328",
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "verboseLabel": "Weighted-Average Remaining Contractual Term (in years) / Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization",
        "terseLabel": "Assumed in reverse recapitalization",
        "documentation": "Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization"
       }
      }
     },
     "auth_ref": []
    },
    "okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Assumed in Reverse Recapitalization Weighted Average Exercise Price",
        "terseLabel": "Assumed in reverse recapitalization",
        "documentation": "Share based compensation arrangement by share based payment award options assumed in reverse recapitalization weighted average exercise price."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable (in shares)",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable (in dollars per share)",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r336"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (In shares)",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (In shares)",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Shares granted",
        "verboseLabel": "Granted (in shares)",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value of options granted",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r348"
     ]
    },
    "okur_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Grants, Maximum Contractual Term",
        "terseLabel": "Options granted maximum contractual term",
        "documentation": "Share based compensation arrangement by share based payment award options grants, maximum contractual term"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodStartLabel": "Outstanding at beginning of period (in shares)",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "verboseLabel": "Options Outstanding",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodStartLabel": "Outstanding at beginning of period (in dollars per share)",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r334",
      "r335"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "verboseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "periodEndLabel": "Outstanding at end of period (in shares)",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at end of period (in dollars per share)",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationShareBasedCompensationExpenseAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r339"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r341"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r340"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r338"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "25% on First Anniversary",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Incrementally Vest Monthly for Three-Year Period Thereafter",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Compensation",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r325",
      "r333",
      "r352",
      "r353",
      "r354",
      "r355",
      "r358",
      "r364",
      "r365",
      "r366",
      "r367"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Grant and expire period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r685"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r354"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Aggregate Intrinsic Value, Exercisable",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Exercisable",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options Outstanding",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r94"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted Average Remaining Contractual Term (in years), Options Outstanding",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Shares, Outstanding",
        "periodStartLabel": "Beginning Balance (in shares)",
        "periodEndLabel": "Ending Balance (in shares)",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShortTermBorrowings",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConvertiblePromissoryNotesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Short-Term Debt",
        "terseLabel": "Short term borrowings",
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r99",
      "r698",
      "r819"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r149"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r103",
      "r104",
      "r105",
      "r106",
      "r122",
      "r184",
      "r189",
      "r192",
      "r193",
      "r194",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r205",
      "r206",
      "r207",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r221",
      "r222",
      "r223",
      "r228",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r261",
      "r265",
      "r271",
      "r274",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539",
      "r659",
      "r662",
      "r663",
      "r670",
      "r700",
      "r820",
      "r822",
      "r823",
      "r824",
      "r825",
      "r826",
      "r827",
      "r828",
      "r829",
      "r830",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://onkuretherapeutics.com/role/CoverPage",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r131",
      "r132",
      "r133",
      "r152",
      "r174",
      "r175",
      "r177",
      "r179",
      "r186",
      "r187",
      "r233",
      "r282",
      "r284",
      "r285",
      "r286",
      "r289",
      "r290",
      "r303",
      "r304",
      "r308",
      "r311",
      "r319",
      "r465",
      "r561",
      "r562",
      "r563",
      "r564",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r589",
      "r610",
      "r629",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r717",
      "r727",
      "r735"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r118",
      "r139",
      "r140",
      "r141",
      "r154",
      "r155",
      "r156",
      "r158",
      "r165",
      "r167",
      "r169",
      "r185",
      "r237",
      "r243",
      "r263",
      "r321",
      "r394",
      "r395",
      "r407",
      "r408",
      "r409",
      "r412",
      "r420",
      "r421",
      "r429",
      "r431",
      "r432",
      "r433",
      "r434",
      "r436",
      "r446",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r476",
      "r479",
      "r500",
      "r527",
      "r546",
      "r547",
      "r548",
      "r567",
      "r629"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r185",
      "r479",
      "r507",
      "r559",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r629",
      "r704"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical",
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/OrganizationAndBusinessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r155",
      "r156",
      "r185",
      "r231",
      "r479",
      "r507",
      "r559",
      "r578",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r589",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r608",
      "r612",
      "r613",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r629",
      "r704"
     ]
    },
    "okur_StockIssuanceCostNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuanceCostNet",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issuance Cost Net",
        "terseLabel": "Stock issuance cost net",
        "documentation": "Stock issuance cost net."
       }
      }
     },
     "auth_ref": []
    },
    "okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Conversion Of Convertible Promissory Notes, Shares",
        "terseLabel": "Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes (in shares)",
        "documentation": "Stock issued during period, conversion of convertible promissory notes, shares."
       }
      }
     },
     "auth_ref": []
    },
    "okur_StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Conversion of Convertible Promissory Notes, Value",
        "terseLabel": "Issuance of Class A Common Stock for the conversion of Convertible Promissory Notes",
        "documentation": "Stock issued during period, conversion of convertible promissory notes, value."
       }
      }
     },
     "auth_ref": []
    },
    "okur_StockIssuedDuringPeriodSharesConcurrentFinancing": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesConcurrentFinancing",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Concurrent Financing",
        "terseLabel": "Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs (in shares)",
        "documentation": "Stock issued during period, shares, concurrent financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger (in shares)",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r36",
      "r64",
      "r67",
      "r91",
      "r296"
     ]
    },
    "okur_StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Exchange of Capital Stock Outstanding",
        "terseLabel": "Common stock shares issued in exchange for the shares of capital stock outstanding",
        "documentation": "Stock Issued During Period, Shares, Exchange of Capital Stock Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock (in shares)",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r561",
      "r629",
      "r642"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "terseLabel": "Issuance of Class A common stock for the settlement of restricted stock units (in shares)",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "verboseLabel": "Issuance of Class A Common Stock from the exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r339"
     ]
    },
    "okur_StockIssuedDuringPeriodValueConcurrentFinancing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "StockIssuedDuringPeriodValueConcurrentFinancing",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period Value Concurrent Financing",
        "terseLabel": "Issuance of Class A Common Stock in the Concurrent Financing, less issuance costs",
        "documentation": "Stock issued during period value concurrent financing."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of Convertible Preferred Stock for Class A and B Common Stock in connection with the Merger",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r91"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issuance of stock",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r63",
      "r64",
      "r91",
      "r567",
      "r629",
      "r642",
      "r711"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of Class A Common Stock from the exercise of stock options",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r64",
      "r67",
      "r68",
      "r91"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent",
        "totalLabel": "Total stockholders' equity (deficit)",
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r67",
      "r68",
      "r79",
      "r591",
      "r607",
      "r630",
      "r631",
      "r698",
      "r712",
      "r729",
      "r746",
      "r801",
      "r852"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity, Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity (deficit):"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Text Block]",
        "terseLabel": "Equity",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r151",
      "r302",
      "r304",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r318",
      "r321",
      "r437",
      "r632",
      "r633",
      "r646"
     ]
    },
    "okur_SubleaseExpirationPeriod": {
     "xbrltype": "gYearMonthItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "SubleaseExpirationPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sublease Expiration Period",
        "terseLabel": "Sublease expiration period",
        "documentation": "Sublease expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r472",
      "r502"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://onkuretherapeutics.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r501",
      "r503"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfCashFlows",
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfChangesInStockholdersEquity",
      "http://onkuretherapeutics.com/role/EquityAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carry forwards",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r392"
     ]
    },
    "okur_TaxCreditCarryforwardExpirationPeriod": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "TaxCreditCarryforwardExpirationPeriod",
     "presentation": [
      "http://onkuretherapeutics.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tax Credit Carryforward Expiration Period",
        "terseLabel": "Tax credit carry forwards expiration",
        "documentation": "Tax credit carryforward expiration period."
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Axis]"
       }
      }
     },
     "auth_ref": [
      "r742",
      "r809"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title and Position [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "okur_TwentyTwentyFourEmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "TwentyTwentyFourEmployeeStockPurchasePlanMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Four Employee Stock Purchase Plan [Member]",
        "terseLabel": "2024 ESPP [Member]",
        "verboseLabel": "2024 Employee Stock Purchase Plan",
        "documentation": "Twenty twenty four employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "okur_TwentyTwentyFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "TwentyTwentyFourEquityIncentivePlanMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/MergerAgreementAndConcurrentFinancingAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationEquityIncentivePlansAndEsppPlanAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationStockOptionsAdditionalInformationDetails",
      "http://onkuretherapeutics.com/role/SubsequentEventsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Twenty Twenty Four Equity Incentive Plan [Member]",
        "terseLabel": "2024 Equity Incentive Plan [Member]",
        "documentation": "Twenty twenty four equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfAdoptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfAdoptionMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Standards Update [Domain]",
        "documentation": "Amendment to accounting standards."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r157",
      "r158",
      "r159",
      "r160",
      "r170",
      "r229",
      "r230",
      "r234",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r262",
      "r263",
      "r267",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r463",
      "r464",
      "r475",
      "r476",
      "r477",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r508",
      "r509",
      "r510",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552",
      "r553",
      "r554",
      "r555"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/CommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r268",
      "r269",
      "r272",
      "r273"
     ]
    },
    "okur_UnamortizedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "UnamortizedCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unamortized Compensation Cost",
        "terseLabel": "Unamortized compensation cost",
        "documentation": "Unamortized compensation cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized tax benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r373",
      "r384",
      "r686"
     ]
    },
    "okur_UnreleasedRestrictedStockUnitsAssumedInMergerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "UnreleasedRestrictedStockUnitsAssumedInMergerMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails",
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unreleased Restricted Stock Units Assumed in the Merger [Member]",
        "terseLabel": "Unreleased Restricted Stock Units Assumed in Merger",
        "documentation": "Unreleased restricted stock units assumed in merger."
       }
      }
     },
     "auth_ref": []
    },
    "okur_UnvestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "UnvestedRestrictedStockUnitsMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/NetLossPerShareScheduleOfAntiDilutiveSecuritiesNotIncludedInDilutedNetLossPerShareCalculationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock Units [Member]",
        "documentation": "Represents information relating to Unvested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "okur_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationSharesReservedForFutureIssuanceDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unvested Restricted Stock Units under Two Thousand Twenty Three Plan [Member]",
        "terseLabel": "Unvested Restricted Stock Units under 2023 Plan",
        "documentation": "Unvested Restricted Stock Units under Two Thousand Twenty Three Plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://onkuretherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r24",
      "r25",
      "r107",
      "r108",
      "r111",
      "r112"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/LeasesScheduleOfLeaseExpenseForOperatingLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease expense",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r487",
      "r697"
     ]
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://onkuretherapeutics.com/role/ShareBasedCompensationRestrictedStockAwardsRsasAndRestrictedStockUnitsRsusAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r179"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://onkuretherapeutics.com/role/ConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares used in computing net loss per share, basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r172",
      "r179"
     ]
    },
    "okur_WorkforceSalariesAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://onkuretherapeutics.com/20241231",
     "localname": "WorkforceSalariesAndBenefits",
     "crdr": "debit",
     "presentation": [
      "http://onkuretherapeutics.com/role/SegmentScheduleOfSegmentReportingInformationBySegmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Workforce Salaries and Benefits",
        "terseLabel": "Workforce salaries and benefits",
        "documentation": "Workforce salaries and benefits"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477787/942-405-45-2"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "35",
   "Paragraph": "44",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-44"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-7"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481284/470-20-25-10"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483043/710-10-30-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "36",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477123/405-50-65-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-9"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479845/805-20-65-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482477/820-10-65-13"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-5"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477346/946-830-45-39"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r732": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r733": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r734": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r735": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r736": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r738": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r739": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r740": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r741": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r742": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r743": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r745": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r746": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r747": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482190/360-10-35-3"
  },
  "r749": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r750": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r754": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r755": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r756": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r757": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r758": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r760": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r761": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r762": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r763": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r766": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r775": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r778": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r790": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r791": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r793": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r794": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r796": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r797": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r800": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r801": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r802": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A"
  },
  "r803": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r804": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r805": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r807": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r808": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r809": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r810": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r811": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r812": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r813": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r814": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r815": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r816": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r817": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r818": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r821": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r822": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r823": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r824": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r825": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r826": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r827": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r828": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r829": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r830": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r831": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r832": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r833": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r834": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r838": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r839": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r841": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r842": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r843": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r844": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r845": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r846": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r847": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r848": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r850": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r851": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r854": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column E)(Footnote 6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>94
<FILENAME>0001193125-25-058954-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-25-058954-xbrl.zip
M4$L#!!0    ( "Z =%JA'A/R, (  ,(&   1    9#$X-#@V-61E>#(S,2YH
M=&V]54UOVS ,O1?(?R \H*<DCKT&S1+'0#Z\-JB;!*VQKD?%IF,"MF1(\MKM
MUT_*1[O#T%/2BP!2%-\C]20&M\E]' :WT60>MBZ"9)'$41C][/A?NU[@[DWC
M=P\!$$Q7\V>8WLQ6\>IA[#S=+I+(@<?D.8[&3DD<.P72MM##I9 5*YT06A?F
M_ RY1AD&\\6/8_ +9;H8#KI]X@ZPDK;<),!<.SN8]3&L8G)+O*-%/>S5>@0'
M>R.T%M7>E0NN.XK^X-![MW-64?E[F%"%"I;X @^B8@9I$B]NEF-'6I).&$S#
MZ+6@#6FP%4/@3L/ 7=N2_\? \T] (;Q;W]] '*_!(IVOU/"Q(8TPZ/7@@Y).
M@N3Y?A^\:UW HY:(^MR5S9'_0MF&V<J4Y_?\3K__;?!1E?[5";63[L2\$\],
M<&4L$#DL>(8UFL68#[@E96(P@W6S*2F%29J*AFOB6_A.LOH<H3TAI >"6H N
M$!J%EJMH)+ F,ZJ76 NI(6/:<+UG,BTN^4;5(Z_7!M/8?AM>R%RK1%5C^I;&
M9A4E[4_EQ!E/B96@M'%4!DY9D!6_:R1"4J!D-3::4M4V74J[[=8%\;1L,G/8
M;"+Q-C">'9-+S(V3IV@=EFEN&]:8SLK=?H$LLWV\_.)=78^BUQJE5M88C(#X
M(87MOV2:!']G=6J46HI=5QK5_4A[I[E+5[GP61_'V_,2I9 L$V?_/_X1GG\0
MWA'3-2/#O)3# #&CP?KL$#+.W>SZ"U!+ P04    "  N@'1:1'_]J)GJ P 8
MC1\ $0   &0Q.#0X-C5D<&]S86TN:'1M[+UI5]M8MC_\OC^%%MW5-UG7.!Z8
M4Y7_(H14<2L)+""W;C]O:LG2L:V.++DT .Y/_^SA3)+E 3!@0'?UK0"6C\ZP
M]SY[_.V?_]_-*'2N1)(&<?3+?[6;K?]R1.3%?A -?OFOPXNCDY/_^G\?_O;S
M,(/'X-$H/0B#Z,<O&\,L&Q^\>W=]?=V\Z25A,TX&[SJM5O<=?MQS4[$A'\=/
M_4!_P7YXYQU_J!^=&OJZ2\^V]_?WW]&G^M$TJ'H0!FV_^[^O7RZ\H1BYFT&4
M9F[D%>82S)E[^7E?E":>"J\YB*_>P0?PC<Z6>C!(XZU.>W?>T/R$^D+\(T_T
MTW$$OXEL*!)W+/(L\-*F%X_H!>U.MVUF,TZ$YV;"G_F>_7=NXB5Q*-Z9A]77
MO3B/LF12O2#Y86%17IXD0 NSOB$_+7Q%W'C#ZL?QD\*CD0OKK'Z6/BH\G 9>
M]:/P0?'!;)S,>!(^*3R:IYL#UQWKI_MNVJ-]E!\4'KX)YYSM_WVQ*#//DCG'
M Y_JJ2;9]+OACT7"NIDU6!O)%5A"_-_'\R_F\:SZ>?/HNRQQH[0?)R,W Y['
MMW4V6YW-]H[-)?.66^9P>.DF['+A&VK7Y[VWO;W9VMO4]#V;\5'X;* 0$JX/
M_V1!%HH/9Z<7SN'7G]_Q;W_[>20RU_'B*!,1[$$F;K)W^+WWCC=TDU1DOWR_
M_+RYM^'@2S;%7WEP]<O&$3^^>3D9BXUW,,@[^8I>[$^<-)N$XI<-7,#F4 2#
M8780X?3#]SW7^S%(@&7\32\.X^3@>AADXOW&AY_]X$I]SP_2<>A.#IPHC@1\
M%-P<X.@BX1\#WQ<1_0B??\M'(@D\)W)'^$T1''R*/?A;E-'4G !9GK[1[G;W
M=O=VMF EM-B;[%ST?]DX:[7_A/\AZ5S&[<Z?7?YY0V]3X3VS7WL<P7Y.#GT_
M$6EZD8'\.$W.DO@J(*DX-8WM]I+3.#I]L"ETEIK"GQ_S% XR3?',72_[*D8]
MD<#["J\3J?P!M_WP)DCO,/,C.+7$#4\B7]S\+B;+;1"M*[BY C;<VH+]:L%%
MMM/=W6UO+_UV13&?@]1SPW\)-_D,?TGO\/[MC0_XQSN^^0P^C?V[OGMGX\/G
M?RW]YD-XK4^O#MW!'=ZVN_$A2W(Q];YW10Y-1%_@92?2#S^C]#M(2;^ ]SBD
ME1QD0"Z_;*3!:!RB6*2_#1.<!E[TF^HF;]ZD/L@9&MX>DWY-XSRAWTA+.9!K
MH>F>'::GD<U.CGQ($,7I7P,?_] /1.+0#$6E3#XZ^;U(8.4OPWCO*L<?T]&:
MUY&ZE!&Q;+8[(,KU6/(3/9#^YKO"ZA8OMKN&B^VN<+&S!.9Z+!H6EF2?0 3S
M&;?:\#_U3?.9F:MOGBULD?KD?EO4M;9H;>BBL$7=6VQ1=X5;A"S3ZJ[;UA18
MIM5]$/G06</%=AY,&/[YQ>T=@^XZQCN/59@\16,%%"08-9N<A?"FP\C7#WV<
M&%7FP3=*4KT8X)OE[SZ\[V8<!EX@)^SX 7Q,_H8-:6H=+#5]O$H/IC?@YW>5
MKS';:^;SE(*^?) "+*AA'/HGHS$HMP)GF+ZV$U4/S]F,YWFZ1_%HG&<B^<U-
M_&LW$; !%W$_PQ]?VQD3UR[<C^=YS)_S) JRG-;S.;C!GUXM#\_>B^=YMD"R
MHS@Z"MTT/;3/E#P2.%WZZ+1_D<7>CW4_R3F35H],K_?9G]O'5W9N'Y_WN457
M(&R"7BC.R#>2")^6>P%CBO3H)9^EO".7V8#G>+A;M=GRJ&;+@SGCMFJSY>G-
ME@<\W=IL61^SY0&/N39;GMAL>5@6KLV6YWUNM=GRC,[M.RCM:2;\<_AO$GB9
MU-F_@U!)OT>^2"ZOX\MAG*=NY%]>PXPGE\-$")1-!9$+OW]S1^LO6POSI$OR
MWCOP7 \^$2$J@)4+/TS3?"3\$UAB,A#)BSGJ6Z_Y>1ZNI%/Z[^<X3U"%R"8G
MD8>3NWI)W+OT2E_(08[&83P1@JCV+$^\(5#S2S[.^>M]GH=:6-3I&--)[>,[
M!/O,?PZ&2FFBZL\SE_<\3^M3/(++(O"..,7</BD0,_#AI7MSF&?#.,$\S#4_
MLEDS5I]7+O9YGQLL]G_R)$A]N.YA+] '@NH]_/LE]MS0_NQEGBT)UCOOQO,\
M_#H:\]31F,<YW$^B5PC(',$R@^RSZP7A,^#8JMD:!T/%(I_G>7T-HF"4CWBN
M:9*=N]%@;94;F-^!-4'\M3#_9WH$[LWS/@)[_L_S"*I<#N<7WU^2YC]WB<_S
MU-C/2\MYR3I#T:UM+?=YGAI[\ X'B1#EE U51W?H_94':4!*,&Q!F3U?,%LN
M.MBE7S=C*Z4&6GD&SY.<I,Y<5*1?@SB8L_!G<I+5Q5?UB3["B:Y%9=F,\[^-
M?^ 05ND'88[QA OAY0E(.I$>WWAA[@O_<Q*/.,^&< %.^\=N$@71(#T3R<70
M3<3'2?4 ZTY,#[KL)_11/!NRC$=!FL;)Y%N<B9H>'YL>IW?_-1'BHA!538(K
M7_:CA\_6F?[F)>74A/@(LG#Q ;PN<KQCLE1-GP]&GT^>RK7.! N;(MS$&Q["
MV.)*A#$ED!_?C.&D"LHD!XVUX8A!8./'65\"FSMMR^^U:!->$TW\*B*1N"'L
MQJ$_"J( V,9%_GIE5+'4-KPFNJ@#4Z_GK.O4PY=_QJ!%$4QIY(G-CZ@A6;N1
MOH33)@5PB56^ID.?Z4M=*JCQYQ+?X<QZU-OC"'Y=>QMDJ6CWW$U;08ATP>Z9
MDL]7'HZA^D<K^0#S4A>&Z/)>"D:BFTPNW%#8U%PSP^MAAN7?/HM<E/?_=C18
ML^<]V/.6-=X+L[!>)#LN7QB^:@Z\1198S7X/SWZ'OD_)56YXY@;^273DCH/,
M#9?FA!7S[[-@K/D$/G=':V)_07?-N<C<(!*^"C&\K.MC/I57K[TF[Y=#WFM-
MI#61W-V94RO(+T5!?GG4>7]UM,;X>C1*O:.F^_*HMB:ZUW3:]Y51S^+P:\Y?
M,K^A-@&7-0%?PND7^R:>)<$5C'D6NMY4+>A+LZM,!*5JS0]ZZD_>7*UXZD=A
M$ 6>&ZH4P M>6B7KJS)6^<SS8?WJB4OC>L[Z7Q4AU(5^3Y^LO0:%?NM,EG6A
MWRLJ]%LS0JP+_5Y9H=^:T5]=Z/?DA51/6NBW=N18%_JM&WVN5Z'?FA'L;0HZ
M7BHL_.J*099^Y3HAT:\S>=:U9:_VK%_P&;_*LZWKR9^ZGGS-:**N)U^3>O(U
MHXL7JF76*M]RQW\:B4O8O4N1 #<0OWP$#NF7_#ETH^9>!@9?-#B*4VQTB?(U
MN5I[0E@X=?7@HIUX3511TJ!XRZKTYI=3H7[;);\F<JAQ*%[^&2]K#_[)KD!T
M\:&S$+:8M2QZ)G$C.-K+Z]C^^O]B*Z-H\$R)XZ'@V N[HI-%EM_;FC;O1)MP
MR]>T^4"TJ??V-=%FW=[J-9QRW:+DE;0H66<BK(%R7@]0SDNDWKI,=JV+#Q^W
M3'9]J?-C39V+J?-C39V/2)UU@>03%DBN&2W<*H=L9C/?/[_%T:8:*M6?7P89
M5JF=1'YP%?BY&]:9:,\@$VWAZ^_>)GFIH2NI1BZO@LYJ;KTUM]8<^&HY\+7S
MA#NC%WK-$R^1)]P'[!S_"GBBUNIJ_JFUNH</!\U2U-:1,6K5P\*7J;NMO+Y#
M_Q2/,*'!.XKS*$LF]C%SSOBE>W.89\,X>09A^EDS5I]7+O8UG;8*(A_!LZXG
M5^J+X)A6=.C["7PH4OG#.K,X3/I@T:SQF<H5OZ8C7PS)_$)A(Y\*@7G-SK_&
M#'Q4S,"G.OUVZ\_6ECI]_?,=<K/6^=C7+P>JW=IL;2U[V/:S#W'8M\\BN4/J
MWI3Q;OL.SO+$&X)2_5S](RLEL*7?NHR+9/XNKS+58&V F->,N^HTU]>9YKI6
M1/@8(GZ=J?%I!'0M&Y<GRR4S!&NR?&RR7)B5^*+)<DEI>2XB$6NWV!<Q<$/I
M95I3"D0?U]0T9=&V7DHM M>1UNZ2)'TW+?29T?332-5GRDFW?^]ZY9(_<R:N
M^;'FQYHIIFZVF77?7^)HD(EDA'\W.5LU$SUS)JHZUCN7R->L>VO6/4Q/H]I-
M]*SL\0<BQR "HH/'IPE,??)<".RE)N&N;Y#I ?)P7S=OU,[0-16^#^0,75<"
MJUU-:T6SZVG:OCS8@G75A6IVK-GQ%7I^UY4=7ZB=46O\ZTMRM8?TM0G_5^PA
M?4 F;'5EH4.W+G1YA$(7ZR2[FZVN5;QPKY,L!)YJ8-DZX_86(935UT]M7\;P
M Q/A]D,2X9\7>2\5?^6HF5^5QBY]5-/MNK@99YW+C <>@6&V;U%R1L\^+,.\
M+**NS[NH;^W\V6W5X/X/J!^W=C:[K95H527^E#_?P5@M%)^5^3GP S>97+@(
MAV.^\L*$P%,Y[E8L?&[UXLJ#G8$9M8Y2K_4@M]S=N>CV+%$[)I^#8_)5J1(K
M8BI2)>[#3+-1_FHV>[G(>S4'E]3%$D_>WYU:JXFUFOC<U,1UY8?Z)JH5OI=]
M7>A83;?NBOWX7;$+P;A"'&1U!UNW.W_:@]UZJ(/MU!T3[W9/O**.B18==AZ.
M#NO^78_;O^MQ3K6&'7UHV-''.<>Z,VF=M?WP=-:MM9%:&UD#<Z=;:R-/IXT\
MX*G6VL@C:B,/>(ZU-E)K(X_C]*KEQ:/)BP?S<3U6:>ZS./1:7CP@G=5:XY-I
MC8\C/1X09^-9G'T-('%/.LNC@(D,8T=_?K_X9(Y])-PT3\2'((VW.NW= _A0
M#:(^TJ/B,-5#ID,W$>GTJ'+=].E=AOVKGTT/FF?) 7YRAP'_)=RD>D#\Y X#
MCN&Y6<O&S^XP))S GW">?U[@KIFQJ=>KR8W$[WS+1R)QLSBY\VE.CX!__22B
M>!1$E2,O?:+%0=Z5%K%P%RZ85Z;WEH*D\M,%N_LNN#F :<9YXHF4?QT*UP>6
M_/D=S.3#SX7_.&DV"4',A:!_;@Y%,!AF!Q$VZPS?^T$Z#MW)@1-$^.G[C<(7
MD-,VW3 81 >80"*2XL?7@9\-#_::VT'TWGHT%/WL_<A-!D&TB3\?.&Z>Q>HO
M";V>_E0<37Z>Q>.#UCA[[\C?>W&6Q2/^4Q^8?S,-_B,.]O2O?7<4A).#2Y!V
MJ?--7#OG\<B-WM-GU[S67ASZ[RO6<I@Z_2 4OG,=9$,G&PKG0GAY O<M#.5&
MOG-\XPTQY=)!B1BD*$P=^-]7-_&&3J?5<##YPS%;7K$4IV(M3FDQSM1JG'_^
ME<?9^]*B^(_O'6LI#FUGZ=BFUJY.61_RN1@$:0;\@2LJ'.DPR,1F.G8]F%84
M7R?N^+T3B@SVB_X*E@M._P8FP8N[F1[\6]S\Y]_;.ZWWW6YWL[/7V=WO\!:I
MG9K:+[,56V--.HH0INA@XP,//SV.3>#M9FN)L=[WX@381OVE/;YQTC@,?.?O
M+?J_Y=[57?RNSGW>9=/3UA+TU+X'03%SW)JBOG\[N3S^Y%Q<'EX>7\P\Z-LR
MQA,LY.+XZ/OYR>4)K.+PVR?G^/^.?CO\]NNQ<W3Z]>O)Q<7)Z;?5K:[SZ*O[
MPTV'P,-9'#6<3\VC)DBP[:W])1ASYUZ,N> BL7EIYTZ\U&S!8T5V>L_74Z?]
MT[3L7_)Z*BQGWG'O++RPIBGY+C?6V>G%Y>;QY\_'1Y<G_WOL''X]_O8)_O_2
M^7;:=-K.Y>F"RZABGNO <_;34Q]^/CW_6K&L5=Q4]GB;8/EM!C>;P\ '&^^
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M'E*ML('JP;4 )0+^S<>@,% X \Q3F)O$J@#Z]\(8\;H+F;C9, :SJ>>F*D,
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M&J/7B3WA%!#AOB6;4H3+^XKZKI#/#"AP"$,F@W#B@2AR&\[ !7D48T0/>ZO
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M2!;$O>[H0W4U!UBH1]*FTW#:7>4P:&\9W9*N0NF7].&F^.<@>R]U.Q(P[+'
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M#7 @B@E66]5VFAD]AG\MP2=A.5R%@W:OV99^Z5K_J?EBM7RQN[7;V-O9G:<
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M?$KTZ$Q]ZBLJ#"PI_SE$#!\ZH40CF4YP/$/U#)6ZY.%K4$@Z;D07B;$CW+7
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MK?/ 6VK.J3GG=IR#\I_\/ I?0AKC*D UVPY7.I,.1JG[2-T "RWY"@<N&D_
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M 06W8[%\#.PW,"CAONAEK,E9*Z1F=O_8[C1EZQ78KU 9'?_H;C>[Q3^KHYR
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MDJ.QA%A78H4J,B5XUG424UXJ0['RNL7-T$4_'$41E#"VS%IU;&D<1^0/00>
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MOI!5US1E^$IDU]P%F_:TFQ+F5Y7CFOJ"PO8CTWQ3%P"-()A/#+]X0HP2=N6
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MKI&#)Q%AZ7 G6DW !.(C<1P*R''@HVM\6LI0')?Y:U-2ZKBJ1.CT?KQ($)H
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MA?M*W%1O81QN()Z[#%(X0N[C=G:#!C]4;^I51V^'3]*$^ZQ/KK[H[BAWHHO
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M\D9:C#@?VE0/1-\,O*3@,T::=A<64Y.Q37B0M8)ARE99ETOY/4Q*86FMZKH
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M?HD$J$U\NP2XRE]A"]C9G8ZU#<+'"G5I&W:C-PJ9I!YY<!LWC10^<T4S>?Y
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M8F '^N;S)J7D!)@\Q-H@B4A2BE@DH&',38615 +IG7@*EJ;2^Z;,H*;WE@K
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M3F'3[H.?H*=,+!XR#[^6TI_D&4[&@_4<0CK<= FLC<%5AO^W&7[Z2JX!!Y9
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M.]D/1%9:#[AWZ?$AW%1PAN"7T /@X5BU"/Y#B ?"F AH%9%O"]>I0S6-X$
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MOVX5-?AT\?+L8M*03,1+&W4$:*'3@.00T1Y&EB:H/H<+<\\+WK?M6J>\4JZ
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MZL_-[@[Q;46N2N5HFJO:J^A^OS)4^\ADVZGW_):AZ4/9R$M:Y][(+SS4H1!
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M$W427A"FVGKX MO'+E-0A82G!AA*,EVT^34G*,+2A.Y1B2I@3SO*$$CXESS
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MPBSG83D/]Y:=C1->X=Q2$X6HY(5U?I&Z7T?J."X*'6W4[F-'51U;(9JGEK9
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M3>LH5Y )M#MR3>)=U8&>#)_LAC6]/'BCA6<65-V$K"46UV9+4TG!Y3K4AO0
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MC]LV'[S(/P_7Y5?/R-?FA5_MO0:Z=A7!XT@,1W7Y#(&X8HR;NB)/*/>A&W<
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MN'MH^P,8#'[GEJ*E+/!W,$811YQ0)7V$#^)"3>6$H&!3#5WX/GN[<@GI!!(
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M>JW")KXE-RBW$LI-_0(?B^HD3%E TWA]@KRPN48<'JC-\FOJ!]KETOF9"]/
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M^"]"@'3CBLJ$S48Q P^&B]B:5^&M..G;D++DZ<EUP6WP>0W@<*UC,/@3%@K
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M[3H,=)G5( G$A1!D)-"SLT$4OP8=H)0/<&*\W:*CD@Z[K+IP\+^"ZF,42<W
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M,!R$:P=SPJ>98SQ\A&.5-S!F(*W/06#9>$8R,DO(O!T-DIZ]Q)G-A'HOSH+
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M*X)-H\$CA*^32YH;_BTV%MLPV!F#1V!-?A\+(V]MOZ#D,/734<KW;DU&"":
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MBJIJ3&*M7G(MM_&\Y4I$N2*TH2!T+?QKX7]@X7?!YGE> VPP\KW(25L+\%J
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M.\.5+9G^1@M%#1\OP*34RM>%K_F(RF"I?%W_O-_?O98][A:1A6V6/+*NIOG
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MV0@BW[?M'^Z_%8)"GS?+9.HJ]LLIJ:8!Z0OZ[F*Z:&L+;SE/MDUJZB5;%T^
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M6BE>6M% M(X2&8E^4<E>N.Y*D(%<RC8=MW:WMUM#LBVND"?H)ZC2W>AQ2FN
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M_A _2=C*$H,*V!";3#UW7H#33S,K40Y%W@6W9YJ8E($DLNI"MK._."(D1XZ
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M%AF-[*5@!_8+FB 93&#%N>', [P/F:J;*#6W$&ZAD:IYMW1B6;O'18KULL+
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MA20LM$+P<5BB7D39*T6PY71^/TO.<U9!EMIRE=R:'>>"-U) V'V"'.OJI$C
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M_JM0\^_LQ]_RT6#GS*Y\N5L[%A[0R#Z^,XP(I*$0DDA[%Z)5EL%3"/YG4D5
M$E**ODRY</%Y@!G1#/DP:]Y]&;HF*GJ1YEA?68\:X#-\P3TB;G$X".2@Y228
M1&.E$U3DFC>\Z[B1TA_4(_F8UC(M-1M7\,:Z50+-X ](<;9U-&>AD7B62 68
M&8L;3_>#7;;#NTR*+CH[6P??RR":=M!^)_C=@=]E?O_N/8WTQV'=;-LY"+YW
MUEL[VL*! IBS67?"B[:WW$@>OO"&!<=*P -'JJ%EWU-Y!,A&4LCA!,.T<DU
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MLJHF7<&>KGP1;2\K>ZZ:B->D)50<MHP2?)-&=;0@%..4+3 7\9>K^(:N)VB
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M3%%D^<1PYFR'\6WV5?&\H$WI![6<Q)B50M,9%J@.5_8R;NUL>P5'UDNJ0>>
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M/JML>&3:P]<7]!.\#/I;1V56B)\;%=HX.RM?>#U8K*,&1M]X;'VHC1BYVG)
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M8Z@DXH9SA!XU1O4O_0V2/^2V>/6O:IXA1,^/4Z028DW.@W16R07)4$YCEM1
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M7YYGS8-$BY*Y88 [6Y4?$[VHS1M?ZH43QS9!L=&E(0(P[WT&_+'YLG^'/)O
MO9)>9SL'Y+NH7IXK\R<_\I!L!B40EB>HG:/WI,EH^ R+1)='*W/(46DTQ10]
M@49O<HY^:7T)*A62PM[*$+H6@$^17C:R4:$QIWOD,I_F'OL43;]:+ [H9009
M5[)OP25['V:!NBJJFDR= B2E[O:8?2U9B.@YNDX6I6(TN+OQN=#A#BYR)<XR
M!*08K&;.,B8.+"P[^I4F#=W!?'EZZ\8O"/](JRM!%I]&<8<G-#KCXCKQ"!CW
M@:5ENX_Q_!%@4X$BO)>4(*3X<'%% 2Z9%>7O71F*&:7V@Y&)B@.F'YB#\(XP
M,YRO#9<4QZUQP];,5-TST?WI\9K5] :2CU*!NS^=04T,\UL!ZA!UFQM+8TT]
M*22MM"^%G4?T@X,+X V70.(_@$=S3Q;?JSURBGN7<00@5,[^;64*WW!D__M]
M9/]V(_MC(1'+?6H,$L6M]LB6%?0%&>9RH48!0SOQV=X BM*Z#![G4TU(T2A$
MI_4 G@Y:W#*O7Y-0?L=7FS_N_MHG7>D;*K#-Q1RTU1AZ*5))AY/?,/U"*INX
M3-;8;1D#*_%WLB;R>LZLN\:YCM%.<1.8T?K'N IQ5SVD-P$.)Z_MG6/,B2Q4
M51+EC<^EFT4<6&HABI?-3>K1JD"V*GU5H2_0X%6T>06>J>0X&TJ/JHV3>$X=
M"Z)6V[(KT;K&76,TZ(#6,7UUMS^:EO]Z8#5>*%A6!LA;4"<.NZ8#.8(T"#@C
M@1V=J9109QY=9S>[U)BA:O#V))L+X)CEEX<9QLY6(F!D<+"IU.5C7A5<L!/B
M0?8R1*"1^*''I-WTC1^@UMC4Y#3+3#ZDN;-H!&XZSG):R5:G(=$6G1^YY/3Q
M49B/HN#A(L=)->N=*'< +D_TO,"OP@3=3>ALN#LLFO!)#W(F/ .2#\Y5I5^$
MI@<<LG A<M(GZ+F61!UIAU%.6:G=,5P\B-@#LFRNT!:R/L:(/$(I)[YV32PI
MMAL%XU9O\_#SA5<00'?14%B^-";#B5TZ @BQX/Q[(YUT85?JW]',@@%,63%H
MV*M+8T.F&FZ.]9COXBL\!A'7=CC[Q,PB).A*'ET5#2<+/24E\?2E@^V=V*1H
M.%$T'LE<>RWOK?FDYQFOC>&?""?G&N$H1@/J74 ,01%KE_?$KO1A-+I;]OR8
M;5%:+>G0N+<Z,B'"Q/P27A-4LYF[MA8^(#)@PKK;TQJBVY&=[LV2Q>"Z,#'_
M84S=KX*0=1B.]M%U"<0Q^D;0S2P%6:Q!B-.JKB7I(E6*+%#SK$ 0EF*-5L Y
M%"")%>. $[@@;@W'UU4.[>KDZ!5!"7HJ/?N(4#)2/"43;6S1\E%57-S2RCT'
M]W;H$4#9%FWI3=B)<K9)>D_>XI@E[)F9NRR X;=L3C*X<C0"T_<AO:7( !1R
MV#P5GX%+4_FA3V[:K)Y!3@[\LL "8)[+Z3F(1_3,:$?M'9F$Q&MT=2K<@G2L
MCS>_Y="<!]90PP5:[TROH&PLB/AC_UCNJ3;W5)M74VWVC;F@QD:C+;$9DPA]
MDE8NA).).)"'F*O.3HO>]T-JAE^9F$(J-0[W3<KWDGXCDKY P50RN4RY#PRC
MT%DYPS-IHOY\'%?9R]Y>]FY(RRZZ)J@_;98JGAE9=)Q[#*6FU+!+H\V-^?@\
M^MQ>1/<B>B,B:F]RJC>N CINW7=7]U*WE[H;D3H/-\CR?\$]%&[9TD=05',&
MRA$H4";6I<#2)^VZ9>S*O7CNQ?-&Q%/8U.>3534/%>RB$D<R^E'NRE-H-TVG
M'.RS$!DRX8F]O.[E]4;DU8J:%J$4X.9-)L^RM):FDC/DZLZX_*(.CM!:..N+
M+-6HG6\)$8+ZW-4WS<F)$F>J"9\=QMX,-ZU7S^[C>XG?2_Q-2+R'2#6::XS#
MLK/\8\Z5C#6AI5&#XOZ_]>56=]O5Y+?,D#S;R/B@F"' (WOHR#APKLFT=HE.
M;%?FDZ[\@# 3".E6Q?^=Y[C%W+((GT$F62B+X91O+#,/Z95Z <4Y,EF:S,-B
M/1;"C"OH>LWZA<Y:!@7*93:,";2-$2+.S$&V(+EZ82AU(K,2T*#49 TA@XG4
M:"FCT+P#CVZ@B_5)-P*;4^4J00S<()7BTC8<B;8W^IO@/S0'3;0!9<88-JH6
M*B@]NYLXX'8RZIK/&M:V;.,SYII"$/'*_IKEZE-W1/2!V45:"YZ 630([)(P
M-1_Q!1JF;^E8&#H5TH'1<5TJ0U;(_'S3=+T_[)%YMXO,XXRKEO,0)*%B*AB(
M.,3-_LG0OO@*1*9[$7S=AGM:##H[T+<O0?X=\,\$,-6ZGUYY/B-4[+?C,LKH
MR*;!AY&:%#Z:4Y#-X?!>4H^(Q99DJZ\XPC,R=) /Q'.2P Q<,![7JQ6DMZ^Z
M7HRGI@U^&*N[%49@> #FP_X(O9HB9,23*$\6?EO58[@KQ=0%?EXN\[$P*S?T
M\;H23>LS/CQO-R/Y#^.2#DLP0AJ:S"A2VR-V%-5YI&J'Q7@A$\'9%?!.>FG"
MM+2I1+TJD*D)<X"= &0DZGF-&Q/E#TU)"\>8J/!.V@D1RA/74I3&M%C/N@?Q
M,?8F-:"2^E#,D([W!8 8)6TW@0+3&:,9)(XPOMC:Z,0X622"\VH&9N[$2=$T
MK;7/F>\[0_"CBZJ^R'Q#N;I"E1S)TI6&[U=5$O:/P_/#R1E*'MN#]UF] D%5
M6YEZI]<^*?W\$U,M 8YR-^5BSS*5X&XM.?,6:^Q.C5,!AIY3B4H\/T;,3KZ9
M+#J"[JJ(AK8@TIQ'4,2T.FM:'0\5B^I9??=9^@RU,E+R0I!Y>][>7] CY>"W
M]!/(M4\ 1'P_\EL)M3(BSW<?D1"K>0-@0FLJ4X- ;]R=3@6:T*+NS8&7Q7ZG
MJ!K/CSBF)+%LS!=K]&U,H2AB0H\S(TR<=K@$3BG!.L(Q8 Y:@6NN)&:A(T]U
M6--L4U$YE:B%Q>3XD4S&XQ/&/0HARR5VP(@I/,PY;()6^S"-N+]B_G%^]O[M
M""UT7UJ\?:"+E@E#FKUM9-Y3"U<D8D@A54^5\,9)]-WX"%84K'0Q7OQJMRP7
M7\SSB$@95YD=+--BX9U.^8<;@CI?EK4SD"+,M1$?-\33$ *Q1.K?@MA+U0^$
M#(A!8O()T&I#XVD>"^0NE2:+FLBBD6S_SA\:2E]RA)!()31Q<@E6\4F?,E*V
M@;@?G$1I:X#8ON&JD;B^"O@^9?N!W#7X--#F3DME!']_BQI,U(V+"!C;2JB/
M;:W"@-6'MDT/4S31Z-A%'QNIL*.R;;6WG5F=CVDWUHIT,A,IQ ,2T13X^\)>
M3[M?:M6W8$'[ \,BCFOGJK8G04CN,[D:$M #DH6^7DL-:T\IVX<2*U-GR_>=
M-\)85C<8]SY_130*F)2O@W5 -:%Y@ETBR"!,$;W[Y.;SODF1E1?@/AAM:VIP
MVK!:09G>KV41AGSY/N+0H *ZF\:S;&W@E'A3PY0!A_OTQ;-3I1I&MPK"]_:.
M=51US"=2BUVL_:O^V.F)94;"Q7J N^AJS<A'5ZM: RJ<-UAK6L6(XA_-]"R7
MV%@#%#TR45L,9DJ]D*GTVZZPSPD?D5I+,4M22^7$)_Z,CWY KS4E<L2=9G#-
MAKU\(S*E[(HV.>')([@&>[*J\HP\(&:)$\AV562SKF F#P;N(FH7J9VXTPPS
M[#!Y!O3:L^#T1>(B_31U'EHYK#X0%-YTBDF18^ G8/6&LD"=O'EF.KG0LCX^
M>GQO>O_>@_M,Q!H4'.EKT\J[W(CZX=\1\11/AJE5J9,N-1[H:71/F(J !D!R
M*;=:1]WUA (J3(I)9*8S5N(@:%]*),+7F<7<JK^HC=9K.!-*T;6W,?G""R@C
M-L8X""$;3'Q5\)\T*VM4X=5&1.F&0JQ;<EQ,$45>+K"?Y%(=\J_?^QBV.>_^
MD(*J18U?HJ!6/\5* V\![U6T=3'.2V["[)/P.A 3,L=9O#Z-FB/!U6M]\Y1I
M7DDX*.I/F/ U?YG5MD4A<4UK/S.IQ@N[CP@/R)LB_F6EE&J:P/HX9FU$E@:5
MCGX"G43&+*A18?>\:M(+#O4[-YMND$9TB%\%I8;*9;%9(=KEI?*'AFD>N%@G
ME' MJ/YJC$UKQ[)R,:6> $U9^'7@[EN^4\$)M3$A7B$JL^PIH<J=EMP'\KFZ
MT=D8YQU947Y"7.CQ<61ZOI9KVP43%\.@RR]?FR.'K?2LD-P-23\<0M^V0%19
MIV%7<(U\NN/L>Q3.>(7[3M*WOKT0<89%O$5;R!4/O^$X_?'1T3Y0?XN!^I$
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M(4R(7W9:K59YVV;9Y'0)\H4M[>'_YVR:,V&_@6U[G6FU.?$U 1HW"5LIOV;
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M_']ED<4MP]P=:KPRICCY;Q0M/(M( ,X"(.&.PHB;-2XY4.#O.&=,W(>TASO
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M?Z:/E)58LFLO<*O.@)X0#>Q2M6>B$+$"(='A^RUDF#)@9:Q?$VG]$;@*0\D
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MS.3RBD0>VNG\L B',YF#*>HSFR";(<$*;!%MP9R3.<JC( :R\1ED#;TQ&C:
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MZLA57#RWL#7FYEYU<QOU;MG-K?/PW=R&3[";V\8>5XAGZDT\^$URN_92*T;
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MJ_B>""V^/:6I)1R??/X@\R48_P?G:Q?R?6;6MBNVC;0 &<8M@B=9A3P",TF
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M+J'YW2C^J8!<RBZWC$(]C<!"K"H$HKEB"2>BE$P(+H+! :F@$&00(8((,#^
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M 8>N-?.,&^9IF*=115MRE3+J/D;BQCIPVL^&B<9]NSMLN&@?N&AOF.5D>HV
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M3_"WTW4:#Y%A@Y^\2C%@D_-:!0ER1T$S'K=" -9Q:+; =M[AO(W!R^?>LOX
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MO(2*3EV'NV.Y$VQ[7KEY4TQN8'8XP& ]64LW]/R Q!56:<0&Z?2Y?8\^U2U
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MNQ?WO#\5]^-8 >H\<,SL?$4-9KKCE-/!=*$P?*X>.'.7R$LDAU;KC7-.6/3
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MEW-BZ&DSXP.YW"-/IYP!9JH:5J\7CF1(=%)?'>^?8FJM<A'*8&1?(3G9N54
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M <%\^@CBC-I4?L&.*>O&I 7J%&21 QVU+(UX$+K")*LJ46(F-A/&$ T' /Z
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MA1^R;&(*TJ]01&V^27V6$V#D^S5\WI.N@ 6*+,GXE,D>W-!:,G1B !I&\>)
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M%62FB:[!Q+OTHHB=8)M[:H,IK??Q_6%KO3PX90,D!A2N6/&WW/OGV:5QF!P
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M\M<9,R#IX6H!)W#'O .,?O)*3UX0Q'B.FIJ:F@X7(*+VWG'E8+*O%2,DG,T
M_EHSOUYW5S5]F*+W.8V NB_@C$+93@V0D;Z:;\)$2>)4R_,N'Z%>WZZVW>I1
MS3;J>RU*_<L;I&(K,6HI5F*S A*[[E::1:&*S:+2VPP\+I\L5C%V=SL9A(6$
MA82%A(6$A<0F(;%;N=2;,*V+ZI_9ML;F\5,-;S_ SI/4:Q/U0W5AQ\T5@YIG
MZLA#=19TM73VJZ[L&VNLZ-/"K@!KY<YODU"VE)$'U0EZSSLVTAN@-]^+GJ[
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M()Q \CK\%'_OHB!.<8(9J% SI;"5OV]-_C8W/$?/$8_XN]B(7'[E Q8>>D)
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MV"$V"QO!:XA^88TWJ3_H\8I&_D@@9N'68I 0 V<8 H&DL'Y\?2S?S^^(F78
MHD\*8/$( -H'VA_*C2!DPA3P%V^X$<XO\30)O@-$%4<>N_/@T1)E?ERM4FTX
M\ F[!RYR9RZQ2B,57:/1ADZ"<&#@/<12UV+6A7]\%O QG!@04."<=Y/P1D2L
M'S5<!WF'2]>K57$#+5@2P P9&^YG*I[/5M:<:GOSC&-2W\'?M9+]FB9WQN,H
M0Z [>3D[,CCCD4]VJDJS5KXU!1$NO9Z/:".7?97>.&=CN&=^I5'0X^<\W(7
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MV(I=6$-,BP3>BR<NU+!O8B- [#XN*OHE^(5PK(%V<87P5B#_V&6=I_MT@TH
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MTDNRW]<\TVPN.I1=8ZA;.GX%"]M=YO@U-$9L;HI@V3S.6.*:JF4)(J^4X"5
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MJ<]I6K!"&P-&1+]4*7*($>6YDL\21,2]VW8DNA>+1/>;!:]:0[01(INEZ<9
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M6_]1H_^]S2;L@CC)5B$5.44@'N#9",'H,9M?%?4ZO./6'OR\\V'@PW,9!QR
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M]X]Z;O+WI#;(TH GG:[=[:R2KEWOE/G:QY2O_5X:K:IJABW7WV[]7R]4J.>
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MA&.::"7^2DDO(#L\"H<)DPRGGKOQ?E#.Z)RI V24G9TF A@QU/R1/SNX#&Z
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M9D20"-I4O-E8=@ M>(L'IJAT#.F6=J#+)5\N^9TN^89>\I]IG5<L,/@%PI^
MTEFPUBO6X[V#NP+TOF&?*/24M)4 WK=#3Q\ZH ]GH,[(TU9_E?NBW!=%V1=-
MO2^R;&_8"KST<34CRA,\<#8;$S*5ZYG&OMHC/B)1^1+42L%[@<DG[64+LZXP
MT&,88LMMA^V;Q:S"T, WN^KD!,4(3V<,LT#36260P:^H$'UA>D1("##XT#$8
M(Q$8C&L:2LL9:!H P^ Q S10T3I&(S'3,*U:W[*='A$$$\.?BAXH@<.D#1R.
M;5^]>]Y[<#K(*#T9S56@%&Q9NF:&_/\IK+_#X1W'#Y%TROZ&)P]FG@^3FXH!
MCD6],2TMLV<U<EP8OA/9%DCQ(+S]FWP_+\]T1XK;Z(6$/OD Y!GLQ<V*X=O9
M,W'G^7!G0(2=>*YX5MMG%+I#ZM9D6F@5\$>5H[5 /3']#'KD](YR* N7J00/
M&8#P O<\:RQ.(%<S,%&H!0_,)=O0C!@G=D%B#MI9-C&JJ-L>K13\8.#6J;V"
M*PA3+^P9.==C6L3@1=%,]\#'^0?1^C3'",3_#RA_4YJRQ?%5P,P&L.(I,/!5
MK=!WN$!)]GR37G'PV9UY1,?F5IO"4:-H-YP\@I8&OSY^/-TOYL0WTJ1PWL0[
MM7U,_"J<78WVS/).O: SWS[/&]N:N498+M+>[C2+--WM<[>UN^D68A^W"S7?
M[?.W<W;QQ<M(H=K+%]F1,,9I56%OGQO%>'@1GE&PO0;FEC*E!C9'J W$SV=A
M^TM"L^[G4"$@'T/9GIQA7XEY@?: G(BAMCR#>\^?G<^$/TG:ID-Q.S-A4/F,
M01"&*6B2M#>&]F3,#E60_9(=F\;^S7N>?%SJ>GT,= ZK^CR )1X[_&2$7WF^
M(H;RU$J1!(DJG01]FD1G'7*.LBDLN=(?XDMF[HJ)LP>,;GHQ8OIF,P;?.?6]
M@1!# HC^S_EBYEI>BMF8?^K.MM<P3]DQZ](=OK?'X^!J=*GF]<GS;X X44KG
M1L1*6XN5SO(9FIWNV46]74UW)F BPC88$YJV#'L$X9@;0)'[:8]AWPP9@!<=
M\"G0[0E>,1/CYT5T^P"+WR@A29#FJWSV[["#$,E]$P2*9;!B\ !HM@*A>MC!
M(;,T*N;:6_?VT%J0UIN[#N)$V4J;BKE*9J$_M(FA;\4>Z()'XRZA'XLN(PUU
M,+>S-0BIF!9<K3G$%48Z94<GC@AN"E6\V\G/ RE$UF6O:I%P=H:6>)H*%]L
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MABJKY,XD!QE+VX*TFM3LV2_MU6#N,_?"_@HR)I9[/O=Y^R+:?MR_%]YTS#B
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MNW-TH/-0 <XYIE X7;-E<(,U0W58(Y-KEE\A,+__OH3TF SW\-M2@EQ!K%T
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MLZ2B0=WU ;N*@F'EC:^[(>PWIF*7!4$ @DUJ<R9I Z0&N@&_[5YW(>PMGUT
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M!ZBT@G8L%=^I\"3OR=;0-V&A>QF 7H+)B,E^M#C<V='G;V>XS0BT%$/VE-/
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M:[@I(?A0'S%IP@H6^;V6K%^?!3CK37L.YJ .;8G G2X9A[2R@-6F_)R>59?
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MD+&X>02DO*1DB*3.1\18)+7-<XM95$T7N);&9 BJC-V:6$IYB[@NKY5*K0"
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MMNCUQP0+TSNG1JGV3[_IX_!\+%0[3KL-M 4NT1RJUX(^1(X6V);S>#**JH3
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MZC+\/'DTD\$KL!P:M=?1\%73P^D\/^.\I]%K+4S+[M?KMS\@?RXB_SOR3X7
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MV7Z3-\O.OV8UO-LNJ3A:BEU3:*6,<6-PR8"C[Y[Y9GZ9@J8"1A%)C!\].DQ
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M]='E8WV 4:.Q)MKRHU?861TW:^].FFH@4M>5<DQK1EL,M8'.AW+H1!4M\/F
MN1!\,I=3HL%U!>JQ1<<9J2?]^@H;:&ZS8^/:R@H%E7ZDFM+WNTXKL?CE_&.?
MZTBVN;N&BX?78]IG'4XWY,:)0'M(TOH\:,-F MUBP>HSSGMYMJ2D1\'=SK$?
M[*PTAE:!0)6Y=ME#-,9VL?F6-,W^>$J#]WW.^5%JFB.03"0%@9B6_AJPI>XI
M5],1[3[ <Y/KD-."$L1C-Z1KJ3HD8U/$4_&9E!"?T(-[M(S)7PZ?L('5?)CJ
M0;%> 7G5H";2@*5@7R4W!G8=?7?*_^4"-Y;2R\5V;$'I-+.?GFN5V1&1:H*1
M\UH!;P]Q\KWNQK,\9<URO;OP@7?QJ8966KH;TU1&O#V8O;,8?@'$,#]XA?]&
M[6'YL!YE8:.^C;#[6[#&%>!%MR<7M69SZ9:_KZ-?S"K%&AZLE.'L%F^#BL]"
MPM&*9(JVQYWR-^S#Y9_]E\7N'B[F&;]V>'"PR-&)WB$ZKNW>;C!6'I,4? #-
MG4E/)+*L)&XXV>46P#8D%!+$8YJ8QF24*$GM&&-.#9$CP \E>';;(UX@:56D
MG:F(419U5[9TL,1MJWXXZ9TJ196_WJN.[=7]!Y(5:P2%XQ717W2??:B9W#0D
MCB?6OD$0[9?N>]T0= 6PCF&UGJF<M:F<W@:G,&@JV[X4%[1O6FZ%A5"+46N:
M&KJ6#76"^ B<,$;=(!E.),8>AG>H:ABK%[#EJ-^L7 &,A_ES\RJ>TB)/8<.6
MT14BP[S#T(\*AE,O0:UF+NG&C?!3@L-8B!9N#YIV7G:RF$QE=%9,4/ZU%X(W
M\/ 4VEQA=<_V"]^"457*LP=\F9V6O@T*FQ-$]Y[T=^CK&E1O;::CM5/0;*40
M!D7)?-$SO]_MEE*#2"_IO04_)+\VY3<C*D=X2#I;4CFK "[5X_TZ*-VY 6(K
M[:":%ONH77[3LXDH!3.F'WY<3I8>*2 49EV9T>.H@D/'9(]I,HDV]+GXR\-U
MS]J&W$Q<EG']N<&&W2G9^P*!FV('>2BJA3/U*P J6J+486_+[PK059A_O@*^
M CB\YK2A[DAB5.PR:U:"YEF%6"YS24\],+@DO_F%W U++MH\36>L)FY:8V.E
MM,MHN<8,/=&,JGI]IL\1EOA5!ROZ0[IMB7#%Q_@;Z]FY+\*W\.M1T6>%8KL"
M>GY+N&1[J%B/6_FB0?9OJK1WJS=LSJO[HES#LG",BB$]M9#-Y=W@F6ZGA7CA
M\4]B?!K] E$>G4T4A(*=>R?:[65KT+A)>(%3^HSR1?Z[H6#?/DO[B(2SN*WZ
MPRV>X62Z@H'1:;9I@HPX5NM4N'Q.2F90'T2TDI*R?R;IZW8ZZ?LO51Y7@)NZ
M9XY44R''?3[1H9@V&9,-L24;+&_E?1>?GFJ3:?0ID!@ I8$B&4V)3G-&LAZ4
MFY#-P]!RR@T=@74+1A[97:X880B.J+L@Z=X9&2M*Z]C)@]/IUM#H'=9'*SDH
M"%<H:MMK")1XTJ:M4&K&[>;<A!+'9F0DE4R[406UB>)86=N8#Z$=VM)S'1PZ
M<+*NTN/4UF41L!G2?CP8\+"/8\=N?EFP3RVS!L71+/.!*O^.YT%,+%DYSFTA
MY074-!(HBR,FJ@4JWK3)K5W#12@+Y.27\Q+&:&D,#*D%,6#V &K:*9IM[GO"
M90XWZAE05%\<ZO22G-,1V%/C]V+>+8=LQ2%[X>&ZCJN2EO:'TA!*Q8ZT8/BZ
MILK<]&E<JLWB=0KVA?E(X9U]4W/M:3/CTG5^"\6-D;<:$:7RZ<\8NNNX^P>0
M"MMN>R&DX1O?$B&OH/+$:-Y'5P"_].2:9S03PK*V(KT.KB<:XH,G+E;T+XJ\
MS[)?V<6"*)JGKP#/]JG$WTYJOM6876?GTBL<4M?:]M#2C=.ECP5$^0+= ]Y[
M4999D>F!+CW823%'CARR*+*#)['OW6F7M^]8$#2C:#<D?:S@.<C]R10&1XQ=
M&EZ;IGJ*!-MYS:W?MI&+2G%K-"ZV>'\04Y)9/%LPDE"2<S<CNO@Z0\)-"9$:
MBCDPC:#D6E+R9H(XHD)!SR12U<B'291$P%D^:0C(+4>=>ATDMI!+!BY)(M#.
MJ*#.*BQJF"S4U,;FVOLD*^ F$"LV[NC3DIB([S)2'/C3ZWL)<R8G&8[Z=X\I
MQ"'R-VJ9CO%B>\..HS=\QR6:]!N@/JU%6E5UNUU]D1C2.GS_E#03E!,DJO6O
M3V;L'N59;MBJEB#;UADMC3G7K8P".!;[[\N]MR6TLU1*?&!.P7# 9FRP5D#@
M53E]P" 0PYVI)?Q!0TYKM+A.X.7T;C@6-JF'8Y!:]6=!\QY#UTHKZH8#NTB%
MW/698_/E! 0'A-U27^%HS#%I;5Y)ZD-N7J491V5V@_ZT]U*R[F#7T9U0^_ED
MKZ1^%<GY&7UK<KV&]#'^C*Q"QUP*ZQCJAVJ"<2WQJ[SP^GZ>%9:&\6S4YT/A
MSGIM0'3ER;T:[IWZ+M *UF*6J.2>O>YQ._MX&Q.\-T'#(OALMN0P>)[OD6^U
M9BD<\F0!N8N<CX(=3S-UU;(SE>E9RV@B2F/U-(?Z*& I0SN]H]2W[;$)F3H:
M0N/&OE3HT5:J;JQ*@=B]]%;>1#TRFG56V2*47* $OY=!Q8(AT_3:+W(&HN(M
M4]Y%W2+%>MC/A;AD"'=LZ=Z_!W-_MC_,J<PF\E19K^"PBC#$VDL&E!K#?AJ!
M7OS41:!33"ZC@*(#J#AL><!>V4U0$>^+H&1!M/F7A/5!SPGF1%O#"DQ*^D"Q
MXUR:C)ZA_I1C#V *A)LJ1C:"R:=Q<DEJ@:NLHZ(I)Y#JC4JG2D4#/K!=;DZI
M_G/,DB$)QMKF,3&I.Y_I:?%]&]A9S1.LM,\NNHZ<"GVGE6AAD;@N+RF24#,8
MQ$UH< J&_<)N-06R#X<RXW15\N,)4NC2?2';6#&[8:)RO>9[B1S4;1,;'O)#
M([7O=M0U)7F>KG1][268L41XM.*?#*_&>&G 7/>]]?A'!-B%S$8.\Y*D\AB*
M2[8RH>F)0H50CSK7K6V;KQN=!J9A#X<W>M ,\K>T:]\6J5@-WSJ.JFXU":&F
M6-!]T RP,R2(B5$Z]WB"Z"_O5&)E\+1!]WL5U]VRKW.YL?CB%#:M5*S3>F#'
MK2O(DNIIXTHXZPA?"7%S27C#,[^(D]7^46,2=\C)/4KR$U^;MK*V$D^.(2M,
M_QRKFF16T(YB\V._UN,OD-286+/2'E8E/4T]AI+5@I3\%]Z5-1:;E.<LB?QI
MW13$Q)I&/Y:2V(;9C3?T&_FCMK[-0=NM))=VVXAAR=^YEN]58RKA0/:;ZE$[
M7V8OYY'9T\(C L/'),;0,C6U]OI..2H'W>LSMP71&8@*K"Q))QI*<H8$Y,RM
M&0Z%W8)@#=FU3A'E'BNV3FB7]*?TP?5UJ\V*.V'DGTI"(2XV?16:FFT02YE4
M#JWW>]75D4\6J\$*@'*W4D2H2$;A:;NTOI/3BZR:MV5N$%J8D/RSI>.YQ30&
MH/'MN0H4*/U+C!@5NR^%4:[ODT16DQF*=S75CC B-!AZW;6>(@_^MXJ0[B0-
MX85%9:,I3_A@R%90$)"J#A1 ;D=]%%RG29'(G&E/X9@R8=J30!B_SC!Y%+?A
MU6,JY:]@C]:\VB!U_5166\D=J=U-UK?.EZ\;O[998L7'PX6,[!_':>IUC:B;
M6GVU@%!@&[Y_1JVCM39%P;ZD:4]SZI'X+3F] CAE6)X-WVIHGW I=0W*2\_P
MYP_ C_7]N++8(&"0S%W%_'7ZJ?UBF71_;-8&Z X$T06(R02L ]9F@:"PNY(Z
MO6.V DJP\A+S/#YH.4$!062F:Q#AM&-@FQP0, IT6F(!)4Z9\U9^YAUK'%7O
M=^A?]D^93YCLY40/BVB6M>RDL#I\N!Z_D<7WKDR*2AHV-W-7%GK2<3K,'):K
MG>L=YQG5XC#^ LEV*_RII>67(SE^(>,<;W=#Q"(L)"3@VGWWNBM W>6ZM02D
MJE:I\"#F#)3E]NI=[_2LHT%MU)#"M\SP S[GJ+6MZ2!DXNZH[$JG.K  &FI[
MLVF=:G"?-YG[TLI&5J^RJJ#@0,7*L9L-]LR%8(Z1*:!_SK-K)KY>\V!P;;E,
MZ:!=<5-,*<-6<V^TOU^2\1'WHP7]_B90BQB@>!4$>#-L?B'A/I$$FE6=JB!P
M H8F#3QN1N\(A1$0MO$TI[FE!5!'O?,ER:[\5/BB,H)7N7+H(74O;6VDU0.S
M5;,-C:=MFQ4@\9<UI:FI]T)!>BNQ;DTVQ275]KLN'*>1GO1<?4U9;?:B=0:Q
M)7L:VK/[RTZ@&9<AS<E,XB 3(8^X.3N@>\>=*<]NC2>Q)<'7:11R;##3I1ZK
MM=U?3"\73&X@FRBKN9VKJ[>3B2&MH?]?KW%Z"N1]:NB4WJBM-^%]U[3HK?V,
M9 :TMX0COF3(F+DLYU+58F"=;2K#T!2W;"95+"^QA;M>-+'Y:,S2*\>Y3EU]
M&/\%!Z>CMYVYX*G&@EDSQ1LZSIA)^[2:_G8]FUS_S$C)F&X2OWCO:,&+=/-#
M[3/E"=^WL3/31^V.$A)4C5MQ[WEPAPS;JH52>FC+0WR%<4]LJEA8E?&C8X6S
M(1#C(V37W$@84W)'"F?!K97D44I;5<UX/;$9>&H61F!U12]Z%EJ3V9JA3>I0
MC)>02F>1"\Z]L3U_AP"$CP\!$-Q_:\&-GJMGDFY]?R6K=$,^/;+=WK=8;KOE
M.J&M![L@_88A?\H(PE%EJ!*^YYR5F4TO&M$-QWY\YT/$?B931-Q*BLR.SE8Y
M>2Z9EF[N?%Z&#QJ#2D>?ZU%8>%'%0^G_6MW.0+R@<1"20""#+&7.A-&-!,[;
M[,VL"O)](!+"JS9D']'Y4#FLK*2,RHU+=5SP$URF1F.W<2]]L)!YW637NE#)
MZR-<3"9]2RM7J,^>MU#D4\,-B'D'Q:)O@=-A;>7:IC*?J1)#7DS^UJ DT:,Z
MGL0#0OJP=VQ*%E7=PY>(;G!!_N#ZIJA#I"F,AR=1A<>O"4KX:K:/U*@JUT/Z
M5+P9FH[@Q@W6%YX <!ZVR$.:]K#*E[YNB+$:$,<9Y]ISC/A91K9XIE19A'(9
M&I,6$OA#GNI?9T*GK:CCEK5/-'7QD)Q@YX@J3*\<[-<PL"65<A=6=/3SM>.V
M P.! **'':8-HQ:A;IE&$_K@,G5UK$YTL?RU29%.2'>06(<]@*2?"P94S*R@
ML?9@LI'U7FM&6RH;OGB+3932OJF0BE.H14D"*;906AH1B<[-['$-S?@(=TR:
MPY)?0,,&VLD][(^A*&BON(A /)<7%'_R?+;]Z:-0B?.'X[;(!CS2-O.@FW+*
M]!-RGKSA.1IR_N299NUL(WN5=TLW#10R]U%.NY0W960><=P);7.0I=P"$I&$
MS&M O#Z,%TTH9JEB(V+BPVFLY3C)I1_T"D)7_;D&5^=2+]X.R'WN3J_&DAN-
MJ3X(IW^!?99<8#*TVQ EA\**3(QX9 G1>37PBBVYBW1?^G-;EV5<2+>V\Q20
MGG118>JBF=OA>74M8*?=KS;Y[F[M$.5NSXN!KQ9"C- A379(EHEQ;70O!0%@
MGQI;:*U9S>E=L<_\IQ*;JJBC.Y&+- M-WEX<K'<0BJ>A:&7Q"E/*/+FYS=@?
M8#I^%U5A(Q$R?"0:R!'V,W."Z@&9[/)IK_C@<MC#0NV;2*+C8MVIJL!.C'G+
M/- AN(6&"U5J\_)0_W9;(A0=^)[FBWA&]GH.#4=BA0+S73FD]"K)+!N%1BX]
M\?UZ'J&XV.>!P6__47+'.[X"N&YS7Q8M7BS6=7 )(HB2;G+XK<I\J8X;F12_
MV;<2>TSVO!Q5Z<F8W,/YE>V3PW"/KAM.8,H??'(R4DD\:'@%<*>9*=4LL*+/
M;+S<EZA7%AT0A;=)RS1M$Q-CM*7TCXA)9J.T:_-O]AA8TP[Z6,RUA:/FE-R)
M:(9(08^(AP:5,+X0^6N1B66E]-!C>,EX!_H2^IF<:@4H&? >B/')5TR9F)2U
M;<1&U?WT]60 69@XN1-'2)E"JO\[SYL>(7=N.'CF555)=FPA'".BI0/I\RIM
MLUBAFG>CX?'&9AFND7>O)P)!L<!M:++G=H'7T07%BX9U^?+EC]=!ED$E)2%6
MA98OP]#J1\%JJ=(DV@9$1HAU7"\>0[FN"<BBB5UQW;9<]7TD:#!<^/SB@%6Y
MN  /L]""T_%%N.)AS6"#"X4K%+"5LH0>9OA UYTV9&22=U"WC85_AIEAV7R,
MWM?5E"TBGV:^[\G>ZD77"?2P$PI+KM,KC$%<?UZ80DC<9>;XMOL59E_G%@RH
MN4'[OLK<@[%19]0B_@FC]4*)OY )=W6Y7VVBP >/_MK-Z%ODK$Z:!,9"BA9Q
M2?CYG52?[6A#8/2O#!_2=HT7LP-&?:VC.='/[Y8^HLG.,R]_ R-@?9S%S+ZC
MKLL4-*" +V3SU:Y99)KA1*%K.P);.1TZ7*4P-E^N\]Q3X[%0K^73W;U8()RI
M2R.S8&P&-G2D8Z-9SB.IQSP3HZ@3XIFR'=%JUAT"KTBEN\XN4E; \VPP>D08
MSXY_8WO[4;R<:$\+4$%4/,3H$?(+U</!X)?F+)E6!>SF,1FM,O!*E[!WRQ;F
MOBQG901<'H/.M8Q>#&VPL>DN.6XS?GE_@-CH4SMAQ_Y&Y>ME7@*IC' /$-4G
M_9ZIR$PW_$BR5<'..:P':^BBW/F/L3P,2E!W=/*P4B/]7VCO+N3TP,SX!;I
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M)!Q" %LG8':';5JG97M92<<EBRXOT,D28J/U@U6TQ8Q+">CS.,)J],U-_1O
MK^-CU"FBNN9;29;;M%X&WH5RO"DQ=U<,]A)3/):1BE]/9H!YI+/W<H,]F-)
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M/=6LGQ4L0'@8??+FSJ6#H".5ELZ:VDC6-(_T5'%0?'1"@'!#AY3F2:R[[G?
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M_1>9N>\-.X/1HA$EUIH$=97TC:A0E!;.R+##$OTGQQXQ?^R^WV=AC:UF^N\
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MWW@VL:7/\>/3ZI69SK^!>C/#X^C\_PG077?:ZN[R_"KI>9?C;-'W"FIU]8)
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M1\C;V<O8G75IF&HK*%DC+@NOE6C&R=0"@I(\#\A;*NFUM7VTM?4X:>EY5%2
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M9&@+*=EEG8-QTT\6F([5/5H.;B0-) D(33V%1KGWGU:9#;!5\_)@ZL9P,NH
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M^\UZX].:M[G<;@:^UIU1 UBW"KSHW%VF[[:G SO?JG5318OZAQ0H%9_*K[C
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MQH2V=;RT(.2^A)AS$Z6J1_!XFL94V?2#.B%].]:!OC1\567MHWX.5SZWC](
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MNXD3\*'<#V:W2DHMU;X81UM&**M>^&A;6 PI>VB-[&+S&R650_**-HQ0]T#
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M8[7^F'C:1+I#U<P;7^=&CQR"^,6E+N,M4@VE0CZ#>7YG'W8FNFZ1-P5^&Y#
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M8L4GVM.7QO+DGGKUU#=F%IC%H66SCQ50"ZLG]5_E3^(>D#]ZO"<^>]2<C'7
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M F6W% WWM.MKT"8XV(/I/GV6E)6DZ"C>^C <]*92O*CXT5SQ9<TZ:0YWZ')
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MT&"3@X+(=<Z]9KA[SK7W.OO<>YYS]G/^?#_ZZ6]4U?AJC%%5H^JM0:'!G\+
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MFU7ACJ'PJ@["O?H3N_VRS=9K +>ZR)G/#V!?QPS6H8[SMP/OB=)GF7=2C+N
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MUI^K2?8?42T<=-767Q%DU8ZFBDT)K2/G:@M"N;D3;_,_VT&'AAJYW*;ZKB>
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M10/I88&<FH/]FWEI39#*.LJ46QG*>'P-!(_$G)C/C24O"F&4:QK\>UYL7.%
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M^2%-QV!SHFPUMP3M.RZLYE-!P>!O1B=.24>@QR26I;DY./W">BN-?F.^@X]
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M#SZ=OKZ0+MM;Y@#LII'F,%_.T?DH^\S*P,&F2^>?GJ6ZT_?(EJ5(^*-4^VN
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M!,J$Q4[V4 52+_.Q]U"##G .=:P%]O4LO*R4K2?BC9!X#8':\Y3+V_/V3=T
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MIK\@R_C4E>C6X[4\_MQ=%CT)<K9CXRFM+T%*.N5*!6:YM>,I-8Q,J(6M1#+
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MFA@&>P!<AX?C/$CP.;KW4<&OM4DBW6?&SEY(OD(5E@HNU,#I')T9SMS(5DE
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MYHY3/U;6C9N96^@3>! BH]AQ2'_K*-!28DY*'2O)N+W)HS!%W:UH?_YQ_:Y
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M6@A<7,J)??-T9E1TR,LAUBK3I=GN$.L<[KI^;CH;?EA%CF5,0M_PPG%%L:_
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MK7":V.N&>EHKY9<_"XPQRX+:>K-7L"E8.S+XPX1>XI%X*8E[6Q-WA'RT[P)
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M8N/G#*I(F^IF:>*.GXQCX"J% '7+T48C#(T/U77#E'-SRXX#"5 JGK()_K^
MD!N7EBWZ6_O6WTX*"QECF'IB=<I*P]O"MRZ!W16GV19UGCA1#6$E_D*5%GUF
M722.NBU:-;5# 04]H&]0#W7$>I-\UKN*?;(BMK2I*>ENK?PX^N-XWP;QOIU;
M;G%;N)LF6\'<\$1YA9]M!1:/>_.(-GZ=5W'EU]@]S0$C;_@#JK./1,WHD&&U
M:6,:8-&HC/RHP2 Z,E+#T?Z2G;O7D999R'5NIA<'>7 Q/8%,P<I5:"0#Z2XI
M1?[[3M*Z\<J,]8NW4,GU4I/?6-DG=QISI\*?]DV@UOK^!U!+ P04    "  N
M@'1:W]W&D%]_ 0"U*@( $0   &<Q.#0X-C5G,#!N,#8N:G!G[+T'6!1-LS\Z
M2,ZB@I($"2)AR1D!D2P2)&=<=A=8%UC878(@H"*@(E$)$E621"4G 44%)(CD
MG"5')4K:_X+Y?7W/_;[G?.?>Y_POC=/37=U5OZKJ[IJ9GGU&;#=V&#A\045=
M!<##)3X\/@# SC/7Z-@A,4BT'=*)581?$) \KZY)0 #L)64F/%, GY%3E>D0
M .#^,1W2 4A0*!$I81$I2:9#A "')AR"0J*1-AA6(R0*R@IB58';NJ!@K.*L
MNG H#,4/14+<OTKDW)=X^*0T:/MH1BQ$HD4AXO."]</]-NG]MO&]=MR!MU\C
M=T+!'3':+A@G%PRN2KA'TT%C]*R12/O]'NJ.&!C,T<7A>WGOK&B/VJM3[_/J
MP=WW>IR'8_9X?LJ$H;3 #C!]96/]'V!?&7102*2-'@SCXJ1M?06"(U, .@ *
M0.+^; !60 ^  1C !7#:9R%S^M'[NYCS]AC';QI16+O [3%PQWV1N#KI?F]%
M31.-K]Z0V>M_"/2;Q4=^L5C;"0-'.J)QU./[=CEA'+\;@3/2&O6CHFN+UOS9
M@G)4_%EQQ/RL7+2V1_^H:-EB7']4E!WLE7Y4<'[\*?H\!&'[S1%?%01T5<\K
MXD[X^V4H*RL4Z6)]#CD,?$^J*,>_T<[;_[W?>114W\ 1H\*N:X\!?DGG[:&L
M?Z+KHNTQ^W0==_MSJ)??R62N, @&B5("8\ _9H6.K0[Z^ZS8*W\[*^X[ 6:#
M^9-X?=S,_Q-=#V+_E:Z#@IPS^4$^C)OR3D9V,-S@XL8+[FC[W6-4>PVZ.)W.
M(S$8I(,]TM'V&PO%]Y8]%7ZA4WZGZ\)M[7YM(/_>@-/M!WEOYN#/?]5A;^WB
MA@7O^WE_5IW>;Z/Z:8'\]:]<!)3[U;U5;;I?I_]1/[DO=7F_3OJ=#V^?B^OP
M5S=_'_ZO*/BK^V4U0,#&!M=BC\N)OC%]I3Q^&/.#(KR?F^+R[Q2Q_1STD[(O
M<V._C%M)V#\F_*F]YO]\V[XO2+YZ=%\OX-"YK\>W-J4?;8?^UG;RAP^_UAGV
M2OCR/RS;3_BNN.J>M82 +2 (..(.<>#'@OHM_4+;X]CC_,<./]+/\ $XNMC;
M?U44(+)&NCA"T7]9O1",T'>%]Z;\+],-^,N\!,[_F+]?U=#],3WWC2%"V\,A
M,+2A_<6]!8;W&P[A?ANN< 1W$.]7U)5^D4ULBT*Z./U&(D*BX+;P'[%366^/
M27N?AJM3@ETP2%68(PP%QL"@^]I?=?H>^LF^=MZC[+6H.]BR_K]@/[X+ROZW
M"\B^\W^G:*)M?[_($('M,?I@V]]H5! 8C@_FCE%'J^EK7OP>QDB^DW_K3&J'
M1'DHV,-MOWN*^JOQ:M_)>]Z%PFS +OMQC-05AL+\H;OA=_+OW<FM;161]DC4
M+\ZE^<IP7O5'PYX:6DC'O3,I!NF$NUBA8;\ZCLP>Y\B_42FL]P/BW^CDJ+VP
M]Q?R_EHZ\Y5O;SK++P$_Z33[1;RO\8G@V'YM;T )]NM[_8&C/-\<]@AWX"(/
MWC  /'V)HU,!)P \;#=V'J!0@"*M85:*FL A[ ) M5\#H-?W^+!]P"V @H2$
MA)2$@I24@H:<C)R&EIJ"@IKVQ-&CM$>/GJ"AV$_?3G].>)3DY)14E(>IJ X?
MHZ*B.K:741W[RD+SKPC O@1H2'#*/\+'8P,.T>#AT^!A!W"&DF'?X.$"#!XA
MWG[ZYD9\ .\0 2$1,0DI&3G>7QOQ@$/XWQL/ W@$>/B'" X1$A.1$.)3B. :
M:? )3AT1(E2X!#[*YGQ#F.A8V./<\^P<M+JOK$5$43=;%(DYP_661CY!T&)T
M3_)\3RO=UX<J5R=AQ(^W&HS"/N??>MWF,K:LPO4@V:\@XDW[QY64PK<=XZN&
M-J[^D:E%-9T3:Q*J1K9N 5%IQ;5=D^LTP*%#.&T)]G4B)B(4VU?AE- 1 IP&
MSFQ'"85OA!W;T^"5;LN2"(?U".IFN*(>+00M^HF3:$\!XM-BU:TX)9*.0Y4-
MQ#&PT1\J_+,&7#]5P/8"%/C[F#2 /+#(YY60N;.PZ;@]-GJMW:UG:P$+2&(!
M#\/$UI[F-C?(J+[MV/HQG0:OQ,K%Y9#UE,KF(;<OM5OM>]0TW/&@P2M<=F'Q
M2VU#$^2C%W):<FU L\N2K]8S\SF>W 2+:RMH70(YS; XYZ.6=Y>_,U[U[,G:
M=^=?+JK/)XL519:W\D,+SFY%3Q90HV7!%D4<J2E5)A[*4G00LY@),P/_J(*B
MJ4'F::ELG[3<+;Y-3P.W':=IBK)Z9I?1>@<O.A)IZ2<3O8N3LG-K,LBT383\
MJ]8[$7X=GP43-3[;>:NF;'+% )3U#K%3S>M&8<5M2<@I+^K)JMB5S@?!KG?B
MAU27JWPVA^K5+Z(^U]#2TTO1R19"A#I-3<U'&5Z:[V3#U_EZY8HP<8'*!A_-
M.)]YCU)]Z.W>FKN*/HD%&E,7'^\&[E!V=PX]I4I+&+A+A!!A"9X8-K&4NQ@4
MV6>Y=N.13YZ\7)'XLQF.U*>;'2W]7:4/0SPS,QKB+?MB=AX4#+@5370L.#B@
M*\.-64PVD3IU-N*@+D:^(P,O"]00"]T^:I-80$*S<CXA9$/>J#TO4==$,OY"
M8SV*I]+_[F?.Y7-#:\*,LYBU@;S:\H[<\GXL\&%QAV63TT?KG"\C5%QT9U N
M^ [WLW;I;%F)X_,FD::]7BJ=YB\G0RTUC">% ER;5VVG:2]X%V%B'R)JE!MA
ME(AY?D2CHR<<87K&Y;UG<9_1AQV6JNG= *X/;01H)GH&)X66UU_4)"0$^^XY
M6UGHYPYE&VZN,_(2EE])?_TEOCR/&0LPYN_2<HIF;_:T9-9ZGVO(JY_Q,NC)
M+7)$Y*S*@IJ*6[% R;I'XM2.J'=\E]-F[/RS(WWF,^?0Q6JA6DU-O>N[[EB
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MJ[("IE6ZI#V#Q*UKB]OM#RKDX@N%/U0W7WK<9WFJ6FG>TT>LWC+"FS3&<BU
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MV!?EET8"$XF'E0KE)];&/B:'/PA7YTC#]NSOFIW:WR<R^KJO!@#4@ ( !9"
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M##?,WS>B_A0^_O/I .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0
MY #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D .0 Y #D
M .0 Y #D .0 Y #D .0_#$+V\],.,$>H+)L;F[P<M@]0!(@("(D("8B(]K]<
M2T)VF(R,E)3L&!4UQ>'CQTZ<.'Z,CHZ!F9.%@9&=B8Z.E8^5_307-P\W/0M(
M$'1&D/,,]YD](7C$Q,1D)&1'R<B.GF&@8SCS;Z?]3P/CNQ*!?ODT\!N :?\[
MOS^_^HM+A$1X!,2'2/!QK9## ![^H4,$1)2D!,0$1*1XI-^^"DQ#?.24T%%:
M!;VP%I)C=&R7=/4-P,[A]W.%Q5!HS(W'22,BHN+GC[-+*.?EO^*P=KG)*:GX
MI+KU!)<AU/5!Q-*GTTHPWX(S*A";US@0.KS?X/<_^'((1V>@P?OM@\2X1(.G
M('3JT.^?XMU,N1(;=!@=<V68"EYW\]/S[*12]!@!JK/SX0GF!^\;4HZZN(TQ
M"/#Z#A)\/1%JS%_PML,\V,\CK W:[MF]R*%V/_KU1"M0R/WE<:O>?JY+B_EG
MU@=^%I(U@?7#ZS>^G72W=!-CF#EE]O-31EI"3SZ7R Y_.^E7MJ=-!*AK[>=J
M!Z#_5X(^W4.C(WQ_:R$K31X+'.:QNJ(WOG6JU;"P*(&;.S#Y,KKP=K.HGU7)
M_S;##D#_!T$;^Y]>;^QH&U^]05A_.R@"L[O$(P83Y4N):+Q'3#0G%1%C:FRA
MS1CW4MVN<5[-8/+_-WXY /T=E.<7T(C@;ZP?^J=4-NM]W.G<O\+J(*9'@\7I
M! ]9XIG)IA&+RQ_SLW#_O]$;!Z#_+F@;+A\-S4RD_S 9Y:@WN7K#]ALND:F[
M'X:/@B$E32BF=U[Z?Y=5!Z#_DZ#&>]/!FYOLQ2L#;9U)<=*DT&)WR(UWWO7I
MMTYT+] &7:X#A)G).I],MN@D[7PNG[U;F7',I]+(R]F(TOOI[0R2V]=OW_ZW
M,B8_>*^/B[Q:]OOS!?/R98G)EQAOW[[+QG:(C?5?RJAKRM>E*N^NJF]E62D)
MB V5-JT896@/6&^>HMED8SOSKRJ21T=WGE(F<0ZR^;)8BBZ^>4UHY[)9W-W3
M@K?O/OVW9$CMHGRG(DH,X[" E,+*A?XST=5L;+?_16>0GP)#60>K$Z4,-P,V
M>2]D@K7C,KT4=VA38$[Z9[# M9S-T6<9?BR+$4/F!J^M,MAX;OZ+7OJ9$9\R
M=4T<T&[E18=FRV@OI$T?4QG]J6"@%-\?^/BR]HOU%/^RS_-N"P;RDNP)W,__
M8N@>,>_YO^1XG*#;^>$4/Y7X->-[5+VG5'WU5TJ=L0F)Z.27>NHGAB.FZ.UQ
MXA9>IR<0DK_.)AS''N,?_</GYQ?JZTEV;=QLAF4JFR?;3PZ5O4J]8A@1\>I_
M>+Y3DJ]^[@F8DO%8-V&F/5T2XA=Z1"SX*N7UA/.9B:TYA%B@UT/>6GL[0YMI
MY (3S%H\-NZ^ZD48M.Q#*',LNL'G=,?; M\G6=0WG>:Z+LST/0C?OLW])HLJ
M8M*)48+RX^<SD&P]N 1AA[ZRMO;M:8X8V]MCEZ'QRW?JJ.^/&'X60W?V1*Y^
M5KE1<%6.JZK6_6GGS6;'^#S$887XX8D3;>N'M$UG!L*[JW->!\!!1?4!KXQ0
MGB4FQB@VFHK2SXBC'\AHX"^F(82F5X)D-3_3GX:_JXX/>2"ZJ:' <C?^M61&
M[9V1:T6,\;(VJ:;SX'=SJP4?SX_TTG]8?;+C1^_QIB*7=Z9_H>LNMZ2L"GYD
M[MGD4.^Y"*YC?8@"A>0ZBRN9H2^[Q)_@)YAS<,Q#:OE'J2_P>=VBE:&!BY",
MS*3IF3]S<FWPUM<I;"VM],V@4OWP2+0VA"-OZGWD-"2L17^@@5Z3=8C1O'I2
MTN-<SRQOE)V <N0V&)%9:2W1Q"E! ?8_,9!A.8R'CEM\X7TF>,<OMY+I+6=C
MKL6C](=)$HJ%X7@C'4X$._5O*E5;*VGN*V_4]%D%9$P$)SQZ.,V<H.W7Q"Y^
MOUX\Q)AWNI'2R_%TM7AY@^F)F1+%A);M9P0!5*%Z!*/UC0Z=[LA;'TN)5]8#
M1BO:S3)!'>U--U7?<BJ@S5O2HQOQ"B94FDT+7#Z:RVG5]3%>::"'E$C',94H
M\N+?7IK! JE7:MW;'&F*>](1PPE7>GCP^%+\'JGU!RO)BPSN;'TYEHQI-[=\
MUT-^.><93-8KK^BF1(FHEF4/PU RD2IG#SA2ZC'T0]T[-D_%6'82$%KK@\(2
MY\E((\ZW'FZO767N%>AC5B5,K*5SPH^+Y0;@A^'5^F111(W9MZTQ9A5W-LG2
MPD &,F)]FNRQ.]X?A!'%ML5G[^I*;_+8!&'\%$/29U.+/[2WBH<U(6XMP/D[
MFUTMG[VU./2$FF:TCX@^DF1Q7>T,1WQ*B_BY44N\NK!0'O9-@Y=]Y:E/FJ?4
ML4 $ZF0#)&*(8D/&\%+4]@C2;NN\L>?AR^6RO7D9%1%BH4XA-*6/'TVH-"7X
M$5L50%[P7GWJ()N#!10NR01KAMQJ1X<\DN'K\#<J.I$<;D14RZC1/U8'-";X
M?5J(<>*D.U2AHVI7(F>C_P9*<?60FIJ4 WOH9^;8NYOR>%V&_1@%12.,@(MY
MY#NQ!"SP8(EAN(O%&(\@(I!YQ'/G50$=HD,,!HDQ9X-8DN+#!P&S$X''C07;
MGZOZE"DH<,P+!.6)O2G!#Y/!LQ)<$V79@>O"/K;Y^)EL@?+&XL2I%CJBML$D
M<RQ?%^Z5_86KVW1OJ6-!BZK-ZW%Z5.R1F?(>5V7G;.8I(VIK/EIXN6%'5]&3
M'';V/L88!BJH?<^43HS6A^1NZRZQ1<JN!CUMS?L?_>;JC6/'"H*^>/4@%58^
M\XMT+R;S9*FJZT$JV^6>C*L-'J%/0&/"*&Y0+85>O:JPPO_^*2[,;2.JT+%3
MS_03R]ZNG%^VV(H;4O9(WND4>$+#\H2-+? 46'FTO%W2D[+?<96B*SCXZ.G4
MJPCFEUX?K_N^9WW3>5&*)'(+D_H8<0-T1*;2U9(H*&V!+(WHX7.^0J*3,NUR
M,M/CE-,=YN2$QOQEEVO%"H]?F2PZ4TMMP+U8(G[</LC7:0GO7?A<H331JXAC
MR)M!J\_;\:(HN*A9-S10#0LZ+KPN+ISUP=+E+A<-]//N]?!I=2("'CWENQ0B
M^/Y$J+)'^2M"%9,E$)'JC6F$ ONBJ61U6:*JM%!Z3 <YQ(& TO_A0_L1)D4%
M.>;DD@W79XDK8C?ED[,474I'+Y2.IZ:AH7$!)X]</:F.;W;?>?NP%[4_)LA/
M"*0(SY:X;:4_G^UO6,95WLY$Y(,J>A8I.IYTX2(-+>$LM:8H!G7QE%!I3R4W
MP$^8L\04DN[2=!).VD5Y1-]:)A758<8>%B'C6K<&*&"!6),J;[AR\=$Q<J+C
M$,K-:6VUR7L]]$W-;NE)PD_X3/5>%=>GMEVR'+5?E!*[G]N"8%%PPKLVF]1'
M:1.)\36Z="TK[$,!0PQN5>F=C:E!49T["_ :QA:H7WDM:6\E.)9V5Y+#WN7P
MA1VOX&ZFMMDZV/1YN0AC\V>Y770=UO;,8K+O;;4M'!XH0:\V-=^[UY/(WWB[
M;\I"GT<P, Y^5",2%Y-@&94])@:\P_8C2Q6/2X^<8_2Z<&BUAS3@:>KP_-I,
M[^Z*5"NQN'A!_#S]9((E+3?S0QB:ERY6,/Y]LXG%)=&B+]RF)S?AGP6\;4^]
M^NBYDU&R6]?'F@YR"!Z><4*-4&11-4SMIJO-3SU>BN0LLBZ7X7=5;VQ?<(;<
MH)<*9NP=J7/U,V^E>Y!U@LU&M_,A@K=_P+$CE34R9/V.E$1'A:E ('F0\1;K
MTKR+)W<.W68#!NED%]]L?P_I:\9WF\R6$'ZW(]#YHBL/+PPJHEY-(_(1\7!0
M]'[YZ_ 'P=$% E&9+OZ#,UL=4 S&P0D<,1Q*VB]^2/_F^$"X3X^%+=>6/LLH
MSYW%::-#6&!>EB67:]=@LW5:A-#@ EO 4;.&=W7$42+R%2\)7V(8DWCEI/,M
M>'(Z:)W5-66L+]^Z3@)J%HG6-;7XL!-+"C8:F(]2OY5;D2VH'WF?WY9_94,%
M"^C>\A*@"&LZ"O-7><?H[^#)1,)>36)0'BE?'5D>%SGKMQ9#-M5_8L.\*YR:
MM5O8O"_7<-PIXW74!>DTM2TOOJQCXWW1%@GYJDF7I3R\>.]/H[=LR[QRY'UU
MPU8'1J<58<6:3F4=PI%W^4K4$T@I&S]*>*A-&X1,&^'[?+,E)>W97,S6PUWC
MJL8KPYL4+3O/F.46^-LZE+@)8'&D^++6"LWRNC0K#E1A2S!,-8.Y!A*3(T54
M47.V.?LE(3QH+E+\W='>C7X11(P"@0?9B'% ;N_@YG$F&4R"=.>]WOK4 *')
M5]$-1EUA^DV4D,P<ZAJ:D=B/^=(#(%5X);VY]I5WV1GDZ'Z100E8(3>+ =M[
M$_LE/I[]^]>VTMT:^2QR=!B\'PM 6#H)2^OV[L(R AOS:BFT(^'T3!<9WGL.
M9'2&D'*A5DI488:L&4D%O5D%>>K'#(*O=1#F-%AD=S-XT8=[#\<(B/5:OVQW
M.4T\1,]-S#8%#ILGGB;ZF+6!/FKB#)))S35/GS7]0'[+\5WC:L$\^3V[3$5C
MC^6;3Q>B:O7;.PP+Z@:)M"AS)82!@8*YWM+LKJ*"2RGP)_F==1MP6W#W7(FQ
MQ?T2B: W'U%R\1E\7N'I1@/<PWV<>NF9 DZ5C].XA..#8_4W2.W8/QG$RX]=
MS8IF"+AC>TWL>(!;^/./$Z\S8_.6CL:J0%J?EM&T<*8=&2FV$F*A9#\=UM+V
M^NBJ3.<<O_-*W)K'D:3RD7M6E]]27'T^P)J)!@3NV705=W8!WJMGC]<QG'O>
M:1>EIA]!=^$= 346@*>X>JVE7CTQ-.;8T$JVX*':2EHT%9-(8^J3D5XF+*['
M?.O-Y$USK\OXZQ\?W-G62+[&%<##K.GRXF5]Y/93:ZJ(IM49W[ 5VJV1:U?]
MG97\>3E[26>$FZ\[85"P*<1UK@4KN2D1E0?1HS)^LS1-H@7.C6":O/,L?+<0
M4F\'\;)DH=FRPI=]IOH.]^:XHW+<IVV=KQ&;<;UB)VE$H(*2V&=)<E=C> :#
M<H_F&I(46G("VF=A^40+(PP:%E&/PA('LQ[KTQWG+INN>7OEK8LKSZR+O4UD
M2GMK^VQ!;EGRS;GB\7S756JC'GKKX.S&U+Q^KC1B_F-UG<>IJ7*&WN#BR"QY
MC#X\GT0QP+HL+Q6>R![(J-09S"2)%\U^]GI?E;/!K _4P/]);JZA*>_T9>>&
M@"/BFE;J^ *ON)D+Z2K*\A+&E EA!(T)D:[$M;Q4X/FSCW)@]PK& @3G:TP9
MW&W+VI4T+.&#+8P6PYTRN\,/7)0C:K,9O%^[%+B@#"YU7FI7H D+K9L(D\*7
M-2P/W>Q(5(E1?U3[V2AO")F1/"^>^UZD-,W,."Q?0/?259WN$%KCY^_2QK;B
MCC')%1-6$S-?RVOFN['D)WJ\>>__Q<$"]AX9\DNGHV=L+Y0P@DIB0KKO8P&>
M@<*Q.2Y7W&U,^>$/FKB[F'LO<M_+ <R1B&"[9D4Z"LT;V6X>FQEK^OJ%X_-!
M+T6AZZ*PZ"7""VV.(:!NJIS^68-7R\+I.:?IU4;80>R5/77H)<HZU:Y7AJ 2
M+$!FON#<]U3@05N7VKS*^<X71T;>%4"35D!65JB6^,@G4Y.52;YHAO7MM-R<
M4\D;KI3;I0*Q!1=\5MOL6;;&=JD45OU/O5DS%V.BKC('/X9^O-UXH];X7GX#
MZ[53YWUP-N#FYM.*._*?<Y ]MGG- 95E2%]]\3L81>NWW<()\\[IV<%/U$]6
M=\?AGX/7P:+/RP0E,8,1;UY0YF$!9()>F=S12[7(&SVTUE82</)SJ1WPA$F_
M3)NG\S8/.5(>5GRQHP_OHOSH+DQFE=NL5AAE&H4+-Y\[M$Y DYY&])0;)-E#
M%V7$?:=.<3-/TQG2$H8^SSL,;UY^P**475WP[9E/J8:&YIB2$H'2.24EPC3W
ML@\FH,]= S-)R4F!H*O0YE,/ZQS[*AP%XLO/?!+)0&1'6_J?'VV>G3%NJUCH
M871%W7BX50T/[@EP#F9^$W%4 5S>UJ5Y5&RP[O4-RF:^M1OUYQ/(Q[*D0+5*
M93I)QQ4B+P85GBK]. 6SX_+Q'>U88V6];JP8HP)^[<QT]W*VI= ";;XYM'C@
MV8/VPMSQ9^2]GU4@0B70K&PGM&*, ASP'2$?&ZS#QP+9L8G);W>!RLJ4G5:*
M+T7;1XEG6AX:W.7S\>/-:>F=QHVF.33JACW>LTZ!9KZB>Q%/Y".'3#>Z5 .P
M@&5GR[N:12S >%^UAY=<CM;/">I!:SB9;'[J2HF^3C]RI6#UP2)?))?8Q]S7
MH1_[(YXBK4[ Y1Y&E,$K=.O4H%URE&^0[]X#Z:ER\8X1@B)Q#$*R=+8VG2^H
MPCML"@= ZU? EQ#9:5G7L<#9(\0A5:"&\ [7L^ T5=[+)?W646C+'2/@&H=]
M<PJ*@A-5-M5P0:OP[I,I2+8#)^0$"OII%B]!]0/Z) '['%=%V'6HIRE58S_*
M!-*[-BO4A+X&DO);1D(K)5-STEWITE*?WLWI,GG&,3ZF>PXB S#Z1&,$I$^T
M=E11@3?Y9,T<<](S(M/?7*PMD. *!>KFNQ^$I$32&IT<ZSM-DNJO\29/&IX_
MG#Z"UWJ6RCR?GOK"Q.L\N>;7A[<(7_L.9'&!95DR+@W0'2,B?ENT;0N3T-"X
M0J_%(437?#+3]SI!"-Z@N)_<T^]; 'M["!+/T]X;5#[>O=N:T:TWR3.D@P64
MX2;FM&3R0[R5)9DSCU6WQMVZ:)VZ9F[???1O/OZ3W+Y19QB?MJZW<K?_(Z]6
MVU;ZIC)-R>W;3]A8ZT=-T2VI;#7=X<%%C3-&N@IJ;!TQ7N=9LD91]!XJ'0YM
M%FL[X.HP#;_I*QQ9U^:/:%+ 1NDDX(U0;\-7,TVH3?ZZS +]D2@F"4V^^<&-
MC]<N)Y+"B4<?WRUBK#$N5XZ^$RF3>]J?E*'G:?*[^78N88C;Z:9'-],\>7R>
M51KS/)%N;[MTE/&%XT:B[\TL9>2;&,O:BLI-+F6*<*&\^AH:6E%%F^6J4^OA
M1IYMXH WWZL'!:YQY=X]]]-CY@)(/O0'BBS%W3@9^B155)Z=HR6!&6-"=U>G
M+>K6$>I1LE&OR"-"&QD-C$1(&*E 0^LZ],ESH@?(&.DB37")":72Q;#F8.F;
M4\FWXL=<YVH\BR,V>OB, S0VOG29^8F&F@WP6IQ]G*Q*H?B%/F$Y<B'\:53K
MRM':QT%,#_$Z[*^RJ-@35MV<W@G2AJP8J'3.HZ^D(78\7FZ3&#)S#I<XNY*&
MO[MHHLUAFJ=[1%RHD9YH$X_ ;[F&L&8C4&F5MC,V(N*S N^&:EL[0L5X2;@3
MD<?./B/UD4;V;5_>H J9N1!-@Y_ 4Z>E\?N'*EUE:S96U&U&1!;C16(3[\)<
MK0BK':G?]-K58%K)B!4T3] <JDD@BCR[S''_Q>?-:^0S+^2OI.4:3SGH6Y6W
M5'<;J_6>&]1.CJ_R *=+RMLW)Q]_$ZG!=R+@HF9!)\*UT*!312,#Q1FSP($_
M0^A52#S_<.7F!A90+5B6T"Y 8K0IQDR"B](;^ 9C(+G3]_' =05(YYB;'9JJ
ME\[7-%&$4L0__Z@8<H8U?C9J37R$UY"]JC]C\=A\1K"_>/3P_8^E[SEL1AI"
MB6U3W+(%"YM;$DXA%/A%MP!&;QWSQ%QI>K;,-]?XD#;V :#+*I[F@0GLY5R"
MA4]J0>&5S:K,C#,EQA/!-!FU5V9"41]E/QFJ#,X^W:)+GYD>7.@6<DTM&3QA
M@Y9_G>LM&WE)'51%29+D61=Y;55!RMZZ:"J\2=OC@TME&SJH.B&#>\R=D:E_
MW%O)ME[\L&^TJ]AP S];Y#2JXEQOZ9FX&F6MY4&WEQ.35!9]>-W9F]XO)5UC
M";4]BEL4D=G):)>+^ 9Y 4R!:@.)9]A?EJYJA:SX)C5L1TA:2M='NXFGWD+<
M84Q\YRD>MVY_ZLI8C.8I*\$!Y3Z&RB?A TJFUOZ/GYSB"):"=E(FCQ>$2YP1
M&+A3)3;*DATH%\"_<9QH3O->(&C3:EQ$J24QO>$%89;FM:$>Y'(E??.[5"QP
MPN"%P),X9X_7[<=Y+=['2#-$KXY 9A.J.R=43/#R4?EK)HI\Q?:BD*#%0S'F
M#:9:%ALZT7J:;G-2 : U#P0AQX>6VE="GTGQXPOBWJOR&T0TT\;97A?B)XF,
MF;X-3Y]-OWC=Z0F$S]%UJ<O1J<F+^X:SPVG!E@I-!Y ,W(J2KV!9[SFT.Z'[
M?0T6*(\T$4C,K91ZVZOAG]#=( 43X: ^?*EZ_7BY$T?<MIQ?W\HEWXSGWO<6
M1-=I,JU,CA6**"=<HQ$*I9^M<UA-91AEOH<%>E.X>G!&D16XFFTO^^\V"&QT
MH'-S$NQ64BY,LX4%S<.+2I-]>'!&*?-%Q4E:!S7CC/KLZ/,^P )Y?JC'DG%+
M8I>+>PZLIZU^:U&OLR([S8&I[,NFL8J5-V+B!6=JY@+C:PS=%4^<V:VJKXK4
M"6+>T]\O9I\V+8DZ"IGG/C'?OE;J1^/DAM ]/U$S*G&\M/9^*XHL;#;7G]XJ
M&2?..5A:ZE[ JVC =CVT,M]\7='TK"-!OG:?KJI8;U: -CM17:^$2EL]7J\V
M]RJ_7UUT3#4;CSS#8O_$)F\'UT*NU^$77=Z3$BV6Z?(N@5.W5*=PP75R()0!
M"[2 EO5DEV9AHTO9S3O'%2YMW&TCW'QM=2532L&$_/%5?&&1?M6G'W6N.2=I
MG.9\L]QIO-2^DTWP*KRSSA)B!U''-PY*MAE[CMRX.&:/?[? IM>SG-\!0QVJ
MQ /G= )Y*UT?/M>-DJ/=[+5YLTE70^L8WG^%&PKW>SM_EE;IZ@13%V5M5$O"
MARK-4].GUY/+3,U E*&O2!ZH@7U-33B]/XA(45QO_(S*RNB[YPPSE)ASCQDS
MK"DJBJD\PQ-(I.G,&!^59NPUHYTKU+3@=K@V>H31X&A(ILZ-)9ZF&Z+V=AAU
M(W_'A>&9''";/MUU]^,E$OH>&BZJ0S&CD>3^7!\J>;-@RL^;M"56M>VOW\XX
M0>VQ)HG:H$Z>H&7VS;NI(J*26X@%N%<_$6V^MO0&<ER2ZFS<( EG^8@-.BA!
MJQ*^_-O'^$7>ND=IK$N3NU2^7U,@/2UM)^*M)4,^./;<8XTBJJ5;@+!E9(ZD
M44+HZ%L.)"U_PWCI6&5#2YW($L%9YX0W <\M/G% @P^WG1^9H9;:/C]3YAH6
M-I7QI1IV/Y;1;%;@RK!(WZ?3_KDM.6DIUU; [^U1D?<I]946.!QEBI $CE:5
M<JVR6$"]?:5(QB7HPWG.(]'PAI1K[QF);$&OY0^1VUKKHQ"CZL+UAT\Y+ICW
M&[7@>SR90A-6$8!I5/4G*D?TN.SU(Q?@K$#C%Q3+'9X5VC?7DGHT\M56ABX'
M;FM;I!VRJR5_=7-^I2,RFB<E*Q5ZO^G,^_.6'[0RJZ+XUJ ES;!C1]XE7T S
M:3O-D_B#D[& 2%=;M)4-2Y[O\[N2\@U7[FY4U_I/(S#/B)@CWL^+8$1S6.,:
M'4+OY2^%"ELIPGT \-,"9U2D?X>VJBR!M3',KU1&$%67H*,P;HX@>R4XYWM3
M\=B-.+=3G1U2WBT-4SL"HE4J)7Y9A.]%DP&BG<<*[V2.SJ9"A/B J#>=RI(A
M.R-9TFKFBZIK=<XUD=8!AV478!87\QOQ R_>0L@8R5VL:V@O.VX-U7WE].:T
MVF#SS),&8UCBM?',Y*;#0PZ20>MSAWMFK,/1NNQII_):7\1M#20))<Q5*!-;
MO6$0KI:085IQ+-#3+<PMR7,GRAQC98K/;IANNC;;/2&&*73$=[KK_,71D**@
MZJ[= **$W ^$!Z<5HZ6Y3?2(46/@>5B4K\?-.>=[Y1K'.-,$ZVREQE]<H4D<
M]9WM:"CGP )Y]<V%"KML97<GF,/Y,#&@3 3#9'G1H^Z6AU^4]6N;-\5>&B<>
M-T/P"([;BR[IU7>/VT?P!TK0) R+S^E&/U/L'AV QXPYA9/[R?)2A-!T/&1F
M5&F=BR-JUNUHB0SGWR ;,%-5M/7/+M2]8SX=LZ2 S^=OPKVMFAIG='N>UC4&
MP2DKX: R!;U&4S<Y(PD]US@W=<DHH>8%7 -=*$_I>D\T0O_2P]Z-8JV!RTR3
M-NC.QI#R]M*343Y%GFF]8QMBF,&:?D*7?'.>7,J)F M"G%)I:7<O9:P?4N '
MR9Q;O.HV45H9.9WJ^M Q&"HL55'T.AI^-DCQV6/1]9WP(>][5A-B:,<WB;W6
M\H^IWS:DP =RO.\L!D$TXLSHSE$L[^9F3E*>&"O/ 23P%>'!69U$Q$Y-[AT=
MS7QY#=6^<\-4B#%-]M(H9G%SOY([%%'B-:WOC0*($JN,>97'+I:,T;26W6R&
M']-^<.7AF9&PUITW]Z/.YTXI*KD42-@)G>:[_5J4ZU9J\GW$ZK;;AO @T7;'
M2G/(H^0O6JO/R'G)1O_+;9N\X])MEB'CM>(,KGU#3&ZF7%&OJB7]*]+&11,T
M7_I.6=#H%Z3=O>(4?"1R#)DLYI*J\O8H.=/$O67.]PU.@+M*Z[&6E\\_FII7
M'WN?;PI:_?327,,8WL-KJO6YZ_"Y@9%W.KGSD<MV;TRCPR]Q#J9GIT<C9J52
M/GYD4FE<9_*?JYY%K:F8#VA-O/)/[]-7T42G>L90!QBQ:E_P:RG"KX+T@P=.
M<P>[/R48336Q=;3(4VA4>>D3=?DD<,QHNH=<_9*&_Q*C#8$3AHF^.>Q5%L>U
MXS8?E,+>/2D_3J! :7]/RKU:5:#M8C1H8XR405I5*&*E=>VM7%%-R74%VR1!
MCW/F1P$X&Q9(8KA2SEE?-_U8^"&!&&&+'%=\ 'OD6.1<Y:JVL_5<L:?[$.5S
M[P]Z%[2?OH M\6JHM5P<K+U',+D=V3@Z*@$=.84<?LR=O1%UL63.L%VW,N%V
M:5:X8<&2_G/?SPHR[W?BDI\EY>:0)[^1I-EP)"9S3PJZ&?'%'A(MT[]#[+P:
M0:B8ZS7G&L2!4.N$77L\6&'(<H/L:%[+_ DWZAIM[YET<UD%7_G;YHM$UB\T
M'F^EN)2-V%X+U9K[F)8H?FCDN6PPH]S.8^L=IS>;=F\QFJE%T? 1IF/V]R1K
MM:H])RMJH]JF&&F9\W,+0VSNV@7F=WCICU_?$,O;\&NK63WJQ^<$?B&!S&^5
ML610NP7^ K5$<Y1LON/4H)P9E1-XNS8QL#*&+E;3,#&Z)B@9-"QM'O+6BSH8
MX^#W\#H_ICTRFGM _<*7RP\?+MUHA+-&(:7&B\6J9X=CL8!:E/Q-[S2,IG1O
M&E^)<Z&71I""I,HVP!%#_YGE,^U]*UY7V9%,[].U_+#!T^VZK2^G-X[;9JS;
M ,W\FJ7C4T8)[[(X884F( D- X)C!D2/VBJ>2Q@\<TQW:G17L;KK-V=TTSBW
M\&4#8[>,<I^Y\*YK9A=,"1E%V'OK(KH9Z6C7O-M45Z%R.; #1@T1JTZ-GPRX
MWDR 9.SN.HL?E6F<$0#QI\H?-:NHSU@ER3C&!PY^6'NZI"0L:UAB/'+QPG0O
M7I&B\X>/D7WWM 3UFR\="V)GSY@+$. 9[])DA&3AW0ZR.49;Z'3=7;I,D!2M
M_;DB=GF%)NH&\86VX)#G?4Z@ZGE51<+*HALWU8:TQ CBEQAR&(.OSHT;>+^Y
M'Z_%L?E4_LVX4<VQ,M4WDE?RQ@*'+JG"'UV.\GUJYY=W-NXZQ:!%<829S)$G
M3MX<]_G7#>EVOI2:2VXR(:W.KIDMOCZ9$;)-/@6NN/:E!WXLW$WD5<WZ1ZYF
M?=NH.LV+NH*N@4+96(#RDOG<.H.['0_^O8LNB&X5+=8Y_%,%M(S!&.3=Y_<N
M#7PBT#%L)2[,>7C_H5EV79>C:_^#-?(VSF5R\%U&$,@_TCU=T1<:JL8TUV^Q
M?TLWI!:=KU9 42#<\$KW(<.ZHCIY_S232(,P>FGAD@464"RIOG\"3)*2D@([
M5J!<T*:G(@PA85YXMI7LD_&E2FFHSR!_/F1#RFW@T.7Z_E.W)L=LHF<S/]JW
MGG>-CB'2A*\L<G66R-WEGG!\.!^"$19[DKVEH<88]W1:-M)71N[DYK0WI>%@
M+?5<4<#L.!8XDK%F].:+PPD?7TB"4NMDAD@#Q( <;]IUW?=YO[B'!K/8Q4NR
MS4<N<G1*Q7VANL#D964BJK]B<+1=4OS$J.?@I",E<']#(%04_^A$&^'C]N$9
MH3:UD6%;HMWGR9_DSM;&J/C>G7(0?JMQ:G'DL1\6Z/0X.:KU_GK9[BT,U,E
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M@P?1-5=.X<$@)!Q#K[FB!/:-<)^] MLUB)[PT,H:<>.28/#BB<*=.*&NKB%
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MLFL!-XE_1F_<!I'><4(X>9ZSU8_^]G8($<>6/APA.X6&<%0L:2'_P69@<MK
M!?_:<S>2,6,]9\2YEF-D&_,A!&EJ&$VIBW:G9IDN=2PPH>C-F ?0*KE3D36
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M$<6X:>$#L[:VE@$$'Z]!HY6&]NUT9\_@A/P'D2!ZX^L':4W-O&,Q,1&C_;(
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MWO]8-#KBA4*E3'F'\HZ*CIZJ+,79.E6W3O,EY$"2%>DMI88*/W7$I4\M7N]
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M->YT=9F;G9^;'6>K'_)^JT!;R]?\*4[, S; :A%D+++N""2.3'_,0\7AD_=
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MELO[J>#&5)(FT6V4;-^]!&G+]\SB2)6/SD('AEC;M2B(S9^3Q:/3SK"_-)_
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M6NP<93>(S<P>=SJ,R.MJ*AC31;ZH:2IT1\.;(AR!N:(?A!]&7H:N0P@HV3X
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M_OV0A"MI<[&)ZT2ZY#,@9OPG5]7B4(?5=!&K.4RG22H3-O[C >0K^Q?!^)A
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M+OA;7=R.-*D'4J,N?'J+*!%245!_'(&SY,]E5?7;G-.J\DI'ES527]X@-^K
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M!25%X,PW]_P)8X?XK=YW$EM1+[P8(%4N)@Z='$-QS8RPW-2"I,(""_0"!@J
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MO,2-!5^L5*1K]'*X1;Q$LN8.U;,L,ZHJ,)DH)R176$ 5]&<C<E.OT(RDK=7
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M4N@$2NE':]*CJ7L;8U>]Q8@Y7Z<^]<L3NOTV"?"?'4VNLDCYF)M['FC^4L]
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M"+8I:E83Z=YITB)HT?ND::@74FN<]<4R[]4&*Y9+TINF.8/R9T!@59OO_Q>
MRVB0SX\/TS3/@$W:SEX\X "/9EA.=\^=7W;)N ?R6"5:U#A?)JOP<.M;7W"T
M@1)X5-E F3QZU#JK.MDBETXP[1E0MR9_2R.(5+G4=S4&KRURGC"U=@(Z^.C7
MO?P,*-'(8O?Y&QP3W<ZR]P=OK\'5D="H5?V;6/*L57#90J10?06[T-,ZXKVM
M4LO'?J;>MZ^K&X9W=<,PV>6):&:&ZUF. 0FG,/":+P)BV*<]^@.ODJWQ4>M6
MT\:K4G[." ^/7$)[NUJPA7I5=Y!MZ<Y=,%0^V-Z@_%HK-%)8ZKA8$KHV%MEC
MO=ROF?!H>RJZ4U_/FP'LKP:KE;:<%I+6OTYXMBJ(3KV $/8CTG>LUFI0%@7G
MX(A;U1N-\."KVS//\UJH0UC?X?$M!+-Q'CBMUHJI[G"?T.$6\+5SZ*MSB/EO
M!MO:6-P4&Y@4#IT!$]0R[]_RJ!VPI>LYA.,&V-:]H\ZG3W\&L $EU3)WBQ![
M'NO!NNGMQYPR'D#BKI3T2BWZY)-AP\P&TR$W+5DRASU41'//M-SU@H&[3_B5
M\)0LO0H-HO8YC<=EGRMLY41$^!:DWN,5G,.Z4<@<*[P]<0:%YR=]'MMI23'U
M).7"^!ZD-VLK+S"*JFST0)NZ[M:R,(M$O>+DZD'WX1A!5U14YVPD<Z9?UM)9
M.]PT(7Z9W\<C54?H=8"F<-)K=<L$I%&VQIP5>7/OX/CI[P"L8Q5G&HD'0LQM
M2W( O]+ ->*/];N'\KI_&DOY@I1P"+=*O?#,C,>AZ[MX<#66OO$<7IJ5<A^8
M5QJ-RB/[_<,C[OW,0<( 46D,ZG88C7F_NAA*L9N-6B1Q]FL1!>W]!K0I(AV6
M_.XERG46[OA- _=*5V1] PY9V0/W#9A)$Z=)8O_]_#$6!+0>[%$*'C3V:1AZ
M7[,>*7#[IOODQ;#6Q/YGJ];5JO&XA9$3*\C >W?_]T\JKA;QF\*#(-^*LX(R
MYWPJ)2V\H>O]!6^+1S,PQ:#^,T 2K-RD1:B;%<"L&#F8>?TCM17;")%H6O)V
ML%"H8?89X%O5V<8HE!=S'B'C RI^!L 80%+8,VUNIK?EZ)1E',2UAD:5KI8L
M4YTH+JG,W6UA/W:AWQ566"@+"'<M\61!P^P<4@L]@#:Y8:L$]\"U:+$]P6<
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MH+]'IK]5++F#23;B""H59<)H[$I1K.,GAE=3@GE4QOS2H;6H]$QHT?';&OK
M"4FNE(2NEBQ^C-FN(<.P.%%\46U\@+4.PA9@K5--6+_O^P<"25UKEYXB56%Q
M+AO!0)CN.7[/Z#<"!>SGHPX\YA4P^?1UN&XX!<*35;QL43?SK-HL6->#DFI?
MR;^IO6ZLB?=6-F3@#<PJB$&":#-HK+&8A =O8CHG/VB\:=@#;.CMN"O,2*N4
MR]Q9%[7KT)XW;E\4E$7VTVE=]QQD[;(TF',2[[? ^<MF+>+MXN:3TJWW0>+Z
M/,O<ZJVE!%&A/B,M#S-U.D=GD#)96PAVM[@LOG$X2Y-Z_@PX1UNWY'>',T#F
M[S+*\!&;XQP&[RN6!2WS'XH>,7Z[&?970WUZD[SI Y&U:U.1U!2G@;\:;HYU
M(@J%E\I#0^];,C959N?D9.>HQ/?%3ZF'8B"2S-C;O9G1P!Z86!;G!'^Z,ZN-
M]#:+<;A"]'QQFGO AOREO,"_#A95#T/Q%7&RU-1!9CN\][A="0#%%Y<XLE:+
M(?GM29I%7GA<DBIOD1'14T'TQN[Q$G;E,P!Q^TSDZL=Z_*8N,>XK2K_"+2_Z
M^D>U:^(*HT?8(/O'\^S)D/.Y1M0QB$8/\FJ.WR KKWH&$]((<71NW>H1W6EY
MR3%9>!VT^X8-M3K1+W8L^ST7ZN@GRS1VQ6AS3JD-#KU%E%Z_/;)$)DO_6E"7
MELZDH\O LE'3[$)":E(<RI+/^M[']7C?V?:?NH*PV>%^T<FG[FZ0&9'-Q$/I
M5(<;A,.FN1:6M<Y7Q\396@79+POB2?7QLZ=DT0+?B6&D,O:_P^M9:&4GYVEP
M/@MM1FG,1%CT.F2[*RWTK?NOV*;*KG3P=8<.37IT1WG9D+5#P7C-QQ*]LWJR
MQ5B5T+]"8_EB'<[09P/81\/I74("\OKL<&2=0H>K$CXB=0]GKSW)ZW\X_EC0
MLGKXN?G]2+CTBC:YXMIMUE:UZO3L)#^;O")F?(]TU*4A1=KET#73&AQ1$#PF
M]@,U]5&>#?L4LR2F[=J 7RSLA0Z7)Q^H35/WE#$1?5YM=6\;9$!IX>\]\1WE
M>K(=21N=1^E"3)C0HF[UK*<\@H:LF$.5-\^5BW\O;G5M!QP/*;<\/BTU*ZKT
MIPT'Z99]+S3TT..'(PQD6D?79+Y]V:L%KKS1T*7 (I3].J&UB]=%N/6F >W]
M$*U@]HE9:[]QU^WCNJ9/N6&.YD=X>?R [*]'RW=[FKI\*5L@8A=5*WTXB<+*
MN=?)J(:;"![7PNF\;L>@O&*_EEJQK@&_(80NG+,:F'WMW^*NHE#T"V%4_4=Q
MX6_Z5[062;]E L2Z_UP"1:$8\+PW^?Q$'BUJ>G9+WM%%+8XH]4*ZVO< A-TM
M&! JFB'!+\_R2.C2I?R:V+]G2:8_B*PD!KA*G!OMBBA#.ME)9CC)=DSK_&MH
MAMF7%4XI+I%VAT0C;)+TX U-G 0JN3X=$FGXW*5H%*7SIKL5^YU[JC0(1(/&
MN#%2:905L>30@HLH9=\,*)@,U.L)$%<K#2SEFSJP5$3Y<E1:#@&X .B2NA6<
MHRXSVPZ?\\.13@/23THSLAV3S^"^E> /1-J[[.P+>$VB3<\MR+D4)#TL-S^
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M<RJ$ '_YV^4'-)6HWINOO>]U"5%F7EP[60K"'(E4_A_VWCHNKFQ;%RV"!ZA
M<'=)D. ."<'='1*@<'</$ @2@A,**-RA@$(+=W>74+B[)$$#)"^]N_?M[G//
M?7?OWN^<=W[GWG^JQEJUJM:H,=><<XPYOV\,Z_^F__Z_BG(ZVW_C36@,?E7^
M98S(=4Q^FLI^@>W19AD\A14A]*C3<L&UQ*(IM;Q^[#("@1PDXNFT%*H7_U]$
M^__2IOWGE8LS_NV]D/%^Y>_8RM(W%9EZ-MU[EI9E.=VB?7[ T2$Y8]OJF[J
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M?;]8>&=#Q5AG.-MU  =PV"XOQ['8E//E7&.'=P_V^$ICW;OG,;4Y61GZ9[[
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MT9.03W6=BJ[<C3PKI^6#8E5DTL<FJEJA=YF47Y6.;C#CNY]UNB^^+R'Z!IO
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M8:>9;_03D_,8K5B$@"E9RT0"G2FDH\_R8.GS\S5BL6&X<C;GCQ^]T"ESR/O
MQ%6<!SDXN%Y6I$8E*2AQ5\89%\MVTB9!MO-[PNSW%5B_?ED5%,A?\W7Q..E3
MG L.RB)=U3Z^'-A7R)8A-Q><*2CU)94"K33FZZ$.:R%J3TH:GL[H>Q=I9;ZW
M%4,)JS9^V1R.AML!7SQ/$/RN+*,$@?:^FK?*SZ\?'J&[ KD")LF=CR%UNV]=
M4 \6/ NB9W'6;9?9-(EJ,V1KCVBN5?QFVJBG^*0=@\=XH6]S&S\F-(XX#7)7
MC9D(>6,"MM=8QY*K\JMXUY98J9W,FFL=0ZOJMZ;ZUA,+XK[8,\1D&>V0=!!X
M9A!+AC#'3TU#9*='65:,F:K<PE<V9)>"@2'29SH+)@WSRR=CO:Z:[P5GX5,A
M!#%D"UQ!80</5)2'7;,F+Y]LLI--OJ[@X1?H5F5V5#H.,6 6J@@L!N-?0<_Q
M]_DC)Q8)=!2-+O#Z.Z1]^7*J;(, \9,6%>7@*;21&8*Y;T(E^\[2[*8GK[$E
M%_42RJ(:K**VU@)W:,>=R<-&)@QJ?7!46%J48V!&O.ZS>"GVYTX,S@2W43 J
MT52K9I,!R[+K*V!W9*4'8E#$0-H("%)L3]JT,[X21+YZ&F6@4.: V]P;XK@\
MB-&@HUO97]$9N[O&!^_F7LP*<53,4].6,)9&-::(!F=Z\NMM.>[61G7N#:*2
M2P@&&WZ/*5]NV!5N"Q%^F'"BV_?3&=]9UI[0I9C .%:2S1^V%CLBWF>T/D/?
M!8_?Z(+^E0P1.]&/]FZQ-[$NXYZZ$%;J**->>LILLBY IZX>BTP1ZV1/S"'E
M)+YB$U"XLK^OR6+9<XO0L1<(+;MV-(P"VW(IW49+0$MH3[PP:4>2O7JV6TX^
M%4X$:)U)J^+3!3-)XZ,I@\C(YF(!R*Z;'Y]?Y%?\  37WRD;9Y^H5:W[27D7
M7+^O#7I%_<BN*<]X43_3QW8WF?DMRN22+K!3P-:?L%#4PK)'0U;JF1MW6UBA
ME6T_R\#.Q&:-6-&IS3G'YD#V9QF"J@V(CN8&N3:?O[U039CEW+<(A+":]*:2
MEV7WI7#D6T-5;8-+(@WU3AI_.'=\HMY<U"!#?'TBG]*1)K>(S&/2A1*NAAF[
M>C:XBL,(:P#)9 !.-Y\9;-BD(+CXL2$//-^/Y[/B(/V)9@H(:' VVGK.K_!J
MML ?ECHR[_;5KTU]M.<CQ>*#P#E\.6K+_!\ @/';7Z)!L78<@V(7U*X;13GZ
MQGEX5'&:<?\['%(!4R'L\* G"3PH-)O+L8&MFZ?7=S\ >W"N<BVBS$$E^M=N
M$&&#)PX\FM4^*J78J8,KAY2IQY2T'J)B8<=Z/A>G-5,/O72UA*%Y[6[P+<\K
M!^9G:I]:-J+8+7JU'L3B+MH<[B,\( LR<UD8]-:W<4[JQBRL10EDP@B#]R"D
M<7,-^(FUT)8<NLG"-0=/J&/MM8#*I[EP/+DADF<M.,:$6B<S,1IH<^B4J5?]
M"Q<<:2'.'.2=92FFI4J\'"E(] BCW98'KJAC#-MPAPU_=O->WJC"'ITFNW=L
MPB/X MS=>R+]2\$BQ*!F#JJ:41V[)P<'U4.9,9B2V\5Q)R"RI4&&[<$JMY->
M:+B [#P4^KE#U-B6(470HMC#P#@KA!WZ-8S7.,2YU\W.ONZA'BO)QH[2QCY5
ME[_&ANOMQQ6R;ITR/GE-98M\@@DME8-4<MBNG=SI1[\-KRU^FK+/X!B7"RZ(
M39F &IIL'3)*V0I_N/D.S,&K?H&S#7P6+1Y=FD$H;:%2/K0H+02F0K[)O-R1
M="7]&=SNUQ\_-K$[5CS@T'.,GF[9V:>;>]=PK9)#6F+/_-9Y[O&<H.>HO#1]
M6&F!G6(^?<>KH^7K[&J<0Y;_+S+8;*;\C/!]A?X6X3>3+N64GLU"V_$,3^'N
MZ8Q3*_/5$ <O')D6W/4X(8I.D2[,N-I3WM9F*UC^2 P5>F_*#X!/?B!T"<.+
M9ILR2MNX*N?6W**@HA#L30&\ZWEWO*^CR)]0V3IV^MI60+#XA-?C49&'F.D:
MQ9=IL/W<L!ZUS*SF)(_ANZJ39YT>0!S["PH7)U)S2H)F*O1PK2#QC0KO/&33
M,JV=Y[CZUH?F)K35<B.9Z%.DU+WH4:HQG,O!DV(.8\=2M" 5]3J=QBF*-D4#
MH'G22"V7 :]3#GB92XK0?696%UUE0$K%+SOFY<12!X)\)?G-]R3/JKV0!_JV
M^NH28<4]1\(C[KU?;;,PYAE89ZJXK;,H1NSC&\QW&BPQS@APZ\I>ASO..$#K
M7QW/X@HZ64AZ^F*,<[Y!M]U"6#9,@HPTWW'VD10[>,R!=X80[_>-J)[062,4
MPSH\0\ ^1U2XL'HQ;.OOVT*0(NPI_I<;7SL:/S]0F:Z*0=*O;,.O7+=^340-
MUYC@ETP;41H<OVCVN9U0=B3W!&HTAE:U3W$(;,IO!KJ1^+H. 63L85"4<!51
M=LN=;VY"L$37O+!U"759#2J3C#"!,-%*<$8X\P.,V^1MZSH-_>./<[?VV$6Y
MA5&R!,I+<[&Q%3X2XPX)_,M%I5>DHC(<_!#0BQM^WHBE=7HR50YS$=I!N!5N
M:](WM\Z1^M9J1:?<<G!#C6.^!B\_?T,LUF60/VEI(4O7I;^FS)#A?=O3 9!G
MB^\-?++9T\&9)F0?U;OKD\IPJ F$%0?YB=387-*W,;\M<6*QGH;[;?3G1ZEQ
M[<B+>Z2KPNONA44SU$^Z#46#MI>(#4*C8YBJLABSD0ZPXC;!4::%_D],"]T8
M"KNWEDLO[=#:.>ELSB@N?WH]2&CJ?ZUF@M0+HYIJMUN*EGO!YZ.V![:L^*:W
MCLPUH[9MFIZSV(B"SX>-J>#TOKDXKZ 0L_ZO[.U'GW\ WK%/-P8X2PW0Q;"D
ME5(X8%N? ?B?3:)3=!P?4PT<!2JX_0#8YQ:4VHCPH\'S'[7 ^AK1XB^<P4EG
M;=QQ86HZM0MVQLF#\Z=Y+J(A>D[G'*TM-)MOHL?P$"XURYG*/7Q6)N.]NA3L
M^2WL$2&+BA[!D*H8-_/\4B]D'@P&!U"U:.K164F+0%BYGJ/PG+X-*H_=4VI=
MP4=N\&VO(2]_%<.PSBH9,P?*=5%E#5LG\,.GT,3*$0.]KX=N<HPH*DDN;=0U
M:Z7%Q; ":&9NQEFW+$&T?V)K1]#$9.HVPO53G3NS=5G57OVCB27(WL&BBKF_
MX\JH%W%8EAP0F?$4Q[H"=1W: #VZ#@"3%6>44XQS)!V)X[Y2D39^(3'.F^A1
MWC@_;5+&IV':M$3:I3/37SLQY>AV#_0:=,K?@=<F.61WI\ABUT$^2H)JC?>V
MB^UD_0C875!/SH(VIK0W%L./ZPY;^_;EE<B=&X@@D'#!QBG;* A_8ARR,RDJ
MK;8JCC%O[047MS6C#6C3>Q1FLX*QC<&",&LT7,UC;5$!DZXZ%Q&<N\#74@M\
M'G!V#GE$B(@^7);95=/+]= _W=_OC-O=J.<YTU[DCSJ+SCRD[ L>Q'JZX5G+
MX;=*;RI.@M@P&+]YH8YP[WE6N?<=]O3%[A(LW]!ZTW%>6-[-<5QMY)SFW9'N
MV\F]0M(E *$''+]FB@\>P,Y:P4*!:6))TJ63QNO;?N1^%+W=G'[7O"%FQ7-5
MLO7/YS.APQ&91?%2E'9 Z8F YOAST,<)X@:P)EV*O2:7M2KK%#!#&(Y1%[]Y
MCO(U'D+WQ9#>;84_8R7V%_^W<%.98OW.6!O'H0^SY,09.Z<B[V.WB"CEV6IR
M 0J,MY=_B3$<>C)O&[$9AO9XCMC<(D!6._HLP?.I*@A,#:LV$7H*^RQ,=MMK
MGDQ*[SPX\FA8B[K!ZJK\@TK8V;V8@YCQ >PTPJK(LU;406<_I3OS;'19"/:1
MGV9HTXVW>T%3Z>K(_MICU%0D72KMQ5EZ\%&XBU&(<K670"2G#J^=:W!DY<3<
MX$8WY^R<:"I.*RU*ECEC).PJS[:$W478+K3.^G ]NGRDI<\S2"#S/+&FHYP$
MG5#-;(E+PCT;PFWQOH57XJ:)E/LT9;T%UVVE3)DF2&;",YA8H-7:Z]&<D2T'
M460:C+JLV,7]%*XMC#8D/[*SG)?'@"<6[S5&C,6#L?#!MN)J,*\H!L*3MD#E
MTR0+E#D:YED_)YP^NX?7?:!L6R0/29-5I4#JL,@LE72[_:*]1)[GAT;8H.B:
M%UD(.V7U8&C05=DO<O.TGQ,)&Y-V'41%EQ> #D*+*\,H78C]&IPA.6G*.!R[
M(ZY+GENKF!<L1@X@N.F! ^6G!9+(7M2%>' <WVN:&$FJ=EK&6S>10=WTYZ$E
M]E<?>C\IBRGW[=*XUZA(L($"E.R1W="6,X3*1^1-Z\T4E>H6>WELGYC3(HHX
M#=9KA?(=@.C6M*@BJNQ6YVZZ#.:1UP=/LJ1 U'/.=SQ\'D(_'P57R[*4E?S)
M-=9[Q3#'L$5U)MF/$>E:TLVR6L[+3UAA]7ZS^S,:F#9T#=K.\5V?4X #2&7K
M \:I#YFK'QX=&*$=\G$L@FDR18Q9D88%Y-;+WA@TGK\CIXR9R4V4U#/C5'V#
MO+WX_3S6ZQLL*H]S%BK"&+QL%X1$22E"X_@*+>CYI'SV[ZM%M$L17C1_@);F
M_)YV-]?DSPE\4O<-Y>EQ!E'#@=5D=[H&'G1%[D'\&?D!<Y(-2.WTR2_'HCAG
M$S$T575=VM27N2CM&A06HZ9Y6WM^ .CEA<(>]6?CC,CF4N"_?\8G8#B;6&=W
M(.=>#7EO6/8"8 \$V"/)!KYH$EQ=6AL__CDR[TI,L1P^L4..9E3B"3MB8@ZW
M.!RTIQR"!SN+4W=R:DN&.6Q$"A>A#Z%4!%0!WGYY/^RCHT7AT7Y$^?&=X./%
MI""A_)/1!/,7MRG-C[<,;-Y]XN+'[8]>0"TL@K-6.UK!=TZQ6B5YKAH]4LS-
MJ[CUTBG)$13SO#L8(I% Z3^0XS0,=*:$JK2ZPRH'@TN)=*-R02LH[N4B6W$9
M(9;FR#\ .\>VW3JEVAO['MGY>+I&2_.SP[#-+J*HL"Y7:D^%F@A>L6 N5$3A
MME?UPTA$N)TB;4EJ4[_GVMH#' >2]44B8'YF(?2KK',/X>Z[B@9%$<4M'X0!
MIE!8R.!0$PZ[!1^(XD APLKZDY(J$#G'S6D/7Q;9DX+Z;ND'X&:V'LVD%(A=
M4%S4[4Y9A'TZ'Y^KVZ[?89'EKX"#PVAFF\;>]!"+G%2<H>DY_/A\Z\3KJ\+I
M%0F/R]9"\M.WO8**$>[, 76&/4G:XP7^%YI(]Q9:1<P*7X<4JT5$25%]!0,0
M=S*+7_<E3\I"X*DBZ9LE5#YQ$RJ2/"UO4S7R+;G%\PE37 C?K9EZ'D/5+8_%
M_$="=#5UM[[=<)\=&9"1Y$%S)L.H@YL$^CD+@3.!0W;&:9!'2R^'SPU#J-WY
M3BLU23]<:W3MGC'>[)9W6I5D%6D[[9,_EG['J8PX_X)<8LK$=/V%,LKZ!R#E
M'0%'_[)MZ5P"1XSC4.E=&:CCTV5E>K5H^Q-//JD),%4B<.]@&M7P!:S$M*SD
MU%64(5PO6)0&5WS;[Z^G;_DGDD+^LU2M7\D*:*5[3QA@D74*<I3Z^(KT&9,A
M]&1>0<=K%$.(/V9WQ+6=5M/0F)G1TM3HQ+Y (2V(X9Q7D-G8X,]J=?CS_7%8
M_T06(GH6R#O[YD&-^4UN[$':F93CO\V9[45',U>1D]\P#?$+92-4>XP9X]V-
MD$, 9<WN$1,3R"\ S^3^?BVZZVQ)=D$I&-.VQ 2B1UF!OQ4EV'>*);_T1M$&
MUX0M]\]$1'O%VX>JM0)K6MU>+/Z_RW0>_W,^<B$"CV^CDH&U6HL<YZ/%.26.
M^?&"\2D7T2N5^>IH\.I(<@]4,4(6YZ*BZ"H9BHT-LLDXE(PBJZ<+?Z>"?V0?
MQD; O X==MJ2PQH,)9NU3_RJ(YI]<,;9[AF>Y+_XRU#Z<%>Z1UW5X(<(FR>'
M-)&YF1*)&TEOCYS/0RHKG"4I\&0)N*H%4R;FJD)H)@0 :&OM?^#AV>E,3,WW
MT%<4!!?R-XB50SC/* 0H8OQD0^USL9'BEQ.&_OS@_ Z$8OF=P<GT\.](*%3>
M'.>QVU_04?\)C^7_>U+W@C^GBN@]_!ON>?A7W'/$\G\G;H3FWW!IT+HP(TKV
M0)M!?/U%X/CK -N9OR/5)/77G$0O!#9GTG%V,POO?#\.T>(N_2HFOFWY.K,:
MJY$J14?^F^@LD.F;]OE D^6=Y&^B"MK7<<T ,04+W C'7T7YCA6? Z?^$J5<
M/)S?1$'R<3'EZXLG'U_2-OPJ,B/[[):T4Q5P1T@)_"KF_Z9'H3I&V/]9*F&;
MMFP%5OSRJX[4,3L'Q)ZUE7#([K:W*U6HW1^?\I=O!/^O\?Y5E>Y_50FV3->,
M]486BT\H5K<-6?3+GJ*YKI7A?I3F"_JU12C0K_KBB>&?)B'<:([_CN;XSU0)
M:_SYKRH]31XX,2/!_M(AB\WGX;8:?_Z$ ^W+BR%?^[;O^7_8X,4_H/[O9X3_
M?U0";M$5:5..O+)!W@H)HT7D.RZ]>:CZV]=^WQ>4Y/J_EOL754+RV=W_FTK2
M 7W,Q$V?M7:$C=53'8\[]0A^KX^%_=^"+LKSCQ?-^?>7G/ZW17/^4<SRKW#I
M_^$'O8?\VU_[!SS3W[RADGPI:9,X)(:M!^'=*9#1B%[%,B\RWTF5[\!7F-\0
ML'-H73H7;TH@JJ*R$^K\A^[>NM#H%?/$UO$3E*Q7BNGK=\^I0EV^4S#NOJ\X
MCZJ;DU.I)"Q'S']#CAEOR?Y&2_2@P.@\UKQVPR\#LG<UY?(&%P:!*C6POUR;
MF(P?:>9I9B_F&&B4^F9;+_U]:HDG\K7-L&%];T,$W-\AGR+I"G/#4(>M1MJC
M4H<;%BD)I9J0L N[C/,,YB''5:8KVC2F,[VCU5:5=<_T<>2C%[0NH76?EN,9
MYIQL3O9Y6.V^8)WWT4L2U..I("#*E>11BUJ%/YB*$C\14DIW9U,84Y@IM+]E
M7SDP<2D6SKGF&?R(Y6E:E'NJ:3>QW#'WY7;75WK%- FGH%$64DL>9)/Q*3<)
M;^E1^R;3*JVE)WO/W'7M1?0U/$P=YE*Z%A[1 $>B[NUR9L<0MO)%WHQ5E2UO
MVVEX)&YS=PB:K+L]B S?F*LM6997/!;&<A"EX%.$](,/B6KCD-A7%*[,I@DC
MFSXKVS1/+I<1DR66HG@I@'#C=N.0.N)3S[/W(QIWZ*;@X 57:)TARTG]81+'
MX!I<([6!/E-?:!$@'GJ[ULJBYR*V<!E67;W@"_)8EG!^UTU+:NGAN>6Z+V':
MEY*0C&D*/5SN>OK>IH2,XE*S1G^7&S#@.[[4KL3\IK"GP3?LLS3!9\W9/@80
MLV4I0A2%B;U5<_U(P*59I^>FY*=-JV4Z,)W).]#-+L)/":ZBA"2\0F'!8&A&
M$LYC<RRRG9!Z]C0>B:<?DF?W<WMNH'3==8L[M.[ V?C+(69Y<A6KF_> DZU/
MA9PJB6QZL$.^0K2YB5>F5IB,J/YHI)+^- [H1;S$[_Y7O13]#ST<E?N/A(_W
M,T-_#!,P(92_5&^]]VS:6)2)=6XU++;CX"*#?-OK#U16XKD13XP_/SG+/BB$
MI:MVI&ZLUY_Y;AKF! PGX@!,0+(E[(SN206-9+LZ@]W$W@N[I5G+"?.3&1O'
MH>=O]?/*)'6^7=,7'C=+^R]:@"DNJW8_1K<-;@VBFTHV\JAY'YPOB814Z'I9
M9% R)-12Z:)EJ%^EAZ^$\!NIVK6L.,X-NY] H'.7_=KWAB%Z&SRS0'HZ?R'*
M2/LX@3ABH0E4L*+,AV-5*/#X-LCCC>:2F]LJ[1Q*%A!6?)LD7:5MDTQJG UN
M*TQ[L%!XK(G#,^((*Z9FU>]V+!YYL^":H.:Y][3D@*_YE7?!K!"E;+BY/SKC
M+<=S[PD5RL*\-SHX'@Z15RK8'V=QM0=V4M$FJ"A4',8#7A$^SUFRTH^LK+WS
M(Z?M(1K,DG<.#:'MXKW+%N*ACF!YEC C@96R4!@C('I0*]1!3 TXJYCGZZMU
M""F[WGW8_[XJFIZCWJXFBW4K_F0(S0YW8!-PE?T(;>DKHLR OJRXL* '+(P(
M'U4U:6B+@=@8&7U5A5)U7%%NH5MD9=.TCXJJA:46F)N.X3@V!XUD=/CJE'_9
M5[:HU5XJ7;J<TNBS2!HQ]<$A'Y.T,;K"YD.\Z&/&G[$=#&-W=.?7P:O.?9W(
M*(_NC4)4?RHRKYS /]#/+0,_<AX<=1[!]>&6*+5HG'KEH)7,:C^:&0-E&B8(
MN8'(@&8/M@Q+XZP?^CAX?.I'&[M;,&W(G$4YQE50A#S_.2#N_ M9%JDL_$#O
M3WUP["1<F.-0);\GG]$P4"A*9OI8E%546+MA&2&AF$ML&[VN%@'J6_,J>I=D
MURR60,FN/2S"DJ*<QV2^O(4 A[&CP?SRI$!0AYO<DL12NV2CC=YWR^Q;T<!U
M+/<3"=W^Z[%8U,4GMJ5/#I[NE$(M&,7X.-'DS3W7D.@M>V_,<.A,C<1</5 /
MOBK+&LS!Q\)DO3KP4D8U.50%DZNY@Q=9[/8JE^&S3?F!B\.)$K=O;6Z3%2NZ
MZ^RB)8H;#-@O-./C$WPMQ7J\>>AYJ<&D/751JI+L%F%M9 CK+:XFN1@308#K
M'NT+;1L0BOJLLJIF1'$>A!@L5K!H(#$0JGED%1V/<(GZ)5=&2EA!N=T+I&RT
M(, 91Q('0?>TW U3)>(U_:!;^H'@H(O(((.3A)&P28=/X..)V)NDJ; V2-,R
MZANVD808ZY[)H4>^.W@I0M?<1E2;YK7[LF0N_%1PP_U*C\(7CMKGM9,]WU+[
MS"7)@\:U[$=B'Y6*C*6DV/S\<%AF&K6I:5/>OGBM>068.H[C3(44AW-!0*3X
M2JB;6+'[&'Q[W)0+;[]T&9LN\\=97'VS4/J,;A>BW<W_>J_O:&"O9!^U+OZ"
MURDT.JJ;S8'#U ;9<D+,IV+E!R *RIZ"-FVLJH)(E_8()E)7_PI_S$O1BD.:
MH!I$ _\EU9^7[Z(QGY;KO#H<ELF4/F*ZRFS8"7G?+]@7B];M4-+4J7;P=*AP
M2M@[B/WMV+CV^,A=1KCU4DW>'><2EQG7*&WFOMY77><2D9UBS_GF";0U4<"S
M807O #;EH&?@1AE+!2OQYU)19"/B$QCL(-^A FO+[W>*>88X0YKI8T&2M/0V
M_E9JF> DC[]"N&(3.@8I9J[-1><GQF&-3'&39#' L*-#],=$@K#>F3:+R4!@
M E@KS,706$S-&7$LBZ9,27PK.Q49>3F$V_5N,WO.LLT!;;%EJ^CDT/)"56?W
MV6OH)DG(RW,=8>9E7BL^"_"]'':\S%#X(*&,H;< ?&LW4S+)^%PU2C^F4IMP
M3X8N8Z%7G62<26$Y!EE<17V/%K539D-DNQVX (751X*GU:;K#>0IZ]D;D>)6
MY+<T%.-L"O(>;XP0!]>X1,(JYV=K*8TV0O.WLXJ<7DC,EL^ZZ*I-:T\?GO'T
M+9#"IJ:AZRDCE'F^]\S%81F0"WQ9?/]GSM9WVJ\52. IU,A+3I;\PVPXV,',
MELC;+H/E0JZ6;N)!VH]PK -B'QMNMMIP&S2/GC3F>G4=A/?C<%2.AX ,9/1=
MO_BK>8:U_NS3%!33#2$IK$*Q#]<$JT?YWUG\G$,U<J%*7 Q'18T&!Q;N9:&Q
M0ICTX]8T6P)?8B2K;PH,;IX>@[&D<93B)",X\#04-;&JG8/"Q1!%<0T";/<L
MSZJT.EFWS#5EKOI<_0S6%%6+.MJU^S]?HE69++$S,73-%"Y[5!]H];.I>ET<
MVT$H!MW$KIW'12]WX4:?^S@_ $TC#C="9PDO"BK5-'@M]W>]A:,N7!,'D"1L
M["?%Y>G-H]RCAHUS.L"[S5P#N1QZF;-V/?S-[!X286T[U(AH-V!9:/-B.5C_
M&\^X;>SD')&@Y?@S1^5%7<B-LG97_C&WTO$Q]8F FVS(7&E&G&>1M@GSRA-Y
MB[YN4:^G5M%K5=UZOM4C]YWH*M*D81R3KYTOZ@X!0T^'/%4FU^9(MZ]+>/]*
MP2.1)%4\&_R'ZXMIQU>EL^R,(#(JL_C%%R*1=91#3]L?Z</XF'+7K>NU561D
MY/=3KG %L =&T7=#/_/E$:@/ZII6A-5E"@DRR^.-H)L#C5&>)/4UD]&;ZQS9
M4"C9T5O2E=CI3<99DV4#T-::G]$]ZJLN)!.6A]KFVZN][&:(=1G@R[-A?&EB
MI(S&4=GKG9</+<Q//<&][$":XGS,UX&R!33DT08.#+\[1_! LW/O#T[5"1NS
MOC:W+:\#8EN-RR<T3/WI4=B1/GH.T0 EW>@M5SMH5IJ,6=AY"W/WC16E58!&
MC%+ET8W7/ Q/9]OE&[C7=1$SGQ(^[;O-(DW#L[,DF&UW#02[SO85<HW\HC<\
MM,648BU@B*M 311V%\<J)];WZ($5'RVF3TBP,)>>*!$*NDZ9,5!]28H2$:-Y
M$-S+)\6I*9YK XK)B.(6UA5$@V=;I8H$#2=)Z'$54K3/#TM;MJK-:4MGNO3R
M&&V@?>$_IHJ#0EZ!F&$=E_(9G0B[DZ/(0J8C^S(0Q4Z?;*2B#&BBG5UXL=CA
M&F-Y;[THK\'@*4UQ+H0?#=PB-UG,/0QZRS[LN?H26#"0Y^!5^F8*V@99U::4
MJN4^XT,*YR*_T_ 7#S68TJ$OJU>?6JB\+/TLO99BG1<P22Y[S.1U6T;^QN=)
M&6FXC7,=90%\<N<[9N,P3YO1%&5%?/_'Q%2)TO<NT524[0OLR2Q/289K8X+)
M*M%1%EZ,<"VZH2ZE$:8X&6U6/^QS\N5L(O$(U6[764=.:ZWXX!@P5EUO,CSL
M@D98:VQ@H&S!YB8HX.QBS4'M,HHR]>>@ZY],O5AD8T7H11X$2[:DOBRL"2YP
MU$]6^IH(H&C$SRHFT.4KZ0&+*A;I6[6NL,_HE-%-$_+8VNIUBFE>"G4(_NR4
MP^(O)]=UV#F,S@*X.^"7 U7&H?#R![GQ&VULBSS\]?3E-6+EXQVZNWFCP'6P
M*99]2F:O_&O?XB@M'66UJ5U2ZE6\U#.KY*6RP$DBI!^ !9'731(9V)NT,9R$
M.),W#_NLE+4FW(9T )BW?2H_ *EN?AG!,?<+"G-+>DS!,4M#.5A]#GZ=@XTQ
M1N_1YQZL=JMUY['SB^!,]CTY6V$*J;.A1V:25.N0L![O(O,,;)FHLWY^*/MZ
M;4/G!R""Y@B1ITLWF1S"V'<NJ4P9KM D5;G8C^Y@7ZE=35LI<U6;;!O=X7"'
M_M;3K=$5A_H'P,E7^AM4]<N$OLN*4'>#S+[2T) -Z^D%'KA345JU6ZLU-0LP
M(O <<Z7X4[C":;/>X1[KN544M;(ZUJ9W0D@K()AG<6T5TL=4X1C#._PZLN)<
M6UM'L9>>)K(:(ZHU?\<BS4@(:?CY]Z&D!IO(A8CR6:)[ZFF=%8[IODO.R^:-
ML'2+^ 39%B0HSSA[X\FVQ&$58E-PPJ()FK-C\V11C;S,[=,@!> V:-"M%6A#
MU6U2-[_,<7G8ZDC;-#,H9FSD;OG"[PLRV0\ @;<HPS6Q]-'KZ(J)<J@0>1HE
MXPN:+S&$0T3]ON43+1<ZHO(2QKJA#,7^=<.A%#+JJN3I\C%J_%'OKT^W'HV3
MV\BB;RP)&%HWZIU6]_-@@*);%_KN8DH1/ABBT.5<N]:NBYQ(A=)A2P<WFX)@
M24':DQG&G'ZQQK@'L<73,&J8:5$7@:Z1A'N@'R6?&/TGI+/6,<J]\V-CIIT;
MZG!H%J\_ :S0Q=^W$Q&N:SWB-(C.?*15J3YA_34:% TK;YB1VV=D/X7,-=3R
M/$?K\N%OE+]4,=R'ULJ[ET!H%PF<(JT9D=NBE^@-4T33,%_7@P0N9>V^+?P
MC+K>-S/\ %2E2Y^;_0#P13"Y2YL65.Y]'T9E<'BLJDRI],7)O7I@8E>HWP?A
MXT-(7DV7*4P^%WLZ,XJW9'/JHOF>#, 1O<L]Y16_<O*SXUSKJG>L=H*IK]\\
MOW$PFJXVLI(-=OT!0) Y74@X3;^^U'[_O9>YTWX//F+YX6RZP$W*; ')Q64
MJ3/ZT% Y<$&%^98@"S4GO%QSE1=+TC8O+:BDK*H:8VN<75>8Y@&&CWNW18';
M?F48<>LJR_X*R+T.\MC$AB+HB(IR*"2*JRSE@YSW@_(4C=OP0],F;GSMUZH=
M9Y,M07N=V]L+^^*$S_/*6=>7\$*MG?O8"V'5RP[VQS8@#_JE02/,T6-V=-&K
M^SLHJYQW71&)V3VUCMJBK8WSENY *JJR)K83]&-\JAUPH@,)X96X)W$>H?\O
M1[#HKIL-]ESWB23E7X+,8V95/GVHA^=SIK< DCXEDTY%,UH"IRAKY,[=J[4-
MZ0IYB:U-20?H& X&T#EDV;Y'2"PT$I-/F=H;.$]VK]/"@7QL<;57O9 TI'.'
MIYMHB97F<YG<CHSP"#Y!9=D9OFJDM1EFP^<R"K%Y.[,V6 INH%T)-A+7L-09
MG;<\'J]Y8OJ'DS_ E^D[U#RS?ZDZH%ER+NMC!Z!SP^8X1V9U,Q8Y,=JMIOI0
MSRL=*/3XP),[&^G[433SV2CJ6+\*@DU$6E6US!"'E6045 ]Z@95\R1P6*"VQ
M>5G1H"6L.62<@G@C9-[D^+C,H1_+P(Y,PD&:S34J9K0<U>5.P.V#I'?;H5D/
MTL3ZAU[-TN,K['9HZ GEN:IH%@/2 17EV^4;8N))+F3E)JTPXD#U;DT1]:+6
M1^R>51>[F;;3'W@KWAWIA,]*>N8USHK:3D^IC0P6I.ZZO; 1LI1#Z&2&<([V
M39HWO*HB%Q2Y_U8P"U=_FXR">:J?3 M(O-H>"!G- IJ-$*N*%6%BB3DD?16W
M?;7J']\6:Y1,A#LA^0EX5"VB[6DH)L5-@64/\Y#N.F0]\<[=)1I[*)!Y$]+[
M[(:=O%M"B",YEHO5N8XZ 5XI#*V3K7LH+)/Y+=<K/:7SZE@\2$L&M_,KPCEZ
M1$>!H2<Y996OJY3;H\A-#H<*K48TB.J1 L8'?M;6\1<B;[MX9P7-8@6?6";4
MOK U&+L23(/Z+74"$N'&SI8,^;V>&#!W]@3^QK$8/7-2<5(#5S\*41IH6-@S
M\ $EN:'#%5F3+]FMJ$H!K*@XJ<S_&2B"L2,CZ,A9_$'K'E<L>#BP"1YK08FX
MT#24FZ^M35$IE:P6IWP9<(ZGI_HT8.#.E,"'"TY4S!2?;5&V9H DGO[>V,?E
M#O?SZP6\F ,0]>RDVK2&8'SKV."B6$+S@[]<91,+[*D2"$K.*D*_*3=6=AT;
M'#]R_7J^]G/8*1;FB]TQ#%S8_ ' ,"QRG:JZ&W;Z6SSL%8]./KG8#*K&E]<8
M0DH@L:$%M>@X.P@%('E*]U=V;(P-VALKK=$[C,VB&J+'Z$.[ E@KLS<SHI_S
M;ZI^IX/^ '0U@>GJQ4_-*NJEM1GI#[+]Z;R_:_EV1/47V6Z_B>[MFH[^@%;3
M1ULZ8 6V:GW=XFL1TZ_."(RS%Q!A-+=8G9?%S(1(I [ CQ&>%@/!]>* /@A;
MMZNN29G&808A&EQJ#@K1@5?7^T70)&8:^@![IX]Y%FNS\A0,(E,R*/FF4F%N
M>B??29$0!OZ6K<V/<M1=9%*./T$&M:TFCQF[+GPJHF?.#J8:XZ7+N)_YI0,&
MD+/Z&2?.7X=EO7.FA R*]"1.==_;I34,;!@=M0(2T'-07VV^Y9C5^3[?IX<P
M.!)2_#C=BRA[^[4JM?E)_LC.<HAHT.B+ZE--5O,I=N.JJ9FA2X.S7IAD,9^Y
M9W&RTZ![:N)@HF'RTTJSJW:JC<T0&Z/+!8?M)('&M"90F[")[).54YG>9P4&
M9%7A#O YB*R6^+!S48-GF?+HE"PI[:C)V4'#EA@&'<>\O=,[%LHW;>,V30C$
MI7 =!(+>R\AF'K0KL[$)(\_TP4M%CG=OR!S<L/LDN>GGAN)( U.,Y@VU[$W1
MR>T,+4AH^^H3"R=5&3!2%@STW1WB/D66,=\=(E9,.JI:;S2/7^N75##:I0P*
MXTS_ 4"AZ*_2[MD;TGFL"&K4XFOVPD9XNL-Z&F5!.-@??1FSP9:-%669MF6Q
M;\=IW,-"KF"POY +5L)PRBBQ-V])[IN,W=BB_W;T.-M8CIIQ[ ;37B"V\W.&
MZ<<!X&9X.\7L277FTR;YD@,2AC =(K$BM[>?7JY_X^^)FHSNJD<&V32K) B'
M#UI6))OSO-BU@AHWYN-GKF*>.0"/!QKJ0<@1<! + A!:_RU:#6UT=)PCJ*CJ
M$ERF8ZB85SFGN5*1)-0M*^\47],PX,G;K)4>),1^_W!MH5(%/3BX26;0M3CI
M(BG&9L2Y8IAK?P @OJ'VFI@B=<=QR-=[BZ$:6WA7!KBFE/I83.AQ,^E2PW&7
M^-11#EQ+OEKXEB!.1I;UT\;FP2=<$<9TOZQNEY$IZ]=^1<?A0(E5\Z8[?6>'
M,]M0I6FBQVFD:ZRAT/>C%CU$,QIB8[,/="CZ5I0NHVYXU)I$I^"035L+(!,L
M;#2BV( &5E3A'?*M;XMBYQ 7@]D6YUX\+ //3-D9@^#FF**IF_':\.SN4YY4
MPRN6@VC",0@DH3JA2%/\H26G;8*0!$K('J-6;4G$YI36Q!KV(S7$O);"H*/'
M9TIKFB*;D6B7RH8,XQ7L1EW[^BEI"0EE6:51O2<;]ESU'7-107L80KU?)C^X
M4 )R^_#UV1L"T/EM;YXPQ(]#01@^3OX $*;CTN"G;,,(4CZ;*<*^A$+HNP'V
M%,NIOJT;HTVH)6 [/D"6'MP'U#;K2^(!*6E38<.5DZK3=/SNRH4"M0*D.>EO
MLN+'O?P.7]5"/[$Y=-;SR*'F3KN9I%;5,$WW[:V2OXY;FDL0DQ.+<HJPOZ@5
M6U@O=K@<&EP$P K+\+DSQCYULM#@8BZ4\5N6"YZDZZSY2RIYUMF]D10&N1;9
M%.X[-:W!:.NU-6:7GVEVHA*H*U 8G1#"N.W'F6IYTZ_L==[0S;IX1G^FE,PD
MV2M/W%*E;Q! NMX*QJI:R=;:<\(6%3'40>]M[HW_A0TYJ8W\XJ-EN)3@*V(9
MD$O!.C=]OUM6UFHYI/TOX$5_>=ELC6YOW S\3O_+R-G\^.= &M@(^OLA&5"R
M*)GXE;L7WB)YQ1DQ\G#\O?:\ K;?N5UD*N[HSJP& -GF>\E0ZL+C:5G[KODI
MGLA9OR*(.G@G0<;G"_:7?6,5;S-8=@(IA!KE,UBHR-K-B)L^!WT<0IW7XWTE
M>QFI@#7ZBJP;_,E0P3P/N<Z.B?R5Y ] ?(AH6)?\.)^0?P=)'HH!<^O:G8U_
MH_++:9'C>7U![P,#<4T?;B%@UH.Y+J]P:^79%+O'BX>OPT8E=^N72W*X:[1O
M'@\BRS@X+_X K#N:.? 85A'F%H[G(11#-ZX,^B4P'5@7"!BB87[I:/HXK7(<
M!'0A"DV"<".&1WG@@BAHL%X$M_H,YW99-_BR 6__(=U%V-,2FS3W*0Z.35;"
MXDC8K .]S0);] TPD9G2%;@3]5:(U3*J<K$2C%*S8.EG#@%3%+AYD5(H9B3G
M"5 D&;2V3XD+>#2.SG?I8(8<&-_!9T/L0.?5HE_%B<VY)7"DC;URU[CX/)HP
M76",J;5@*%DXI0&9&E:URVJ<];, ?4LY<H)CXT-BDZ&T-S(LQ77+1Q=P^\),
M6VM*Y#W% 1S/>4&AU".A+<_0J@)A&VN.!A"Q+,HLIYXM Y_ZRZFK"(NHOEUX
MGLWL"$4XD^TC<K-AE3AKELHZPM0KTA-"-?%"/3T/&]H8G=;QN.V5S"L:X)0"
M,#DRQT&&N$6"R2!!?:3?:HW-60O6_S!9V]KK46MG!SQ!=C6PF3Y<IA<T9=$)
M;J7:$"ZAT".5X$3!:1HSQ;F3,Q FJ)>WG?0D+TAMJCB649 ->=VV?QIG'/]G
MA-G+Q?;?LMU]_'T/&1\5*RRP)6#J-!BBUF!UVW_,<4T[,[G4+F1F7OY #W$&
M!.EG'Y]53.+I(3,F-N*A[URG7/&-@XQVTA%R(R%[$O@H+4QYWDK5<\..K^#?
MZ![<+>*378F56?M5CW8X//>]QT-/YA7*Q\40X6;M4>O'QZ*+CK)9A,YM$1]$
M/!?,,U>:>1\-DEF;C+LC;JDAQ:W^>3([AJU'799$1*7TQ:@?/:<$XN$0S6<"
M^_<Y555EUDMDW%C<?8-Z^O0&EQG'SB.$^[@^=I*&B3(OL(.0&7?D4FF<,,F-
MH6YDW:*Q[YY-XOKXD5V"6W-&13#H12?+<:SM#,@FN $X;WVEJ#_&23]!TTOY
MLIRGG[U5?9W*5.)'MC&=,F(5?Q;ZC0X;YQ:L_B]SS[J#W.1H<#UQ==117RE3
MKPMQ&+?=B=CQZ>]6($81_D(6"36RY" [?7+)7Y;.2 &B6%,T[-@2#I&?S1H6
MF>^3+$0_GEZ(%;0?U$^<2 R?(SDGL#%S$#4TL_91IIYK]C><^?;TG:K;D%*_
MW+N8T9I_:#4]/RVIJ?(#D$0Q\LCF(KA=1Q*?T3\Z.CK^QDY4@.ZHA3$@@A5L
MA!]6YJ%24ONI_'P6Y= YZFU3QS>@H?BV&3+C1PEJ7>N<TD;U^9FI?G9CJGJ[
M@?746#USN;/'1-]?A7Z40/;NO/;]^IK286Y80E>K.P6L1[9+K4]OO3 ,66XU
MVCN[CX%MO[KLE)3%3)!%^F(P.2".)%?QL\% ;HR@5]VM,-+@D&1KM&F-8?95
M_"4#??WWA\8N,Y_I&,Y V8D'M!Y\V]'8O[319"6 &\GW+R,+D..]P?P*78,D
M\[6G=F$F%=8A.*3VY&"5+2F*>H6YH4-'EFZ2J4%)37UUB>>V.MW(BDL'^CRH
MG3\[+?/S5@^TN#6,):]GLJXHU.DNW)S>_'R0?AXH]\BU;N[$FL$:QAEN*]VC
M,9*\]TU5,G,"'9-QKXOHZ![A]<T1VW*5SPFEA^EG/;STHJ.Y6_BE*T39&1W!
MT]&D5^#C[EM.A-X2=6PB\J(7\ZEI,OLD788HS)>Q/N2 8<M53&-2$ ,9$9:Q
M6,+_P]Y;AL75;.NB3;#@$""X6]#@!!H"'2QX<'>G<6D(DI#&"=U!&^@ P=U=
M$]S='9K@%IP()#>?+-GKWG/7^M8YS]I[G;W_C&?6,T=7O54]9]6H,=\:8T36
M.0=#>_))O_78<P* 71"0#/H?B0C_:"P+(S%C7<S5N.DY92[_05_[6Y/3"#A4
ME+PUDK'R.TFEY4[3E8H4.1F<BHHI%#MN?79(,G'=4 YSH/8'0$W?-:=KOG.%
M-/<MD3Z.O;5O<^KMX3NT27U#,QMKLSZ1(T)PN!Q)"A,VRJT4BI+5,%3DMLTO
MA%7WL/B*Y]H1@323;SBLNB7RKQVRR[Q>J&Q%4A I!$P/.SL[@UFL#7IC0HP$
MT0) .?:UQH?3V<@I635YP/>G+/CT;:_]CN5 64ZUSXQ@FC_M$O7]HIAS!$'U
M4]_&#*T&]J@$N<_;UN8T'6 D*L4=V$%;LL@(K;;DQH27.Y7((Z'P;.TU)7P"
M<)L,K&M<E(OOG>N]V:7#SWS+2HU6$ODR)RNG4W4=DTJ[ +1KN^;FFQ5\UZ3J
M9E$J:D$BQGO8F9DW9=-QSYY-36HWZ%&R.*O2 [!DU^N?_5-LDI\&04BWIJ#D
M9U&1U+31PB$AE-D7$F(]X>1PFAA^D=7NI^#]K$$.NI&X7/&(132P0S;*O:+]
M:M:L<-_A.-$CVBAE!S;"%X!57CGFQXB><I+D;G!7 &&QW=J%[PYEAL5!O9C*
MA@0_R,EL<G=KUHON]_96M9RALQT1$VY]Z2-EF17HG073V3O%U#R^]T$.-.2]
MY=ID%0T4):G3FGY,DV3-X%X(OFLC/"PQ.O(M)&J(:==4(N,^"-]#;L7@HP-8
M,1@MUCQS]6]IP4Q_CI*N_!=Z<!0TK$MZ5=K1MT/M@8G0[2^1TXGW'?\(C?H/
M^W3^GOA#.4/^GO@CY/W_I?A'$S;_??'W%G%=%34VY\FY9D1#L$6A.^_TF!!*
M5J_V69JISWG%%L;&047ZRP=,V@Y9CYH/=LP'<7KFS"6^/WN2/_'$PV=N]$,B
MZ>OR]SXWF6%JV:&_Z7)0F 8>? 'AOI7_75>=K_G+W!F47#3Z=]W?J^9R(?M=
M][>J[^HL/OA=][>JB8O^+X8A[$M.%/;8^1=ZM9E:\T'<#T#>RP</EC#I FO5
MO2D(<9 [;=-CKD]Y"_^OZ?&_!(:;V?M?5GF>#[\>A<9EW@%YVK[W5?*<LW"=
M/;&P0PS2)!Q=',.W"KMH5(P[8"&\_3R1_R9=^R\"P[_[0\OD[T=-=#YY^]Y%
M!8^XHT I !'!_DU($9-;<]QYP58HZ;]+?_Z38$S%_>VX_L454*RKXXNUZDCY
M+;RV'%OW:TC;O$[R;PWB3__[]OA?#:/@%QB&?_Z8S'49+9[=IE^=[4HM,_'V
M;$CJE<&S_Y2#BW_LA-A_".UP%];]CYL0)"08HFRW81R+-"=<EBV)C_]R'2?Q
M1ZPC7V:Z?J:_.*<*_V++%J;\[8'(_U_Q1ZQ!PDU-"O*\*4+&IA4WX90 --T5
MYGH])476"=U@/.2&V/VS+>3R]WB!A87;^\L?OO2^W +-Q8'6A\H&SZWAU>?V
MB!&#'?'RW"34L0.VY;"?SL8==NO.' 'RJZ4(7E*33SZJN9FAM4K<'4Q-L1,M
MKF=W<(3-DR0GID&TXRUFG-3T<X3/%"R*X2+)U'U!56(XVL8V=<UN7Y4N^09&
M[*PWCT[ KA@[R>P.? Z5]Y_]8W_'/^P 8)YJ-=DMO=H[.$[2U)KH%,E%ZMO,
MAM)$-FE?G$*-SN3E!RZL@ZP=;/@_#4F>C3UL\E:5?MY@A6="P2UBHILH=,>0
MQY[?4YQ!\X(Q3L[@.8%UVE&[W3-;<A9%RMX"JNG5_?7<, 2N?XX:2&<N?C]^
M#;&QJK"#,/=/[#68[ AQI-*,+!>8%)5-=.Y_KT3TK8PJ'MK[.L78&Q7"=6"9
M5UA<VJ D=,GLX\.]83V6M12QAKB<,EK?ADZ]?3I,,A@RR:6VIG1?):@W._I!
MN2\5IVF1SK<@TAU;@2')C.V85^BQ=D]J#,HOQ);4I :GM :+J1$'BMQB)-?'
MXH?]F;'RV,^[$_5*ZLH7^#,"PGJ.;8AE1NR=:NUV6AP&<NSL)^L_G9MP'M;5
M&.YE%S?VD7@3#V[,]J-JA3-4KQGCY TG1KDBJ"RY\+IY2)2X?>Q#:3]S&E<=
M[=%(47$+_M.?QG"0I\"T?M8 2K.KVMB)F[[VQKP? -5'%41+=HUFWAZF2K(D
M:.=*!BMZVYXT;U$/@)X/.Z$O%G(*WNGKJ-"8EWS@Z05?R\B/>9=%'<\6ITE;
M=XY&FKN1^\,"JP[J*:F%XI](H3_LL:;\R*-KVZ:D:-<^DUPL6I6KV_-L?G&'
MI-9&D0DT/J%9JPG/[8,$P$QF&Y;LLTN#:&,E9,[+QW&68K?$@P9Q/^;2NFB8
M:V,^AO&1$RNRI R$&<O$9::E89FTC/O8F ")]]Z2HA;1C ,F9FSI...JL <,
M5BH@V\$TM>4YCUG#ET*LNREVW[E9Y-N<RQQ_.6UJ?ZDGN'K8[Y:;66GW&@E\
M>@UT+8-P=%+@*= 'I,S.O7?8]/;O8[2-RFT*$:H]&DKR1L0:IXB'- C3Q^E6
M(K@?(0_\;<E)P_+7Q,"*)N;5^7HWE;U;9T80L'T<,%$O58!\YRZJ.> R39%7
MA$XGT!+]XZR@=N.FBOH):,BM8!QZ\_HTIS"Z'$&-](UB3(7%B\%&':F@CS<^
MV/Q3)SV*/IHR6K926\)OW4ETQNJY'%+VV!*F9Z$OSJLPJR@>=2W:=LR]C1&^
M4Y^]9BPP^ "\MT+8-,:()G5LWX'<[<#2))=6-AA(8< =\"*[K=-G+<W/*QCC
MNZ^?$#N6X"'MB0?E-?8J-@6I[U\ITAG"\NT4O,#FB'&<5:$130_Z%'<8?$ND
M:2:)?.8DW= B\]44Y>ASFPU1]-TQ83H2<D5,1R(":\Y\:(_'/3T9D?R\)#A<
M#^#)6M<%L7&A(8=>0[*JC8I=]8T06A/:8F:&YDTY/P#OY6CZ"V?+. S KL*)
M6GU>#<U5&Q+BX$(;*%<#7:?8(Y>Q6-H:??B3$$XDM,L/&4*BYF6;.\0C3(Z%
M5!KRA)T1)<[27NT?/T[">2.0KD#23>DD@7RZ9MVL TF[]-^4R- "#O<>::,V
M^S-;F=O_B1R"/X7\F !"H$?/>#,18H)G[)\#ID;IT\D:S-T3C8G<_.6!OE"#
MV_1!2I)TKAJ6.+)*@\AB)=0\:<<G(9OBZN:>K8P_Y^IL 9^K=P26;]/W:YS)
MGDG8 SQGA]PO$V*_3>N]/OBD[TSAUFRE*+]4=W@41^OA=#<',BOV?*RM?SOP
M 6]DH=^44GV,&,0%B>M_T'9[1'3_6Z D*\QQJ?181G#I@P@F?4*5E- *VT>%
MN?D'7<$HSN6%-#3@D((Y&9TM&2%'][0!I'\)UE%CS_V6ENS0M;9&^5,<J?'@
M!H1KA4^Z<4)_JB^&O\TT.KS:;FIR5B);?-'&=\#Y56C*P++0L/U@2!;SS59<
MG,(>F[N-,_6H%UP&K37)I'T>J:JO8FA.CEYT],174?;9];;31]<N1E?3 Z45
MU 5C3?8.4K<GF8?<T*(%K' CQ6N0TUA9\SY&6DH);2V6<5O*C'S\;<MXR(/_
MC25U(WHC"(Z!EQ]WSDBXR_X#0#H'GG.+D= ?]G_0_FQC&?1F!_DEL#[E84*E
MX(I^>]U"6Y^@H'C2Q,LL98W;JE[S6]4?@"W0U+'N/:VE8B?.O7?ZPII-AZ]"
ML977A0@P#H>/%YO@[Q%N)\AHB '_LKK$Q-0T>$S4##MN=6<?S;0B6=F$'%I0
M418D+\];G @6[S,R])%Q&#YK3*O_K+Q]M=C&NW'@(K4]HQ_AK/>U%Z>HJ  V
M.=0!!*N,%E'%-=@9CZN@)#TB'YQ.^P'IGTWTF&KB(*-1<J;M,UA'[@-+H'[2
M:]=%H>(K+4VKD! W<LWE0IJP+HM[6A*"]@]1U$*$0P^3XBYY\=()A;,G5]$@
M8LV+!T,[:=I(2E7;MO796;8<?B^JH/V#!=G;Z+7WB0P[ MAE#(NU,#*$XR>*
M ^$K35*\/=2KD=@:[3; U@?/M4D(9Q/J1O/5;EFUPCQ?W7%!$:&=[3!U2RO-
M8!.J C6DOV#U P PZ5-GZ)/@^P%X+;W>3='&N/$5GS2\H&59-G>&^9'C?,"7
M36DVV,6G;Z]TG'!JFR(SH]=[#?@/"25.)W3JE6QY@"']8RS[_5^34070?@\]
MN!/WMR5)?0LNVA^ A;H^WB?'ZK*?RWN7ZT#8;6M5V&B3HHE5X?>JKF#[2VIN
M[YO]PD1<@*JU=7$)"5U>BW/XO9WZMKU)YXN58<?O8^KJA&L]1ZC<A[%%<M]
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M0"_CP VY5.HY9-KV&> V'#_>_&6YZ3N2/\GU09?.I,%KXZ Z7473)Q]C1XZ
MAJDLC(H;=_!$!;L2_6KP37A\I5QG2M]HCKH:C8AOTPIM8:!?\YE;=%,N*5[@
M5VW0<IN^R,IQ0Y?WJ$/CSHUTMK\[?([-*/H#\$4*NB!\>?^K8PDGC%?E(S@O
MN!$8 C$V3IGWE"RQ":750MEW+QJT/E.,/)R<Y[<ERRZHV_$[0@X8G_W<E?@8
MUWYO32\4QMH$ )SI 6T<S(0>/3,I8T_OE!\I:JI%G!RVC_=QXP$]2Q!6A%="
M7H&L"<BX29^, V,5AR;4[I+4Z)C18N]44T>KI'^Y<PS&L0<8;I;D0Y^72/N.
M;+G<Z$E#7_C19_]+M[SB##[!DD891F?B*M0Q_G"Z+]TS+$-8RTRRRN7$8JU^
MU';L=:LY#\'P5FJ JO6INSXCA?AD+VVKU4$X38VV#!8#.:RD67TG)JU_U.6U
MON1HU=:07?>]KPQU*K83&=29A1AJY#1X'9M>+1N/-W0[GEO+4E/WAM?B!],(
MXDW^L\S2M[L:>"N5/:*<MONIM<?E;1J&6%HB7T^!/.FK"8BC/J<]3!)LCL.X
M5R?K_BH7!.Q@NMZ,1F*<@:RO!?8/!_$*C/>MRANT=9^@6,E)1!6 <2/NP_30
M#SP@Q[SW"]QEOEC@R9GN71NW3+B&!E?81!Y\+[PRG0UYKH\)+JP)Q]F8Q1P/
M6<5&;WQ58Q_,F*\1<NJ*^UY_S@$U38YX'9K__'!F5*">D_!:[K1%J+_6M59"
MIT]8H\;,Y2I-P*'H>WFYG].CYRL,#^SD7F4<E=0QWQT6L\OMFJ7&DV\J=V$C
MXPWG_YC*2+#Y6?T'H$WWL-%_R[.OKC&9I*>]3X%.Q3YWCG ]1YK/WC9E[H6Y
M^WR% S0KET?<& )=\ZR2N&]>1GHUPD#X%*[: ?[XG$;69%+!>KPDR?O1$(W.
MLV=60#:VZ $U;3IYLS)K)W/]CA;#4@N'^<YU'+[%YGBZ_@?-+FV"7=F'LKI,
MKI[:$JG!9\V@0NS;+<X<%8%*"R!YW9>36"T%AG=P([P/]W3LXOAM]80:YQDS
MBBF==<BMZHMIHX)DE\YH$$>F7W90^L&"P%C;OZ%P_(6S^1<B9QS_GTY><.;]
MB<=)I_:'N!A_V*CY>^*/. /_+@GF7QS&[^\1>O]7L2E^"RJM;1)=YM@\.3YD
M-I@L5>XCFR;H*)Y5HOS@Q>[1\L'M4G-",]!7X@< <IS+94DF[0TY]OE^M**T
M0M>2_K+%5XN</YKASPK'\)71#RLM1;@I\D1_4O!5=-TQ/UZ9#E-ECOC3?6!.
M@U?%M>O^DWP2V>O?[Z=/+#7-?6OP8=*^F_7M]_OJOT.(+0I]=OO[?8[?$3S5
MZ?P?B+]#)!K@^M-+\!-CY%#8+S^!5YHY[#U0]6H[>OX<2*D^')&%6_=OVK]_
M3XC&OK_:Q2J_SR'136N%]@UC9)Z2;2/]!++3-<X?GH'<\J/.)*7BZG*=Z-;]
M8TMP_V<\_Y408WZ:K>85OP8VTP6O;,/S']#@K:JP$TFA: 2YY*R [@QUO^H)
M_M?ORK_!:/]_0Y1M^G^W;?!77.(D?:38JB.']:I5#/''PN>@"\['_\U'[%\+
M$?'G"JO^[/74_4:GZN/;_"6+M6J$ZM[=3=SV<&S/FVZ![9<E=C:?L6:^,G/W
M83*(CMEP_"H?.H3\3_&/%GGN6M%DVU=3[$9*NFN>.U\]^4U>_7<O2@OAV[P8
MR.@W).Z5/EPX##LB]EO/V5XX#/U5_C<N6O]6?&%WMZD^@%L2/W!)*K8MFXB6
M[)>+-++_]D7_.[\^/(8['4(+..U](T*9#R?^T_^T_V)%&V=+MABPT@E^<JT<
MAKS,U&.^9HM# 153:SA<>># *N].6;D7X$5 P"3A";'YA!>=VL,S%:C@U^9W
M-T-G;Y[Z'@J8XE.K5&L;%]K[P;GK,/*-+,X;E=X%CAD>/)! /A1HJP";=>*9
M"&%XANVAD>@Z/QK,^ 2KND\#1QKLU(A2*'%'SB2$NE8.34.G(U/_[&UD N)6
M6"RK$7*$[_%*WGOR@'L[T_TYW7G.D!A^$Z$#SV^4TB)JLVZ?SV!L)6W[];?N
MA1E<3UGCFD=@DY)B)G"35VPO&E6PEYW%6/3U7_/-6;+:UH#TJ#J2[02]9*AJ
M>.##HQ<4K";ZF*!([P0U\T@G ;7.T?Z2_/SLW(8ZJ*B@F W^J_:#>*\QZ0F(
M _6V7&_;MJ)()D4<HFKH13?#+QOZ4^&8<(H![A 6"SZOJ'Z 6-+0VUQ\^>C]
M?#N8<V(=9#[#6NQU6KB$;Z,;25W;^6W '<+"UXBQH$D[!MB,[Q FXE)F]*L9
M.T)!O?<,4:UZV7^"GJJ?QA;%FU(^@#D[I,61E^BRD)#CRVTB3BO^!"=13D;>
M\(-5/\_G!D(#VX)XI0H%#UH8B]YCG*P^:3.G05S\;"89>5"O&/6@"X<%EX1_
MJG5>B4BG'_+P+7LI8X/ 4-PB^>??O0.\*CUN%$;[)4"C[)+@F('V*2$S)<%-
M\'-E@EJ39IKZQ$\"N$,^"42&>Z9K?1I>"$,.K^<B=8+XCV%-]KM:CRAH3%PI
MXQOP-I9L(,OR:M@NPMH?0J'9=P[KYC\V/ = 0S*9=QY5T)BUE$$H.NY'\HD9
M,#M?)LP,6A?D@>MK@;QYW2[]?D'/%4U.[\>?M+$F V\S.GSJ9/#K3'192Y&4
MX7./1&43JFD@?KB$Y:\5^KSSVHP>'$.^X"<F>8@ZI"D8UG4)5+G1]>,@BZQC
M9)_7*LG*AY_<7 >$.;J#AQHE_ "K>PP#^UO]Q3TN8RJB@_9S:@Z=UP^,1-XI
M*@I7#5.+INM+6\,OZ#3)7V)9O87P=EXT'%@O/]BQ9%5:3>EG?<2@B:G%>5HN
MT$M.?L_AZY0S? "_/*H!V)*!J80!M;86W=\6'/X!^/P36KIEJP>DH'O"LO4Y
MN*!^N1AI*JNOPA3$:U<Q"%9:G"-"VQ\+H-R05%%[#A\+K425%P6:""?-O%DO
M8J9*"Z]<W''^PM()/7X=OU(E&G>2SIILHN30=<W-PS"KVSS'&H.\&S'H[AS!
M82-Z>!)TD&_HJM/P6I=N<.TAGJ(NJ5W8%]O2.?P.4&MT$_S4E)VX4L6C!)R?
M&$<GPA-@4YBZ1$.C&)I15Q.RU:9AE?>.5%&%8-3NY TT-5>4&!)NIS3\JO7S
M,[4_GD'C/TOPR2\(W%#9_P#$3-XH'Y3$0M2?]E>JY2N9S0HD^]N+=V\",.*?
M^6QD>:1G([Z%E=</A3K'9V2G'T(:YT6='T,)Y1B>P+['\[L^]]5P.'EQ-5JG
MU-,L^V@T(P?/85K-U*/4,1R<$E./@$5L/6J%E0^YTS,T891',1A'"C,X1LUQ
M[A:G*W^UFY7S"K1\XT6-*ALJ'L_D.GG_VH*=NYX';MRBH%Y>](%^8:PKX[W,
M[7*Q&P-J\.U]Z+ZS@9_JJ:(2K>?=&A1;Y".JNB ^U_=CRF$UJ]X"&N$61;GY
M5;@>]"X%B-1J7?L-!+&9Z;LR#'CHL49W"IC4P+5!*# GLPP!Y3JF,)B>$L_1
M%PNIW7PZ3*[<(2':6??5JF\660)^!Y(9E-5@<%86P5MX6Q]A!_FLI%?>IR:K
M#8_1^PB.6;E,59!Q#,L+88\51=_=-+KZUO8!TW&'8BBJ^&,F](N:&B_9E-W\
M*HLCN+=JGM!!PG:(L*I1,8KGFNLMJX#"_,>B5^T#I-208/-W[-9"#4[;(BGV
M\@+8?9JOK>#[RZ_*?6ZNAC1*!Q O/1.FU'H:D^56/D38(MY/[L^G&S@*S2)2
MXTD>N!K[PH.?WZ^E2"><-&1"AD=W/5MYQI0+C8N?;DT?(=DT,=&(^ 0"9@8J
MZK[L3/+0U\>+033OE1V5$\X>Y?/##(6VADD:DOUWSQX)BHEW8[U*Y8CEDYZ?
M2+ZWT::L/N'&H+.E4O/UU>KFR%O@RIKGX;VJ:H4K2;LY_,B34%H-S*6"R9/B
M[OGX]_62$E_6,#$SD+Z*I#G6U8)/C4 >'-)Z9GG.-;LKC5XDFG.6QCTN[Q<G
MY6VK#>DT\8>'[,IK:BRQDYT*'29_ )2RMW4L JW.9>:YV) KIBQ/"PI?'?.A
MF[N[LVX318Q7D"%5*Y>K1-CBV_<^D=]+Z%)[,N+GF(KH>WISUI_^5@AT;X'A
M!R#7SZZE#ICJ5>>U\,ZYP54EQV3LEDXW;JFC9;U)_7'9\4,5O31+;_!G:/[R
M-S6YT\H/P2\^W)U[1##":ONN3,6J[(&!6KZ_JH@Q^?:U/FE.3F[.]]JF3=K7
M9_.SL,VT^CLA&K+U2%7YS"&I]^<T^T5.+'YQ^8K"+9QI"N.@U3O%NV\4*-6/
ME"+S*NK?ZT^N<15E2=5P^UA;NA;.'[VO+K]]0Y5.9'EX-A:2(&V.>VDZ,?NP
MVA(O0ZAJPVGW*.ETE8L[N$@"AJ 2Y/7"^6+XJI'QP!>OKGG>VJ47I:A4CF.1
M8==7AKBI ?J6:JT>)<7JJ,BZYQ8[$\PE!*=6.^'#;Z*&/#1] \7"/?)$"%Q6
MY^1]7H?,Y<?[=55;MP.%3@[-#E/$B.8Y#ZRJC#AY1TKM<F\K*%T; 5OO2H0F
M0Y#K!\)?#6T^EY#.S34030]^/IKUL_/6O)NRL7I/30LO[:GT[;&U,=G7![EV
MW)T^,YU#\BR8G4,BLKGA!FGKD]L4\4;K)D0_ /:BL"H1>MA'"$:O8'/PN!)3
MPS('E?:,S Y% \<Q(74?OY[WV^@'M5%R[NSXB<M.K@]?-W!;N+:)L!*X![Q^
MUV+<!D!#@3Y#GEBVT*T1+3T\+A#4G=:=E&-W'NOOWH&EHB-VW/25@TC6^SFY
MBK)KVRJGPZ.,E[SH7+13OKN\#<2E4$^LFG#X/J9R=R8:#X:O2@]8H,9>I] '
MG6\'"WN%NS;JSBD?!.260W>>S6\>16&!XGU;T(,7DE\%84S$HKOC)5V)'$T<
MJ9OYE/X "/AH0?E*2 P=N1@P33=6, [%'XMS&<P)?P6)A[4IZ6H8JB_L[D1G
M8]^D,OMYF>ZS6)6N>'N%'%_C'!S[N2YI&P+KMI!/05ZCAG;*&35&A<[UGPMY
MA:NT-+OOPBG?%L]N>XD3&8(4#E]59+R6OU;0ZK?R,<[.]0[>*AY@!9OXXS#X
MMU@>Z++!A^2=&^3ZBSBMG#WJ<IAB:6[M7Z[6>JS21MRWI$F/SUJF+ FMBK=]
MAW5:5_XM#4V'EB/W57A609>_"LJEH=@N,BQ@7HT7K+!3#:J1K!ZF;0J2D=A;
M;L*"?[1-4*/\/O&D<\A[ N0AT&#-G-3%82,N4C-VK.U[]!"E$D!#7E^YQB<8
MDYE=3TBO1!1BUW%=ZE" 9^+ ^GY#4IEZZ)@QJ48%7=T*R0YE>3V+MO@$=Y:V
M8<;1">75MLJ7Y(%Z5,R@!'+.39^H=Y%-R(L;86P1RAC[/H)8RGGD_ITILQ'%
M7>=3#N?X :@S?L>] \T*I4.6^_H?_@"DZO%+?7\CG\R-(.XA",)LG!G0!C>V
M1=1M1<N6=22[$CF.O?P!>)OHK]XUDP*'#E@CC$=,M:L#"JG9X.FII!4LY_U$
M'X1I#Y3FL0E'\B5):1,?SK2.&+.YHS9IN9'MZR_T VK3%_A*Y)VJ'3[A+F_7
M:S5GK*D/<+.]"?4:>FV8NKBA/CY.SJTZ$S=?=04_)6^70D1S(5.<G*@G43A)
M,#!>];(0MEN6B;EOI?6!R-6 0_/4+'@RQ<Z;<(XDBEI6W=H^(@N3 =,B]70K
MFT<I5V)PL&]9)B-C@4YV(S\_],ABQI&JA0?^(F_C4D4_VQED55:[#.9RSQNL
M0GQM";+95IBD2$ME5?<81AN41,^Q5_@*RJDR8NR</X,L5-07]HB+F&[JDE3:
M++ \[R>6P5.A-..\*(HL3?'%/9@U*KO&TELIZ2("S HYP.#?[1]]EC@C:!-Y
M77,Z^R:GJUJ18-"1F\EF4LC@R9S<^)[@%J\C*]%=K1W9E!<&(@?@AR)BSN^]
M@SK-YK$[[XH3FJ9Z%L)$YDQ<&L\5ZQ#^8K,S(%X;>$$,[#DSB5@HP5A G4@U
M/;FU77(EL$R]PN=[:HR#Q/@' 7X6O_7O>H%O8Q5VFZ]]&E8%'I-V7[XI1_85
MB8@$MF-/:TO>P[OA<S4D';KFJJ=!C.46Z%BIVD:Q1,\\^\*25>41 >C/!M?)
M;J*U-^WHO/LP76HDF%7:[9=,;DT#8TV$?.O6G%A:3VVNEDC/O#ZF179#[V2C
M5+#0.RY)44',\[P3^B >>&[S#"A-M[*I9T22?7V=4(YN 8.T@>NM'IRO?JF>
MO'NXJ')(DX[7)WVF,ZL4/%J(E%PVF9Q4L$YRV3M6B>I!BD4/:"Y>)HE,=='F
MWIN_1':4*_(5LFZA<&0ULKF6->3MJRP/7$:;?<%4#QPQJMH!'&:*,!B-X,EV
M;FU5@G=2=KL@0'_:^:<)ZP)R[4AA7PMG0Q1S1>\?I,NB<W&#G1AXXH.]EE+[
M798J"?:G?7D(#DXK2J#0:/_F 6-R87Q!)18XJ Q=4&,YA'S&^X),>V9VA)9L
MO'* M?J12*D#C9+D*\_6.[:]2(W&CY&9WJ)<3D+@^K8C7A'3[VXI]C=-V]@5
MG;C%T]8!]Q,J)O%&OD;/0<O.;18Y]XUI&\2IO0C]Q@2(%V*W/ONT\ EUD@ZH
M.=>8'3U\?N<!9]&V/?OZ;,@):%0 MEU!X AU:B51/01Y5Q3 @649['$=X81G
MVGRSE5NQ_6\TN&YJ7\%.:Z^H"OE2N)REG,JL,\N:3S8:M3I1"6M%E+2A1]R>
M$T$Y$_5Q'O*B/+"+VH;%_-F)Y<^"ENXS_=W7+SDQZ"*F4%3S'B^2*F$BR'Q<
ME5#]Z,7"=_AD.@QS[^V)95S5AO'/MT#@=AW$(BV=?5Z5+FZ+C?"PK21JX02&
MOF6_IWT09V%4[_ :-%LDD(S?IPUVC^M<)1D6?+HC$FS?3RNTA.B9<>#*+L\N
M*,F'U)+V+A@<5H^44X6,/WNQGYY;ZJ(2<MA=!R]MU7VI*PNB"&(]HPMA_S2#
M$3-XFL?+9"S\TL9%[3F*V\DG55&=T(2[UWA@?C:FU^98QQG-LW-:'\?CL4 /
M0N+05&=RKG^PGK*(93.:*:,=ZWSH%+.SPSAGM?=U&T:"^/7]R:=?TJF&-,^E
MWP/>4!C$W.+E.YS!\5Y@=DW7EN)'2]P% /P,<!Y7>TG[SS8.V$S2D[0N\29+
M& T:I9BJL=:>X6"X>D'LXU:%,+6]G^=2 PFJ>7CA!2[9UPXQVE1<+?W%*:.7
MU0KGL8S!Q &'\?;HH;P4C[Q<7-Z?JO 0N?;=,3%2+ QI&:<P,#$G7K&8G&6M
MG7??(>!CJ->M1GDTAB-ZF.S[P\5>"K >7?J31ZCXJ^1UE!743JJH>]"U$\[8
MRG8Q1=Y3Q..&MT_$7:3%OO"WZ^ZH+W(/0@B91GZJDHCG\KLZ(6EU:C:4U M6
M_P&XX)JPSL]N;R0,1WPTI7EP).P"5TXE+&2"+;ZX:>!B?\/WB :O1]O<]+6+
MR&<$*C$9[_5^BNJ;4^.&-HM--",/5_I*1W-<>>6#M!JC%@M5MH;1Y8QM,'Y4
M/Q0-V,K(^*H=L3CL$FG=9Q"/-')R>&4;OR1V&_-SR[)(*^E[YH>]7/9(B")&
M,:#G/DK.L3&^4C,5'[DL.GQ9W6^[OYAEG'T=#.BCG 8( DR"A[YO[" YVK<K
MJ*QWEZ).6;'"#V<I9(VHG2"D90\#UNB^$^P^CI)_U5_]QV@3_WD"3Z\>&H\B
M0C=7P=01WRD2MCP:ZXH;<6&^:QGF_EG\E*!$6IXU2%GOKC64O]_:1I4&V;N)
MO4RQ&XGM.6Z;L43G6&K['E87$;B!%?'N2_6(6S:!'R?GWII0T=Y&U!303%_@
M5=[Q25I#TG;SFI)[I**YDH8NI41'@@(]VLFFWB3CS08L3F%^P]J01@%41@60
M0G/27CBJG7$MSF_0[-%!Q2$?4<^]^Q+\LUZB3D1\1G+8D9%?)LK,)B'$PK4%
M?DW;D( R_\#,3-19'H_;;TI@0J)!VE"MARU\VV,%CT:$DQ"0"PN?$@R'\_>^
M:>0-!6T=@1>-KB*$/V'8X4YGUQGOXJ?G@%34.@/?8]VO,9Z+76S0Q$:IJ&"R
M 2USH0^8W ;@HEBU_L'F,-MR://3S;*L_,)XEC17!'MKS20.S>.MYDC^"<2H
M?*(<0Y@IG90S7WAU!G5D>EM\I53!,3>9M_<T_UV'HJR"4%<;'GR';]#YGWJZ
M/.0>X;H=9*=0NA(6]'!KCZ7!#\Z(G\W**VG(DT3#,[C\AE[7,5LX#'\2)]3Z
MX/UKVISDC]H:!*JN\'S*[<A/SC!"[&/N*SEJO6^FF(TD;EEY>=CQ=XV&O]Y9
M'LJR)7XA(CP^\V2WV!+N +]Z.K[]KK%B-!P:#Z7'@B)P'7SW92FM_>\LRC$D
MCO=IXFUDL"N1]JI;+]+.$:%AOM 1%J[_C"%,5CGUA-#JD36^:V#+3U7JNMFO
MP% 3\B V*1WK+W91%708#R<S,K@<WI)+:G:10D3B:H6)&A\N$+^XI]7!<ZK!
M0_+>P6M]TPOD)41%"S]]E_6"J-8XMXP\WGB/3@_KB>^3R=,? %'#LDU03/)'
M?24-0[RLTH+H;);?Q^U:CCKQ_E<5;W8NW*><5F-23YGQJ3Y[H@5DP#.R'>PR
M,CAM@Y/EKBO%)Q)::]/7/.?E*/&&)Q0E'T;;B3[-P#/IP^]ZM7K7; +CH6?C
M2T27TP_ YL=]\S(^NNI)]8$]YZM==LN1:D7EWJ:"<9GY/$WL+6&2,=*<#%$E
MFG#Y-ZZ5TAY&]=^DZI=W)-;<<G*]&E*8P$*[:&[9N.4)/+HI"=AZ"T>][ ,&
MNQMQDVDA5G/4F\Y 'Z^AJ?CJJ<Y!/Y;P^^'R-++4$_U8[13[D<+E]XOQ8BV:
MGFG-A-L7+1'7JYE<;Z4L-/+R;?%?I[B8WZ0%*3L2.RZ5U>K-K]$U1R/CWDB,
M.I.(\FN$!E,4'P31!?X^Z%[L/P<=TX69:##C;E&6L_"I(KXJE4B,@P-]YOV\
M(,2<1Z**1_V$;C]6H?>)Z!/L$$'"D;RGS'?-?FU&^B;MY1>=)$PZ$4R@XVY1
M5OZK7$0?OB4,X].\*&^H#+<9,CX#:9A;4!#.R0YI+;=&5X6?-,)V9NO_X;A
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ML:/A$A9GMS?!$A+BG]FD;L]>,$S75$X#_"D\__3*.N%9Y[L.:QOF%:BXZ]L
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M\K< ,%^J3[A\TT#LM/U&G@K<QWPC:#:T\MXI0X@-M'+Y+N7Y<LWV.TMY29F
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M&H(.C](+F&C6V>A)6\X1PO(;],JK?.3KE[\NS-<'*<Q@:0#R:<7RM#T)/8O
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MI=D8^9K>^4N_QAGD"-KJP9>/9,L%6>KQD_*M>V^#8VS?%HW/B5T 0%9)RJK
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M90\:T@:0=QL^&$@CT?TJ.P!716/BWJ5(N9<6K+Q_L8W%-^+%-YAJV[H@IQ[
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M1U"%;QT6?ZZGP?)O?DDH6P6V.K-3)(O$>+1:ZG/XYGE\QGA>RH]$A *QZC;
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M5ERS'&IH,,2ROLIM$O>,C3)-[2M"X9A*T+U1B2KOU,K D&.FRVGPAPN#U:)
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MD,?.:_G+X7;U_KDO#2 #<#0LOEXQ0[KA8$@52J7-;T'T[OO0UW*GO^X=-+I
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MBUK[K3KP5MWH9CWUH-DJ[7?%.J'Q^@2\*P%/+>[:I!G@\!![#,9EJX46&H]
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MJ(QJ=WF;:<Z)#-\PS"3G/"Y^SB=>EU_6RV_Q .93BA_YIAUTD@(T2U0.15(
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MASJ%()36Z8I,>4P'Y[/G1<@Y5*!K3K;;;4O(BD1!;MVR5;UY[OR3C?WDU*4
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M[[K3([-^>D5 VFA:$2J14D7KP7"253MZ QF31A_BS>JC,!TU#$WAJU=Y9>N
MZ-WW97"\(K[B9>/$9U%Z^BDYSK&2S)ZSU]ZQ43<7RE+4.[Z-J.?G%#2\)VUA
M3VP4F>2:2(4Y3:N(Q_NNC2.YZKQ;F%'E0B(=Y4M+^TG(&-N<QX?W!>Y>'^@?
MI-Z^$175,5KU2,[!'MF'Q>+[#Z#99.>"W_LE+2GCOK IZINP9C[0 H>AH^A%
M#B44230=ZH<-[&7[0[&Q"-/JT3) M&R9O[0KLM-T[*FX&>CR'C-J%)S'E$3,
M>.3Y33AY:20CY!%!;SQK47JPN#WY)57-PHNCF>ML6=2=W(WU_8H4H)'?VM"B
M-R6TT4&[#CW_\>9(R<W[[O?WR1<%RJYSM:PK0S98VM=Y;EKSBA89^SD.C!E;
M"LMK>L*];?3+!C]/GJ:T3U6DQ(21O7+*'S(_+&HE/*< "8Z$7B^7@3KJ3*<
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M*2K.?0KJA(9C/'"G 4EQ21!87 HL(<TM#@*#0& I$/#]TX.M!^"/:;[J0Z$
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MV[]U0.E[_/^O%/B5?TN!?X(I;$UIL"H&1MB<^EJJ2@2"$QPL8R\)DP#928G
MX#*2(M)G).5$[&0N2HO(22 D$.(@";BXG,S6(/[*^P^Y6F@<W@Z]^9V)$I4@
MZD05?1$A"0?!0=(BDA((N(CX&6E)$3E[$%Q$"G01)"MK;P<Z8R_W7?1/[/\0
MK4F=;ACLI?_,<%LAV-4.B]OZ+D61YWN(X/D'PR;/5M "VVV-NA(,@][\; ,!
M5Q#[A?[OC%0<.^KZ1)W'2A>Q&!2WG:NKBQ/,;I-K,R1PXS&_D-S1\&_1YT?D
M^0[UDZ1_=.RW'O"_TF.JESNY_\_Z^\-8W/_H^6^ZN6F)GZ?Z_Y^=QMG])UUV
M^J=_2TJ )$%G9&1%),6EQ$7LY:3/B-C)VI\1D8;#9,4OPB5EQ6'BW^4[_<Z_
M_X[AX8A _SV42E'_?P^E/[7Z=R&;<<W##HLXYT"=J4K_]8[SN\A?>?Y=-LR1
M&DH1<"6Q[XS?"?\W#=M_+RS]'P[;SRO@_^W#]OM%YM]B\[>@_?7303N7_Y/U
MYC<R_KF>?0U=ZIO!Y[_G5 I;V\J?AW9+,3LI>W'019B]B)V$!%Q$^J*]-#4G
MB1"1E0#)RL'L8##$Q:VQ_!OO[T3#_T=]_@?O[T1C_H_,^J\R_CFP/]GUE_WP
M=Y?\L1DX1[7#I@_@?K,^G[=S^->-S7^@]K\[Y:\ "F+_/?5^ZL765Y74C3)"
M2?IG[K_(=#_#_72+]_7^4>S;#23UWE7LQ\WK[V;B_W[:!MD&V0;9!MD&V0;9
M!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&
MV0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!MD&V0;9!OE?!J'[Z\_!$6BX
M(H\'C[(2I1=0 7;OW+5[U\[=N[=^AW8OW6$ZNGW[Z([2'SIPF.7HL6,L1YF9
M63GXN5C9>-F9F;F%N7E/"IP6/'V<2T1<Y)0X_ZG3IS:%T.S9LX=N+QTC'1WC
M*59FUE/_<=KZH5_:C[L:?_JAWY< Q]:O]O[T([X L'O/SEU[:7?0[*-6.QX&
M:&AI:7;NH#NX9]]NVETT# #-YH_\,NS><^2$!..YO4=Y9 SMW*[FY#*S2)IB
M<?B0L =/6EJ9>$'GC0C/I:1E58SMKX56'>.#F.2].Z/Z'N9^/>$%XD;;$/])
M 35U#2@\7/-68OX'*A(;58-?]0"H.#MH=N^A5IYGH&I)!::EZK!W!\VNS;_>
MIZK!L.N$Q)%S;HP\DE+2AE>?Y!RU"WG>\O[\M7>[J0JH&&%S^7#V,JIJ51]:
M?_TMWJG[P'^8#L@WU$4U.6640&M#6HU>3B9[+8&(X;3B[) LF>'TI9O]9 OL
MA6@4VTA_ZK6;UFWE<B>M!@33W^KONQ:%<\%_2$9RMZ.P'N8N'^=3(SG*EVGZ
MKHR)UOC@LK-9.[29QIR<TXA#YLX1I:!)>]6WC[ ?ZDBI"A^-D-T,^?6W @HM
MDEJ7R*+$B"<?&E_UAUO<&3BN\WYH5S,=)H<".(5[%>GU.2\AJ@>9=$#6[%H1
M*A'HA(]-G(+/M&\=A\6=U#YP+U0@Q6)9U!!2Y7_%Y_J8UG%&]L^<'1+$<-S#
MO;=$1%H'H0(:6M;:\A3@XNFHT<\A9]]0?6!G4;25D3"V+RV21Y0I*S:M4D9G
M3"[;6<X_R#G%T!#K?\7WRB5CLHKVD=<0:=?JF$'>D+0X FU+HWJ!U>@+0TF2
MVJ3,[232-"PIA7ST"+EV,3"D4$\4^[Z*K6(@*3.!:"&8)LAP;,3$7]7WC&?P
M^'*C7S+;H?E3Y7C:5<X#@M$%I:&(6Z1W6@>(-TVUI"Q&%@0CW31?)[C<+\]5
M7ZRW:J\3]#0\N[KG96O- ;U0A\(S/9&XN&)5?3IBH :^J*,NQ[#3B*QY-QP.
M 4W=?5=UZO@5KB LB#0NR$O5K/RL[_7[A7G=-%XE_214%!CQI+!Z([! PB$E
MTM!$-L3/A(7(>)?YNC[J5N'1[" .XQ$/]\[22X;U'?YWLFHYWM"?[38MZ2$H
M511-UGU&.H1>DKUX;:JFI"'P3'FW!][_3D 'GKF[X$:4OHJU4*9)OEO_9"LH
MZ+15IWQ "TNQ2=U[DQU>](09O]Z#\U#G@)N<&5F/_8,$05$@TT+V2A]BDX*G
MX'OPD="LJ%S1B* $UCL+@9_B@G4^25[QIAUR@ET3T)*^%R3S :I8>R?.!,(<
M-8LFA?"F%!OI\GQTP8'J%WBN1M$8S5( 1X*7K,X+2*I0FM\I]U8U/K1I[0B:
M1;$1&V,(%%Y5=U>8-1K.X*Z0A_:)? !'-B<=[[]]:G9]KD+A?MGDN'\*<[VN
M,/;E//937Y#S9R9@<<^;8+@.;@1G5OT!*N=ZQ[ZU'[6$Q>,+%L->KTF\Z11[
MX[_[#P#8=;QPO50C$9F<,UEKE_ZLYD:<.9,I^'**VXT5O6KP)YI+UV\X9<L;
M=WY\K5B::M#YJKRFP&;Y;#L%H$LT6/)-ZHEK=!Z.&C>\G 1[2"!:94<<EZC9
M]XS4ON!&6WI.ST4>=;1G]DBG)UP:NIR0;O;JA2#KW5>6<=I-(A2@5=N]VQ;J
MTGTQ,:/(N$$;>A ,EGOBE3-CO9QB"/&GD=G#X0Z>MM;U[ DO#9I.0Q?D!P>9
MX$%,6,T:N_0@>BL.RW00?_8%<X'20<%(72V6 ]FR9<1,O0);@.V*FVZ]8\^:
M4\^'!SUZ6<,8+>\[IT^1;-F.LXJ5A1@:2MT<&ET+BD[)MY).J4,;M ^DS\DZ
MIIV,N- ][CW8BA9<$221R'K'JI;@^[K.!,# \R9]A0__2"QVUGZE*YTW5W$Z
M'>[-&9W^W!!*YSX!T!5AO-6+)_8?.&(^&VIL3);W*$P*--W+N%87(_N0>'2_
M)KO8P1KGM7,A[?E'!J=Y]#M2<$-7TX>J$O7I./SRK>-L2O<'(EJ/1]\&!XUE
MAV1A[K(_>UAUQ</SM*)&1M;JFMV1 ;RQR7N;06FW4C:J>M7+M?V+SD5TQ+*:
MVE0YYX,:!0?!$Y:^95-EV#?^.<FZQA_FA^,DGUVZ.LB=)'\TN]-R.:2TR;O$
MU.HDP@*438ILE2.6!MR "KX_P>;6^ZJ1;=3ZNGI=C^?IV)9ZJT9)S<6Q>^]Y
MQ XL&( ?L0NI(7N6=*70BV_:@X/[D\JETT;?Q20X",9)GW?*U:VP03WT]U8J
M"G=.X^(Y/T7,#8.4*?0]ZXL<CSO];HHV\^JG3MZH(.?$J&>;H<?WRDYMIZB/
MG8^E%[*@)M#:)5-(6X'K9/R]=PK[WMDDALZOV?7L+B[E%XGR*M5=^M+.D>[#
M%61E-3 Y<$7^!KL$?[H+\P5$<7E4UM[>?KG9*)-^U?4D-9.:![DRQPMG]2^1
M\[V\/JM/IPL8.[B\?*-]Z&93S2YG FD8P'_:#;*N\@]T@YKK[_C$'YZYF':<
M>^&:)XE7Z_1HD%EGV*,1K%CLH;/ GY;MF2?-3$=5PWB+9,'N\QALM=2;E?2L
MI$1G<"YI+^NS"'.&DL_D U<NM34=U-$2D<YI8"Q1DN4-N3SA!>P9[NL 62VI
M%S *DHI5);A+>U.CGURK"-6JM L#65,G^"/J:G1<=+DKU0Q1W)(+MQ)&QZ:-
M+, ;U=14C:T2EAX#E_6EC=^76MPU/ZH[-%Y>2]87) 9KX!YGAIBK66H;+*>8
MY%SH) G<WOL8<9W>,K-",.B:Q:JZ/@4XV ;B6' X:>\V C!5]Q7DKRJKFIIV
M"SGV>MPRBPK1S,2%9'EPOH,JW-G]ITSEI?:BWD"9C*RB5_H'#EY&EG9Y9PS'
M>5YM_O-#$BDU(R Y*>[T4*/LD)><$EXBTJN@ G[WH:# A?32>UH]62;O80I_
M-NVYMX0G?ZQA7SK\BB^]M+I\HMWK$P-+Y QP[,A IFM=3CTV 7[W!:&M@&7L
M=<S6^"<40$X17Y]=WQUF9O,DMTL4Q%&DN\L*GUM/>]$;<JG!F63'Y/GA>:,\
M3V]$&MGR;('%_%+AI]F\Q5BIB),U@5U](W-Y+_RY.8R,H@9S65\D+^F:A(N$
MAV<EA=BG108A63L%I)W%2FNB0]P,^TY-%Y5=R(I+].C'&X$^?7RGY]$C4^72
MF8DRQ]XV->JUA,IJ0W0E)9I@L7-%V,7Q)KK8/_#TL<\,I_;S<W3TK"@%94E'
M@+!VKA5'IR!_."T20H/UG ((*5U+H4$1?' ,%&$3LY(W/(8:&,LAC9>PDL=(
MQ6>5S]W>U3%H*/AJEP]?;L*P6QBH/I[G]". DRG\0;Z.1H?Q"[U75KS)7A),
ME\='^0G\2,Y5<)K@L5<O8H_>6=07/7K@BMT+0E&3LLI!'[XPGDU^ZP7X&X#F
MRG1#9NXBNL20+SXWKTA9YFP3#2G(6<B$B<5?D'#E/]T)_5=IIP8RHC2]HX'
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M^+;/Z5_O\<+>$C3NZ(O%!N>TR!5/;,;Q;W'K-0='W2M07D):7YM#LWJXD_3
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M!LB;/;:5"%&BY/0WG%OTBM@AJX3BXYI%NQV)C!!200JTB,I6F,O*B#PZV\
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M2^#5IIM&A_DY:4GCM-(^4JC(K^US):QT#:KU?C7L:<U%/U\>$8GTJ3ZOA_R
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M6_#^M-%WW$<SI01^^%W%UMNV/P;DH33 1SD2XMNS^F^^:#),Z/V:<\GM,<<
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M,?]DVMS_V$8GI_J[WQXZUEC\..?S?\/HU2O/^N26@E,LQ19R@BA>;8E04!>
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M,7'(+4@N*&.\W !>DLMP 2NM6I]G.I-TC^E_7S^_&>8/WCR\<73>HG-'; ;
M][<;KIOPP-\G7P$?2Y)%5_9#K]#XW_S<Q_[?[R/.#S<)6_"IYG0M&::-NO=7
MBW>XIM=:_F*V0 APB$,05[<+^%62'O>K#KO1N!;<-\O6=C+7NXY/IU!VFD.%
M67DD)L*GVW,/#(=])UQJXSIE?NOWJAI6=A+(J/CH8YW: [OQS;;B#Y5.G"=X
MD]ETO>7N,--/S'^-XMR''EF'#-ZBOVL2GS];,)1XR4/#20X;D^5'XD#8^(Z:
MWIO:7<8J5OS2G=^*KT^/JTW]6LF#B?&.FC5<V-V1%;VNVI9/B?7DC<4@R.A9
M#D[F*&])A#S'$Q7NPE1Y\-P@A8.]F*+1\2:17ST<$6457"(P2YJQRE&5BJ+/
M@]WP]"=.TYMOP>MK7X\+MU.&$2VCQ>&+N"7;]W9^NOT;C+T.&\B2JLO^9>S8
M@QA?E.N:U02 =]V'@C1'F[!@Y%_KI8ML//&-"_CH()*$!W6<CHT!D:$?$4"M
M] #2]*9+Y_6TJ/D^B(WTW=A0ZXEHPCNP(Z: ;DQ-V*D^>'1ZLJ_\!0;"[>'N
M..1F<D#7-'(AVG9"O%[6]P41.B]=-%M,[DGN<:1\]I:9@VCZ!C[L=R#7@#L]
MD2K9F*+$T*)(7Y3;KX^J**(!71V*118)[TMJG0>RHL@4NBR(H:-T+FA!:RW)
M"5.\E-B/;8EL"N1"[_4]_71N&C>H &V+ 2[!VSUO-@H'2Z%W>DV";X+=OA0Z
M2R9'8XJ'WI"2A(X24)0@FL5@,)<]%5#??W2:M/_-5]->^%:R2SKR'MF[+"M1
M8K[Z4&;"W0?W45G0R6/=I#)36+EIN*<B*N7;2+'<8\A(!-4ZU8]-'%1</L;!
M<\E81^#;:*H2Y^H7F!*+G3?U@-(??Z^!4^G9WMZ-4)G9+;\R$&/V"Q*&32]:
M//UG)2-V/N()DR=%615,!E5M\]9V[B6D#/LD;,'M!C#$#(_[C>]"-O!&9_7W
MU08<B7DU&V:_]0U3%++GPWL'6GNE&6Z6@T$T5V:?H@&?"N?RZ]&>OS-Y_*/#
M&<"E.O1N5="Y  -;0N7DX=38-[Y%<?01/*=[92]TVBT'6DX^D&R<8K#7,6O:
M6VY;A#8OB?EQ[W\%JW%4W"QD8D>B6H=.Q6[__FEO>@_G=L+T^?5BKHW[&FSN
MME&]\S02C0EV:%@$P1Z%)RE6ZHF  +I#5FOZZ;7Y*1DY5<?$$?MNSLE363W%
M0)H"<U.9 :0?S9>(LLFVUX/J"8IS?Y@K;(;[GC")I^?RW0[\166Y.%/-^D6#
MA,S \:_9,8SJ_>.G!-@K<<3N6IUIU[V2 UYOH$;V4&+E==UHI#.F @:J[O U
M?TEO?0IEBXT,.O/&\[C@LTM79W#20=ERQVJB+)&Z%1M 24?>=8IG^&W 47X0
MYF*EJDM:A@=VXYNNV5EQM5@#%MR@>,!N*?5G(RT*L:-R>")7PLN+4EF((TA:
MH*@VN-'ZH2X.UB?C*&31J-.1IV\N?8M;4^=!;_\$\8MY<J<I\36L)8J0+.".
M^-)H_Z)MZ&:'BX5R%2VA3*5L'GI8;XL90XK"S#.,;ED <622BV+ST):!8G%V
MWBCYN^OJY#E5G:TWB%<W^/(S--^[>?^Y&6S1Z WT4].3HDB[+%(5*8EKO9,8
M@Z*$3/>9.D5_Q/5]]@G/R2FLUP$G*B 4:#//,J+;.7B::86$CO=X64YGW#JD
M,@T!IM\*![1G>5W7^;2>J_-M' P@CZ,8NT'A7^TP>HI#%8NV:[G."2OH$GE7
MOJ:5>THX<8MQ/I)PK_G4,QSVX--VI]H6F@1!7'N"<$7>)L08'++PYE>F1%\?
M][&7D((GKA(PN];]K=;14<FW_X'0HA073231)]2_;,2:U]O;G5): X2C >KD
M*<+4?5/_?B,^!;7RKNW6BT;(^C64H'ED(F+SIU:I%?L!P*S5*"58_(3IPM[Q
MQ_W6 SO2HO6NGE1/H/#2@8^^T24C-K'/U:NTPIT,44Q1]^F-V: 7H*&A6V3'
MI<_[52/+MX!K.<&R2AH^Q-O719I]A NWK.IRZ\8 #D)Y4<K<,Y%K2#OSPO3A
M"-VKZMA567J%A<%<EA-AC;W3S<6X,8TC8+BQ:)RW_<N/1JAM;39>V/HB#"%9
MN>.%]CKA8YK#RN^$G'J@ZR>.MS4W>([7S7HHJW'+^\7C2Y K+ZH4>[+$*Y\^
MS*(\&$USBTS4D]0:C:I= 1$?LBJO6Y4GU][:XLNQWV&Y5$/#UN;E!95WBN]D
M".ZL9_XLPH;]A2\C3URDVC%:W0461^=@?](I&">3K/R26+U!J) /8*O+4#^H
MR3Q.,_K"837F4WRS:_4;#'J?ED:W07PJ71YM^8!RHZKL;H#KQ""-SJJP/KX"
MW_[MC&6@U75%B&$<I:W.3YF0@/)H?UIE<FRZ$ONF"B'%T-33,<186<3 $9 ,
MFK7ZZ_X[\!6?HSX9#L=LVU+I%>K-E]';A==660F."B%)51.2"W/OD#>WIQ,Y
M/L(10/1N#_3!.+OH0_I[O2UA6N1:AQ@)\='00T>!,S.1O>$/)J9"Q>$Y,F4(
M)QB'D':?E>NH<71+  W(TVOH%:LL/KFV!#/W^J8^4BY2P1<U^E E>O1/:OYY
M1#JPPEK2GC@5\!^7L1%89[-$*F9<1U>J[QO/KTLP$OZL<YDG%7JMV\Q E_HC
MF<P[C_&$/W;G\@9_?@1B2=_BDN@\9RXA3H;7R$H#\>V6>4):]^-ZF'F/Z3C<
M*[1#:?+F'<_DR9+<[>@]$W_(#?^.;X.]SA;#RR=,7/M-4L?9C1N9.=R3TK?3
M9F'^Y6/RJUK^;H;-J^<Y WQMGNWRS&^Q[C/K1^<%>?5_-!/-&"F,/&$BZX <
MG?@T,BN 0' J?"TW=+7>G["I+*VRJCV;"5*1]5+Q'[1/K]JRV6'=KXP#M>4X
MNU.X6[(5BK7?"XA"<P<8;,:+N"''7"^/; 76]D[9&>#!I<6<@0Y]G&NQN-7V
MA\*7:=$1XN4)VIM9]J)9JAK=>JRSA#JW+@VB[/0A#:*4=]%)B='@-F4[&IJJ
M-[>5L@TBC0E:-*.*M3=F#2%35@,G3 S%S&.V$Z:UD7<0!<-Z/C5C X%C$C?9
M&&G_"<%PB"4'.@I:T^'CH:,&6Y+/#"0OQA GD;([+CJ"N)=1U:TI\=QW*THK
M=RP'UDG-^2F*PZK[%8K!8NA*013-IU,VU S@)GV$V1!0N!/Y@JG*O-G&(?RR
M856'>E%\W>^G<G_[H;L:%Z*D$T+S]*C__JKKN4^UGL33(==].E4'HJ>MEZ]A
M)<O!C.S=P?T/N<M72+&G TZ8'-NG?V&*>\#TTRP4<LG0@$_;,$GAA]0Y[_WU
MGG$_*;=2;[A,^B8&)F%=G78J>KKXZ+;I.V)'0<;ZB!V73QE*$@(O*@@T3;\&
MRC=M\#2/CKE-C,IPJ%:Y#%($B0NAE4GOH+#;N?H[60[BK+T/0FO =7[NC_:B
M?'L-/7,6Y.M\DC8]6R:"O.X7!33,.YE0>HL-+S3E)'J^6)>6%]U6MW.F3F(U
M*?;6_8E0UJ H)&>Q@D<%H-A0==W;@-]K0O-YER,RCL/3MEE5?]R*/V]@L K<
ML.LE"P#8<7"HW68V[B"0?<*<'.<GGBHW ^P:7"M$!XP\7<EC,24!6._WOBA3
MTNQ!1PI#OM'*D ]YOOMYA@V%WW<AZ?EZC--PC$U<IY5^= )LZRWM_W]"FW4X
M(M!H3TO]LH:/Y?CRL7+KP#]%M?5Z%^"$J>2;<^N>_:;(GTW2_O';2/<JZ.@;
M+X6M'@@W0YVZ5W?&AK"-VMZ*_RPR#@XN%M7\;JF&3IO=Z1/R_T0J[)GL;QD2
MG!Z?I2T!<%QC9YROO0-X.F/>1W$/$R_T!HC-/+,]\AL+4P%OVE6-.^[S),J)
MN!F7G'&+\\]"+&%2Z+U%\4/\(W=$;X8M1[*J&;0;KN ,IK_KY8S^;Z\^BU9%
M=\6FR1FZ #^"8!-9R *IH>C,W;2=Z]XUDWH>!7H+  &\\-%C54W-W^>X)K%X
M>Z":6PQHTZ:/&6\#Z/,NKH#G 6NRONFFT^N2:>D).]?+Z+,AKA5U]B+22O)N
M_$J0G\OZ>*#/3,I8M@S8Z]@*,++TC0*HK7&_%O+4X_Q$[(<UR*-9]I[6)*I@
M0,="Q7Z1^<L)WC4&TS4)#9%PL90BG*(N?2X&#6"-;@@K'\S)N*A. !Q7J+%I
MGHL#G/-J1WL6K<SU%]>\SZEUWIC5CUKBLBFR7\EV;9R;T2;=)A;FFIC C$[5
M79-YL!!/R\=Q%R:II*1*.'66&&;Y\E^M\ZAS+0X6MN_)2%](Y[Q=;<W,DV92
M6#O"03CC'(/1),7YCFPGJ??9;T?E>A*NZ>LAL:4>$ZFZ+GWW+!=ZNO,7EJ8A
MGU&J<\:SWG<]00-[)#!OREYK>P/%!2 *D)W7GI,^U$6*;4I?LW-N&)%RR,@S
MNQACW3_>U& W]8!RM<,(T IEFXJ[*VX5%>6?;UY8_*60JA6]X#Z1X:]")C*V
MJ#7WV+U+3*V*VS Q)?F1FL:VX]H_$N>*<Z%M+T<RY%^K%J_G;X:XVDG@>"L6
M.Q_CB!8E0KLW3$:*+]'D@R_!8:)/R=.;GG+Z\6QL%47:'S9__U=7X/_/:OFO
M</H91[]C52'5[^3MW="!""RW) QQH.!&$_B,]7Q6:+T#M;N[(]SUP1E^E;'M
M O+6F+FIE*+!I6?>169K#[8\X.T)VDX6G<J>)TREB85?:APN$0>7:EB$7<9;
M_?-C5%H>E-KB+J2]XZL=B'ZQ-]CMR216+ GQ'1PQSAW@9#&R2^I\_'1K"\XH
M,NE4G:BO%Z $TQZ&?%C_IU)C8DXN"U^&.@^I>WG1BE>'S(P$XYX4-B,0>SON
M,PC)[%N4#!%<]WW4ZL4?=:)Z851_H>*IB<SD=.;H4D][\Q"23BMAS>LU2HI#
MMIW'XD%_W&L*>>P+?;*^27D]RVO"2S&UX4&'GGN9Q4R,=LOF;TY6$X)QLGB;
M6)_@BF)H&6!_1,&%N=TP%H%]1I)8F!B8(WK01#&<3Q4;?*"C2[<S.;+?070>
MS$WG)WDG>P?=3M'>VSC[_/';QOO;>B%:55WSO3XK"5*T]2!T5'$W1C53A2_=
MP][F>@QUZ9(+M%BZ./51@6=>C&/:X93O/" 5?#L50?,F\CW^/NP9?.?E _F=
M-NL3)BBX4NQ2XPIVI\)@EES9;>;Z3,7<]_XV77F!2)RUXBFV8C+_AP";)/=Y
MR5K(KY*?^<KT&?<VGQKM]B [L1()>/(9!=NAF_E9(SP,^(ZYZ'!2F5GO:1PB
MWKMM1GO,9(U18,J!GY"S77E9-;H4QP,FZ<!C?"5;J-RDS5*#CC+ XAG%EJ_,
M92""&:\[<"R0@A3X]NV;8:J%[9#=V9[53V[@!*0Y'%Y  KD])#6;SM#LU/F5
M'S1_7BUR-3:&HM4M+PX$(!\I*CKFF\@=O/(0-*_67M[[(\GGYHBU4?G^_F#5
M)5*1SQ31$T1AZ\/N*IB;-&GERQ]QX.G\.CIZW#(OZP;?DR81*.*>4>'_:O&L
MM6K5JM"(YN:>EARN(:N,C*HFE&O*P"8[=R[0L;O_+S:$53.?9]D7Y2];.($L
ML/H\%FG"C_+Y    <(>016AVKHDL#IE/<6-OKBNGQ)"?M;,1%A/+4;SI7'1^
MS(0[9 #>:8$0!L)CL(Z<4AZ,S&L=0KT-9E;S]4MDSW0J4OI%AX%S<5FW5R$X
M*B[%69_0@BPYK;WN/?_!,D]F8;US54.V($U^(A"BZU3SN%7"H0Z!2K^2XN?5
M>"E8I"&#ME1(IQ&),_.SBJS?Y6%MK]T"I:]HP*AR6*"\:IJYVK,KB*?[H."8
M<+;]FB)Z":F\JJ.BS,JF.28-2W9!E%DL+RY]0>FQ]"R&?>-3<B-%U40Q%_+&
MQ)@(CH1UR\MM[9&P]5$M(R$[!G]LFGPNN#DZN08_ -5O'W543/HX$I!<D(%0
MZ\ZV=">G7K/5*PMCQPP5<8'WZQ"6NF9Y*@*!H)4H&$M:67^)F'AB='-3)3I(
MTX1,KE$FC+;DQ"%Y^UKC'=^47%]6Z$&3W2$"%-:'"Z7O1J&>B> \X7T=>SB2
MQ1B!&O"I 7YT1J]--G!LI%4,!4=RWEXJ.K0_BMK=&O*-;IIBE#9[. E"L?35
M 56U&I?NT**"J[KQ]]MY$KZ+#</=[O*I&R,7#3&I8VA!6%O$$.G2O\#D_'\V
M3_^YD:J52:>=,%W<)OJ55SJ.5UASGS"9)OQC ]4T&.4G.'@ AG QG8[Z_2_(
MS%;FX&"%^F?'18]'5XXF]FK3\S)"S84,I1/K(N\J4\0=AC\E7PY*D1QN5=7'
MU3N*YY4$ ",JQ4:.;%%/\/)S.G4Z6@"[NSB6\81*2VB7E]CIY2-GO;!NC K-
M7SYCRVW1[^NW^=A7(5%EG<'5YD*=O$NO3IC"CR6L9=3+G);T$YRDG%?-$.X-
MHR3.W2S.^@528JW_UN+(ZP*4XYAHXOG:.'-B#%!'] S0\&KSQL.,O)Q@Q?B7
MR"K>^0F^T!"IIP5XP,LTB6NRNF/MG:AL?!BK<\V@A;#. [H>?U@A%;T'U:/'
M.LCH%T>MGM->LY0(LI@'9P^H(UQHHRD!>)8TSHS8KMC,+_CG[V/(^#*A)*S#
M'";@\PI^EESD'QDYK,4]OZ_XHV[ GS60_E1Z&P$JK8OWR_\CZHB5%A,7)T1]
MBWKIXHOJ%C#, ?(]TT]VK_]+GWWW:!$302=,9S7O7]\,IODS1S@$[W1_L]FZ
MY?:C/1'I>5]CM%/D@49FTT;$ E-%\W_?0-LG:[POY$&W5FQ&LF_-"5.,.X-R
M>3MM(SR -VBEMG[PT#.J<?F01^;8[+#]][-GMA?/X ;572#70>G<T<T=_2_-
M*-FEBOC7+:DC:6H</Z,O(0C$7(/[!A<EK1Y,%DZ<1=4_/M#5(F75RXK7E15?
MDT$Q$J$+#:>!\]A$A9Y ;9/RBIULLFG%1J3I+V$NYY :+:]RWH"*;5^-(TO8
M(U6J_72?SP_T;[G4:*"[!EOVUX%-_K,67S9OS@XB^?)+V52]/U>:1HX09TXC
M?T4G],MC=1Y@[)PU5GG:.Y<\N"4]BY8FJVOZ;([-.&[LF:=UC7=3T7[@55(K
MRCVYQJK+O#G0@)=]UBBD_&TN@K+17W093M.="0R*_G+ (JUO+=@X;&;2DNLA
M0!**51[S"#WUD;MFMNK1HT<A&ZD"?55ZKDP*$\DNP75+PB4%^KD(](<2HQGX
MTKO'+AS+4CM#I6=)0QQI!::A .A6)+TW*]'2,^N-C;49\O0E7W9D/9N&5K>X
M'F;GN9_=\\MCWF^J<VKOES%CQH-Y>I[84=L&2.F%&#" 6'=U2?(Z9LKJ:^T6
M=Z9MDFM:]B%!K]?^QN(#1O#& &TFQSM8!0'(,9;<&D=862NW)A8<Y*S[#\<&
M-CUP[+#;Y^L(DT.M$2S>K6Z(P='!::ABXIY+('V+T'H^):[!M5'&]WEZ38#M
M,AV":/JVY#^LF!GD[5'^>7=\3IVC!#T)A3%'3VO9/6Q$.7OS*51F?>Q6E+ZN
M2DN/'H$NLACM*TD:J=H46L%:4D*"0OB58>C@S#$)VJ+C,*6?<&1K9#D#X?DN
MPIU3"BC(KOG)&HS0]OKFRZ\QA):489=+/BM*X7D<]\FLBXF8\9#LT(M%.)%V
MEN'=T50G'!6HE4B_4PV?PK/Y%U",!IH!DAP& [SK8<M)TFFDCWK1%C*T914K
M)?0>=3JT0:5&[2I&IL+";L2'>_0!O.2B[LRH;]R$OZ)37%L4'0B<BHIR@ F[
M\0Q8:T5HJ#%6;3(F]YE4]9F86HNR\XLC;4C/Q%+J(6@QUAKGI2%HW3Z776Y<
M*(+3/U/V:.;S-9O.H)!7U94J$T5B3OGA]0](2;>-B4)'#L@8M?2V_M(&KNO*
MIKOCZ<,S)B4?O=PCK-%9U7(^E5BN^(/.Z<U-:9LIMIOI@ D=_B:I(,P:9F2]
MWG3KZ#&9XX)DCL6XR\(KLS38M9"B!6+UQJ;PH&5:ST=R<&7>%GG))CZXT?]B
MK<-()P5%,J3(B#)>VXVJI7^JXGIKCRF8>^8^V]S%%@CN<:&?QU2W[.L<]]JM
M[O5%75MB">-[KX&-RA<;FK0I\^P;+O*@K)I0E;/SV0\*"G$X[6"U,NVMJ1B;
M1-(VJ^TGX]%%5=5\<L^BI]=O8K6@NMI/DX";PY_CB5:73YADV51!GUR\4UPL
MK$&,Y=#KAPO0]IP.\.KA=0(AKW;;\-=I P0$R:UGH.8I][Y5,'Y%/:J<QQO"
M5@T?>7+L[KI[>2NI'>;2M-=<^T6UUX2^3]#)'-HX86J9 .7\6V^S^W35KE2>
M,$7W&Z\K,,;3_<0=U!\PW2;__M](]?TZ&[-#<C;17U(1S^C",=.H%A?OB)?M
M*-->9M#<P8!TY%.>$3PE7LN!NS:,)W4/9*^(3^3KG_?T4?GVDC3[CE8K^*DF
MTT$E0]IKHP2H9](^3R9ZD*UBQM][4R>VV_@PI HI'+VMV]8$%] J-]I&M>EK
MKJ,#6Z.% Z\_^WSTW*3)OC [RVZV)[?TG9E\+)KB$;F6[(ZD6K&TQGGR%@Q)
MEO/IP8*HRP#?)@M79Q<S+F[7]M,NVH;3C#AE8L''<W"8%H>ZVI,^4-ND#;3(
MANT26E1(^]O-")7MVR[7*C<YK)+KNA9G<L+*>F@,A$=+=,T<@,BPJUZW_\/K
MP3]GX7]H.^W5QS'K9_LJ)'98X@$NY=:W5LT?O\>8!N;/2QT]^K-R]\]%P^KC
MTT"""4!EZ:7 PHW:N'JH7++[+SO1Q<%>3X!F%E#5:W"X<RQ20/JF$ D=S"AI
M'UITOT":O])RJP2-7.E1#6QXVS0P[%/AVIU-)F9YC@&A$I<#7!MS?-9@+3;$
M]1^JA@/Z[(^AN?CP&A%+U[M!%AT]6IU\82V6\TN2L^TH1-J0L)BR:/E%2]8<
M/D\3D]'/1=E?BC!(%NG1%R1'N0<C7M&]:%/AJ3@8:%L@QZJP&@ZY9J<7".7N
M!V4+B J!LU\/KZZZ<AY_BFRKV'*,8>E<[IZ;"9IK1#H-/ ZY&F^!7I0?&"G:
MN"\6F@[\]GH8-IT;XE>@VQ!_N<= TB[(_5Y:EV%;@PB%@]8HRY5PO#IQHP%[
M\PS_'INFU]'#U#>QAPZ9Q[ 3)L2W3O%')MG%V1%W3YB>A??BN0.8M6/.RC+[
MI;TK-E0H#/S!J&$N@)WA"D>7IQ/X0L,VPGY1][IJW2"[466P5:P.5UF+FOOW
MQ:PM;C+.YU_; 5 .M%(PN9\Y]FUO+Q.GW[5,'[_+N7<VQ -Q_/5YER,N:A9$
MX4#X"8B^H'H9)4IL^P@5-Z/&1DE?K'(WN78=E4OJ,ZW)W99G<6*Q);I'H<&K
M!]P#,D6/!!0(+[27M+9.0=?_#I-_;,R5CW\>)@?&%8,IJ%MGAM-[#!QS=&=L
MZ**T'%3T/E$+']J4%,$2>8 0_>K\#SW'EP[7NIX266; 8]FK_F1>0%H6%9U
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M#7G,(%D[#.7*60AB:XB@_K8//BL.:44TC_4X56_>RB-?'1VU2,$O1;:!X^Q
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M7<=\K?-3EU:ZX)HLMC3?M17]CI,+Q!"8_N-%B7U 9(*QQICY=EG&7I"'>MM
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MARVWQMZUU=.(.*9EKM77>VJQ(_A[_*YCDK')WW-^1_4B$9%JB66[:D^"S&>
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M(8BW)?;5;Y_KK304'8S"WBJ":/%[=9(M8\OB1+5AM29+SUJ6%OL^3VX?Q5\
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MNT]O5GX0YI"7/A7,,GJNI NXNV'^#.]4>3BO$3J<HZS?M^R%7$N]#*XR'T$
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MEOR@2!ZH,3-;+8Y]M7#8F6F.3/=T!BEL)*3E.Y>BL725&%![D&I"\4ZJEK=
M+//L9SR6!!2:P(\-A/KF(\NDGL..E^>4P34,BB:'3WH<YY^(QAB,\#@8,Q3
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MV35/T3?]R^Q\3B8^UJI$O?T.J;Z2#(VP*-NR]O%A7^M"="02M'_8.KP:2?-
M@IG)W"]2*CLBIJ,3)R)IFQF%54%@[;?I]6^$U,UD9V\(?^Q=+'?&N,)3^LTK
M Q:O)D.46EA90F<<P^(+(.BK_777\?-.V'QL!E8QB,$LF"DWM]R<>(6-<CQV
M!KBZSQC?I:.G2L%@,+/'ITSQXGI=-DJ"\@JK ?*FU:OI^J$ >[Z7?^D8+UT\
M75-]7MP_YBSJ[A[G"K%GG5*<20//I.G)8OWX$7,Y0QH;7V<=$"!,N*)6V88G
M8V??>4E+/Q/G'F'&5F]:1P86X\#YBI5[.PJ!QQ J8V.0Z^A+%!F.PAASO+UX
M!-^BT_:F@&-JN^I]"<8KJ[)TC"P/0WJM@V+<72P;1@QZ&Z/'"99):.H5<@^(
M_+01^XK^32C6PC,^IV89M'04+  6CV-82HXI\9&<^%+-^([S!2/;5XFNE5V,
M,70IB4F]7B=SVMUY%40GUT_G(RT]_65&Z,W[TM&'1GX@W9CZR'"43%XT!_N>
M( *S)MD<$2<C_B<($>$T=K#2MC<36*+N_L<,]I???VTJS RI1!DA0M:@_+ "
MC<D73Y*&!P0QN.T2G@NQ H%+&.F'U25=+*@W_*EE>K^6,:FA+=QIN2J4$SNJ
M UIOY=>"0A:C6!>W5 /\8*EAD9>1O%U@EX#H.-;!G#DFN@"NLH-8Q7.+]NDO
M3YE%*PUF.MQ-<-"AN_7&T9)\3U[_#/!8=6CU XM!M,CXO#JNS)2;25NM'_"#
M]<__9^'O[^*CK_=(-U(ME!W-W!:0N^(_GWO3PD:Z[N:F:>W1=6&*Y*K\Y,?,
M$,48)A4.7Z2;I:*^Z*-Y&U8M]2YO@-R+?W[=?V=?). '^_< 0&/%D][17)[,
MO$A.;&IX$Q%^#PH*P-B? +,$3L3R->(K_<O2@(G'\-T/49S?C(EB#>K: CLW
M'5_44_W&9[^"Z9-P0"I$K:/ $H/'X= ;BM2%=$UV9[P,&]?Z+5NL<TFI8AL\
M&('5CB^)WRT0/-BU\3F]3T:;U;M'<@U/'EC4V+$-V^(;5**@R H%TY84#/OF
M>N%(\M!UWUQC]/4T:99AFX;>YCZSFT@\QK8Y;!=WO:\TJCMID?)T.6U/CV R
M, MLB9MJLGR]WW$Z@<O65'?)=P.RXS(1[&< 'WR%-O$:[4C*224RAR>91HAH
M<]6 $$:(ZOTV164C3FQKER?<SP :*TW:M:JZ3:9*L09=Y^35@F'*Q$Z-]>DZ
MENH&CQ)0Q79.[WW[)&6!VRJ'JGHXD\0Q$V]DV!;.9]&/*.@<EU$N:L#)FC<@
MW5I][^UJM/]=?=W@GC/ J2XM&(2C,[C'?Q^&UM+0J  &UF_%SN;;2\VE&LI*
MR@=H@N.H[1T6/ %'V'1MKVTK)]VR3%T:-[^ZE4$=0UYF&*Z!KA/)D1IU [[R
M:R-YI>PS35"<P=V>U?\)(3,7:CHO1^>ST03D9[5 ]5:9TUISG.N'!Y>VCC3@
M'&@]FO#1V%1,A";,9"8QM2!NF<,TKJXXA4Y6^MO#?E*9:@MUGKXK73-"V92S
MW<!"8J3&QV,/-]Z4/+I2V6^8'=V9$\.5)@%:=Z#H,++IFW^JN>&UXH_Q'_Z*
MP3&16>7$HDVI'T#L/-@YR,_)4#&IBI):HGBV=W 5ZP;S_NFN[HCFP%Z'3#ZK
M\F,9W7#QR.7;1>2>YT ]4*)&D@.*0OS:=&  X>DQHNIY^!D:R'IX(5(#61+\
M;"RMARV4MMM,?B/ZAX>:&O_R6KR;Y$UBIA0G#CI+<4O?4K0B%Q)S)! =I4D:
M$*W^*\-(11>Q]8.M)<(8<7EL."8MO,D.6DG^G:A>S'.CC-2;IAR<B? -[_)U
MDL#GN&6X17-:_;:MJQ1>LRC%K1W8=#=AZ:@/7V_(U)R$:F* PFV[0X2MU)F2
M4(,SBN,>HK-!]5C6O#0U,<]XRTOOCKZ.BCY4&G&I#3QR:1LE@5'XS-X[%RLZ
M4R%R.I\:&[ZVSF[LBS1Q*5RB@*FK&-65/A</&?A55CEAE<9]=&MXQ5;BR+,0
MC.:/V0ADP:OW2K7ULQ;/X7.Z.L6LVL\BE'IU\V%@(!0"TF3IX0!V+B-MTU2=
M_*S:!FF>EC:>R9KOH!^/-)Z_)R5KN,W3T8FQRM\7OT(CYJMR:8H_(9;2*_:A
M,))*$61V:60YTEK*\A6%1Y"FM/S(9P (-LB>>"-@T1SV-KHY-#S7X\%XS"ZQ
MD%Z&=O(DR,Y]O^AY[P2;?/TPMXW,4>6^,^!J8?P_06.,L/@O@*;\S-?%26H^
M@Q$LD6.>4B]XG1SLDSJ>'!J68^2 48KZRCQLAO,HY5_0$J,**<8UY\E<<M;L
MKKM5D_TF>P51\D*+><=)UU,'K<GZJQ4H-:4J43FC*GS8>R(0LO^A5*2,=X29
M_CKB^:V7*W!R4E1<57?P2Z^L)F 3_=JCK#YSH:CK/-G/ '=T_SI:7M!#&.F
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ME^A5(O";FW^_<IUF6@5%U@&?L?S>U.5-C]_=W[@:QQZY81-\3-;X>';&@F_
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M8VV$T$L]VT:3!ZP<Q525<(_=#SP:BPA#Z"U6C1'M*CCS?M0P-\0^4I0#8V;
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MY:?!']<$9,U8 6E64!3R(,'T<)-.\0%F+[;*X 4YPRE0=0=3,['H$U94S*2
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MA[<B&%G=\2_1-&5:UIN0]"2C:31]"MP5VI#@/_T&*_7IM<E'(7)EY,*C8R?
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MDI9[JCF0NQ3OA=&1NUS#5]UH0HU56&_%%7LAHE ?FGRBCYVVG;Q1LT1'CX/
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M\YS]!4C!.OY<>?6SZ#6KJB>+Y?](.>5-0&EAP+-Y&=4;WJVWF.[8[IBOD'9
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M--#)#UR)D=;4G]XP3\ ;.S!;J<031=E2=WOE,'&O)C%>TSY*8]J,/J>N+6$
MW':-I0BGXUST;ZY;J:E8P#\52/X-</CS@>F"_P=:8C_\K7R_2:XRQH@^ S8#
MR'8%%;"$,RZ!67$1\JG=Z^OO<+?#+0RN[TJ-2$!'"LFCBBF83\TS]XW<N&T7
M%#J!&ZJWG*OBH(RBY+\'B=K?+Z'?%66EYW)>A)(/L=L;XF]_X8L]JN^7$G.N
MT(F#\[<3>E\ZCZR7E%+9*UD-5'FV$R@NB9W3J7;8W&GAS[=/]R!O\;+L<+_-
MK#DHK!WMM)EW4<KHH6;<<#P$_\P"1N=(V=N#'F- E +E*WV[IEQL(*C=;U".
MXA;:L_)E5NSXKM?-[&&1 2%6R C7M_VI[8J)M&J8&;<P^/N(,2T:,S]-IB49
MO<#3AMJ4H-VQ.OIP=[&',RKZ4N']O($K\E*K(-EV$@949C']*/G-7QL +_[5
M 3B?QX<[O=$"&]/>:N*+\H^6@S T']/6BP OIS[H@",4I*5B*@DWN>W7)@L:
MJ&N:L?C8"#*GWYRG4\?W!9J"SIKDA>F>%*SI[!G;Q>!<"Y0A&PW6(?9)YK<X
M%^3C:;\ A+]& /LY<OL*#MX?>NM?W8:N[;ZB_BP]9';<2]5^<%N=?KV,F%Y@
MVR[AI#XIZ6S='U/D]K@TWM(:X'5U=(XBXU-81"YU*6#9]34/AJ>Y!T5*IGSE
M=P"\AJ!.0Z]?#L$NP<16KWW"_=9 _0.&)10=F&:CSE"@B]DJ^H=2S=WX5TP!
MNLM2^MFR?K Q]>LT<BBI#-;Z!$,+_7<3[)*0_1>J^=9>QO=Q A$S0L5XD)TO
MAY'1GY?(VX(.]YC^UH.:V?1%E[$N%3DG(Y>@8J8)G(EMVWNSE9Y-_""9DPYH
MKD6=T;Y5C 0"7=LS-H"* ;AO!*EO'%<M3JF&5N2VL:J. :]IN/].YR/?NZ8T
MZ@OZO3[!&ZG/=>-6&A+='D#U>Y?( 9Q/]J,)!>.V(WB4XB7[5J7?1GB9!^L,
M!)S4#\]<AU?PH+RWCHZR-_ 6S5ZR!7LMWC]L:9RT"B3/:?$SUY\&:W#/*UF/
M$C[56+3:/]UOUI24/F6[_>^>A_>VKO]>K=?+6GO29W<UVMNC;_O* JY%1449
MPJ).'HH^\G(_@0AS8)5@3EROXA0B-8#0UK3>AR:UAA<!NOG!I(0WA.4B<D38
MB7Y.B2>F??!GI\D)BX_UAYX"6E]4]X\6Q6FM9ZZ7Q1&6 R38CV9U0/#?X-!3
MWH6[5=V/]L)EBQG'EEJNXW$%J@VRZ]/38 >Q''=5:P#6OTPF%K,U!',-_#S8
M$+KP:/[9B'RCH:)W1\(^N<4I9H**"=T+4T$X**N)PZQ91)Y+_GCNXA[9M$DP
M6'F%5$PF)US9MLF7@GBVKPA#22$>LCE_[V+6#HL,$6"NZYP&0O( 6W\IX]0G
ML,'?AS '$Q2X>Y,F;1SMQ$+3#O3C',^=3@<<-[0S8RVU<A:#BAA8I);M,SE%
MM8P8J<T7A<75KY]>=7IC)Q9B_0%W?#+G_ G D;8*ENX[/.63T5D&O!,8+;56
M7'H_K< XUMKS_@%>!+ZY&>OZ'Y]0]AR=Q;[@OGXZ?L8?>P/<>8XDT\[W."R?
M$N<$NV3EJ&"FK'MIKS^W_:,GB.&X6_'6%3[@8,OYN_L+BNRN 3%UOJ4M&&*1
MT;QW,:ZW]R$PQZ"_ E]Q0LZU56TO%G;@8=\>N2\)IX(WMS"PS<U9JU$%V?#<
MO*VHBKSH1X0V"'S,H!+;^'N1*$;6-SFI;Y"MG@UG.L+HPPF"HUSR2T , G8)
MZ:ABAM;MW9O,_3J-,6(Z[B9]AIM=/)Z!NNE7O?E@'3YP=;DHSFT5Y-44"A'8
MWSB+:7C@[Q$G<X$"_FH#V&-C4UPUHV ?(15[N]\1*KMR[AJER(O8* 4/@D*&
M 5X(U-S"+)G(3"^(H>:_.I3>/&2L%NU*R^_\['#&^^Y^?>?M,]A/C)2T?$*E
MHH%K4C,_W<+!>M8+F#QU02&(%/&&O5Q4ZOJILBC0MGD"?^+[F26_DYHYOPF'
M6)%7Y/P'_JB5:-O(91]DQ.T41+;()SBBY5S>U0HMX>WN@/RUT4"9;:/GR\7D
M4N^@* )4 CY"4@P%'#I8DB6('/]!#RADC-NK!;SN./O\(UCO]?%U?7W.=N2;
M2W;[-,7?#_]V,_^+XJT+&EKK$;WW-JHR-X[<VU%VR#)H\(H2&:J_B;_I?5>7
M*245=?SHP405,_B9Z5@KTYN;*VHJ360]%8G?XVPR'W"\M[J_\7WGU@",6_MX
M;N1J!=L;>\='X3$IQ/VDGC#:BY*XZBBGDCS_4%=D!>IX#W?W&]ZS>\B7XPJ=
MQW#ZKQ;M#, N#E?7UU%R]%[O4:B2>ER6Q<BL$M$(E Y5Z_Z3FV1EI!<P24HV
MM,,1S7[IPJAP!L[X^6C(*98W672P >)N;0XC06'K0QIF7%;P**74.^V;0$H(
MT+V@>C6<SXO$Z4#L!0%'YG(;CNKH8Z9J'4_/H\!V'F)OW2#[[.VZ,RR?!+\C
MU^Q!!O X*/2X%JLWJ"A[<W[>1:XQDB1W$<"W*5DZBMCD9YF@%FK7>XIQ'C\#
MO$=!E,$BUT<XBR;%B%,O#IF4T,8CDQ6Y5YV<FU,S?>RU\!+Q:6#3#Q7"%R\2
M#AET'I\K>)9@HCZ,KS4-M&C*!?SQ3I=U/$=*,R!$ES)807V 4=MKX5!L?G>/
MV.Q-SK@75CMKVWC0, -S(^!1@9]B0=9B@C0G_^]J*&_@8E[1?=76R1S)_=9[
M9!O'P;<"(#50GL! _>BU@6CBNA<O(T/]#:SI-^ITIA=T.LU>"<-W7M7V;_9:
M3&2$;?Z[8U@^@/T* T.7(NZ=YEX=&&Q*K<?SFT9D4S^\Q4<3J_J-$<?42P-B
MONWU>/ 48'J&,D^Y'J /_\QKFH V-7O!WCVL 6 PX8(4&@-(*^-TT/!A/!L;
MN>?/'U SU-?AF3P[#_&]&JY/RQ*40]@J89(I>G$%YY+?GM<#2(VO^6_EEJ3$
M(9Y8>2@*I ^\#)>66L!?*A#;R$@G*7Z>=N0$EESOYYK?[]V]8FX0_.Z'6I1&
M3</M.Y5[<__,^Z#W 0  >/7W.5TMZP+;.3I4FOEDDW G!LQB:H<=-*9@/;.8
MZG%/:V:X% %/5H5?'I'\%*K^#-#T_YZ,]AX,XO,& \A7+]D<RNCY"CTA'X@T
MZJK/PXMWIW5="ADPB(T3L+*H2J5/UA"W#"""<0>RVC[EE!R'OX^(R0)=Q2)Y
M?;!+D#T)[VZU/L;$2)P_!1K<UK@/'ET/WS [.&"]?9.XTZ:FI@J[_[6O W!$
MENL:VZZPSUL"?G'Y<)JSDK 1[O['RSTN ;Q-+#Q5A=D?7!2[%F&FIX188_\U
M<A?P+<O 3JZ(@(N3?Q:&S@$[RIZZ*.Y6YS"BE;&^.6K&20NZD$<N\0Z:ZDU1
M5,^VNF1EL?VP?P#&:R2!L_S LKH^L6MA+_.0K:76>UI9Z43.'Y?^'S3J&L,@
M,508&"X%7(D0\I?^0Q4\ 3_BY)3D.V33O#+$!/:DPE*(&MFI!'/TC;\H$5W6
M0#[YI?P_R7&WJN2?;\0C!M[>K#-B_H>P3MC!'#JD+[Q+";AX4@H>SC^K_!_
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M^CP>F#UG,%A;50/&>PN\>P"Q7NN;>BE)BJ3/WN9HL&]853N8$@A10=TM*QK
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MBH(;0,E 0<5 L3U ZBCU]AL*%9*6^RG(Z9L9J0 4E/OV'SAXZ# U#<5?*RD
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MHR^Y9F+B.26[565\J%=[P)C*T,;G\4V@&=\F6^>S$7N53A9KH2M#<N4]4O!
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MLAIFW;0N%596[6=AE5U;7A,VE4.ZY8(UK@6)FSK"O5L,#(\GGKPWVQC<;_3
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M"NE@C^%2@Z$Q,#@<BB)YV(\36%'\I^8_B"&94T$5!;7'(%'&2"1<^;(1V56
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M@4VZ%9=EYYP\T$*\7I,@LP*>]TN%D;6=^#:Q\ZQY=A;CJ&7P"3P[..5F>XF
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M$BP9/3ME6G2W@H%&D<+$M+57P[UR^F03,K6!V!<;K7!3<T3<_=W)H-N,[2[
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M2F96[BICY3H%_URR22^OXS;@&.?%L:QK(]L U+WNM0LVHFG(T5,QT7PA6?E
MVPJ;*>X7U[J2<:^M+-[)#GVJERH6$%H:I4J_YEPU)KWZ^[JZ)O]X1N;T&3KV
M\?Z$S+;+4)$Q/GA[NKZ-SXD-B<[HERK'W9PWXF^54"J9=Z_@D=ZGZ'8LS76F
MF9\@DMHL:.\N;T5= ZS_Q.UWQ?9*H >-\38 ^OQV[.4FMKSSQ^"=DV7)K+G,
MDX+ W <6N2WL9JEC#MS\>%]  8.!K]"9,Z%,A(TT:3N(3%I2[!NSNMS;DU,$
M6U) .8((./,X1MB^-3M6#'\ZWW\#]VZA>/S\$FYF2Q>E%S);^O+Z')+A1&95
M4M5F4^!!"VG!JT7AA8]Q8UFF1_!@]-,!:52.)=X[8;Z/Y8S$' [6FI>:S+T*
M=V1BJLSL+E6PC/X"%SN]XNB R'79!LPB,)[(RQ"$#@>2=DVBJ+QH>BAK_2S3
M6*KUS$HF3*8CK #KPE/:*CO/KR.;GIXJ9>3D>-L)+.=0<S<VX!GS@8GB];0W
M3G8ND1.7C.5.4;9\U Y+,?![*C _J+F.\^LL2 C/Z^4L'7YC=<QRV/. K]A8
MI)9YKE=5!G.7;)MURI%;>G8,&<2*0+T)HI#I6"X,GJHY&,W(HN375['L.4"K
M28AKYKDPLG3D0;,R#'3%89WE&0NK4M:H&MK$J/[X)KIO*&Y$/T</V[ZR9&(=
MSQZ'$1'QC.#8<D(,/.IS37=A#TQ&-:Z\50]+B<DO1YBLW$ Y+F">M:KSK5JQ
M0;R$O8P):=>D-45$(D+50^K+Q#9E0=L R_-B3]K,:U6X'RH+AHLYYN(]>:UU
M8D_??F_I$ZG04&#!WA.WN98%WU_=/&BS&EM2@IX+E]P&2!*].LHCFK6?^_BJ
M9Y]DF\$LN#5D3&=5?GS9MOJR)J;+>ZWX8WQ$[I)Z1#\^/?Q&JYZOU4)<T%+F
M**(1ZU+OX,2MSHH66K]WH<*Z!M>E<*]DE$75LA#T2<TFI":LKJ]YMEO:=*2\
MWL*&58NHUD,CH.^4\9F@7*-@'"ZK$N9I)^ULK"*@:-C:OO+4PF1\HI-!3O1?
MKDM_I@,<_V)M2/S%VK!?=S[*YL55@;[3IX;%Z=U7W1BU^[NG"C33L[LJ&(Z6
M8-.B4G'NT[60TG 6L?62TB-)?U _7FO*TP'^'KAOJB:+N'(C[6,:963L<,07
M6$^X8RE+=J@F@]CQ"3]=K_-2S6R"P\ FVXNKQ01+Q# 6-%=H6/6P%''8"*K%
MXE<UK;7H'Y.>ZC[WR8,P>B.^A"K!F\TVH@(:D93%5)]Q-:Y+R2QK7;]9P7U,
M&W1)?.0BT@;>MG75<VQD*3A5WNF.8[&N/LW3>\OK67+)@O)H5F)I3"B^>.+%
M<0%&S&U=4/5)@4!?^@BB ZA ;#RXQ.CS37:E&L=%)=="J^)>CE%UUU,% FI;
MJ?79,@-*1H$/V7XWXZ6WZ7ZTV<;JF1;U1VU([8((K4V[.^B.SJ</;SRZM+%/
M?3^%JKN -M>C^^SVZQAXE,B9;MYYU3&&$F9B,-&I%#LQG-S9TB&*27C\&2UT
M%>&:-QO "%8"BUN.9D6.V?2/=V\#?I>6C -5@Q&RC18T8KZ,?O'<\,LOV-VF
M$MFDCSH0?11S(OS<E@?DQ,V]K_2D01*CYO4T<M>%H_(V&YM4JB]I,!HUQ66O
MVJ!L-UY=[K]4"YWUJ3X^ (4NS[:$@4Q8,&*G_-YD:P2U1R2]^>(I^NZ8CXRH
M;?U(EG;1V+T:UTO7L*@<FQ0O:8[!\:>J?*_9F2]HSYL7P=K.W>T"F14(S%$*
M5MOL#S"$=INY'MX&?.2W._9<S-C6SEXJ/Z5(=3XT0;'F/7KZ_E!=8VHUOW&^
MK8832JC.A"E_06S(#/4ZY&5847G65"SB";@H_/5]T]+^^0+@)-$FU/W#QTJ$
M].>1Y[&-#SSQ*WKIEU;9/V=)=F,$3N*<N')X7_3?2BA3ZYPH6[WQY/6'+ *'
M@F-6?XQY;&-6,.O2O&SB&=$C#]K[3(6!.1;AZF&,D9J(^'=WJ)Y('B]2ZXO)
MJHLD"D@5#3Q$@W,7/54LP&R:_'D78Z8AIC=P'[)FJE\:IF\\!26&AF#Z+]:A
ML*8ET?XI>9@NYN+$ZM>AZ675-%<-S$J/OYO-VQ_1P2S5U;>B*WV5?4CT>@X1
M*J0SCWH8[BD<QA!7OC24'K90W<CAU\\<P\XB+6HS!+5-R)KI>5S]^M(EY*R?
M++9F 9UC^S*K:MKB2P/3W"/[=&W9M[;,*>9=Z6KGY!?NGFB<CFU=S"]UR4%^
MOAJ)L,VURY[0H[>LMVSM9!&D5LL!&RH]+/>47AH+JG55<.]N (W7Q3W0LX-5
MO35XP!;Z6QQU);N(AER  T6+W9EK[4L',M_ 6,4_JT<K&CL5>4YK?6D)#J9Z
M_=BC-9GGBD9ALI>AG5F@MS/V5DS(%F^W]31$<TDC\V67I4,"KEJ%+<R,5\QF
M!>E^)H$-YF>$O'._*+#!VPW-9,$I5UZ"IOG-XSSR\ECF**_YDI%U3JC%V:R9
M;G#28F1\9II$*]A9./+0.MJ+Y_UL"_V!8L^T&VV:V.8QM-6"R;FNCS*5*34C
MS,2-JB!+V=)IQ#;@S0WWVYDX^?S''4(O&W-'P?Z%3U!,5IZ/.I^B8^HM<TR0
M?H\>.-O0![<6?7[ W#GHM5 Q/?WDPHO.)TEU5Z0LA')+@$LNN-,.T_>J#-(^
MR-%'<U#F:O)-1"!JN?-N3=^U)=S-+$@6\FVA,9**UW(T]0DKLLYQH6@JJ[^F
M\D@,U-G=/<#0GWY)>BR] UUR))\%&\ TX^);-'(OU0QG'@XT\E\_M?.)\@Z"
M-;C@Q5)N+2IW/?;*?O@ A3TC\D3OQ,!I66EN/'T41I\;?K@'<(C!&1/+TW7L
M\S'H6)BLZ=5C["'R,VTQV1,O4241EZ[O/RMP&'&Q%U8NM%A3ND%T>A9%.$+/
M;*;U:1:GD!_!WJFY[MD???VT3_?YKDY6GS2IJT.<*3@3COAN,$PY(A6L4WA8
M>?K&?8V48L*]!,AU"LOAYQRFQ1KBE]Y=W+A&M]'A7&E;W6XRSE920%=TKZY2
M)NQE7JCZDB?I*0VI0OM$E_=%V3([GH9;NR"@PVEL46H,,\W#B6C[\LCV@=DV
M(-8!!;COJB3,G%PME545[EQL/C1S@<TLD&7JL^0J>[.N(U8LK.@LW(KK4&A\
M:_[PPM5K-_G-1+^L,E6-*F/\[]VA"*HSL(B\2*QHMO,<>45!.SSV($K+!Z,%
MA>8IQA%=5ADE_KVE"7#B:E[2C-_-;0!U=.#W9>H)"EG_:07G]3'@H\*7$<Z'
MM3.F,V](OO/7K92OB:JFR5PDQ?#-I3#6\G0I9/X4 ,B0<3>H@.NG5A1?QE+Z
M<E#<1;[)B4_H%9:&<]_"&8IELZ8S.GH6=^I3.N>M'(]=E<S3:'XSE%D6EC7>
MWV$38>16U]B'ZF@)X_3;8EM_GKJ2HYI^>R3X[8Q"]Z!<$6BSJD72NEM_$NAI
M>ZLVD/4F,+:APDVGR22HX[9KA9PLHVP=6^-B?B<N'S)./.D0R2U7T)X4[I@2
M=_=J#U@\*#-Z?%T%9G4C])CXQ6S==;U(*2$A1/ +8(^E5&M08PPVUK\A[<WB
MIQ*S/P:YBQ\']0LUG8]OQG>C[/-1!6=2]+*J7D7 8DICC-[Q.[[C/#"@L&Q8
MUNSPN6'.Y8T)O*P\YF[6V#: TO716^LW,/;$8$\=<5/$O8KW$48JVC=?SUTS
M_1(P-I3$\-'_:7[Z+# 7O(Q^&IT]5*7.1==TH?FX4FY9$!2"1R"MT.)WCPF_
M,$A_ZH.+*Y T,6MYP5S#QO7ND6O%#/+^,C?.BP M?B,6-@4/,2O\S+]Y[X$1
M7E= 6<! V8(YZ_5P-@P?;9244=_SKFMX6D>)-CPU.$^WV"ZFTV[K7/F5NHX$
M+U6F0 6-1=/DQ!(4TYEDT=)>YLW21Y\W'/FGW*IM\QZJ1:J[#CR/M\8-R/;W
M>QP(J4=GP@I3TWFUFBRF27?KS'I%7<;/:_C9VDH+U'E:[V9V]'\JZ,P9GH1<
MTR@X_/B!IM 4>ME?NS24-;\ 5YI4'.(C;JN7^3[*-=#;6K1]B7!I3&U:8P%X
MK9BR+_BTJ7F\"#J_M:0\S(?S^#QF&F1E6\TQ8E.LS@6ZZN*\Q7EAQ*&Y8&K(
MPC<K(B<:88]U3"AB'^1\*@1ZG[\^?:_R"D8]+E6H!>U4R,@^.([KI#<NH2&4
MO3$$S@&SIAUSQPV]&\\"Q8]+;\4K!AUWY\%S;,J-N\F+BA1\6O#N'<4\JUE)
M\9JGA"4OI8KJ.XP 34"3%>:91#Z7C/B.='FVT'0SX=AK>ALKH9D-N-&.(FD,
MI.[RM:/-SRH&$A+.^9LU&B8L1O#$XZ3/)CT3M&:^WG0^ZW.DSH(LK\V&_@)S
ML\8[27.MS_D"%QWL+*YU7Q&V\7LC$LACIJI]ZR+!I#_A$;%DO)SQB$<&I,8Y
MJ&!1UFR^J'%+R/B%]>W[H2HJ2G%HHH]A>?7#*']\-+;0$/)".BP3:R)FZB/
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M;HYCE"]42@87'+I@AA3VGW+7%;:$!/9?U1IP%K"JW"]NGKD(+A8>/6SM;C"
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MS$<)V3MQPXF24;-<D(&U]=I3B<,+UQML.TP]+[D^[7MG6B3#*C2<KO59W;#
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M@CY?;;>)@&\2?-#8[)><N73>JN0JE4D"'>(@Q;TJ5WE-T"+I:WS2HJW0\OT
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M8U:6.">QFOJJ18/V59Z)C;33ZE+ZHXWJ"*GO,6C(4#F4U,'@4)3J2[R53D6
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M,VHWZK5?G<2ZOU]52D)+@3W!HW8L'PQ^.3Z1$#C,N"M&K<\,XI5I[K4<1YG
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M5+>'I+>J]-JE1]=GA"O4CN".X;W$P;%81NW3)%],OD?MJR$VK=]3<OS";6[
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M1D;'.<N!?I[6&;?TP7-YK:E)]-S\5JG7ILB>EE;3&L\YB^)?N(AUJ3YEZ=4
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M<=<"E%;2ON#S.,KKI&TA+1/(S%HD;Z[]&=+HP::D@5@Y0;1'['+HBK0Z7DF
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M_PT?[WZ2C;#&8NW%^/B0&%[S/:MX(2@[/A=S>SX!7GX^@(2TB[TY! [#,EG
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MY!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y!#D$.00Y+\,<O+/[XS
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M9[YA&YWTE+;498Z,&/!'S%1M%WM=3MRL!MC8"%.JG7*TQ[1:6&A4%SMJ\G3
M?M4F>7)&XR%T44FSE!<##G-_>DJ!;*/SA(FMTX?<,)C<],.\VR?;7#+NN0RN
M;\9=4?R\6&@4E\.C?):%T<9PPMFD-S(8(1S[KBW O[;'&:\5+Z>[-/?Y,MW
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MF"%[6NXQB@4#Y;F"0=M%Q4C%(*P"'=4$-\2>H@)XWDXO*6-.\RJ@HJ+YX86
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MPQ-EF;'."J1]&$>>>JJL&BA:)4.8RG:AR%-_!D\$#)6O/#<<Y 0Y8YQ:KOA
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MI$^)M$8\.DKN%X1U?"/C4B[53AK+<[Z_5>9T.1$][:\S><NP2Y2S*])0V7_
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MU,:.S<3FV(6W;<</6XV,0=DX^>(6S\5Z&&W'E8QNXX&*%2^VX!B^W<)TUD/
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MG==9<O(]>>@AZ&1JDHLHMSK];/,^78XRIKVU=:XL'A!E76'#RGN&UK@X;#C
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MJPNQ"IAR<(__B:C<K_[GWDU+[]--G_YR^V//H6J@@I^RSR/M8<#9Q+]H>0!
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MQT9A,Y73GB^:CW6Y##6_K(/.FMBTD:1A["XHKCJ@MG''/:  ;SQ&)$;VO7^
M@[>[=J?J3K0UCQC?X8I#!VE'-ZU,[V\G)D=&I6? ZLVK%1.R3!RZ/(X-QZ)1
M+?,*^/2ZO"/3$C<*0>DO R8^Q+WMC*,N=*K%K.1:LXAZO#BS@!IP[^MCE\)!
M1Y6<@:=]"\4(HZ[6D>[G30>3PUF(&CVYMH%UV*$&$2GZ&E<OLQ9N'UEL]4Z
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M:ZXD[%/L'@\$P-4[U8@HGC)]NAPB#]Z5C;?''[/K"6,\:4G9WC%B(9T0^H$
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MR>WB[7ID^%4PR@XS"+@@X2.V6JR[0NNCWQXBCS-UAVHG\P)S97"8(H&P<]'
MU!'YYKJPJP#3Z83>^!F3,XZ\%F+__NMI9[!"OV0';G$/@/>@Y,\N$K&\7"?8
M5L817]W=UDO!!)I +UJ@W6]!QL;20$:AUX'-<-UZ2AIZ%CE1G/7(:'A62!=]
MF@!.:GP47QKEU9K5P@*M]%E4/NW[G//LY-H<WFN"SQ>=ZOY;=(T9GD>K9?3V
MV'64R[/(P=RV\+O++YR1388U.E>+TVMM53.@(1E]U8(WVM_ACN9 )LGSZ^:#
MTNVQ*3OS>.L%N0Z<__FHK))K[4J$0F-VCFL3<%K>Q+C1S1M7*J9NMT"*CW\4
M3."*WC]4V+AZ>9\UTSK(Q>!;7EY;3'FK3Q##:U1/NK(]E$\*[56<*+%$'6@^
MF^*OZK;O8\<CEI2$B84(>)K&2#WG0+#_/3K^<*W'A_.'UQVJHEY#QY^*>\"Y
MQPT>DEEH3I8SS0S<R<G$5%.K1/G_\QE?P5*AY_^3 4/GSJG@J$E9M^P(%:MH
M&:]\1K/JU0N>I^CJV+#3'M#"PECGN,/3J2NY^W!X&8O;.CUO&ZMS61BC.^J)
M4 %.Y)<F\O$JYSX2=NY',FQHG4?2-5F<^]]JS00K7$I<(_<G23+2G@+4F8;K
M6[J#DD T6""Q\^#7=RVT%6>_$9L)SC..BZEEHF"UPLI^^P'V_+K7=@^^>?F(
MV\3P^H;+ED/MM4<AQJ6*/7U"#?X>QM<5(9 $BN $\L:>2GY-P?6AW_PKN@U0
MGRE:6$*)_MZQ,3%(8-LBR-0T./%B5E2:VO9>T;$0"A4A7R+@-[4BH%F5><:A
MC+HUXZ8N9J\XQ)R61'%.2NR(U/.%L,+KD?9PI$7PIM82WFL)-SD7\/I8\R]N
M&]GY3,]*V A?@<J%],?&L^CK<R5:;F@MX/(<F"+).3=Y4SDJ<F&QWKE8D;_P
MDW61\ML'W W@P:J**M\FF9%4?!$!"_(GJT(/IFRLV:>B<SXVY25@*8BM>RB^
M?7Z7&/IFNEA'\$$LHYDX&^^/EAL+T3/.]?N>$YVB! KO,;/%H6![Q_-3PQG'
MZ(UJ3Y80C%_6EG9-(:JA!S(P ,E40,N=<>2:T-@/7^ ;C^*>V&Q@1,7%V>\+
M2BS4%)R;@W0AJ49=#_Z88:+8OSS *./BA]RTK"I'[9Y#A"-)$O+(X;D)'C[?
MM]+]-*]9Q -NHC]FO!9C=MH_BC2;O;NAH-@-FC?ID_'NW!'&=@-E4"KDA%:/
M]'PZ$F!U]>%C*PFD."*P>"P5(EA$.TR10 5(^"I@YGQK\DTVK+;B[DGSND'C
M<D\S*VG7^M?;RA1^G%8_ 82F9<]^MARNR@T\X]"=2R:3O7X%/:[)D6F=M00E
MN2PX1*R1#M\E9ENSQ>JY*;IJVI<.&R%C,"NJSZ@74':$RP6[#9>'U2\PN>*+
M$K.$"] J&_6J2[6K:$9>/:'-=2'4J7?[%8P> (G2XU0:20O9>?G&FV;:D;8Z
MEBD\]&V_6.YVNN>LY%99EI'!IL67\@ZF-3Y>9X$&8^E[!3@T<,<&,S\GBH[4
M:W:(R^>5\AM]FLLAMVO(K8Y1I&,R'GG6=FV&%[V@%OU@N:1]2W'G^E^WA*+=
ME'6M*C2D 1"/!V%PQ]-XSN5-,TRRK:14JG'@(SA_VFXS0&3A.U&+V>'N)2^2
MS@N8%$4O;K=2>BR6!F0F (6;:D8=X\&]1'5871%TRC?85B@I>RRS+$X,X\^_
MOZ>"M](R+3)F4VD\32N%E@_C[RCT(F3\0=[PFAG':Y;CWBW30OO#]1($<U?'
M]YTB29*/GZ^5NO5QU:SAK!>\E4V08U\1ZR%I7QMC?C?YJS2QU$S;UMMB9<(6
MYH.H,Z(!P<,.5I++G]W[IWCH*^=1O*BU0=S %1QF2R'H76Z\X;2&1 7\*S,%
M5 2++++9,G!FP?V73$>G(OG*^"T;A '35,Y*N!3([#!$VSZ^'/UR,)+-6/JB
M,)"[0;5"BGY]A+ :5QPB("YV47R@U;^.L: :.BMWN"^5U\LVAN9'1>&_</!+
M_#LJJ%E4#Z<"F+6V!=@,19H$OBO 7;+C%[EGP:XH U\'%T7]Y3OWVS55'.KJ
MC[ACXV.,GY4#(>Y!"ZYZU=T@V)#+%.6(*T@CS.S9"2A/>F:I$Y[N)#38UB*3
M%3!U3,PXO^TR^OBQ1OV.WO#[NDT5\\K0C/7S87$'#QO;W1KF.+72>E!#JWL\
ME LOR"(Q7>XH'4'9;,:I"U)U@@PU+NGP&%?]VS9LKL#PZ^7.0^)7QI03*)BD
MD%",@-EWEM],?),T8" ^(;@BKSM^.>-8[\$BI4@L:,_Q6S"EPS ANESM\37Y
M5/$DRA&?T:CC!0E%I4VHQ (B]Y0S^(SCSZO39QP7-C0<D/V0ZWR\C:QN _'O
M_ QX\OO*YMN"GK*GA0J,'>@9QP\-TA=+5GA_[ASY"H*>AI,+]X->#ZBIYRDF
MVO9BL:6*$B"3.>RR[/G7'Y\B9J<>YD1\FB#J->&*3Y]"HS??Y@OXFKPL$]1B
M4T]_#,Y:T5+/_& 3I)G(@SWCH+D@UX7@*N#T>&$>PX$YW]$YHAJ!!WAT:0+P
M[FZ5YF6CH#P+\N>R1)=@_8+YO9T?\QT3$B7E^J?O*$SJ%SLTK(:$-7D"QDQL
MQ]8<OT%V,BYL"$0HQ-8*W;5$N7LM*"KKAHW1%&*-G&ZT5"A8U$A.Y7OO_YAX
MQA$E W&PN4L4%-M%5 <X[FHWS !%SSAB;4^1IY?Y;M 2J#ZDQQ_M1#E_]WNS
MZ"P^4LPF?UX*ZRZ4^BZB_YPG_.XDWB0AD>\>45,VPF!A #KU3<=J7A267_N-
MUW9@O8#*/(E*3YOFE>(N]':;B^'/R@BU7<?S%$Z-&VYIJ%X@-(_D'P#3D ">
MO.TH+O.PNS(_'V<OM=4^"$\'[8F5[/_CRR:J6^['SAMD%A0;1KLSW?"+3ZKA
M6B>OF>"DHN=@6_>!QHE+B?F2)Q!YSE=HE.=WFY&.N.\@((X.?["0Z@!GDY]^
MM"8PMO]!+M1,>?8D]$J3?GUB1\,7VHN01GLP\>/A3RSJ.,&AV,8%SV-UD#QN
M..T%L(([46TO;KO$&(==4^OC"2W^XSYS_B;TQ.G#R'_X^F7F.#M? 9-Q :YU
MY#6_<MI,SJP*?,VL4EO23K23]X82-L0*SC@4<PX@\+S^,LHUHO:-Z@5C?YPR
MA$GJ?:K$-\]O<R2_L):$&OF._)]G'-<L"(%\%W2BCTC%WZ^]IY77^?=QQAA)
MX@HG3T X=7Z72WW_4512I"E;V46:TU2U@'"(RTM?__#H?\#K:L9^7&9!X7&4
M1OM"]^'I^9&#BE=G'-/*#4>R9QP_R35<>+^!3/$]O<3)/59J^>W$X@E 8QSY
MD=G>3H@V[&H?)SO2QT)"\%FA9A;9)^ K3:2 >?3V&0=\OC[[/3&_]\>99=4F
M>*7?=YC0THW%UV?\2(H7E._"[!1]*USP? 2-;4@[R6B'A^$=J[9*U[:M]!M?
MQ[=/3#HZ.NMEOJA]Q>Q.9-U5,E%*"N.NJ62O^H6L2;VJ,'[!QV? $.>IS;Y-
M\GKE'%$GV^1A2W=.O;@G"F"U+8N#1K0F'H,?@]P(FCF"(4]N'>@/Q!;N Q0J
M)PL:ODAU:)?5M/Y1NA H(W/&\9?[YMM&9X^E5R&:J!=S-L#%&&60\>2,W:>N
M*V(]?WQJ!\ID95MSI\"NR10<#61:F/RFEA\UH-]^QG$38OE)KE-L>^H$OY P
MZR;_ RZF7DO]'KG45S^CXA@CVR/VO).[X!L^ZSQV(#U._-AZ1M<A'79Y\!?0
MM,\+;$*2L!GTI3*\OD^,RBBSZ0[,=DZ9_W54=<)H\N#!]/J#6T$U6.@BI!HV
M]4WF"!O#R2N93@<VW:56>@87-*S[Q61. \5E"_)=29=^*[U*YK0IU=GG!B_7
M <Q=FLUT][\#=W[[D/0T92Q]J0(^8;^6J\;ZX\,3E.7R4!&9(-R57I9T()BQ
M_[(U<-DC[##LNX#1G5^ID0[7TT,*7]_^V\*7JI).W3V,ZE\N%,O\BLL9.N-8
M]MY7J%CSF'25<QO4M/G -NSH2 T%PXQ[O;\71G  +U; W(KF]FKK8XWZ*KC
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M9S X9S X+FIP9^R]!T!3V[(_O!$%15!!*=*E*;V$T(M*ER:0 %)$4N@DD!!
M$#GJ42D" @)254!*:-*;@ I21$!ZM] [@A0%(5^(8CG'<]^]W[OO_M^]CX7)
MWFO6FOG-S)HU>Z^U<4/H(;P%#IU1UU('R(A%B$P(  BS1Q%G[=!N:*P=VH43
M)"(&R)S6TMV]&]@J$%8R,X"<A5>#=1< $/^Q[CH+[,5@9$#B8F(2K+OV "!=
M>S@&C47;N'&:H#$(3F%.?6VH(?%P&H>U1R&Q6$XC)-S-'HWB-+1'(#$B"#3<
MDR2?ER3_T)Z'B_GO;3E6^TJ,[_15U\-(;7*DMM&M=N*'C%3;[X*Q1[GIX]Q<
M<&[$ZIXMVEFLFQ$,C78B]=!"N2&1*)SS]OG64<4)LU4_2.(ULO?<ZG':WFV+
MY[M,)$;/VAD)43.%? /[PG 6@T;;&"'=<"[Z, <XD4P-G 4P )KX8P-P D8
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MZNV6+15^H--LTPWM;>U^;-B_W4#4[1MY*W+(9[_HL#63B<-"MGTD114?J>W
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MV4[P5%\Z;U&V6K2<;3G_!?:3XS!./UTF2,[_F:*+M?WY4D)A[>0&L;;]B78
MCB3R(3W=M+":$%V=[62U=YO\4^=]=FB,URDG>]MM3QW\8KSF-GG+NPBDC36.
ME*WVN2,Q;K_H;KQ-_KG[?IBM"MH)C?G!N;1?&$YK?&O84D,/C=HZ[G-#NQ O
M25CDCXZC<B(Z\D]4:A@I[?V)OA^SE=S^0";-IA-?^+;"6?D]\)U.2SHE^Y*%
M=A\AU;8&E))4IR:YM..KP^YOZ4H\?0L 82>)]!* "2 C]!!F >I3"#0,::6B
M"^PBS $'2#4 \=L6'Z$?^!V@WKMW[[Z]U/OV4=/NI]I/2W^0FOH@/=/AP_2'
M#S/14I/*U\.O"QG-_OTT!V@.'3APZ,B! P>.;'T=./*%A?;O$4!X M#N)2I_
MGYR,"]A%2T9.2T88)!I*1:@A4R9JN8>,5+ZZD1P@V[5[#P7EWGU4^\G^V$@&
M["+?;CP$D.TF(]^U>]<>2HJ]>\BI0<1&6O+=Q^C$]YPRL#[,Y7I%@N)(Z(/<
MT]P\](9/82!)S-56%4K>,*/W[Q;@6#!#8MXU/M5P"$+M69*;%&,;= BYF/][
M=3MN^(/Z\3O)UPLB:CI&EAX6/N\<73:V<;\1F5)4VS6V(JUA8NMQ,RJUN*Y[
M?)46V+6+J.UNDDZ4%'O )!6.B=/M)FK@RG5XC\25T"-;&CPU;'T/XH&]PUP-
M4S&BAV,E%W@IMA2@Y ,_:R,JD<2(4(-*N2&'OJGPUQH<_ZX"H0^@)B=AT@+*
MP#)+3A)[OO.*%+Y&^_7;+O]7WG'7U[53O:O,4GO(X]?4)]B66.<]Q@7NG1/"
M5X8[SKF#F-@LRB7R<<JZ57J1WG'S2[[O ZE>QM'T@CPT(W.O/_T8$J\A?3G\
M3?FJ\M-<7D7HQ9(H:1RCQ%M69EV4X_WP8LN'9!OHA\:KQI_Q?2LRA;/'SYJY
MEV: [EN&((V]1)]=.F<1)V>I?UG(D0!,R-K8])]M:J \3I-LB;@)1[FLEFM4
MS<R])@"C<WHAQ9N&IQ4SVSPEM#^5'%U]QZI_UJL($',&7JK*AVY$D'?+:8IA
M,G:[']\(C%VWH72*.9F@*/)FG>+J]$)C1:F,:ZI,GHWBFY78U? KHVLC',,\
M[\:47[9\UE+4GYT+!LOB /!QC&__(/?F:.<F9B2KJ-C8;"!NER5P<XBNK<WG
MW1/XY:'2ZU="8TM+W"\\AC!IKLLX@8=Q5MI,EV$NK*7]G,KO?"<$C[.^ EI8
MDVQN'O'$>7'T5WR1]C B=-F7I\<J;HS%HENATR=BJK:L:'9I8#"H;_YR2PJ>
M #3-Y0Q?(P!.^01 DY< 2)=5!1_<R&O9X(Q_&KA* #@V]M@>J<(5#&3__L;$
MP\![NM@QT,J[WAX>?WEJ4'YZL'PI@0#HM^6TJWB7[:\P?)V.0Y4^'WW9D&=F
M6?7IT= 8.&C9YU9__J>J)8?"*A.OQ@QA],PJZC>5"7M[>^5D>_:;X^(Z/N>G
MJD^M,#&338!"UJT/H@]\]@W9O)H@VVGDR'W\/H+.,FZ,\=S4/;WUHW-] B'P
MV#7%K$WT!'J#BT_T[$1/3F'3E$B!.26RJ^Q)CXARXILYU.RT5$A&!:X@M[@J
MM=>.?;68+6CW)U"K>X?#9LZROL&-ED<QU3<6)B0;;0>3'#,(@!*GM9_Z1_^V
MCZ>6?7$GZV^?V"]_+VJ].75V+D1\I2SYO;3G\8WR-N4Y2RLO[*LU<1?79_=+
M\PO[6;@N1PXJRRK/G \G "Z3!$",;S-CC0!\,)IZ#U_W2/8=**MJUEZ9UR0
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MW!J2G:%.+:^.F'L->@\$A:Y$@N,ZS:M4"E"YL?%KNO/Y2YOX5BT>R!XJ0^*
M0[;&.RO+.K%;1NJ42]0NM^C^F=793;Q^?T5[<<(LAIL,W$>17+J0Z=OVN?/,
MY_%N>(P:IDTEI=&<(TXIZ*##&=.*N]V*713%S&UL4]5%>=4SWDX$0,,RUI0
MF'RJ,NE\G7F[]0$-Y5K.J75UK?IU\>PDA%X[+K5E<WAF3:""IGG9*95^-E-L
M4BNW&0ZLS.9TU#BNH#[7OB$ #/%5%R 3[<4=[6C*&R6^G8+[I0\+BB\KCI@X
MW^*Y?*MW8#-DR0-<%;OTIH*V]&*=G>1M#Y7F=EKEV'E=0WBHNA2O^XAI7T9
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M99\EO&5Y!ELQA2R^?0K+.>&SY6NB>WP)O:3U[3'2BL[DRPJ8N)X'3@$(  W
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M7(T^?G]>O;@);3"UN :.U'DYT>,E4.8U93IE-X986N1S"@V,M6S(U1L23B0
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MQ[S:*([FRP45KCJX"YO3:19:!#=EU(PV^DLM7.&GM%18@#QE75J4,$4XR(;
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MQFL<"S]06&N_%J[0MWVN7XS2<XNB<H;JZD35=EI&IUR<D>+)<,V^(?0QA@"
M.P4=3J3$&[3G227%+(]"QJ#K]2@C&:\;6I*@6[97V"KZS?6)<Q3<[S/")W?J
M\2O(A"#-J3VJ^O&3U/;,HK<":D=F$PI$ O4.Y9N+E3_:4.0V[EO)0,!7,J,7
M,J+NM9UTEMOWZ)45/-O'&:HF:8@*;:OO&LW%JF(64P=^4\D8Z)>Z(\:KV^#!
M=)DF-0BZ#K;$IQ?/&TE#C>A;EJ*+RJ[/1-Q9PO>R=C;1&DJ/?WZ56W#SMUG/
MUV_H%9]:4;\J-^,?4NU"RSD/ZVO<?S\QK.Z>>>C3%/]H6%XEHM/,WX#6[+5-
MHJOM"PHK+:630P=SM>?2LXL>L]F&GX+>#3!E7<^>* N;QG/3TA\6*@E*J)&J
M/9^)6^GE<=/)N/XJHR\Z ZN3SW6D3#(EM;6F1$T$)$0G:UDI+=FETZT<>/=(
MQ#QE7_H2K:[?JBR'9XS-M-XD/<:APCPCBN'<,=2  ]YZ@X--43Z^_.$#OX"X
MBPZ)OMR\KJU9PJB@M\\.E.CT<&$M(O8Q"T88O)@3VN"S\3;/[-FEC>39AS$S
MH_=_U)#OT5"**'6UV4-S_7WV@;17'5$!O<NB-(Z=[3PO@H-5H9TPZ4!>G5)9
M;<8E! &(;+S'OA$^:'WRR3JO4$28+JR,%Y842\,R$'@$=1YJD6]1>IA'2GGI
M<GYG;P%6E^V2?L"YL4L3=<7'N:&TAR77\W?5_;^^6?EG%85"J3[F]%AA73;)
MMF+_1=5N6:5EE0Z "Q']]0]!?2\'_1\$>\:S+N1I#M9V%](SSAEE!P=$^@<C
MV22/S&+&TH_8U9Q/>OQ' +*1R-Y3PGH?(P,B/BS,!?OCYQ[G*U[XUQCWK5!>
M.]3$JWAU7/*@L3:;9 X\/ @?!%63<YF;-+I0I*^P6'G./M%[(*,0:A: IX"P
MF8=T-79)<V1%91YXA4,IFXN:#EPN.O](_E1GR893!=QUK=?KR2RE\?!RWG)0
MW31RFKQ@AV6'98=EA^4_B@66)?%B^N'KH[R70I\+TOK-+R76=D*FH0#RY'^1
M;N'B&E\7=<-4G\1MUUF5AEB'0OA0!  >.^!:2[\(:UF1\:DA/T&\/+!&L;Y+
M2PGC%SV2MB)K-M)DPJLG.227$H#_+![ !U-H$U/WO'A#SB;VPQRK0C4;2/?3
M*IL+RJT%[@76NG+TW1C39 RZI<3E [5;D_3X@(RTG&UN!7/RDUOOMRG;S"SQ
MH)[70887_B3N $US] Q:/5V,6V&;PFX='/WP\_I-BG&=%>DDR%W:!/9W7R@'
MQ>ITVB_[5%_#IGBSM.)U]K9L4VZ6P%/LJY3>/2UM5PR:Z.3;;;M%2?=5>E<]
M(-H.J7#\QY13_)-RVY0M55+^I-P6Y:#+7RIW]T_*?:54OQ1OEWQSS^7MP&1"
M[9)#^"[0-N6;;_\5WOZ#05\I?\/;.P;M&/2_QJ"!/QDT\.]MT'_<".T8M&/0
MCD'?[Q3^50:M_L&@FG.YP@G+"K?[Y@YUO*B=+KT%;3H<"!)QA8)TWHG=C3NY
M]:=%#MIM%%_:E/1MN\ 0TN_1,JRQP0>HB'V]M21OQ)6T]:7Q997HU/-;Z]K6
M+S<P_V[R+/C Y M4H=S2( $0G"< 3_4O4K%H& ^R=+Q+:;@E&+^GW<U+T&SU
MN'\^;T_GTI7\E<#9O(734XU(-WK)69V!B=>!&=-Z^H]#Y,\P*>9@C5=U@AU&
MRB&IDORG)Q82^*.HRTS>W5#AL1>*_CC;@%->]>T)F!BZN0?:>9Z1%2H7;RX%
M6<O&V$1G7]*\[\S'\;Q(Z.2J1"LV)2VT:LW9R]&K5681A,:(X\=%=%6;(!TW
MC4S3)7-O1B<YI./A)H46XP+9^DU85:AJ+][YNL?,VJU-K=[E$TPSBOXS'Z]W
MTN1WJT&F<"]489^AC!;ZMH66Z<(1RZTJEA"_1S6C?2-0B'[3D>Y9LJ$,/J:,
MFOV7<H+#W4.E);$69;T"XS4W4;=SZ3,.V]_<!^V9ZC79[1Q\7#$+TM"?U"V<
M_C)M3SNFC8^AJ%M?P]PS-2"%4I 'EMV%=WTP:%/GZ;  Z7/T&8K4&EPPS5'/
MB(H&#1M9"DRZ#!I'N_)XUN*N]E?R03 "J2%9^?Z,;?""*+4K:;$G/^^Q,E#T
M3E[HSQQ53UV#@E0;L.0N5TSAU#[H?&OF#&?+WCL]T7=H-LS N%B!7'JIT4@;
M954S[2*(=:,/P[&*/.V!MDR[NL*^%_B9F("T:"R9S?F<KGZNMH=MV7(X?"C7
M=?;R\W,(.6>FA!:/DLZSYAF)"=G14-Z@C,)2$>U/$<V*D*K)6*J>3H-7K\0=
M$^*:APG  OK<[E84=\&[+%Z85\8@PNUV_:>[W;+T6,MN)=4ELD<F,[IVCYJT
MZ5^7"=@+0 UYO#X[Y<VK/+U85^+0Y!IY8Q1WE2HMKSNHL1"D\RI9\EU YMW$
MU>N#L)S@7,[0!KX,BYC2TFC75!'M#D_73L6 5'T/IER+#)H'!@PFA5!Z1E?=
M\SSG+7Y[?.XA-?MJ859%NTU&F+/\'+/JLZZIR8EIT2,+'<]FSS%E+)C<Q3M_
M]%:)@+XZI8V)U!H)96'QT$A!M< N&7*8:-^8<FOPYZX]+,30D19^G OOV5 3
M2WNRIU%)H5HZ(#GU_F-#+5"E('2BT^,!<9P$+U7T.[D%&KEG78T440N="*A,
M'@4K:[G)T 7+>S]B<UMFI-0-[\./.D@+!T0G.K=P=59-O/@0).X34TZG%V@3
M?(-/IU;K3E H=U._Q+#)X@<R1^O/&G8UM'+:BCZ*AJ!A'K0:UL>^]H9I5R!-
M9!2-_5I8]^\.O#Z"]'0/ V:=(8UU#CDB6AU.)0 U%#G:T2EZ7=A#MM!WF>LZ
M:^>RR 4?V)^7@F(?;ZQ-NFRT@0LLH[.T!1SE=JOJT[KGW+(1RPEG\,VMGN,\
M>A(@-[_O:,"[8+XI&><_SI_'5US]7'0A>?7.4L4] I#3N&K3=^G!:OBEKF7.
MADI'K]OD;0@)=,SKY*/236A#@)SO4];4*5(K\ .9C':K:]C;&5&&8V<*?=17
M!\">21JV"3XUSK+:C*K^66R]Z8UI"0MZK1:M*(?4)F1: /Z9)<T3J4\1\.3*
M4SR](CKJXMCU4.RQ[EC(BM>G$U/#-A-O L:*X>VA9V-,Q=A\]LPE%*5XV:A0
M!PID.I3FL#=S#Q\:0)0.E_'D:;!!.OPR%RJYLKVQYQ'C)XJ]LCYS94T\'82H
M,[VT/B'1VAPZ%YP4S3W<-6 B\CC$AB._P;M40^M IMT2)K,\(=\\S#8LLB(O
M\</[V ME$#,/:3#NOK]EV7&I<PMW Z&G^]RN&=DF!4NU=J;,;<2:S:I9A+<^
MNM5I1*^J$<P4=\+_%M+J]<Q\@<7(PP1PI$S<P*CFLMG,QU;&N!=##4YYKPR*
M.ATBPQ!61Q=5TF.0SV,6TN?;A%?PB<.*#V:N\UN'ACB&,EJ!0"'I846Q-.VR
M+X(2W. 1LA')SQOB&W+>+*G/J"\99EUX&..><?]AI''J6C1#WF5-7 ;8(M/-
M*T<WH!-UYIXKUO*>B:.9ESQ/48PF\\ME :A!8T.^B+X6<]O^$U-ISLLO8R*Z
M*<[4:I<H2[H[1*\M&F5X0SK%W[WC-7[DO[!X<C5>O0QTL2D[/4;:U:)3=K'^
MXZ6#_NMQC^1D&?VS0WBM#!E>R]9 &9C->!.#CW<TQ0B.Z+0R^WFZ\AJA/ 4"
MUB:8^GHL&DP?-V:%I:9K)MGC87SV[^\=E'!6A=,J:=[I44\1DF7K/\>6W>&^
MJFEB"3K/);>21%\_T<H:9Y?5'^T"A0G4NX 5W^4^*S04SS;.]HHU$3UG9 *I
MS"M*3($X:($ZY]07N'+$7[=@RA;>=#+RI\1)&VFK[WY0:J@BY&$C% )3;,V3
M*C6_=_PH54ZJLS!.5X[;XO:+B>5" U #YF6,7=#A=V;+#:"!V,\=?F^4G0<N
MMQ]_G-C168,/2&6E2I3F@K$+Q8X5IU/H?C#O^(T92@IIZBT*0/9]'@#_//)N
MQRW"T<(L$T6<F1\>_]C_!077!@Y99*;N(&ZL,;;AGQL]4K69<$W$[[FJ<1(T
MHZ;TF/EY08;*887I!2@&A@7+^*,.99^)1:UZC0LKM9A?W.]07*ZCV8QX Z[0
M)$U+(.V_GK3_B6251AP>N6=W)U6M34U#6EJLQ6.-K,.2QTK:RMWP2!:V(=68
MEJ52[_!/\:UZRZ;[A!.R(E8^CJOG6[HKTAZ&AX=LUN5O23E-?\UQM<(Q_7PE
MSR=NGP-Z(I5<#H*I[B[4W\.$E72XMM7[)/"#W__=R4%3)P\=B.E-3$Z*250O
M-I;"CX8Y+[%KTV LG"=!?371]&9+JGI*EY/V!V48& N<&'P^W# ]HK^^,2:_
MKYN7K=%0[05_NX'/_OJJS;C17#2SN+C^]R%BQ;/2_^^S^%]"ILVRC"%6;DC3
M&L_OM\B!C0I^5O?JCDJ[>\MV+YO4= W.) "O:-HF91,JS[.0-PPB^8L>QS/_
M$!_@V7V\=@3#X"PY@T\)2!3U%\2%$X#VKG.8H-[WXNY_[YS?&[05MJ,ROT5,
MQ-.*QQMK^A, \OIHW\S82= AJ/4MH?7XP]R7<IM8H'FNLOA2@4-!AS_90E<X
M" !(,37G$P[ZV:YBN&;EUCN+EF>,W9#6?"A4R95N?,^D<8,?],ZRR$>Y4HQN
MLP=?1M1F%";R,)35+PL".0^1O!9R*_KM+/<;E^9DL9<1=RZ.5HSW?[2LO1FO
M.[F8/C;SNF?5*J29Q91:_<CCR@W;X+(S5'A&6<P GB5LK1W5(3&Z(%,KMFJ/
M%PB:L)[E*)J_5QNRIK.K=1WUZ;,= 4A^HIUFL[U??FJI?VO=\F9KV2*JOB0G
MG58M?%DLQXE1+:(^JZEWRJG!'>S#U_S&6=*C$:I6-,H^K75V\-S1A'.I1RG?
M"U_U$A_$7SD[L9*=<.U,A/MGMG-0HYM\ :JA[!GXL23&VO,BO$,6(?$T;[75
MI2PTV'KYG&XWW)&H&5&S<7@<$*M[K=J4XZ!UVA2+35&U7B%-1\1D8;.>4_?M
M]6>>4HW7K8S7A4$/<$:%#Z%>Y4J/3L33=Q9K>*G'TL#DF(TK/3*L2Q2C%4M3
M \,^94N=+L7>3X,,#<1_OA,R-+#OPG,<9-DD1K@KA6(JSUC6;$3G0Z/D4MB)
MR5XV;OMP:=4NGLL28_AH9.')+C;*"QE2HAF5#^<H&RM&-LYGY#6"+3X=^.Q\
MW=E36_NC7D C2^)5RV;;I/@$5#?&E^?TVC-/B<;K')!U7J)R9\:Y,CI[EP/'
MJ//.SQ>8! 8)-%BI^_4@NB$-M% CVRP(%57OC=F>##W/X'X/^!N]O.:1#O<S
M <'#0TI\1<\?;/"I\.(JY:\') D_2W3G*I.$Z@QT?HBIBAIXN(%Z*B7OSI=>
MU68H*(*C&@VSQ%ET-L;,*,KD[S<3MZ1VBWJAWJ'&LJKNW&!6BLP]>6T2I-$E
MN)$XZY=NGXPOT]8N.SUA$1 "00>&(8MMU/>KE(D6:M^<[78<+4MA>0S*C,G+
MSC[3/=;9*'J:D>9&NS:\\!3JOL9#R7WX&N_.%_Y-,0G+.JT&GG>HKFGTOB[H
MO#4OST8O:*[&$N[@U) 11@"6"(!$16OMD4+8(/>0F7F':-B)>T)!G>YG LN0
M!  +$^MB+GQ7/Q5MGSI0_#)#$I]M(AA7&:%0XKW']/W&Z[QQQX>F&0(?!JVR
M,Q(<8V:6KYR:C-K3^\AGFKJH@3H4'<V:YRBOL&SQLE11X-*P7:;1Y.([=J'H
M8P4"?%/++; Y_HR:P,;01TRI%+VN:FI'5F.@,6? T.L&4X,6G?2>%9JPA0.W
MQ(HXR_4Q96?ES$H7N[TTTQ.TPIR6.>F;*J-4(-"E9<BJ#>I5?8B-UR>;P/R-
MW38M-YWOENM^# @8"XD,TT*$!@?UBG0TT4MY:3M+BEX--3#L&8&,#D):^L2$
M;[3[\5:<;1/"+:9DW,O&1R/\GT^=/"'7;^'%T:8C 7VEX9H+P:- ^LR"26J0
M%MZA+O38[P1 I^^L-L3EG-@L1#<[*RA/J=C\>6I0OX%16WK']?! L<(D^E<2
MP9_.]/G!+T\TE0I:/L_U.:,V\NHU341]7O](J %M6G9T8Z[,[;US-QW$P%=F
MDA-K#EGDTC^M#VO.O%P08K54"'U\[L/"/9DJ=<\7\_XHZ,J 1<$='-WT<XI\
M F \4%)$UR\5(!:1,*GK<K^X- (RK\6-J<\(#_?7>L5N#E4HB"R3\_+WL']P
M/;127[&^0\VJ0O_L/_) S?$2JR$!8-:_J'N;O["UBRM8RY!?N 56/PZ&-JLU
M0$U0U9>K,3'2Q:D'>1DG8A+%U!9/A=&%4/9$-1>M!,^Q'\P5C7>>91OP.AIH
M>;;I:8ZJ%<_18R?>^_A?FD;;S;U[NT[WJ>MUZV"UN"/^ (T7UR?.AGT:UV:T
MQ\V]-3P.;DO9XG5Q;&5LH- \H\ !LY+K[Y,O\52JJ<05%WBXO#2;NG;MO%^I
M\).[-P)J7XQU"_GE3TU-22L)K3?G4):$)Y!Z*];$K1"!ZAA%>DOU9CJF8CWX
MXV"TW9T094L.H[-CLB;/S]$;";5<9BJ_M,\C(!\[R*UJK)A6CC.YV_!Q&^F]
MM__%V8JD\M\'\R6;0! NX0'_.@J#J!D0Q3'<V F'$7P$QA*Q .\-*SU4VSUD
M9\12M*I>I[7?]):Q+!AJQ*NV:=MR;4:K9<L?"NQ#>M[H80]7B N7+X,2T\7U
M^";IXP-+L,9:CG*C!D5>R:S2BB;+5M/TYW7W!EQOB?,*=P7T-&(?.BV%='=A
M,0V8WM#6MZMTV'Y?EO)@HC2=DBW-_%.<C&XN7[RDE3(R_&ZLL8K>% UI%>$J
MMH4R(X(=<?G+HLS'[P?#M*_CB[(CG%:6D@/VJ&);)09IZ25Z5]G?$!V^[:W'
M6]YZYI^K.DSOE8A'09ETE!::-H-7^HXD#H)N2KJ78X95YBZIJ/&1!S</MOL4
M9JDU58K4V=:Z??SJZ>JG*SSC6Z-'*\7%%3\O>MA]#"1S,8^!&NKX=EI8NL^D
M\D0H\R#$A+M=H;TC67UJ34L$>K XM[5-MK>VCN],QQCH]4'7XXI?_4X*EV&\
M8+Z:$00ZOJ#:BH'ON\ETX),6+"L]LMBM,]2O:TI:,2UEURA(  4-KTL8%VKQ
MQNJ6"N ?<&X/VTUB8)&<KV.13Z_K_5K"94Y7ON0O8DZ(&%8W%9B7_B*>00QE
M]]]V)XJ&4=^^\RT2OX7UW<).2HH*VDNW$;\G/5WA_9#U%9T$0?T\.TT&/!$X
M<HV']YN\;V%M(XP[]3\Y32HU)4X;?).WK=P-6#>$=<M8,9G*"OZL_M[ M:E@
M)3>8Z_("+E*:%+2?47,*$69"CZ'U8=!3]A$3,6G9WBO'#21GI6"N,<$T7B<>
MO[Q^M4)X]<2HQT?4 @\!<"  :S;FK_=F*TOD;TJ'[#;AB#Y' %@:4U'YXK\W
M/,U1YX;-MBA\4M?4ZDUZJ5[+;5K4X6C$H]O:?SAM?%NO@/]4/_^?"JI_-V,/
MY60@Z5D+Z5S%I;@6<[CH;^7)G;/B"89Z1T"A%QM?9ZA'396LRMV=Q=0E>&5[
MY[6D+7IRE7Q^T?+QS< YM&.^1EP<\Y*A:P4\- <V,H87$!#E1_9-TU5>%;C3
M0#\YS(41%:#CV)X.+98BM^8+0C/=<ON&8-D.0:&??4Z/==M4\7,U>7&7_E)+
MP?],K_^?"K'_.6-#.XT4W H6]:4_NA:?\U&Z:DZ\2R#)J8.J!^4LB\L)W# ;
M"1IP/L<1MJDB[IA&Y G,3/.!0O+K2RLU!.],JC5@U1JTRY_2UXT9^]8NO T8
M_B"H/'PQ46I:CAC7ZD[0!I>B.H&<:98AS80[H^LMES4U^27AEY(<8[7ILWDP
M8R-.(7T5&M]<>NM#@5G=LW]39_Z?BIS_,&/;7YW,17H96T3*#&8=V9<6ZRZP
MF$, 4L4QV_?SKB&6M -0J'% ,[YJ^?%4$+X)=*N#"*I)-T-KE=E@QUYN'A<Z
M.ZV_'DEY53#D928!"!I'*@6@.MJES+S,53'%_DW>'_3K\RJ*F@QN'*>H8-*Y
M0526?4C_)V5=U?^F\_7^OJ'9]8.=<U_NJ[^Z:#715VBJLIH C-D6+!, D:GP
M")O U[*MFX?*>D4[Z5>EVU#HU &S'B@4V]6BF#R7'9:0)QF<S306Q!JL7M^!
ML8G3#DM0'Q3'E Y&?+!QS)4:KV:*S'X[R_S&E3N6Z\D4,WV#1\ULH^2XHV='
MA9A-T(PG,BLT%-W7,9R6YB"0FBYS.Z:0-LW/S\\_EU:6+#C6X$Q\;&^7NR^K
M>#P"8)!^M++]T)WLVW/XW:!OO]HID,CGD.;?G%H[R_@"M,#)<8$K,<4N+;WY
MYC?"NVS'=JE2MBF+YI/D-RJR6Z#UI=@3)H7TM!9^&34!]S$'KT=*6D3,JHU!
M99UN84:Z"U\_?'GP/@"XC(-+'07XO*72'/M&(8ZA4)G6(P=.52=TC6:.Z'S,
M-[JI69NMYVUP,>+D&N57L'-PM08$3  C<&7E8&1%R,=LQPKMZ"5\D$ZGP>%X
M(GHI:W2A@5'\D1$ H+8YL6@SOR);4<=J;<4G1%PXWQQ0B3,8:7HS@_4.EGE6
MJ7-NL^Y@R6](HHW@0H\S_K:1#OABS<GD)@^/BR_L>U<N2RG)7,@>K4\4CVP@
M-R_F>"VP[D%3MQI0.5B;8/7!RZ?3!JY>?^VGANJHSZ_O84',4JK,@R6;"R;]
M)2CEQ]"5.=:JL:7UZ+NM>9Q=LU\ZNFX,Y12[C!( Z=2!E[5!H13%7WK*.LO'
M)V1V9DQ%OY#U;9I<!8DG(<BR]^LLZ729C>CA(L:;A_,_/[="O6O<1.N71@>Q
M<-&@!GP],V8'I%G#P>EX_<WRFZ*?*I3&;"2=_,"ECP3SU%N,1Z$-M,?=.R4\
MG*0Q!4^INVE6CV"R=2T7,\(^B P&8.6I5=^!"8!\JOC\4]\?+:VR<^W>$C;Q
MHX8L5S__276KQ]#QST26D$VNGYM*-'0^L66P%N9X@&R\<D8X=#X.9(69C<G*
MLH%:?<6W;6 GVF R3N]3?F-X_=>VD50ZL.7UER_M>@\YNG_I^,7'& (0VS[W
M/S$:+"'S1*U^<&CYEYY?M/HV0*>R^DD=_Z2^8W36C7V\82E93+49$1X>&#8W
M4:0S#Y06TCE5'SU:R99[\:;(5]E/_E'9_^:NV5'_[U+?*NYGNIS970<'O/U0
M>H;)D[1@ N#G_L9@^JO2'O\[E'YZK GSYB?G2JZ\NY64E).68N:P.B=J+%@\
ME7(1,QK:6IVV:6\UFS%@&RN5Z!*SP:"&T]\T#Z/1JBX)C8J]VI8,?2626&7I
MR#HGJJZIY4'2A:$UUP@CGE*E ;8:C./[HTULBR3EQ_^=(L-,D'F"GS=2 %^D
M6:,![B\O<AX^WAEC4WA68B^_O8/@0"TW(H(-'Y 6%[UPMZC<S2GW,/0\6N5"
MKU2(G4YMBVHS1PLX;Z\[=1M;[!%%SJMJ*5F-BO-2SZT,%_C%3R26.=ZRC]--
MLBG/-ZFNT&E7/@2XW?\G_.\ZLIL%E_LK?9F5)\7V:\R6CR\D;88#Q^YNM^YO
MEVQKGVA;%U;("3!^%JT8&)9Z*^[AT:19=BO7!#;M3*;XCJ!S; SC?/E1-N;8
MEC;+-6<"$+$Z_S;U\76V)%U&DZ$!D?X(X=D.@\SL(*X&*$BG:/."EJ2:3Y6Y
MJ]ZQ9QX"GU"0I=OU72^"3:2.@QD=H>Z)HM*R!UI7#E? RV+SVF%'3X2%64('
MZ9N[FDRB=3:#CJ<_93Y5;DT5/VE2V3,FAY=LFAAQP#MOVCU6-='H81Z^9;PV
MK?N\(+]-LU2]-%$3G_'BRCXVA;OAZG(:!68/*RM'M4VSW&[GOLC"0J&E@B;^
M_:"7O5YU F>;1Z!J P-IC_N/=.GN-L]LK@M)J6DPOAL6IH'V''%WG09+C3=F
MQL7=:.HF *'IFRQ58;^GS;<F%*6DY-"ARZ*1C@A5W=:IM%B3./O+97@VT#NF
M"_@8&:LC#F/B4T%67<JWLY?@5P1R'T('^44"3U4D6SJ%FEB!C7IQS^B9I,_<
M/7\C^VUA<_3"RS ! 8>4\G#1^H.ZS@FS@055?LY'HJ+M0L-?+F'C1AVXY(5"
M#PTS]8H;!XS<+WT:P/"0UZN0J4X6U,@+P1*=%T\O8Y/$8'^/MM]NVN-.^>-%
MGMB+;,\?+9J^[]R3HZ6;:\_@$&\LF[X_Z;)K_2C$>%J4&>S#_I <.7?WQAF%
M?>"%4+!M<."E9#V+HJGQT/'6R!-1#._D'+,@U*F1)K)E01;M\ C0Z>)V]J"I
MJ9$*F&GV-+T09&)C.FPTG-D_:D1]23[)J[%I3^JA:B]3_J%TC2PYKEEU90>?
M3Y<OZ"^E&BDV:IK*'VQM$KIXIC \B34]L^:\157?7)[L X$U?- )6 JD4Y='
M]QR4>15?J&QF*];'.[]TM0;<*_NJ+]U<Y_EY#3PXX]-TA/K1IYU,C1PP@3/:
M :_*^!^&6OA52J"BD?E=>ZZOJ7=UM+]^'V;8T7B8@\=OMFG*KQ(DZ]<L732P
M(!4W/0,QL;<+@Z@Y1KS(0F6>&.U)2-J3S+H?>C5'BJ)SD*'*1SL6JZ:K:R*M
MI'2) '"+!HE][DG2[]ZO"SZ_%(E0TWH\:&KP9F77J0._Y^ZW@4<Q)2;*,O)H
MK(8ZE"OV,]I['^KC%S4RF,-6$#\1:?X-8?S2>1-ZX^CR5F-E.CGU4X((8X><
M6WZE(R<=7)[K";5+\14;=,WS%]?D:$DM8IS(6V]E>F:H9=\O/140?S9<NS39
M5;$^([*S"5]N_BAR^$6F=9"K6F*=C0\TKQNJ=F11KZN4VT0V9JX+XSKZ/$K6
MJO?]*,T]+>H\>P:S>'79\CNWPO\_]MX[K*UDR1N6QSD/.6.;:(MD@LC@@$06
M&"21@\E&9!$-&!S&-DE@LA')%DE(($P0(!$<R&"!"2('DW..)GZ>.^/9O>^=
M9^_>?7:_N^_WW?KKT-U5]2MU4UU]3ITZFVX(2R:$7SO>F3MF=8C[3"GD AT_
MI-\GX_I,?SI'+*@E%'?2^"ER5>!$1Y8H4_F0N2>68( M,T;@(L=0/(O(]61F
M^"[P0R+K,L/X!=O-F /#Y(QPI5>@ATQR:V9%$^([-<RS$B_I!W/S7OO+AWOI
MSW6VD!V(@[&N_A_,3[_ KKKD)+7#S1Z,Q;]GBTK-1_FWPQ=(&GJ@HDB3;CYO
MW>>1\2%)R"H33%-/TC8_EU2481/T_'"EJR<=XO;',:TAO)F"MZVO/(M25PP6
M!&3%$W#5L2// U^7/(J\XG$I JJB_EG&Q]/QOE-,C%D\+_@(<#=UQ[ I_%;O
MZ/;/%]X CN6OK&KM.RI-2M_NWO'+.I1*6TM++#X";'X+6AC0C5/^<#J[_C<_
M=\WZ05*$T1)^"[1+27(2"/*PN&8]$ZW'YHWH3Q,(/JAW*3C,/0SH,=IWGZ*B
MC5$5=^[ G)[PI$'"I>!FB8KE1>)&99?N7!+.PKZ- 3Z8AQG3C3"#VES;-%Z]
M9!JEW$A5.IFF2A,W1/2')'L.E"F]$.T$6B_8<2SU\2%I!F!:B[6+ZI0>1!("
M,U-= "LDA67X.+#5+=O_E)7$#'1:H$?8K;*CS:LSS=I2SK]D;]D_ IS5NK2H
MNHEV3 FI(+KL-*4+#CHLYJF+!^!F;^Z[WSDGMF]A[-R"9DE4YKT")%$L0\UP
MZ;E-DM,&-QJ8)_40DLH+CUK+'",$+P>P9 IQ@9BT$\\ARTVVF^NS).GH;#86
M8!&^:N[9I:9<QEX8<DR%@.I,NX19^98'L3-'73IL9CD^4; 3KR>W $XTEI@:
MXY-=LH>IO+!/O87@4C'[/@G(U$[X$<"MX<JM]L\-8RL?7V9^"&DVFJ@TOX]-
M@.:R3Q8J ?')V@+\-=[,P!!Z#0X02"6:-RET5D>YJ*[.'0Z'ZNJIV692:F?6
M>@+6/!_Z.#1"/+*\ZTJDY\['%YU33U!5YH^$.I,0BI86[?:;S?@(A[:AT2-
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ML**\_X-V@"8^\*T<TAL9=2S[6]5([]!@0#ZK!;%/OQBBY1/DB,\SD<&*3;@
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M!"C1V&_.,:]&>2<0PWH4I3=U1%8%1BII1<%]WQ27D=^]$";X<]!<Q4;D6MC
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MS;%XWN9 F_U'E8E[,DBJ\T:/<A#L,.C0\3#D"%!;<02@W/+6/94NZET:[I)
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MZYNL?=)=SX9S=QNO06FM;7SF=2"_V/2K?'!FZ@6$P<>3(D%5X"C5^J&'##+
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M-%DHHC(IV=L>^UIH<GW!I]%EJ[=;W@@F(&Y&;)(KA@WG8H!B](]/7;ED56'
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M.<NXK1*-TWU<AD^629A_[+1=B/[F0$@P7CTF<,+_(]I]Z6JNMU+:(A0F+Q"
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MKED^W**,W):F095S3)<?/-04I;J\S7 G,^G=\.ALG%3R@_."S==%:H]=_N@
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MP.BF^?/;GVUDI\L1"$U$)RLO9(_Y3R/;?VQ/%,,KO9,,0:EDMNB8+*U-*HE
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MNA9%E^IA$HU!T]@=;PBS %,YL 2^3^KXX,[B",?;%NRFRUMDR?4/1GG#0^Q
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M;-)]W2JD!]<:<%=\?26A>[GO3M*ZV_:%Y<MRDS.+5X?MK=/]>^;9PS;T<"[
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MWP2,FVF212\1)Y2,@$!&9(7R%RDNKHZP\AY$N;E8#A%-L8RA"ZIW(\5&$MS
M;<]/H-AL6^YS9O4QORFMA4;O/&$.0S<3^YK(TB!LX.?:ZV6V>NMOVSW<=,%&
M8@D:";(N$/"/^6*Z]=:*'&17Q<(-E?Z);")A&OD^#HZM2S\^<,!.D8<S5U_'
MPCOJKEVRA1WR5@0^:S9;]<6)[TQ<=E2#,[B*SB&H\:Q8DK%$0\1$+S;=QW1:
MC3G*EQKNR=C([_2R]V:8S,T7>?%7(/D7X(AIT4PQNQ9_^9K1IH&+V$A1>]/[
M"UWZZQF#)-J](P6<0VX_MEP]/=:7.\I'N/BO\ZK?)Q5=CBSQE]1+>(@H->0
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M/2TR_"3Z=^/BW[T+^IMSZVMOS4-/"IVZ^$KBGOO"]!*U7T$9K$Z3\1_6D$O
M',5=\@6S2)MGI"G$(17P\QI2WWA):RK4OK3!PQ5.7VDA'35N \Q01(5%VKG8
M9$%#MB(S8D.+K>.'#$WH6M"K@2O%#;*;44<!J21D_EP]& DH;K"2W8F)R,O)
MSPVSS<M_RI$2$U_"Q=AY]A53T7X;WQV5D)5IO5+!@:9[6.F4,?N2S'IF@G54
M#T ,OEZ=="%W.CC%^#OU;+>;",E)$A83!F1ZL5.*[ IL"D:WQ\H'U*P(EG.*
MR"2/AB&,R^JZ0_C+(CL![?YN<@0:VZ4?SYI^$3BPYEXVL 1.C90T/<>P3! F
M+K-:)S/&Z*<)@ 'L(L7I+0NT\&)N6'OCM-S1]@@\147&U  >8;UF-@=@"VHW
MZNP4VY,;9[4@S--.(276P$"I+E-CDQ;ET+-:]3T*U50V$]D#5J_N'1)J6GM4
M?QLF:E/X$(%M5<C1 H:XVU_WHA,KU%.G3MX,MYSJ$X-CM_T7U2=]7;YU[G"?
M9JN- E0P-+0,FE.^.:>S&BVM4\6[MHMR\@DH[Z*"IQCQ=;*0K8K,-.U&^)B>
M2C'GI^;^ = A9I#;/< 2V^D8]'9SNG)(.<#+*TOBW"?S(@ZS!.YUXL,><X3/
M)IR>H% KYP9WK:3M2LB>>U;.96[W2'A%6B[',MN;]X4I%Z!U/?>;2P38#].C
MJVV=PFUD)'>/[GSF([T\:C+WFQ%O8VP63M8"%H.6#>)?J@Z^W1NEJXN4JRI[
M_OEUCV1I@K" $233>_*Z*&'-M%0'*,&K+$U;&>$!N63.FX)>W%;-E<"-N-:.
MRI9_[#06F BJ\XPLZJ9]:%%^]LY.CUS>5#"W$[84Z>(DH*YS:;!]N_D51KBA
MK\3;Q'Y>8LV/&,-X_GS]5-R8> EY;L3,N31BMK#4<J[ EV'6+YH?T!CR#-AJ
M;8G;I]LY:Z>U8LCS;%1+2PP6U5,>>\ZL6%'2@?U A]&P[,I]W7YSG+.C;X*@
M3V.L?D:7:6\U5>\[T^-NJ_"*8!FE.%.Y.0YDI@DSKZS?*?UD,_6NH.T>\=<]
MT5ZNA'8^A4??F<(MBTAF5*//\D"D-P78%N]-/T67=58;E3?N<_63?N>:):P'
M,3KKL*[EUF5H[+4HQT=,R"KG;29E<464MAF;"0QD7]<-#%2QGPD.*)6I/!ZG
MP;%Y>,#AQ;O*^PS/1\B*<GE# >Z,N+%N[_F@^PL?AH4_9B9_9[I?3.GJ[M8"
M(E "_0WZ\6#IOE<E=TB6A5.(KHUFCCS;J1Y29HP/Y"/VZ8W3*I3XY^>W+;63
MX+S*H$A<-3)&7;T-N_:'U-8H77^V$C@'Z71J/2:"UAQR1&IOJDK0\,DN:;(,
MJIDXU!Z]-%IU_,-YR&..(,O[M)KQ-]$J$JJ(X=56<:<W"34%,X2;]H%2X7D%
M"^G#RASO.CHW0,L\YA]I5IUK9B](U3\I?"=M9IUWA#=CQ9T0Q<[;8K<MK'Y2
MX@Y?72O;30QN.B\K#2G;9<.*%_^B_,H1Q<4IUG\_JFO39D2TJ,X5]36Q[2>D
M=<<_UB:GJKT[1$09!1*SUW1W4_?&K  R>GRX'*[Z:3;Y R)3=UG%BA>:6ZV[
MZH9,+#W-4%<"PZ*Q6"04"PZMS\03)[XSY674W=?\N!^-C2IHJ'/NG>E'YKO?
MO27RY.HAU$E@7$Z>#IZ%53&MVG%Z9L)C4(]),2+B\],HB4YW>:?HBTQG%_Z;
MLM'?/]*(8ULJ/^&7CR,28A.RA,6RNBLLP HDE0*0O?XY7U(70[OW122E+;@R
MGHEXJ>Q.B%D3A2%V&3><!KBU2QO.Z*6R8Y_?P;,UOS&4$'*CD[OTU=VDD4B*
M[*3&=Z;-9^)ZOF^WHAS5$"6FL/E5L(ZH^:L)?#,N(S1(5+3=+?\[DTL>7N_+
MA+85]I6:8*% :D95\>U;WDS']H7!0.ZZ4R8J7Z00\3:(XD@:]\A4SBK-=(=B
M"SAAKS:*]6T-<=41,L?X= @7BR6QVNY+.5+/JF5TT.?66H@QD*='Y"QF173C
MKRH/<$B_L3^LJL23[_D8UL$-D];_5>1LXVY4]H_=#?]6S&*"7 TJ'18Q8>5K
M7-UI'RG)X3'*D9:QIH>>;.%:L-[A6SPS8KP29OM4R]%(X_F5=?NQ8J,9Z[WU
M*(_@\;<6;J'N$P.;AM'"GPZT(?_U%_+OL\+^>]@#.&(^EVY &UCL4EAD>M8F
M(B(KZ4 9A\%Y<T7;QQ4>=P<,(\49W,11WYQ$;]OWNQ9H"L$ "*^^8?]PJJ+'
M>-!Y,^AX*NY2&\1*)"?QNNO'.;?AX;G9R^E0 [)7OD>X+\AAH0VY;^DPFQ?\
M(;M0]6W_Q665[OF\0S0B])Z]BJ[\N+NQ &E]XL@K7C#XJO&M65Q^+$=ZXU>>
M&/6=KM6!XO,#B1G]Q[>1X?(Q);JQICOQ-S8?_!'/-9]K5]SL!GMZ.LAT6-)Y
MLRE4=W",%R[_H0N281,)=DP$F@F/<*JK,ZZI"3/*0-%7H[VL1Y@MMS43R1Z!
M6\B>#ME,?# ]9+CL.].ETY]NUCCOW;KP.CP$0$9, 7W+3X_BK;4[_ G+%WXF
MN5N<WIT]<>G;47F"ZGNUK3.>N*[_-W$L5\P:QBJ-?P!59LDR!@*6COD/^;US
M6?@Q^;K1!CX(YPWCAKWZ/2U65OU1B6#)3OF5QJMO^H]3^O+F?:Z0RZEKDKF^
MP-.12<PK.=[\$VFKF#V-%!WP(<3)K&2GJ;#9=&ON^/=U03R=,/!$.6,GH.[@
MV!(3K^0?Z*?_(/Q=8ZB<_/+DX_T6HKAQUU?:Z&*[RHQPSP-M&FIZ-X]K:("8
ME9WW4E-C#-^O_4A_4'-30.K0$KH3E+SQ,C,)"#Y6'^?>W9B]#EBT0EPKH9\#
MFQ/$AAMK ,!,BNNNU12Z.B0C-"U17\3>=2FM#-G'L]O>W)>K/]26H"10.QE.
M"%#,Q1)S$*4"?G[DC+0"Z0FJ2?>1%*:2A3<;9?%L[-YTEKNEL#KQZ*_ON+JE
M"+8"EETTEFOQIVZ\&?Q4?[HHF,#P9>D$"./M8YHGK.#8NP'EXE_7\:30N\),
MFK_B@<.]I=/=1-KN1.H^SE_Q\6#;MFQ+JLAFPIV#CK_B,8NHZ_>0"]G#.@]8
M,G_%Y?\+EN=P%;9!.&?GZ:(RBJAED;>X83]J,TGN?/+T$R^Z1I;HIT>ZD6</
MA1# ,?Y;1)K<HMP9K.RLHZ_Q;6MG;MR&DD_2^PQ=5#K[JKPK6/U#'[ZYF)'N
M%!F!BI\^UKK>D*U*WC!<YAXX'[+-Z%.M7K^#:K9^16?S#RT*!B(,'/,;9)XJ
M%J(!:,?!=OT&HV@!I5](#U>++_,0Q-ZJ_BGCZ.6??U9J2AS;"/#$'=K5_3*_
MXHT;#=G7R?Z&RX*OC[;^BO\YQT2FO\>3Z7\QR^67!?4Q^!@7%XFV HV5 1YW
M+4"0C,RGWPV$?_LY]E\'CFHCN[SZ9*X64'"N&]#$J-B<P4)+P"S0V5.;F8!:
M>OT*I9_FDYYF]0B9],&F!?$R\6 6-FP:(K(U]\NY&5+3(T_W2U66>44)&%V1
M&X5*[5 <40,>$5EA,[4K])W)P^;T)FWY:DD9_3N3A$?VF^],E><"9KY&7PCW
M.NB/G!Q<3-%R: A@%1K3,+PUF; [V.C>W_V=:>581!*+C!F(MJYK)WK5I^3P
M8RRQ[*3W$,&[>6N=M3$DJ*^J+H"+8_$L''"%2QM-(?L4)L2J!U?!")%0]#9$
MXD5@F5V89SD_MIH(J+P>[AE?>*J(X%"+7-AJ]VD1G)<)1/9IA)<-V&->5XBZ
MS P7UH+995T@*KY@$"K1?_ND9/2K;K9Z-O:DA@K@RT$$\N9S>IPUT#_$J6HR
MP2^K)?S-UA'MY+#VW6$]E#!-))(GKDT^1,-TG"ZW^^;D4"OWTQ3?0FOGY)+/
M%A*Q/G[F=3-:]EDP(GA.VCSE5LI)51,-[W8&7&U>(!XXCG8H,5)8+^<OX"_(
M;;Q#K>:ZW@G<.[%!5A'R&>XVY$=TN607]6RG1&3,RNN?,[OL-/JVTQCN+JV+
M7B$W3^4H))DD02XF%;K[Z2VNM1+M[/#FZ%(@'BVPNA*OPCD5Z.(1;VQ:RVX$
M0_B$,MC$AAGK .'.'N<L3'Z?GHHK]W"^-OHK?YN*%L"A<)/O%;\YZLP[R0L4
MS>?L9O/&S6F4F)G(,4D&++KUCRAH%/XG!8VTGPH:3%?NWOG9WTY1XC[#-T-E
M[$2_,S4W_5B(-*NZ0A\M4[^F<QKNF:ENB*S*#'X+3>S<"-BKNS)4D$IMIK;U
M3VX^7WB[A5E\BDQPT8#FN-^EL >VUW4/CU.^NA$H=GH-P/($9.$01%@_$C>Y
MU=+TP<)<Z59<O$!A_;H8E]>R=F#/;NO251-6F4^?%Q8VEX;22OF^,\GB-?L-
MX\ZU]A]OYK2IM"=_++$^NPT.[=Q,-AHM[9?80)KFD]O?Z1T7MM <+%TOYMJ=
MKNS1U]="S169>$?Q2S*B'QS(>_T'%[F_#?_,7_LIMD6M'#"MB&HDT^^G!S8\
M0;;/$E9*:U._K?1 @RX#^L\.S#D^@%SLI][!;_+S+[6+65:W3EA51Z<*H_/3
M(I_HVW'HIGQ,ZH#ZS=6=[B9BB.YVD/A%6$:FQD<CBNG+;.9Q)'27%5S2.D5#
MNX+\OR%V.K^F@$@DL;!#*G"E^';]^F"PRF6W >>H38_.WTQP2_4[8ZHV52X>
M./'/##W^.OS;W'[\?2Q_;]O^?JE[X%K,<FV +AL8Y94(EL-)#J&RSW*&:#CD
MU9]'XNW?^0XSF!GWIQ8A]C,F@DQO1WF -\-<H\F6'> \NXR)(7C1)'A\(/X!
M:89ZRJ+D$&CLD6+JG..0C,/\=OG\=)9.<BM0Y.+Q?-"!.[-\TZJC0F P^#M3
MA('U;K[=\9G$XS;X#,AQ+HL\7)@?YIXZ>@?]!8-(U_F\'QC]2B6<O8';PU='
MO 23ZR/EA["](KTY=>=S:\35Y N5TN7H6,O(\0&N+AHQVLI7/UYF/?GH#Y&=
M\_?.<:=_M_.^R'F#:7\Z]G7J0R2.IU<THTEW$QB T&\'@T\\.]HHPF$4[)B_
MP3T\*?5:6>,+TGWH"-,*.[V0ZBOI:;!NN1<E?;X68/<@$#75-40YM6_L2KJ)
M_PSLDP>X> 8A$6+:]!/,<Z#>6BY_\6/5ZV&\]<?WEEN%L3^QUXY$U+J!!E[Z
M/*PQJWOYC+QB\@OK>9HEI#^]XM;T@2!"J-HEE[&\W-<<D8MFRT$(NHG[4L8D
M_03X50EQ7!,CNG%T):W1_EYF5OJUI9UA;ONL$5??I8KV=P>F@VHA4E2K21@#
M'-BUR:2NR:>'X1<XRG0P]X_THW_08_[1O59,3&K(RYR@7)=[MT#*"5TW%:GP
MKV0""(;NFE!7KGP:!7!9;Q[W*ZD=5Y_!F#4W:(D[=<$]V)5WA1UJF[RQM0W>
ML;,\P4]+;2.=X[WM2'0VGW[JF25JOSNP%1LE1GJCH>1G51_&MF@@Q @0OD]X
M8$_X\LY$S5"%']-)XX9S%: +7RTK;VQK8R\[SXK&&W-PQ)>P^<#BI568[DA6
M4CI=" D)1 NH# N;48F"B4?>:9'3KM82\K9CQK]9 UI7(N7I'K=9W/EZ:RW=
M&]Z%EU])3B_Q$NWR0 __9I]7<T.C,MCVJS.5_=2?$/4%1K4N04]S0KK7]YT?
M741-YB_ KOT)<393\ROA-X,\:-=!Z)\8>?Y$Z/IQ3U5@_^6L+IC_;5809ZZO
MB/I4=TMSH91[ZA/);.;PE<1$5-))_\@2,B^E0:A\43QB"]'*DTI<84]TE)[N
MAEG^5I#;X"7W?1T^^;8N1@K@)3M_XM2>;$NFZD(0M_PF 6PW,GVRHJX"!ON6
MA_3<:%CM])?D42D)*1M"19=?J![P6#L&<4DB-63IC4T0K.S51'XKI>;Q0K3C
M,>?(R&B;?US_6T;_NQKT?T56 1_ME%3N(4S+5IM)S57 \R+\CO."__&66 @:
MO1'9GCP/_F;(_=L<+[_^T],CR0N;6BY%(>YF-:]JZ-Y>F!R($U]19P87_J%H
MR0^!AM:= 38ZX"RH62.2Y#^%3[80>9%@@QJ6?1-D4#9:;>@'S00V&%6)K;>S
M]&$4V/SS=3-@+USEG)CO5(''3^KDX7>C:!%S3AV*A0'"M1J:4H0)_6?3;+1<
M-TX"6^-X1#<E2P<8H-())[8@,623].?,64<2VLQ3N,&\MD#SI#,D.'BB6QU6
M)YWT9NO1BDG! *,\.-,T>68BD]M@>JI>_8<0/;-_G?/YYJQ8$,7"<Y$(5;FG
MP3UR>R+XI3^19%]R+GR6?SD264+D++-83C)-@ S,=LHF"B_%ZC-:Y@\@;A)2
MTT_/*AWI%ZHQC!HR,M3'SG+14E"R(&PA6<:T%WKM"&_'\%409?(N$9-;G"SO
M0M*QI-LC<2[\@!7)&P8/C9RLM9/8J6[=^M" %XB/77,WB45A8'0AK52E.A]J
M$+!--3A58(\I_&@& ]@]$N7W-Z#Y3Z$V^>]],O^$$256X$!*T(4XJEF+!J\R
M*,0P4:XFX" 8;&C5 =V^,22V>.T8TLTOT=BP-L=]]@0)E@)UG#CT7,; QT)J
MB;_>1>O!IXKA>='IX@H-B@K)OE@@B=5B<,KG3>US[]7VFM*=!W5?.-&,.,'&
M<ZGO3MF@0[2,F[_.\D>NEFMH*FJI_!"99,9HU\?GSX[NBMS94>\I7('B+N;3
M.H")5\Z'_%;_B0.(-\65*3I;4=1]-LE]%N(!J/Q21VR4>#L01ECQUH\'>UO?
M1/V0+'<Y;4_HIS[Z/)_)9O<M,!GD&Z#H!D+-'K!_.%%,T-4#@Y E5L]>SY)9
M;:G"N,FO+ 2.<0>[=)X*CAE$CJ9N"5)E9F%UDLZ4RN1+ QMR,TB&K+ ,IVG,
M93[QWRL$&@@7Y?MS4X'DJSB"(#8B022UP/^7Z/W;/9FW_0+PG7@DJ6;0,E*F
MG:O/B(75PEN]U_KI?[C>P?UVJ)ZH(04VUVO="#-A,6#%=WZFSQ=(WJO8N'!R
MF.(]/1!J5W^BTM?IB_Q<=W!-W4^:S2^0\@W/F8\C>(NEC6\R0;,MV6Z[X>_D
MB1E5&R.]*_O>Y:C=)SA2!W[/\<BI&.9M<M:RQR]PR,_4<6=X%&7_(RMOZRM>
MI? K*>+]V"IQ;-7B.ONWX_B#[F Z&(NK\R("+WRB+NTY-)I\9TJ*VXW\%N62
MSU]T:6;G>F$:GK-S\TY1:G-+(*$04T"(22I;593O;*84T]G%V]EC5-0C.J/-
MIF78X<--"L7VB*@>H+?I2DJD3O[)CO6QUBFUNQ#XY40'=YH0,H@]95FF,[A0
M(]NELT;6*OJZ1.)!GV/C>I*7'UYPP[O/EUH>8^,6@# &M5LPMB%9#6R=, ^3
M:Z^9A#[^=P6+/WM$UHWX=<)U(^D?@;DF\U!P-[XK1>B\A-KC85H-DC@<P,=Q
M1DYV/NLHDA.OK!]?-9W8'_4T,\6II:?F*<##<JSS*8!=G2,K\30,-RL9&R(%
MQK,4^S>6T+(;I]JN2W^+TM3CMF;MWU"0T0+Z:-QBCUT+O1E1."0A)I!7!52V
ML$P#[H7SATI3WE7BOCR0="\;L4U&GG?5WF+4K4O=-?F(K-)0<I"7N'\EY#(&
M5QXZ4]P"WCC-EC6K%?@RECBD)/SPFRYCS,I^RJ3_;BDKZY-R]?%Q)J8G#_Z%
MAOFKPXV_K 3/;OR!ICUP^L\;@?._]@9,:E?_]#!P6;5D_CO30Q%*P:L98AC2
M"7D1F0,7=[<%K#I$/4":H3X3!>OCJ$2.:J&J5[J1TF(,RARNRDODI3Y!5EZ%
MT_E6'QB5SMQMF3_1'],.F^+'55@4MF8EJMY\J6SC%K)$'D,'":8U3^<JY?B5
M+WQH&24<&[RFH^?7L-D]=#;S_40D2RMDLCX6XB6"O01G]$OV# %M%?55X=4N
MF6"9=$"5B:U;B^RT(D$. I-]\D$UETKP9;TUX>I$U"K7 F!R_"KCV13TLD_-
M=-3VY+G$ A)JT];\I'4$[KC B>A!;7S#J[794$WGF $=B#OV:=2BP02H[\>.
MKM6^Q=VI"G"P*"CP+T88+B;Q+-+J0-URNG_M;.F9]EZQCD=52 =O?:)I;U15
M_CO'J]7L "B;D,JJDV-Q9 1-"*4"F2QA=Q]\S\?77G.O5+=''"SA)S,+L!9(
M/V&YZ-L];751%"X^RF,4+KY6:@L=<+^J!RB_UK[DCR>-]S\UU"E+@C!?LN'2
M\[ME8@9RRT?( ":QB_ H&-KA=5+E4KN:SDV(H?[V7=BF.!VLH:%?CK!=5I2J
MA-@5R0?'UB:5;51>BM(4@Q>MVP( !1=OI37(N0SAS[9;E#T.(KB1 @323;@K
MS'".R>56L5:V,U0GNY-6,Q).M+G-&C;^F_L;^"6I/A 7P"09#,O],<4+9W./
M-MVN^1!%$NK)SZ1EY53Y3-+NWA^KO(^26G[3O7U-RM=TI;W^5:F/;V2Z7Y*)
MJJYC2N$9H;/MIZ(6 UL'?+ U$JZG\[&#=HP5(SI#8_)6:"[2OV?V"I/->_9K
ME^O&K+,8#&2^Q89SMTTUJ_,1\40>_J!L_O.'4 ?-C&=/X<_"\)>P#FOVRB?5
MX0XX('8:4*Q(ABP?-0W2+8=Y< 6AG[:8/P>O-O%-2U>90"X;05 ?[<J2'GG=
M>\Q,<+A45TY!^;O(GXMO&9>\*]FU)NH%GMFFN%UI0J5;Z#\'N9AXFA%G22H&
MUR55\JWU.'3QG*-@<KOI.T.Y)9K?I(;91-I"W_PQE[UGH\GYB5IG3%1]LO00
MXC%[+DE&+#IQCQ8%=B4]D'OCHM&^-P.K/XZF8HEEGB#D2S>9X2FJR\!>_H3=
MCSJ=F&WZSA3R\.3Y%(D 0(S(* H.M,IC=,E^ELN#487H-$+V!4[>AF2]Q1R6
MCWUKC^\2W(@O^^F%,0-X-AD:F+6])<VUPXGX]6WTE8#BZD[&]>YN(;5L8G$2
M5""S!/)Q E1=/Z#3"TC_\9H^OB]I@%Z(T[L]-5U5U]F2L')9#QV4H?+ DU=L
M\ZTT78]+W!@P7X1;&$SSP>&F=Z,Z3_4M;9LUE%7FG.DD\/%BP+J*X-Y21'7U
M;#;7[GL_>)E:M&1O$,.AJ&Y@1,N]>S >*A*3??X^ 9M5HH>!W=O_MGO<+-=H
M#B-5',_"E1%QIG76XX@M/N\>O+G]GIL0$0"&=.('TW*,P ,LTOUAUIBB"U$K
MAY*0GQ=7RL[I8QDA8@+I:,PB/,+-9+8/R%TX9R1D-SXXH3'F#4#4.(:?&ITW
MX\GQDTB( B@&*%@5Q2DGW=UX0G+5T 3R5.&$&5(,,VY[N-IT(29*QWHE8Z(_
M7WL?>WV@?^=Y/HH.[T'F8%%['S!KI-^YYE^&^/_ \?!_OC(170G@AIJA=,!9
MRR+G3ENO7WDQ%QF!;YC:T6K.IG\\36C,F4JZ]WCGZ;C1%]W:-[L- VMSJY]#
M'L][8;_F6=_9&ZWL"NDH?A7J.5)@<N3]]0JN./2/&7^).T:+#M@YLLF\[7?U
M#X%]_^9X#SAL&92B27 3LL3A^(4_[84:E<C.4/MEK534#=]CJB+Q;V9WE+XS
M6:<L=1995=GB6UU2OB%J5],6+N2@-H1\O9L,:R[S4)$B?>C0CF'@%3WA&%?_
M'3*\E7CEB9A(6J=  5+,#@S[9K9R;Z(/&Z.NB>$7_I#XC [*M'#=N<"53^W\
MJL4X_L92CF3C2,((7\=]2@^H;T%COC-U9#SIW;^5+_HYO-2=<;YP"'/U 9/N
MZS^P'/W=\$^<NW#K3;Z1BC:C82V8#Q;%VZ6UT5?%I.E&K)%RJYD!)VJ&,:2:
M9 ZG$>;#H'@D6]_[;^0D0@O* 0K)^#RT5"+# YT8!'0K.DT^U2H_(F;4RFAQ
MOPF8?%=Q8D*ZW;1+PC5]+.UC(U&'S3+&S/$]MK"E]6 ^S=.^NU,/?E8,JNRT
M"_[.I+M:,$@][1SYUO3L@.?D(2%-:)G7UDQ&% Y7N.E@_\ A8YJ+UOKT['08
M(070Q !+@Y/>1U!(586E'Z/N!IYV^*JPXQCP4*C;P/<'[(G+@PV/Q.SR@,!/
M*ND3TXN9PP=3+!0^NH@HLA /]-4:W.\;&O^%. M'3-\LRIC1K/S))/8GXI..
M7V+F89+/2ZY?3*[]>[+Q,?"5XD@_#2WAK7%VE\J)ER-I+OBP9Y[[_)F/ONJS
ML;1\[9-*R@_V0\-^(!/]<?TMC*WPU200^&:$KWW B&GLT.(RC%RW-F'@*,*?
M/'6R\?R"D4ZF;"0OE$4>&>#JP][^0U+ P8[8)D71G"?C48T]S9.&4V:I\UI@
M?Y':R7"X<EDZ;*LOJUITIB7F]"U):/^X_W18T!R-:O9#B(E1O*+?F7D*F)AY
MW(0)]FIREE,M,%97[Y&P]J:I J?T^H+U3=O\HZ4A&;M4Z@>(*P-)Z!_-'VIV
MUY1M!OVH[H]T1WOV+8R(J+HNK;P.EJ>U#2A5%_;K_:-'QR1)/B]^M*X [,AO
M/$NI33\1GP4IM-;'/UHWQO,_6J5UF><GXG7"O(@B,V+Z%O 7DU^(_?^WLD'[
MO&QU;M7\4S<,",A<NZ;)T(#PZI],$XKQ01:UFLY].+GU-V/QGWY9._/4;EO+
MF7?+6AB9&T0MEEQL*F1\31MTO(=B'L7-Y_9)?FICB:IRJ?$'UOVV:&>:>(CZ
MZ<#K$NY]H? O]G1WJ_"&VXTW@,%[ M^PU !O6^ZBD]?/U*I%?%YDZV VU>E+
M1Z-6>-)Y1JKTWTPS]#ME]+^^W<H(N<$<U&B.8K>M$1KT;.6CY*&/LR,Q2U0T
M+85KNG'AR]BMPV\?1;=O7&SD<.2L.SVN(T*HH+!_2%IUV"AAP5'ZOQ66HIYM
M?+HG(;V9&YQ42R%EB9FL/NKO!H9:[=Y#9?,ALSW9KPH$IO",5@-O]P<S^K/0
M+VEH=1QNH8K!BEJ6XNAA[83)VMVEV@3G(+I0PJ8FJB)2_;1-S,0+@S>W9WIT
MY().LCFY ^K%H1GO<9.9<YLKWYD*391K5[7R!JK+MJ4J!XN26F/FNA4!:&>Y
M"2((.['?_^BIV!)!WVU)\K 4D,YR7GFRL/!^CZ3+)BZM&ACS>4HH\[.%9->Z
M28F,>3\NMB63Q;MM:;_FON)^G<(&".@J\<*[E#EJD(Y!DU1,FF4]#=U2HF#*
M_/!P1=>0[\,<;GIM <N@/:4?B=!4]8VW8AB8:L )L/(";.G527M>LT3)TP6-
M0&!L"#?&(@E?=8OAPL:#:FA&?6>J/''F3//BY3O]@.D.4^M"8P=)/-DO(Z*Z
M#X/0<YJ;G7<6P.6B%0ISW4L%[4I=$K.O*CUD*>PP.Y-'41Q1V8XG@_PQ%4!3
M+1\7?ONO"37]LN'^0YQ5R'F7>6$B[.N7?1M'$4&WWY!@ 8D>:^FUM5,90;B%
MU19ETLY6=*M @YR^@AZOQMRDH0Y/.F?1 F,O%X2?/R![=(.S,36857MF(<4R
MJ!"=1I'#Y20N6:E6KHW!0 [O9.E97ST?Q<3!TBB2/5=>LB(?IA[F9K9%20H7
M^'8K1;/%.#9I7HD>L93LE/Y+)_\C:D!_%?Z %A\3&ZQ?K5KP2[FB7I!4@D),
M=T^;(!A$U5V"YX^,(?O*E=(-E%6]NPX9C9[=_ (-,-EI>J(W0G<;,EP6I0\@
M)[FUWE%Z_LY#3JKCY?[KO-V5@+BC*77H 4KVL/_-7+%WN$NNSY]SQ<83X/"0
M5; ZK#R1&U[ZW.W"J7G] \2L0)S D.@$HF0ZN91=5K:ZXK^JY[\>_MFWN;\?
MV&3T4R*8Q'@O.K5RHVG6=UQ]U_OFKTL*Z\P:V%\-O*#-\ _*?N1EJ8=M0@JV
M&?)=44M,4A'JTO"J/5XQAK[G;.)%M/..?5E(5CG1^G0>"@*:O*T;Y]H915-E
M6.M<WH::HG_4]DXL\BZWH*&Z#XQ!9SOU]@$9OKP-I'IP/Q<3JM5RQ.+388-[
MLB[O:Q_-OZOH/WG3PPU.\DT CB-_+&]I)L^(>RW@XKDX+L?A)<9,U>AUUIS+
M3-+$_ZHE_IENVN&Z^_$<24AB6?=Q9YE':85 39@>_S?3G42/X3!%-X9[W*L:
M/Q@9[!\HE 41R]H4*_5>S^0[^3G\9J<?M7K#/]3)HM3]<D2RY0(8;CY6%*H%
MTWT% WCNZF<7IIT/\K42# I!['1Z#%K76S[6VK(:L6"&\_ZF-.ZM$H>DRN&\
M5Q(2V_J7VH.F=EF>BA$Z93N?H.IO]T@>GCUR 2ZQ"=!%2<S% .6GMK2[0Y)8
MA0Q"4FQ"DHC/9&_:-_3(PQ+R,2.>]Z&YK_@!JI*^5M8Z:;;[7'!%;RUURT</
M6P^%OAKLJVP[,!BK32[5+]6 I7059*M7WG]/L:U_OGYN14X,T=]UTF=U<#@!
MD>;67W5>,ZY,S>'-IFQ5'@CT]M-@>P(]0>!'CQ TL-9IOQXN06R*C/Q4U:TF
MO*U;84)FL2QNNWY=UO &VY)8W.$NYP,LIJ;&0UX2/N6*F6G2E]E31*8K) 7[
M$C@(W)*60AVL+#SQN?$3'_8DN\0'NA^[IHCK =LKCL\Y.2;ZH9/%XXG@<?4
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M$GYLQ@NA42@T_\IVY8<\X0?B);<9[U2Z*9B[4/Q)HKKZ8P\N^4C3UI$U0XV
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MSHEVC8^_-']UXD^^X4\]>_Y*Y_Z_5@G<^0<?L/ \1[":+D?+JV1DP%JP"M!
MQ>?J>R__IP'P[Q-&^U8<\H\X6,?12Z_$*D_'Z*<S$_QPL?U IUBW*-GI4_FA
MTMS+X[=0/W@6YG'KE2L@;&'M.))Z,S')*2'C<^L@BJEARX;\'*JGCJ9ITVV2
M8\FM],M&KQH0B58C1>0%O?_%CCVOV45%N!F@LUQWPM\ U?<T3 PH^ =J&2HG
M-\CCEU.D!\\]Q^Y;D-3C8!R[C+O=O&J]3__'SUU7_YR"V?L?TS*'O/ZL-@ZJ
MO +%]LPN)4[N6P(4Q DDE^,[BN-+\V]9]YG;&[6FU3B+8A=[32V?OJ'4:'5D
M3/SAS2/^Y6YIB&K=-/$I'+<PD&@V%<C0,D;EAU#R'/' H;A%C4MYS=(U#H +
M@A.JF[WJX2#W<;!J-,7I-'_DB[=?YO;U1AON'(0C4:I82KV/ZT@<D5XCHL>^
M7I^/I: QD>Z13BJ HA8%&Z#=QKG\;1XEEY[)8TXKJ?9W!R.CMO!$8_L!2 <<
MN2'I"S_FM.;H])J[)?H9AP.$39M[N8450Y*7V-_:'PSPY+VWD:SM]1WXA"57
M0H"8U#YE@&1<T0S,KRU:L8MX7KY+\HIY_"T_P?HI0F4H;O]H\5/;CE0QE?0O
MZ8_V:K$M$\ZK5&R_MT5GUV>XI28A4<:S5NG>Q9]?ZKI=/!7C6M$ E@>[P0R"
M(D$B6*BSG-Q-W@;CC_#X"W9JC6(12F2Y$G+_ \9*2"Z@Q*Y_Z;RX1$-ZO'/R
MAJIG\SC(VE*]C=TFXS$XK^";/N;TDM?==O?V:D2=:[BJ]F=<U=O('9AQ1IX&
M5O=S[(!VY=07DPSE#5&ILFX8E6"\[54N&2^H%1[MU<QS5L&=HZ*<+/5 UK@;
MN<;W@R=YL>>[=#UXD;(>4L*"7#'7U_O"*(S+)&;DHN=O;/& JE$O0Q5<%B]@
MCA6F61+,QC>$+X87-D4HCA.2\6?-\1=2V^^.B9=8!JOX!?:R,[0^_."AP3"_
M4!ZOE)_FM=PWA3]3O8-D#;RS/ZOR>16_U"I"%HYBAXW%.C!W-8Z.*<M3:!4W
MK$& 92-3#:W 3?)IGJAK0J=C=)\CU75'\"B0NK'Q4.S#(1[W?X4AD9SZUZUU
MOS*.4"MQ/W@$P.4_>!QMPZWOR7ZX.;J?8&0*/ST0F=I!\"26G,SQ*=>Y]6O!
MSJ^RW!_8&77KPZ[[!AXR9]F9)S]WX]U;NU,+K7<NO"R^U//HNY=?5D1#[]P7
MHY01(TJD_!R(L*ETZ[WRL2V/2T_^(9A28J]7WYW_,8F2W1;^^$NA[2XE.N=S
MSY=6^!AOP[>3Q^:B@7_X";2VG?3[PP&7"&P+ :"O2$A%O.*L^!KF+76S-5#)
MNA^4K+2>XS?@AEYGLT!)J>MH58.J'BA4*VO,Z?=)J !DM][F(P>SU3B6<"N,
M)DJ1 ,HJH2MZP*_[V\2;9W-*GG[\/5C@WD)L[&L>GO]CI,6_T[_) #I1/78)
M2:-95%/.>A99U88J2B,<-C,N[Q'X2>K&_[5*);2^O6PAD;!J:H'WP\U!ZN+*
MG%JIGU;54NAA;D5Q/;82<OBV%.(61VSMW/"Z=7PR E#C'V>S;'<K?\<1GH<Z
MOW7#',8'A;I[5<O"W.87%(_TLF2?.5GBJ[.Z9F'-<^<VU2+XT")UN'9>,Z61
M54KR!8D<T+B6BI!,_AN@S#GI<@'K=.WE4$!S3=AWRMEA:NXE4K&(]=&,Q:=%
MJ:R6\JR>%Y=:NWL68?P0/P(R5BP]*"[0IKB-WUFHE)N[]I&H ]B@&,>^2/Z=
MWH.1("/S(1_ >N%N=\*=O[?!LC2.5OKWK<=Y%95E2]%^\)P++7#9,0!_FO$B
M4\A+&31KS<#*K$3@55KQFR:)='V#XHW/<GBI,3>DIG5T02"M?E6B1[?6V^3%
MH[=^W-L23^X\T:W,ZWHPQGO&KQK(/+>D2$_&;RH.VA1W%VVD&3!7Z;G9)HH=
M8,!M'W4AV%NZ',=UE_S$^5G!8D6+R]'V+YJH[RWLG&X-+5.2LA7^!P_N.>7!
M\)T"T.+/X8)C\6W\X$D',1US(KH.B($+OI33+54-Y?CSD"L/AN=FMDKT EV7
M\V%4+?G7^]M2FI.XW8;061M&S:AJQP4A1'AUY>WXE N6IWDT?LW ZJ*(LQ!4
M,K1&1"#L]YF_O^9],6QZ-[25K69)V#@K^4?7TI(=3#V.*R /'Z[6%@E$4;$=
MFC87DR[S'#- ^3HAEK3[C9EHKX4%T"(=WZWR8;KUV.5_O^C5XX>:C5Y>#8QL
M/L'8L$L(>. L5PT!#RM&J?<;K@3JL0$ NF6SVU?A:>>[15^MU^4/)RV4S#Z8
M7+GT@Z<GAB.LL[!S;^,W\<9!0.8XR\),/G]L:(>BAAE$SI:%)UO.W(^A#;RS
M<U?5<J,&[>CYN">:6B2AJ@;=/ F99LA5D^-6*-(*#./XR2=8>O&&V2BQ1-#C
M($8RG]KS\4DQ"X5>?R=N,<A,T3I%E#'0;&MK*G[J8[_M&-!0P0T.*BFHTL\]
M/+ ?GRQ#_8!(!?M.YGT[YOB^8#S=8=F;#6O)GEETC!W:G#6>=3$7>,-_0-5$
MMSE8Y#A0I:R;TA0)"L9&T#MW?V<&F.@QWF5*J79MR)6VW(@MNT9^2N=H=,",
M-&=';I[W>G)KX"R[!?-@LW? 8M4^TT#=+[X3AZN)YKV\M?:H;]'@2/]D7E#:
M?A1H@0;U:E%C1$ :?;W*CXR7B8K'[V4<5C-@R&8!I4F=?5#=%/\38LZ7>D72
M]YON=<I17O(&!EV_.NX-4 2L#L4(]I$N&H14C9Q=D(#)I1]$*L;&L0VTK+(J
M>[*[ NMZ91<6@D8]BIHZ!YAK*FV]6M"X,B$M&\A YWMGY?.KF*>E7ZM I>L>
M!,W4]QIV.I?\!3TYCT2;57LY27Q3 *IANSAGXE"F0H6?J2RW%8>WKHV\(WON
MZ,4*A2-)0G;%_4'',&B_SK8U9R]2)#1PR$Z,UQ[Y@\="=YH<1V@>\7H!7355
M\#W:U&8;NGAI/Z>!9?B*TGYV"4%8TFE"SA#9A6-OY73AUB=<CCM+8/#;PHS6
M5?NLZXTHY]HX(F"&8G&!I5'Q=DF75&,$C>KBQIQP*/XD]B;+I++?D1;*&W\Q
M<!IY,GOQ1)DZ<6@&*Z;9)I4V.8>(\"B][I3IG68%M/:JO6&@;]JUA32$@E,N
M]B$5)BZKGX!;?%3>GE*VG*(]J[+^+AQ\G7K#]NHYEY.I+;H?N_^HK T5R496
M)[TG+P[3=Q2-$$V>7LTZ7W[383H&&&O'-RQ[^('L^I JQ4!$,M9?$-TM+R?N
MW-"?KG(%69+7V!\2^<T@\$'J,>-!*RXX77,TY_GE[K<<18< (!=]O<7!%,N%
MR8F D,K)VG27@(<MA'<LWVM\K$7^MIT'6-'4-^:/'997!FV<2,<.3!N,BSY:
M//]1L8 )LX-J!6.$(Z@R"I9IR GK^/(DC'?SXTOS:0=_\$3=X>YM>E4U]8<P
M I/V.0R@1$6O<XE*([&UR S2I.G<0V)'/@HXL!A!BBL'6B*!CK@V 4&YML".
MB]^B@>[Y '90<(%^S>I%S 0L0K$,%$? 5+,C6[D7@X8BZ*.?]<>7N(F3Z2?A
M4.VF ?OM%+GOJ)V[>@5]]0+9Z[5CGZO>P9#:SWO"GH9[D;-]<D+''&]U2+YG
MV#L/RT3($N?H/C/.\D#-S[P&GLZ"^6BO\\\*W3\ \]!U3BJ8[M2VENYLK[ZW
M^DZS?ZP*+T*8Z,2LHF$NCA/R0<V2J>UQP.GS];PTCCO*>0X%H6*1E(#<,^)U
M/E[U'0^=HAF3%#ERX0, \U1FB S*#S)[U?KS=8!VCRL4D0S8A,Y-:9S(,P]S
M/K+/P=8VY!Z)MJ6\[PQ>!-IEA]ST;-\O\H3>%%=*%Z8U6[&M STMR2.?];0$
MNI DBYFMN2P+Q[ 7%J)^>J%PBP:X4P *M!Z3)G([]YS^YF<\UI.!/'+J#R\R
MT)U"%[1HIGA.S<7&[]"C@>4)?L>2S()A?E+QZ(ITMBR7B MEPKS%L='M=_G$
M]D[7&&DF%KY-MVE;3!7T44P"K4 OG%BVM \]A+";M/]$4<XDM$D>Z<8"YZ'.
MEZ[<?S.G2:UU\1=5+F#=4WX@$5Q0G&O,S1B>H<Q:X^H? QS>A3Y0 4FU[UAZ
M%HTC5D<8F2%^F6 W104.^SX+?L#MB\D%5CVKS2#? ].?G(2A3CM[7E6*K^#$
ME,Y.P3VH8"B8CRD_9H\;T-/MTW*BF%XRI:*E5(,_L,9OHYL/>@R[>RH_1QK@
MI9A0W5CKVTJE^B6"\@^/P64=QF4]R=4V],A!I+=$X!![==KIF7-_];4&Y@G#
MW50F!LW$T4+*1:23-H/#?_#(Z%TC=1IH>5R ]HXM/,L:*8/8VA2U8+T)/WA4
MVI=-0R*=-J_IZ!MPNR2<] >I&2"97!E#@4"K]"3-;M=)>&R9]&_/GA%G'=P:
M/YHH._#*/IG/#406-D_9&++W1$^N#RSS$^$%7<]E\O#5(\->].XX 3VHF;9X
MG[-H_?BH/VK)UR-YI,PHK$=\=@8(@;9!\+>34VP#7CZY77UB!I?H %>A0;K!
M#D4TCJ'T!2>HXRIT<K^ID?:SY*Y(.^U7Z) *5+E<"#SLVTUTE9'22/$];?9(
M^T"N,J/#\*GWT/\6E.\Q7%Q>X3WSPN2R)@EH=V2Z'%)1O.C432IE:_&/9]0@
M%4)U2.YL==/!V#ID_">A,9T[K"E+N)HHDM3?IQ<X8 RQ*U'/707N.WO(YGSO
M[9.O4S'Y5=PV5=1M3>&506QTE%EV\:;!>6="Z<0Y\@2+4L@HEX<49A&3 A6X
MD&G@E\>''\GJ=D@.W?KCY/MQKWG-6'KBH9&2Y(6GK4^=F:VO7&GGWQEL1YY]
M3LY."Q<[VTLQ-([X!?'IO=S*=^1_9V7_8/8].F#)#@*F%/MWJ_2I(9*NQ+SZ
M;GLC(FM=J<M(5P4G@^8X6D5,;WE=,5W<9P8K5LR/&/*5;L?QM\L[^J8T68UD
M4*':N2D)4OD=1V7'WHU7ID:R_,,_>KW8JHF[D_-L3LVX2_"5R2BR)@4EJ:!X
M3/@MC_W _XR3_2?],\N.D*O\L);56%]D^$;^\M_KCA?D6EG"(](H$;$#..MU
MJV2S8C.N.(X^W,PN.7=>"$S))?%Z6&]<!'DWT;<PT5X:!P<Z AKL/E-2!S(V
M9K;G(5"K'SRRQY(THY'-C!OURZH(E T./R;'[3:*_MW"E5:0(5G:_TKF@D8@
MRQB1TAO,FK\\+Z/-2H6&R,C11C\]0ACF?OE-$C?++S=X<'U!--LZ7(N!W/0;
M(HGF7+6W.SR=RA2+]AE+LIH;)JI%O73<'+QQ12%_^[K)UW)N5"QW":IG,0*]
MZVWQ1%08D6;=HP4*+U<><\I=,<2=2W&BSK'5<^V8=#,/KC\N0Z$SJ4K3\^&[
MUR*Z 2D(.US$?3)VP%9*\FE'^G&A(;HPUBP!1\]:=U9@&4-=:B[(1TN&KZ4&
MK;0%.OD*:&^GZORA?/08JH1%IMO2\JQ]"+Y:&;0N<KH ?Q7<%W/!HKW*\1NW
M?5Y/6XWQ(7>3Z+?2%Z(0\*H)NL;2MABQSW.?(=]-N-.$S3<VC4A_?,W!THCU
M#GR$2,YD2L<3(@+/4FF)W!#&"(UI5T.Y@G%CB9GJYV5E<V%J]+[U(PXT>[2:
MDC_3R>7%XKBE]JI^S=G!)%C34*$>BBCQOH:P>)D2F]I/H6[3UHWF:05W/Z?T
MOQ+ZT W]( L[5SL86W$G1A8K^5CLZT@1.<M4YWN?1KR?W45PB.6#]M%PCT4A
MM_:3P7!*?]NEOF83Y[FXR0<3(R.PJXN9X+V-XXD19D3R,GA.^8%DKZP,M3!R
M,(Z63*'N>-UX+*HLHG:27LJ8C)B !LHQ##TY"^0FPM*&-.HWP08[RR;5=@+N
MZZ?%;,(%N71M2J&^A_J.ILZ[\+: 7/R:1^IC3F2(LI,R"+QI- FWE+0B6#R1
MD/BN/"XC8]!?6W XY%68VSR60B_*?<%"QDDI]Q!F8BFUF;H)6;T-#S%/0OJ\
MR+GU#.(HK8HJ-:W&<EA6@X<]\ESS\7^]<(^5%JIWFGP/B/0J:A,(M(E^Z/+Z
M\<G9%V3L=^7(]M##0[?F3E"*LR=-HY.YD#52A,5*SXDU+>NG'D9YA^Q]Z(*J
MPEIT-X^BU$"O&6>GN.1Q"=5@&Z&W<?0SC+Z!WI<S?MOG36:M>D[)*/CNQ-CU
MUHM9M#]Q$KJMT6ML5TBS.,IH\6[24,\[KKXH#Q%@B=*$&)A<A<X^-0VE*P_?
MSXJ*ES"NF48[.K:PS"7GO;;L-CS8DMQR1%S#7N4X1 _B[&QR\:].&-*(\D!2
MO@T_-0_(C?O56BO_:*W!BKQB>],C0R6:Z?H @R_S!<ER;A9;7(YNN54B=>)8
M@TX\T[.9@OL^O)0?5&)BG@)J9]/ANK$=8ST&[^M='"Q:'9277/ULAP:I/0(3
M!<?M>KMF_43.6Q1E4-1_#L\U)7A6XJN?P[M#;DNL(K]2KRN.DZ)(9U#HC-G*
MA*77 Q+2XL5%1<]8$QX$'Z=]!(=R:Y@?HM;Y0CK[^0N^DG?Z1SY,]K,W[N F
M-M>0(_:2>"+IT!B9*#MCS#':=$[A>7<_Q27,[<@V,V7[*_L'3T7[5(=(NB#W
M%1B.KF79N_KQFY&XUG8K5E^=U0-_=98P!BOU?;T=Y.5"QD8V0899SS22K>JQ
ME'60\M286(T=:.="OY0K\:'3N/X-, -A42JE!R$Y:#5O0_G9LD@ZO6%_IZ)W
M^6#/(/QF-1C:UTHH\\YQT  .ET,/%WJR-6(.3<8T=]S*PYF:JCH92$]H5]OE
M%HYG;"V-V+T>S@+O-5[%1[02J4M@.*ITG+$31F#,BG@PA0#L+_?;FR+3T^.L
MQM&)XPXQ"\581[JOJ:EL?APG"_2I1!I%K2Q:HA%F;(['L@7KGM'SL]J' ,^2
M6W^U,K1CS4AT\7(\8?#&7 YBXD/\ZP&#D)/T-/HHDEWO(!.D9EX(4Z"0++]G
M:QS_>L M<FP>?LZ!C779+?G! YE7Q=K^?)-#GZB^-^WR?_9$^M][8E=&[+*O
M!_Z#*9AOVKL%ZP$T^3SX*#? .FT\KC O;=J77=;_>+4@*2#+$=>\X3U%[_%F
MC*[:*3-ST[B!P:H]XBG5YEQG(K4<&AQRA,GAWW4.&//QB(3_;.:GJ['X5 KU
M4QRU*"^BQ1"J(?D4'84'VK(A@S7._.5PC#"WXF/-:X[-5C)Q&T F8DGDR3NO
M/V9N3Y!FG5 UVKG/1];-*"*T[C?$/%7LM=MBJ6A5 F4_D:%_V#6D,?DS)7[G
MB=)[KV/LUKD6<Y-%Z*4M^39P'T')@>N@RM5U2WO]!=H=UF=1?J%-?XW8T4)<
MVI!T-9"OY'6J%ZIT7,,4^6&2MK=YYW+UU*$=T*.+E;=S&G1O8[P#2W2#['PF
MV.EBUVP#64;I#H%97'X@,@+>DA$RY%MT:S4Q9H)YG5EF$IL8V5.]W$[.R1_4
M>6=PM459Y[ D0\^)O@AS$(F6+W#XW>]$+\>]J"3ZM7Q^/EI#\*16B*(1IV#4
M$T8AZ::\I7.JSV80[3R"*QAEZXFD@V4Y)SG)(A++<T8G W*3%P;LP'H=90+R
M2,IWCZ,M>2J7?"J<T/U]"*<#37@/RB>-0!FUVVJ<&/71YPGG_*O W 90B,/I
M9.G^H!H1$':T=)-H=Y^Y=:NUF$C/UBF4<)*1^=4]F16TNPJ.3P1%$ 1@LA8T
MVA,=IVD9L[Y#H69Y[&C;7E_UE@N<Z4>PA62'%1**14Y89/(7#^[/O?<<Z?BM
MKP5V3G^VJ8)/0$1$ (0%SIYY<A)V?ZA%RV6S>,<\6,I 2>DT*=ZP2U1;>XY-
M-\LX<]#2#E QN0ZULU_5 ,,Z4Q1VL3V<-O6.FR<E5I>FP;%AA@\'3J#@OWW*
M)CVO[L1GS,3B9Z'0\SM'H)$55VX]HZ-5!AU/##M4EU&2NVUI*:P[!:V1<@RW
M_53<#QX;UF[9WM<5W., MN]L$EQ[=;>53)!>5I,D$QF,Q3BI_97B13J4EKUJ
ML\+.2&\FUHE==&+%$J_XO&88CO$ PSU0BB6I8,,N18H6[NDH3&/M!P\^RZ=Z
M(LV,N!Q,S\C,W=#KJP-#!<(9W1HE_&_#%U9@U<H%E@ %&O">DGC.N]?]D#A#
MWYR9A^C"_=6(G_%KHXA$7;3[@"/QR2>/[B9(=X9 C>%-TX6 ;TY2GIKI?#36
M] %C6J(%TBQ[L('6SH5L).M9?3Q1,R4Q=[J:Z6)JBV2-R9%^\/!#-YFZ*4E-
MD/FM['C#HTJ>T9JP ^4%P@#B]O'&FN+6[ =#7&=$0J( P]8K>M8[.<EBY!,@
M@YK=7*.2'&W \^@X31) "U'F0.]\RL]I)3[BA=NH,!!K:^6F/MEI+#+W[-)#
M0\F,#W[[E%S@[$5>8F8D&/!5<O%&J,9VW'0)+G%N2Z#&^LN)\?,4M[,%+.!^
MU>2U OMT/6(38A!^200J$"*H;ZG:^]-08%BUJAR6]6"KSW0OI=+!F8(;^Z0.
M7C_FVAX?LB<8Y^L>?/65IN-J-TR'RMAY=&AK-T6H;VBJ">PO7$'/F\28T!>2
MV:W]D)2ND?BFY$?TDNP\@8DSE2V6UN#WU[QQM!YO&:_9(6IV_Q8VNR/[!(72
M,WAP6,4<6M4D73U/S41P768BE$I7.ANAT-YVSFL4]BS#OQD(''GF7F&QW+_K
MG$;:#$ADZ3E\+N%2#-EZH."GU(K,9 0?LM9^,0M5$BR<-N)AUV<IRK#X.D:=
M+A0,^"#X[+_=06FJ^D2-X]<$'8HAG(1C:4#S; :%B9UNJS5O-'NYU^#!>W3.
MD4$$<O5\AR1W?3#+!< 6P7:[G1,[*</C%J MR71#W?Y0U],"W6O@4+2*X\X#
MK8MNEI(2WK/$Z!:CT!< UCQ9I5<ET2LJW+O1ZJ7PP\4#J#JHW75;D6R#IN?%
MB*&A]. '8VR]>FV+;()BGI562/UTI"'*3]FSPO%K$-#]":Z(4HL9F0>4G"R_
M>6CI;8?^M)JPBOK7<^RU2-)2-1NY]-59358YG-GCC.Z[CE@<!IFK(^MU2$V&
MSPZ92/5X"94Z";[S9_W@:=(*?K+H@>W5FD>>$R VA=ETX,@.!S[$I:KBL?AA
M*J)I"X"^IL\3XXH_Z1JE<PL=7'VWB^K=F!;N)%/.S1%XU%2ET! OJ%7W1MO7
MS2I#&5$<"<Z0S#0_L5?^_E9HS'NF&W?$!PKX #&?2^XU+*H1$8#%;D^<#\Y>
MCZ4-M@]Y!K^^"[J)];!CJB/Z-*><\F/W2#?;ZW<G*/DNKC]>3WUT*0AOO^U.
M9'LV/XUQK1"F56K_$>!>-"IXC:VG\=-C<@B6?G3@CNWSKV*V0>B@D!(INBE+
MQV(6+R*FN8%M+140*(J-C8UKC.41&//^ WWB=1IOY,R--DFU0:]YF3+0[2D-
MX'.$D/F--L*X2CN7(Z%U;8R[3?)\Q)/@=I'/K9$/LWLU=82U#2STNZ&"QB R
M%,_,-NEK-9P@LE&8(-[41&-3Z_V)^"[C^8Z$)[_+[IH>=#C_6+#%/=>/3PV>
MCYO%3J8;I/N^;1K1;="E4Z.=5C]S'614>@S=(Y-UDZ&Z;6'[A&)NS5*/C(;B
M"<F/^S\M Q2X@9N4$O'DRH6<@_6[E3!'1R;OMQX'^FHW_.)F_Y3BY4,/7ICJ
M(G&#+F@T'^DY+24X[>0,=B1Q'A.%B(K1GGR^(G'-20JLRK!8&"]NMC:8:'2V
M%8')O.()6V-5*],8J.C71+V%64S>5* ?1,:.7\150JJGDE?"*UC%R6? 07(+
M'SX27W:X];_9(/R?R20HU9M:_S:SH'[DFR/9;4/H(I,Q2MW9$'13S1]:+WFU
MG?B:>^S>O/0-+?M8.A8\K:5AHW7Y+.),1(,HG]!*V.!!CH@7QAPPN5=OK3LN
MRB]5?4O)H =ZH(;?5=(6VU!U-QT9^KI<3DF\>4%R@ V2Q%&*:FY_C5V-MQ;]
M^.[QLV;MB$Q\NYR=\EBSLN?<P$ ;*%SW\?S6G;+^<?FF5 PI6#[[W;ZW^$P0
MF]U.IG;AK?HNF1WK6>>[[N91[7;DVCXUD6/I4/)UXD*B$V46..TL$QG4(\6P
M<O6O'T;:=2UYFNJ+^Z1 UX#3<S88F=)7)PCEU]*74U,$WD"LK\GD9<@=)JY,
M8;%M(B*ZG7726HV.QKU YOGBU($:0WU/]3D<;FP39JC-A,4)B)V_>$*A[[=+
M?49GR"]R^_NNUZU["**1N9>@-)>K 6DV>CT'X@6NV; &@%Z4N 6JELI9(F>N
MP\V[J8)&3V+[I%L$[SP$&>5V8+'INGUN95W=,".Y0+6Q](35YFHP>SHB,SJ'
MYU5@7D:?[#A K3A^%QJ(#* C?VN D\?-KUC;?,HQR,67%9?L=K>I<Z(!84NS
MM:R"17-+XUVAJ6KSIX/G: *4"-KU?O"HKQLM"PG($(*KL#WI*ZP2AZ6]2K&D
M>C7I:KG^H,/BO1W%M*SV(F)\TU1&E/),4]XO/#/LOV(L'7G&L^>?DR 9YX<N
MM2W9@NMF=7.:3G'$^G[P6+O,73)'=66]F .&OG?=.?Z[#$7-APW BJZEG$^=
M%EJ\6FT E7W:&"/EF[_A[A^;L_2#AR$D*?%\V9I<G+U+8P_(S%.*R$)W/G[X
M-A?=1B&_^B"RHL/"Y[))YQ.\F^^T*^7R->ND^3R_=U@9?9(I:M$$\4/_X'D^
MAEJRZEC59>5<,&YU\PNX4(PGI_R"H#R6!Q1>:\E<T$8)N>';*-Y??]_'^OU_
M<H+EO][0R",K8F?Y5*3RX/ 2>?K>NY0"\R>S0?X=4,18>JKZ])S<VV-2V?<,
MG.C$&!%HXF^R C!\^. Z^.\)4U+!QTU!^Q]U-D;Y U%$<MGUN-ZW?!XB7ZI_
MA@E 3FF-2LKZK +/6GPJ2$BX74$F:DQ6/(Z@I;[-;_>)W!]X5' :6H\,_GN!
MY]_R D? ]_)J!M:K?7NSO65D>^"93HO;*3RAP'9:E^8OS?(/7N_>YN.7R,6/
M%C/4*@@ 3^+.R:R_:3A$(5,""+('Q6F;X%^0.39YCP+3Q?&_"I6_"O^H^%_X
MUU,)A@<^X\O,5MOM!W5GC+OEUS1N+A%)&<T"%W!G'MR"JVQ38>#KJ4(RRO;]
M&&O_P@%+)GRN$-2J4),*T^7*&9NFX'_=6NMO%W4M_Y?"OG_AH^H5#!/=GW!1
M*?)656^^\,"XXKKX;7H0M+T=IH9L\L+87E72?UZ PR6*^T@\#M 2GZQ:/Y Z
M3I]QA>0JQ7[@.>#+PW-4<HX)DIP!.@?K*2,TO N:2IW4PAY\Z':0\B@SCE?.
MJ!WAM@D4X3+."<[MKQ%U^VWH[-M(WRP8&*1Q\]YO; GZ]CQTROJI-\D@+[>T
M>C:(%"S>(MZF<G8KV3YNT4:]D$[ZZ0I[O=YT!M^Q&*WND;\VQN8(ZH%$H&+^
M)6\<[',)XI+\6%*!F^E^2!)*/#[;G' W@=2[7ZA)\@?/'A<'LX]Y.PWD*&.W
M'SSD0&<5%J$&':W:A0.T'QXVU(S+]'";B__!L]CI?NM&[LU1[7K'FG:5S;G^
MJ_1B-G1T5>RA_=-BYJ +W)HO+UD60\E=PPUN:(F A"[9BSD:4G!%<Q1%:8MP
MVJ"XY6-E57YC;'.B'?5);1$;(,(MYT?<K.EAX%I$Z,, =NJ&:I.7WP;%<R-P
MMZVU,'/_F]ZA4M4/F[[Y*+4+\E>UABDK2 JIR=GJ=^9V)HU:3!P;?JA'V^TR
MWB9;C:+%B,ORJ@-<U-BZUA&/%WRJ@SJ&,)7M3&H:@DB*:$ _/#E6PG"+J?;U
MH:01 1[)'#]^X]W66/)&NF'][XK<2GU]I457*CE1">E"YD/4.*]YZ"/5A(#A
M>7F),0Z^\^YC2R0*TIC<B,LFO&@)PXPLD_@*R.[+)^OM#A!\1;JQ>JGA89W,
M6:,CS4]N9]]--'/-)???I;#5J-J*A;&'>]E%*ZEM.=JN4"$\B+>2W\%G?4@K
M0&2$X3WAW"8_.5I.K%C"L65!8G+&';&;QDM/K0->KK+[K1+(>5G()S\CRB"K
ME.:.Y$#@EY>LD9E +R[0]DK;GH:MY'??9"$.M,2H$#:M#5J7NC3'L(Z&VLTW
M$<\8_=M4+Z75"[Y'*8-VR_*)3NU!2/V(F)*$)I>MRHS V:W'O2YJ;>#Z&_..
M*?/9BS4&%[^%9W^-2E'0J)6WB23MAI[2CKRDDK#G[60--+BS\X7S1]OR8K]1
M5>$^*ZM.X\YEW*<W<X\HF.U+>R=FS '!(F_Z]:*\9[^G1T3+5R,Q^%Y@BRBZ
MQ3#Z/7>8T_%)PB,"+C)"S>.MZX[YP?/8SXYE35'H=!4QT8VZ:NB"+^76,QPM
M1F?WBYROL3.;5)<EUK;?O\\UJ-7UBM9T2YO6\\"-5[/M%[;+!X?G2%XM'&WU
M2?SY\686P()O_ #0BIHBDPB!Z44?,N,/+R<EK(I@JET=*( 2S0M&N8<\@F('
ME<&8<!+"-/*%&6_ZZ.)\84/W[<)/9)'E(NX<<I;3=>![."9=W  JG)H.>$+V
M=>]P=G"B]']IK8BXQMPUC!?M:G/+C]08"U'>WH1PEZ^FMD0X%#79 ^;]J676
MY@?L*.!^V50.1S*>0'<X-_9;QW4[,.+L%/5YMMYB :8BL)G-;.O"A3X:/ZK@
M>*'AA:?M7*%S2M"#:W>+WCH\B_8,OCK+?Q%C[.)8(A,]>CGSQ!?.VJ!'',%I
M3;C"*F*&FVWL54DU4B>_UD?];"'#<D%'.98J./E,!C08;*3J ;&.[X*-A-="
MQH,>')#W9'F#03^#8&N83#\3=G&T/#W>ZZ;?MWI6VK2Y%/2 ,52S5\$O33&/
MN'[C>2S;747/KYA >!?YK)"<--TB5Y3H3SMFE$!VS7_)BB47S>8F!0Q8A"/H
M6!$H% 0%"3]8Q)J*\L9;?Q&T%/[!<UC[0*J(O).3AW4F3R9XNE,9=/'6JSN5
M1@Z2">XW/#A0F-Q5B^N.PCWUI^I<J<$?68 ')8G!$<J>$ PZA),3D%&W&#)K
M&D\?X N^R]V&?,#<DK.!PCR94)#0$[Y'QR5=\K7?6:E>@0=5OGB''%"8O]PR
M5[2&&$_KK'/^8\\]S=?+M._9/;$JFW  8 Q?&#&?DAJ6# *)^>N*+IQV!/6J
MG%#0MY?)#PYN)\.P=^D=<O/.6M,SLD-B5H*3:\&BQ"^:%8/:#7)E%^@N4H[<
M$$HNR8<MLWD7@TD8#S4,6<M (><KU:*2\F!;:+S:6B\7:MPOU&^)S:K8--D.
MI"F++/;'I2MIO?"E4 ;CUK7#BC'4M#0HCK]M.9,Q#?-S:>4K%O:(B/3XJ+)8
MC.V(-%5VLN%"W1V?^D,[C*(SHF=^1M15:T>"O8@%C[L*R*1 4TV+50].6*I8
M1N!UA=^+ IJ?N" ;H=H( ^^T1;#9BY)D-A44#A(0@'GKJ?1D&^:U:"_%N182
M"/341<FM]1 D=P;B#-GKP7MUF?29*+&ZQA6)XT(URZL!07%+[+PP[NBEY-,O
M1\ (\,.US194<KIE$'('S!QI4]2&:WQA[.TT=P^*%S=K2A;20JKUVX(^HM3^
M* L>042#);=2H%%*Y[X:=\/T;K9IRY2$E_\C1/YODC/_,X4!BEG5[!TD-5BR
M+_S#U4$#VO6="WA\[("6>/]0;!SA3.N^;O@U2R?16;@UOW'X/%59H*V_4#/H
M<?_U?$C0QA7!.[D*LF#RT?<'G8P%(%<7*#(>97KJ6.G^0$#$XX5GK.NCVY5X
M*4/M2NE9<0VC?,.;/#Q'O/YUH>Z_  $YIDJ/2_M\@IR'?=KL3:A)PD.V3UVH
M8UR0DDCF.,L#.<()%P."A72M(G,N[T7\CWJ$/VG_GYB9^47_] \/_P<V[+$,
M)[+$V--8"K1B=U/@J_!R?X7H_(A[T9B'B5X;0"'<FQDXJ\J;]%[N!P\RU2BQ
M-%IK:KB>CAVH/KLTL3I7TBX&."=><9ACIUW:T_4(.B@'/6E20RQKK]?WFI";
M Z_-)JR(CJ:]+ZYJD;( R&929DWFNXHR%"=,_8("7EBF#\O=%9$M2 K$9I35
MB&<>DNF!W/BJYU<S1BER 5V?7P]Z-IY6(!*B)WE@=U#V29);+A.L"9F]6IW?
M=(*^" V& _GICA$GQT7S$P/-OK)9LQEIN67.H04%ON?Z>F^\LA4Z92NO#.UN
M$S+TA')$P-[/XET1EJ8/40%RP67]JE:I)5'7&8J %TERP([3"B%6WIB2!K5:
M[J7P!J$!I4S%S](97MG9FH8#DM8^+^0Z4,5^';S>,LI02O]\&TA;!%Z<+G%;
MJ'(0X>,5=(E7-1@*T-%"21$4?'=N>]UNWRT)6V,LH_(S6%4+:2<]S%+C--*3
M=<N=W]YO'\2M5%H^3?O,.V<-$P=0!:B$V1;"+.%;B[']X+&.8,N@T+-9$'J_
ML;$3-%2;Y>"]\^C(Z<638<0^UZAMT46EPA :T"AOP2-0C1/%HM#-=Y*7G8ZD
M.+PK'QBC^BYE@(CP#,Q A %\6O;CGM++NW<IK>Y("B4/I.&L9?3ZVL&$@".Z
MF#=+[)/5G3MRMQKCTQ:VIZ[I7M4L05'IY:#^-Z\7)Z]<'WEHW,]!]$^W'O/$
MU8BV:9P*9;V15TEFMSXRJUX)<<A50Q'FFTH;K>,#^*G'1Q;/#2R=6*0+(B^<
MCF"OC*9QN^6=BCS1]FNC 2;:V>+,9)F@<IV T"40F;A\3BS/E9<QI1R]*=H2
MT2C8P?<L9/8:L(K=VN^RS0[L,'SFK11@HLP>F# Z])QE:8LI"K)HH1),<P$;
MZ(Z+C[I& H# ^2,%K_O\':@$ZZ:M[H@+LA$!<]363.$85RM3\X>8$R3]H24I
ML!9V\HA57#L#C4C6#LP8$U/\[58JL/D'C^1CJL.-Q315($P#[B:3JQ!U]TA7
MDO^V/:Y%WC/H>HN&=Y1CF<S23 :6LDEP8[YIZLU\VQZ/+(ZS*V_3U^JA*.3.
M5EYDJ#Q[Q,/3Z%:S;23)X-RB  -U%,KBFG?."9X,E"B(-X1.\^KK'QK7?&\U
M3- F(;>L-HV7]ZVUW&KJZ[;5:A_V1Q]I*Z;% ,W=@59]%P?E9R[HJ#C%KNP8
M1#@5J7(*:%DR?A<LZ!FQU+1QMO>2.@N!O1)@X8B,0 X.U+&-A!]@\2#M.6JY
MS,'8VT>H53VV]WV5IQL-EIU-E$]- 4KP-%J9]N9^!3$KTUB%YN T WY#]NC$
M;YUT,NQG].NP<:[@V.V335 =735-;MHV;OL*P\+.P/U3*J5VQLN2:?C08M"B
MAE&OF__,PV?.9%ZFIM$I0_&Y5<S1H)*:R0UHM&8_Y 930D+.;9F-MTU*<[B;
M\BJ,,!]:[^RC5E&QU9UKY]'ZE X9Z':CAY\;L^(MV3NY()54\@'5FL"V% <#
M&F=,9[.C,HT^]!_^]?&YXMFD0ZU;JWYXN*>GC7]?I=X28*QH\!('XUQ@N--I
MZN33$-0'Z3%)KWXH![K!'.' /JS:6+&2HW0",8?J)WW62VV%M8*50;;7A[B<
M9 VG3*'^R.6%DE JTTB6Z>\%9F1UQF37E:#RH-TZ>>#4<$.> &F]*K5$N1?5
MV>FWM=$=((&1' F5W<VO71,BDRN;URWCBL[6'RW&V@\O2LZ.C=4ZMN:K$7G7
M]P5SB-IK\%51!2:5GJV/0D7H)7S[O#+F=,6',?2L**M-SJ8HPPT+WZN3!=TK
M>,0?IS8 ($(+*E]6J-M*&DS!YHOIW>Z.\43/=/$4R,@#UX)1I@S0GZ75JT\A
MTI5FD":SQEZ6/_O5[-7&BC&EM<<"T!YVUSWC#2C'KD1'\'[=39[]F.5[JSKB
MPTB7>M])G=U54E:/]IV=W"@W,YXFB.N7H/?P=XY!'A!!%C+$I+JH15%,8*TD
M/Z8>%V&1MGQ%0R0)J>:0N[%J\/+X@F8D$J=P[87:>@$2N7:,'M%,VX1J3&T)
M*OD-+*)/':A/%*E<6L*(L[6$WCRLW2/)>+N,)KUM'\IQ,#1&VQDO$1]:LK7
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MEV.?>7T@[&?$-D-S,9.P!-[*IY,FA8.O=__FL)9<)QFW\SPV1*L!#076PWO
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MCQV3)WC22\'RFR'E!.?+V8XC+%MR&NTFQS_49Y^/2=6GB+.\4 N.XU3C031
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MQYV[9CY:[;VR\&XFK[QY!K-EEJE<Q7PIF\(5#QBMAHY3YA]7V<E!/8FY&QA
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MO;NS>E_O9@, %2 /@  X8 &  6;@!F!#R",))V(OM_OH^>1_TX(9$ 3X":<
M\/VYW@&6O1O 2FIJ .?N0P7@$-'QO8>Z1+OWQXG.[#ULWP6'$='_R*.)+GQK
M0TQ(!/8>)S$13G<BP;W\[CWW*"*IO?SN<\1,/]N]._"[O"6$<YR0_?JL\MOO
MWMUUYC_?1! 4Y.5GOJ!G"P/!,8B+@""_H(@DOY"D@# SOZBDD+"D$#_P_46$
MO9O;L41?]<'C 2"6^#L6R=%8DN_Y'T_*2(E(ONE.^G/_B$3_[!^1[,_](R;Z
M+H-(B?B'[!_'U6_EO=^]YY?;>_1#WQO@!XC4%9UMK0!@W\;_"1OC!^1$;)!(
M!TD^/AB"UWRW5[R6<"B?L[D#GP O/Q\@+>?L8&YI#T8R6X"M;6$R+'/%Y2S,
MMB 9%CT1-7XU!P6PC>U5%R>PEHNZMJ6+O:4$B$5.]HBTLZ0SU $*1IHS.T,A
M,(2DLPS+GG!)0GZ7S,?"O-<$:2_#\M66^FHWF!7@3F!F45Y^'DN"G9C%)'@%
M1(6%Q<6YF0GVY.?C%^,3X.<1%)0DF%1$B/G;P2)[A)!*.X&L)#6O*'V#(Y1D
M6+[U"X/!\&*$>.%.UGP"$A(2?/R"?(*"/(06/(C;,*2Y,P\,P?I5R'<Y5\ (
M2R?;O1=%F'?+YA9P%%*&A>4(\T_'5R"'GX!^,2"A@F! (;[?,1'Z_7NF[U;_
M'1/(\@>/ \H)LM<?D"4?& *&@F%(!(%/X)_ U-3^:S@H]+><"*0B&OE?<R)V
M'U'R:8(1<)23)5@13="$]?>B-,'_8*C?BR(T_ZT@A^\1]P]6_U[]U8RR?TJ0
M)@R(Y TG. AE"7:2E;=T@EN8(YFOV"*0MA (V(G@83\'L#3?+\U_$D,PIZ2"
M$]@<"7?2AL,ALC>T]EQ%A!<$@3#K@IT0NTXCPBO(*RC-]]>V?Q&C!@?96MV^
M8HX$R^[.%SS\0CP"PMK?YPLN?A%"^E7(3RU_IPKX;S)$)(4)DX_(SS)^:OE7
M/0CQ"#)'FO]+FOS<]B<Y($M)*[@3U!PI:PLUMP;S@1T05M)\?U)_;8JT14)^
M9F?^%GCR$.2OU.\5$-O=\9>$F,.L95B<>;X]0V>1_=]X9TZ:[ZO O\#S_1U_
M3_^_JKJKON77,?U-![3 CO_4 =GO\_]_I<"O_'L*_!U,>B^D):_ +5&[H:]R
M1?;KU$KHG2WHSPB1%! 7 0GQ6XGQB%KQ\_-8B0D+\H@+B@KR@"V%K C_0 )B
M%E]']5=A?P-2@2&0YK#=ETID"01>6P*(@ 1(0EP"+,HC+BILS@,R%Q;A,9<P
M-^?A%Q45M! $@<0LA,R_B_Z)_6^BKQ+B#^YT^]^SY-Z<[&#NA-A["46&Y?N<
MP?(WAEV>O5E,TGS/#60MX;#==S3 (&F^7^C_S$C ,2<L6(3 EK5R@D.9S1T<
M(+:6YKM<NW,$,Q+^"PD- WV;CGZ,PW>HGR3]K6._=8G_2(\1YNA_H[>VOQEJ
M?C$A<6%^$(^0"%B(1YQ?V(+'@E]HMVAA(2$D(BS.+_)#ONWOAOJO&!@;,.R_
MFF9^:O7/0G9C'F/N!):W)CBM[']]-?9=Y*\\_RS;TH8PS8!!LGS?&;\3_B\.
MV_\11_UY:OY_Z9.$J=CVW_'*G[3\81?FOW7R-Z'W_U.G_^>!^"_-N?N!^!?J
M7Y?4?UIXOJU(7U^"-(?\M""B4 3KBUH(6@J(F OQ6(((2ZBPN* $C[FHE3"/
MA !8 ,PO(@#BEQ#]+OPW,OZ^>G^- :5=+_[7G$IZ[R+Z?S)%_X7]=])!?ZJ\
M*QWT;TH'_:['?TJ'_X^,^X\R_CZ\/UGWESW CVNC[]SR!%/L>L)?IH*]<+]L
M;OV/%W/_AMK_[)J_ DCS_6OJ_=2+O;=$"9L#L*SPS]Q_DH_\#/?3MO;KGIGO
MVZ:9L%_G^[%A_UT\_N>/?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0
M?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0?9!]D'V0?9!]
MD'V0?9!]D'V0?9!]D'V0?9#_,,B1/_\+/!@&DF'!L,C)XG&  D!ZX"#IP0.D
MI'O?U3UTY-B1(X</'SE)277T&-W)4Z?H3M+2GF%D9SI#S\I 2\O,S<QZGN,B
MY\733#S\/!?XV2]<O+ KA(B,C.S(H2,GCAPY<>$,[9D+__:Q]^%B8EN2HS]]
MN+@28-S["O%/'R4& %*R P</D1 3'2947]_[+C'Q[C>!#Y,1'R0Y0/+MH\74
M9,?/"9R0OWGH)(LCC:"(>28=J_!E7032*XA62-,I^,4[L68V48NL@?,<"E>T
MM+U![^<)TLX04$A^A@( HCUIA#H!:J+=[P^3[((0$Y-\JZ,^0("1OWGP!(NY
MH]>+S).L@LU![[[,LPE?_O5KP9-/KUQ2](JJTWYO>;[\<4BFWCV8L<8FKW%[
MCUU;1.+Y+?<GZ6N?.4*B:4=F-YM0P;RB03VZE94]?R1>&.^6Z"%_?HEQP[\]
MZ#VEV,>0#T+4R9$,M%3O/[KX-[Z0;[KP@@'TP;#ZRR:K/9/0RZA8IU(_"QK5
MZ:JD18/4OLO<\>O3E=C9 X&\N(W8B9/:C8P%*;3A"5NZM%;EW(O9A298@?S>
MT=SG1!5VN*Q\J=<+>C)-<P/O6!MK6LLJ5^3OO!PY*SMU=(?/+*)S*^0>LVVG
M0" S9CT]8& [*=VF7O&AAJ &&U!:4WB![="#V*'\8]F&2J?LS6T*9Y\?L^9A
M$QOV[E>LMH!='+9[G@JK%26C=#AC3-KOT*NV=K%:.NK1DCZCVOQ:  \DH*<P
M?>F"I X=ER.JY%+UY-&02>R<\@/[NF>CTKZ^>$#GS<JM=D)_4LI)]<[)/#,R
M+A!5?I+9PSSQU'BH.EH Q&5EXME284OV?MVH7 "][5M[8&(MZ6%J3VKZQR*B
M]?<,8\?(W$MOH TY[;VV#"4+GNN"!+E?07L8=\KZ%]*U#R@>'#0[+K!Q."3J
M<09;GT17B1]\35Y2T<NS5C&B4N?#I0[1BYUGFV8WN9<.TK>[X,CBNV5#"K!7
M7?E17-;1]<WOAOH1[.:/+_5C;^.2!Z^O7,[+')3J#_WP++/EJORSXCBCCBS*
MJN:-L<,IC%P.*]<#'\%&@S*/J"?S'I^8.?V*$R3XC+NID.C6B6L+HE:].EZ)
MN6BJ&[5K;]8/0:^^*_:A M&W&9;L>)Q.G"(_[>K8?B_*)]HU@YOW997=&:TZ
MOV+&9]TM#/JNS"L;'C1S91-+=SUN]\.I8I*[TL_[JFC0K]]1W@F9U#, B6"?
M5PW3!WX W_+MJ_CL*,^A.'\T->*\R@F?(>?>=,9[A@RC.:UK4FE)3S^^.Q@&
MS8')N,0^?OF%]K/(P3BN@TY],"<T_86J:+8)3NSUXZ.3AXDZ ^#"QX?U"^K]
MI:.L.FLZ RIYIT>E',H%PR7UDS]E!F73."MCKLYX'\VY43TOIUQT\]0GG=%^
M>&K^:0HMOT1?=W7CNXY:L& $DIUTAN["D'C[$^E+]MPF\*:^BP>K:F!F.BW=
MKIJ#J(.8AOO%-*%*1+?--\J%Z?^X&3BS$GY:S+(W+!6G)D5+A^;B]4U]-RQH
MS:3*?@!;@P?\ WIB^UB:1Y=AY(?0M: I/<R:\4X*U8F,I6K#M]X!%JG!T0VC
M..3Q/\SNOA5[%E27M_FZ0F0EW%VM<SXLE4>DY^Y='&I)_H+B\<)*Z$5U7(I^
M@PZD08JZ_M53>'NYMD&BA42LS.U.S"'!FXB.L^*9Y\^/N$28G:,?>10DQQKX
M'C.=(,TYZ,LED#BN&/KQ?4])#'D<[Z1&,/E-ZF/4"LXA&4DVTG=$LXZI"($]
M6!6H(GIM&;;.A)$87;P9 !*B>(M!TO^AN,C]Z(&8"JN/?G,AQP?F#47:I$H*
M/AAN2N%9LA4<'08I*;\HJ=K7 $^8="[I*4;<C@UC64BQH+\A:M<BJ!_5)I'H
MH$MI+?>@0LGL2>E!![GJV=>B-B^%UYZ\2M<_]BXR&<1QBSQ/LP <8!/)QF??
M.5" 4/\<^S8WJJHMBZNKW/1BHY7$)DV(W8Q=2.E@_7P5*6ZQ8%K4&%&=6-O'
M!W29$KFZ$+OI=-30B3N@"^WOR<Y^BL4#XX=X[L#40]4%-VA?OGG74SV#M1AM
M!$^W,^A2L<KJ;CDH23FGXQI,G*/<$@2Q;GV^%JE/SGX=A4OR] $O[(2*GE![
MVZ"-SAV$;D7/EC>3]IXTHR&,F.Y;[]#=$?,JV83% ]Y$9 ZNQSP?DO$\JQED
MGL]"#Z0QI09TV5R89U+I?=/)-3I9=!E-$@DZ_A#-DF2H,BTM>*';>(R)^:20
MVKR<NAW#\+-4MS!ZGGZ8U31C_LO'=G8A61MV2R?TJ;$1=' NC4NBLX5C/MUD
M)[3NR2Z3NI#+SJH\$.^1"#23?2UYF^[YHK(IG:JT?X"H?]US-)$B]SR'BE[6
M.'M#VW'A:67!PR[8[D^#DP8TT_W>$@03XFCF'GYLJ<72"F M,@]/C_<6&+M6
M^]6*%[X)^>R<-D[5=P-5'==V:EONOKLR.S_8RG^5\7:9JL%+D6HF WGN9[>-
MAYBP]M65%S).OA'.[N%[71\RKQ)TN494F3%"X\)LCNFG,]<"*,FQ4V"68J&:
MB]12Z!SF?+/H*F5XKYE[0699WVD/G2Q&9<7*;E_K?'\YACG[@YXJO--B7,F)
M@Y2A-<XB,Z-V6:8W1$<W'ZLV6U@L(+-R(RT9K;B.17_RQZ7F'+ARZ<J5/Y.3
M?+F^NB[=3E$73$=KA%;=:\I18]-I"1>R-=3"0R\,YZU+&(Y1U)'V75.9H7^5
MV.9R24/Q[@JG5,Q3#,]449);C'BDT35)R'GG(LX6.71YV"13*9E^W5&GZO%A
M2^,:BH=7>XX5U 2N715N//9H#9M'*_/^4C5R1*9#?40\,M[&,@K:I0^"7T08
M-GS$]!2J:@^G.VK<Z^E<,QY_]9A4#-;0PUR^G'#M>CEPMRM_GOWN'W.+78@8
M"I&AI2NGE;&!$>V^M +] YL=ZHX:I^K%2*U?,-FP6GKT)X_.'K:YD%O](IC+
MR4G;;]"]QN(&U)G#+S$]=SI/1"2#9O/T;3:,7K&[%UK'V3*#_)R7?\!YB@BL
MOR?YPX(GKP2-^=OK2Q_RG;S]SO<&9G-%KADY=A@U8@)/#)<R/=B9!ZJ7H=S$
MR#=$M\@M,^.!F)W+$S)\4?&)!6#?TN"GRB2W2#S*G0JSNU5W7DEM]2_07;[9
M@A()._QEK7C.E45 I*=>!G/@)=.-^2<JJJRG<!7A->9M'KUJ\2D!GYI]56D&
M<DT^RT2SRN_813SL*M90YF*:6Z6ZV ^MV0YYF)1+R^?G<HW/Y0FZXV'%W:BZ
M#XS4W/[0)$=#,0U5BZX'HKEW,R^+,M3 WO+>'#C/V9<Z^,?M(V]H]2"CU@54
M=^.:S<%"MRDO3K$N^6-U7JO/4$F)^)M(5+2^7 H0Y;;B8-6OWR[L+V2?E7]2
M/>?G9\ ONC,=N**MER6V@_CH<=3C6(:ZF+B<GP2'L'?KV<]X@%UQD]5C3#KP
M2^+\(=8MG??#2Q[4O2&AQ?%^E?//=LS^\*]]!G*+M:J]Q5;35A&&"V4]S4PL
M!>TR=>D7>340(6V5%$QIJS0#\G%_4-2^7L8POJ48_F5YLB$H5)"%FA@MA;QP
M 78"ETE%/7FM=S!D84N-Z38C'8:RSM_YL&=NDK/W=/A#N^:"VE4T_5P76O,0
MQZGL=3>9!,74HU01'QWI^6&7AZ-9)V>4D_X@N2G/9GIZ[79DUNPZ*\A_).A%
M1=/=2Z[JMG<"#+DQ304=:K5S]RK[(PYI4(D'I=T*HPM\\'0N]I#50)2$NRMO
M5O*JBBY="62,_[C,X2,2%25FA;8,(-WD/"[N>V3$DM[QAUA*KK4XVE.(\(H:
MW#E7+H[I(S+6\V_Q[BL-U A?H0RKF">>2V&*J]O16N/E;,4#RV54@]?(X\Y5
MK DS'<G^4F7>6F2#<9P:UV;J8O-8IKVTOJ;<.)P1P(T-[:<2G+_4,K9V8&8K
M3,15;/+!&7N=KH=\%[R"<][(5,1*Q>:4IBKC@:O:LA8:Z^1D7>(>2WWZRSTS
M>(!+;48B[<OZ';"Q*6<=I+8#(5,_33O7)8<'>$;DPK9BDVY).7Y@P@-U6HUV
M:7RSJ[:31QQ#_81%+7HWO=$W+GA,>>[PH,Q.(A=%>'U+51I&GU2,6=<S-SDH
MZ IQ5=P;BU8;?D';0L?$++>F36%55_E)^,/8XIG9,$3Y+6S0>)RDJ_ZP<("0
ME(_50%[^_5XI:(&>1U9H&+_ES"0Y=R\6 U*7DWTM7-9<U#=B?->-SR^\W5ZI
M.N]R1=Z.JNK]SRN<LS1YLY.UD&)N=P[6F,Z@SF7]LRUK#T\N3^1*,<ZV>GZ>
M7^2"QPO342%.74UK3.+($+\E6#TV;8A>9^YP"-,%(?6.D5*Z5H_*S'V)JIW!
M];^@3XVQA8SJNCG5&^>Q^S&<:GE+V<"\GB3J-5#M_7%2YLMZI"A4!R-^L-\(
M/ISP7!?M60NRK)R\7T(_<XOB&<9FH2<VQ?$YW7NP &HD,7ER<SJ5DCH,S8;6
M=9?[(W'!_CP9ZYTZT9'!2RHDL-K8C@BZZ[;U$A\FHJZ!G]^Y'AB3A ? %JZ"
M=JGIF!-/XIZ$$-8:F:&@?K_-V+$2V%/:7)P#*=3K:<T@;]E &)5YD[-KL^*M
M^HFNXD S9CV^ID)*L4=E\Z@^AIM=TI7KO!^JQ^;#D[6V3SM)'0R:_=R*>TEY
MMKU]NFN09W+)>$ Z5,)07FI63^5+F,_"!.3I[3O^<V<GX#<[$H;FM,''J.AC
M"@CN)[=B$O4L:T/_(=H2+C1XOY%DCHA,;@I&6<R>G&%:/WDUY4;HY36<T(:G
M^XC>/).B7C,+>0&//,V;,:+UL"TU,_TDZ#SKO<#XF%H5T^)AAYXH'Z5M[\[Y
M2+\-C++E"S0?#T\*W(&40R[2?-)[_;/NJ]S7:\Z@<M97F:3S807+,G2<UK:&
MY961;?-S"(BJ0^:KL['!17Q==Z 5F[V2BS'O-#>0,S4<'@3?W&0.LY,%3.,3
MV#\^#_-W$3T--N__ "MU"T4I=EA-WX*JL>6"[9^3!&R]HF)O[JZ<B7?">6Q9
MXX$9KJ>ES^0F"8'1C@>\Y =F*%Y8M'0UHP\_Q-V>??)T':6Y<\3!_>A=!MWX
MT $FNGNL4STT4S,N'<Z=?D[1IGJH'3O[MR8F/C[R0P*+9@^D_->NP^8*+]RM
M?BFM63_\QD6WJEZ8-Z+5E=2_-@PS77ZVNC0^ _ 9OLE+.RB;T[81\91_DG.A
MZ@1CL2HNWVS\58G4X-FL:NR+P)K6B&M$[XI]D;@-+JUN>[7>.MN-Z^^'ZN<@
MQ<7OX3IBGU<8U[8/!_B=4WO3;>]^O@!UY;SX1U ,DZ%!A!'7D/USJJ NY[&=
MJN+-1'=RF5O67W.'P@Y:S(MEN[1W3H,"08OJHW[$+BA.7%MT8YCCL\-9(EFF
M(@6L@J7%9U]ANO0BR&[*)X@_K[^;N>[[Z?,"F7G1)(]9E8R0F8IAIMDYAI8&
MDC\< 4Q/H# -1[9Z0;G9#=7$K">JW%2V7RH^C03T7E\K?X\[$W;SZ*-"K%9-
M8:Q,<(FG[+7DE=LUG9\<):__<7/FI'Q+P3IE:5C-R5Q256U'D<Y(/3/#P/L#
M1&5O*1JU%59-OI33)_(W?C3/%3'2?"\11<\TSQ2<51JR;+(53_\L9;',J@,N
MQ;!8R.AZP>.8N$'\$C8@DO6LDP'<V;BY&M0C@^.> VGD9GD4R=V3/S9DO6T&
M7\>MA: =:W8"]'888S:)X\6[\( >;@>]PSDU%+;-X+.&]I@^)+'X1P0Y1WJ:
MFFYI(C;NU&@0+JHX;?6$\\TG S/Z"P6;C:&D4<]78.37NC>%[4NLHK+MF<*>
MRC,T]&91M[JU571SW5LS<M&\+LI;Q]-@:3$F]-JF]WB70_;][,;W/?X]7H(]
MU8IO$('8B5:/\22HA'^CHX^^P8F>Q\KE4NOW>2RU:^Z>L5I./S9I8' B/X*O
M(5 ,<J3%5=)NTE!*NS\M0O8 VF @K,!-DPH/'))9>_BN).!>E9O H[)U ]J>
MD4CO=BM7F7G*:LMKH,^UI2V-#_PJQQPG1SU=/+(VAQ*/.R@K=M=8IBO;5<4"
M1^D]Q6Z46_G+P:I)M''<(P_:+4\J;ZEWOCR66J9UP]',].,U\N.B='(AF7-?
M<F-GAA,, [NFV!]5N?;1,UL7GZT)BO59G7XAS=\H='F>5V]4?[R3#0GO04_U
M(K&)@WW/W@]LKTC5YRP006[.%5[)Z6:BBG[_)87'2$M] KR*<3:O25&^.)YD
M9GU^KG)=C"-1+*:OZ$QZ9LV4Z5DP?'"]N]GD78-SIT^F\>KTT)O!/XKQP-36
MS<-4.0$E'QI>5X=7-K )5 -/'L]\&M0+)>E:F-70R-KN"?1#VVPIO?'IAT6^
M7LTYR"6NSB5U45JY=X0GR*_M8).AWH,(N[X0[Y[U0R^"+RC?/Y'?[R ==(&/
M&*F4T2H9[/%JS-41:@OW'40[]G_4-;;'+92)S@SFSW.]6**B?5-4(R(J^(0]
M $UL:"PI?O#3EAV]HS/)")?'23KELX39 S2X&4ZWTWYV16F3B]-EKG5>\ZST
M\N>G'L,/\8!=H"NK6]#3Y8FUER?S3\1%P-AZ'KQ@P=35MDC-JN@BSS9*D#OS
MN>4_[6=>V[I4 W.9*:LMZ@BKYGNP:,+J>'2@$K-HHJ;PH-O41+C'ZT-U1]ZQ
MZU?.PJ#%+,93[]5T0IHVMBSX&KA2Z)SY[G\:I]Q>X<IZ]GG4C[(21D?5% R%
M5PU8_.%ZWYJ*'CE^R*2<7)7%4@.=<X#IZCW/>_<._4CD&)I&0PN(6T29UY,#
MS1RDR)(X0GL%;0T]-$\UUVI\-'KM$SZY*?)QCF+U>1*_3R=E,=<3ORV)]S:O
M YN;G4,91)&-).%JU <P9A/],^K/<A\<7U."EO$%^SA@[AZWN7XW1<OHQ&FE
MMP>A+REH<UJ%<TTI(3!YS\PA=#&T3N.UC@9E@4A0<U$TM[]QDDBWAK";CU]?
MAK"\RKR4]X+=ML;2*[TK\KW&+329\?,>ER<VQ =W/-"/A"+;H=1$NM*@@5<1
MR[G27.Y$/NY^F;I.S*.TFZ)&YFN"+Q)G#9PSK%U#!'6FY;A5+9T=3<[?8]DH
M5MV6B0.]/UQ'_I)Z<<NWENK=I^,JL8MH>)V#VF"E)063B /+D8</>AC]#(>K
ME:1:%&Z)A3U=/G+Z_@KT5EX-6!!VAWF9@O&J"?,]81=EU2%D.L]3QQNBHF+%
M>0R?UM,&68@ANP:5!<&EX=9K7D?\:QQDKT7,2D^4ET#"*H>[3._Y#.J'<U,^
M4/(3:!AQD#6_L='?M1"JQ<%>+Q*G5XD1BF.&'"EK)I,2ZRI*;%H0Z3K-^%A.
MIQ*IRT&VYK)-_C#7T$A6*!'G5A+RX-Z%UVM,7")CK64[1TWY[M?EZ[@X!:@K
MM$&SMJ\P;*>ZQ51;:G9^:"MB>6 KT=-0C)I,3V/W]E&_Q6DQB0<P).A^:+XL
M&-I\P,/0EL$JO:HH5)?YLWNJ)Z755LCIH!4('JB2;OI8^.9$5\5'9 1SJK/1
M>VF87^9<:K3!G$1)?,T;_3MJG\ND#$"O/HK6OS%Q[ESW3GLEWW"R-))MU==U
M5*<:</'J!]\>AS(^:BX(;:[*3IR2>0L;8;MRLOQ$ :.R]@A3<(VZG>&3J7SS
M6HWDKB]^=P.;/A6S=41)38N%A7W@TCEVT\%!]NKRU&+"ER^/RIAAO3HCK/1L
M,/\A= %$?I%\XMA-R0Y/G2P#S+"#7HRZ 8/Q:(#G\3MY^E0K:/!SR])5 >F.
MK>C96-Z[5XZIGQS7>IDSO#;6.1_%E3]ZUD3T!@1^@#TE(RH:]<5R?NM60]EV
M^_@]_FSMLN#*GOB&NJ'*\=6E'D@R[\DO=B9T23LAH:L/2(Q)+BWK:3(_="13
MM%Q.9VS+(@EYRT1YB72&,Z)B4[).F8_&)T3V*)P2H"RE4V:ADFQV%AEZ5% <
M]*(X1B;L)0LQ"S/W43S0F>^!G'MGG4&?BX.]>B/]N.N,X=7-)@>L5VNNB 8U
MJ*H/$7FR11K6-Y2<Q[8"L?T0W!-9VACI(#I)'&U[EMQB:30)9D?N5*9;4" <
MJ&,?^]"&D?I!LW,_NJJFN$=6PIA,Z"G7_1+:FLFZ,?9K&.T2U\>23*5&'WRB
M7V]*%]EEBPF%1V-\9X[U.[3$;S$,6"[13*'9\H?6ZH=)X*6&'[P?=QC3/+EI
MKY$05_KAO3PW:U,2MK396G/\]1=(3 724<1KK-$\*^(E)?K%-.Z&11_N-MGF
MQ$:ZS?@)=5?Q#A^6+@1=KS"%U((PQN3X/?Y,\=J"5(CPQ4JLWGTOKV(,DTNR
M^/VW)4JOBMFW[@0DPA2*?2Z-< Y?89CP7(%GT& _/OM0IF^(&;DUFU%">B:4
M_#3%423/@Q*U$8 2#XB\N4(3=KQ WA>K6=8WFK;8.VW3U2]B/"03"114//Y8
MV/YN\HSDXR*U8XKS$7R,?BVZ_,X)S@*JU(_*8:^"\D;T2H0_UT<HZTCQL#=S
MN4PWKX:@6 YA"YJ?I5D&B#AEPBZML=DP-*QSRHYEFXLQS19>YCK11-T!;GGM
M73H01NYXAC%:F+[Q=D-72P%E#/N)/2M-R26$NP;%#U05NS"V]]P[)WVI65G;
M1NFS@9SOJ(BG'%S4/S3?Y[D$VCL1=I%[;3:F":U[F3DVEPGPA>LT!D7LM"=@
MA"+(=%)K-T6KIR*'LM2AEKT9C'I768YL^AKS5MI8.>>N1B]&9L<[,\I>>_?K
MO9C_7Q+%Q4^-\V(;L1N_J9IGRZS)O[>2[=Y3 V*R*>F7OCG3R$I?#NWM=:\1
MUB0V8&4@<PLDU,099MVI2\GMAETU'5U&;])H3/2=MV?H2\GT]A:_\D4NA' E
M'3NNK3-;C&VU\3_..T+.5EL^$"#JO\I5\4=W!WL:\FYQBT!0K^5#@R_3QPPN
M),V DT02PMYVUQJ)U#M$^X\PZOK.T2XNBZ,TY'B<<2+AY&?():$+\AXO7S&E
MBR3(J;][S=/^ .)(M""22N\;8CT.U5'5^VS^\0:;2(7UFU7[TF-7J:F)J(_]
MYQ/2;*T;,1R>Y==>C98L5NI_5)Y\,EJH8#3AKU6Q%<"SBCJP8B ]$"NJ[++5
M8<Y[9^75-I^&Q[$VNFK&V2=T.G-2!94M&@L&]N2'5Q3E>L6^&+P^].NJ?J1X
M*%J62Y*S*JP?==%N>JVO UJ/F4Y5I!JDO?_0H,*TM%CC08XU1JD?.^E]_W,[
MSJ75,+-K^M6;",?<-V]-E1^0-5C.6W,%-7?7G=,C>Q)LN/+V>/:S&#+W[0>%
M"PP7JHHYE,_=?]R<J^/E62TZBJO/Z($?<72L"X[A''!IP(86J9!NE3O+A[]G
M@)R:H3Z1TH\:DEV0O3RS(H76(3L4@P?ZMB]AI/P*9J;:4HK]-F0BY$Z+'.(N
M<SZ[L.+GGCYEDK &#WPW61?>R<8;77>?!Y>O?3*0&H%&& ;*\*)?9;:\[C.,
M]58:4"T-<?KRT3OW$C'[O*K7 @[L.,DC$?C)8KHUUY Q 5;5X^.XFF9&)2Q#
M01?@9BB?@>BO!XU,+<AK;<I;@1KMGO,&UEP='*N7=N@O";CKOJDT-%CQ99$L
M\.Z+5*\9:XT;DBDP'O*[5HGNMY>WKGMA^%T#MN)O.](KM&+7.I--;M_R[WGK
MZ2UQ7BF$\E"XT_'L]RCU&X=G-6[E]-6U)UB%E9K7([@:>.=))@JG\U$%:J;7
M'K?4]@=C9?E2 #;BU.OJH@GG_]">_Y)U9EY8)-5&/O3GX?L/)N0Q,J_Q@&IK
M?Z4(\LQ8HYU<R]+J/(6\J[GLA\3-A!UR$?,?N?\CCO[?)G2RKIKN88GE]^S*
MIQL9;=@B,*15IT81@8^-<3-TT=6CT,]& 5GG7;G%(LU78\>?<W2=Q /(_G=6
MJ=P_LK$LNROLOY!P2W5):E^EXU$\+./3FU6O8\90_3S)%]73%@AM3#EFN1$=
M?8_[@<0UL>=&ZFU"XIBCZ"D![3LDDNA9!N/*#ZMF5C-/97H]7N8?!HZKO\5<
M./1B92THP6YTYT$8<[]+O^6;-?GUI#MPR",J2Y\(I<\!5623+'>G&F["U<RJ
M"ZXPJ==[<T05'_>V>2B?)C3]=@)'URW_!/J2<=5QNFPI6JFJ5$)W13M/ FPM
MT9_P0>Q>;F')O22?0G1QQ.))Q1E<QJVX+9%V6)L^DTLYV\W&05K26>+#P3SN
MH.Y5J\VGJ?Y;%4Y#PUF17.:I-5U!_N,2S]4KD&<_Q!7523I*6F&5GH2SQI%
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MAZDMNYF5<H8>8<8U$.!G%Y^+,L8>ZYO1)J=]Q3MZ:%]&#\ZOF.$B S4<>GE
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M;=G,9G'N$/JZ)VU(:J_&6TFBQ-N_R!63<'?F=UT<&3(-04'10>GY!6B?VWV
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MZ>+3X9*?839E82.#Y;5T!YJ<N%_6!J_;]&G0HG%USZ7,X@?FV(4=;6\4T$P
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M/(:&5.OE'([]ZD2.U>Z=7@1@^TT[HZ$XE]^JGXS31B7%X,<_1&:0#(/&[_O
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MT4J=2Y.%E2)\42WZ2HI)8S%U"D=]K-:;H!/--()MBA68XA-V!/P9_J!I<T"
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MA3<YY+]"JY>'?+1OC+.V58M/CALA! 4IL&;V_GSE/KCSWM7@NJCB\&MF5'O
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M>4%-@Y 0V$O73N(9 P3,W*HG\0$ ]_<DOC9 ZN(B*2(D*"A\$I\($-&P![O
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M;%W@**<_D8CA+O:V]C]CJK+N'I/6/@U7I[1$(>&J$!C$Q1()L=[7WL/IX))
M]KWS'F6O1<W1EOU_8?P$*!?HGRXL^\;_,T4#8?OGBP^Q)11YS=+V3S0J, 3'
M!W%'JB$N7=.X<A#>2 _(?^I\Q [NXJD(M;<]L!3U]\%?.B#O6=<:8F.)VH]O
M1UPA+LC?=-<_(/^Y.[F5K1(<"G?YQ;BTWQDNJ/YLV%-#$P[;.Q]!PIUP%S$$
MY%?#D4%QAOP;E<)J/U#^C4[NLA<._T+>][\SW_GVEK/"(O 'G7:_B/<];A$>
MVZ_M32C)?GVO/\!0\<-@+W#' UQQ!%<;P='C@1, 'K87.P=0*%K#K2 62AH
M/G8>H-JO =:W]OBP:. .0$%*2GJ$E.+($0I:<C)RVN/4%!34QT_0T1VGHSM!
M2[&??IQ^G_ HR<DIJ2AIJ*AHCE%141W;RZB.?6>A_7<$8-\ M*0XY5\0X'$
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M .#0QO\-&V-'%<3LD$@G:0$!&(+?<F]4_&"XHX"[I9. $+^@ ""KX.YD"7:
M(-FM(+;V,#F.A8IJ#G9[:SD. S$-00TG)8B=_25/%XBNI^8UL*<#6,J:0T&>
M3-9=VMW1R1&"M&1W=X3"$-+N<AS[PJ5QY3VR  ?[?A>D@QS'=UL::FBS*\%=
M(.SB_((@,,Y.[!)2_$+BHJ*2DGSL.'L*"@A*" @)@H2%I7$F%1-A_Y$XY,EP
MN:R+M8VTSD65'W"XFAS'CW&YN;GQNXGPPUUL!82DI*0$!(4%A(5!N!X@A <,
M:>D.@B$XOPLYD',1@@"[V.^_1,.^5[>T@J.0<AP<9.R_I.] 3K\ _<F N :<
M 44$?L>$&_?OF0ZL_CLF:_!/'B>4"W1_/-9@ 0@4X@B!(1$X/J%_ M/0^-=P
MCHZ_Y40@E5V1_YH3L??X5D '@H"C7, 095><)IR_%Z4#^0=#_5X4KOMO!3D=
M>-P_6/V@^;L9Y?^0((N;$&EM%[@U"@QQD5<$N\"M+)'L%^T12'LH%.*"6V&_
M.K"LP)^Z_R(&9TYI)1>()1+N<@T.A\IKZ^XO%3%^:RB471_B@MA;-&+\POS"
ML@)_[?L7,1IP:WL;CXN62(C\7KP "8J A$2O'<0+7D$Q:1'![T)^Z?D[52!_
MDR$F+8H+/F*_ROBEYU_UP/FCM272\M_2Y->^O\BQ!DO;P%T<+9'R]HZ6MA !
MB!/"1E;@#^J?NR+MD=!?V=E_.)XB%/EGZD$#U'YO_J6AEC!;.0YWT(_W"SCD
M_U^\3R@K\%W@7^ %_HZ_K_]?5=U3'_Q]3G\S %V(\S\-0/X@_O\K!?[,OZ_
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MY3XUH#@?G\$0-4/"=)7;!&>"%U2P^2RAWK+2P%^](PL@4AE!-LB23CXNQWC
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MK-.ILQ:AGM&72V"7_MC:&'OJ=KV%'+ZPWH0Z'1_V]VWG$L(];8P;XHOVP;F
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MH5 NIH_7'OK??=CS?_\9PZW;D \BW)X7X"*#CHRZIY7DH5H+@@)K)DZ\LVQ
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MO:C:7Z5X59P45UZO4T3!%(1LRO:FZDLZB;!^.=/\5S$^[+N9?P-02P,$%
M  @ +H!T6EY.A+&]GP( &T@# !$   !G,3@T.#8U9S$P9S0P+FIP9^R\!U@4
M2=<OW@@"!I($D2Q!#.0<!"1(4 D2E2@, PR3@)DA"AAVP54R I*5*%FR@"21
M))+SD$') RA)XMP!Q75W?;_[A?=_[_\^#Z7=776JSOF=<ZKJ='?5T/@^_"A
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MP  'H /8$?)HPH':S^UM*-+];UIP "* $.$0!@YV:T@X]Q<"534U@8M[B\L
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M;82DQ, @?G&PI16_E;B8%;^TB+@4O[B(I)6-L*2EE82XR(%\R*_&]]\Q7.S
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M"V;I%,^N1T@_'^9<-D'0N5R3FL45ZACH*0PWG:C!>NE4?&EHL$*'E&?Z/Q1
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M87J,38&0]S:)_NP&J^*C?;![ Q4P;KB-[(Y_II<XC*E!3A]+_K7,",C&%?$
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M8@.S7L.:6]3?QV<F9CM8<,8B8I-:Z] 7A'3%WH$N?.,))>O -\<FO) 1?[K
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M,%*VC^FWF?-2<[Q9/YM;F-G_MCZ=S_\#6/P]2# 3VKQV]?;W9Q@4 G881>>
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M1!E !""F4YOP"VQDVI#SS!,/'9R-2%"E^/TTTJUS^&IW=X\E)7I5FU(Y=%I
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MLHNMJ/.*+0?%:,X)]Q=Z9L_+Z?/BF_FG@*(1/N@Y%F0&YTN.LW:1^0QU1_^
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M8OT5>.*JT,DZ?4DA8LM3S_"OK]BD! WN/0_?SPD9S)+*XPY[>M[8O&_GYW[
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M!+*#OCQ6_[KL7>+%]/34K1A[KLJW;1J<6.X<*(11.&)#;\:X=X\EJKC<K89
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M #O+8P,=/CEYCD/,<$<\+ 5'%B%V9VI:^6&FKW?+J(^V#MN1/#\QS0T)TNK
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M%^J&0-9#Q(=EKD!1^"=*V\];+,(BH_TNPMG^)DT'WOD-$VC$KH6.BB851?(
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MG&V?^$VW%4E&]?3N".O.V3-2JEO2.#G(IS6W$1"2'DU>\OH7(!HR)+8#F\W
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M&;35ER'9/-AD%E>Z8K^4U\J538KV+0@/3\WBSE$D>5;K5NW3DO+9 ;*X*$W
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M10CDB'PVNV^7Y<LPCH_[-]9_.J6PQ(G72%HWXKK8;$].Q#4IVP./!U(J]Q_
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M?</6!=&DF%W.HFZ9:(U6S[SP*+H"=$BJ50BE<:,+<Z>\BIS5J;9G$X0/W*X
MAUN@E,U;LD*P-/\^[/LREX"2E12%5&F_L*P^YKES4BG9#JA6,+B&= EV.?O4
M035,_:[2."2 \ZUB:'2C5V, 'F=IB:!+D4U<NVNM;N36L7E 2EC$C9.>PQ^/
MF5UT; C$Q<%/ZHB;A0I:Q\8G*$>1HO<D-T[+&$=N,XB%:_FY, 1N9D9; $<U
M.(NIJ'6&N!7P5@),URG$PC7)[Q_.E-7QVX^ PMOZE+?L=]2*$M)*<%8V[_>[
M-+9>BR/P0TNAOB5@K\E$]=\&O<*J,5^X>N;OK!=[BAG4#&!8::K)I\8_ZQ:F
MG7,@I^2]D293LHSWH2!CT$1#N;T]6;^J69L/ZQN,I'_)-.Q]&9(O(;)(D,29
M]'&X'9&:QGS "M"5)!P Z&;QT]DISW :T\FX$_F(C)"_W;_Z9UQVM>DJ4LJ_
M/VS:Z(S68+Q_5(EM$,+XFF%\Q0Z 7X42^O"D5F7&S"K?6=)4@?-##QG@Y#8Y
M%85_D*>9MEUDPGQN#=.QQFN%=EV-'DM."+UG/Y3Q !BTCCQY]?G<&RI6)W4H
M0N6NC,?,]F&]83 @;225HFO7XVX"=8DZL</F4MC;E*[A=I@O'K&A=E$)EZ Z
MQQGDVQE2!3+63N^VL3S/YM=F)?Z5Q$XB3C\!2RP%0S'H(#JIOW#1L3GG-A9F
MI]$<$<XIK3=D0RI$EX=\2Z(MH+VM]:T_S_5J3YT*FZ:Y@34#/(7P]R-*#&YN
M"B)^>K9!>'=*'Y8^JIA JO0Y/ACVVNNE.?H<0OZJF?[&"AD;D92XL_.]J<Q]
M] =R)W'4UX!]J5>)LUMS<UU/"\:AF>-I;"#I:362S:H?YWD!)ZN*)0) BGI=
M PR.5A4MSWVF)-[BMB:WW]L> S9I_KK/FLR57+#?_&;0THW-KZD[B35LRP25
M7)&E[-#5+3D'O\,LN_]AX[YOM_(#L3V-+?^>;9THTEINR93P&8UU,2XE8V)3
MG+6 %>>:-K'Y0&<9FH'4L.2>MQH"9G>3E2=^/?T]KW5))CS^2(!25]50&W1R
MG>08OU!QGQ.Z@=?;QEIZ$K=C(*B0-&L3E7.\<$IC(;0O25*_Z6M%-\33Q"TV
MZ$(P3UMQ/\[0?1/_GGML%HFK^VK81@I10:!+BI#D2*-?6(=X$5W/]IKAR T\
MEZPH9$6,SA6 .6JFEIXCRO:T:$QEPY8DUD,A@P86WV2PJ[]Y9J9NFS!E_N,C
MW@KTN:4;63\+BTB<?YN%F;)M$8I&)=T,7. L^<S>[]WKQ0A"-W:63Q2R-<PM
M0P4"I5G&'-/^\!\OPA5U]90Q@H?6N$_,.,:O\:^?M6N+JR732 85&LL6NB ]
M4I!^C[#TDF#;R&RZV<64B$8R_.SU" O'6D$A6#;*9US;U(1GQ8///O_]:H(\
M&QGHI-Z#=1]D)(!/USCCDGQJTMG7,G\OX:;CN@,&/Y\&5Y-3+[H>O<>D)8,S
MJ)+U;T)MJ>(?X";04B"33%)9V+2_YRZ(;J*Z"@)U(W>EWFS>W.$O%D2$E4(I
MS93=\TK</XXI?_S0D[?1*SKH%LR"YBT;'AGB4(K2<KSEKY(J.CK:;4!BYYOQ
MVG1T+12F?B\()W9_2M>E:G1$V=!)Z$VCK"35F\KGHYC1V7H*&;I!F3Y2("8D
MRA') _TX&)E<+>CD9+E^@Z .KS]L ^V1Y<Q,213?7@&M;W@S2<9,L28V/KV;
MMX&K/0\4U$^]9OQLYRP@Z@&FQ.J3C/AD>P\[A8)$5*_KL(#>= CTA[8'<L+,
M ?1]2EM?W%35=%38C0& Q[Z']WXYB:+9,*^,-D9)X"0SAV+V)K4PUYKJ/9S2
M^T'"(&C\A9O8:PZEBG*J .WAZCC1_3&AE,JG X>AC8QN9'XP9O"N?%6'#- Z
M2:Q46S>M :,MM!+'O-[XD?VK9N*"22,NI:!92ZO#6!\T#>>\R8H(?]8[N3>*
MV5G@3;C9TT7FQSJ\=1.&*=D@2N=.FTA;6B-\(4)$SCO1Z>BUEEZ(2LL#^9\#
MU6U(A(%]_K+B4TP:&].FVP+1B1U9C]W6\I,8",+3M88MN!"&)F&CT9*?APSY
MS>8:"@H:<[*O?84!W->3&ZN,-LL%(2J1=GWKLX[BA5H'1&08TEU?-[IK^,ZY
M7LF2V,5B!T%JYZ#Q$#3(P;ZDJ"1X6PT(/E#R,57XN<'#"7B"R$)6SN0+EI-B
MD<TGYX*=1VZJ5 @<]/U =*50HRA/_ZG,H"^4JZ/2:+/L6%AYTX([RZT8]Q'2
MPRKN7?Z7>NQ!\Y8TJ2..MY2_'LH$E.#@*0W?,<$,URP!E#%=\4/O9/0-42@C
M5['?'D_^KE@ $E%]=$PM2#V07$.IM"T::Z>TG$#FH2##A$K;M"IJW:E$)K04
M6CZ?$=!,2'AD=E?SHO3U') U)?I@2 )XK##X<,LZ.VC\.*@>&0(7@[MLECA0
M-D![%NBN#3Y5[NTV,I\9#Z_#"!)7-*,M%'TH:HFP#C8D7LXW,DA"B,1G96YX
MR!1DY[G$30LB1FP37H%<4%52*IQ]FXP:WS_)Q<RQ5XN+YWLL4$?F34-4M*?
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MN%K8RB[3>OYNPWK:N&/Y/<\&[#3C9=KW?F=](-LF:.IAIZQ2P!O.J'!R -5
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M%KL0FH:P3%*O[<! _STZD;V=+9T;,H3!WW:8F5#5QW61)FJ#GOFUNN@47?&
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M3I6FYK,8J ='][>[UJQV#VF#W]G3) F'[;'.PL#9PGT?ZE^O26"\0D>;#^P
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M!>'& *,]UBA5$6@U[LK8R[+<PJ>5W& ],J,)V\MT5M:Z77#_]GVVX+Q/L3<
M9G#/;GNEFAA2G78W)4-8S=%H\\&"]DQ(B'^ZM^8-8/C2]<K\HYW^4]#0$L$O
M_I<S%F<>%3> K..#T]%?2TWZ!9&M+W_:WP!,BA/#3A$G@NH6AB:FV%\=Q[ /
MGX=+&>.72[G7<9EN&L@]5_HI34!G0V=$A4G!=Z>J;B$R9]Y6,MQF->@UQE6[
MH9H[4]&Z=V5^BI_ZZ-?SN>FUA[T1G>\$J8 ZVBZ6;M!Q+A)4^FF-8,1E?XM>
M!S&B]>W@>ZUFP5SR?=#^<][G)"/L(UJKZ,;*5V6V1D%OKY>)L<Y=*7F1A]>
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M+IPYYZ+'SG8RZQP03IP)1CQ\F";_=H-'XS7'9,QR=(/'N$_17JS%J6GWTH;
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MJ" (FC2-Y0MM>N=[7#%5FJS3F2T1ZWV*'+$OC3BZV]:L++S2S')4Z0,^!SI
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M!@;'YI<9[%15PM1 5ALMI^L^"&N.[/F?3XO>JA(N@>:*\X:6(MZZ+('GM*+
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MW*=(GEKA3W>PM+*[]RR7@GQ_@9_S;$>1A*M&0%8ZPPR?7 $#*AEABU1%^I(
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M<AXF#JJ]Z1J:/O@)<ME?\(Q9GE'0$C6;-EP.\F3!;>&2[16R:T._3!RXZ0K
MI0Q!))DN.XK=(T&NQ-64 >0\D62K*C6>B$;)[8-W 0FA4.WEO3Y%XO.%/#_[
M'Q4/JLO3*"J*<^_</MA(+1SQ/N0^=WBJLNF;P]H?5 4:MT)*7\T#3VT$-@K3
M5[H&P"PG[YSB+T>T#:519\,D7FEY)\]VI!E8^R671SF8RL'[3)#P)Z 9'<OI
MN.5^\@^G/>L[GG#^-7 PZ&51.22M_)EMR*-O/N7(^%>1FZ[]9G?WAW1"!D+8
M6G@0P-6C038.21J5[D-NQI\5,0H?>&,*D[($P5972LYR7"3T<RB00FV<:U6^
MKMKL]*3JG>PB,I_-MU&]GT)6@Y&V;'4FAB2FZH55>K[BRN6S D%1D@HI)5],
M>P2CGZBREE/1QR6H>.ZR$',TP$N195,R0E;[/&5--D4N3Y<R)/.+PP*X.+*/
M%>O+&T)V7K]OSFHH/9>T5OVB*L?JO>K7F^T&UT1ZHA./$PP2VJ:-$"((:Z>(
M@>5R$'Q=A2,D14=4)M1C*#_%UN,BTUC<$9G+U"X=+"DG5MJ\I XM.P[UX%3F
M91W=I(^Y%1H$Y,CMO+W[X^!;04UR2^YQ+KPP_UY-:#!J)W9(DIGPNTKPZ)[T
MW4"0OHM'D)?O^!1@SX6O#<>Z%B&?<9?$F(W3,@#6DX4X*#[.D#!3TB#$Z S%
MB"/4?[:#E:H'*T'([5Y#.TOSXGT[KU*?$57HQLG'/#+/#:4@[[/2C+RB)"LO
M3%NTN\0LQ!J);Y0-PW=BY8F#G ,+G+>T?17-20QCH^)"15M4*HZNAK,^(M(H
M]F--NRW<YJY:(K04"U[%L:J(J6]AS<Q,%G80\4G3TU2L+HK.]#DTP5Y<1*X7
M\ K$3Y\V(TLP'WK&1L^.U]=@WF_RE@:EACPM(4HOKNA'D[F9M1A3M1UIK@W2
MI3NM4T:RL/XXKHN?K^OR_ER443RC:%.;$::L?7>X%,2R?K.W R\OYO3TLWD;
M.29DK>U=7(UIQ&95L;HB1E.;T!M^@1AEA\V"BZ)H65OSV=:3J1#[K8 B"+>%
M?V)YO!ZLWZ&O=S@:-06NRCVW5.XLRBJ;#XIL.QLW3WP2>)ZK2889NCND9:PF
M2L!V4NM;NZ @@\=ID^H<C5J$YF> H+7N[I=+-9N7A*R%"G=8LTX\QM.D\U6S
M55G@=BPFO3U:I*25'@(J*WB9/06S#(9\,INCU%3#Q3![R<GF?#=G1QFU@EX6
M1L;HY%-ZTZ%<^BGF2KTYG:6=GMR:'ZD6,$BHP*/TTLK26!P$$Y:? *^_RF^N
M:E!$\PH4&KEUZ"K1#W-%5TH,C%]]LBU<)Q_8MV$OJV)*4*=6'UTP&2Z%_A
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MK6*!UQ*@H2#_8N -3:WUC9E]G=%^D#00>XRK7ZRUM/J)R#]TA4(V?:CB3@\
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MA2^JG'V_\9(TU]M4$'V&'V;THP@'2*[;%8EBYWKJO6+O4$LC(*'ES\W,#^S
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MA@.S0GC>5<"@G9'UK4&8@3[6_1I-_ABM?C4MJYM3]Q2;&Z/]2R84;"O>6[4
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M!9JG923O,ZF]4,LN>N1%&O D$JWU?9N[+@*?%=Z9G'A?N/A$^./XIW;^5%K
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M8;"H48\ZG#<7A=BY,ON/_P0%6'0TON49#55&K*>W>42*V-@]G_/RMJCTMO)
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MN-)5L3/QF$V4HI[+5HD=Y*<U: 6#^><:;!-I:V1;.Z^],VLJ4CNX9;/U.K_
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M==\?LZ7&5TV4BN!Y0K+Z\-Y@A2TETV-939> -Q82M3.A8V) _,ZT^;9<]"]
ME?<>>^&T8(UCF[6.J*SMO**&69AW ;1.5&YQD8[+R^<#N4[J^&2LZAMT":V'
MISK_7C/^1YXSD<)HU4[R9:U9 7C$.4)"UV?3V*'(DY]_H7:<!ZFV7O,+(,$D
MWM#>(?YD$GUU ;,C0-F>",ZFT2AY5"(Q&>/B_&BF$C=<-A*)#")AWG:S\T'?
M=B"=$!U>!<HKQ70>P";ZK?DW-_!&Y!)>CXBO5I(-!.S'Q:&T*\+$TK#  @+/
M+?'BY:^,!1 X&2,KL4;)U/W'4=IH"%Q<P)$E8M$N@EQK4N$=F;:F2--WJU\
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M7PF# Z6+&#/3Q]4G.QK&A#R61_LI7-/??GQK'?79/JL]0^IF4?VG$$,,LI:
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M:G,C** !'ZG+'EL#7(<UAI+:.HH==NO'NCG51?6?SG^FGC8?4'WJUQEK^PN
M)(1?Q-+O^47IL9=YM20"?6M4SM(L>_P@J50CTF_NY<PSJ?B:-7@3?GWR!ZM)
MTX15M(RFCNUYK=]V1Q3D^^NERV>T*_6G ._Z,S9'+%[-$507_WX16'AFJO\
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MS,E=2]8]R@HW#3^.>R!$;+9+/%@GE"%$S^'\8:!FS<,OQ1869'N18\TKCW\
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MWU\.5IO6G)K:"N%V_VSV)QY><Q)/OIN]%N"3:W#,\.P.LUG>:+K5UL :_UD
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M^/2=4^&C02([3/MX3K[SM6[DHJV'.V5,2 R8W'^LVD;YQ('=A25&445F$:.
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MR$B:HO]_KUNJJN+_3OP/4$L#!!0    ( "Z =%H9$ 4+%C(  ,][   1
M9S$X-#@V-6<S-6HU,"YJ<&?MO =4$UW7/SKT(D6**%6J"AIZ%X* 4J5(KV)(
M D12( E=1+$CTL$"BB(=Z4U!Q 8JB$@1E-Y[$:4H]29!$!6?[WGO^]W_7?^U
M&)W)G-U^^^QS9I\RK%GYN-(%;-?3TM4"R B')IDF *R,<\P;NV#P&)P+QHU?
M1EP24-30-:"D!(@''P^9#4#!+:+-0PX A/\\Y%0 O:*,@JR"@H.DE"Q)4H0D
MN3U;UFX!DMBI;+3_19M?=*( B:=,XO43^823C%3:YH9%H/%&'G@W#SRA2$6D
M&>/PIHX8#)(DH8O&P^%H#]3:/?%7$XDEEIE)NJ8(;Z*$!@)/U/EI$XXUA*#@
M9D>LS-;!5A6,L1B,DRD<[^%FY'@22B S ,8 %L 0_CD!_( I  ?P@ ?@1E*A
M=UN77C.C@<2C?WC$X.B!0.(1:)))0IF.)*UI8*V_&K>#1'ERT"\U9MU08R,W
M/ *#QA&H.TGU<L.CURI!J*0C=KU@XHPS^,G!HC5_%M#XGX6CCDC<>L'0&>^Y
M7CB"0AY>+Q#B^-.T!M35^4<@5AT$3+0U"%T!H"#=P_CY81@/QT.8+F#MT,:B
M_Z!I(/^4T\#"S,S1>"TA$R0>V'!H(&'\F]%-<$@\B6[LC3R$5U%=;0& WA,.
MQ6.PAR%XR'JO,'8VQJWU"N+]CU]-4A#@3OC-S)L1>O1F=%,H<I5NC(4>LEXG
M;X=B,6Z6+G!"XQ+:"X%V7HL8$Y%A0O!) X/'8U!(#-KYAPK#&H?HP@8ZXQK=
M!.'LLI&Q;8U!\&V=3.PY%..K/I!IOF@F- OYVB^I5^TA\9A^UD#MS*H6)2.I
M2'Q:;4AESO4R'\GJ5U*9;DV/C*2U=_MJF->:?Q6%8H9TKP-(.#D1.$C"E?J'
MTBKEWLU;ZQ1ITM6&<%VCR)&NH)\4DLUOI'M"NZYL>E ,$=G_^SQ2+&A7(TKR
M"R _M'K^X!U>YY'_P>-;C^%JF8MX1Z&^7K/5ZAT@B'"2:#  1ZBA).&?#+#^
M2/UR;* 1=8BZ?Q58/WXF$ #M@42NN@I0.V(\T##<;\\O%"^UYC*QTV_H<,!O
M/1/06._!JVZ8K'?0U>K@D @H'&>!/$I\Q,A^P:$B\0@WK(23AE30/;S!-HTS
M%N/A]@N)&H-%."/6L^<14Z*2$8E&*#-"// 8;3@:CH7@X3"2]SYN:\F??E68
M2"%R=%'._/\'ZD_A@47^,H20@O\KQ0#G_.LP0PU!XLT@SK_0F*!P@A[<&Z^+
MTS$S.+J6R&C7R+\(T[E@L+[J2(3S6J285RNOLT8F1A<&=X)XD#(9G2<<B]]$
MW&*-_*OX-D=G30P2@]T07)95!0WM=0;1#4,,FOA+A\>X$88K''QCX.B1A$#^
M065P)*7$/^C;L,3$]QN9]#3M6]4C=F>US\!/.@OIEFPU0U&RDTK$!J4DE1E(
M2C=^!.PNX10GW'8!@,4A OT4L L@6_FX,@XPJ,,PCG '30. ?&4"8"*5 -@9
MHMY**W >8*"EI:6C9:"C8V#91K^-90<S P/SCEUL;#O8V':Q,)".'S^;'V2,
MV[8Q,C%N9V+:SL[$Q,1.O#"QKZJP_!L#*T\!%EJ"\W<IR 0!<A8R"A:RE79"
M1>E77I*I$;RD(B,=/\)( 9"14U)1T]#2T6\C^YU)&!THUIC; 3)*,@IR2G(J
M&FI:*@H&&0*3A8)2@%6*2OT8A$W0_:PT-7OXO5P-(>$=)L\<962Q@76:-"(1
MII^[IZ X.8Z$O'-[#D>:P8X\OX^7WUEOW@/_DG_^18-'[U>MO5&)%PJB7S;V
M32<55GSHG[%P\KP8DUQ4V30PJZ!MZ>QUZ7I*\:OFP3D6@)R<X"TER2<::BHY
MD@L"4JR4! _<!=FHI,^&LQ,]>&92]UE&V+$;&QBA:;H#BI.=$J$F.D"S1^YY
M/<&)^SMA1\SE\?">=1?^[L'>GRZLM  ,%"1,%D -F#&+L-I]O.1"N]I($:I1
M,6_PHLFKXO!1U2C5FF6'%.AL &A7B"B@?,OT(/@17FSDS1N/&)ZCMK'7G&S%
M_*.Y=7!WJMHU4;@RWO*D8N?[D]G301T2IBEJ^WF_>?K>*(+RG/E,R\3!M?QN
M/(L1YW\M?UA<X?[T7'</OFL%L-V]E^,6N#KTJG_AHW?N2CY62P[;7!'+T= 5
M0--A."MEVFO>->_I*T]JN4\^6>WAF&$L[UOJ4!1T/NC (W[G\5Z%IY@#DPVT
MKZ;5RH4=9DM$Q4W:[MS[D*<JC[YTLH4+DNFR.,K[O;/):PFU?][2>'ALX1"_
M7+GN],/J@,S[JNG%G5<>:;*GA!RLQ3SCL3_W(3%O7L+TM*V]01_W*-M#Q*/'
MZ-:%FL69U$S'-SQA;"$5;O*)D3HW;EMR+LL%]!U0U5GRB&-5>P;[)@KA$Z5M
MMPD)=8GX*I'1:7US)F#$($9A^N8G):_F2[;!UYX53I1]7:;@\[)>"@IXGJYF
M"LYPF+FJM*296C8Y/&-E[]?16[JGQ^M)5L"M]HFJ@.5SS<L[ZR,_WA,2-7,\
M.3IP9&R^1?<,<.@]$[D'O5F$;MQ P4[%,S3"0ZPFP\(7!^>CR]_[>3UC]*HG
MJTL>TM5EM<NT4CT*U@2AK>M"#UY!Q8KQE7T*>&M[=?9B7\N\ZQ(H>AX_#[X^
M)#828;KR?L;\2E->YI/)3]_>2GA FQ[5H.<43LQP#BLL2=1-SZX YZ<]K2J*
M<@Y 3SK9SX*K0)Z0X(MT.RZ&OB^97?94&U9= ::"RJ6-:($PNIDP;R-*K\O7
MAZ;X'\4;/\GI\O##CJ 57[W).G#?O1TZ]58!USYMZRJ^[!]].G0Z:@506NP9
M5O[H/NPU/D9XH >N!]0=1\U<Y=X_TFE?,?_FFE%"-1HWGGFK"45QVA81L%0Y
MHECK7QAPO[1Y!="VF9$OB;M%$<MABA/F>^=Z:>E[DE$DD\QY!J%S?%8L+.;/
MYJ4+&-->SN<-;,O;%1"'L[+M+=B)7@$2!S+CBAO?VMY&^D)"VL$LSY]6#3WZ
M&#-_P^\!]&C3P*[<)X:]7K/&G=IV-8*EUJY/&[<)7%O.?W*Q/_ZJ_%'%I<B+
M6HXO7>Q$7I[1V:&_9,^\=/?C8LOM\NX#*T"Y2+1YS,SH_J3EZ&QOQIRCQ=-0
M]X;OVUR3\)5=9CT]N_W#1Q3=A"[*? >9&7(XC*\ !;Z&TPJU:8G:*?FOO.H-
M5![WGF.@%8[+C3H?H+&W4BR3)O9V["5GO>H'S4Z#3W.+R J^%M9X9K6=)74_
MM47EVL69B,+Y98[C6@;HA.M6=7:L0K<;OK\44^OE3IYA2JJ;2AO^-EE5>!.5
M^S9+6-;23V&AK?:=GWGYI1>M ](O*7@<CW677\>8<^YY<N*[;>H;SWVO00&?
MSKT[*'XNQZI[]);5Y/URS+!ECK_>2+M"&EZ,\YRIE*'0$87N_$6V2Q<G<:.E
MWULF5@"Z9;;ICO3J^:29D]5/4OOQIXN#%]W#_4,^#C&[@&/3G^35SQ:.Y9:.
MVG5J#ZT =LL/9O+#KS6,5V45<^6I2M<:"=Z\_396-7L%V&8TOS_@R'(THD_J
MM0@WN3'X-C[BC-!(VPK /8XH3]%9 <@BO[O8Q/<R4,PH,/"I(@/F+^U; 8+1
MYQI+*L%,IZD/3K+G53H$\]MP8Y(''EJ<CJDU@C]P+3MR+O;*LF1)N796\%M;
MWDM! ]0F5I7VT#,'X*$(\/TRCJ6]I>^=%T]NO\^C?9F)'%T;%#)8T3+<%="K
MZS8^B\Q>7/(=!&<L':N9?W4!QWE+RDTJ3X%+W_Z$QX*K5SJBTSS@[;S'?!:N
MV?Y<?4FL6D5FF=2W6K1?ZFN72JERW/BC,4Q]ZR2TV%]$;0I3/W_=8/A3X0R#
M<\^3M]?&4.$B3VXCV\=PY4II[I]?"5S968DP+XX\NRQ5,F"H;;UT833N>/RA
M[/'#:(%W>0<\KLMGU]L;JHJ$.!T,B,M?+GC4FC7LSRT8W)G!:]$JS;G8Y:]U
M3;O4P56LG*OS[J+?3L3,X$B :?7(@=';G(&CLSDPZ(+73O-,RZ960G;URI_V
MK'-N^%@[R('>-=]],_*:\7SQ!?W]N2D"M2_AY)44'-+56,:..P,K0-M)!^=E
M/\-7^RYK74Z?.7SCE<,H_SE,PO3;IAFFVU?O-(VC[>7:N&7(*XMJ\A=O5U5=
M,+<T0*4GRY>,DCV 'G*UJ;MOTU3<TE1H8'HP.V"E;L;<03JC/?1$Q4=Q/"N?
M2/8U7ML5H'>7JFK5<QT=<EIEFSO,HW=DF!O;J@U'AA*JX@WE[DXF3YH7M-MC
MU-X=&[9WJFB>M@'=3^B"MFU#97#=&J,)&VAJ*EV.J)UO,#+,P<_-G K7-L@0
M#<E+>*54U&'8ML?!%1[5D]=>6]KDG.0\5*;O2NBT)2&20H$L5WJNW70_'?IM
M']GKA+CREKF>@^ YTR.[YF19S*Y;+29;-3\\-LW39M/0/</3#!ML<BD6C>KG
M&L4Q@AB=4_27U.IM]=LG<R=L&!<D6AZTYH\?CU6UNK8<USJ$65P!C ):_"7F
MOUBM +!VKT]EJAWW%K13V$;&8?.E <_G3U^O7WP9T=7<Z!O]S7[[593_S<)'
MW_G.)!6I!"T9+1AS:\J7SYG'5>=/E5CY.414/ZA***]?NMTTEM>"\#LY70SU
M^S@X-G/LB]K X,<I?TR^?XR:Z?Q!*&8IN?7[D_AYN0.8CVK.:L[3X-I1F1>8
M[ ,+:O4K ..(+_CZEWH3'I[@9Q]LK[E.[@!?:AWN#RI6JO$_REQY>E=K4;;I
M3/+Q%>#SPR>AW\RM;_M^;;2.L.NMSRH>"^:++&+T5\8M?QB>QZ"UCH\Y+<?7
M3Q^H*%\2^U0^=CQ?-<"H>7IL>DZ+4/-/L[?C;P^O #(C*T!3U(&EZPL2G4/+
MU=/:!_V9M3%%:L]\P?%UNH9H+4./VY;R%]7V?=!$3'\*VO>^+!LW%W?OT3O/
M#]Q8Y0:CHY6O/<X)CF1YZDOY;_]B/>QKB,L+4!]'Q:=,V^<W+;M.ZSMFYRXE
MKP#Z#0M'9<:YH:?4I_VMYOQY.^[T.Z2?KKQ5CI@_6-9Q*8/[(5]V"GBR?48^
M,3E+2PLM#A:0>!12*I_^8,$H8= 7<U#>4'[$IIIW6NUYAF6?C6_%+E0QW+.G
MSVJV&-TU4,Y1DCE'HU3J[UH>=L]R;/>G9N2TFO,$^,GXDYA)S-?8I?BAQGF'
M,43Q+"9IQ,\?1>BRTV4&G4F?II= G1]U#>PX!M0RG*#6L7XC+Z9Y*L,M2_WL
MYHKJ6VP&_=EE&K^>KE@<@DZ,R'<'1]3ML!RU-7=&=QHTH3)O-/J6SR:TE#E8
M#JG9K-?3*'_\(#2 IF[F?OMT0&S'Q0#X4L3W:?";DMJ"=YWZGH/^*4WQ=1,S
M7O.$IUQ51 "*?%'[*NG31 %,_G5E62:NS8IKTB96#&68W4#(N".8C.GHL>F
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M<M;>>4C\]M)C]8V*Q(]7*F!Z0O=9>Y^S6;_]WS^V0+9 MD"V0+9 MD"V0+9
MMD"V0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V
M0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V0+9 MD"V0/Z70>A_?B$)CH:I"GH)
MJH%76@%-@)J2BIJ*DIJ:]!E=6OKM]/1T=/3L3,P,VW>R[]JUDYV#@XM79#<7
MMQ /!P?_ 7ZA/7M%Q40Y=X,D0?LD1?:)[B,:(:.AH:&GI6>CIV?;Q\7!M>\_
M/E:_4VQ/=GC#=XI? CRDCP[__ 0QX:"BIJ2AI2 G<DVV V04%&14%-0TV^BH
MB!^=)R.GH 2H6*AI6 6DU-F.06C9!:7=S^Z0UPB_E_>,0TC!Q!&+S\VO:Q"6
MT[+ >9R/>+%3)JJ^6_:P.30P,CKA,\$F%QD)<<-GJ  *2C)R*FH"#\0"D)-1
MD%-14%!2_. 1 5D$I*A8V:2/":I#V-V?"9^M^QQ^+_?7KP./W#*)(H]* I)<
M098%UPT?A"9.XQAJ'C\<TJPMC7A[RMW"?70[6:V7^-X+ON/<"+8"5/>-%P9Z
M#S5-!2KT-:I8Z8390P^'[!KQ;4P_W\&A(#>@]3JU=<<S2_:C)H%N;Z,+;G>D
M[7HV?S(S6?XJL\FP4K%W+NRP*=.N[N(<K[BG0I0XGM-!-]X?2"ME=GG</V@V
MN-MM02Q:MTI!ZO[GUD4F9-DV7E&]'*2HGC']#R]%#_T'A414J/E^W2$?;*^$
M)SY02$NUVEC)\I& =@N5_>BA[Q9/NET-CFCI<:0T'1K1ZMK]8'%&M8!])#7?
M6D6P/'?_B878QNOG.P1;T'GNY QO#"G//^AV?::JT]ZC&%0V_#KV6&X')+:_
M@[*5WH+A>DQ!!N/,,]%M[Y1PO4$90S6\R./OPFEL-:->-M9@S9QL<>[O+]S+
M'68Z>'<":UQCV[S'OD8*5&=K&9MSON EGE7#)/QLA$\<DU/ZE#A([WP2K:.I
M+W1WA/#G*]L2FPOENF_DLCSBV4]KJ,24(9?;(WDY]Q;DWL56'0W_P 39P@L<
MWA6&$&P;WZT2LF\)B5F1+.0=BTE3C,)A!VO5O_:D?JJ+WE=5YC42D]W->@1J
MH3T"4N=[US%QT%J/4__0ERG5YZD*O$=P<7EV$47O3VMJXT]_G4P=CK"_*?*&
M=<?CT4MB<J#DZ:_-T6EP^R@S'M&WL,BV_5=LOO3,IQC&=%1_%\1BO0]+>3Q_
M<)W#Z+2K,N-$+]V)7% ;<U@29N^ G*]A<"$E.FP^^EO%J0 +L>(T?/IX</K1
M(VE#+YKH^2)43AUQ!>_V0O$E^'E#GNN;O$HNU+>4H_U2'P/?;4E3YY#_\)MY
M3$&0KEY@A(ZQ$B5N1^%T86VWOC[Z07^?_WBMR^CD+KD/W:<T+#F3+!_Y?1=.
M41EZXVL2_4F8/6D?E4NV&'?2\]8YN<_([\<.&BEUCO&9^GT<RXUCB8,MSI2Y
MQC]^4)[0V5->ER'O*A<34,)56]!X*\#4(:[<UKBTO4['+.:L;DPW)2:$YIIG
M-S_#'<"2&E$>+%]>?VN^IT2HBLTE@/+9\5L%!Q>?Z*E%/XRLB+D\$Z"D.<!7
M9S$QK!P9[*A-<[YUWX)KR_G2LNG6@K[!WM83J2E%P</J88."#\Y5"(5-]OCE
M:N?8>:#F)[E:74O;.ZX+J._3B1ED^N+]&7#?DW'L$U9S/._%28]!]NWG^6&I
MD6> R:R''Y^\:ZV+"56^$Y7U'4119 FN4%F0C6_RC3^1=E*/H_%S3#('K/IX
M4,Y^0ZM=@=/#,GVA!L/2/":-A7>\WW3=Z9X=2$'H]1;U?7E3(:KWE!@G43TR
M/9,S)E%W^2?J^W4>YSJ?F8L5/7I3XC4=O0EW1SL9\+ECKXH./^#MGN[_Q#<Q
MF>MCO(!)GPKWV,U'#T?'KRW5Y]6?U:*1":,6&_<L H]]G.-VS2Q4/2_Z6)D.
MU?2&\IY5C^(9=9Y0S9=F^STSKKK=U;Z&@M_<'F/V]H+!:T-=,1[NJ@A<8 2U
M-Y9_.V7EG?@]&H//'[*+P79JZKL73"0UI@GH'E=F9:*=I$X6DW^%E!_H \T%
M7XF(&T]4+2UA?P  O*P P'#'?D9D+0$4#CR.Q83C+R??+UC\QMW]:!MW^Q4+
MF1(EC*]0J&&T4Y."*;(PK"I7X.O#<VW*\2N UP?I9R<BW:_L<32^,.MR#,+$
MROKU# ]YP$[%&FPV^F150E'QA%\Y;0BJ7$\RTZ+7_3;G(^E;(7"0+K(DVZ"'
MS*281FX[60VR5?4.;U+FQ\QY&,1P?U#TY,+^JWM/^GWZD-GA]-K-WE&%7N/B
MD,O=^;,J@=J@3I2GUM7&8QX6L1<\SQ_2'YJNBXMI4A3=^_%T,->0:=?[G*#K
M^#N3@UT5*FP>EBW<2:6"VY44OZC/ D8?Q>K,R^YJ2UCI7]D]8:=7FW]YX23W
M='O!5%>'K8R-16?#5"1'-6,B@_^P&%@X.#ZQZ6YF?I)3@D>(=,1=BQ8*5UYU
M'K51.S!U3_H;U<_:^EB;)WP(9NFB.#(=&STS9F/7B<=[J]#L"HF/W2[6FYTZ
MM;]!-S'6CXT+K6\??.G6.R\.TZ\\YJ^<0OCJ_1SVTEJ67TZ'9NVTMPV:B4FX
M/R[G]>D^I2"NSU<X*<?_YMZ9H"\\,K8/OXQG+\)]_5^&O.=QSQ#20YS4*,4'
M)W;-IZ>+E(R+L1?UT5AT:[E%/PC3I73/J*P+N-&R)*!F;J[7X&YST^_RR_.3
MLH6^FHKOR-3@UCV& 5;W:2[=NSD8J\GG46DW$UT=UGM^>N^962:-<E0SI\5<
M1)]V3""3'FXHHV4_6HS=7$OJK6<IJ]2C$JF@A@ACKK!1:(2%B6KEW2>%&4Z]
MX%/%$X['W)OW]!3I'QWU8XV0Y#UD<3#TF,WNJNIYT/+^):YV9<V>MMTU:E9-
M,5_REJ\&!*T 6F7Q#)%Q:6\FFKMB[),#+PFXB^0+// ,SA3?*R3$WV?YX3GR
M:O#@@*$/ILH?CE;,CTCB<\H=>9%6X#]HH%ZD7UIA"K+C&N>NE9V:,6][<*+W
MX5P?TZR)[\0A-/,>E! JK'4^0K]&-Z[Z0HS5[CE<J+U#E+9X]YW')4P/XYUN
MO;.XTHBJA?J\S@+:4KNZE$,[E,XMU'BB$GHY)I'7W(H?7T_0.>1>F)*JAKFD
MU]?Q7.]4K9.!P8,3U5EFK4L=_6P(W*<K;C=>J"?K:&+21/G.##%ZV&,5HHRZ
MM;J7KJKEL^?H-OI\=DJNK/URXK:X1\2WM+SXL,37AW1]GN=1#_??*D!]T9^2
MA^)\][^3'K%SWH:"B^WV-SIF-BFB-L ]-PQ:,K6HW8=Y9MZPH*5V\I:90]JK
MJFTY@Z@[G>*UKC6*K<6ZU2BO7<,F.P1@^W:RA6GY6+I8,H]U?CZ77/[X_O('
MN;8=Y=MU=4]4J(8(-!:/ELCQ?J MJ=4S!;T'(G* 3A6E)N3X_1$E931C>,;Y
MRU-"]W3===QF0R,2'F2>FGJUJ_]%YJ&3\<'- 0U\\R-9D1\-@QH&-5K17T#A
M278B%]+0KP_AO+:9'-)187N*S_!PIC<VB7C#8XJAZ8P4#)KU$]$33FWC%8Z,
M\*<>W8:*M?0RU#&_:BBZFQY]3E"=3/V,EH8),_F#$U-=JBD7.Z]QR')8W AO
M@3R.3@/Q"[-UGFT^D\525NLY['T;K!=T)V*^PWK*Y,K"R:3'0L<?I(C<$XX7
M>Q8SVCQN*@4_^<B^;_ZE+V:?W\,NBR/QQB.J FXO.2-1DT5:7[>]UOUL>K++
MOR?;3[5E$<69PEGXLD''YZE>1_B@7Y /[*N0VY==@'-8:ED::H_\XPL[MN4(
M,GP<K8+3\28$26(#%6@8NKX.]UKB%,0MF8W&M)-E;AN>^[3GB;/=QZ:>]S'B
MX6Y7CJ;$&(FD?#%D9CK/TH.1>W/'<.=.@7%Q6;-]L[@;'M$AE^C$F=/LG>TR
MTO6BCX*NW/UR050OZ\<,C(K"6J Z)/4:%4U?$L6+O<*+G>F)XGG.PV_>/GP_
MCNP61<K3I)WM[&Q6=14\:M_NQS+#?*22W21@'SES7=#7,ON^0R695Q_ E%Q.
MH1//#UYR"+A48Z>D&=Z8L:>G+3>>3^;SD6#X+6W,O&I"5Y,\_TYR:[H;4:%S
MZ"_T0LES0KW?/_#V33XP=_P@6 MJL\TZ24NF?0YS*MIOR72<]T-I2)Q-TYA.
M:SY^Y@T5LW#J"?[/>UN46>R2,@[DX9/3;R,]])@U_=Z[N8FHO+\W3LDUPZ/<
M8XGG%:MF=>A>O&\9]<7+P$</\NC8;4AW3)NNWJ6SJ64[O7<N[464N'5$\VX[
MKBRQRW@%D)23,>OG[7DS)SO>TS*3C@OOI+G$OI^'X\YYR_&$4;$/_*4L)YP#
MP[)$C:=V%**+7A?K+ 47S5UZ8]R5>.?SR7"W.AFN8Y)VJ-EY*MX/IT>^S*E(
M%Y89)CW)Z,6K[Y/]$ASE6C$!\9R.GKOD!D::44TL24]H.(AJBBHQ"L7XU?ID
MWT_&D%E]W;$"W%1[DG_/I3JRB@_W24O;OA^S^\;I^2!LS\YM*<)3LZ\^0YNF
M]]<)E8IK[ H)++9P S(?08L3FE%.8I)Z6A;9E<<&7"M?0:^X(&?I]OMHTGL<
MSUUZGK0_]X5W0'V*TIS:M#XM-MH_8060*IS7.)V>?O_^$VF-Q=X9@^,S'GE'
MFCY>%)SP//L^_[&;5""XY4Q#R_%N\BDN_>X[;_+TBBTC7P>E^6 LO'+C'%L:
M'-J:=+_"RBRN$P995.120KEU9IW-@$5HB9)(?Z)425(TL]$]<%5LL'&:C:19
M;QRLYG!'1:GVHNVY[RFC7/4=%@YUF"F'H::IABG><\[7.)<Z/A2$93:$O[W5
MS.W]WNNVZ^?=3P.5OH(["\?CVF865*!G:]-='[UP,$JI3=[957T\CN=5BN((
MMY7*X^'LK/V%'I4WKV3@VTJ/3AY65KCEQ0E25#4/=:ZGXW6]@UQ@_E G_AZF
M'!O@5#WD;A4>>>:ND=Z(7IF/N=*19V..+'5]737JSC=//*XNLHL%507G76"Z
M]##DLQ:M:F61TS/Y*W,*N&\<8Q,'ONX< FF?]S)RH+Q3UL;LC[(O'*NS>:?B
MT^16[15#JR[.VUC2Z:[:-<4WU6YS=>F\Z^Z*XH"7 ?4/Q*8S3%]V,"K9';]D
M&2)T :L69:+3<OZ+.I#WA@]\)NOB)QA(_V1#6M'(TQ<A%<^%GK26]J.F]1[B
M>/(;H:77_%#<$A8%8^+RUVV<)IX?%.05%NB#A=$!78&&S*%<22C%NHP17U9=
MI<,?;*E:=F1KBPW2+[04<UAK7O8IV#$AJD2Y7;$K4,G+K*FE*->YT<:]>L=9
MIC>:HQKM$3W;$#IZ@6=T5'2%/5Z5)ZD@;>UW%C/>SHGK+9#^U#X[_VE>K*WC
M*?K L$_(09$K._LGJ#DUJFR0&,8>,^U$+ZP2M+6^;SD^K1';6(>#4F=_*N^F
M.+H"^&@OI;L^W'\3[UE9",^PL$:SMIP7JKA1/<'^FG(BZ40<@Q?]<'JFO^([
MW8J^EEN(DVZGT[[5>"U)36:EC]I?6*9_H'9C<MS2QG$NE]=>>L8MJNJ$IY&.
M^TLG+2;Z*[PJKO[(RC<2ABZNYLG]GZZX1^0\J;%]T],3)>E_WNRZ!T1,]TC?
M2S8CD_>'^,^];F9P=65KP9G;C6.WFUCYJ.>=MJ&K,I\T9/12/39[,_^JTZ/+
M%\#W.0:J]*QCSO>=_9:^6U1I+N0V[GA]R?V]-?GR<=AK0GF%R'?=+H<-('0/
MFYW>\+F-70]K'7ZG7F5>$D'#X-9_I]"UD45>U#FHV(]ZKS)-PENET)*D.V,7
M)D)]=FB5(A6L7YQ*%K8JIO[Z#*FC<?I"5'US3KLSZ/W-8XZ'M,W+1<1>/>+^
MX&DO"D;??]56YXSDKG6>5]"<L)4#QQ1=;#.A_^CUCO>8UA<],UJ3UZ^KSM8*
MV5*G+8C7"6E:[:3HIDG.;#YH'LW85/_@Q,3>NUW*4Y\S+N#$'K_I[F?-)"3V
MX->K*V4^B4K-VE<>=CSP([K@]^J[C>J.%7^/>1ESUU[5FN<*#UOOG3LM-U)'
M^Y-5.SCA4Q="0 ]IV'>W=QM;!,>)-.A+U);/[/)S,8^UJQ&0%7B>QG'=B(HI
M_N%R^8?44RG\DJ6%$0L,20:&(<E1B3.@N,!3;H\#AC.K'>V2DR2,CD.O?Q)5
MO57+4D+M,^?%=VFHF<\T][YZ@[+O 1AU_4UQ]KU*W:6OA@7CV&[)^:N60B;B
M0W/9QN&U;_K[#^95.YI'?E+\0NU7>F1W49&JB?Q>E'VVD_P>>UTFQ?I$GA5@
M8-\#?TKSCBP+1&/D<5UHKMVC$=&FH;Q^G8:&4RW2'"-MS#G^E(&ZE<L^3':C
ML^VISK77./2Y?#&Q.AIVFA=F:1+NTBIVU@I9<_7V'+^[/!F^(&?9%/SMGN,2
M5>BGY 1IWPZ) RW]K4*/6Z^:?>=#!\9!]N+CXIEV[#6[?5]DQJ[@EJ-B*R;V
M^MWB[19A?G(X('BQ)UFEU32@)R9T6;6VUYC3HK1!85M92T<#6J0:VZH99"&9
M4##)8,'3KM5K.3@NF6F2_!H>!<YKO79/0$R8V5JSY%X!/>R^I:MLC4<*C*9W
M,C.YBO7T3)UPA*+WK>\VXGHMJ.:NE'L%Y>=N=$K;F)ZY-M/+G6ZXCZZO0SSQ
M#+ZQZ^!B=^CWT4[3XZTYK:U1HTROQ_DT:5$)9&+63P<.#1YW;VF$S+Z]$G-!
MYK'"<\&'[*;-E _=_#\P%J(;NFA50R9=/T>AVI>M.[OCZ<DMNV.S9YR\2@X'
M]%@8!"YP?1$12.X,%1-[@172T1J]QBHM+:U.B>4/<]VA]X$[Q2-CS]S1AY.+
MA9SY/2G.(S039!KSL'N/TI[2DNU;Z'3^SIUR5L7(AKQCH>85Y%6\C2VB(#KS
MI"(= (LT]C4RJVB\$CDPIA,\RAT$TM'1B[J0XK.-0N5RJO^]VJ]IDM.C!]Z$
MW1164Y(*LRBHU.U_$3.?$^]T4L&X@RKO.[*\LM N(>?I5]V*CZV7OWJP7'#^
MLB-0A>ZNO/"K!@ZA+QQT^CJFYYE@9/%Y&44U!O*#F%!YOMMQ?<[O>5!'9JE-
M?-SVIUUM"1R3:8Q@C^1\3MNG-9P>$^AGS,CIQ'*BI>EIT+4*)=#+U& /LOQS
MDW</R&<>;JQ.&(_HKBIN,^D\R1G&-O?2F4K'1%<O]T66:\]PJCGK?'LRJ.CH
ML&LP'))4=&;[CM*:D[PZWT>?4\7T"AW+]WFBRJ[$&9W/I6*<$(4)?YPD:B6F
M O11'6F/5+4U.6'3'M2P E!([-$\Z7ZPK,2',FVOTBL;<DSW56)C+!(;0ROA
MB1PD3ZP?=,GL?%I!6L&)U!VI>\MYZ++9Y=*\&LKEWYK>4;P\I+@"M*?>SCYU
M^%;6%8\+;&T'8>YWQ<UWQ5:+-699:Z(]ARZ+7%=$3T1']98K[=C#I*7-8O9M
M.:8IF7V*-E\^&GI/8M_9K\9L,F@O#A'%5@Y1K(WNM+WF6.+^C^PYI]V/>?I;
MBT^1L8'F??W"FY*$]SUYCC5)B'R:_9BK\(,:+)ZE)P E-%M]=T]V<?)8$[YM
MC[87%4K 0#@P,>TDW2L5M[U/DNQL;%'Z[KIZK'0F46X KX&99]K4$8>DRJ4\
MU^:3ZKUWL\G!RWY2Y8]J\SNX5X EW"$_K<9:N\"X7!L1@\MT=%&%]V+:7IEA
M>/N9>1S+QN>O%6==*;*#O"YJXXA(C@W )W4I38"$+T!+SWY.<_4)264)YJV5
M!:7DMLUX20WUOMCU8%M;*0SAF6@7JQEQ/(+[\C:_$?T;X+")IP.^QKN]1AM=
M#WC&S-M[#+8QY+P0[7#_<.?*;D,CLF.3G5GAUF97?-$G0L*C/26*1J_P+IR9
MFB5WG3/7/(>-=0WJFWE>*E*A$]@+%>O0F7[($BCI?<Y!3"OC<H3Q>,) U&*T
M_,-JRXOJ-KB)NWLR+6F;;?W8[BKS!L][O<]M]+_T/"^=3=LNH6ULX7,W+>_5
M=Y)CQF$']YIDZ_BJ,+/%A?BDE?S8R/FQJV,CX6!KW^+TP=%:,)H;%*Y6'6^4
M'IW:CZ"9NDQG=)9^0JYL/Q\#;=CV'OY*)V4[=\,'LF=N]Z?VI?;>5)T!B=V6
M[RN6;#)RLM4$"21';&]A98T*.<2D\21-[_*;JYZ![>^:I2E&;&RBJC[:A%_K
MBA9.#+_SV'6VF;'4HTAXCUF2'&>4=. 3F#! ]^KXCD@]<OE))\=A\5:!F9+H
MIP'ON&GYJ?930JQY'DY7Z)I$4<+SJODZ/4K:.-T_J+K;<(Q8:(WHL94H>'MY
M#>0,#&=U?)MI M6?XI20OLBQBY$]*C%"$40_*:>F1TYK-4C.W [Z^ VMM;P#
M[C#V]GA/SLL47@W.L+;S,:\ITVCX><X]3QP^)";/>/NR96QT10JO>.W8@AFK
M IF&ESJ/3'4\5T02&2<J7_L<[I$=:[%]M!)"'/2<:<1$,FHO !$*K;5N$)*3
M%JI+O*OXXC4HDR8B0HLVV\:8)6;AH-OT/(C/76!@^YL3BL-4-6W;%<_0D+VX
MKC>;9VN3WR)H>S^S(I\SIYZ]F^HPTR*9=<'='53XA@34>&G&3M$<)T&EJS>6
M;E)1V;9IO,^Z>^K#03URFB[1%:#)M?R[4 !]$ES=$5[VVC1".*?7/_;L4U6I
M$*57GZQE[^Y_B_@4SGG46SFPYZW9M4;Y MGA0Q/T)G3?WSQHY0V1NV=BC\"H
MB>L%QD?,S\7ASYZ-? K0\ /DA(%>3,'0^D9.BVWQ2]LLZ0L@B&&8>?2^U"\4
M:7(B>N0*QM8?G]@>%=7W8-RY?<"6G^>>NN8-U2,ZF:(V[-&)HF*[^(,#]\]&
M47F"K\M_3K2:R$?571'6TM',%%(Q'++1-<KA\;8L*S;,Y>C_'/5(&KUS>^!Y
M->&4283*<]8PUKAO#-\:V_?1EHZ'B PS^-2>;)UJ;I$2B)Y0K"^M#[!2882D
M5V!MX2ER<M5Y*G3Z1T6\%[M"$\T#HZ@98SZPUF#0[-15G.IB55%F2?OBHO?=
M$8YLRD];V[946_GT_P!02P,$%     @ +H!T6B".WTDMJ   DA4! !$   !G
M,3@T.#8U9SDV9SDV+FIP9^Q\!UQ45[<OML1H-"$&32Q?"*A11IC>$###]-XK
M()ERIO<^8XLF&D7!@(**+:(B#()!!44LT<2&L8,%6U")BKT;ZSLP&(TE[7[W
MWN^]E_.+A+/W*GNM_5]KKSU[#T^.//DIXET&A4Z)Z- AHM.Y3N<B(IXTI6_6
MN]WV1"C4ZDI0:FPJ($%MLT#]2CL4G@"#1B2-\-N5:A/@CE8!.H,U.>9J[::8
M:(,F.4:*9L/8=B*@-]""3D 8Y(C409,:KXD9D=(MR9_HM]@M@%L9[;>8K:Y$
M?W),F_!$\/?69FA,=!N)VY0<0VCMB):Q>=%$FQ.(QB3 XM4P&"(:BT^ 8U!H
M.'Y8- *&@$%A."@"'0_')J)1B3!8=/L3D](-_)GDU&@3!21*NSKP+3FFW2Z?
MSY?@0R;8G#HH'(_'0V$(* (1#U+$NP)6M](?;W7%AH4\E4,"7&JGP>XVV*S1
MK>]*E<WC3HZ)Z1;]W!-6I%'_JL?N<9K;M&C44, ,6 "KVP7Z$ Y]%1]H^J^,
MKW3\:YBH=(ON]QEU4(-%]SIV-OOWF2V65W*ZW ) ^_N<+E' #D %@,OF<:H!
MD#SVU8+(7O=?$43V@FY\I2B#V>QQN9U*M\WY:H'/$?R>1T6\/W"H&VI_M3]=
M;I+!\F>, <D JPM$D^LU3J%8_Y13*+;7^*(5&'^$BE?QV36OF56P V1#0G^-
MB];0T*@3M3:G1>E.4=KM9H-:V1H@4+O-Y0Z'2Q+T&<5OV=P&MQE(^<T V@*-
M8';_MO5IA]G0.L)$L](*3HX_7@-HE1ZS.R9%A\> _R5!PS0O2(2^++)M2"]J
M;QV1YEF(_Q?&Y03L2H,S)H5B, /1'*4%2'R!2>.RPV#8!*5A<*R?,%SL IS6
MEZF<3AP2AD;#VFA8-K72'"TRO$@%A\=SU>YX,!&BHF'81!0B$8%L8R +1:\@
MCX;#GM$C$(GP7^F%;79'2P!G*R*?<2$2,&W]]&=A\QLB!#H!EA >(]6IM.L-
MZF@W",KGU%+,-E\T4:]TNMNHVGZ<_KPH&HZ)5IG!-23:#?C=T6J00*EV@Y);
M?[7J $VTVQ9M\P).N]-@=2<\XQ7I@6BMS0Q*-5AUX&]@/HU6@@N$W0FXP*P0
M;;!&NT$2C4WM:4VVB6U,SX;3ZA17?*K-K'EEA\!F45I?ITQM,]N<?TE;:JN%
M+[01D^'@.L5.QJ.CY<D(=#0S&8YXB02# "G@*)"BE1@D>8$";(&]3BZV52X<
M),$],R3^O_-IT_!:M.L0."L.\6]'.RX1ADF$X?X"VI&_TO_/HCTN+JX51R!D
MM&:#3M\*=@#$O0&$NLUB-P-N("&:9P:4+B :7! \(+I #'I #[31A?'VE%(3
M;0><H"B;&G"Y$D#)_P3&/X'Q8F" 6$?!_D)@H'^E_R<P7A<8S_#_8L^O(?-/
M8/R[ J.MGOL3@0$.'_'[@8&*9RN=:GTKU-&M%1*(]C]8,Y#/<R#@K<'QW[YJ
MI"J=+\9&>T];I03#O50DZ95> *R0W*#5!JL)Q!E8*2EU0%O%%(W P1*>!AB%
M+HLF<$C1 K) S(GF"<@4%IU*$T4+B0(Z3_1/G+P4)T2VG/FZT/E_.S!0V+\:
M&.T<_Z.!$8Z(_\W-PS\0_]^'. :.1&!1?P7B^$04+A&.^EV(_Y8#E@C_E>-_
M%.+_U$7_!,-_:S# 88E(5"+LKP0#'"1_RO&_\&%1M,ZI#+A V\ 21V4$U.[6
M$DC3UMH*<#6(&+#\<45;;!J#U@!H_LGY_\"\%>9H6"(*_I=@COB5XQ^8_P/S
MOP'SOW@.\>HSAR2_Q9[(!MQ*C=*M)"G=0$HK/N-AR'@X2M2.:RP$ADY$PI*@
M+]&^**<5+8$_)>49Y0LRB$X ;'V-#,SS,IZC?)4,FU-DLYE3PL>[SX=0:]A$
M#Y$:K!J;SS7T.5GM'"\($^D]%I55:3"[_N)13>O_[$JG"V@]/4N.>7JF&/,2
M0[NFUL/51)]!X]:G(-"8MG$]U_1[3'J@M7I+0:&>,;4W_1Y7^UD9@T>F/N-[
MZ0#M93Z#!4P-*5"\$8HB$/A"DX(AT!%2"3HR04A(I1,()"B63W")J7JOAHH/
M*JEX'YW$]K )!!3?9.80(#!"VY-* .E;'S*A#<X$?BLS^/ )J5 (BD R44PJ
M!,-,H(K"#%JHBD '.W5\<BI!3$[5B2FI.A,UE2]G$'TZ:JI.QR(1;$RBSQ:.
M3%(J@4TB^%K_\4D$%(],P'%)J6P1)94O(OM]*JK?I:;Y<=I?__G(M%2?FD,B
MP.2@!CE5+Q90!+:VOC:!OR'^B_^@.-!0OH[  LTE^,B"L,D$NH# 9PM T\@$
M99OU-$*K=7PRX=G#IQ!\="KH%AJ18 +- _MT=-*+=.T^)!!!:T&_J.E$OHT%
M=A-!!22"CD\$VT"/@(*L;'"RV +0_Q2Z@.[G2\A4,H)L4,O)8K:=JD_U2_U\
M R\UO$:Z:7JV7V' $04!G9=LY@<%(I.#&9 C>42.F&\U8;A!CEXC5M!$))B'
M3F?8V RB7J?0,T#7.80PB9LC8:8Z R@HC]PF$,X5P10R*<6LE,+]&ID9+U4@
M]':EQ>U22=%>.5( UU@U*$!FQVII<(@6R27KY4J:@6YA&E !CM$&(9K00HG9
M#L@MBC:!#I65@0"L:*;1SI1:[!B#W>'PN)Q*C-<F /T+FD\GI?)!N/#E9"((
M"%6KS_1D4BJ1+&2+R12Q@*.GZQ1^G8(<:!-H4]%\%#9-@!)RB!0)PZ#VDH,,
MDH"DTRN%XH#4(,>RB*E(GI #,,@ZOT9L\NG:3&88%12J06/24,1(G(,;] 5T
M]C:!, @OJ&<(36ZV2(SF"<P:N51B5\DH<$ &%Y@5%HU-*;4[552X1X7X(_/;
M!$)(9H94:D8;%!:[1VU58+0F!]=D5RJM#J;%X< $W$X'Q M5@D CM2*"W HQ
M$HZ Y3$@  VM16B@@)3J%,JDYK#)"#4\J+*SU B74R!+=1E\'JK.I",'7 ZU
M!B*A8E02OP1T,0IJ-O, T-D(P":4 3:,GD$BR1%*J=M/Q3F1="-;0PTOZD:#
MD2*Q2!PN%,(O$<&,.#PT$(!3$2X[S0LJL4!9+))"Y'/A;$R3$654&0"FGHAS
MX/ Z@50/LEBI9B3>Z@ L4B#L0ZG5+W7C4VEJ!)8L9A@M?*Z>CM42$4R;3(I7
MN31$F S/D)E4 3X=[R5*#$0S1!)DFXA:I2*5SV$2-1"K$>:7Z$T\7#A2@B82
M1"+6>Z@JL=7HMM'T1J/'XK9;I H[RD_GB80<FID@]5(,&!9.BH PG4XM#JH-
MN*UNF8<'T^&T-KW5(T>ZT7QY>%+@"@K;R*8PR5JOV$:1NP P7EDJBA10*@ $
MPH;1*#%Z@IU,01)-.+Z:P/&;Q&PWGXF%<9D.KD-I5F($-C?4X0X8>:HV@1@M
MB:<1L:@4EIG.AQE3 8%$"9,I[52FB^&"!O%0)@9 HH-(+$+C<[AP;@O>R^#1
M#4XU%9&*EAJ0;)$:S50#)(O#1 N7Q5*^D@&1:TU(*5X$%5@L,E40Z64"'%M0
MB63+)5BQ7F'6H.EF@5 O)QII7K?!2=<Y("Z$#Q+P8H(&9Q"M#<)P.B?-T290
M[_$Z-5:.7>TR,=QHI\( ]V/4=K</[\')' *N,<B$*4T>C@^0$)@HAQX)]1'5
M>FC 840[\'BNV^=@2MQ>A\FO00O#&=N2*J0PU7Z)(,!*Y1DH5+I3(,%PG0*A
M/96IHQ&%1A8,0R$*# XI1,5C:\QH!8R(ACNP;CO60T2PA1:$FRP5 @*[7:)O
M$RB0PQ0F$ME-YSA0#K]6R L&H02B%RZ5!MU.D3B(UWK-:#Y"Y!/145J8GBU'
MJ.T8IHNB<F*L5*^6(E4J>0Z)U8$P2;GA;(/0\> R,0M@8MP0/D$%0YO(!HE-
MR(2I_'X)6<#TDK$DK$B+$W*97I[=&T1"69X@W"AVL^!**1KF4(D4#%N0 ^*8
M$YX4$) 2.]5@5J;:>%)TJI2/YY.P&B73I<=Y(5H>$VJAB<EN#M5*09G<#CR6
MHF'XR* R) MAA$DL9 3,)=*2Y1 2*?P9*8L&SC-%@I=H]'BS%VZD2!F QAOD
MX=P0D48$0_CA -)CD8EU4H@;@1,*?0B<,N#W680H")MK4*/-%+X> \. \X7G
MM0F$<F4X#U[LL;%$0A8*8U2+1 BW1ZS7:[BI7H&4@<"K!1(91,X(*  4@@/Z
M+.#PDE4DK!"*$X)@!7 0)=8!Z#"\=MA(]#2%A<M5FK$,K= OQ0D%5 Z$A@TH
MI4B!$ >U^^%HJI7II3C$?HG1CL-I+0Z4$>*$$AB 0 384VE<$<VI,6$9&'T8
M-C"FF4S2*E@$O8=%PMNH-J(3E@JH$'Q 2A<(W32ID&M3&?Q2N]2&X) ,3BJ4
M[;%K+:D*)5P%M;$$+)7$36'ZB1B)/;Q7<&--7&R 19<C-1 :E=,:0Q(LT<MT
M,%U"-R\HQ6&4)AR;:@2D&AZ<)V:P^#(RWJA2PNTP(P(;$''):(K"PC9H)5!A
MFT 3B:DCJ3TVOX3F12.@'"%7223R G06'.VDBRQ2)MZ-0IDM0K$@0()367Z:
MR>FD&ZA\#I^FQIHE4CX@QLM K5:6P]@F$)!#60YEJM(/6#QFOP6E]]@5.D#K
MX-%A))<#3[:Y.6X\F$@I2, -D6$1,"7,J^*B/2HEGR#TB90J0"AP\W5&DY,?
M7I=I:DD@Z M"B&0I1:-E0TP.FT3NA$O$8@+5BK01"% T"@6A:GU\MYYOA5L#
M6+6,3 GR%#*RVZ\T6]P**RR 4Z ,*)L_O 3(?1*I#0/SX]A0G5Y%I$/](KL6
M1_!Z\% ,GX6%.HQ&E *:2D10;5ZVQ4IDI&(X>)<-3!)FK1:@0:E@,48+0.1"
M#[1-H)]E1T(@*BS40T,BH1(:3<<SXWQ.(]H$@QGT.J^!ZX%8D4BQR@C5<'D$
M+0NMEY&"#+M#1^#+? 1$JQUPIA9G4 /A)0 B"Q(=2D#)88G)5"X^%<V!^E$R
M+\X/1=G]*!):RV9ZH#Z"1"F!M@\:"24P;2A<*LYKH8@M.)^2" ^887"WAMHF
M$&T4V&SHH!V.4E",)J8+PT3:)$27',Z@ 3H<&R"T:G3ZT7:8$R[EV9%NHHT&
MP5&P",;S&OT2^]-%B@% \70*%DK@B-5A[O9N<VM;:P]<T,[GU@9%=H&"R0"P
M'#'H0YW,J]-"F.UL3F_X9/$WMH 3T.9@"1+"=#.A2&2[-E_J,VVO-5\:GF6(
M4L,BFD#O06!^D!'%0GJ$6CRNG4BF13E@3JA6TRKT-\/%0BE2LQ:+]8*(L!.\
M6HB#&\XV;?,FL>-@&!G&8(5A$3JQ$0H0\5B3%B=^62P,M!-*H#P32TB5V&40
M"!8)M8=]V*KA5TN54(M1B" 0_4@[CZ'Q.D#?TT%G>ZUA,#E2<7X>6H+S8W@\
M&[CN<? :C$JC%O!44+%;8$2W"51+22R<6"UD,]DVKK]=L9\*AS*=.+-3"G !
M4@"K97'(/H 3I("KC$*1RJ1"P)GE\+4^C#QL@P+/ H';)A#GYZ:2M!*FB015
MMR._?3BMYKP:]>#R'[!#&1*;76Y$:[Q>D97!#AA8TO"Z'' $7$J8':[D"+5J
M4KLP)HR'\VH#)AA/K-**->"KF*7$N:5HG]! D\IL2B8'KF8[27B$)T@PJMH5
MM0GD,'ALCY5"I=F0"!3H+Y@3BWT&'X03X[5#3%(1$@ZERYT*FM'(8AH#;)D9
M7#4Y$B&;BZ58U>"^D.$WB%SACZOL=#<#RH8&! Z<3P\+BJD>I )I$,&<2K1"
M:C(:3!8%107SL#@8-<E%((GQ'IM3P4IEJWT&.,0$M0C0++A*0N<P7>%E5( 7
MB55FGECG1NBM!H493Q?!H8# QL/:=0BHBBJE\L'=)$O%<#F$!KD7Z^:9>'"%
M6 ICN20:@],EX;.@!"H(<(X\G&V<?HE*+T$PG2*\$Y/:2@&2>1%ZJ!7,JIKV
M=ST, J7(Y XL1:;QA]L<$!8$)T,;"0Z.'V1W\_"FL$ ZRH%L9Q-!%;P E^GB
M0MDJL8;M\K)4;H?$3U))P50F5GG5?"K&R//C,%2Z0(0S"I@&!QZ B,PD!EUB
MY B5C#:!,FDPX"#)> &LAQ50^N!$K<# 0-NP@)@F\I/H)B_79+*I$6I>JDZ(
MIVK<#JL<'B!K.$XMRJZ2P'A(,=5%E(GM0;0ZG!P"4)/?KH% ;$J)0^T#X :I
M0"8E,YU^ \472!7K!7H!G6>0^+P"P(.0D?@*OHIMMR(#4!H0,-*"@!F00CD0
M'2!'V<-W/6$6%-OO%AJ03+;1!E-QO0P^("<H;5B'D(3@"JU&-J"26[A>&8RB
M1ZN\6 0@0<E52I@9E,26:/@N!4=,8,+E&K<_/$*<0\<R$1 :FHF-M,KP1(Q"
M[A=J+0QU0!"0NKUTK03,K':)P:*GXZ5"!1)MPB$E%K&0C8'980Z!!4+QDR%&
MK)0#AX<C10;.E#F(5_+0YJ!20L#XA Q%0$DT0>T.'%^.LY/)/H;:+<,"<"('
M)]!CU!0H.F""J&!!G!<*UF1*J-WL9RDP2(A5%/[,@2,48B .MP)'P# Q AQ5
MPH02E7 \SJ]&L/U<E-U$4AK16+!FA1D%"@96I 2D*IC$9)?I VBR&^ISIYH]
M!I^1P36&MV9JE50A(E*,%IR+9W$&&6 BE7'14#25 Y5QD!"I'QKD8U2XH EJ
MI3A!,%I$4 <:R0.K7+8*XN&A530HA\@+<D40M:Q-(#C[N "8$R4!#P\B,&KA
M?BA+#D7;9&$9&AK:BO-SZ ZKA*7G^PDLP*9Q6)T>@4'#,4)!Q\*Y0JB#Q619
MJ.BP#U.1;BW7$.1ZV:D*1BJ9Y..0H 266^-0J;0DK]OOX.!\*#@ 8>&TC"!)
MHU)H_3@8B0WQ2G$HT"P8WZ,7(/!"A,<K"6=L)ARE@[.U"(<$X= J[02.SFBD
M(_Q0-D?!Y=.T=)Y.XK/")3:5R8EVH,!JS&5(93#,$@792+#A5"PZ&LQ63))1
MA)5"PELS-HU$]$.P:+ 2(N/$&!XV:(9P\5P>$W KW22T225P6L44N#05!9&#
MFSJRPX$2LP&VCL&0X:U:K-["<[C8)"/*QPT72VZ()2C$B70,E"X8Y$BQ'!]&
MJVT/;@^J->X]?HF6 @58.+]. FX$B%(<PFQ7\= &FMFCL*>R: #@<(G( JPZ
M/"D&@,WV,N!H$H8+D<DY1BW)3S?Y83(WG*/AJ) T*P9,80JA@<B$&_5&O,!.
M%#-E8K4.*5-P>3RU08_DRM1T@E<'"8<>GL@S!#%(#U:(<U,\*J&2BW+;)>#&
MV2#G&DEVB51LHK'Y.AU,*G(BB$*4RVE &LQLL@G<Q]BY;D#(#IA2_7R'T@D/
MGT&@_!R*S"QQHKT>E )K\>EQ?IG+B#![Z5"N$.:6$81$&%NO,K/4%(P9BK1B
M83@CWF25NRV FH[&T2$*<#&CL5E\K3F\O0TRT"8X24S'*M$XA$P&ARA1;!$)
M8U1:J"Z1WY$J4#CT,@FX76,YQ5!*0&5S*Q1J-9]%%LB\3+H)CT4HH"XKFL91
M(L+Y,!5MAGFE&H'+9( 9)5(8@#.:R3H/7"]%@;6LF4GE!,"=L!F)8WOU= +6
M@+ ;F "?%R0;34HI#U1$LM/)*+X18S"%SX=(* =<P[#;^5 ?5F.$,1A(IP;E
MXJ&]")L"J_#+R!)K*D4-,E(L*",8S4ZK@8P7P,6I5A3+Y:5C8301DVB6^IC@
M@M,F\.551V@5NWDN/%]G<;,\;*%/2-:;>"ZE3F=4DQ4\&MO',5I\5H*00C/Y
MU5"S'JUD,- R EY/#]<V4 Y7X<41F%)10"V"B,"M$A9JED#-8)O5HX4(#% <
M3 X-F$TX,]0$I:&=(H@41*";JP&K-8(1S&9V/]3,8J!9X46*0-0:<4@MSN''
M>;1!) U*]VLA2K46+0P 0FC@3W9*:'XD-2P02FD= NKY(7@AX&Y1"D5CK5"3
MO#6+\G!V!8^A1?/\$*4*0T%+8%H!$8L0JZA*OEIJ,?$8$)[,P-6%1PCA!VE!
MI04082Q0DMTFA]I%6B85_[L1J 4P(KL$(N;@%3Z9P.B@!WEDDSZ<ONRI/)J)
M)-+PM;: 6&%2&]QT)@9G!<18MY3BM\'-C(#$Q*(B#6BQW.06>'AT"8N,I3E-
M>HN%*V RB6P85H@E"=T<0[B<@_@,9(I591/K#:FL5 D2K%&$ $1@I@<X5HO%
M)#.!%35%+!:G"L06'8434)J@0I'!:3"X)"P"V:%T"+EZFT"LY:LEX>0 IGP3
M%"P?]")X .YHKST<# /4 X/PH1*S0,7WM%M,\.+=4+P<^MKJI4W@WRAA?E.]
M$*A@56( -^0\J.+9R4'X6."EPY"_<$CUVM.6I+;OCB72K2ZWTJH&Z*04L"'!
M8- DHC!@10H'5/%(C0H1C\.B-/$J#0H?#VCP&#0>T !X'+9-\&_97Q)-:C\_
M;!>M^8NBGV-_2337:= 9K$KS<S0>#R@?34+ <'@$"H],I9!2X7 \'$7 H?$P
M$A*.AN&(N*>R7\'_D@X!8-486D_VB&:ERY72_H6EIQ)>Z'W9>,!I\ (:BM-F
M^9.'5DEM7\E+-+P\(5@5"@Z6<*IX%%R+BX=A4?!XG%*)CL>IX "@Q2# 8A.6
M!'V)_572-2_/R5^1KGF5OYY)M_WM:7DM_ZO4.%\S,Z_L?2$8?CLU+\\;S>!R
MVYR!5QQ+"@''O^=8LNT;DXE*==NIL4L)#J5UZ,^UO9[I%># ()0:M5:ECM>H
M,?!X+1JE!:</I8['P@"\&HE1JY1(U%/YKP/';W3X]("U]9@8%0^'Q</A(ABV
M];X1 O'TF/@YJM<+<=FT;I_2"1!TX#3^B?/B5W&]7GK[1=$4Z%/&IPU_+E/^
M9TS<G\N%?V/B7G='X/_^B0NW_C80GT;URX&;]-S7A1.%;J73[;'SG#:MP0RD
M\%KO%B=!?X?B-7+:+S4(/:I7WX3XK<P7J'^;;40\72)-Z9(87 :5&> ^O?&<
M(G)Z@#:K7D?P>V)$3J75!2(:L*H#*12EV?4J4;\A>ED:A]=Z3RD%_BMG>\/+
ME&REO[5+: @"?WZ5(QDLB;X4% :7@$8@L6&0A]M>1:E/P<$2\"@T&@9[2JA_
M):'':G"G\&R@@UQ/"=N:7H#*"\-^A5&MW\E^U;V45*7NWY5'*%9W8NLMK]8+
M=2G/W=YJ'?AO^GZ?G:*T&,R!L(#G6=O;_XA9#:2\I+6M]?<96TU,:?T1#7^>
MLZWY]9S>\"4[H1N$L"X%!H,GP,(S^G+GZX6T7HRVN0QNX"FT7VS^ Y/!P Z[
MG"[(;'T2>)34X='/O;%_XXNGY/_=R\HKX-!Z9>]_' TO*OW_!0RIOP%#ZK\#
M#.'6WZ:,7_//BQGF:>;AF97N-B6O2C^_4W^F$ .M4?S[H$QA*UM79^4?TLF!
MUKNA?TC6=@WT+Z[3KS7RJ0>$/J5;K:<Z;1[[7_3!7[\:F*AK5=,VIZ3P%B(Z
MK#ZZ37]X%_X<T>_+:4,\['FFU\9 &PFQ]=ZM\J65YH_M_2\9_L(@7&WVMEGW
MBNNY[<8\1_3'$ELO2Z?P!%PB62ALYW>_Q@\O<K:6-J#FUE30E@V>M?XQL\6F
M 4U@RYGM;&WO?\RF!N,F!8-(0*(1>!BBG;>M\4^H#(=3"AR5 (=C,;^.^&G[
M'TL(M 7:RS:WM_^Q@+:OT:7 $T#UZ%^YPXVO1\WKXOH9Q;\95R_?#/__!%@O
MZ?R+R,*C$D!4PF#(OXLL!"H!"T/C_S:PX E8# K[GXHL9C+L[P"I;0:I H+\
MK\WHW\=?ZQ= GEL9E*\LQ=H9_K>"\]D?$?@G-G]?Y]/8Q"3@, @,'O>W8Q.6
M@,6AD##XWXM-; +(#/_/#<UG0_N_(#@1:/1_9'BVNO'_DWC\KT7C"]Q_.1C_
M:P48/@&/Q_^[8O%5>Z?G.O]@[_ W]F.OV7(EV4$6GM.F\:@!9_OGG#P2)=IL
M4#F5SD T')W0:O%OJ+H]KX[TPG?CPJT"$B6E&ZC[Z1\3_5TG_]N>?Y3\H^0?
M)?\H^4?)/TK^4?(?I:3;LS]'#E@UR3&^F!$I3XY%$"/>Z-SEC2Z=WWBCRQMO
MOOE&UV[O=NOVUEO=WN_YSMOO]GG_@P_ZO-^[=]\!@S[JVR^V?^_>T<.B8P=_
M,C1NZ(<?Q</BA\ &#1DZI%5(AS???+-;UVZ]NG7K-:1O[[Y#_O+SY+N(R*X=
M:&^:.W6(B>@8V:%39(<G/T3TC^@0T;%3APX=(GY].K_9J<L;'3MT!7O3WHWH
MT*E3AXYO]'CKC<X=NW;NTB6B0\=.G;M$OO'>QV_V@O-G[G\_JO<',02A6*)<
M5'0 @40)'$[7^,JN?41Y,S;'HE-S,:2!6++*_<7*58,\$Z[AU)K53=>)WB^W
M@,+[=FA_GJGNT*DCZ"JP#QK9H?6E2^<.G3IW"A. BB/Y@O=Z?0Q?U/E]0J4R
MQK$9,3YW?VS3M>M/&B/>!JDZ1G:*C!@1\0C.9+Y]I<1=7K>D@B,FCC!=6+]P
M?=&I)Q'P>WL&=>A3=>LD]R2_\;[MDZM#A_R_\+H\+^_]\BR4[O.?0R& GKRB
M^,;8&PL'/8E ?'5EZ+"N&]K><PX?#(P(T#_]?^"UATY%//I0LGW\ULMJR*X\
M;MOT+MO[0/HD O(@[[NI;6X9<GD,=L;=F3,C_C-?#XD$J74A+WJVJ<$Y)^/L
M@C;3N.AQ["4/TED=H6TF+6Z;90'O/_IUB;$O#9A2=P?@M\P+F7<4[)T][A0O
MY<[&N3L?U W/9)]]U#PH(N;_AE=T?OW7/^QHF+:E;'_9A@ V;U1;>TKZ1BMT
MJ^WNH/'_(;'^9UZ%9TJ&YH9*/YIZ<>BP>T\BOK[Z;8\Q/?J_=Z#RJC:]IJXY
M\..C<(JP+"1,O_E(E-=Y9!O\J.$)_>8_ZY76<.OKK9R*[-E>/EYT-#=A(2ES
M_<*2C\+3,Z#-D+S/(_^37V/3+GQ<N-!( 8Z*FH5:4M68R)0;X^_^)P'FWXF]
M 361E3\>NC$P:S+G8][H.4\BHKX;M>9)Q(]CD5-(:>,>;C^#FQGQ.T]G^K@?
M%SW(8L8P'P/O'!?(?H\V<L3ES(<KKC!CQC5N^B7S>,%K)"9N*CXPIF+PNRV/
MY]+OK)W]&F%3S+]\]>CVH-SXA; G$1N_8;Z&K,-[S3<=8R'C:H9-<?ZR=E/4
MIM>IC0A'WOW1XW;XCG0>I=NG?O@D0CPPM[P]Z%X]"/?]F$=G']$US&7[^US]
MI*7SM^%VY_V%Z8IA?1C#15.3+2V5X[Y;L[_R(^3!^<Z2;/:N#753:@(SORA9
M2RXZ<"LAU-"[MKPB/E\V[]Y1).!%3*.2SL6FKSU1M7+!M\,_&ZVZC.X_+VM.
MRN?MSO%4+&5.U??V/T#O'W:AY^B$^*B^%=LQXG>_#H_'>#]F3#/HE$P2=WVK
M3SJ;YBOV[>.*&HU92Z>$'@^>7W+AH^F]^.)(:<.,:?N2XBYLL+E*UC1J2B>M
MZVVYCG8LL09UW5=M<$WO&_SN:H<](SW"^."$"?L'%5](NEUW=EG!&Y3*$4 M
MYUK^A55?GB.=/3%C,:BUZ^VH^M6WW:M7[>T7%Y>_>P(ZLQO9)-ZS)9B+H$7T
M^-?*AMXG8G7,^3]3J:Q5U([F8G'Z7?6C7$3S[9BY/XB<,45%15?)GX)RIG?Q
M#+M=A?IZ;[\60VX9RI*^?!0M=/PF$"EJOI7953(F<]0&Q65SF84<XB2("U&F
MS":(\\3%VOB1Z4,&?/[F1V.:NNT%#O>>#Y'55:T]7IB3?2F[-^9RW&+^KGE7
M)2MB$I(^\X)*_@7D?OW#+\ H>;^^%:YY:RE%SM *V+_&3\H*=6O!Q5T8:%Y]
M<-M15>[ZZ:890TKO%,WYO".ZKK1>A!2M+ PNS<:L+<%XCR](LL1]LF+F.5S2
MX>KL442I6&T1JHIS8\9I*-/20SIOU*<70:^(/AH\;JL#-9%P0_=0VN%*>ST;
M:7D2<?.C:6<F-.F^W.E/5."-R^?/)TN:-<[MTF_/.F/B%A<N/[&KMMNFKWOC
MXAX\B>AV]< M;_ 1=UEQ<75Z8T-.<=[2JOZ*,OZ14>)R47J"3Y?KR-NYJ&S"
MQJP%*W,DN]G\?D 6Y0:^@E6T[.PWNE^1NE7*CQHTK ']#H78?4#L\?79QL'B
M<4<CZKJ5T:\M"M0?Y)$M!Q*<#0<3*P>.<<)S4_,V8LH:Y'7-JE!,S!6XP=H'
M4I6RM%96K@!R5E17D_,'KEVL>/35XJB^ZS,3K^R)J!Z_YSR;BEFV:K=4;"XX
M+.S!FKGRP*Z8Y!]=?;IOB.PYN6T,Z%FFRQL;Y)8EY?,_%#KF3B[.QM9<V1*Z
M\C.)??$BQZ5MA_C+&:6'I'3=;LU*<?HWBSPF@]I]@'0T,N>(22P6#L_W.3M4
M=1FSV?<6JZG[RJ5KY"U#]1?F32LP_&RK$XE)E.+;3R)^&?9N1']JMZ1HY!<M
MW8SWCVD:9@II7R]NRB_Y>0-_UT3CO6]/\H;;[?VC[;.XBV\U%UP=%*JH'CYW
M=G;.())L_^[&D^L?[CQSTE<Y8EKV=)*+OV/J5X.C4O8E1T1T['+E.E%3Q*A=
M2OQLO$;#%I^L&'4\V\1/,H:6Q6_1=>7IZ>;E"PY+,X\-/?2^#&M6?W2EN?'X
MJ7_U\0_X#DQ-XL@HL7UR1-^R'C\//^NLWT]I7A-;_7&I^ 2O))3CZM4"P')&
M9MQC*:7Z1TO4^9.S+EG)Z3$K&M_<9QHVJR2A(C2QW!U5;Z.UE"[9=IPCJG,Z
MJX1!/#8NN)^/^2SL2]*3B*IQ-S:!R>])A/%)1/,X9ZL[WYENK,DQXF6AV=3!
MB 6K]_R4\L7-RPNE+2TG^X=NI:\K<%=O^86_LCIO8;;(/$H_Y_3UEK/8=8N_
M9!Y^X_Z!"2?*!F9=6%8Q=+;I:#=R$DY$M2P>W<?<'&6?4C,N.H$G75>T6$+?
MDK" /<)3C>3$H"$_C<Z]/ETL%A_?^%YS[?#A*2D9VQU2QZ+%A4.,%X=^4Y Y
M5[.RJF+<D:S:[V:^/2;W'?7RA^[1J8,/[%P]%W=N[\=9DS;F-+VWDR#EBOLF
M1.W;,9TTTEPT?F#D1\Y%@$E_*HW5N-WYZ<JJ@9F/YYV]S<^DL@=O)6<D<;=Y
M-;E]USZ(^C2OZX4,VDIJ7S%A34Q,Y7H5L&-]UI3YY^94H&"'J'0T@/((1D_.
MA/"O/.@WK^2]\?\J6I>W@)13%.JZH'2FZ2PEM.S(LJ_2S\N'[4^LSE_Y?0YZ
M*H0O7\!>LN?2_>\*NF;7\-9A-U2MKMNF-NR$V(_? %QK9[P_K1"SL]>Q@=:3
M.<;F/C<[[6O-D)[P3N'CAD>8&9<=L%:8C_IRU6;JL-7N$_G#A?%?3:-8[J^L
M_?JMB!"*^W;/0Z[TC[^]$+RP=)$J19)2/#CAMHC$JKA]?!E]\^&N=]C>QF+%
M@Y@%U3/.78B;G9T[]_K\NI+2^<=F^:9'>,&9_Z!E0&QT[K[MV^H.A:KFI@UG
MGF;=^WQ'MP=?G.QU_O;\C8_$;//RXLNI,;MZY:]P3_TJH>^4,]>B1B"5F[7K
MIF9>^*7BZ[26(?VBB*6'\!E555^2ZQ)Z)6W*.]OSATY3FX0CO]_\J*"@*7E=
MT89/2FB17X>PNB%E^>('V$^F]=SWP04M(TNOI21/B8T\?[BX_QQ6D_"'XD\C
M^K_3=?3 S4502;#;Q0PR,2'GR"3]$F,,OG^]2)3QH'KNXY]\W[6ZA*G[<<35
MTF'AI;UC>RV15+?"S'6;J1OZA@Z%SAA&TQ=&2A3W1GKV*NHO*#+0\F-!'^UH
MWY;9^Z=4UM5F/KHQWCAAT\'T(6FV60\F+;C4=UT/.FTZY[LRR;*^/Q>+/[@3
M*KKY:.[!(=J?:K\T<M[]T*-@CB'W*K^!P+^G0Q]C7*Y@N<SC3[0I5I<N2-0/
M+/0MCLG&S&N^'OUAA\Q&G&C52,\#]]+JPIK;;'-.@:%(IMAJ<F7/4M9M,G[R
M\]/RAU0S^GAFUBFPU'FZ'VE?O]_LLF5ZU^4_W>FF"#T@DS.BB/>*=[]=3J8V
M2;LUG-HQ=?WA$SC%I.W:U2/1;RQ<N__HE<E;)X6&QL[IM_I$\>+&'#+WS7'3
M<S]=14@W<J+*[Z1=F;^(\6'94-MZQ?Y#!(BW_^&:\KJBJRS+Q^JPN@H_K4DP
M@[)W$#JYJ,E?.K[D?L4VXQ+1;E&=8_J6Q6+A6'S-F@[J3OD_G4I/0U_^HMH[
MLR!^2N^AW\SJYTB.[-,]NVZV2)3Y)&)&J$U:6V4T)F7$V>&7.B:O.@]_/"Z4
M1SNT]YOMOSP.T=LHWO;TS/V:=EY-!RBAJJS+\Y?^O'=RV>JKW:]L:EEW&6\]
MB)[J+CJ#^QD$=-7ZM-R*:ZLFGBSY7/'-BM7;NWEW$],\54*^^*"QGS-9LT8,
MD9TKZ].3LB%*L3;S\?7ULS9G=A7-^_@8Q*37AX8<92)2?_[QK-A9QG?.?O#I
MY39S8S*L[]]9]Z&QY?C9*;-9\- Y?-U:2E7IAO10R>0I=:'.WXJJ1J/(QH:9
MWC'4XH1J?UG_[ G%BWY,+ZJ(K*L_,>U&DYA7W28H,KQI 8$8+N\^#9>,G6[V
MN?1 /GAQTW;12"MCI=B;M%=[Z-&TNFU%GQPY]>:E$>26M$&]%U=*&A-RK\_T
M.);;2,T<W2>(HB9^8%_Q1T57D_K;5PA#MVZO'+5QX=HEV:&E2[;L[9C,WW-4
M=<80N2-K]G7KB;IJ1DOHP6H#M_C2K,&BG35&JWM%\82%\_=0E7M%]\O9#R_4
M1>ULR?",67GML.J (R6'R=Z"H5TNB1JH2FA4#JB:^,N'>Y)T<S'K-]5^%;S<
M)VU0_T-'8N7]8J,EM)J)*V/B+L=9&[</?MAW0=1R[+J1']Q:4+YD]:$3EOI*
MQ- #D^)K^OY<\\LUU\ZOBHH?6C-^[MYC!G_G U)#R[ILO'W9ZGK*D3LGS]_\
MUV?JR(PF90"[V)5]85,$_<J3"$6]?<68_06K5XM2%O195V@X[=9O/6K:GSDQ
MO6G M,&(M1D[9[Q1?7CTQ_J3/2V^4<<QC:-^J-JSI.!-4E[L[')7X<.J>^1K
M8MB<Z\X>PW7K#X[=[[-0D_/.[D*G#>CL@70[,_QM8]RR.&Q\QI,(9?6CXDL^
M"WVIQ7NLQ\J*C4OS2WF/!\TQR::-\JU(29_[>?X;I8<E%Z=>+<R:T'BB[S%U
MV8+55\EY@R@6]!QQW0;I6S48WXTK^"^;LB[T_&IQPTU)XX(+905#AYF/'@-2
M#LZ=Z3UT\M07\T+J[CL441)?R]CN2U;1=I8L"ZWQ(JH791VFQB#['9S3?T&"
M")+P9NVB P4&=_F9U$,-4N+P0X65L=,K\RO2[SE#5TCI%6FKUXYDC5]=_S#&
MR$CH;5[G_/&!A;SQ,G< "9*48*S\U_1MZ3DGIZR<NG/3C$.T??=O\J'=UXR)
M+-4L6GXZ1JX,%8]7;;E4=7XN/N-8P@/GO) 1/2;O[HAW"JT/NA14FS(V?O!-
M2<FDJ"/43S[,-^KBZH\1&PJW!Z;?F5EC'&J^?6F5"/X9("RZYLR%S\GL.UA1
M^]U!>_J#1[9W[M=4]2EI#BU5%Q4:#-X\VAQD+V7V,0ZT88/CX@CJS'_EK6IA
MH[^O*%MQ)5@=RKNX;5"R$/8U>D#LR)Q1AW,C(YU39NF<,;-^^O25>XT1GQA/
MO)FI/^C->??6J+-9U?/W%E3E7I6$:&?/\),,V7LX+-NY$6*I:.F@@3.6"UG3
M6)=2MXXZT4+B"&?^5*GSYBS[IJ;QXA!C]#'-UPU;OW3BKXBV7"6S$J[A!_1:
M<?[VH['3RJ>J(-/>J]\N9TV]:;ODLW$?E-5-O;,L;FC+V/>TM?8IHP_6]V&.
M*9BTOWMN@YC6X"&GQ@W>8HF+0??!;[N]/4[3< 0W; ;5?H;H6[GEG*&E9%DZ
M&GEDA03Z^::[TI1NCT?&WS^*NGV18-_KV[2*(\F\U"<'ON<2+L\0XSH^/;-+
M(*I_UMQK65-WG>YV8I]]:NGM$9T%QC'P+KULO2]\-, 3VR3O%X>.%*NOY0HW
MB[S8>P=GYV\^M'Z#Z6+&?//MU?L/;:M(V[60$MK1[W'!JBTGST$'WSZ>(SY+
M&AE:=]>WZ""T9-%!X?<9TL&[T0,=2Z9VDKZUC;MR;9W-NTLLMD^9=RXJ8R'S
MU#U,4T;<ZJKJ<^Z#XDI*_KVO=-TV#>5C8\JD6UB#+R_5?U#!W=0PMM[!Q]SN
MR^[\7GSLV:7'<KJ>Z%:KC*462[M/]/HJGD3P[Z-+2NJI"1G9%Z=I%MT>L  L
M#1\5E=XF)RQ<FWXY[^#B#UHDQ9&[NFW_*BX4:[^DBYN[YNK9A+JZG?IR:*BP
M0'XN!^4JO2"<YII_.VWG_,?H[6>[C'CPZ=%057[A[:A.)RL-:^6"RC5YAA--
MR647-<,/7N\Y_<ZHAC'UUQSD[3O79%B?1"SBYI^L'3*WY\-CV0_/+RL?4!Q_
M-WYX_/<">>B8OV1T?M3^'_/0NV+ST\N-,4T[IDPJ3F*GKOW)NK-D-?8M["3$
M9@\;8L^]OI)*WI!-C?OAMM55$\4?>^?3"TL/!VL>HM-1[/>KEQU<F;QV6>'\
M'95%/QR-3)]\M7L_V;9+9_+??MC[8CFUQ#.XXL"L.>=K=>8S_;B9/5+Z%6R0
MYT\??K>)CUB $LK)VO5K[N27U5M7I0MV088/J&*^\\7,\<OWX+W>PEIP%[<Y
M*NNFM6F&-*,"$[R?YMFO4QB:IW:MF65!WG9..?,@HF'LC^^=O)+?6+$N;57_
M%2%C@Z/^H69&LN(A?@!8U&;<VW+EQ-KC=N66J-23_M0QCQ<<[9$\PRC7%2VE
M9296[C76'#ML$/>K33H[XNCCAI);GH/\M(1";TUV2:EYP^R2*1TIN]=?6@$Y
M7L.>:4QP;?H@VCZF"(J>-?(]0\*==1<M*44Y(W\H*81VB=*,FF'JOW!HV73!
M^'T'3-FN4?LB+_;K\GY4SX(:==;>J,2=A6YGI7COG@.U!KRPZY33R<;+F=[J
M:X>7E+^W_]A'/;8,64)E,W)*EE)K=H_J-WC<E1M%_AWKNTN,\Z,,L^@C;V6?
M+*(-'E4:5UJX=?R.YKK%2URY)7/JS@6; HBYUZ]-U&X\CG,<\.T8EG_@V.5*
MP@#1M6T5ZO3IH^:O+)OH'-QH^ZY?OVWK&NSV([O[$-"5ACBU/*; J+.0IO9:
MN*GGM6K'SMJD.1P!9VK3&[??>>OPF!ZA@L+JT!O#5N>[]SN8<;&1#^)^# &*
MFMM*X;BAVUNR2H=L,K9TFVP8O-SM+BE[^X-C3N_PFRNS2K)*YJ3KQO:HF',P
M<<+=+2>+#N=4U:?% L//5!-'[DF@ Z<%@\OFGK9&BEU[%GR+E%Z;6*;^Z>2Y
MLA;9KN2,0;JH <75TX%5U.IM5Z1QR=*>Z2$EHN$XL:E,E&X[WEFQHCX*8IMP
M>CF0 >F7/\,TI)QZSL57U%9NB,)CBVZL/A2?X?_I@?1@IKO\Y!JQJ.[PTBWE
MY=>4IB/-.<,J7 6UFU5*?L 7,V# 3>:I*Z=6B2OV<H'RG ODV/[WZ;+L_,NF
M^;/0-7OOU_3I7N-S:K#YC2=KOZCH? G;=XZA ETE6KWOV&E:[\';IG:#?M44
M5PM$^HH1:X]/VG)JRR#RIB^[O[%PQ;IC5U%K@N9R<ARZ]X)%R)_NQ94L3U=&
M^JXV"V<?4A!YIAS0H5_+C?H$C.P;LZB!8P)*CTQ5L; IW9P09TG9Q.-S5QV[
M%O#7G"@I7UU5F%#1(.7VDZ=)T[JKIL>SXK8^7H:OF[=CR@+QMFO[#/&^4ESJ
M)J/TPB^7;TGZ,1R.[<F).UJJ,I9;\/WG?D@)-4<Z9AXO7GPGZ4G$)/2;C^$+
M[[\S+TH.?=AOI"<C;S'WN/5=*22#(&7\(,O,7LU>$RI"#CF[)P!;7[MJU:/9
MJ-LW64>OW%KS(#FC6_V/1T_G9<PDDZSP:9=C'I5T.1[1]=V2%-:3B*S3AFY?
MG-U[KZ+3B4V/U=?G\3950Q^.6#;BNN!)Q/G4^^&/-;-FW/EROV)ZQO>FHDK>
MEF_W[_@E,ZFAAPJ?7L^*#01^(?08N>9 X<(OYW^R=-@M[X[+WA;]Z4)%W;I)
M^(S'[Z$QLJW.&W$5#_TU7=</2K^ZKI/@_(#DI5=[;2>C[ <2/RP\3'GTU4J4
M^,3JR36G)CZ 9023\[^]4#LF^<",RK@+/VG>4='R8LH44U9G+1AT^RHDX0.W
M9'%]XTW6"7,];"==-VI@<"?OT+!0'KHEF]MGYS81)&,Y5'%JPH.$1>M.KJB_
M6W)1F[.@?OI40)5[C'$./WER-LDD[4$6B4FW9]\N6+Y)'P\MJH):C!5,.\5;
MMV"I8OE<*VK<YY.G; WY:;-/[)QW[U)*U&K%M?&+3IFE@P88\?FP87,/X/E]
M-GN1M3U%8M:-<X$?C-E=2M!;OZ!>.+:TF^)"/&W/WI#\R*U9RLD_T/BA4 VK
M(CU[V^C/Z.M:CI5?G/3 .G/"RE%C)M:/R:_B_D27SLX_7^NOBTFX-#B%\9BW
M=N@F(^1QQ:%JTZ1O5A1.VCUL]:T;F"'.TFW)Y<Y-ZN'T;T$WG)J)GA=W?,7[
M#^/X!X^MWN7ITB,TI:Q+<J=Y,[X[-QBSX-[-6*R54M&WI.;D^KD;NU<583:N
M8-WMD%)8P^;<WZ$42^X(BINE^,O&<^/JTF\,Z?_5&U+.>SCR_L.>-2W50LG^
M!N34T97HWNG%=\H:3W4IG7;%V"SM_N4P9I5VV=)#*-&ZPIK5B9+A+H'IRZAA
MR\Z$KLW)>-RGKBZV5_^2VE^Z+ERU)ZN^;^^<B\1QBZ<L#^6NHJ*05>=GLR!B
M/&W=5+II8-.VA2(!7S R'DZM9 ]@*TB-Z=M7UGX;FEHU"RA//[?PZQ@[M=P6
MS)N:H;#VP?^<QCFP7[I8L?..*V;PX2\F9G;H$_0?3JG0T8ULH!3WK_K""<O$
MAPA\8_Z5J5,FH=QSAZFK1UX:/?]!+GR#-*[VZPMK<?ONUS)/H8\W5#<J)E_9
M'?Q^F)AMI#6[&F -=47^47?RX=,__()D#X3,Z9$MY7"Q;7S#W4]J/AL5EU;9
M!"]/7S&U'_[VV1[)VR6F;H\[E:)#1GJIR0"8D]A)PTR#2;.F2G?.%$L3FD],
MNG+V^ORQ&QK$:SB=EA\?63>RBN2^];8)&[-1Q%X/;FGPR6DT8Z\O=@OF=:J8
M>GGT@%6*\@T;=^KZ5&Z[/F=OPFC9YNH#021O!$\OLU7?.=BX>FO-R;Z<[=7&
MI=>$7:?.B^7WSRJ9+>+%QR>KBRJ/E0[5GU9+%A3$D7)[;7'%DH^2'QYO?EC_
M\/:#Y"<1ARNJ'U1E/FY>=B%Q)S"ID!X]ON&]JJ0/"L\::V]F[.#/B]*STY;Z
MZ>M;NN=7S+\U"Y4?VF$\<HZ\)BZYSUCDM,]BBS=RO8N;>E?T6[(3V&];=B:V
M;$+IUXG&9>9F\=BT^763ZT_4] DL_BE-?K)*O%!VS#KKPZ4%]9>$TJILS3'(
MFFE7MH3,G\3Y#P]F5N0=LE\[NZZH<%+.5=/IM>M&[BRCS:5E_6!L@H6RIN9?
M4]34W8B[\OWFE,D-04I3^:$SUN(%PQ=D=*X4H]>;<C.GH5U?9JR_QP"W>1-=
MZ7V/^^E-O4CIVNJ6;4+) 2EZN;L2718'480:1BEJXSDBDK%9[*I]4TXLJ>IR
M=U+A_(^=:_<2;6O2#E"]']WCA&:IDC:9/MPV,C1Y[II/EB]\D*P_=F=25?KE
M-?=QL_-[+26YB,-'GLK+/BIJ)I^8D=/4^^;H1]>D&Q<R[M*9UF(S#'/R+D:&
M:<PJ&Y@;LR%J-.J(]Y*-=+U$]].9+],>!D>EGX2NH5^Q'^G[[<$?[JE-@YTU
M_*P*$__H+M_5;1^UQ.R_^(A\/'ZZ(.UBQ:RTAPVAEL8W!,GU5Y8U!B%])^^>
MN05=N]^5GW[VY/FR[)XK5YY:FU1VH)?^_IPA&;PCU7UZ&FO*Z;!R8VAQ_OJ:
M/7W&GL[LXAW[[JV)\]VK#]6JSQ?E7^1Z/"/3>J779%[+Q2S<(.;WT<WJ]HUS
M],<'V.('] O^N:ZUV_)YU&$V*M8X-TFE0DE"Z*3WF\DG0V.G%T]1+LOZA#EP
MCSJR;.#LQK&]/DR/&2RMGRQ<'WM^/IN_Y="\AL:Q.85G>KP_+$NVM(06%54Q
M5BSF^^)&_#!UYXZT6V\)&H>\5[,_L4R):Y@2]6'5F:-['G:8%_%NVSE2YLTA
M8T_G[<A[$C&'>/?]UH\$#IA6W/N$]R3B1LOT1VOZK2)6S$E+F;E.D#9D4$6H
MK#AO?NY*"A(8N3T&7W<W1ADEG %IZ3C[46ZLNY$JV-Y_[_BK(9- MC_JQY'0
M?$36'*XB+A(WHJ'QG-0P0"=.6,8P#+LD5^>O=@R;+JF\<O0LB5*QY_:6%8/A
M$_?2'Z1<L#"_N3PK:WAS%J"8\YY_81?6.V1)I1 8C=H2*HKQK[FZ>?E/*X@M
MY<BEGMT;SVG&:3*^$2T]W;+(B:\[O :0VGR[R'L1T.E=EXY>;?_>^\7G4ZH&
M!(G\48#QF#)7-OGPIJYG1Q7.9N\6'Y\7.B7?=6U_E\><-]PG#CR)&)-W]D$V
M"0V=1(M5I9[;<A?]P7+2\<EK1>E7M\%WU.[ZJ'/AA++Q:04%ZP28K,L#ME>C
M<MP_CG96;,'JXL5;FOK//;AMP:K!50<:+TKMF<O<YUSL):'JE,',@0V5XZ9L
MW?9S[-R)F6]^L$>*%VU)N-UQW-N%H4>+;_7,67'P,/; \NODSKG#X+3MJH'.
MX5N,H80KHP?T+#W<I]N"7NXK7ZVJ]_9M(.5'-62K,V*PRKU'M ?B8D+88--8
M@?KK?=>V%MV6E.V[K]AO6173L&]Q!J],_!X\=,BLC$K/"JU?/QMAG[BH"NLM
MZ!%84C(775<PY*C84JA%7UR9U?#]JI4UQC)I]Q_!Q-&741%I0?5M6"7 G#M2
ML3N++D'G>4,5YV+A\PN:?$5Q%<)Q4[\Z]/!CXX !ZH-]T!L23<?W4$XLOPWI
MM']!3ZFK;\[T7,>F[2V"+0T7RJN@;Q[VEQ_Z^4B%\X=#F]\$JF[6;B$'+6MZ
M:--FLEO*%DCR!R_ZZ:KB!&[HMW+#K0W)\>QU2P^PZI=G Z6NZDT_9-Y:%J=+
M$)_:^64GTP-F=3$[8U'_71.%0UN6D35OK:KLOO]ZTV66S??5X^4WQM2<N-9<
MBDZ8=$5<74[@QS74W0OU#OH'K%GY<VBXVS#Q^P:L]?B"I'.?] @.%QHIYVN7
M+CBTL^6R35K/'\2,W"V6'9^<DQ[S<")Y^XAIWW\OF7DHL7$ HB6M?_J8]_-$
MG$-B2G9V__*CV?W/Q=3LR#ZYEE1W94>_W4!%0J]K-9I]!8J)BW*TUQL:S*:,
MP9C^M[+GTDKF%LY)C[M'GZ8>.P"Y_(JY*8UG'^.M*-!H1@-=@O IPY']-$=]
M7ZQLIM2(H](>S_]ESZ7",M+QN5N6?I&I&'**OW5;[N%C][9AM$7;?K:@Q<?B
M2G*V%!^^[XL[>[/8+=Y]/"[SWJ>UO)W=-J8D3#BUC;)J>&357$Y&^:10U5I2
MXY,(R4.UWY'826::G[&H:LSH=7.&+ET-!W(H_!]6!*MRO-MC8M#@3CG*=Z]R
M(YG;]>[4-9<..VLE=?.K1E\T>T@6"F1_W?':MVKZ*.OFKA^U,ZGW^0QIL9NR
MIBI]^?1+9<M[,D8FA/K$SOL9/UM\[$3VDO2;,?>N3;W+O@:,'=EQ1:/@*N'(
M87*)HDY\9O$HC=,<0D=5I,==@OC.-'^RO.<YZ4F(F]J1?^C(-Z:6DI*AIZ?'
M-YKU)=O*&I+\Y+T7UWZQ>>,R-E^N*ZULN5 !0V#C#YQ0[)@S?,"W:UW\Y<:F
M?Y7. _"PVEG#0VG9A\YLKLHKXQY A*K2.'6%]/SE9).X7Y*U\:SH^V-W%NT\
M>@^O28]OK!J0]7W*_#6"K9"RV#S:'5WN;LEBM?I?9TG75JZ?4@.;TS6_) $A
M?Q*AOYRX(TK0;VMY?4,/#A72FXK>=9%,8MV,*[@@W:T;^TU32[_:7JB^WI-?
M)W+?J]]97?O614IR5&#EO.9OVL_UN.TWOG8LO+/BL33\D?B]6\[*'=O--4+G
M&1QO!/+"PB<1?; C-F$?;X;>V>P4^081.TD8.P?.E_<3)HA&QD?"+V;NNW(!
M%Z-@>S 57PDD@TY+-^QQ'MRV_-K<E:6K<E@#NFSZXI@+3?0,: F%;@>S([_=
M+5TY;1GI+.V,,3:MKO9NA>_<QZ*3M6O*UTS:T_V;.=,8Q4+^]N'[>T%':22A
MT+U?WKY?=V;4OJ3HEK3=5[E;2U97-:?U.R>B7H>O&9)[6<F?75=4Q8^TS]TU
M7&+7[B97Q*];D+:;G9Q1JZXLT@R38(&ZR[^<K!$+ ,[4"L7PY@&#O\E+A*Q?
M14<)!=6B*8/V'"#5L.?O>ER^9,]#6\?9#8>/C;'LG3!_A*'0>B;4^ZT"_%U'
MZ79S[*#K"7OJBI8-OMU\?&E^Z-:6\RWEEA7FAE68BJ)#/U=/64Z:,MVDF/))
MN5"=M #KRJO"=EH7O+NDO#?M%)]RD8G1MYP1R?O-O])X?3AD0P![X[-3%W9#
MI%3*>4_4XS4\;1_AI7K*CC-'1%N:L[EOB<$QE^V>5I&:M7(_0?P@_N053_R9
M!$%#8GD#]U1<W='"R9<KTIO@N\Z,=/V\MEI\T7;T)K>EL7C8K-JTC&T_EL[:
MW9%VOD$\>MR@BKHG$2?/Q0_\J:#KZMW:@J4;1-\7QX5&?7QKO2!16WP KS:'
M:N<6%%TUKEA^-;HR[9N#I:I)^=.JEB8>6/+6SJUE7G'RJ/6?2?OVOLY>7G*A
M:K0;AC\T2K"YKX.V\-8:]("XP5<HBS^8,KWB](J?UDVXO<*/._3^M0.\0QD)
MZ/._6-$>QLY89VS_']&QSJ:H =D7ZDI/CR#K,Z#TQ;?*HW(F[AJ(NIQ1VG^V
MO#]85LVZ+,:5979^Z[/ZJ*I&KO#X\M7H/;O)[T=NNQ,"I#U<N5Y'_I8F,;*N
MB^X!C9\^Q#UR@N7ZM5VCOK#VS9I]V##RYZJY=_(CI4F;C 7-V$Z-D@67/2LT
M8NN8NNQZ3R0=<ZQ_SK;ZN?LSJD.3:\09#Z[/V-XU_?W]IL3A[/YW&>L8PTW2
M+(V%6K,G'=@S:F6H[,N'-S8BE];?S^H1M41;>TJSH"*19&3<^YA=$[6'4MQO
M)NEDZ1E2IYOGNKPSIK)PS1?=OX2O:Q++OB8U9R/.-WBUXYY$L"S'#/<GY!7V
M3925EJHT,%*].E:E+#<Z8S[.T%_TS.)=FY)6L?Q>P=#X?0<'UGY[8=Y<;N;Z
M0PYVIB+D+"K@M7Z6^XHK-QV3MP0,)<T%A7F*G84+WH[$E[L.UU>(2 _KW]F5
MN6K0MHH3HQI6?+/J4(;V_[#WWF%-96W?:&8<>QND-QVI$@0%#$@?!Q#IAF03
MZ0,(2$) 0I4ZHZ(0BE)"+QH@I$"0$B @,H*T(""0T'N5+D@'X3"VYWN_T??Z
MSKG.>:_O?.^S_MAK75=^:]WW^MWW6NM>>Z^]XR[\RF,A-,&R9-3IIM_ML.F&
MSMON+VN?M'$H50*6T\DNSYFMK]\*$4QTGRV, A9D+(M!8S^<VCV8II]>N!/*
M,A._WC]>:6K!0(7=8,:!B5918$5$E4'.:%"8Y+2T@36GP=6X<MB;=C4RV=?T
M;*288BY"L<F$L 86$MNF[H+6CN"7.1>"I0*><HW;,SED@+8^$VXWYBR*X-+(
MB2&R-*_.B8WI4Q&!8QKV!P\#2?<02 ;WH*!#9N&KM^=ZC=@!))B/BJSH-? R
M+^IOZJ=??[L+<@R0\6_M,2MN):*I!-R*"_EF;I(BSY@[3W_Z?@;QQ8]Y8JJ.
MJE<R/5T/;DL,N)JYO.Z=BWZ7YSZ"AIWUUYU$+_1,>+DUQEJ?^O/N9#5D)/EN
MHQ2RM> XU(T4<,(AU*Q64H8FS=A,:>I+!!;%3FQBX\UZUC6?9.O2I<N,D2HL
M)N!FX \C=#9<S4#X9BC8P'S?"^R"CBG]^"%O.?A88U?LYEVL8\MQ21' 5J8^
M)-\M++S\)7+.AEW1T& 2FK%@UEPP^"/R^,6>PU.CNZ!,]8+1*):TYE@HL11)
M=ZMHUC2ZP7ER=J2PN*9*^>WTS2Q2Q*R_^]4.^HV)3')R"C:L853#\^5\";-D
MX"=/8+5@=K4?W:;_5CSR4,RA^H1E9(FC/11 *!=6QJ[]M1/!4C)LS3U;UC58
M9RFL#9,'$RTBO4XG@\O]7IA)W[D8-EHEK79R68WT[)TJY5*_)VX&4ZID6'<5
M7I7KS<MO6N&U9F..VX+Q[C.<LZ.2?=A<BN83SQ()I)%UXMN171 O%]S!BIR@
M;W\Q))2N,*E<W"=^.YCX=EV\S8S<>GL6W'BW0"G$_)AK!"/''5?_"$EV=9C;
MQMK=NS)=?/L':$;J36_T(#S2]8.88+ C7S0:C=[,C[08?677T7/4Q,KG3%N2
M;63M<JEYIC93<OK)5;%&*V;5W$+S0- O2DVN>2[7D9:"F;GLQ4DOWM43*+E=
MJ%0.P_$N+2V7MMER7SS>I?]YHD#?65/*2C@Z>XY6?,1%ONG\_*.(: OQ/XBO
MP7C[/F(8G8W[3O/MQ"<0P=H2762_C#ZSTLP&JT@4QX50NRPSJZ.\$+YT3KD*
MSA-YU_6HGM+WR[6TG!S2Z T&A4<%;W2+^:TF%T6X^W.),139]F8M\;_O!S6A
M\U;$HMM\,0NB4XW$\41^]T+XXDF4&7&<08O0OIIVQ"[07VKKS=:6GB$.03V.
M9"N7.+\0(]#M<<0I3T5P!A7_$Q?EF)G5$22#;YR8Z"<+22(U]QH\QXBQU8?%
M.V)L+GI:G+\U9TH6>;-D/JM'N^7(:QR&."+6EA/X(Y@N2XQ:L+ +'+]^X8\[
MH8SUA$F95GH]-L=+EC5A 28$UJC^! (=^GBBV-CT5/?[DUM?SL/M6^J(H\2%
MK3YEREW1@%D+Z1B''E?*/UT>$_1@(KOH@[8D+DIUSB[3W8P<[B([/J%/%@MD
MG3LNF4'S+'G0^R"/W%X@6DS5>5;+^JM )D]?B(P>399(7_M)WNS"/<J<XS'/
MG@4H3+;S),]:.]2M*4[;/L4,+<EI%A(QR"C?6Y3^O)&'RKZL07PV<(HYK34;
M[/>[<UY4DS/UZGAO4G]C*N-Y2L+@)I6@76,D$E6U,=!!+A8#"Z<]KZ?"]3^0
M0Z[W<=Z*  @> V49].XSW=P^W/G&2GN.CJ'-=>_%=TNM[J_W'%W"/. 'ZHH5
M?DAWV >?95\',V9,WXKB":TE2ZI D#:R$;Y4]GC'#O>>WOO*$Q$/=4QDEZ?+
M(W2%7;F2XJ^(<\Q" /5JY'E4Q8":BWU+A=Q36E/ZG_P3*9E9 <?GS5ZH02+)
MZHMXC(Q ;07UG>6#/&F%"](KEWPS[C4Y>0W-Z/1*>-!413I( C&:C/H.TY19
M!V ,*30:=)^"F_A5.<*I2AU9:A9C-$BE>?'S2_"L@YU&;!<+E8\6K2E2J]FK
M7,9J87?NW3_Q\P4S94U3/+HG^L6<=T[BXWZS6J5+!!T57K;<=^[/)EP&4IYG
M:Y!R5LRB]7+E\UI;RLSCPSPKE@M_*X21JYIE0L;=.=E=42>:5YIA/)(SV3_&
M3ZV+%KRIOH0B2N'D &W#*9@]KQ#!3GL)+=:(4$ELZ3F(RH:DWK0 7\E^4@JW
MFH44^=M)BH:RO3%D8BA $PH*A3[')N,:[O9<[N?V9*V9M'MK_7Z746^^"[KF
M3C:7(Y\)]SGN,B'F/0[<B>)6-'SA77;9:E5S(X4)7.LB1GJ39(GI\T2VC7:C
MH/6R\AW^7="'\I.M-4=OM245Q#\T:W)42TF4\N1WOM:+,"R@4?ADN/E]%H5&
MU=1Y_6D8)J"E!1^S_OG,K__IB8X?- ,[=T'OI/8"UT3Q'>9]*0-;9MDNZ&Z%
M8'9.AX03*>-!G),+9TQ5U[LN+YA]KE\:L=QTXUPY_43,*K:MYZ&9Z5Q'KJJ3
MIS8;M/L",4 36CBF6'XNT@OPEW8.R/9[V0=9]I5OO>+U)/H!%1L'=LQ?DGD[
M;L=6;F"BZ"VMXF-]'=A7U1_<XWC]G8%]1F)!DV9.:#2#U>W>=FM;5',P(H_K
MSHG:9  9H5[== )79E7NZEQ:76NS_#H,"]BQY+V\YTU\6-X7U-ZK'RO3ADY+
M!61)FYAKD&_E+!6;WC0+2:P-"NDD0P3&K*ZN+SY_3RQ*R\P=GFZA2,RV*;5J
M\Y_UB\-S^*Y?T,(HN$;)[_0S?FJDK1EGM=S8(\!:/KD$2C-NE#QSU/3ZF+;-
M[55R/>4!E1WCR-/0=/T=G3CM<XC"U.%P>0[K%-TW;7H*#"%'6$%,&](/LR>#
MDY]?15V-[H3O;:0W&W'XH]$63^.2(L>A-YCVEUR [FZ7-2%GLAA#"(,9QO@-
MQ>O/&(CCSZ#([?DZM9:E/=@[R+,8.$Q)*KZ$%VXPAR0@?,GB8K].+U\EW7T/
M$VQKHMB7=4V]S8HNB\R-DL<?9K<WFX5$6-B<3ND> RX?]3[BG3P?R52*/%I-
MDF:NW&KTQ)_C6^\_Y0S.:+>W&(>[E\R)-_3?([2G\&IQ'WYOA8XS"]L?S#P%
M8\+T)-7KXC1-R#(Y[E$YFG K^$#H?<@V]U2_^TM<0$>CWN\/UFZ1TR.R<]"H
M7U#</#T8:<L*-KJF05?_8VE542_/-?V>^4=_,I> ]@)$U1C\1A]I6"%(=OR8
M4F1Q-Z%HKFT8P7XJV7Y)CT]!4KF_W/',M'O\<<T5/+_9 68QEB//WXC2;0AI
MA9C5>#^RYP3<5F-;#KUYE^W.6F0Z]8JRHTW6+MAD:;ZK1&^G8&B6]*[F9F\\
M>)WUFX)UX8O0G-8>>4?+A&=]TC OC:$EJ5H^ULH2^4/I(E>BQ3N8#C7=TCUO
MF-/VYA9;M?8QZ4<VN0Q*YS%@@)+?6.EF]W$L?#P:I)9^9DEP]8?3W<L\NR!U
MEHX(ZLM1ZH\#1OW\;4MSR,$YMIP)0@E@<;,G%ZFAGY_QXG'_1E23?F"@W(J@
M9B3VL$BD^.M5&B!LBU><>9WX:2).X7_;9&XS'/B>-&\6,%?2EWH])(KUU^2K
M:-U'6O#>P7#7NO''O[D>[!.P%AX6VJ!"SLOTQGFF+B]+X0HJ+K_.?C Q7I[T
M0M0B3R'R^9!UR;O;1CDN\OQM9EL_S),LL5[U&RE=Q<6 92SJ=II(,R+>BWO%
MOFFISH7DJ:H\[7"MTY9K+_*D*HA9$$,W2+^]0S]9L4H=JC;M0LU2S6927-#R
M-?K@3LG1KH%RO_S&5=^JLN,0*@2]]<>+ ;-SW=:DUAG#Y&-&1T\YYR0+8(FL
M9D6Y2IZ^6RN.AQ0"Q(D>=DYY+J6Y=0[*M.*G;QA%2T$/L,E0FKSE<#EK:(GG
MUK(:_>G0Z0#(%=U-Y484EW8^3F87U/8+ADPQ6RW'3/)JU4(Y%<8ZI@/VY\S'
MG3[9K9?E-*6L67ZJ7<N4KV+^-7)*L)ZI??[..,"@_CJ]PGWXL'85J\4(R<^R
M2J.]_,E)ZY*,C/GY2*2BM7!*G<L ,7VJCZXRTQ_DVQ8G*($,Z$A"58QD-4!Z
MY&5>VZOSWX^*T.QFT)IJQS6KEI:24RUMR,PW5DXTAT<!3<EW:,PV@R-Z1\ZC
M&[U2)LA"ZJC 96L^%_U%[OD#-.[Y41WYP4LPI![_&,[&E(V/N"'?&H&9;P38
MXP_1+;?_\.I1-NW0J0IV2$'?7/,38))4I3SRA904V53.L?Y>#KRIRPP7*01$
M,")3JVI<-DTNMHW; /"ZD5G9]7M^#;_Z*SNRN4J,^IFI[KY:PLH F4)7=3!D
M&R3;M;L&/HB,,R^W1\["[4X\"FQ3 (?2&AC/$Q>'A!X-SY>MN79N^JZ0BU94
MKR:6Z)/T8]]3H@% 6[KW&3;R'11*3N@CX08"H_&DR(+((T1.$]Y1YW! WYZJ
MG_TLQV4U5Z/*,"JS8-KO5!>NO4[4HU$%(T0+PUV#4C'C?6E<\E#$N,_<$1^[
M[&SL(;YPK'P&#W-,4[/J%]Z_!\2A>"/\A0$C9IQF60!;X%+@US<91O,V:Y8W
MV^[I=$\-IRW ]I$S_9<D;;-#91,MA"@IY.2DA$E@7_[!4W-& 4\ZXE#'>UH-
MNM8X<:9NA%1&35=$LPF%DXXJ$8^ PBXOCOHG1?;-F?:-N:/[^:]-=_/T3PG<
MFJ#)Q[\BY^F+RUZ@G"T%K:]!PMW3QE!FB0!0)?3#,E_J!>(MB&JNBWPHEYF:
MTC5S(0+;=)TDT# -&#2^1O_QY60YV\<#0)D%HI2WH6NQAS^?/.9#V[CG%CKU
MS*26Q:7E+M]^X5USJ?&48CB2?IO8Z=H_:O3Z>+VD]*%2N,&=V^7F%'0 F7[=
MQF1_<CBB!-P9E'4QUT+H ]%YW;QSZHDSU*3F2N^1AY43EP<N.%R"H](HP7V1
M?NPQN/J#'D<&.O/R(-N<3-2AHF6,;KY;;!''^S)$?<B'8(3/X7 [U.'4>@VF
MO[BELP6/F2?:)/6JGO%8)!Y[IY]]! "NDGV.QEJF+%0-PV*/7N?KEW,W[TBA
M]7.)!*.<;(DW6GO-^=':=FHJ-[M!H/8FXESK=%* :AVZ7RP[ ,'5O\5&@\K.
M.Y/G)ZO^+ 7]8-IYVQX!K?+W[5'>=NNH&:HS+%*&9LAS)DON"(&I#.J'W@WZ
MT8M?3^3_!#X9HSY2FO3;DPVY'<D_UEQW00G;CJ="BG=!&X]JW<[]C3GA0+G:
MJGZ=92VUXMG1F&K.+ZA?%*W G@$[WF/7,T'&NS3+&A0[,70E,ZB8!JBYNX>%
MMCV@*K!:ES)+8V/+U;*<*0A-/W.6#OI7.F'C8<FA4+9%(Q0/(W/R3,IRG420
M!8Y"-@(Y453DA5RV$RD_$(N<II715?BAR#3R^/7:&E%+O=4Q$P@ #:V/< $0
MQS7U%^2'OC3XK2<C_U/Z">G+AT22L5B?:$4DIR"8!K!-IT_#QYH5''&W$\=^
MT^B)M$NB5Q$4I+D_O-D$1;@\)908%Z=AN:J/ @C[%Q" 0<X#DZDK>ZL-0^=S
MFX<^WT6,^OQ2T?\DTB>-9_JL/ZRVP=;7F?X(J4@UM-<:5_U#IAU6K;?OEZP'
MEVUL;?)KF2BSM$Q#C5\^5M&@;*+%>T9L3N1-%:6C0O\ ?3-]<X/SS\0F;:W
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M:E5TM[:H915>R=?+SFG!0@RX'3H#6-:'5NC+4RJ.L\1F>7$+P=""VE4E16%
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M "WKTV.##+<RK_[]WH>4"O O'M"BX"].U*2VZAU1Y>?+:#T=DEP02D<<+5U
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MGP!DTS-S_'GFN^*/_,\4.G+K!,PI#E.SBRNY>W*#4M=B"!*X$3;_<2RK*T9
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MJ0[D=+L/X%AY@@@IBMQ0*],/Y162;\,-CEZCHH4>7UQPG9=TJ+0>.0I7\<<
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MF.T_HKOL2@']:.-VD? .F"\-&^RZ,%R8<!X-;HYI+4=<XR74<Z=)7I3DXO5
M%(W2_?S?,#JP5$&3QE=XW@Z(GJW-FL+6XUAHKZ7V4<:B#D]V<;K@72<A4:7
MF+>%+\NSZEP?=X;9\9\H[[X-TI7FK 8Q>U\CN"'T;F:X;G0?(@1([-Q8U6B*
M@ZLCT6\'K( TBZR0K"9<C\]E#;3!A&H4":?7JZS)UZ@QUP@ILV RATPMY_.)
M[MWJB+CGE=_%RV6 =6YDJ4 !=JH97H!O<RX! 0#,X[%F )>,+VX* #@[_@\
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MI3W..CU9--!K-=8(I<TE\X"')I''^V?XLX&L73!IR!^_1C+B/*,YG@EY8JY
M)UAH: DGT'W3IO4P0&?'L/!7Y[@CB2/^+Q?I,(S5/78?TI\4=HF8K&:AX&Y!
MU3TW.P6LHB1)^ JL5S@C#9^U0$/ZQ'PSN6Z!1 5[!1+*7%NCR7W6BYVTQ_P(
MU7$)B4TUD;?+?N7O[?)6=#,XP32.[*ZTI+VD82'<MH47EM0TI;5(7V&FWQSR
M:P#!;+U?Q-V(6900<=*TRDZL'RNEL519EVF1X)&:U&JV-\R.>?U:+)UZPU7<
MY&-JAI= 6_$TPO2@"B-JO)S\#DE6$"G&QA2-RB:\[[,:4T7T_+"W8A"66=I:
MH!I_>U^SR3Q[1[A_'U.\2%6\ZDO ^Y49WKO/;96KW]QREN![07^BP,0+HF>&
M"NFP2:E"[QM+#YTO8/1*%Z_M&'P"=&=0U$R&AM&.;265\ID?$8U+7F/FSM1J
M-VWK36;B#4LW/;Y\'3YPK$)Q<RK".D4>2HZI#-^PY9/9WCL[7) <PY"T]EB#
MJ=<L@,*4[CB$N%\]BUYB(<0KES:2U!K "]G[>SS3@."^_W69P&7/\MYGJQ^M
M_IWZCM%U?_KFS%\N@__U5=5GG2D': >3!9P53"0@Y<U/%M*CM7E2METB$KA^
MK8)1O>N.V?5\ G!_MW9^2<MVXOF!GNJ#!JV,RZ\'_5[57=_[GU@?,Q+7Y0#Q
M2^_?? )(\M3E'XA(3%_7%(-1ZKC$GQCOJ5UM?O1R(2+JR<?3G<?.</X-V1Y7
MA?;Z=$=T3ZQ^ CSGRGQBNJ=SM?D)ZR#D$L/D$=9?T^YS>:^>?"XO0%SC_?O/
MW,*_3&::G;V[I.4U,7&@)_Z5(<I;DP2+.JO-D[X=%)%PS*XWXKOOUK[/X)'K
MFXCBJ2,>G).8OC;H-UY7MQ?M?.@_/]?K#8KB*HTLTI.92SNGGP7E?63LMO[&
M)/%[@_ZSU?_@^M*@UWYO]3]D^=)/_VSU/V3YTD^_=^8?LGS)]EMH[T7I/R24
M$.E#VY&C,YJ?O/G?G+5Q@:Y*9]__K*A\.9VZ^^>_Z+&&:=C"9_6'RR_;P&MN
MAV "_TI_^#/P672-8WB?ZE=RR!-P\L] ?[6-__/PK]>FOQY9_XZA^%_#W>RY
MG%UXL\-7\A=9?773M/FUMX_>_0O4[VZ:GG[MA%_^'/1=;#.I=W)-]NS"E;CQ
MK@V55,I7^M.?@2^SPUKWR4Y?R=%1P)]6]B\5F3\-_]KZZ"_9_MM9UG^[ROS_
MSE6F!%#&008##B21FX9X][WN'H,J:9HUQR^&'KMGL%']$U?&Y0"]"*M!;<FK
M]"7 O8E'Q5([;U]_01ZZR"6>(-&_R?,;&B"L>7<I^J#LY1<TH*7N"_L7]"]'
MS<Y^8?^"!JAX?V7_@OXF*8KGWUY8D'MW_CTO9) L%ELN$^ N83OX,V^?G[;Z
M=X5+T*&7]R/L?SI4<G?GH$$\_=C IBS@/S/A1S(AGF; P(P]=3ZG$P?../@%
MX-,^M\GSM\4:Y(<7I.#6+1E9V_V^NX!O&DNR!S7_UE@P*?1V@X&2$/#G;Y+B
MG*^^_$TVP*&_-784_'9 *@"IB9'[(@% S!>\_^AOC3UP<A**> E0[FWN_[&?
MY4V^-T7H6@(<$^N,N/LWQ.SB<O1K0/H%2%F Z+F.1XN[9[Z.)\#2X)57109.
MKS?VL0">_R<)ANL"O! S7,)@ ++^YV^D_F,&[O]%@O+(V@O\($H+ M_X&1#Q
M:>A_ %!+ P04    "  N@'1:7[7(B"$3  !'S@  $0   &]K=7(M,C R-#$R
M,S$N>'-D[3UK;^.VEM\7V/^@S9>= O4XR73:3M"TR&/2ZT5>2#)M%XN+@I9H
MF[<RY9)4$O?B_O<])/66*%.RH@17_F+(XN%Y\W$.*?*'GYZ7OO.(&2<!/=X[
M>+^_YV#J!AZA\^.]4,Q&W^_]].-__L</_S4:_8PI9DA@SYFNG?.+R;7SV^G=
MI3.A7"#J8N<\<,,EIL(9.0LA5D?C\=/3TWMO1B@/_%   ?[>#99C*/]%$W3N
M/KS?A[_P=/#]Z HQ=S$ZW#_\Z/S?_G='^Y^.]K__N_//VZM_C4:2!>XN\!(Y
M K$Y%M=HB?D*N?AX+R(6T#]"AL4">%QA(.=J:H#OFX/##P<@EX\E>Q<!6Y[C
M&0I]<;SW9XA\,B/8VW- $90?!8#$'J6JDX!+<9\^O _8'$#V#\:_75W>*YYC
MY#ZA?^2@GZ?,C^$_C&7Q%'$<@S^7X"/L!Y\^?1JKT@04$)$:U"0R4A;>$TF%
M+/#'L2Y,N:C!^]MEAHF0C^8(K1+P&>)3!1H5*,7%P&X04L'6>18X=M_/@\=Q
M5)BO$#(&KFFJ$97FJGB85$-#00X0/[N+:DA9D@.E"-R@&E85Y8 Y<:M!H2 '
M"!H2ZQ7FE;I3)7F\8L4,B*&DH(,5PZYLMD8S?AI#RV.!CX&J*T;X>>4CBD3
MUA?P/Z')1)D[>)EGC F3($E1GCW!"A5RW$'Q6!;+.ONC_8/1X<&>[ L0I8%
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M.EVG&=$AFUCG,G,VR[^J-L(WI;Q$G!3=*3-U]CLR7XB;V1>.TT%'@F3Z_(N
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M!LUB7<#]QKFL,C4(&WF?&DJ)R["<E#SW<2R?G"H1QO02U=FW01--AF30[*K
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M-!(G6T*G &*AEZJJ]7ZUGO:P*(%"Q=OU!+91I.-#WM<3!*@__1]02P,$%
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M&.WTI8XPKQ#L'XB1W!M5.PIRC<JK@I ;A.^>8 I\T\8(.O992K>%+^@.01\
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MZ"'-ZA36HSS9?I! X8I M0F8";P>]O6VVGJHK+N?=^12_8*'7PF0>0FL-&-
MRB(3G74W=B/#0/.  [F)YO34H&"*9E8 1%Y"E%5US;$>"+!8]W4W9 >.S,DV
M.C%![#HPXWC=WAES)()CW3.^NWUZ*>I<SI6X(B#T>M5M1I@*)NON\W:6+*VE
M"K9= YSR>#BL.]);'$=JUPBRNH#3Z\;=ZFC:A&7=$;_C@%(;29.=HV$/H0:
M=0=\TV,M)R^XY'S+J04S=2CD&&_!I?"L.^R;4<<Q9L$HAQ\1FM'=Z1C?KGZF
M[XX@W#S:(?73ZMXZZ,KKZ=E.5["D!NO!!V;75P;&$I'BO@[^N"U#9SU@P=!?
MK]7U9$.741HTX/6&7J9E-C=<(-;C&,PMPDJ,;!:%*<'KP#&C@XU"$M70D\5C
M]7+&390FE_EI])R642:@A%,#\'N],3%C1@B&XW#<KZWCEKYBDJ/D/,(Y;*;(
M*(ZK&7U:$B5GH.<X%:U \LJ =(#SFRHN#H-]Y[3??MM:8\\ 9YX!#BP>#@XC
M_=H]9-N?#A=@@'* "Y0:*@YWRU.K[S"\]??4!Q23=]ROY<+89_+8S3RD[3-Y
M+)AUMB6VZ3,Y9)?)8S?^>9U<)H]WI$RR@001T-?5.^_84>R*#8_)8[Z+"P=)
M".%Y%B@9@,.D+C?N7D'QXIEWY-4VRNO^HI/_MOPAQ.-U=LP[]GI?84S$FOP6
MPNUT/8AAGSK&]?!.:FO0#<+U0[\,[9LU!%W,JQ^#VIZM"S8+<7?:?M_UB_2C
MJGPJ</HG8J4!U&L =.+5/<@&2VQ,%@+PS-BI;Y!,F6DJ P+/]C!;K+3Q6 C5
M,V-D7)6DC/(DS5FYTC1; "Q>/4KL<;,%RD:,GBY#5^D?%36CT!2?]1]0'B/>
MA8QI4P!O\&N1#%T0\7O&>PR]!@!Q<([]?'N0#J8@(OZT]QQJ%2>[7X++IZ7*
M&AN+]>=@;+'%W8/(*P$RSS<]75EJXP@B#%!_3Z)8$S .8/>N!2:@:$'3-4RA
M-F#U:K;0(TX94! !ABUI-98N02W YODVU9 L-I @(@>WI)2N6)P:@&D 1V4E
M$$&$!FY)J+90B:H!.J_YT3I2M(5$$B3HP0-AA9",'T^?HGP*'2MG>)0,QQUA
M]Z!?![?+/,8TUN8,-?_/4M]MD647!?X18=$\I=G29'<W-'/2+C^[K1&X$-P8
M'&[!][QN#HP8,=R?[_']A0?ER[CKYQT8!Y3QP(7@!J$SR!B=;?^]#"L.MA"\
M(&I,S1;TK,(@6O.V32-Q8XFF?B*PJ7BS2M^A&(I*PCV[-0P*>E<#M*,B0G#3
MX."H;0 ..HI:N[!3\6K^<M]/=/3@SHE$UHD70>D7:1[EL>"25;<=P.752F:!
MWPZXW;F72#I;1SIYS0"JH2_IYK!#2 <M[(;7Z$?])^-5?=4  /9JD>MK]=X
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M@-^!"XVM-[<-T%>(.R\+8U8!MHU<@!SWJT5?&S]V?&-/MYW)WH[7H[(=/CM
M#R)]('OMX&9&T5YYN2V!#D*,KK"Z!$O !Y%[<+G47!3X%CU7.'Z*2+U[:,L+
M)\'F%PAP23N"68N@DW>X@ALIP4;^0JLS0ZLCGZ$'U>5\H]9D;S?$N#L+(YX)
MU$8.0]F2O;8Q'!%2T, .E/P]+9_NGQ!S(JI?:5RX"4F7\H[M@R*\)C1WL<1;
M44D0Z1/9:U;SIM?W'"2ZA%_DH"%J#V9'BE$S(8%B696 .MNOO6EO%"Q]=[+G
M]T&#/K855E451-9(=:U9,>P!<J]WL'8[B2[N,%)0@L3T?_2"X07.O[!5>GL[
MEOX!.O3Z+UHEFZ?=MMWM%IW\_#6N4\#=PL1\_OB(A.;@?@4!'KVNB'JF9!^Z
M"2/?9A?@KCH;G W\>H[TUW<:J$$D_+PN\KB.M%M>D.7):F:ME:!RY:3:!NP.
MO=XU:MXTZ<&29 WMA\Z-N.;Q0_/^RF6^G(_@P*X?B]"AU<GND=\-JQZ)[)[0
M&3^G;_1K"VV.;*0.L6SL,S,:5-.\;2T*6A57A"'D=[=I@V$5B!P2M>R9O&<W
MVI]GI<?CF3*D%6'7X?<:H@L[.A Y^5RL/(K2DF##[B&Q-,EK@O!>X_KM\B/"
MR"'(AL&P"0==^'C19^"*/$?U?=3";L6YN.+19MH>[.O\FH [D]D-.8=B+;L?
MA^(Z[+<5[0F"5C,;7'=N&*#[M0)W)MV2"CCL:YG:..PK7CPWIV\J^4; ,(_\
MKNV"2@>^NMK1 (=Z+9L;?_&-*TS?-7A#UKZCT.;<N$& ZO=*W\92W04ZAV4;
MB9EEDM'G74_FMRA'Q0U."WQ??$-X*GB SK ] #K\[5@'Y!R*>TX./<;3*%_,
M1*"!DXK <9N0ZPC3(_8+.J//RF9#2A&]?S2,@/5]1]ED= /6]P51S@R)!_O"
MR;)KUSON)O^5)%J=4P/T$-[;PPTW3!:%,$+(\,P2L#D6(6F,L[0NP'2T;U0.
M4Q<2H,X9 U8("9.=LQ=*@+HK&JV^F,+9]#4;C]$4/BR,..<7GNS[?8I <40P
MMFD"."$D)F8 .X.I??S81KH47G1WH-<0*,#O0]!:.Q$3;"$D%&[E2*#/L*1)
M?7-5Y+<H1K"[3L;MX[]H[ZC3#BC2JVU4<Y.I#\U"!N'NU[^HN9D\CW .!S_H
MF7$UJS+JP7D&2H^%H4KRR@#4JP5$CT-5/"$D%%YXC&SXB8S*4SCRSD'XOT59
M)3K&*=4'N%Y#S/3HTX DSA'<D]'BKIK-(CR'62.=YBGT+YIBH#&C@;0W108]
M#G6P8?#NOK8^(3)1R*I,#K[8L-=O?X%GAQ 5G^P?N[E985HCU%3#NC,323]8
MRT0K"?1%@:_1CQ9,7.3P8Q-W323V"JUV8#B[V<\K63$4V&3.5 800[!PW$/;
ML%=-&C&D^;Y8Q4$KCASZE.T8!LIGL\C'%X)!PQ)9H9@MG+,6UHNOW+Q#)W,*
M0#*%*M0&R!Y3E9I.G,K 0C")<(6EHDJ-B@JU :KOW*7*A&CRN0DR!"M(+WR&
M,M_V0ZQLTNW7&%([8C\567(Y>\;%2[.>2%=.02V Z/7\K#R\V"1*D3DSA!!<
MM@B#?[V1!?^8W%(7>LX:N/9W.(*YN39SLLHQ1'?VF)&*AKE=?Z,$8'%DJ96N
M0PR5<73:%M7=>T"VU>I[.3#1KS1/M06[A$3/WT!+LVHFU/1:&9#;2]01LWMN
M:Y@AJ[MW:V2ZC5[ENFV7 7F]W+FJZG9;UC >BZFH0./'59S876,"%(;\\^H
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M*G,\7"L'XCNZ8- /4^:KE\/+-I 0DM,8\^![%K1/B-5'MW@&,"B2QE%&+34
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M5^<7EU=G5P]?0UJ/*UB']N6*5-\6:'^PJ.L$8V7FH[I.XW#.&9TDJ)G>MIU
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MPG'BVR<S#YTGW\"#_"/]0MTY$)_0R#+"'T"<!<XFDP),B52F4'Q 'WDN]K\
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MALLO #D/9\0G9"GY9W'Z)=$%_@S]( "GD$#^5!9JVQ%@D99A@$HW"DHPZ8;
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M>'0"WG4LRT%8<5?2H;Q"[4<1;T*CLX-?]GMP;I"DE$)W,5,SA2A7B+,%XYG
M54^]6U)KBZYA6#H(43/[ ;<?@_1N,$Y@Z"%A/$#X7G8IIWD\/G!!ES:[6]HS
M(-Z745XNZIR4J682W[)"C_@I25/JF^G-/L;B0I)?I,9S-X]R8UJ+2B7QT;C8
M13RFWST>?RJHO>&5QLW*]ZK$.ZL;5?8T?.[P'"23U)NNJI(W-_P(7MM]'>L/
M?V-J@H3WA_U^RX)=T1;%2;'>9L4A9]&=M!(^O+M3KE@5MGJN0/5B@H-7-6X>
MRRA)Z1:T7AM=9KE[F;A)5#V:Z33IA[ 6'Z!!-46ZR&_V/S0?)K#Z<@LIHGV:
M)NLH G<5D>+/G6I9VUZM.D$9/@U^!LL8NH 9S,+/QH0=?Q6L<CM/PMG14I8T
MH(QCW3,#IHX^MQ8F&83U8M.AN<ZU0KP3XKU@3--9D-Z9$UGBX@*="1EWZX8J
MU)W/B0/$SW\B/CZ)='R\KN2M3$98JEO9RX2$GMX'&!;.C"GFMAU]I>#8R& P
M9H45 +SSXT\8;XDMUACK9:SX!9A5*LKTL2GJL=DW8\/\E'/2B(4Y#_)@#)EW
M-CTA#%HIA5[1PPRX^1/@1EGT2&F&R6K@N6KV.%/:M >0.1OUS,,SEU7S)QZJ
MVF,QO09;9[14R6^*>W$J6Q]/SY<'F""Q\.( ?]+GM'.7^DQRE[HBB(84 1S&
M_,(?TT7R61#?\SI!P-W*%X4S\G.Y+O9$3>=!"\(64<,,/FP&PKZ<V1PZ$!ZW
M9B^E=(BBBNH1^+?E]-%YPX*&%6M]'(7+F\U2>KXO+#.Q<H)!PV,NOVA9R8!G
MHE#A!Z\%J=SB=+J^O.(,&A".%10^#G6(5C>H:K*RI[< 7.*"RC"7N:"99HTR
MHL$#76#^<"X+Z;G#H,S#RAN&BXP98U95O;CVN+M[U<O9!TX@Z#'"-5IF22Q"
MJ+<WO# :F+M;7/S!=;X@'=QDW ]#:P& WC;BML3H;\:,OB\G=ALE\?O7.YSB
M[#9/LOPA^X#S)YR/]6%J>J&X,(W$8SP8)4>O^#""B%&DSVIPF@&ZL*GB#S"\
M[XF_UXL?C LSH=[)@WF!_"P.;-S8*_U7/?9Y?^QWPMA[R?VYR9^BM%HQ$NZ+
M;)O$[!^\$$]1*^]F4RDGVMZ3W[!L3IM\W9GH>\PDFDLC0M"B0W>%>I3K@E@-
M;7H,U5!'+7E-&K#/[)=903-,DID5,>';T'F3#_V OY3OM_J2<O-_ZE@L2ZZG
M18RL_13ZE7X,L:\!)=Y[5AK3TOM#D:2X +V.N)11S>IN-!;EQ?-4.RJRRK@E
M?*_M'B72=?+H#;2\"^>?36-4MPYD+C0/P1!Q9OU[P<Y]\I0FFV1-W[P3.+*9
MBVP)>,24M4S"%:6V(Y)B#7P>&"_:8;>+<O9PK$%*2#-R0^/0I-R@."$PQ'=^
MIT\Y9A, F2,DNT>-#QY#Q%<(R%6V(=!X?]008$L):32D\=Q?@\4Z1@UD+\ !
M-XI648V91C/JC>9:$M^8*^9JQ;!N7AI%)2CCTKEQ!^L"FZL\2QJV\U!.6M X
MG<]]+(M7/ZM@_$2YN\/[+"_U<[>YB\^5KIIO80'(FZ*F;2 [)Y/JA46>0>\@
M>'$+WUGU!D217;Q(!%10$;-)0H5D$ Y1+ =@>3$3=IO=)A@U;.@1_ */0TCP
M!H%X2[E&ASB0J]/3D!<%QOUZ!E9Q)%-'KY PR"!"A'98#>M[A! P&B$+;0&+
M<1L(B9BWP8\7&[B(<EI?C18B9-66+1R@NHM'W&OX'J*D;DJK@/+:YH$X2)/N
MA[ Q*1X$,#;^4M,'$#(ZSR+##+A_=!& %G"]SHJ. "$AW>@AC8CQ@O7+*,E_
MB;8'W"Y.;5:(^FX>$6_@?X@9VARQ]IWM42BK29NQ&*+(9B# @&3C. W]@*&D
M\S\J+($[T0F"?"#K--)\)RO "VT*1H]J!25/SP5AFE%Z\86^Z$&?^6"7(_E]
M\3,>:[5PLDY4O#[EXR*=^+(,ZXVJ[BP$S>^.<@HK5-$(Q"N/&$OQ11CG@?23
M(TG9J!E@W%BE.^IZ^<Q<U'(OOYY<0ZLJW0#OJ]V$&-A.T3&>OF2@28)F5 GY
M?F9(^7KF;8_S\I6^OT2/UVA1[OW.UEL;^_I];LTHB>3-+]9GA5@O!JZF7S#>
MV'*$)*]RV0T/+-#<CJ[<R(0 /[MS'ST2@SK8FDG2OH@K]!&#GGJ-P:>UQ4&?
M@YVNU_D!QYWZ)_9K<HN^?M.UC9)(LK9IGVYAH]"6W-8#),GBMAL=GQ<!ZJO5
MQ 1$_MS\_6B*_J\0C)!:<;^@J:+ ?*0$OF%-"+/*ST2M5_L!W*@8BV7%=8NQ
M0/9S#,0>L;4Y+1PT]'G@,^11..7A+_&&X=?E&A4.1J3J])-(1@M%/V?;F!@Z
M9X/6J'5,)[.GX3.IS$$R%8; 7>MT(4 SR5S!)>23N2++B\VTWZ?%G=LWK._P
M-J)OF]'Z"NR \Y&^<ET]MFYSQCB5L$?KFJP#(?%1_SY](/Y\GJ$?PGR><0\+
M^^^[K-K,(I,IAXA^I1:<X0\^%2TK<Y?B41BX'M^C+5P/;B\F?I6NLQU^B+ZT
M3%O,7=I>'DU3S[WP:A5KC4CSWI8ZB+G&8AR&,+,8!"@(V4P!^FZP(-(Y,@6*
MP%WV*#%(<]C BPUX+( /XSR)<]\E)5^?L<N*-!<<I^M>=,?"G3K2\?K$H9N$
M8G&ZIG]]&;.E$)X7'C6@XHM[(T8S'+S:^&Y70J$A5N<8[2$+[O*7E35X0S1.
M%.-@.OGQ//:,URV1*2F*+&=1+%-Y%HN.?I_.T\L@?\R,/U_6=N+/YL%Z=K=A
MD3PUYVM,'%Z:&S\V^W9LZ"MS\[X9*6'+;E8900/<&&S]J]HN@IA)%A829 X9
M#4D[ZU\:C],<@?N0#7P"BAL*SNYA^@'EX;' OQ^(]!<OEL<HZBX^CQ_5?(NE
M\>JFB+<-9.MC4KUP6F?0.PA>K ZPU7T $:.OIBA !GSK,8G_D'!N/I8VX67"
MPNE]5"3%S:9;\Y=O5-J2P*RBY*MQ^32&DJ]%U"@IAR!B1-#-IE].^Y1O6CL5
MMSDEZ"75C")G Y&CH<A@:ZSQZ.VMM("A:[7>FF4\.RM^,JA16PQWSS&[R7+T
M6(_YOCOF!WIJ6M*7._">5C*@[TMNFC+R15M&GH)CGR?D]_LM+@C%[3;[W+Q1
M63-+/DD^M<YVCPF]H\_(%90RH2.E"[ 2'!27XMHU.T/'_H!USU02&2N?K1H?
M5_T7?C$P4;2KE$!_!YX.X(0Y4S4T+>"\F-"G M]L+HHR(9K%A<96A@T]&H7
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ME-2AVA6J.4(52[P)HDRA]O52P) NJ.X%[_I$>YW$5#L;JAV6?$$/K:O-'F\
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MQM+J\S^0-"2RF\ZF38%@=F#MU>'S/(J^\7[,K@&0U0"CQ[9UH0DJ9]'X0]
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MI63*CO#8XW(.39T=758%!()L(7(X,C=AN7*I0EIT26&T>UHK!\"1O6I:\2G
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M&N#!RI3@//>EEEQQ!9 "LCG9FE45$-2[NO;;WO(ICZ,XH&\/04(,<WO)ZH!
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MY]S=F;U8F*4IX<X"<P.[[9.E#=N#'33V35=K16B'7:(>/5EV)>K!PX-K<9T
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MB&3N*N+9MZV]CQY1![[NHSP:(R*9MPX'/ZG&2,J?C(IV:90 5Q,28P^4K5X
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M3:$YNEKLG_E%4 /'J)VI!:79,1K[A&_*DIAD.2C/+QA99 (3B&:*KA=CHV$
M(]5J5A;TW]7M7__C<0%&.^NN%V0"0K[<%="@YFNMYUTD46MS,_#X#2"_5?^]
MS$IZ\6<9%V]7*;MECE\)#Q93YG8W;H#--<B6-R$C@NL#6TRX]W7M=T6+) AG
M29#GAOM=61TV)+#72>O]K@:,JSL]A$B!&B!]P,=6888?^9Y6QXV842D45W>
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M-61E>#(S,2YH=&U02P$"% ,4    "  N@'1:1'_]J)GJ P 8C1\ $0
M        @ %? @  9#$X-#@V-61P;W-A;2YH=&U02P$"% ,4    "  N@'1:
M43_O_&,; @#!RP( $0              @ $G[0, 9S$X-#@V-6<P,&XP-2YJ
M<&=02P$"% ,4    "  N@'1:W]W&D%]_ 0"U*@( $0              @ &Y
M" 8 9S$X-#@V-6<P,&XP-BYJ<&=02P$"% ,4    "  N@'1:7 420$"F 0!2
M&P( $0              @ %'B < 9S$X-#@V-6<P-V<P-RYJ<&=02P$"% ,4
M    "  N@'1:>.C%;-.Z  #0$ $ $0              @ &V+@D 9S$X-#@V
M-6<P.&<P,BYJ<&=02P$"% ,4    "  N@'1:]+R9%<"W   Q#0$ $0
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M-6<Q,&<T,"YJ<&=02P$"% ,4    "  N@'1:&1 %"Q8R  #/>P  $0
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H<BTR,#(T,3(S,5]P<F4N>&UL4$L%!@     2 !( ?@0  $P$$@    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>d184865dposam_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:okur="http://onkuretherapeutics.com/20241231"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="okur-20241231.xsd" xlink:type="simple"/>
    <context id="PAsOn12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="PAsOn03_31_2023">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:LabEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">okur:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">okur:DomesticTaxJurisdictionAndStateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MaximumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:Performance-BasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">okur:ClassACommonStockAndSeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">okur:ClinicalResearchSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePreferredStockSeriesCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:ConvertiblePromissoryNoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">okur:UnreleasedRestrictedStockUnitsAssumedInMergerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_OneTimeTerminationBenefitsMemberusgaapRestructuringCostAndReserveAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OneTimeTerminationBenefitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">okur:Non-EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">okur:Non-EmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:Performance-BasedStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:BusinessContactMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-10-04</endDate>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">okur:ReneoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-10-04</instant>
        </period>
    </context>
    <context id="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesCPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="P10_04_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-10-04</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To01_31_2025_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">okur:MergerAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-31</endDate>
        </period>
    </context>
    <context id="PAsOn06_30_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-01-01</endDate>
        </period>
    </context>
    <context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">okur:TwentyTwentyFourEquityIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-01-01</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">okur:RestrictedStockAndRestrictedStockUnitsRSUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001637715</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_shares">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="Unit_Year">
        <measure>utr:Year</measure>
    </unit>
    <unit id="Unit_pure">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_USD_per_Share">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Segment">
        <measure>okur:Segment</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2024To12_31_2024" id="hidden133878648">POS AM</dei:DocumentType>
    <dei:EntityAddressStateOrProvince contextRef="P01_01_2024To12_31_2024" id="hidden133878651">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressStateOrProvince
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="hidden133878652">CO</dei:EntityAddressStateOrProvince>
    <dei:EntityCentralIndexKey contextRef="P01_01_2024To12_31_2024" id="ixv-16444">0001637715</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="P01_01_2024To12_31_2024" id="ixv-16445">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="P01_01_2024To12_31_2024" id="ixv-16446">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="P01_01_2024To12_31_2024" id="ixv-16447">true</dei:AmendmentFlag>
    <dei:EntityRegistrantName contextRef="P01_01_2024To12_31_2024" id="ixv-47">ONKURE THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="P01_01_2024To12_31_2024" id="ixv-17514">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityPrimarySicNumber contextRef="P01_01_2024To12_31_2024" id="ixv-17515">2834</dei:EntityPrimarySicNumber>
    <dei:EntityTaxIdentificationNumber contextRef="P01_01_2024To12_31_2024" id="ixv-17516">47-2309515</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="P01_01_2024To12_31_2024" id="ixv-97">6707 Winchester Circle, #400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="P01_01_2024To12_31_2024" id="ixv-17517">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode contextRef="P01_01_2024To12_31_2024" id="ixv-17518">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="P01_01_2024To12_31_2024" id="ixv-17519">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="P01_01_2024To12_31_2024" id="ixv-17520">307-2892</dei:LocalPhoneNumber>
    <dei:ContactPersonnelName
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-17521">Nicholas A. Saccomano</dei:ContactPersonnelName>
    <dei:EntityAddressAddressLine1
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-117">6707 Winchester Circle, #400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-17522">Boulder</dei:EntityAddressCityOrTown>
    <dei:EntityAddressPostalZipCode
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-17523">80301</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-17524">720</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="P01_01_2024To12_31_2024_BusinessContactMemberdeiEntityAddressesAddressTypeAxis"
      id="ixv-17525">307-2892</dei:LocalPhoneNumber>
    <dei:EntityFilerCategory contextRef="P01_01_2024To12_31_2024" id="ixv-17526">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="P01_01_2024To12_31_2024" id="ixv-17527">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="P01_01_2024To12_31_2024" id="ixv-17528">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="P01_01_2024To12_31_2024" id="ixv-17529">false</dei:EntityExTransitionPeriod>
    <dei:AmendmentDescription contextRef="P01_01_2024To12_31_2024" id="ixv-224"> EXPLANATORY NOTE  Post-Effective Amendment to Registration Statement on Form S-1  OnKure Therapeutics, Inc., a Delaware corporation, filed a Registration Statement on Form S-1 on October&#160;23, 2024, which was declared effective on October 30, 2024 (the &#x201c;Registration Statement&#x201d;). This Post-Effective Amendment No. 1 to Form S-1 (the &#x201c;Post-Effective Amendment&#x201d;) is being provided to include the fiscal year ended December 31, 2024 financial statements, contained in the Annual Report on Form 10-K for the year-ended December 31, 2024 filed on March 10, 2025 (the &#x201c;Form 10-K&#x201d;), as well as updating certain other disclosures, including those based on the above-mentioned Form 10-K.  The information included in this filing amends the Registration Statement and the prospectus contained therein (and all amendments thereto). No additional securities are being registered under this Post-Effective Amendment. All applicable registration fees were paid at the time of the original filing of the Registration Statement. </dei:AmendmentDescription>
    <us-gaap:LeaseExpirationDate1 contextRef="P01_01_2024To12_31_2024" id="hidden133878813">2026-12-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:SegmentExtensibleList contextRef="P01_01_2024To12_31_2024" id="hidden133878841">http://onkuretherapeutics.com/20241231#ClinicalResearchSegmentMember</us-gaap:SegmentExtensibleList>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheOneMemberusgaapVestingAxis"
      id="ixv-17537">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_MinimumMembersrtRangeAxis"
      id="hidden133878817">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration
      contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      id="hidden133878837">http://fasb.org/us-gaap/2024#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember</us-gaap:PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="hidden133878830">P2Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MinimumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="hidden133878831">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17544"
      unitRef="Unit_USD">110761000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17545"
      unitRef="Unit_USD">29876000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17546"
      unitRef="Unit_USD">2242000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17547"
      unitRef="Unit_USD">3890000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17548"
      unitRef="Unit_USD">113003000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17549"
      unitRef="Unit_USD">33766000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17550"
      unitRef="Unit_USD">1025000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17551"
      unitRef="Unit_USD">1432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17552"
      unitRef="Unit_USD">770000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17553"
      unitRef="Unit_USD">478000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17554"
      unitRef="Unit_USD">109000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17555"
      unitRef="Unit_USD">58000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17556"
      unitRef="Unit_USD">114907000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17557"
      unitRef="Unit_USD">35734000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17558"
      unitRef="Unit_USD">2968000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17559"
      unitRef="Unit_USD">3417000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17560"
      unitRef="Unit_USD">7026000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17561"
      unitRef="Unit_USD">3660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17562"
      unitRef="Unit_USD">536000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17563"
      unitRef="Unit_USD">208000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17564"
      unitRef="Unit_USD">10530000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17565"
      unitRef="Unit_USD">7285000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17566"
      unitRef="Unit_USD">549000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17567"
      unitRef="Unit_USD">466000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17568"
      unitRef="Unit_USD">11079000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17569"
      unitRef="Unit_USD">7751000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2024"
      id="ixv-17570"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="PAsOn12_31_2023"
      id="ixv-17571"
      unitRef="Unit_USD"
      xsi:nil="true"/>
    <okur:ConvertiblePreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17572"
      unitRef="Unit_USD_per_Share">0.0001</okur:ConvertiblePreferredStockParOrStatedValuePerShare>
    <okur:ConvertiblePreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17573"
      unitRef="Unit_USD_per_Share">0.0001</okur:ConvertiblePreferredStockParOrStatedValuePerShare>
    <okur:ConvertiblePreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17574"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesAuthorized>
    <okur:ConvertiblePreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17575"
      unitRef="Unit_shares">7404919</okur:ConvertiblePreferredStockSharesAuthorized>
    <okur:ConvertiblePreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17576"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesOutstanding>
    <okur:ConvertiblePreferredStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17577"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesIssued>
    <okur:ConvertiblePreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17578"
      unitRef="Unit_shares">6840620</okur:ConvertiblePreferredStockSharesOutstanding>
    <okur:ConvertiblePreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17579"
      unitRef="Unit_shares">6840620</okur:ConvertiblePreferredStockSharesIssued>
    <okur:ConvertiblePreferredStockLiquidationPreferenceValue
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-17580"
      unitRef="Unit_USD">195823</okur:ConvertiblePreferredStockLiquidationPreferenceValue>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="PAsOn12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17581"
      unitRef="Unit_USD">0</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
    <us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17582"
      unitRef="Unit_USD">129825000</us-gaap:ConvertiblePreferredStockNonredeemableOrRedeemableIssuerOptionValue>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17583"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17584"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17585"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17586"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17587"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17588"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17589"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17590"
      unitRef="Unit_USD">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17591"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17592"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17593"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17594"
      unitRef="Unit_shares">943840</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17595"
      unitRef="Unit_shares">12660590</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17596"
      unitRef="Unit_shares">12660590</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17597"
      unitRef="Unit_shares">313747</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17598"
      unitRef="Unit_shares">313747</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17599"
      unitRef="Unit_USD">1000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17600"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17601"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17602"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17603"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17604"
      unitRef="Unit_shares">226285</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17605"
      unitRef="Unit_shares">686527</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17606"
      unitRef="Unit_shares">686527</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17607"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17608"
      unitRef="Unit_shares">0</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17609"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="PAsOn12_31_2023_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17610"
      unitRef="Unit_USD">0</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17611"
      unitRef="Unit_USD">258551000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17612"
      unitRef="Unit_USD">209000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17613"
      unitRef="Unit_USD">-154724000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17614"
      unitRef="Unit_USD">-102051000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17615"
      unitRef="Unit_USD">103828000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17616"
      unitRef="Unit_USD">-101842000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17617"
      unitRef="Unit_USD">114907000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17618"
      unitRef="Unit_USD">35734000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17619"
      unitRef="Unit_USD">43795000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17620"
      unitRef="Unit_USD">32115000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17621"
      unitRef="Unit_USD">10591000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17622"
      unitRef="Unit_USD">4819000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17623"
      unitRef="Unit_USD">54386000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17624"
      unitRef="Unit_USD">36934000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17625"
      unitRef="Unit_USD">-54386000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17626"
      unitRef="Unit_USD">-36934000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17627"
      unitRef="Unit_USD">2013000</us-gaap:InterestIncomeOperating>
    <us-gaap:InterestIncomeOperating
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17628"
      unitRef="Unit_USD">1623000</us-gaap:InterestIncomeOperating>
    <okur:InterestAndOtherExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17629"
      unitRef="Unit_USD">300000</okur:InterestAndOtherExpense>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17630"
      unitRef="Unit_USD">1713000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:InterestIncomeExpenseNet
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17631"
      unitRef="Unit_USD">1623000</us-gaap:InterestIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17632"
      unitRef="Unit_USD">-52673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17633"
      unitRef="Unit_USD">-35311000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17634"
      unitRef="Unit_USD_per_Share">-15.28</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17635"
      unitRef="Unit_USD_per_Share">-15.28</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-17636"
      unitRef="Unit_USD_per_Share">-124.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-17637"
      unitRef="Unit_USD_per_Share">-124.41</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17638"
      unitRef="Unit_shares">3447071</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17639"
      unitRef="Unit_shares">3447071</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-17640"
      unitRef="Unit_shares">283817</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-17641"
      unitRef="Unit_shares">283817</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17642"
      unitRef="Unit_shares">3738936</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17643"
      unitRef="Unit_USD">64389000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2022_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17644"
      unitRef="Unit_shares">182769</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17645"
      unitRef="Unit_USD">2656000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17646"
      unitRef="Unit_USD">-57074000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2022"
      decimals="-3"
      id="ixv-17647"
      unitRef="Unit_USD">-54418000</us-gaap:StockholdersEquity>
    <okur:StockIssuanceCostNet
      contextRef="P01_01_2023To12_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="-5"
      id="ixv-17648"
      unitRef="Unit_USD">700000</okur:StockIssuanceCostNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17649"
      unitRef="Unit_shares">2818192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17650"
      unitRef="Unit_USD">53059000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17651"
      unitRef="Unit_shares">283492</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17652"
      unitRef="Unit_USD">12377000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17653"
      unitRef="Unit_shares">127476</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-17654"
      unitRef="Unit_USD">-2711000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17655"
      unitRef="Unit_USD">-9666000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2023To12_31_2023_ClassACommonStockAndSeriesCPreferredStockMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-17656"
      unitRef="Unit_USD">-12377000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17657"
      unitRef="Unit_shares">3502</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17658"
      unitRef="Unit_USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2023To12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="-3"
      id="ixv-17659"
      unitRef="Unit_USD">65000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17660"
      unitRef="Unit_USD">199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17661"
      unitRef="Unit_USD">199000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17662"
      unitRef="Unit_USD">-35311000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17663"
      unitRef="Unit_USD">-35311000</us-gaap:NetIncomeLoss>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17664"
      unitRef="Unit_shares">6840620</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17665"
      unitRef="Unit_USD">129825000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2023_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17666"
      unitRef="Unit_shares">313747</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17667"
      unitRef="Unit_USD">209000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17668"
      unitRef="Unit_USD">-102051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17669"
      unitRef="Unit_USD">-101842000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17670"
      unitRef="Unit_shares">-6840620</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockMemberusgaapStatementClassOfStockAxis_PreferredStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17671"
      unitRef="Unit_USD">-129825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17672"
      unitRef="Unit_shares">6154093</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17673"
      unitRef="Unit_USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17674"
      unitRef="Unit_shares">686527</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17675"
      unitRef="Unit_USD">129824000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17676"
      unitRef="Unit_USD">129825000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <okur:StockIssuedDuringPeriodSharesConcurrentFinancing
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17677"
      unitRef="Unit_shares">2571736</okur:StockIssuedDuringPeriodSharesConcurrentFinancing>
    <okur:StockIssuedDuringPeriodValueConcurrentFinancing
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17678"
      unitRef="Unit_USD">54428000</okur:StockIssuedDuringPeriodValueConcurrentFinancing>
    <okur:StockIssuedDuringPeriodValueConcurrentFinancing
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17679"
      unitRef="Unit_USD">54428000</okur:StockIssuedDuringPeriodValueConcurrentFinancing>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17680"
      unitRef="Unit_shares">3343604</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17681"
      unitRef="Unit_USD">65499000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17682"
      unitRef="Unit_USD">65499000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17683"
      unitRef="Unit_USD">-2085000</okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts>
    <okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17684"
      unitRef="Unit_USD">-2085000</okur:AdjustmentsToAdditionalPaidInCapitalReverseRecapitalizationTransactionCosts>
    <okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17685"
      unitRef="Unit_shares">267269</okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesShares>
    <okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17686"
      unitRef="Unit_USD">6120000</okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue>
    <okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17687"
      unitRef="Unit_USD">6120000</okur:StockIssuedDuringPeriodConversionOfConvertiblePromissoryNotesValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17688"
      unitRef="Unit_shares">7700</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17689"
      unitRef="Unit_shares">2476</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17690"
      unitRef="Unit_USD">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17691"
      unitRef="Unit_USD">26000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <okur:AdjustmentForFractionalSharesInTheReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17692"
      unitRef="Unit_shares">-35</okur:AdjustmentForFractionalSharesInTheReverseRecapitalization>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17693"
      unitRef="Unit_USD">4530000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17694"
      unitRef="Unit_USD">4530000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17695"
      unitRef="Unit_USD">-52673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17696"
      unitRef="Unit_USD">-52673000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17697"
      unitRef="Unit_shares">12660590</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="0"
      id="ixv-17698"
      unitRef="Unit_USD">1</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis"
      decimals="INF"
      id="ixv-17699"
      unitRef="Unit_shares">686527</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_AdditionalPaidInCapitalMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17700"
      unitRef="Unit_USD">258551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024_RetainedEarningsMemberusgaapStatementEquityComponentsAxis"
      decimals="-3"
      id="ixv-17701"
      unitRef="Unit_USD">-154724000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17702"
      unitRef="Unit_USD">103828000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17703"
      unitRef="Unit_USD">-52673000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17704"
      unitRef="Unit_USD">-35311000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17705"
      unitRef="Unit_USD">4530000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17706"
      unitRef="Unit_USD">199000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17707"
      unitRef="Unit_USD">459000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17708"
      unitRef="Unit_USD">417000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17709"
      unitRef="Unit_USD">203000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17710"
      unitRef="Unit_USD">143000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17711"
      unitRef="Unit_USD">142000</us-gaap:AmortizationOfFinancingCosts>
    <okur:Non-CashInterestExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17712"
      unitRef="Unit_USD">120000</okur:Non-CashInterestExpense>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17713"
      unitRef="Unit_USD">-54000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17714"
      unitRef="Unit_USD">-2256000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17715"
      unitRef="Unit_USD">1497000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17716"
      unitRef="Unit_USD">-5927000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17717"
      unitRef="Unit_USD">1713000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17718"
      unitRef="Unit_USD">-281000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17719"
      unitRef="Unit_USD">-210000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17720"
      unitRef="Unit_USD">-51117000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17721"
      unitRef="Unit_USD">-34546000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17722"
      unitRef="Unit_USD">15925000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17723"
      unitRef="Unit_USD">52000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17724"
      unitRef="Unit_USD">246000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17725"
      unitRef="Unit_USD">15873000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17726"
      unitRef="Unit_USD">-246000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfPrivatePlacement
      contextRef="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-17727"
      unitRef="Unit_USD">58881000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="P01_01_2024To12_31_2024_PrivatePlacementMemberusgaapSubsidiarySaleOfStockAxis"
      decimals="-3"
      id="ixv-17728"
      unitRef="Unit_USD">4327000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17729"
      unitRef="Unit_USD">57736000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <okur:PaymentOfReverseRecapitalizationTransactionCosts
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17730"
      unitRef="Unit_USD">2045000</okur:PaymentOfReverseRecapitalizationTransactionCosts>
    <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17731"
      unitRef="Unit_USD">53783000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
    <us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17732"
      unitRef="Unit_USD">723000</us-gaap:PaymentsForRepurchaseOfPreferredStockAndPreferenceStock>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17733"
      unitRef="Unit_USD">6000000</us-gaap:ProceedsFromConvertibleDebt>
    <okur:PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17734"
      unitRef="Unit_USD">142000</okur:PaymentOfIssuanceCostsAssociatedWithTheIssuanceOfConvertibleNotesPayable>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17735"
      unitRef="Unit_USD">26000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17736"
      unitRef="Unit_USD">65000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17737"
      unitRef="Unit_USD">116129000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17738"
      unitRef="Unit_USD">53125000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17739"
      unitRef="Unit_USD">80885000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17740"
      unitRef="Unit_USD">18333000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-17741"
      unitRef="Unit_USD">29876</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2022"
      decimals="0"
      id="ixv-17742"
      unitRef="Unit_USD">11543</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-17743"
      unitRef="Unit_USD">110761</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="PAsOn12_31_2023"
      decimals="0"
      id="ixv-17744"
      unitRef="Unit_USD">29876</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17745"
      unitRef="Unit_USD">219000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17746"
      unitRef="Unit_USD">23313000</us-gaap:ConversionOfStockAmountIssued1>
    <okur:ConversionOfSeriesCPreferredStock
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17747"
      unitRef="Unit_USD">129825000</okur:ConversionOfSeriesCPreferredStock>
    <okur:ConversionOfConvertibleNotePayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17748"
      unitRef="Unit_USD">6120000</okur:ConversionOfConvertibleNotePayable>
    <okur:AssetsAcquiredInConnectionWithTheReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17749"
      unitRef="Unit_USD">17222000</okur:AssetsAcquiredInConnectionWithTheReverseRecapitalization>
    <okur:OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17750"
      unitRef="Unit_USD">9459000</okur:OtherLiabilitiesAssumedInConnectionWithTheReverseRecapitalization>
    <okur:ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17751"
      unitRef="Unit_USD">40000</okur:ReverseRecapitalizationTransactionCostsIncludedInAccountsPayable>
    <okur:ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17752"
      unitRef="Unit_USD">37000</okur:ConcurrentFinancingIssuanceCostsIncludedInAccountsPayable>
    <okur:ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17753"
      unitRef="Unit_USD">89000</okur:ConcurrentFinancingIssuanceCostsPaidByReneoPriorToMerger>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12668">&lt;div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;1. Organization and Business &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;OnKure Therapeutics, Inc., (&#x201c;OnKure&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. Using a structure- and computational chemistry-driven drug design platform, OnKure is committed to improving clinical outcomes for patients by building a pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer. The Company was formed in 2014 as Reneo Pharmaceuticals, Inc. (&#x201c;Reneo&#x201d;) under the laws of the State of Delaware. On October&#160;4, 2024, the Company changed its name to OnKure Therapeutics, Inc. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Merger with Reneo &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;On October&#160;4, 2024, Radiate Merger Sub I, Inc. (&#x201c;Merger Sub I&#x201d;) a&#160;wholly-owned subsidiary of Reneo completed its merger with and into OnKure, Inc. (referred to herein as &#x201c;Legacy OnKure&#x201d;), with Legacy OnKure continuing as the surviving entity as a wholly-owned subsidiary of Reneo. This transaction is referred to as the &#x201c;Merger.&#x201d; Following the Merger, Reneo changed its name to OnKure Therapeutics, Inc. Legacy OnKure remains as a wholly-owned subsidiary of the Company. The Merger was effected pursuant to an Agreement and Plan of Merger, dated as of May 10, 2024 (the &#x201c;Merger Agreement&#x201d;), by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation Radiate Merger Sub II, LLC, a Delaware limited liability company (&#x201c;Merger Sub II&#x201d;), and Legacy OnKure. In connection with the Merger Agreement, certain parties entered into a subscription agreement with the Company to purchase shares of Reneo&#x2019;s common stock for an aggregate purchase price of $65.0&#160;million contingent upon the concurrent consummation of the Merger (the &#x201c;Concurrent Financing&#x201d;).&#160;On October&#160;4, 2024 (the &#x201c;Closing Date&#x201d;), the Merger and the Concurrent Financing closed. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Merger was accounted for as a reverse recapitalization in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;). For accounting purposes, Legacy OnKure is considered the accounting acquirer and Reneo is the acquired company based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#x2019;s board of directors and senior management. Accordingly, the Merger was treated as the equivalent of Legacy OnKure issuing stock to acquire the net assets of Reneo. As a result of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company and the reported operating results prior to the Merger are those of Legacy OnKure. Legacy OnKure&#x2019;s historical financial statements became the historical consolidated financial statements of the combined company. All issued and outstanding Legacy OnKure common stock, convertible preferred stock, restricted stock units, and options to purchase common stock prior to the effective date of the Merger have been retroactively adjusted to reflect the exchange ratio for all periods presented. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;See Note 3 for further discussion. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risks and Uncertainties &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The board of directors of the Company discusses with management macroeconomic and geopolitical developments, including inflation, instability in the banking and financial services sector, tightening of the credit markets, international conflicts,&#160;cybersecurity, and sanctions so that the Company can be prepared to react to new developments as they arise.&#160;The board of directors and the management of the Company are carefully monitoring these developments and the resulting economic impact on its financial condition and results of operations. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidity and Capital Resources &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company had recurring losses from operations, an accumulated deficit of $154.7&#160;million and cash and cash equivalents of $110.8&#160;million as of December&#160;31, 2024. The Company&#x2019;s ability to fund its ongoing operations is highly dependent upon raising additional capital through the issuance of equity securities, issuing debt or other financing vehicles. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company had determined that substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of at least 12 months from the date of the issuance of those financial statements did exist. However, following the completion of the Merger and Concurrent Financing, as described in more detail in Note 3, management believes the Company&#x2019;s cash and cash equivalents will be sufficient to fund its current operating plan for at least the next 12 months from the date of issuance of these consolidated financial statements and as such substantial doubt has been alleviated. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s ability to secure capital is dependent upon success in discovering and developing its drug candidates. The Company cannot provide assurance that additional capital will be available on acceptable terms, if at all. The issuance of additional equity or debt securities will likely result in substantial dilution to the Company&#x2019;s stockholders. Should additional capital not be available to the Company in the near term, or not be available on acceptable terms, the Company may be unable to realize value from the Company&#x2019;s assets or discharge liabilities in the normal course of business, which may, among other alternatives, cause the Company to delay, substantially reduce, or discontinue operational activities to conserve cash, which could have a material adverse effect on the Company&#x2019;s ability to achieve its intended business objectives. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The accompanying financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. The financial statements do not reflect any adjustments relating to the recoverability and reclassification of assets and liabilities that might be necessary if the Company is unable to continue as a going concern. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on the Company&#x2019;s financial condition and its ability to discover and develop its product candidates. Changing circumstances may cause the Company to consume capital significantly faster or slower than currently anticipated. If the Company is unable to acquire additional capital or resources, it will be required to modify its operational plans. The estimates included herein are based on assumptions that may prove to be wrong, and the Company could exhaust its available financial resources sooner than currently anticipated. &lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1
      contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      id="ixv-17754">2024-05-10</us-gaap:BusinessAcquisitionDateOfAcquisitionAgreement1>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="-5"
      id="ixv-17755"
      unitRef="Unit_USD">65000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-17757"
      unitRef="Unit_USD">-154700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-17758"
      unitRef="Unit_USD">110800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12709">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2. Summary of Significant Accounting Policies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP and reflect the operation of the Company and its wholly owned subsidiaries, OnKure, Inc. and Merger Sub II. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company operates in&#160;one&#160;operating segment: clinical research. All equipment and other property and equipment are physically located within the United States&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and disclosure of contingent assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates. The most significant estimates relate to external research and development expenses, and the fair value of stock options and restricted stock awards and units. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;from&#160;non-owner&#160;sources.&lt;/div&gt; The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods &lt;div style="display:inline;"&gt;presented&lt;/div&gt;. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred in performing research and development activities. The costs include employee-related expense, including salaries, severance, benefits, share- based compensation, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to manufacture or have manufactured clinical trial materials, depreciation, and facilities and overhead costs. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records research and development expenses in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase common stock, and restricted stock units for common stock, are granted to employees, board of directors, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;and&#160;non-employee&#160;consultants.&lt;/div&gt; Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of 10 years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. The Company will continue to apply this process until enough historical information regarding the volatility of its stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes&lt;/div&gt; with maturities approximately equal to the expected term of the stock options. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. (See Note 12). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes stock-based compensation expense for grants under its various Equity Incentive Plans and employee stock purchase plan (&#x201c;ESPP&#x201d;). The Company accounts for all stock-based awards granted to employees and directors at their fair value and recognizes compensation expense over the award&#x2019;s vesting period. Determining the amount of stock-based compensation to be recorded requires the Company to develop estimates of fair values of stock options as of the grant date. The Company calculates the grant date fair values of stock options using the Black-Scholes valuation model, which requires the input of subjective assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. The fair value of restricted stock awards granted to employees is based on the quoted closing market price per share on grant date. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Due to the lack of marketability for the Company&#x2019;s common stock prior to the Merger, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#x2019; Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted prior to the Merger, the Company had considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#x2019;s research and development programs, including their stages of development, and the Company&#x2019;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#x2019;s financial position, including cash on hand, and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock; and the market performance of peer companies in the biopharmaceutical industry. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The carrying amounts of the Company&#x2019;s financial assets and liabilities, such as cash, receivables, prepaid and other current assets, accounts payable, and accrued expenses approximate their fair values because of the short maturity of these instruments. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All highly liquid investments with maturities of 90 days or less, at the time of purchase, are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value. The Company&#x2019;s cash and cash equivalents consist of money held in demand depository accounts and money market funds. The carrying amount of cash and cash equivalents was $110.8&#160;million and $29.9&#160;million as of December&#160;31, 2024, and 2023, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&#160;1. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions above federally insured limits of $250,000 as of December&#160;31, 2024 and 2023. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held and of the money market funds in which these investments are made. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company carries its property and equipment at cost, less accumulated depreciation, amortization and impairment, if any. Expenditures for renewals or betterments that materially extend the useful life of an asset or increase its productivity, such as leasehold improvements, are capitalized. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden133878817;display:inline;"&gt;three&lt;/div&gt;&lt;/div&gt; to &lt;div style="display:inline;"&gt;seven years&lt;/div&gt;. Leasehold improvements are amortized over the &lt;div style="-sec-ix-hidden:hidden133878837;display:inline;"&gt;shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets&lt;/div&gt;. Repair and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasing &#x2013; Lessee Accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. The Company&#x2019;s operating lease agreements are primarily for office space and research labs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For operating leases with a term greater than one year, the Company recognizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;the&#160;right-of-use&#160;(&#x201c;ROU&#x201d;)&lt;/div&gt;&lt;/div&gt; assets and lease liabilities related to the lease payments on its balance sheet. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The ROU assets represent the Company&#x2019;s right to use the underlying assets for the term of the lease and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising for the agreements. ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is periodically reviewed for impairment unless a triggering event occurs. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, except for the ones that depend on index or rate, are excluded from the calculation of the ROU assets and lease liabilities and are recognized as variable lease expense in the statements of operations and comprehensive loss in the period in which they are incurred. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As the interest rate implicit in the Company&#x2019;s leases is not readily determinable, the Company uses its estimated incremental borrowing rate in its present value calculations. One of the Company&#x2019;s lessee agreements include an option to extend the lease, which the Company does not include in its minimum lease term unless it is reasonably certain to exercise such option. Operating leases with a term of less than one year are recognized as a lease expense over the term of the lease, with no asset or liability recognized on the balance sheet. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently payable and deferred taxes. The Company accounts for income taxes using the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, and operating losses and tax credit carryforwards. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is recorded to the extent it is more likely than not that some portion of a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company&#x2019;s significant deferred tax assets are net operating loss carryforwards, tax credits, and accruals. The Company has provided a valuation allowance equal to its net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that most of its deferred tax assets will not be realized. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accounting for uncertain tax positions requires a more likely than not threshold for recognition in the financial statements. The Company recognizes a tax benefit based on whether it is more likely than not that a tax position will be sustained. The Company records a liability to the extent that a tax position taken or expected to be taken on a tax return exceeds the amount recognized in the financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has no unrecognized tax benefits as of December&#160;31, 2024 and 2023. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as general and administrative expenses. No such expenses have been recognized during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in the United States and the United Kingdom (&#x201c;UK&#x201d;). As of December&#160;31, 2024, the Company&#x2019;s tax years since inception are subject to examination by taxing authorities in the United States, and the UK tax returns from 2018 forward are subject to examination. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncemen&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;issued&#160;ASU&#160;2023-07,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt;&#160;to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company&#x2019;s 2024 fiscal year annual reporting period, with early adoption permitted. The disclosure related to this ASU are in Note 4 below. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2023-09,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Taxes (Topic 740):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which&lt;/div&gt; requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;div style="white-space:nowrap;display:inline;"&gt;220-40):&lt;/div&gt; Disaggregation of Income Statement Expenses&lt;/div&gt;&lt;/div&gt;. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this pronouncement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on its financial statements. &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <okur:BasisOfPresentationAndConsolidationPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12712">&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Basis of Presentation and Consolidation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s consolidated financial statements are prepared in accordance with GAAP and reflect the operation of the Company and its wholly owned subsidiaries, OnKure, Inc. and Merger Sub II. All intercompany balances and transactions among the consolidated entities have been eliminated in consolidation. &lt;/div&gt;</okur:BasisOfPresentationAndConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12718">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Segment Information &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company operates in&#160;one&#160;operating segment: clinical research. All equipment and other property and equipment are physically located within the United States&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;.&lt;/div&gt;&lt;/div&gt; &lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17759"
      unitRef="Unit_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates contextRef="P01_01_2024To12_31_2024" id="ixv-12726">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Use of Estimates &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preparation of the Company&#x2019;s consolidated financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;and disclosure of contingent assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Although these estimates are based on the Company&#x2019;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates. The most significant estimates relate to external research and development expenses, and the fair value of stock options and restricted stock awards and units. &lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12754">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Comprehensive Loss &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Comprehensive loss is defined as a change in equity during a period from transactions and other events and circumstances &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;from&#160;non-owner&#160;sources.&lt;/div&gt; The Company&#x2019;s comprehensive loss was the same as its reported net loss for all periods &lt;div style="display:inline;"&gt;presented&lt;/div&gt;. &lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="P01_01_2024To12_31_2024" id="ixv-12761">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Research and development (&#x201c;R&amp;amp;D&#x201d;) costs are expensed as incurred in performing research and development activities. The costs include employee-related expense, including salaries, severance, benefits, share- based compensation, fees for acquiring and maintaining licenses under third-party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#x2019;s behalf, costs to manufacture or have manufactured clinical trial materials, depreciation, and facilities and overhead costs. &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <okur:AccruedResearchAndDevelopmentExpensesPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12766">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Accrued Research and Development Expenses &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company records research and development expenses in the period in which the Company receives or takes ownership of the applicable goods or when the applicable services are performed. The Company is required to estimate its expenses resulting from its obligations under contracts with vendors, consultants, and contract research organizations, in connection with conducting research and development activities. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result in payment flows that do not match the periods over which materials or services are provided under such contracts. The Company reflects research and development expenses in its financial statements by matching those expenses with the period in which services and efforts are expended. The Company accounts for these expenses according to the progress of the preclinical studies or clinical trials, as measured by the timing of various aspects of the study or related activities. The Company determines accrual estimates through a review of the underlying contracts along with the preparation of financial models considering discussions with research and other key personnel as to the progress of studies, trials, or other services being conducted. During a study or trial, the Company adjusts its rate of expense recognition if actual results differ from its estimate. Nonrefundable advance payments for goods and services, including fees for process development or manufacturing and distribution of clinical supplies that will be used in future research and development activities, are deferred and recognized as an expense in the period that the related goods are consumed, or services are performed. &lt;/div&gt;</okur:AccruedResearchAndDevelopmentExpensesPolicyTextBlock>
    <okur:PatentCostsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12771">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Patent Costs &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company expenses all costs as incurred in connection with patent applications (including direct application fees and the legal and consulting expenses related to making such applications) and such costs are included in general and administrative expenses in the statements of operations and comprehensive loss. &lt;/div&gt;</okur:PatentCostsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-12776">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company maintains an equity incentive compensation plan under which incentive stock options and nonqualified stock options to purchase common stock, and restricted stock units for common stock, are granted to employees, board of directors, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;and&#160;non-employee&#160;consultants.&lt;/div&gt; Stock-based compensation cost is measured at the grant date, based on the fair value of the award, and is recognized as expense over the requisite service or performance period. The fair value of stock options granted to employees is estimated using the Black-Scholes option pricing model. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Black-Scholes valuation method requires certain assumptions be used as inputs, such as the fair value of the underlying common stock, expected term of the option before exercise, expected volatility of the Company&#x2019;s common stock, risk-free interest rate and expected dividend. Options granted have a maximum contractual term of 10 years. The Company has limited historical stock option activity and therefore estimates the expected term of stock options granted using the simplified method, which represents the arithmetic average of the original contractual term of the stock option and its weighted-average vesting term. The expected volatility of stock options is based on the historical volatility of several publicly traded companies in similar stages of clinical development. The Company will continue to apply this process until enough historical information regarding the volatility of its stock price becomes available. The risk-free interest rates used are based on the U.S. Treasury yield in effect at the time &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;of&#160;grant&#160;for&#160;zero-coupon&#160;U.S.&#160;treasury&#160;notes&lt;/div&gt; with maturities approximately equal to the expected term of the stock options. The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero. (See Note 12). &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recognizes stock-based compensation expense for grants under its various Equity Incentive Plans and employee stock purchase plan (&#x201c;ESPP&#x201d;). The Company accounts for all stock-based awards granted to employees and directors at their fair value and recognizes compensation expense over the award&#x2019;s vesting period. Determining the amount of stock-based compensation to be recorded requires the Company to develop estimates of fair values of stock options as of the grant date. The Company calculates the grant date fair values of stock options using the Black-Scholes valuation model, which requires the input of subjective assumptions, including but not limited to expected stock price volatility over the term of the awards and the expected term of stock options. The fair value of restricted stock awards granted to employees is based on the quoted closing market price per share on grant date. &lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm contextRef="P01_01_2024To12_31_2024" id="ixv-17762">P10Y</okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsMaximumContractualTerm>
    <okur:CommonStockValuationPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12803">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock Valuation &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Due to the lack of marketability for the Company&#x2019;s common stock prior to the Merger, the Company utilized methodologies, approaches and assumptions consistent with the American Institute of Certified Public Accountants&#x2019; Audit and Accounting Practice Guide: Valuation of Privately-Held Company Equity Securities Issued as Compensation to estimate the fair value of its common stock. In determining the exercise prices for options granted prior to the Merger, the Company had considered the fair value of the common stock as of the grant date. The fair value of the common stock has been determined based upon a variety of factors, including the prices at which the Company sold shares of its convertible preferred stock to outside investors in arms-length transactions, and the superior rights, preferences and privileges of the preferred stock relative to the common stock at the time of each grant; the progress of the Company&#x2019;s research and development programs, including their stages of development, and the Company&#x2019;s business strategy; external market and other conditions affecting the biotechnology industry, and trends within the biotechnology industry; the Company&#x2019;s financial position, including cash on hand, and its historical and forecasted performance and operating results; the lack of an active public market for the Company&#x2019;s common stock; and the market performance of peer companies in the biopharmaceutical industry. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant changes to the key assumptions underlying the factors used could result in different fair values of common stock at each valuation date. &lt;/div&gt;</okur:CommonStockValuationPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="P01_01_2024To12_31_2024" id="ixv-12809">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Fair Value of Financial Instruments &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is required to disclose information on all assets and liabilities reported at fair value that enables an assessment of the inputs used in determining the reported fair values. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The carrying amounts of the Company&#x2019;s financial assets and liabilities, such as cash, receivables, prepaid and other current assets, accounts payable, and accrued expenses approximate their fair values because of the short maturity of these instruments. &lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12834">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Cash and Cash Equivalents &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All highly liquid investments with maturities of 90 days or less, at the time of purchase, are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value. The Company&#x2019;s cash and cash equivalents consist of money held in demand depository accounts and money market funds. The carrying amount of cash and cash equivalents was $110.8&#160;million and $29.9&#160;million as of December&#160;31, 2024, and 2023, respectively, which approximates fair value and was determined based upon Level&#160;1 inputs. The money market account is valued using quoted market prices with no valuation adjustments applied and is categorized as Level&#160;1. &lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-17764"
      unitRef="Unit_USD">110800000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-17765"
      unitRef="Unit_USD">29900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="P01_01_2024To12_31_2024" id="ixv-12839">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Concentration of Credit Risk &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains accounts in federally insured financial institutions above federally insured limits of $250,000 as of December&#160;31, 2024 and 2023. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held and of the money market funds in which these investments are made. &lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-17766"
      unitRef="Unit_USD">250000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17767"
      unitRef="Unit_USD">250000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12844">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company carries its property and equipment at cost, less accumulated depreciation, amortization and impairment, if any. Expenditures for renewals or betterments that materially extend the useful life of an asset or increase its productivity, such as leasehold improvements, are capitalized. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally between &lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden133878817;display:inline;"&gt;three&lt;/div&gt;&lt;/div&gt; to &lt;div style="display:inline;"&gt;seven years&lt;/div&gt;. Leasehold improvements are amortized over the &lt;div style="-sec-ix-hidden:hidden133878837;display:inline;"&gt;shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets&lt;/div&gt;. Repair and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="PAsOn12_31_2024_MaximumMembersrtRangeAxis"
      id="ixv-17768">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12853">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Impairment of Long-Lived Assets &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. No impairment charges were recorded during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-17769"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17770"
      unitRef="Unit_USD">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12858">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Leasing &#x2013; Lessee Accounting &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company determines if an arrangement is a lease at inception. The Company&#x2019;s operating lease agreements are primarily for office space and research labs. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;For operating leases with a term greater than one year, the Company recognizes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;the&#160;right-of-use&#160;(&#x201c;ROU&#x201d;)&lt;/div&gt;&lt;/div&gt; assets and lease liabilities related to the lease payments on its balance sheet. The lease liabilities are initially and subsequently measured at the present value of the unpaid lease payments at the lease commencement date. The ROU assets represent the Company&#x2019;s right to use the underlying assets for the term of the lease and the lease liabilities represent the Company&#x2019;s obligation to make lease payments arising for the agreements. ROU assets are initially measured at cost, which comprises the initial amount of the lease liability adjusted for lease payments made at or before the lease commencement date, plus any initial direct costs incurred less any lease incentives received. The ROU asset is periodically reviewed for impairment unless a triggering event occurs. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Variable lease payments, except for the ones that depend on index or rate, are excluded from the calculation of the ROU assets and lease liabilities and are recognized as variable lease expense in the statements of operations and comprehensive loss in the period in which they are incurred. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;As the interest rate implicit in the Company&#x2019;s leases is not readily determinable, the Company uses its estimated incremental borrowing rate in its present value calculations. One of the Company&#x2019;s lessee agreements include an option to extend the lease, which the Company does not include in its minimum lease term unless it is reasonably certain to exercise such option. Operating leases with a term of less than one year are recognized as a lease expense over the term of the lease, with no asset or liability recognized on the balance sheet.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12884">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Income taxes are provided for the tax effects of transactions reported in the financial statements and consist of taxes currently payable and deferred taxes. The Company accounts for income taxes using the asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis, and operating losses and tax credit carryforwards. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A valuation allowance is recorded to the extent it is more likely than not that some portion of a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date. The Company&#x2019;s significant deferred tax assets are net operating loss carryforwards, tax credits, and accruals. The Company has provided a valuation allowance equal to its net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that most of its deferred tax assets will not be realized. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accounting for uncertain tax positions requires a more likely than not threshold for recognition in the financial statements. The Company recognizes a tax benefit based on whether it is more likely than not that a tax position will be sustained. The Company records a liability to the extent that a tax position taken or expected to be taken on a tax return exceeds the amount recognized in the financial statements. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has no unrecognized tax benefits as of December&#160;31, 2024 and 2023. The Company classifies interest and penalties arising from the underpayment of income taxes in the statements of operations as general and administrative expenses. No such expenses have been recognized during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in the United States and the United Kingdom (&#x201c;UK&#x201d;). As of December&#160;31, 2024, the Company&#x2019;s tax years since inception are subject to examination by taxing authorities in the United States, and the UK tax returns from 2018 forward are subject to examination. &lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17773"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17774"
      unitRef="Unit_USD">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12893">&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Recently Issued Accounting Pronouncemen&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;ts &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2023, the FASB &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;issued&#160;ASU&#160;2023-07,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures&lt;/div&gt;&lt;/div&gt;&#160;to update reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses and information used to assess segment performance. This update is effective beginning with the Company&#x2019;s 2024 fiscal year annual reporting period, with early adoption permitted. The disclosure related to this ASU are in Note 4 below. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In December 2023, the FASB issued &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;ASU&#160;2023-09,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Taxes (Topic 740):&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Improvements to Income Tax Disclosures&lt;/div&gt;&lt;/div&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&#160;(&#x201c;ASU&#160;2023-09&#x201d;),&#160;which&lt;/div&gt; requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit, and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December&#160;15, 2024, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In November 2024, the FASB issued ASU &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024-03,&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Income Statement&#x2014;Reporting Comprehensive Income&#x2014;Expense Disaggregation Disclosures (Subtopic &lt;div style="white-space:nowrap;display:inline;"&gt;220-40):&lt;/div&gt; Disaggregation of Income Statement Expenses&lt;/div&gt;&lt;/div&gt;. This ASU requires more detailed disclosures, on an annual and interim basis, about specified categories of expenses (including employee compensation, depreciation, and amortization) included in certain expense captions presented on the face of the income statement. This ASU is effective for fiscal years beginning after December&#160;15, 2026, and interim periods within fiscal years beginning after December&#160;15, 2027. Early adoption is permitted. This ASU may be applied either prospectively or retrospectively. The Company is currently evaluating the impact of this pronouncement. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company continues to monitor new accounting pronouncements issued by the FASB and does not believe any accounting pronouncements issued through the date of this report will have a material impact on its financial statements. &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <okur:MergerAgreementAndConcurrentFinancingTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12938">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;3. Merger Agreement and Concurrent Financing &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As described in Note 1, Merger Sub I merged with and into Legacy OnKure, with Legacy OnKure surviving as a wholly-owned subsidiary of the Company on October&#160;4, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the Closing, each then-outstanding share of Legacy OnKure common stock was converted into the right to receive 0.023596 shares of common stock of Reneo based on the Common Exchange Ratio, which was reclassified as Class&#160;A Common Stock in connection with the Merger, and each then-outstanding share of Legacy OnKure preferred stock was converted into the right to receive 0.144794 shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio; provided that one holder of Legacy OnKure preferred stock elected to receive 686,527 shares that it would otherwise have received in the form of Class&#160;A Common Stock in an equal number of shares of Class&#160;B Common Stock. Upon the closing of the Merger, (i)&#160;an aggregate of 6,470,281 shares of Class&#160;A Common Stock and 686,527 shares of Class&#160;B Common Stock of the combined company were issued in exchange for the shares of Legacy OnKure capital stock outstanding as of immediately prior to the Closing and (ii)&#160;outstanding shares of Reneo common stock were reclassified into an aggregate of approximately 3,343,604 shares of Class&#160;A Common Stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, each then-outstanding option to purchase shares of Legacy OnKure common stock was assumed and converted into an option to purchase Class&#160;A Common Stock based on the Common Exchange Ratio, and each then-outstanding RSU of Legacy OnKure corresponding to shares of Legacy OnKure preferred stock was assumed and converted into RSUs covering 213,254 shares of Class&#160;A Common Stock based on the Preferred Exchange Ratio. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each share of Reneo common stock, each option to purchase shares of Reneo common stock and each RSU award covering shares of Reneo common stock that was issued and outstanding as of immediately prior to the Closing remained issued and outstanding in accordance with its terms and such shares, options and RSUs, subject to the Reverse Stock Split, were reclassified as Class&#160;A Common Stock but were otherwise unaffected by the Merger; provided that, to the extent not previously vested, all such options and RSUs held by Reneo&#x2019;s directors and executive officers vested at Closing. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Merger Agreement, Reneo entered into a subscription agreement with certain investors, pursuant to which the investors subscribed for and purchased, concurrent with the closing of the Merger, an aggregate of 2,839,005&#160;shares of Class&#160;A Common Stock at a price of approximately $22.895&#160;per share for aggregate gross proceeds of approximately $65.0&#160;million, including the conversion of previously funded Convertible Promissory Notes principal of $6.0&#160;million and accrued interest there on of $120&#160;thousand, on October&#160;4, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the effective time of the Merger, the authorized shares of Class&#160;A Common Stock of the Company are 200,000,000&#160;with par value of $0.0001&#160;and Class&#160;B Common Stock of the Company are 10,000,000 with par value of $0.0001. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, in October 2024 the Company adopted the 2024 Equity Incentive Plan (the &#x201c;2024 Plan&#x201d;) and 2024 Employee Stock Purchase Plan (the &#x201c;2024 ESPP&#x201d;). Under the 2024 Plan a total of 2,480,000 shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. Under the 2024 ESPP, an aggregate of 137,500&#160;shares of Class&#160;A Common Stock are currently reserved and available for issuance. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Merger was accounted for as a reverse recapitalization in accordance with GAAP, with Legacy OnKure as the accounting acquirer of Reneo. Legacy OnKure was determined to be the accounting acquirer based on the terms of the Merger Agreement and other factors, such as relative voting rights and the composition of the combined company&#x2019;s board of directors and senior management. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As a result, Legacy OnKure&#x2019;s historical financial statements became the historical consolidated financial statements of the combined company for accounting purposes together with a deemed issuance of shares, equivalent to the shares held by the former stockholders Reneo, the legal acquirer, and a recapitalization of the equity of Legacy OnKure, the accounting acquirer. The final transaction amounts have been recorded as a reduction of proceeds in stockholders&#x2019; equity. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At the effective time of the Merger, the net assets of Reneo were recorded at their acquisition-date fair value in the financial statements of the combined company, which approximated book value due to the short-term nature.&#160;Reneo&#x2019;s development programs had ceased prior to the Merger and were deemed to be de minimis in value at the transaction date. No goodwill or intangible assets were recognized. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of the recapitalization, excluding the Concurrent Financing, the Company acquired the assets and liabilities listed below (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;57,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;15,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;553&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(9,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net assets acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;65,499&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</okur:MergerAgreementAndConcurrentFinancingTextBlock>
    <okur:CommonStockSharesConvertibleConversionRatio
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="6"
      id="ixv-17776"
      unitRef="Unit_pure">0.023596</okur:CommonStockSharesConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleConversionRatio
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="6"
      id="ixv-17777"
      unitRef="Unit_pure">0.144794</us-gaap:PreferredStockConvertibleConversionRatio>
    <us-gaap:PreferredStockConvertibleSharesIssuable
      contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-17778"
      unitRef="Unit_shares">686527</us-gaap:PreferredStockConvertibleSharesIssuable>
    <okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-17779"
      unitRef="Unit_shares">6470281</okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding>
    <okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding
      contextRef="P10_04_2024To10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-17780"
      unitRef="Unit_shares">686527</okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding>
    <okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17781"
      unitRef="Unit_shares">3343604</okur:StockIssuedDuringPeriodSharesExchangeOfCapitalStockOutstanding>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis"
      decimals="INF"
      id="ixv-17782"
      unitRef="Unit_shares">213254</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17783"
      unitRef="Unit_shares">2839005</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17784"
      unitRef="Unit_USD_per_Share">22.895</us-gaap:SaleOfStockPricePerShare>
    <okur:GrossProceedsFromIssuanceOfCommonStock
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-17785"
      unitRef="Unit_USD">65000000</okur:GrossProceedsFromIssuanceOfCommonStock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="-5"
      id="ixv-17786"
      unitRef="Unit_USD">6000000</us-gaap:DebtInstrumentFaceAmount>
    <okur:DebtInstrumentAccruedInterest
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_ConvertibleDebtMemberusgaapLongtermDebtTypeAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="-3"
      id="ixv-17787"
      unitRef="Unit_USD">120000</okur:DebtInstrumentAccruedInterest>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17788"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17789"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17790"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn10_04_2024_CommonClassBMemberusgaapStatementClassOfStockAxis_CommonStockMemberusgaapStatementEquityComponentsAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_ReneoMemberdeiLegalEntityAxis"
      decimals="INF"
      id="ixv-17791"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17793"
      unitRef="Unit_shares">2480000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17794"
      unitRef="Unit_shares">137500</okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-12967">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of the recapitalization, excluding the Concurrent Financing, the Company acquired the assets and liabilities listed below (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:84%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Amount&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash and cash equivalents&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;57,736&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Short-term investments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;15,979&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other current assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;690&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;553&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(9,072&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Long-term operating lease liability&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(387&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net assets acquired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;65,499&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17795"
      unitRef="Unit_USD">57736000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17796"
      unitRef="Unit_USD">15979000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17797"
      unitRef="Unit_USD">690000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17798"
      unitRef="Unit_USD">553000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17799"
      unitRef="Unit_USD">9072000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <okur:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17800"
      unitRef="Unit_USD">387000</okur:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLong-TermOperatingLeaseLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17801"
      unitRef="Unit_USD">65499000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13049">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;4. Segment &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is a publicly listed company with a single reportable segment: clinical research. Because the Company has one reportable segment, before adopting the ASU, it provided only the entity-wide disclosures required by ASC 280. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The &lt;div style="-sec-ix-hidden:hidden133878841;display:inline;"&gt;clinical research segment&lt;/div&gt; has no revenues. The accounting policies of the clinical research segment are the same as those described in the summary of significant accounting policies. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Chief Operating Decision Maker (&#x201c;CODM&#x201d;) assesses the performance for the clinical research segment and decides how to allocate resources based on operating expenses as reported on the income statement. The measure of segment assets is reported on the balance sheets as total consolidated assets. The CODM considers a variety of factors, including actual and projected expenses in deciding whether to invest funds in the clinical research segment or into other parts of the entity, such as for acquisitions or to pay dividends. The Company does not have intra-entity sales or transfers. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s CODM is the senior executive committee that is comprised of the Chief Financial Officer and the Chief Executive Officer. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical&#160;Research&lt;br/&gt; Segment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Direct program expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;27,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Indirect program expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Workforce salaries and benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;15,102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General corporate expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest and other expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of loss:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Adjustments and reconciling items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;52,673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17802"
      unitRef="Unit_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:Revenues
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17803"
      unitRef="Unit_USD">0</us-gaap:Revenues>
    <us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription contextRef="P01_01_2024To12_31_2024" id="ixv-17804">The Chief Operating Decision Maker (&#x201c;CODM&#x201d;) assesses the performance for the clinical research segment and decides how to allocate resources based on operating expenses as reported on the income statement. The measure of segment assets is reported on the balance sheets as total consolidated assets.</us-gaap:SegmentReportingExpenseInformationUsedByCodmDescription>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13075">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s CODM is the senior executive committee that is comprised of the Chief Financial Officer and the Chief Executive Officer. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:76%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:16%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Clinical&#160;Research&lt;br/&gt; Segment&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Operating expenses:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Direct program expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;27,398&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Indirect program expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;2,157&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Workforce salaries and benefits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;15,102&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Stock-based compensation expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;4,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General corporate expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;5,199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest and other expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;300&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Segment net loss&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;54,686&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Reconciliation of loss:&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 2em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Interest income&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;(2,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Adjustments and reconciling items&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2,013&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 5em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net loss&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;52,673&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <okur:SegmentReportingCODMIndividualTitleAndPositionOrGroupName contextRef="P01_01_2024To12_31_2024" id="ixv-17806">Chief Financial Officer and the Chief Executive Officer</okur:SegmentReportingCODMIndividualTitleAndPositionOrGroupName>
    <okur:DirectProgramExpense
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17807"
      unitRef="Unit_USD">27398000</okur:DirectProgramExpense>
    <okur:IndirectProgramExpense
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17808"
      unitRef="Unit_USD">2157000</okur:IndirectProgramExpense>
    <okur:WorkforceSalariesAndBenefits
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17809"
      unitRef="Unit_USD">15102000</okur:WorkforceSalariesAndBenefits>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17810"
      unitRef="Unit_USD">4530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <okur:GeneralCorporateExpenses
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17811"
      unitRef="Unit_USD">5199000</okur:GeneralCorporateExpenses>
    <okur:InterestAndOtherExpense
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17812"
      unitRef="Unit_USD">300000</okur:InterestAndOtherExpense>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024_ClinicalResearchSegmentMemberusgaapStatementBusinessSegmentsAxis"
      decimals="-3"
      id="ixv-17813"
      unitRef="Unit_USD">-54686000</us-gaap:NetIncomeLoss>
    <us-gaap:InterestIncomeOperating
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17814"
      unitRef="Unit_USD">2013000</us-gaap:InterestIncomeOperating>
    <okur:AdjustmentsAndReconcilingItems
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17815"
      unitRef="Unit_USD">2013000</okur:AdjustmentsAndReconcilingItems>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17816"
      unitRef="Unit_USD">-52673000</us-gaap:NetIncomeLoss>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13220">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;5. Leases &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s headquarters are located in Boulder, Colorado, where it leases 14,790 square feet of office and lab facilities under&#160;operating leases that expire in &lt;div style="display:inline;"&gt;&lt;div style="-sec-ix-hidden:hidden133878813;display:inline;"&gt;December 2026&lt;/div&gt;&lt;/div&gt;, with rights to extend for a 5 year period. In the Merger with Reneo, the Company assumed the lease in Irvine, California, where it leases office space under a lease agreement that expires in November 2026 (&#x201c;Irvine lease&#x201d;). In January 2025, the Company entered into a sublease agreement on the Irvine lease. See Note 16 for further discussion. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Right-of-use&#160;assets&lt;/div&gt;&lt;/div&gt; and lease liabilities for operating leases as included in the Company&#x2019;s financial statements are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;478&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Noncurrent operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;674&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Lease expense for operating leases as included in the Company&#x2019;s financial statements are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Lease term, discount rates, and additional information for operating leases are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term &#x2013; operating leases (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows for operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate maturities of the Company&#x2019;s operating lease liabilities were as follows as of December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total future minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17817"
      unitRef="Unit_sqft">14790</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseOptionToExtend contextRef="P01_01_2024To12_31_2024" id="ixv-17818">with rights to extend for a 5 year period</us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend contextRef="P01_01_2024To12_31_2024" id="ixv-17819">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="PAsOn12_31_2024" id="ixv-17820">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13226">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;Right-of-use&#160;assets&lt;/div&gt;&lt;/div&gt; and lease liabilities for operating leases as included in the Company&#x2019;s financial statements are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:65%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:12%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;right-of-use&lt;/div&gt;&lt;/div&gt; assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;770&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;478&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Current operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;208&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Noncurrent operating lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;466&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total lease liabilities&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,085&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;674&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</okur:ScheduleOfLeaseRelatedAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17821"
      unitRef="Unit_USD">770000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17822"
      unitRef="Unit_USD">478000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17823"
      unitRef="Unit_USD">536000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17824"
      unitRef="Unit_USD">208000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17825"
      unitRef="Unit_USD">549000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17826"
      unitRef="Unit_USD">466000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17827"
      unitRef="Unit_USD">1085000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17828"
      unitRef="Unit_USD">674000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LeaseCostTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13344">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Lease expense for operating leases as included in the Company&#x2019;s financial statements are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:80%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease cost&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;236&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Variable lease expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;187&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17829"
      unitRef="Unit_USD">236000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17830"
      unitRef="Unit_USD">173000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17831"
      unitRef="Unit_USD">187000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17832"
      unitRef="Unit_USD">201000</us-gaap:VariableLeaseCost>
    <okur:ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13419">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Lease term, discount rates, and additional information for operating leases are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As&#160;of&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average remaining lease term &#x2013; operating leases (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1.87&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2.92&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Weighted-average discount rate &#x2013; operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.5&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating cash flows for operating leases&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;315&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;210&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</okur:ScheduleOfLeaseTermDiscountRatesAndAdditionalInformationForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2024" id="ixv-17834">P1Y10M13D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="PAsOn12_31_2023" id="ixv-17835">P2Y11M1D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2024"
      decimals="3"
      id="ixv-17836"
      unitRef="Unit_pure">0.045</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="PAsOn12_31_2023"
      decimals="3"
      id="ixv-17837"
      unitRef="Unit_pure">0.045</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17838"
      unitRef="Unit_USD">315000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17839"
      unitRef="Unit_USD">210000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13496">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate maturities of the Company&#x2019;s operating lease liabilities were as follows as of December&#160;31, 2024 (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:86%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2025&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;571&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2026&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;560&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total future minimum lease payments&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,131&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: imputed interest&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(46&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(536&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Operating lease liability, net of current portion&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;549&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17840"
      unitRef="Unit_USD">571000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17841"
      unitRef="Unit_USD">560000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17842"
      unitRef="Unit_USD">1131000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17843"
      unitRef="Unit_USD">46000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17844"
      unitRef="Unit_USD">536000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17845"
      unitRef="Unit_USD">549000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:EarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13572">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;6. Net Loss Per Share &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company computes basic loss per share by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, without consideration for common stock equivalents. Diluted net loss per share assumes the conversion, exercise or issuance of all potential common stock equivalents, unless the effect of inclusion would be anti-dilutive. For purposes of this calculation, common stock shares to be issued upon &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;if-converted&lt;/div&gt; method for the convertible Series C Preferred Stock, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;if-converted&lt;/div&gt; method for the convertible promissory note, exercise of all outstanding stock options and restricted stock units were excluded from the diluted net loss per share calculation for the twelve months ended December&#160;31, 2024 and 2023 because such shares are anti-dilutive. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Series C Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5,191,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;6,135,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Promissory Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;149,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;178,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;214,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unreleased restricted stock units assumed in the Merger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;17,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,965,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,527,974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13578">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Anti-dilutive securities outstanding during the period not included in the diluted net loss per share calculation include the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:3%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Series C Preferred Stock&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5,191,375&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;6,135,306&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Convertible Promissory Notes&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;149,650&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Outstanding stock options&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;178,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;214,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unreleased restricted stock units assumed in the Merger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;17,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;7,965,103&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;6,527,974&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17846"
      unitRef="Unit_shares">5191375</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ConvertiblePreferredStockSeriesCMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17847"
      unitRef="Unit_shares">6135306</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17848"
      unitRef="Unit_shares">149650</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_ConvertiblePromissoryNoteMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17849"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17850"
      unitRef="Unit_shares">2393824</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17851"
      unitRef="Unit_shares">178232</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17852"
      unitRef="Unit_shares">213254</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_UnvestedRestrictedStockUnitsMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17853"
      unitRef="Unit_shares">214436</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17854"
      unitRef="Unit_shares">17000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"
      decimals="0"
      id="ixv-17855"
      unitRef="Unit_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17856"
      unitRef="Unit_shares">7965103</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-17857"
      unitRef="Unit_shares">6527974</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13704">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;7. Fair Value Measurements &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ASC Topic 820, &lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Fair Value Measurement&lt;/div&gt;&lt;/div&gt;, establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing an asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;ASC Topic 820 identifies fair value as the exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC Topic 820 establishes a three-tier fair value hierarchy that distinguishes between the following: &lt;/div&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;1 &#x2013; Observable inputs such as quoted prices in active markets for identical assets or liabilities. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;2 &#x2013; Inputs, other than quoted prices in active markets, which are observable for the asset or liability, either directly or indirectly. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:6pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:5%"&gt;&#160;&lt;/td&gt;
&lt;td style="width:3%;vertical-align:top;text-align:left"&gt;&#x2022;&lt;/td&gt;
&lt;td style="width:1%;vertical-align:top"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: left; line-height: normal;"&gt;Level&#160;3 &#x2013; Unobservable inputs in which there is little or no market data, which requires the Company to develop its own assumptions. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability. The Company&#x2019;s financial assets are subject to fair value measurements on a recurring basis. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company categorizes its money market funds as Level&#160;1, using the quoted prices in active markets. The fair value of the Company&#x2019;s investments in certain money market funds is their face value and such instruments are classified as Level&#160;1 and are included in cash and cash equivalents on the consolidated balance sheets. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;No assets or liabilities were transferred into or out of their classifications during the years ended December&#160;31, 2024 and 2023. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As part of the Merger, the Company acquired certain short-term investments in debt securities that were carried at fair value and classified as current assets &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; and represented the investment of funds available for current operations. During the year ended December&#160;31, 2024, the Company sold these short-term investments for proceeds of $15.9&#160;million which resulted in a realized loss of approximately $54,000. The Company had no &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;available-for-sale&lt;/div&gt;&lt;/div&gt; securities as of December&#160;31, 2024 or 2023. &lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17859"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17860"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17861"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17862"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17863"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17864"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-17865"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-17866"
      unitRef="Unit_USD">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="P01_01_2024To12_31_2024"
      decimals="-5"
      id="ixv-17867"
      unitRef="Unit_USD">15900000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17868"
      unitRef="Unit_USD">-54000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17869"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17870"
      unitRef="Unit_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13763">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;8. Prepaid expenses and other current assets &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses and other current assets consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid clinical trial expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid insurance expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;537&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,553&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherAssetsTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13766">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Prepaid expenses and other current assets consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid clinical trial expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;152&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,192&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Prepaid insurance expense&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;537&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;68&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,553&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;630&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total prepaid expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,242&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,890&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherAssetsTableTextBlock>
    <okur:PrepaidClinicalTrials
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17871"
      unitRef="Unit_USD">152000</okur:PrepaidClinicalTrials>
    <okur:PrepaidClinicalTrials
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17872"
      unitRef="Unit_USD">3192000</okur:PrepaidClinicalTrials>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17873"
      unitRef="Unit_USD">537000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17874"
      unitRef="Unit_USD">68000</us-gaap:PrepaidInsurance>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17875"
      unitRef="Unit_USD">1553000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:OtherPrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17876"
      unitRef="Unit_USD">630000</us-gaap:OtherPrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17877"
      unitRef="Unit_USD">2242000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17878"
      unitRef="Unit_USD">3890000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13875">&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;9. Property and Equipment, Net &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware and software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;189&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(1,119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Depreciation and amortization expense for the years ended December&#160;31, 2024 and 2023 was $459,000 and $417,000, respectively. &lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-13878">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Property and equipment, net, consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:68%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Lab equipment&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;705&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;706&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Leasehold improvements&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,090&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Computer hardware and software&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;189&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;141&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Furniture and fixtures&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;160&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, gross&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,144&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,097&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Less: Accumulated depreciation and amortization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(1,119&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(665&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Property and equipment, net&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,025&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17879"
      unitRef="Unit_USD">705000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LabEquipmentMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17880"
      unitRef="Unit_USD">706000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17881"
      unitRef="Unit_USD">1090000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_LeaseholdImprovementsMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17882"
      unitRef="Unit_USD">1090000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17883"
      unitRef="Unit_USD">189000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_ComputerHardwareAndSoftwareMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17884"
      unitRef="Unit_USD">141000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17885"
      unitRef="Unit_USD">160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023_FurnitureAndFixturesMemberusgaapPropertyPlantAndEquipmentByTypeAxis"
      decimals="-3"
      id="ixv-17886"
      unitRef="Unit_USD">160000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17887"
      unitRef="Unit_USD">2144000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17888"
      unitRef="Unit_USD">2097000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17889"
      unitRef="Unit_USD">1119000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17890"
      unitRef="Unit_USD">665000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17891"
      unitRef="Unit_USD">1025000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17892"
      unitRef="Unit_USD">1432000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-17893"
      unitRef="Unit_USD">459000</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:DepreciationExpenseOnReclassifiedAssets
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-17894"
      unitRef="Unit_USD">417000</us-gaap:DepreciationExpenseOnReclassifiedAssets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14026">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;10. Accrued Expenses &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contract manufacturing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trial costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;7,026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued compensation includes severance costs. For further information see Note 14. &lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14029">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Accrued expenses consisted of the following (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:66%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;br/&gt; 2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,663&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued contract manufacturing costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,565&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,627&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued clinical trial costs&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,302&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;370&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;7,026&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,660&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17895"
      unitRef="Unit_USD">3173000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17896"
      unitRef="Unit_USD">1663000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <okur:AccruedManufacturingExpense
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17897"
      unitRef="Unit_USD">1565000</okur:AccruedManufacturingExpense>
    <okur:AccruedManufacturingExpense
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17898"
      unitRef="Unit_USD">1627000</okur:AccruedManufacturingExpense>
    <okur:AccruedClinicalTrialCosts
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17899"
      unitRef="Unit_USD">1302000</okur:AccruedClinicalTrialCosts>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17900"
      unitRef="Unit_USD">986000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17901"
      unitRef="Unit_USD">370000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17902"
      unitRef="Unit_USD">7026000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17903"
      unitRef="Unit_USD">3660000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14141">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;11. Equity &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 210,000,000 shares of common stock, of which 200,000,000 shares have been designated as Class&#160;A Common Stock and 10,000,000 shares have been designated as Class&#160;B Common Stock, both with a par value of $0.0001 per share. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The number of authorized shares of common stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#x2019;s stock who are entitled to vote. Each share of Class&#160;A Common Stock is entitled to one vote. Class&#160;B Common Stock is not entitled to vote on any matter on which the holders of Class&#160;A Common Stock or Preferred Stock are entitled to vote. All holders of common stock are entitled to receive dividends when and as declared or paid by the Company&#x2019;s board of directors, subject to the preferential rights of the holders of preferred stock. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Class&#160;B Common Stock is convertible into a corresponding number of shares of Class&#160;A Common Stock upon written notice of the holder, subject to defined beneficial ownership limitations. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is authorized to issue 10,000,000 shares of preferred stock, with a par value of $0.0001 per share. As of December&#160;31, 2024, none of these shares of preferred stock have been designated or issued. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Convertible Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2023, the Company&#x2019;s Preferred Stock was classified as temporary equity in the accompanying consolidated balance sheets given that the holders of the convertible preferred stock could cause certain events to occur that were outside of the Company&#x2019;s control whereby the Company could be obligated to redeem the convertible preferred stock. The carrying value of the convertible preferred stock is not adjusted to the redemption value until the contingent redemption events are considered probable to occur. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&lt;div style="text-decoration:underline;display:inline;"&gt;Series C Preferred Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2023, the Company entered into a Series C Purchase Agreement pursuant to which the Company issued 2,818,192 shares of Series C Preferred Stock at a purchase price of $19.06 per share, which resulted in gross proceeds of approximately $53.8&#160;million, as well as the conversion of all Series A Preferred Stock, &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;Series&#160;A-1&#160;Preferred&lt;/div&gt; Stock, and Series B Preferred Stock. In conjunction with the Merger, immediately following the Closing, each then-outstanding share of Legacy OnKure preferred stock converted into Class&#160;A or Class&#160;B Common Stock. No Convertible Preferred Shares are authorized, issued or outstanding at December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s convertible preferred stock had the following characteristics as of December&#160;31, 2023:&#x2003; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Conversion of Preferred Stock into Common Stock &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each share of preferred stock, at the option of the holder, was convertible into a number of shares of common stock as determined by multiplying the number of shares of preferred stock being converted by the conversion rate. The conversion rate in effect at any time for conversion of preferred stock is determined by dividing the Original Issue Price by the Conversion Price. The Original Issue Price for the Series C Preferred Stock was $19.06 per share. The Conversion Price was subject to certain adjustments as provided in the Company&#x2019;s restated certificate of incorporation. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The preferred stock would have automatically converted to common stock upon the closing of an initial public offering of the Company&#x2019;s common stock in which &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;the&#160;per-share&#160;price&lt;/div&gt; is at least $38.19 and gross proceeds of not less than $75&#160;million, or the date and time specified by vote or the written consent of the holders of at least a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;an&#160;as-converted&#160;basis.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Voting Rights &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Each preferred stockholder was entitled to the number of votes equal to the number of shares of Class&#160;A Common Stock into which such holder&#x2019;s shares are convertible. At any time when a defined number of shares of Series C Preferred Stock are outstanding, the Company was restricted from certain actions described in the Company&#x2019;s restated certificate of incorporation without the vote or written consent of the holders of a majority of the then outstanding shares of Series C Preferred Stock voting or consenting as a separate class on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;an&#160;as-converted&#160;basis.&lt;/div&gt; &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Dividends &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company could not have declared, paid or set aside any dividends on any shares of any other class or series of capital stock unless each holder of the preferred stock first received a dividend based upon a formula in the Company&#x2019;s restated certificate of incorporation. No dividends were declared during the years ended December&#160;31, 2024 or 2023. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Liquidation Preference &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Upon any liquidation, dissolution or winding up of the Company, certain qualifying mergers, sales or transactions with a special purpose acquisition companies, and other deemed liquidation events as defined in the Company&#x2019;s restated certificate of incorporation, unless the holders of a majority of the then outstanding shares of Series C Preferred Stock, voting as a separate class on &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;an&#160;as-converted&#160;basis,&lt;/div&gt; elected otherwise, prior to and in preference to any distribution to the holders of common stock, holders of Series C Preferred Stock were entitled to be paid out of the assets of the Company legally available for distribution, or the consideration received in such transaction, an amount per share of Series C Preferred Stock equal to the greater of: i) 1.50 times the Series C Original Issuance Price plus all declared and unpaid dividends on Series C Preferred Stock or ii) such amount per share that would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately prior to such event. If upon liquidation, dissolution, or winding up of the Company, the assets and funds of the Company are insufficient to permit the payment of the full preferential amounts to the holders of preferred stock, then the holders shall share ratably in any distribution of the assets available for distribution, in proportion to the respective amounts which would otherwise be payable in respect of the shares held by the preferred stockholders. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;After the payment of all preferential amounts required to be paid to the holder of shares of preferred stock, the remaining assets available for distribution to its stockholders would have been distributed to the holders of shares of common stock, pro rata based on the number of shares held by each holder. The liquidation preference as of December&#160;31, 2023 was $195.8&#160;million. &lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17904"
      unitRef="Unit_shares">210000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17905"
      unitRef="Unit_shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="PAsOn12_31_2024_CommonClassBMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17906"
      unitRef="Unit_shares">10000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024_CommonClassAMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17907"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17909"
      unitRef="Unit_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17910"
      unitRef="Unit_USD_per_Share">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-17911"
      unitRef="Unit_shares">0</us-gaap:PreferredStockSharesIssued>
    <okur:PreferredStockSharesDesignated
      contextRef="PAsOn12_31_2024"
      decimals="0"
      id="ixv-17912"
      unitRef="Unit_shares">0</okur:PreferredStockSharesDesignated>
    <us-gaap:PreferredStockSharesIssued
      contextRef="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17913"
      unitRef="Unit_shares">2818192</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-17914"
      unitRef="Unit_USD_per_Share">19.06</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValueOutstanding
      contextRef="PAsOn03_31_2023"
      decimals="-5"
      id="ixv-17915"
      unitRef="Unit_USD">53800000</us-gaap:PreferredStockValueOutstanding>
    <okur:ConvertiblePreferredStockSharesAuthorized
      contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17916"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesAuthorized>
    <okur:ConvertiblePreferredStockSharesIssued
      contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17917"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesIssued>
    <okur:ConvertiblePreferredStockSharesOutstanding
      contextRef="PAsOn12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      decimals="INF"
      id="ixv-17918"
      unitRef="Unit_shares">0</okur:ConvertiblePreferredStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="PAsOn03_31_2023"
      decimals="2"
      id="ixv-17919"
      unitRef="Unit_USD_per_Share">19.06</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockConvertibleConversionPrice
      contextRef="PAsOn12_31_2024_CommonStockMemberusgaapStatementClassOfStockAxis"
      decimals="2"
      id="ixv-17920"
      unitRef="Unit_USD_per_Share">38.19</us-gaap:PreferredStockConvertibleConversionPrice>
    <us-gaap:ConversionOfStockAmountIssued1
      contextRef="P01_01_2024To12_31_2024_MinimumMembersrtRangeAxis"
      decimals="-6"
      id="ixv-17921"
      unitRef="Unit_USD">75000000</us-gaap:ConversionOfStockAmountIssued1>
    <us-gaap:Dividends
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17922"
      unitRef="Unit_USD">0</us-gaap:Dividends>
    <us-gaap:Dividends
      contextRef="P01_01_2023To12_31_2023"
      decimals="INF"
      id="ixv-17923"
      unitRef="Unit_USD">0</us-gaap:Dividends>
    <us-gaap:PreferredStockDividendPaymentTerms
      contextRef="P01_01_2024To12_31_2024_SeriesCPreferredStockMemberusgaapStatementClassOfStockAxis"
      id="ixv-17925">i) 1.50 times the Series C Original Issuance Price plus all declared and unpaid dividends on Series C Preferred Stock or ii) such amount per share that would have been payable had all shares of Series C Preferred Stock been converted into common stock immediately prior to such event.</us-gaap:PreferredStockDividendPaymentTerms>
    <us-gaap:PreferredStockLiquidationPreferenceValue
      contextRef="PAsOn12_31_2023"
      decimals="-5"
      id="ixv-17926"
      unitRef="Unit_USD">195800000</us-gaap:PreferredStockLiquidationPreferenceValue>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14222">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;12. Share-Based Compensation &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s share-based compensation plans are described below: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2024 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2024, the Company established an equity incentive plan (the &#x201c;2024 Plan&#x201d;). The 2024 Equity Incentive Plan became effective upon the closing of the Merger, and will continue in effect for a period of ten years from its effectiveness, unless terminated earlier by the administrator. The 2024 Plan provides for the grant of stock options, RSUs and RSAs to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;employees,&#160;non-employee&#160;directors,&lt;/div&gt; advisors, and consultants. Under the 2024 Plan a total of 2,480,000 shares of Class&#160;A Common Stock were initially reserved for issuance. In addition, shares reserved for issuance under the 2024 Plan will include shares of Class&#160;A Common Stock equity awards granted under the Reneo 2021 Plan and any shares of Class&#160;A Common Stock equity awards that were assumed in the Merger. As of the effective date of the 2024 Plan, awards granted under the 2011, 2021 and 2023 Plans that are forfeited or otherwise become available will be included and available for issuance under the 2024 Plan. Under the 2024 Plan, the Company may grant stock options, stock appreciation rights, restricted stock awards, restricted stock units, and other awards to individuals who are employees, officers, directors or consultants of the Company and its affiliates. The Company issues new shares in settlement of equity awards under the 2024 Plan. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2023 RSU Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In September 2023, the Company established an equity incentive plan (the &#x201c;2023 Plan&#x201d;). The 2023 Plan provided for the grant of restricted stock units (&#x201c;RSU&#x201d;) to employees, directors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2023 Plan were cancelled. &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2021 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In February 2021, the Company established an equity incentive plan (the &#x201c;2021 Plan&#x201d;). The 2021 Plan provided for the grant of stock options and RSA to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;employees,&#160;non-employee&#160;directors,&lt;/div&gt; advisors, and consultants. Upon the close of the Merger, all shares available for issuance under the 2021 Plan were cancelled.&#x2003; &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2011 Equity Incentive Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2011, the Company established an equity incentive plan (the &#x201c;2011 Plan&#x201d;). The 2011 Plan provided for the grant of stock options and restricted stock awards (&#x201c;RSA&#x201d;) to employees, &lt;div style="white-space:nowrap;display:inline;"&gt;non-employee&lt;/div&gt; directors, advisors, and consultants. Shares are no longer available for issuance under the 2011 Plan, which was subsequently terminated in March 2023. Upon the close of the Merger, all shares available for issuance under the 2011 Plan were cancelled. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition, as part of the Merger with Reneo discussed in Note 1, the Company assumed outstanding awards under the following Reneo Equity Incentive Plans and certain awards not issued pursuant to a Reneo Equity Plan: &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Reneo 2021 and 2014 Equity Incentive Plans &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In March 2021, the Reneo Board of Directors adopted the Reneo 2021 Equity Incentive Plan (&#x201c;Reneo 2021 Plan&#x201d;), which is the successor to Reneo&#x2019;s 2014 Equity Incentive Plan and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;UK&#160;Sub-Plan&lt;/div&gt; (&#x201c;2014 Plan&#x201d;). &lt;/div&gt;&lt;div style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;2024 ESPP &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2024, the Company established the 2024 ESPP. Under the 2024 ESPP, an aggregate of 137,500 shares of Class&#160;A Common Stock are currently reserved and available for issuance. As of December&#160;31, 2024, no &lt;div style="display:inline;"&gt;offering &lt;/div&gt;periods have been established under the 2024 ESPP. See Note 16 for discussion of the increase to the available for issuance as of January&#160;1, 2025. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Shares Reserved for Future Issuance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had reserved shares of its common stock for future issuance as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt; Reserved&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Common stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units under the 2023 Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unreleased restricted stock units assumed in the Merger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;17,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Available for future grants under the 2024 Equity Incentive Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;747,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Available for future grants under the 2024 Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;137,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,509,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Stock Options &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Options granted under the Company&#x2019;s equity incentive plans have an exercise price equal to or in excess of the market value of the Class&#160;A Common Stock at the date of grant and expire no more than 10 years from the date of grant. Generally, options become exercisable ratably over a period of &lt;div style="-sec-ix-hidden:hidden133878831;display:inline;"&gt;three&lt;/div&gt; to four years from the date of grant. Stock options granted &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;to&#160;non-employees&#160;generally&lt;/div&gt; vest quarterly over &lt;div style="-sec-ix-hidden:hidden133878830;display:inline;"&gt;two&lt;/div&gt; to three years. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of the Company&#x2019;s stock option activity and related information for the year ended December&#160;31, 2024 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:49%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;br/&gt; of Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;178,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;16.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;8.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed in reverse recapitalization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;467,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;47.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,775,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;18.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2,476&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;10.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(23,610&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;38.34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;23.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;7.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;654,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;38.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;All outstanding options as of December&#160;31, 2024 are expected to vest. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested stock options of $26.5&#160;million, expected to be recognized over a weighted-average period of approximately 2.8 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price and the estimated fair value of the Company&#x2019;s common stock as of December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The weighted-average grant-date fair value of options granted for the years ended December&#160;31, 2024, and 2023 was $16.05 and $5.51, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company has granted performance-based stock options. During the year ended December&#160;31, 2023, the Company granted 8,449 performance-based shares, which are included in the table above. The company recognized $30,000 and $13,000 in performance-based compensation expense for the years ended December&#160;31, 2024 and 2023, respectively. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company estimates stock awards fair value on the date of grant using the Black-Scholes valuation, with the vesting being subject to service requirements. The Company accounts for forfeitures when they occur. The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;126.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;32.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Risk-free interest rate. &lt;/div&gt;&lt;/div&gt;The Company bases the risk-free interest rate assumption on the U.S. Treasury&#x2019;s rates for U.S. Treasury &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;zero-coupon&lt;/div&gt; bonds with maturities similar to those of the expected term of the award being valued. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected volatility.&lt;/div&gt;&lt;/div&gt; The expected volatility assumption was based on the volatilities of a peer group of similar companies whose share prices are publicly available. The peer group was developed based on companies in the biotechnology industry. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected term. &lt;/div&gt;&lt;/div&gt;The expected term represents the period of time that options are expected to be outstanding. Because the Company does not have historical exercise behavior, it determines the expected life assumption using the simplified method, which is an average of the contractual term of the option and its vesting period. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Expected dividend yield. &lt;/div&gt;&lt;/div&gt;The Company bases the expected dividend yield assumption on the fact that it has never paid cash dividends and has no present intention to pay cash dividends. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Restricted Stock Awards (RSAs) and Restricted Stock Units (RSUs) &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;RSA typically vests 25% on the first anniversary of the issuance date and incrementally vest monthly for the three-year period thereafter. In the event of a termination of services, all unvested shares are forfeited, and the Company has the option to purchase all outstanding vested shares at their fair market value. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;RSU vests based on a service-based requirement and a liquidity event plus service requirement. No RSU had vested as of December&#160;31, 2023. The following table summarizes RSU and RSA activities during the year ended December&#160;31, 2024: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;214,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested (RSA)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(544&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had unrecognized compensation cost for unvested RSU awards of $2.8&#160;million, expected to be recognized over a weighted-average period of approximately 2.0 years. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In addition to the RSUs in the table above, in connection with the Merger, the Company assumed 24,700 RSUs which were fully vested at the time of the Merger. The RSUs were releasable upon set time frames after completion of the Merger. From the Merger through December&#160;31, 2024, 7,700 RSUs were released. The remaining 17,000 RSUs were released in January 2025. There was no unamortized compensation cost related to these RSUs as of the Merger or December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;2024 Employee Stock Purchase Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In October 2024, the Company&#x2019;s Board of Directors adopted the ESPP, which became effective immediately upon completion of the Merger with Reneo. As of December&#160;31, 2024, no shares have been issued under the ESPP. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Share-Based Compensation Expense &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table shows the allocation of share-based compensation expense related to the company&#x2019;s share-based awards (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,634&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company recorded accelerated share-based compensation expenses related to modifications of RSUs under certain separation agreements of $1.7&#160;million during the year ended December&#160;31, 2024, which is reflected in the above table. See Note 14 for further discussion on severance. There were no such modifications during the year ended December&#160;31, 2023. &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2024To12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-17927">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17928"
      unitRef="Unit_shares">2480000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance
      contextRef="P10_04_2024To10_04_2024_CommonClassAMemberusgaapStatementClassOfStockAxis_MergerAgreementMemberusgaapBusinessAcquisitionAxis_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17930"
      unitRef="Unit_shares">137500</okur:CommonStockCapitalSharesReservedAndAvailableForFutureIssuance>
    <okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14278">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had reserved shares of its common stock for future issuance as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:81%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:4%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;br/&gt; Reserved&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Common stock options outstanding&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested restricted stock units under the 2023 Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unreleased restricted stock units assumed in the Merger&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;17,000&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Available for future grants under the 2024 Equity Incentive Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;747,867&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Available for future grants under the 2024 Employee Stock Purchase Plan&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;137,500&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total shares of common stock reserved for future issuance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3,509,445&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</okur:ScheduleOfCommonStockCapitalSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17931"
      unitRef="Unit_shares">2393824</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_UnvestedRestrictedStockUnitsUnderTwoThousandTwentyThreePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17932"
      unitRef="Unit_shares">213254</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_UnreleasedRestrictedStockUnitsAssumedInMergerMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17933"
      unitRef="Unit_shares">17000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17934"
      unitRef="Unit_shares">747867</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024_TwentyTwentyFourEmployeeStockPurchasePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-17935"
      unitRef="Unit_shares">137500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17936"
      unitRef="Unit_shares">3509445</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-17937">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-17938">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis_MaximumMembersrtRangeAxis_Non-EmployeesMembersrtTitleOfIndividualAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      id="ixv-17939">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14377">&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A summary of the Company&#x2019;s stock option activity and related information for the year ended December&#160;31, 2024 is as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:92%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:49%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="14" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Options Outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&lt;br/&gt; of Options&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Exercise&lt;br/&gt; Price&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Remaining&lt;br/&gt; Contractual&lt;br/&gt; Term&lt;br/&gt; (in years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Aggregate&lt;br/&gt; Intrinsic&lt;br/&gt; Value&lt;br/&gt; (in&#160;thousands)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding &#x2013; December 31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;178,232&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;16.74&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;8.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;16&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Assumed in reverse recapitalization&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;467,100&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;47.39&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,775,318&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;18.13&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Exercised&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2,476&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;10.19&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expired&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(740&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.62&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(23,610&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;38.34&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options outstanding &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,393,824&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;23.54&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;7.90&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Options exercisable &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;654,636&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;38.08&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.07&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-17941"
      unitRef="Unit_shares">178232</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2023"
      decimals="2"
      id="ixv-17942"
      unitRef="Unit_USD_per_Share">16.74</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="P01_01_2023To12_31_2023" id="ixv-17943">P8Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-17944"
      unitRef="Unit_USD">16000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17945"
      unitRef="Unit_shares">467100</okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalization>
    <okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17946"
      unitRef="Unit_USD_per_Share">47.39</okur:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedInReverseRecapitalizationWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17947"
      unitRef="Unit_shares">1775318</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17948"
      unitRef="Unit_USD_per_Share">18.13</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17949"
      unitRef="Unit_shares">2476</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17950"
      unitRef="Unit_USD_per_Share">10.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17951"
      unitRef="Unit_shares">740</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17952"
      unitRef="Unit_USD_per_Share">21.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="P01_01_2024To12_31_2024"
      decimals="INF"
      id="ixv-17953"
      unitRef="Unit_shares">23610</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17954"
      unitRef="Unit_USD_per_Share">38.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17955"
      unitRef="Unit_shares">2393824</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-17956"
      unitRef="Unit_USD_per_Share">23.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-17957">P7Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17958"
      unitRef="Unit_USD">1000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-17959"
      unitRef="Unit_shares">654636</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="PAsOn12_31_2024"
      decimals="2"
      id="ixv-17960"
      unitRef="Unit_USD_per_Share">38.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-17961">P3Y25D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-17962"
      unitRef="Unit_USD">1000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-17963"
      unitRef="Unit_USD">26500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      id="ixv-17964">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17965"
      unitRef="Unit_USD_per_Share">16.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2023To12_31_2023_EmployeeStockOptionMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17966"
      unitRef="Unit_USD_per_Share">5.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-17967"
      unitRef="Unit_shares">8449</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-17968"
      unitRef="Unit_USD">30000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_Performance-BasedStockOptionsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-17969"
      unitRef="Unit_USD">13000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17970">The weighted-average assumptions used in the Black-Scholes option pricing model to determine the fair value of the employee stock option grants were as follows: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&#160;Ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term (years)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5.77&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;5.73&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;126.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;32.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.80&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4.31&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2024To12_31_2024" id="ixv-17971">P5Y9M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="P01_01_2023To12_31_2023" id="ixv-17972">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-17973"
      unitRef="Unit_pure">1.262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-17974"
      unitRef="Unit_pure">0.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="4"
      id="ixv-17975"
      unitRef="Unit_pure">0.038</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="4"
      id="ixv-17976"
      unitRef="Unit_pure">0.0431</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-17977"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="2"
      id="ixv-17978"
      unitRef="Unit_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      id="ixv-17980">RSA typically vests 25% on the first anniversary of the issuance date and incrementally vest monthly for the three-year period thereafter.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17981"
      unitRef="Unit_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="P01_01_2024To12_31_2024_RestrictedStockMemberusgaapAwardTypeAxis_ShareBasedCompensationAwardTrancheTwoMemberusgaapVestingAxis"
      id="ixv-17982">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-17983">RSU vests based on a service-based requirement and a liquidity event plus service requirement.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-17984"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-17985">The following table summarizes RSU and RSA activities during the year ended December&#160;31, 2024: &lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:6%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Number&#160;of&lt;/div&gt;&lt;/div&gt;&lt;br/&gt; &lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&lt;br/&gt; Average&lt;br/&gt; Grant&#160;Date&lt;br/&gt; Fair Value&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested balance as of December&#160;31, 2023&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;214,436&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Granted&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Vested (RSA)&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(638&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.83&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Forfeited&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(544&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;RSUs outstanding &#x2013; December 31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Unvested balance as of December&#160;31, 2024&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;213,254&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22.88&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17986"
      unitRef="Unit_shares">214436</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2023_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17987"
      unitRef="Unit_USD_per_Share">22.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17988"
      unitRef="Unit_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-17989"
      unitRef="Unit_USD_per_Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17990"
      unitRef="Unit_shares">638</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17991"
      unitRef="Unit_USD_per_Share">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17992"
      unitRef="Unit_shares">544</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="P01_01_2024To12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17993"
      unitRef="Unit_USD_per_Share">22.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17994"
      unitRef="Unit_shares">213254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17995"
      unitRef="Unit_USD_per_Share">22.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-17996"
      unitRef="Unit_shares">213254</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="PAsOn12_31_2024_RestrictedStockAndRestrictedStockUnitsRSUsMemberusgaapAwardTypeAxis"
      decimals="2"
      id="ixv-17997"
      unitRef="Unit_USD_per_Share">22.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="PAsOn12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="-5"
      id="ixv-17998"
      unitRef="Unit_USD">2800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      id="ixv-17999">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P10_04_2024To10_04_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-18000"
      unitRef="Unit_shares">24700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P10_04_2024To12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-18001"
      unitRef="Unit_shares">7700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="P01_01_2025To01_31_2025_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-18002"
      unitRef="Unit_shares">17000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <okur:UnamortizedCompensationCost
      contextRef="PAsOn12_31_2024_MergerAgreementMemberusgaapBusinessAcquisitionAxis_RestrictedStockMemberusgaapAwardTypeAxis"
      decimals="0"
      id="ixv-18003"
      unitRef="Unit_USD">0</okur:UnamortizedCompensationCost>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-14941">&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The following table shows the allocation of share-based compensation expense related to the company&#x2019;s share-based awards (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Research and development&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;2,896&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;98&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;General and administrative&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;1,634&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;101&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;4,530&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;199&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-18005"
      unitRef="Unit_USD">2896000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_ResearchAndDevelopmentExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-18006"
      unitRef="Unit_USD">98000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-18007"
      unitRef="Unit_USD">1634000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="-3"
      id="ixv-18008"
      unitRef="Unit_USD">101000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="-3"
      id="ixv-18009"
      unitRef="Unit_USD">4530000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="P01_01_2023To12_31_2023"
      decimals="-3"
      id="ixv-18010"
      unitRef="Unit_USD">199000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="P01_01_2024To12_31_2024_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-18011"
      unitRef="Unit_USD">1700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
      contextRef="P01_01_2023To12_31_2023_RestrictedStockUnitsRSUMemberusgaapAwardTypeAxis"
      decimals="INF"
      id="ixv-18012"
      unitRef="Unit_USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15036">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;13. Income Taxes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be recovered or settled. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the income tax benefit are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax at statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State taxes, net of federal deduction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(0.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(22.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(24.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of deferred income taxes are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;53,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D tax credit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,903&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;978&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;90,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(90,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(22,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;As of December&#160;31, 2024, the Company had approximately $3.1&#160;million of net operating loss carryforwards (&#x201c;NOLs&#x201d;) and $0.8&#160;million of research and experimental credits which expire through 2037, and approximately $216.5&#160;million of federal and state net operating loss carryforwards which have an indefinite life. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div&gt;&lt;/div&gt;&lt;div&gt;&lt;div style="line-height:normal;display: inline;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At December&#160;31, 2024, the Company had federal and state tax credit carry forwards of approximately $6.9&#160;million. The Company has not performed a formal research and development credit study with respect to these credits. The federal credits will begin to expire in 2034, if unused. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Pursuant to Internal Revenue Code (&#x201c;IRC&#x201d;) Sections 382 and 383, the Company&#x2019;s ability to use NOLs and research tax credit carry forwards to offset future taxable income may be limited if the Company experiences a cumulative change in ownership of more than 50% within a three-year testing period. The Company has not completed an ownership change analysis pursuant to IRC Section&#160;382. If ownership changes within the meaning of IRC Section&#160;382 are identified as having occurred, the amount of NOLs and research tax carryforwards available to offset future taxable income and income tax liabilities in future years may be significantly restricted or eliminated. Further, deferred tax assets associated with such NOLs and research tax credits could be significantly reduced upon realization of an ownership change within the meaning of IRC Section&#160;382. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during periods in which those temporary differences become deductible. Management considers projected future taxable income and tax planning strategies in making this assessment. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;At December&#160;31, 2024 and 2023, the Company has not accrued any interest or penalties related to uncertain tax positions. The Company does not anticipate that there will be a significant change in the amount of unrecognized tax benefits over the next 12 months. The Company recognizes interest and penalties related to uncertain tax positions in income tax expense. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company is subject to taxation in the United States and the UK. The UK subsidiary operations ceased in 2024. The Company&#x2019;s federal and state income tax returns for all years will remain open to examination by federal and state tax authorities for three years from the date of utilization of any net operating loss carryforwards. The Company&#x2019;s federal and state returns since inception are subject to examination due to the carryover of net operating losses. The Company has not been, nor is it currently, under examination by any tax authorities. The UK tax returns from 2018 through 2024, are subject to examination by the UK tax authorities. &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15040">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The components of the income tax benefit are as follows: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:11pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:10%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:9%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Years&#160;ended&#160;December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Federal tax at statutory rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;21.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;State taxes, net of federal deduction&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;3.6&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D credits&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.2&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(2.3&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(0.1&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Change in valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(22.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(24.7&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Income tax benefit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;0.0&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;%&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18013"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18014"
      unitRef="Unit_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18015"
      unitRef="Unit_pure">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18016"
      unitRef="Unit_pure">0.036</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18017"
      unitRef="Unit_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18018"
      unitRef="Unit_pure">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18019"
      unitRef="Unit_pure">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18020"
      unitRef="Unit_pure">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18021"
      unitRef="Unit_pure">0.22</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18022"
      unitRef="Unit_pure">0.247</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2024To12_31_2024"
      decimals="3"
      id="ixv-18023"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="P01_01_2023To12_31_2023"
      decimals="3"
      id="ixv-18024"
      unitRef="Unit_pure">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15167">&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Significant components of deferred income taxes are as follows (in thousands): &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="text-align:start; BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto"&gt;
&lt;tr&gt;
&lt;td style="width:71%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:8%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:7%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;As of December&#160;31,&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2024&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center"&gt;&lt;div style="letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2023&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets:&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Net operating loss carryforwards&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;53,984&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;9,027&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;R&amp;amp;D tax credit&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;837&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred R&amp;amp;D expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;32,729&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;11,123&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Accrued expenses&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;1,903&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;783&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Share-based compensation&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;978&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;104&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 3em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Other&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;424&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;337&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Total deferred tax assets&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;90,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;22,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(90,855&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:right"&gt;(22,211&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 1px solid rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:11pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Deferred tax assets, net of valuation allowance&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right"&gt;&#x2014;&#x2002;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1px"&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-top: 3px double rgb(0, 0, 0); line-height: normal;"&gt;&#160;&lt;/div&gt;&lt;/td&gt;
&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18025"
      unitRef="Unit_USD">53984000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18026"
      unitRef="Unit_USD">9027000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18027"
      unitRef="Unit_USD">837000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18028"
      unitRef="Unit_USD">837000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18029"
      unitRef="Unit_USD">32729000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18030"
      unitRef="Unit_USD">11123000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18031"
      unitRef="Unit_USD">1903000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18032"
      unitRef="Unit_USD">783000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18033"
      unitRef="Unit_USD">978000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18034"
      unitRef="Unit_USD">104000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18035"
      unitRef="Unit_USD">424000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18036"
      unitRef="Unit_USD">337000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18037"
      unitRef="Unit_USD">90855000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18038"
      unitRef="Unit_USD">22211000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18039"
      unitRef="Unit_USD">90855000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18040"
      unitRef="Unit_USD">22211000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2024"
      decimals="-3"
      id="ixv-18041"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="PAsOn12_31_2023"
      decimals="-3"
      id="ixv-18042"
      unitRef="Unit_USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-18043"
      unitRef="Unit_USD">3100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration
      contextRef="PAsOn12_31_2024"
      decimals="-5"
      id="ixv-18044"
      unitRef="Unit_USD">800000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpiration>
    <okur:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod contextRef="P01_01_2024To12_31_2024" id="ixv-18045">2037</okur:DeferredTaxAssetsOperatingLossCarryforwardsSubjectToExpirationPeriod>
    <us-gaap:OperatingLossCarryforwards
      contextRef="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-18046"
      unitRef="Unit_USD">216500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-18048"
      unitRef="Unit_USD">6900000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="PAsOn12_31_2024_DomesticTaxJurisdictionAndStateAndLocalJurisdictionMemberusgaapIncomeTaxAuthorityAxis"
      decimals="-5"
      id="ixv-18049"
      unitRef="Unit_USD">6900000</us-gaap:TaxCreditCarryforwardAmount>
    <okur:TaxCreditCarryforwardExpirationPeriod
      contextRef="P01_01_2024To12_31_2024_DomesticCountryMemberusgaapIncomeTaxAuthorityAxis"
      id="ixv-18050">2034</okur:TaxCreditCarryforwardExpirationPeriod>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2024"
      decimals="INF"
      id="ixv-18051"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued
      contextRef="PAsOn12_31_2023"
      decimals="INF"
      id="ixv-18052"
      unitRef="Unit_USD">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15379">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;14. Commitments and Contingencies &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Legal Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;Merger Proceedings &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In connection with the Merger, two complaints were filed in the Supreme Court of the State of New York, County of New York, captioned&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Thomas&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;v.&lt;/div&gt;&lt;/div&gt;&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Reneo Pharmaceuticals, Inc., et al.&lt;/div&gt;&lt;/div&gt;, Index No.&#160;654628/2024 (filed September&#160;5, 2024) and&lt;div style="font-style: normal; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="font-style:italic;display:inline;"&gt;&#160;Kent v. Reneo Pharmaceuticals, Inc., et al.&lt;/div&gt;&lt;/div&gt;, Index No.&#160;654642/2024 (filed September&#160;6, 2024) (together, the &#x201c;Complaints&#x201d;). The Complaints generally allege that the Proxy Statement/Prospectus filed by Reneo with the SEC misrepresented and/or omitted certain purportedly material information relating to Reneo management&#x2019;s financial projections for Reneo and OnKure, the data and inputs underlying the financial valuation analyses that support the fairness opinion provided by Leerink Partners, Reneo&#x2019;s financial advisor, and potential conflicts of interest with Leerink Partners LLC, Evercore Group L.L.C., and LifeSci Capital LLC, which were the placements agents for the Concurrent Financing that closed concurrently with the Merger. The Complaints assert violations of negligent misrepresentation and concealment in violation of New York common law and negligence in violation of New York common law. The Complaints sought orders enjoining the proposed Merger, or in the event that the Merger was consummated, orders rescinding the Merger or awarding actual and punitive damages, as well as all of the plaintiffs&#x2019; fees and expenses in connection with the litigation, including reasonable attorneys&#x2019; and experts&#x2019; fees and expenses. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;We cannot predict the outcome of the Complaints or any other litigation that might be filed arising out of the Merger or the Concurrent Financing. The Company and the individual defendants intend to vigorously defend against the Complaints and any subsequently filed, similar actions. It is possible additional lawsuits may be filed arising out of the Merger or the Concurrent Financing. Absent new or significantly different allegations, the Company will not necessarily disclose such additional filings. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;From &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="white-space:nowrap;display:inline;"&gt;time-to-time&lt;/div&gt;&lt;/div&gt; in the future, the Company could be involved in disputes, including litigation, relating to claims arising out of operations in the normal course of business, which may have a material adverse effect on the Company&#x2019;s consolidated results of operations or financial position. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Clinical Trial Collaboration and Supply Agreement with Pfizer &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In August 2020, as amended in December 2024, the Company entered into a clinical trial collaboration and supply agreement under which Pfizer Inc. (&#x201c;Pfizer&#x201d;) agreed to supply drug product in connection with a clinical trial. The agreement continues until the earlier of the completion of all obligations of the parties or the termination of the contract by either party as defined in the agreement. The Company may terminate the agreement if the clinical trial is deemed to be unsafe, regulatory authorities raise concerns, or if Pfizer does not uphold its obligations outlined in the agreement. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Indemnification &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In the ordinary course of business, the Company may provide indemnification of varying scope and terms to vendors, lessors, business partners and other parties with respect to certain matters including, but not limited to, losses arising of breach of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with members of its board of directors that will require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs because of such indemnifications. The Company is not aware of any claims under indemnification arrangements, and it has not accrued any liabilities related to such obligations in its financial statements as of December&#160;31, 2024. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Severance &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;A former officer of the Company terminated his employment with the Company on May&#160;24, 2024 and entered into a separation agreement and release on that date. The separation agreement and release provides for payments and benefits including continuing payments of base salary for a period of 14&#160;months following termination of employment, payment for or reimbursement for COBRA premiums for up to 14 months following termination of employment, a full accelerated vesting of his equity awards and extension of the post-termination exercise period applicable to his Options through the earlier of 12 months following termination of service or the applicable option expiration date. During the year ended December&#160;31, 2024, the Company recorded an expense of $622,000 for these severance benefits in research and development expense, of which $326,000 remains unpaid and is included in accrued compensation. See Note 12 for discussion of stock-based compensation recorded for the modifications of equity awards discussed above. The related RSU shares were released in January 2025. &lt;/div&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;Certain Reneo employees became employees of the Company to assist with the Merger transition through the end of the year December&#160;31, 2024 at which time they were terminated and received severance benefits in accordance with the Reneo severance agreements. The Company recorded expense of $225,000 for severance benefits for these employees for the year ended December&#160;31, 2024, which is included in General and Administrative expenses and of which, approximately $154,000 remains unpaid as of December&#160;31, 2024 and is included in accrued compensation. &lt;/div&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Employee Benefit Plan &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company established a qualified 401(k) plan in June 2021 which covers all employees who meet eligibility requirements. The Company matches its employee contributions up to a maximum amount of 4% of the participant&#x2019;s compensation. During the years ended December&#160;31, 2024, and 2023, the Company made matching contributions of approximately $360,000&#160;and $294,000, respectively. See Note 16. &lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2024To12_31_2024_OneTimeTerminationBenefitsMemberusgaapRestructuringCostAndReserveAxis"
      decimals="0"
      id="ixv-18054"
      unitRef="Unit_USD">622000</us-gaap:SeveranceCosts1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-18055"
      unitRef="Unit_USD">326000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:SeveranceCosts1
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-18056"
      unitRef="Unit_USD">225000</us-gaap:SeveranceCosts1>
    <us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense
      contextRef="P01_01_2024To12_31_2024_GeneralAndAdministrativeExpenseMemberusgaapIncomeStatementLocationAxis"
      decimals="0"
      id="ixv-18057"
      unitRef="Unit_USD">154000</us-gaap:DeferredCompensationArrangementWithIndividualCompensationExpense>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="P01_01_2024To12_31_2024"
      decimals="2"
      id="ixv-18059"
      unitRef="Unit_pure">0.04</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2024To12_31_2024"
      decimals="0"
      id="ixv-18060"
      unitRef="Unit_USD">360000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="P01_01_2023To12_31_2023"
      decimals="0"
      id="ixv-18061"
      unitRef="Unit_USD">294000</us-gaap:DefinedContributionPlanCostRecognized>
    <okur:ConvertiblePromissoryNoteDisclosureTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15452">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;15. Convertible Promissory Notes &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In June 2024, the Company entered into convertible promissory note agreements with certain of its existing investors for up to $12.0&#160;million. At closing, the Company received total proceeds of $6.0&#160;million and had the ability to draw up to an additional $6.0&#160;million in the event the Merger with Reneo had not closed by September&#160;30, 2024, but no additional draw was made. The notes bore interest at rates from 6% per annum. All unpaid principal and accrued interest were due in December 2025, unless earlier converted. In October 2024, the unpaid notes and accrued unpaid interest automatically converted into shares issued in the Concurrent Financing at the price per share paid by investors in the Concurrent Financing. See Note 3 for further discussion. The Company incurred $142,000 of debt issuance costs related to the convertible promissory notes during the year ended December&#160;31, 2024. Debt issuance costs are amortized as a component of interest expense over the term of the related debt using the straight-line method, which approximates the interest method. The Company recognized $148,000 in interest expense related to the amortization of the debt issuance costs for the year ended December&#160;31, 2024 and a $114,000 loss on the conversion for the year ended December&#160;31, 2024, both of which are recorded in interest and other expense in the Statement of Operations. As of December&#160;31, 2024, the Company had no accrued interest related to the convertible promissory notes. &lt;/div&gt;</okur:ConvertiblePromissoryNoteDisclosureTextBlock>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="PAsOn06_30_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-18062"
      unitRef="Unit_USD">12000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:ShortTermBorrowings
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-18063"
      unitRef="Unit_USD">6000000</us-gaap:ShortTermBorrowings>
    <okur:AdditionalProceedsFromAcquisition
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="-5"
      id="ixv-18064"
      unitRef="Unit_USD">6000000</okur:AdditionalProceedsFromAcquisition>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="2"
      id="ixv-18065"
      unitRef="Unit_pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-18066"
      unitRef="Unit_USD">142000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-18067"
      unitRef="Unit_USD">148000</us-gaap:AmortizationOfFinancingCosts>
    <okur:GainLossOnConversionOfDebt
      contextRef="P01_01_2024To12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-18068"
      unitRef="Unit_USD">-114000</okur:GainLossOnConversionOfDebt>
    <okur:AccruedInterest
      contextRef="PAsOn12_31_2024_ConvertibleDebtMemberusgaapCreditFacilityAxis"
      decimals="0"
      id="ixv-18069"
      unitRef="Unit_USD">0</okur:AccruedInterest>
    <us-gaap:SubsequentEventsTextBlock contextRef="P01_01_2024To12_31_2024" id="ixv-15456">&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;16. Subsequent Events &lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top: 6pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;&lt;div style="display:inline;"&gt;Sublease&lt;/div&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;In January 2025, the Company entered into a sublease on the Irvine lease for all of the leased square footage. The sublease rent payments will be approximately $450,000 over the term of the lease, which expires in November 2026. &lt;/div&gt;&lt;div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&lt;div style="font-style: italic; letter-spacing: 0px; top: 0px;display:inline;"&gt;Available for Issuance Increase &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s 2024 Plan provides that on the first day of each fiscal year, the number of shares of our Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) 2,407,100 shares, (ii) 5% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the Company&#x2019;s board of directors may determine. The Company&#x2019;s ESPP provides that on the first day of each fiscal year, the number of shares of Class&#160;A common stock available for issuance thereunder is automatically increased by a number equal to the least of (i) 481,500&#160;shares, (ii) 1% of the outstanding shares of all classes of common stock as of the last day of the immediately preceding fiscal year, or (iii)&#160;such other amount as the board of directors may determine. On January&#160;1, 2025, the number of shares of Class&#160;A common stock available for issuance under the 2024 Plan and the ESPP increased by 667,355&#160;and 133,471&#160;shares, respectively, pursuant to these provisions. &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:PaymentsForRent
      contextRef="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="0"
      id="ixv-18070"
      unitRef="Unit_USD">450000</us-gaap:PaymentsForRent>
    <okur:SubleaseExpirationPeriod
      contextRef="P01_01_2025To01_31_2025_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      id="ixv-18071">2026-11</okur:SubleaseExpirationPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_MaximumMembersrtRangeAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-18072"
      unitRef="Unit_shares">2407100</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <okur:PercentageOfNumberOfOutstandingSharesOfCommonStock
      contextRef="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="2"
      id="ixv-18073"
      unitRef="Unit_pure">0.05</okur:PercentageOfNumberOfOutstandingSharesOfCommonStock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-18074"
      unitRef="Unit_shares">481500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <okur:PercentageOfNumberOfOutstandingSharesOfCommonStock
      contextRef="P01_01_2025To01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="2"
      id="ixv-18075"
      unitRef="Unit_pure">0.01</okur:PercentageOfNumberOfOutstandingSharesOfCommonStock>
    <okur:IncreaseInNumberOfSharesAvailableForIssuance
      contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis_TwentyTwentyFourEquityIncentivePlanMemberusgaapPlanNameAxis"
      decimals="INF"
      id="ixv-18076"
      unitRef="Unit_shares">667355</okur:IncreaseInNumberOfSharesAvailableForIssuance>
    <okur:IncreaseInNumberOfSharesAvailableForIssuance
      contextRef="PAsOn01_01_2025_CommonClassAMemberusgaapStatementClassOfStockAxis_EmployeeStockMemberusgaapSubsidiarySaleOfStockAxis_SubsequentEventMemberusgaapSubsequentEventTypeAxis"
      decimals="INF"
      id="ixv-18077"
      unitRef="Unit_shares">133471</okur:IncreaseInNumberOfSharesAvailableForIssuance>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
